Physical O O
mapping O O
220 O O
kb O O
centromeric O O
of O O
the O O
human B B_GENE/B_LOCATION
MHC I I_GENE/I_LOCATION
and O O
DNA O O
sequence O O
analysis O O
of O O
the O O
43 O O
- O O
kb O O
segment O O
including O O
the O O
RING1 B B_GENE
, O O
HKE6 B B_GENE/B_BACTERIUM[BIO]
, O O
and O O
HKE4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
synthesis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O O
endo O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
adduct O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
[ O O
4aS O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
5S O B_LOCATION/B_PROTEIN[GENE]
, O O
8R O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
8aR O B_LOCATION/B_MEASURE
, O O
SS O B_MEASURE
] O I_MEASURE
- O O
9d O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulting O O
from O O
cycloaddition O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
substituted O O
C O B_PROTEIN[GENE]/B_LOCATION
( O O
2 O B_NUMBER[MEASURE]
) O O
- O O
C O B_PROTEIN[GENE]/B_LOCATION
( O O
3 O B_NUMBER[MEASURE]
) O O
double O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
bond O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O O
achieved O O
in O O
a O O
chemo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
and O O
diastereoselective O B_LOCATION
way O I_LOCATION
from O O
quinone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1d O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
presence O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
ZnBr O B_LOCATION
( O O
2 O B_NUMBER[MEASURE]/B_LOCATION
) O O
. O O

DNA O O
elements O O
recognizing O O
NF B B_GENE
- I I_GENE
Y I I_GENE
and O O
Sp1 B B_GENE
regulate O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
multidrug I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
resistance I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Radioimmunoassay O O
of O O
plasma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gonadotropins I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
; O O
problems O O
of O O
specificity O O

Patients O B_PERSON
randomized O O
into O O
the O O
active O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
treatment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
groups O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
A30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
( O O
n O B_OTHER/B_MEASURE
= O O
49 O B_MEASURE
) O O
and O O
A60 O B_PROTEIN[GENE]/B_MEASURE
( O O
n O B_OTHER/B_MEASURE
= O O
48 O B_MEASURE
) O O
received O O
topical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
with O O
3 O B_MEASURE
. O O
0 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diclofenac O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
2 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
hyaluronan O I_MEASURE
gel O I_MEASURE
0 O I_MEASURE
. O O
5 O B_MEASURE
g O I_MEASURE
twice O O
daily O O
for O O
30 O B_MEASURE
or O O
60 O B_TIME[MEASURE]
days O I_TIME[MEASURE]
, O O
respectively O O
. O O

As O O
tat B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
itself O O
dramatically O O
increases O O
HIV O O
- O O
1 O O
gene O O
expression O O
, O O
it O O
too O O
is O O
presumably O O
regulated O O
in O O
the O O
latent O O
state O O
, O O
and O O
may O O
also O O
be O O
activated O O
by O O
mitogenic O O
stimulation O O
. O O

To O O
clarify O O
the O O
difference O O
, O O
both O O
the O O
Crk B B_GENE/B_BIO
II I I_GENE/I_BIO
and O O
Crk B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
23 I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
proteins O O
were O O
expressed O O
in O O
E O O
. O O
coli O O
and O O
examined O O
their O O
binding O O
capacity O O
in O O
vitro O O
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Systemic O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
increase O O
bone O B_DISEASE/B_GENE
mineral O I_DISEASE/I_GENE
density O I_DISEASE/I_GENE
appear O O
to O O
be O O
involved O O
in O O
the O O
pathogenesis O B_DISEASE
of O O
ossification O B_DISEASE
of O O
the O O
posterior O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
longitudinal O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
ligament O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
these O O
factors O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
may O O
be O O
activated O O
after O O
middle O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
age O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Thus O O
, O O
in O O
V O O
. O O
furnissii O O
, O O
the O O
E B B_GENE/B_BACTERIUM[BIO]
. I I_GENE/I_BACTERIUM[BIO]
coli I I_GENE/I_BACTERIUM[BIO]
manX I I_GENE/I_BACTERIUM[BIO]
equivalent I I_GENE/I_BACTERIUM[BIO]
comprises O O
two O O
genes O O
, O O
which O O
are O O
separated O O
in O O
the O O
genome O O
by O O
two O O
other O O
genes O O
of O O
the O O
ptsM B B_PROTEIN[GENE]/B_BIO
complex I I_PROTEIN[GENE]/I_BIO
. O O

Id B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1H I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Id B B_PROTEIN[GENE]
- I I_PROTEIN[GENE]
2H I I_PROTEIN[GENE]
seem O O
to O O
be O O
human O O
homologues O O
of O O
mouse B B_GENE/B_DISEASE
Id I I_GENE/I_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
and O O
Id B B_PROTEIN[GENE]/B_MEASURE
- I I_PROTEIN[GENE]/I_MEASURE
2 I I_PROTEIN[GENE]/I_MEASURE
, O O
respectively O O
, O O
and O O
have O O
potential O O
to O O
encode O O
154 O O
and O O
135 O O
amino O O
acid O O
proteins O O
. O O

Characterization O O
of O O
insertion O O
mutations O O
in O O
the O O
Saccharomyces B B_GENE/B_DISEASE
cerevisiae I I_GENE/I_DISEASE
MSH1 I I_GENE/I_DISEASE
and O O
MSH2 B B_GENE/B_DISEASE
genes I I_GENE/I_DISEASE
: O O
evidence O O
for O O
separate O O
mitochondrial O O
and O O
nuclear O O
functions O O
. O O

Transcription O O
of O O
FN B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
chloramphenicol B B_GENE/B_DISEASE
acetyltransferase I I_GENE/I_DISEASE
fusion O O
genes O O
carrying O O
the O O
base O O
substitution O O
in O O
one O O
or O O
more O O
of O O
these O O
G O O
- O O
rich O O
sequences O O
both O O
in O O
vivo O O
and O O
in O O
vitro O O
revealed O O
that O O
the O O
base O O
substitution O O
in O O
any O O
G O O
- O O
rich O O
sequence O O
results O O
in O O
reduction O O
of O O
promoter O O
activity O O
, O O
although O O
the O O
downstream O O
GC O O
box O O
( O O
GCd O O
) O O
plays O O
a O O
primary O O
role O O
. O O

Morphologically O O
, O O
corrugation O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
internal O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
elastic O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
lamina O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
of O O
vessels O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
was O O
often O O
observed O O
in O O
the O O
vehicle O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
treated O O
group O B_ORGANIZATION/B_PERSON
, O O
but O O
was O O
not O O
prominent O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
GLNVA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
treated O O
groups O B_ORGANIZATION/B_PERSON
or O O
healthy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
controls O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

A O O
GT O O
- O O
rich O O
sequence O O
binding O O
the O O
transcription B B_GENE/B_LOCATION
factor I I_GENE/I_LOCATION
Sp1 I I_GENE/I_LOCATION
is O O
crucial O O
for O O
high O O
expression O O
of O O
the O O
human B B_GENE
type I I_GENE
VII I I_GENE
collagen I I_GENE
gene I I_GENE
( O O
COL7A1 B B_GENE/B_LOCATION
) O O
in O O
fibroblasts O O
and O O
keratinocytes O O
. O O

Each O O
received O O
20 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mL O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
one O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
three O B_PERSON/B_NUMBER[MEASURE]
test O B_PERSON/I_NUMBER[MEASURE]
solutions O B_PERSON/I_NUMBER[MEASURE]
: O O
levobupivacaine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
levobupivacaine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
fentanyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
microg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
/ O O
mL O B_MEASURE/B_LOCATION
, O O
or O O
levobupivacaine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
fentanyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
microg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
/ O O
mL O B_MEASURE/B_LOCATION
. O O

The O O
XPR2 B B_GENE
gene I I_GENE
from O O
Yarrowia O O
lipolytica O O
encodes O O
an O O
inducible O O
alkaline B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
extracellular I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protease I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shows O O
that O O
the O O
annual O B_MEASURE
rate O I_MEASURE
of O O
de O B_DISEASE
novo O I_DISEASE
aneurysm O I_DISEASE
formation O I_DISEASE
is O O
relatively O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
( O O
0 O B_MEASURE
. O O
89 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
and O O
that O O
the O O
cumulative O B_MEASURE/B_DISEASE
risk O B_MEASURE/I_DISEASE
becomes O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
after O O
9 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
years O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

It O O
was O O
found O O
that O O
Nopp140 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binds O O
primarily O O
to O O
the O O
CK2 B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
regulatory I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
subunit I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
, I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
beta I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Juvenile O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
idiopathic O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inflammatory O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
myopathies O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
the O O
value O B_MEASURE/B_PERSON
of O O
magnetic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
resonance O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
imaging O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
the O O
detection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
muscle O B_DISEASE_ADJECTIVE[DISEASE]
involvement O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Previous O O
analysis O O
of O O
this O O
motif O O
in O O
the O O
lactose B B_SPECIES[BIO]/B_TIME[MEASURE]
permease I I_SPECIES[BIO]/I_TIME[MEASURE]
( O O
A O O
. O O

Combined O O
chemotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
VM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
26 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
BCNU O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
recurrent O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
malignant O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
gliomas O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O O
operation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
irradiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Like O O
other O O
IAPs B B_BIO/B_GENE
, O O
ch B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
IAP1 I I_GENE/I_DISEASE
contains O O
the O O
N B B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
terminal I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
baculovirus I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
IAP I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
repeats I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
and O O
C O O
- O O
terminal O O
RING O O
finger O O
motifs O O
. O O

Effects O O
of O O
long O O
- O O
term O O
use O O
of O O
raloxifene O O
, O O
a O O
selective O O
estrogen B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
modulator O O
, O O
on O O
thyroid O O
function O O
test O O
profiles O O
. O O

The O O
donors O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
10 O B_PERSON/B_TIME[MEASURE]
patients O I_PERSON/I_TIME[MEASURE]
were O O
ABO O B_DISEASE/B_MEASURE
- O O
incompatible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
for O O
five O B_NUMBER[MEASURE]/B_PERSON
pairs O I_NUMBER[MEASURE]/I_PERSON
the O O
ABO O B_DISEASE_ADJECTIVE[DISEASE]
incompatibility O I_DISEASE_ADJECTIVE[DISEASE]
was O O
major O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Alternative O O
splicing O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
serotonin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transporter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Interestingly O O
, O O
basal O O
MAPK B B_GENE
, O O
but O O
not O O
Raf B B_GENE
- I I_GENE
1 I I_GENE
, O O
activity O O
was O O
constitutively O O
enhanced O O
in O O
Jak1 B B_GENE
- O O
deficient O O
HeLa O O
cells O O
. O O

This O O
case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
report O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
describes O O
the O O
treatment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
a O O
patient O B_PERSON/B_BIO
with O O
periodontosis O B_DISEASE/B_LOCATION
. O O

The O O
aim O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
this O O
work O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O O
to O O
organize O O
chemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
in O O
a O O
client O B_PERSON/B_LOCATION
- O O
server O B_ORGANIZATION/B_LOCATION
environment O B_ORGANIZATION/I_LOCATION
using O O
Database O B_ORGANIZATION/B_ENT
Management O I_ORGANIZATION/I_ENT
System O I_ORGANIZATION/I_ENT
and O O
Web O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fashion O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
client O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interface O B_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Cerumen O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
management O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
hearing O B_LOCATION/B_PERSON
conservation O I_LOCATION/I_PERSON
: O O
the O O
Dallas O B_LOCATION/B_PERSON
( O O
Texas O B_LOCATION/B_PERSON
) O O
Independent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
School O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
District O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Lactate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
pyruvate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
actual O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pH O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
venous O B_BODY_PART_OR_ORGAN_COMPONENT
blood O I_BODY_PART_OR_ORGAN_COMPONENT
of O O
newborn O B_PERSON/B_BIO
calves O I_PERSON/I_BIO

This O O
article O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
focuses O O
on O O
a O O
general O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
approach O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
the O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
ARV O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Platelets O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
and O O
RBCs O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
each O O
animal O B_BIO/B_PERSON
were O O
labeled O O
with O O
51Cr O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
99mTc O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
respectively O O
, O O
and O O
were O O
rapidly O O
injected O O
into O O
the O O
right O B_BODY_PART_OR_ORGAN_COMPONENT
atrium O I_BODY_PART_OR_ORGAN_COMPONENT
while O O
blood O B_BODY_PART_OR_ORGAN_COMPONENT
was O O
sampled O O
from O O
the O O
ascending O O
aorta O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O O

The O O
comparisons O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
swimming O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
performance O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
before O O
and O O
after O O
treatments O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
deltamethrin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
have O O
shown O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
locomotory O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
ability O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O O
rainbow O B_BIO/B_PERSON
trout O I_BIO/I_PERSON
which O O
at O O
the O O
end O B_MEASURE/B_LOCATION
of O O
strong O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
exposure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
e O B_DISEASE/B_LOCATION
. O O
g O B_PROTEIN[GENE]/B_MEASURE
. O O

Protection O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
33 O B_MEASURE
. O O
3 O B_MEASURE
% O I_MEASURE
, O O
36 O B_MEASURE
. O O
6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
and O O
37 O B_MEASURE
. O O
0 O B_MEASURE
% O I_MEASURE
were O O
achieved O O
in O O
groups O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
had O O
received O O
, O O
respectively O O
, O O
1000 O B_TIME[MEASURE]
20 O I_TIME[MEASURE]
- O O
krad O B_PERSON/B_MEASURE
cercariae O I_PERSON/I_MEASURE
, O O
1000 O B_MEASURE
10 O I_MEASURE
- O O
krad O B_MEASURE/B_PERSON
cercariae O I_MEASURE/I_PERSON
, O O
2000 O B_TIME[MEASURE]
40 O I_TIME[MEASURE]
- O O
krad O B_MEASURE/B_PERSON
cercariae O I_MEASURE/I_PERSON
and O O
2000 O B_TIME[MEASURE]
60 O I_TIME[MEASURE]
- O O
krad O B_PERSON/B_MEASURE
cercariae O I_PERSON/I_MEASURE
. O O

In O O
Types O B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O O
and O O
II O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
capillary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
walls O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
became O O
thinner O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
more O O
capillary O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lumens O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
visiable O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Thus O O
, O O
primate O O
vs O O
. O O
rodent O O
promoter O O
selectivity O O
mediated O O
by O O
the O O
TBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
TAFI B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex O O
is O O
likely O O
to O O
be O O
the O O
result O O
of O O
cumulative O O
subtle O O
differences O O
between O O
individual O O
subunits O O
that O O
lead O O
to O O
species O O
- O O
specific O O
properties O O
of O O
RNA B B_GENE/B_BIO
polymerase I I_GENE/I_BIO
I I I_GENE/I_BIO
transcription O O
. O O

The O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
pretreatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
the O O
non O O
- O O
competitive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NMDA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonist O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
+ O B_PROTEIN[GENE]/B_DISEASE
) O O
MK O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
801 O B_NUMBER[MEASURE]
on O O
the O O
behavioral O B_DISEASE_ADJECTIVE[DISEASE]
alterations O I_DISEASE_ADJECTIVE[DISEASE]
induced O O
by O O
repeated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
restraint O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
stress O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
investigated O O
. O O

When O O
gene O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
conversion O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
is O O
initiated O O
by O O
a O O
double O B_NUMBER[MEASURE]/B_LOCATION
- O O
strand O B_DISEASE/B_GENE
break O B_DISEASE/I_GENE
( O O
DSB O B_DISEASE/B_PROTEIN[GENE]
) O O
, O O
any O O
nonhomologous O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
DNA O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
that O O
may O O
be O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
at O O
the O O
ends O B_LOCATION/B_GENE
must O O
be O O
removed O O
before O O
new O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthesis O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
initiated O O
. O O

In O O
this O O
reconstituted O O
system O O
, O O
RNAP B B_GENE
IIA I I_GENE
, O O
but O O
not O O
RNAP B B_PROTEIN[GENE]/B_LOCATION
IIB I I_PROTEIN[GENE]/I_LOCATION
, O O
can O O
transcribe O O
from O O
the O O
DHFR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
cDNA O O
clones O O
encode O O
a O O
polypeptide O O
of O O
657 O O
amino O O
acids O O
with O O
a O O
bHLH O O
( O O
basic O O
- O O
helix O O
- O O
loop O O
- O O
helix O O
) O O
domain O O
, O O
characteristic O O
of O O
a O O
large O O
family O O
of O O
transcription O O
factors O O
, O O
and O O
a O O
PAS B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
Per B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Arnt B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
- O O
Sim B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
domain O O
in O O
the O O
amino O O
- O O
terminal O O
half O O
region O O
. O O

FTF O B_ORGANIZATION/B_LOCATION
( O O
Joint O B_ORGANIZATION/B_PERSON
Council O I_ORGANIZATION/I_PERSON
of O O
Civil O B_PERSON/B_ORGANIZATION
Servants O I_PERSON/I_ORGANIZATION
and O O
Functionaries O B_PERSON
) O O
: O O
clarification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
about O O
membership O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
main O B_ORGANIZATION/B_LOCATION
organizations O I_ORGANIZATION/I_LOCATION

Lumbar O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spine O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bone O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mineral O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
density O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
BMD O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
by O O
dual O B_MEASURE/B_LOCATION
- O O
energy O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
X O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
ray O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
absorptiometry O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DXA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
increased O O
by O O
0 O B_MEASURE
. O O
6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
3 O B_MEASURE
. O O
6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
and O O
8 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
after O O
48 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
weeks O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O O
groups O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
L O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
M O B_LOCATION
and O O
H O B_OTHER/B_PROTEIN[GENE]
respectively O O
, O O
responses O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
groups O B_LOCATION/B_PERSON
M O I_LOCATION/I_PERSON
and O O
H O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
being O O
significantly O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
in O O
L O B_OTHER/B_PROTEIN[GENE]
( O O
p O B_MEASURE/B_LOCATION
< O I_MEASURE/I_LOCATION
0 O I_MEASURE/I_LOCATION
. O O
05 O B_MEASURE
, O O
Mann O B_PERSON
- O O
Whitney O B_PERSON
U O I_PERSON
- O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
. O O

Synergy O O
between O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
gamma I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
transcriptional O O
activation O O
is O O
mediated O O
by O O
cooperation O O
between O O
signal B B_GENE
transducer I I_GENE
and I I_GENE
activator I I_GENE
of I I_GENE
transcription I I_GENE
1 I I_GENE
and O O
nuclear B B_GENE
factor I I_GENE
kappaB I I_GENE
. O O

1H O O
and O O
15N O O
magnetic O O
resonance O O
assignments O O
, O O
secondary O O
structure O O
, O O
and O O
tertiary O O
fold O O
of O O
Escherichia B B_GENE/B_BACTERIUM[BIO]
coli I I_GENE/I_BACTERIUM[BIO]
DnaJ I I_GENE/I_BACTERIUM[BIO]
( I I_GENE/I_BACTERIUM[BIO]
1 I I_GENE/I_BACTERIUM[BIO]
- I I_GENE/I_BACTERIUM[BIO]
78 I I_GENE/I_BACTERIUM[BIO]
) I I_GENE/I_BACTERIUM[BIO]
. O O

A O O
cDNA O O
for O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
microfibril I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
associated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glycoprotein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MAGP B B_GENE
- I I_GENE
2 I I_GENE
) O O
was O O
used O O
to O O
screen O O
a O O
human O O
leukocyte O O
genomic O O
DNA O O
library O O
in O O
EMBL O O
- O O
3 O O
vector O O
. O O

Furthermore O O
, O O
ERK B B_GENE
phosphorylation O O
was O O
substantially O O
prolonged O O
in O O
LC O O
/ O O
BRY O O
- O O
treated O O
cells O O
compared O O
to O O
those O O
exposed O O
to O O
BRY O O
alone O O
, O O
and O O
pretreatment O O
with O O
the O O
highly O O
specific O O
MEK B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitors O O
, O O
PD98059 O O
, O O
U0126 O O
, O O
and O O
SL327 O O
, O O
opposed O O
ERK B B_GENE
activation O O
while O O
protecting O O
cells O O
from O O
LC O O
/ O O
BRY O O
- O O
induced O O
lethality O O
. O O

The O O
cholesterol B B_GENE
7alpha I I_GENE
- I I_GENE
hydroxylase I I_GENE
gene I I_GENE
( O O
CYP7A B B_GENE/B_LOCATION
) O O
is O O
transcriptionally O O
regulated O O
by O O
a O O
number O O
of O O
factors O O
, O O
including O O
hormones O O
, O O
bile O O
acids O O
, O O
and O O
diurnal O O
rhythm O O
. O O

CNS O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
preventive O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
without O O
cranial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
irradiation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
effective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
all O O
the O O
groups O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
ALL O O
patients O B_PERSON/B_LOCATION
. O O

Additionally O O
, O O
the O O
members O B_PERSON/B_BIO
of O O
this O O
family O B_PERSON/B_LOCATION
display O O
strong O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
sequence O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
homologies O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
between O O
their O O
larger O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
effector O I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
binding O I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
/ O O
oligomerization O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
domains O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Aspartame O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
a O O
synthetic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sweetener O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
commonly O O
used O O
in O O
soft O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
drinks O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and O O
many O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
foods O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

The O O
rat O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anococcygeus O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
muscle O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
used O O
in O O
postsynaptic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
purpose O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
this O O
presentation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
to O O
review O O
the O O
current O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
state O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
knowledge O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regarding O O
5 O B_NUMBER[MEASURE]
, O O
8 O B_NUMBER[MEASURE]
, O O
11 O B_NUMBER[MEASURE]
, O O
14 O B_MEASURE
- O O
eicosatetraynoic O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid O I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ETYA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Ro O O
3 O B_NUMBER[MEASURE]
- O O
1428 O B_MEASURE/B_LOCATION
) O O
and O O
its O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
lipid O B_DISEASE
metabolism O I_DISEASE
. O O

A O O
Meis1 B B_GENE/B_DISEASE
cDNA I I_GENE/I_DISEASE
clone O O
that O O
encoded O O
a O O
novel O O
member O O
of O O
the O O
homeobox B B_GENE/B_BIO
gene I I_GENE/I_BIO
family I I_GENE/I_BIO
was O O
identified O O
. O O

The O O
S B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
typhimurium I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
aspartyl I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
asparaginyl I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
hydroxylase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
homologue I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
designated O O
lpxO B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
was O O
cloned O O
into O O
pBluescriptSK O O
and O O
expressed O O
in O O
Escherichia O O
coli O O
K O O
- O O
12 O O
, O O
which O O
does O O
not O O
contain O O
lpxO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
levels O O
of O O
soluble O O
L B B_GENE
- I I_GENE
selectin I I_GENE
and O O
ICAM B B_GENE
- I I_GENE
1 I I_GENE
in O O
the O O
serum O O
were O O
determined O O
by O O
the O O
ELISA O O
method O O
. O O

The O O
highest O O
TTX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
content O O
is O O
10 O O
. O O
0 O O
microg O O
/ O O
g O O
in O O
N O O
. O O
livescens O O
. O O

On O O
the O O
other O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
hand O I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
hypokalemia O I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
induced O O
by O O
diuretics O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
may O O
also O O
be O O
accompanied O O
by O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
depletion O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
total O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
body O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
K O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
bringing O O
about O O
more O B_DISEASE
general O I_DISEASE
consequences O I_DISEASE
. O O

Glutathione B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
reductase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activities O O
in O O
liver O O
, O O
kidney O O
, O O
lung O O
, O O
and O O
brain O O
were O O
not O O
affected O O
by O O
diet O O
. O O

Here O O
, O O
we O O
describe O O
the O O
nucleotide O O
( O O
nt O O
) O O
sequence O O
and O O
genomic O O
organization O O
of O O
ipiB B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O O
ipiO B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Vancomycin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
tetracycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
eliminated O O
toxin O B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
stools O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
and O O
delayed O O
death O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Soluble O O
fibrin B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monomer O O
complexes O O
in O O
thromboembolism O O

Comparison O O
to O O
the O O
murine O O
homologues O O
of O O
these O O
molecules O O
reveals O O
a O O
high O O
degree O O
of O O
conservation O O
between O O
the O O
products O O
of O O
one O O
of O O
these O O
genes O O
, O O
Fc B B_GENE
gamma I I_GENE
RIIb I I_GENE
, O O
and O O
the O O
murine B B_GENE/B_MEASURE
beta I I_GENE/I_MEASURE
gene I I_GENE/I_MEASURE
in O O
primary O O
sequence O O
, O O
splicing O O
pattern O O
, O O
and O O
tissue O O
distribution O O
. O O

Acidosis O B_DISEASE
provoked O O
by O O
30 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
CO2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
irreversibly O O
increased O O
the O O
BDRT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
however O O
the O O
TRT O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
not O O
changed O O
. O O

Others O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
for O O
example O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
11 O B_MEASURE/B_LOCATION
labeled O O
short O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
chain O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
fatty O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
acids O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
are O O
on O O
the O O
horizon O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O O

The O O
average O B_MEASURE/B_LOCATION
progression O I_MEASURE/I_LOCATION
was O O
11 O B_MEASURE
. O O
6 O B_MEASURE
( O O
SD O B_MEASURE
9 O I_MEASURE
. O O
0 O B_MEASURE
) O O
. O O

80 O B_TIME[MEASURE]/B_GENE
bp O I_TIME[MEASURE]/I_GENE
) O O
surrounding O O
the O O
site O B_LOCATION
of O O
transcription O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
initiation O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Ultrastructure O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
toxin O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
formation O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O O
Cor O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
diphtheriae O B_MEASURE/B_BACTERIUM[BIO]
PW O I_MEASURE/I_BACTERIUM[BIO]
- O O
8 O B_NUMBER[MEASURE]/B_LOCATION
cultured O O
in O O
the O O
presence O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
penicillin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

EMT B B_GENE/B_DISEASE
was O O
localized O O
to O O
chromosome O O
5q31 O O
- O O
32 O O
, O O
a O O
region O O
that O O
contains O O
the O O
genes O O
for O O
several O O
growth O O
factors O O
and O O
receptors O O
as O O
well O O
as O O
early O O
activation O O
genes O O
, O O
particularly O O
those O O
involved O O
in O O
the O O
hematopoietic O O
system O O
. O O

Tbx6 B B_GENE/B_DISEASE
maps O O
to O O
chromosome O O
7 O O
and O O
does O O
not O O
appear O O
to O O
be O O
linked O O
to O O
any O O
known O O
mutation O O
. O O

Kaposi O B_PERSON/B_LOCATION
' O O
s O O
eruptive O B_DISEASE
disease O I_DISEASE
. O O

It O O
is O O
not O O
tested O O
yet O O
, O O
whether O O
the O O
extent O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
glaucoma O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
damage O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
should O O
be O O
better O O
quantified O O
using O O
reference O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
plane O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
1 O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
or O O
2 O B_MEASURE/B_LOCATION
. O O

Importin B B_GENE/B_LOCATION
beta I I_GENE/I_LOCATION
mediates O O
nuclear O O
translocation O O
of O O
Smad B B_GENE
3 I I_GENE
. O O

The O O
encoded O O
protein O O
contains O O
an O O
amino O O
terminal O O
PDZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
domain O O
, O O
followed O O
by O O
a O O
predicted O O
coiled O O
- O O
coil O O
region O O
, O O
a O O
PEST O O
domain O O
, O O
and O O
a O O
carboxy O O
- O O
terminal O O
SAM O O
domain O O
. O O

Using O O
lasers O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
PRK O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
involves O O
reshaping O O
the O O
cornea O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
so O O
that O O
its O O
refractive O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
power O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
is O O
increased O O
. O O

However O O
, O O
sphincter O B_MEASURE/B_PERSON
length O I_MEASURE/I_PERSON
decreased O O
with O O
age O B_MEASURE/B_DISEASE
from O O
24 O B_MEASURE
. O O
3 O B_MEASURE
to O O
14 O B_MEASURE
. O O
8 O B_MEASURE
mm O I_MEASURE
. O O
, O O
maximal O B_MEASURE
urethral O I_MEASURE
pressure O I_MEASURE
from O O
88 O B_MEASURE
. O O
7 O B_MEASURE
to O O
55 O B_MEASURE
cm O I_MEASURE
. O O
water O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
maximal O B_MEASURE
urethral O I_MEASURE
pressure O I_MEASURE
during O O
voluntary O B_TIME[MEASURE]/B_DISEASE
contraction O I_TIME[MEASURE]/I_DISEASE
from O O
221 O B_MEASURE
. O O
4 O B_MEASURE
to O O
166 O B_MEASURE
. O O
3 O B_MEASURE
cm O I_MEASURE
. O O
water O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Several O O
studies O O
have O O
demonstrated O O
that O O
the O O
corticotropin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
releasing I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
test O O
( O O
CRF B B_LOCATION/B_GENE
) O O
is O O
useful O O
for O O
the O O
aetiological O O
diagnosis O O
of O O
Cushing O O
' O O
s O O
syndrome O O
: O O
in O O
Cushing O O
' O O
s O O
disease O O
, O O
as O O
opposed O O
to O O
ectopic O O
ACTH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
secretion O O
syndrome O O
, O O
the O O
hypothalamus O O
- O O
pituitary O O
- O O
adrenal O O
( O O
HPA O O
) O O
axis O O
can O O
still O O
be O O
stimulated O O
by O O
CRF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Transcription O B_GENE
initiation O I_GENE
from O O
this O O
region O B_LOCATION/B_BIO
was O O
also O O
detected O O
in O O
vivo O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
when O O
the O O
cloned O O
rRNA O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cluster O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
a O O
multi O B_NUMBER[MEASURE]/B_ENT
- O O
copy O B_GENE/B_LOCATION
plasmid O I_GENE/I_LOCATION
. O O

The O O
results O O
of O O
the O O
transient O O
- O O
transfection O O
assay O O
showed O O
that O O
the O O
Sp1 B B_GENE/B_LOCATION
binding I I_GENE/I_LOCATION
element I I_GENE/I_LOCATION
located O O
in O O
the O O
core O O
region O O
( O O
positions O O
- O O
- O O
64 O O
to O O
+ O O
1 O O
) O O
of O O
the O O
alpha2 B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
integrin I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
plays O O
an O O
essential O O
role O O
in O O
the O O
alpha2 B B_GENE
- I I_GENE
integrin I I_GENE
promoter I I_GENE
activity O O
and O O
its O O
downregulation O O
by O O
Erb B B_GENE/B_DISEASE
- O O
B2 B B_PROTEIN[GENE]
. O O

Principal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
component O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
using O O
psychosocial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
factors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
women O B_PERSON/B_MEASURE
showed O O
two O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
psychosocial O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
structures O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
i O O
. O O
e O O
. O O
the O O
second O B_SEQUENCE[MEASURE]/B_PERSON
principal O I_SEQUENCE[MEASURE]/I_PERSON
( O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
SOC O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
high O B_DISEASE_ADJECTIVE[DISEASE]
lifestyle O I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stress O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
the O O
4th O B_SEQUENCE[MEASURE]/B_PERSON
principal O I_SEQUENCE[MEASURE]/I_PERSON
components O I_SEQUENCE[MEASURE]/I_PERSON
( O O
high O B_DISEASE_ADJECTIVE[DISEASE]
supernatural O I_DISEASE_ADJECTIVE[DISEASE]
HLC O I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
PHLC O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
) O O
. O O

Expression O O
of O O
FNCAT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increased O O
on O O
serum O O
treatment O O
indicating O O
that O O
the O O
region O O
of O O
the O O
FN B B_GENE
gene I I_GENE
between O O
positions O O
+ O O
69 O O
and O O
- O O
510 O O
bp O O
mediated O O
serum O O
responsiveness O O
. O O

Interaction O O
of O O
the O O
v B B_GENE
- I I_GENE
rel I I_GENE
protein I I_GENE
with O O
an O O
NF B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
kappa I I_GENE/I_LOCATION
B I I_GENE/I_LOCATION
DNA I I_GENE/I_LOCATION
binding I I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
. O O

This O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
not O O
the O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
alterations O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
deposition O B_MEASURE/B_DISEASE
of O O
inhaled O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
particles O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
capsaicin O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
brought O O
about O O
by O O
volume O B_DISEASE
restriction O I_DISEASE
. O O

Providing O O
appropriate O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
care O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
to O O
both O O
sexes O B_PERSON/B_LOCATION
. O O

To O O
test O O
this O O
hypothesis O O
, O O
we O O
developed O O
a O O
system O O
of O O
transient O O
transfection O O
of O O
rat O O
adipocytes O O
with O O
constructs O O
containing O O
glyceraldehyde B B_ENZYME[GENE]
- I I_ENZYME[GENE]
3 I I_ENZYME[GENE]
- I I_ENZYME[GENE]
phosphate I I_ENZYME[GENE]
dehydrogenase I I_ENZYME[GENE]
( O O
GAPDH B B_GENE/B_LOCATION
) O O
and O O
fatty B B_ENZYME[GENE]
acid I I_ENZYME[GENE]
synthetase I I_ENZYME[GENE]
( O O
FAS B B_DISEASE/B_LOCATION
) O O
promoters O O
fused O O
to O O
gene B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
reporter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CAT I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
the O O
green O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
unicellular O I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
alga O I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
Chlamydomonas O I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
eugametos O I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
cellular O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
division O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
is O O
readily O O
synchronized O O
by O O
light O B_COLOR
/ O O
dark O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cycles O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

SHBG B B_GENE
concentrations O O
in O O
women O O
were O O
also O O
significantly O O
higher O O
at O O
T O O
- O O
2 O O
and O O
T O O
- O O
3 O O
when O O
compared O O
to O O
T O O
- O O
1 O O
values O O
. O O

Simvastatin O O
decreased O O
levels O O
of O O
total O O
cholesterol O O
by O O
20 O O
. O O
8 O O
% O O
, O O
LDL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cholesterol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
by O O
29 O O
. O O
7 O O
% O O
, O O
triglycerides O O
by O O
13 O O
. O O
6 O O
% O O
, O O
apolipoprotein B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
B I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
by O O
22 O O
. O O
4 O O
% O O
, O O
alpha O O
- O O
tocopherol O O
by O O
16 O O
. O O
2 O O
% O O
, O O
beta O O
- O O
carotene O O
by O O
19 O O
. O O
5 O O
% O O
, O O
and O O
ubiquinol O O
- O O
10 O O
by O O
22 O O
. O O
0 O O
% O O
( O O
P O O
< O O
. O O
001 O O
for O O
all O O
) O O
and O O
increased O O
levels O O
of O O
HDL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cholesterol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
by O O
7 O O
. O O
0 O O
% O O
( O O
P O O
< O O
. O O
001 O O
) O O
and O O
serum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
insulin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
by O O
13 O O
. O O
2 O O
% O O
( O O
P O O
= O O
. O O
005 O O
) O O
. O O

The O O
more O O
severe O O
the O O
CRF O O
, O O
the O O
more O O
likely O O
that O O
total O O
HDL B B_GENE
and O O
HDL2 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cholesterol I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O O
be O O
low O O
. O O

They O O
are O O
growth O O
- O O
inhibited O O
by O O
TGF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
beta1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

To O O
investigate O O
the O O
in O O
vivo O O
role O O
of O O
this O O
chimeric B B_GENE/B_MEASURE
bZIP I I_GENE/I_MEASURE
protein I I_GENE/I_MEASURE
in O O
oncogenic O O
transformation O O
, O O
its O O
expression O O
was O O
directed O O
to O O
the O O
lymphoid O O
compartments O O
of O O
transgenic O O
mice O O
. O O

This O O
is O O
consistent O O
with O O
the O O
need O O
for O O
a O O
nuclear O O
retinoid B B_GENE
receptor I I_GENE
function O O
in O O
RA O O
- O O
induced O O
ERK2 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O O
. O O

In O O
the O O
virus O O
- O O
infected O O
cells O O
, O O
translation O O
of O O
the O O
M1 B B_GENE
protein I I_GENE
was O O
reduced O O
to O O
10 O O
to O O
20 O O
% O O
of O O
that O O
of O O
the O O
wild O O
- O O
type O O
virus O O
; O O
however O O
, O O
the O O
translation O O
of O O
neither O O
the O O
nucleoprotein O O
nor O O
NS1 B B_GENE/B_BIO
was O O
significantly O O
interfered O O
with O O
, O O
indicating O O
the O O
important O O
role O O
of O O
NS1 B B_GENE/B_BIO
in O O
translational O O
stimulation O O
of O O
the O O
M1 B B_GENE/B_BIO
protein I I_GENE/I_BIO
. O O

Some O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
were O O
excited O O
, O O
others O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
inhibited O O
by O O
, O O
and O O
only O O
some O O
were O O
directionally O O
sensitive O B_DISEASE
to O O
the O O
optomotor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
stimulus O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

LT B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
beta I I_GENE/I_DISEASE
transcription O O
is O O
maximal O O
in O O
the O O
thymic O O
medulla O O
and O O
in O O
splenic O O
white O O
pulp O O
. O O

A O O
novel O O
Cdc42Hs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mutant I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
induces O O
cellular O O
transformation O O
. O O

Interactions O O
were O O
also O O
detected O O
between O O
full O O
- O O
length O O
HSF1 B B_GENE
and O O
the O O
small O O
subunit O O
( O O
gamma O O
) O O
of O O
TFIIA B B_GENE
. O O

We O O
report O O
that O O
Nim1 B B_GENE
possesses O O
intrinsic O O
serine B B_ENZYME[GENE]
- I I_ENZYME[GENE]
kinase I I_ENZYME[GENE]
, O O
threonine B B_ENZYME[GENE]
- I I_ENZYME[GENE]
kinase I I_ENZYME[GENE]
and O O
tyrosine B B_ENZYME[GENE]
- I I_ENZYME[GENE]
kinase I I_ENZYME[GENE]
activities O O
. O O

A O O
short O O
conserved O O
motif O O
is O O
required O O
for O O
repressor O O
domain O O
function O O
in O O
the O O
myeloid O O
- O O
specific O O
transcription O O
factor O O
CCAAT B B_GENE/B_LOCATION
/ I I_GENE/I_LOCATION
enhancer I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
binding I I_GENE/I_LOCATION
protein I I_GENE/I_LOCATION
epsilon I I_GENE/I_LOCATION
. O O

Androgen O B_MEASURE
ablation O I_MEASURE
- O O
- O O
50 O B_TIME[MEASURE]/B_ENT
years O I_TIME[MEASURE]/I_ENT
later O O
. O O

In O O
conclusion O O
, O O
ORCA3 B B_GENE
regulates O O
jasmonate O O
- O O
responsive O O
expression O O
of O O
the O O
Str B B_GENE/B_BIO
gene I I_GENE/I_BIO
via O O
direct O O
interaction O O
with O O
the O O
JERE O O
. O O

Also O O
, O O
the O O
absence O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
PdNi O B_LOCATION/B_BIO
between O O
the O O
segments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
reduces O O
the O O
heat O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
production O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
seed O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O O

Theoretical O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hyperuricemia O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

ORF3 O O
encodes O O
a O O
putative O O
periplasmic B B_ENZYME[GENE]
c I I_ENZYME[GENE]
- I I_ENZYME[GENE]
type I I_ENZYME[GENE]
cytochrome I I_ENZYME[GENE]
with O O
a O O
molecular O O
mass O O
of O O
94 O O
, O O
000 O O
Da O O
and O O
contains O O
seven O O
c O O
- O O
heme O O
- O O
binding O O
motifs O O
but O O
shows O O
no O O
sequence O O
homology O O
to O O
occ B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
ORF1 O O
. O O

Doxazosin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
produced O O
increases O B_DISEASE_ADJECTIVE[DISEASE]
in O O
both O O
mean O B_MEASURE
and O O
maximum O B_MEASURE/B_LOCATION
urinary O I_MEASURE/I_LOCATION
flow O I_MEASURE/I_LOCATION
rates O I_MEASURE/I_LOCATION
of O O
1 O B_MEASURE
. O O
01 O B_MEASURE/B_PERSON
ml O I_MEASURE/I_PERSON
/ O O
s O B_OTHER/B_MEASURE
and O O
3 O B_MEASURE
. O O
2 O B_MEASURE
ml O I_MEASURE
/ O O
s O B_OTHER/B_MEASURE
respectively O O
, O O
compared O O
with O O
0 O B_MEASURE
. O O
21 O B_MEASURE
ml O I_MEASURE
/ O O
s O B_OTHER/B_MEASURE
and O O
2 O B_MEASURE
. O O
2 O B_MEASURE
ml O I_MEASURE
/ O O
s O B_TIME[MEASURE]/B_DISEASE
on O O
placebo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Hypoxia O B_DISEASE/B_PROTEIN[GENE]
decreased O O
the O O
rate O B_MEASURE
of O O
spontaneous O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
impulse O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
initiation O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
SA O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
nodal O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
fibers O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
by O O
decreasing O O
the O O
slope O B_MEASURE
of O O
diastolic O B_DISEASE
depolarization O I_DISEASE
. O O

BACKGROUND O O
- O O
- O O
Platelet B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activating I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PAF B B_LOCATION/B_GENE
) O O
has O O
been O O
implicated O O
in O O
the O O
pathogenesis O O
of O O
airway O O
hyperresponsiveness O O
in O O
asthma O O
. O O

TFEC B B_GENE/B_BIO
RNA I I_GENE/I_BIO
is O O
found O O
in O O
many O O
tissues O O
of O O
adult O O
rats O O
, O O
but O O
the O O
relative O O
concentrations O O
of O O
TFEC B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
TFE3 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNAs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
vary O O
considerably O O
in O O
these O O
different O O
tissues O O
. O O

Our O O
results O O
show O O
that O O
unlike O O
the O O
case O O
for O O
sos1 B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
sos2 B B_GENE/B_PERSON
gene I I_GENE/I_PERSON
function O O
is O O
dispensable O O
for O O
normal O O
mouse O O
development O O
, O O
growth O O
, O O
and O O
fertility O O
. O O

Studies O O
of O O
HS2 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
gamma I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
gene I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
reporter I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
constructs I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
carrying O O
CACCC O O
box O O
deletions O O
revealed O O
that O O
the O O
CACCC O O
box O O
sequence O O
of O O
the O O
gamma O O
gene O O
promoter O O
mediates O O
the O O
activation O O
of O O
the O O
gamma O O
gene O O
by O O
FKLF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Advisory O B_PERSON/B_LOCATION
Committee O I_PERSON/I_LOCATION
report O I_PERSON/I_LOCATION
recommends O O
that O O
US O O
make O O
amends O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O O
human O B_LOCATION
radiation O I_LOCATION
experiments O I_LOCATION
. O O

Animals O B_BIO/B_PERSON
were O O
divided O O
into O O
six O B_LOCATION/B_ORGANIZATION
equal O I_LOCATION/I_ORGANIZATION
groups O I_LOCATION/I_ORGANIZATION
as O O
follows O O
: O O
( O O
1 O B_SEQUENCE[MEASURE]/B_LOCATION
) O O
no O O
oral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
water O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
no O O
hemodilution O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
no O O
IV O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
saline O O
) O O
; O O
( O O
2 O B_SEQUENCE[MEASURE]/B_PERSON
) O O
oral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
water O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
hemodilution O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
IV O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
saline O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
; O O
( O O
3 O B_SEQUENCE[MEASURE]/B_LOCATION
) O O
oral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
water O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
no O O
hemodilution O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
IV O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
propranolol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
; O O
( O O
4 O B_NUMBER[MEASURE]/B_LOCATION
) O O
oral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
water O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
hemodilution O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
IV O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
propranolol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
; O O
( O O
5 O B_NUMBER[MEASURE]/B_LOCATION
) O O
oral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
propranolol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
no O O
hemodilution O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
IV O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
saline O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
and O O
( O O
6 O B_NUMBER[MEASURE]
) O O
oral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
propranolol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
hemodilution O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
IV O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
saline O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

First O O
, O O
a O O
GATA B B_GENE
- I I_GENE
1 I I_GENE
motif I I_GENE
was O O
found O O
to O O
bind O O
nuclear O O
factor O O
( O O
s O O
) O O
, O O
presumably O O
the O O
GATA B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
1 I I_GENE/I_MEASURE
factor I I_GENE/I_MEASURE
, O O
present O O
in O O
K O O
- O O
562 O O
cell O O
extracts O O
and O O
in O O
living O O
K O O
- O O
562 O O
cells O O
. O O

BPN O B_DISEASE
can O O
be O O
experimentally O O
produced O O
by O O
intratracheal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
inoculation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
microorganisms O B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
high O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
concentrations O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
ventilator O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_SPECIES[BIO]
- O O
associated O O
BPN O B_DISEASE/B_BIO
by O O
ventilating O O
baboons O B_PERSON/B_BIO
with O O
oleic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
acid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lung O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
injury O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
mouth O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
asymmetry O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Additionally O O
, O O
these O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
implications O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
understanding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
mechanisms O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
HIV O B_DISEASE/B_VIRUS[BIO]
- O O
1 O B_MEASURE/B_DISEASE
latency O B_MEASURE/I_DISEASE
and O O
reactivation O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
. O O

This O O
inhibition O O
was O O
due O O
to O O
competition O O
from O O
the O O
EMC O O
virus O O
IRES O O
present O O
in O O
pEP B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
2A I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
transcripts I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
as O O
well O O
as O O
the O O
expression O O
of O O
proteolytically O O
active O O
2Apro B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Some O O
may O O
affect O O
the O O
folding O O
pathway O O
or O O
the O O
affinity O O
for O O
chaperonins B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

Diet O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
imbalances O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
aflatoxicosis O B_DISEASE

48 O O
. O O
35 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
5 O B_MEASURE
. O O
07 O B_MEASURE/B_PERSON
mg O I_MEASURE/I_PERSON
/ O O
l O B_OTHER/B_MEASURE
in O O
R3 O B_LOCATION/B_PERSON
; O O
p O O
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
and O O
in O O
the O O
AUC O B_MEASURE
( O O
0 O B_MEASURE
. O O
50 O B_MEASURE
h O O
) O O
( O O
1429 O B_MEASURE
. O O
92 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
284 O B_MEASURE
. O O
23 O B_MEASURE
in O O
PR O B_MEASURE/B_PROTEIN[GENE]
vs O I_MEASURE/I_PROTEIN[GENE]
. O O

The O O
effect O O
on O O
FIV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
of O O
progressively O O
deleting O O
these O O
nuclear O O
factor O O
binding O O
sites O O
was O O
examined O O
by O O
linking O O
LTR O O
deletion O O
mutants O O
to O O
the O O
chloramphenicol B B_ENZYME[GENE]
acetyltransferase I I_ENZYME[GENE]
( O O
CAT B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
gene O O
. O O

A O O
series O O
of O O
sequence O O
fragments O O
were O O
placed O O
5 O O
' O O
to O O
the O O
chloramphenicol B B_ENZYME[GENE]
acetyltransferase I I_ENZYME[GENE]
( O O
CAT B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
reporter O O
gene O O
and O O
ability O O
to O O
mediate O O
transcription O O
of O O
CAT B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
response O O
to O O
IFN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
gamma I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
or O O
LPS O O
treatment O O
was O O
studied O O
following O O
transient O O
transfection O O
in O O
the O O
macrophage O O
- O O
like O O
cell O O
line O O
RAW O O
264 O O
. O O
7 O O
. O O

As O O
part O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
large O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Dutch O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
prospective O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
multicenter O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
Netherlands O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Cooperative O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
on O O
the O O
Adequacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Dialysis O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
2 O B_NUMBER[MEASURE]
) O O
, O O
we O O
consecutively O O
included O O
all O O
new O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
with O O
end O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
stage O B_DISEASE/B_LOCATION
renal O I_DISEASE/I_LOCATION
disease O I_DISEASE/I_LOCATION
for O O
whom O O
residual O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
renal O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
be O O
obtained O O
0 O B_NUMBER[MEASURE]/B_LOCATION
to O O
4 O B_MEASURE/B_ENT
weeks O I_MEASURE/I_ENT
before O O
the O O
start O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
dialysis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Module O O
2 O O
of O O
RifA B B_SPECIES[BIO]/B_LOCATION
lacks O O
a O O
beta B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
ketoacyl I I_GENE/I_MEASURE
: I I_GENE/I_MEASURE
acyl I I_GENE/I_MEASURE
carrier I I_GENE/I_MEASURE
protein I I_GENE/I_MEASURE
reductase I I_GENE/I_MEASURE
( O O
KR B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
domain O O
and O O
the O O
one O O
in O O
module O O
3 O O
has O O
an O O
apparently O O
inactive O O
NADPH B B_LOCATION/B_MEASURE
binding I I_LOCATION/I_MEASURE
motif I I_LOCATION/I_MEASURE
, O O
similar O O
to O O
one O O
found O O
in O O
the O O
Er B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
PKS I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
while O O
the O O
other O O
eight O O
KR B B_LOCATION/B_PERSON
domains I I_LOCATION/I_PERSON
of O O
the O O
Rf B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
PKS I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
should O O
be O O
functional O O
. O O

In O O
murine O O
cells O O
, O O
FPGS B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
is O O
controlled O O
by O O
two O O
promoters O O
that O O
, O O
as O O
we O O
show O O
here O O
, O O
vary O O
substantially O O
in O O
their O O
efficiency O O
, O O
at O O
least O O
in O O
the O O
context O O
of O O
a O O
reporter O O
gene O O
assay O O
. O O

Should O O
we O O
use O O
thiazide O O
diuretics O O
in O O
hypertensive O O
patients O O
with O O
non O O
- O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
dependent O O
diabetes O O
mellitus O O
? O O

Reduced O O
glutathione O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
whole O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
blood O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
decreases O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
within O O
a O O
blood O B_MEASURE/B_LOCATION
Se O I_MEASURE/I_LOCATION
range O I_MEASURE/I_LOCATION
of O O
1 O B_MEASURE
. O O
01 O B_MEASURE
to O O
2 O B_MEASURE
. O O
28 O B_MEASURE
micrograms O I_MEASURE
in O O
the O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
Se O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
area O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Sucrose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O O
in O O
source O B_BIO
leaves O I_BIO
is O O
the O O
predominant O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
carbon O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
source O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
developing O O
sink O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
tissues O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
in O O
most O B_BIO
higher O I_BIO
plants O I_BIO
. O O

A O O
personal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
view O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
future O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trends O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
field O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
immunoassay O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
concludes O O
this O O
review O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O O

In O O
accordance O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
Ann O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Arbor O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
classification O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
we O O
observed O O
12 O B_MEASURE
CS O I_MEASURE
IA O I_MEASURE
( O O
21 O B_MEASURE
. O O
3 O B_MEASURE
% O I_MEASURE
) O O
, O O
2 O B_PROTEIN[GENE]/B_LOCATION
CS O I_PROTEIN[GENE]/I_LOCATION
IB O I_PROTEIN[GENE]/I_LOCATION
( O O
3 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
) O O
, O O
14 O B_PROTEIN[GENE]/B_LOCATION
CS O I_PROTEIN[GENE]/I_LOCATION
IIA O I_PROTEIN[GENE]/I_LOCATION
( O O
25 O B_MEASURE
. O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
and O O
27 O B_LOCATION/B_PERSON
CS O I_LOCATION/I_PERSON
IIB O I_LOCATION/I_PERSON
( O O
49 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
. O O

Numerous O B_MEASURE/B_PERSON
genes O B_MEASURE/I_PERSON
of O O
this O O
family O B_PERSON/B_BIO
have O O
been O O
identified O O
in O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
with O O
the O O
largest O B_MEASURE
number O I_MEASURE
found O O
in O O
vertebrates O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
GST B B_GENE/B_BIO
- O O
CBL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
LZIP B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fusion O O
protein O O
contains O O
a O O
binding O O
site O O
for O O
the O O
SH2 B B_PROTEIN[GENE]
domain I I_PROTEIN[GENE]
of O O
the O O
p85 B B_ENZYME[GENE]/B_PERSON
subunit I I_ENZYME[GENE]/I_PERSON
of O O
phosphatidylinositol B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
mapped O O
to O O
Tyr731 O O
, O O
which O O
is O O
present O O
in O O
the O O
sequence O O
YEAM O O
. O O

We O O
have O O
previously O O
shown O O
that O O
UNC B B_GENE
- I I_GENE
4 I I_GENE
expression O O
in O O
the O O
VA O O
motor O O
neurons O O
specifies O O
the O O
wild O O
- O O
type O O
pattern O O
of O O
presynaptic O O
input O O
. O O

Significant O O
differences O O
were O O
observed O O
in O O
the O O
composition O O
of O O
nuclear O O
transcription O O
factors O O
bound O O
to O O
cis O O
- O O
elements O O
within O O
the O O
LDH B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proximal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
somatic O O
versus O O
germ O O
cells O O
. O O

Above O O
this O O
transition O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
temperature O O
the O O
calcium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
antagonist O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
lowers O O
fm O B_LOCATION/B_DISEASE
more O O
pronouncedly O O
than O O
below O O
. O O

( O O
1986 O O
) O O
described O O
optic O B_DISEASE
nerve O I_DISEASE
degenerations O I_DISEASE
in O O
patients O B_PERSON/B_BIO
with O O
Alzheimer O B_DISEASE
' O I_DISEASE
s O I_DISEASE
disease O I_DISEASE
and O O
Sadun O B_PERSON/B_TIME[MEASURE]
published O O
a O O
dropout O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
retinal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ganglion O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
range O O
from O O
30 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
to O O
60 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
. O O

It O O
has O O
become O O
clear O O
that O O
there O O
is O O
not O O
one O O
mediator O O
responsible O O
for O O
ALI O O
, O O
but O O
rather O O
a O O
complex O O
interplay O O
exists O O
between O O
diverse O O
proinflammatory O O
( O O
e O O
. O O
g O O
. O O
, O O
lipopolysaccharide O O
, O O
complement O O
products O O
, O O
cytocains O O
, O O
chemocains O O
, O O
reactive O O
oxygen O O
species O O
and O O
arachidonic O O
acid O O
products O O
) O O
and O O
anti O O
- O O
inflammatory O O
( O O
IL B B_GENE
- I I_GENE
10 I I_GENE
, O O
IL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
PGI2 O O
) O O
mediators O O
. O O

We O O
then O O
supplemented O O
these O O
spliceosomes O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
purified O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
proteins O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
or O O
yeast O B_BIO/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
extract O O
fractions O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
as O O
a O O
functional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
second O B_NUMBER[MEASURE]/B_LOCATION
- O O
step O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splicing O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Contrast O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
radiography O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appears O O
to O O
be O O
an O O
especially O O
inaccurate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
document O O
PUD O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
CF O B_LOCATION/B_DISEASE
because O O
the O O
duodenal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
mucosa O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
typically O O
appears O O
nodular O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
distorted O O
with O O
poor O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
definition O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
mucosal O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
folds O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

We O O
now O O
show O O
that O O
the O O
FRAP B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ser2035 O O
- O O
- O O
> O O
Ala O O
mutant O O
displays O O
similar O O
binding O O
affinity O O
when O O
compared O O
with O O
the O O
wild O O
- O O
type O O
protein O O
, O O
whereas O O
all O O
other O O
mutations O O
at O O
this O O
site O O
, O O
including O O
mimics O O
of O O
phosphoserine O O
, O O
abolish O O
binding O O
, O O
presumably O O
due O O
to O O
either O O
unfavorable O O
steric O O
interactions O O
or O O
induced O O
conformational O O
changes O O
. O O

A O O
Brassica O O
cDNA O O
clone O O
encoding O O
a O O
bifunctional O O
hydroxymethylpyrimidine B B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I B_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
thiamin B B_ENZYME[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphate I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pyrophosphorylase I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involved O O
in O O
thiamin O O
biosynthesis O O
. O O

Titres O O
of O O
antistreptolysin B B_VIRUS[BIO]/B_DISEASE
O I B_VIRUS[BIO]/I_DISEASE
in O O
mothers O O
of O O
children O O
affected O O
with O O
Down O O
' O O
s O O
syndrome O O
. O O

Differential O O
decay O O
of O O
a O O
polycistronic O O
Escherichia O O
coli O O
transcript O O
is O O
initiated O O
by O O
RNaseE B B_GENE/B_BIO
- O O
dependent O O
endonucleolytic O O
processing O O
. O O

Defects O O
in O O
RT6 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
coincide O O
with O O
increased O O
susceptibility O O
in O O
animal O O
models O O
for O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
dependent O O
diabetes O O
mellitus O O
and O O
other O O
autoimmune O O
diseases O O
. O O

By O O
means O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
early O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
detection O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O O
correction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
possible O B_DISEASE_ADJECTIVE[DISEASE]
causes O I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
goal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
of O O
increasing O O
therapeutic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
can O O
be O O
achieved O O
. O O

We O O
have O O
previously O O
described O O
the O O
partial O O
purification O O
of O O
Ap4A B B_GENE
hydrolase I I_GENE
from O O
S O O
. O O
pombe O O
[ O O
Robinson O O
, O O
de O O
la O O
Pena O O
and O O
Barnes O O
( O O
1993 O O
) O O
Biochim O O
. O O

Effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
new O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
positive O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
inotropic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
agent O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
OPC O B_LOCATION/B_PROTEIN[GENE]
- O O
8212 O B_NUMBER[MEASURE]/B_LOCATION
) O O
on O O
intracellular O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potential O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
isolated O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
canine O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
ventricular O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
papillary O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
muscle O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]

The O O
unc B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
101 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
sli B B_MEASURE/B_GENE
- I I_MEASURE/I_GENE
1 I I_MEASURE/I_GENE
, O O
and O O
rok B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
1 I I_GENE/I_MEASURE
genes I I_GENE/I_MEASURE
encode O O
a O O
distinct O O
set O O
of O O
negative O O
regulators O O
of O O
vulval O O
differentiation O O
. O O

Thirty O B_NUMBER[MEASURE]
- O O
seven O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
with O O
severe O B_DISEASE/B_LOCATION
temporal O I_DISEASE/I_LOCATION
lobe O I_DISEASE/I_LOCATION
epilepsy O I_DISEASE/I_LOCATION
were O O
studied O O
interictally O O
with O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
18F O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
fluorodeoxyglucose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O O
PET O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
each O O
of O O
three O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions O I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
resting O O
, O O
during O O
emotional O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
speech O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
while O O
performing O O
a O O
visual O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
recognition O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
task O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

SYC1 B B_PROTEIN[GENE]/B_DISEASE
( O O
suppressor B B_PROTEIN[GENE]
of I I_PROTEIN[GENE]
yeast I I_PROTEIN[GENE]
cbf5 I I_PROTEIN[GENE]
- I I_PROTEIN[GENE]
1 I I_PROTEIN[GENE]
) O O
was O O
identified O O
as O O
a O O
multicopy O O
suppressor O O
of O O
cbf5 B B_GENE/B_SPECIES[BIO]
- I B_GENE/I_SPECIES[BIO]
1 I B_GENE/I_SPECIES[BIO]
and O O
subsequently O O
was O O
found O O
to O O
be O O
identical O O
to O O
RRN3 B B_GENE
, O O
an O O
RNA B B_GENE/B_TIME[MEASURE]
polymerase I I_GENE/I_TIME[MEASURE]
I I I_GENE/I_TIME[MEASURE]
transcription I I_GENE/I_TIME[MEASURE]
factor I I_GENE/I_TIME[MEASURE]
. O O

Newly O O
hatched O O
F1 O B_PERSON/B_ENT
nymphs O I_PERSON/I_ENT
of O O
Aiolopus O B_BIO
thalassinus O I_BIO
( O O
Fabr O B_PERSON/B_DISEASE
. O O
) O O
were O O
fed O O
on O O
food O B_BIO/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treated O O
with O O
various O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
concentrations O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
HgCl2 O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
CdCl2 O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
and O O
PbCl2 O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
until O O
the O O
end O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
adult O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
life O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Neuronal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
58 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dopaminergic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
DA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
and O O
200 O B_MEASURE/B_PROTEIN[GENE]
non O B_MEASURE/I_PROTEIN[GENE]
- O O
dopaminergic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
non O B_DISEASE/B_LOCATION
- O O
DA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
in O O
the O O
ventral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tegmental O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
area O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
VTA O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
of O O
female O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
monkeys O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
recorded O O
, O O
and O O
correlation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
bar O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
press O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
feeding O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
sensory O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
and O O
change O B_DISEASE_ADJECTIVE[DISEASE]
in O O
motivation O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
investigated O O
. O O

Both O O
sequence O O
analysis O O
and O O
restriction O O
fragment O O
length O O
polymorphism O O
analysis O O
revealed O O
a O O
high O O
degree O O
of O O
sequence O O
( O O
97 O O
% O O
homology O O
) O O
and O O
structural O O
similarity O O
among O O
members O O
of O O
the O O
ART B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
CH B B_GENE/B_DISEASE
family O O
, O O
indicating O O
their O O
common O O
origin O O
and O O
recent O O
penetration O O
into O O
chicken O O
DNA O O
. O O

Three O B_NUMBER[MEASURE]/B_PERSON
of O O
these O O
positions O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O O
novel O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
that O O
they O O
had O O
not O O
been O O
identified O O
to O O
be O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
binding O O
PC O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
previous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
crystallographic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
analysis O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

We O O
demonstrate O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
2 O B_MEASURE
- O O
deoxyglucose O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
uptake O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
isolated O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
primary O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
rat O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
adipocytes O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
3T3 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
- O O
L1 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
adipocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
pretreated O O
with O O
U73122 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

The O O
elevated O O
levels O O
of O O
inositol O O
phosphates O O
resulting O O
from O O
N B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
epi I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
qQ209L I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
were O O
similar O O
to O O
those O O
obtained O O
with O O
carbachol O O
activation O O
of O O
the O O
M1 B B_GENE/B_LOCATION
muscarinic I I_GENE/I_LOCATION
acetylcholine I I_GENE/I_LOCATION
receptor I I_GENE/I_LOCATION
. O O

In O O
addition O O
, O O
wild O O
- O O
type O O
and O O
mutated O O
DNA O O
templates O O
were O O
used O O
as O O
probes O O
in O O
DNase B B_GENE
I I I_GENE
protection O O
experiments O O
to O O
determine O O
sites O O
of O O
protein O O
- O O
DNA O O
interaction O O
. O O

We O O
tested O O
the O O
hypothesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
PEH O B_DISEASE
is O O
associated O O
with O O
reductions O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
TPR O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
sympathetic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
nerve O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
activity O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
SNA O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Salt O B_ENT/B_DISEASE_ADJECTIVE[DISEASE]
wars O I_ENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

RESULTS O O
: O O
BMK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
other O O
19 O O
contents O O
significantly O O
decreased O O
depolarization O O
parameters O O
Vmax O O
, O O
APA O O
, O O
OS O O
, O O
and O O
MDP O O
, O O
which O O
was O O
similar O O
to O O
that O O
of O O
TTX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
different O O
from O O
that O O
of O O
Nim O O
and O O
BaCl2 O O
. O O

In O O
the O O
latter O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
the O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
adjacent O B_BODY_PART_OR_ORGAN_COMPONENT
matrix O I_BODY_PART_OR_ORGAN_COMPONENT
had O O
several O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
characteristics O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
fibrocartilage O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
including O O
chondrocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O O

Mannich O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
bases O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BIO
of O O
vanillin O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxime O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

All O O
exon O B_GENE/B_DISEASE
/ O O
intron O B_GENE/B_LOCATION
splice O I_GENE/I_LOCATION
junctions O I_GENE/I_LOCATION
follow O O
the O O
GT O B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
AG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
rule O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
. O O

Previous O O
work O O
has O O
shown O O
that O O
glucose O O
repression O O
of O O
PRB1 B B_GENE
transcription O O
is O O
not O O
mediated O O
by O O
HXK2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
by O O
the O O
SNF1 B B_GENE/B_DISEASE
, O O
SNF4 B B_GENE/B_DISEASE
, O O
and O O
SNF6 B B_GENE
genes I I_GENE
( O O
C O O
. O O

Comparison O O
of O O
the O O
encoded O O
ERCC3Dm B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
the O O
homologous O O
proteins O O
of O O
mouse O O
and O O
man O O
shows O O
a O O
strong O O
amino O O
acid O O
conservation O O
( O O
71 O O
% O O
identity O O
) O O
, O O
especially O O
in O O
the O O
postulated O O
DNA O O
binding O O
region O O
and O O
seven O O
' B B_GENE/B_LOCATION
helicase I B_GENE/I_LOCATION
' I B_GENE/I_LOCATION
domains I B_GENE/I_LOCATION
. O O

The O O
pyridostigmine O O
inhibited O O
AChE B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
recovered O O
only O O
in O O
the O O
100 O O
mumol O O
kg O O
- O O
1 O O
kg O O
oxime O O
groups O O
at O O
the O O
end O O
of O O
the O O
experiment O O
. O O

In O O
the O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
moderate O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
buccal O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
Class O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
II O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
tendency O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O O
55 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
of O O
the O O
molars O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
in O O
a O O
Class O B_MEASURE/B_PERSON
I O O
relationship O B_PERSON/B_MEASURE
when O O
evaluated O O
from O O
the O O
lingual O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
side O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
, O O
whereas O O
45 O B_PERSON/B_NUMBER[MEASURE]
% O B_PERSON/I_NUMBER[MEASURE]
belonged O O
to O O
mild O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
1st O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
degrees O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
) O O
Class O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
molar O B_DISEASE
rotations O I_DISEASE
present O O
in O O
81 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
of O O
the O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Mutation O O
of O O
this O O
threonine O O
to O O
isoleucine O O
had O O
no O O
observable O O
effect O O
on O O
either O O
nuclear O O
localization O O
of O O
E1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
DNA O O
replication O O
of O O
the O O
intact O O
viral O O
genome O O
. O O

Serum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
prolactin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
oestradiol O O
levels O O
at O O
different O O
stages O O
of O O
puberty O O
. O O

This O O
suggests O O
that O O
the O O
duration O B_MEASURE
of O O
varicocele O B_DISEASE/B_BACTERIUM[BIO]
per O O
se O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
could O O
affect O O
DHT O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seminal O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plasma O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Left O O
ventricular O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
responses O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O O
dopamine O O
in O O
dilated O B_DISEASE/B_PERSON
cardiomyopathy O I_DISEASE/I_PERSON
as O O
assessed O O
by O O
two O B_NUMBER[MEASURE]
- O O
dimensional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
echocardiography O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
compared O O
with O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
thallium O B_MEASURE/B_DISEASE
- O O
201 O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
scintigraphy O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Detailed O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comparison O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
urinary O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
excretion O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
purines O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
in O O
a O O
patient O B_PERSON
with O O
the O O
Lesch O B_PERSON
- O O
Nyhan O B_DISEASE/B_GENE
syndrome O I_DISEASE/I_GENE
and O O
a O O
control O B_PERSON
subject O I_PERSON
. O O

This O O
enzyme O O
is O O
distinct O O
from O O
other O O
known O O
E3s B B_GENE/B_BIO
, O O
including O O
E3 B B_GENE
alpha I I_GENE
/ O O
UBR1 B B_PROTEIN[GENE]
, O O
E3 B B_GENE
beta I I_GENE
, O O
and O O
E6 B B_GENE
- I I_GENE
AP I I_GENE
. O O

This O O
evidence O O
, O O
together O O
with O O
the O O
ability O O
of O O
a O O
carboxyl O O
- O O
terminal O O
coding O O
sequence O O
starting O O
from O O
the O O
BamHI B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
complement O O
a O O
shy1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutant I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
suggests O O
that O O
the O O
Shy1p B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contains O O
two O O
domains O O
that O O
can O O
be O O
separately O O
expressed O O
to O O
form O O
a O O
functional O O
protein O O
. O O

The O O
zinc B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
finger I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
A20 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
tumor B B_DISEASE/B_GENE
necrosis I B_DISEASE/I_GENE
factor I B_DISEASE/I_GENE
( O O
TNF B B_GENE/B_LOCATION
) O O
- O O
and O O
interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IL B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
) O O
- O O
inducible O O
protein O O
that O O
negatively O O
regulates O O
nuclear B B_GENE
factor I I_GENE
- I I_GENE
kappa I I_GENE
B I I_GENE
( O O
NF B B_GENE
- I I_GENE
kappaB I I_GENE
) O O
- O O
dependent O O
gene O O
expression O O
. O O

A O O
visibly O O
distinct O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
muscular O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
hypertrophy O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
mh O B_DISEASE/B_LOCATION
) O O
, O O
commonly O O
known O O
as O O
double O B_DISEASE/B_LOCATION
muscling O I_DISEASE/I_LOCATION
, O O
occurs O O
with O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
frequency O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O O
the O O
Belgian O B_PERSON/B_LOCATION
Blue O I_PERSON/I_LOCATION
and O O
Piedmontese O B_COLOR/B_PERSON
cattle O I_COLOR/I_PERSON
breeds O I_COLOR/I_PERSON
. O O

For O O
the O O
population O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
patients O B_PERSON/B_BIO
with O O
melanoma O B_DISEASE/B_LOCATION
levels O I_DISEASE/I_LOCATION
III O I_DISEASE/I_LOCATION
and O O
IV O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
significant O I_NUMBER[MEASURE]/I_PROTEIN[GENE]
differences O I_NUMBER[MEASURE]/I_PROTEIN[GENE]
in O O
survival O B_MEASURE/B_DISEASE
rate O I_MEASURE/I_DISEASE
were O O
associated O O
with O O
thickness O B_MEASURE/B_LOCATION
( O O
less O B_MEASURE
than O O
2 O B_MEASURE/B_LOCATION
mm O I_MEASURE/I_LOCATION
or O O
greater O B_MEASURE
than O O
or O O
equal O B_MEASURE
to O O
2 O B_MEASURE/B_LOCATION
mm O I_MEASURE/I_LOCATION
; O O
p O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE
, O O
001 O B_MEASURE
) O O
, O O
though O O
not O O
with O O
level O B_MEASURE/B_DISEASE
. O O

At O O
least O O
one O O
such O O
complex O O
is O O
eliminated O O
by O O
preincubating O O
the O O
nuclear O O
extract O O
with O O
an O O
antibody O O
with O O
broad O O
cross O O
- O O
reactivity O O
with O O
Ets B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
Ets B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
thus O O
confirming O O
that O O
an O O
ETS B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
s I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
recognizes O O
the O O
- O O
12 O O
motif O O
. O O

Mutant O O
beta2 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
adrenergic I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
receptors I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
with O O
a O O
Tyr O O
- O O
to O O
- O O
Phe O O
substitution O O
at O O
Tyr O O
- O O
350 O O
do O O
not O O
display O O
agonist O O
- O O
induced O O
desensitization O O
, O O
Src B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
recruitment O O
, O O
or O O
Src B B_GENE
activation O O
. O O

Role O O
of O O
distinct O O
mitogen B B_GENE
- I I_GENE
activated I I_GENE
protein I I_GENE
kinase I I_GENE
pathways O O
and O O
cooperation O O
between O O
Ets B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
ATF B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
2 I I_GENE/I_LOCATION
, O O
and O O
Jun B B_GENE
family I I_GENE
members I I_GENE
in O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
urokinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
plasminogen I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
induction O O
by O O
interleukin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
tetradecanoyl O O
phorbol O O
acetate O O
. O O

Immunoblot O O
analysis O O
of O O
purified O O
and O O
protease O O
- O O
digested O O
intracellular O O
mature O O
virus O O
( O O
IMV O O
) O O
and O O
extracellular O O
enveloped O O
virus O O
( O O
EEV O O
) O O
showed O O
that O O
the O O
A36R B B_GENE
proteins I I_GENE
were O O
present O O
on O O
the O O
surface O O
of O O
EEV O O
with O O
type O O
II O O
membrane O O
topology O O
, O O
but O O
were O O
absent O O
from O O
IMV O O
. O O

Here O O
we O O
demonstrate O O
that O O
several O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
associated O O
with O O
NHEJ O B_GENE/B_DISEASE
perform O O
essential O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
functions O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O O
the O O
repair O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
of O O
endonuclease O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
DSBs O B_DISEASE/B_GENE
in O O
vivo O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
failure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
suggests O O
that O O
these O O
assembly O B_DISEASE_ADJECTIVE[DISEASE]
competent O I_DISEASE_ADJECTIVE[DISEASE]
but O O
complementation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
- O O
negative O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
alpha O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
mutants O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
lack O O
an O O
as O O
yet O O
unidentified O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
s O O
) O O
. O O

Psychopathological O B_DISEASE_ADJECTIVE[DISEASE]/B_EDU[ORGANIZATION]
, O O
vegetative O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
vital O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
parameters O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
assessed O O
every O O
hour O B_TIME[MEASURE]/B_ENT
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Considering O O
an O O
inulin O B_MEASURE
clearance O I_MEASURE
of O O
less O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
80 O B_MEASURE
ml O I_MEASURE
/ O O
min O B_TIME[MEASURE]/B_PERSON
/ O O
1 O B_MEASURE
. O O
73 O B_MEASURE
m2 O I_MEASURE
, O O
the O O
cut O O
- O O
off O O
value O B_MEASURE/B_LOCATION
for O O
serum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
creatinine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
11 O B_MEASURE
. O O
5 O B_MEASURE/B_PERSON
mumol O I_MEASURE/I_PERSON
/ O O
liter O B_MEASURE/B_PERSON
for O O
men O B_PERSON
and O O
90 O B_MEASURE/B_PERSON
mumol O I_MEASURE/I_PERSON
/ O O
liter O B_MEASURE/B_PERSON
for O O
women O B_PERSON/B_BIO
. O O

These O O
data O O
may O O
indicate O O
redundancy O O
between O O
members O O
of O O
the O O
NGFI B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
Nurr1 B B_GENE
/ O O
Nor1 B B_GENE
subfamily O O
and O O
could O O
explain O O
why O O
no O O
phenotypic O O
disturbances O O
have O O
yet O O
been O O
found O O
in O O
mice O O
in O O
which O O
the O O
NGFI B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
been O O
inactivated O O
. O O

Manual O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sample O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clean O O
- O O
up O O
procedures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
well O O
as O O
the O O
addition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O O
an O O
internal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
standard O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
not O O
needed O O
. O O

To O O
directly O O
address O O
this O O
issue O O
, O O
we O O
used O O
a O O
tetracycline O O
- O O
regulated O O
system O O
in O O
human O O
U2OS O O
osteosarcoma O O
cells O O
and O O
thus O O
found O O
that O O
BCL6 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediates O O
growth O O
suppression O O
associated O O
with O O
impaired O O
S O O
phase O O
progression O O
and O O
apoptosis O O
. O O

TAAG O B_GENE/B_LOCATION
sites O I_GENE/I_LOCATION
that O O
serve O O
as O O
functional O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
late O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promoters O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
OpMNPV O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
were O O
found O O
to O O
mediate O O
transcription O B_GENE_EXPRESSION_ADJECTIVE[GENE]
initiation O I_GENE_EXPRESSION_ADJECTIVE[GENE]
at O O
only O O
basal O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
levels O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
context O B_LOCATION/B_MEASURE
of O O
the O O
AcMNPV O B_GENE/B_BIO
genome O I_GENE/I_BIO
, O O
suggesting O O
that O O
late O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
promoter O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
activation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
may O O
be O O
virus O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specific O I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O O
the O O
family O B_BIO
Baculoviridae O I_BIO
. O O

Stability O O
of O O
125 O O
I O O
- O O
labeled O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
used O O
in O O
radioimmunoassay O O
of O O
insulin B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
absence O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
i O O
. O O
m O B_DISEASE/B_PROTEIN[GENE]
. O O
medication O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
levels O B_LOCATION/B_PERSON
over O O
1 O B_MEASURE
, O O
000 O B_MEASURE
U O I_MEASURE
must O O
be O O
carefully O O
screened O O
in O O
order O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
rule O O
out O O
SNM O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
organic O B_DISEASE/B_LOCATION
pathology O B_DISEASE/I_LOCATION
associated O O
. O O

Paclitaxel O O
caused O O
a O O
rapid O O
and O O
transient O O
increase O O
in O O
c B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Jun I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NH2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
terminal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
JNK B B_GENE/B_LOCATION
) O O
activity O O
, O O
a O O
proposed O O
mediator O O
of O O
stress O O
activation O O
pathways O O
. O O

These O O
results O O
indicate O O
that O O
H B B_GENE
- I I_GENE
2RIIBP I I_GENE
( O O
i O O
) O O
is O O
a O O
member O O
of O O
the O O
superfamily O O
of O O
nuclear B B_GENE/B_BIO
hormone I I_GENE/I_BIO
receptors I I_GENE/I_BIO
and O O
( O O
ii O O
) O O
may O O
regulate O O
not O O
only O O
MHC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
class I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
but O O
also O O
genes O O
containing O O
the O O
ERE O O
and O O
related O O
sequences O O
. O O

Two O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
courses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
chemotherapy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CBCDA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
VDS O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) O O
failed O O
to O O
gain O O
any O O
improvement O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
and O O
the O O
pain O B_DISEASE
resulting O O
from O O
recurrent O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
bone O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
metastases O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
managed O O
mainly O O
by O O
the O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O O
the O O
best O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
supportive O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
care O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
show O O
here O O
that O O
Spb1p B B_GENE/B_LOCATION
is O O
able O O
to O O
bind O O
[ O O
( O O
3 O O
) O O
H O O
] O O
AdoMet O O
in O O
vitro O O
, O O
suggesting O O
that O O
it O O
is O O
a O O
novel O O
methylase O O
, O O
whose O O
possible O O
substrates O O
will O O
be O O
discussed O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Lateral O B_DISEASE/B_LOCATION
PF O B_DISEASE/I_LOCATION
OA O B_DISEASE/I_LOCATION
was O O
more O O
common O B_DISEASE_ADJECTIVE[DISEASE]
than O O
medial O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
PF O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
OA O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
P O B_MEASURE/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
0001 O B_MEASURE
) O O
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Urbanisation O B_DISEASE/B_PERSON
is O O
associated O O
with O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
prevalence O B_MEASURE
rates O I_MEASURE
of O O
some O O
risk O B_DISEASE
behaviours O I_DISEASE
. O O

However O O
, O O
additional O O
studies O O
on O O
cell O O
lines O O
and O O
whole O O
animals O O
are O O
required O O
to O O
understand O O
GnRH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
signaling O O
in O O
the O O
context O O
of O O
other O O
hormones O O
during O O
the O O
reproductive O O
cycle O O
of O O
mouse O O
and O O
human O O
. O O

Serum B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
angiogenin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
concentrations O O
in O O
young O O
patients O O
with O O
diabetes O O
mellitus O O
. O O

This O O
duplicated O O
genomic O O
region O O
is O O
also O O
linked O O
tightly O O
to O O
D1Z2 B B_GENE/B_DISEASE
, O O
a O O
genetic O O
marker O O
containing O O
a O O
highly O O
polymorphic O O
VNTR O O
( O O
variable O O
number O O
tandem O O
repeat O O
) O O
consisting O O
of O O
an O O
unusual O O
40 O O
- O O
bp O O
reiterated O O
sequence O O
. O O

ATF6 B B_GENE
, O O
a O O
basic B B_GENE
- I I_GENE
leucine I I_GENE
zipper I I_GENE
protein I I_GENE
, O O
was O O
isolated O O
by O O
binding O O
to O O
SRF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
in O O
particular O O
to O O
its O O
transcriptional O O
activation O O
domain O O
. O O

Cetn1 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
possesses O O
the O O
sequence O O
features O O
of O O
an O O
expressed O O
retroposon O O
: O O
the O O
gene O O
lacks O O
introns O O
, O O
the O O
open O O
reading O O
frame O O
is O O
not O O
interrupted O O
by O O
stop O O
codons O O
, O O
and O O
the O O
coding O O
region O O
is O O
flanked O O
by O O
a O O
pair O O
of O O
direct O O
repeats O O
. O O

The O O
largest O O
one O O
probably O O
corresponds O O
to O O
the O O
precursor O O
form O O
of O O
PS2 B B_GENE
in O O
E O O
. O O
coli O O
. O O

The O O
Aspergillus B B_GENE/B_MEASURE
uvsH I I_GENE/I_MEASURE
gene I I_GENE/I_MEASURE
encodes O O
a O O
product O O
homologous O O
to O O
yeast B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
RAD18 I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
Neurospora B B_BIO/B_GENE
UVS I B_BIO/I_GENE
- I B_BIO/I_GENE
2 I B_BIO/I_GENE
. O O

On O O
average O B_MEASURE/B_SOCIAL_CIRCUMSTANCES
these O O
maximum O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potency O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
estimates O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
within O O
one O B_MEASURE/B_LOCATION
order O I_MEASURE/I_LOCATION
of O O
magnitude O B_NUMBER[MEASURE]
of O O
the O O
inverse O B_MEASURE
maximum O I_MEASURE
dose O I_MEASURE
tested O O
. O O

VAV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
SOCS1 B B_GENE/B_DISEASE
form O O
a O O
protein O O
complex O O
through O O
interactions O O
between O O
the O O
VAV B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
NH I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
terminal I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
regulatory I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
region I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
SH2 B B_GENE/B_MEASURE
domain I I_GENE/I_MEASURE
of O O
SOCS1 B B_GENE
in O O
a O O
phosphotyrosine O O
- O O
independent O O
manner O O
. O O

The O O
originally O O
embryonic B B_GENE/B_BIO
gamma I I_GENE/I_BIO
- I I_GENE/I_BIO
globin I I_GENE/I_BIO
locus I I_GENE/I_BIO
duplicated O O
and O O
acquired O O
a O O
novel O O
( O O
fetal O O
) O O
pattern O O
of O O
expression O O
in O O
a O O
defined O O
time O O
period O O
( O O
55 O O
- O O
40 O O
million O O
years O O
ago O O
) O O
during O O
primate O O
phylogeny O O
. O O

Clostridium O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
botulinum O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
in O O
marine O B_LOCATION/B_PERSON
sediment O I_LOCATION/I_PERSON

Northern O O
blot O O
analysis O O
with O O
GPR37 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
probes O O
revealed O O
a O O
main O O
3 O O
. O O
8 O O
- O O
kb O O
mRNA O O
and O O
a O O
less O O
abundant O O
8 O O
- O O
kb O O
mRNA O O
, O O
both O O
expressed O O
in O O
human O O
brain O O
tissues O O
, O O
particularly O O
in O O
corpus O O
callosum O O
, O O
medulla O O
, O O
putamen O O
, O O
and O O
caudate O O
nucleus O O
. O O

Our O O
studies O O
indicate O O
no O O
single O O
trans O O
- O O
acting O O
factor O O
is O O
absolutely O O
essential O O
for O O
enhancer O O
activity O O
, O O
and O O
that O O
the O O
enhancer O O
activity O O
of O O
MerI B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
mediated O O
via O O
a O O
combinatorial O O
and O O
additive O O
mechanism O O
. O O

In O O
human O O
WI38 O O
cells O O
, O O
the O O
E1B B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
19K I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
gene I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutant I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
viruses O O
had O O
a O O
substantial O O
growth O O
advantage O O
over O O
the O O
wild O O
- O O
type O O
virus O O
, O O
yielding O O
500 O O
- O O
fold O O
- O O
higher O O
titers O O
. O O

To O O
elucidate O O
the O O
mechanism O O
of O O
these O O
hormonal O O
effects O O
, O O
we O O
have O O
studied O O
the O O
regulatory O O
regions O O
of O O
the O O
PFK B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
transfection O O
experiments O O
. O O

Consequently O O
, O O
during O O
the O O
evolution O O
of O O
mammals O O
, O O
it O O
is O O
the O O
CKbeta4GT B B_DISEASE_ADJECTIVE[DISEASE]/B_SEQUENCE[MEASURE]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_SEQUENCE[MEASURE]
I I B_DISEASE_ADJECTIVE[DISEASE]/I_SEQUENCE[MEASURE]
gene I B_DISEASE_ADJECTIVE[DISEASE]/I_SEQUENCE[MEASURE]
lineage O O
that O O
has O O
been O O
recruited O O
for O O
the O O
biosynthesis O O
of O O
lactose O O
. O O

Furthermore O O
, O O
disruption O O
of O O
pcr1 B B_GENE
reduced O O
expression O O
of O O
fbp1 B B_GENE
, O O
a O O
glucose O O
- O O
repressible O O
gene O O
negatively O O
regulated O O
by O O
PKA B B_GENE
. O O

In O O
solution O O
, O O
[ O O
( O O
125 O O
) O O
I O O
] O O
- O O
labeled O O
ankyrin B B_GENE/B_BACTERIUM[BIO]
was O O
found O O
by O O
ND O O
- O O
PAGE3 O O
to O O
enhance O O
the O O
affinity O O
of O O
spectrin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
self O O
- O O
association O O
by O O
10 O O
- O O
fold O O
. O O

Transcription O O
analysis O O
of O O
the O O
EcoRI B B_GENE
D I I_GENE
region I I_GENE
of O O
the O O
baculovirus O O
Autographa O O
californica O O
nuclear O O
polyhedrosis O O
virus O O
identifies O O
an O O
early O O
4 O O
- O O
kilobase O O
RNA O O
encoding O O
the O O
essential O O
p143 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Anesthesia O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
radical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
surgery O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
arteriosclerotic O B_DISEASE
coronary O I_DISEASE
disease O I_DISEASE

5 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Intravenous O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prizidilol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrochloride O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreases O O
resting O O
blood O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
pressure O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
left O O
ventricular O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
area O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
increases O O
pulse O B_MEASURE/B_DISEASE
rate O I_MEASURE/I_DISEASE
and O O
has O O
virtually O O
no O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
left O O
ventricular O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
ejection O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
fraction O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

In O O
this O O
study O O
, O O
the O O
subcellular O O
location O O
, O O
domain O O
structure O O
, O O
and O O
biochemical O O
function O O
of O O
metaxin B B_GENE/B_BACTERIUM[BIO]
were O O
investigated O O
. O O

The O O
human O B_GENE
cDNA O I_GENE
was O O
cloned O O
and O O
sequenced O O
; O O
it O O
was O O
shown O O
to O O
have O O
an O O
open O B_GENE
reading O I_GENE
frame O I_GENE
encoding O O
a O O
296 O B_MEASURE
- O O
amino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
acid O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein O B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
which O O
could O O
be O O
identified O O
four O B_LOCATION/B_BIO
peptides O I_LOCATION/I_BIO
previously O O
identified O O
by O O
micro O B_GENE
- O O
sequencing O O
purified O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Our O O
aim O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O O
to O O
evaluate O O
this O O
technique O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
by O O
cross O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
calibrating O O
the O O
DXA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
with O O
the O O
carcass O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
chemical O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
a O O
heterogeneous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
population O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
nondiabetic O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
Wistar O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O O
diabetic O B_PERSON
GK O I_PERSON
rats O I_PERSON
( O O
21 O B_MEASURE/B_ENT
animals O I_MEASURE/I_ENT
were O O
used O O
for O O
precision O B_MEASURE
error O I_MEASURE
and O O
reproducibility O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
determinations O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
26 O B_NUMBER[MEASURE]
were O O
used O O
for O O
accuracy O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
studies O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
. O O

Flux O O
of O O
the O O
paramyxovirus O O
hemagglutinin B B_PROTEIN[GENE]/B_BIO
- O O
neuraminidase B B_PROTEIN[GENE]
glycoprotein O O
through O O
the O O
endoplasmic O O
reticulum O O
activates O O
transcription O O
of O O
the O O
GRP78 B B_PROTEIN[GENE]/B_DISEASE
- O O
BiP B B_GENE
gene O O
. O O

The O O
preference O O
for O O
third O O
base O O
codon O O
in O O
Y O O
position O O
prolines O O
is O O
U O O
for O O
the O O
alpha B B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
2 I I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
( I I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
VI I I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
) I I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
collagen I I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
as O O
it O O
is O O
for O O
the O O
human B B_GENE/B_MEASURE
fibrillar I I_GENE/I_MEASURE
collagen I I_GENE/I_MEASURE
genes I I_GENE/I_MEASURE
. O O

Small O B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tumors O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
children O B_PERSON/B_LOCATION
: O O
contribution O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
solution O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
the O O
problem O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
differential O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
immunohistochemistry O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
electron O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]

Detonation O B_DISEASE/B_LOCATION
- O O
traumatic O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
load O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
during O O
military O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
service O I_PERSON/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE

In O O
static O B_MEASURE/B_LOCATION
conditions O I_MEASURE/I_LOCATION
, O O
body O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
sway O O
was O O
assessed O O
using O O
a O O
conventional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
force O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
platform O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
eyes O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
open O I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
and O O
with O O
eyes O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
closed O O
. O O

Soggy B B_GENE/B_BIO
, O O
a O O
spermatocyte O O
- O O
specific O O
gene O O
, O O
lies O O
3 O O
. O O
8 O O
kb O O
upstream O O
of O O
and O O
antipodal O O
to O O
TEAD B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2 I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
a O O
transcription O O
factor O O
expressed O O
at O O
the O O
beginning O O
of O O
mouse O O
development O O
. O O

Teratospermia O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
is O O
therefore O O
an O O
important O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factor O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
evaluating O O
fertilization O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
capacity O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
Chinese O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
medicine O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
use O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
among O O
this O O
population O B_PERSON/B_LOCATION
depends O O
on O O
health O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
that O O
having O O
a O O
regular O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
source O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
care O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
Chinese O B_PERSON/B_ORGANIZATION
medicine O I_PERSON/I_ORGANIZATION
as O O
well O O
as O O
a O O
preference O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
Chinese O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medicine O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
two O B_DISEASE_ADJECTIVE[DISEASE]
predictors O I_DISEASE_ADJECTIVE[DISEASE]
for O O
its O O
use O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O O

The O O
greatest O B_DISEASE
risk O I_DISEASE
of O O
preterm O B_DISEASE/B_ORGANISM_FUNCTION
prelabour O I_DISEASE/I_ORGANISM_FUNCTION
rupture O I_DISEASE/I_ORGANISM_FUNCTION
of O O
membranes O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PPROM O B_DISEASE/B_GENE
) O O
is O O
preterm O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
delivery O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

DISCUSSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
The O O
higher O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
absolute O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
knee O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
extension O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
strength O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
measures O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
leg O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
the O O
similar O B_MEASURE/B_LOCATION
extension O I_MEASURE/I_LOCATION
strength O I_MEASURE/I_LOCATION
of O O
the O O
trunk O B_BODY_PART_OR_ORGAN_COMPONENT
in O O
the O O
obese O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
sample O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
compared O O
to O O
the O O
lean O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
might O O
be O O
explained O O
by O O
the O O
training O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effect O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
weight O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
bearing O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
support O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
a O O
larger O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
body O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
mass O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Residues O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
Stauffer O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
R O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
3828 O B_MEASURE
and O O
its O O
oxygen O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analogue O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
the O O
body O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissues O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
cattle O B_BIO/B_PERSON
fed O O
R O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
3828 O B_MEASURE
in O O
the O O
diet O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

The O O
goals O O
of O O
these O O
experiments O O
were O O
to O O
determine O O
whether O O
lactational O O
anestrus O O
would O O
be O O
prolonged O O
by O O
a O O
48 O O
- O O
h O O
fast O O
at O O
days O O
13 O O
and O O
14 O O
postpartum O O
( O O
pp O O
) O O
and O O
, O O
if O O
so O O
, O O
to O O
determine O O
whether O O
this O O
effect O O
could O O
be O O
reversed O O
by O O
treatment O O
with O O
the O O
Ob B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
protein I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
leptin B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

In O O
pituitary O O
GH3 O O
cells O O
, O O
vitamin O O
D O O
increases O O
the O O
levels O O
of O O
PRL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
stimulates O O
the O O
PRL B B_GENE
promoter I I_GENE
. O O

However O O
, O O
electron O O
microscopy O O
revealed O O
that O O
while O O
sec4 B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
mutant I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
cells O O
accumulate O O
secretory O O
vesicles O O
, O O
ypt31 B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
/ I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
32 I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
mutant I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
cells O O
accumulate O O
aberrant O O
Golgi O O
structures O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
We O O
retrospectively O O
analyzed O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
20 O B_PERSON
patients O I_PERSON
who O O
underwent O O
both O O
gated O O
fluorine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
18 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
deoxyglucose O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
FDG O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
- O O
PET O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
equilibrium O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
radionuclide O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
angiography O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
ERNA O B_DISEASE/B_LOCATION
) O O
. O O

However O O
, O O
it O O
is O O
now O O
suggested O O
that O O
the O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
more O O
slowly O O
digested O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
starchy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
foods O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
may O O
have O O
positive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
health O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
benefits O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Northern O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
blot O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
demonstrated O O
that O O
the O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
transcribed O O
separately O O
. O O

Complete O O
activation O O
of O O
signal B B_GENE
transducer I I_GENE
and I I_GENE
activator I I_GENE
of I I_GENE
transcription I I_GENE
1 I I_GENE
( O O
STAT1 B B_GENE
) O O
requires O O
phosphorylation O O
at O O
both O O
Y701 O O
and O O
a O O
conserved O O
PMS O O
( O O
727 O O
) O O
P O O
sequence O O
. O O

Over O O
half O O
of O O
the O O
children O B_PERSON/B_BIO
initially O O
unresponsive O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O O
H O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O O
influenzae O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
type O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
b O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
meningitis O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subsequently O O
developed O O
specific O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
is O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
understand O O
the O O
etiology O B_DISEASE
of O O
HITT O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O O
of O O
its O O
devastating O B_DISEASE_ADJECTIVE[DISEASE]
clinical O I_DISEASE_ADJECTIVE[DISEASE]
consequences O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Five O B_NUMBER[MEASURE]/B_PERSON
sequence O I_NUMBER[MEASURE]/I_PERSON
variants O I_NUMBER[MEASURE]/I_PERSON
were O O
identified O O
. O O

The O O
Ras B B_ENZYME[GENE]/B_LOCATION
GTPase I I_ENZYME[GENE]/I_LOCATION
- I I_ENZYME[GENE]/I_LOCATION
activating I I_ENZYME[GENE]/I_LOCATION
- I I_ENZYME[GENE]/I_LOCATION
protein I I_ENZYME[GENE]/I_LOCATION
- I I_ENZYME[GENE]/I_LOCATION
related I I_ENZYME[GENE]/I_LOCATION
human I I_ENZYME[GENE]/I_LOCATION
protein I I_ENZYME[GENE]/I_LOCATION
IQGAP2 B I_ENZYME[GENE]/I_LOCATION
harbors O O
a O O
potential O O
actin B B_GENE
binding I I_GENE
domain I I_GENE
and O O
interacts O O
with O O
calmodulin B B_GENE/B_DISEASE
and O O
Rho B B_GENE
family I I_GENE
GTPases I I_GENE
. O O

We O O
anticipated O O
SNS O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
function O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
after O O
CVA O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
be O O
asymmetric O B_DISEASE_ADJECTIVE[DISEASE]
and O O
selected O O
null O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
hypotheses O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
bilaterally O O
symmetric O B_MEASURE/B_LOCATION
SSR O I_MEASURE/I_LOCATION
latencies O I_MEASURE/I_LOCATION
and O O
amplitudes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
irrespective O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
side O B_MEASURE/B_DISEASE
of O O
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
/ O O
or O O
recording O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
. O O

Partial O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hepatectomy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
metastatic O B_TIME[MEASURE]/B_PERSON
Wilms O I_TIME[MEASURE]/I_PERSON
' O I_TIME[MEASURE]/I_PERSON
tumor O I_TIME[MEASURE]/I_PERSON
. O O

The O O
adoption O O
of O O
a O O
twisted O O
structure O O
of O O
importin B B_GENE
- I I_GENE
beta I I_GENE
is O O
essential O O
for O O
the O O
protein O O
- O O
protein O O
interaction O O
required O O
for O O
nuclear O O
transport O O
. O O

The O O
presence O O
of O O
a O O
short O O
( O O
70 O O
bp O O
) O O
intron O O
near O O
the O O
N O O
- O O
terminus O O
of O O
the O O
atX B B_GENE
gene I I_GENE
was O O
predicted O O
that O O
contains O O
the O O
canonical O O
GT O O
and O O
AG O O
dinucleotides O O
at O O
its O O
5 O O
' O O
- O O
and O O
3 O O
' O O
- O O
splicing O O
junctions O O
. O O

Moreover O O
, O O
a O O
hybrid O O
protein O O
composed O O
of O O
a O O
PvALF B B_GENE
activation I I_GENE
domain I I_GENE
and O O
the O O
DNA O O
binding O O
and O O
dimerization O O
domain O O
of O O
ROM2 B B_GENE
activated O O
gene O O
expression O O
, O O
indicating O O
that O O
ROM2 B B_GENE/B_MEASURE
recognizes O O
the O O
DLEC2 B B_GENE/B_LOCATION
enhancer I I_GENE/I_LOCATION
in O O
vivo O O
; O O
consequently O O
, O O
ROM2 B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
functions O O
as O O
a O O
DNA O O
binding O O
site O O
- O O
dependent O O
repressor O O
. O O

Tc O B_MEASURE/B_PROTEIN[GENE]
- O O
99m O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
HMPAO O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
brain O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
SPECT O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
compared O O
to O O
CT O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
EEG O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
after O O
seizures O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
childhood O B_PERSON/B_DISEASE
. O O

We O O
found O O
that O O
the O O
central O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
nonconserved O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
region O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
large O B_ENZYME[GENE]/B_LOCATION
subunit O I_ENZYME[GENE]/I_LOCATION
is O O
not O O
essential O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
likely O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acts O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
spacer O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
between O O
the O O
conserved O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
and O O
C O B_PROTEIN[GENE]/B_LOCATION
- O O
terminal O B_LOCATION/B_BIO
regions O I_LOCATION/I_BIO
. O O

On O O
the O O
other O O
hand O O
, O O
NE O O
transport O O
and O O
antagonist O O
( O O
[ O O
125I O O
] O O
RTI O O
- O O
55 O O
) O O
binding O O
assays O O
on O O
whole O O
LLC O O
- O O
NET O O
cells O O
treated O O
with O O
tunicamycin O O
reveal O O
a O O
pronounced O O
reduction O O
in O O
NE O O
transport O O
activity O O
and O O
hNET B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
membrane O O
density O O
paralleled O O
by O O
an O O
inability O O
of O O
NET B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
replenish O O
the O O
higher O O
M O O
( O O
r O O
) O O
hNET B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
pool O O
. O O

We O O
show O O
that O O
the O O
upstream O O
region O O
of O O
the O O
beta B B_GENE/B_BIO
- I I_GENE/I_BIO
MyHC I I_GENE/I_BIO
gene I I_GENE/I_BIO
( O O
- O O
5518 O O
to O O
- O O
2490 O O
relative O O
to O O
the O O
transcriptional O O
start O O
site O O
) O O
directed O O
high O O
levels O O
of O O
transcriptional O O
activity O O
only O O
when O O
stably O O
integrated O O
, O O
but O O
not O O
when O O
expressed O O
extrachromosomally O O
in O O
transient O O
assays O O
. O O

DNase B B_GENE
I I I_GENE
protection O O
analysis O O
as O O
well O O
as O O
oligonucleotide O O
competition O O
experiments O O
indicate O O
that O O
this O O
binding O O
is O O
sequence O O
specific O O
. O O

Plasmid O O
pSP64E6E7 O O
which O O
contains O O
the O O
reading O O
frames O O
of O O
both O O
E6 B B_PROTEIN[GENE]
and O O
E7 B B_PROTEIN[GENE]
was O O
constructed O O
in O O
order O O
to O O
study O O
the O O
expression O O
of O O
both O O
proteins O O
in O O
a O O
coupled O O
transcription O O
/ O O
rabbit O O
reticulocyte O O
translation O O
system O O
. O O

In O O
transient O O
transfections O O
using O O
luciferase B B_GENE/B_LOCATION
reporter I I_GENE/I_LOCATION
genes I I_GENE/I_LOCATION
driven O O
by O O
1 O O
kb O O
of O O
the O O
5 O O
' O O
flanking O O
DNA O O
of O O
the O O
three O O
CALM B B_GENE/B_LOCATION
genes I I_GENE/I_LOCATION
, O O
the O O
promoter O O
activity O O
correlated O O
with O O
the O O
endogenous B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
CALM I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
transcriptional O O
activity O O
, O O
but O O
only O O
when O O
the O O
5 O O
' O O
untranslated O O
regions O O
were O O
included O O
in O O
the O O
constructs O O
. O O

These O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O O
that O O
PGE1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
effective O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
increasing O O
PVF O B_DISEASE
in O O
the O O
liver O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplanted O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
condition O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
; O O
however O O
, O O
the O O
hepatic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
circulatory O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
improvement O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
attributed O O
to O O
this O O
agent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
would O O
be O O
limited O O
to O O
the O O
first O B_TIME[MEASURE]/B_ENT
few O I_TIME[MEASURE]/I_ENT
days O I_TIME[MEASURE]/I_ENT
following O O
transplantation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
derepressed O O
expression O O
of O O
fixN B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
not O O
observed O O
in O O
a O O
purH B B_DISEASE/B_PERSON
mutant I I_DISEASE/I_PERSON
. O O

Nearly O O
1 O B_MEASURE
. O O
5 O B_TIME[MEASURE]
million O I_TIME[MEASURE]
American O I_TIME[MEASURE]
men O I_TIME[MEASURE]
age O I_TIME[MEASURE]
65 O I_TIME[MEASURE]
and O O
older O B_MEASURE/B_PERSON
have O O
osteoporosis O O
, O O
and O O
another O O
3 O B_NUMBER[MEASURE]
. O O
5 O B_TIME[MEASURE]
million O I_TIME[MEASURE]
are O O
at O O
risk O B_DISEASE/B_MEASURE
. O O

Both O O
viruses O O
express O O
the O O
mil B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
raf B B_GENE/B_DISEASE
oncogene O O
product O O
as O O
a O O
gag B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
fusion I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
polyprotein O O
, O O
while O O
the O O
myc B B_GENE/B_SPECIES[BIO]
oncogene O O
of O O
MH2 O O
is O O
expressed O O
via O O
a O O
subgenomic O O
mRNA O O
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
DaunoXome O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
an O O
improved O B_DISEASE_ADJECTIVE[DISEASE]
pharmacokinetic O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profile O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
compared O O
with O O
free O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
daunorubicin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
is O O
well O O
tolerated O O
. O O

This O O
regimen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
considered O O
front O B_LOCATION/B_SEQUENCE[MEASURE]
- O O
line O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
when O O
autologous O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
stem O O
cell O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplantation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
not O O
feasible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
when O O
a O O
rapid O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
response O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
is O O
particularly O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Recombinant O O
protein O O
encoded O O
by O O
ESX B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
for O O
epithelial B B_GENE
- I I_GENE
restricted I I_GENE
with I I_GENE
serine I I_GENE
box I I_GENE
) O O
exhibits O O
Ets B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
like I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
DNA O O
binding O O
specificity O O
in O O
electrophoretic O O
mobility O O
shift O O
assays O O
and O O
, O O
in O O
transient O O
transfection O O
assays O O
, O O
transactivates O O
Ets B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
responsive I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
elements I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
including O O
that O O
found O O
in O O
the O O
HER2 B B_GENE
/ O O
neu B B_GENE/B_LOCATION
oncogene O O
. O O

In O O
area O B_LOCATION/B_BIO
CA1 O I_LOCATION/I_BIO
of O O
the O O
hippocampus O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
numbers O B_MEASURE/B_LOCATION
of O O
normal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
neurons O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
increased O O
11 O B_NUMBER[MEASURE]
- O O
to O O
14 O B_MEASURE
- O O
fold O B_MEASURE/B_BIO
by O O
MK O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
801 O B_MEASURE
treatment O I_MEASURE
( O O
p O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
. O O

The O O
temporal O O
changes O O
in O O
the O O
plasma O O
concentration O O
of O O
immunoreactive B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
atrial I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
natriuretic I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
iANF B B_GENE/B_LOCATION
) O O
were O O
studied O O
in O O
six O O
conscious O O
dogs O O
with O O
an O O
arteriovenous O O
( O O
AV O O
) O O
fistula O O
, O O
a O O
model O O
of O O
chronic O O
high O O
- O O
output O O
heart O O
failure O O
. O O

The O O
revaluation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
at O O
the O O
end O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
a O O
good O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
compliance O I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
proposed O O
diet O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
scheme O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
by O O
children O B_PERSON
, O O
but O O
a O O
poor O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compliance O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
their O O
families O B_PERSON/B_SOCIAL_CIRCUMSTANCES
. O O

The O O
delta O B_MEASURE/B_LOCATION
G O I_MEASURE/I_LOCATION
values O I_MEASURE/I_LOCATION
of O O
these O O
regions O B_DISEASE/B_GENE
were O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
i O O
. O O
e O O
. O O
potential O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
secondary O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
structural O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
elements O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O O
fewer O B_DISEASE_ADJECTIVE[DISEASE]
, O O
than O O
in O O
TIR O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
E O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
coli O B_SPECIES[BIO]/B_MEASURE
. O O

Two O O
closely O O
related O O
groups O O
of O O
transcripts O O
, O O
Sagrp1 B B_GENE
and O O
Sagrp2 B B_PROTEIN[GENE]
, O O
controlled O O
by O O
a O O
circadian O O
rhythm O O
have O O
been O O
isolated O O
. O O

Of O O
921 O O
specimens O O
, O O
95 O O
yielded O O
non O O
- O O
albicans O O
species O O
, O O
mainly O O
from O O
patients O O
with O O
low O O
CD4 B B_GENE/B_MEASURE
lymphocyte O O
counts O O
and O O
extensive O O
previous O O
azole O O
exposure O O
. O O

These O O
findings O O
suggest O O
that O O
eIF5 B B_GENE
- O O
eIF2beta B B_GENE
interaction O O
plays O O
an O O
essential O O
role O O
in O O
eIF5 B B_GENE
function O O
in O O
eukaryotic O O
cells O O
. O O

Three O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
simple O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
methods O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
detecting O O
malnutrition O B_DISEASE
on O O
medical O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
wards O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Compared O O
with O O
controls O B_PERSON/B_BIO
, O O
patients O B_PERSON/B_BIO
in O O
the O O
unmedicated O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
state O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
had O O
low O B_DISEASE/B_MEASURE
smooth O I_DISEASE/I_MEASURE
pursuit O I_DISEASE/I_MEASURE
gain O I_DISEASE/I_MEASURE
, O O
had O O
a O O
higher O B_MEASURE/B_LOCATION
rate O I_MEASURE/I_LOCATION
of O O
corrective O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
catch O O
- O O
up O O
saccades O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
and O O
tended O O
to O O
spend O O
less O B_TIME[MEASURE]/B_ENT
time O I_TIME[MEASURE]/I_ENT
engaged O O
in O O
the O O
tracking O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
task O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Cytokine O O
- O O
mediated O O
I B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
kappa I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
B I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reappearance O O
was O O
completely O O
blocked O O
by O O
the O O
protein O O
synthesis O O
inhibitor O O
cycloheximide O O
. O O

Development O O
of O O
P O O
carinii O O
pneumonia O O
was O O
associated O O
with O O
the O O
stage O O
of O O
Kaposi O O
' O O
s O O
sarcoma O O
, O O
B O O
subtype O O
disease O O
, O O
and O O
the O O
presence O O
of O O
0 O O
. O O
20 O O
X O O
10 O O
( O O
9 O O
) O O
/ O O
L O O
( O O
200 O O
/ O O
mm3 O O
) O O
or O O
fewer O O
CD4 B B_GENE/B_DISEASE
cells O O
at O O
study O O
entry O O
. O O

The O O
effects O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
tilmicosin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
feed O B_BODY_PART_OR_ORGAN_COMPONENT/B_ORGANISM_FUNCTION
at O O
400 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
and O O
an O O
injection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
clinically O O
diseased O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pigs O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
long O O
- O O
acting O O
oxytetracycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
Terramycine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
LA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
at O O
20 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
bodyweight O I_MEASURE
were O O
compared O O
. O O

Those O O
participating O O
in O O
this O O
investigation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
65 O B_MEASURE/B_ORGANIZATION
centers O I_MEASURE/I_ORGANIZATION
= O O
79 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
received O O
a O O
series O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
computer O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
disks O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
containing O O
50 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
99mTc O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
DMSA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
studies O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Pathogenesis O B_DISEASE/B_TIME[MEASURE]
of O O
fever O B_DISEASE/B_GENE
. O O

Two O B_MEASURE/B_PERSON
full O I_MEASURE/I_PERSON
- O O
length O B_GENE
clones O I_GENE
( O O
pBCH1 O B_GENE
and O O
pBCH2 O B_GENE
) O O
were O O
isolated O O
. O O

Childbirth O B_DISEASE/B_ORGANIZATION
and O O
authoritative O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
knowledge O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
ends O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
barrel O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O O
capped O O
by O O
short O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
helices O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Non O O
- O O
finger O O
- O O
coding O O
modules O O
conserved O O
among O O
members O O
of O O
subfamilies O O
of O O
zinc B B_BIO/B_GENE
finger I I_BIO/I_GENE
genes I I_BIO/I_GENE
have O O
been O O
described O O
in O O
the O O
murine O O
genome O O
( O O
finger O O
- O O
associated O O
boxes O O
, O O
or O O
FAX O O
domain O O
) O O
and O O
the O O
human O O
genome O O
( O O
Kruppel B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
associated I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
boxes I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
or O O
KRAB B B_GENE/B_DISEASE
domain I I_GENE/I_DISEASE
) O O
. O O

This O O
combination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
considered O O
pathognomonic O B_DISEASE_ADJECTIVE[DISEASE]
for O O
factitious O B_DISEASE/B_LOCATION
hyperinsulinism O I_DISEASE/I_LOCATION
. O O

Comparison O O
of O O
the O O
5 O O
' O O
flanking O O
regions O O
of O O
the O O
mouse B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
J I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
elements I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
including O O
the O O
conserved O O
putative O O
recombination O O
target O O
sequences O O
, O O
shows O O
no O O
obvious O O
differences O O
consistent O O
with O O
the O O
variation O O
in O O
recombinational O O
efficiency O O
, O O
so O O
we O O
conclude O O
that O O
, O O
although O O
the O O
consensus O O
heptamer O O
and O O
nonamer O O
signals O O
may O O
be O O
sufficient O O
to O O
identify O O
a O O
recombination O O
site O O
, O O
the O O
probability O O
that O O
that O O
site O O
will O O
be O O
used O O
depends O O
also O O
on O O
other O O
determinants O O
. O O

The O O
melanoma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
stimulatory I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
CXCL1 B B_GENE/B_LOCATION
, O O
is O O
constitutively O O
expressed O O
at O O
high O O
levels O O
during O O
inflammation O O
and O O
progression O O
of O O
melanocytes O O
into O O
malignant O O
melanoma O O
. O O

Genetic O O
analysis O O
places O O
CWH43 B B_LOCATION/B_GENE
upstream O O
of O O
the O O
BCK2 B B_GENE
branch O O
of O O
the O O
PKC1 B B_GENE
signalling O O
pathway O O
, O O
since O O
cwh43 B B_NUMBER[MEASURE]/B_LOCATION
mutations O O
were O O
synthetic O O
lethal O O
with O O
pkc1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
deletion O O
, O O
whereas O O
the O O
cwh43 B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
defects O O
could O O
be O O
rescued O O
by O O
overexpression O O
of O O
BCK2 B B_GENE
and O O
not O O
by O O
high O O
- O O
copy O O
- O O
number O O
expression O O
of O O
genes O O
encoding O O
downstream O O
proteins O O
of O O
the O O
PKC1 B B_GENE/B_DISEASE
pathway O O
However O O
, O O
unlike O O
BCK2 B B_GENE/B_BIO
, O O
whose O O
disruption O O
in O O
a O O
cln3 B B_LOCATION/B_GENE
mutant I B_LOCATION/I_GENE
resulted O O
in O O
growth O O
arrest O O
in O O
G O O
( O O
1 O O
) O O
, O O
no O O
growth O O
defect O O
was O O
observed O O
in O O
a O O
double O O
cwh43 B B_DISEASE_ADJECTIVE[DISEASE]
cln3 B I_DISEASE_ADJECTIVE[DISEASE]
mutants I I_DISEASE_ADJECTIVE[DISEASE]
. O O

Twelve O B_NUMBER[MEASURE]/B_PERSON
( O O
92 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
showed O O
cognitive O B_DISEASE_ADJECTIVE[DISEASE]
dysfunction O I_DISEASE_ADJECTIVE[DISEASE]
including O O
impairments O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
memory O B_PERSON/B_DISEASE
, O O
attention O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
and O O
affective O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disturbances O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
anxiety O B_DISEASE
, O O
depression O B_DISEASE
, O O
irritability O B_DISEASE
, O O
and O O
poor O B_DISEASE
frustration O I_DISEASE
tolerance O I_DISEASE
) O O
. O O

To O O
clarify O O
the O O
mechanisms O O
that O O
regulate O O
transcription O O
of O O
the O O
GTP B B_GENE
cyclohydrolase I I_GENE
I I I_GENE
gene I I_GENE
and O O
to O O
generate O O
multiple O O
species O O
of O O
mRNA O O
, O O
we O O
isolated O O
genomic O O
DNA O O
clones O O
for O O
the O O
human O O
and O O
mouse O O
GTP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cyclohydrolase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Therefore O O
, O O
a O O
structural O O
interaction O O
between O O
PsaL B B_GENE/B_BACTERIUM[BIO]
and O O
PsaI B B_GENE/B_BACTERIUM[BIO]
may O O
stabilize O O
the O O
association O O
of O O
PsaL B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
with O O
the O O
photosystem B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
I I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
core I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Reversal O O
of O O
' O O
refractory O O
septic O O
shock O O
' O O
by O O
infusion O O
of O O
amrinone O O
and O O
angiotensin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
II I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
an O O
anthracycline O O
- O O
treated O O
patient O O
. O O

The O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deals O O
with O O
the O O
screening O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
11 O B_NUMBER[MEASURE]/B_BIO
of O O
these O O
plants O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
against O O
the O O
opportunistic O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
pathogen O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
fungus O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
Candida O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
albicans O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Negative O O
modulation O O
of O O
alpha1 B B_GENE
( I I_GENE
I I I_GENE
) I I_GENE
procollagen I I_GENE
gene I I_GENE
expression O O
in O O
human O O
skin O O
fibroblasts O O
: O O
transcriptional O O
inhibition O O
by O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
gamma I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

On O O
the O O
basis O O
of O O
this O O
homology O O
, O O
we O O
examined O O
the O O
potential O O
role O O
of O O
c B B_GENE
- I I_GENE
Rel I I_GENE
in O O
controlling O O
IL B B_GENE
- I I_GENE
2R I I_GENE
alpha I I_GENE
transcription O O
. O O

Expression O O
of O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
p300 B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potentiated O O
HS2 O O
- O O
mediated O O
transactivation O O
. O O

We O O
next O O
developed O O
a O O
rapid O O
purification O O
method O O
for O O
bacterial B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
recombinant I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MyoD I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bHLH I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
affinity O O
chromatography O O
using O O
a O O
calmodulin B B_GENE
- O O
Sepharose O O
column O O
and O O
investigated O O
the O O
phosphorylation O O
of O O
that O O
peptide O O
by O O
PKC B B_GENE
and O O
its O O
interactions O O
with O O
calmodulin B B_GENE
and O O
S100a B B_GENE
. O O

According O O
to O O
the O O
penetration O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
Ca O B_LOCATION/B_PROTEIN[GENE]
- O O
45 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
microleakage O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
scored O O
for O O
each O O
section O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

HL B B_GENE/B_DISEASE
is O O
hypothesized O O
to O O
directly O O
couple O O
HDL B B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
lipid O O
metabolism O O
to O O
tissue O O
/ O O
cellular O O
lipid O O
metabolism O O
. O O

Epstein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Barr I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigen I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
exerts O O
its O O
transactivating O O
function O O
through O O
interaction O O
with O O
recombination B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RBP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
J I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
homologue O O
of O O
Drosophila B B_GENE
Suppressor I I_GENE
of I I_GENE
Hairless I I_GENE
. O O

Maduromycosis O B_BACTERIUM[BIO]/B_LOCATION
in O O
Italy O B_LOCATION/B_BIO

Two O B_NUMBER[MEASURE]/B_PERSON
patient O I_NUMBER[MEASURE]/I_PERSON
groups O I_NUMBER[MEASURE]/I_PERSON
were O O
studied O O
: O O
Type O B_MEASURE/B_DISEASE
I O O
- O O
- O O
with O O
a O O
new O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
ePTFE O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
graft O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
; O O
and O O
Type O B_TIME[MEASURE]/B_PROTEIN[GENE]
II O I_TIME[MEASURE]/I_PROTEIN[GENE]
- O O
- O O
with O O
thrombectomy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
/ O O
or O O
revision O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
a O O
previously O O
placed O O
ePTFE O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
graft O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
author O B_PERSON
describes O O
the O O
technique O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O O
detail O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
presents O O
the O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
25 O B_TIME[MEASURE]/B_PERSON
patients O B_TIME[MEASURE]/I_PERSON
( O O
10 O B_NUMBER[MEASURE]/B_SPORT[ENT]
men O I_NUMBER[MEASURE]/I_SPORT[ENT]
and O O
15 O B_PERSON/B_NUMBER[MEASURE]
women O I_PERSON/I_NUMBER[MEASURE]
) O O
examined O O
for O O
suspected O O
ileostomy O B_DISEASE
dysfunction O I_DISEASE
, O O
recurrent O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
Crohn O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
' O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
s O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
disease O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
or O O
ileal O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
obstruction O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
remote O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O O
the O O
stoma O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Increased O O
susceptibility O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
aphasics O B_PERSON
to O O
a O O
distractor O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
task O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
recall O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
verbal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
commands O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
. O O

Lasting O B_DISEASE
paraplegia O I_DISEASE
caused O O
by O O
loss O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
lumbar O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
spinal O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
cord O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
interneurons O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
no O O
direct O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
correlation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O O
motor O B_DISEASE_ADJECTIVE[DISEASE]
neuron O I_DISEASE_ADJECTIVE[DISEASE]
loss O I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
existence O B_DISEASE/B_ORGANIZATION
of O O
universal O B_MEASURE/B_BIO
non O B_MEASURE/I_BIO
- O O
specific O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
mechanism O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O O
action O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
external O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
upon O O
the O O
living O O
tissue O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
based O O
on O O
the O O
DEL O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
reaction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
suggested O O
. O O

Rv O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
7 O B_MEASURE
. O O
7 O B_MEASURE
+ O O
/ O O
- O O
1 O B_MEASURE
. O O
4 O B_MEASURE
mmHg O I_MEASURE
. O O
ml O B_MEASURE/B_PERSON
- O O
1 O B_MEASURE/B_LOCATION
. O O
min O B_MEASURE/B_PERSON
. O O
100 O B_MEASURE/B_LOCATION
g O B_MEASURE/I_LOCATION
- O O
1 O B_MEASURE/B_LOCATION
and O O
Cv O B_PROTEIN[GENE]/B_BIO
was O O
0 O B_MEASURE
. O O
59 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
25 O B_MEASURE
ml O I_MEASURE
/ O O
mmHg O B_MEASURE
, O O
tau O B_PROTEIN[GENE]
v O O
calculated O O
from O O
the O O
product O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
Rv O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Cv O B_PROTEIN[GENE]/B_BIO
was O O
4 O B_MEASURE
. O O
20 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
1 O B_MEASURE/B_LOCATION
. O O
58 O B_MEASURE
s O I_MEASURE
and O O
from O O
the O O
ratio O B_MEASURE
of O O
delta O B_PROTEIN[GENE]/B_MEASURE
V O O
to O O
delta O B_MEASURE/B_PROTEIN[GENE]
Q O B_MEASURE/I_PROTEIN[GENE]
was O O
4 O B_MEASURE
. O O
95 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
1 O B_NUMBER[MEASURE]
. O O
53 O B_MEASURE
s O I_MEASURE
( O O
P O B_OTHER/B_MEASURE
= O O
NS O B_MEASURE
) O O
at O O
a O O
mean O B_MEASURE/B_PERSON
Pel O I_MEASURE/I_PERSON
of O O
17 O B_MEASURE
. O O
6 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
3 O B_MEASURE
. O O
7 O B_MEASURE
mmHg O I_MEASURE
. O O
delta O B_PROTEIN[GENE]/B_DISEASE
V O I_PROTEIN[GENE]/I_DISEASE
was O O
also O O
produced O O
by O O
changing O O
Pv O B_DISEASE/B_MEASURE
; O O
the O O
average O B_MEASURE/B_PROTEIN[GENE]
tau O B_MEASURE/I_PROTEIN[GENE]
v O O
( O O
1 O B_MEASURE
. O O
95 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_NUMBER[MEASURE]
. O O
37 O B_MEASURE
s O I_MEASURE
) O O
, O O
was O O
shorter O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O O
that O O
with O O
changes O B_MEASURE
in O O
flow O B_MEASURE/B_PROTEIN[GENE]
. O O

We O O
constructed O O
a O O
stable O O
, O O
doubly O O
transfected O O
cell O O
line O O
( O O
TIS O O
- O O
10 O O
) O O
carrying O O
a O O
chromosomally O O
integrated O O
ptetO7 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CMV I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
L I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reporter O O
construct O O
and O O
expressing O O
the O O
TetR B B_GENE/B_DISEASE
- O O
KRAB B B_GENE/B_MEASURE
protein O O
. O O

We O O
suggest O O
that O O
electrical O O
stimulation O O
of O O
the O O
NTS O O
in O O
rats O O
undergoing O O
such O O
surgical O O
preparation O O
to O O
observe O O
the O O
pressor O O
response O O
and O O
/ O O
or O O
increase O O
in O O
pVP O O
, O O
represents O O
a O O
rapid O O
approach O O
for O O
screening O O
the O O
neurosecretory O O
function O O
of O O
the O O
central O O
neural O O
integration O O
to O O
release O O
vasopressin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

To O O
study O O
adaptive O B_DISEASE_ADJECTIVE[DISEASE]
processes O I_DISEASE_ADJECTIVE[DISEASE]
following O O
spinal O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cord O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injury O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
unstructured O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
audiotaped O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interviews O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
conducted O O
on O O
an O O
almost O O
daily O B_TIME[MEASURE]/B_PERSON
basis O B_TIME[MEASURE]/I_PERSON
with O O
a O O
30 O B_MEASURE
- O O
year O B_TIME[MEASURE]
- O O
old O B_TIME[MEASURE]/B_PERSON
divorced O O
male O B_PERSON
during O O
the O O
first O B_TIME[MEASURE]/B_LOCATION
3 O I_TIME[MEASURE]/I_LOCATION
months O I_TIME[MEASURE]/I_LOCATION
of O O
his O O
initial O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
comprehensive O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
inpatient O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
rehabilitation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
. O O

Melioidosis O B_DISEASE_ADJECTIVE[DISEASE]
in O O
Sika O B_LOCATION
deer O I_LOCATION
( O O
Cervus O B_LOCATION
nippon O I_LOCATION
nippon O I_LOCATION
) O O
. O O

Enterobius O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vermicularis O B_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
eggs O B_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
demonstrated O O
during O O
microscopic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examination O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
smear O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
taken O O
from O O
the O O
posterior O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
fornix O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
vagina O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O O

Together O O
with O O
previous O O
work O O
our O O
results O O
suggest O O
that O O
C B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EBP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
may O O
be O O
a O O
general O O
cooperation O O
partner O O
for O O
v B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Myb I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
myelomonocytic O O
cells O O
. O O

When O O
medical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
aid O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O O
sought O O
a O O
false O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
history O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O O
given O O
and O O
the O O
true O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nature O B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
child O B_PERSON
' O O
s O B_DISEASE
illness O I_DISEASE
, O O
heat O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
stroke O B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
, O O
was O O
not O O
determined O O
until O O
after O O
death O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Both O O
DMP2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
DMP3 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
closely O O
localized O O
on O O
mouse O O
chromosome O O
5q21 O O
, O O
corresponding O O
to O O
human O O
chromosome O O
4q21 O O
. O O

This O O
article O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
expands O O
the O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
a O O
numeric O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
example O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
included O O
in O O
the O O
SAS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GLM O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
procedure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
cover O O
several O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
crucial O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
statistical O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
aspects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
relevant O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
ANCOVA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
and O O
to O O
highlight O O
the O O
meaning O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
obtained O O
. O O

A O O
novel O O
alternative O O
spliced O O
variant O O
of O O
the O O
transcription O O
factor O O
AP2alpha B B_GENE
is O O
expressed O O
in O O
the O O
murine O O
ocular O O
lens O O
. O O

Fig1p B B_GENE/B_PERSON
and O O
Fig2p B B_PROTEIN[GENE]/B_LOCATION
are O O
likely O O
to O O
act O O
at O O
the O O
cell O O
surface O O
as O O
Fig1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
: O O
: O O
beta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gal I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Fig2 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
: O O
: O O
beta B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fusion I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
localize O O
to O O
the O O
periphery O O
of O O
mating O O
cells O O
. O O

Crystals O O
of O O
the O O
triple O O
mutant O O
A42D B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
D47P B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
A63L B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
are O O
stable O O
for O O
days O O
in O O
its O O
oxidized O O
form O O
, O O
were O O
grown O O
from O O
ammonium O O
sulfate O O
, O O
with O O
the O O
cell O O
constants O O
a O O
= O O
b O O
= O O
34 O O
. O O
3 O O
A O O
and O O
c O O
= O O
111 O O
. O O
8 O O
A O O
belonging O O
to O O
space O O
group O O
P3 O O
( O O
2 O O
) O O
21 O O
. O O

Nevertheless O O
, O O
PEG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
influenced O O
in O O
vitro O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
drug O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
availability O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
considerably O O
, O O
by O O
increasing O O
both O O
drug O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
solubility O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
dissolution O B_MEASURE/B_DISEASE
rate O I_MEASURE/I_DISEASE
. O O

Normal O O
replication O O
of O O
DNA B B_BIO/B_GENE
A I I_BIO/I_GENE
still O O
carrying O O
the O O
AC3 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
ORF I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation O O
was O O
found O O
in O O
extracts O O
from O O
these O O
plants O O
. O O

Such O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
saturation O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
often O O
occurs O O
for O O
several O B_ENT/B_TIME[MEASURE]
recording O B_ENT/I_TIME[MEASURE]
sweeps O B_ENT/I_TIME[MEASURE]
after O O
large O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
amplitude O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
signals O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
such O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
as O O
eye O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
blinks O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
are O O
rejected O O
. O O

Muscle O O
and O O
liver O O
biopsies O O
demonstrated O O
the O O
same O O
anomalies O O
, O O
again O O
without O O
branching B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
enzyme I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
deficiency O O
in O O
the O O
liver O O
. O O

Possibility O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
using O O
gynecologic O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nurses O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
independently O O
administered O O
health O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
centers O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION

Airborne O B_MEASURE/B_DISEASE
rabies O I_MEASURE/I_DISEASE
encephalitis O I_MEASURE/I_DISEASE
: O O
demonstration O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
rabies O B_DISEASE/B_SPECIES[BIO]
virus O I_DISEASE/I_SPECIES[BIO]
in O O
the O O
human O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
central O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
nervous O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

T1 O B_PROTEIN[GENE]/B_LOCATION
and O O
T2 O B_MEASURE
values O I_MEASURE
were O O
calculated O O
from O O
guinea O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
pig O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
brain O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
in O O
vivo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
at O O
0 O B_MEASURE
. O O
5 O B_MEASURE/B_LOCATION
T O I_MEASURE/I_LOCATION
. O O

Autophosphorylation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
the O O
major O B_GENE
phosphorylation O I_GENE
site O I_GENE
Y1235 O I_GENE
upregulates O O
the O O
kinase O B_MEASURE
activity O I_MEASURE
of O O
the O O
receptor O B_GENE
, O O
increasing O O
the O O
Vmax O B_MEASURE
of O O
the O O
phosphotransfer O B_ENZYME[GENE]
reaction O I_ENZYME[GENE]
. O O

Clinical O O
development O O
of O O
interleukin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
10 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

By O O
cloning O O
genes O O
encoding O O
benzene O O
- O O
degradative O O
enzymes O O
, O O
we O O
found O O
that O O
strain O O
JS150 O O
also O O
carries O O
genes O O
for O O
a O O
toluene B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
/ I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
benzene I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
monooxygenase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Our O O
data O O
suggest O O
that O O
association O O
of O O
TBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
with O O
the O O
TATA O O
box O O
may O O
be O O
regulated O O
, O O
directly O O
or O O
indirectly O O
, O O
by O O
a O O
substrate O O
of O O
Snf1 B B_GENE
. O O

Fusion O B_NUMBER[MEASURE]/B_GENE
proteins O I_NUMBER[MEASURE]/I_GENE
were O O
isolated O O
by O O
affinity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chromatography O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
APTG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
Sepharose O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
differed O O
from O O
cued O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recall O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O O
in O O
the O O
instructions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
, O O
which O O
directed O O
subjects O B_PERSON
away O O
from O O
the O O
memory O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
aspects O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
the O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
asked O O
them O O
to O O
complete O O
each O O
three O B_NUMBER[MEASURE]
- O O
letter O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cue O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O O
the O O
first O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
word O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
that O O
came O O
to O O
mind O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
. O O

Real O B_PERSON/B_NUMBER[MEASURE]
- O O
time O B_NUMBER[MEASURE]/B_ENT
two O I_NUMBER[MEASURE]/I_ENT
- O O
dimensional O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
echocardiographic O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
studies O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
mitral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
valve O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O O
short O B_MEASURE/B_PERSON
- O O
axis O B_TIME[MEASURE]/B_LOCATION
view O I_TIME[MEASURE]/I_LOCATION
were O O
obtained O O
from O O
10 O B_PERSON/B_MEASURE
normal O I_PERSON/I_MEASURE
subjects O I_PERSON/I_MEASURE
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Sixty O B_NUMBER[MEASURE]/B_LOCATION
- O O
one O B_NUMBER[MEASURE]
percent O I_NUMBER[MEASURE]
of O O
the O O
patients O B_PERSON/B_BIO
had O O
damage O B_DISEASE
within O O
7 O B_TIME[MEASURE]/B_ENT
years O I_TIME[MEASURE]/I_ENT
of O O
onset O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O O
mean O B_MEASURE
3 O I_MEASURE
. O O
8 O B_TIME[MEASURE]
yrs O I_TIME[MEASURE]
) O O
. O O

It O O
was O O
previously O O
shown O O
that O O
Vi B B_GENE/B_DISEASE
antigen I I_GENE/I_DISEASE
expression O O
was O O
regulated O O
by O O
a O O
system O O
similar O O
to O O
the O O
rcs B B_DISEASE_ADJECTIVE[DISEASE]
regulatory O O
system O O
involved O O
in O O
colanic O O
acid O O
synthesis O O
in O O
Escherichia O O
coli O O
. O O

The O O
map O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
based O O
on O O
the O O
CEPH O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reference O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
pedigrees O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
includes O O
over O O
4000 O B_MEASURE/B_ORGANIZATION
new O I_MEASURE/I_ORGANIZATION
genotypes O I_MEASURE/I_ORGANIZATION
, O O
our O O
previously O O
reported O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plus O O
29 O B_GENE/B_PERSON
allele O I_GENE/I_PERSON
systems O I_GENE/I_PERSON
from O O
the O O
published O O
CEPH O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
version O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
5 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
database O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
and O O
was O O
constructed O O
using O O
the O O
program O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
package O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
CRI O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O O
MAP O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

To O O
identify O O
the O O
GRK6 B B_GENE/B_LOCATION
homologue I I_GENE/I_LOCATION
on O O
chromsome O O
13 O O
, O O
several O O
sets O O
of O O
closely O O
- O O
spaced O O
primers O O
were O O
designed O O
based O O
on O O
the O O
GRK6 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cDNA I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sequence I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
then O O
used O O
to O O
amplify O O
human O O
genomic O O
DNA O O
by O O
PCR O O
. O O

In O O
the O O
absence O O
of O O
Mg2 O O
+ O O
, O O
the O O
extent O O
of O O
destabilization O O
of O O
tRNAPhe B B_GENE
is O O
greater O O
but O O
appears O O
to O O
be O O
confined O O
to O O
internal O O
regions O O
of O O
the O O
acceptor O O
and O O
T O O
psi O O
C O O
helices O O
, O O
as O O
evidenced O O
by O O
the O O
selectively O O
enhanced O O
exchange O O
rates O O
for O O
imino O O
protons O O
associated O O
with O O
these O O
base O O
pairs O O
. O O

Studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
26 O B_EDU[ORGANIZATION]/B_LOCATION
patients O I_EDU[ORGANIZATION]/I_LOCATION
. O O

Serum B B_MEASURE/B_GENE
alpha I I_MEASURE/I_GENE
- I I_MEASURE/I_GENE
amylase I I_MEASURE/I_GENE
, O O
trypsin B B_ENZYME[GENE]
, O O
trypsin B B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
lipase B B_ENZYME[GENE]
and O O
total O O
protease O O
activity O O
in O O
the O O
pancreatic O O
tissue O O
was O O
studied O O
as O O
indicator O O
of O O
the O O
treatment O O
efficacy O O
with O O
5 O O
- O O
fluorouracil O O
electro O O
- O O
cumulation O O
. O O

1 O B_MEASURE
The O O
effects O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
high O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
doses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
piretanide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
new O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diuretic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agent O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemically O O
related O O
to O O
frusemide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
bumetanide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
evaluated O O
in O O
twelve O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
with O O
severe O B_DISEASE/B_GENE
chronic O I_DISEASE/I_GENE
renal O I_DISEASE/I_GENE
insufficiency O I_DISEASE/I_GENE
( O O
creatinine O B_MEASURE/B_DISEASE
clearance O B_MEASURE/I_DISEASE
below O O
25 O B_MEASURE
ml O I_MEASURE
/ O O
min O B_TIME[MEASURE]/B_PERSON
) O O
. O O

Synthesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
22 O B_MEASURE
- O O
oxavitamin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
D3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analogues O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

This O O
effect O O
is O O
independent O O
of O O
the O O
Gal4 B B_GENE
protein I I_GENE
, O O
as O O
it O O
operates O O
in O O
a O O
gal4 B B_DISEASE_ADJECTIVE[DISEASE]
mutant I I_DISEASE_ADJECTIVE[DISEASE]
background O O
as O O
well O O
. O O

Consistent O O
with O O
the O O
large O O
pocket O O
of O O
Rb B B_GENE
binding O O
to O O
TAF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
250 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
large O O
pocket O O
domains O O
of O O
both O O
p107 B B_GENE/B_DISEASE
and O O
p130 B B_GENE
are O O
able O O
to O O
bind O O
to O O
TAF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
250 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
vivo O O
. O O

50 O B_NUMBER[MEASURE]
- O O
nucleotide O B_MEASURE
) O O
intron O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
to O O
AA O B_GENE/B_DISEASE
. O O

The O O
educational O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
program O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
the O O
significant O B_MEASURE/B_ORGANIZATION
factor O I_MEASURE/I_ORGANIZATION
that O O
influenced O O
the O O
change O B_MEASURE
of O O
concern O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trajectories O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
the O O
recurrent O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
/ O O
non O B_DISEASE/B_LOCATION
- O O
recurrent O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
factor O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
influenced O O
the O O
change O B_MEASURE/B_ORGANISM_FUNCTION
of O O
concern O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O O
in O O
pamphlet O B_PERSON/B_ORGANIZATION
group O I_PERSON/I_ORGANIZATION
. O O

Amplification O O
of O O
4q21 O O
- O O
q22 O O
and O O
the O O
MXR B B_GENE/B_MEASURE
gene I I_GENE/I_MEASURE
in O O
independently O O
derived O O
mitoxantrone O O
- O O
resistant O O
cell O O
lines O O
. O O

Activation O O
of O O
the O O
receptor O O
induces O O
Ret B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphorylation O O
that O O
leads O O
the O O
survival O O
- O O
promoting O O
effects O O
. O O

In O O
patients O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
which O O
these O O
criteria O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
not O O
met O O
only O O
the O O
reproducibility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
VO2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
obtained O O
in O O
both O O
the O O
P O B_PROTEIN[GENE]/B_LOCATION
- O O
MET O B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
the O O
C O B_OTHER/B_PROTEIN[GENE]
- O O
MET O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
indicated O O
that O O
the O O
maximal O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
VO2 O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
these O O
4 O B_PERSON/B_DISEASE
patients O I_PERSON/I_DISEASE
had O O
been O O
reached O O
. O O

This O O
paper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
describes O O
a O O
course O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
an O O
agoraphobic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
female O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
patient O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

A O O
previously O O
developed O O
kinetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O O
used O O
to O O
identify O O
major O B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemical O B_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction O B_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathways O B_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involving O O
PAH O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
the O O
afterburner O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Henry O B_PERSON
Quastler O I_PERSON
brought O O
experience O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
an O O
actual O B_MEASURE/B_LOCATION
x O I_MEASURE/I_LOCATION
- O O
ray O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
treatment O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
and O O
Dr O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Critical O O
review O O
of O O
tests O O
for O O
the O O
HBs B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antigen I B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
detection O O
of O O
infectious O O
blood O O

A O O
direct O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
statistically O O
reliable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
correction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
enzymes O B_PROTEIN[GENE]/B_MEASURE
with O O
the O O
initial O B_TIME[MEASURE]/B_LOCATION
state O I_TIME[MEASURE]/I_LOCATION
of O O
the O O
patients O B_PERSON/B_DISEASE
has O O
been O O
established O O
in O O
an O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
25 O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
aged O O
from O O
18 O B_MEASURE
to O O
60 O B_MEASURE/B_ENT
years O I_MEASURE/I_ENT
in O O
prosthesis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
+ O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
the O O
mitral O B_MEDICAL_DEVICE[OBJECT]/B_DISEASE_ADJECTIVE[DISEASE]
valve O I_MEDICAL_DEVICE[OBJECT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
n O B_MEASURE
- O O
9 O B_MEASURE
) O O
and O O
closed O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
mitral O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
commissurotomy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
n O O
- O O
16 O B_MEASURE
) O O
. O O

DSS4 B B_GENE/B_PERSON
- I I_GENE/I_PERSON
1 I I_GENE/I_PERSON
is O O
a O O
dominant O O
suppressor O O
of O O
sec4 B B_GENE/B_BACTERIUM[BIO]
- I B_GENE/I_BACTERIUM[BIO]
8 I B_GENE/I_BACTERIUM[BIO]
that O O
encodes O O
a O O
nucleotide O O
exchange O O
protein O O
that O O
aids O O
Sec4p B B_GENE
function O O
. O O

These O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
indicate O O
that O O
KCTG O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
can O O
contribute O O
to O O
improved O O
monitoring O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
pregnancies O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

The O O
MI O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
site O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O O
predictive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
hemodynamic O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
left O O
ventricular O B_DISEASE_ADJECTIVE[DISEASE]
dysfunction O I_DISEASE_ADJECTIVE[DISEASE]
both O O
at O O
rest O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
during O O
exercise O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
: O O
anterior O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
MIs O I_PERSON/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
are O O
more O O
impaired O B_DISEASE_ADJECTIVE[DISEASE]
than O O
inferior O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
MIs O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
. O O

The O O
vaccine O O
was O O
highly O O
immunogenic O O
, O O
since O O
111 O O
of O O
113 O O
patients O O
( O O
98 O O
% O O
) O O
produced O O
anti B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HBs I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
10 O O
mIU O O
/ O O
ml O O
or O O
more O O
) O O
. O O

The O O
interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IL B B_PROTEIN[GENE]/B_LOCATION
- I I_PROTEIN[GENE]/I_LOCATION
2R I I_PROTEIN[GENE]/I_LOCATION
alpha I I_PROTEIN[GENE]/I_LOCATION
) O O
chain O O
gene O O
contains O O
a O O
sequence O O
similar O O
to O O
the O O
immunoglobulin B B_GENE
( I I_GENE
Ig I I_GENE
) I I_GENE
kappa I I_GENE
( O O
kappa O O
) O O
enhancer O O
NF B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
kappa I I_GENE/I_LOCATION
B I I_GENE/I_LOCATION
binding I I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
. O O

Comparison O O
of O O
the O O
derived O O
amino O O
acid O O
sequence O O
with O O
that O O
of O O
the O O
HCMV B B_GENE/B_PERSON
UL99 I I_GENE/I_PERSON
gene I I_GENE/I_PERSON
product I I_GENE/I_PERSON
reveals O O
34 O O
. O O
8 O O
% O O
identity O O
in O O
an O O
overlap O O
of O O
66 O O
amino O O
acids O O
. O O

Although O O
mutant B B_SPECIES[BIO]/B_GENE
pex5delta I I_SPECIES[BIO]/I_GENE
cells O O
expressing O O
a O O
yeast B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tobacco I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Pex5p I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chimaera I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
failed O O
to O O
import O O
a O O
GFP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
Eci1p B B_GENE
reporter O O
protein O O
, O O
they O O
were O O
able O O
to O O
grow O O
on O O
oleic O O
acid O O
. O O

Consistent O O
with O O
this O O
observation O O
, O O
introduction O O
of O O
Smad B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
into O O
a O O
TGFbeta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
insensitive O O
LEF1 B B_GENE/B_LOCATION
/ O O
TCF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target O O
gene O O
confers O O
cooperative O O
TGFbeta B B_GENE/B_DISEASE
and O O
Wnt B B_GENE
responsiveness O O
to O O
the O O
promoter O O
. O O

In O O
analogy O O
to O O
human B B_GENE
CD70 I I_GENE
, O O
mCD70 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcript I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O O
are O O
strongly O O
but O O
transiently O O
up O O
- O O
regulated O O
during O O
lymphocyte O O
activation O O
, O O
which O O
is O O
in O O
line O O
with O O
a O O
role O O
for O O
the O O
CD27 B B_GENE
- I I_GENE
CD70 I I_GENE
receptor I I_GENE
pair O O
early O O
in O O
the O O
immune O O
response O O
. O O

Serum B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IgM I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
showed O O
a O O
highly O O
significant O O
increase O O
in O O
all O O
types O O
of O O
brain O O
tumour O O
when O O
compared O O
to O O
controls O O
. O O

Beyond O O
the O O
first O B_DISEASE/B_MEASURE
year O I_DISEASE/I_MEASURE
post O I_DISEASE/I_MEASURE
- O O
renal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplantation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
there O O
was O O
no O O
difference O B_MEASURE
in O O
C O B_DISEASE/B_GENE
( O O
IO O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
between O O
LRD O B_DISEASE_ADJECTIVE[DISEASE]
and O O
CAD O B_LOCATION/B_DISEASE
allografts O I_LOCATION/I_DISEASE
. O O

Vk8 B B_GENE
/ O O
Jk2 B B_MEASURE
and O O
Vk1 B B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
Jk5 B B_GENE/B_MEASURE
rearrangements O O
encoded O O
the O O
respective O O
L B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
V I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regions I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
phenomena O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
nursing O B_PERSON
are O O
deeply O O
rooted O O
in O O
the O O
human O B_PERSON/B_LOCATION
condition O I_PERSON/I_LOCATION
. O O

Clinical O B_MEASURE/B_LOCATION
findings O B_MEASURE/I_LOCATION
plaque O B_MEASURE/I_LOCATION
index O B_MEASURE/I_LOCATION
, O O
PI O B_LOCATION/B_PROTEIN[GENE]
; O O
gingival O B_MEASURE/B_DISEASE
index O B_MEASURE/I_DISEASE
, O O
GI O B_LOCATION/B_PROTEIN[GENE]
; O O
bleeding O O
on O O
probing O O
, O O
BOP O B_LOCATION/B_DISEASE
; O O
pus O B_DISEASE
discharge O I_DISEASE
, O O
pus O B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
; O O
and O O
probing O O
depth O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
PD O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
both O O
PT O B_LOCATION/B_PROTEIN[GENE]
- O O
01 O B_MEASURE/B_LOCATION
and O O
control O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
measured O O
at O O
every O O
visit O B_PERSON/B_LOCATION
for O O
4 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
weeks O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

One O B_NUMBER[MEASURE]/B_PERSON
of O O
these O O
elements O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
resembles O O
the O O
binding O O
site O B_LOCATION/B_MEASURE
of O O
a O O
previously O O
identified O O
cellular O B_DISEASE/B_SPECIES[BIO]
" O O
transcription O B_GENE/B_DISEASE
" O O
factor O B_MEASURE/B_LOCATION
. O O

NER O O
was O O
also O O
measured O O
by O O
a O O
plasmid O O
host O O
cell O O
re O O
- O O
activation O O
assay O O
using O O
a O O
vector O O
containing O O
a O O
luciferase B B_GENE
reporter I I_GENE
gene I I_GENE
. O O

Plasma O B_MEASURE/B_LOCATION
Pi O I_MEASURE/I_LOCATION
, O O
tibia O B_MEASURE/B_LOCATION
breaking O B_MEASURE/I_LOCATION
strength O B_MEASURE/I_LOCATION
, O O
and O O
percentage O B_MEASURE/B_DISEASE
of O O
tibia O B_MEASURE/B_DISEASE
ash O B_MEASURE/I_DISEASE
were O O
increased O O
by O O
raising O O
dietary O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
Pav O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
in O O
the O O
presence O B_LOCATION/B_MEASURE
of O O
. O O
392 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A1 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
either O O
level O B_MEASURE/B_LOCATION
of O O
Ca O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
total O B_MEASURE
of O O
114 O B_MEASURE
animals O I_MEASURE
were O O
infected O O
by O O
E O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
coli O B_BACTERIUM[BIO]
O2 O I_BACTERIUM[BIO]
: O O
K1 O B_PROTEIN[GENE]/B_MEASURE
: O O
H4 O B_MEASURE/B_LOCATION
by O O
the O O
hematogenic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
route O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
the O O
fungus O O
Neurospora O O
crassa O O
, O O
nit B B_GENE
- I I_GENE
2 I I_GENE
, O O
the O O
major O O
nitrogen O O
regulatory O O
gene O O
, O O
activates O O
the O O
expression O O
of O O
unlinked O O
structural O O
genes O O
that O O
specify O O
nitrogen O O
- O O
catabolic O O
enzymes O O
during O O
conditions O O
of O O
nitrogen O O
limitation O O
. O O

The O O
matrix O O
of O O
the O O
CBs O O
contains O O
the O O
diagnostic O O
protein O O
p80 B B_PROTEIN[GENE]/B_DISEASE
- O O
coilin B B_MEASURE/B_LOCATION
, O O
which O O
is O O
colocalized O O
with O O
the O O
U7 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
small I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ribonucleoprotein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
snRNP O O
) O O
, O O
whereas O O
the O O
attached O O
and O O
embedded O O
B O O
- O O
snurposomes O O
contain O O
splicing O O
snRNPs O O
. O O

During O O
an O O
observation O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
period O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
12 O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
after O O
halving O O
atenolol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
from O O
a O O
mean O B_MEASURE/B_LOCATION
dose O I_MEASURE/I_LOCATION
of O O
82 O B_MEASURE
mg O I_MEASURE
to O O
41 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
no O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
changes O I_DISEASE_ADJECTIVE[DISEASE]
in O O
systolic O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
and O O
diastolic O B_MEASURE/B_DISEASE
blood O B_MEASURE/I_DISEASE
pressure O B_MEASURE/I_DISEASE
or O O
in O O
response O B_DISEASE/B_GENE
rate O I_DISEASE/I_GENE
( O O
defined O O
as O O
a O O
diastolic O B_MEASURE/B_LOCATION
blood O I_MEASURE/I_LOCATION
pressure O I_MEASURE/I_LOCATION
of O O
95 O B_NUMBER[MEASURE]
mm O I_NUMBER[MEASURE]
Hg O I_NUMBER[MEASURE]
or O O
less O B_MEASURE
) O O
were O O
observed O O
. O O

Comparative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
volumetric O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O O
defined O O
as O O
the O O
difference O B_MEASURE
between O O
mean O B_MEASURE
corpuscular O I_MEASURE
erythrocyte O I_MEASURE
volume O I_MEASURE
in O O
peripheral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
MCVB O B_LOCATION/B_DISEASE
) O O
diluted O O
in O O
urine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
supernatant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
after O O
centrifugation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
mean O B_MEASURE/B_LOCATION
corpuscular O I_MEASURE/I_LOCATION
volume O I_MEASURE/I_LOCATION
of O O
urinary O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
erythrocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MCVU O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

PATIENTS O O
: O O
33 O O
HIV O O
- O O
infected O O
, O O
zidovudine O O
- O O
experienced O O
patients O O
with O O
serum O O
HIV O O
RNA O O
levels O O
of O O
at O O
least O O
20 O O
, O O
000 O O
copies O O
/ O O
mL O O
and O O
CD4 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
counts O O
ranging O O
from O O
50 O O
to O O
400 O O
cells O O
/ O O
mm3 O O
. O O

Within O O
the O O
last O B_TIME[MEASURE]/B_ENT
few O I_TIME[MEASURE]/I_ENT
years O I_TIME[MEASURE]/I_ENT
, O O
the O O
WWW O B_ORGANIZATION/B_LOCATION
has O O
grown O O
enormously O O
. O O

These O O
data O O
, O O
taken O O
together O O
, O O
suggest O O
that O O
CRF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
produces O O
its O O
behavioral O O
activating O O
and O O
anxiogenic O O
effects O O
, O O
at O O
least O O
in O O
part O O
, O O
by O O
increasing O O
the O O
activity O O
of O O
LC O O
noradrenergic O O
neurons O O
. O O

On O O
the O O
basis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
8 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cases O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
the O O
authors O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
report O O
different O B_LOCATION/B_ENT
clinical O I_LOCATION/I_ENT
pictures O I_LOCATION/I_ENT
all O O
caused O O
by O O
cardiac O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
toxicity O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
5FU O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
sequence O O
of O O
Vac1p B B_GENE/B_BIO
contains O O
two O O
putative O O
zinc O O
- O O
binding O O
RING O O
motifs O O
, O O
a O O
zinc O O
finger O O
motif O O
, O O
and O O
a O O
coiled O O
- O O
coil O O
motif O O
. O O

Although O O
cardiac O B_MEASURE/B_DISEASE
output O B_MEASURE/I_DISEASE
decreased O O
slightly O O
with O O
PCF O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
hemodynamic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
due O O
to O O
PCF O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
unlikely O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
account O O
for O O
the O O
observed O O
fall O B_DISEASE_ADJECTIVE[DISEASE]
in O O
PaO2 O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Anti B B_PERSON/B_DISEASE
- I I_PERSON/I_DISEASE
Jo I I_PERSON/I_DISEASE
- I I_PERSON/I_DISEASE
1 I I_PERSON/I_DISEASE
antibody I I_PERSON/I_DISEASE
was O O
not O O
present O O
. O O

The O O
first O O
operon O O
, O O
orf1 O O
- O O
tolQRA B B_MEASURE
, O O
is O O
iron O O
regulated O O
throughout O O
growth O O
, O O
but O O
iron O O
- O O
regulated O O
expression O O
of O O
tolB B B_GENE/B_BACTERIUM[BIO]
and O O
oprL B B_DISEASE/B_GENE
fusions I B_DISEASE/I_GENE
occurs O O
only O O
in O O
late O O
log O O
phase O O
. O O

S O B_LOCATION/B_DISEASE
. O O
aureus O B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
leakage O B_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
into O O
the O O
totally O O
submerged O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specimens O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
detected O O
in O O
1 O B_NUMBER[MEASURE]/B_LOCATION
of O O
5 O B_MEASURE/B_PERSON
samples O I_MEASURE/I_PERSON
incubated O O
for O O
4 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
while O O
no O O
leakage O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
detected O O
in O O
specimens O B_BIO/B_PERSON
incubated O O
for O O
3 O B_NUMBER[MEASURE]
, O O
5 O B_NUMBER[MEASURE]
, O O
6 O B_SEQUENCE[MEASURE]
, O O
7 O B_SEQUENCE[MEASURE]
, O O
and O O
8 O B_NUMBER[MEASURE]/B_ENT
weeks O I_NUMBER[MEASURE]/I_ENT
. O O

We O O
examined O O
the O O
contribution O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
cryptic O B_GENE/B_BIO
plasmid O I_GENE/I_BIO
, O O
pRmeGR4b O O
, O O
to O O
the O O
nodulation O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O O
Medicago O B_BIO/B_DISEASE
sativa O I_BIO/I_DISEASE
by O O
strain O B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GR4 O B_BIO/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Rhizobium O B_BIO/B_LOCATION
meliloti O I_BIO/I_LOCATION
. O O

It O O
also O O
appears O O
that O O
in O O
patients O B_PERSON/B_LOCATION
with O O
laboratory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
prerenal O B_DISEASE
acute O I_DISEASE
renal O I_DISEASE
failure O I_DISEASE
( O O
i O O
. O O
e O O
. O O
, O O
a O O
RFT O B_MEASURE
less O I_MEASURE
than O O
1 O B_NUMBER[MEASURE]
. O O
0 O B_MEASURE
) O O
, O O
the O O
response O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
treatment O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
unpredictable O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
in O O
fact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
may O O
have O O
a O O
worse O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prognosis O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
in O O
those O O
with O O
a O O
RFI O B_MEASURE/B_ORGANIZATION
greater O I_MEASURE/I_ORGANIZATION
than O O
1 O B_NUMBER[MEASURE]
. O O
0 O B_MEASURE
( O O
5 O B_MEASURE
/ O O
7 O B_MEASURE
deaths O I_MEASURE
vs O I_MEASURE
10 O I_MEASURE
/ O O
48 O B_MEASURE
deaths O I_MEASURE
) O O
. O O

Paraplegia O B_DISEASE_ADJECTIVE[DISEASE]
associated O O
with O O
intraaortic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
balloon O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pump O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
counterpulsation O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CTP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
GDP O B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
GTP O B_GENE/B_LOCATION
, O O
ITP O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
did O O
not O O
affect O O
the O O
response O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Using O O
green B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fluorescent I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fusions O O
we O O
demonstrate O O
that O O
the O O
SYT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
SSX B B_LOCATION/B_GENE
and O O
the O O
SYT B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
SSX B B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
proteins O O
are O O
nuclear O O
proteins O O
. O O

The O O
anaesthetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
management O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
41 O B_PERSON
patients O I_PERSON
who O O
underwent O O
cardiac O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
transplantation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
during O O
a O O
40 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
month O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
period O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
at O O
Clinica O B_LOCATION/B_PERSON
Puerta O I_LOCATION/I_PERSON
de O I_LOCATION/I_PERSON
Hierro O I_LOCATION/I_PERSON
is O O
reviewed O O
. O O

Acute O B_DISEASE_ADJECTIVE[DISEASE]
respiratory O I_DISEASE_ADJECTIVE[DISEASE]
distress O I_DISEASE_ADJECTIVE[DISEASE]
syndrome O I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
data O O
suggested O O
that O O
mutant B B_DISEASE
PS1 I I_DISEASE
may O O
cause O O
disease O O
as O O
a O O
result O O
of O O
reduction O O
in O O
PS1 B B_GENE
function O O
. O O

The O O
analysis O O
of O O
the O O
organization O O
of O O
the O O
sequence O O
of O O
the O O
human O O
ABP B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
DAO B B_LOCATION/B_PROTEIN[GENE]
gene O O
reveals O O
that O O
the O O
2 O O
. O O
4 O O
- O O
kilobase O O
messenger O O
RNA O O
is O O
transcribed O O
from O O
two O O
close O O
origins O O
identifying O O
the O O
proximal O O
promoter O O
. O O

Most O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
after O O
all O O
, O O
is O O
not O O
the O O
ionization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
technique O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
but O O
the O O
stage O B_ENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
a O O
47 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
five O I_MEASURE
- O O
year O B_SEQUENCE[MEASURE]/B_LOCATION
survival O I_SEQUENCE[MEASURE]/I_LOCATION
rate O I_SEQUENCE[MEASURE]/I_LOCATION
in O O
T1N0 O B_PROTEIN[GENE]/B_MEASURE
as O O
compared O O
to O O
T2N0 O B_PROTEIN[GENE]/B_DISEASE
with O O
28 O B_MEASURE
. O O
6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
and O O
T1N1 O B_PROTEIN[GENE]/B_MEASURE
with O O
19 O B_MEASURE
. O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
. O O

To O O
investigate O O
the O O
step O O
of O O
spliceosome O O
assembly O O
at O O
which O O
Snu17p B B_GENE
acts O O
, O O
we O O
have O O
used O O
nondenaturing O O
gel O O
electrophoresis O O
. O O

We O O
also O O
show O O
that O O
an O O
internal O O
fragment O O
of O O
U24 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
methylation I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
guide I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
snoRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
encompassing O O
the O O
upstream O O
antisense O O
element O O
and O O
the O O
D O O
' O O
and O O
C O O
' O O
box O O
motifs O O
, O O
can O O
support O O
the O O
site O O
- O O
specific O O
methylation O O
of O O
rRNA O O
. O O

Mammalian O O
ribonucleotide B B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reductase I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shows O O
S O O
- O O
phase O O
specific O O
expression O O
and O O
consists O O
of O O
two O O
non O O
- O O
identical O O
subunits O O
, O O
proteins B B_PROTEIN[GENE]/B_DISEASE
R1 I I_PROTEIN[GENE]/I_DISEASE
( O O
large O O
subunit O O
) O O
and O O
R2 B B_PROTEIN[GENE]
( O O
small O O
subunit O O
) O O
. O O

Effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]
of O O
radiation O B_DISEASE
nephropathy O I_DISEASE
in O O
the O O
rat O B_BIO/B_PERSON
. O O

Recombinant B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MsERK1 I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
rMsERK1 B B_GENE
) O O
, O O
when O O
overexpressed O O
in O O
Escherichia O O
coli O O
, O O
is O O
recognized O O
by O O
antibodies O O
raised O O
against O O
MAP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
rat I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Xenopus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sea I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
star I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
by O O
anti B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphotyrosine I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antibodies I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
identification O O
of O O
SRP54sc B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
SRP54sp B B_GENE
provides O O
the O O
first O O
evidence O O
for O O
SRP B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
related O O
proteins O O
in O O
yeast O O
. O O

We O O
previously O O
demonstrated O O
that O O
AKT2 B B_GENE
, O O
a O O
member O O
of O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
is O O
activated O O
by O O
a O O
number O O
of O O
growth O O
factors O O
via O O
Ras B B_GENE/B_DISEASE
and O O
PI B B_GENE
3 I I_GENE
- I I_GENE
kinase I I_GENE
signaling O O
pathways O O
. O O

So O O
it O O
is O O
sometimes O O
more O O
convenient O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
use O O
the O O
back O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
Radon O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
transform O O
R O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_MEASURE/B_LOCATION
and O O
then O O
to O O
correct O O
the O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
taking O O
into O O
account O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
attenuation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Before O O
flecainide O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
all O O
patients O B_PERSON/B_BIO
had O O
easily O O
inducible O B_DISEASE
VT O I_DISEASE
that O O
was O O
morphologically O O
identical O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
their O O
spontaneously O O
occurring O O
arrhythmia O B_DISEASE/B_PERSON
. O O

An O O
additional O B_MEASURE/B_LOCATION
dose O I_MEASURE/I_LOCATION
of O O
20 O B_MEASURE/B_LOCATION
- O O
25 O B_MEASURE/B_PERSON
Gy O I_MEASURE/I_PERSON
was O O
delivered O O
to O O
the O O
site O B_LOCATION/B_PERSON
of O O
original O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
involvement O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
using O O
an O O
implant O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
when O O
feasible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
prominent O B_DISEASE/B_MEASURE
fracture O I_DISEASE/I_MEASURE
of O O
women O B_PERSON/B_TIME[MEASURE]
older O B_PERSON/I_TIME[MEASURE]
than O O
75 O B_NUMBER[MEASURE]/B_ENT
years O I_NUMBER[MEASURE]/I_ENT
is O O
the O O
hip O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
fracture O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
type O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
II O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
osteoporosis O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

The O O
expected O O
products O O
of O O
the O O
cloned O O
bph B B_GENE
genes I I_GENE
, O O
except O O
bphA3 B B_GENE/B_BIO
, O O
were O O
observed O O
in O O
E O O
. O O
coli O O
in O O
an O O
in O O
vitro O O
transcription O O
- O O
translation O O
system O O
. O O

It O O
is O O
our O O
conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
Sonoclot O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
coagulation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
analysis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O O
unlikely O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
identify O O
patients O B_PERSON/B_BIO
with O O
prolonged O B_DISEASE
bleeding O I_DISEASE
time O I_DISEASE
in O O
whom O O
platelet O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
count O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
other O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coagulation O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
Pearson O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
s O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
correlation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O O
that O O
the O O
subjects O B_PERSON
who O O
had O O
higher O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scores O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
SSMS O B_DISEASE
during O O
the O O
drum O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rotation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
generated O O
the O O
following O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
a O O
) O O
a O O
higher O B_MEASURE
rating O I_MEASURE
of O O
over O O
- O O
all O O
sickness O B_DISEASE/B_MEASURE
( O O
r O B_PROTEIN[GENE]/B_MEASURE
= O O
0 O B_NUMBER[MEASURE]
. O O
76 O B_MEASURE
) O O
; O O
b O O
) O O
a O O
higher O B_MEASURE/B_LOCATION
ratio O I_MEASURE/I_LOCATION
of O O
spectral O B_MEASURE/B_LOCATION
power O I_MEASURE/I_LOCATION
of O O
EGG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
4 O B_NUMBER[MEASURE]
- O O
9 O B_NUMBER[MEASURE]/B_LOCATION
cycles O I_NUMBER[MEASURE]/I_LOCATION
per O O
minute O B_TIME[MEASURE]
( O O
cpm O B_MEASURE/B_PROTEIN[GENE]
) O O
between O O
drum O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
rotation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
and O O
baseline O B_MEASURE/B_ENT
periods O B_MEASURE/I_ENT
( O O
r O B_OTHER/B_PROTEIN[GENE]
= O O
0 O B_NUMBER[MEASURE]
. O O
63 O B_MEASURE
) O O
; O O
c O O
) O O
a O O
higher O B_MEASURE
net O I_MEASURE
percent O I_MEASURE
increase O I_MEASURE
of O O
spectral O B_MEASURE/B_LOCATION
power O I_MEASURE/I_LOCATION
in O O
the O O
EEG O B_MEASURE
frequency O I_MEASURE
band O I_MEASURE
0 O I_MEASURE
. O O
5 O B_MEASURE
- O O
4 O B_MEASURE
Hz O I_MEASURE
between O O
drum O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
rotation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
and O O
baseline O B_TIME[MEASURE]/B_LOCATION
periods O I_TIME[MEASURE]/I_LOCATION
on O O
C3 O B_PROTEIN[GENE]
( O O
r O B_PROTEIN[GENE]
= O O
0 O B_NUMBER[MEASURE]
. O O
29 O B_MEASURE
) O O
and O O
C4 O B_PROTEIN[GENE]
( O O
r O B_PROTEIN[GENE]/B_MEASURE
= O O
0 O B_NUMBER[MEASURE]
. O O
31 O B_MEASURE
) O O
; O O
d O O
) O O
a O O
higher O B_MEASURE/B_LOCATION
ratio O I_MEASURE/I_LOCATION
of O O
spectral O B_MEASURE/B_LOCATION
power O I_MEASURE/I_LOCATION
of O O
EEG O B_MEASURE
frequency O I_MEASURE
band O I_MEASURE
0 O I_MEASURE
. O O
5 O B_MEASURE
- O O
4 O B_MEASURE
Hz O I_MEASURE
between O O
drum O B_MEASURE/B_ENT
rotation O I_MEASURE/I_ENT
and O O
baseline O B_TIME[MEASURE]/B_ENT
periods O I_TIME[MEASURE]/I_ENT
on O O
C3 O B_MEASURE/B_GENE
( O O
r O B_OTHER/B_GENE
= O O
0 O B_MEASURE/B_LOCATION
. O O
31 O B_MEASURE
) O O
; O O
and O O
e O O
) O O
a O O
higher O B_MEASURE
level O I_MEASURE
of O O
net O B_MEASURE
increase O I_MEASURE
in O O
skin O B_MEASURE/B_DISEASE
conductance O I_MEASURE/I_DISEASE
from O O
baseline O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
drum O B_MEASURE
rotation O I_MEASURE
( O O
r O B_MEASURE/B_GENE
= O O
0 O B_NUMBER[MEASURE]
. O O
30 O B_MEASURE
) O O
. O O

Salts O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
of O O
these O O
four O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
metal O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
ions O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
may O O
be O O
added O O
to O O
the O O
growth O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
medium O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
to O O
facilitate O O
selective O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
isolation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
of O O
Acinetobacter O B_BIO/B_GENE
. O O

The O O
consensus O O
mammalian O O
ER O O
stress O O
response O O
element O O
( O O
ERSE O O
) O O
conserved O O
among O O
grp B B_SPECIES[BIO]/B_GENE
promoters I I_SPECIES[BIO]/I_GENE
consists O O
of O O
a O O
tripartite O O
structure O O
CCAAT O O
( O O
N9 O O
) O O
CCACG O O
, O O
with O O
N O O
being O O
a O O
strikingly O O
GC O O
- O O
rich O O
region O O
of O O
9 O O
bp O O
. O O

Acute O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toxicity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tests O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
conducted O O
to O O
measure O O
the O O
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
first O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
instar O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Toxorhynchites O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splendens O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
commonly O O
used O O
mosquito O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adulticides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
malathion O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
naled O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
resmethrin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
positive O O
correlation O O
was O O
also O O
established O O
between O O
the O O
level O O
of O O
FP9C B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O O
and O O
the O O
degree O O
of O O
cell O O
differentiation O O
in O O
vitro O O
. O O

Effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
acute O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
exposure O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
cold O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O O
pulmonary O B_DISEASE
arterial O I_DISEASE
blood O I_DISEASE
pressure O I_DISEASE
in O O
awake O B_PERSON/B_BIO
rats O B_PERSON/I_BIO
. O O

When O O
labeled O O
by O O
the O O
described O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
99mTc O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
on O O
DTPA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
coupled O O
antibodies O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shows O O
instability O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
serum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O O
superior O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
stability O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
99mTc O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
on O O
antibodies O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
without O O
the O O
attached O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DTPA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Unlike O O
CSK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
SH3 B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
domain I I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
HYL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
was O O
unique O O
since O O
the O O
ALYDY O O
motif O O
was O O
absent O O
. O O

As O O
the O O
mechanism O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
intractability O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
cell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
function O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
involved O O
in O O
the O O
defense O B_ORGANIZATION/B_DISEASE
against O O
infection O B_DISEASE
was O O
evaluated O O
. O O

88 O B_MEASURE
, O O
3739 O B_MEASURE
- O O
3743 O B_MEASURE
) O O
) O O
. O O

OBJECTIVE O B_MEASURE
: O O
To O O
report O O
a O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
fulminant O B_DISEASE/B_PERSON
neuropathy O I_DISEASE/I_PERSON
with O O
severe O B_DISEASE
quadriparesis O I_DISEASE
associated O O
with O O
vincristine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
chemotherapy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

The O O
median O B_TIME[MEASURE]/B_PERSON
survival O I_TIME[MEASURE]/I_PERSON
time O I_TIME[MEASURE]/I_PERSON
was O O
18 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
. O O

Hemorrheological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
proposed O O
pharmacological O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
uses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Its O O
phosphorylation O O
strongly O O
potentiates O O
its O O
ability O O
to O O
activate O O
transcription O O
of O O
the O O
c B B_GENE
- I I_GENE
fos I I_GENE
promoter I I_GENE
through O O
a O O
ternary O O
complex O O
assembled O O
on O O
the O O
c B B_GENE
- I I_GENE
fos I I_GENE
serum I I_GENE
response I I_GENE
element I I_GENE
. O O

Fus3p B B_GENE
and O O
Kss1p B B_GENE/B_LOCATION
together O O
increase O O
the O O
expression O O
of O O
CLN3 B B_GENE/B_DISEASE
and O O
PCL2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
promote O O
budding O O
, O O
and O O
Kss1p B B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
inhibits O O
the O O
MAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cascade O O
. O O

Consistent O O
with O O
our O O
observation O O
that O O
AP B B_GENE
- I I_GENE
1 I I_GENE
binding O O
does O O
not O O
contribute O O
to O O
c B B_GENE
- I I_GENE
Jun I I_GENE
coactivation O O
is O O
the O O
observation O O
that O O
the O O
activation O O
of O O
PU B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
c B B_GENE
- I I_GENE
Jun I I_GENE
is O O
blocked O O
by O O
overexpression O O
of O O
c B B_GENE
- I I_GENE
Fos I I_GENE
. O O

A O O
possible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
correlation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O O
mandibular O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
growth O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
retardation O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
palatal O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clefting O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
discussed O O
. O O

Time O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dependence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
frequency O B_DISEASE
potentiation O I_DISEASE
in O O
the O O
isolated O B_BIO/B_NUMBER[MEASURE]
guinea O I_BIO/I_NUMBER[MEASURE]
- O O
pig O B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
' O O
s O B_BODY_PART_OR_ORGAN_COMPONENT
atrium O I_BODY_PART_OR_ORGAN_COMPONENT
. O O

We O O
found O O
4 O O
highly O O
conserved O O
regions O O
to O O
vertebrate B B_LOCATION/B_ENZYME[GENE]
Hsp90 I I_LOCATION/I_ENZYME[GENE]
exclusively O O
and O O
27 O O
amino O O
acids O O
conserved O O
among O O
but O O
differing O O
between O O
Hsp90 B B_SPECIES[BIO]/B_GENE
alpha I I_SPECIES[BIO]/I_GENE
and O O
Hsp90 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
beta I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequences I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Characterization O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
trinucleotide O B_DISEASE/B_GENE
- O O
and O O
tandem O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
repeat O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
containing O O
transcripts O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
obtained O O
from O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spinal O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cord O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cDNA O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
library O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
high O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
density O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
filter O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
hybridization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

We O O
present O O
here O O
the O O
complete O O
primary O O
structure O O
of O O
human B B_GENE
gp330 I I_GENE
, O O
the O O
human O O
variant O O
of O O
the O O
principal O O
kidney O O
autoantigen O O
causing O O
Heymann O O
membranous O O
glomerulonephritis O O
in O O
rats O O
. O O

The O O
platelet B B_GENE
membrane I I_GENE
glycoprotein I I_GENE
IIb I I_GENE
/ I I_GENE
IIIa I I_GENE
receptor I I_GENE
inhibitor O O
abciximab O O
is O O
used O O
for O O
the O O
treatment O O
of O O
patients O O
undergoing O O
high O O
- O O
risk O O
percutaneous O O
coronary O O
interventions O O
and O O
is O O
used O O
in O O
approximately O O
one O O
third O O
of O O
coronary O O
interventions O O
in O O
the O O
United O O
States O O
and O O
a O O
growing O O
number O O
of O O
procedures O O
in O O
Europe O O
. O O

In O O
the O O
conscious O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
animals O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
the O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reached O O
statistical O B_MEASURE/B_LOCATION
significance O I_MEASURE/I_LOCATION
when O O
the O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
exposed O O
to O O
12 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
oxygen O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
nitrogen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
which O O
produced O O
a O O
fall O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
arterial O B_MEASURE
PaO2 O I_MEASURE
of O O
44 O B_MEASURE
. O O
7 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
5 O B_MEASURE
. O O
0 O B_MEASURE
% O I_MEASURE
. O O

Prenatal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
genetic O B_DISEASE/B_GENE
diseases O I_DISEASE/I_GENE
. O O

Human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
epidermal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
EGF B B_GENE/B_DISEASE
) O O
, O O
a O O
naturally O O
occurring O O
protein O O
, O O
has O O
been O O
implicated O O
in O O
the O O
protection O O
of O O
gastrointestinal O O
mucosal O O
integrity O O
. O O

A O O
ready O O
- O O
made O O
prosthesis O B_MEDICAL_DEVICE[OBJECT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
placed O O
on O O
the O O
external O B_LOCATION
side O I_LOCATION
of O O
the O O
ribs O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
vertically O O
bridging O O
the O O
flailed O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
chest O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
segment O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
fixed O O
to O O
the O O
first O B_LOCATION/B_SEQUENCE[MEASURE]
upper O I_LOCATION/I_SEQUENCE[MEASURE]
and O O
first O B_SEQUENCE[MEASURE]/B_LOCATION
lower O I_SEQUENCE[MEASURE]/I_LOCATION
intact O I_SEQUENCE[MEASURE]/I_LOCATION
rib O I_SEQUENCE[MEASURE]/I_LOCATION
as O O
well O O
as O O
to O O
the O O
mobile O B_LOCATION
segments O I_LOCATION
of O O
the O O
affected O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
ribs O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O O

DESIGN O B_PERSON/B_MEASURE
: O O
Prospective O B_LOCATION
case O I_LOCATION
study O I_LOCATION
( O O
Canadian O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Task O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Force O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
classification O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
2 O B_NUMBER[MEASURE]
) O O
. O O

Site O O
- O O
directed O O
mutagenesis O O
of O O
the O O
T4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
endonuclease I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
V I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O O
role O O
of O O
lysine O O
- O O
130 O O
. O O

A O O
minimal O O
pheromone O O
induction O O
domain O O
, O O
delineated O O
as O O
residues O O
301 O O
to O O
335 O O
of O O
Ste12p B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
is O O
dependent O O
on O O
the O O
pheromone O O
mitogen B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
activated I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
protein I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
MAP I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
kinase I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
pathway O O
for O O
induction O O
activity O O
. O O

The O O
library O O
will O O
thus O O
be O O
useful O O
for O O
the O O
selection O O
of O O
cosmid O O
clones O O
which O O
carry O O
CDC B B_GENE
genes I I_GENE
from I I_GENE
yeast I I_GENE
by O O
complementing O O
first O O
, O O
with O O
the O O
vectorial O O
yeast B B_GENE/B_BIO
gene I I_GENE/I_BIO
URA1 I I_GENE/I_BIO
, O O
the O O
pyrimidine O O
auxotrophy O O
of O O
most O O
cdc B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
strains O O
and O O
then O O
, O O
with O O
the O O
respective O O
CDC B B_GENE/B_MEASURE
wild I I_GENE/I_MEASURE
- I I_GENE/I_MEASURE
type I I_GENE/I_MEASURE
genes I I_GENE/I_MEASURE
, O O
of O O
the O O
temperature O O
- O O
sensitive O O
mutant O O
alleles O O
. O O

These O O
mutant B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
rps7 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
leaders O O
were O O
ligated O O
into O O
an O O
aadA O O
expression O O
cassette O O
and O O
transformed O O
into O O
the O O
chloroplast O O
of O O
C O O
. O O
reinhardtii O O
and O O
into O O
E O O
. O O
coli O O
. O O

In O O
addition O O
, O O
both O O
activated O O
Ral B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GDS I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
like I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor O O
and O O
Raf B B_GENE/B_DISEASE
stimulate O O
cyclin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcription O O
and O O
E2F B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O O
and O O
act O O
in O O
synergy O O
with O O
PI B B_GENE
3 I I_GENE
- I I_GENE
kinase I I_GENE
. O O

From O O
the O O
present O O
results O O
a O O
concept O O
of O O
hormone O O
- O O
dependent O O
AR B B_GENE/B_DISEASE
activation O O
is O O
proposed O O
, O O
which O O
requires O O
a O O
functional O O
, O O
direct O O
or O O
indirect O O
intramolecular O O
interaction O O
between O O
the O O
TAD O O
and O O
the O O
LBD O O
. O O

Like O O
the O O
DMA B B_SPECIES[BIO]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
but O O
unlike O O
all O O
other O O
mammalian B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
class I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
zebrafish O O
gene O O
codes O O
for O O
two O O
cysteine O O
residues O O
which O O
might O O
potentially O O
be O O
involved O O
in O O
the O O
formation O O
of O O
a O O
disulfide O O
bond O O
in O O
the O O
alpha O O
1 O O
domain O O
. O O

Down O O
- O O
regulation O O
of O O
Id1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
correlated O O
with O O
mitogenesis O O
and O O
occurred O O
when O O
quiescent O O
cells O O
were O O
treated O O
with O O
growth O O
factors O O
that O O
activate O O
G B B_GENE
protein I I_GENE
- I I_GENE
coupled I I_GENE
receptors I I_GENE
and O O
receptor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
but O O
not O O
with O O
a O O
non O O
- O O
mitogenic O O
cAMP O O
analog O O
. O O

Secretogranin B B_GENE
II I I_GENE
( O O
SgII B B_GENE/B_LOCATION
) O O
is O O
a O O
secretory O O
polypeptide O O
stored O O
in O O
large O O
dense O O
core O O
vesicles O O
of O O
neuroendocrine O O
and O O
neuronal O O
cells O O
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
In O O
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
SDB O B_DISEASE
, O O
even O O
snoring O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
was O O
independently O O
associated O O
with O O
hypertension O B_DISEASE/B_LOCATION
in O O
both O O
men O B_PERSON/B_BIO
and O O
women O B_PERSON/B_BIO
. O O

The O O
electron O O
spin O O
resonance O O
study O O
also O O
demonstrated O O
that O O
the O O
formation O O
of O O
superoxide O O
- O O
DMPO O O
spin O O
adduct O O
was O O
strongly O O
inhibited O O
by O O
a O O
selective O O
cyclooxygenase B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O O
, O O
etodolac O O
, O O
in O O
a O O
concentration O O
- O O
dependent O O
manner O O
. O O

BK B B_GENE/B_BIO
- O O
induced O O
translocation O O
and O O
overexpression O O
of O O
PKC B B_GENE
isoforms I I_GENE
as O O
well O O
as O O
coexpression O O
of O O
inactive O O
or O O
constitutively O O
active O O
mutants O O
of O O
different O O
PKC B B_GENE
isozymes I I_GENE
provided O O
evidence O O
for O O
a O O
role O O
of O O
the O O
diacylglycerol O O
- O O
sensitive O O
PKCs B B_ENZYME[GENE]/B_LOCATION
alpha I I_ENZYME[GENE]/I_LOCATION
and I I_ENZYME[GENE]/I_LOCATION
epsilon I I_ENZYME[GENE]/I_LOCATION
in O O
BK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
signaling O O
toward O O
MAPK B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Embryonal O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mortality O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

A O O
lead O O
phthalocyanin O O
method O O
for O O
the O O
demonstration O O
of O O
acid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
hydrolases I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
in O O
plant O O
and O O
animal O O
tissues O O
. O O

Here O O
we O O
describe O O
the O O
characterization O O
of O O
cDNAs O O
encoding O O
two O O
unusual O O
E2Fs B B_GENE/B_BIO
, O O
E2F B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
E2F B B_MEASURE
- I I_MEASURE
5 I I_MEASURE
, O O
each O O
identified O O
by O O
the O O
ability O O
of O O
their O O
gene O O
product O O
to O O
interact O O
with O O
p130 B B_GENE/B_BIO
in O O
a O O
yeast O O
two O O
- O O
hybrid O O
system O O
. O O

Interestingly O O
, O O
unlike O O
PAK65 B B_GENE
, O O
HPK1 B B_GENE/B_LOCATION
does O O
not O O
contain O O
the O O
small B B_GENE
GTPase I I_GENE
Rac1 B I_GENE
/ O O
Cdc42 B B_GENE
- O O
binding O O
domain O O
and O O
does O O
not O O
bind O O
to O O
either O O
Rac1 B B_GENE
or O O
Cdc42 B B_GENE
, O O
suggesting O O
that O O
HPK1 B B_PROTEIN[GENE]/B_DISEASE
. O O
activation O O
is O O
Rac1 B B_GENE
/ O O
Cdc42 B B_GENE
- O O
independent O O
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
compared O O
with O O
the O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
pair O O
- O O
fed O O
non O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
treated O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Control O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Group O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
were O O
measured O O
by O O
enzyme O O
- O O
linked O O
immunoabsorbent O O
assay O O
in O O
plasma O O
samples O O
obtained O O
from O O
the O O
hyperthermic O O
isolated O O
limb O O
perfusion O O
circuit O O
and O O
systemic O O
circulation O O
. O O

However O O
, O O
only O O
plasma B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fibrinogen I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations O O
showed O O
statistically O O
significant O O
positive O O
associations O O
with O O
IMT O O
in O O
both O O
groups O O
. O O

Without O O
a O O
team O B_ORGANIZATION/B_PERSON
, O O
there O O
is O O
little O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
hope O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
for O O
fetal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
survival O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
mortality O B_DISEASE/B_MEASURE
will O O
be O O
80 O B_MEASURE
- O O
100 O B_MEASURE
% O I_MEASURE
. O O

Analysis O O
of O O
deletion O O
and O O
substitution O O
mutations O O
in O O
the O O
MER2 B B_GENE/B_BIO
5 I I_GENE/I_BIO
' I I_GENE/I_BIO
exon I I_GENE/I_BIO
demonstrates O O
that O O
the O O
unusually O O
large O O
size O O
of O O
this O O
exon O O
plays O O
an O O
important O O
role O O
in O O
splicing O O
regulation O O
. O O

To O O
study O O
the O O
signaling O O
pathways O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O O
regulate O O
cytoskeletal O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
rearrangements O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
we O O
set O O
up O O
a O O
conjugate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
formation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
assay O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
using O O
Jurkat O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
T O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O O
effectors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
- O O
sized O O
latex O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
beads O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
coated O O
with O O
various O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
as O O
artificial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
APCs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Reexamination O O
of O O
the O O
cdc4 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1 I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutant I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
revealed O O
that O O
, O O
in O O
addition O O
to O O
being O O
defective O O
in O O
the O O
onset O O
of O O
S O O
phase O O
, O O
it O O
is O O
also O O
defective O O
in O O
G O O
( O O
2 O O
) O O
/ O O
M O O
transition O O
when O O
released O O
from O O
hydroxyurea O O
- O O
induced O O
S O O
- O O
phase O O
arrest O O
. O O

All O O
such O O
polypeptides O O
containing O O
263 O O
or O O
more O O
residues O O
derived O O
from O O
the O O
C O O
- O O
terminus O O
of O O
P130gag B B_MEASURE/B_GENE
- O O
fps B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
i O O
. O O
e O O
. O O
residues O O
920 O O
- O O
1182 O O
) O O
were O O
enzymatically O O
active O O
as O O
tyrosine B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
kinases I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
. O O

A O O
structural O O
model O O
for O O
Vpu B B_GENE/B_BACTERIUM[BIO]
is O O
proposed O O
in O O
which O O
the O O
membrane O O
anchor O O
precedes O O
a O O
region O O
comprising O O
two O O
amphipathic O O
alpha O O
- O O
helices O O
of O O
opposed O O
polarity O O
, O O
joined O O
by O O
a O O
strongly O O
acidic O O
turn O O
that O O
protrudes O O
into O O
the O O
cytoplasm O O
and O O
contains O O
the O O
CK B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
- I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
2 I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
phosphorylation I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
sites I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
recombinant O O
containing O O
the O O
full O O
- O O
length O O
polyhedrin B B_PROTEIN[GENE]/B_BIO
leader O O
sequence O O
gave O O
levels O O
of O O
N B B_GENE
mRNA I I_GENE
comparable O O
to O O
those O O
of O O
AcNPV B B_GENE/B_BIO
polyhedrin I I_GENE/I_BIO
mRNA I I_GENE/I_BIO
. O O

Immune O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
impact O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
Lactobacillus O B_BACTERIUM[BIO]/B_DISEASE
acidophilus O B_BACTERIUM[BIO]/I_DISEASE
on O O
asthma O B_DISEASE/B_PERSON
. O O

Thus O O
, O O
CARP B B_GENE/B_BIO
is O O
a O O
YB B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
associated I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
and O O
represents O O
the O O
first O O
identified O O
cardiac O O
- O O
restricted O O
downstream O O
regulatory O O
gene O O
in O O
the O O
homeobox O O
gene O O
Nkx2 B B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- I I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
5 I I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pathway O O
and O O
may O O
serve O O
as O O
a O O
negative O O
regulator O O
of O O
HF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
dependent O O
pathways O O
for O O
ventricular O O
muscle O O
gene O O
expression O O
. O O

Each O O
receptor O O
must O O
therefore O O
engage O O
a O O
unique O O
subset O O
of O O
the O O
available O O
signaling O O
elements O O
- O O
- O O
at O O
least O O
partly O O
through O O
the O O
selection O O
of O O
proteins O O
with O O
src B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
homology I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
2 I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
domains I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
SH2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

A O O
proposed O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
model O O
for O O
the O O
SMase B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
sphingomyelin O O
complex O O
structure O O
was O O
built O O
to O O
investigate O O
how O O
the O O
SMase B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
specifically O O
recognizes O O
its O O
substrate O O
. O O

Two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
estimates O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
fractal O B_MEASURE
exponent O I_MEASURE
are O O
considered O O
which O O
do O O
not O O
suffer O O
from O O
this O O
limit O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
one O B_NUMBER[MEASURE]/B_PERSON
derived O O
from O O
the O O
Allan O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variance O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
was O O
developed O O
by O O
the O O
authors O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
one O B_NUMBER[MEASURE]/B_LOCATION
based O O
on O O
the O O
periodogram O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Births O B_PERSON
, O O
marriages O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
, O O
divorces O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
deaths O B_PERSON/B_DISEASE
for O O
July O B_PERSON
1997 O I_PERSON
. O O

In O O
conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
in O O
coronary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
artery O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
disease O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
patients O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
exercise O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
redistribution O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
201Thallium O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
cardiac O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
imaging O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
with O O
reinjection O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
at O O
rest O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O O
identify O O
severely O O
ischemic O B_DISEASE_ADJECTIVE[DISEASE]
but O O
still O O
viable O B_DISEASE_ADJECTIVE[DISEASE]
myocardium O I_DISEASE_ADJECTIVE[DISEASE]
and O O
may O O
be O O
particularly O O
useful O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
prognosis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
such O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
the O O
recovery O B_MEASURE
curve O I_MEASURE
of O O
the O O
R2 O B_MEASURE/B_PERSON
component O I_MEASURE/I_PERSON
of O O
the O O
blink O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reflex O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diminished O O
in O O
patients O B_PERSON
with O O
tension O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
type O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
headache O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
compared O O
with O O
the O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

When O O
recombinant B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gE I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
produced O O
in O O
HeLa O O
cells O O
was O O
probed O O
with O O
the O O
same O O
antiphosphotyrosine O O
antibody O O
, O O
a O O
dimeric B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_COLOR
gE I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_COLOR
form O O
at O O
130 O O
kDa O O
was O O
detected O O
on O O
the O O
cell O O
surface O O
. O O

Transforming B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
TGF B B_GENE
- I I_GENE
beta I I_GENE
) O O
inhibits O O
cell O O
cycle O O
progression O O
, O O
in O O
part O O
through O O
up O O
- O O
regulation O O
of O O
gene O O
expression O O
of O O
the O O
p21 B B_GENE
( O O
WAF1 B B_PROTEIN[GENE]/B_LOCATION
/ O O
Cip1 B B_PROTEIN[GENE]/B_MEASURE
) O O
( O O
p21 B B_GENE/B_DISEASE
) O O
cell O O
cycle O O
inhibitor O O
. O O

The O O
results O O
suggest O O
that O O
both O O
superficial O O
and O O
deep O O
cortical O O
venous O O
drainage O O
of O O
the O O
cat O O
kidney O O
should O O
be O O
considered O O
when O O
measuring O O
renal B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
renin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
release O O
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Detection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
recurrent O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
head O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
neck O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
cancer O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
is O O
feasible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
FDG O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
PET O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

There O O
were O O
no O O
differences O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
incidence O B_MEASURE
of O O
fractured O B_DISEASE
zonas O I_DISEASE
. O O

DSIP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
found O O
to O O
significantly O O
increase O O
slow O B_DISEASE/B_PROTEIN[GENE]
- O O
waves O B_DISEASE/B_MEASURE
( O O
delta O B_DISEASE/B_ENT
sleep O I_DISEASE/I_ENT
) O O
in O O
the O O
sleep O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
EEG O I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Accuracy O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
predictive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
value O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
ultrasound O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
acute O B_DISEASE/B_PERSON
rejection O B_DISEASE/I_PERSON
. O O

7 O O
- O O
Nitroindazole O O
( O O
7NI O O
) O O
, O O
a O O
relatively O O
selective O O
neuronal O O
nitric B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
synthase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
nNOS B B_GENE/B_LOCATION
) O O
inhibitor O O
. O O
was O O
intraperitoneally O O
administered O O
to O O
the O O
guinea O O
pigs O O
30 O O
minutes O O
before O O
the O O
onset O O
of O O
local O O
anoxia O O
. O O

Mutations O O
that O O
extend O O
the O O
specificity O O
of O O
the O O
endonuclease O O
activity O O
of O O
lambda B B_GENE
terminase I I_GENE
. O O

The O O
gene O B_GENE
set O O
in O O
this O O
mitochondrial O B_BIO/B_GENE
genome O I_BIO/I_GENE
is O O
a O O
subset O B_MEASURE/B_PERSON
of O O
that O O
of O O
Reclinomonas O B_SPECIES[BIO]
americana O I_SPECIES[BIO]
, O O
an O O
amoeboid O B_BIO/B_PERSON
protozoan O I_BIO/I_PERSON
. O O

An O O
evaluation O O
of O O
a O O
positive O O
control O O
for O O
platelet O O
neutralization O O
procedure O O
testing O O
with O O
seven O O
commercial O O
activated O O
partial O O
thromboplastin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
time O O
reagents O O
. O O

The O O
prosomal B B_GENE/B_BIO
RNA I I_GENE/I_BIO
- I I_GENE/I_BIO
binding I I_GENE/I_BIO
protein I I_GENE/I_BIO
p27K I I_GENE/I_BIO
is O O
a O O
member O O
of O O
the O O
alpha B B_GENE/B_PERSON
- I I_GENE/I_PERSON
type I I_GENE/I_PERSON
human I I_GENE/I_PERSON
prosomal I I_GENE/I_PERSON
gene I I_GENE/I_PERSON
family I I_GENE/I_PERSON
. O O

A O O
single O O
clone O O
, O O
which O O
was O O
conserved O O
and O O
had O O
near O O
- O O
perfect O O
homology O O
to O O
eight O O
human O O
/ O O
rodent O O
expressed O O
sequence O O
tags O O
, O O
was O O
used O O
as O O
template O O
for O O
5 O O
' O O
and O O
3 O O
' O O
rapid O O
amplification O O
of O O
cDNA O O
ends O O
and O O
SPICE O O
( O O
system O O
for O O
polymerase O O
chain O O
reaction O O
amplification O O
of O O
cDNA O O
ends O O
) O O
reactions O O
to O O
obtain O O
the O O
3 O O
. O O
6 O O
- O O
kb O O
cDNA O O
, O O
LGL2 B B_PROTEIN[GENE]/B_LOCATION
( O O
Genbank B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
AF I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
110195 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
encoding O O
a O O
deduced O O
polypeptide O O
( O O
lgl2 B B_GENE
) O O
of O O
963 O O
amino O O
acids O O
. O O

These O O
tiny O B_PERSON/B_BIO
premature O I_PERSON/I_BIO
infants O I_PERSON/I_BIO
also O O
received O O
PN O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O O
significantly O O
longer O B_MEASURE/B_LOCATION
periods O I_MEASURE/I_LOCATION
of O O
time O B_TIME[MEASURE]
, O O
and O O
the O O
longer O B_TIME[MEASURE]
the O O
infusions O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
administered O O
the O O
greater O B_MEASURE
was O O
the O O
risk O B_MEASURE/B_PERSON
of O O
cholestasis O B_DISEASE
developing O O
. O O

The O O
SM O B_DISEASE/B_GENE
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
selection O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
exon O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O O
the O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
exon O B_GENE
3 O I_GENE
. O O

It O O
is O O
always O O
present O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
has O O
a O O
discrete O B_DISEASE/B_MEASURE
origin O B_DISEASE/I_MEASURE
and O O
insertion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Medical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
management O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
of O O
early O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
stage O B_DISEASE
breast O I_DISEASE
cancer O I_DISEASE
. O O

Five O O
girls O O
with O O
Turner O O
' O O
s O O
syndrome O O
aged O O
12 O O
to O O
17 O O
years O O
showed O O
LH B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values O O
( O O
5 O O
. O O
0 O O
- O O
14 O O
. O O
5 O O
IU O O
/ O O
12 O O
h O O
) O O
at O O
the O O
upper O O
end O O
of O O
or O O
slightly O O
above O O
the O O
normal O O
range O O
and O O
pathologically O O
high O O
values O O
( O O
22 O O
. O O
2 O O
- O O
43 O O
. O O
5 O O
IU O O
/ O O
12 O O
h O O
) O O
for O O
FSH B B_PERSON/B_GENE
. O O

In O O
vitro O O
death O O
assays O O
with O O
transient O O
overexpression O O
of O O
deletion O O
constructs O O
of O O
both O O
isoforms O O
using O O
beta B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
galactosidase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O O
a O O
reporter O O
gene O O
in O O
MCF7 O O
cells O O
suggest O O
the O O
following O O
: O O
1 O O
) O O
the O O
nucleotide O O
binding O O
domain O O
may O O
act O O
as O O
a O O
negative O O
regulator O O
of O O
the O O
killing O O
activity O O
of O O
DEFCAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
2 O O
) O O
the O O
LRR B B_DISEASE/B_PROTEIN[GENE]
/ O O
CARD B B_LOCATION/B_GENE
represents O O
a O O
putative O O
constitutively O O
active O O
inducer O O
of O O
apoptosis O O
; O O
3 O O
) O O
the O O
killing O O
activity O O
of O O
LRR B B_DISEASE/B_GENE
/ O O
CARD B B_LOCATION/B_GENE
is O O
inhibitable O O
by O O
benzyloxycarbonyl O O
- O O
Val O O
- O O
Ala O O
- O O
Asp O O
( O O
OMe O O
) O O
- O O
fluoromethyl O O
ketone O O
and O O
to O O
a O O
lesser O O
extent O O
by O O
Asp O O
- O O
Glu O O
- O O
Val O O
- O O
Asp O O
( O O
OMe O O
) O O
- O O
fluoromethyl O O
ketone O O
; O O
and O O
4 O O
) O O
the O O
CARD B B_PROTEIN[GENE]
is O O
critical O O
for O O
killing O O
activity O O
of O O
DEFCAP B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
6 O B_MEASURE/B_BIO
patients O I_MEASURE/I_BIO
( O O
9 O B_MEASURE/B_ENT
kidneys O I_MEASURE/I_ENT
) O O
irrigation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
Solution O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
G O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
renal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
pelvis O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O O
performed O O
for O O
the O O
dissolution O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
their O O
infectious O B_DISEASE
stones O I_DISEASE
. O O

The O O
use O O
of O O
sigma B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
54 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promoters I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
known O O
to O O
require O O
cognate O O
binding O O
proteins O O
, O O
could O O
allow O O
the O O
fine O O
- O O
tuning O O
that O O
provides O O
the O O
temporal O O
ordering O O
of O O
flagellar O O
gene O O
transcription O O
. O O

The O O
association O O
of O O
I B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
92 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
p92 B B_GENE
, O O
p84 B B_GENE/B_MEASURE
, O O
p75 B B_GENE/B_MEASURE
, O O
p73 B B_GENE/B_MEASURE
, O O
p69 B B_GENE/B_MEASURE
, O O
and O O
p57 B B_GENE
was O O
completely O O
reversible O O
after O O
treatment O O
with O O
the O O
detergent O O
deoxycholate O O
( O O
DOC O O
) O O
. O O

To O O
our O O
knowledge O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
no O O
transcription O B_GENE
factors O I_GENE
have O O
previously O O
been O O
identified O O
that O O
exhibit O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
androgen O O
- O O
dependent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
epididymis O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O O

Focal O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
or O O
regional O B_NUMBER[MEASURE]
8 O I_NUMBER[MEASURE]
- O O
to O O
20 O B_MEASURE
- O O
Hz O B_MEASURE/B_LOCATION
low O I_MEASURE/I_LOCATION
- O O
voltage O B_MEASURE/B_LOCATION
epileptiform O I_MEASURE/I_LOCATION
paroxysms O O
in O O
either O O
hippocampus O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
( O O
10 O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
) O O
, O O
amygdala O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
( O O
1 O B_MEASURE/B_PERSON
patient O I_MEASURE/I_PERSON
) O O
, O O
or O O
both O O
( O O
1 O B_NUMBER[MEASURE]/B_PERSON
patient O I_NUMBER[MEASURE]/I_PERSON
) O O
preceded O O
initial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
motionless O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
staring O O
. O O

The O O
lack O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
heterozygous O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
positions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
essentially O O
facilitates O O
on O O
the O O
one O B_PERSON/B_MEASURE
hand O I_PERSON/I_MEASURE
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
on O O
the O O
other O B_PERSON/B_SEQUENCE[MEASURE]
hand O B_PERSON/I_SEQUENCE[MEASURE]
the O O
detection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
new O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
alleles O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

Epithelial O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
cell O B_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
activation O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
is O O
achieved O O
by O O
the O O
cooperative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
interaction O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
of O O
apparently O O
ubiquitous O B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcriptional O B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
parvovirus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B19 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
from O O
the O O
viral B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
p6 I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
promoter I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
( O O
B19p6 B B_GENE
) O O
is O O
restricted O O
to O O
primary O O
human O O
hematopoietic O O
cells O O
undergoing O O
erythroid O O
differentiation O O
. O O

The O O
effectiveness O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
pathogenetic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
expediency O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
correcting O O
disorders O B_DISEASE_ADJECTIVE[DISEASE]
of O O
lipid O B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
metabolism O B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
in O O
atherosclerosis O B_DISEASE/B_PERSON
with O O
enterosorbents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
is O O
substantiated O O
. O O

To O O
prevent O O
section O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
wrinkles O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
usually O O
encountered O O
with O O
the O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O O
coated O B_NUMBER[MEASURE]/B_LOCATION
single O I_NUMBER[MEASURE]/I_LOCATION
- O O
hole O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
grids O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
a O O
simple O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
developed O O
. O O

The O O
Cryotherapy O B_ORGANIZATION/B_LOCATION
for O O
Retinopathy O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Prematurity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
has O O
shown O O
that O O
this O O
number O B_MEASURE
can O O
be O O
halved O O
with O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Ultrasound O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
guided O O
fine O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
needle O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
aspiration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
biopsy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
US O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
FNAB O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
) O O
revealed O O
normal O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
- O O
looking O O
squamous O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cells O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Bleeding O B_DISEASE
was O O
successfully O O
prevented O O
in O O
28 O B_TIME[MEASURE]
patients O I_TIME[MEASURE]
with O O
the O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O O
a O O
combined O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
incorporating O O
IV O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
desmopressin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
an O O
antifibrinolytic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agent O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
tranexamic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) O O
, O O
and O O
local O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
methods O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
surgical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
glue O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
compression O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
techniques O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
) O O
. O O

Hetero O O
- O O
oligomerization O O
of O O
Smad4 B B_GENE
with O O
the O O
pathway O O
- O O
restricted O O
SMAD B B_GENE/B_LOCATION
proteins I I_GENE/I_LOCATION
is O O
essential O O
for O O
Smad4 B B_GENE
- O O
mediated O O
transcription O O
. O O

This O O
fragment O O
contains O O
two O O
complete O O
endo B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glucanase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encoding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
designated O O
celCCC B B_DISEASE/B_GENE
and O O
celCCG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

One O B_NUMBER[MEASURE]/B_PERSON
of O O
them O O
is O O
its O O
limited O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensitivity O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
weak O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactions O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
are O O
common O B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
mammalian O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
cerebral O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
cortex O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Analysis O O
of O O
the O O
5 O O
' O O
and O O
3 O O
' O O
termini O O
of O O
the O O
transcripts O O
produced O O
in O O
vivo O O
from O O
the O O
puf B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
operon I B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
of I B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
R I B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. I B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
sphaeroides I B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
PUF B B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
delta I B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
348 I B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
- I B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
420 I B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
( O O
three O O
transcripts O O
; O O
0 O O
. O O
59 O O
, O O
0 O O
. O O
64 O O
, O O
and O O
2 O O
. O O
63 O O
kilobases O O
) O O
lacking O O
the O O
puf O O
- O O
intercistronic O O
terminator O O
structure O O
were O O
identical O O
to O O
those O O
of O O
the O O
corresponding O O
puf B B_GENE/B_BIO
transcripts I I_GENE/I_BIO
derived O O
from O O
wild O O
- O O
type O O
R O O
. O O
sphaeroides O O
2 O O
. O O
4 O O
. O O
1 O O
( O O
four O O
transcripts O O
; O O
0 O O
. O O
50 O O
, O O
0 O O
. O O
66 O O
, O O
0 O O
. O O
71 O O
, O O
and O O
2 O O
. O O
7 O O
kilobases O O
) O O
showing O O
that O O
the O O
transcripts O O
begin O O
and O O
end O O
at O O
the O O
same O O
sites O O
. O O

The O O
optimum O B_MEASURE/B_DISEASE
cooling O I_MEASURE/I_DISEASE
rate O I_MEASURE/I_DISEASE
from O O
RT O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
5 O B_LOCATION/B_PROTEIN[GENE]
degrees O I_LOCATION/I_PROTEIN[GENE]
C O I_LOCATION/I_PROTEIN[GENE]
resulting O O
in O O
maximum O B_TIME[MEASURE]/B_DISEASE
survival O I_TIME[MEASURE]/I_DISEASE
of O O
human O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
spermatozoa O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
was O O
found O O
to O O
be O O
0 O B_MEASURE/B_LOCATION
. O O
5 O B_MEASURE
to O O
1 O B_MEASURE
degree O I_MEASURE
per O O
minute O B_TIME[MEASURE]
when O O
cooled O O
from O O
RT O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
5 O B_LOCATION/B_PROTEIN[GENE]
degrees O I_LOCATION/I_PROTEIN[GENE]
C O I_LOCATION/I_PROTEIN[GENE]
and O O
subsequently O O
frozen O O
- O O
thawed O O
in O O
liquid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitrogen O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
LN2 O B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

The O O
cerebellar O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cortical O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vessels O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
they O O
are O O
compared O O
to O O
the O O
cerebral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
vessels O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Transesophageal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
echocardiography O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
risk O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
factors O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
for O O
stroke O B_DISEASE
in O O
nonvalvular O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
atrial O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
fibrillation O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

22 O B_TIME[MEASURE]/B_LOCATION
- O O
Veneto O B_MEASURE/B_LOCATION
Region O I_MEASURE/I_LOCATION
) O O

Preventive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
health O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
counseling O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
tailored O O
to O O
the O O
needs O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
this O O
group O B_ORGANIZATION/B_PERSON
may O O
be O O
most O O
beneficial O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Strains O O
lacking O O
a O O
functional B B_GENE
RPL16A I I_GENE
gene I I_GENE
grow O O
as O O
rapidly O O
as O O
wild O O
type O O
, O O
whereas O O
those O O
containing O O
a O O
null O O
allele O O
of O O
RPL16B B B_GENE/B_DISEASE
grow O O
more O O
slowly O O
than O O
wild O O
type O O
. O O

Neonatal O B_DISEASE_ADJECTIVE[DISEASE]
hyperthyroidism O I_DISEASE_ADJECTIVE[DISEASE]

After O O
Northern O O
blot O O
hybridization O O
, O O
two O O
Cx31 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
8 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kb I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
detected O O
in O O
total O O
RNA O O
of O O
the O O
human O O
keratinocyte O O
cell O O
line O O
HaCaT O O
and O O
two O O
transcripts O O
of O O
2 O O
. O O
2 O O
and O O
1 O O
. O O
9 O O
kb O O
in O O
total O O
RNA O O
of O O
E6 B B_PROTEIN[GENE]
/ O O
E7 B B_MEASURE/B_PROTEIN[GENE]
transfected O O
human O O
keratinocytes O O
( O O
HEK O O
cells O O
) O O
. O O

In O O
summary O O
, O O
FGFR3 B B_GENE
signaling O O
pathway O O
utilizes O O
two O O
GRB2 B B_LOCATION/B_BIO
- I I_LOCATION/I_BIO
containing I I_LOCATION/I_BIO
complexes I I_LOCATION/I_BIO
; O O
Shc B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
GRB2 B B_MEASURE/B_GENE
. O O
Sos B B_LOCATION/B_DISEASE
and O O
80K B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
H I I_GENE/I_LOCATION
. O O
pp66 B B_PROTEIN[GENE]/B_LOCATION
. O O
GRB2 B B_MEASURE/B_PERSON
. O O
Sos B B_LOCATION/B_DISEASE
; O O
these O O
two O O
complexes O O
may O O
alternatively O O
link O O
FGFG3 B B_GENE
to O O
mitogen B B_GENE
- I I_GENE
activated I I_GENE
protein I I_GENE
kinase I I_GENE
. O O

In O O
an O O
effort O O
to O O
identify O O
factors O O
involved O O
in O O
the O O
expression O O
of O O
this O O
important O O
erythroid O O
- O O
specific O O
regulatory O O
protein O O
, O O
we O O
have O O
isolated O O
the O O
mouse B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
EKLF I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
systematically O O
analyzed O O
the O O
promoter O O
region O O
. O O

Their O O
main O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
representatives O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
are O O
the O O
American O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
diagnostic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
and O O
statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
manual O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
mental O B_DISEASE
disorders O I_DISEASE
, O O
DSM O B_LOCATION/B_DISEASE
- O O
III O B_TIME[MEASURE]
, O O
its O O
revised O O
version O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
DSM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
III O B_TIME[MEASURE]
- O O
R O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
international O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
classification O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
mental O B_DISEASE/B_LOCATION
disorders O I_DISEASE/I_LOCATION
iCD O I_DISEASE/I_LOCATION
- O O
10 O B_SEQUENCE[MEASURE]
. O O

Any O O
opacity O B_DISEASE
on O O
a O O
chest O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
radiograph O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
has O O
a O O
wide O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differential O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

At O O
the O O
same O B_TIME[MEASURE]/B_LOCATION
acoustic O I_TIME[MEASURE]/I_LOCATION
power O I_TIME[MEASURE]/I_LOCATION
, O O
the O O
rate O B_MEASURE
of O O
chloride O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
formation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O O
20 O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
kHz O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
ultrasound O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
greater O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
when O O
a O O
probe O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEDICAL_DEVICE[OBJECT]
with O O
a O O
larger O B_MEASURE/B_PERSON
tip O B_MEASURE/I_PERSON
area O B_MEASURE/I_PERSON
was O O
used O O
, O O
but O O
significantly O O
less O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
the O O
rate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O O
900 O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kHz O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
contrast O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
Torpedo O B_SPECIES[BIO]
, O O
where O O
only O O
a O O
single O B_GENE/B_MEASURE
transcript O I_GENE/I_MEASURE
is O O
seen O O
, O O
the O O
mouse O B_SPECIES[BIO]/B_DISEASE
expresses O O
several O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNAs O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encoding O O
different O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
isoforms O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Four O O
families O O
of O O
homing B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
endonucleases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
have O O
been O O
identified O O
, O O
including O O
the O O
LAGLIDADG B B_GENE/B_LOCATION
, O O
the O O
His B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
Cys I I_GENE/I_DISEASE
box I I_GENE/I_DISEASE
, O O
the O O
GIY B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
YIG I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
H B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
N I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
H I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
endonucleases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Convergence O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
trigeminal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
input O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
with O O
visceral O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
phrenic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inputs O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
primate O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C1 O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
C2 O B_MEASURE/B_PROTEIN[GENE]
spinothalamic O I_MEASURE/I_PROTEIN[GENE]
tract O I_MEASURE/I_PROTEIN[GENE]
neurons O I_MEASURE/I_PROTEIN[GENE]
. O O

The O O
GvpE B B_GENE/B_LOCATION
protein I I_GENE/I_LOCATION
involved O O
in O O
the O O
regulation O O
of O O
gas O O
vesicles O O
synthesis O O
in O O
halophilic O O
archaea O O
has O O
been O O
identified O O
as O O
the O O
transcriptional O O
activator O O
for O O
the O O
promoter O O
located O O
upstream O O
of O O
the O O
gvpA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encoding O O
the O O
major O O
gas O O
vesicle O O
structural O O
protein O O
GvpA B B_GENE/B_MEASURE
. O O

Nosographic O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
problems O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

In O O
early O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
midgestation O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
embryos O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
it O O
is O O
expressed O O
in O O
telencephalic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O O
diencephalic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
mesencephalic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
regions O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
but O O
from O O
day O B_TIME[MEASURE]/B_LOCATION
11 O I_TIME[MEASURE]/I_LOCATION
. O O
75 O B_TIME[MEASURE]/B_LOCATION
of O O
gestation O B_ORGANISM_FUNCTION
its O O
expression O B_GENE
disappears O O
from O O
dorsal O B_ORGANISM_FUNCTION/B_MEASURE
telencephalon O I_ORGANISM_FUNCTION/I_MEASURE
and O O
is O O
confined O O
to O O
diencephalic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
mesencephalic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
regions O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
training O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
programs O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
had O O
a O O
duration O B_MEASURE/B_LOCATION
of O O
30 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
, O O
5 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
/ O O
week O B_TIME[MEASURE]
, O O
and O O
was O O
performed O O
on O O
a O O
motor O B_PRODUCT[OBJECT]/B_DISEASE
- O O
driven O O
treadmill O B_PRODUCT[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Phylogenetic O O
analysis O O
using O O
a O O
neighbor O O
- O O
joining O O
algorithm O O
showed O O
closest O O
similarity O O
of O O
the O O
horse B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
mu I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
chain I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
- I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
encoding I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
constant I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
region I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
to O O
human O O
and O O
dog O O
sequences O O
. O O

Using O O
probes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
from O O
these O O
regions O B_LOCATION/B_DISEASE
, O O
rearrangements O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
been O O
identified O O
in O O
each O O
of O O
nine O B_NUMBER[MEASURE]/B_LOCATION
cases O I_NUMBER[MEASURE]/I_LOCATION
of O O
t O B_DISEASE/B_GENE
( O O
8 O B_MEASURE
; O O
21 O B_MEASURE
) O O
AML O B_DISEASE/B_LOCATION
examined O O
. O O

Cloning O O
and O O
nucleotide O O
sequence O O
analysis O O
reveals O O
that O O
BUR6 B B_PERSON/B_GENE
encodes O O
a O O
homolog O O
of O O
DRAP1 B B_GENE/B_DISEASE
( O O
also O O
called O O
NC2alpha B B_GENE
) O O
, O O
a O O
mammalian O O
repressor O O
of O O
basal O O
transcription O O
. O O

BRAP2 B B_GENE/B_PERSON
also O O
shares O O
significant O O
homology O O
with O O
a O O
hypothetical O O
protein O O
from O O
yeast O O
Saccharomyces O O
cerevisiae O O
, O O
especially O O
in O O
the O O
zinc O O
finger O O
region O O
. O O

Earlier O O
published O O
data O O
, O O
indicating O O
Sp1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding O O
to O O
the O O
R1 B B_PROTEIN[GENE]/B_LOCATION
alpha I I_PROTEIN[GENE]/I_LOCATION
/ I I_PROTEIN[GENE]/I_LOCATION
beta I I_PROTEIN[GENE]/I_LOCATION
regions I I_PROTEIN[GENE]/I_LOCATION
, O O
could O O
not O O
be O O
confirmed O O
, O O
suggesting O O
that O O
the O O
R1 O O
initiator O O
element O O
may O O
function O O
independent O O
of O O
Sp1 B B_GENE
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
reduced O O
metabolism O B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
cotinine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
proliposomes O B_LOCATION/B_PROTEIN[GENE]
and O O
MP O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
apparently O O
responsible O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
sustained O O
plasma O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
nicotine O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
levels O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Activation O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
HIV O B_DISEASE/B_GENE
- O O
1 O B_NUMBER[MEASURE]/B_DISEASE
requires O O
the O O
binding O B_TIME[MEASURE]/B_GENE
of O O
host O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
cis O O
elements O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
proviral O B_GENE
long O I_GENE
terminal O I_GENE
repeat O I_GENE
( O O
LTR O B_GENE/B_DISEASE
) O O
. O O

The O O
yeast B B_GENE/B_PERSON
mitochondrial I I_GENE/I_PERSON
Hsp70 I I_GENE/I_PERSON
, O O
Ssc1p B B_GENE/B_LOCATION
, O O
functions O O
as O O
a O O
molecular O O
chaperone O O
with O O
its O O
partner O O
proteins O O
, O O
Mdj1p B B_GENE
( O O
DnaJ B B_GENE
homologue I I_GENE
) O O
and O O
Yge1p B B_GENE
( O O
GrpE B B_GENE/B_PERSON
homologue I I_GENE/I_PERSON
) O O
. O O

Increased O O
TRE O O
DNA O O
binding O O
failed O O
to O O
lead O O
to O O
increased O O
transactivation O O
correlating O O
with O O
the O O
inability O O
of O O
SB O O
203580 O O
to O O
increase O O
phosphorylation O O
of O O
these O O
AP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
rice O B_GENE
gene O I_GENE
consists O O
of O O
four O B_GENE/B_NUMBER[MEASURE]
exons O B_GENE/I_NUMBER[MEASURE]
. O O

However O O
, O O
and O O
in O O
contrast O O
to O O
other O O
MMP B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
genes I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
no O O
significative O O
synergistic O O
effect O O
on O O
CAT B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
activity O O
between O O
the O O
AP B B_LOCATION/B_ORGANIZATION
- I I_LOCATION/I_ORGANIZATION
1 I I_LOCATION/I_ORGANIZATION
and O O
PEA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
elements I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
found O O
in O O
the O O
collagenase B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
found O O
. O O

The O O
equation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
mean O B_MEASURE
trabecular O I_MEASURE
number O I_MEASURE
passed O O
the O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
whereas O O
the O O
validity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
equations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O O
mean O B_MEASURE/B_LOCATION
trabecular O I_MEASURE/I_LOCATION
separation O I_MEASURE/I_LOCATION
and O O
Tb O B_PROTEIN[GENE]/B_LOCATION
. O O
Wi O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
appeared O O
limited O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Methodological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
considerations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
limiting O O
causal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assertions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
permissible O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
nonexperimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
are O O
discussed O O
. O O

In O O
contrast O O
, O O
postmitotic O O
neurons O O
possessed O O
extremely O O
low O O
levels O O
of O O
E2F1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O O
assessed O O
by O O
the O O
electrophoretic O O
mobility O O
shift O O
assay O O
and O O
Western O O
blotting O O
. O O

Recurrence O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
hepatic O B_DISEASE
cyst O I_DISEASE
after O O
partial O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
excision O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
drainage O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
complicated O O
by O O
fistula O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
formation O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
between O O
the O O
cyst O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
the O O
duodenum O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Reversal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O O
mefloquine O B_DISEASE/B_GENE
resistance O I_DISEASE/I_GENE
in O O
rodent O B_SPECIES[BIO]/B_DISEASE
Plasmodium O B_SPECIES[BIO]/I_DISEASE
. O O

Possible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
consequences O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
binder O B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
distribution O B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
through O O
powder O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
aggregates O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
are O O
discussed O O
. O O

The O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
parvalbumin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contains O O
the O O
putative O O
polyadenylation O O
signal O O
AATAAA O O
13 O O
nucleotides O O
upstream O O
from O O
the O O
polyadenylation O O
site O O
. O O

The O O
delta O O
Mo O O
+ O O
SV O O
tumor O O
DNAs O O
from O O
B O O
- O O
lineage O O
tumors O O
were O O
typically O O
rearranged O O
at O O
the O O
immunoglobulin B B_GENE
gene I I_GENE
loci I I_GENE
and O O
contained O O
germ O O
line O O
configurations O O
of O O
the O O
T B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
suggest O O
equilibrium O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complex O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
formation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O O
OTC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
PVP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
it O O
being O O
mainly O O
the O O
complex O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
which O O
is O O
i O O
. O O
v O O
. O O
injected O O
when O O
both O O
products O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
combined O O
in O O
an O O
injection O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
formulation O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

We O O
conclude O O
that O O
the O O
MMF O B_DISEASE
lesion O I_DISEASE
is O O
secondary O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
intramuscular O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
aluminium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydroxide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
containing O O
vaccines O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
shows O O
both O O
long O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
term O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
persistence O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
aluminium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
hydroxide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
an O O
ongoing O B_DISEASE
local O I_DISEASE
immune O I_DISEASE
reaction O I_DISEASE
, O O
and O O
is O O
detected O O
in O O
patients O B_PERSON/B_BIO
with O O
systemic O B_DISEASE
symptoms O I_DISEASE
which O O
appeared O O
subsequently O O
to O O
vaccination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

To O O
examine O O
the O O
effect O O
of O O
the O O
cAMP O O
signal O O
transduction O O
pathway O O
on O O
transcription O O
of O O
the O O
gene O O
encoding O O
the O O
catalytic O O
subunit O O
of O O
glucose B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
G6Pase B B_GENE/B_LOCATION
) O O
, O O
G6Pase B B_GENE
- O O
chloramphenicol B B_ENZYME[GENE]
acetyltransferase I I_ENZYME[GENE]
( O O
CAT B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
fusion O O
genes O O
were O O
transiently O O
transfected O O
into O O
either O O
the O O
liver O O
- O O
derived O O
HepG2 O O
or O O
kidney O O
- O O
derived O O
LLC O O
- O O
PK O O
cell O O
line O O
. O O

Whereas O O
the O O
sequence O O
of O O
alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
actinin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Noegel O O
, O O
A O O
. O O
, O O
W O O
. O O

By O O
contrast O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
clonidine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O B_MEASURE
micrograms O I_MEASURE
/ O O
kg O B_MEASURE
) O O
elicited O O
an O O
immediate O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
prolonged O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
fall O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
blood O B_DISEASE/B_GENE
pressure O B_DISEASE/I_GENE
and O O
heart O B_MEASURE/B_DISEASE
rate O I_MEASURE/I_DISEASE
when O O
given O O
into O O
the O O
vertebral O B_BODY_PART_OR_ORGAN_COMPONENT
artery O I_BODY_PART_OR_ORGAN_COMPONENT
, O O
but O O
not O O
intravenously O O
. O O

The O O
shift O O
from O O
complex O O
I O O
to O O
complex O O
II O O
seen O O
only O O
in O O
SCM B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
- O O
producer O O
T O O
cell O O
lines O O
upon O O
activation O O
was O O
completely O O
suppressed O O
by O O
cyclosporin O O
A O O
. O O

( O O
We O O
observed O O
a O O
ferritin B B_GENE/B_MEASURE
value O O
as O O
high O O
as O O
47 O O
mg O O
/ O O
L O O
in O O
one O O
patient O O
. O O
) O O
Results O O
with O O
all O O
these O O
kits O O
did O O
not O O
inter O O
- O O
compare O O
well O O
for O O
ferritin B B_PROTEIN[GENE]
concentrations O O
greater O O
than O O
300 O O
micrograms O O
/ O O
L O O
, O O
a O O
finding O O
that O O
casts O O
further O O
doubt O O
on O O
the O O
controversial O O
use O O
of O O
serum B B_MEASURE/B_PROTEIN[GENE]
ferritin I I_MEASURE/I_PROTEIN[GENE]
measurement O O
in O O
cases O O
of O O
iron O O
overload O O
. O O

Post O B_DISEASE/B_MEASURE
- O O
CPB O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
cardiac O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
index O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
was O O
superior O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
B O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
3 O B_MEASURE
. O O
9 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
3 O B_MEASURE/B_SPORT[ENT]
vs O I_MEASURE/I_SPORT[ENT]
. O O

ER B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
less O O
potent O O
than O O
ER B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
alpha I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
in O O
activating O O
E2 O O
- O O
stimulated O O
ERELuc B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O O
( O O
4 O O
- O O
vs O O
. O O

The O O
expression O O
pattern O O
of O O
LjEmx B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changed O O
dramatically O O
during O O
embryogenesis O O
; O O
expression O O
was O O
seen O O
initially O O
in O O
the O O
entire O O
neural O O
tube O O
and O O
mesoderm O O
, O O
which O O
were O O
secondarily O O
downregulated O O
, O O
and O O
secondarily O O
in O O
cranial O O
nerve O O
ganglia O O
and O O
in O O
the O O
craniofacial O O
mesenchyme O O
. O O

Disruption O O
of O O
PML B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
subnuclear I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domains I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
the O O
acidic B B_GENE
IE1 I I_GENE
protein I I_GENE
of O O
human O O
cytomegalovirus O O
is O O
mediated O O
through O O
interaction O O
with O O
PML B B_GENE/B_DISEASE
and O O
may O O
modulate O O
a O O
RING O O
finger O O
- O O
dependent O O
cryptic O O
transactivator O O
function O O
of O O
PML B B_GENE/B_DISEASE
. O O

Furthermore O O
, O O
the O O
GC O O
- O O
rich O O
sequences O O
could O O
confer O O
Sp1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dependent O O
transactivation O O
to O O
a O O
heterologous O O
prolactin B B_GENE/B_LOCATION
minimal I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
. O O

Twelve O O
patients O O
of O O
leprosy O O
with O O
arthritis O O
and O O
161 O O
patients O O
without O O
arthritis O O
were O O
studied O O
for O O
immunological O O
parameters O O
like O O
immunoglobulins B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
IgG B B_GENE/B_LOCATION
, O O
IgM B B_PROTEIN[GENE]/B_LOCATION
, O O
IgA B B_GENE/B_LOCATION
) O O
, O O
C B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
reactive I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
proteins I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O O
rheumatoid B B_GENE/B_DISEASE
factor I I_GENE/I_DISEASE
. O O

Several O O
reports O O
assert O O
that O O
prolactin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
affects O O
the O O
delta O O
5 O O
and O O
delta O O
4 O O
pathways O O
through O O
its O O
effect O O
on O O
the O O
activity O O
of O O
3beta B B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydroxysteroid I B_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dehydrogenase I B_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
3beta B B_DISEASE/B_LOCATION
- I I_DISEASE/I_LOCATION
OHSD I I_DISEASE/I_LOCATION
) O O
. O O

The O O
NrfC B B_GENE/B_LOCATION
polypeptide I I_GENE/I_LOCATION
, O O
M B B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
r I I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
24 I I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
567 I I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
contains O O
16 O O
cysteine O O
residues O O
arranged O O
in O O
four O O
clusters O O
typical O O
of O O
the O O
CooF B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
super I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
family I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
non O O
- O O
haem O O
iron O O
- O O
sulphur O O
proteins O O
. O O

Zonography O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O O
urology O B_LOCATION/B_PERSON
( O O
author O B_PERSON
' O O
s O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transl O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O

( O O
i O O
) O O
p60 B B_MEASURE/B_GENE
bound O O
fast O O
- O O
migrating O O
, O O
underprocessed O O
wild B B_GENE
- I I_GENE
type I I_GENE
ICP22 I I_GENE
and O O
ICP22 B B_GENE/B_MEASURE
lacking O O
the O O
carboxyl O O
- O O
terminal O O
24 O O
amino O O
acids O O
but O O
not O O
ICP22 B B_TIME[MEASURE]/B_GENE
lacking O O
the O O
carboxyl O O
- O O
terminal O O
40 O O
amino O O
acids O O
, O O
whereas O O
the O O
previously O O
identified O O
cellular B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
p78 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
R O O
. O O

Stress O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thallium O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
201 O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
myocardial O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
imaging O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
used O O
in O O
two O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
angina O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
free O B_PERSON
patients O I_PERSON
with O O
severe O B_DISEASE/B_LOCATION
congestive O I_DISEASE/I_LOCATION
heart O I_DISEASE/I_LOCATION
failure O I_DISEASE/I_LOCATION
to O O
identify O O
clinically O O
silent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
areas O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
ischemic O B_DISEASE_ADJECTIVE[DISEASE]
myocardium O I_DISEASE_ADJECTIVE[DISEASE]
and O O
to O O
distinguish O O
between O O
scar O B_DISEASE_ADJECTIVE[DISEASE]
and O O
reversibly O O
ischemic O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
myocardium O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
as O O
a O O
cause O B_DISEASE/B_MEASURE
for O O
akinesia O B_DISEASE_ADJECTIVE[DISEASE]
of O O
left O O
ventricular O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
wall O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
segments O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
community O B_ORGANIZATION/B_LOCATION
- O O
acquired O O
bacteremia O B_DISEASE
was O O
mainly O O
due O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O O
E O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
coli O B_BACTERIUM[BIO]/B_PERSON
. O O

Y1 B B_PROTEIN[GENE]
, O O
Y2 B B_PROTEIN[GENE]/B_BIO
, O O
and O O
Y4 B B_PROTEIN[GENE]/B_DISEASE
/ O O
PP1 B B_MEASURE
. O O

Low O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
plasma O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
glucose O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
concentrations O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
may O O
or O O
may O O
not O O
be O O
sufficiently O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
result O O
in O O
symptoms O B_DISEASE
can O O
be O O
observed O O
as O O
a O O
concomitant O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
several O B_DISEASE
diverse O I_DISEASE
diseases O I_DISEASE
. O O

Developmentally O O
- O O
regulated O O
interaction O O
of O O
a O O
transcription O O
factor O O
complex O O
containing O O
CDP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
cut B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
early B B_GENE
histone I I_GENE
H3 I I_GENE
gene I I_GENE
promoter I I_GENE
of I I_GENE
the I I_GENE
sea I I_GENE
urchin I I_GENE
Tetrapygus I I_GENE
niger I I_GENE
is O O
associated O O
with O O
changes O O
in O O
chromatin O O
structure O O
and O O
gene O O
expression O O
. O O

Procedures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O O
perfected O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
method O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON

After O O
a O O
shift O O
to O O
37 O O
degrees O O
C O O
, O O
the O O
mutant O O
Rat7 B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1p I I_GENE/I_LOCATION
/ O O
Nup159 B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
1p I I_GENE/I_MEASURE
is O O
lost O O
from O O
the O O
nuclear O O
rim O O
of O O
rat7 O O
- O O
1 O O
cells O O
and O O
NPCs O O
, O O
which O O
are O O
clustered O O
together O O
in O O
these O O
cells O O
grown O O
under O O
permissive O O
conditions O O
become O O
substantially O O
less O O
clustered O O
. O O

The O O
mRNA O O
for O O
this O O
protein O O
is O O
expressed O O
in O O
the O O
T O O
- O O
ALL O O
cell O O
line O O
Jurkat O O
and O O
has O O
been O O
designated O O
HUG1 B B_GENE/B_SPECIES[BIO]
, O O
for O O
HOX11 B B_TIME[MEASURE]/B_GENE
Upstream I I_TIME[MEASURE]/I_GENE
Gene I I_TIME[MEASURE]/I_GENE
. O O

The O O
STS B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequence I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
WI I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
14920 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
in O O
fact O O
derived O O
from O O
the O O
3 O O
' O O
- O O
untranslated O O
region O O
of O O
the O O
human B B_GENE
PUNC I I_GENE
gene I I_GENE
. O O

Its O O
activity O O
was O O
twice O O
that O O
of O O
a O O
construct O O
where O O
the O O
CAT B B_GENE
gene I I_GENE
was O O
driven O O
by O O
the O O
H B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2Kb I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
5 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
' I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
H2TF1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
KBF1 B B_PROTEIN[GENE]/B_LOCATION
site O O
) O O
and O O
comparable O O
to O O
that O O
of O O
pRSVCAT O O
construct B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
carrying I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
the I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
strong I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Rous I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sarcoma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
LTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

ORF3 O O
appears O O
to O O
encode O O
the O O
homologue O O
of O O
the O O
well O O
- O O
conserved O O
proteasomal B B_GENE/B_LOCATION
26S I I_GENE/I_LOCATION
regulatory I I_GENE/I_LOCATION
subunit I I_GENE/I_LOCATION
. O O

The O O
tam B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Aspergillus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nidulans I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encodes O O
a O O
739 O O
- O O
amino O O
acid O O
protein O O
with O O
similarity O O
to O O
Uga35p B B_LOCATION/B_GENE
/ O O
Dal81p B B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
DurLp B B_MEASURE/B_GENE
of O O
Saccharomyces O O
cerevisiae O O
. O O

Little O O
honoured O O
in O O
his O O
own O B_PERSON/B_LOCATION
country O I_PERSON/I_LOCATION
: O O
statues O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
recognition O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
Edward O B_PERSON/B_DISEASE
Jenner O I_PERSON/I_DISEASE
MD O I_PERSON/I_DISEASE
FRS O I_PERSON/I_DISEASE
. O O

A O O
pharmacokinetic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
interaction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O O
LY354740 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
diazepam O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
leading O O
to O O
the O O
lowering O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
plasma O B_MEASURE/B_DISEASE
level O I_MEASURE/I_DISEASE
of O O
free O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diazepam O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
was O O
also O O
demonstrated O O
. O O

The O O
promoter O B_GENE/B_LOCATION
of O O
this O O
methyltransferase O B_GENE/B_LOCATION
gene O I_GENE/I_LOCATION
lacks O O
an O O
identifiable O B_GENE
TATA O I_GENE
box O I_GENE
but O O
is O O
characterized O O
by O O
a O O
CpG O B_LOCATION/B_MEASURE
island O I_LOCATION/I_MEASURE
which O O
begins O O
approximately O O
723 O B_MEASURE/B_LOCATION
nucleotides O I_MEASURE/I_LOCATION
upstream O O
of O O
the O O
major O B_GENE/B_MEASURE
transcriptional O I_GENE/I_MEASURE
start O I_GENE/I_MEASURE
site O I_GENE/I_MEASURE
and O O
extends O O
through O O
exon O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
1 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
into O O
the O O
first O B_GENE/B_LOCATION
intron O I_GENE/I_LOCATION
. O O

No O O
promoter O O
activity O O
could O O
be O O
detected O O
with O O
various O O
mouse B B_GENE
Fli I I_GENE
- I I_GENE
1 I I_GENE
promoter I I_GENE
- O O
CAT B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
constructs O O
containing O O
600 O O
bp O O
of O O
the O O
5 O O
' O O
flanking O O
region O O
, O O
the O O
complete O O
exon O O
1 O O
, O O
the O O
5 O O
' O O
end O O
of O O
intron O O
1 O O
and O O
/ O O
or O O
retroviral O O
LTR O O
sequence O O
. O O

The O O
D O O
. O O
discoideum O O
proteins O O
were O O
entirely O O
conserved O O
over O O
the O O
four O O
regions O O
known O O
to O O
be O O
important O O
for O O
GTP O O
binding O O
and O O
all O O
contained O O
the O O
C O O
- O O
terminal O O
CAAX O O
aa O O
motifs O O
shared O O
by O O
other O O
Rho B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O O

An O O
81 O O
- O O
nt O O
tandem O O
duplication O O
of O O
the O O
C O O
- O O
terminal O O
coding O O
region O O
is O O
located O O
adjacent O O
to O O
the O O
termination O O
codon O O
of O O
the O O
CyIIIb B B_GENE
gene I I_GENE
, O O
a O O
potential O O
relic O O
of O O
a O O
slipped O O
mispairing O O
and O O
replication O O
event O O
. O O

Only O O
53 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
of O O
all O O
injuries O B_DISEASE
and O O
12 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
of O O
serious O B_DISEASE/B_PERSON
injuries O I_DISEASE/I_PERSON
involved O O
children O B_PERSON
, O O
and O O
in O O
contrast O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
1950s O B_TIME[MEASURE]
and O O
early O B_TIME[MEASURE]/B_LOCATION
1960s O I_TIME[MEASURE]/I_LOCATION
, O O
young O B_PERSON/B_LOCATION
adults O I_PERSON/I_LOCATION
appear O O
at O O
greatest O B_MEASURE
risk O I_MEASURE
in O O
the O O
1980s O B_TIME[MEASURE]/B_LOCATION
. O O

The O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
tested O O
on O O
7 O B_PERSON/B_BIO
rats O I_PERSON/I_BIO
with O O
48 O B_MEASURE
- O O
hr O B_TIME[MEASURE]/B_PERSON
- O O
old O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
myocardial O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
4 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
sham O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
operated O O
controls O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

Here O O
we O O
examine O O
the O O
population O O
of O O
gammaS B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
adult O O
human O O
lens O O
and O O
the O O
structure O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
CRYGS I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
slope O B_MEASURE
of O O
QD O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
versus O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
QEMF O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
the O O
four O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
tubes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
near O O
unity O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
extent O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
odontoblast O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
process O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
human O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
dentin O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Mouse B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
macrophage I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subunit I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CD11b I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cDNA I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
CR3 B B_GENE/B_DISEASE
complement I I_GENE/I_DISEASE
receptor I I_GENE/I_DISEASE
/ O O
Mac B B_GENE
- I I_GENE
1 I I_GENE
antigen I I_GENE
. O O

Enoxacin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
has O O
been O O
shown O O
to O O
be O O
an O O
effective O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
well O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tolerated O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
convenient O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
gonorrhoea O B_DISEASE/B_BIO
. O O

We O O
assessed O O
cardiovascular O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
variables O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
blood O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
O2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
contents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
order O B_SPECIES[BIO]/B_DISEASE
to O O
characterize O O
O2 O B_DISEASE
transport O I_DISEASE
in O O
ponies O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
during O O
treadmill O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
exercise O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

The O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O O
discussed O O
with O O
reference O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
mechanisms O I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
by O O
which O O
parasite O B_DISEASE/B_PERSON
development O I_DISEASE/I_PERSON
might O O
be O O
controlled O O
. O O

The O O
80 O O
kb O O
preceding O O
the O O
expression O O
site O O
has O O
few O O
, O O
if O O
any O O
, O O
functional O O
ORFs O O
, O O
but O O
contains O O
50 O O
bp O O
repeats O O
, O O
INGI B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
retrotransposon I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
like I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
elements I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
and O O
novel O O
4 O O
- O O
12 O O
kb O O
repeats O O
found O O
near O O
other O O
telomeres O O
. O O

The O O
predicted O O
proteins O O
show O O
strong O O
homology O O
to O O
an O O
ABA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inducible I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glycine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
rich I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
maize O O
embryos O O
and O O
to O O
the O O
mammalian B B_GENE/B_PERSON
RNA I I_GENE/I_PERSON
- I I_GENE/I_PERSON
binding I I_GENE/I_PERSON
protein I I_GENE/I_PERSON
A1 I I_GENE/I_PERSON
of O O
the O O
heterogeneous O O
nuclear O O
ribonucleoprotein O O
complex O O
involved O O
in O O
pre O O
- O O
mRNA O O
splicing O O
. O O

Increase O O
in O O
[ O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ca O O
+ O O
+ O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
counteracted O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
verapamil O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
RAD O B_DISEASE/B_GENE
. O O

We O O
compared O O
the O O
quantities O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
collected O O
with O O
both O O
pollen O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
traps O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
during O O
February O B_TIME[MEASURE]/B_LOCATION
, O O
March O B_TIME[MEASURE]/B_LOCATION
and O O
April O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1988 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
1989 O B_TIME[MEASURE]/B_LOCATION
. O O

Cbl B B_GENE
is O O
a O O
signaling O O
molecule O O
with O O
multiple O O
functional O O
domains O O
: O O
an O O
SH2 B B_GENE
domain I I_GENE
which O O
binds O O
phosphotyrosine O O
residues O O
, O O
a O O
RING O O
finger O O
domain O O
which O O
acts O O
as O O
a O O
ubiquitin B B_LOCATION/B_ENZYME[GENE]
ligase I I_LOCATION/I_ENZYME[GENE]
, O O
a O O
proline O O
- O O
rich O O
region O O
which O O
serves O O
as O O
a O O
docking O O
site O O
for O O
SH3 B B_GENE/B_BIO
- I I_GENE/I_BIO
containing I I_GENE/I_BIO
proteins I I_GENE/I_BIO
, O O
phosphotyrosine O O
residues O O
which O O
serve O O
as O O
docking O O
sites O O
for O O
SH2 B B_BIO/B_GENE
- I I_BIO/I_GENE
containing I I_BIO/I_GENE
proteins I I_BIO/I_GENE
such O O
a O O
CrkL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
p85 B B_ENZYME[GENE]/B_LOCATION
subunit I I_ENZYME[GENE]/I_LOCATION
of O O
PI B B_GENE
3 I I_GENE
- I I_GENE
kinase I I_GENE
, O O
and O O
a O O
nuclear O O
localization O O
signal O O
. O O

Surprisingly O O
, O O
apo B B_GENE
- I I_GENE
iso I I_GENE
- I I_GENE
1 I I_GENE
- I I_GENE
cytochrome I I_GENE
c I I_GENE
is O O
absent O O
in O O
cyc3 B B_GENE/B_PERSON
- I I_GENE/I_PERSON
strains O O
, O O
although O O
apo B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
iso I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
2 I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
cytochrome I I_GENE/I_LOCATION
c I I_GENE/I_LOCATION
is O O
present O O
at O O
approximately O O
the O O
same O O
level O O
at O O
which O O
holo B B_ENZYME[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
iso I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytochrome I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
c I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
found O O
in O O
CYC3 B B_GENE/B_NUMBER[MEASURE]
+ I I_GENE/I_NUMBER[MEASURE]
strains O O
. O O

Here O O
, O O
we O O
identify O O
the O O
analytical O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
form O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
PDF O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
one O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
the O O
order O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
parameter O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
low O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
temperature O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
phase O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
2D O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
XY O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
model O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

The O O
ventricular O B_MEDICAL_DEVICE[OBJECT]/B_BODY_PART_OR_ORGAN_COMPONENT
demand O I_MEDICAL_DEVICE[OBJECT]/I_BODY_PART_OR_ORGAN_COMPONENT
pacemaker O I_MEDICAL_DEVICE[OBJECT]/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
VVI O B_DISEASE/B_LOCATION
) O O
was O O
implanted O O
three O B_TIME[MEASURE]/B_ENT
years O I_TIME[MEASURE]/I_ENT
ago O O
and O O
because O O
of O O
further O B_DISEASE_ADJECTIVE[DISEASE]
impairment O I_DISEASE_ADJECTIVE[DISEASE]
of O O
cardiac O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
performance O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
an O O
av O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
sequential O B_DISEASE/B_MEDICAL_DEVICE[OBJECT]
pacemaker O B_DISEASE/I_MEDICAL_DEVICE[OBJECT]
( O O
DDD O B_DISEASE/B_LOCATION
) O O
was O O
used O O
to O O
restore O O
atrio O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
ventricular O B_BODY_PART_OR_ORGAN_COMPONENT
synchronisation O I_BODY_PART_OR_ORGAN_COMPONENT
. O O

It O O
was O O
predicted O O
that O O
the O O
Stroop O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
task O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
would O O
trigger O O
greater O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consumption O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
ice O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cream O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
than O O
a O O
fearful O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
film O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
that O O
this O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
would O O
be O O
more O O
pronounced O O
for O O
binge O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
eaters O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
than O O
non O B_DISEASE
- O O
binge O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
eaters O B_PERSON/B_ORGANIZATION
. O O

Our O O
data O O
are O O
in O O
line O O
with O O
the O O
hypothesis O O
that O O
E2F B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functions O O
as O O
a O O
growth O O
- O O
and O O
cell O O
cycle O O
regulated O O
tethering O O
factor O O
between O O
Sp1 B B_GENE
and O O
the O O
basic O O
transcription O O
machinery O O
. O O

There O O
was O O
a O O
positive O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
correlation O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
between O O
change O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
from O O
baseline O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O O
parietal O B_COLOR/B_PERSON
lobe O I_COLOR/I_PERSON
gray O I_COLOR/I_PERSON
- O O
matter O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cytosolic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
choline O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
expressed O O
in O O
terms O B_MEASURE/B_DISEASE
of O O
choline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
creatine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resonance O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ratios O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
cognitive O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
performance O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
measured O O
with O O
the O O
Alzheimer O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
' O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
s O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Disease O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Assessment O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Scale O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Cognitive O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Subscale O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Colonization O B_TIME[MEASURE]/B_DISEASE
increased O O
with O O
level O B_MEASURE/B_PERSON
of O O
care O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
: O O
from O O
9 O B_MEASURE
per O O
cent O B_SEQUENCE[MEASURE]
in O O
independent O B_PERSON/B_LOCATION
residents O I_PERSON/I_LOCATION
of O O
apartments O B_LOCATION
to O O
60 O B_MEASURE
per O O
cent O B_SEQUENCE[MEASURE]
in O O
patients O B_PERSON/B_LOCATION
on O O
an O O
acute O B_LOCATION
hospital O I_LOCATION
ward O I_LOCATION
( O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE/B_LOCATION
. O O
0001 O B_MEASURE
) O O
. O O

IRA2 B B_GENE/B_MEASURE
, O O
a O O
second O O
gene O O
of O O
Saccharomyces O O
cerevisiae O O
that O O
encodes O O
a O O
protein O O
with O O
a O O
domain O O
homologous O O
to O O
mammalian O O
ras B B_GENE/B_LOCATION
GTPase I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
activating I I_GENE/I_LOCATION
protein I I_GENE/I_LOCATION
. O O

Exon O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
A1a O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encodes O O
most O B_DISEASE/B_LOCATION
of O O
the O O
5 O B_TIME[MEASURE]/B_LOCATION
' O I_TIME[MEASURE]/I_LOCATION
- O O
untranslated O B_GENE/B_LOCATION
region O I_GENE/I_LOCATION
. O O

Co O O
- O O
operativity O O
of O O
functional O O
domains O O
in O O
the O O
muscle B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
- I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
specific I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
transcription I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
Myf I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
- I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
5 I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Creatinine O O
and O O
creatine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
phosphokinase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CPK B B_MEASURE/B_DISEASE
) O O
. O O

In O O
our O O
initial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
we O O
treated O O
MCF O B_PROTEIN[GENE]/B_BIO
- O O
7 O B_MEASURE
cells O I_MEASURE
with O O
paclitaxel O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
which O O
results O O
in O O
the O O
arrest O B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
in O O
G1 O B_MEASURE
with O O
4n O B_MEASURE/B_DISEASE
DNA O B_MEASURE/I_DISEASE
content O B_MEASURE/I_DISEASE
( O O
pseudo O B_PROTEIN[GENE]/B_MEASURE
G1 O I_PROTEIN[GENE]/I_MEASURE
) O O
. O O

These O O
alterations O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occurred O O
at O O
both O O
the O O
mRNA O B_GENE
and O O
protein O B_GENE
levels O I_GENE
but O O
did O O
not O O
significantly O O
affect O O
the O O
subcellular O B_MEASURE
distribution O I_MEASURE
of O O
any O O
of O O
the O O
four O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
isoforms O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
glyoxysomal O O
and O O
plastid O O
molecular O O
chaperones O O
( O O
70 B B_DISEASE/B_LOCATION
- I I_DISEASE/I_LOCATION
kDa I I_DISEASE/I_LOCATION
heat I I_DISEASE/I_LOCATION
shock I I_DISEASE/I_LOCATION
protein I I_DISEASE/I_LOCATION
) O O
of O O
watermelon O O
cotyledons O O
are O O
encoded O O
by O O
a O O
single O O
gene O O
. O O

Suspected O O
pelvic O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
endometriosis O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
was O O
prospectively O O
evaluated O O
in O O
31 O B_PERSON/B_ORGANIZATION
women O B_PERSON/I_ORGANIZATION
with O O
T1 O B_MEASURE/B_PROTEIN[GENE]
- O O
and O O
T2 O B_MEASURE/B_LOCATION
- O O
weighted O O
conventional O B_LOCATION/B_MEASURE
spin O B_LOCATION/I_MEASURE
- O O
echo O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CSE O B_LOCATION/B_DISEASE
) O O
magnetic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
resonance O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
imaging O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alone O O
and O O
in O O
combination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O O
T1 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
weighted O O
fat O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
suppressed O O
( O O
T1FS O B_LOCATION/B_PROTEIN[GENE]
) O O
and O O
gadolinium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
enhanced O O
T1FS O B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Gd O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
T1FS O B_LOCATION/B_DISEASE
) O O
spin O B_MEASURE/B_ORGANIZATION
- O O
echo O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
techniques O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Seroconversion O B_DISEASE/B_TIME[MEASURE]
after O O
hepatitis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
B O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
vaccination O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

A O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
bilateral O B_DISEASE
testicular O I_DISEASE
germ O I_DISEASE
cell O I_DISEASE
tumors O I_DISEASE
in O O
a O O
23 O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]
- O O
old O B_PERSON
male O I_PERSON
is O O
reported O O
. O O

Total O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
body O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BMD O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
r O O
= O O
0 O B_MEASURE
. O O
30 O B_MEASURE
; O O
P O B_OTHER/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
02 O B_MEASURE
) O O
and O O
femoral O B_MEASURE/B_PROTEIN[GENE]
neck O B_MEASURE/I_PROTEIN[GENE]
BMD O B_MEASURE/I_PROTEIN[GENE]
( O O
r O B_OTHER/B_GENE
= O O
0 O B_MEASURE
. O O
39 O B_MEASURE
; O O
P O B_OTHER/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
002 O B_MEASURE
) O O
were O O
positively O O
correlated O O
with O O
weight O B_MEASURE/B_BIO
- O O
bearing O O
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
but O O
not O O
with O O
non O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
weight O B_MEASURE/B_DISEASE
- O O
bearing O O
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

The O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
castor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oil O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
alone O O
, O O
as O O
well O O
as O O
in O O
combination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
with O O
PGI2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
indomethacin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O O
gastrointestinal O B_DISEASE
functions O I_DISEASE
have O O
been O O
examined O O
in O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Checking O O
for O O
patient O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compliance O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
( O O
n O B_OTHER/B_MEASURE
= O O
10 O B_MEASURE
) O O
with O O
a O O
FK O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O O
concentration O B_MEASURE
of O O
0 O B_MEASURE
ng O I_MEASURE
/ O O
mL O B_MEASURE/B_LOCATION
were O O
re O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
analyzed O O
. O O

K O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
hematopoietic O O
form O O
of O O
PTPN6 B B_GENE
transcript I I_GENE
is O O
initiated O O
at O O
a O O
downstream O O
promoter O O
separated O O
by O O
7 O O
kb O O
from O O
the O O
first O O
. O O

The O O
residual O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
small O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
rRNAs O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
[ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
poky O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
] O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
appear O O
to O O
be O O
synthesized O O
via O O
the O O
upstream O B_GENE
promoter O I_GENE
( O O
s O B_PROTEIN[GENE]/B_DISEASE
) O O
, O O
but O O
are O O
missing O O
37 O B_MEASURE
- O O
44 O B_TIME[MEASURE]/B_LOCATION
nucleotides O I_TIME[MEASURE]/I_LOCATION
from O O
their O O
5 O B_GENE/B_MEASURE
' O I_GENE/I_MEASURE
ends O I_GENE/I_MEASURE
, O O
indicating O O
either O O
that O O
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
rRNAs O B_GENE
are O O
processed O O
abnormally O O
or O O
that O O
abnormal O B_NUMBER[MEASURE]
5 O I_NUMBER[MEASURE]
' O O
RNA O B_GENE/B_LOCATION
ends O B_GENE/I_LOCATION
are O O
unstable O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
. O O

Extra O B_MEASURE/B_LOCATION
dose O B_MEASURE/I_LOCATION
due O O
to O O
extravehicular O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
activity O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
during O O
the O O
NASA4 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mission O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measured O O
by O O
an O O
on O O
- O O
board O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
TLD O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Unconventional O O
mRNA O O
processing O O
in O O
the O O
expression O O
of O O
two O O
calcineurin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
isoforms I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
Dictyostelium O O
. O O

The O O
deduced O O
amino O O
acid O O
sequence O O
of O O
this O O
open O O
reading O O
frame O O
is O O
significantly O O
homologous O O
to O O
the O O
HSV B B_GENE/B_BIO
1 I I_GENE/I_BIO
UL49 I I_GENE/I_BIO
. I I_GENE/I_BIO
5 I I_GENE/I_BIO
gene I I_GENE/I_BIO
product I I_GENE/I_BIO
, O O
and O O
as O O
with O O
UL49 B B_GENE/B_BIO
. I I_GENE/I_BIO
5 I I_GENE/I_BIO
, O O
it O O
contains O O
a O O
potential O O
signal O O
sequence O O
and O O
transmembrane O O
domain O O
characteristic O O
of O O
membrane O O
- O O
associated O O
proteins O O
. O O

It O O
has O O
been O O
demonstrated O O
that O O
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
pontomesencephalic O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
parabrachial O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
region O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
PBR O B_DISEASE/B_PROTEIN[GENE]
) O O
by O O
microinjection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
cholinergic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
electricity O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
cat O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
produces O O
potent O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pain O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
suppression O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
which O O
is O O
not O O
antagonized O O
by O O
the O O
opiate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonist O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
naloxone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

GAGA B B_GENE
factor I I_GENE
is O O
known O O
to O O
remodel O O
the O O
chromatin O O
structure O O
in O O
concert O O
with O O
nucleosome B B_GENE
- I I_GENE
remodeling I I_GENE
factor I I_GENE
NURF B I_GENE
in O O
a O O
Drosophila O O
embryonic O O
S150 O O
extract O O
. O O

Also O O
, O O
like O O
TUB B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
it O O
has O O
a O O
wider O O
pattern O O
of O O
tissue O O
expression O O
than O O
either O O
TULP1 B B_GENE
or O O
TULP2 B B_GENE
. O O

After O O
nine O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
months O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
GFR O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
improved O O
spontaneously O O
to O O
32 O B_MEASURE
ml O I_MEASURE
/ O O
min O B_TIME[MEASURE]/B_PERSON
/ O O
1 O B_MEASURE
. O O
73 O B_MEASURE
m2 O I_MEASURE
despite O O
no O O
improvement O B_DISEASE_ADJECTIVE[DISEASE]
in O O
his O O
hypertension O B_DISEASE
. O O

First O O
, O O
ste12Delta B B_PERSON/B_GENE
cells O O
differ O O
from O O
cells O O
with O O
disruptions O O
of O O
the O O
upstream O O
signaling O O
elements O O
( O O
e O O
. O O
g O O
. O O
, O O
ste4Delta B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
ste20Delta B B_GENE/B_DISEASE
, O O
ste5Delta B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
ste11Delta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
ste7Delta B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
or O O
fus3Delta B B_PERSON/B_GENE
kss1Delta B I_PERSON/I_GENE
cells O O
) O O
in O O
that O O
they O O
clearly O O
retain O O
some O O
capacity O O
for O O
inducing O O
Ste3p B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphorylation O O
. O O

Herein O O
, O O
we O O
report O O
that O O
CRE O O
- O O
decoy O O
oligonucleotide O O
treatment O O
results O O
in O O
an O O
increase O O
in O O
the O O
p53 B B_GENE
protein I I_GENE
level O O
in O O
MCF O O
- O O
7 O O
human O O
breast O O
cancer O O
cells O O
that O O
express O O
wild O O
- O O
type O O
p53 B B_GENE
. O O

The O O
selective O O
5 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HT2 I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocker O O
ketanserin O O
was O O
found O O
to O O
reduce O O
maximal O O
urethral O O
pressures O O
in O O
healthy O O
females O O
by O O
about O O
40 O O
% O O
without O O
reducing O O
blood O O
pressure O O
. O O

It O O
thus O O
seems O O
likely O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
that O O
genistein O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
affects O O
a O O
common O B_MEASURE/B_LOCATION
pathway O I_MEASURE/I_LOCATION
downstream O I_MEASURE/I_LOCATION
of O O
these O O
signals O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
B O B_LOCATION/B_DISEASE
. O O
glabrata O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
B O B_LOCATION/B_DISEASE
. O O
straminea O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
and O O
B O B_PROTEIN[GENE]/B_LOCATION
. O O
tenagophila O B_SPECIES[BIO]/B_DISEASE
under O O
outdoor O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
electrocardiogram O B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
tachycardia O B_BIO/B_DISEASE
. O O

Identification O O
of O O
a O O
putative O O
chromosomal O O
replication O O
origin O O
from O O
Helicobacter O O
pylori O O
and O O
its O O
interaction O O
with O O
the O O
initiator B B_GENE
protein I I_GENE
DnaA I I_GENE
. O O

The O O
primary O O
structure O O
of O O
cholesterol B B_GENE
esterase I I_GENE
displayed O O
no O O
significant O O
homology O O
with O O
other O O
lipases B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
although O O
the O O
putative O O
lipid O O
interfacial O O
recognition O O
site O O
of O O
G O O
- O O
X O O
- O O
S O O
- O O
X O O
- O O
G O O
is O O
present O O
in O O
the O O
cholesterol B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
esterase I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequence I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
essential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
questions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
about O O
hepatitis O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
C O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE

The O O
transcriptional O O
initiation O O
site O O
of O O
RAG1 B B_GENE
was O O
localized O O
at O O
A O O
, O O
26 O O
bp O O
upstream O O
of O O
the O O
putative O O
translational O O
initiation O O
codon O O
, O O
ATG O O
, O O
by O O
the O O
primer O O
extension O O
assay O O
. O O

Coronary O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
arteriographies O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
ventriculographies O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
corresponding O O
to O O
274 O B_TIME[MEASURE]/B_PERSON
consecutive O I_TIME[MEASURE]/I_PERSON
patients O I_TIME[MEASURE]/I_PERSON
( O O
January O B_TIME[MEASURE]/B_LOCATION
, O O
1975 O B_MEASURE
- O O
October O B_TIME[MEASURE]/B_LOCATION
, O O
1978 O B_MEASURE
) O O
with O O
significant O B_DISEASE/B_LOCATION
coronary O I_DISEASE/I_LOCATION
lesions O I_DISEASE/I_LOCATION
are O O
reviewed O O
. O O

Visualization O O
of O O
the O O
cells O O
by O O
phase O O
contrast O O
microscopy O O
indicated O O
that O O
murine B B_GENE
PKCepsilon I I_GENE
expression O O
in O O
the O O
presence O O
of O O
glycerol O O
resulted O O
in O O
a O O
significant O O
increase O O
in O O
the O O
number O O
of O O
yeast O O
cells O O
exhibiting O O
very O O
small O O
buds O O
. O O

Sonography O B_PERSON
depicted O O
the O O
true O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
morphology O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
these O O
cystic O B_DISEASE/B_LOCATION
lesions O I_DISEASE/I_LOCATION
more O O
clearly O O
than O O
CT O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
and O O
the O O
sonographic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
findings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
virtually O O
excluded O O
uncomplicated O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hepatic O B_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cyst O B_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
diagnosis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Protein B B_NUMBER[MEASURE]/B_PERSON
kinase I I_NUMBER[MEASURE]/I_PERSON
C I I_NUMBER[MEASURE]/I_PERSON
transiently O O
activated O O
heteromeric B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
N I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
methyl I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
D I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
aspartate I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
channels I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
independent O O
of O O
the O O
phosphorylatable O O
C O O
- O O
terminal O O
splice O O
domain O O
and O O
of O O
consensus O O
phosphorylation O O
sites O O
. O O

A O O
24 O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]
- O O
old O B_PERSON
pregnant O I_PERSON
woman O I_PERSON
started O O
to O O
have O O
hyperemesis O B_DISEASE
gravidarum O I_DISEASE
6 O I_DISEASE
weeks O I_DISEASE
before O O
admission O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O O

Highly O O
significant O O
similarities O O
were O O
detected O O
between O O
the O O
N O O
- O O
terminal O O
region O O
of O O
P30 B B_GENE/B_LOCATION
and O O
those O O
of O O
GENA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
[ O O
the O O
product O O
of O O
another O O
unidentified O O
gene O O
( O O
geneA B B_GENE/B_LOCATION
) O O
located O O
upstream O O
of O O
the O O
aceEF B B_DISEASE/B_GENE
- O O
lpd B B_PROTEIN[GENE]/B_MEASURE
operon O O
] O O
, O O
and O O
GNTR B B_GENE/B_LOCATION
( O O
a O O
putative O O
transcriptional O O
repressor O O
of O O
the O O
gluconate B B_GENE/B_BACTERIUM[BIO]
operon I I_GENE/I_BACTERIUM[BIO]
of O O
Bacillus O O
subtilis O O
) O O
. O O

In O O
vitro O O
DNA O O
binding O O
assays O O
indicate O O
that O O
the O O
elements O O
identified O O
can O O
specifically O O
interact O O
with O O
c B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Ets I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

They O O
are O O
found O O
to O O
have O O
several O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
advantages O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
over O O
the O O
conventional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
indices O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
skewness O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O O
kurtosis O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
square O B_MEASURE
root O I_MEASURE
of O O
b1 O B_PROTEIN[GENE]
and O O
b2 O B_PROTEIN[GENE]
) O O
and O O
no O O
serious O B_DISEASE_ADJECTIVE[DISEASE]
drawbacks O I_DISEASE_ADJECTIVE[DISEASE]
. O O

They O O
elicit O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regional O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cerebral O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flow O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
rCBF O B_LOCATION/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
patterns O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
even O O
though O O
sign O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
language O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
dependent O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
on O O
spatial O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
information O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Siglec B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
predicted O O
to O O
contain O O
three O O
extracellular O O
immunoglobulin B B_GENE/B_LOCATION
- I B_GENE/I_LOCATION
like I B_GENE/I_LOCATION
domains I B_GENE/I_LOCATION
that O O
comprise O O
an O O
N B B_GENE
- I I_GENE
terminal I I_GENE
V I I_GENE
- I I_GENE
set I I_GENE
domain I I_GENE
and O O
two O O
C2 B B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
- I I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
set I I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
domains I I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
, O O
a O O
transmembrane O O
region O O
and O O
a O O
cytoplasmic O O
tail O O
containing O O
two O O
putative O O
tyrosine O O
- O O
based O O
signaling O O
motifs O O
. O O

Determination O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
LD O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
50 O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
30 O B_MEASURE/B_LOCATION
) O O
during O O
infant O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
period O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
and O O
growth O B_TIME[MEASURE]/B_PERSON
period O B_TIME[MEASURE]/I_PERSON

The O O
availability O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
commercial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PCNONLIN O B_ORGANIZATION/B_LOCATION
) O O
is O O
needed O O
to O O
carry O O
out O O
matrix O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
handling O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
calculations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
introduction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gives O O
also O O
the O O
history O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
Research O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Programme O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MZ O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
XVII O B_MEASURE
and O O
its O O
implementation O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
several O B_LOCATION/B_ORGANIZATION
regions O I_LOCATION/I_ORGANIZATION
of O O
Poland O B_LOCATION
. O O

The O O
fecal O B_MEASURE
excretion O I_MEASURE
is O O
found O O
to O O
be O O
only O O
one O B_MEASURE/B_LOCATION
third O I_MEASURE/I_LOCATION
of O O
that O O
measured O O
in O O
urine O B_BIO/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
COR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
biosynthetic O O
gene O O
cluster O O
in O O
P O O
. O O
syringae O O
pv O O
. O O
glycinea O O
PG4180 O O
is O O
encoded O O
by O O
a O O
32 O O
- O O
kb O O
region O O
which O O
contains O O
both O O
the O O
structural O O
and O O
regulatory O O
genes O O
needed O O
for O O
COR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
synthesis O O
. O O

Model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
pheasants O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
using O O
single O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
doses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
the O O
insecticide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Lindane O B_PERSON/B_PROTEIN[GENE]
) O O
the O O
herbicide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Terbutryn O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
a O O
mineral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fertilizer O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
calcium O B_LOCATION/B_ORGANIZATION
ammonium O I_LOCATION/I_ORGANIZATION
nitrate O I_LOCATION/I_ORGANIZATION
) O O
and O O
the O O
fungicide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O O
HCB O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

In O O
this O O
technique O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
the O O
posterior O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
wall O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
of O O
the O O
neopharynx O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consists O O
only O O
of O O
the O O
prevertebral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissue O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
while O O
the O O
flap O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
forms O O
the O O
anterior O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
and O O
lateral O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
walls O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
most O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
hosts O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
were O O
equines O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
31 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
, O O
bovines O B_SPECIES[BIO]
( O O
25 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
and O O
raccoons O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
19 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
) O O
. O O

A O O
single O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
HD O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
session O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
using O O
cellulose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
triacetate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
polysulfone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
membrane O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significantly O O
increased O O
water O B_MEASURE/B_DISEASE
content O B_MEASURE/I_DISEASE
both O O
at O O
forearm O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
and O O
lower O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
leg O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
p O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

Both O O
claR B B_PROTEIN[GENE]/B_DISEASE
and O O
car B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
expressed O O
as O O
monocistronic O O
transcripts O O
; O O
the O O
level O O
of O O
transcript O O
declined O O
rapidly O O
after O O
48h O O
in O O
complex O O
media O O
, O O
but O O
low O O
sustained O O
levels O O
of O O
both O O
transcripts O O
were O O
observed O O
in O O
defined O O
GSPG O O
medium O O
until O O
96h O O
. O O

claR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
car B B_PRODUCT[OBJECT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
not O O
significantly O O
expressed O O
in O O
mutants O O
disrupted O O
in O O
the O O
ccaR B B_GENE
gene I I_GENE
, O O
a O O
regulatory O O
gene O O
that O O
controls O O
positively O O
clavulanic O O
acid O O
and O O
cephamycin O O
biosynthesis O O
. O O

Whereas O O
mutant B B_PERSON/B_LOCATION
6C4 I I_PERSON/I_LOCATION
specified O O
a O O
wild B B_GENE
- I I_GENE
type I I_GENE
- I I_GENE
size I I_GENE
Pol I I_GENE
protein I I_GENE
, O O
we O O
detected O O
no O O
full B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
length I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Pol I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
7E4 O O
- O O
infected O O
cell O O
extracts O O
. O O

The O O
hepatic O O
isoform O O
of O O
6 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
phosphofructo I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
kinase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
/ O O
fructose B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
6 I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
bisphosphatase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PF2K B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
Fru B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BPase I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
transcriptionally O O
stimulated O O
by O O
glucocorticoids O O
, O O
whereas O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
blocks O O
this O O
stimulatory O O
effect O O
. O O

Being O O
implicated O O
in O O
insulin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
GK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
gene I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
regulations O O
as O O
a O O
common O O
transcription O O
factor O O
, O O
IPF1 B B_GENE/B_DISEASE
/ O O
STF B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
/ O O
PDX B B_MEASURE/B_GENE
- I I_MEASURE/I_GENE
1 I I_MEASURE/I_GENE
is O O
likely O O
to O O
play O O
an O O
essential O O
role O O
in O O
maintaining O O
normal O O
beta O O
- O O
cell O O
functions O O
. O O

The O O
Caenorhabditis B B_GENE/B_LOCATION
elegans I I_GENE/I_LOCATION
NK I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
2 I I_GENE/I_LOCATION
class I I_GENE/I_LOCATION
homeoprotein I I_GENE/I_LOCATION
CEH I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
22 I I_GENE/I_LOCATION
is O O
involved O O
in O O
combinatorial O O
activation O O
of O O
gene O O
expression O O
in O O
pharyngeal O O
muscle O O
. O O

Mouse O O
embryo O O
cells O O
( O O
C57BL O O
/ O O
6 O O
, O O
H O O
- O O
2b O O
) O O
transformed O O
by O O
the O O
E1A B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
E1B B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes O O
of O O
adenovirus O O
type O O
5 O O
( O O
Ad5E1 O O
MEC O O
) O O
are O O
highly O O
immunogenic O O
. O O

The O O
largest O B_MEASURE
age O I_MEASURE
adjusted O O
differences O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
between O O
men O B_PERSON/B_BIO
with O O
low O B_DISEASE/B_LOCATION
and O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mood O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
were O O
for O O
the O O
AH4 O B_DISEASE/B_ORGANIZATION
( O O
3 O B_MEASURE/B_LOCATION
points O I_MEASURE/I_LOCATION
, O O
t O O
= O O
5 O B_MEASURE
. O O
6 O B_MEASURE
, O O
p O O
< O B_NUMBER[MEASURE]/B_LOCATION
0 O I_NUMBER[MEASURE]/I_LOCATION
. O O
0001 O B_MEASURE
) O O
and O O
the O O
CAMCOG O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
2 O B_MEASURE/B_LOCATION
points O I_MEASURE/I_LOCATION
, O O
t O O
= O O
5 O B_MEASURE
. O O
8 O B_MEASURE
, O O
p O O
< O O
0 O B_MEASURE
. O O
0001 O B_MEASURE
) O O
. O O

Our O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O O
that O O
resting O O
Tl O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
201 O B_MEASURE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scintigraphy O I_MEASURE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
limited O O
value O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
detection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
coronary O B_DISEASE/B_LOCATION
artery O I_DISEASE/I_LOCATION
disease O I_DISEASE/I_LOCATION
in O O
patients O B_PERSON
with O O
Hurler O B_DISEASE
syndrome O I_DISEASE
. O O

We O O
demonstrate O O
that O O
the O O
WRM B B_GENE
- I I_GENE
1 I I_GENE
protein I I_GENE
binds O O
to O O
LIT B B_GENE
- I I_GENE
1 I I_GENE
in O O
vivo O O
and O O
that O O
WRM B B_GENE/B_PERSON
- I I_GENE/I_PERSON
1 I I_GENE/I_PERSON
can O O
activate O O
the O O
LIT B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
when O O
coexpressed O O
in O O
vertebrate O O
tissue O O
culture O O
cells O O
. O O

RESULTS O O
: O O
All O O
primary O O
tumors O O
were O O
positive O O
for O O
CAM5 B B_GENE
. I I_GENE
2 I I_GENE
. O O

Nuclear O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
extracts O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O O
Sertoli O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
found O O
to O O
cause O O
an O O
E O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
box O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
gel O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
shift O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
when O O
the O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
stimulated O O
to O O
differentiate O O
in O O
culture O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
not O O
under O O
basal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
conditions O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

On O O
the O O
sixth O B_TIME[MEASURE]/B_LOCATION
postirradiation O B_TIME[MEASURE]/I_LOCATION
day O B_TIME[MEASURE]/I_LOCATION
the O O
absorption O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
phenobarbitone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
sulphafurazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
mecamylamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
returned O O
to O O
the O O
control O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
level O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
but O O
the O O
absorption O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
quinidine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
isoniazid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
still O O
retarded O B_DISEASE_ADJECTIVE[DISEASE]
. O O

To O O
determine O O
the O O
transactivation O O
potential O O
of O O
each O O
of O O
the O O
four O O
Ahr B B_GENE/B_LOCATION
Sp1 B I_GENE/I_LOCATION
sites I I_GENE/I_LOCATION
, O O
we O O
fused O O
the O O
Ahr B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
to O O
a O O
luciferase B B_GENE
( O O
LUC B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
reporter O O
gene O O
and O O
transfected O O
the O O
construct O O
into O O
the O O
Drosophila O O
cell O O
line O O
Schneider O O
- O O
2 O O
, O O
which O O
contains O O
no O O
Sp1 B B_GENE/B_DISEASE
or O O
Sp1 B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
like I I_GENE/I_LOCATION
factors I I_GENE/I_LOCATION
. O O

We O O
determined O O
that O O
Hop B B_GENE/B_MEASURE
( I I_GENE/I_MEASURE
T42 I I_GENE/I_MEASURE
) I I_GENE/I_MEASURE
contains O O
a O O
glutamic O O
acid O O
- O O
to O O
- O O
lysine O O
substitution O O
at O O
amino O O
acid O O
residue O O
695 O O
( O O
E695K O O
) O O
. O O

The O O
organotins O B_LOCATION/B_PERSON
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
binding O O
of O O
biotin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
the O O
protein O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
protection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
regions O B_LOCATION/B_PERSON
of O O
the O O
central O B_ENZYME[GENE]/B_LOCATION
domain O I_ENZYME[GENE]/I_LOCATION
in O O
the O O
vicinity O B_LOCATION/B_MEASURE
of O O
the O O
active O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
site O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
and O O
the O O
C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
terminal O B_LOCATION/B_MEASURE
domain O I_LOCATION/I_MEASURE
from O O
chemical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cleavage O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
psh3 B B_GENE/B_MEASURE
( I I_GENE/I_MEASURE
+ I I_GENE/I_MEASURE
) I I_GENE/I_MEASURE
gene I I_GENE/I_MEASURE
encodes O O
a O O
protein O O
of O O
215 O O
amino O O
acids O O
, O O
which O O
shares O O
a O O
high O O
degree O O
of O O
structural O O
and O O
functional O O
similarity O O
with O O
Shr3p B B_GENE/B_BIO
. O O

The O O
impairment O O
of O O
the O O
nocturnal O O
secretion O O
was O O
related O O
to O O
the O O
subjects O O
' O O
age O O
and O O
, O O
for O O
the O O
GH B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
secretory O O
pattern O O
only O O
, O O
also O O
to O O
the O O
MMSE O O
score O O
. O O

Thus O O
, O O
the O O
antibody O O
class O O
switch O O
appears O O
to O O
be O O
directed O O
by O O
induction O O
of O O
accessibility O O
, O O
as O O
assayed O O
by O O
transcription O O
of O O
germ O O
line O O
CH B B_DISEASE/B_GENE
genes O O
. O O

This O O
growth O O
- O O
inhibitory O O
effect O O
was O O
suppressed O O
by O O
the O O
mpk1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
delta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mutation O O
, O O
suggesting O O
that O O
hyperactivation O O
of O O
the O O
Mpk1 B B_GENE
pathway O O
is O O
toxic O O
to O O
cells O O
. O O

The O O
chicken O O
genome O O
contains O O
two O O
functional O O
nonallelic O O
beta1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
galactosyltransferase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Recombinant B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Human I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Erythropoietin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Platinum O O
- O O
Based O O
Chemotherapy O O
In O O
Advanced O O
Ovarian O O
Cancer O O

Homodimers O O
of O O
RIP60 B B_GENE/B_DISEASE
( O O
replication B B_PROTEIN[GENE]
initiation I I_PROTEIN[GENE]
- I I_PROTEIN[GENE]
region I I_PROTEIN[GENE]
protein I I_PROTEIN[GENE]
60 I I_PROTEIN[GENE]
kDA I I_PROTEIN[GENE]
) O O
purified O O
from O O
nuclear O O
extract O O
bind O O
two O O
ATT O O
- O O
rich O O
sites O O
in O O
oribeta O O
and O O
foster O O
the O O
formation O O
of O O
a O O
twisted O O
720 O O
bp O O
DNA O O
loop O O
in O O
vitro O O
. O O

Endodontic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
deciduous O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
teeth O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
using O O
the O O
formocresol O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amputation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Some O O
of O O
these O O
physiological O O
responses O O
are O O
regulated O O
via O O
activation O O
of O O
transcription O O
factors O O
such O O
as O O
activator B B_GENE
protein I I_GENE
1 I I_GENE
( O O
AP B B_GENE
- I I_GENE
1 I I_GENE
) O O
. O O

To O O
test O O
the O O
role O O
of O O
myb B B_GENE
family I I_GENE
members I I_GENE
in O O
progression O O
through O O
the O O
cell O O
cycle O O
, O O
we O O
comicroinjected O O
c B B_GENE
- I I_GENE
myc I I_GENE
and O O
myb B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
vectors O O
into O O
serum O O
- O O
deprived O O
quiescent O O
SMCs O O
. O O

Overall O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
graft O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
patient O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
survival O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
HAT O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
33 O B_MEASURE
. O O
3 O B_MEASURE
% O I_MEASURE
and O O
75 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
, O O
respectively O O
. O O

LAC9 B B_GENE
is O O
a O O
DNA O O
- O O
binding O O
protein O O
that O O
regulates O O
transcription O O
of O O
the O O
lactose B B_GENE/B_BIO
- I I_GENE/I_BIO
galactose I I_GENE/I_BIO
regulon I I_GENE/I_BIO
in O O
Kluyveromyces O O
lactis O O
. O O

We O O
determined O O
the O O
complete O O
nucleotide O O
sequence O O
of O O
the O O
gypsy B B_GENE/B_BACTERIUM[BIO]
element I I_GENE/I_BACTERIUM[BIO]
present O O
at O O
the O O
forked B B_GENE
locus I I_GENE
of O O
Drosophila O O
melanogaster O O
in O O
the O O
f1 O O
allele O O
. O O

The O O
same O O
high O O
degree O O
of O O
sequence O O
homology O O
between O O
the O O
two O O
F O O
. O O
diplosiphon O O
PC B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
PC B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
beta I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequences I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
85 O O
and O O
77 O O
% O O
, O O
respectively O O
) O O
was O O
found O O
at O O
both O O
the O O
nucleotide O O
and O O
amino O O
acid O O
levels O O
, O O
and O O
similar O O
results O O
were O O
obtained O O
for O O
interspecies O O
comparisons O O
. O O

A O O
wound O O
model O O
for O O
decubitus O O
and O O
leg O O
ulcers O O
consisting O O
of O O
human O O
dermal O O
fibroblasts O O
in O O
type B B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
I I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
collagen I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
dermal O O
" O O
equivalent O O
" O O
matrix O O
( O O
DEM O O
) O O
was O O
exposed O O
in O O
vitro O O
to O O
electric O O
fields O O
similar O O
to O O
postulated O O
endogenous O O
fields O O
in O O
wounds O O
. O O

A O O
group O O
of O O
factors O O
known O O
as O O
activating B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ATF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
have O O
been O O
found O O
to O O
bind O O
to O O
the O O
latter O O
and O O
related O O
sequences O O
found O O
upstream O O
of O O
early O O
adenovirus O O
promoters O O
induced O O
by O O
E1A B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
and O O
these O O
factors O O
are O O
highly O O
homologous O O
to O O
the O O
CREB B B_GENE/B_TIME[MEASURE]
protein I I_GENE/I_TIME[MEASURE]
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
these O O
cases O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
patients O B_PERSON/B_BIO
w O I_PERSON/I_BIO
with O O
high O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Loa O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
microfilaremia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
also O O
developed O O
milder O B_DISEASE
neurologic O I_DISEASE
manifestations O I_DISEASE
causing O O
functional O B_DISEASE
impairment O I_DISEASE
lasting O O
for O O
at O O
least O O
one O B_TIME[MEASURE]
week O I_TIME[MEASURE]
after O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

The O O
vertebrate B B_GENE
transcription I I_GENE
factors I I_GENE
TCF I I_GENE
( O O
T B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
LEF B B_LOCATION/B_GENE
( O O
lymphocyte B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
enhancer I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
binding I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
factor I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
) O O
interact O O
with O O
beta B B_GENE
- I I_GENE
catenin I I_GENE
and O O
are O O
hypothesized O O
to O O
mediate O O
Wingless B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
Wnt B B_GENE/B_LOCATION
signaling O O
. O O

Some O O
of O O
these O O
DNA O O
: O O
protein O O
complexes O O
were O O
also O O
present O O
, O O
but O O
at O O
lower O O
levels O O
, O O
in O O
nuclear O O
extracts O O
from O O
untransformed O O
rat O O
cells O O
suggesting O O
the O O
possible O O
involvement O O
of O O
cellular O O
factors O O
in O O
the O O
mechanism O O
of O O
down O O
- O O
regulation O O
mediated O O
by O O
Ad12 B B_GENE/B_DISEASE
E1A I I_GENE/I_DISEASE
. O O

Hypocalcemia O O
is O O
usually O O
due O O
to O O
either O O
a O O
disturbance O O
in O O
the O O
parathyroid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormone I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
adenylate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
cyclase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
system O O
or O O
a O O
disturbance O O
in O O
vitamin O O
D O O
metabolism O O
. O O

Activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
reconstituted O O
, O O
however O O
, O O
by O O
combining O O
fractions O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
that O O
were O O
enriched O O
in O O
the O O
two O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
components O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

If O O
failure O B_DISEASE
to O O
solve O O
invisible O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
displacements O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
due O O
to O O
increased O O
memory O B_DISEASE/B_MEASURE
requirements O I_DISEASE/I_MEASURE
, O O
then O O
the O O
primates O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O O
perform O O
at O O
chance O B_MEASURE/B_LOCATION
level O I_MEASURE/I_LOCATION
on O O
all O O
3 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
problems O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

In O O
seven O O
patients O O
( O O
7 O O
. O O
8 O O
% O O
) O O
with O O
new O O
Q O O
- O O
waves O O
and O O
a O O
pathologic O O
CK B B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
MB I I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
profile O O
( O O
group O O
II O O
) O O
troponin B B_PERSON/B_LOCATION
T I I_PERSON/I_LOCATION
reached O O
median O O
levels O O
of O O
10 O O
. O O
47 O O
micrograms O O
/ O O
l O O
( O O
quartile O O
6 O O
. O O
34 O O
- O O
12 O O
. O O
50 O O
micrograms O O
/ O O
l O O
) O O
( O O
P O O
< O O
0 O O
. O O
001 O O
I O O
vs O O
II O O
) O O
. O O

Mineralized O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
bone O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
nodule O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
formation O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
by O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
populations O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
young O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
adult O I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
rabbit O I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
alveolar O I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
bone O I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Mouse B B_GENE/B_PERSON
GRK6 I I_GENE/I_PERSON
- I I_GENE/I_PERSON
C I I_GENE/I_PERSON
displays O O
none O O
of O O
these O O
motifs O O
. O O

Comparisons O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
benazepril O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
hydrochlorothiazide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
and O O
in O O
combination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
have O O
shown O O
that O O
benazepril O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
20 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
once O O
daily O O
is O O
as O O
effective O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
or O O
more O O
effective O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
lowering O O
diastolic O B_MEASURE/B_DISEASE
blood O B_MEASURE/I_DISEASE
pressure O B_MEASURE/I_DISEASE
than O O
hydrochlorothiazide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
25 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
once O O
daily O O
and O O
that O O
the O O
combination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
benazepril O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
20 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
hydrochlorothiazide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
25 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
a O O
possibly O O
synergistic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
diastolic O B_DISEASE
blood O I_DISEASE
pressure O I_DISEASE
. O O

The O O
132 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bp I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
PHO8p I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fragment I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
connected O O
at O O
position O O
- O O
281 O O
of O O
the O O
5 O O
' O O
upstream O O
region O O
of O O
a O O
HIS5 B B_MEASURE
' I I_MEASURE
- O O
' B B_GENE/B_LOCATION
lacZ I I_GENE/I_LOCATION
fused O O
gene O O
, O O
could O O
sense O O
Pi O O
signals O O
in O O
vivo O O
, O O
but O O
a O O
20 O O
- O O
bp O O
synthetic O O
oligonucleotide O O
having O O
the O O
same O O
sequence O O
from O O
- O O
544 O O
to O O
- O O
525 O O
of O O
the O O
PHO8p B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
could O O
not O O
. O O

1988 O B_MEASURE
) O O
. O O

Sequences O O
within O O
the O O
UAS2 O O
element O O
of O O
the O O
ENO2 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
bound O O
a O O
second O O
protein O O
which O O
corresponded O O
to O O
the O O
ABFI B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
autonomously B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
replicating I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequence I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
protein O O
. O O

Plasmid O O
subclones O O
of O O
recombinant O O
phage O O
lambda O O
Asm152 O O
were O O
able O O
to O O
complement O O
both O O
Escherichia B B_BACTERIUM[BIO]/B_PERSON
coli I I_BACTERIUM[BIO]/I_PERSON
gltB I I_BACTERIUM[BIO]/I_PERSON
and O O
A O O
. O O
sesbaniae O O
Asm O O
- O O
Vi O O
mutants O O
; O O
NADPH B B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glutamate I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthase I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O O
was O O
detected O O
in O O
all O O
such O O
strains O O
complemented O O
to O O
Asm O O
+ O O
. O O

The O O
sequence O O
of O O
LZ321 B B_GENE/B_PERSON
matched O O
that O O
of O O
RREB1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
transcription O O
factor O O
that O O
bound O O
to O O
a O O
Ras B B_GENE
responsive I I_GENE
element I I_GENE
( O O
RRE B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
very O O
different O O
from O O
the O O
sequence O O
with O O
which O O
we O O
isolated O O
LZ321 B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Steady O O
- O O
state O O
levels O O
of O O
murine B B_GENE
MMR I I_GENE
mRNA I I_GENE
were O O
measured O O
in O O
the O O
macrophage O O
cell O O
line O O
J774E O O
, O O
which O O
is O O
known O O
to O O
express O O
the O O
protein O O
at O O
the O O
cell O O
surface O O
. O O

Basal O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
reduced O O
to O O
20 O B_MEASURE
and O O
50 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
when O O
the O O
UGA O B_GENE
stop O I_GENE
codon O I_GENE
was O O
replaced O O
by O O
UAG O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
UAA O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
respectively O O
, O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
the O O
finding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
in O O
E O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
coli O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
translation O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
terminates O O
more O O
efficiently O O
at O O
UAG O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
UAA O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
at O O
UGA O B_PROTEIN[GENE]/B_LOCATION
. O O

Discriminant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
function O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
suggests O O
that O O
AUDIT O B_PERSON/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scores O I_PERSON/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
successfully O O
identify O O
SAT O B_GENE/B_DISEASE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
SAT O B_GENE/B_DISEASE
- O O
negative O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
patients O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
; O O
the O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
accounted O O
for O O
42 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
of O O
the O O
variance O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
correctly O O
classified O O
84 O B_MEASURE
. O O
6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
the O O
sample O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Coronatine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
COR B B_LOCATION/B_ORGANIZATION
) O O
is O O
a O O
plasmid O O
- O O
encoded O O
phytotoxin O O
synthesized O O
by O O
several O O
pathovars O O
of O O
phytopathogenic O O
Pseudomonas O O
syringae O O
. O O

Both O O
the O O
5 O B_MEASURE
' O O
and O O
3 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
' O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
untranslated O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regions O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
also O O
show O O
significant O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
similarity O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
murine O B_GENE/B_BIO
gene O I_GENE/I_BIO
, O O
with O O
79 O B_MEASURE
and O O
70 O B_MEASURE
% O I_MEASURE
sequence O I_MEASURE
identity O I_MEASURE
, O O
respectively O O
. O O

One O B_PERSON
patient O I_PERSON
exhibited O O
a O O
non O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
sense O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
( O O
codon O B_LOCATION/B_PROTEIN[GENE]
388 O I_LOCATION/I_PROTEIN[GENE]
) O O
, O O
which O O
changed O O
a O O
glutamine O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
codon O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CAG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
to O O
a O O
stop O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
codon O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
TAG O B_LOCATION/B_PROTEIN[GENE]
) O O
. O O

The O O
transcriptional O O
activity O O
of O O
P B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
450 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
11 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
studied O O
with O O
an O O
in O O
vitro O O
transcription O O
system O O
using O O
nuclear O O
extracts O O
prepared O O
from O O
bovine O O
adrenal O O
cortex O O
. O O

Renal O B_PERSON
dysplasia O I_PERSON
with O O
multisystem O B_DISEASE
malformation O I_DISEASE
- O O
- O O
a O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
9 O B_DISEASE/B_PERSON
cases O I_DISEASE/I_PERSON
. O O

This O O
bud O O
morphology O O
results O O
at O O
least O O
in O O
part O O
from O O
a O O
cell O O
cycle O O
delay O O
imposed O O
by O O
the O O
Cdc28p B B_GENE/B_DISEASE
- O O
inhibitory O O
kinase O O
Swe1p B B_LOCATION/B_GENE
. O O

Eleven O O
of O O
the O O
12 O O
exons O O
have O O
complete O O
sequence O O
homology O O
with O O
the O O
RBM B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
1 I I_GENE/I_MEASURE
sequence I I_GENE/I_MEASURE
. O O

Copyright O B_LOCATION/B_PERSON
1998 O I_LOCATION/I_PERSON
Academic O I_LOCATION/I_PERSON
Press O I_LOCATION/I_PERSON
. O O

Laparoscopic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examination O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
year O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
surgery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
revealed O O
an O O
enlarged O O
, O O
thin O B_MEASURE/B_COLOR
- O O
walled O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
, O O
and O O
fluid O B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
filled O O
uterine O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
segment O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
cranial O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
to O O
the O O
midcornus O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
occlusion O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
sites O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
all O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
three O O
proteins O O
copurified O O
through O O
several O O
biochemical O O
fractionation O O
steps O O
and O O
could O O
be O O
coimmunoprecipitated O O
by O O
using O O
antibodies O O
against O O
GCD1 B B_GENE
or O O
GCD2 B B_GENE/B_DISEASE
. O O

Cellular O O
fractionation O O
and O O
Percoll O O
gradient O O
centrifugation O O
combined O O
with O O
immunoblotting O O
show O O
that O O
p67 B B_GENE/B_LOCATION
cofractionates O O
with O O
nuclei O O
and O O
is O O
enriched O O
in O O
resistant O O
structure O O
that O O
is O O
insoluble O O
in O O
2 O O
M O O
NaCl O O
, O O
25 O O
mM O O
lithium O O
3 O O
, O O
5 O O
' O O
- O O
diiodosalicylate O O
, O O
and O O
1 O O
% O O
Triton O O
but O O
is O O
soluble O O
in O O
8 O O
M O O
urea O O
. O O

For O O
the O O
first O O
time O O
also O O
a O O
genomic O O
sequence O O
for O O
a O O
red B B_SPECIES[BIO]/B_PERSON
algal I I_SPECIES[BIO]/I_PERSON
lhc I I_SPECIES[BIO]/I_PERSON
gene I I_SPECIES[BIO]/I_PERSON
is O O
presented O O
. O O

Elimination O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
brush O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
border O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
as O O
well O O
as O O
of O O
glomerular O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
marker O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PROTEIN[GENE]
proteins O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PROTEIN[GENE]
was O O
significantly O O
lower O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
after O O
intravenous O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
low O B_DISEASE/B_MEASURE
- O O
osmolar O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
CM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
iopamidol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
370 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
832 O B_MEASURE/B_LOCATION
mOsm O I_MEASURE/I_LOCATION
/ O O
kg O B_MEASURE
) O O
than O O
after O O
meglumine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diatrizoate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
76 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2100 O B_MEASURE
mOsm O I_MEASURE
/ O O
kg O B_MEASURE
) O O
. O O

Raman O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
scattering O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
VO2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
single O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
crystals O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
: O O
A O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
effects O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
surface O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
oxidation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Combination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemotherapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
advanced O B_DISEASE/B_LOCATION
ovarian O I_DISEASE/I_LOCATION
cancer O I_DISEASE/I_LOCATION
. O O

Making O O
sense O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
out O O
of O O
oxygen O B_PERSON/B_LOCATION
sensor O I_PERSON/I_LOCATION
. O O

In O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
a O O
silent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
baseline O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
, O O
CBF O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increases O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
observed O O
in O O
auditory O B_BODY_PART_OR_ORGAN_COMPONENT
cortex O I_BODY_PART_OR_ORGAN_COMPONENT
bilaterally O O
and O O
in O O
the O O
right O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
superior O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
parietal O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
right O B_BODY_PART_OR_ORGAN_COMPONENT
dorsolateral O I_BODY_PART_OR_ORGAN_COMPONENT
frontal O I_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
right O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
premotor O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
regions O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
with O O
no O O
modulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
as O O
a O O
function O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
attentional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
condition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

In O O
vitro O O
, O O
c B B_GENE
- I I_GENE
Src I I_GENE
phosphorylated O O
FAK B B_GENE
Tyr I I_GENE
- I I_GENE
925 I I_GENE
in O O
a O O
glutathione B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
S I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transferase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
FAK B B_GENE
C O O
- O O
terminal O O
domain O O
fusion O O
protein O O
, O O
whereas O O
FAK O O
did O O
not O O
. O O

METHODS O O
AND O O
RESULTS O O
: O O
The O O
effect O O
of O O
prolonged O O
nitrate O O
therapy O O
between O O
2 O O
days O O
and O O
6 O O
weeks O O
during O O
healing O O
after O O
infarction O O
on O O
serial O O
parameters O O
of O O
ventricular O O
remodeling O O
( O O
scar O O
expansion O O
, O O
scar O O
thinning O O
, O O
ventricular O O
dilation O O
, O O
and O O
hypertrophy O O
) O O
and O O
function O O
( O O
asynergy O O
or O O
akinesis O O
plus O O
dyskinesis O O
and O O
ejection O O
fraction O O
) O O
by O O
serial O O
two O O
- O O
dimensional O O
echocardiography O O
, O O
hemodynamics O O
, O O
postmortem O O
topography O O
( O O
computerized O O
planimetry O O
, O O
geometric O O
maps O O
, O O
and O O
radiographs O O
) O O
, O O
and O O
collagen B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
content O O
( O O
hydroxyproline O O
) O O
was O O
studied O O
in O O
64 O O
instrumented O O
dogs O O
randomized O O
2 O O
days O O
after O O
left O O
anterior O O
descending O O
coronary O O
artery O O
ligation O O
to O O
various O O
nitrate O O
regimens O O
( O O
n O O
= O O
32 O O
) O O
over O O
the O O
first O O
2 O O
weeks O O
( O O
subgroup O O
1 O O
: O O
2 O O
% O O
transdermal O O
nitroglycerin O O
at O O
8 O O
AM O O
and O O
4 O O
PM O O
, O O
n O O
= O O
6 O O
; O O
subgroup O O
2 O O
: O O
2 O O
% O O
transdermal O O
nitroglycerin O O
plus O O
2 O O
. O O
6 O O
mg O O
of O O
sustained O O
- O O
release O O
oral O O
nitroglycerin O O
at O O
8 O O
AM O O
, O O
3 O O
PM O O
, O O
and O O
10 O O
PM O O
, O O
n O O
= O O
5 O O
; O O
subgroup O O
3 O O
: O O
oral O O
isosorbide O O
dinitrate O O
, O O
30 O O
mg O O
at O O
8 O O
AM O O
and O O
4 O O
PM O O
, O O
n O O
= O O
11 O O
) O O
or O O
6 O O
weeks O O
( O O
subgroup O O
4 O O
: O O
isosorbide O O
dinitrate O O
, O O
n O O
= O O
10 O O
) O O
and O O
in O O
matching O O
controls O O
( O O
n O O
= O O
32 O O
) O O
. O O

The O O
essential O B_BIO
oil O I_BIO
composition O I_BIO
of O O
three O B_BIO/B_NUMBER[MEASURE]
Zingiberaceae O B_BIO/I_NUMBER[MEASURE]
widely O O
used O O
as O O
medicinal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
aromatic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
plants O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
S O B_LOCATION/B_OTHER
. O O

Gel O O
shift O O
analysis O O
of O O
protein O O
binding O O
from O O
nuclear O O
extracts O O
to O O
these O O
caveolin B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
DNA I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequences I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
together O O
with O O
DNase B B_GENE
I I I_GENE
footprinting O O
, O O
confirmed O O
nucleoprotein O O
binding O O
to O O
the O O
SRE O O
- O O
like O O
elements O O
as O O
part O O
of O O
the O O
transcriptional O O
response O O
to O O
LDL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
FC I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

A O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
objective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assessment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cervical O B_DISEASE/B_ORGANISM_FUNCTION
ripening O I_DISEASE/I_ORGANISM_FUNCTION
: O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
prostaglandin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
E2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
and O O
prelabor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
contractility O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
The O O
MC O B_LOCATION/B_PROTEIN[GENE]
/ O O
UA O B_LOCATION/B_MEASURE
ratio O I_LOCATION/I_MEASURE
improves O O
the O O
sensitivity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
the O O
prediction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
poor O B_DISEASE/B_LOCATION
perinatal O I_DISEASE/I_LOCATION
outcome O I_DISEASE/I_LOCATION
when O O
it O O
is O O
combined O O
with O O
the O O
NST O B_DISEASE/B_PROTEIN[GENE]
. O O

Evaluation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
materials O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
technics O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
vascular O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
surgery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
using O O
111 O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Indium O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION

The O O
claustrocortical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
connection O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
investigated O O
in O O
13 O B_SPECIES[BIO]/B_TIME[MEASURE]
cats O I_SPECIES[BIO]/I_TIME[MEASURE]
with O O
selective O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
injections O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
30 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HRP O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
three O B_LOCATION/B_BIO
subdivisions O I_LOCATION/I_BIO
of O O
the O O
auditory O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
cortex O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
. O O
( O O
ABSTRACT O B_TIME[MEASURE]/B_ORGANIZATION
TRUNCATED O I_TIME[MEASURE]/I_ORGANIZATION
AT O O
400 O B_LOCATION/B_MEASURE
WORDS O I_LOCATION/I_MEASURE
) O O

Applying O O
the O O
experience O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
mentioned O O
above O O
, O O
4 O B_MEASURE/B_LOCATION
- O O
META O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
used O O
to O O
bond O O
a O O
proprietary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
photocuring O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
microfilled O O
composite O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
material O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
to O O
Class O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
V O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
cavities O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
freshly O O
extracted O O
human O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
teeth O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
phP1 B B_GENE/B_MEASURE
mutation O O
was O O
induced O O
by O O
insertion O O
of O O
a O O
1 O O
. O O
2 O O
- O O
kb O O
P B B_GENE/B_LOCATION
element I I_GENE/I_LOCATION
into O O
the O O
5 O O
' O O
transcribed O O
nontranslated O O
region O O
of O O
the O O
proximal O O
polyhomeotic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

METHOD O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Six O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
instruments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
reviewed O O
: O O
the O O
Berg O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Balance O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Scale O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Berg O B_PERSON/B_DISEASE
) O O
, O O
the O O
Clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
Sensory O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Interaction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
Balance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
CTSIB O B_DISEASE/B_PERSON
) O O
, O O
the O O
Functional O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Reach O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Test O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
Tinetti O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Balance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
Performance O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Oriented O O
Assessment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
Mobility O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Problems O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
Tinetti O B_PERSON/B_DISEASE
) O O
, O O
the O O
Timed O O
" O O
Up O O
and O O
Go O O
" O O
Test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
TU O B_LOCATION/B_PROTEIN[GENE]
& O O
GT O B_ORGANIZATION/B_PROTEIN[GENE]
) O O
, O O
and O O
the O O
Physical O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Performance O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Test O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
PPT O B_DISEASE/B_ORGANIZATION
) O O
. O O

Genome O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
timeline O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

Initial O O
computer O O
based O O
similarity O O
searches O O
identified O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
retinoblastoma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
RBP B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
) O O
, O O
Drosophila B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
melanogaster I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
male I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
specific I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
lethal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Msl B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
S B B_GENE/B_SPECIES[BIO]
. I B_GENE/I_SPECIES[BIO]
pombe I B_GENE/I_SPECIES[BIO]
altered I B_GENE/I_SPECIES[BIO]
polarity I B_GENE/I_SPECIES[BIO]
- I B_GENE/I_SPECIES[BIO]
13 I B_GENE/I_SPECIES[BIO]
( O O
Alp13 B B_GENE/B_MEASURE
) O O
and O O
S B B_GENE/B_SPECIES[BIO]
. I I_GENE/I_SPECIES[BIO]
cerevisiae I I_GENE/I_SPECIES[BIO]
Eaf3p I I_GENE/I_SPECIES[BIO]
, O O
a O O
component O O
of O O
the O O
yeast B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
NuA4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
HAT B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complex O O
( O O
Galarneau O O
et O O
al O O
. O O
, O O
2000 O O
. O O

The O O
pressure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurements O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
under O O
steady O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
flow O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
conditions O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
showed O O
that O O
the O O
hemodynamic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
performance O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
including O O
pressure O B_MEASURE/B_LOCATION
gradient O I_MEASURE/I_LOCATION
and O O
effective O B_MEASURE/B_DISEASE
orifice O I_MEASURE/I_DISEASE
area O I_MEASURE/I_DISEASE
) O O
of O O
SPAB O B_DISEASE
is O O
superior O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
that O O
of O O
its O O
stented O B_PERSON
counterpart O I_PERSON
, O O
especially O O
in O O
the O O
smaller O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
sizes O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Serum O O
prolactin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
rapidly O O
decreased O O
after O O
institution O O
of O O
treatment O O
, O O
with O O
actual O O
normalization O O
( O O
less O O
than O O
20 O O
ng O O
/ O O
ml O O
) O O
by O O
the O O
3rd O O
month O O
. O O

We O O
report O O
five O O
of O O
13 O O
evaluable O O
patients O O
undergoing O O
allogeneic O O
sibling O O
BM O O
or O O
PBSC O O
transplantation O O
for O O
MM O O
between O O
1990 O O
and O O
1997 O O
who O O
met O O
the O O
criteria O O
for O O
adjuvant O O
alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
IFN I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
therapy O O
. O O

Moist O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
healing O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
versus O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
wet O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
to O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
dry O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
this O O
report O O
, O O
we O O
identify O O
Tyr319 O O
as O O
a O O
functionally O O
important O O
phosphorylation O O
site O O
in O O
the O O
ZAP B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
70 I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
interdomain I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
B I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
region I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

These O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O O
that O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
power O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
laser O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
irradiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
can O O
be O O
used O O
for O O
promotion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
vascularization O B_DISEASE/B_ORGAN_OR_TISSUE_FUNCTION[ORGANISM_FUNCTION]
and O O
take O O
of O O
tissue O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
transplants O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

RESEARCH O B_ORGANIZATION/B_TIME[MEASURE]
DESIGN O B_ORGANIZATION/I_TIME[MEASURE]
AND O O
METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
A O O
total O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
26 O B_PERSON
IDDM O I_PERSON
patients O I_PERSON
with O O
normoalbuminuria O B_DISEASE/B_LOCATION
were O O
randomized O O
into O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
with O O
one O B_NUMBER[MEASURE]/B_ORGANIZATION
group O I_NUMBER[MEASURE]/I_ORGANIZATION
receiving O O
placebo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
n O B_MEASURE/B_LOCATION
= O O
13 O B_MEASURE
, O O
age O B_MEASURE/B_PERSON
36 O I_MEASURE/I_PERSON
+ O I_MEASURE/I_PERSON
/ O O
- O O
3 O B_TIME[MEASURE]/B_ENT
years O I_TIME[MEASURE]/I_ENT
, O O
BMI O B_MEASURE
24 O I_MEASURE
. O O
5 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
1 O B_MEASURE
. O O
1 O B_MEASURE
kg O I_MEASURE
/ O O
m2 O B_MEASURE/B_PERSON
) O O
and O O
the O O
other O B_SEQUENCE[MEASURE]/B_PERSON
group O I_SEQUENCE[MEASURE]/I_PERSON
receiving O O
an O O
average O B_MEASURE/B_SOCIAL_CIRCUMSTANCES
of O O
15 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
lisinopril O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
daily O O
( O O
n O B_MEASURE/B_LOCATION
= O O
13 O B_MEASURE
, O O
age O B_MEASURE/B_PERSON
34 O I_MEASURE/I_PERSON
+ O I_MEASURE/I_PERSON
/ O O
- O O
2 O B_TIME[MEASURE]/B_ENT
years O I_TIME[MEASURE]/I_ENT
, O O
BMI O B_MEASURE
24 O I_MEASURE
. O O
4 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
9 O B_MEASURE
kg O I_MEASURE
/ O O
m2 O B_MEASURE/B_PERSON
) O O
. O O

Previously O O
, O O
a O O
cDNA O O
( O O
GT2 B B_GENE/B_LOCATION
) O O
encoding O O
this O O
protein O O
was O O
isolated O O
from O O
a O O
mouse O O
3T3 O O
- O O
L1 O O
adipocyte O O
library O O
and O O
was O O
sequenced O O
. O O

Expression O O
of O O
human B B_GENE
complement I I_GENE
receptor I I_GENE
type I I_GENE
2 I I_GENE
( O O
CR2 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
CD21 B B_PROTEIN[GENE]/B_MEASURE
) O O
is O O
primarily O O
restricted O O
to O O
mature O O
B O O
cells O O
and O O
follicular O O
dendritic O O
cells O O
. O O

The O O
6 O O
. O O
5 O O
- O O
kb O O
genomic O O
fragment O O
contains O O
the O O
complete O O
coding O O
region O O
of O O
MyoD B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
distributed O O
over O O
three O O
exons O O
, O O
plus O O
2 O O
. O O
3 O O
kb O O
of O O
5 O O
' O O
- O O
noncoding O O
sequence O O
and O O
1 O O
. O O
4 O O
kb O O
of O O
3 O O
' O O
- O O
noncoding O O
sequence O O
. O O

Synthetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
on O O
furan O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derivatives O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
the O O
wittig O B_ORGANIZATION
reaction O I_ORGANIZATION

The O O
apparent O O
binding O O
constant O O
of O O
6 O O
to O O
calf O O
thymus O O
DNA O O
is O O
1 O O
. O O
68 O O
X O O
10 O O
( O O
5 O O
) O O
M O O
- O O
1 O O
whereas O O
netropsin B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
under O O
similar O O
conditions O O
gives O O
a O O
value O O
of O O
1 O O
. O O
85 O O
X O O
10 O O
( O O
7 O O
) O O
M O O
- O O
1 O O
. O O

Phenotypic O O
screening O O
of O O
mutations O O
in O O
Pmr1 B B_GENE
, O O
the O O
yeast B B_ENZYME[GENE]/B_PERSON
secretory I I_ENZYME[GENE]/I_PERSON
pathway I I_ENZYME[GENE]/I_PERSON
Ca2 I I_ENZYME[GENE]/I_PERSON
+ I I_ENZYME[GENE]/I_PERSON
/ I I_ENZYME[GENE]/I_PERSON
Mn2 I I_ENZYME[GENE]/I_PERSON
+ I I_ENZYME[GENE]/I_PERSON
- I I_ENZYME[GENE]/I_PERSON
ATPase I I_ENZYME[GENE]/I_PERSON
, O O
reveals O O
residues O O
critical O O
for O O
ion O O
selectivity O O
and O O
transport O O
. O O

Molecular O O
cloning O O
of O O
cDNAs O O
encoding O O
alpha O O
- O O
subunits O O
of O O
guanine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nucleotide I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulatory I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
G B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
has O O
revealed O O
the O O
existence O O
of O O
nine O O
species O O
of O O
alpha O O
- O O
subunits O O
. O O

No O O
transactivation O O
of O O
the O O
ovalbumin B B_GENE
promoter I I_GENE
( O O
pLovTATA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
template O O
control O O
was O O
observed O O
. O O

Pros O O
and O O
cons O O
of O O
selective O O
inhibition O O
of O O
cyclooxygenase B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
versus O O
dual O O
lipoxygenase B B_GENE
/ O O
cyclooxygenase B B_ENZYME[GENE]
inhibition O O
: O O
is O O
two O O
better O O
than O O
one O O
? O O

At O O
11 O B_MEASURE
. O O
5 O B_TIME[MEASURE]
years O I_TIME[MEASURE]
of O O
follow O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
up O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
521 O B_MEASURE
major O I_MEASURE
coronary O I_MEASURE
disease O I_MEASURE
events O I_MEASURE
had O O
occurred O O
, O O
261 O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
fatal O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
260 O B_MEASURE/B_LOCATION
non O I_MEASURE/I_LOCATION
- O O
fatal O B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
etiology O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
established O O
in O O
73 O B_MEASURE
( O O
76 O B_MEASURE
. O O
8 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
out O O
of O O
95 O B_MEASURE
cases O I_MEASURE
. O O

Morphometry O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
intestine O B_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
pig O B_BIO/B_PERSON
. O O

Serum O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
zinc O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
copper O B_BODY_PART_OR_ORGAN_COMPONENT
levels O I_BODY_PART_OR_ORGAN_COMPONENT
and O O
urine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
copper O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
concentrations O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
men O B_PERSON/B_BIO
were O O
significantly O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
in O O
women O B_PERSON/B_BIO
, O O
while O O
there O O
were O O
no O O
differences O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
serum O B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
urinary O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
zinc O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
copper O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O O
age O B_TIME[MEASURE]/B_PERSON
. O O

HDE B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
found O O
to O O
be O O
exclusively O O
targeted O O
to O O
and O O
imported O O
into O O
peroxisomes O O
in O O
both O O
heterologous O O
expression O O
systems O O
. O O

GeneCalling O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
successful O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
detecting O O
members O B_PERSON/B_LOCATION
of O O
complex O B_BIO/B_LOCATION
metabolic O I_BIO/I_LOCATION
pathways O I_BIO/I_LOCATION
and O O
uncovering O O
novel O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
were O O
either O O
coincidentally O O
regulated O O
or O O
directly O O
involved O O
in O O
such O B_DISEASE/B_ORGANISM_FUNCTION
pathways O I_DISEASE/I_ORGANISM_FUNCTION
. O O

Transformations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
with O O
circular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plasmids O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
yielded O O
slowly O O
and O O
irregularly O O
growing O O
geneticin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
resistant O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mycelia O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
which O O
1 O B_MEASURE/B_LOCATION
% O B_MEASURE/I_LOCATION
of O O
nuclei O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
contained O O
plasmid O B_GENE
sequences O I_GENE
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
In O O
these O O
patients O B_PERSON/B_LOCATION
control O O
of O O
ventricular O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
response O B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rate O B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
either O O
HBA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
+ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
VVIR O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
pacemaker O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
or O O
atrioventricular O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
modifying O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
drugs O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
+ O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
VVI O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
pacemaker O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
will O O
lead O O
to O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
improvement O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
exercise O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
duration O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
quality O B_MEASURE/B_LOCATION
of O O
life O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
other O O
regions O O
include O O
potential O O
binding O O
sites O O
for O O
transcription O O
factors O O
ATF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
NF1 B B_GENE/B_DISEASE
, O O
and O O
a O O
CCAAT B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
binding I I_GENE/I_MEASURE
protein I I_GENE/I_MEASURE
. O O

Both O O
purH B B_GENE/B_DISEASE
and O O
purD B B_GENE/B_LOCATION
genes I I_GENE/I_LOCATION
constitute O O
a O O
single O O
operon O O
and O O
are O O
coregulated O O
in O O
expression O O
by O O
purines O O
as O O
other O O
purine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
genes I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
are O O
. O O

The O O
patient O B_PERSON
demographics O O
( O O
means O B_MEASURE/B_LOCATION
+ O I_MEASURE/I_LOCATION
/ O O
- O O
standard O B_MEASURE
deviations O I_MEASURE
) O O
were O O
as O O
follows O O
: O O
age O B_TIME[MEASURE]/B_PERSON
, O O
57 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
12 O B_TIME[MEASURE]
years O I_TIME[MEASURE]
; O O
sex O B_PERSON
, O O
nine O B_NUMBER[MEASURE]/B_PERSON
males O I_NUMBER[MEASURE]/I_PERSON
and O O
three O B_PERSON/B_NUMBER[MEASURE]
females O I_PERSON/I_NUMBER[MEASURE]
; O O
APACHE O B_DISEASE/B_MEASURE
II O I_DISEASE/I_MEASURE
score O I_DISEASE/I_MEASURE
, O O
15 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
3 O B_TIME[MEASURE]
; O O
diagnosis O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
9 O B_MEASURE
of O O
12 O B_PERSON
patients O I_PERSON
with O O
pneumonia O B_DISEASE
. O O

In O O
situ O O
hybridization O O
reveals O O
strong O O
signals O O
for O O
Zep B B_GENE
mRNA I I_GENE
in O O
the O O
cerebellum O O
and O O
olfactory O O
bulb O O
with O O
moderate O O
signals O O
detected O O
in O O
the O O
hippocampus O O
and O O
cortex O O
. O O

TNF B B_PERSON
- I I_PERSON
alpha I I_PERSON
effect O O
was O O
eliminated O O
by O O
a O O
2 O O
- O O
bp O O
substitution O O
mutation O O
in O O
the O O
NF B B_GENE/B_LOCATION
- I B_GENE/I_LOCATION
kappa I B_GENE/I_LOCATION
B1 I B_GENE/I_LOCATION
binding I B_GENE/I_LOCATION
half I B_GENE/I_LOCATION
site I B_GENE/I_LOCATION
of O O
the O O
NF B B_GENE
- I I_GENE
kappa I I_GENE
B I I_GENE
cis I I_GENE
element I I_GENE
. O O

UV O O
- O O
cross O O
- O O
linking O O
studies O O
suggested O O
that O O
these O O
two O O
complexes O O
represent O O
one O O
and O O
two O O
molecules O O
of O O
ADR1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
bound O O
to O O
DNA O O
. O O

As O O
already O O
available O O
for O O
the O O
other O O
known O O
mammalian O O
members O O
of O O
this O O
enzyme O O
family O O
, O O
we O O
here O O
define O O
structural O O
and O O
functional O O
features O O
of O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
lymphoma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proprotein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
convertase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
LPC B B_DISEASE/B_LOCATION
) O O
. O O

The O O
M O O
- O O
phase O O
induction O O
activity O O
of O O
Cdc2 B B_PROTEIN[GENE]/B_LOCATION
- O O
Cdc13 B B_MEASURE/B_GENE
is O O
inhibited O O
by O O
Wee1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
tyrosine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
kinase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
which O O
phosphorylates O O
Cdc2 B B_GENE
on O O
tyrosine O O
- O O
15 O O
. O O

Nucleotide O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sequencing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
revealed O O
a O O
2076 O B_NUMBER[MEASURE]
- O O
base O B_GENE
pair O I_GENE
open O I_GENE
reading O I_GENE
frame O I_GENE
encoding O O
a O O
692 O B_MEASURE
- O O
amino O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
acid O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

But O O
it O O
is O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
the O O
two O B_PERSON/B_ORGANIZATION
hemispheres O I_PERSON/I_ORGANIZATION
differ O O
in O O
the O O
manner O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
which O O
they O O
make O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
semantic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
structures O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
: O O
the O O
left O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
hemisphere O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
selective O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
manner O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
appropriate O B_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
solution O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
specific O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
task O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
and O O
the O O
right O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
hemisphere O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
a O O
more O O
diffuse O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
and O O
global O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
manner O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

Supportive O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
xenogenous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
peptides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
patients O B_PERSON/B_BIO
with O O
metastatic O B_DISEASE
breast O I_DISEASE
cancer O I_DISEASE
undergoing O O
aggressive O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
chemotherapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
modified O O
AC O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
protocol O B_NUMBER[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
: O O
a O O
prospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
randomized O O
double O B_MEASURE/B_COLOR
- O O
blind O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

The O O
pregnancies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O O
terminated O O
at O O
19 O B_NUMBER[MEASURE]
and O O
12 O B_MEASURE/B_ENT
weeks O I_MEASURE/I_ENT
of O O
gestation O B_ORGANISM_FUNCTION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
respectively O O
. O O

Single O O
substitutions O O
of O O
three O O
highly O O
conserved O O
phenylalanine O O
residues O O
( O O
Phe O O
- O O
15 O O
, O O
Phe O O
- O O
17 O O
, O O
Phe O O
- O O
27 O O
) O O
by O O
alanine O O
and O O
substitution O O
of O O
one O O
histidine O O
( O O
His O O
- O O
29 O O
) O O
by O O
glutamine O O
, O O
all O O
located O O
within O O
the O O
putative O O
RNA O O
- O O
binding O O
sites O O
RNP B B_PROTEIN[GENE]/B_DISEASE
- I I_PROTEIN[GENE]/I_DISEASE
1 I I_PROTEIN[GENE]/I_DISEASE
and O O
RNP B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
abolished O O
the O O
nucleic O O
acid O O
- O O
binding O O
activity O O
of O O
CspB B B_GENE/B_BACTERIUM[BIO]
. O O

The O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
terminal O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
forces O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
left O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ventricular O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
activation O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
same O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
direction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
as O O
the O O
delta O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
wave O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
superiorly O O
and O O
to O O
the O O
left O O
at O O
- O O
60 O B_MEASURE
degrees O I_MEASURE
or O O
inferiorly O O
and O O
to O O
the O O
right O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
at O O
+ O O
120 O B_MEASURE
degrees O I_MEASURE
, O O
forming O O
a O O
single O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deflection O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
over O O
0 O B_NUMBER[MEASURE]
, O O
12 O B_MEASURE
seconds O I_MEASURE
' O I_MEASURE
duration O I_MEASURE
, O O
are O O
the O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
delayed O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
activation O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
anterior O B_BODY_PART_OR_ORGAN_COMPONENT
or O O
posterior O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
fascicle O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
of O O
the O O
left O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
bundle O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
after O O
a O O
long O B_DISEASE/B_MEASURE
delay O I_DISEASE/I_MEASURE
. O O

The O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
encoding O O
these O O
carotenoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
E O B_OTHER/B_LOCATION
. O O
herbicola O B_SPECIES[BIO]/B_DISEASE
Eho13 O I_SPECIES[BIO]/I_DISEASE
are O O
clustered O O
in O O
a O O
7 O B_GENE/B_LOCATION
kb O I_GENE/I_LOCATION
DNA O I_GENE/I_LOCATION
fragment O I_GENE/I_LOCATION
. O O

The O O
results O O
show O O
that O O
while O O
a O O
larger O O
polypeptide O O
substrate O O
carrying O O
the O O
HD1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3C I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
processed O O
more O O
efficiently O O
than O O
a O O
polypeptide O O
substrate O O
carrying O O
the O O
POL B B_LOCATION/B_PROTEIN[GENE]
/ I B_LOCATION/I_PROTEIN[GENE]
Zn I B_LOCATION/I_PROTEIN[GENE]
site I B_LOCATION/I_PROTEIN[GENE]
, O O
cleavage O O
of O O
the O O
synthetic O O
peptide O O
substrates O O
containing O O
these O O
two O O
cleavage O O
sites O O
occurred O O
at O O
similar O O
efficiencies O O
. O O

Using O O
transgenic O O
lines O O
a O O
detailed O O
analysis O O
of O O
the O O
Hoxa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
7 I B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancer O O
- O O
directed O O
expression O O
during O O
embryogenesis O O
was O O
performed O O
. O O

lacZ B B_GENE/B_PERSON
expression O O
was O O
first O O
detected O O
in O O
the O O
allantois O O
at O O
day O O
7 O O
. O O
5 O O
p O O
. O O
c O O
. O O
and O O
in O O
mesoderm O O
and O O
ectoderm O O
at O O
day O O
8 O O
. O O
5 O O
of O O
gestation O O
. O O

An O O
ERp60 B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
like I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
the O O
filarial O O
parasite O O
Dirofilaria O O
immitis O O
has O O
both O O
transglutaminase O O
and O O
protein O O
disulfide O O
isomerase O O
activity O O
. O O

At O O
promoters O O
that O O
initiate O O
with O O
+ O O
1 O O
GGG O O
, O O
T7 B B_GENE/B_SPECIES[BIO]
RNAP I I_GENE/I_SPECIES[BIO]
synthesizes O O
a O O
ladder O O
of O O
poly O O
( O O
G O O
) O O
products O O
as O O
a O O
result O O
of O O
slippage O O
of O O
the O O
transcript O O
on O O
the O O
three O O
C O O
residues O O
in O O
the O O
template O O
strand O O
from O O
+ O O
1 O O
to O O
+ O O
3 O O
. O O

Serum O O
levels O O
of O O
angiotensin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
converting I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
enzyme I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
well O O
maintained O O
. O O

The O O
UL3 B B_GENE
ORF I I_GENE
of O O
204 O O
amino O O
acids O O
shows O O
significant O O
homology O O
to O O
UL3 B B_PROTEIN[GENE]/B_LOCATION
( O O
nuclear O O
phosphoprotein O O
) O O
of O O
HSV O O
- O O
1 O O
( O O
62 O O
% O O
) O O
and O O
PRV O O
( O O
53 O O
% O O
) O O
. O O

On O O
Western O O
blots O O
, O O
the O O
same O O
antibodies O O
recognized O O
the O O
recombinant O O
protein O O
migrating O O
slightly O O
slower O O
on O O
SDS O O
/ O O
PAGE O O
than O O
chicken B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
axonin I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
- I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
1 I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

For O O
routine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
medical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
applications O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
no O O
sophisticated O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adjustment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
CHESS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pulse O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O O
needed O O
, O O
as O O
reported O O
in O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
methods O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

The O O
10 O B_BODY_PART_OR_ORGAN_COMPONENT
eyes O I_BODY_PART_OR_ORGAN_COMPONENT
injected O O
with O O
human O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
RPE O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O O
STAGE O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
2 O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
or O O
less O B_NUMBER[MEASURE]
in O O
4 O B_TIME[MEASURE]/B_DISEASE
weeks O B_TIME[MEASURE]/I_DISEASE
. O O

This O O
report O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
establishes O O
that O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
homozygous O B_DISEASE/B_ORGANISM_FUNCTION
sickle O I_DISEASE/I_ORGANISM_FUNCTION
cell O I_DISEASE/I_ORGANISM_FUNCTION
disease O I_DISEASE/I_ORGANISM_FUNCTION
on O O
growth O B_DISEASE/B_ORGANISM_FUNCTION
patterns O I_DISEASE/I_ORGANISM_FUNCTION
in O O
childhood O B_PERSON/B_BIO
is O O
apparent O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O O
the O O
age O B_TIME[MEASURE]/B_LOCATION
of O O
6 O B_NUMBER[MEASURE]/B_PERSON
years O I_NUMBER[MEASURE]/I_PERSON
. O O

The O O
remaining O O
77 O O
nucleotides O O
at O O
the O O
3 O O
' O O
end O O
of O O
domain O O
II O O
and O O
all O O
of O O
domains O O
III O O
( O O
655 O O
nucleotides O O
) O O
and O O
IV O O
( O O
770 O O
nucleotides O O
) O O
are O O
not O O
present O O
in O O
DIssE B B_BIO/B_GENE
RNA I B_BIO/I_GENE
. O O

The O O
biological O O
actions O O
of O O
VHR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
oocytes O O
clearly O O
distinguish O O
it O O
from O O
other O O
dual O O
specificity O O
phosphatases O O
, O O
which O O
have O O
shown O O
inhibitory O O
effects O O
when O O
tested O O
in O O
oocytes O O
. O O

The O O
presence O B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
chloroquine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
saliva O B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
from O O
seven O B_PERSON/B_BIO
healthy O I_PERSON/I_BIO
volunteers O I_PERSON/I_BIO
for O O
21 O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
a O O
single O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
600 O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mg O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
oral O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dose O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
established O O
by O O
chromatographic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O O
spectroscopic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methods O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
gp41 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptide I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Glu I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Leu I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Asp I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Lys I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Trp I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ala I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fused O O
to O O
the O O
C O O
- O O
terminus O O
of O O
Sj B B_GENE/B_DISEASE
GST I I_GENE/I_DISEASE
forms O O
a O O
loop O O
stabilized O O
by O O
symmetry O O
- O O
related O O
GSTs B B_GENE/B_LOCATION
. O O

Comparison O O
of O O
bioreactive O O
and O O
immunoreactive O O
gastrin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Also O O
, O O
PTx B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
no O O
effect O O
on O O
shear O O
- O O
dependent O O
activation O O
of O O
JNK B B_GENE
. O O

A O O
score O B_MEASURE
( O O
APACHE O B_MEASURE/B_LOCATION
II O I_MEASURE/I_LOCATION
) O O
was O O
calculated O O
to O O
assess O O
the O O
severity O B_MEASURE
of O O
disease O B_DISEASE
. O O

We O O
tested O O
several O O
growth O O
regulatory O O
genes O O
that O O
are O O
repressed O O
in O O
senescent O O
cells O O
for O O
ability O O
to O O
restore O O
activity O O
to O O
T B B_GENE/B_PERSON
[ I I_GENE/I_PERSON
K1 I I_GENE/I_PERSON
] I I_GENE/I_PERSON
. O O

We O O
analyzed O O
the O O
contribution O O
of O O
the O O
three O O
different O O
types O O
of O O
UV O O
- O O
inducible O O
mitogen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MAP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ERK B B_GENE
, O O
JNK B B_GENE/B_LOCATION
/ O O
SAPK B B_MEASURE/B_GENE
, O O
and O O
p38 B B_GENE/B_LOCATION
) O O
to O O
the O O
activation O O
of O O
the O O
murine O O
uPA B B_GENE
promoter O O
by O O
UV O O
. O O

The O O
high O O
degree O O
of O O
sequence O O
conservation O O
together O O
with O O
the O O
ability O O
to O O
direct O O
nucleolar O O
protein O O
transport O O
supports O O
the O O
hypothesis O O
that O O
MAK16 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
play O O
a O O
key O O
role O O
in O O
the O O
biogenesis O O
of O O
60S B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
subunits I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Characterization O O
of O O
a O O
nuclear B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
deformed I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
epidermal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
autoregulatory I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
DEAF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
- O O
related O O
( O O
NUDR B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
transcriptional O O
regulator O O
protein O O
. O O

Here O O
we O O
show O O
that O O
the O O
sck1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
cloned O O
as O O
a O O
high O O
copy O O
number O O
suppressor O O
of O O
a O O
mutation O O
in O O
git3 B B_SPECIES[BIO]/B_GENE
, O O
is O O
able O O
to O O
suppress O O
the O O
defects O O
conferred O O
by O O
a O O
mutation O O
in O O
any O O
of O O
these O O
git B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Hamdija O B_PERSON/B_MEASURE
Karamehmedovic O I_PERSON/I_MEASURE
; O O
Ibn O O
al O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
Nefis O B_PERSON/B_LOCATION
, O O
" O O
Mudzez O B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
al O I_LOCATION/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Kanum O B_PERSON/B_LOCATION
" O O
, O O
Republicki O B_LOCATION
zavod O I_LOCATION
za O I_LOCATION
zdravstvenu O I_LOCATION
zastitu O I_LOCATION
Sarajevo O I_LOCATION
, O O
1961 O B_MEASURE
, O O
1 O B_MEASURE
- O O
219 O B_MEASURE
; O O
Mr O B_PERSON/B_MEASURE
ph O I_PERSON/I_MEASURE
Samuel O I_PERSON/I_MEASURE
Elazar O I_PERSON/I_MEASURE
, O O
Ajnija O B_PERSON/B_LOCATION
Omanic O I_PERSON/I_LOCATION
: O O
" O O
Bibliografija O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medicinskih O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
djela O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
u O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SR O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BiH O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
do O O
1895 O B_NUMBER[MEASURE]/B_LOCATION
. O O
" O O
Medicinska O B_LOCATION
knjiga O I_LOCATION
Beograd O I_LOCATION
- O O
Zagreb O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1984 O I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
Besides O B_TIME[MEASURE]/B_LOCATION
, O O
the O O
great O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contribution O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
bibliography O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O O
given O O
by O O
dr O B_PERSON/B_LOCATION
Lujo O I_PERSON/I_LOCATION
Taler O I_PERSON/I_LOCATION
, O O
prof O B_PERSON/B_GENE
. O O

dr O B_LOCATION/B_PERSON
. O O

The O O
longest O O
cDNA O O
insert O O
identified O O
was O O
2 O O
. O O
2 O O
kb O O
and O O
encoded O O
the O O
entire O O
462 O O
- O O
amino O O
acid O O
open O O
reading O O
frame O O
of O O
rat B B_GENE/B_BACTERIUM[BIO]
CgA I I_GENE/I_BACTERIUM[BIO]
including O O
an O O
18 O O
- O O
amino O O
acid O O
hydrophobic O O
signal O O
peptide O O
. O O

We O O
have O O
used O O
systemic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
application O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
ototoxic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
drug O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
amikacin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
to O O
induce O O
total O B_DISEASE
cochlear O I_DISEASE
haircell O I_DISEASE
loss O I_DISEASE
in O O
the O O
chinchilla O B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
in O O
order O B_SPECIES[BIO]/B_DISEASE
to O O
create O O
an O O
animal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
profound O B_DISEASE/B_LOCATION
deafness O I_DISEASE/I_LOCATION
. O O

Cotransfection O O
with O O
C B B_GENE/B_LOCATION
/ I I_GENE/I_LOCATION
EBPbeta I I_GENE/I_LOCATION
and O O
GATA B B_GENE
- I I_GENE
1 I I_GENE
expression O O
vectors O O
produced O O
a O O
5 O O
- O O
fold O O
increase O O
compared O O
with O O
cotransfection O O
with O O
the O O
C B B_GENE/B_LOCATION
/ I I_GENE/I_LOCATION
EBPbeta I I_GENE/I_LOCATION
or O O
GATA B B_GENE
- I I_GENE
1 I I_GENE
expression O O
vectors O O
individually O O
. O O

Among O O
the O O
different O B_DISEASE/B_BIO
epithelial O I_DISEASE/I_BIO
cell O I_DISEASE/I_BIO
lines O I_DISEASE/I_BIO
tested O O
, O O
only O O
RTS3b O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
allowed O O
an O O
expression O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pattern O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
similar O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
that O O
observed O O
in O O
naturally O O
infected O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
benign O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
condylomas O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

In O O
contrast O O
to O O
the O O
p16 B B_GENE
- O O
mediated O O
G1 O O
block O O
, O O
G1 O O
arrest O O
mediated O O
by O O
the O O
cdk B B_GENE/B_DISEASE
inhibitors O O
p21Cip1 B B_GENE
or O O
p27Kip1 B B_GENE
cannot O O
be O O
bypassed O O
either O O
by O O
inactivation O O
of O O
pRb B B_GENE
or O O
overexpression O O
of O O
E2F B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
family I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
members I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
addition O O
, O O
the O O
authors O O
found O O
one O O
an3 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
allele I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
an3 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
W138A I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
in O O
which O O
a O O
dTph1 B B_GENE
element I I_GENE
had O O
inserted O O
30 O O
bp O O
upstream O O
the O O
translation O O
start O O
, O O
without O O
inactivating O O
the O O
gene O O
. O O

Case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
nephrotic O B_DISEASE
syndrome O I_DISEASE
caused O O
by O O
gold O B_DISEASE
preparations O I_DISEASE

To O O
investigate O O
the O O
role O O
of O O
bHLH B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
MC3T3 O O
- O O
E1 O O
osteoblasts O O
, O O
which O O
undergo O O
a O O
developmental O O
sequence O O
in O O
vitro O O
, O O
we O O
analyzed O O
the O O
transcriptional O O
control O O
of O O
osteocalcin B B_GENE
gene I I_GENE
expression O O
by O O
stable O O
transfection O O
of O O
an O O
osteocalcin B B_GENE
promoter I I_GENE
- O O
luciferase B B_GENE
chimeric O O
gene O O
( O O
p637OC B B_PROTEIN[GENE]/B_BIO
- I I_PROTEIN[GENE]/I_BIO
luc I I_PROTEIN[GENE]/I_BIO
) O O
and O O
assessed O O
the O O
role O O
of O O
E O O
- O O
box O O
cis O O
- O O
acting O O
elements O O
in O O
osteocalcin B B_GENE
promoter I I_GENE
by O O
DNA O O
binding O O
assays O O
. O O

In O O
summary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
only O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
related O O
effect O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
noted O O
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
hydrocarbon O B_DISEASE
nephropathy O I_DISEASE
in O O
male O B_SPECIES[BIO]/B_PERSON
rats O I_SPECIES[BIO]/I_PERSON
, O O
which O O
is O O
not O O
considered O O
relevant O B_DISEASE_ADJECTIVE[DISEASE]
for O O
human O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
health O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
this O O
study O O
, O O
we O O
show O O
that O O
HNF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
member O O
of O O
the O O
steroid B B_GENE/B_PERSON
hormone I I_GENE/I_PERSON
receptor I I_GENE/I_PERSON
superfamily I I_GENE/I_PERSON
, O O
binds O O
the O O
AF B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
on O O
the O O
apoB B B_GENE
promoter I I_GENE
and O O
through O O
it O O
activates O O
transcription O O
in O O
transient O O
transfection O O
assays O O
in O O
both O O
liver O O
and O O
non O O
- O O
liver O O
cell O O
lines O O
, O O
HepG2 O O
and O O
HeLa O O
, O O
respectively O O
. O O

Gastrointestinal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
accumulation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
indium O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
111 O B_TIME[MEASURE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
labelled O O
granulocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
reactive O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
arthritis O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O O

Acute O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
intoxication O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
cypermethrin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
NRDC O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
149 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

We O O
have O O
previously O O
shown O O
that O O
the O O
transcriptional O O
activator O O
CREM B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
highly O O
expressed O O
in O O
postmeiotic O O
cells O O
. O O

No O O
interaction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O O
epidural O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anesthesia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
observed O O
. O O

In O O
late O B_TIME[MEASURE]/B_LOCATION
October O I_TIME[MEASURE]/I_LOCATION
, O O
1974 O B_MEASURE
, O O
Staphylococcus O B_DISEASE
aureus O I_DISEASE
postoperative O I_DISEASE
wound O I_DISEASE
infection O I_DISEASE
was O O
recorded O O
in O O
a O O
nonhuman O B_SPECIES[BIO]
primate O I_SPECIES[BIO]
( O O
Macaca O B_SPECIES[BIO]
mulatta O I_SPECIES[BIO]
) O O
which O O
had O O
recently O O
undergone O O
surgical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
operation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Twenty O B_NUMBER[MEASURE]
- O O
six O B_NUMBER[MEASURE]/B_ENT
calves O I_NUMBER[MEASURE]/I_ENT
were O O
subjected O O
to O O
a O O
technique O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cryoablation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
order O B_SPECIES[BIO]/B_DISEASE
to O O
establish O O
an O O
animal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
complete O B_DISEASE
cardiac O I_DISEASE
denervation O I_DISEASE
. O O

Our O O
current O O
study O O
aims O O
at O O
clarifying O O
the O O
role O O
of O O
myristoylation O O
in O O
caveolar O O
targeting O O
using O O
well O O
- O O
characterized O O
acylation O O
mutants O O
of O O
two O O
model O O
proteins O O
, O O
namely O O
Gi1 B B_GENE
alpha I I_GENE
and O O
c B B_GENE
- I I_GENE
Src I I_GENE
. O O

The O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
deferoxamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
B O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
on O O
the O O
blood O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sugar O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
behavior O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
intravenous O B_PERSON/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
glucose O I_PERSON/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
loading O I_PERSON/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
in O O
healthy O B_SPECIES[BIO]/B_PERSON
persons O I_SPECIES[BIO]/I_PERSON

We O O
infer O O
that O O
RecA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
mediated O O
cleavage O O
of O O
UmuD B B_GENE/B_BIO
is O O
another O O
role O O
for O O
RecA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
SOS O O
mutagenesis O O
, O O
probably O O
activating O O
UmuD B B_GENE/B_BIO
for O O
its O O
mutagenic O O
function O O
. O O

SETTING O B_MEASURE/B_LOCATION
: O O
Participants O B_PERSON
in O O
the O O
Physicians O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Health O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
a O O
randomized O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
aspirin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
carotene O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O O
U O B_OTHER/B_MEASURE
. O O
S O B_LOCATION/B_DISEASE
. O O
male O B_PERSON/B_LOCATION
physicians O I_PERSON/I_LOCATION
. O O

The O O
prevalence O B_MEASURE
of O O
microalbuminuria O B_DISEASE/B_LOCATION
, O O
defined O O
as O O
an O O
UAER O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
the O O
range O B_MEASURE
of O O
15 O B_MEASURE
- O O
150 O B_MEASURE
micrograms O I_MEASURE
min O I_MEASURE
- O O
1 O B_TIME[MEASURE]
in O O
an O O
overnight O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
urine O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sample O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
was O O
3 O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
95 O B_LOCATION/B_MEASURE
% O I_LOCATION/I_MEASURE
C O I_LOCATION/I_MEASURE
. O O
I O O
. O O
interval O B_MEASURE
: O O
1 O B_MEASURE
. O O
9 O B_MEASURE
- O O
4 O B_MEASURE
. O O
0 O B_MEASURE
) O O
. O O

The O O
Rep B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
adeno O O
- O O
associated O O
virus O O
type O O
2 O O
( O O
AAV O O
) O O
are O O
known O O
to O O
bind O O
to O O
Rep B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
recognition I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequences I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
RRSs B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
in O O
the O O
AAV O O
inverted O O
terminal O O
repeats O O
( O O
ITRs O O
) O O
, O O
the O O
AAV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p5 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
the O O
preferred O O
AAV O O
integration O O
site O O
in O O
human O O
chromosome O O
19 O O
, O O
called O O
AAVS1 O O
. O O

LIP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
DIP O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
less O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
IIPs O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
both O O
characterized O O
by O O
ground O B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
glass O B_MEASURE/B_LOCATION
attenuation O B_MEASURE/I_LOCATION
. O O

The O O
levels O O
of O O
TPAR1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNAs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
dramatically O O
down O O
- O O
regulated O O
in O O
regenerating O O
rat O O
liver O O
when O O
compared O O
to O O
normal O O
adult O O
liver O O
. O O

Copyright O B_LOCATION/B_PERSON
1999 O I_LOCATION/I_PERSON
Academic O I_LOCATION/I_PERSON
Press O I_LOCATION/I_PERSON
. O O

The O O
authors O O
suggest O O
that O O
alprazolam O O
may O O
have O O
enhanced O O
specificity O O
for O O
a O O
subpopulation O O
of O O
benzodiazepine B B_PERSON/B_BIO
receptors I I_PERSON/I_BIO
. O O

Southern O O
hybridization O O
analysis O O
of O O
BenR B B_DISEASE/B_PROTEIN[GENE]
and O O
BenS B B_LOCATION/B_GENE
transformants I I_LOCATION/I_GENE
suggested O O
that O O
plasmid O O
integration O O
occurred O O
most O O
frequently O O
at O O
the O O
chromosomal O O
bens B B_LOCATION/B_GENE
locus I I_LOCATION/I_GENE
, O O
however O O
evidence O O
for O O
gene O O
conversion O O
and O O
heterologous O O
recombination O O
was O O
also O O
observed O O
. O O

The O O
analysis O O
of O O
the O O
effects O O
of O O
eight O O
signaling O O
molecules O O
in O O
the O O
TGFbeta B B_GENE/B_LOCATION
, O O
FGF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Hh B B_GENE/B_LOCATION
, O O
Wnt B B_GENE/B_LOCATION
, O O
and O O
EGF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
families I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
tooth O O
explant O O
cultures O O
revealed O O
that O O
the O O
expression O O
of O O
edar B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
induced O O
by O O
activinbetaA B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
whereas O O
Wnt6 B B_GENE
induced O O
ectodysplasin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O O
. O O

In O O
mouse O O
, O O
two O O
high O O
- O O
affinity O O
binding O O
sites O O
with O O
an O O
apparent O O
dissociation O O
constant O O
( O O
Kd O O
) O O
of O O
50 O O
to O O
100 O O
nM O O
have O O
been O O
mapped O O
in O O
the O O
5 O O
' O O
ETS B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
upstream O O
from O O
the O O
early O O
pre O O
- O O
rRNA O O
processing O O
site O O
. O O

Single O B_NUMBER[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
oblique O I_NUMBER[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
view O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mammography O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
periodic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
screening O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
breast O B_DISEASE
cancer O I_DISEASE
in O O
women O B_PERSON/B_BIO
. O O

Radiative O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
corrections O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
to O O
pi O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
l2 O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decays O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

This O O
deletion O O
disrupts O O
the O O
PU B B_GENE
. I I_GENE
1 I I_GENE
Ets B I_GENE
domain I I_GENE
. O O

In O O
turn O O
, O O
production O O
of O O
sufficient O O
amounts O O
of O O
TraR B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
apparently O O
is O O
sensitive O O
to O O
a O O
cellular O O
function O O
requiring O O
RNase B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
predicted O O
product O O
exhibits O O
91 O O
% O O
amino O O
acid O O
identity O O
to O O
the O O
murine B B_GENE/B_PERSON
voltage I I_GENE/I_PERSON
- I I_GENE/I_PERSON
gated I I_GENE/I_PERSON
potassium I I_GENE/I_PERSON
channel I I_GENE/I_PERSON
protein I I_GENE/I_PERSON
Kv1 I I_GENE/I_PERSON
. I I_GENE/I_PERSON
7 I I_GENE/I_PERSON
( O O
Kcna7 B B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
which O O
plays O O
an O O
important O O
role O O
in O O
the O O
repolarization O O
of O O
cell O O
membranes O O
. O O

Phytohemagglutinin B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PHA B B_PROTEIN[GENE]/B_DISEASE
) O O
, O O
the O O
seed B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lectin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
common O O
bean O O
, O O
accumulates O O
in O O
protein O O
storage O O
vacuoles O O
of O O
storage O O
parenchyma O O
cells O O
in O O
cotyledons O O
. O O

This O O
dynamic O O
nature O O
may O O
be O O
relevant O O
to O O
the O O
ability O O
of O O
E47 B B_GENE
both O O
to O O
homodimerize O O
and O O
to O O
heterodimerize O O
with O O
MyoD B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
Id B B_GENE/B_DISEASE
, O O
and O O
Tal1 B B_GENE
. O O

Blood O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
samples O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
( O O
30 O B_TIME[MEASURE]/B_LOCATION
ml O B_TIME[MEASURE]/I_LOCATION
) O O
were O O
collected O O
via O O
an O O
indwelling O O
arm O B_PRODUCT[OBJECT]/B_LOCATION
catheter O B_PRODUCT[OBJECT]/I_LOCATION
at O O
rest O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
at O O
minutes O B_MEASURE/B_ENT
13 O I_MEASURE/I_ENT
and O O
28 O B_NUMBER[MEASURE]
of O O
exercise O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
for O O
determinations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
plasma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
EPI O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
serum O O
free O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fatty O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
FFA O B_LOCATION/B_PROTEIN[GENE]
) O O
, O O
serum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glycerol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
GLY O B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
blood O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucose O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
GLU O B_LOCATION/B_PROTEIN[GENE]
) O O
, O O
and O O
blood O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lactate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
LA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
concentrations O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Among O O
these O O
, O O
four O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
had O O
the O O
AIDS O B_DISEASE_ADJECTIVE[DISEASE]
syndrome O I_DISEASE_ADJECTIVE[DISEASE]
, O O
while O O
42 O B_NUMBER[MEASURE]/B_PERSON
individuals O I_NUMBER[MEASURE]/I_PERSON
were O O
HIV O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
carriers O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

Subjects O B_PERSON/B_LOCATION
were O O
73 O B_PERSON/B_COLOR
male O I_PERSON/I_COLOR
and O O
female O B_PERSON/B_MEASURE
employees O I_PERSON/I_MEASURE
of O O
the O O
Xerox O B_LOCATION/B_ORGANIZATION
Corporation O I_LOCATION/I_ORGANIZATION
joining O O
a O O
newly O O
developed O O
health O B_ORGANIZATION/B_PERSON
fitness O I_ORGANIZATION/I_PERSON
program O I_ORGANIZATION/I_PERSON
. O O

Overexpression O O
of O O
p50 B B_GENE
in O O
transient O O
cotransfection O O
studies O O
using O O
the O O
proximal O O
CRP B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
( O O
- O O
125 O O
/ O O
+ O O
9 O O
) O O
linked O O
to O O
a O O
luciferase B B_GENE
reporter I I_GENE
caused O O
a O O
3 O O
- O O
fold O O
increase O O
of O O
luciferase B B_GENE/B_LOCATION
activity O O
, O O
while O O
C B B_GENE
/ I I_GENE
EBPbeta I I_GENE
overexpression O O
caused O O
an O O
18 O O
- O O
fold O O
increase O O
; O O
simultaneous O O
overexpression O O
of O O
both O O
transcription O O
factors O O
increased O O
luciferase B B_GENE/B_MEASURE
activity O O
approximately O O
600 O O
- O O
fold O O
. O O

Our O O
results O O
suggest O O
that O O
it O O
might O O
be O O
possible O O
to O O
augment O O
IN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
function O O
in O O
vivo O O
through O O
a O O
heterologous O O
domain O O
. O O

While O O
differential O O
expression O O
of O O
the O O
two O O
transcripts O O
was O O
not O O
found O O
, O O
the O O
promoter O O
controlling O O
LT1 B B_GENE
/ O O
LT2 B B_PROTEIN[GENE]/B_MEASURE
transcription O O
is O O
regulated O O
in O O
a O O
cell O O
cycle O O
- O O
dependent O O
manner O O
. O O

Schottky O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
- O O
barrier O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
heights O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
Ti O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
TiSi2 O B_LOCATION/B_PERSON
on O O
n O B_PROTEIN[GENE]
- O O
type O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
p O B_MEASURE/B_PROTEIN[GENE]
- O O
type O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Si O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
100 O B_NUMBER[MEASURE]/B_LOCATION
) O O
. O O

A O O
survey O O
of O O
children O O
with O O
HBsAg B B_DISEASE
markers I I_DISEASE
related O O
to O O
their O O
parents O O
HBV O O
markers O O
. O O

Immunological O O
studies O O
also O O
failed O O
to O O
demonstrate O O
any O O
significant O O
change O O
except O O
for O O
a O O
significant O O
increase O O
of O O
natural O O
killer O O
( O O
NK O O
) O O
cell O O
activity O O
after O O
IFN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gamma I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O O
. O O

Fetal O B_MEASURE/B_PERSON
PaO2 O I_MEASURE/I_PERSON
fell O O
somewhat O O
during O O
the O O
recovery O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
stages O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
in O O
both O O
NIT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
control O B_LOCATION/B_ORGANIZATION
groups O I_LOCATION/I_ORGANIZATION
. O O

Genetic O O
analyses O O
indicate O O
that O O
most O O
of O O
the O O
dominant O O
mutants O O
are O O
cis O O
- O O
acting O O
and O O
that O O
the O O
recessive O O
mutants O O
define O O
a O O
minimum O O
of O O
three O O
complementation O O
groups O O
, O O
indicating O O
that O O
defects O O
in O O
several O O
different O O
genes O O
can O O
restore O O
higher O O
levels O O
of O O
HIS4C B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
. O O

Rat B B_ENZYME[GENE]
cholesterol I I_ENZYME[GENE]
side I I_ENZYME[GENE]
- I I_ENZYME[GENE]
chain I I_ENZYME[GENE]
cleavage I I_ENZYME[GENE]
cytochrome I I_ENZYME[GENE]
P I I_ENZYME[GENE]
- I I_ENZYME[GENE]
450 I I_ENZYME[GENE]
( O O
P B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
450scc I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
gene O O
. O O

Histopathologic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
studies O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
displaying O O
spongiform O B_DISEASE
changes O I_DISEASE
in O O
the O O
gray O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
matter O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
neuronal O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
loss O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
and O O
atrogliosis O B_DISEASE
confirmed O O
the O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Creutzfeldt O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Jakob O B_DISEASE/B_GENE
disease O I_DISEASE/I_GENE
. O O

Pig O O
uPA B B_SPECIES[BIO]/B_GENE
promoter O O
- O O
CAT B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
constructs O O
were O O
more O O
active O O
than O O
mouse O O
constructs O O
in O O
this O O
assay O O
. O O

Cloning O O
the O O
cDNA O O
for O O
a O O
new O O
human B B_PROTEIN[GENE]/B_BIO
zinc I I_PROTEIN[GENE]/I_BIO
finger I I_PROTEIN[GENE]/I_BIO
protein I I_PROTEIN[GENE]/I_BIO
defines O O
a O O
group O O
of O O
closely O O
related O O
Kruppel B B_GENE/B_BIO
- I I_GENE/I_BIO
like I I_GENE/I_BIO
transcription I I_GENE/I_BIO
factors I I_GENE/I_BIO
. O O

By O O
computed O O
homology O O
search O O
, O O
we O O
noticed O O
significant O O
similarities O O
between O O
US3 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PK I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
p21 B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
activated I I_GENE/I_LOCATION
kinase I I_GENE/I_LOCATION
( O O
PAK B B_GENE/B_PERSON
) O O
, O O
which O O
is O O
activated O O
by O O
the O O
Cdc42 B B_GENE
or O O
Rac B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
mean O B_MEASURE
amount O I_MEASURE
of O O
blood O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
loss O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
prior O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
time O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
injection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
4 O B_MEASURE
. O O
5 O B_MEASURE
units O I_MEASURE
( O O
a O O
range O B_MEASURE/B_LOCATION
of O O
3 O B_NUMBER[MEASURE]/B_LOCATION
to O O
10 O B_MEASURE
units O I_MEASURE
) O O
. O O

In O O
response O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
acoustical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
the O O
properties O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
response O B_MEASURE
latency O I_MEASURE
, O O
discharge O B_MEASURE
pattern O I_MEASURE
, O O
frequency O B_MEASURE/B_LOCATION
tuning O I_MEASURE/I_LOCATION
, O O
binaural O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
interaction O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
and O O
habituation O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
were O O
examined O O
to O O
allow O O
an O O
appraisal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
differentiation O B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
the O O
MGB O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
by O O
electrophysiological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
means O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

These O O
8 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
oxoguanine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glycosylases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
hOgg1 B B_GENE/B_DISEASE
( O O
human O O
) O O
and O O
mOgg1 B B_GENE
( O O
murine O O
) O O
, O O
are O O
homologous O O
to O O
each O O
other O O
and O O
to O O
yeast B B_SPECIES[BIO]/B_GENE
Ogg1 I I_SPECIES[BIO]/I_GENE
. O O

The O O
CHED B B_ENZYME[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
protein I I_ENZYME[GENE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
includes O O
the O O
consensus O O
ATP O O
binding O O
and O O
phosphorylation O O
domains O O
characteristic O O
of O O
kinases O O
, O O
displays O O
34 O O
- O O
42 O O
% O O
identically O O
aligned O O
amino O O
acid O O
residues O O
with O O
other O O
cdc2 B B_GENE/B_BIO
- I I_GENE/I_BIO
related I I_GENE/I_BIO
kinases I I_GENE/I_BIO
, O O
and O O
is O O
considerably O O
longer O O
at O O
its O O
amino O O
and O O
carboxyl O O
termini O O
. O O

CONCLUSIONS O O
: O O
These O O
results O O
suggest O O
that O O
, O O
by O O
interacting O O
with O O
cellular O O
transcription O O
factors O O
and O O
cofactors O O
, O O
vIRF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
may O O
modulate O O
the O O
expression O O
of O O
the O O
early O O
inflammatory O O
genes O O
and O O
potentially O O
deregulate O O
the O O
immune O O
system O O
. O O

However O O
, O O
in O O
7 O B_PERSON/B_MEASURE
patients O I_PERSON/I_MEASURE
with O O
normal O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CT O I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results O I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
latter O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
method O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O O
areas O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
cerebral O B_DISEASE
activity O I_DISEASE
anatomically O O
correlated O O
with O O
neurological O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
signs O I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
or O O
vascular O B_DISEASE_ADJECTIVE[DISEASE]
lesions O I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
report O O
that O O
Gcn5 B B_GENE
, O O
a O O
histone B B_GENE
H3 I I_GENE
acetylase I I_GENE
, O O
plays O O
a O O
central O O
role O O
in O O
initiation O O
of O O
meiosis O O
via O O
effects O O
on O O
IME2 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
. O O

The O O
carboxy O O
- O O
proximal O O
regions O O
of O O
the O O
VP1 B B_GENE/B_SPECIES[BIO]
, O O
which O O
contain O O
very O O
low O O
amino O O
acid O O
homology O O
, O O
displayed O O
evidence O O
of O O
conservation O O
in O O
structural O O
features O O
such O O
as O O
a O O
hydrophilic O O
, O O
highly O O
basic O O
domain O O
. O O

Interferon B B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
inducibility O O
of O O
IFI16 B B_GENE
may O O
be O O
regulated O O
by O O
an O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
/ I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
beta I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
stimulated O O
response O O
consensus O O
element O O
in O O
the O O
5 O O
' O O
UT O O
exon O O
, O O
as O O
a O O
similar O O
motif O O
is O O
conserved O O
in O O
the O O
corresponding O O
position O O
in O O
the O O
related O O
myeloid B B_GENE
cell I I_GENE
nuclear I I_GENE
differentiation I I_GENE
antigen I I_GENE
gene O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
400 O O
WORDS O O
) O O

DESIGN O B_PERSON/B_MEASURE
- O O
- O O
A O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_OTHER
randomised O O
double O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
blind O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
placebo O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
controlled O O
parallel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arm O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Genealogical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
suggested O O
mainly O O
a O O
mother O B_PERSON
- O O
to O O
- O O
offspring O O
transmission O B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
STLV O B_GENE/B_DISEASE
- O O
1 O B_MEASURE/B_BIO
. O O

These O O
back O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
mutations O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
led O O
to O O
a O O
modest O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decrease O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
kinase O B_DISEASE/B_GENE
activity O I_DISEASE/I_GENE
, O O
decreased O O
tumorigenic O B_PERSON/B_DISEASE
potential O B_PERSON/I_DISEASE
in O O
chickens O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
, O O
and O O
an O O
unexpected O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
transforming O O
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
rat O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
quantification O B_MEASURE
limit O I_MEASURE
was O O
50 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
ml O B_MEASURE/B_PERSON
for O O
each O O
of O O
PHT O B_NUMBER[MEASURE]/B_PERSON
, O O
m O B_PROTEIN[GENE]/B_DISEASE
- O O
HPPH O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
p O O
- O O
HPPH O B_DISEASE/B_LOCATION
. O O

Individual O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
intolerance O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
betaxolol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O O
continue O O
to O O
occur O O
and O O
care O O
is O O
always O O
required O O
when O O
patients O B_PERSON
with O O
cardiac O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
or O O
respiratory O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
dysfunction O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
are O O
exposed O O
to O O
any O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
antagonist O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Pretoria O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Pasteurisation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
feasible O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
reliable O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
under O O
a O O
range O B_MEASURE
of O O
conditions O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

In O O
the O O
present O O
study O O
we O O
use O O
a O O
tnaC B B_GENE/B_BACTERIUM[BIO]
- O O
UGA O O
- O O
' B B_GENE
lacZ I I_GENE
construct O O
lacking O O
the O O
tnaC B B_GENE/B_BACTERIUM[BIO]
- O O
tnaA B B_GENE/B_BACTERIUM[BIO]
spacer O O
region O O
to O O
analyze O O
the O O
effect O O
of O O
TnaC B B_GENE/B_BACTERIUM[BIO]
synthesis O O
on O O
the O O
behavior O O
of O O
the O O
ribosome O O
that O O
translates O O
tnaC B B_GENE/B_BACTERIUM[BIO]
. O O

The O O
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
KP O B_LOCATION/B_DISEASE
- O O
103 O B_MEASURE
, O O
a O O
novel O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
triazole O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derivative O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
against O O
pathogenic O B_BIO/B_DISEASE
fungi O I_BIO/I_DISEASE
that O O
cause O B_DISEASE/B_SPECIES[BIO]
dermatomycoses O B_DISEASE/I_SPECIES[BIO]
and O O
its O O
therapeutic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
efficacy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O O
plantar O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tinea O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pedis O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cutaneous O B_DISEASE
candidiasis O I_DISEASE
in O O
guinea O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
pigs O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
investigated O O
. O O

Restriction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
isolated O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genomic O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
clones O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
indicated O O
that O O
the O O
endogenous O B_GENE/B_LOCATION
sequences O I_GENE/I_LOCATION
abutting O O
the O O
3 O B_LOCATION/B_GENE
' O I_LOCATION/I_GENE
ends O I_LOCATION/I_GENE
of O O
the O O
94 O B_MEASURE
- O O
A O B_OTHER/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
94 O B_MEASURE
- O O
K O B_PROTEIN[GENE]/B_LOCATION
transgenes O I_PROTEIN[GENE]/I_LOCATION
are O O
separated O O
by O O
less O B_MEASURE
than O O
20 O B_MEASURE/B_LOCATION
kb O I_MEASURE/I_LOCATION
, O O
providing O O
strong O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
support O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
single O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
integration O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Serum O B_PERSON/B_MEASURE
triglycerides O I_PERSON/I_MEASURE
also O O
showed O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O O
birth O B_NUMBER[MEASURE]
to O O
6 O B_TIME[MEASURE]/B_LOCATION
months O I_TIME[MEASURE]/I_LOCATION
of O O
age O B_TIME[MEASURE]/B_PERSON
, O O
but O O
a O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
from O O
6 O B_TIME[MEASURE]/B_PERSON
months O I_TIME[MEASURE]/I_PERSON
to O O
1 O B_TIME[MEASURE]/B_LOCATION
years O I_TIME[MEASURE]/I_LOCATION
of O O
age O B_TIME[MEASURE]/B_PERSON
. O O

Female O B_PERSON
Wistar O I_PERSON
rats O I_PERSON
receiving O O
alcohol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
5 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
in O O
drinking O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
water O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
during O O
lactation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
( O O
N O B_OTHER/B_LOCATION
= O O
7 O B_MEASURE
) O O
were O O
compared O O
to O O
normal O B_PERSON/B_BIO
controls O I_PERSON/I_BIO
fed O O
ad O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
libitum O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
N O B_OTHER/B_LOCATION
= O O
6 O B_MEASURE
) O O
. O O

Antisense O O
oligonucleotides O O
complementary O O
to O O
the O O
5 O O
' O O
end O O
of O O
PKC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
zeta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequences I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
significantly O O
reduced O O
the O O
collagen B B_GENE/B_DISEASE
lattice O O
- O O
stimulated O O
alpha2 O O
and O O
MMP B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
. O O

Overexpression O O
of O O
a O O
HIF B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1alpha I I_GENE/I_DISEASE
construct O O
with O O
deletions O O
of O O
the O O
basic O O
domain O O
and O O
carboxy O O
terminus O O
blocked O O
reporter O O
gene O O
activation O O
by O O
endogenous O O
HIF B B_GENE
- I I_GENE
1 I I_GENE
in O O
hypoxic O O
cells O O
. O O

We O O
hypothesized O O
that O O
conjugated O O
estrogens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
contain O O
several O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
vasoactive O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
estrogenic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
compounds O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
may O O
favorably O O
influence O O
the O O
vasomotor O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
acetylcholine O O
in O O
men O B_PERSON/B_SPECIES[BIO]
. O O

In O O
Experiment O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
levels O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
were O O
: O O
amprolium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
ethopabate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
. O O
02 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
; O O
salinomycin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
55 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
; O O
monensin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
99 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE/B_PERSON
; O O
and O O
lasalocid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
110 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
. O O

Residues O O
crucial O O
for O O
Ras B B_GENE/B_DISEASE
interaction O O
with O O
GDP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GTP I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exchangers I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

4 O B_NUMBER[MEASURE]
. O O

In O O
serum O O
- O O
starved O O
NIH O O
3T3 O O
cells O O
, O O
v B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
raf I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
increased O O
mdr1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
approximately O O
10 O O
- O O
fold O O
compared O O
to O O
a O O
v B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
raf I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
frame O O
- O O
shift O O
control O O
. O O

Searching O O
the O O
human O O
DNA O O
data O O
base O O
of O O
expressed O O
sequence O O
tags O O
( O O
EST O O
) O O
revealed O O
novel O O
partial O O
sequences O O
similar O O
to O O
, O O
but O O
distinct O O
from O O
, O O
the O O
sequences O O
of O O
the O O
previously O O
known O O
PEF B B_GENE/B_BIO
proteins I I_GENE/I_BIO
. O O

Under O O
control O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
conditions O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
in O O
the O O
presence O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
3 O B_MEASURE
micromol O I_MEASURE
/ O O
kg O B_MEASURE
MIB O I_MEASURE
and O O
VER O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
the O O
maximal O B_MEASURE/B_LOCATION
effect O I_MEASURE/I_LOCATION
of O O
noradrenaline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
reached O O
at O O
0 O B_MEASURE
. O O
1 O B_MEASURE
micromol O I_MEASURE
/ O O
kg O B_MEASURE/B_PERSON
whereas O O
in O O
the O O
presence O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
10 O B_MEASURE
micromol O I_MEASURE
/ O O
kg O B_MEASURE/B_PERSON
MIB O I_MEASURE/I_PERSON
and O O
VER O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
it O O
was O O
reached O O
at O O
a O O
dose O B_MEASURE
of O O
1 O B_MEASURE
micromol O I_MEASURE
/ O O
kg O B_MEASURE
. O O

It O O
is O O
also O O
affected O O
by O O
the O O
HAP2 B B_GENE/B_DISEASE
/ I I_GENE/I_DISEASE
3 I I_GENE/I_DISEASE
/ I I_GENE/I_DISEASE
4 I I_GENE/I_DISEASE
transcription I I_GENE/I_DISEASE
factor I I_GENE/I_DISEASE
complex I I_GENE/I_DISEASE
and O O
by O O
SNF1 B B_GENE/B_DISEASE
and O O
SSN6 B B_GENE
. O O

The O O
effective O O
use O O
of O O
superoxide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dismutase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
human O O
erythrocytes O O
in O O
the O O
late O O
stages O O
of O O
experimental O O
influenza O O
infection O O

Two O O
different O O
genes O O
( O O
polA B B_GENE/B_BIO
and O O
polB B B_PROTEIN[GENE]/B_BIO
) O O
encoding O O
family B B_ENZYME[GENE]
B I I_ENZYME[GENE]
DNA I I_ENZYME[GENE]
polymerases I I_ENZYME[GENE]
were O O
cloned O O
from O O
the O O
organism O O
by O O
PCR O O
using O O
degenerated O O
primers O O
based O O
on O O
the O O
two O O
conserved O O
motifs O O
( O O
motif O O
A O O
and O O
B O O
) O O
. O O

The O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
on O O
survival O B_DISEASE
of O O
adjuvant O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatments O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
including O O
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
or O O
postoperative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
systemic O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
or O O
postoperative O B_DISEASE
intra O I_DISEASE
- O O
arterial O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
chemotherapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
are O O
currently O O
under O O
evaluation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Structure O O
and O O
regulation O O
of O O
the O O
luteinizing B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hormone I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
disease O B_DISEASE_ADJECTIVE[DISEASE]
processes O O
that O O
affect O O
transplant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
patients O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
both O O
before O O
and O O
after O O
transplantation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
are O O
not O O
seen O O
frequently O O
in O O
the O O
general O B_LOCATION
practice O I_LOCATION
of O O
gastroenterology O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Single O B_DISEASE/B_MEASURE
white O B_DISEASE/I_MEASURE
flash O B_DISEASE/I_MEASURE
ERG O B_DISEASE/I_MEASURE
, O O
photopic O B_DISEASE
ERG O I_DISEASE
, O O
scotopic O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
ERG O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
flicker O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
ERG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
were O O
recorded O O
in O O
30 O B_PERSON/B_TIME[MEASURE]
cases O I_PERSON/I_TIME[MEASURE]
of O O
unilateral O B_DISEASE
CRVO O I_DISEASE
. O O

However O O
, O O
to O O
encourage O O
good O B_ORGANIZATION/B_PERSON
contact O I_ORGANIZATION/I_PERSON
between O O
the O O
farmers O B_PERSON/B_BIO
and O O
the O O
inseminating O B_PERSON/B_BIO
personnel O I_PERSON/I_BIO
, O O
it O O
is O O
beneficial O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
herdsmen O B_PERSON/B_BIO
are O O
present O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O O
cows O B_BIO/B_PERSON
are O O
inseminated O O
. O O

Soft O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
independent O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
modelling O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
class O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
analogy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
SIMCA O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
applied O O
to O O
identify O O
near O O
- O O
infrared O O
( O O
NIR O B_LOCATION/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
spectra O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
ten O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
excipients O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
used O O
in O O
the O O
pharmaceutical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
industry O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

Multiple O B_DISEASE_ADJECTIVE[DISEASE]
organ O I_DISEASE_ADJECTIVE[DISEASE]
failure O I_DISEASE_ADJECTIVE[DISEASE]
( O O
MOF O B_LOCATION/B_DISEASE
) O O
following O O
major O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
trauma O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurs O O
in O O
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
perfusion O B_DISEASE
deficits O I_DISEASE
, O O
a O O
persistent O B_DISEASE
inflammatory O I_DISEASE
focus O I_DISEASE
, O O
or O O
a O O
persistent O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
focus O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
dead O B_DISEASE
and O O
/ O O
or O O
injured O O
tissue O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Western O O
immunoblot O O
analysis O O
detected O O
p55gag B B_GENE
and O O
its O O
cleavage O O
products O O
p39 B B_GENE
and O O
p27 B B_GENE/B_MEASURE
in O O
purified O O
particles O O
derived O O
by O O
expression O O
of O O
gag B B_GENE
and O O
gag B B_PROTEIN[GENE]/B_DISEASE
- O O
pol B B_GENE/B_DISEASE
, O O
respectively O O
. O O

Cefminox O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
shows O O
greater O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
vivo O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activity O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
than O O
that O O
expected O O
for O O
the O O
MICs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
excellent O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
efficacy O I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
safety O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
high O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
resolution O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
MF O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
ERG O B_LOCATION/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seems O O
more O O
sensitive O B_DISEASE_ADJECTIVE[DISEASE]
than O O
low O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
resolution O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
MF O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
ERG O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

3 O O
- O O
5 O O
- O O
fold O O
increases O O
in O O
EGF B B_GENE
receptor I I_GENE
but O O
not O O
p185 B B_GENE
( O O
neu B B_GENE/B_DISEASE
) O O
tyrosine O O
phosphorylation O O
occur O O
following O O
Gi B B_GENE
- I I_GENE
coupled I I_GENE
receptor I I_GENE
stimulation O O
. O O

Next O O
, O O
to O O
examine O O
the O O
regulation O O
mechanism O O
of O O
CD44 B B_GENE
/ O O
ERM B B_LOCATION/B_GENE
interaction O O
in O O
vivo O O
, O O
we O O
reexamined O O
the O O
immunoprecipitated O O
CD44 B B_GENE/B_LOCATION
/ O O
ERM B B_LOCATION/B_GENE
complex O O
from O O
BHK O O
cells O O
and O O
found O O
that O O
it O O
contains O O
Rho B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
GDP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dissociation I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
GDI B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
a O O
regulator O O
of O O
Rho B B_GENE
GTPase I I_GENE
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
showed O O
a O O
significant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O O
on O O
the O O
active O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
task O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

On O O
days O B_TIME[MEASURE]
7 O I_TIME[MEASURE]
, O O
21 O B_MEASURE
, O O
and O O
35 O B_MEASURE
postinoculation O I_MEASURE
( O O
PI O B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
all O O
birds O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
received O O
sheep O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
erythrocytes O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
intravenously O O
. O O

To O O
determine O O
cis O O
- O O
acting O O
elements O O
controlling O O
the O O
rat O O
B B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
50 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
GAP B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
43 I I_GENE/I_MEASURE
gene O O
expression O O
, O O
the O O
genomic O O
DNA O O
encoding O O
exon O O
1 O O
and O O
the O O
5 O O
' O O
flanking O O
sequence O O
was O O
isolated O O
. O O

In O O
this O O
paper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
authors O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O O
measured O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weight O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
1 O B_MEASURE
, O O
259 O B_MEASURE/B_PERSON
white O I_MEASURE/I_PERSON
women O I_MEASURE/I_PERSON
aged O O
65 O B_MEASURE
- O O
74 O B_MEASURE/B_ENT
years O I_MEASURE/I_ENT
from O O
the O O
Epidemiologic O B_SEQUENCE[MEASURE]
Follow O O
- O O
up O O
Study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
First O B_ORGANIZATION/B_LOCATION
National O I_ORGANIZATION/I_LOCATION
Health O I_ORGANIZATION/I_LOCATION
and O O
Nutrition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Examination O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Survey O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
to O O
examine O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
overweight O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
coronary O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heart O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disease O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
incidence O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
mean O B_TIME[MEASURE]/B_LOCATION
length O I_TIME[MEASURE]/I_LOCATION
of O O
follow O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
up O B_LOCATION/B_TIME[MEASURE]
, O O
14 O B_TIME[MEASURE]/B_ENT
years O I_TIME[MEASURE]/I_ENT
) O O
. O O

Through O O
genomic O O
library O O
screening O O
and O O
PCR O O
- O O
based O O
genomic O O
walking O O
we O O
have O O
now O O
cloned O O
the O O
mouse B B_GENE
E I I_GENE
- I I_GENE
Tmod I I_GENE
gene I I_GENE
, O O
whose O O
coding O O
region O O
spans O O
approximately O O
60kb O O
containing O O
nine O O
exons O O
and O O
eight O O
introns O O
. O O

TNF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
stimulated O O
these O O
changes O O
in O O
part O O
by O O
increasing O O
transcription O O
and O O
stabilization O O
of O O
RNA O O
for O O
amphiregulin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
an O O
EGF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ligand O O
, O O
and O O
amphiregulin B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
directly O O
increased O O
HPV O O
- O O
16 O O
E6 B B_PROTEIN[GENE]/B_DISEASE
/ O O
E7 B B_MEASURE/B_PROTEIN[GENE]
and O O
cyclin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNAs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
obtained O O
included O O
1 O B_NUMBER[MEASURE]/B_PERSON
) O O
the O O
mean O B_MEASURE/B_LOCATION
frequency O I_MEASURE/I_LOCATION
of O O
abnormal O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
teased O O
myelinated O B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fibers O B_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
its O O
upper O B_MEASURE
limit O I_MEASURE
value O I_MEASURE
of O O
95 O B_MEASURE/B_PERSON
% O B_MEASURE/I_PERSON
confidence O B_MEASURE/I_PERSON
interval O O
, O O
and O O
2 O B_NUMBER[MEASURE]
) O O
the O O
mean O B_MEASURE
densities O I_MEASURE
of O O
total O B_MEASURE/B_PERSON
, O O
large O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
myelinated O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
fibers O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
of O O
unmyelinated O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fibers O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
their O O
lower O B_MEASURE
limit O I_MEASURE
value O I_MEASURE
of O O
95 O B_MEASURE
% O I_MEASURE
confidence O I_MEASURE
interval O I_MEASURE
for O O
each O O
decade O B_MEASURE/B_PERSON
. O O

Fusions O O
between O O
the O O
GAL B B_GENE
DNA I I_GENE
binding I I_GENE
domain I I_GENE
and O O
full B B_GENE
- I I_GENE
length I I_GENE
mSin3 I I_GENE
were O O
also O O
capable O O
of O O
repression O O
. O O

None O B_PERSON/B_NUMBER[MEASURE]
of O O
the O O
19 O B_PERSON/B_MEASURE
women O I_PERSON/I_MEASURE
with O O
probable O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
RA O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
and O O
100 O B_NUMBER[MEASURE]
of O O
the O O
116 O B_MEASURE/B_PERSON
women O I_MEASURE/I_PERSON
with O O
definite O B_DISEASE/B_LOCATION
RA O I_DISEASE/I_LOCATION
met O O
the O O
1987 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
criteria O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

The O O
initial O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
oral O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
administration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
the O O
1 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
2 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
doses O I_MEASURE
of O O
enoximone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
improved O O
central O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hemodynamic O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
parameters O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
apparent O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
preferential O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reduction O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
limb O B_DISEASE
vascular O I_DISEASE
resistance O I_DISEASE
and O O
augmentation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
blood O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
flow O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O O
the O O
limb O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
region O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
( O O
peripheral O B_DISEASE/B_PROTEIN[GENE]
musculoskeletal O B_DISEASE/I_PROTEIN[GENE]
system O B_DISEASE/I_PROTEIN[GENE]
) O O
. O O

Antibodies O O
against O O
REAP B B_GENE
- I I_GENE
1 I I_GENE
inhibit O O
in O O
vitro O O
RNA O O
editing O O
reactions O O
confirming O O
its O O
role O O
in O O
RNA O O
editing O O
. O O

The O O
full O O
- O O
length O O
cDNA O O
was O O
cloned O O
and O O
sequenced O O
, O O
and O O
the O O
inferred O O
amino O O
acid O O
sequence O O
was O O
found O O
to O O
encode O O
a O O
novel O O
protein O O
, O O
which O O
we O O
named O O
cystatin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
M I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
with O O
40 O O
% O O
homology O O
to O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cystatins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
similar O O
overall O O
structure O O
. O O

42nd O B_PERSON
annual O I_PERSON
meeting O I_PERSON
of O O
the O O
American O B_ORGANIZATION/B_LOCATION
Academy O I_ORGANIZATION/I_LOCATION
of O O
Oral O B_PERSON
Pathology O I_PERSON
. O O

BAG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
also O O
prevented O O
growth O O
arrest O O
following O O
UV O O
- O O
irradiation O O
- O O
induced O O
genotoxic O O
injury O O
without O O
interfering O O
with O O
accumulation O O
of O O
p53 B B_GENE
protein I I_GENE
or O O
p21 B B_GENE/B_DISEASE
( O O
waf B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
) O O
expression O O
. O O

The O O
side O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
pulmonary O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fibrosis O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
occurs O O
in O O
20 O B_NUMBER[MEASURE]/B_LOCATION
to O O
30 O B_MEASURE
percent O I_MEASURE
of O O
patients O B_PERSON
receiving O O
this O O
drug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
. O O

These O O
larger O O
sizes O O
, O O
however O O
, O O
are O O
consistent O O
with O O
predictions O O
from O O
the O O
DNA O O
sequence O O
of O O
the O O
pol B B_BIO/B_GENE
gene I I_BIO/I_GENE
. O O

Primary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
care O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
programs O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O O
the O O
indigent O B_PERSON/B_LOCATION
. O O

N0 O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disease O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
more O O
favorable O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
than O O
N1 O B_PROTEIN[GENE]
or O O
N2 O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
disease O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
. O O

In O O
serial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
recall O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
short O B_MEASURE
- O O
term O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
memory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O O
repeated O O
items O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
are O O
recalled O O
well O O
when O O
close O O
together O O
( O O
repetition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
facilitation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
, O O
but O O
not O O
when O O
far O O
apart O O
( O O
repetition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
inhibition O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
; O O
the O O
Ranschburg O B_MEASURE/B_PERSON
effect O I_MEASURE/I_PERSON
) O O
. O O

In O O
addition O O
, O O
two O O
cis O O
- O O
acting O O
elements O O
direct O O
the O O
first O O
zygotic O O
expression O O
of O O
Kr B B_GENE
in O O
a O O
striped O O
subpattern O O
within O O
the O O
central O O
region O O
of O O
the O O
blastoderm O O
embryo O O
. O O

Two O B_NUMBER[MEASURE]/B_LOCATION
hundred O I_NUMBER[MEASURE]/I_LOCATION
and O O
eighty O B_NUMBER[MEASURE]
- O O
three O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
, O O
217 O B_PERSON/B_MEASURE
females O B_PERSON/I_MEASURE
( O O
median O B_TIME[MEASURE]/B_PERSON
age O B_TIME[MEASURE]/I_PERSON
24 O B_TIME[MEASURE]/I_PERSON
years O B_TIME[MEASURE]/I_PERSON
, O O
range O B_MEASURE
0 O I_MEASURE
. O O
5 O B_MEASURE
- O O
73 O B_MEASURE
) O O
and O O
66 O B_MEASURE/B_PERSON
males O I_MEASURE/I_PERSON
( O O
median O B_TIME[MEASURE]/B_PERSON
age O B_TIME[MEASURE]/I_PERSON
20 O B_TIME[MEASURE]/I_PERSON
years O B_TIME[MEASURE]/I_PERSON
, O O
range O B_MEASURE
0 O I_MEASURE
. O O
75 O B_MEASURE
- O O
72 O B_MEASURE
) O O
, O O
were O O
examined O O
. O O

The O O
Robert O B_LOCATION/B_PERSON
Wood O I_LOCATION/I_PERSON
Johnson O I_LOCATION/I_PERSON
Foundation O I_LOCATION/I_PERSON
: O O
billion O B_PERSON/B_ORGANIZATION
dollar O I_PERSON/I_ORGANIZATION
force O I_PERSON/I_ORGANIZATION
for O O
health O B_PERSON/B_DISEASE
- O O
care O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
change O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

We O O
have O O
isolated O O
a O O
unique O O
murine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
FLT3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cDNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
codes O O
for O O
a O O
variant O O
isoform O O
of O O
FLT3 B B_GENE
, O O
devoid O O
of O O
the O O
fifth O O
Ig B B_GENE
- I I_GENE
like I I_GENE
domain I I_GENE
, O O
by O O
comparison O O
with O O
the O O
prototypic O O
form O O
. O O

P53 B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
mutations I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
also O O
offer O O
new O O
approaches O O
to O O
the O O
study O O
of O O
the O O
origins O O
of O O
mutations O O
in O O
human O O
cancer O O
. O O

( O O
1993 O B_MEASURE
) O O
8 O B_MEASURE
, O O
94 O B_MEASURE
- O O
99 O B_MEASURE
) O O
. O O

Desarrollo O B_MEASURE/B_ENT
de O I_MEASURE/I_ENT
un O I_MEASURE/I_ENT
modelo O I_MEASURE/I_ENT
matematico O I_MEASURE/I_ENT
general O I_MEASURE/I_ENT
para O I_MEASURE/I_ENT
los O I_MEASURE/I_ENT
procesos O I_MEASURE/I_ENT
fermentativos O I_MEASURE/I_ENT
, O O
Cinetica O B_MEASURE/B_ENT
de O I_MEASURE/I_ENT
la O I_MEASURE/I_ENT
degradacion O I_MEASURE/I_ENT
anaerobia O I_MEASURE/I_ENT
, O O
Ph O B_PROTEIN[GENE]/B_LOCATION
. O O
D O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Particle O O
bombardment O O
of O O
barley O O
aleurone O O
with O O
a O O
B22EL8 B B_GENE
promoter I I_GENE
- O O
GUS B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
beta B B_PROTEIN[GENE]/B_BIO
- I I_PROTEIN[GENE]/I_BIO
glucuronidase I I_PROTEIN[GENE]/I_BIO
) O O
construct O O
demonstrates O O
that O O
the O O
promoter O O
( O O
3 O O
kb O O
) O O
is O O
active O O
in O O
developing O O
barley O O
grains O O
. O O

Changes O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
BHR O B_DISEASE
were O O
found O O
to O O
correlate O O
significantly O O
with O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
levels O B_MEASURE/B_GENE
of O O
24 O B_MEASURE
h O O
mean O O
SO2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
NO2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
smoke O O
; O O
48 O B_MEASURE
h O O
mean O O
NO2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
smoke O O
; O O
24 O B_MEASURE
h O O
lag O B_MEASURE/B_LOCATION
NO2 O I_MEASURE/I_LOCATION
; O O
although O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O O
only O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
accounting O O
for O O
approximately O O
10 O B_MEASURE
% O I_MEASURE
of O O
the O O
variability O B_MEASURE
in O O
within O O
- O O
subject O B_PERSON/B_MEASURE
BHR O I_PERSON/I_MEASURE
between O O
visits O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_GENE/B_LOCATION
sequences O B_GENE/I_LOCATION
of O O
isoforms O B_PROTEIN[GENE]
beta O I_PROTEIN[GENE]
to O O
epsilon O O
contain O O
a O O
PEST O B_LOCATION/B_MEASURE
region O I_LOCATION/I_MEASURE
which O O
could O O
induce O O
rapid O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
intracellular O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
degradation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
isoforms O B_PROTEIN[GENE]
beta O I_PROTEIN[GENE]
and O O
delta O B_PROTEIN[GENE]
. O O

Characterization O O
of O O
regions O O
of O O
fibronectin B B_GENE/B_BIO
besides O O
the O O
arginine O O
- O O
glycine O O
- O O
aspartic O O
acid O O
sequence O O
required O O
for O O
adhesive O O
function O O
of O O
the O O
cell O O
- O O
binding O O
domain O O
using O O
site O O
- O O
directed O O
mutagenesis O O
. O O

The O O
clinical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
valproate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
ethosuximide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
related O O
to O O
this O O
differential O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
modulation O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
thalamocortical O B_DISEASE
excitability O I_DISEASE
. O O

Elements O O
regulating O O
cell O O
- O O
and O O
stage O O
- O O
specific O O
expression O O
of O O
the O O
C O O
. O O
elegans O O
MyoD B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family O O
homolog O O
hlh B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

An O O
analysis O O
of O O
the O O
c B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kit I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
5 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
' I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
flanking I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
using O O
the O O
bacterial B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloramphenicol I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetyltransferase I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CAT B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
assay O O
) O O
in O O
human O O
erythroleukemia O O
HEL O O
cells O O
, O O
which O O
express O O
the O O
endogenous O O
c B B_GENE
- I I_GENE
kit I I_GENE
mRNA I I_GENE
at O O
high O O
levels O O
, O O
showed O O
that O O
a O O
region O O
from O O
- O O
180 O O
to O O
- O O
22 O O
is O O
important O O
for O O
the O O
expression O O
of O O
the O O
c B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kit I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

After O O
5 O O
days O O
stimulation O O
with O O
G B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CSF I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
10 O O
micrograms O O
/ O O
kg O O
) O O
1l O O
of O O
blood O O
was O O
drawn O O
, O O
kept O O
unprocessed O O
for O O
3 O O
days O O
and O O
reinfused O O
24 O O
h O O
after O O
completion O O
of O O
chemotherapy O O
. O O

OAT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
has O O
become O O
safer O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
recent O B_LOCATION/B_PERSON
years O I_LOCATION/I_PERSON
, O O
particularly O O
if O O
monitored O O
in O O
special O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
anticoagulation O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
clinics O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

However O O
, O O
the O O
relative O O
substrate O O
specificity O O
of O O
RSK3 B B_GENE/B_BIO
differed O O
from O O
that O O
reported O O
for O O
other O O
isoforms O O
. O O

Our O O
data O O
indicate O O
that O O
the O O
various O O
subunits O O
of O O
the O O
human O O
P B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TEFb I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex O O
may O O
play O O
distinct O O
roles O O
at O O
multiple O O
stages O O
to O O
mediate O O
Tat B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
activation O O
of O O
HIV O O
- O O
1 O O
transcription O O
elongation O O
. O O

Corresponding O O
oligonucleotides O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
used O O
to O O
screen O O
a O O
rat O B_GENE
liver O I_GENE
cDNA O I_GENE
library O I_GENE
constructed O O
in O O
the O O
plasmid O B_GENE/B_SPECIES[BIO]
cloning O O
vector O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
pcDV O O
. O O

In O O
fifty O B_NUMBER[MEASURE]/B_PERSON
non O I_NUMBER[MEASURE]/I_PERSON
selected O O
ductal O B_DISEASE/B_PERSON
carcinomas O I_DISEASE/I_PERSON
of O O
the O O
breast O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
we O O
found O O
that O O
a O O
marked O O
tumoral O B_DISEASE
inflammatory O I_DISEASE
infiltrate O I_DISEASE
( O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE
. O O
025 O B_MEASURE
) O O
, O O
perinodal O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
tumoral O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
infiltrate O O
( O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_NUMBER[MEASURE]
. O O
01 O B_MEASURE
) O O
, O O
sinus O B_DISEASE
catarrh O I_DISEASE
( O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
, O O
follicular O B_DISEASE
hyperplasia O I_DISEASE
( O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_NUMBER[MEASURE]
. O O
025 O B_MEASURE
) O O
, O O
mixed O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pattern O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
lymph O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
nodes O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_NUMBER[MEASURE]
. O O
01 O B_MEASURE
) O O
and O O
with O O
54 O B_TIME[MEASURE]/B_ENT
years O I_TIME[MEASURE]/I_ENT
of O O
age O B_TIME[MEASURE]/B_PERSON
or O O
younger O B_TIME[MEASURE]/B_PERSON
( O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
correlated O O
significantly O O
with O O
lymph O B_DISEASE/B_MEASURE
node O I_DISEASE/I_MEASURE
metastases O I_DISEASE/I_MEASURE
and O O
/ O O
or O O
high O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
histologic O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
grade O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Capillary O B_MEASURE/B_DISEASE
tortuosity O I_MEASURE/I_DISEASE
was O O
a O O
function O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
sarcomere O B_MEASURE/B_DISEASE
length O I_MEASURE/I_DISEASE
in O O
all O O
animals O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
this O O
relationship O B_PERSON/B_MEASURE
was O O
not O O
changed O O
by O O
hypoxia O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Sox8 B B_GENE/B_PERSON
maps O O
to O O
the O O
t B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
mouse O O
chromosome O O
17 O O
and O O
to O O
human O O
chromosome O O
16p13 O O
. O O
3 O O
, O O
a O O
region O O
associated O O
with O O
the O O
microphthalmia O O
- O O
cataract O O
syndrome O O
CATM O O
and O O
the O O
alpha O O
- O O
thalassemia O O
/ O O
mental O O
retardation O O
syndrome O O
ATR O O
- O O
16 O O
. O O

Directional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
growth O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
a O O
smectic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
A O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
smectic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
B O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
interface O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
lying O O
along O O
a O O
forbidden O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
orientation O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
TCR B B_GENE
beta I I_GENE
enhancer I I_GENE
was O O
active O O
on O O
both O O
the O O
minimal B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
simian I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
40 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
a O O
TCR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
beta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
variable I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
both O O
TCR B B_GENE/B_LOCATION
alpha I I_GENE/I_LOCATION
/ I I_GENE/I_LOCATION
beta I I_GENE/I_LOCATION
+ O O
and O O
TCR B B_GENE/B_LOCATION
gamma I I_GENE/I_LOCATION
/ I I_GENE/I_LOCATION
delta I I_GENE/I_LOCATION
+ O O
T O O
cells O O
. O O

U O B_OTHER/B_MEASURE
. O O

Recently O O
, O O
we O O
demonstrated O O
that O O
platelet B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
derived I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
growth I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
PDGF I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
beta I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
stimulation O O
, O O
but O O
not O O
various O O
other O O
growth O O
factors O O
, O O
inhibits O O
transcription O O
of O O
alpha1D B B_PROTEIN[GENE]/B_LOCATION
- O O
, O O
but O O
not O O
alpha1A B B_PROTEIN[GENE]/B_LOCATION
- O O
or O O
alpha1B B B_GENE
- I I_GENE
ARs I I_GENE
, O O
resulting O O
in O O
reduced O O
norepinephrine O O
- O O
mediated O O
SMC O O
growth O O
. O O

Southern O O
blot O O
analysis O O
following O O
reverse O O
transcription O O
and O O
PCR O O
showed O O
that O O
B2R B B_GENE
is O O
expressed O O
in O O
most O O
mouse O O
tissues O O
, O O
except O O
the O O
liver O O
and O O
spleen O O
, O O
which O O
is O O
consistent O O
with O O
the O O
wide O O
distribution O O
of O O
B2R B B_GENE
activity O O
as O O
deduced O O
from O O
pharmacological O O
studies O O
. O O

Long O B_SEQUENCE[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
term O B_MEASURE/B_LOCATION
renal O B_MEASURE/I_LOCATION
function O B_MEASURE/I_LOCATION
in O O
on O O
- O O
heart O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
beating O O
donor O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
kidney O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
transplantation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
: O O
a O O
single O B_NUMBER[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
center O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
experience O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

The O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
intensity O B_MEASURE
of O O
pain O B_DISEASE
evoked O O
by O O
heat O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
is O O
relatively O O
exhaustive O B_DISEASE_ADJECTIVE[DISEASE]
: O O
the O O
influence O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
various O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
local O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
stimulus O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O O
general O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
factors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
upon O O
threshold O B_MEASURE/B_DISEASE
values O I_MEASURE/I_DISEASE
has O O
been O O
well O O
studied O O
, O O
as O O
has O O
the O O
relation O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
pain O B_DISEASE/B_MEASURE
and O O
stimulus O B_MEASURE/B_DISEASE
intensities O B_MEASURE/I_DISEASE
. O O

The O O
vaccine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
was O O
at O O
least O O
80 O B_DISEASE_ADJECTIVE[DISEASE]
% O I_DISEASE_ADJECTIVE[DISEASE]
efficacious O I_DISEASE_ADJECTIVE[DISEASE]
against O O
Chlamydia O B_BACTERIUM[BIO]/B_DISEASE
and O O
Campylobacter O B_VIRUS[BIO]/B_DISEASE
spp O I_VIRUS[BIO]/I_DISEASE
and O O
appeared O O
to O O
be O O
protective O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
centromeric O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dodeca O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
satellite O B_LOCATION/B_GENE
of O O
Drosophila O B_SPECIES[BIO]/B_GENE
forms O I_SPECIES[BIO]/I_GENE
altered O O
DNA O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
structures O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
in O O
which O O
its O O
purine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
rich O B_GENE/B_BACTERIUM[BIO]
strand O I_GENE/I_BACTERIUM[BIO]
( O O
G O B_PROTEIN[GENE]/B_LOCATION
- O O
strand O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
forms O O
stable O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
fold O O
- O O
back O B_LOCATION/B_MEASURE
structures O I_LOCATION/I_MEASURE
, O O
while O O
the O O
complementary O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O O
strand O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
remains O O
unstructured O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Pneumatic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dilation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
lower O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
esophageal O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
sphincter O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O O
accomplished O O
by O O
endoscopic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
visualization O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
positioning O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
a O O
modified O O
polyurethane O B_MEDICAL_DEVICE[OBJECT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dilator O I_MEDICAL_DEVICE[OBJECT]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
90 O B_MEASURE/B_LOCATION
F O B_MEASURE/I_LOCATION
diameter O B_MEASURE/I_LOCATION
) O O
without O O
fluoroscopy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O O
17 O B_PERSON/B_ORGANIZATION
consecutive O I_PERSON/I_ORGANIZATION
patients O I_PERSON/I_ORGANIZATION
with O O
advanced O B_DISEASE
symptomatic O I_DISEASE
achalasia O I_DISEASE
. O O

Mean O O
CD4 B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
percentages O O
were O O
lower O O
postpartum O O
( O O
21 O O
. O O
9 O O
+ O O
/ O O
- O O
3 O O
. O O
4 O O
) O O
than O O
prepartum O O
( O O
45 O O
. O O
1 O O
+ O O
/ O O
- O O
6 O O
. O O
7 O O
) O O
in O O
all O O
five O O
patients O O
studied O O
, O O
although O O
proliferative O O
responses O O
to O O
the O O
mitogens B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phytohemagglutinin I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pokeweed I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
unchanged O O
during O O
the O O
study O O
period O O
. O O

The O O
second O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
VacFix O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
uses O O
a O O
0 O B_MEASURE/B_LOCATION
. O O
15 O B_MEASURE
mm O I_MEASURE
thick O I_MEASURE
plastic O I_MEASURE
bag O I_MEASURE
loosely O O
filled O O
with O O
1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mm O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polysterol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spheres O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Mean O O
24 O B_MEASURE/B_LOCATION
h O B_MEASURE/I_LOCATION
urinary O B_MEASURE/I_LOCATION
excretion O B_MEASURE/I_LOCATION
values O B_MEASURE/I_LOCATION
confirmed O O
this O O
observation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

However O O
, O O
the O O
safety O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
design O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
assured O O
as O O
long O O
as O O
all O O
patients O B_PERSON
received O O
three O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
courses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
chemotherapy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
is O O
unusual O B_DISEASE_ADJECTIVE[DISEASE]
in O O
phase O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O O
studies O O
in O O
Japan O B_LOCATION/B_PERSON
. O O

The O O
results O O
indicate O O
that O O
the O O
RNA O O
in O O
T7 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RNA I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymerase I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
not O O
free O O
of O O
steric O O
interactions O O
in O O
the O O
ternary O O
complex O O
and O O
not O O
available O O
for O O
structure O O
formation O O
until O O
it O O
is O O
at O O
least O O
10 O O
bases O O
away O O
from O O
the O O
site O O
of O O
polymerization O O
. O O

The O O
STP1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
locus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
located O O
on O O
chromosome O O
IV O O
close O O
to O O
at O O
least O O
two O O
other O O
genes O O
involved O O
in O O
RNA O O
splicing O O
: O O
PRP3 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
SPP41 B B_GENE/B_DISEASE
. O O

An O O
ICU O B_MEASURE
length O I_MEASURE
of O O
stay O O
shorter O B_TIME[MEASURE]
than O O
24 O B_NUMBER[MEASURE]
h O I_NUMBER[MEASURE]
was O O
not O O
related O O
to O O
the O O
frequency O B_MEASURE
of O O
group O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
errors O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
vitro O O
, O O
SHIP B B_GENE
catalyzes O O
the O O
conversion O O
of O O
the O O
phosphoinositide B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PI3K B B_GENE
) O O
product O O
phosphatidylinositol O O
3 O O
, O O
4 O O
, O O
5 O O
- O O
trisphosphate O O
( O O
PIP3 O O
) O O
into O O
phosphatidylinositol O O
3 O O
, O O
4 O O
- O O
bisphosphate O O
. O O

Like O O
pimethixene O O
and O O
cyproheptadine O O
, O O
WA O O
335 O O
has O O
no O O
distinct O O
antagonistic O O
qualities O O
against O O
bradykinin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
. O O

To O O
confirm O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
obtained O O
using O O
the O O
HPLC O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
ESI O B_LOCATION
- O O
MS O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
procedure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
fractions O B_NUMBER[MEASURE]/B_LOCATION
of O O
the O O
glycosides O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
four O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
berries O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
were O O
separated O O
, O O
hydrolyzed O O
, O O
silylated O O
and O O
the O O
sugars O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
analyzed O O
using O O
gas O B_DISEASE/B_PROTEIN[GENE]
chromatography O B_DISEASE/I_PROTEIN[GENE]
- O O
mass O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spectrometry O B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
clone O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
will O O
be O O
useful O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
identifying O O
the O O
genetic O B_LOCATION/B_PERSON
determinants O I_LOCATION/I_PERSON
of O O
FIV O B_GENE/B_DISEASE
- O O
Oma O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
s O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biological O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activities O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
WEB2 B B_GENE/B_MEASURE
gene I I_GENE/I_MEASURE
encodes O O
a O O
1 O O
, O O
522 O O
- O O
amino O O
- O O
acid O O
protein O O
with O O
homology O O
to O O
nucleic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
acid I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dependent I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ATPases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Evidence O O
that O O
the O O
AT1A B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activates O O
transcription B B_GENE
factor I I_GENE
- I I_GENE
Stat91 I I_GENE
and O O
/ O O
or O O
a O O
related O O
protein O O
. O O

There O O
was O O
91 O B_DISEASE_ADJECTIVE[DISEASE]
% O I_DISEASE_ADJECTIVE[DISEASE]
concordance O I_DISEASE_ADJECTIVE[DISEASE]
between O O
ST O B_PROTEIN[GENE]/B_DISEASE
- O O
RD O B_LOCATION/B_DISEASE
/ O O
RI O B_LOCATION/B_PROTEIN[GENE]
/ O O
LRD O B_LOCATION/B_PROTEIN[GENE]
201Tl O I_LOCATION/I_PROTEIN[GENE]
and O O
R O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
ST O B_PROTEIN[GENE]/B_DISEASE
/ O O
N O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
+ O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
Inf O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
99Tcm O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O O
tetrofosmin O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
imaging O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
regarding O O
reversibility O B_DISEASE
. O O

The O O
two O O
complexes O O
were O O
detected O O
with O O
a O O
similar O O
activation O O
kinetics O O
upon O O
IL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
4 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
stimulation O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
dauricine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
verapamil O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
a O O
salutary O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effect O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
extracorporeal O B_DISEASE/B_BIO
circulation O I_DISEASE/I_BIO
. O O

These O O
results O O
demonstrate O O
the O O
preferential O O
endometrial O O
cell O O
- O O
type O O
expression O O
of O O
BTEB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
suggest O O
its O O
regulatory O O
role O O
in O O
pregnancy O O
- O O
associated O O
endometrial O O
epithelial O O
gene O O
expression O O
. O O

Spen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
the O O
only O O
known O O
homeotic B B_GENE/B_BIO
protein I I_GENE/I_BIO
with O O
RNP O O
binding O O
motifs O O
, O O
which O O
indicates O O
that O O
splicing O O
, O O
transport O O
, O O
or O O
other O O
RNA O O
regulatory O O
steps O O
are O O
involved O O
in O O
the O O
diversification O O
of O O
segmental O O
morphology O O
. O O

Long O B_MEASURE/B_DISEASE
- O O
term O B_TIME[MEASURE]
follow O I_TIME[MEASURE]
- O O
up O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
kidney O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
donors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
: O O
a O O
longitudinal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Recent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
research O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
on O O
lipolysis O B_DISEASE/B_SPECIES[BIO]
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
The O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
it O O
is O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
use O O
a O O
modified O O
Stroop O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
task O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
as O O
a O O
measure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
implicit O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
processing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
alcohol O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimuli O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Six O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
( O O
24 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
developed O O
sepsis O B_DISEASE
and O O
only O O
one O B_NUMBER[MEASURE]
survived O O
. O O

None O O
of O O
the O O
10 O O
sequences O O
has O O
hitherto O O
been O O
recognized O O
as O O
part O O
of O O
the O O
p53 B B_GENE
signaling O O
pathway O O
. O O

The O O
Prompt O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
and O O
Praise O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
condition O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
superior O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
the O O
other O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
two O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
encouraging O O
participation O B_PERSON/B_ORGANIZATION
in O O
low O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
interest O B_MEASURE/B_PERSON
recreational O I_MEASURE/I_PERSON
activities O I_MEASURE/I_PERSON
. O O

The O O
majority O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Ig I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
heavy I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IgH I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
constant I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
locus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O O
been O O
cloned O O
and O O
mapped O O
. O O

A O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
analyzed O O
right O B_MEASURE/B_ORGANISM_FUNCTION
ventricular O I_MEASURE/I_ORGANISM_FUNCTION
size O I_MEASURE/I_ORGANISM_FUNCTION
and O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
201Tl O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
uptake O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
determine O O
if O O
there O O
was O O
a O O
relationship O B_PERSON/B_MEASURE
between O O
201Tl O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
uptake O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
systolic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
19 O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
with O O
pulmonary O B_DISEASE
artery O I_DISEASE
hypertension O I_DISEASE
who O O
were O O
being O O
evaluated O O
for O O
heart O B_DISEASE/B_MEASURE
- O O
lung O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
transplantation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

The O O
transcriptional O O
start O O
site O O
( O O
s O O
) O O
of O O
the O O
IA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
mapped O O
by O O
5 O O
' O O
rapid O O
amplification O O
of O O
cDNA O O
ends O O
to O O
97 O O
bp O O
upstream O O
of O O
the O O
translational O O
start O O
site O O
. O O

The O O
RAG B B_GENE
- I I_GENE
2 I I_GENE
gene I I_GENE
encodes O O
a O O
component O O
of O O
the O O
V B B_GENE
( I I_GENE
D I I_GENE
) I I_GENE
J I I_GENE
recombinase I I_GENE
which O O
is O O
essential O O
for O O
the O O
assembly O O
of O O
antigen O O
receptor O O
genes O O
in O O
B O O
and O O
T O O
lymphocytes O O
. O O

The O O
lamina O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
densa O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
was O O
always O O
interrupted O O
by O O
numerous O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
small O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
gaps O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
in O O
some O O
areas O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
basement O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
membrane O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
could O O
not O O
be O O
identified O O
over O O
a O O
long O B_TIME[MEASURE]/B_LOCATION
distance O I_TIME[MEASURE]/I_LOCATION
. O O

We O O
have O O
characterized O O
21 O O
mutations O O
in O O
the O O
type B B_GENE
VII I I_GENE
collagen I I_GENE
gene I I_GENE
( O O
COL7A1 B B_GENE/B_DISEASE
) O O
encoding O O
the O O
anchoring O O
fibrils O O
, O O
18 O O
of O O
which O O
were O O
not O O
previously O O
reported O O
, O O
in O O
patients O O
from O O
15 O O
unrelated O O
families O O
with O O
recessive O O
dystrophic O O
epidermolysis O O
bullosa O O
( O O
RDEB O O
) O O
. O O

The O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
when O O
used O O
to O O
stimulate O O
the O O
collection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
at O O
antenatal O B_ORGANISM_FUNCTION/B_PERSON
or O O
postnatal O B_PERSON/B_LOCATION
visits O I_PERSON/I_LOCATION
, O O
nonetheless O O
provide O O
an O O
accurate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
description O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
under O O
- O O
3 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
mortality O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
trends O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O O
differences O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
two O B_TIME[MEASURE]/B_PERSON
periods O B_TIME[MEASURE]/I_PERSON
examined O O
- O O
- O O
before O O
1984 O B_MEASURE
and O O
before O O
1989 O B_MEASURE
. O O

Both O O
residues O O
are O O
conserved O O
in O O
the O O
three O O
phosphorylated O O
paralogs O O
but O O
are O O
absent O O
in O O
the O O
ones O O
that O O
were O O
not O O
substrates O O
of O O
RsbT B B_GENE/B_NUMBER[MEASURE]
: O O
YetI B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
YezB B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
, O O
each O O
of O O
which O O
bears O O
only O O
one O O
of O O
the O O
conserved O O
residues O O
; O O
and O O
YtvA B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
, O O
which O O
lacks O O
both O O
residues O O
and O O
instead O O
possesses O O
an O O
N O O
- O O
terminal O O
PAS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
domain O O
. O O

There O O
is O O
a O O
good O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
correlation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
between O O
the O O
occurrence O B_DISEASE/B_MEASURE
in O O
any O O
particular O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
vascular O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
segment O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
transient O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
contractile O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
response O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
intrinsic O B_DISEASE/B_MEASURE
tone O I_DISEASE/I_MEASURE
as O O
assessed O O
by O O
relaxation O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
papaverine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
10 O B_MEASURE/B_LOCATION
( O O
- O O
6 O B_MEASURE
) O O
M O B_MEASURE/B_LOCATION
) O O
. O O

Both O O
atracurium O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
100 O B_MEASURE/B_LOCATION
mumol O I_MEASURE/I_LOCATION
litre O I_MEASURE/I_LOCATION
- O O
1 O B_NUMBER[MEASURE]
and O O
laudanosine O B_MEASURE
1 O I_MEASURE
- O O
50 O B_MEASURE/B_LOCATION
mumol O I_MEASURE/I_LOCATION
litre O I_MEASURE/I_LOCATION
- O O
1 O B_NUMBER[MEASURE]
enhanced O O
the O O
release O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
3H O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
NA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
evoked O O
by O O
field O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
stimulation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
2 O B_MEASURE
Hz O I_MEASURE
, O O
24 O B_MEASURE/B_LOCATION
stimuli O I_MEASURE/I_LOCATION
) O O
, O O
but O O
did O O
not O O
affect O O
resting O O
release O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

S16 O B_MEASURE/B_LOCATION
, O O
16 O B_MEASURE
. O O
8 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
P O B_OTHER/B_MEASURE
= O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
. O O

The O O
Zn B B_GENE/B_BIO
- I I_GENE/I_BIO
15 I I_GENE/I_BIO
DNA I I_GENE/I_BIO
- I I_GENE/I_BIO
binding I I_GENE/I_BIO
domain I I_GENE/I_BIO
comprises O O
three O O
zinc O O
fingers O O
separated O O
by O O
unusually O O
long O O
linker O O
sequences O O
that O O
would O O
be O O
expected O O
to O O
interrupt O O
specific O O
DNA O O
site O O
recognition O O
. O O

Replication O B_GENE/B_MEASURE
regions O I_GENE/I_MEASURE
from O O
plant O B_BIO/B_DISEASE
- O O
pathogenic O B_BIO/B_GENE
Pseudomonas O I_BIO/I_GENE
syringae O I_BIO/I_GENE
plasmids O I_BIO/I_GENE
are O O
similar O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
ColE2 O B_BIO/B_DISEASE
- O O
related O O
replicons O B_GENE/B_BIO
. O O

There O O
has O O
been O O
no O O
significant O B_DISEASE
toxicity O I_DISEASE
associated O O
with O O
repeated O O
5 O B_MEASURE/B_PERSON
- O O
FU O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
instillation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O O
the O O
airway O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Twenty O B_PERSON/B_ENT
male O I_PERSON/I_ENT
volunteers O I_PERSON/I_ENT
were O O
studied O O
during O O
almokalant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aiming O O
at O O
plasma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concentrations O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
Cpl O B_LOCATION/B_PROTEIN[GENE]
) O O
of O O
20 O B_MEASURE
, O O
50 O B_MEASURE
, O O
100 O B_MEASURE
, O O
and O O
150 O B_MEASURE/B_LOCATION
nmol O I_MEASURE/I_LOCATION
/ O O
l O B_MEASURE/B_OTHER
. O O

Consistently O O
, O O
we O O
show O O
that O O
phosphorylation O O
by O O
protein B B_GENE
kinase I I_GENE
A I I_GENE
inhibits O O
Sfl1 B B_GENE/B_PERSON
DNA O O
binding O O
in O O
vitro O O
, O O
and O O
that O O
a O O
tpk2Delta B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutation O O
increases O O
the O O
levels O O
of O O
Sfl1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
associated O O
with O O
specific O O
promoter O O
elements O O
in O O
vivo O O
. O O

The O O
response O O
sequences O O
were O O
localized O O
between O O
- O O
67 O O
and O O
+ O O
30 O O
in O O
the O O
simian O O
cytomegalovirus O O
IE94 B B_GENE
promoter I I_GENE
and O O
upstream O O
of O O
position O O
+ O O
9 O O
in O O
the O O
HCMV B B_GENE/B_BIO
IE68 I I_GENE/I_BIO
promoter I I_GENE/I_BIO
. O O

Some O O
CHOP B B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
C B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EBP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
heterodimers O O
apparently O O
bind O O
to O O
alternative O O
DNA O O
sequence O O
and O O
thereby O O
regulate O O
the O O
transcription O O
of O O
other O O
genes O O
. O O

To O O
identify O O
and O O
determine O O
the O O
function O O
of O O
Ino2p B B_GENE
in O O
yeast O O
cells O O
, O O
we O O
raised O O
antibodies O O
to O O
a O O
beta B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
galactosidase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
Ino2 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fusion O O
protein O O
. O O

Northern O O
blot O O
analyses O O
were O O
used O O
to O O
examine O O
the O O
regulated O O
expression O O
of O O
the O O
cys B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
14 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
+ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Typicality O B_MEASURE/B_PERSON
is O O
probably O O
a O O
better O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
representation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
Alexander O B_PERSON
, O O
Dunbar O B_TIME[MEASURE]/B_PERSON
and O O
others O B_PERSON
' O I_PERSON
conclusions O I_PERSON
than O O
specificity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
which O O
was O O
always O O
too O O
absolute O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
a O O
term O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Additions O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
NH4 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
up O O
to O O
200 O B_MEASURE
micrograms O I_MEASURE
1 O I_MEASURE
( O O
- O O
1 O B_NUMBER[MEASURE]
) O O
were O O
not O O
stimulatory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
whereas O O
at O O
1 O B_MEASURE
. O O
0 O B_MEASURE
mg O I_MEASURE
1 O I_MEASURE
( O O
- O O
1 O B_NUMBER[MEASURE]
) O O
levels O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
Ke O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
50 O B_MEASURE
% O I_MEASURE
greater O I_MEASURE
than O O
for O O
NO3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
enriched O O
medium O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

Cardiovascular O B_DISEASE_ADJECTIVE[DISEASE]
drug O I_DISEASE_ADJECTIVE[DISEASE]
use O I_DISEASE_ADJECTIVE[DISEASE]
and O O
hospitalizations O B_DISEASE_ADJECTIVE[DISEASE]
attributable O I_DISEASE_ADJECTIVE[DISEASE]
to O O
type O B_DISEASE
2 O I_DISEASE
diabetes O I_DISEASE
. O O

The O O
arrangement O O
of O O
amino O O
acids O O
in O O
the O O
helix O O
1 O O
and O O
helix O O
2 O O
regions O O
is O O
quite O O
similar O O
to O O
those O O
of O O
Mxi B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Mad B B_PROTEIN[GENE]/B_BIO
, O O
but O O
different O O
from O O
those O O
of O O
E2F B B_PROTEIN[GENE]/B_LOCATION
- I I_PROTEIN[GENE]/I_LOCATION
1 I I_PROTEIN[GENE]/I_LOCATION
and O O
DP B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
. O O

They O O
contain O O
a O O
large O B_MEASURE
( O O
0 O B_MEASURE
. O O
9 O B_MEASURE
X O I_MEASURE
10 O I_MEASURE
( O O
3 O B_NUMBER[MEASURE]
) O O
to O O
1 O B_MEASURE
. O O
88 O B_MEASURE
X O I_MEASURE
10 O I_MEASURE
( O O
3 O B_MEASURE
) O O
base O B_LOCATION/B_MEASURE
- O O
pairs O B_PERSON/B_MEASURE
) O O
intron O B_GENE/B_LOCATION
in O O
the O O
middle O B_MEASURE/B_LOCATION
of O O
the O O
gene O B_GENE
and O O
are O O
further O O
interrupted O O
close O O
to O O
the O O
5 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
' O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
end O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
gene O B_GENE
. O O

The O O
present O O
study O O
also O O
emphasizes O O
the O O
need O O
of O O
establishing O O
dose O O
- O O
response O O
curves O O
to O O
correctly O O
assess O O
the O O
relative O O
contribution O O
of O O
the O O
different O O
regions O O
of O O
steroid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
activation O O
of O O
transcription O O
. O O

Routine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
default O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
retrieval O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
home O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
visits O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
given O O
to O O
ensure O O
maximal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
drug O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
compliance O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

D O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
and O O
Long O B_PERSON/B_COLOR
, O O
C O B_OTHER/B_PROTEIN[GENE]
. O O

By O O
contrast O O
with O O
ama B B_GENE/B_BIO
- I I_GENE/I_BIO
1 I I_GENE/I_BIO
, O O
rpc B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
1 I I_GENE/I_MEASURE
was O O
not O O
deleted O O
by O O
mDf4 O O
or O O
larger O O
deficiencies O O
examined O O
, O O
indicating O O
that O O
these O O
genes O O
are O O
no O O
closer O O
than O O
150 O O
kb O O
. O O

Accordingly O O
, O O
constitutive O O
downregulation O O
of O O
expression O O
of O O
accessory O O
molecules O O
of O O
the O O
MHC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
class I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O O
reveal O O
differences O O
between O O
H2 B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
class I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
I I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
alleles I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O O
antigen O O
presentation O O
not O O
encountered O O
when O O
the O O
expression O O
levels O O
are O O
augmented O O
. O O

Anovulatory O O
cycles O O
with O O
an O O
apparently O O
normal O O
level O O
of O O
blood O O
prolactin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Legionella B B_DISEASE/B_ORGANISM_FUNCTION
antibodies I I_DISEASE/I_ORGANISM_FUNCTION
in O O
domestic O O
animals O O

By O O
differential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
screening O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
a O O
Xenopus O B_GENE
laevis O I_GENE
egg O I_GENE
cDNA O I_GENE
library O I_GENE
, O O
we O O
have O O
isolated O O
a O O
2 O B_MEASURE
, O O
111 O B_MEASURE/B_GENE
bp O I_MEASURE/I_GENE
cDNA O I_MEASURE/I_GENE
which O O
corresponds O O
to O O
a O O
maternal O B_GENE
mRNA O I_GENE
specifically O O
deadenylated O O
after O O
fertilisation O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
. O O

Similar O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
immunological O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
disturbances O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O O
observed O O
in O O
SCI O B_DISEASE/B_PERSON
but O O
not O O
in O O
the O O
PC2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
subgroup O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
i O O
. O O
e O B_DISEASE/B_PROTEIN[GENE]
. O O
patients O B_PERSON/B_LOCATION
examined O O
later O O
than O O
6 O B_TIME[MEASURE]/B_LOCATION
months O I_TIME[MEASURE]/I_LOCATION
after O O
injury O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrates O O
that O O
Fluosol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
significantly O O
attenuates O O
neutrophil O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adherence O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
cytotoxicity O B_DISEASE
, O O
and O O
enzyme O B_DISEASE_ADJECTIVE[DISEASE]
release O I_DISEASE_ADJECTIVE[DISEASE]
in O O
an O O
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
microvascular O B_DISEASE
injury O I_DISEASE
. O O

Using O O
the O O
same O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
electrical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analog O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
we O O
present O O
an O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
that O O
allows O O
calculation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
parameters O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
as O O
well O O
as O O
the O O
corner O B_MEASURE/B_LOCATION
frequency O I_MEASURE/I_LOCATION
of O O
the O O
network O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
f1 O B_PROTEIN[GENE]/B_MEASURE
) O O
, O O
without O O
need O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
for O O
similar O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
assumptions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

We O O
further O O
examined O O
the O O
interaction O O
of O O
JAK2 B B_GENE
with O O
the O O
GHR B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytoplasmic O O
domain O O
by O O
two O O
lines O O
of O O
investigation O O
. O O

These O O
p21 B B_PROTEIN[GENE]/B_LOCATION
- O O
E2F B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes O O
, O O
while O O
present O O
in O O
young O O
G1 O O
cells O O
at O O
very O O
low O O
levels O O
, O O
were O O
elevated O O
in O O
senescent O O
cells O O
. O O

There O O
is O O
little O O
similarity O O
among O O
the O O
sequences O O
upstream O O
from O O
the O O
CAP O O
site O O
of O O
the O O
Spec2 B B_GENE
genes I I_GENE
except O O
the O O
TATA O O
consensus O O
sequence O O
and O O
a O O
repeating O O
trinucleotide O O
, O O
AAC O O
. O O

Thus O O
, O O
d O B_PROTEIN[GENE]/B_LOCATION
- O O
delta3 O B_GENE
- O O
carene O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O O
about O O
four O B_SEQUENCE[MEASURE]/B_ENT
times O I_SEQUENCE[MEASURE]/I_ENT
more O O
potent O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
sensory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
irritant O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
I O O
- O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
pinene O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
whereas O O
the O O
difference O B_MEASURE
with O O
I O O
- O O
alpha O B_PROTEIN[GENE]
- O O
pinene O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
more O O
marked O O
; O O
as O O
a O O
sensory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
irritant O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
I O O
- O O
alpha O B_PROTEIN[GENE]
- O O
pinene O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
almost O O
inactive O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
reconstituted O O
RNA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
polymerases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
containing O O
the O O
mutant O O
alpha O O
subunits O O
were O O
examined O O
for O O
their O O
response O O
to O O
transcription O O
activation O O
by O O
cAMP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
CRP I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
the O O
rrnBP1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
UP I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
element I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

The O O
study O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
combination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vinblastine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
CCNU O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
single O B_NUMBER[MEASURE]/B_DISEASE
- O O
agent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
triazinate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
dactinomycin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
) O O
failed O O
to O O
provide O O
any O O
meaningful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antitumor O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
these O O
patients O B_PERSON/B_BIO
with O O
advanced O B_DISEASE
renal O I_DISEASE
cell O I_DISEASE
cancer O I_DISEASE
. O O

Our O O
results O O
indicate O O
that O O
GCN4 B B_GENE
contains O O
two O O
activation O O
domains O O
of O O
similar O O
potency O O
that O O
can O O
function O O
independently O O
to O O
promote O O
high O O
- O O
level O O
transcription O O
of O O
the O O
target O O
genes O O
HIS3 B B_GENE
and O O
HIS4 B B_GENE
. O O

Those O O
diagnosed O O
as O O
having O O
affective O B_DISEASE/B_LOCATION
disorder O I_DISEASE/I_LOCATION
( O O
n O B_MEASURE/B_LOCATION
= O O
96 O B_MEASURE
) O O
, O O
according O O
to O O
DSM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
IIIR O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
criteria O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
were O O
compared O O
with O O
the O O
other O B_DISEASE/B_MEASURE
non O I_DISEASE/I_MEASURE
- O O
affective O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suicide O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
attempters O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
n O B_OTHER/B_MEASURE
= O O
161 O B_MEASURE
) O O
. O O

Tax B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
demonstrated O O
to O O
interact O O
directly O O
with O O
CREB1 B B_GENE
but O O
not O O
with O O
other O O
bZIP B B_GENE/B_BIO
proteins I I_GENE/I_BIO
, O O
including O O
CREB2 B B_GENE/B_LOCATION
and O O
Jun B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Anxiogenic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
pentagastrin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
patients O B_PERSON/B_BIO
with O O
social O B_DISEASE/B_LOCATION
phobia O I_DISEASE/I_LOCATION
and O O
healthy O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
controls O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Ischaemia O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
reperfusion O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injury O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
kidney O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
: O O
current O B_TIME[MEASURE]/B_LOCATION
status O I_TIME[MEASURE]/I_LOCATION
and O O
future O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
direction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

Non O O
- O O
dialyzable O O
transfer B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]

We O O
also O O
demonstrate O O
that O O
a O O
p110RB1 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutant I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
which O O
is O O
refractory O O
to O O
cell O O
cycle O O
phosphorylation O O
but O O
intact O O
in O O
E1a B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
large B B_GENE/B_LOCATION
T I I_GENE/I_LOCATION
antigen I I_GENE/I_LOCATION
- O O
binding O O
properties O O
, O O
represses O O
EIIaE B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
50 O O
- O O
to O O
80 O O
- O O
fold O O
greater O O
efficiency O O
than O O
wild B B_GENE/B_TIME[MEASURE]
- I I_GENE/I_TIME[MEASURE]
type I I_GENE/I_TIME[MEASURE]
p110RB1 I I_GENE/I_TIME[MEASURE]
. O O

Subgroup O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
failed O O
to O O
show O O
any O O
benefit O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
etoposide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
patients O B_PERSON/B_ORGANIZATION
with O O
monocytic O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O O
myelomonocytic O B_DISEASE
disease O I_DISEASE
, O O
or O O
in O O
any O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
diagnostic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
subgroup O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

The O O
IGFBP B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
IRS B I_GENE/I_DISEASE
and O O
PEPCK B B_LOCATION/B_GENE
IRS B I_LOCATION/I_GENE
both O O
bind O O
the O O
alpha O O
and O O
beta O O
forms O O
of O O
hepatic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
HNF B B_GENE
- I I_GENE
3 I I_GENE
) O O
, O O
although O O
the O O
latter O O
does O O
so O O
with O O
a O O
sixfold O O
- O O
lower O O
relative O O
affinity O O
. O O

Polyglutamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
containing O O
protein O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fragments O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
have O O
been O O
shown O O
to O O
accumulate O O
as O O
aggregates O B_DISEASE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
nucleus O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
and O O
in O O
the O O
cytoplasm O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
, O O
and O O
to O O
induce O O
cell O B_DISEASE/B_GENE
death O I_DISEASE/I_GENE
when O O
expressed O O
in O O
cultured O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
, O O
leading O O
to O O
the O O
proposal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
polyglutamine O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
aggregation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
is O O
an O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
step O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
pathogenesis O B_DISEASE
. O O

It O O
is O O
suggested O O
that O O
on O O
presentation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
tail O B_DISEASE
tip O I_DISEASE
necrosis O I_DISEASE
in O O
kittens O B_PERSON/B_BIO
a O O
diagnosis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
neonatal O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoerythrolysis O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
isoagglutination O B_DISEASE/B_BACTERIUM[BIO]
should O O
be O O
considered O O
. O O

Microscopically O O
, O O
cartilage O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
showed O O
markedly O O
stunted O B_DISEASE_ADJECTIVE[DISEASE]
and O O
disorganized O B_DISEASE_ADJECTIVE[DISEASE]
endochondral O I_DISEASE_ADJECTIVE[DISEASE]
ossification O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Our O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provide O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O O
differential O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
splicing O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
in O O
the O O
extracellular O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
region O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
a O O
receptor O B_GENE
gene O I_GENE
generates O O
receptor O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
variants O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
different O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ligand O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
binding O O
specificities O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Sucrose O O
- O O
specific O O
signalling O O
represses O O
translation O O
of O O
the O O
Arabidopsis B B_GENE
ATB2 I I_GENE
bZIP I I_GENE
transcription I I_GENE
factor I I_GENE
gene I I_GENE
. O O

Wolf O B_BIO/B_PERSON
- O O
Hirschhorn O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
syndrome O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
WHS O B_LOCATION/B_DISEASE
) O O
is O O
a O O
malformation O B_DISEASE/B_GENE
syndrome O I_DISEASE/I_GENE
associated O O
with O O
a O O
hemizygous O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
deletion O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
distal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
short O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
arm O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
chromosome O B_GENE/B_MEASURE
4 O I_GENE/I_MEASURE
( O O
4p16 O B_MEASURE/B_GENE
. O O
3 O B_MEASURE
) O O
. O O

Our O O
aim O O
was O O
to O O
check O O
whether O O
, O O
during O O
PG O O
- O O
DS O O
administration O O
, O O
serum O O
lipase B B_ENZYME[GENE]
activity O O
changes O O
simultaneously O O
with O O
serum O O
amylase B B_GENE
activity O O
, O O
and O O
, O O
if O O
so O O
, O O
what O O
the O O
reason O O
is O O
for O O
the O O
detected O O
change O O
. O O

A O O
long O B_NUMBER[MEASURE]/B_LOCATION
- O O
term O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
follow O O
- O O
up O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
a O O
children O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
s O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
psychiatric O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
day O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
treatment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
center O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Sequencing O B_GENE
and O O
restriction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
enzyme O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
demonstrated O O
that O O
this O O
single O B_NUMBER[MEASURE]/B_LOCATION
- O O
copy O B_GENE/B_LOCATION
gene O I_GENE/I_LOCATION
contains O O
11 O B_GENE
exons O I_GENE
and O O
spans O O
9596 O B_NUMBER[MEASURE]/B_GENE
base O I_NUMBER[MEASURE]/I_GENE
pairs O I_NUMBER[MEASURE]/I_GENE
. O O

In O O
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
II O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
MDL O B_MEASURE/B_PROTEIN[GENE]
72 O I_MEASURE/I_PROTEIN[GENE]
, O O
974A O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
proving O O
to O O
be O O
a O O
useful O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adjunct O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
conventional O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
no O O
consensus O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
on O O
indications O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
exists O O
and O O
, O O
according O O
to O O
the O O
literature O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
are O O
contradictory O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
effect O O
of O O
the O O
NMDA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antagonist O O
( O O
+ O O
/ O O
- O O
) O O
- O O
CPP O O
on O O
the O O
conditioned O O
- O O
reflex O O
activation O O
of O O
an O O
operant O O
reaction O O
in O O
the O O
brain O O
electrical O O
self O O
- O O
stimulation O O
test O O
in O O
rats O O

Within O O
any O O
cell O O
line O O
, O O
several O O
Tcfs B B_GENE/B_BACTERIUM[BIO]
and O O
TLEs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
are O O
co O O
- O O
expressed O O
. O O

Constructs O O
containing O O
fragments O O
of O O
the O O
upstream O O
region O O
of O O
the O O
cytotactin B B_GENE
gene I I_GENE
fused O O
to O O
a O O
promoterless O O
gene O O
for O O
chloramphenicol B B_GENE/B_TIME[MEASURE]
acetyltransferase I I_GENE/I_TIME[MEASURE]
were O O
transiently O O
transfected O O
into O O
chicken O O
embryo O O
fibroblasts O O
to O O
define O O
functional O O
promoter O O
sequences O O
. O O

We O O
investigated O O
the O O
pattern O O
of O O
evolution O O
of O O
bronchial O O
albumin B B_GENE/B_DISEASE
, O O
IgA B B_GENE
, O O
and O O
IgG B B_GENE
levels O O
in O O
ventilated O O
ICU O O
patients O O
in O O
relation O O
to O O
nosocomial O O
pneumonia O O
. O O

Mortality O B_DISEASE
among O O
patients O B_PERSON
with O O
CAVB O B_DISEASE/B_GENE
is O O
still O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O O
has O O
not O O
declined O O
within O O
the O O
last O B_TIME[MEASURE]/B_LOCATION
decade O I_TIME[MEASURE]/I_LOCATION
. O O

Mutations O O
away O O
from O O
splice O O
site O O
recognition O O
sequences O O
might O O
cis O O
- O O
modulate O O
alternative O O
splicing O O
of O O
goat O O
alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
s1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
casein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

SETTING O B_LOCATION/B_PERSON
: O O
A O O
private O B_PERSON/B_LOCATION
office O I_PERSON/I_LOCATION
- O O
based O O
fertility O B_LOCATION/B_ORGANIZATION
program O I_LOCATION/I_ORGANIZATION
. O O

Promoter O O
, O O
spliced O O
leader O O
, O O
and O O
coding O O
sequence O O
for O O
BICP4 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
largest O O
of O O
the O O
immediate B B_GENE/B_NUMBER[MEASURE]
- I I_GENE/I_NUMBER[MEASURE]
early I I_GENE/I_NUMBER[MEASURE]
proteins I I_GENE/I_NUMBER[MEASURE]
of I I_GENE/I_NUMBER[MEASURE]
bovine I I_GENE/I_NUMBER[MEASURE]
herpesvirus I I_GENE/I_NUMBER[MEASURE]
1 I I_GENE/I_NUMBER[MEASURE]
. O O

The O O
limb O B_DISEASE
defects O I_DISEASE
, O O
oligodactyly O O
and O O
syndactyly O O
, O O
have O O
been O O
traced O O
to O O
improper O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
differentiation O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
apical O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ectodermal O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
ridge O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
AER O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
and O O
shortening O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
anteroposterior O B_BODY_PART_OR_ORGAN_COMPONENT
limb O I_BODY_PART_OR_ORGAN_COMPONENT
axis O I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Our O O
data O O
suggest O O
that O O
the O O
ZF B B_SEQUENCE[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_SEQUENCE[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
HD I I_SEQUENCE[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
class O O
of O O
homeodomain B B_GENE/B_BIO
proteins I I_GENE/I_BIO
may O O
be O O
involved O O
in O O
the O O
establishment O O
of O O
the O O
characteristic O O
expression O O
pattern O O
of O O
the O O
C4 B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
PEPCase I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
gene I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

There O O
was O O
no O O
correlation O O
between O O
starting O O
platelet O O
- O O
associated O O
IgG B B_GENE
levels O O
or O O
changes O O
in O O
platelet O O
- O O
associated O O
IgG B B_GENE
levels O O
with O O
therapy O O
and O O
the O O
increment O O
in O O
the O O
patient O O
' O O
s O O
platelet O O
count O O
. O O

We O O
investigated O O
whether O O
two O O
WT1 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
splice I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
variants I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
lacking O O
or O O
including O O
a O O
three O O
- O O
amino O O
- O O
acid O O
( O O
KTS O O
) O O
insertion O O
between O O
the O O
third O O
and O O
fourth O O
zinc O O
finger O O
in O O
the O O
DNA O O
- O O
binding O O
domain O O
could O O
repress O O
the O O
IR B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
in O O
vitro O O
. O O

An O O
oligomer O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthesized O O
to O O
this O O
region O B_LOCATION/B_MEASURE
of O O
homology O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
produced O O
two O B_GENE
DNA O I_GENE
- O O
protein O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
complexes O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
oviduct O B_GENE
nuclear O I_GENE
proteins O I_GENE
. O O

The O O
deduced O O
amino O O
acid O O
sequence O O
exhibits O O
95 O O
. O O
3 O O
and O O
76 O O
. O O
1 O O
% O O
identity O O
with O O
the O O
CAD B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequences I I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of I I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hamster I I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Squalus I I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acanthias I I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
contrast O O
translocation O O
of O O
G1 B B_PROTEIN[GENE]
to O O
the O O
Golgi O O
was O O
not O O
observed O O
when O O
G1 B B_PROTEIN[GENE]
was O O
coexpressed O O
with O O
NSm B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
although O O
NSm B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
itself O O
was O O
still O O
detected O O
in O O
the O O
Golgi O O
. O O

Since O O
simian B B_GENE/B_DISEASE
virus I I_GENE/I_DISEASE
40 I I_GENE/I_DISEASE
( I I_GENE/I_DISEASE
SV40 I I_GENE/I_DISEASE
) I I_GENE/I_DISEASE
large I I_GENE/I_DISEASE
T I I_GENE/I_DISEASE
antigen I I_GENE/I_DISEASE
and O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
papillomavirus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
16 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
HPV16 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E7 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
also O O
bind O O
host O O
regulatory O O
factors O O
, O O
we O O
investigated O O
whether O O
these O O
viral O O
proteins O O
can O O
complement O O
E1A B B_DISEASE/B_GENE
mutants I I_DISEASE/I_GENE
which O O
are O O
defective O O
in O O
early O O
gene O O
activation O O
. O O

We O O
further O O
showed O O
a O O
significant O O
repression O O
of O O
promoter O O
activity O O
( O O
> O O
40 O O
fold O O
) O O
by O O
E2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
lacking O O
the O O
amino O O
acid O O
sequence O O
RSRS O O
) O O
when O O
the O O
E47 B B_GENE
reporter I I_GENE
construct I I_GENE
, O O
containing O O
a O O
hexameric O O
E O O
- O O
box O O
site O O
, O O
was O O
used O O
. O O

Similar O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observations O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
obtained O O
when O O
these O O
mutated O O
versions O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
site O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
evaluated O O
by O O
transient O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cotransfection O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
assays O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
CV1 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
shear O B_MEASURE/B_LOCATION
bond O I_MEASURE/I_LOCATION
strength O I_MEASURE/I_LOCATION
recorded O O
for O O
the O O
Novabond O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O O
significantly O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
17 O B_MEASURE
MPa O I_MEASURE
) O O
. O O

A O O
400 O O
- O O
bp O O
fragment O O
( O O
bp O O
- O O
339 O O
through O O
+ O O
71 O O
) O O
of O O
the O O
CD22 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
subcloned O O
into O O
a O O
pGEM O O
- O O
chloramphenicol B B_PROTEIN[GENE]/B_MEASURE
acetyltransferase I I_PROTEIN[GENE]/I_MEASURE
vector O O
and O O
after O O
transfection O O
into O O
B O O
and O O
T O O
cells O O
was O O
found O O
to O O
be O O
active O O
in O O
both O O
B O O
and O O
T O O
cells O O
. O O

RESULTS O O
: O O
There O O
were O O
no O O
significant O O
differences O O
in O O
the O O
mean O O
serum O O
vitamin O O
A O O
, O O
E O O
concentrations O O
and O O
vitamin O O
E O O
/ O O
cholesterol O O
ratio O O
between O O
pregnant O O
women O O
with O O
normal O O
hemoglobin B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
hemoglobinopathies O O
, O O
while O O
confounding O O
variables O O
that O O
might O O
affect O O
serum O O
vitamin O O
levels O O
i O O
. O O
e O O
. O O
maternal O O
age O O
, O O
gravida O O
, O O
BMI O O
, O O
gestational O O
age O O
, O O
hematocrit O O
, O O
hemoglobin B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
mean O O
corpuscular O O
hemoglobin B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
concentration O O
and O O
blood O O
group O O
were O O
not O O
different O O
. O O

Fourteen O B_TIME[MEASURE]/B_LOCATION
samples O I_TIME[MEASURE]/I_LOCATION
, O O
seven O B_NUMBER[MEASURE]/B_LOCATION
each O O
of O O
IR64 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
IR66 O B_MEASURE/B_PROTEIN[GENE]
were O O
studied O O
with O O
regard O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
moisture O B_MEASURE/B_COLOR
content O I_MEASURE/I_COLOR
, O O
germination O B_MEASURE/B_LOCATION
test O I_MEASURE/I_LOCATION
, O O
abnormal O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
seedlings O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
speed O B_MEASURE/B_SPORT[ENT]
of O O
germination O B_DISEASE/B_BIO
, O O
conductance O B_MEASURE/B_LOCATION
of O O
leachates O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
, O O
total O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dehydrogenase O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
total O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
free O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
amino O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
acids O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
total O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
soluble O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sugar O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
fat O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
acidity O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
gelatinization O B_MEASURE/B_PERSON
temperature O I_MEASURE/I_PERSON
, O O
gel O B_MEASURE/B_DISEASE
consistency O I_MEASURE/I_DISEASE
, O O
amylose O B_MEASURE/B_ORGANIZATION
content O I_MEASURE/I_ORGANIZATION
, O O
translucency O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
per O O
cent O B_MEASURE
whiteness O I_MEASURE
. O O

Electrophoretic O O
mobility O O
- O O
shift O O
assays O O
between O O
viral O O
RNA O O
and O O
BMV B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CP I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptides I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
either O O
proline O O
or O O
alanine O O
substitutions O O
revealed O O
that O O
the O O
interaction O O
is O O
nonspecific O O
. O O

Thus O O
, O O
over O O
a O O
wide O B_MEASURE
range O I_MEASURE
of O O
arterial O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dimensions O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
obtained O O
with O O
caliper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
estimates O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
luminal O B_MEASURE/B_LOCATION
area O I_MEASURE/I_LOCATION
and O O
diameter O B_MEASURE
are O O
comparable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
those O O
obtained O O
with O O
videodensitometry O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
the O O
XR O B_LOCATION/B_PROTEIN[GENE]
- O O
70 O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
system O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Neurodevelopmental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
assessment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
at O O
1 O B_TIME[MEASURE]/B_LOCATION
year O B_TIME[MEASURE]/I_LOCATION
is O O
predictive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
school O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
performance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
outcome O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
adolescent O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
period O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
reviewed O O
the O O
different O B_NUMBER[MEASURE]
published O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
acute O B_DISEASE
high O I_DISEASE
dose O I_DISEASE
methotrexate O I_DISEASE
neurotoxicity O I_DISEASE
and O O
the O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
underlying O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Drug O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
AAPMC O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
directed O O
at O O
reducing O O
the O O
amount O B_MEASURE
of O O
Cl O B_LOCATION
. O O
difficile O B_BACTERIUM[BIO]/B_DISEASE
in O O
the O O
colon O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
promoting O O
normalization O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
intestinal O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flora O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
yield O B_MEASURE/B_LOCATION
of O O
endocervical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
incidence O B_MEASURE/B_LOCATION
of O O
dysplasia O B_DISEASE/B_GENE
was O O
determined O O
for O O
both O O
the O O
prenatal O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
the O O
postpartum O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
Pap O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
smears O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
performed O O
for O O
this O O
group O B_ORGANIZATION/B_MEASURE
of O O
patients O B_PERSON/B_BIO
. O O

No O O
significant O O
difference O O
in O O
plasma O O
ET B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
was O O
found O O
between O O
cardiac O O
and O O
peripheral O O
sampling O O
sites O O
( O O
pulmonary O O
artery O O
; O O
1 O O
. O O
07 O O
+ O O
/ O O
- O O
0 O O
. O O
28 O O
, O O
right O O
atrium O O
; O O
1 O O
. O O
02 O O
+ O O
/ O O
- O O
0 O O
. O O
28 O O
, O O
peripheral O O
artery O O
; O O
1 O O
. O O
12 O O
+ O O
/ O O
- O O
0 O O
. O O
23 O O
, O O
peripheral O O
vein O O
; O O
1 O O
. O O
14 O O
+ O O
/ O O
- O O
0 O O
. O O
38 O O
fmol O O
/ O O
ml O O
: O O
N O O
. O O
S O O
. O O
) O O
, O O
or O O
among O O
patients O O
with O O
uncomplicated O O
MI O O
, O O
unstable O O
angina O O
( O O
1 O O
. O O
00 O O
+ O O
/ O O
- O O
0 O O
. O O
32 O O
fmol O O
/ O O
ml O O
) O O
, O O
and O O
healthy O O
subjects O O
( O O
1 O O
. O O
01 O O
+ O O
/ O O
- O O
0 O O
. O O
29 O O
fmol O O
/ O O
ml O O
) O O
. O O

Dose O B_TIME[MEASURE]/B_ORGANIZATION
- O O
dependent O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pharmacokinetics O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O O
emphasis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O O
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
I O O
metabolism O O
. O O

Inhibition O O
of O O
DNA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
topoisomerase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
by O O
the O O
p53 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tumor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suppressor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Activation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O O
HIV O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
UV O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
must O O
therefore O O
involve O O
additional O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cellular O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
processes O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O O
those O O
triggered O O
by O O
DNA O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
damage O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
for O O
generation O B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
a O O
full O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

4 O B_NUMBER[MEASURE]
. O O

Microsporum O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
persicolor O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O O
an O O
easily O O
misinterpreted O O
dermatophyt O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO

We O O
propose O O
that O O
, O O
while O O
Y O B_OTHER/B_PROTEIN[GENE]
. O O
lipolytica O B_SPECIES[BIO]/B_PROTEIN[GENE]
CEN O B_SPECIES[BIO]/I_PROTEIN[GENE]
DNA O B_SPECIES[BIO]/I_PROTEIN[GENE]
is O O
essential O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
plasmid O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
maintenance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
, O O
this O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
can O O
be O O
supplied O O
by O O
several O B_DISEASE/B_GENE
sub O B_DISEASE/I_GENE
- O O
fragments O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
which O O
, O O
together O O
, O O
form O O
the O O
active O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chromosomal O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
centromere O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
this O O
second O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
clinical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
paper O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
the O O
genetic O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
features O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
case O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
microphthalmia O B_DISEASE/B_LOCATION
in O O
sheep O B_BIO/B_LOCATION
reported O O
by O O
Wagenaar O B_PERSON
is O O
discussed O O
in O O
greater O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
detail O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Our O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reveals O O
a O O
consequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
adhesion O B_GENE
receptor O I_GENE
- O O
mediated O O
signaling O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O O
which O O
is O O
potentially O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
regulation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
T O B_DISEASE/B_GENE
cell O I_DISEASE/I_GENE
activation O I_DISEASE/I_GENE
, O O
including O O
production O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
cytokines O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
expression O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
proto O B_DISEASE
- O O
oncogenes O B_GENE/B_DISEASE
, O O
many O O
of O O
which O O
are O O
controlled O O
through O O
3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
' O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
AU O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
rich O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
elements O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
gap B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein O O
knirps B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mediates O O
both O O
quenching O O
and O O
direct O O
repression O O
in O O
the O O
Drosophila O O
embryo O O
. O O

The O O
family O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
histories O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
obtained O O
from O O
the O O
parents O B_PERSON/B_LOCATION
. O O

The O O
DW O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
directions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
uniformly O O
sampled O O
the O O
diffusion O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ellipsoid O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
surface O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Here O O
we O O
demonstrate O O
that O O
CD40 B B_GENE
or O O
IgM B B_GENE
receptor I I_GENE
stimulation O O
of O O
primary O O
B O O
cells O O
results O O
in O O
transactivation O O
of O O
this O O
enhancer O O
. O O

This O O
cell O O
line O O
expresses O O
productively O O
rearranged O O
immunoglobulin B B_GENE
genes I I_GENE
as O O
well O O
as O O
the O O
Oct B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
at O O
high O O
levels O O
which O O
are O O
comparable O O
to O O
those O O
observed O O
in O O
activated O O
murine O O
splenic O O
B O O
cells O O
. O O

The O O
relationship O O
between O O
CSF B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
somatostatin I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
peripheral O O
thyroid O O
hormones O O
was O O
assessed O O
in O O
11 O O
affectively O O
ill O O
patients O O
before O O
and O O
during O O
carbamazepine O O
treatment O O
. O O

Both O O
RNA14 B B_GENE/B_BIO
and O O
RNA15 B B_PROTEIN[GENE]
wild I I_PROTEIN[GENE]
- I I_PROTEIN[GENE]
type I I_PROTEIN[GENE]
genes I I_PROTEIN[GENE]
, O O
when O O
cloned O O
on O O
a O O
multicopy O O
plasmid O O
, O O
are O O
able O O
to O O
suppress O O
the O O
temperature O O
- O O
sensitive O O
phenotype O O
of O O
strains O O
bearing O O
either O O
the O O
rna14 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
the O O
rna15 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
suggesting O O
that O O
the O O
encoded O O
proteins O O
could O O
interact O O
with O O
each O O
other O O
. O O

Treatments O O
were O O
two O O
adrenocorticotrophin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
ACTH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
preparations O O
given O O
intramuscularly O O
at O O
2 O O
. O O
2 O O
U O O
/ O O
kg O O
, O O
one O O
of O O
the O O
ACTH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preparations O O
given O O
intramuscularly O O
at O O
1 O O
U O O
/ O O
kg O O
and O O
a O O
synthetic O O
polypeptide O O
with O O
ACTH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
like I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
activity O O
( O O
tetracosactrin O O
, O O
cosyntropin O O
) O O
given O O
intravenously O O
at O O
5 O O
micrograms O O
/ O O
kg O O
. O O

It O O
is O O
very O O
probable O B_DISEASE_ADJECTIVE[DISEASE]
that O O
this O O
change O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
due O O
to O O
mechanical O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
by O O
injecting O O
a O O
hypertonic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
solution O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
MT O B_LOCATION/B_PROTEIN[GENE]
- O O
141 O B_NUMBER[MEASURE]
at O O
a O O
rate O B_MEASURE/B_LOCATION
of O O
70 O B_MEASURE/B_LOCATION
- O O
- O O
130 O B_MEASURE/B_PERSON
ml O I_MEASURE/I_PERSON
/ O O
dog O B_TIME[MEASURE]/B_BIO
. O O

It O O
is O O
not O O
well O O
known O O
that O O
giant O B_DISEASE
cell O I_DISEASE
arteritis O I_DISEASE
can O O
cause O O
fatal O B_DISEASE
complications O I_DISEASE
due O O
to O O
rupture O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
aortic O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
aneurysms O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
or O O
cerebral O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
myocardial O B_DISEASE
infarctions O I_DISEASE
. O O

PRIP B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contains O O
two O O
LXXLL O O
signature O O
motifs O O
. O O

Basal O B_NUMBER[MEASURE]
urinary O I_NUMBER[MEASURE]
17 O I_NUMBER[MEASURE]
- O O
hydroxycorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
17 O B_MEASURE/B_LOCATION
- O O
OHCS O B_DISEASE/B_PROTEIN[GENE]
) O O
values O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
elevated O O
in O O
9 O B_NUMBER[MEASURE]
/ O O
12 O B_TIME[MEASURE]
patients O I_TIME[MEASURE]
and O O
low O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
dose O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
dexamethasone O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
suppression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
favoured O O
Cushing O B_PERSON
' O O
s O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
syndrome O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
8 O B_NUMBER[MEASURE]
/ O O
9 O B_TIME[MEASURE]
patients O I_TIME[MEASURE]
. O O

Like O O
the O O
human O O
gene O O
, O O
the O O
Drosophila O O
gene O O
encodes O O
at O O
least O O
three O O
isoforms O O
of O O
full B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
length I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dystrophin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
like I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
dmDLP1 B B_PROTEIN[GENE]/B_DISEASE
, O O
dmDLP2 B B_GENE
and O O
dmDLP3 B B_GENE
, O O
) O O
, O O
regulated O O
by O O
different O O
promoters O O
located O O
at O O
the O O
5 O O
' O O
end O O
of O O
the O O
gene O O
, O O
and O O
a O O
smaller O O
product O O
regulated O O
by O O
an O O
internal O O
promoter O O
( O O
dmDp186 B B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

Accordingly O O
, O O
infection O O
of O O
IFN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
pretreated O O
HeLa O O
S3 O O
cells O O
with O O
an O O
E3L O O
- O O
deficient O O
VV O O
( O O
VVDeltaE3L O O
) O O
resulted O O
in O O
increased O O
phosphorylation O O
levels O O
of O O
both O O
PKR B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
eIF2alpha B B_GENE
. O O

The O O
goal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
of O O
our O O
work O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
to O O
determine O O
hearing O O
thresholds O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
patients O B_PERSON/B_BIO
with O O
hearing O B_DISEASE
impairment O I_DISEASE
due O O
to O O
hereditary O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
motor O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
sensory O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
neuropathy O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
HMSN O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Influence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
dietary O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
supplementation O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
Streptococcus O B_LOCATION/B_BACTERIUM[BIO]
faecium O I_LOCATION/I_BACTERIUM[BIO]
M O I_LOCATION/I_BACTERIUM[BIO]
- O O
74 O B_NUMBER[MEASURE]
on O O
broiler O B_MEASURE/B_BIO
body O B_MEASURE/I_BIO
weight O B_MEASURE/I_BIO
, O O
feed O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
conversion O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O O
carcass O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
characteristics O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
, O O
and O O
intestinal O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
microbial O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
colonization O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
reveal O O
preferences O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
particular O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
initiating O O
nucleotides O B_LOCATION/B_BIO
( O O
ATP O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
> O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
= O O
GTP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
> O O
UTP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
> O O
> O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
CTP O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
) O O
and O O
for O O
starting O O
positions O B_LOCATION
downstream O I_LOCATION
of O O
the O O
Pribnow O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
box O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
7 O B_MEASURE
> O I_MEASURE
> O I_MEASURE
6 O I_MEASURE
and O O
8 O B_MEASURE/B_LOCATION
> O I_MEASURE/I_LOCATION
9 O I_MEASURE/I_LOCATION
> O I_MEASURE/I_LOCATION
10 O I_MEASURE/I_LOCATION
) O O
. O O

Trimethylcolchicinic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
methyl O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ether O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
d O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
tartrate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
TMCA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
; O O
NSC O B_LOCATION/B_PROTEIN[GENE]
- O O
36351 O B_MEASURE
) O O
was O O
administered O O
daily O O
by O O
mouth O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
71 O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
patients O I_PERSON/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
malignant O B_DISEASE/B_LOCATION
lymphomas O I_DISEASE/I_LOCATION
. O O

Gene O B_PERSON
transcripts O I_PERSON
are O O
detected O O
on O O
tissues O B_DISEASE/B_LOCATION
such O B_DISEASE/I_LOCATION
as O O
bovine O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
liver O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
kidney O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O O
lung O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
and O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Assessment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
ammonia O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
urea O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
content O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
metabolic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
base O B_DISEASE/B_ORGANISM_FUNCTION
disorders O I_DISEASE/I_ORGANISM_FUNCTION
in O O
white O B_BIO/B_PERSON
rats O I_BIO/I_PERSON
. O O

The O O
immediate O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
remote O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
surgical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
renal O B_DISEASE
adenocarcinomas O I_DISEASE
. O O

Vibrio O O
cholerae O O
iron O O
transport O O
: O O
haem O O
transport O O
genes O O
are O O
linked O O
to O O
one O O
of O O
two O O
sets O O
of O O
tonB B B_GENE/B_BACTERIUM[BIO]
, O O
exbB B B_PROTEIN[GENE]/B_LOCATION
, O O
exbD B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
predicted O O
amino O O
- O O
acid O O
sequence O O
includes O O
an O O
N O O
- O O
terminal O O
signal O O
sequence O O
of O O
27 O O
amino O O
acids O O
, O O
a O O
27 O O
amino O O
- O O
acid O O
pro O O
- O O
region O O
, O O
a O O
251 O O
amino O O
- O O
acid O O
catalytic O O
domain O O
typical O O
of O O
a O O
serine B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protease I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
trypsin B B_ENZYME[GENE]
- O O
like O O
specificity O O
, O O
and O O
a O O
C O O
- O O
terminal O O
hydrophobic O O
extension O O
which O O
is O O
predicted O O
to O O
function O O
as O O
a O O
membrane O O
anchor O O
. O O

To O O
examine O O
the O O
biochemical O O
mechanism O O
of O O
Tax1 B B_GENE/B_ORGANIZATION
transactivation O O
, O O
we O O
have O O
developed O O
an O O
in O O
vitro O O
transactivation O O
assay O O
in O O
which O O
wild O O
- O O
type O O
Tax1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
able O O
to O O
specifically O O
transactivate O O
a O O
polymerase B B_GENE/B_SPECIES[BIO]
II I B_GENE/I_SPECIES[BIO]
promoter O O
through O O
upstream O O
Tax1 B B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
responsive I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
elements I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
. O O

Interestingly O O
, O O
PMA O O
- O O
, O O
PDGF B B_GENE
- O O
, O O
and O O
serum O O
- O O
induced O O
GHR B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteolysis O O
was O O
associated O O
with O O
substantial O O
decreases O O
in O O
GH B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
activation O O
of O O
Janus B B_GENE
kinase I I_GENE
- I I_GENE
2 I I_GENE
, O O
which O O
were O O
also O O
prevented O O
by O O
IC3 O O
. O O

Thus O O
, O O
IF O O
- O O
laser O O
therapy O O
has O O
a O O
certain O O
antioxidative O O
effect O O
by O O
increasing O O
SOD B B_GENE
activity O O
in O O
RA O O
patients O O
' O O
blood O O
cells O O
and O O
reducing O O
the O O
production O O
of O O
highly O O
reactive O O
oxygen O O
and O O
nitrogen O O
forms O O
. O O

Reactive O O
mesothelial O O
cells O O
, O O
usually O O
seen O O
as O O
exfoliated O O
cells O O
, O O
were O O
consistently O O
strongly O O
positive O O
for O O
alpha B B_GENE
1 I I_GENE
- I I_GENE
antichymotrypsin I I_GENE
and O O
more O O
variably O O
for O O
alpha B B_GENE
1 I I_GENE
- I I_GENE
antitrypsin I I_GENE
and O O
lysozyme B B_GENE
. O O

Recombinant O O
propeptides O O
containing O O
mutations O O
of O O
one O O
of O O
the O O
three O O
tryptophan O O
residues O O
were O O
three O O
orders O O
of O O
magnitude O O
less O O
effective O O
as O O
inhibitors O O
of O O
mature B B_ENZYME[GENE]
cathepsin I I_ENZYME[GENE]
S I I_ENZYME[GENE]
than O O
the O O
wild O O
- O O
type O O
propeptide O O
. O O

The O O
highest O B_MEASURE/B_DISEASE
incidence O I_MEASURE/I_DISEASE
was O O
observed O O
for O O
V O B_OTHER/B_PROTEIN[GENE]
. O O
alginolyticus O B_BACTERIUM[BIO]/B_DISEASE
( O O
92 O B_MEASURE
- O O
100 O B_MEASURE
% O I_MEASURE
) O O
, O O
followed O O
by O O
V O B_OTHER/B_MEASURE
. O O
parahaemolyticus O B_BACTERIUM[BIO]/B_DISEASE
( O O
67 O B_MEASURE
- O O
92 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
, O O
V O B_OTHER/B_LOCATION
. O O
fluvialis O B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
( O O
34 O B_MEASURE
- O O
67 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
, O O
V O B_OTHER/B_DISEASE
. O O
vulnificus O B_BACTERIUM[BIO]/B_DISEASE
( O O
8 O B_MEASURE
- O O
17 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
, O O
V O B_OTHER/B_LOCATION
. O O
furnissii O B_BACTERIUM[BIO]/B_DISEASE
( O O
0 O B_MEASURE
- O O
17 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
, O O
V O B_OTHER/B_MEASURE
. O O
mimicus O B_BACTERIUM[BIO]/B_DISEASE
( O O
0 O B_MEASURE
- O O
17 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
and O O
V O B_OTHER/B_MEASURE
. O O
cholerae O B_BACTERIUM[BIO]/B_DISEASE
non O I_BACTERIUM[BIO]/I_DISEASE
- O O
O1 O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
( O O
0 O B_MEASURE
- O O
8 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
. O O

Acute O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
morphine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
did O O
not O O
increase O O
the O O
locomotor O B_MEASURE
activity O I_MEASURE
of O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
withdrawn O O
for O O
1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
day O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
after O O
withdrawal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
3 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
the O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
that O O
in O O
controls O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
and O O
after O O
5 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
days O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
the O O
increase O B_DISEASE_ADJECTIVE[DISEASE]
was O O
clearly O O
larger O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O O
in O O
controls O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
patients O O
with O O
active O O
TB O O
, O O
cytokines O O
that O O
were O O
elevated O O
in O O
serum O O
were O O
IFN B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gamma I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
IL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
IL B B_GENE
- I I_GENE
10 I I_GENE
. O O

Isolation O O
and O O
properties O O
of O O
Drosophila B B_GENE
melanogaster I I_GENE
ferritin I I_GENE
- O O
- O O
molecular O O
cloning O O
of O O
a O O
cDNA O O
that O O
encodes O O
one O O
subunit O O
, O O
and O O
localization O O
of O O
the O O
gene O O
on O O
the O O
third O O
chromosome O O
. O O

We O O
show O O
that O O
Fos B B_GENE
down O O
regulates O O
several O O
immediate B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
early I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
genes I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
c B B_GENE
- I I_GENE
fos I I_GENE
, O O
Egr B B_GENE
- I I_GENE
1 I I_GENE
, O O
and O O
Egr B B_GENE
- I I_GENE
2 I I_GENE
) O O
after O O
mitogenic O O
stimulation O O
. O O

This O O
study O O
demonstrates O O
a O O
novel O O
link O O
between O O
alterations O O
in O O
platelet B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
derived I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PDGF B B_GENE/B_LOCATION
) O O
regulation O O
of O O
ornithine B B_ENZYME[GENE]
decarboxylase I I_ENZYME[GENE]
( O O
ODC B B_GENE/B_DISEASE
) O O
expression O O
during O O
malignant O O
conversion O O
. O O

Circulating O O
immune O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
complexes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
determined O O
by O O
the O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
phagocytosis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
immunofluorescence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

The O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IFI16 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
member O O
of O O
an O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
inducible O O
family O O
of O O
mouse O O
and O O
human O O
genes O O
closely O O
linked O O
on O O
syntenic O O
regions O O
of O O
chromosome O O
1 O O
. O O

In O O
agreement O O
with O O
this O O
model O O
, O O
elimination O O
of O O
the O O
ADAM13 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytoplasmic I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
increased O O
developmental O O
alterations O O
attributable O O
to O O
ADAM13 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
proteolytic O O
activity O O
. O O

Diabetic O B_DISEASE_ADJECTIVE[DISEASE]
osteopathy O I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
third O O
GEF B B_GENE/B_LOCATION
, O O
GRP3 B B_GENE
( O O
KIAA0846 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
activated O O
both O O
Ras B B_GENE/B_DISEASE
and O O
Rap1 B B_GENE
and O O
shared O O
significant O O
sequence O O
homology O O
with O O
the O O
calcium O O
- O O
and O O
diacylglycerol O O
- O O
activated O O
GEFs B B_GENE/B_ORGANIZATION
, O O
GRP1 B B_GENE
and O O
GRP2 B B_GENE
. O O

A O O
new O O
simple O O
identification O O
of O O
rheumatoid B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I B_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
nitrocellulose O O
was O O
developed O O
that O O
allows O O
quantitative O O
detection O O
. O O

Comparisons O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
defective O B_DISEASE/B_GENE
HTLV O B_DISEASE/I_GENE
- O O
I O O
proviruses O B_BIO/B_GENE
predict O O
the O O
mode O B_LOCATION
of O O
origin O B_TIME[MEASURE]/B_DISEASE
and O O
coding O B_MEASURE/B_PERSON
potential O I_MEASURE/I_PERSON
of O O
internally O O
deleted O O
genomes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Reversal O O
of O O
biliary O O
sphincter O O
spasm O O
with O O
low O O
dose O O
glucagon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
operative O O
cholangiography O O
. O O

Previous O O
studies O O
have O O
shown O O
that O O
the O O
IME1 B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
required O O
for O O
sporulation O O
and O O
the O O
expression O O
of O O
meiosis O O
specific O O
genes O O
in O O
Saccharomyces O O
cerevisiae O O
. O O

A O O
case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
comparison O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
acquired O O
immune O B_DISEASE
deficiency O I_DISEASE
syndrome O I_DISEASE
( O O
AIDS O B_DISEASE
) O O
in O O
homosexual O B_PERSON/B_BIO
males O I_PERSON/I_BIO
with O O
spindle O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
- O O
endothelial O B_DISEASE_ADJECTIVE[DISEASE]
cell O I_DISEASE_ADJECTIVE[DISEASE]
abnormalities O I_DISEASE_ADJECTIVE[DISEASE]
and O O
with O O
recrudescent O B_DISEASE/B_PERSON
melioidosis O I_DISEASE/I_PERSON
. O O

Intrathecal O O
injections O O
of O O
small O O
volumes O O
of O O
the O O
alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
adrenoceptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
agonists O O
, O O
xylazine O O
and O O
clonidine O O
, O O
into O O
the O O
cervical O O
region O O
of O O
the O O
spinal O O
cord O O
of O O
conscious O O
unrestrained O O
sheep O O
produced O O
a O O
dose O O
- O O
dependent O O
analgesia O O
of O O
the O O
forelimbs O O
as O O
measured O O
using O O
a O O
mechanical O O
pressure O O
device O O
. O O

Second O O
, O O
CGGA O O
- O O
containing O O
sequences O O
placed O O
at O O
- O O
88 O O
in O O
the O O
delta B B_GENE/B_PERSON
MTV I I_GENE/I_PERSON
- I I_GENE/I_PERSON
CAT I I_GENE/I_PERSON
reporter I I_GENE/I_PERSON
plasmid O O
conferred O O
insulin B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responsiveness O O
to O O
the O O
mammary B B_GENE/B_DISEASE
tumor I I_GENE/I_DISEASE
virus I I_GENE/I_DISEASE
promoter I I_GENE/I_DISEASE
. O O

In O O
the O O
absence O O
of O O
c B B_GENE
- I I_GENE
fos I I_GENE
gene I I_GENE
expression O O
, O O
c B B_GENE
- I I_GENE
Fos I I_GENE
protein I I_GENE
appears O O
to O O
be O O
replaced O O
by O O
proteins O O
of O O
Fos B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
family I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Fra B B_PROTEIN[GENE]/B_LOCATION
- I I_PROTEIN[GENE]/I_LOCATION
1 I I_PROTEIN[GENE]/I_LOCATION
) O O
and O O
ATF B B_PERSON/B_GENE
family I I_PERSON/I_GENE
( O O
ATF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
ATFa B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

The O O
dopamine B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D1 I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dopamine I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonist O O
SCH O O
23390 O O
dose O O
dependently O O
( O O
7 O O
. O O
5 O O
- O O
30 O O
micrograms O O
/ O O
kg O O
s O O
. O O
c O O
. O O
) O O
antagonized O O
the O O
stimulant O O
locomotor O O
effect O O
on O O
both O O
drugs O O
but O O
did O O
not O O
prevent O O
their O O
antiimmobility O O
effect O O
on O O
the O O
behavioral O O
despair O O
test O O
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
obtained O O
show O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
expression O B_GENE
of O O
the O O
gene O B_GENE
is O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
at O O
23 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
and O O
is O O
induced O O
rapidly O O
at O O
37 O B_TIME[MEASURE]/B_LOCATION
degrees O I_TIME[MEASURE]/I_LOCATION
C O I_TIME[MEASURE]/I_LOCATION
. O O

Characterization O O
of O O
Chlamydomonas O O
reinhardtii O O
zygote O O
- O O
specific O O
cDNAs O O
that O O
encode O O
novel O O
proteins O O
containing O O
ankyrin B B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
repeats O O
and O O
WW O O
domains O O
. O O

Adenomas O B_DISEASE
in O O
the O O
upper O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
gastrointestinal O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
tract O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O O
found O O
in O O
all O O
of O O
the O O
patients O B_PERSON/B_BIO
: O O
Vater O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
' O O
s O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
papilla O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
- O O
- O O
12 O B_NUMBER[MEASURE]
, O O
duodenum O B_BODY_PART_OR_ORGAN_COMPONENT
- O O
- O O
nine O B_NUMBER[MEASURE]
, O O
and O O
gastric O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
antrum O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
- O O
- O O
seven O B_NUMBER[MEASURE]
. O O

Microenvironments O B_LOCATION/B_ORGANIZATION
dominated O O
by O O
cyanobacteria O B_BIO
( O O
BPC O B_PROTEIN[GENE]/B_LOCATION
) O O
had O O
a O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
pH O O
( O O
pH O O
7 O B_MEASURE
- O O
8 O B_MEASURE
) O O
than O O
those O O
dominated O O
by O O
lichen O B_SPECIES[BIO]/B_DISEASE
( O O
LTL O B_LOCATION/B_PROTEIN[GENE]
) O O
( O O
pH O B_MEASURE
4 O I_MEASURE
. O O
5 O B_MEASURE
- O O
5 O B_MEASURE
. O O
5 O B_MEASURE
) O O
. O O

A O O
total O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
64 O B_MEASURE
uncomplicated O I_MEASURE
Type O I_MEASURE
- O O
2 O B_PERSON/B_MEASURE
diabetic O I_PERSON/I_MEASURE
individuals O I_PERSON/I_MEASURE
of O O
higher O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
middle O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
class O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O O
rich O B_DISEASE/B_MEASURE
socio O I_DISEASE/I_MEASURE
- O O
economic O B_MEASURE/B_LOCATION
status O B_MEASURE/I_LOCATION
were O O
studied O O
. O O

A O O
drop O B_DISEASE/B_LOCATION
of O O
methylprednisolone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
vehicle O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
constituent O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
placed O O
on O O
the O O
dissected O O
plantar O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
nerve O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
proximal O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
to O O
the O O
stimulating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
electrodes O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
after O O
recording O O
control O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
responses O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
A O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
fibre O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
volley O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
sciatic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nerve O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
C O B_PROTEIN[GENE]/B_MEASURE
- O O
fibre O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
evoked O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
reflex O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
discharge O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
flexor O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
motoneurons O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
) O O
. O O

Basic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
helix I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
loop I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
helix I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O O
act O O
at O O
the O O
E O O
- O O
box O O
within O O
the O O
serum O O
response O O
element O O
of O O
the O O
c B B_GENE
- I I_GENE
fos I I_GENE
promoter I I_GENE
to O O
influence O O
hormone O O
- O O
induced O O
promoter O O
activation O O
in O O
Sertoli O O
cells O O
. O O

Using O O
yeast O O
two O O
- O O
hybrid O O
screening O O
, O O
we O O
isolated O O
histone B B_GENE
H3 I I_GENE
as O O
an O O
interacting O O
factor O O
of O O
CIA B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Concentrations O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
Co O B_LOCATION
, O O
Cu O B_LOCATION/B_TIME[MEASURE]
, O O
Fe O B_LOCATION/B_MEASURE
, O O
Hg O B_LOCATION
, O O
Mn O B_LOCATION/B_PERSON
, O O
Sb O B_LOCATION/B_PERSON
, O O
Se O B_LOCATION/B_PERSON
and O O
Zn O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
IAEA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
milk O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
dry O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
) O O
standard O B_MEASURE/B_LOCATION
A O I_MEASURE/I_LOCATION
- O O
11 O B_MEASURE/B_LOCATION
were O O
re O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
evaluated O O
with O O
the O O
help O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
instrumental O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
radiochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
neutron O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
activation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
( O O
NAA O B_LOCATION/B_DISEASE
) O O
. O O

Gallstone O B_DISEASE
- O O
formation O B_DISEASE
has O O
traditionally O O
been O O
attributed O O
to O O
supersaturation O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
bile O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
with O O
cholesterol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Sixteen O B_TIME[MEASURE]/B_LOCATION
patients O I_TIME[MEASURE]/I_LOCATION
on O O
maintenance O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hemodialysis O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
underwent O O
dialysis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
either O O
cuprophane O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
n O B_MEASURE/B_PROTEIN[GENE]
= O O
8 O B_MEASURE
) O O
or O O
polymethylmethacrylate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PMMA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
; O O
n O O
= O O
8 O B_MEASURE
) O O
membranes O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
for O O
1 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
week O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
then O O
switched O O
to O O
the O O
opposite O B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
membrane O I_LOCATION/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
during O O
the O O
second O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
week O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Gene O O
expression O O
is O O
in O O
part O O
controlled O O
by O O
chromatin O O
remodeling O O
factors O O
and O O
the O O
acetylation O O
state O O
of O O
nucleosomal B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
histones I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Each O O
patient O B_PERSON/B_ORGANIZATION
was O O
seen O O
for O O
5 O B_NUMBER[MEASURE]/B_LOCATION
to O O
13 O B_MEASURE
postsurgical O I_MEASURE
maintenance O I_MEASURE
visits O I_MEASURE
. O O

Furthermore O O
, O O
Grap B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
associated O O
with O O
a O O
Ras B B_GENE
guanine I I_GENE
nucleotide I I_GENE
exchange I I_GENE
factor I I_GENE
mSos1 B I_GENE
, O O
primarily O O
through O O
its O O
N B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
terminal I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
SH3 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
domain I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Recurrent O B_DISEASE/B_MEASURE
infections O I_DISEASE/I_MEASURE
, O O
episodic O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lymphopenia O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
impaired O B_DISEASE
cellular O I_DISEASE
immunity O I_DISEASE
. O O

After O O
3 O O
months O O
of O O
intervention O O
, O O
sustained O O
physical O O
training O O
was O O
associated O O
with O O
the O O
decrease O O
of O O
FVII B B_GENE/B_DISEASE
and O O
PAI B B_GENE
- I I_GENE
1 I I_GENE
levels O O
. O O

Thirty O B_NUMBER[MEASURE]
- O O
three O B_NUMBER[MEASURE]
percent O I_NUMBER[MEASURE]
had O O
elevated O O
titers O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
above O O
1 O B_MEASURE
: O O
20 O B_MEASURE
dilution O I_MEASURE
) O O
. O O

Xa4 B B_GENE/B_DISEASE
is O O
a O O
dominantly O O
inherited O O
rice O O
gene O O
that O O
confers O O
resistance O O
to O O
Philippine O O
race O O
1 O O
of O O
the O O
bacterial O O
blight O O
pathogen O O
Xanthomonas O O
oryzae O O
pv O O
. O O
oryzae O O
in O O
rice O O
. O O

In O O
uraemic O B_MEASURE/B_LOCATION
patients O I_MEASURE/I_LOCATION
, O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
maximum O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
serum O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
concentrations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
found O O
after O O
a O O
single O B_MEASURE
7 O I_MEASURE
. O O
5 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
iv O I_MEASURE
dose O I_MEASURE
. O O

The O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
buthionine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfoximine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
BSO O B_LOCATION/B_DISEASE
) O O
and O O
disulfiram O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
( O O
DSF O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
on O O
the O O
urotoxicity O B_DISEASE
induced O O
by O O
cyclophosphamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CPA O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
was O O
examined O O
in O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

All O O
the O O
previously O O
mapped O O
structural O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
encoding O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
phage O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
LL O I_PROTEIN[GENE]/I_BACTERIUM[BIO]
- O O
H O B_MEASURE/B_OTHER
were O O
included O O
in O O
the O O
sequence O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

When O O
a O O
longer O O
- O O
714 O O
to O O
+ O O
78 O O
fragment O O
of O O
the O O
PBGD B B_GENE
promoter I I_GENE
is O O
used O O
, O O
the O O
- O O
70 O O
GATA O O
mutant O O
still O O
displays O O
erythroid O O
- O O
specific O O
activity O O
and O O
is O O
cis O O
- O O
activated O O
by O O
the O O
5 B B_GENE
' I I_GENE
HS I I_GENE
- I I_GENE
2 I I_GENE
enhancer I I_GENE
, O O
while O O
the O O
- O O
100 O O
CCACC O O
mutant O O
is O O
completely O O
inactive O O
in O O
the O O
absence O O
or O O
in O O
the O O
presence O O
of O O
the O O
5 B B_GENE
' I I_GENE
HS I I_GENE
- I I_GENE
2 I I_GENE
enhancer I I_GENE
. O O

Surprisingly O O
, O O
in O O
adult O O
animals O O
, O O
the O O
suprabasal O O
expression O O
of O O
dnRXR B B_GENE
alpha I I_GENE
significantly O O
reduced O O
the O O
ability O O
of O O
topically O O
applied O O
tRA O O
to O O
stimulate O O
proliferation O O
of O O
undifferentiated O O
keratinocytes O O
in O O
the O O
basal O O
layer O O
of O O
epidermis O O
. O O

In O O
many O B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
other O B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
contractile O B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
protein O B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
gene O B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
families O B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
, O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
encoding O O
cardiac O B_GENE/B_PERSON
isoforms O I_GENE/I_PERSON
are O O
expressed O O
early O O
in O O
skeletal O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
muscle O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
development O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
and O O
are O O
later O O
repressed O B_DISEASE_ADJECTIVE[DISEASE]
. O O

1995 O B_NUMBER[MEASURE]
. O O

For O O
il8ra B B_GENE
, O O
it O O
is O O
formed O O
from O O
two O O
exons O O
, O O
whereas O O
for O O
il8rb B B_GENE
, O O
seven O O
distinct O O
neutrophil O O
mRNAs O O
are O O
formed O O
by O O
alternative O O
splicing O O
of O O
11 O O
exons O O
. O O

Endocarditis O B_DISEASE/B_GENE
remains O O
a O O
life O B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
threatening O O
disease O B_DISEASE
with O O
substantial O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
morbidity O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
mortality O B_DISEASE/B_MEASURE
. O O

The O O
gene O O
encoding O O
the O O
cellulase B B_ENZYME[GENE]/B_BACTERIUM[BIO]
( O O
Avicelase B B_LOCATION/B_BIO
) O O
Cel1 B B_ENZYME[GENE]/B_LOCATION
from O O
Streptomyces O O
reticuli O O
and O O
analysis O O
of O O
protein O O
domains O O
. O O

From O O
this O O
comparison O O
of O O
aa O O
sequences O O
, O O
the O O
ATPK7 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
considered O O
to O O
be O O
a O O
member O O
of O O
a O O
novel O O
subfamily O O
of O O
Ser B B_GENE/B_BIO
/ I I_GENE/I_BIO
Thr I I_GENE/I_BIO
PKs I I_GENE/I_BIO
in O O
plants O O
. O O

Of O O
these O O
, O O
23 O B_MEASURE
( O O
13 O B_MEASURE
. O O
6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
were O O
due O B_DISEASE_ADJECTIVE[DISEASE]
to O O
GIB O B_DISEASE/B_PERSON
( O O
Upper O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
GIB O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
= O O
19 O B_MEASURE
, O O
Lower O B_MEASURE/B_LOCATION
GIB O I_MEASURE/I_LOCATION
= O O
4 O B_MEASURE
) O O
. O O

The O O
E O B_OTHER/B_GENE
. O O
multilocularis O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
Mongolian O B_SPECIES[BIO]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
gerbil O I_SPECIES[BIO]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
system O I_SPECIES[BIO]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
can O O
replace O O
the O O
natural O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
canid O B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
hosts O B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
as O O
a O O
new O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
way O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
obtain O O
infective O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
eggs O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and O O
to O O
analyze O O
host O B_SPECIES[BIO]
- O O
parasite O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactions O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

E1 B B_GENE/B_NUMBER[MEASURE]
recognition O O
sequences O O
in O O
the O O
bovine O O
papillomavirus O O
type O O
1 O O
origin O O
of O O
DNA O O
replication O O
: O O
interaction O O
between O O
half O O
sites O O
of O O
the O O
inverted O O
repeats O O
. O O

We O O
found O O
that O O
secretion O O
of O O
chitinolytic O O
enzymes O O
by O O
cultured O O
L O O
. O O
major O O
parasites O O
is O O
inhibited O O
by O O
blood O O
or O O
hemoglobin B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
hence O O
these O O
enzymes O O
are O O
apparently O O
absent O O
from O O
the O O
blood O O
- O O
fed O O
infected O O
flies O O
, O O
where O O
the O O
cardiac O O
valve O O
appears O O
undamaged O O
. O O

Patients O O
in O O
the O O
mucinous O O
cyst O O
group O O
had O O
significantly O O
lower O O
CA B B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
125 I I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
cystic O O
fluid O O
levels O O
compared O O
with O O
women O O
with O O
endometriomas O O
and O O
dermoids O O
( O O
P O O
& O O
lt O O
; O O
0 O O
. O O
05 O O
) O O
. O O

SATB1 B B_GENE
interacted O O
with O O
CDP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
through O O
its O O
DNA O O
- O O
binding O O
domain O O
, O O
as O O
demonstrated O O
by O O
glutathione B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
S I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
transferase I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
GST B B_LOCATION/B_GENE
) O O
pull O O
- O O
down O O
assays O O
. O O

Plasma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
prolactin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
concentrations O O
in O O
pinealectomized O O
ewes O O
receiving O O
melatonin O O
treatment O O
and O O
in O O
pineal O O
intact O O
ewes O O
maintained O O
under O O
a O O
non O O
- O O
24 O O
- O O
hour O O
photoperiod O O
. O O

It O O
is O O
targeted O O
to O O
peroxisomes O B_BIO/B_GENE
when O O
expressed O O
in O O
mammalian O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
yeast O B_BIO
. O O

The O O
transcriptional O O
start O O
site O O
, O O
identified O O
by O O
primer O O
extension O O
and O O
S1 B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nuclease I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay O O
, O O
is O O
34 O O
nt O O
upstream O O
of O O
the O O
translation O O
initiation O O
codon O O
. O O

Nonlinearities O B_DISEASE_ADJECTIVE[DISEASE]
in O O
cochlear O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
hydrodynamics O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
. O O

Electronic O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
structure O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
and O O
optical O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
B12O2 O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
crystal O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

Spongiosa O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
regeneration O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
the O O
millipore O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
chamber O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE

The O O
predicted O O
5 O O
' O O
and O O
3 O O
' O O
ends O O
of O O
the O O
transcript O O
are O O
in O O
very O O
good O O
agreement O O
with O O
the O O
previously O O
determined O O
size O O
of O O
the O O
LEU3 B B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
message O O
. O O

This O O
cDNA O O
corresponded O O
to O O
FGF B B_GENE
- I I_GENE
binding I I_GENE
protein I I_GENE
( O O
FGF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BP I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
a O O
secreted O O
protein O O
previously O O
shown O O
to O O
bind O O
acidic O O
and O O
basic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
FGF I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
to O O
modulate O O
their O O
activities O O
. O O

Analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
replicative O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
intermediates O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
shows O O
that O O
plasmid O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
YRp7 O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
contains O O
the O O
chromosomal O B_GENE/B_LOCATION
replicator O I_GENE/I_LOCATION
ARS1 O I_GENE/I_LOCATION
, O O
initiates O O
bidirectional O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
replication O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
a O O
100 O B_LOCATION
bp O I_LOCATION
region O I_LOCATION
within O O
the O O
sequence O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
required O O
for O O
autonomous O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
replication O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
. O O

Such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
suggest O O
that O O
there O O
are O O
no O O
differences O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
BMR O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
age O B_MEASURE/B_PERSON
- O O
and O O
weight O B_MEASURE/B_PERSON
- O O
matched O O
Asian O B_PERSON/B_LOCATION
Indian O I_PERSON/I_LOCATION
males O I_PERSON/I_LOCATION
, O O
other O B_PERSON/B_LOCATION
tropical O I_PERSON/I_LOCATION
populations O I_PERSON/I_LOCATION
and O O
Americans O B_PERSON/B_SPORT[ENT]
. O O

Rewarding O O
properties O O
of O O
methylphenidate O O
: O O
sensitization O O
by O O
prior O O
exposure O O
to O O
the O O
drug O O
and O O
effects O O
of O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
D1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
D2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antagonists O O
. O O

Similar O O
to O O
what O O
was O O
observed O O
for O O
P O O
. O O
putida O O
, O O
a O O
psrA B B_BACTERIUM[BIO]/B_GENE
null O O
mutant O O
of O O
P O O
. O O
aeruginosa O O
also O O
showed O O
a O O
90 O O
% O O
reduction O O
in O O
rpoS B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
; O O
both O O
mutants O O
could O O
be O O
complemented O O
for O O
rpoS B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
promoter I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activity O O
when O O
the O O
psrA B B_GENE/B_BACTERIUM[BIO]
gene I I_GENE/I_BACTERIUM[BIO]
was O O
provided O O
in O O
trans O O
. O O

psrA B B_PERSON/B_BIO
mutants I I_PERSON/I_BIO
of O O
both O O
Pseudomonas O O
species O O
lost O O
the O O
ability O O
to O O
induce O O
rpoS B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
at O O
stationary O O
phase O O
, O O
but O O
they O O
retained O O
the O O
ability O O
to O O
produce O O
quorum O O
- O O
sensing O O
autoinducer O O
molecules O O
. O O

The O O
role O O
of O O
the O O
putative O O
C2 B B_MEASURE/B_PROTEIN[GENE]
domain O O
of O O
Nedd4 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
not O O
been O O
elucidated O O
. O O

ZF87 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specifically O O
binds O O
the O O
ME1a1 O O
element O O
with O O
higher O O
affinity O O
than O O
the O O
ME1a2 O O
element O O
. O O

We O O
found O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
thromboxane O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
evidenced O O
by O O
the O O
major O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
urinary O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
metabolite O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
3 O B_MEASURE
- O O
dinorthromboxane O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
B2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
in O O
the O O
oestrogen O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
group O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
as O O
compared O O
to O O
the O O
orchidectomy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Multivariable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
logistic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
regression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
showed O O
that O O
mean O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
blood O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
glucose O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
level O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
for O O
the O O
first O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
2 O I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
days O I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
p O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
002 O B_MEASURE
) O O
, O O
obesity O B_TIME[MEASURE]/B_DISEASE
( O O
p O B_MEASURE/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
002 O B_MEASURE
) O O
, O O
and O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
internal O B_DISEASE_ADJECTIVE[DISEASE]/B_MEDICAL_DEVICE[OBJECT]
mammary O B_DISEASE_ADJECTIVE[DISEASE]/I_MEDICAL_DEVICE[OBJECT]
artery O B_DISEASE_ADJECTIVE[DISEASE]/I_MEDICAL_DEVICE[OBJECT]
( O O
p O B_MEASURE/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
02 O B_MEASURE
) O O
were O O
all O O
independent O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
predictors O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
deep O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
wound O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infection O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

However O O
the O O
precise O O
function O O
of O O
DNA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PK I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
DNA O O
double O O
- O O
strand O O
break O O
repair O O
is O O
not O O
known O O
. O O

This O O
new O O
receptor O O
, O O
TOR B B_GENE/B_DISEASE
( O O
thymus B B_PROTEIN[GENE]/B_MEASURE
orphan I I_PROTEIN[GENE]/I_MEASURE
receptor I I_PROTEIN[GENE]/I_MEASURE
) O O
, O O
is O O
most O O
closely O O
related O O
in O O
both O O
its O O
DNA O O
- O O
binding O O
domain O O
and O O
ligand O O
- O O
binding O O
domain O O
, O O
90 O O
% O O
and O O
53 O O
% O O
, O O
respectively O O
, O O
to O O
ROR B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
RZR B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
clusters O O
with O O
these O O
two O O
receptors O O
and O O
RZR B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
beta I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
a O O
phylogenetic O O
tree O O
, O O
when O O
both O O
the O O
DNA O O
- O O
binding O O
domain O O
and O O
the O O
ligand O O
- O O
binding O O
domain O O
sequences O O
of O O
nuclear O O
receptors O O
are O O
compared O O
. O O

In O O
this O O
report O O
, O O
we O O
have O O
examined O O
whether O O
PTP1B B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
effects O O
transformation O O
induced O O
by O O
p210 B B_GENE/B_LOCATION
bcr B I_GENE/I_LOCATION
- O O
abl B B_GENE/B_DISEASE
. O O

S1 B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nuclease I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O O
of O O
the O O
RNA O O
from O O
a O O
number O O
of O O
QT6 O O
- O O
LD O O
clones O O
gave O O
similar O O
results O O
, O O
indicating O O
that O O
the O O
LD O O
population O O
was O O
composed O O
of O O
viruses O O
with O O
similar O O
but O O
not O O
identical O O
deletion O O
endpoints O O
. O O

Association O O
of O O
Smads B B_GENE
with O O
lymphoid B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
enhancer I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
binding I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factor I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
1 I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
/ O O
T B B_MEASURE/B_GENE
cell I I_MEASURE/I_GENE
- I I_MEASURE/I_GENE
specific I I_MEASURE/I_GENE
factor I I_MEASURE/I_GENE
mediates O O
cooperative O O
signaling O O
by O O
the O O
transforming B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
wnt B B_GENE
pathways O O
. O O

The O O
three O O
OAS B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
flanked O O
by O O
markers B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
WI I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10614 I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
cen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
and O O
D12S2293 B B_GENE/B_MEASURE
( O O
tel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
and O O
are O O
contained O O
within O O
three O O
sets O O
of O O
overlapping O O
cosmid O O
clones O O
. O O

22 O O
. O O
6 O O
% O O
of O O
patients O O
were O O
found O O
to O O
be O O
positive O O
at O O
histology O O
in O O
the O O
corpus O O
mucosa O O
; O O
all O O
but O O
one O O
of O O
these O O
patients O O
had O O
elevated O O
circulating O O
IgG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
H O O
. O O
pylori O O
( O O
Group O O
C O O
) O O
. O O

Rottlerin O O
also O O
inhibited O O
the O O
activation O O
of O O
MAP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MEK B B_GENE/B_LOCATION
) O O
in O O
response O O
to O O
activated O O
Raf B B_GENE/B_DISEASE
, O O
but O O
had O O
no O O
effect O O
upon O O
c B B_GENE
- I I_GENE
Raf I I_GENE
activity O O
or O O
ERK B B_GENE/B_DISEASE
activation O O
by O O
activated O O
MEK B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Quasidiatomic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Ly O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
alpha O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
producing O O
H2 O B_LOCATION
+ O O
- O O
Ne O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
collisions O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
at O O
keV O B_LOCATION/B_MEASURE
energies O I_LOCATION/I_MEASURE
. O O

The O O
NH O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
2 O B_MEASURE/B_LOCATION
) O O
- O O
terminus O B_LOCATION/B_MEASURE
of O O
all O O
three O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contains O O
a O O
POZ O B_MEASURE/B_PROTEIN[GENE]
domain O I_MEASURE/I_PROTEIN[GENE]
, O O
a O O
conserved O B_LOCATION
120 O I_LOCATION
amino O I_LOCATION
acid O I_LOCATION
motif O I_LOCATION
involved O O
in O O
transcriptional O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
repression O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
protein O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
dimerization O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
. O O

The O O
isolation O O
of O O
crt5 B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
262 I I_GENE/I_MEASURE
, O O
an O O
additional O O
cdc B B_GENE/B_PERSON
allele I I_GENE/I_PERSON
of O O
POL1 B B_GENE/B_DISEASE
/ O O
CDC17 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
suggests O O
for O O
the O O
first O O
time O O
that O O
directly O O
blocking O O
DNA O O
replication O O
can O O
provide O O
a O O
signal O O
to O O
induce O O
the O O
DNA O O
damage O O
response O O
. O O

crt2 B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
mutants I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
show O O
a O O
defect O O
in O O
basal O O
level O O
expression O O
of O O
RNR1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
lacZ B B_GENE
reporter O O
constructs O O
. O O

Greer O B_PERSON/B_COLOR
, O O
and O O
L O B_OTHER/B_PROTEIN[GENE]
. O O
A O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
prospectively O O
studied O O
serum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
prolactin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PRL B B_PROTEIN[GENE]/B_LOCATION
) O O
elevation O O
after O O
different O O
types O O
of O O
documented O O
seizures O O
in O O
17 O O
patients O O
. O O

However O O
, O O
both O O
peptides O O
1 O O
- O O
49 O O
and O O
63 O O
- O O
87 O O
bound O O
to O O
PDE B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
solid O O
- O O
phase O O
binding O O
assay O O
. O O

Values O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
K1 O B_PROTEIN[GENE]/B_LOCATION
and O O
Vd O B_DISEASE/B_PROTEIN[GENE]
were O O
significantly O O
increased O O
in O O
the O O
tumour O B_TIME[MEASURE]/B_DISEASE
tissue O I_TIME[MEASURE]/I_DISEASE
. O O

The O O
mutation O O
also O O
preferentially O O
limits O O
( O O
compared O O
with O O
total O O
protein O O
synthesis O O
) O O
translation O O
of O O
an O O
induced O O
gene O O
that O O
depends O O
on O O
five O O
AGA O O
codons O O
, O O
i O O
. O O
e O O
. O O
, O O
the O O
lambda B B_GENE/B_PERSON
cI I I_GENE/I_PERSON
repressor I I_GENE/I_PERSON
gene I I_GENE/I_PERSON
. O O

Five O O
RNA O O
transcripts O O
of O O
about O O
1 O O
. O O
2 O O
to O O
1 O O
. O O
7 O O
kilobases O O
were O O
mapped O O
to O O
a O O
part O O
of O O
the O O
genome O O
of O O
insect O O
iridescent O O
virus O O
type O O
6 O O
( O O
Chilo O O
iridescent O O
virus O O
; O O
CIV O O
) O O
between O O
genome O O
coordinates O O
0 O O
. O O
832 O O
and O O
0 O O
. O O
856 O O
within O O
the O O
EcoRI B B_GENE/B_SPECIES[BIO]
DNA I B_GENE/I_SPECIES[BIO]
fragment I B_GENE/I_SPECIES[BIO]
F I B_GENE/I_SPECIES[BIO]
. O O

Other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
similar O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
patients O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
must O O
be O O
found O O
before O O
it O O
is O O
established O O
that O O
the O O
colloid O B_DISEASE/B_BIO
cyst O I_DISEASE/I_BIO
is O O
part O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
nevoid O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
basal O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cell O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
carcinoma O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
syndrome O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Portions O O
of O O
the O O
3 O O
' O O
- O O
coding O O
and O O
3 O O
' O O
- O O
untranslated O O
regions O O
were O O
found O O
to O O
be O O
missing O O
from O O
the O O
7 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
8 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kb I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
topo I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNAs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
Northern O O
blot O O
analysis O O
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
a O O
double O B_DISEASE_ADJECTIVE[DISEASE]
mutant O I_DISEASE_ADJECTIVE[DISEASE]
( O O
E482A O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
D489A O B_MEASURE/B_PROTEIN[GENE]
) O O
which O O
removed O O
negative O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
charges O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
along O O
one O B_LOCATION/B_ENT
side O I_LOCATION/I_ENT
of O O
the O O
helix O B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
negligible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
fusion O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
activity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

A O O
GTP O O
/ O O
GDP O O
exchange O O
assay O O
was O O
used O O
to O O
assess O O
the O O
potential O O
role O O
of O O
Ras B B_GENE/B_DISEASE
in O O
the O O
pathway O O
leading O O
to O O
ERK B B_GENE
phosphorylation O O
; O O
DADLE O O
failed O O
to O O
stimulate O O
GTP O O
/ O O
GDP O O
exchange O O
in O O
comparison O O
to O O
PMA O O
. O O

Phenotypic O O
analysis O O
demonstrates O O
that O O
trio B B_GENE/B_ENT
and O O
Abl B B_GENE/B_PERSON
cooperate O O
in O O
regulating O O
axon O O
outgrowth O O
in O O
the O O
embryonic O O
central O O
nervous O O
system O O
( O O
CNS O O
) O O
. O O

Recombinant B B_PERSON/B_GENE
caspases I I_PERSON/I_GENE
are O O
typically O O
produced O O
in O O
Escherichia O O
coli O O
expression O O
systems O O
with O O
the O O
attendant O O
problems O O
of O O
solubilization O O
, O O
re O O
- O O
folding O O
and O O
activation O O
of O O
the O O
protease O O
. O O

The O O
gene O O
encoding O O
rat O O
peptidylglycine B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amidating I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monooxygenase I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PAM B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
contains O O
26 O O
protein O O
- O O
coding O O
exons O O
. O O

This O O
bound O O
[ O O
3H O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] O O
iloprost O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
with O O
high O B_GENE
affinity O I_GENE
and O O
stimulated O B_DISEASE_ADJECTIVE[DISEASE]
cAMP O I_DISEASE_ADJECTIVE[DISEASE]
production O I_DISEASE_ADJECTIVE[DISEASE]
when O O
exposed O O
to O O
agonist O O
. O O

Structure O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
connective O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
stroma O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
epididymis O B_BODY_PART_OR_ORGAN_COMPONENT
in O O
the O O
zebu O B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT

Free O O
protein B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
S I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
deficiency O O
in O O
acute O O
ischemic O O
stroke O O
. O O

In O O
a O O
series O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
papers O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
the O O
staging O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
for O O
melanoma O B_DISEASE
was O O
critically O O
analyzed O O
, O O
and O O
many O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shortcomings O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
identified O O
. O O

Reproduction O B_TIME[MEASURE]/B_PERSON
and O O
maternal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
of O O
the O O
rat O B_BIO/B_PERSON
when O O
thiamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
intake O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
is O O
limited O O
. O O

Total O B_MEASURE/B_LOCATION
meso O B_MEASURE/I_LOCATION
- O O
pore O B_MEASURE/B_LOCATION
volume O I_MEASURE/I_LOCATION
and O O
surface O B_MEASURE/B_LOCATION
area O I_MEASURE/I_LOCATION
ranged O O
from O O
0 O B_MEASURE/B_LOCATION
. O O
004 O B_MEASURE
- O O
0 O B_MEASURE
. O O
08 O B_MEASURE
cm3 O I_MEASURE
g O I_MEASURE
( O O
- O O
1 O B_MEASURE
) O O
and O O
from O O
0 O B_MEASURE
. O O
33 O B_MEASURE
- O O
6 O B_MEASURE
. O O
9 O B_MEASURE
m2 O I_MEASURE
g O I_MEASURE
( O O
- O O
1 O B_MEASURE
) O O
respectively O O
, O O
accounting O O
for O O
up O O
33 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
the O O
BET O B_MEASURE/B_LOCATION
surface O I_MEASURE/I_LOCATION
area O I_MEASURE/I_LOCATION
. O O

The O O
NF B B_GENE
- I I_GENE
kappa I I_GENE
B I I_GENE
precursor O O
p100 B B_GENE
( O O
lyt B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
10 I I_GENE/I_DISEASE
, O O
p97 B B_MEASURE/B_GENE
, O O
p98 B B_MEASURE/B_GENE
) O O
generates O O
after O O
proteolytic O O
processing O O
a O O
52 O O
kDa O O
subunit O O
, O O
which O O
can O O
bind O O
to O O
kappa B B_GENE
B I I_GENE
- I I_GENE
motifs I I_GENE
. O O

CONCLUSION O O
: O O
The O O
biodistribution O O
of O O
111In O O
IgG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O O
similar O O
to O O
that O O
of O O
99mTc O O
- O O
HMPAO O O
- O O
labeled O O
leukocytes O O
. O O

Based O O
on O O
29 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
determinations O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
glucose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
from O O
sinigrin O B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
analyzed O O
under O O
different O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
conditions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
accuracy O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
total O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucosinolate O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
determination O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
94 O B_MEASURE
. O O
8 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
7 O B_MEASURE
. O O
3 O B_MEASURE
% O I_MEASURE
. O O

Receptor B B_GENE/B_PERSON
- I I_GENE/I_PERSON
type I I_GENE/I_PERSON
serine I I_GENE/I_PERSON
/ I I_GENE/I_PERSON
threonine I I_GENE/I_PERSON
kinases I I_GENE/I_PERSON
( O O
RSKs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
have O O
been O O
organized O O
into O O
two O O
distinct O O
classes O O
known O O
as O O
types O O
I O O
and O O
II O O
on O O
the O O
basis O O
of O O
sequence O O
similarity O O
. O O

In O O
a O O
previous O O
study O O
of O O
transforming B B_GENE
growth I I_GENE
factor I I_GENE
- I I_GENE
beta1 I I_GENE
- O O
mediated O O
inhibition O O
of O O
the O O
cyclin B B_GENE
A I I_GENE
promoter I I_GENE
, O O
we O O
mapped O O
the O O
inhibitory O O
effect O O
to O O
the O O
ATF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
in O O
the O O
present O O
study O O
of O O
IFN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
gamma I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
treatment O O
, O O
functional O O
analysis O O
by O O
transient O O
transfection O O
showed O O
that O O
inhibition O O
of O O
the O O
cyclin B B_GENE
A I I_GENE
promoter I I_GENE
persisted O O
despite O O
mutation O O
of O O
the O O
ATF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
NF B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
Y I I_GENE/I_LOCATION
, O O
or O O
CDE O O
elements O O
. O O

The O O
RsmA B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
mutant I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O O
like O O
its O O
parent O O
, O O
produces O O
N O O
- O O
( O O
3 O O
- O O
oxohexanoyl O O
) O O
- O O
L O O
- O O
homoserine O O
lactone O O
( O O
HSL O O
) O O
, O O
a O O
starvation O O
/ O O
cell O O
density O O
- O O
sensing O O
signal O O
required O O
for O O
extracellular O O
enzyme O O
production O O
. O O

The O O
inactive O B_GENE
X O I_GENE
allele O I_GENE
, O O
however O O
, O O
is O O
hypermethylated O O
in O O
leukocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
, O O
presumably O O
reflecting O O
early O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
X O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inactivation O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
events O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
become O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
gene O B_MEASURE/B_ORGANISM_FUNCTION
dosage O B_MEASURE/I_ORGANISM_FUNCTION
in O O
expressing O O
lineages O B_BIO/B_DISEASE
. O O

Intensive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
viral O B_DISEASE
hepatitis O I_DISEASE

Also O O
, O O
the O O
RVW O B_DISEASE/B_PROTEIN[GENE]
hypertrophy O B_DISEASE/I_PROTEIN[GENE]
, O O
the O O
IVS O B_DISEASE/B_LOCATION
hypertrophy O I_DISEASE/I_LOCATION
, O O
and O O
the O O
RV O B_DISEASE/B_MEASURE
high O I_DISEASE/I_MEASURE
pressure O I_DISEASE/I_MEASURE
load O I_DISEASE/I_MEASURE
to O O
the O O
LV O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
through O O
the O O
IVS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
may O O
be O O
related O O
to O O
the O O
small O B_DISEASE/B_PROTEIN[GENE]
LV O B_DISEASE/I_PROTEIN[GENE]
, O O
high O B_DISEASE/B_PROTEIN[GENE]
EF O B_DISEASE/I_PROTEIN[GENE]
, O O
and O O
abnormal O B_DISEASE/B_PROTEIN[GENE]
two O B_DISEASE/I_PROTEIN[GENE]
chamber O B_DISEASE/I_PROTEIN[GENE]
inflow O B_DISEASE/I_PROTEIN[GENE]
in O O
the O O
PS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
before O O
BV O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Analysis O O
of O O
the O O
DNA O O
- O O
binding O O
and O O
transcriptional O O
activation O O
functions O O
of O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Fli I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
pattern O O
of O O
expression O O
and O O
differential O O
processing O O
suggests O O
a O O
role O O
for O O
inrpk1 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
some O O
aspect O O
of O O
SD O O
photoperiodic O O
- O O
induced O O
flowering O O
in O O
morning O O
glory O O
. O O

Progressive O O
immunodeficiency O O
in O O
a O O
patient O O
with O O
IgA B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deficiency O O

RMR O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
positively O O
correlated O O
with O O
TEF O B_PROTEIN[GENE]/B_LOCATION
( O O
r O O
= O O
0 O B_MEASURE
. O O
613 O B_MEASURE
, O O
p O O
< O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
and O O
net O B_PROTEIN[GENE]/B_DISEASE
TEF O I_PROTEIN[GENE]/I_DISEASE
( O O
r O B_OTHER/B_GENE
= O O
0 O B_MEASURE
. O O
648 O B_MEASURE
, O O
p O O
< O O
0 O B_MEASURE
. O O
005 O B_MEASURE
) O O
in O O
the O O
luteal O B_BODY_PART_OR_ORGAN_COMPONENT
but O O
not O O
the O O
follicular O B_BODY_PART_OR_ORGAN_COMPONENT/B_ORGANISM_FUNCTION
phase O I_BODY_PART_OR_ORGAN_COMPONENT/I_ORGANISM_FUNCTION
. O O

ESR O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spectra O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Er3 O B_LOCATION/B_MEASURE
+ O O
in O O
SmB6 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
single O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
crystals O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O O
Dynamic O B_PERSON/B_LOCATION
Jahn O I_PERSON/I_LOCATION
- O O
Teller O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effect O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
a O O
mixed O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
valence O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
compound O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

The O O
N O O
- O O
terminal O O
exon1 O O
had O O
no O O
homology O O
at O O
the O O
amino O O
acid O O
level O O
with O O
NGFI B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
mammalian O O
homologue O O
. O O

This O O
paper O O
describes O O
a O O
longitudinal O O
study O O
in O O
which O O
clinical O O
parameters O O
and O O
aspartate B B_ENZYME[GENE]
aminotransferase I I_ENZYME[GENE]
( O O
AST B B_GENE/B_ORGANIZATION
) O O
in O O
gingival O O
crevicular O O
fluid O O
( O O
GCF O O
) O O
were O O
monitored O O
bimonthly O O
over O O
a O O
6 O O
- O O
12 O O
months O O
period O O
in O O
970 O O
sites O O
from O O
7 O O
treated O O
periodontitis O O
patients O O
. O O

We O O
conclude O O
from O O
these O O
observations O O
that O O
the O O
cTnC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
' I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Ile I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
composite O O
enhancer O O
that O O
functions O O
through O O
the O O
combined O O
interactions O O
of O O
at O O
least O O
five O O
regulatory O O
elements O O
and O O
their O O
cognate O O
binding O O
factors O O
: O O
three O O
or O O
four O O
E O O
- O O
boxes O O
, O O
a O O
MEF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
a O O
MEF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consisted O O
of O O
1 O B_NUMBER[MEASURE]/B_PERSON
) O O
fitting O O
first O B_SEQUENCE[MEASURE]
- O O
and O O
second O B_SEQUENCE[MEASURE]/B_LOCATION
- O O
order O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
autoregressive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
models O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
AR1 O B_PROTEIN[GENE]/B_DISEASE
and O O
AR2 O B_PROTEIN[GENE]/B_DISEASE
) O O
and O O
2 O B_SEQUENCE[MEASURE]
) O O
obtaining O O
the O O
power O B_MEASURE/B_PERSON
spectra O I_MEASURE/I_PERSON
of O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
by O O
fast O B_DISEASE/B_MEASURE
- O O
Fourier O B_MEASURE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transform O B_MEASURE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
identified O O
Tyr O O
( O O
112 O O
) O O
and O O
Leu O O
( O O
175 O O
) O O
within O O
the O O
RNA O O
- O O
binding O O
domain O O
of O O
the O O
U1 B B_GENE
70K I I_GENE
protein I I_GENE
to O O
be O O
cross O O
- O O
linked O O
to O O
G O O
( O O
28 O O
) O O
and O O
U O O
( O O
30 O O
) O O
in O O
stem O O
- O O
loop O O
I O O
, O O
respectively O O
. O O

Kudzu O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
extract O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BIO
shows O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BIO
potential O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BIO
for O O
moderating O O
alcohol O B_DISEASE_ADJECTIVE[DISEASE]
abuse O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Furthermore O O
, O O
the O O
data O O
suggest O O
an O O
immunological O O
non O O
- O O
responsiveness O O
to O O
enterotoxin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
A I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
in O O
a O O
considerable O O
portion O O
of O O
the O O
patients O O
. O O

BCV B B_PERSON/B_GENE
mRNAs I I_PERSON/I_GENE
5 I I_PERSON/I_GENE
and I I_PERSON/I_GENE
5 I I_PERSON/I_GENE
- I I_PERSON/I_GENE
1 I I_PERSON/I_GENE
appear O O
to O O
be O O
used O O
for O O
the O O
synthesis O O
of O O
the O O
12 O O
. O O
7 O O
- O O
and O O
9 O O
. O O
5 O O
- O O
kDa O O
proteins O O
, O O
respectively O O
, O O
which O O
demonstrates O O
a O O
pattern O O
of O O
expression O O
strikingly O O
different O O
from O O
that O O
utilized O O
by O O
MHV O O
. O O

Disaster O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
medicine O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION

The O O
longest O B_PROTEIN[GENE]/B_DISEASE
S1 O I_PROTEIN[GENE]/I_DISEASE
- O O
S2 O B_MEASURE/B_LOCATION
interval O I_MEASURE/I_LOCATION
at O O
which O O
S2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
failed O O
to O O
capture O O
( O O
effective O B_MEASURE/B_DISEASE
refractory O B_MEASURE/I_DISEASE
period O B_MEASURE/I_DISEASE
) O O
was O O
longer O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
by O O
5 O B_MEASURE
. O O
5 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
8 O B_NUMBER[MEASURE]
. O O
2 O B_MEASURE/B_PERSON
msec O I_MEASURE/I_PERSON
at O O
twice O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
threshold O I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
0 O B_MEASURE/B_LOCATION
. O O
05 O B_TIME[MEASURE]
less O I_TIME[MEASURE]
than O O
p O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
0 O B_MEASURE
. O O
10 O B_MEASURE
) O O
and O O
5 O B_MEASURE
. O O
5 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
3 O B_MEASURE
. O O
5 O B_MEASURE/B_PERSON
msec O I_MEASURE/I_PERSON
at O O
5 O B_MEASURE/B_LOCATION
times O I_MEASURE/I_LOCATION
threshold O I_MEASURE/I_LOCATION
stimulation O I_MEASURE/I_LOCATION
( O O
p O B_MEASURE
less O I_MEASURE
than O O
0 O B_NUMBER[MEASURE]
. O O
01 O B_MEASURE
) O O
when O O
the O O
basic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
drive O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
extrastimuli O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
delivered O O
to O O
separate O B_PERSON/B_PROTEIN[GENE]
sites O I_PERSON/I_PROTEIN[GENE]
. O O

The O O
use O O
of O O
specific O O
somatic O O
cell O O
hybrids O O
have O O
allowed O O
us O O
to O O
locate O O
the O O
YAC O O
contig O O
telomeric O O
to O O
the O O
D3F15S2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
locus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
in O O
a O O
region O O
which O O
is O O
frequently O O
deleted O O
in O O
lung O O
carcinomas O O
. O O

Experiments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
performed O O
without O O
polarization O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
with O O
cathodic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
anodic O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polarization O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
adsorbent O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Chronic O B_DISEASE
active O I_DISEASE
hepatitis O I_DISEASE
and O O
cirrhosis O B_DISEASE
of O O
the O O
liver O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

This O O
regulation O O
is O O
mediated O O
by O O
several O O
kinases O O
that O O
phosphorylate O O
specific O O
residues O O
in O O
the O O
different O O
functional O O
domains O O
of O O
the O O
p53 B B_GENE
molecule I I_GENE
. O O

These O O
data O O
show O O
that O O
the O O
processing O O
of O O
specific O O
target O O
transcripts O O
, O O
such O O
as O O
the O O
P B B_GENE/B_BIO
- I I_GENE/I_BIO
element I I_GENE/I_BIO
mRNA I I_GENE/I_BIO
, O O
is O O
regulated O O
by O O
a O O
functional O O
PSI B B_GENE/B_DISEASE
- O O
U1 B B_GENE
snRNP O O
interaction O O
in O O
Drosophila O O
. O O

Effect O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
dimethyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfoxide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
cooling O O
rates O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
unrestrained O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
four O O
calves O O
given O O
Haemonchus O O
contortus O O
larvae O O
, O O
the O O
serum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
pepsinogen I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
concentration O O
rose O O
quickly O O
to O O
reach O O
a O O
mean O O
of O O
3 O O
. O O
5 O O
iu O O
tyrosine O O
on O O
day O O
14 O O
after O O
infection O O
. O O

These O O
results O O
strongly O O
suggest O O
that O O
HSV O O
- O O
1 O O
infection O O
inhibits O O
host O O
cell O O
splicing O O
through O O
the O O
action O O
of O O
ICP27 B B_GENE
. O O

The O O
T O B_PROTEIN[GENE]/B_MEASURE
( O O
CCO2 O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
was O O
related O O
to O O
the O O
PCO2 O B_MEASURE
by O O
a O O
Pearson O B_MEASURE
product O I_MEASURE
coefficient O I_MEASURE
of O O
0 O B_MEASURE
. O O
79 O B_MEASURE
( O O
p O B_MEASURE
< O I_MEASURE
. O O
0005 O B_MEASURE
) O O
, O O
with O O
a O O
mean O B_MEASURE/B_LOCATION
difference O I_MEASURE/I_LOCATION
of O O
1 O B_MEASURE
. O O
94 O B_MEASURE
( O O
T O B_PROTEIN[GENE]/B_OTHER
( O O
CCO2 O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
> O O
P O B_OTHER/B_PROTEIN[GENE]
( O O
CO2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
and O O
95 O B_MEASURE
% O I_MEASURE
confidence O I_MEASURE
interval O I_MEASURE
of O O
- O O
0 O B_MEASURE
. O O
12 O B_MEASURE
to O O
4 O B_NUMBER[MEASURE]
. O O
07 O B_MEASURE
. O O

Transformation O O
of O O
chicken O O
embryo O O
fibroblasts O O
( O O
CEF O O
) O O
with O O
the O O
Gag B B_GENE/B_LOCATION
- O O
Crk B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fusion O O
protein O O
results O O
in O O
the O O
elevation O O
of O O
tyrosine O O
phosphorylation O O
on O O
specific O O
cellular O O
proteins O O
with O O
molecular O O
weights O O
of O O
130 O O
, O O
000 O O
, O O
110 O O
, O O
000 O O
, O O
and O O
70 O O
, O O
000 O O
( O O
p130 B B_GENE/B_MEASURE
, O O
p110 B B_GENE/B_MEASURE
, O O
and O O
p70 B B_GENE/B_MEASURE
, O O
respectively O O
) O O
, O O
an O O
event O O
which O O
has O O
been O O
correlated O O
with O O
cell O O
transformation O O
. O O

Urease B B_BACTERIUM[BIO]/B_ENZYME[GENE]
activity O O
, O O
judged O O
as O O
the O O
amount O O
of O O
ammonia O O
production O O
from O O
urea O O
, O O
could O O
be O O
measured O O
at O O
25 O O
ng O O
per O O
tube O O
( O O
S O O
/ O O
N O O
= O O
1 O O
. O O
5 O O
) O O
with O O
Jack B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
bean I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
meal I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
urease I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
. O O

Here O O
, O O
we O O
provide O O
direct O O
evidence O O
that O O
the O O
meiotic O O
defect O O
caused O O
by O O
either O O
unregulated O O
cAPK B B_GENE
activity O O
or O O
unregulated O O
ran1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
+ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
is O O
due O O
to O O
inability O O
to O O
induce O O
transcription O O
of O O
the O O
mei2 B B_GENE
+ I I_GENE
gene I I_GENE
, O O
which O O
is O O
required O O
for O O
meiotic O O
initiation O O
. O O

Optical O O
rotation O O
of O O
the O O
second O O
harmonic O O
radiation O O
from O O
retinal O O
in O O
bacteriorhodopsin B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
monomers I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
Langmuir O O
- O O
Blodgett O O
film O O
: O O
evidence O O
for O O
nonplanar O O
retinal O O
structure O O
. O O

Ultrasonography O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
a O O
diagnostic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alternative O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
may O O
replace O O
arthrography O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
K562 O O
cells O O
, O O
using O O
the O O
bicistronic O O
vector O O
, O O
selection O O
with O O
colchicine O O
led O O
to O O
at O O
least O O
20 O O
- O O
fold O O
higher O O
expression O O
of O O
the O O
MDR1 B B_GENE
gene I I_GENE
product I I_GENE
than O O
did O O
selection O O
with O O
G418 O O
, O O
suggesting O O
that O O
the O O
stringent O O
MDR1 B B_GENE
selection O O
system O O
is O O
very O O
efficient O O
for O O
obtaining O O
overexpression O O
of O O
foreign O O
genes O O
. O O

In O O
this O O
report O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
several O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
health O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
behaviors O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
investigated O O
in O O
relation O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
maintaining O O
mobility O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
during O O
4 O B_TIME[MEASURE]/B_LOCATION
years O I_TIME[MEASURE]/I_LOCATION
of O O
follow O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
up O B_LOCATION/B_LANGUAGE
among O O
6 O B_MEASURE
, O O
981 O B_MEASURE/B_PERSON
men O I_MEASURE/I_PERSON
and O O
women O B_PERSON
aged O O
65 O B_MEASURE/B_ENT
years O I_MEASURE/I_ENT
and O O
older O B_TIME[MEASURE]/B_PERSON
with O O
intact O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mobility O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
baseline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
between O O
1981 O B_MEASURE
and O O
1983 O B_MEASURE
who O O
lived O O
in O O
one O B_NUMBER[MEASURE]/B_LOCATION
of O O
three O B_NUMBER[MEASURE]/B_LOCATION
communities O I_NUMBER[MEASURE]/I_LOCATION
: O O
East O B_LOCATION/B_PERSON
Boston O I_LOCATION/I_PERSON
, O O
Massachusetts O B_LOCATION
; O O
Iowa O B_LOCATION/B_PERSON
and O O
Washington O B_LOCATION/B_PERSON
counties O I_LOCATION/I_PERSON
, O O
Iowa O B_LOCATION
; O O
and O O
New O B_LOCATION/B_PERSON
Haven O I_LOCATION/I_PERSON
, O O
Connecticut O B_LOCATION
. O O

Our O O
analysis O O
indicates O O
that O O
a O O
gene O O
correction O O
mechanism O O
has O O
been O O
operating O O
on O O
the O O
Hbbs B B_PROTEIN[GENE]/B_DISEASE
chromosome O O
to O O
keep O O
beta B B_PROTEIN[GENE]
s I I_PROTEIN[GENE]
and O O
beta B B_PROTEIN[GENE]
t I I_PROTEIN[GENE]
evolving O O
in O O
concert O O
, O O
whereas O O
on O O
the O O
Hbbd B B_GENE/B_PERSON
chromosome O O
, O O
beta B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
dmin I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
has O O
diverged O O
considerably O O
from O O
beta B B_PERSON/B_GENE
dmaj I I_PERSON/I_GENE
. O O

Structure O O
and O O
regulation O O
of O O
KGD2 B B_GENE
, O O
the O O
structural O O
gene O O
for O O
yeast B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dihydrolipoyl I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transsuccinylase I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
dehydrated O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
animals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
at O O
Ta O B_MEASURE/B_LOCATION
38 O I_MEASURE/I_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
, O O
Tb O B_PROTEIN[GENE]/B_LOCATION
and O O
EWL O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
were O O
both O O
significantly O O
altered O O
( O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE/B_LOCATION
. O O
001 O B_MEASURE
) O O
from O O
the O O
normally O O
hydrated O O
state O B_LOCATION/B_PERSON
and O O
were O O
measured O O
at O O
39 O B_MEASURE
. O O
9 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
2 O B_MEASURE
degree O I_MEASURE
C O I_MEASURE
and O O
0 O B_MEASURE
. O O
84 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
09 O B_MEASURE/B_LOCATION
W O I_MEASURE/I_LOCATION
. O O

kg O B_MEASURE
- O O
1 O B_MEASURE
respectively O O
. O O

We O O
identify O O
YY1 B B_GENE
recognition O O
sequences O O
within O O
the O O
vitamin O O
D O O
response O O
element O O
( O O
VDRE O O
) O O
of O O
the O O
osteocalcin B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
that O O
are O O
critical O O
for O O
YY1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dependent O O
repression O O
of O O
vitamin O O
D O O
- O O
enhanced O O
promoter O O
activity O O
. O O

Back O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
ground O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
affect O O
the O O
outcome O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
steroid O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
withdrawal O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O O
patients O B_PERSON/B_LOCATION
with O O
chronic O B_DISEASE/B_LOCATION
type O I_DISEASE/I_LOCATION
B O I_DISEASE/I_LOCATION
hepatitis O I_DISEASE/I_LOCATION
- O O
- O O
statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
importance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
mode O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
HBV O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
transmission O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]

Point O O
mutations O O
of O O
Stat3 B B_GENE/B_LOCATION
within O O
the O O
interacting O O
domains O O
blocked O O
both O O
physical O O
interaction O O
of O O
Stat3 B B_GENE
with O O
c B B_GENE
- I I_GENE
Jun I I_GENE
and O O
their O O
cooperation O O
in O O
IL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
transcription O O
directed O O
by O O
the O O
alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
macroglobulin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Three O B_PERSON
patients O I_PERSON
with O O
Mirizzi O B_DISEASE
type O I_DISEASE
II O I_DISEASE
syndrome O I_DISEASE
and O O
two O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
with O O
Mirizzi O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
type O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
I O O
syndrome O B_DISEASE/B_PERSON
were O O
treated O O
laparoscopically O O
. O O

Synchronous O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
multicentric O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
giant O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tumour O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
a O O
case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
report O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O O
review O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
literature O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

From O O
the O O
comparison O O
of O O
the O O
nod B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
box I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequences I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
( O O
brady O O
) O O
rhizobia O O
with O O
a O O
more O O
divergent O O
nod B B_GENE/B_LOCATION
box I I_GENE/I_LOCATION
from O O
Azorhizobium O O
caulinodans O O
, O O
we O O
now O O
propose O O
a O O
modular O O
build O O
- O O
up O O
of O O
the O O
nod B B_GENE/B_LOCATION
box I I_GENE/I_LOCATION
with O O
the O O
sequence O O
A O O
- O O
T O O
- O O
C O O
- O O
N9 O O
- O O
G O O
- O O
A O O
- O O
T O O
as O O
the O O
binding O O
target O O
of O O
the O O
NodD B B_PROTEIN[GENE]/B_BIO
protein I I_PROTEIN[GENE]/I_BIO
( O O
the O O
NodD B B_GENE/B_MEASURE
box I I_GENE/I_MEASURE
) O O
. O O

The O O
prgX B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
is O O
adjacent O O
to O O
prgQ B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
provides O O
the O O
promoter O O
for O O
prgB B B_GENE/B_BACTERIUM[BIO]
expression O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
A O O
discriminant O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
predicting O O
surgery O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcome O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
seizure O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
free O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
vs O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O
non O B_DISEASE/B_LOCATION
- O O
seizure O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
free O B_DISEASE_ADJECTIVE[DISEASE]
) O O
was O O
computed O O
separately O O
for O O
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
patients O B_PERSON/B_BIO
with O O
left O B_BODY_LOCATION_OR_REGION[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
( O O
n O B_MEASURE/B_PROTEIN[GENE]
= O O
79 O B_MEASURE
) O O
and O O
right O B_SEQUENCE[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
n O B_MEASURE/B_PROTEIN[GENE]
= O O
62 O B_MEASURE
) O O
temporal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
lobectomy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O O
LATL O B_LOCATION/B_PROTEIN[GENE]
, O O
RATL O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

It O O
is O O
likely O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O O
these O O
recordings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O O
incomplete O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
; O O
the O O
actual O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
activated O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
is O O
estimated O O
to O O
be O O
about O O
300 O B_MEASURE
in O O
the O O
acutely O O
sensitized O O
preparation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
. O O

The O O
possibility O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
use O O
this O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
common O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
diagnostic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
problems O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
indicated O O
. O O

Genetic O O
analysis O O
of O O
the O O
role O O
of O O
herpes B B_GENE
simplex I I_GENE
virus I I_GENE
type I I_GENE
1 I I_GENE
glycoprotein I I_GENE
K I I_GENE
in O O
infectious O O
virus O O
production O O
and O O
egress O O
. O O

A O O
conventional O O
N O O
- O O
terminal O O
signal O O
sequence O O
was O O
not O O
detected O O
in O O
the O O
NodO B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Dynamic O O
expression O O
of O O
broad B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complex I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
isoforms I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mediates O O
temporal O O
control O O
of O O
an O O
ecdysteroid O O
target O O
gene O O
at O O
the O O
onset O O
of O O
Drosophila O O
metamorphosis O O
. O O

The O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
carried O O
out O O
according O O
to O O
the O O
BSI O B_SEQUENCE[MEASURE]/B_LOCATION
( O O
1980 O B_MEASURE
) O O
recommendations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
testing O O
restorative O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
materials O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
vivo O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Cellular O O
lysates O O
were O O
analyzed O O
for O O
luciferase B B_ENZYME[GENE]
and O O
beta B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
galactosidase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activities O O
. O O

Cytokines O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
steroid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
hormones O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
use O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sets O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
signal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transduction O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
pathways O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
seem O O
to O O
be O O
unrelated O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
findings O O
suggest O O
that O O
the O O
proteolipids O O
of O O
the O O
vacuolar B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
H I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
+ I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
ATPases I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
evolved O O
in O O
parallel O O
with O O
the O O
eubacterial O O
proteolipid O O
, O O
from O O
a O O
common O O
ancestral O O
gene O O
that O O
underwent O O
gene O O
duplication O O
. O O

This O O
mutant O O
also O O
functions O O
in O O
vivo O O
as O O
a O O
trans O O
- O O
acting O O
dominant O O
negative O O
regulator O O
: O O
the O O
transcriptional O O
inducibility O O
of O O
the O O
HIV B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
long I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
terminal I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
repeat I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
which O O
contains O O
two O O
potential O O
NF B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
by O O
phorbol O O
ester O O
( O O
PMA O O
) O O
is O O
inhibited O O
when O O
it O O
is O O
co O O
- O O
transfected O O
into O O
CD4 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
+ I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
T O O
cells O O
with O O
the O O
delta O O
SP O O
mutant O O
. O O

In O O
addition O B_MEASURE/B_LOCATION
, O O
measurements O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
shielded O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
and O O
unshielded O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
syringes O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
containing O O
99mTc O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
labelled O O
radiopharmaceuticals O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
carried O O
out O O
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
tests O O
the O O
hypothesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
O2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
a O O
critical O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
component O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
myocardial O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
protection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
afforded O O
by O O
BCP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Biomass O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monitoring O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
pressure O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
drop O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
cocurrent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
biofilter O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION

This O O
alternative O B_LOCATION
splice O I_LOCATION
acceptor O I_LOCATION
site O I_LOCATION
is O O
also O O
used O O
by O O
a O O
biologically O O
active O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provirus O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
an O O
efficiency O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
approximately O O
5 O B_MEASURE
% O I_MEASURE
compared O O
with O O
the O O
upstream O B_LOCATION/B_TIME[MEASURE]
site O B_LOCATION/I_TIME[MEASURE]
. O O

Homology O O
is O O
much O O
higher O O
( O O
64 O O
% O O
) O O
between O O
the O O
28 O O
- O O
kDa O O
protein O O
and O O
regions O O
that O O
are O O
strongly O O
conserved O O
among O O
the O O
members O O
of O O
the O O
serine B B_PERSON/B_BIO
protease I I_PERSON/I_BIO
family I I_PERSON/I_BIO
. O O

We O O
have O O
isolated O O
and O O
structurally O O
characterized O O
genomic O O
DNA O O
and O O
cDNA O O
sequences O O
encoding O O
ribulose B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bisphosphate I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carboxylase I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oxygenase I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Rbu I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
P2 I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carboxylase I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activase I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
barley O O
( O O
Hordeum O O
vulgare O O
L O O
. O O
) O O
. O O

Expression O O
of O O
putative O O
constitutively O O
active O O
forms O O
of O O
DdMEK1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
ddmek1 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
null O O
background O O
is O O
capable O O
, O O
at O O
least O O
partially O O
, O O
of O O
complementing O O
the O O
small O O
aggregate O O
size O O
defect O O
and O O
the O O
ability O O
to O O
activate O O
guanylyl B B_GENE
cyclase I I_GENE
. O O

Constant O B_DISEASE_ADJECTIVE[DISEASE]
slowing O I_DISEASE_ADJECTIVE[DISEASE]
of O O
median O B_MEASURE/B_LOCATION
MNCV O B_MEASURE/I_LOCATION
and O O
SNCV O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
ulnar O B_MEASURE/B_PROTEIN[GENE]
SNCV O B_MEASURE/I_PROTEIN[GENE]
without O O
changes O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
morphology O B_MEASURE/B_LOCATION
, O O
amplitude O B_MEASURE
and O O
duration O B_MEASURE
of O O
MAP O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
SAP O B_DISEASE/B_PROTEIN[GENE]
have O O
been O O
observed O O
in O O
92 O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
, O O
with O O
persistent O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
abnormalities O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
64 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cases O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
after O O
six O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
months O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Moreover O O
, O O
such O O
mutations O O
lead O O
to O O
a O O
dramatic O O
transition O O
in O O
chromatin O O
structure O O
: O O
the O O
DNase B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
hypersensitive I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
replaced O O
by O O
two O O
stable O O
, O O
sequence O O
- O O
positioned O O
nucleosomes O O
. O O

During O O
chronic O O
treatment O O
with O O
salmon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
calcitonin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
alkaline B B_GENE/B_DISEASE
phosphatase I I_GENE/I_DISEASE
activity O O
and O O
urinary O O
hydroxyproline O O
excretion O O
decrease O O
on O O
an O O
average O O
of O O
50 O O
% O O
in O O
patients O O
with O O
Paget O O
' O O
s O O
disease O O
. O O

187 O O
- O O
200 O B_MEASURE
. O O

Because O O
of O O
the O O
structural O O
similarities O O
the O O
new O O
gene O O
will O O
be O O
termed O O
scERV2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
from O O
now O O
on O O
. O O

Experience O B_TIME[MEASURE]/B_LOCATION
in O O
a O O
Kenya O B_LOCATION/B_PERSON
district O I_LOCATION/I_PERSON
hospital O I_LOCATION/I_PERSON

The O O
2 B B_GENE
. I I_GENE
3 I I_GENE
x I I_GENE
10 I I_GENE
( I I_GENE
3 I I_GENE
) I I_GENE
base I I_GENE
SUF12 I I_GENE
+ I I_GENE
transcript I I_GENE
contains O O
an O O
open O O
reading O O
frame O O
sufficient O O
to O O
encode O O
a O O
88 O O
x O O
10 O O
( O O
3 O O
) O O
Mr O O
protein O O
. O O

Cortical O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
somatosensory O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
evoked O O
potentials O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
median O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
nerve O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
revealed O O
significantly O O
delayed O O
peak O B_MEASURE
latencies O I_MEASURE
of O O
N20 O B_PROTEIN[GENE]/B_MEASURE
, O O
P20 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
P25 O B_PROTEIN[GENE]/B_MEASURE
, O O
and O O
N26 O B_MEASURE/B_PROTEIN[GENE]
, O O
although O O
N16 O B_MEASURE/B_PERSON
latency O B_MEASURE/I_PERSON
was O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
new O B_PERSON/B_ENT
family O I_PERSON/I_ENT
of O O
rate O B_TIME[MEASURE]/B_PERSON
- O O
adaptive O O
pacemakers O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
accomplishes O O
this O O
circadian O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rate O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
modeling O O
the O O
patient O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
' O O
s O O
sleep O B_DISEASE
- O O
wake O B_TIME[MEASURE]/B_ENT
cycle O I_TIME[MEASURE]/I_ENT
using O O
a O O
time O B_SEQUENCE[MEASURE]/B_LOCATION
- O O
of O O
- O O
day O B_TIME[MEASURE]/B_LOCATION
clock O I_TIME[MEASURE]/I_LOCATION
inside O O
the O O
device O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Progestins O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
present O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
future O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O O

Bilirubin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
red O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
metabolism O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
relation O B_PERSON/B_DISEASE
to O O
neonatal O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
jaundice O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Each O O
of O O
these O O
materials O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
were O O
placed O O
by O O
means O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
three O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
different O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
placement O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
techniques O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Bulk O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
pack O B_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
Horizontal O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
layering O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Vertical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
layering O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
) O O
into O O
class O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
II O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
cavities O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
extracted O O
human O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
molars O B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

This O O
ligand O O
- O O
independent O O
pathway O O
can O O
function O O
through O O
another O O
androgen O O
- O O
regulated O O
promoter O O
as O O
shown O O
by O O
the O O
use O O
of O O
the O O
mouse B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mammary I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tumor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MMTV I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CAT I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reporter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Stress O O
- O O
induced O O
suppression O O
of O O
the O O
prolactin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
afternoon O O
surge O O
in O O
ovariectomized O O
, O O
estrogen O O
- O O
treated O O
rats O O
and O O
the O O
nocturnal O O
surge O O
in O O
pseudopregnant O O
rats O O
are O O
accompanied O O
by O O
an O O
increase O O
in O O
median O O
eminence O O
dihydroxyphenylacetic O O
acid O O
concentrations O O
. O O

The O O
sensitivity O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
ergometry O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
and O O
treadmill O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
testing O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
75 O B_MEASURE
and O O
62 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
respectively O O
. O O

Morphologic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
that O O
rhe O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
renal O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
calyx O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
pelvis O B_BODY_PART_OR_ORGAN_COMPONENT
control O O
ureteric O B_DISEASE/B_GENE
activity O I_DISEASE/I_GENE
in O O
the O O
rabbit O B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Children O B_PERSON/B_BIO
with O O
repeated O O
proteinuria O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
during O O
follow O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
up O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tend O O
to O O
have O O
a O O
higher O B_MEASURE/B_LOCATION
incidence O I_MEASURE/I_LOCATION
of O O
pathologic O B_DISEASE
findings O I_DISEASE
on O O
the O O
i O O
. O O
v O B_PROTEIN[GENE]/B_LOCATION
. O O
- O O
pyelogram O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Parelaphostrongylus O B_VIRUS[BIO]/B_DISEASE
odocoilei O I_VIRUS[BIO]/I_DISEASE
is O O
redescribed O O
from O O
worms O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
collected O O
from O O
the O O
type O B_SPECIES[BIO]
host O I_SPECIES[BIO]
( O O
Odocoileus O B_SPECIES[BIO]/B_LOCATION
hemionus O I_SPECIES[BIO]/I_LOCATION
columbianus O I_SPECIES[BIO]/I_LOCATION
) O O
in O O
California O B_LOCATION
, O O
as O O
well O O
as O O
material O B_LOCATION/B_BIO
from O O
experimentally O O
infected O O
mule O B_SPECIES[BIO]/B_PERSON
deer O I_SPECIES[BIO]/I_PERSON
( O O
O O B_OTHER/B_PROTEIN[GENE]
. O O
h O O
. O O
heminus O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
) O O
in O O
Alberta O B_LOCATION/B_PERSON
. O O

The O O
carboxyl O B_PROTEIN[GENE]
globular O I_PROTEIN[GENE]
domain O I_PROTEIN[GENE]
was O O
found O O
to O O
be O O
encoded O O
by O O
six O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
exons O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O O
appear O O
to O O
delineate O O
its O O
structural O B_LOCATION/B_MEASURE
subdomains O I_LOCATION/I_MEASURE
. O O

Expression O O
of O O
the O O
Asp O O
but O O
not O O
the O O
Ala O O
gB B B_DISEASE/B_MEASURE
mutation O O
resulted O O
in O O
an O O
increase O O
in O O
the O O
steady O O
- O O
state O O
expression O O
of O O
gB B B_GENE/B_DISEASE
at O O
the O O
plasma O O
membrane O O
( O O
PM O O
) O O
in O O
U373 O O
cells O O
. O O

Thus O O
integration B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
host I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factor I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
required O O
for O O
normal O O
type B B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
1 I I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
fimbriae I I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
phase O O
variation O O
in O O
E O O
. O O
coli O O
. O O

Insulin B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
has O O
been O O
expanded O O
by O O
development O O
of O O
human B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
insulin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
new O O
modes O O
of O O
injection O O
, O O
including O O
insulin B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
pumps O O
. O O

Because O O
levels O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
Vo2DIR O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Vo2INDIR O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
both O O
groups O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
we O O
pooled O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
septic O B_DISEASE
and O O
control O B_DISEASE/B_ORGANIZATION
animals O I_DISEASE/I_ORGANIZATION
. O O

Further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
interventions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
: O O
nephrectomy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O O
2x O B_NUMBER[MEASURE]/B_LOCATION
) O O
, O O
resection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
ligation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
inferior O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
vena O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
cava O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
( O O
1x O B_NUMBER[MEASURE]/B_LOCATION
) O O
, O O
resection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
replacement O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
left O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
renal O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
vein O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
1x O B_SEQUENCE[MEASURE]/B_LOCATION
) O O
. O O

OBJECTIVES O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
The O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
tested O O
the O O
hypothesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
stimulating O O
the O O
central O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
noradrenergic O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
system O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
using O O
the O O
new O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
noradrenaline O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
re O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
uptake O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reboxetine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
would O O
result O O
in O O
a O O
dose O B_MEASURE
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
enhancement O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
memory O B_PERSON/B_DISEASE
for O O
emotional O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
material O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
man O B_PERSON/B_BIO
. O O

We O O
examined O O
the O O
mechanisms O O
by O O
which O O
two O O
different O O
types O O
of O O
photonic O O
radiation O O
, O O
short O O
wavelength O O
UV O O
( O O
UV O O
- O O
C O O
) O O
and O O
gamma O O
radiation O O
, O O
activate O O
transcription O O
factor O O
NF B B_GENE
- I I_GENE
kappaB I I_GENE
. O O

However O O
, O O
coligation O O
of O O
Fc B B_GENE
gamma I I_GENE
RIIB1 I I_GENE
with O O
B B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Ag I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
BCR B B_GENE/B_LOCATION
) O O
inhibits O O
BCR B B_GENE/B_LOCATION
- O O
mediated O O
signaling O O
by O O
a O O
mechanism O O
that O O
may O O
involve O O
recruitment O O
of O O
phosphatases B B_GENE
SHP I I_GENE
- I I_GENE
1 I I_GENE
, O O
SHP B B_GENE
- I I_GENE
2 I I_GENE
, O O
and O O
the O O
SH2 B B_ENZYME[GENE]/B_LOCATION
containing I I_ENZYME[GENE]/I_LOCATION
inositol I I_ENZYME[GENE]/I_LOCATION
5 I I_ENZYME[GENE]/I_LOCATION
' I I_ENZYME[GENE]/I_LOCATION
phosphatase I I_ENZYME[GENE]/I_LOCATION
( O O
SHIP B B_LOCATION/B_GENE
) O O
to O O
the O O
phosphorylated O O
Fc B B_GENE/B_LOCATION
gamma I B_GENE/I_LOCATION
RIIB1 I B_GENE/I_LOCATION
immunoreceptor I B_GENE/I_LOCATION
tyrosine I B_GENE/I_LOCATION
- I B_GENE/I_LOCATION
based I B_GENE/I_LOCATION
inhibitory I B_GENE/I_LOCATION
motif I B_GENE/I_LOCATION
. O O

Using O O
the O O
standard O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
scoring O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
children O B_PERSON
with O O
full O B_MEASURE/B_LOCATION
scale O I_MEASURE/I_LOCATION
IQ O I_MEASURE/I_LOCATION
< O I_MEASURE/I_LOCATION
or O O
= O O
84 O B_MEASURE
on O O
the O O
Wechsler O B_PERSON/B_LOCATION
Preschool O I_PERSON/I_LOCATION
and O O
Primary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Scale O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Intelligence O B_EDU[ORGANIZATION]/B_DISEASE
at O O
age O B_NUMBER[MEASURE]/B_PERSON
4 O I_NUMBER[MEASURE]/I_PERSON
- O O
5 O B_TIME[MEASURE]
years O I_TIME[MEASURE]
were O O
poorly O O
identified O O
( O O
sensitivity O B_DISEASE_ADJECTIVE[DISEASE]
54 O I_DISEASE_ADJECTIVE[DISEASE]
% O I_DISEASE_ADJECTIVE[DISEASE]
) O O
from O O
the O O
composite O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
S O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
B O B_MEASURE/B_LOCATION
IV O I_MEASURE/I_LOCATION
score O I_MEASURE/I_LOCATION
at O O
age O B_PERSON/B_TIME[MEASURE]
3 O B_PERSON/I_TIME[MEASURE]
. O O

11 O O
: O O
5801 O O
- O O
5812 O O
, O O
1991 O O
) O O
present O O
evidence O O
that O O
the O O
Vps18 B B_GENE
/ O O
Pep3 B B_MEASURE/B_PERSON
protein O O
colocalizes O O
with O O
the O O
Vps11 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
Pep5 B B_MEASURE/B_PERSON
protein O O
to O O
the O O
cytosolic O O
face O O
of O O
the O O
vacuolar O O
membrane O O
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
includes O O
200 O B_PERSON
patients O I_PERSON
treated O O
from O O
1964 O B_MEASURE
to O O
1978 O B_MEASURE
, O O
with O O
an O O
age O B_TIME[MEASURE]/B_LOCATION
range O I_TIME[MEASURE]/I_LOCATION
from O O
15 O B_MEASURE
to O O
102 O B_MEASURE/B_ENT
years O I_MEASURE/I_ENT
, O O
who O O
required O O
329 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
generators O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

We O O
conclude O O
that O O
the O O
BR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
C I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
early I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
gene I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
directly O O
activates O O
late B B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
gene I I_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
transcription O O
by O O
interacting O O
with O O
late B B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
gene I I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
cis O O
- O O
acting O O
regulatory O O
elements O O
and O O
that O O
this O O
interaction O O
is O O
responsible O O
for O O
the O O
temporal O O
linkage O O
of O O
early O O
and O O
late O O
ecdysone O O
- O O
induced O O
gene O O
expression O O
. O O

The O O
specificity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
sensitivity O B_MEASURE
of O O
this O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
limit O B_MEASURE
of O O
detection O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
plasma O B_MEASURE/B_LOCATION
0 O I_MEASURE/I_LOCATION
. O O
025 O B_MEASURE
micrograms O I_MEASURE
/ O O
mL O B_MEASURE/B_LOCATION
and O O
< O B_MEASURE
or O O
= O O
0 O B_MEASURE
. O O
0125 O B_MEASURE
micrograms O I_MEASURE
/ O O
mL O B_MEASURE/B_LOCATION
for O O
febantel O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
its O O
metabolites O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
respectively O O
) O O
were O O
sufficiently O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
to O O
enable O O
us O O
to O O
characterize O O
the O O
time O B_TIME[MEASURE]/B_LOCATION
course O B_TIME[MEASURE]/I_LOCATION
of O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
the O O
plasma O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
after O O
oral O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
therapeutic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
sheep O O
. O O

We O O
have O O
identified O O
the O O
gene O O
encoding O O
sigma B B_GENE/B_LOCATION
E I I_GENE/I_LOCATION
using O O
a O O
genetic O O
screen O O
designed O O
to O O
isolate O O
trans O O
- O O
acting O O
mutations O O
that O O
abolish O O
expression O O
from O O
either O O
htrA B B_GENE/B_BACTERIUM[BIO]
or O O
rpoHP3 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
two O O
promoters O O
recognized O O
uniquely O O
by O O
sigma B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
containing O O
RNA B B_GENE/B_BIO
polymerase I I_GENE/I_BIO
. O O

Cytokinetics O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
of O O
the O O
Krebs O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
2 O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
carcinoma O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Through O O
effective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
use O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
laboratory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
testing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
database O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
it O O
will O O
be O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
shift O O
away O O
our O O
vague O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
management O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
pre O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
analytic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
phase O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
quality O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
so O O
far O O
to O O
its O O
established O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
based O O
on O O
objective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
evaluation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

These O O
patients O O
developed O O
severe O O
diabetic O O
symptoms O O
including O O
glucose O O
intolerance O O
, O O
weight O O
loss O O
, O O
impaired O O
energy O O
utilization O O
, O O
and O O
nerve O O
and O O
brain O O
disorders O O
that O O
were O O
refractory O O
to O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

One O O
promoter O O
, O O
p53P1 B B_GENE
, O O
is O O
located O O
100 O O
- O O
250 O O
bp O O
upstream O O
of O O
the O O
218 O O
- O O
bp O O
noncoding O O
first O O
exon O O
; O O
a O O
second O O
, O O
stronger O O
promoter O O
, O O
p53P2 B B_GENE
, O O
maps O O
within O O
the O O
first O O
intron O O
. O O

Both O O
PMP20 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
products I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contain O O
the O O
carboxyl O O
- O O
terminal O O
sequence O O
AKL O O
, O O
similar O O
to O O
the O O
putative O O
SKL O O
peroxisomal O O
sorting O O
sequence O O
( O O
Gould O O
, O O
S O O
. O O

The O O
likelihood O B_MEASURE/B_PERSON
of O O
death O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
more O B_MEASURE
than O O
3 O B_MEASURE
times O I_MEASURE
higher O I_MEASURE
among O O
patients O B_PERSON
in O O
the O O
ERA O B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
II O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
mortality O B_MEASURE
risk O I_MEASURE
ratio O I_MEASURE
3 O I_MEASURE
. O O
82 O B_MEASURE
[ O O
95 O B_MEASURE
% O I_MEASURE
CI O I_MEASURE
1 O I_MEASURE
. O O
48 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
to O O
9 O B_MEASURE
. O O
84 O B_MEASURE
] O I_MEASURE
, O O
p O O
= O O
0 O B_MEASURE
. O O
006 O B_MEASURE
) O O
. O O

Barium O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mucosal O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coating O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
judged O O
to O O
be O O
better O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
the O O
members O B_PERSON/B_BIO
to O O
whom O O
magnesium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulphate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
administered O O
( O O
p O B_MEASURE/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
0007 O B_MEASURE
) O O
. O O

In O O
both O O
immortalized O B_DISEASE/B_GENE
and O O
normal O B_TIME[MEASURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
diploid O I_TIME[MEASURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
human O I_TIME[MEASURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_TIME[MEASURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
wt O O
AAV O B_DISEASE
targeted O O
integration O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
ch O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
19 O B_MEASURE/B_BIO
. O O

The O O
corresponding O O
tetrapeptide O O
sequences O O
SSPD O O
and O O
SATD O O
for O O
human B B_GENE
and I I_GENE
mouse I I_GENE
PKC I I_GENE
- I I_GENE
epsilon I I_GENE
, O O
respectively O O
, O O
are O O
unusual O O
for O O
caspase B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
lipopolysaccharide O O
- O O
binding O O
protein O O
is O O
a O O
secretory B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
class I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acute I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
whose O O
gene O O
is O O
transcriptionally O O
activated O O
by O O
APRF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
STAT B B_GENE
/ I I_GENE
3 I I_GENE
and O O
other O O
cytokine O O
- O O
inducible O O
nuclear O O
proteins O O
. O O

Tritium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
concentrations O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
environmental O B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
water O I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples O I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
found O O
to O O
be O O
determined O O
within O O
an O O
accuracy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
10 O B_MEASURE
% O I_MEASURE
by O O
this O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O O
Vi O B_MEASURE/B_PROTEIN[GENE]
/ O O
Vf O B_MEASURE/B_DISEASE
was O O
14 O B_MEASURE/B_LOCATION
- O O
25 O B_MEASURE
. O O

This O O
region O O
does O O
not O O
contain O O
a O O
consensus O O
estrogen O O
response O O
element O O
, O O
and O O
ER B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding O O
to O O
this O O
DNA O O
sequence O O
was O O
not O O
observed O O
. O O

These O O
proteins O O
, O O
called O O
variant B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
surface I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glycoproteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
VSGs B B_LOCATION/B_ORGANIZATION
) O O
, O O
are O O
expressed O O
from O O
a O O
specific O O
locus O O
, O O
the O O
VSG B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ES I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
strangulated O O
intestinal O O
pathologies O O
of O O
horses O O
are O O
accompanied O O
by O O
a O O
local O O
activation O O
of O O
the O O
neutrophils O O
, O O
that O O
can O O
be O O
revealed O O
by O O
measuring O O
the O O
tissular O O
enzymatic O O
activity O O
of O O
the O O
granulocytic O O
enzyme O O
myeloperoxidase B B_ENZYME[GENE]/B_MEASURE
( O O
MPO B B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

A O O
deletion O O
analysis O O
of O O
the O O
FAS1 B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
lacking O O
the O O
previously O O
characterized O O
inositol O O
/ O O
choline O O
- O O
responsive O O
- O O
element O O
motif O O
defined O O
a O O
region O O
( O O
nucleotides O O
- O O
760 O O
to O O
- O O
850 O O
) O O
responsible O O
for O O
most O O
of O O
the O O
remaining O O
activation O O
potency O O
. O O

Here O O
we O O
report O O
the O O
fabrication O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
single O B_NUMBER[MEASURE]
- O O
molecule O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transistors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
based O O
on O O
individual O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
C60 O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
molecules O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
connected O O
to O O
gold O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
electrodes O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
homeodomain B B_PROTEIN[GENE]/B_LOCATION
transcription I I_PROTEIN[GENE]/I_LOCATION
factor I I_PROTEIN[GENE]/I_LOCATION
CDP B I_PROTEIN[GENE]/I_LOCATION
/ O O
cut B B_PROTEIN[GENE]/B_LOCATION
interacts O O
with O O
the O O
cell O O
cycle O O
regulatory O O
element O O
of O O
histone B B_GENE
H4 I I_GENE
genes I I_GENE
packaged O O
into O O
nucleosomes O O
. O O

They O O
encode O O
proteins O O
whose O O
core O O
regions O O
display O O
great O O
similarity O O
to O O
Aspergillus B B_SPECIES[BIO]/B_GENE
HAPB I B_SPECIES[BIO]/I_GENE
, O O
HAPC B B_DISEASE/B_LOCATION
and O O
HAPE B B_DISEASE/B_PROTEIN[GENE]
and O O
to O O
known O O
HAP B B_GENE/B_BIO
homologs I I_GENE/I_BIO
from O O
other O O
organisms O O
. O O

Furthermore O O
, O O
the O O
cognate O B_GENE
binding O I_GENE
protein O I_GENE
is O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
both O O
rat O B_SPECIES[BIO]/B_GENE
and O O
human O B_SPECIES[BIO]
( O O
HeLa O B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
) O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
nuclear O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
extracts O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Transient O O
cotransfection O O
analyses O O
indicate O O
that O O
the O O
cooperative O O
association O O
of O O
NF B B_GENE
- I I_GENE
IL I I_GENE
- I I_GENE
6 I I_GENE
and O O
RelA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
with O O
the O O
IL B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
8 I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
results O O
in O O
synergistic O O
transcriptional O O
activation O O
. O O

Heart O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
rate O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
during O O
the O O
behavioral O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
avoidance O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
shown O O
to O O
be O O
as O O
susceptible O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
experimental O B_DISEASE
demand O I_DISEASE
as O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O O
shown O O
approach O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
behaviors O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O O
be O O
influenced O O
. O O

Function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
retained O O
when O O
one O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
copy O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
of O O
the O O
sequence O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
suggesting O O
that O O
this O O
sequence O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
represents O O
an O O
essential O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
element O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Decreased O O
plasma O O
level O O
of O O
antithrombin B B_GENE
III I I_GENE
was O O
assumed O O
to O O
be O O
one O O
of O O
the O O
major O O
factors O O
underlying O O
hypercoagulable O O
state O O
in O O
nephrotic O O
syndrome O O
. O O

NO2 O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
pollution O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
on O O
major O B_LOCATION
trunk O I_LOCATION
roads O I_LOCATION
frequently O O
exceeded O O
British O B_LOCATION/B_ORGANIZATION
and O O
European O B_LOCATION/B_PERSON
Union O I_LOCATION/I_PERSON
air O I_LOCATION/I_PERSON
quality O I_LOCATION/I_PERSON
standards O I_LOCATION/I_PERSON
, O O
while O O
particle O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pollution O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Cotransfection O O
of O O
pINV O O
- O O
2473 O O
, O O
a O O
construct O O
containing O O
2473 O O
base O O
pairs O O
of O O
hINV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
upstream I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
linked O O
to O O
luciferase B B_GENE
, O O
with O O
POU B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
homeodomain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Oct1 B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
Oct2 B B_GENE/B_DISEASE
, O O
Brn4 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
SCIP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Skn1a B B_GENE/B_DISEASE
or O O
Skn1i B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
results O O
in O O
a O O
strong O O
suppression O O
of O O
basal O O
promoter O O
activity O O
. O O

87 O B_MEASURE
, O O
7270 O B_MEASURE
- O O
7274 O B_MEASURE
) O O
. O O

I O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Transcripts O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
initiating O O
at O O
the O O
CAGT O B_GENE/B_LOCATION
motif O I_GENE/I_LOCATION
( O O
proximal O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
transcripts O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
were O O
abolished O O
by O O
deletion O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
proximal O B_GENE/B_LOCATION
TATA O I_GENE/I_LOCATION
box O I_GENE/I_LOCATION
located O O
at O O
- O O
29 O B_TIME[MEASURE]/B_LOCATION
relative O I_TIME[MEASURE]/I_LOCATION
to O O
CAGT O B_MEASURE/B_GENE
. O O

Genomic O O
DNA O O
blot O O
analysis O O
indicates O O
that O O
the O O
trout B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
L2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
locus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O O
a O O
cluster O O
- O O
like O O
organization O O
similar O O
to O O
the O O
trout B B_GENE
L1 I I_GENE
locus I I_GENE
and O O
the O O
IgL B B_GENE/B_MEASURE
locus I I_GENE/I_MEASURE
of O O
several O O
teleost O O
fish O O
. O O

Although O O
the O O
energy O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
based O O
DFT O B_MEASURE
was O O
not O O
affected O O
by O O
isoproterenol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
from O O
6 O B_NUMBER[MEASURE]
. O O
1 O B_MEASURE/B_LOCATION
+ O I_MEASURE/I_LOCATION
/ O O
- O O
1 O B_NUMBER[MEASURE]
. O O
5 O B_MEASURE
to O O
6 O B_MEASURE
. O O
0 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
1 O B_NUMBER[MEASURE]
. O O
7 O B_MEASURE
J O I_MEASURE
) O O
, O O
it O O
was O O
decreased O O
to O O
3 O B_NUMBER[MEASURE]
. O O
7 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
1 O B_NUMBER[MEASURE]
. O O
6 O B_MEASURE
J O I_MEASURE
in O O
the O O
third O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stage O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
infusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
E4031 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
isoproterenol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
p O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
01 O B_MEASURE/B_PERSON
vs O I_MEASURE/I_PERSON
. O O
baseline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
vs O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
isoproterenol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
. O O

Gore O B_PERSON
& O O
Associates O B_PERSON
, O O
Inc O B_ORGANIZATION/B_MEASURE
. O O
) O O
standard O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
wall O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
graft O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
segments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
varying O O
in O O
length O B_MEASURE/B_LOCATION
from O O
4 O B_NUMBER[MEASURE]
to O O
12 O B_MEASURE
cm O I_MEASURE
. O O

The O O
dynamics O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
interaction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
retention O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
3 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
hr O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
CPB O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
was O O
quantified O O
with O O
autologous O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
In O O
- O O
111 O B_TIME[MEASURE]/B_BIO
labeled O O
neutrophils O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
INN O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
in O O
4 O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
20 O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Yorkshire O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pigs O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
28 O B_MEASURE
- O O
35 O B_MEASURE
kg O I_MEASURE
, O O
5 O B_PERSON/B_LOCATION
sham O I_PERSON/I_LOCATION
; O O
5 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
CPB O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
, O O
1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hr O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
5 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
CPB O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
3 O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hr O I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
5 O B_MEASURE
CPB O I_MEASURE
with O O
heparinized O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
circuit O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
3 O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hr O B_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
; O O
anesthetized O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pigs O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
injected O O
with O O
INN O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
500 O B_MEASURE
- O O
650 O B_MEASURE
microCi O I_MEASURE
) O O
, O O
30 O B_TIME[MEASURE]
min O I_TIME[MEASURE]
before O O
CPB O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
heparinized O O
, O O
and O O
underwent O O
CPB O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
a O O
roller O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PRODUCT[OBJECT]
pump O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PRODUCT[OBJECT]
, O O
a O O
hollow O B_LOCATION/B_PROTEIN[GENE]
fiber O I_LOCATION/I_PROTEIN[GENE]
OX O I_LOCATION/I_PROTEIN[GENE]
( O O
Bentley O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CM O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
50 O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
5 O B_MEASURE
. O O
0 O B_MEASURE
m2 O I_MEASURE
) O O
and O O
AF O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Bentley O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AF O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
025 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
0 O B_MEASURE
. O O
25 O B_MEASURE
m2 O I_MEASURE
) O O
at O O
2 O B_NUMBER[MEASURE]/B_LOCATION
. O O
5 O B_MEASURE
- O O
3 O B_MEASURE
. O O
6 O B_MEASURE/B_LOCATION
l O I_MEASURE/I_LOCATION
/ O O
min O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
3 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hr O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
region O B_LOCATION/B_MEASURE
immediately O O
following O O
the O O
promoter O B_GENE
and O O
5 O B_MEASURE
' O O
to O O
ORF1 O B_GENE/B_SPECIES[BIO]
has O O
a O O
potential O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
transcription O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
terminator O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sequence O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

Studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O O
recurrences O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
gingival O B_DISEASE/B_PERSON
hyperplasia O B_DISEASE/I_PERSON

Preface O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
and O O
acknowledgements O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

We O O
conclude O O
that O O
clonidine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
micrograms O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
kg O B_MEASURE
produces O O
sedation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
comparable O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O O
diazepam O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
0 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O
2 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
and O O
also O O
attenuates O O
the O O
intubation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
response O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
without O O
increasing O O
the O O
incidence O B_MEASURE
of O O
complications O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Pancreatic O O
expression O O
of O O
the O O
glucagon B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
gene I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
depends O O
on O O
multiple O O
transcription O O
factors O O
interacting O O
with O O
at O O
least O O
three O O
DNA O O
control O O
elements O O
: O O
G1 O O
, O O
the O O
upstream O O
promoter O O
element O O
, O O
and O O
G2 O O
and O O
G3 O O
, O O
two O O
enhancer O O
- O O
like O O
sequences O O
. O O

We O O
have O O
compared O O
the O O
ability O O
of O O
GST B B_GENE/B_BIO
- O O
Bem3 B B_MEASURE/B_GENE
to O O
serve O O
as O O
a O O
GAP B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
Cdc42Hs B B_GENE
relative O O
to O O
other O O
members O O
of O O
the O O
rho B B_GENE
- O O
GAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subfamily O O
and O O
found O O
the O O
following O O
order O O
of O O
potency O O
: O O
human B B_GENE
platelet I I_GENE
Cdc42Hs I I_GENE
GAP I I_GENE
> O O
p190 B B_GENE
> O O
Bem3 B B_GENE
> O O
break B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
point I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cluster I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
whereas O O
p85 B B_GENE
, O O
like O O
Bem2 B B_GENE
, O O
shows O O
no O O
GAP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activity O O
or O O
any O O
ability O O
to O O
bind O O
to O O
the O O
GTP O O
- O O
bound O O
form O O
of O O
Cdc42Hs B B_GENE
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Men O B_PERSON
presenting O O
with O O
urethritis O B_DISEASE
and O O
women O B_PERSON/B_BIO
presenting O O
with O O
PID O B_DISEASE
both O O
have O O
significantly O O
greater O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
peripheral O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
blood O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
mononuclear O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
cell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
proliferative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
responses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O O
the O O
DK20 O B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strain O B_BACTERIUM[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
C O B_VIRUS[BIO]/B_DISEASE
trachomatis O I_VIRUS[BIO]/I_DISEASE
than O O
controls O B_PERSON/B_BIO
. O O

The O O
PDSS O B_DISEASE/B_GENE
identified O O
17 O B_MEASURE
( O O
94 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
of O O
the O O
women O B_PERSON
diagnosed O O
with O O
major O B_DISEASE/B_LOCATION
postpartum O I_DISEASE/I_LOCATION
depression O I_DISEASE/I_LOCATION
, O O
the O O
EPDS O B_DISEASE/B_ORGANIZATION
identified O O
14 O B_MEASURE
of O O
these O O
women O B_PERSON
( O O
78 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
, O O
and O O
the O O
BDI O B_LOCATION/B_DISEASE
- O O
II O B_MEASURE/B_LOCATION
identified O O
10 O B_NUMBER[MEASURE]
of O O
the O O
18 O B_PERSON/B_MEASURE
women O I_PERSON/I_MEASURE
( O O
56 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
. O O

Men O B_PERSON
and O O
women O B_PERSON/B_BIO
entering O O
psychotherapy O B_LOCATION/B_ORGANIZATION
more O O
often O O
had O O
negative O B_DISEASE
Wish O I_DISEASE
elements O I_DISEASE
than O O
others O B_PERSON
. O O

Single O O
amino O O
acid O O
substitutions O O
were O O
shown O O
to O O
result O O
from O O
the O O
mutations O O
pdr1 B B_GENE
- I I_GENE
2 I I_GENE
( O O
M308I O O
) O O
, O O
pdr1 B B_PROTEIN[GENE]/B_MEASURE
- I I_PROTEIN[GENE]/I_MEASURE
3 I I_PROTEIN[GENE]/I_MEASURE
( O O
F815S O O
) O O
, O O
pdr1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
K302Q O O
) O O
, O O
pdr1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
P298A O O
) O O
and O O
pdr1 B B_MEASURE
- I I_MEASURE
8 I I_MEASURE
( O O
L1036 O O
W O O
) O O
, O O
whereas O O
the O O
intragenic O O
suppressor O O
mutant O O
pdr1 B B_GENE/B_BIO
- I I_GENE/I_BIO
100 I I_GENE/I_BIO
is O O
deleted O O
for O O
the O O
two O O
amino O O
acids O O
L537 O O
and O O
A538 O O
. O O

Both O O
merR B B_GENE
genes I I_GENE
consist O O
of O O
a O O
408 O O
bp O O
ORF O O
coding O O
for O O
135 O O
amino O O
acids O O
. O O

Amniotic O O
fluid O O
ionic O O
concentration O O
in O O
response O O
to O O
chronic O O
fetal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
vasopressin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
infusion O O
. O O

The O O
same O B_BODY_PART_OR_ORGAN_COMPONENT/B_ENT
slice O I_BODY_PART_OR_ORGAN_COMPONENT/I_ENT
was O O
imaged O O
three O B_TIME[MEASURE]/B_LOCATION
times O I_TIME[MEASURE]/I_LOCATION
each O O
with O O
sequences O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
using O O
spatial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presaturation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
not O O
. O O

Molecular O O
cloning O O
of O O
the O O
alpha B B_GENE
- I I_GENE
globin I I_GENE
transcription I I_GENE
factor I I_GENE
CP2 B I_GENE
. O O

The O O
most O O
distal O O
active O O
site O O
in O O
TIGA B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
created O O
by O O
excision O O
of O O
a O O
66 O O
- O O
bp O O
intron O O
. O O

Denaturing O O
gradient O O
gel O O
electrophoresis O O
( O O
DGGE O O
) O O
with O O
sequence O O
analysis O O
showed O O
that O O
PGCL4 B B_GENE
is O O
a O O
major O O
member O O
in O O
the O O
female O O
mammary O O
gland O O
, O O
and O O
in O O
the O O
submaxillary O O
and O O
lachrymal O O
glands O O
of O O
both O O
sexes O O
, O O
while O O
the O O
counterpart O O
in O O
male O O
liver O O
and O O
the O O
coagulate O O
glands O O
was O O
found O O
to O O
be O O
PGCL1 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. O O

All O O
possessed O O
cutaneous O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
receptive O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
fields O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O O
the O O
distal O B_LOCATION/B_BIO
segments O I_LOCATION/I_BIO
of O O
digits O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
2 O I_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
3 O B_NUMBER[MEASURE]
, O O
or O O
4 O B_NUMBER[MEASURE]/B_LOCATION
. O O

Sesame O B_PERSON/B_DISEASE
seed O I_PERSON/I_DISEASE
should O O
also O O
be O O
considered O O
a O O
cause O B_PERSON/B_DISEASE
of O O
allergic O B_DISEASE
reactions O I_DISEASE
to O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
products O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
cosmetics O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Ligand O O
binding O O
of O O
multi O O
- O O
chain O O
antigen O O
receptors O O
and O O
hematopoietin B B_GENE
/ O O
cytokine O O
receptors O O
results O O
in O O
rapid O O
activation O O
of O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PTK B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
- O O
dependent O O
signalling O O
molecules O O
such O O
as O O
phosphatidylinositol B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PI B B_GENE/B_LOCATION
3 I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
kinase I I_GENE/I_LOCATION
) O O
. O O

The O O
UASB O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
reactors O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
treated O O
a O O
VFA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
mixture O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
( O O
with O O
an O O
acetate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
propionate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
butyrate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ratio O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
5 O B_NUMBER[MEASURE]
: O O
3 O B_MEASURE
: O O
2 O B_MEASURE
on O O
COD O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
basis O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
or O O
acetate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
the O O
sole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
substrate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
at O O
different O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
COD O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O O
sulfate O B_MEASURE/B_LOCATION
ratios O I_MEASURE/I_LOCATION
. O O

The O O
authors O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
emphasize O O
absence O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
specific O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signs O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
vagal O B_DISEASE
involvement O I_DISEASE
, O O
importance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
diagnosis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
surgical O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
extirpation O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
mildness O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
post O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
operative O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
course O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Now O O
: O O
pleasure O B_PERSON/B_LOCATION
in O O
work O B_LOCATION/B_PERSON

This O O
article O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reviews O O
current O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
concepts O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
pathophysiology O B_DISEASE/B_LOCATION
and O O
summarises O O
clinical O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
features O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
natural O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
history O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
available O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Previous O O
data O O
suggested O O
a O O
subtle O O
increase O O
in O O
serum O O
P O O
at O O
the O O
time O O
of O O
hCG B B_GENE
injection O O
without O O
LH B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
surge O O
reduces O O
the O O
PR O O
of O O
women O O
having O O
oocyte O O
retrievals O O
for O O
IVF O O
; O O
this O O
study O O
compared O O
PRs O O
of O O
recipients O O
in O O
a O O
shared O O
oocyte O O
program O O
according O O
to O O
the O O
donors O O
' O O
pre B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
hCG I B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
P O O
level O O
. O O

Adequacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
Haldane O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
transformation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
in O O
the O O
computation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
exercise O B_MEASURE
V O I_MEASURE
O2 O I_MEASURE
in O O
man O B_PERSON/B_MEASURE
. O O

M O B_OTHER/B_MEASURE
. O O
, O O
Adrich O B_PERSON
, O O
Z O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
Fournet O B_PERSON/B_LOCATION
, O O
B O B_PROTEIN[GENE]/B_DISEASE
. O O
, O O
Capon O B_PERSON
, O O
C O B_PROTEIN[GENE]/B_LOCATION
. O O
, O O
Bonicel O B_PERSON
, O O
J O B_OTHER/B_PROTEIN[GENE]
. O O

Association O B_ORGANIZATION/B_LOCATION
between O O
hyperhomocysteinemia O B_DISEASE/B_ORGANISM_FUNCTION
and O O
ischemic O B_DISEASE
heart O I_DISEASE
disease O I_DISEASE
in O O
Sri O B_PERSON/B_BIO
Lankans O I_PERSON/I_BIO
. O O

Radiological O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
imaging O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
such O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
as O O
UGI O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
series O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
CT O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
scan O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
useful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
arrive O O
at O O
an O O
accurate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
diagnosis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

The O O
architecture O O
of O O
the O O
hRap1 B B_GENE/B_LOCATION
Myb B I_GENE/I_LOCATION
domain I I_GENE/I_LOCATION
is O O
very O O
close O O
to O O
that O O
of O O
each O O
of O O
the O O
Myb B B_GENE/B_BIO
domains I I_GENE/I_BIO
from O O
TRF1 B B_SPECIES[BIO]/B_GENE
, O O
scRap1p B B_GENE
and O O
c B B_GENE
- I I_GENE
Myb I I_GENE
. O O

80 O O
v B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ets I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
encoded O O
amino O O
- O O
acids O O
located O O
immediately O O
after O O
the O O
v B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
myb I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
v B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ets I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
junction O O
are O O
not O O
found O O
in O O
P54 B B_GENE
/ O O
56c B B_MEASURE
- I I_MEASURE
ets I I_MEASURE
, O O
the O O
translation O O
product O O
of O O
the O O
c B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ets I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proto I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
oncogene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
nor O O
in O O
a O O
set O O
of O O
cellular O O
proteins O O
of O O
64 O O
, O O
62 O O
, O O
and O O
60 O O
kDa O O
related O O
to O O
but O O
distinct O O
from O O
P54 B B_GENE
/ O O
56c B B_MEASURE
- I I_MEASURE
ets I I_MEASURE
. O O

We O O
have O O
raised O O
antibodies O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O O
a O O
peptide O B_GENE/B_MEASURE
specific O I_GENE/I_MEASURE
to O O
the O O
predicted O O
protein O B_GENE/B_LOCATION
product O B_GENE/I_LOCATION
of O O
this O O
second O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Because O O
controlled O O
- O O
release O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
niacin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seems O O
to O O
be O O
more O O
potent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O O
crystalline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
niacin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
product O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
substitution O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
without O O
dose O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
adjustment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
should O O
be O O
avoided O O
. O O

Interobserver O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agreement O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
Nottingham O B_ORGANIZATION/B_LOCATION
histologic O I_ORGANIZATION/I_LOCATION
grading O I_ORGANIZATION/I_LOCATION
scheme O I_ORGANIZATION/I_LOCATION
for O O
infiltrating O O
duct O B_DISEASE
carcinoma O I_DISEASE
breast O I_DISEASE
. O O

This O O
dose O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
Na3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
citrate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O O
no O O
clinical O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
symptoms O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggestive O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hypocalcaemia O B_DISEASE
in O O
these O O
subjects O B_PERSON/B_BIO
, O O
even O O
though O O
the O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
acid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
citrate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
dextrose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
NIH O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
formula O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
A O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
ACD O B_DISEASE/B_LOCATION
- O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
under O O
identical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
conditions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
has O O
been O O
reported O O
to O O
reduce O O
significantly O O
the O O
level O B_MEASURE/B_LOCATION
of O O
total O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
calcium O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
serum O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
and O O
concomitantly O O
increase O O
the O O
number O B_DISEASE
or O O
reactions O B_DISEASE
occurring O O
in O O
donors O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Latex O O
products O O
( O O
gloves O O
, O O
balloons O O
, O O
and O O
condoms O O
) O O
directly O O
bound O O
IgE B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
from O O
all O O
four O O
patients O O
. O O

The O O
phosphoprotein B B_GENE
pUL69 I I_GENE
of O O
human O O
cytomegalovirus O O
( O O
HCMV O O
) O O
, O O
which O O
is O O
a O O
herpesvirus O O
of O O
considerable O O
medical O O
importance O O
in O O
immunosuppressed O O
patients O O
and O O
newborns O O
, O O
has O O
previously O O
been O O
identified O O
as O O
an O O
early B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
late I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
viral I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
can O O
stimulate O O
several O O
viral O O
and O O
cellular O O
promoters O O
and O O
thus O O
exerts O O
a O O
rather O O
broad O O
activation O O
pattern O O
. O O

Southern O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
performed O O
on O O
genomic O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrated O O
altered O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
CpG O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
methylation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
within O O
intron O B_GENE/B_LOCATION
1 O I_GENE/I_LOCATION
in O O
DNA O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
all O O
BCC O B_DISEASE/B_PERSON
compared O O
to O O
normal O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
mortal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
human O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
mammary O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
epithelial O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
HMEC O B_DISEASE/B_BACTERIUM[BIO]
) O O
. O O

Previous O O
studies O O
have O O
shown O O
that O O
TGFbeta1 B B_GENE
expression O O
is O O
upregulated O O
in O O
mouse O O
keratinocytes O O
infected O O
with O O
a O O
v B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_SPECIES[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rasHa I I_SPECIES[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
retrovirus O O
, O O
although O O
the O O
functional O O
significance O O
of O O
this O O
has O O
not O O
been O O
clear O O
. O O

An O O
increased O O
incidence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
ATN O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
been O O
reported O O
since O O
the O O
introduction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
of O O
cyclosporin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Using O O
a O O
GTP O O
- O O
dependent O O
, O O
brefeldin O O
A O O
- O O
sensitive O O
in O O
vitro O O
AP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O O
assay O O
, O O
we O O
have O O
determined O O
here O O
the O O
parameters O O
of O O
the O O
AP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O O
reaction O O
. O O

The O O
overall O B_MEASURE
rate O I_MEASURE
of O O
biohydrogenation O B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
C18 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
2 O B_NUMBER[MEASURE]
was O O
14 O B_MEASURE
. O O
3 O B_MEASURE
% O I_MEASURE
/ O O
h O O
, O O
but O O
declined O O
1 O B_MEASURE
. O O
2 O B_MEASURE
% O I_MEASURE
/ O O
h O B_OTHER/B_TIME[MEASURE]
for O O
each O O
percentage O B_TIME[MEASURE]/B_LOCATION
unit O I_TIME[MEASURE]/I_LOCATION
increase O I_TIME[MEASURE]/I_LOCATION
in O O
C18 O B_MEASURE/B_PROTEIN[GENE]
: O O
2 O B_NUMBER[MEASURE]
added O O
to O O
the O O
substrate O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Plasma B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
enteroglucagon I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
measured O O
before O O
and O O
during O O
three O O
hours O O
after O O
a O O
standard O O
meal O O
in O O
21 O O
untreated O O
adult O O
patients O O
with O O
suspected O O
coeliac O O
disease O O
who O O
all O O
had O O
villous O O
atrophy O O
of O O
the O O
small O O
intestinal O O
mucosa O O
and O O
malabsorption O O
, O O
and O O
in O O
nine O O
control O O
subjects O O
. O O

After O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
body O B_MEASURE/B_DISEASE
mass O B_MEASURE/I_DISEASE
index O B_MEASURE/I_DISEASE
, O O
trait O B_DISEASE/B_PERSON
anxiety O I_DISEASE/I_PERSON
and O O
anger O B_LOCATION/B_DISEASE
- O O
in O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remained O O
independent O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
predictors O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
diastolic O B_DISEASE/B_LOCATION
blood O I_DISEASE/I_LOCATION
pressure O I_DISEASE/I_LOCATION
among O O
the O O
women O B_PERSON/B_BIO
. O O

Regulation O O
of O O
the O O
human B B_GENE
stress I I_GENE
response I I_GENE
gene I I_GENE
GADD153 I I_GENE
expression O O
: O O
role O O
of O O
ETS1 B B_GENE
and O O
FLI B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
products I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
PRP4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Saccharomyces I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cerevisiae I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
an O O
essential O O
part O O
of O O
the O O
U4 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
U6 B B_MEASURE
snRNP O O
, O O
a O O
component O O
of O O
the O O
mRNA O O
splicing O O
apparatus O O
. O O

132 O B_MEASURE/B_ENT
varix O B_MEASURE/I_ENT
ligations O B_MEASURE/I_ENT
were O O
performed O O
during O O
44 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
separate O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
EVL O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
sessions O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
. O O

Here O O
RFX B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
X2BP B B_PROTEIN[GENE]/B_LOCATION
/ O O
DNA O O
complexes O O
were O O
formed O O
on O O
all O O
class O O
II O O
isotypes O O
regardless O O
of O O
the O O
ability O O
of O O
the O O
X O O
box O O
region O O
to O O
bind O O
either O O
factor O O
individually O O
. O O

The O O
psi B B_GENE/B_DISEASE
zeta I I_GENE/I_DISEASE
gene I I_GENE/I_DISEASE
has O O
a O O
nonsense O O
mutation O O
in O O
exon O O
1 O O
but O O
has O O
identical O O
promoter O O
sequence O O
and O O
RNA O O
processing O O
sites O O
to O O
the O O
zeta B B_GENE/B_BIO
gene I I_GENE/I_BIO
, O O
raising O O
the O O
possibility O O
that O O
both O O
psi B B_PROTEIN[GENE]
zeta I I_PROTEIN[GENE]
and O O
zeta B B_GENE
are O O
transcriptionally O O
active O O
. O O

Prospects O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
chemosterilant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
genetic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
control O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
rodents O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Serum O O
PRL B B_GENE
concentrations O O
significantly O O
increased O O
after O O
MCP O O
administration O O
in O O
normal O O
women O O
, O O
hyperprolactinemic O O
patients O O
with O O
normal O O
sella O O
and O O
patients O O
with O O
microadenoma O O
, O O
but O O
not O O
in O O
macroadenoma O O
patients O O
with O O
and O O
without O O
suprasellar O O
expansion O O
( O O
SSE O O
) O O
. O O

The O O
Id4 B B_GENE/B_BIO
protein I I_GENE/I_BIO
contains O O
a O O
HLH O O
domain O O
highly O O
conserved O O
among O O
the O O
dnHLH B B_GENE/B_BIO
proteins I I_GENE/I_BIO
from O O
mouse O O
and O O
drosophila O O
. O O

The O O
coding O O
region O O
of O O
nifA B B_GENE/B_BACTERIUM[BIO]
was O O
determined O O
using O O
a O O
translational O O
lacZ B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fusion I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
by O O
site O O
- O O
directed O O
mutagenesis O O
to O O
identify O O
which O O
of O O
four O O
in O O
frame O O
AUG O O
codons O O
was O O
used O O
. O O

Peptide O O
competition O O
studies O O
have O O
localized O O
a O O
cyclin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
A I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
interaction I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
site I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
a O O
Lys381Lys382Leu383Met384Phe385 O O
sequence O O
within O O
C O O
- O O
terminal O O
negative O O
regulatory O O
domain O O
of O O
human B B_GENE
p53 I I_GENE
. O O

Heterodimerization B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutant I I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RXR I I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
failed O O
to O O
alter O O
GFP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
VDR B B_PROTEIN[GENE]/B_LOCATION
and O O
nlsGFP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
VDR B B_PROTEIN[GENE]/B_LOCATION
distribution O O
or O O
activity O O
. O O

Like O O
troponin B B_GENE
Cs I I_GENE
and O O
calmodulins B B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
PfCPK B B_GENE
also O O
contains O O
four O O
EF O O
hand O O
calcium O O
- O O
binding O O
motifs O O
. O O

A O O
third O B_PERSON/B_ORGANIZATION
group O I_PERSON/I_ORGANIZATION
( O O
n O B_OTHER/B_MEASURE
= O O
10 O B_MEASURE
) O O
was O O
assigned O O
to O O
receive O O
the O O
canalith O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
repositioning O O
maneuver O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
without O O
mastoid O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
vibration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Upstream O O
of O O
the O O
afa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cluster I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
1 O O
. O O
2 O O
- O O
kb O O
region O O
was O O
found O O
to O O
be O O
96 O O
% O O
identical O O
to O O
the O O
RepFIB B B_LOCATION/B_GENE
sequence I I_LOCATION/I_GENE
of O O
one O O
of O O
the O O
enterotoxigenic O O
E O O
. O O
coli O O
plasmids O O
( O O
P307 O O
) O O
, O O
suggesting O O
a O O
common O O
ancestor O O
plasmid O O
. O O

The O O
cats O B_BIO/B_PERSON
with O O
stage O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
2 O B_DISEASE
lymphomas O I_DISEASE
that O O
were O O
FeLV O B_BIO/B_GENE
- O O
test O B_DISEASE_ADJECTIVE[DISEASE]
negative O I_DISEASE_ADJECTIVE[DISEASE]
had O O
the O O
best O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
response O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
treatment O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

We O O
hypothesize O O
that O O
the O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
acidic O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
activators O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
to O O
specifically O O
interact O O
with O O
multiple O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
components O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
transcription O B_GENE/B_LOCATION
initiation O B_GENE/I_LOCATION
complex O B_GENE/I_LOCATION
likely O O
underlies O O
the O O
dramatic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
functional O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
synergy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
exhibited O O
by O O
this O O
class O B_PERSON/B_MEASURE
of O O
activation O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domains O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

Where O O
the O O
resonator O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
has O O
two O B_MEASURE/B_LOCATION
holes O I_MEASURE/I_LOCATION
, O O
these O O
terms O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
should O O
be O O
somewhat O O
modified O O
: O O
A O B_OTHER/B_PROTEIN[GENE]
is O O
the O O
combined O B_MEASURE/B_LOCATION
area O I_MEASURE/I_LOCATION
of O O
the O O
two O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
holes O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
L O B_PROTEIN[GENE]/B_LOCATION
is O O
16 O B_MEASURE
/ O O
3pi O B_MEASURE
r O I_MEASURE
( O O
~ O O
1 O B_MEASURE
. O O
7r O B_MEASURE
) O O
for O O
a O O
simple O B_LOCATION/B_MEASURE
hole O I_LOCATION/I_MEASURE
in O O
a O O
thin O B_MEASURE/B_DISEASE
- O O
walled O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
vessel O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
r O B_OTHER/B_PROTEIN[GENE]
is O O
the O O
radius O B_MEASURE/B_LOCATION
of O O
one O B_LOCATION/B_MEASURE
hole O B_LOCATION/I_MEASURE
( O O
Seto O B_PERSON/B_LOCATION
, O O
1971 O B_MEASURE
) O O
. O O

Histological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
immunophenotypic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O O
12 O B_NUMBER[MEASURE]
large O I_NUMBER[MEASURE]
cell O I_NUMBER[MEASURE]
lymphomas O I_NUMBER[MEASURE]
( O O
11 O B_DISEASE/B_NUMBER[MEASURE]
B O B_DISEASE/I_NUMBER[MEASURE]
cell O B_DISEASE/I_NUMBER[MEASURE]
and O O
one O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
T O B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cell O B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
two O B_NUMBER[MEASURE]
small O I_NUMBER[MEASURE]
noncleaved O I_NUMBER[MEASURE]
cell O I_NUMBER[MEASURE]
lymphomas O I_NUMBER[MEASURE]
( O O
B O B_OTHER/B_DISEASE_ADJECTIVE[DISEASE]
- O O
cell O B_DISEASE/B_PROTEIN[GENE]
phenotype O B_DISEASE/I_PROTEIN[GENE]
) O O
, O O
and O O
five O B_MEASURE
low O I_MEASURE
grade O I_MEASURE
B O I_MEASURE
- O O
cell O B_DISEASE
lymphomas O I_DISEASE
( O O
two O B_DISEASE/B_NUMBER[MEASURE]
small O B_DISEASE/I_NUMBER[MEASURE]
lymphocytic O B_DISEASE/I_NUMBER[MEASURE]
and O O
three O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
follicular O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
mixed O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphomas O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
. O O

The O O
deviation O B_LOCATION/B_GENE
site O B_LOCATION/I_GENE
is O O
equivalent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
exon O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
1 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
exon O B_MEASURE
2 O I_MEASURE
splice O I_MEASURE
site O I_MEASURE
of O O
the O O
mouse O B_PROTEIN[GENE]/B_SPECIES[BIO]
C O I_PROTEIN[GENE]/I_SPECIES[BIO]
- O O
subunit O B_GENE/B_LOCATION
. O O

The O O
determination O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
diacetyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
, O O
2 O B_NUMBER[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
3 O B_NUMBER[MEASURE]
- O O
pentanedione O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
acetoin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
performed O O
in O O
two O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
steps O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

There O O
also O O
may O O
be O O
osmotic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
challenges O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
mucosal O O
cell O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
function O B_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
as O O
evidenced O O
by O O
the O O
different O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reaction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
rates O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
hyper O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
hypotonic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
saline O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

In O O
F9 O O
, O O
which O O
is O O
a O O
prototype O O
of O O
embryonal O O
carcinoma O O
cells O O
expressing O O
hst B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
expression O O
of O O
hst B B_GENE
gene I I_GENE
is O O
positively O O
regulated O O
by O O
a O O
downstream O O
octamer O O
motif O O
that O O
functions O O
as O O
an O O
enhancer O O
. O O

The O O
reading O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
achievement O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
students O B_PERSON
with O O
learning O O
disabilities O B_DISEASE
who O O
received O O
reading O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
instruction O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
through O O
the O O
DISTAR O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O O
compared O O
to O O
that O O
of O O
similar O B_PERSON
students O I_PERSON
using O O
basal O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reader O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
materials O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Two O O
putative O O
ATP O O
- O O
binding O O
domains O O
were O O
identified O O
, O O
one O O
in O O
the O O
amino O O
- O O
terminal O O
half O O
of O O
the O O
argA B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
encoded I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
other O O
in O O
the O O
carboxy O O
- O O
terminal O O
half O O
. O O

Chronic O B_DISEASE
granulocytic O I_DISEASE
leukemia O I_DISEASE
in O O
children O B_PERSON/B_LOCATION
. O O

Purified O O
phosphorylated O O
PhoP B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
( O O
PhoPP B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
) O O
had O O
a O O
half O O
- O O
life O O
of O O
approximately O O
2 O O
. O O
5 O O
h O O
, O O
which O O
was O O
reduced O O
to O O
about O O
15 O O
min O O
by O O
addition O O
of O O
the O O
same O O
molar O O
amount O O
of O O
* B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
PhoR I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
the O O
cytoplasmic O O
region O O
of O O
PhoR B B_GENE/B_DISEASE
) O O
. O O

This O O
transformation O O
suppression O O
by O O
Rb B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
further O O
shown O O
to O O
be O O
due O O
to O O
transcriptional O O
repression O O
of O O
neu B B_GENE
using O O
Rb B B_GENE
expressing O O
effector O O
plasmid O O
and O O
neu B B_GENE
promoter O O
- O O
chloramphenicol B B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
acetyltransferase I I_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
reporter O O
gene O O
. O O

Before O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
started O O
, O O
trabecular O B_DISEASE_ADJECTIVE[DISEASE]
bone O I_DISEASE_ADJECTIVE[DISEASE]
alterations O I_DISEASE_ADJECTIVE[DISEASE]
could O O
be O O
observed O O
which O O
were O O
typical O B_DISEASE_ADJECTIVE[DISEASE]
for O O
Paget O B_DISEASE
' O I_DISEASE
s O I_DISEASE
disease O I_DISEASE
of O O
bone O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
as O O
there O O
were O O
bulky O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
trabeculare O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
increased O O
remodelling O O
surfaces O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
giant O B_DISEASE
osteoclasts O I_DISEASE
. O O

T O B_PROTEIN[GENE]/B_LOCATION
. O O
infestans O B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
, O O
T O B_PROTEIN[GENE]/B_LOCATION
. O O
delpontei O B_SPECIES[BIO]/B_PERSON
, O O
T O B_PROTEIN[GENE]/B_LOCATION
. O O
rubrovaria O B_SPECIES[BIO]/B_LOCATION
, O O
T O B_PROTEIN[GENE]/B_LOCATION
. O O
sordida O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
T O B_PROTEIN[GENE]/B_LOCATION
. O O
guasayana O B_SPECIES[BIO]/B_LOCATION
and O O
T O B_PROTEIN[GENE]/B_LOCATION
. O O
vitticeps O B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
from O O
infestans O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subgroup O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
T O B_PROTEIN[GENE]/B_LOCATION
. O O
pallidipennis O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
from O O
rubrofasciata O B_LOCATION
, O O
were O O
studied O O
. O O

Overexpression O O
of O O
N O O
- O O
terminal O O
mutations O O
disturbs O O
mitosis O O
and O O
produces O O
elongated O O
cells O O
, O O
Using O O
a O O
PCR O O
approach O O
, O O
we O O
isolated O O
a O O
putative O O
homologue O O
of O O
Prp4 B B_GENE
from O O
human O O
and O O
mouse O O
cells O O
. O O

1 O B_NUMBER[MEASURE]
. O O

Biochemical O O
studies O O
and O O
studies O O
of O O
cells O O
expressing O O
mutant O O
IL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
indicate O O
that O O
IL B B_GENE
- I I_GENE
2 I I_GENE
- O O
induced O O
tyrosine B B_GENE
kinase I I_GENE
activation O O
initiates O O
a O O
complex O O
signaling O O
cascade O O
. O O

BACKGROUND O O
: O O
Peripheral O O
kappa B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agonists O O
may O O
provide O O
a O O
new O O
therapeutic O O
approach O O
for O O
the O O
treatment O O
of O O
functional O O
dyspepsia O O
. O O

Fourteen O B_PERSON/B_ENT
eyes O I_PERSON/I_ENT
( O O
38 O B_MEASURE
. O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
developed O O
DLK O B_DISEASE
after O O
an O O
epithelial O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
defect O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
representing O O
an O O
odds O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
ratio O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
13 O B_NUMBER[MEASURE]/B_ENT
times O I_NUMBER[MEASURE]/I_ENT
. O O

The O O
yeast O O
genome O O
contains O O
a O O
single O O
ORD1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
resides O O
on O O
chromosome O O
XI O O
. O O

The O O
system O B_ORGANIZATION/B_LOCATION
consists O O
of O O
a O O
TV O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
unit O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
compatible O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
to O O
IBM O B_LOCATION/B_DISEASE
PC O I_LOCATION/I_DISEASE
/ O O
AT O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
software O B_ORGANIZATION/B_LOCATION
. O O

The O O
N O O
- O O
terminal O O
sequence O O
of O O
the O O
extracellular B B_GENE
MEP20 I I_GENE
, O O
TKVAS B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
, O O
was O O
found O O
at O O
aa O O
194 O O
- O O
198 O O
within O O
the O O
ORF O O
. O O

Isolates O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
B O B_GENE/B_DISEASE
. O O
burgdorferi O B_BACTERIUM[BIO]/B_DISEASE
from O O
humans O B_PERSON/B_SPECIES[BIO]
, O O
rodents O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
I O O
. O O
dammini O B_SPECIES[BIO]/B_DISEASE
are O O
usually O O
indistinguishable O B_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
strains O B_BIO/B_PERSON
of O O
B O B_PROTEIN[GENE]/B_DISEASE
. O O
burgdorferi O B_BACTERIUM[BIO]/B_DISEASE
with O O
different O B_DISEASE_ADJECTIVE[DISEASE]
major O I_DISEASE_ADJECTIVE[DISEASE]
proteins O I_DISEASE_ADJECTIVE[DISEASE]
have O O
been O O
identified O O
. O O

Cloning O O
of O O
the O O
GATA B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
binding I I_GENE/I_LOCATION
protein I I_GENE/I_LOCATION
that O O
regulates O O
endothelin B B_GENE
- I I_GENE
1 I I_GENE
gene I I_GENE
expression O O
in O O
endothelial O O
cells O O
. O O

The O O
Synechococcus B B_GENE/B_BACTERIUM[BIO]
gene I I_GENE/I_BACTERIUM[BIO]
rps1 I I_GENE/I_BACTERIUM[BIO]
encoding O O
S1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
located O O
1 O O
. O O
1 O O
kb O O
downstream O O
from O O
psbB B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
, O O
which O O
encodes O O
the O O
photosystem B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
II I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
P680 I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
chlorophyll I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
a I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
apoprotein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Two O B_NUMBER[MEASURE]
- O O
dimensional O B_MEASURE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
echocardiographic O I_MEASURE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
parasternal O I_MEASURE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
long O I_MEASURE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
short O B_MEASURE
- O O
axis O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
views O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O O
obtained O O
during O O
graded O O
bleeding O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O O
rapid O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
withdrawal O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
blood O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
from O O
an O O
arterial O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cannula O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
with O O
increments O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
5 O B_MEASURE/B_DISEASE
% O I_MEASURE/I_DISEASE
each O O
up O O
to O O
30 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
of O O
calculated O B_MEASURE/B_PERSON
blood O B_MEASURE/I_PERSON
volume O B_MEASURE/I_PERSON
. O O

A O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
rate O B_MEASURE
of O O
recovery O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
time O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
detection O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O O
mycobacteria O B_BACTERIUM[BIO]/B_DISEASE
from O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specimens O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
newly O O
developed O O
Mycobacteria O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Growth O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Indicator O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Tube O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MGIT O B_LOCATION/B_GENE
) O O
, O O
the O O
biphasic O B_DISEASE/B_PERSON
Septi O I_DISEASE/I_PERSON
- O O
Chek O B_MEASURE/B_BACTERIUM[BIO]
, O O
and O O
the O O
egg O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
based O O
Ogawa O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
medium O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O O
made O O
. O O

As O O
in O O
IncP O O
alpha O O
plasmids O O
, O O
these O O
operons O O
are O O
transcribed O O
from O O
a O O
bidirectional O O
promoter O O
region O O
consisting O O
of O O
trfAp B B_GENE/B_BACTERIUM[BIO]
for O O
the O O
trfA B B_GENE
operon I I_GENE
and O O
trbAp B B_GENE
and O O
trbBp B B_GENE
for O O
the O O
trb B B_PERSON/B_GENE
operon I I_PERSON/I_GENE
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
These O O
principally O O
structural O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
support O O
the O O
hypothesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
that O O
the O O
thrombus O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
is O O
a O O
self O B_PERSON/B_LOCATION
- O O
sustaining O O
entity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
that O O
may O O
have O O
significance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
pathophysiologic O B_DISEASE_ADJECTIVE[DISEASE]
mechanism O I_DISEASE_ADJECTIVE[DISEASE]
of O O
abdominal O B_DISEASE/B_LOCATION
aortic O I_DISEASE/I_LOCATION
aneurysms O I_DISEASE/I_LOCATION
. O O

The O O
BHV B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
UL24 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
UL25 B B_MEASURE
, O O
UL26 B B_MEASURE
and O O
UL26 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
. I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
5 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
all O O
terminated O O
at O O
a O O
common O O
3 O O
' O O
- O O
polyadenylation O O
site O O
and O O
varied O O
significantly O O
in O O
their O O
relative O O
abundance O O
. O O

Electrophoretic O O
mobility O O
shift O O
analysis O O
of O O
protein O O
- O O
DNA O O
complexes O O
formed O O
with O O
nuclear O O
proteins O O
isolated O O
from O O
I3C O O
- O O
treated O O
and O O
- O O
untreated O O
cells O O
, O O
in O O
combination O O
with O O
supershift O O
assays O O
using O O
Sp1 B B_GENE
antibodies I I_GENE
, O O
demonstrated O O
that O O
the O O
Sp1 B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
binding I I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
in O O
the O O
CDK6 B B_GENE
promoter I I_GENE
forms O O
a O O
specific O O
I3C O O
- O O
responsive O O
DNA O O
- O O
protein O O
complex O O
that O O
contains O O
the O O
Sp1 B B_GENE/B_LOCATION
transcription I I_GENE/I_LOCATION
factor I I_GENE/I_LOCATION
. O O

These O O
results O O
suggest O O
that O O
both O O
the O O
distinct O O
DNA O O
binding O O
properties O O
of O O
PMLRAR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
homodimers I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
sequestration O O
of O O
RXR B B_GENE
by O O
PMLRARs B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
may O O
contribute O O
to O O
the O O
molecular O O
mechanisms O O
which O O
underlie O O
the O O
pathogenesis O O
of O O
APL O O
. O O

The O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
showed O O
that O O
the O O
morning O B_TIME[MEASURE]
active O I_TIME[MEASURE]
( O O
MA O B_LOCATION
) O O
individuals O B_PERSON/B_ORGANIZATION
rose O O
earlier O O
and O O
went O O
to O O
bed O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
earlier O O
than O O
the O O
evening O B_TIME[MEASURE]/B_LOCATION
active O I_TIME[MEASURE]/I_LOCATION
( O O
EA O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
individuals O B_PERSON/B_ORGANIZATION
, O O
and O O
the O O
former O B_PERSON/B_TIME[MEASURE]
had O O
a O O
longer O B_MEASURE
sleep O I_MEASURE
length O I_MEASURE
than O O
the O O
latter O B_TIME[MEASURE]/B_PERSON
during O O
days O B_TIME[MEASURE]/B_PERSON
with O O
a O O
morning O B_TIME[MEASURE]/B_DISEASE
shift O B_TIME[MEASURE]/I_DISEASE
, O O
while O O
the O O
opposite O B_LOCATION/B_MEASURE
was O O
true O B_DISEASE_ADJECTIVE[DISEASE]
for O O
afternoon O B_TIME[MEASURE]
and O O
night O B_TIME[MEASURE]
shifts O I_TIME[MEASURE]
. O O

This O O
ERD O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
is O O
recorded O O
over O O
the O O
contralateral O B_BODY_PART_OR_ORGAN_COMPONENT/B_TIME[MEASURE]
central O I_BODY_PART_OR_ORGAN_COMPONENT/I_TIME[MEASURE]
region O I_BODY_PART_OR_ORGAN_COMPONENT/I_TIME[MEASURE]
. O O

Deletion O B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
mutations O I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
were O O
constructed O O
, O O
removing O O
residues O B_MEASURE
2 O I_MEASURE
- O O
30 O B_MEASURE
, O O
31 O B_MEASURE
- O O
60 O B_MEASURE
, O O
61 O B_MEASURE
- O O
90 O B_MEASURE
, O O
and O O
49 O B_MEASURE
- O O
78 O B_MEASURE
of O O
the O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_PROTEIN[GENE]/B_LOCATION
cytoplasmic O I_PROTEIN[GENE]/I_LOCATION
domain O I_PROTEIN[GENE]/I_LOCATION
, O O
as O O
well O O
as O O
a O O
missense O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mutation O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
a O O
dileucine O B_GENE
motif O I_GENE
. O O

Kluyveromyces O B_SPECIES[BIO]
lactis O I_SPECIES[BIO]
, O O
a O O
budding O O
yeast O B_SPECIES[BIO]
related O O
to O O
Saccharomyces O B_SPECIES[BIO]
cerevisiae O I_SPECIES[BIO]
, O O
can O O
grow O O
on O O
a O O
wider O B_MEASURE/B_LOCATION
variety O I_MEASURE/I_LOCATION
of O O
substrates O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
shows O O
less O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
sensitivity O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O O
glucose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
repression O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
than O O
does O O
Saccharomyces O B_SPECIES[BIO]
cerevisiae O I_SPECIES[BIO]
. O O

Low O O
- O O
affinity O O
E2 B B_GENE
- I I_GENE
binding I I_GENE
site I I_GENE
mediates O O
downmodulation O O
of O O
E2 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transactivation O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
papillomavirus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
8 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
late I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Untransformed O O
3T3 O O
cells O O
carry O O
abundant O O
1 O O
. O O
9 O O
kb O O
Hox B B_GENE/B_DISEASE
1 I I_GENE/I_DISEASE
. I I_GENE/I_DISEASE
3 I I_GENE/I_DISEASE
RNA O O
, O O
whereas O O
the O O
methylcholanthrene O O
- O O
transformed O O
MB66 O O
and O O
LTK O O
- O O
cells O O
or O O
3T3 O O
cells O O
transformed O O
by O O
the O O
oncogenes O O
src B B_GENE
, O O
fos B B_GENE
or O O
SV40 B B_GENE
T I I_GENE
antigen I I_GENE
express O O
only O O
low O O
levels O O
. O O

Although O O
analysis O O
of O O
the O O
similarity O O
between O O
the O O
44 O O
- O O
kDa O O
protein O O
and O O
the O O
E B B_PROTEIN[GENE]/B_BIO
. I I_PROTEIN[GENE]/I_BIO
coli I I_PROTEIN[GENE]/I_BIO
RecA I I_PROTEIN[GENE]/I_BIO
protein I I_PROTEIN[GENE]/I_BIO
did O O
not O O
show O O
any O O
significant O O
homology O O
between O O
them O O
, O O
it O O
revealed O O
their O O
identity O O
by O O
five O O
amino O O
- O O
acid O O
residues O O
involved O O
in O O
the O O
formation O O
of O O
the O O
epitope O O
that O O
recognized O O
the O O
paratope O O
of O O
the O O
RecA B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
subsequent O O
epitope O O
- O O
paratope O O
binding O O
of O O
these O O
proteins O O
. O O

Ureases B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
were O O
purified O O
from O O
the O O
recombinant O O
cells O O
and O O
shown O O
to O O
be O O
identical O O
to O O
control O O
enzyme O O
when O O
analyzed O O
by O O
gel O O
filtration O O
chromatography O O
and O O
sodium O O
dodecyl O O
sulfate O O
- O O
polyacrylamide O O
gel O O
electrophoresis O O
; O O
however O O
, O O
in O O
every O O
case O O
the O O
activity O O
levels O O
correlated O O
to O O
nickel O O
contents O O
as O O
analyzed O O
by O O
atomic O O
absorption O O
analysis O O
. O O

Deoxyuridine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
suppression O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
bone O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
marrow O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
culture O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
diagnosis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O O
macrocytic O B_DISEASE/B_GENE
refractory O I_DISEASE/I_GENE
anaemias O I_DISEASE/I_GENE
. O O

Finally O O
, O O
synthetic O O
peptides O O
corresponding O O
to O O
the O O
mutant O O
proteins O O
were O O
assessed O O
for O O
the O O
ability O O
to O O
act O O
as O O
substrates O O
for O O
PR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
psoralens O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
are O O
being O O
used O O
in O O
research O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
projects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sponsored O O
by O O
the O O
National O B_ORGANIZATION/B_LOCATION
Toxicology O I_ORGANIZATION/I_LOCATION
Program O I_ORGANIZATION/I_LOCATION
. O O

Root O B_LOCATION/B_PERSON
surface O B_LOCATION/I_PERSON
caries O O
incidence O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
groups O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inoculated O O
with O O
A O O
. O O
viscosus O B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
and O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O
viscosus O B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
plus O O
S O B_DISEASE/B_LOCATION
. O O
sobrinus O B_BACTERIUM[BIO]/B_DISEASE
did O O
not O O
differ O O
. O O

These O O
results O O
demonstrate O O
that O O
the O O
entire O O
E3L B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
is O O
required O O
for O O
pathogenesis O O
in O O
the O O
mouse O O
model O O
. O O

The O O
development O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
various O B_DISEASE
pathological O I_DISEASE
lesions O I_DISEASE
in O O
thymus O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
spleen O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
lymph O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nodes O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
bone O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
marrow O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
is O O
frequently O O
observed O O
. O O

Recently O O
, O O
we O O
have O O
demonstrated O O
that O O
mouse O O
microglial O O
cells O O
, O O
the O O
brain O O
macrophages O O
, O O
express O O
both O O
IL B B_GENE
- I I_GENE
15 I I_GENE
and O O
IL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
15 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
have O O
analyzed O O
the O O
role O O
of O O
the O O
HU B B_GENE
protein I I_GENE
in O O
invertasome O O
assembly O O
when O O
the O O
enhancer O O
is O O
located O O
at O O
variable O O
positions O O
close O O
to O O
one O O
of O O
the O O
recombination O O
sites O O
. O O

The O O
mode O B_DISEASE/B_LOCATION
of O O
action O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
is O O
often O O
suggested O O
as O O
an O O
explanation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
slopes O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
concentration O B_MEASURE/B_LOCATION
- O O
effect O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
curves O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

This O O
may O O
be O O
another O O
example O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
principle O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
- O O
less O B_NUMBER[MEASURE]/B_PERSON
is O O
more O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O O

A O O
wide O O
conservation O O
of O O
iscSUA B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
genes I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
nature O O
and O O
evidence O O
that O O
NifU B B_BACTERIUM[BIO]/B_GENE
and O O
NifS B B_LOCATION/B_GENE
participate O O
in O O
the O O
mobilization O O
of O O
iron O O
and O O
sulfur O O
for O O
nitrogenase B B_BIO/B_LOCATION
- O O
specific O O
iron O O
- O O
sulfur O O
cluster O O
formation O O
suggest O O
that O O
the O O
products O O
of O O
the O O
iscSUA B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
genes I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
could O O
play O O
a O O
general O O
role O O
in O O
the O O
formation O O
or O O
repair O O
of O O
iron O O
- O O
sulfur O O
clusters O O
. O O

On O O
transfer O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
from O O
glucose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
succinate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
malate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
or O O
glycerol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medium O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
citrate O O
medium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
the O O
Cit O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
+ O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
Escherichia O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
coli O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
strains O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
showed O O
a O O
delay O B_DISEASE/B_TIME[MEASURE]
of O O
36 O B_MEASURE
to O O
48 O B_MEASURE
h O O
before O O
growth O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

These O O
results O O
suggest O O
that O O
camptothecin O O
resistance O O
in O O
CEM O O
/ O O
DOX O O
cells O O
is O O
due O O
to O O
different O O
mechanism O O
( O O
s O O
) O O
than O O
topoisomerase B B_GENE/B_LOCATION
- O O
or O O
P B B_GENE
- I I_GENE
glycoprotein I I_GENE
- O O
associated O O
multidrug O O
resistance O O
. O O

Jornvall O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
B O B_OTHER/B_PERSON
. O O

The O O
pattern O O
of O O
expression O O
of O O
this O O
and O O
other O O
Chi26 B B_PROTEIN[GENE]/B_SPECIES[BIO]
/ O O
Chi33 B B_MEASURE
chimeric O O
promoters O O
suggest O O
that O O
the O O
E B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
region I I_GENE/I_LOCATION
contains O O
cis O O
- O O
acting O O
sequences O O
which O O
activate O O
transcription O O
in O O
aleurone O O
and O O
silence O O
transcription O O
in O O
leaves O O
. O O

Spontaneous O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
coronary O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
artery O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
spasm O O
during O O
coronary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
angiography O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
patient O B_PERSON/B_LOCATION
with O O
exercise O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
ST O B_DISEASE/B_LOCATION
segment O I_DISEASE/I_LOCATION
elevation O I_DISEASE/I_LOCATION
. O O

Four O O
newborns O O
in O O
this O O
group O O
became O O
HBsAg B B_DISEASE/B_PERSON
carriers O O
. O O

Effectively O O
, O O
the O O
upstream O O
, O O
housekeeping O O
- O O
type O O
promoter O O
responds O O
to O O
FIXK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
positively O O
regulates O O
the O O
downstream O O
, O O
sigma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
54 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

K O B_OTHER/B_PERSON
. O O
, O O
Weiss O B_PERSON/B_LANGUAGE
, O O
M O B_OTHER/B_PERSON
. O O

New O B_PERSON
TB O I_PERSON
respirator O I_PERSON
standards O I_PERSON
mean O O
more O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
choices O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
at O O
less O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cost O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Electrophoretic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mobility O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O O
shift O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
assays O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
using O O
oligonucleotides O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derived O O
from O O
these O O
sites O B_LOCATION/B_BIO
demonstrated O O
formation O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O O
specific O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
protein O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
complexes O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

A O O
5789 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nucleotide I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
long I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EcoRI I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fragment I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
the O O
genome O O
of O O
Thermotoga O O
maritima O O
, O O
identified O O
by O O
cross O O
- O O
hybridization O O
to O O
L11 B B_PROTEIN[GENE]
, O O
L1 B B_PROTEIN[GENE]/B_MEASURE
, O O
L10 B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
L12 B B_PROTEIN[GENE]/B_MEASURE
ribosomal I I_PROTEIN[GENE]/I_MEASURE
protein I I_PROTEIN[GENE]/I_MEASURE
gene I I_PROTEIN[GENE]/I_MEASURE
sequences I I_PROTEIN[GENE]/I_MEASURE
from I I_PROTEIN[GENE]/I_MEASURE
Escherichia I I_PROTEIN[GENE]/I_MEASURE
coli I I_PROTEIN[GENE]/I_MEASURE
, O O
was O O
cloned O O
and O O
sequenced O O
. O O

Background O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
reduction O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
various O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
had O O
a O O
prominent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
DTIn1 O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
as O O
well O O
as O O
99mTc O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
DTPA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
biodistribution O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

These O O
data O O
suggest O O
that O O
reduction O O
in O O
PRA O O
may O O
have O O
contributed O O
to O O
the O O
hemodynamic O O
effects O O
of O O
this O O
peak B B_GENE
III I I_GENE
PDE I I_GENE
inhibitor O O
. O O

The O O
following O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parameters O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
measured O O
: O O
onset O B_PROTEIN[GENE]/B_LOCATION
time O I_PROTEIN[GENE]/I_LOCATION
( O O
time O B_MEASURE/B_LOCATION
interval O I_MEASURE/I_LOCATION
from O O
injection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
maximal O B_MEASURE
or O O
total O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
block O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
T125 O B_MEASURE/B_PROTEIN[GENE]
/ O O
75 O B_MEASURE
( O O
time O B_TIME[MEASURE]/B_LOCATION
for O O
T1 O B_MEASURE
to O O
reach O O
25 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
or O O
75 O B_MEASURE
% O I_MEASURE
of O O
control O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
, O O
TOF70 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
time O B_TIME[MEASURE]/B_LOCATION
for O O
TOF O B_PROTEIN[GENE]
ratio O I_PROTEIN[GENE]
to O O
reach O O
70 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
of O O
control O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
, O O
heart O B_MEASURE/B_DISEASE
rate O I_MEASURE/I_DISEASE
and O O
blood O B_DISEASE/B_GENE
pressure O B_DISEASE/I_GENE
. O O

A O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Prematurely O O
inactivating O O
p42 B B_GENE
MAPK I I_GENE
in O O
egg O O
extracts O O
resulted O O
in O O
a O O
corresponding O O
hastening O O
of O O
the O O
first O O
mitosis O O
. O O

The O O
use O O
of O O
ALAD B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
activity O O
and O O
EP O O
as O O
cumulative O O
lead O O
exposure O O
indicators O O
is O O
suggested O O
. O O

Binding O O
of O O
C B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EBPs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
all O O
three O O
spi B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
' I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
UTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
repressor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
although O O
rather O O
weak O O
, O O
was O O
confirmed O O
by O O
electrophoretic O O
mobility O O
shift O O
assays O O
that O O
otherwise O O
failed O O
to O O
reveal O O
specific O O
interactions O O
with O O
other O O
liver O O
nuclear O O
proteins O O
in O O
vitro O O
. O O

Cell O O
cycle O O
regulatory O O
components O O
have O O
been O O
largely O O
conserved O O
in O O
eukaryotes O O
; O O
however O O
, O O
orthologs O O
of O O
neither O O
CAK1 B B_GENE
nor O O
csk1 B B_GENE
have O O
been O O
identified O O
in O O
other O O
species O O
to O O
date O O
. O O

In O O
this O O
study O O
, O O
we O O
cloned O O
the O O
full O O
- O O
length O O
cDNA O O
of O O
mouse O O
PAX4 B B_GENE/B_DISEASE
by O O
RACE O O
( O O
rapid O O
amplification O O
of O O
cDNA O O
ends O O
) O O
using O O
RNA O O
from O O
MIN6 O O
cells O O
, O O
a O O
mouse O O
insulinoma O O
cell O O
line O O
. O O

Kohtz O B_PERSON/B_COLOR
, O O
J O B_OTHER/B_PERSON
. O O

Hence O O
the O O
GAP1 B B_GENE
gene I I_GENE
encodes O O
a O O
protein O O
with O O
characteristics O O
typical O O
of O O
integral O O
membrane O O
proteins O O
translocating O O
ligants O O
across O O
cellular O O
membranes O O
. O O

The O O
results O O
suggest O O
that O O
proenzyme O O
processing O O
is O O
not O O
essential O O
for O O
secretion O O
of O O
PC2 B B_GENE
, O O
but O O
peptides O O
containing O O
mutations O O
that O O
affect O O
the O O
ability O O
of O O
the O O
propeptide O O
( O O
and O O
cleavage O O
sites O O
) O O
to O O
fold O O
within O O
the O O
catalytic O O
pocket O O
are O O
not O O
transferred O O
beyond O O
the O O
early O O
stages O O
of O O
the O O
secretory O O
pathway O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
transcription O B_GENE
influences O O
aspects O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
gene O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
conversion O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
after O O
initiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
strand O B_DISEASE/B_GENE
invasion O B_DISEASE/I_GENE
and O O
/ O O
or O O
mismatch O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
repair O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
MMR O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
. O O

Important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
prognostic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
factors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
physiotherapeutic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
exercises O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O O
intermittent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
claudication O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON

Finally O O
, O O
in O O
samples O O
obtained O O
from O O
two O O
patients O O
with O O
drug O O
refractory O O
ALL O O
, O O
BAC O O
- O O
derived O O
probes O O
applied O O
to O O
archived O O
marrow O O
cells O O
demonstrated O O
that O O
a O O
breakpoint O O
occurred O O
between O O
MDR1 B B_GENE/B_DISEASE
and O O
sequences O O
500 O O
- O O
1000 O O
KB O O
telomeric O O
to O O
MDR1 B B_GENE
, O O
consistent O O
with O O
a O O
random O O
chromosomal O O
rearrangement O O
. O O

Application O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
using O O
an O O
11 O B_NUMBER[MEASURE]
- O O
year O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
microseismicity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
record O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
revealed O O
systematic O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spatial O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
temporal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
slip O B_LOCATION/B_MEASURE
rate O I_LOCATION/I_MEASURE
that O O
were O O
synchronous O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
with O O
earthquake O B_MEASURE/B_LOCATION
activity O B_MEASURE/I_LOCATION
and O O
other O B_MEASURE
independent O I_MEASURE
measures O I_MEASURE
of O O
fault O B_DISEASE/B_LOCATION
- O O
zone O B_DISEASE_ADJECTIVE[DISEASE]
slip O I_DISEASE_ADJECTIVE[DISEASE]
. O O

PC12 O O
cultures O O
that O O
had O O
been O O
" O O
primed O O
" O O
in O O
this O O
way O O
showed O O
an O O
accelerated O O
and O O
augmented O O
differentiation O O
response O O
to O O
nerve B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
growth I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

One O O
of O O
these O O
clones O O
encodes O O
Xenopus B B_GENE
N I I_GENE
- I I_GENE
ras I I_GENE
. O O

The O O
Molteno O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
implant O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
is O O
an O O
effective O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
procedure O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
complicated O B_DISEASE_ADJECTIVE[DISEASE]
and O O
refractory O B_DISEASE_ADJECTIVE[DISEASE]
cases O I_DISEASE_ADJECTIVE[DISEASE]
of O O
glaucoma O B_DISEASE
in O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
eyes O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

The O O
median O O
levels O O
of O O
t B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
PA I I_GENE/I_LOCATION
Ag I I_GENE/I_LOCATION
and O O
PAI B B_LOCATION/B_GENE
in O O
plasma O O
were O O
respectively O O
10 O O
. O O
7 O O
ng O O
/ O O
ml O O
( O O
interquartile O O
range O O
8 O O
. O O
6 O O
ng O O
/ O O
ml O O
) O O
and O O
15 O O
. O O
7 O O
IU O O
/ O O
ml O O
( O O
interquartile O O
range O O
12 O O
. O O
2 O O
IU O O
/ O O
ml O O
) O O
. O O

In O O
the O O
remaining O O
91 O O
patients O O
( O O
group O O
2 O O
) O O
, O O
Pseudomonas O O
( O O
18 O O
) O O
, O O
coagulase B B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
negative O O
Staphylococci O O
( O O
15 O O
) O O
, O O
Staphylococcus O O
epidermidis O O
( O O
23 O O
) O O
, O O
Staphylococcus O O
aureus O O
( O O
16 O O
) O O
, O O
Corynebacterium O O
species O O
( O O
12 O O
) O O
, O O
and O O
others O O
( O O
seven O O
) O O
were O O
isolated O O
. O O

Stamps O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
cardiology O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
: O O
de O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Musset O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sign O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
factor O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
present O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
nuclear O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
extracts O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
wounded O O
potato O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
tubers O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
was O O
found O O
to O O
bind O O
specifically O O
to O O
nucleotides O B_GENE/B_DISEASE
located O O
between O O
- O O
135 O B_MEASURE
to O O
- O O
105 O B_MEASURE
, O O
suggesting O O
that O O
this O O
region O B_LOCATION/B_BIO
contains O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cis O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
- O O
regulatory O B_GENE/B_ORGANIZATION
elements O I_GENE/I_ORGANIZATION
. O O

The O O
leucine O O
zipper O O
region O O
of O O
ATF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
also O O
similar O O
to O O
that O O
of O O
the O O
AP B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
/ O O
c B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
jun I I_GENE/I_MEASURE
family O O
of O O
transcription O O
factors O O
, O O
whose O O
DNA O O
- O O
binding O O
site O O
differs O O
from O O
the O O
ATF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
binding O O
site O O
at O O
a O O
single O O
position O O
. O O

The O O
R260A O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutant O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
as O O
expected O O
, O O
was O O
unable O B_DISEASE_ADJECTIVE[DISEASE]
to O O
support O O
mRNA O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
synthesis O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
a O O
transcription O B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
reconstitution O B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
reaction O B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
as O O
well O O
as O O
transcription O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
vivo O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
a O O
minigenome O B_GENE
using O O
a O O
reverse O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genetic O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
approach O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

PEAP O B_DISEASE/B_GENE
was O O
significantly O O
higher O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
IDC O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
patients O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
compared O O
to O O
controls O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
( O O
48 O B_MEASURE
. O O
7 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
32 O B_MEASURE
. O O
6 O B_MEASURE/B_SPORT[ENT]
vs O I_MEASURE/I_SPORT[ENT]
. O O

Uterine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
contractions O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
began O O
with O O
a O O
mean O B_MEASURE
latency O I_MEASURE
of O O
62 O B_TIME[MEASURE]
min O I_TIME[MEASURE]
in O O
the O O
PGF2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
infused O O
women O B_PERSON/B_SPECIES[BIO]
, O O
in O O
controls O B_PERSON/B_MEASURE
uterine O I_PERSON/I_MEASURE
activity O I_PERSON/I_MEASURE
remained O O
unchanged O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

Were O O
this O O
hypothesis O O
correct O O
, O O
the O O
requirement O O
for O O
elF4A B B_GENE
should O O
correlate O O
with O O
the O O
degree O O
of O O
mRNA O O
secondary O O
structure O O
. O O

In O O
spite O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
presence O B_LOCATION/B_DISEASE
of O O
a O O
physician O B_DISEASE
, O O
the O O
real O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pathology O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
an O O
indian O B_DISEASE/B_MEASURE
population O I_DISEASE/I_MEASURE
of O O
Colombie O B_LOCATION/B_PERSON
is O O
not O O
very O O
well O O
known O O
. O O

Taken O O
together O O
, O O
these O O
results O O
demonstrate O O
that O O
the O O
BSMV B B_GENE/B_BIO
coat I I_GENE/I_BIO
protein I I_GENE/I_BIO
is O O
the O O
sole O O
translation O O
product O O
of O O
the O O
genomic B B_GENE
RNA I I_GENE
beta I I_GENE
, O O
whereas O O
sgRNA B B_GENE/B_BIO
beta I I_GENE/I_BIO
1 I I_GENE/I_BIO
serves O O
as O O
a O O
messenger O O
for O O
translation O O
of O O
the O O
beta B B_GENE
b I I_GENE
protein I I_GENE
, O O
and O O
sgRNA B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
beta I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
2 I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
functions O O
as O O
a O O
messenger O O
for O O
translation O O
of O O
beta B B_GENE
c I I_GENE
and O O
beta B B_GENE
d I I_GENE
and O O
the O O
newly O O
discovered O O
beta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
d I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
retrospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
clozapine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
electroencephalographic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
abnormalities O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
schizophrenic O B_PERSON/B_BIO
patients O B_PERSON/I_BIO
. O O

The O O
concepts O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
were O O
developed O O
by O O
Mines O B_LOCATION/B_PERSON
and O O
Garrey O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
during O O
the O O
next O B_TIME[MEASURE]/B_ENT
10 O I_TIME[MEASURE]/I_ENT
years O I_TIME[MEASURE]/I_ENT
. O O

When O O
the O O
measured O O
beta B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
galactosidase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
in O O
the O O
pWP O O
- O O
transfected O O
cells O O
was O O
normalized O O
to O O
the O O
pCH110 O O
- O O
transfected O O
cells O O
( O O
an O O
appropriate O O
control O O
if O O
the O O
SV40 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
early I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
functions O O
constitutively O O
in O O
various O O
cell O O
lines O O
) O O
, O O
the O O
results O O
suggested O O
that O O
the O O
promoter O O
region O O
of O O
the O O
PLP B B_GENE
gene I I_GENE
contains O O
the O O
information O O
necessary O O
for O O
initiation O O
of O O
transcription O O
in O O
a O O
C6 O O
cell O O
- O O
specific O O
manner O O
. O O

PKK B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exists O O
in O O
three O O
discernible O O
forms O O
at O O
steady O O
state O O
: O O
an O O
underphosphorylated O O
form O O
of O O
100 O O
kDa O O
; O O
a O O
soluble O O
, O O
cytosolic O O
, O O
phosphorylated O O
form O O
of O O
110 O O
kDa O O
; O O
and O O
a O O
phosphorylated O O
, O O
detergent O O
- O O
insoluble O O
form O O
of O O
112 O O
kDa O O
. O O

The O O
P B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
ITIM I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
compelled I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
multi I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphoprotein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
complex I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
binds O O
to O O
and O O
activates O O
SHP B B_GENE
- I I_GENE
2 I I_GENE
, O O
which O O
in O O
turn O O
dephosphorylates O O
SHIP B B_GENE
and O O
Shc B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
probably O O
other O O
substrates O O
. O O

When O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
used O O
to O O
amplify O O
agar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
cultures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
which O O
do O O
not O O
express O O
the O O
fimbriae O B_BACTERIUM[BIO]/B_GENE
, O O
the O O
switch O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
region O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
OFF O O
only O O
. O O

Mechanisms O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
action O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
local O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anaesthetics O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Student O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
health O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON

We O O
now O O
report O O
that O O
both O O
HSCR B B_GENE/B_MEASURE
mutations O O
impair O O
the O O
fixation O O
of O O
Shc B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
RET B B_GENE
and O O
consequently O O
prevent O O
its O O
phosphorylation O O
. O O

The O O
only O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
quantities O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
which O O
were O O
significantly O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
appendicitis O B_DISEASE/B_PERSON
and O O
a O O
normal O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
appendix O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
sex O B_PERSON/B_MEASURE
, O O
duration O B_MEASURE/B_DISEASE
of O O
symptoms O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
anorexia O B_DISEASE
and O O
vomiting O B_DISEASE/B_MEASURE
. O O

We O O
propose O O
that O O
U73 B B_GENE
is O O
involved O O
in O O
methylation O O
of O O
the O O
G1739 O O
residue O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
28S I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
rRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

At O O
the O O
start O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
performance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ride O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
plasma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glucose O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
averaged O O
4 O B_MEASURE
. O O
2 O B_MEASURE/B_LOCATION
+ O I_MEASURE/I_LOCATION
/ O O
- O O
0 O B_MEASURE
. O O
2 O B_MEASURE
, O O
5 O B_MEASURE
. O O
2 O B_MEASURE/B_LOCATION
+ O I_MEASURE/I_LOCATION
/ O O
- O O
0 O B_MEASURE/B_LOCATION
. O O
1 O B_MEASURE
, O O
and O O
5 O B_MEASURE
. O O
7 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
2 O B_MEASURE/B_PERSON
mmol O I_MEASURE/I_PERSON
. O O
l O B_TIME[MEASURE]/B_DISEASE
- O O
1 O B_MEASURE
in O O
CON O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
CHO O B_PERSON/B_PROTEIN[GENE]
- O O
7 O B_MEASURE
, O O
and O O
CHO O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
0 O B_MEASURE
/ O O
21 O B_NUMBER[MEASURE]
, O O
respectively O O
( O O
all O O
different O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

Therefore O O
prostaglandin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
characterized O O
in O O
relation O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
prostaglandin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
F2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
alpha O B_PROTEIN[GENE]
not O O
only O O
by O O
a O O
stronger O B_DISEASE_ADJECTIVE[DISEASE]
uterine O I_DISEASE_ADJECTIVE[DISEASE]
effectiveness O I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
also O O
at O O
the O O
same O B_TIME[MEASURE]/B_LOCATION
time O I_TIME[MEASURE]/I_LOCATION
a O O
pronounced O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
influence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
cardiovascular O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Copyright O B_LOCATION/B_PERSON
1999 O I_LOCATION/I_PERSON
Academic O I_LOCATION/I_PERSON
Press O I_LOCATION/I_PERSON
. O O

Ganglia O B_PERSON
are O O
cysts O B_DISEASE/B_BIO
which O O
frequently O O
occur O O
in O O
the O O
proximity O B_LOCATION/B_MEASURE
of O O
joints O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

Lysates O O
of O O
COS O O
cells O O
transfected O O
with O O
modified B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hGrzB I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cDNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
able O O
to O O
hydrolyze O O
tert O O
- O O
butyloxycarbonyl O O
- O O
Ala O O
- O O
Ala O O
- O O
Asp O O
- O O
thiobenzyl O O
ester O O
( O O
Boc O O
- O O
Ala O O
- O O
Ala O O
- O O
Asp O O
- O O
SBzl O O
) O O
, O O
whereas O O
lysates O O
transfected O O
with O O
unmodified B B_GENE
hGrzB I I_GENE
cDNA I I_GENE
were O O
inactive O O
. O O

Proteins O O
PBP B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
and O O
PBP B B_GENE
- I I_GENE
2 I I_GENE
bind O O
to O O
two O O
of O O
the O O
three O O
promoter O O
elements O O
in O O
the O O
trypanosomatid O O
Leptomonas O O
seymouri O O
. O O

Expression O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
medical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
efficiency O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
by O O
integration O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicators O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
rational O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
utilization O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
budgeted O O
funds O B_PERSON/B_LOCATION

The O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
tries O O
to O O
associate O O
some O O
of O O
the O O
causes O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hot O B_DISEASE
ischaemia O I_DISEASE
during O O
the O O
agony O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
corpse O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
donor O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
to O O
evaluate O O
those O O
that O O
may O O
be O O
caused O O
by O O
sympathetic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
efference O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
removal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

The O O
enzyme O O
encoded O O
by O O
the O O
cloned O O
fragment O O
is O O
equally O O
active O O
on O O
pyruvate O O
and O O
hydroxypyruvate O O
, O O
indicating O O
that O O
the O O
enzyme O O
has O O
both O O
D B B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
lactate I B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
and I B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
D I B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
glycerate I B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
dehydrogenase I B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
activities O O
. O O

Noise O B_DISEASE_ADJECTIVE[DISEASE]
in O O
STM O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
due O O
to O O
atoms O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
moving O O
in O O
the O O
tunneling O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
space O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
. O O

The O O
human O O
sequence O O
contains O O
the O O
element O O
TGACTCT O O
that O O
also O O
is O O
found O O
in O O
a O O
murine B B_GENE/B_SPECIES[BIO]
ras I B_GENE/I_SPECIES[BIO]
- I B_GENE/I_SPECIES[BIO]
responsive I B_GENE/I_SPECIES[BIO]
enhancer I B_GENE/I_SPECIES[BIO]
. O O

There O O
is O O
an O O
overall O O
functional O O
similarity O O
between O O
IL B B_GENE/B_SPECIES[BIO]
- I B_GENE/I_SPECIES[BIO]
6 I B_GENE/I_SPECIES[BIO]
and O O
c B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fos I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoters I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
since O O
transfection O O
of O O
excess O O
amounts O O
of O O
either O O
promoter O O
DNA O O
into O O
intact O O
HeLa O O
cells O O
modulates O O
the O O
function O O
of O O
the O O
heterologous O O
promoter O O
construct O O
. O O

Enhanced O O
phospholipid O B_DISEASE_ADJECTIVE[DISEASE]
hydrolysis O I_DISEASE_ADJECTIVE[DISEASE]
with O O
free O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fatty O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
thromboxane O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
accumulation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
increased O O
release O B_ENT/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
excitatory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amino O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acids O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
decreased O O
tissue O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
magnesium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
levels O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
may O O
each O O
serve O O
to O O
worsen O O
secondary O B_DISEASE
tissue O I_DISEASE
damage O I_DISEASE
and O O
diminish O O
neurologic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
recovery O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O O
spinal O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cord O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injury O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
associated O O
with O O
acute O B_DISEASE
alcohol O I_DISEASE
intoxication O I_DISEASE
. O O

To O O
determine O O
whether O O
the O O
transcript O O
encodes O O
an O O
active O O
enzyme O O
, O O
we O O
developed O O
a O O
novel O O
transient O O
embryonic O O
excision O O
assay O O
in O O
which O O
zebrafish O O
fertilized O O
eggs O O
were O O
co O O
- O O
injected O O
with O O
RNA O O
transcribed O O
in O O
vitro O O
using O O
the O O
Tol2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cDNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O O
a O O
template O O
and O O
a O O
plasmid O O
DNA O O
harboring O O
a O O
nonautonomous O O
Tol2 B B_LOCATION/B_GENE
element I B_LOCATION/I_GENE
, O O
which O O
has O O
a O O
deletion O O
in O O
the O O
transposase B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
coding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
overall O B_MEASURE
objective O I_MEASURE
response O I_MEASURE
rate O I_MEASURE
( O O
RR O B_LOCATION/B_PROTEIN[GENE]
) O O
was O O
50 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
[ O I_MEASURE/I_LOCATION
95 O I_MEASURE/I_LOCATION
% O I_MEASURE/I_LOCATION
confidence O I_MEASURE/I_LOCATION
interval O I_MEASURE/I_LOCATION
( O O
CI O B_LOCATION/B_ORGANIZATION
) O O
= O O
29 O B_MEASURE
- O O
71 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
] O I_MEASURE/I_PERSON
including O O
four O B_MEASURE
complete O I_MEASURE
responses O I_MEASURE
and O O
eight O B_NUMBER[MEASURE]/B_DISEASE
partial O I_NUMBER[MEASURE]/I_DISEASE
responses O I_NUMBER[MEASURE]/I_DISEASE
. O O

We O O
suggest O O
that O O
this O O
relatively O O
small O O
deletion O O
affects O O
a O O
segment O O
containing O O
3 B B_GENE/B_LOCATION
' I I_GENE/I_LOCATION
VH I I_GENE/I_LOCATION
genes I I_GENE/I_LOCATION
with O O
important O O
regulatory O O
functions O O
, O O
the O O
loss O O
of O O
which O O
leads O O
to O O
the O O
ali O O
phenotype O O
. O O

Two O O
SH2 B B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domains I B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
p120 B B_GENE
Ras B I_GENE
GTPase B I_GENE
- I I_GENE
activating I I_GENE
protein I I_GENE
bind O O
synergistically O O
to O O
tyrosine O O
phosphorylated O O
p190 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Rho O O
GTPase B B_GENE
- I I_GENE
activating I I_GENE
protein I I_GENE
. O O

p120 B B_GENE
GTPase B I_GENE
- I I_GENE
activating I I_GENE
protein I I_GENE
( O O
GAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
a O O
negative O O
regulator O O
of O O
Ras B B_GENE/B_DISEASE
that O O
functions O O
at O O
a O O
key O O
relay O O
point O O
in O O
signal O O
transduction O O
pathways O O
that O O
control O O
cell O O
proliferation O O
. O O

A O O
homologue O O
of O O
the O O
MAP B B_LOCATION/B_GENE
/ O O
ERK B B_GENE/B_DISEASE
family O O
of O O
protein O O
kinase O O
genes O O
is O O
expressed O O
in O O
vegetative O O
and O O
in O O
female O O
reproductive O O
organs O O
of O O
Petunia O O
hybrida O O
. O O

Its O O
prognostic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
impact O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O O
superior O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
the O O
T1 O B_PROTEIN[GENE]/B_MEASURE
/ O O
2 O B_PROTEIN[GENE]
one O I_PROTEIN[GENE]
( O O
RR O B_PROTEIN[GENE]/B_MEASURE
= O O
2 O B_MEASURE
. O O
9 O B_MEASURE
; O O
p O O
= O O
0 O B_MEASURE
. O O
0010 O B_MEASURE
) O O
. O O

It O O
encodes O O
a O O
sequence O O
- O O
specific O O
transcription O O
factor O O
that O O
controls O O
, O O
in O O
concert O O
with O O
other O O
gene O O
products O O
, O O
differentiative O O
pathways O O
of O O
tissues O O
in O O
which O O
Scr B B_GENE/B_DISEASE
is O O
expressed O O
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
DMIPP O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
detects O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
regionally O O
hypoperfused O O
myocardium O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
, O O
in O O
which O O
agreement O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
between O O
MBF O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
fatty O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acid O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
uptake O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
deteriorates O O
. O O

The O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
guaiphenesin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
absorption O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
bioavailability O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
paracetamol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
composite O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
analgesic O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
preparations O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Transcription O B_TIME[MEASURE]/B_PERSON
of O O
the O O
inserted O O
gene O B_GENE/B_LOCATION
into O O
the O O
predicted O B_MEASURE/B_PERSON
subgenomic O B_MEASURE/I_PERSON
polyadenylated O O
mRNA O B_GENE/B_LOCATION
was O O
demonstrated O O
by O O
Northern O B_GENE/B_LOCATION
( O O
RNA O B_GENE/B_BIO
) O O
blot O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hybridization O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
the O O
encoded O B_GENE
protein O I_GENE
was O O
detected O O
by O O
enzyme O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assay O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
by O O
radioimmunoprecipitation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O O
that O O
panretinal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
photocoagulation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
offers O O
a O O
highly O O
effective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
means O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
dealing O O
with O O
early O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
moderately O O
advanced O B_DISEASE_ADJECTIVE[DISEASE]
cases O I_DISEASE_ADJECTIVE[DISEASE]
of O O
angle O B_DISEASE
neovascularization O I_DISEASE
. O O

NBSII O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
essential O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
ribosome O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
- O O
stimulated O O
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
. O O

Sixteen O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
( O O
25 O B_MEASURE
. O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
encountered O O
rejection O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
while O O
weaning O O
at O O
median O B_TIME[MEASURE]/B_LOCATION
period O I_TIME[MEASURE]/I_LOCATION
of O O
9 O B_MEASURE
. O O
5 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
( O O
range O B_MEASURE/B_LOCATION
, O O
1 O B_MEASURE
- O O
63 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
) O O
from O O
the O O
start O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O O
weaning O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

ALT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
alanine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
aminotransferase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
) O O
and O O
Hb B B_PROTEIN[GENE]/B_DISEASE
( O O
hemoglobin B B_DISEASE/B_PROTEIN[GENE]
) O O
appeared O O
to O O
be O O
predictive O O
for O O
efficacy O O
. O O

Theophylline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
QID O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
TID O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
BID O O
and O O
now O O
QD O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
? O O

A O O
report O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
on O O
24 O B_NUMBER[MEASURE]
- O O
hour O B_TIME[MEASURE]
dosing O I_TIME[MEASURE]
with O O
slow O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
release O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
theophylline O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
formulations O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
with O O
emphasis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
on O O
analyses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
used O O
to O O
obtain O O
Food O B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Drug O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Administration O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
approval O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
for O O
Theo O B_PERSON/B_PROTEIN[GENE]
- O O
24 O B_NUMBER[MEASURE]/B_LOCATION
. O O

Signal O O
transduction O O
in O O
fibroblasts O O
stably O O
transformed O O
by O O
[ O O
Val12 O O
] O O
Ras O O
- O O
- O O
the O O
activities O O
of O O
extracellular B B_GENE
- I I_GENE
signal I I_GENE
- I I_GENE
regulated I I_GENE
kinase I I_GENE
and O O
Jun B B_GENE
N I I_GENE
- I I_GENE
terminal I I_GENE
kinase I I_GENE
are O O
only O O
moderately O O
increased O O
, O O
and O O
the O O
activity O O
of O O
the O O
delta O O
- O O
inhibitor O O
of O O
c B B_GENE
- I I_GENE
Jun I I_GENE
is O O
not O O
alleviated O O
. O O

Time O B_TIME[MEASURE]/B_PERSON
for O O
action O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
on O O
hepatitis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
B O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
immunisation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Escherichia O O
coli O O
cells O O
expressing O O
a O O
mutant B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glyV I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
glycine B B_PROTEIN[GENE]/B_LOCATION
tRNA I I_PROTEIN[GENE]/I_LOCATION
) O O
gene O O
have O O
a O O
UVM O O
- O O
constitutive O O
phenotype O O
: O O
implications O O
for O O
mechanisms O O
underlying O O
the O O
mutA B B_DISEASE/B_GENE
or O O
mutC B B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
mutator I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
effect O O
. O O

By O O
24 O B_MEASURE
h O O
, O O
there O O
was O O
no O O
significant O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
difference O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
FFA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
levels O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
from O O
shams O B_PERSON/B_TIME[MEASURE]
. O O

This O O
result O O
suggests O O
that O O
the O O
target O O
protein O O
specificity O O
of O O
E2s B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
can O O
be O O
altered O O
by O O
the O O
addition O O
of O O
appropriate O O
C O O
- O O
terminal O O
extensions O O
, O O
thus O O
providing O O
a O O
way O O
to O O
modify O O
the O O
selectivity O O
of O O
the O O
ubiquitin B B_PROTEIN[GENE]/B_BIO
system O O
. O O

Here O O
we O O
report O O
the O O
cloning O O
of O O
the O O
hemF B B_GENE
gene I I_GENE
, O O
encoding O O
the O O
aerobic O O
coproporphyrinogen B B_ENZYME[GENE]/B_MEASURE
III I I_ENZYME[GENE]/I_MEASURE
oxidase I I_ENZYME[GENE]/I_MEASURE
from I I_ENZYME[GENE]/I_MEASURE
Escherichia I I_ENZYME[GENE]/I_MEASURE
coli I I_ENZYME[GENE]/I_MEASURE
, O O
by O O
functional O O
complementation O O
of O O
a O O
Saccharomyces B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cerevisiae I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
HEM13 I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutant I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

This O O
study O O
was O O
undertaken O O
to O O
evaluate O O
the O O
physical O O
and O O
biological O O
characteristics O O
of O O
nebulized O O
interleukin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
liposomes O O
. O O

The O O
atopic O O
disposition O O
, O O
indicated O O
by O O
positive O O
skin O O
reactions O O
and O O
IgE B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
antibody O O
titers O O
etc O O
. O O
, O O
and O O
the O O
bronchial O O
reactivity O O
to O O
inhaled O O
acetylcholine O O
were O O
examined O O
on O O
the O O
following O O
three O O
groups O O
: O O
( O O
1 O O
) O O
20 O O
young O O
adults O O
with O O
a O O
history O O
of O O
childhood O O
asthma O O
who O O
have O O
been O O
symptom O O
- O O
free O O
for O O
more O O
than O O
4 O O
yr O O
; O O
( O O
2 O O
) O O
20 O O
current O O
asthmatics O O
, O O
and O O
( O O
3 O O
) O O
20 O O
healthy O O
young O O
adults O O
. O O

Previous O O
studies O O
showed O O
that O O
a O O
palindromic O O
sequence O O
located O O
at O O
- O O
159 O O
base O O
pairs O O
is O O
essential O O
for O O
induction O O
of O O
cutinase B B_DISEASE/B_GENE
gene I I_DISEASE/I_GENE
in O O
Fusarium O O
solani O O
f O O
. O O

sp O B_LOCATION/B_PROTEIN[GENE]
. O O
pisi O B_MEASURE/B_LOCATION
( O O
Nectria O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
haematococca O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
mating O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
type O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
VI O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
) O O
by O O
the O O
hydroxy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
fatty O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
acids O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
plant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
cutin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
and O O
that O O
a O O
50 O B_MEASURE
- O O
kDa O B_MEASURE/B_LOCATION
nuclear O B_MEASURE/I_LOCATION
protein O B_MEASURE/I_LOCATION
binds O O
to O O
a O O
promoter O B_GENE
that O O
contains O O
this O O
element O B_PROTEIN[GENE]
. O O

This O O
preliminary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
reports O O
an O O
initial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
HMPAO O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
SPECT O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
imaging O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
assessing O O
regional O B_DISEASE_ADJECTIVE[DISEASE]
alterations O I_DISEASE_ADJECTIVE[DISEASE]
in O O
brain O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
function O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
during O O
opiate O B_DISEASE
dependence O I_DISEASE
and O O
withdrawal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

We O O
conclude O O
that O O
these O O
cDNAs O O
belong O O
to O O
a O O
novel O O
GST B B_GENE/B_BIO
class O O
hereby O O
designated O O
Kappa O O
, O O
with O O
the O O
rat B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
GST I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
subunit I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
13 I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
designated O O
rGSTK1 B B_PROTEIN[GENE]
and O O
the O O
human O O
gene O O
being O O
called O O
hGSTK1 B B_GENE
. O O

Based O O
on O O
PCR O O
strategies O O
and O O
expression O O
studies O O
, O O
we O O
define O O
the O O
genomic O O
organization O O
of O O
the O O
FUT8b B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
present O O
study O O
demonstrates O O
that O O
the O O
proto B B_GENE
- I I_GENE
oncogene I I_GENE
c I I_GENE
- I I_GENE
jun I I_GENE
represses O O
transcription O O
of O O
the O O
human B B_GENE
CG I I_GENE
alpha I I_GENE
and O O
CG B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
beta I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
promoters I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

c B B_GENE
- I I_GENE
Jun I I_GENE
repressed O O
the O O
CG B B_GENE
alpha I I_GENE
promoter I I_GENE
through O O
a O O
canonical O O
cAMP O O
response O O
element O O
( O O
CRE O O
) O O
that O O
is O O
known O O
to O O
bind O O
c B B_GENE
- I I_GENE
Jun I I_GENE
and O O
other O O
members O O
of O O
the O O
B B B_GENE/B_PERSON
- I I_GENE/I_PERSON
Zip I I_GENE/I_PERSON
transcription I I_GENE/I_PERSON
factor I I_GENE/I_PERSON
family I I_GENE/I_PERSON
. O O

Pulse O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
monitors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
outpatient O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
dental O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
anaesthesia O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
. O O

Previous O O
studies O O
using O O
partial O O
sequences O O
have O O
suggested O O
the O O
potential O O
of O O
26S B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O O
large B B_MEASURE/B_GENE
- I I_MEASURE/I_GENE
subunit I I_MEASURE/I_GENE
( O O
LSU B B_LOCATION/B_MEASURE
) O O
rDNA O O
for O O
phylogeny O O
retrieval O O
at O O
taxonomic O O
levels O O
comparable O O
to O O
those O O
investigated O O
with O O
18S B B_GENE/B_MEASURE
rDNA I I_GENE/I_MEASURE
. O O

The O O
sensitivity O O
of O O
99mTc O O
- O O
IgG B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scintigraphy O O
ranged O O
between O O
71 O O
% O O
and O O
100 O O
% O O
. O O

The O O
index O B_PERSON/B_BIO
patient O I_PERSON/I_BIO
, O O
a O O
10 O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]
- O O
old O B_PERSON
boy O I_PERSON
, O O
presents O O
typical O B_DISEASE
symptoms O I_DISEASE
of O O
OPD O B_DISEASE/B_MEASURE
type O I_DISEASE/I_MEASURE
I O O
together O O
with O O
bowing O O
of O O
the O O
long O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
bones O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
abnormalities O B_DISEASE
of O O
the O O
thorax O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
spinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
column O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
cause O O
for O O
the O O
increase O O
in O O
plasma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ANP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
in O O
the O O
active O O
phase O O
remains O O
to O O
be O O
determined O O
. O O

A O O
genomic O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
clone O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
representing O O
the O O
5 O B_PERSON/B_LOCATION
' O B_PERSON/I_LOCATION
part O B_PERSON/I_LOCATION
of O O
the O O
message O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
also O O
isolated O O
. O O

Antibiotics O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
CDCA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
mediation O B_NUMBER[MEASURE]/B_LOCATION
are O O
essential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
for O O
symptomatic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
main O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
effects O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O O
myelosuppression O B_DISEASE
, O O
mucositis O B_DISEASE
and O O
peripheral O B_DISEASE
neuropathy O I_DISEASE
, O O
which O O
were O O
all O O
common O B_DISEASE_ADJECTIVE[DISEASE]
and O O
often O O
severe O B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
column O B_MEASURE
densities O I_MEASURE
of O O
frozen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecular O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrogen O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
methanol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
inferred O O
to O O
be O O
about O O
2 O B_MEASURE
. O O
5 O B_MEASURE
x O O
10 O B_MEASURE
( O O
18 O B_MEASURE
) O O
and O O
3 O B_MEASURE
. O O
0 O B_MEASURE
x O O
10 O B_MEASURE
( O O
19 O B_MEASURE
) O O
, O O
respectively O O
. O O

Similarly O O
, O O
an O O
increase O O
in O O
CAT B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
expression O O
from O O
the O O
same O O
construct O O
( O O
pBLCAT O O
- O O
ENDOA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
was O O
also O O
observed O O
in O O
7AQS2 O O
. O O
1 O O
cells O O
. O O

The O O
prevalence O O
of O O
antibodies O O
to O O
HRES B B_DISEASE
- I I_DISEASE
1 I I_DISEASE
peptides I I_DISEASE
pep14 I I_DISEASE
- I I_DISEASE
24 I I_DISEASE
and I I_DISEASE
pep117 I I_DISEASE
- I I_DISEASE
127 I I_DISEASE
was O O
determined O O
in O O
65 O O
normal O O
blood O O
donors O O
and O O
146 O O
patients O O
with O O
immunological O O
disorders O O
. O O

We O O
recently O O
reported O O
the O O
cloning O O
and O O
sequencing O O
of O O
the O O
alpha B B_GENE
7 I I_GENE
integrin I I_GENE
chain I I_GENE
and O O
its O O
regulated O O
expression O O
during O O
the O O
development O O
of O O
skeletal O O
muscle O O
( O O
Song O O
et O O
al O O
. O O

The O O
contractile O O
effects O O
of O O
oxytocin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
prostaglandin O O
F2 O O
alpha O O
and O O
their O O
combined O O
use O O
on O O
human O O
pregnant O O
myometrium O O
were O O
studied O O
in O O
vitro O O
. O O

These O O
involve O O
( O O
1 O O
) O O
subcloning O O
a O O
promoterless O O
sucCD B B_LOCATION/B_GENE
fragment I B_LOCATION/I_GENE
downstream O O
of O O
the O O
lac B B_GENE/B_BIO
promoter I I_GENE/I_BIO
in O O
M13mp10 O O
, O O
and O O
( O O
2 O O
) O O
precise O O
splicing O O
of O O
the O O
suc B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
coding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regions I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
the O O
efficient O O
atpE B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
ribosome I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
- I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
binding I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
site I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
and O O
expression O O
from O O
the O O
thermoinducible O O
lambda O O
promoters O O
in O O
the O O
pJLA503 O O
vector O O
. O O

These O O
mutations O O
prevent O O
FKBP12 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
rapamycin O O
binding O O
to O O
TOR2 B B_GENE
, O O
as O O
assayed O O
with O O
the O O
two O O
- O O
hybrid O O
system O O
. O O

Transcription O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
eukaryotic O B_GENE
tRNA O I_GENE
genes O I_GENE
is O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
on O O
the O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
and O O
B O B_PROTEIN[GENE]/B_DISEASE
- O O
Box O B_LOCATION/B_BIO
internal O I_LOCATION/I_BIO
control O I_LOCATION/I_BIO
regions O I_LOCATION/I_BIO
( O O
ICRs O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
the O O
upstream O B_GENE/B_LOCATION
transcription O I_GENE/I_LOCATION
modulatory O I_GENE/I_LOCATION
region O I_GENE/I_LOCATION
. O O

Failure O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
demonstrate O O
a O O
major O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
anti O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
inflammatory O B_DISEASE_ADJECTIVE[DISEASE]
effect O I_DISEASE_ADJECTIVE[DISEASE]
with O O
alpha O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tocopherol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
supplementation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
400 O B_MEASURE
IU O I_MEASURE
/ O O
day O B_MEASURE/B_LOCATION
) O O
in O O
normal O B_PERSON/B_BIO
subjects O I_PERSON/I_BIO
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
amiodarone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
prevention O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
paroxysmal O B_DISEASE
AF O I_DISEASE
have O O
been O O
equivocal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
this O O
may O O
be O O
attributed O O
to O O
differences O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
defining O O
paroxysmal O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AF O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

High O O
- O O
level O O
expression O O
of O O
sccypB B B_GENE/B_BACTERIUM[BIO]
as O O
well O O
as O O
of O O
sccypA B B_BIO/B_GENE
cloned O O
into O O
the O O
expression O O
vector O O
pIJ702 O O
did O O
not O O
produce O O
detectable O O
changes O O
in O O
growth O O
and O O
morphology O O
of O O
S O O
. O O
chrysomallus O O
and O O
S O O
. O O
lividans O O
. O O

Fas B B_GENE
( O O
APO B B_GENE
- I I_GENE
1 I I_GENE
/ O O
CD95 B B_GENE/B_MEASURE
) O O
, O O
which O O
is O O
a O O
member O O
of O O
the O O
tumor B B_GENE/B_LOCATION
necrosis I I_GENE/I_LOCATION
factor I I_GENE/I_LOCATION
receptor I I_GENE/I_LOCATION
superfamily I I_GENE/I_LOCATION
, O O
is O O
a O O
cell O O
surface O O
receptor O O
that O O
induces O O
apoptosis O O
. O O

In O O
the O O
future O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
transoesophageal O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
echocardiography O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
may O O
be O O
used O O
to O O
measure O O
variations O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
wall O B_MEASURE/B_LOCATION
thickness O I_MEASURE/I_LOCATION
which O O
change O O
the O O
global O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
loading O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
conditions O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
the O O
basal O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
midwall O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
compartments O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
the O O
left O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ventricle O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
studied O O
18 O B_SPECIES[BIO]/B_PERSON
dogs O I_SPECIES[BIO]/I_PERSON
, O O
anaesthetised O O
and O O
spontaneously O O
breathing O O
both O O
room O B_LOCATION/B_MEASURE
air O I_LOCATION/I_MEASURE
and O O
after O O
the O O
inhalation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
a O O
gas O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mixture O B_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O O
10 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
CO2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
20 O B_MEASURE
. O O
9 O B_MEASURE
% O I_MEASURE
O2 O I_MEASURE
, O O
and O O
69 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
N2 O I_MEASURE
, O O
to O O
determine O O
the O O
role O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
histamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
serotonin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
and O O
acidaemia O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
pulmonary O B_DISEASE
hypertension O I_DISEASE
produced O O
by O O
hypercapnia O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Sequencing O O
of O O
this O O
fragment O O
showed O O
that O O
the O O
MRP13 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
coding O O
region O O
specifies O O
a O O
324 O O
- O O
amino O O
- O O
acid O O
basic O O
protein O O
with O O
a O O
calculated O O
Mr O O
of O O
37 O O
, O O
366 O O
. O O

Viral O O
complementary O O
15 B B_GENE
S I I_GENE
mRNA I I_GENE
that O O
directs O O
the O O
synthesis O O
of O O
N B B_GENE
protein I I_GENE
and O O
hybridizes O O
to O O
the O O
predicted O O
N B B_GENE/B_VIRUS[BIO]
gene I B_GENE/I_VIRUS[BIO]
DNA O O
has O O
been O O
identified O O
in O O
infected O O
cell O O
extracts O O
. O O

Electrophoretic O O
mobility O O
shift O O
assays O O
and O O
DNase B B_GENE
I I I_GENE
protection O O
analyses O O
revealed O O
that O O
FP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
bound O O
by O O
the O O
transcription O O
factor O O
PU B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
Spi B B_MEASURE/B_GENE
- I I_MEASURE/I_GENE
1 I I_MEASURE/I_GENE
. O O

Retroviral O O
vector O O
producer O O
cell O O
populations O O
and O O
cell O O
clones O O
were O O
established O O
for O O
each O O
chLTR B B_PERSON/B_GENE
vector O O
, O O
and O O
all O O
were O O
capable O O
of O O
yielding O O
high O O
vector O O
titers O O
( O O
> O O
10 O O
( O O
5 O O
) O O
G418R B B_MEASURE
cfu O O
/ O O
ml O O
on O O
NIH O O
- O O
3T3 O O
) O O
. O O

However O O
, O O
a O O
few O O
sites O O
in O O
the O O
genomes O O
of O O
EC O O
cells O O
permit O O
M B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
MuLVneo I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
delta I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
Enh I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
proviral O O
expression O O
. O O

Increasing O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sensitivity O O
in O O
type O O
I O O
diabetic O O
patients O O
should O O
alert O O
clinicians O O
to O O
the O O
possibility O O
of O O
glucocorticoid O O
deficiency O O
. O O

However O O
, O O
differential O O
utilization O O
of O O
these O O
determinants O O
mediate O O
RAR B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
RXR B B_PROTEIN[GENE]/B_LOCATION
heterodimer O O
binding O O
to O O
DR O O
- O O
2 O O
and O O
DR O O
- O O
5 O O
RAREs O O
. O O

Galactorrhoea O B_DISEASE/B_LOCATION
is O O
a O O
rare O B_DISEASE_ADJECTIVE[DISEASE]
presentation O I_DISEASE_ADJECTIVE[DISEASE]
of O O
an O O
empty O B_DISEASE
sella O I_DISEASE
syndrome O I_DISEASE
. O O

The O O
addition O O
of O O
novel O O
techniques O O
, O O
such O O
as O O
histopathologic O O
ultrastaging O O
, O O
immunohistochemistry O O
staining O O
, O O
and O O
reverse B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcriptase I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymerase O O
chain O O
reaction O O
assays O O
, O O
will O O
help O O
increase O O
the O O
accuracy O O
and O O
rate O O
of O O
detection O O
of O O
disease O O
. O O

Several O O
of O O
the O O
drugs O O
used O O
in O O
the O O
management O O
of O O
MAC O O
have O O
been O O
associated O O
with O O
significant O O
drug O O
interactions O O
involving O O
the O O
cytochrome B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
P450 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CYP B B_GENE/B_BIO
) O O
enzyme O O
system O O
. O O

Arterial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compliance O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurements O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
intraarterial O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pulse O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contour O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analysis O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
a O O
modified O O
Windkessel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
carried O O
out O O
in O O
19 O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
with O O
isolated O B_DISEASE/B_GENE
systolic O I_DISEASE/I_GENE
hypertension O I_DISEASE/I_GENE
( O O
> O B_OTHER/B_MEASURE
or O O
= O O
160 O B_MEASURE
/ O O
< O B_MEASURE/B_OTHER
or O O
= O O
90 O B_MEASURE
mm O I_MEASURE
Hg O I_MEASURE
) O O
and O O
compared O O
to O O
measurements O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
29 O B_PERSON
patients O I_PERSON
with O O
essential O B_DISEASE_ADJECTIVE[DISEASE]
hypertension O I_DISEASE_ADJECTIVE[DISEASE]
( O O
diastolic O B_MEASURE/B_LOCATION
blood O I_MEASURE/I_LOCATION
pressure O I_MEASURE/I_LOCATION
[ O O
BP O B_TIME[MEASURE]/B_PROTEIN[GENE]
] O O
> O B_MEASURE/B_OTHER
or O O
= O O
95 O B_MEASURE
mm O I_MEASURE
Hg O I_MEASURE
) O O
and O O
47 O B_DISEASE/B_MEASURE
normotensive O I_DISEASE/I_MEASURE
control O I_DISEASE/I_MEASURE
subjects O I_DISEASE/I_MEASURE
. O O

Rather O O
than O O
seeking O O
a O O
blanket O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
characterization O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
an O O
essentially O O
heterogeneous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
it O O
may O O
be O O
more O O
useful O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
consider O O
idiom O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
comprehension O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
a O O
secondary O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
manifestation O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
semantic O B_EDU[ORGANIZATION]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
/ O O
or O O
pragmatic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
difficulties O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Methylprednisolone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
U O B_PROTEIN[GENE]/B_LOCATION
- O O
74006F O B_MEASURE/B_LOCATION
were O O
equally O O
effective O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
at O O
preventing O O
neurological O B_DISEASE
dysfunction O I_DISEASE
compared O O
to O O
the O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O O
p O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
; O O
U O B_PROTEIN[GENE]/B_LOCATION
- O O
78517F O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
slightly O O
less O O
effective O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O O
U O B_PROTEIN[GENE]/B_LOCATION
- O O
74006F O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
methylprednisolone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O O
was O O
significantly O O
better O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O O
vehicle O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
preventing O O
neurological O B_DISEASE
dysfunction O I_DISEASE
. O O

The O O
women O B_PERSON/B_BIO
in O O
the O O
intermediate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
calcium O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
had O O
approximately O O
the O O
same O B_MEASURE/B_LOCATION
mean O I_MEASURE/I_LOCATION
BMD O I_MEASURE/I_LOCATION
values O I_MEASURE/I_LOCATION
as O O
those O O
in O O
the O O
low O B_PERSON
calcium O I_PERSON
group O I_PERSON
. O O

International O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
efforts O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
now O O
being O O
made O O
to O O
standardize O O
haemolytic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
conditions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O O
meant O O
as O O
a O O
contribution O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
this O O
. O O

The O O
transition O B_DISEASE/B_LOCATION
from O O
expression O B_GENE
of O O
early O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
meiotic O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
expression O B_GENE
of O O
middle O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
sporulation O I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
specific O B_GENE/B_MEASURE
genes O I_GENE/I_MEASURE
occurs O O
at O O
about O O
the O O
time O B_TIME[MEASURE]/B_LOCATION
that O O
cells O O
exit O O
from O O
pachytene O B_BODY_PART_OR_ORGAN_COMPONENT/B_ORGANISM_FUNCTION
and O O
form O O
the O O
meiosis O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
I O O
spindle O O
. O O

NF B B_GENE/B_PERSON
- I I_GENE/I_PERSON
kappaB I I_GENE/I_PERSON
DNA O O
- O O
protein O O
binding O O
and O O
ICAM B B_GENE
- I I_GENE
1 I I_GENE
promoter I I_GENE
activity O O
were O O
enhanced O O
by O O
IL B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1beta I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
these O O
effects O O
were O O
inhibited O O
by O O
tyrphostin O O
23 O O
, O O
but O O
not O O
by O O
PD O O
98059 O O
or O O
SB O O
203580 O O
. O O

Peripheral O B_DISEASE_ADJECTIVE[DISEASE]
neuropathy O I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
cherry O B_PERSON/B_COLOR
- O O
red O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
spot O I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
myoclonus O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
syndrome O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
sialidosis O B_DISEASE/B_MEASURE
type O I_DISEASE/I_MEASURE
I O I_DISEASE/I_MEASURE
) O O
. O O

Using O O
the O O
two O O
- O O
hybrid O O
screening O O
method O O
, O O
we O O
have O O
identified O O
an O O
additional O O
component O O
of O O
the O O
CCAAT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
myb B B_GENE
proto I I_GENE
oncogene I I_GENE
product I I_GENE
( O O
c B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
Myb I I_GENE/I_DISEASE
) O O
is O O
a O O
transcriptional O O
regulator O O
and O O
its O O
expression O O
and O O
function O O
are O O
tightly O O
linked O O
to O O
the O O
cellular O O
entry O O
into O O
S O O
phase O O
and O O
DNA O O
synthesis O O
. O O

Both O O
the O O
p38 B B_GENE
kinase I I_GENE
inhibitor O O
SB205380 O O
( O O
SB O O
) O O
and O O
cotransfection O O
of O O
a O O
dominant O O
- O O
negative O O
mutant O O
of O O
p38 B B_GENE
kinase I I_GENE
reduced O O
IL B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1beta I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulation O O
of O O
the O O
hBNP B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
promoter I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

CLINICAL O B_MEASURE
FEATURES O I_MEASURE
: O O
This O O
30 O B_MEASURE
- O O
yr O B_TIME[MEASURE]/B_PERSON
- O O
old O B_LOCATION/B_PERSON
gravida O B_LOCATION/I_PERSON
V O I_PERSON
para O B_PERSON/B_LOCATION
0 O I_PERSON
woman O I_PERSON
presented O O
to O O
the O O
anaesthesia O B_PERSON/B_LOCATION
consultation O I_PERSON/I_LOCATION
clinic O I_PERSON/I_LOCATION
at O O
37 O B_MEASURE/B_LOCATION
- O O
wk O B_TIME[MEASURE]/B_PERSON
gestation O I_TIME[MEASURE]/I_PERSON
to O O
discuss O O
pain O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
relief O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
options O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
labour O B_ORGANISM_FUNCTION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
delivery O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
TaqI B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
HaeIII B B_GENE/B_DISEASE
RFLPs O O
will O O
provide O O
tools O O
for O O
the O O
genetic O O
analysis O O
of O O
CR2 B B_DISEASE/B_BIO
. O O

In O O
addition O O
, O O
because O O
SB203580 O O
had O O
no O O
effect O O
of O O
TNF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
or O O
ceramide O O
- O O
induced O O
apoptosis O O
, O O
our O O
results O O
strongly O O
argue O O
against O O
a O O
role O O
for O O
p38 B B_GENE
MAPK I I_GENE
in O O
the O O
induction O O
of O O
TNF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
- O O
or O O
ceramide O O
- O O
induced O O
apoptosis O O
. O O

Cognitive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
measures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
attention O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O O
the O O
Stroop O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O O
Controlled O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Oral O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Word O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Association O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
using O O
the O O
letters O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
" O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
C O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
" O O
" O O
F O B_OTHER/B_PROTEIN[GENE]
, O O
" O O
and O O
" O O
L O B_OTHER/B_PROTEIN[GENE]
" O O
( O O
COWAT O B_TIME[MEASURE]/B_LOCATION
, O O
CFL O B_MEASURE/B_LOCATION
version O I_MEASURE/I_LOCATION
) O O
. O O

Ptx1 B B_GENE/B_PERSON
belongs O O
to O O
an O O
expanding O O
family O O
of O O
bicoid B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
related I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
vertebrate O O
homeobox O O
genes O O
. O O

Effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
dietary O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lipids O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
whole O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
body O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
retention O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
organ O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distribution O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
organic O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
inorganic O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mercury O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Differential O O
transcription O O
of O O
plastome O O
- O O
encoded O O
genes O O
in O O
the O O
mesophyll O O
and O O
bundle O O
- O O
sheath O O
chloroplasts O O
of O O
the O O
monocotyledonous O O
NADP O O
- O O
malic B B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
enzyme I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
type O O
C4 O O
plants O O
maize O O
and O O
Sorghum O O
. O O

Sequential O O
immunoprecipitation O O
showed O O
all O O
detectable O O
p53 B B_GENE
to O O
be O O
of O O
the O O
PAb246 B B_GENE
+ I I_GENE
class O O
in O O
each O O
LPV O O
- O O
transformed O O
cell O O
line O O
, O O
suggesting O O
that O O
the O O
stable O O
p53 B B_GENE/B_MEASURE
was O O
indeed O O
wild O O
type O O
. O O

Tissue O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
gene O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
regulation O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
eukaryotic O B_BIO/B_GENE
organisms O B_BIO/I_GENE
is O O
to O O
a O O
large O B_MEASURE
extent O I_MEASURE
mediated O O
by O O
transcription O B_GENE
factors O I_GENE
that O O
interact O O
with O O
genomic O B_GENE/B_BIO
DNA O I_GENE/I_BIO
sequences O I_GENE/I_BIO
in O O
a O O
sequence O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
specific O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
manner O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Enhanced O O
quantum O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlations O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
bound O B_SEQUENCE[MEASURE]/B_LOCATION
higher O I_SEQUENCE[MEASURE]/I_LOCATION
- O O
order O B_MEASURE
solitons O I_MEASURE
Quantum O I_MEASURE
effects O I_MEASURE
in O O
N O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
bound O O
solitons O B_LOCATION
can O O
be O O
drastically O O
enhanced O O
compared O O
to O O
the O O
fundamental O B_TIME[MEASURE]/B_LOCATION
soliton O I_TIME[MEASURE]/I_LOCATION
. O O

The O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O O
that O O
compromised O O
fibrinolytic O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
capacity O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
a O O
contributing O O
factor O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]
of O O
thrombosis O B_DISEASE
in O O
patients O B_PERSON/B_BIO
with O O
the O O
lupus O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anticoagulant O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
MEE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
was O O
significantly O O
greater O B_MEASURE
than O O
the O O
BEE O B_PROTEIN[GENE]/B_LOCATION
and O O
significantly O O
less O B_MEASURE
than O O
the O O
calculated O B_MEASURE/B_LOCATION
energy O I_MEASURE/I_LOCATION
expenditure O I_MEASURE/I_LOCATION
. O O

These O O
results O O
suggest O O
that O O
E6010 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
of O O
clinical O O
value O O
in O O
the O O
treatment O O
of O O
coronary O O
occlusion O O
. O O

To O O
better O O
understand O O
the O O
relationship O O
between O O
expression O O
of O O
an O O
oncogene O O
and O O
genetic O O
instability O O
, O O
we O O
have O O
studied O O
a O O
cell O O
line O O
expressing O O
an O O
activated B B_GENE
human I I_GENE
Ha I I_GENE
- I I_GENE
ras I I_GENE
under O O
the O O
control O O
of O O
bacterial B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
lactose I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
operon I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
regulatory I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
elements I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O O
changes O O
in O O
methotrexate O O
resistance O O
and O O
dihydrofolate B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
reductase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
dhfr B B_LOCATION/B_PROTEIN[GENE]
) O O
gene O O
amplification O O
following O O
mutant B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ha I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ras I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induction O O
. O O

On O O
a O O
variety O B_ENT/B_MEASURE
of O O
fronts O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
chronic O B_DISEASE/B_GENE
bacterial O I_DISEASE/I_GENE
infection O I_DISEASE/I_GENE
is O O
being O O
found O O
to O O
be O O
significantly O O
associated O O
with O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]
of O O
atherosclerosis O B_DISEASE
and O O
the O O
clinical O B_DISEASE_ADJECTIVE[DISEASE]
complications O I_DISEASE_ADJECTIVE[DISEASE]
of O O
unstable O B_DISEASE
angina O I_DISEASE
, O O
myocardial O B_DISEASE
infarction O I_DISEASE
, O O
and O O
stroke O B_DISEASE
. O O

Long O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
term O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
and O O
curative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mechanisms O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
vesicoureteral O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reflux O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O O
endoscopic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
blood O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Inspection O O
of O O
X B B_GENE/B_BIO
. I I_GENE/I_BIO
tropicalis I I_GENE/I_BIO
, I I_GENE/I_BIO
mouse I I_GENE/I_BIO
and I I_GENE/I_BIO
human I I_GENE/I_BIO
U6 I I_GENE/I_BIO
DNA I I_GENE/I_BIO
upstream I I_GENE/I_BIO
sequences I I_GENE/I_BIO
revealed O O
the O O
presence O O
of O O
a O O
TATA O O
box O O
as O O
well O O
as O O
of O O
the O O
proximal O O
and O O
enhancer O O
( O O
octamer O O
motif O O
) O O
elements O O
contained O O
in O O
snRNA O O
genes O O
transcribed O O
by O O
RNA B B_GENE/B_VIRUS[BIO]
polymerase I B_GENE/I_VIRUS[BIO]
II I B_GENE/I_VIRUS[BIO]
. O O

Characterization O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
an O O
unusual O B_GENE
tRNA O I_GENE
- O O
like O B_GENE/B_LOCATION
sequence O I_GENE/I_LOCATION
found O O
inserted O O
in O O
a O O
Neurospora O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
retroplasmid O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Repeated O O
time O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
course O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
same O B_PERSON/B_LOCATION
patient O B_PERSON/I_LOCATION
were O O
reproducible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
although O O
the O O
absolute O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concentrations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
showed O O
some O O
variation O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
work O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
represents O O
an O O
attempt O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
develop O O
a O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
measuring O O
relative O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
blood O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
flow O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
intestinal O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
capillaries O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
by O O
the O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
sodium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorescein O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Na O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
F O B_PROTEIN[GENE]/B_DISEASE
) O O
as O O
an O O
indicator O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
substance O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PAX8 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
generates O O
at O O
least O O
five O O
different O O
alternatively O O
spliced O O
transcripts O O
encoding O O
different O O
PAX8 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
isoforms I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
data O O
show O O
that O O
both O O
Sp1 B B_GENE/B_LOCATION
and O O
Sp3 B B_GENE
transcription I I_GENE
factors I I_GENE
upregulate O O
HGF B B_GENE
promoter I I_GENE
activity O O
by O O
binding O O
to O O
the O O
Sp1 B B_GENE/B_TIME[MEASURE]
binding I I_GENE/I_TIME[MEASURE]
site I I_GENE/I_TIME[MEASURE]
at O O
position O O
- O O
318 O O
to O O
- O O
303 O O
bp O O
in O O
the O O
HGF B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
. O O

After O O
a O O
1 O B_MEASURE
- O O
h O B_TIME[MEASURE]/B_LOCATION
rest O I_TIME[MEASURE]/I_LOCATION
( O O
for O O
T2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
return O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
baseline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
, O O
subjects O B_PERSON
repeated O O
the O O
5 O B_NUMBER[MEASURE]
- O O
min O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
protocol O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O O
followed O O
by O O
a O O
final O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
MRI O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
/ O O
MRS O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
arrest O O
in O O
the O O
G1 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phase O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
cell O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cycle O B_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
grow O O
a O O
projection O B_LOCATION/B_MEASURE
towards O O
one O B_NUMBER[MEASURE]/B_PERSON
another O O
forming O O
a O O
shmoo O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
projection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Mammalian O O
homologues O O
of O O
the O O
Polycomb B B_GENE
- I I_GENE
group I I_GENE
gene I I_GENE
Enhancer B I_GENE
of I I_GENE
zeste I I_GENE
mediate O O
gene O O
silencing O O
in O O
Drosophila O O
heterochromatin O O
and O O
at O O
S O O
. O O
cerevisiae O O
telomeres O O
. O O

With O O
six O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
reports O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
the O O
literature O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O O
show O O
there O O
is O O
an O O
order O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
melanoma O O
nodal O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
metastases O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
that O O
the O O
SLN O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
histology O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
is O O
reflective O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
histology O B_DISEASE
of O O
the O O
remainder O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
nodal O B_DISEASE/B_PERSON
basin O I_DISEASE/I_PERSON
, O O
the O O
more O O
conservative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
SLN O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
biopsy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
can O O
be O O
performed O O
to O O
adequately O O
stage O O
nodally O O
the O O
patient O B_PERSON/B_DISEASE
with O O
melanoma O B_DISEASE/B_GENE
. O O

The O O
results O O
obtained O O
with O O
[ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
F304 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
R2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
indicate O O
that O O
structural O O
changes O O
in O O
E B B_LOCATION/B_PROTEIN[GENE]
. I B_LOCATION/I_PROTEIN[GENE]
coli I B_LOCATION/I_PROTEIN[GENE]
R2 I B_LOCATION/I_PROTEIN[GENE]
in O O
the O O
vicinity O O
of O O
this O O
helix O O
distortion O O
can O O
influence O O
the O O
catalytic O O
activity O O
of O O
the O O
holoenzyme O O
. O O

Cloning O O
and O O
characterization O O
of O O
the O O
5 O O
' O O
flanking O O
region O O
of O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ATP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
citrate I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
lyase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Cryoglobulinaemia O B_DISEASE
among O O
maintenance O B_PERSON/B_BIO
haemodialysis O I_PERSON/I_BIO
patients O I_PERSON/I_BIO
and O O
its O O
relation O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
hepatitis O B_DISEASE
C O I_DISEASE
infection O I_DISEASE
. O O

The O O
S3 B B_GENE
protein I I_GENE
also O O
contains O O
a O O
DNA O O
repair O O
activity O O
, O O
efficiently O O
processing O O
8 O O
- O O
oxoguanine O O
residues O O
in O O
DNA O O
via O O
an O O
N B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
glycosylase I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
/ O O
apurinic B B_ENZYME[GENE]
- I I_ENZYME[GENE]
apyrimidinic I I_ENZYME[GENE]
( I I_ENZYME[GENE]
AP I I_ENZYME[GENE]
) I I_ENZYME[GENE]
lyase I I_ENZYME[GENE]
activity O O
. O O

25 O B_PERSON
patients O I_PERSON
received O O
20 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
mgs O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
hyoscine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
N O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
butyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
bromide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
rest O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mgs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
propinoxate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
i O O
. O O
v O B_PROTEIN[GENE]/B_LOCATION
. O O
plus O O
diazepam O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
present O O
here O O
a O O
statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
technique O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
we O O
developed O O
to O O
identify O O
the O O
sequence O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
elements O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
that O O
may O O
be O O
responsible O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
for O O
this O O
cell O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cycle O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
regulation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Computed O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
tomographic O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
CT O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
pancreatic O B_DISEASE
ductal O I_DISEASE
adenocarcinoma O I_DISEASE
were O O
studied O O
with O O
the O O
combined O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
early O B_DISEASE_ADJECTIVE[DISEASE]
enhancement O I_DISEASE_ADJECTIVE[DISEASE]
CT O I_DISEASE_ADJECTIVE[DISEASE]
and O O
high O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhancement O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CT O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
72 O B_MEASURE/B_DISEASE
carcinomas O I_MEASURE/I_DISEASE
. O O

No O O
other O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcripts O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
different O B_GENE
length O I_GENE
could O O
be O O
detected O O
after O O
prolonged O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
exposure O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
conclude O O
, O O
therefore O O
, O O
that O O
in O O
the O O
absence O O
of O O
E1A B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
E4orf4 B B_GENE
is O O
sufficient O O
by O O
itself O O
to O O
trigger O O
a O O
p53 B B_GENE
- O O
independent O O
apoptosis O O
pathway O O
that O O
may O O
operate O O
independently O O
of O O
the O O
known O O
zVAD O O
- O O
inhibitable O O
caspases B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
that O O
may O O
involve O O
an O O
as O O
yet O O
uncharacterized O O
mechanism O O
. O O

The O O
antiserum O O
used O O
for O O
immunoblotting O O
specifically O O
supershifts O O
uteroglobin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complexes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
gel O O
shift O O
experiments O O
. O O

The O O
nucleotide O O
sequence O O
of O O
the O O
estrogen B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Oreochromis I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aureus I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
OaER B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
indicates O O
that O O
the O O
hormone O O
- O O
binding O O
E O O
domain O O
is O O
composed O O
of O O
4 O O
exons O O
interspersed O O
by O O
short O O
introns O O
of O O
only O O
0 O O
. O O
18 O O
- O O
1 O O
. O O
3 O O
kb O O
each O O
. O O

The O O
expression O O
of O O
Scmh1 B B_GENE
and O O
rae28 B B_LOCATION/B_GENE
/ O O
mph1 B B_MEASURE
is O O
well O O
correlated O O
in O O
most O O
tissues O O
of O O
embryos O O
. O O

The O O
nucleoporin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
98 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NUP98 B B_GENE/B_DISEASE
) O O
, O O
which O O
is O O
rearranged O O
in O O
several O O
acute O O
myeloid O O
leukemia O O
translocations O O
, O O
is O O
located O O
within O O
this O O
region O O
. O O

We O O
have O O
isolated O O
and O O
sequenced O O
cDNA O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequences O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
corresponding O O
to O O
two O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
novel O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
map O O
to O O
Xq28 O B_SPECIES[BIO]/B_GENE
. O O

A O O
new O O
direct O O
hemagglutination O O
test O O
( O O
HI O O
- O O
GONAVIS O O
) O O
for O O
urinary O O
LH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
compared O O
with O O
the O O
serum O O
radioimmuno O O
- O O
assay O O
of O O
LH B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Diffusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
epidemic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O O
incubation O B_LOCATION/B_GENE
and O O
crisscross O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
dynamics O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

CERIP B B_ORGANIZATION/B_PERSON
interaction O O
. O O

The O O
encoded O O
Arabidopsis B B_GENE/B_LOCATION
U3 I I_GENE/I_LOCATION
snRNAs I I_GENE/I_LOCATION
can O O
be O O
folded O O
into O O
a O O
secondary O O
structure O O
which O O
is O O
more O O
similar O O
to O O
that O O
of O O
U3 B B_GENE/B_BIO
RNAs I I_GENE/I_BIO
from O O
lower O O
eukaryotes O O
rather O O
than O O
from O O
metazoa O O
. O O

Therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
prevention O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
irreversible O B_DISEASE
shock O I_DISEASE
with O O
pharmacological O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
doses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
some O O
corticosteroids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Fentanyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
citrate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
0 O B_MEASURE
. O O
1 O B_MEASURE
mL O I_MEASURE
) O O
and O O
2H5 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
fentanyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
internal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
standard O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
0 O B_MEASURE
. O O
05 O B_MEASURE
mL O I_MEASURE
, O O
100 O B_MEASURE/B_LOCATION
mg O I_MEASURE/I_LOCATION
/ O O
L O B_OTHER/B_MEASURE
) O O
were O O
extracted O O
with O O
Toxi O B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
tubes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
( O O
Toxi O B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Lab O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Irvine O B_LOCATION/B_PERSON
, O O
CA O B_LOCATION/B_MEASURE
) O O
and O O
analyzed O O
by O O
gas O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chromatography O B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mass O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
spectrometry O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Positive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
radioactive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
Guarapari O B_DISEASE/B_LOCATION

The O O
LT B B_GENE
- I I_GENE
beta I I_GENE
gene I I_GENE
is O O
expressed O O
in O O
lymphoid O O
cells O O
and O O
organs O O
, O O
but O O
little O O
is O O
known O O
about O O
its O O
inducible O O
regulation O O
. O O

Ciprofloxacin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
attained O O
a O O
peak O B_MEASURE/B_DISEASE
serum O I_MEASURE/I_DISEASE
concentration O I_MEASURE/I_DISEASE
of O O
1 O B_MEASURE
. O O
2 O B_MEASURE
mg O I_MEASURE
/ O O
l O B_OTHER/B_MEASURE
and O O
a O O
serum O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
half O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
life O B_TIME[MEASURE]/B_LOCATION
of O O
34 O B_NUMBER[MEASURE]/B_PERSON
min O I_NUMBER[MEASURE]/I_PERSON
. O O

Dmyd B B_PERSON
clone O O
encodes O O
a O O
polypeptide O O
of O O
332 O O
amino O O
acids O O
with O O
82 O O
% O O
identity O O
to O O
MyoD B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
in O O
the O O
41 O O
amino O O
acids O O
of O O
the O O
putative O O
helix O O
- O O
loop O O
- O O
helix O O
region O O
and O O
100 O O
% O O
identity O O
in O O
the O O
13 O O
amino O O
acids O O
of O O
the O O
basic O O
domain O O
proposed O O
to O O
contain O O
the O O
essential O O
recognition O O
code O O
for O O
muscle O O
- O O
specific O O
gene O O
activation O O
. O O

Identification O O
of O O
an O O
osteocalcin B B_GENE
gene I I_GENE
promoter I I_GENE
sequence I I_GENE
that O O
binds O O
AP1 B B_GENE
. O O

Treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
is O O
based O O
on O O
antifungal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
most O O
frequently O O
nystatin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
amphotericin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
ketoconazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Mutations O O
abolishing O O
MalK B B_GENE/B_BIO
function O O
not O O
only O O
result O O
in O O
inability O O
to O O
transport O O
maltose O O
but O O
also O O
cause O O
constitutive O O
expression O O
of O O
the O O
maltose B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
regulon I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Drosophila B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
melanogaster I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
casein I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DmCKII B B_GENE/B_TIME[MEASURE]
) O O
is O O
composed O O
of O O
catalytic O O
( O O
alpha O O
) O O
and O O
regulatory O O
( O O
beta O O
) O O
subunits O O
associated O O
as O O
an O O
alpha2beta2 O O
heterotetramer O O
. O O

The O O
aims O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
to O O
examine O O
whether O O
the O O
EORTC O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
European O B_ORGANIZATION/B_PERSON
Organisation O I_ORGANIZATION/I_PERSON
for O O
Research O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
Cancer O B_DISEASE/B_LOCATION
) O O
QLQ O B_MEASURE/B_DISEASE
- O O
C30 O B_NUMBER[MEASURE]/B_LOCATION
core O I_NUMBER[MEASURE]/I_LOCATION
questionnaire O I_NUMBER[MEASURE]/I_LOCATION
alone O O
could O O
distinguish O O
between O O
two O B_NUMBER[MEASURE]
clinically O O
different O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
patients O B_PERSON/B_DISEASE
and O O
to O O
design O O
a O O
module O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
which O O
included O O
relevant O B_PERSON/B_LOCATION
patient O B_PERSON/I_LOCATION
- O O
defined O O
gastric O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cancer O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
specific O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variables O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

On O O
both O O
indocyanine O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
green O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
video O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
fluorescein O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
angiography O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
hypofluorescent O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lesions O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
almost O O
the O O
same O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
size O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
as O O
the O O
light O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
yellow O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
area O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
dark O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
yellow O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
center O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
placoid O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
lesion O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

We O O
have O O
measured O O
percentage O B_MEASURE/B_DISEASE
O3 O B_MEASURE/I_DISEASE
uptake O B_MEASURE/I_DISEASE
in O O
30 O B_PERSON
adult O I_PERSON
Sprague O I_PERSON
- O O
Dawley O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposed O O
, O O
nose O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O O
, O O
for O O
1 O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hr O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
0 O B_MEASURE/B_LOCATION
. O O
3 O B_MEASURE
, O O
0 O B_MEASURE/B_LOCATION
. O O
6 O B_MEASURE
, O O
or O O
1 O B_MEASURE
. O O
0 O B_MEASURE
ppm O I_MEASURE
O3 O I_MEASURE
. O O

The O O
signal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
to O O
- O O
noise O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ratio O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SNR O B_LOCATION/B_DISEASE
) O O
was O O
calculated O O
in O O
the O O
T2 O B_MEASURE/B_LOCATION
- O O
weighted O O
sequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Cell O O
rounding O O
was O O
abrogated O O
by O O
expression O O
of O O
either O O
kinase O O
- O O
dead O O
forms O O
of O O
US3 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PK I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
a O O
mutant O O
protein O O
lacking O O
the O O
acidic O O
cluster O O
in O O
the O O
kinase O O
regulatory O O
domain O O
. O O

Three O O
distinct O O
human B B_GENE/B_BIO
HDACs I I_GENE/I_BIO
are O O
homologous O O
to O O
RPD3 B B_GENE
, O O
a O O
yeast O O
transcriptional O O
regulator O O
. O O

The O O
4 O B_NUMBER[MEASURE]
- O O
nt O B_GENE/B_LOCATION
sequence O I_GENE/I_LOCATION
of O O
the O O
rotavirus O B_MEASURE/B_BIO
3 O I_MEASURE/I_BIO
' O O
TE O B_GENE/B_DISEASE
represents O O
by O O
far O O
the O O
shortest O B_SEQUENCE[MEASURE]
of O O
any O O
of O O
the O O
sequence O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enhancers O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
known O O
to O O
stimulate O O
translation O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

OBJECTIVE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
The O O
audiologic O B_DISEASE_ADJECTIVE[DISEASE]
presentation O I_DISEASE_ADJECTIVE[DISEASE]
of O O
vestibular O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
schwannoma O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
VS O B_MEASURE/B_PROTEIN[GENE]
) O O
associated O O
with O O
neurofibromatosis O B_DISEASE/B_GENE
type O I_DISEASE/I_GENE
2 O I_DISEASE/I_GENE
( O O
NF2 O B_GENE/B_LOCATION
) O O
has O O
not O O
been O O
well O O
characterized O O
. O O

Expression O O
of O O
these O O
chemokines O O
is O O
similar O O
in O O
that O O
both O O
require O O
the O O
NF B B_GENE
- I I_GENE
kappa I I_GENE
B I I_GENE
element I I_GENE
and O O
additional O O
regions O O
such O O
as O O
the O O
CAAT B B_GENE
/ I I_GENE
enhancer I I_GENE
binding I I_GENE
protein I I_GENE
( O O
C B B_GENE/B_LOCATION
/ I I_GENE/I_LOCATION
EBP I I_GENE/I_LOCATION
) O O
element O O
of O O
the O O
IL B B_GENE
- I I_GENE
8 I I_GENE
promoter I I_GENE
. O O

The O O
meaning O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O O
hope O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
health O B_PERSON/B_DISEASE
and O O
illness O B_DISEASE/B_PERSON
. O O

Assessment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
two O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anion O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
exchange O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
resins O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
direct O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
screening O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
method O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
urinary O B_DISEASE
porphobilinogen O I_DISEASE
. O O

Aggravation O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
peripheral O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
- O O
blood O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cytopenia O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
during O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weeks O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
hypocellularity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
bone O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
marrow O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
aspirates O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
at O O
the O O
end O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
suggest O O
that O O
low O B_MEASURE/B_COLOR
- O O
dose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Ara O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
C O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
exerts O O
its O O
main O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
activity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
by O O
suppression O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
leukaemic O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
growth O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
, O O
rather O O
than O O
by O O
induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
differentiation O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
malignant O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

All O O
depressive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O O
improved O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
error O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
measures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
post O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Triaxiality O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
proton O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
neutron O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interacting O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
boson O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Perturbed O O
O O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
6 O B_NUMBER[MEASURE]
) O O
symmetry O B_MEASURE/B_LOCATION
with O O
application O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
mass O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
A O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION

The O O
best O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequences O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
pelvic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
, O O
in O O
our O O
experience O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
IR O B_MEASURE/B_PERSON
or O O
short O B_LOCATION/B_MEASURE
TR O B_LOCATION/I_MEASURE
spin O B_LOCATION/I_MEASURE
- O O
echo O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O O
T1 O B_MEASURE/B_LOCATION
- O O
weighted O O
images O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
and O O
spin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
echo O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
1200 O B_MEASURE/B_PROTEIN[GENE]
TR O B_MEASURE/I_PROTEIN[GENE]
for O O
T2 O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
images O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Cells O O
were O O
co O O
- O O
infected O O
simultaneously O O
with O O
IBV O O
, O O
the O O
recombinant O O
FPV O O
( O O
rFPV O O
) O O
containing O O
the O O
D O O
- O O
RNA O O
sequence O O
and O O
a O O
second O O
rFPV O O
expressing O O
T7 B B_GENE
RNA I I_GENE
polymerase I I_GENE
for O O
the O O
initial O O
expression O O
of O O
the O O
D O O
- O O
RNA O O
transcript O O
, O O
subsequently O O
rescued O O
by O O
helper O O
IBV O O
. O O

Seasonal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
cadmium O B_MEASURE/B_DISEASE
content O B_MEASURE/I_DISEASE
of O O
Murex O B_BIO/B_LOCATION
trunculus O I_BIO/I_LOCATION
in O O
a O O
non O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
cadmium O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
polluted O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
environment O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
discussed O O
in O O
relation O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
predicted O O
isoform O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
L O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
diversity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
across O O
human O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
tissues O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Doctors O B_PERSON/B_TIME[MEASURE]
given O O
intrathecal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
methotrexate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
had O O
headache O B_DISEASE
when O O
20 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gauge O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
standard O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
needle O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
used O O
. O O

The O O
AP B B_GENE
- I I_GENE
1 I I_GENE
recruited O O
by O O
ARF1 B B_GENE
. I I_GENE
GTP I I_GENE
is O O
released O O
from O O
the O O
Golgi O O
membrane O O
by O O
treatment O O
with O O
1 O O
M O O
Tris O O
- O O
HCl O O
( O O
pH O O
7 O O
) O O
or O O
upon O O
reincubation O O
at O O
37 O O
degreesC O O
, O O
whereas O O
AP B B_GENE
- I I_GENE
1 I I_GENE
recruited O O
with O O
GTPgammaS O O
or O O
by O O
a O O
constitutively O O
active O O
point O O
mutant O O
, O O
ARF1 B B_GENE/B_LOCATION
( I I_GENE/I_LOCATION
Q71L I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
, O O
remains O O
membrane O O
bound O O
after O O
either O O
treatment O O
. O O

The O O
formation O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
tumorlike O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lesions O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
cockroach O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
leucophaea O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
maderae O O
after O O
anal O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
blockage O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Fine O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
tangled O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
pili O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
expressed O O
by O O
Haemophilus O B_BACTERIUM[BIO]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
ducreyi O B_BACTERIUM[BIO]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O O
a O O
novel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
class O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
pili O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
found O O
remarkable O O
differences O O
in O O
the O O
expression O O
patterns O O
of O O
MTB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Zf I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
two O O
other O O
hybridizable O O
mRNAs O O
of O O
5kb O O
and O O
8 O O
. O O
5 O O
kb O O
when O O
human O O
brain O O
and O O
primary O O
brain O O
tumors O O
were O O
compared O O
. O O

The O O
two O B_LOCATION/B_BIO
redox O B_LOCATION/I_BIO
centers O B_LOCATION/I_BIO
in O O
the O O
protein O B_ENZYME[GENE]/B_BACTERIUM[BIO]
, O O
FAD O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
a O O
[ O B_LOCATION/B_BIO
4Fe4S O B_LOCATION/I_BIO
] O O
+ O B_MEASURE/B_LOCATION
2 O I_MEASURE/I_LOCATION
, O O
+ O O
1 O B_MEASURE/B_LOCATION
cluster O I_MEASURE/I_LOCATION
, O O
are O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
64 O B_MEASURE
- O O
kDa O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monomer O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
pra2 B B_GENE/B_BIO
gene I I_GENE/I_BIO
encodes O O
a O O
pea B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Pisum I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sativum I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
small I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
GTPase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
belonging O O
to O O
the O O
YPT B B_GENE/B_DISEASE
/ O O
rab B B_PERSON/B_PROTEIN[GENE]
family O O
, O O
and O O
its O O
expression O O
is O O
down O O
- O O
regulated O O
by O O
light O O
, O O
mediated O O
by O O
phytochrome B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

Carotid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
body O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemoreceptor O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
recorded O O
from O O
the O O
petrosal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ganglion O I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
cats O B_BIO/B_PERSON
. O O

Human B B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
murine I I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytotoxic I I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lymphocyte I I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serine I I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteases I I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
subsite O O
mapping O O
with O O
peptide O O
thioester O O
substrates O O
and O O
inhibition O O
of O O
enzyme O O
activity O O
and O O
cytolysis O O
by O O
isocoumarins O O
. O O

To O O
explore O O
further O O
the O O
role O O
of O O
the O O
carboxyl O O
- O O
terminal O O
domain O O
in O O
determining O O
the O O
cell O O
cycle O O
function O O
of O O
CDC34 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
constructed O O
and O O
characterized O O
genes O O
encoding O O
chimeric B B_PROTEIN[GENE]/B_DISEASE
E2s I I_PROTEIN[GENE]/I_DISEASE
incorporating O O
sequences O O
from O O
CDC34 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
related O O
but O O
functionally O O
distinct O O
E2 B B_GENE/B_BIO
RAD6 B I_GENE/I_BIO
( O O
UBC2 B B_GENE
) O O
. O O

MAPKK B B_GENE
kinase I I_GENE
/ O O
MEKK B B_GENE
phosphorylates O O
and O O
activates O O
its O O
downstream O O
protein O O
kinase O O
, O O
MAPK B B_GENE
kinase I I_GENE
/ O O
MEK B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
in O O
turn O O
activates O O
MAPK B B_GENE
. O O

Kondo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
Cu O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
Fe O B_MEASURE
) O O
films O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

However O O
, O O
ADAR1 B B_GENE
and O O
the O O
related O O
deaminase B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ADAR2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
showed O O
significant O O
expression O O
in O O
all O O
regions O O
of O O
the O O
brain O O
examined O O
, O O
including O O
cortex O O
, O O
hippocampus O O
, O O
olfactory O O
bulb O O
, O O
and O O
striatum O O
, O O
where O O
the O O
5 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
HT2CR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pre I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
extensively O O
edited O O
. O O

To O O
investigate O O
its O O
transcription O O
, O O
1 O O
. O O
1 O O
kilobases O O
of O O
the O O
5 O O
' O O
- O O
flanking O O
sequence O O
were O O
fused O O
to O O
a O O
luciferase B B_GENE
reporter I I_GENE
gene I I_GENE
. O O

Influence O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
copper O B_PERSON
addition O I_PERSON
. O O

The O O
0 O B_MEASURE
. O O
018 O B_MEASURE
- O O
inch O B_MEASURE/B_LOCATION
FloWire O I_MEASURE/I_LOCATION
provides O O
a O O
high O B_MEASURE/B_LOCATION
- O O
fidelity O B_MEASURE
continuous O I_MEASURE
Doppler O I_MEASURE
signal O I_MEASURE
. O O

Monosulfates O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
16 O B_MEASURE/B_LOCATION
- O O
oxygenated O O
ketonic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
C19 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
steroids O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
adult O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
human O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
urine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

Under O O
anaerobic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
conditions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
a O O
50 O B_NUMBER[MEASURE]
- O O
day O B_MEASURE/B_ENT
experiment O I_MEASURE/I_ENT
) O O
these O O
organisms O B_BIO
degraded O O
15 O B_NUMBER[MEASURE]
- O O
18 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
the O O
TEM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
20 O B_MEASURE
- O O
25 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
of O O
some O O
alkanes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
and O O
15 O B_NUMBER[MEASURE]
- O O
18 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
selected O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
polycyclic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
aromatic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
hydrocarbons O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
addition O B_MEASURE/B_LOCATION
, O O
WR O B_PROTEIN[GENE]/B_DISEASE
- O O
3689 O B_MEASURE
, O O
WR O B_PROTEIN[GENE]/B_DISEASE
- O O
109342 O B_MEASURE
, O O
and O O
WR O B_PROTEIN[GENE]/B_DISEASE
- O O
168643 O B_MEASURE
were O O
used O O
with O O
per O O
os O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
administration O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O O
determine O O
hematopoietic O B_DISEASE/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lethality O B_DISEASE/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Further O O
, O O
we O O
will O O
review O O
our O O
evaluation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
survival O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rate O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
prognostic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
factors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
for O O
9 O B_MEASURE
, O O
262 O B_MEASURE
patients O I_MEASURE
from O O
1981 O B_MEASURE
to O O
1996 O B_MEASURE
. O O

MEASURES O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
SF O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
36 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
questionnaires O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
completed O O
by O O
patients O B_PERSON
at O O
both O O
initial O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
and O O
discharge O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
examinations O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

In O O
contrast O O
, O O
corticotropin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
releasing I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CRF B B_GENE/B_DISEASE
) O O
, O O
injected O O
centrally O O
produces O O
a O O
suppression O O
of O O
punished O O
and O O
non O O
- O O
punished O O
responding O O
in O O
the O O
conflict O O
test O O
consistent O O
with O O
its O O
hypothesized O O
role O O
in O O
mediating O O
behavioral O O
responses O O
to O O
stress O O
. O O

Temporal O O
recruitment O O
of O O
the O O
mSin3A B B_GENE
- O O
histone B B_GENE
deacetylase I I_GENE
corepressor O O
complex O O
to O O
the O O
ETS B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
domain I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
transcription I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
factor I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
Elk B I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
- I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
1 I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

The O O
cluster O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
mapped O O
to O O
nucleotides O B_LOCATION/B_MEASURE
- O O
464 O B_MEASURE
to O O
- O O
434 O B_MEASURE
( O O
relative O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
nucleotide O O
A O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
the O O
initiation O B_PERSON/B_GENE
codon O I_PERSON/I_GENE
) O O
in O O
genomic O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
DNA O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
addition O O
, O O
FOP B B_DISEASE/B_PROTEIN[GENE]
- O O
FGFR1 B B_PROTEIN[GENE]/B_MEASURE
- O O
expressing O O
cells O O
show O O
constitutive O O
phosphorylation O O
of O O
the O O
positive O O
regulator O O
of O O
translation O O
p70S6 B B_ENZYME[GENE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I B_ENZYME[GENE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
this O O
phosphorylation O O
is O O
inhibited O O
by O O
PI3 B B_GENE
- I I_GENE
kinase I I_GENE
and O O
mTOR B B_GENE
( O O
mammalian B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rapamycin I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
inhibitors O O
. O O

The O O
authors O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
report O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cases O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
orbital O B_DISEASE
cavernous O I_DISEASE
hemangioma O I_DISEASE
diagnosed O O
by O O
Tc O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
99m O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
RBC O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
SPECT O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Ciprofloxacin O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
serum O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
blister O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
fluid O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
at O O
the O O
end O B_LOCATION/B_MEASURE
of O O
the O O
dosing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interval O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
8 O B_TIME[MEASURE]/B_LOCATION
h O B_TIME[MEASURE]/I_LOCATION
) O O
were O O
superior O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O O
almost O O
superior O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
MICs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
sensitive O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
organisms O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
including O O
Pseudomonas O B_BACTERIUM[BIO]/B_DISEASE
aeruginosa O I_BACTERIUM[BIO]/I_DISEASE
. O O

Antibiotic O B_PERSON/B_LOCATION
prophylaxis O I_PERSON/I_LOCATION
in O O
a O O
surgical O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
setting O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON

We O O
identified O O
clones O O
of O O
Chlamydomonas O O
genomic O O
DNA O O
that O O
rescued O O
the O O
Ca O O
( O O
2 O O
+ O O
) O O
- O O
dependent O O
axonemal O O
microtubule O O
severing O O
defect O O
of O O
fa1 B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
mutants I B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O O

These O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
persisted O O
during O O
the O O
first O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
week O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Hyperlipemia O B_DISEASE/B_GENE
has O O
been O O
recently O O
described O O
in O O
children O B_PERSON/B_ORGANIZATION
with O O
migraine O B_DISEASE/B_LOCATION
, O O
being O O
suggested O O
that O O
this O O
alteration O B_DISEASE_ADJECTIVE[DISEASE]
is O O
in O O
the O O
base O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
disease O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Plasma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hemopexin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
homeostasis O O
during O O
the O O
acute O O
phase O O
response O O
. O O

The O O
newly O O
identified O O
repressor O O
element O O
is O O
a O O
rare O O
example O O
of O O
a O O
naturally O O
occurring O O
perfect O O
palindromic O O
binding O O
motif O O
for O O
the O O
NF B B_GENE
- I I_GENE
kappa I I_GENE
B I I_GENE
/ O O
Rel B B_GENE/B_DISEASE
family O O
of O O
transcription O O
factors O O
. O O

Tryptophan O O
induction O O
prevents O O
Rho B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
dependent O O
transcription O O
termination O O
in O O
the O O
leader O O
region O O
of O O
the O O
operon O O
. O O

There O O
remains O O
the O O
physiological O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
problem O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
- O O
one O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
has O O
always O O
been O O
foremost O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
Moruzzi O B_PERSON
' O O
s O O
thinking O O
about O O
the O O
intrinsic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
regulation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
brain O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
- O O
of O O
how O O
the O O
separate O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
actions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
different O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
arousal O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
systems O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
are O O
brought O O
together O O
into O O
a O O
functional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
whole O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

The O O
nramp2 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
is O O
comprised O O
of O O
17 O O
exons O O
and O O
spans O O
more O O
than O O
36 O O
kb O O
. O O

The O O
immune O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
seems O O
to O O
be O O
partially O O
responsible O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
for O O
both O O
protection O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
destructive O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
consequences O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
chlamydial O B_DISEASE
infection O I_DISEASE
. O O

Results O B_MEASURE
: O O
hepatic O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydatidosis O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
177 O B_MEASURE/B_PERSON
patients O I_MEASURE/I_PERSON
. O O

This O O
is O O
similar O O
to O O
previous O O
reports O O
of O O
muscle B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
creatine I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphokinase I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
release O O
in O O
psychiatric O O
patients O O
. O O

The O O
majority O O
of O O
putative O O
TSC2 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutations I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
were O O
found O O
in O O
sporadic O O
rather O O
than O O
TSC2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
linked O O
families O O
. O O

Murine B B_GENE/B_LOCATION
ELAM I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
is O O
encoded O O
by O O
a O O
single O O
- O O
copy O O
gene O O
, O O
spanning O O
about O O
13 O O
kb O O
, O O
which O O
is O O
structurally O O
organized O O
into O O
14 O O
exons O O
and O O
13 O O
introns O O
; O O
very O O
similar O O
to O O
that O O
of O O
its O O
human O O
counterpart O O
. O O

A O O
biopsy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
specimen O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
taken O O
from O O
the O O
frontal O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
branch O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
of O O
the O O
right O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
superficial O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
artery O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
revealed O O
segmental O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
intimal O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
thickening O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
intimal O B_DISEASE
fibroplasia O I_DISEASE
type O I_DISEASE
FMD O I_DISEASE
upon O O
histological O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
examination O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Thus O O
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O O
used O O
in O O
vitro O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
methods O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
to O O
directly O O
evaluate O O
whether O O
isolated O O
human O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
saphenous O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
vein O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
segments O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
respond O O
to O O
vasoconstrictor O O
agents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
arterial O B_MEASURE/B_LOCATION
pressure O I_MEASURE/I_LOCATION
levels O I_MEASURE/I_LOCATION
. O O

We O O
found O O
that O O
the O O
PRP20 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
is O O
identical O O
to O O
the O O
yeast B B_GENE/B_BIO
SRM1 I I_GENE/I_BIO
gene I I_GENE/I_BIO
( O O
Clark O O
and O O
Sprague O O
1989 O O
) O O
. O O

Basal O O
JNK B B_GENE
MAPK I I_GENE
kinase I I_GENE
activity O O
was O O
also O O
specifically O O
induced O O
by O O
deltaEGFR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
which O O
correlated O O
with O O
increased O O
phosphorylation O O
of O O
a O O
54 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kDa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
JNK2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
observed O O
in O O
deltaEGFR B B_GENE
- O O
containing O O
cells O O
. O O

Deletion O O
analysis O O
defines O O
distinct O O
functional O O
domains O O
for O O
protein O O
- O O
protein O O
and O O
nucleic O O
acid O O
interactions O O
in O O
the O O
ORF1 B B_GENE/B_BIO
protein I I_GENE/I_BIO
of O O
mouse O O
LINE B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_VIRUS[BIO]
- I B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_VIRUS[BIO]
1 I B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_VIRUS[BIO]
. O O

PMA O O
produced O O
similar O O
results O O
, O O
but O O
the O O
induction O O
of O O
the O O
WT B B_GENE
AP1 I I_GENE
c B I_GENE
- I I_GENE
jun I I_GENE
promoter O O
- O O
CAT O O
plasmid O O
was O O
smaller O O
. O O

The O O
determination O O
of O O
antithrombin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
III I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
AT B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
III I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
its O O
clinical O O
significance O O

One O B_GENE/B_BIO
ORF O I_GENE/I_BIO
extends O O
from O O
nucleotides O B_MEASURE
415 O I_MEASURE
to O O
1620 O B_MEASURE
, O O
encodes O O
402 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amino O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acids O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
is O O
preceded O O
by O O
a O O
ribosome O B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
- O O
binding O O
site O B_LOCATION/B_BIO
. O O

Glucose O O
consumption O O
of O O
the O O
human O O
brain O O
under O O
the O O
influence O O
of O O
intravenous O O
infusions O O
of O O
glucose O O
, O O
glucagon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
glucose O O
- O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE

D O B_OTHER/B_LOCATION
. O O
, O O
Hughes O B_PERSON/B_COLOR
, O O
F O B_OTHER/B_PERSON
. O O

Deletion O O
of O O
CDC5 B B_GENE
was O O
lethal O O
and O O
resulted O O
in O O
a O O
dumbbell O O
- O O
shaped O O
terminal O O
morphology O O
, O O
with O O
the O O
nuclei O O
almost O O
divided O O
but O O
still O O
connected O O
. O O

These O O
cDNAs O O
were O O
found O O
to O O
be O O
derived O O
from O O
the O O
3 O O
" O O
- O O
untranslated O O
region O O
( O O
3 O O
" O O
- O O
UTR O O
) O O
of O O
the O O
methyl B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CpG I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MeCP2 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

A O O
) O O
During O O
O2 O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
ischemia O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
both O O
extracellular O B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
[ O O
K O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O O
] O B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
change O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
pH O B_MEASURE/B_LOCATION
in O O
the O O
subepicardium O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
are O O
significantly O O
less O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O O
in O O
the O O
midmyocardium O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
generation O O
of O O
dorso O O
- O O
ventral O O
polarity O O
during O O
Drosophila O O
embryogenesis O O
is O O
regulated O O
by O O
the O O
action O O
of O O
12 O O
maternally O O
expressed O O
gene O O
products O O
, O O
the O O
dorsal B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
group I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Ultimobranchial O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
body O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
parathyroid O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
glands O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
of O O
the O O
freshwater O B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
snake O I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
Natrix O I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
piscator O I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
vitamin O O
D3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
administration O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
. O O

These O O
observations O O
suggest O O
that O O
the O O
AF O O
- O O
1 O O
region O O
of O O
PPARalpha B B_GENE
is O O
partially O O
silenced O O
by O O
corepressor O O
proteins O O
, O O
which O O
might O O
interact O O
in O O
a O O
phosphorylation O O
- O O
dependent O O
manner O O
. O O

Two O B_TIME[MEASURE]/B_LOCATION
authors O I_TIME[MEASURE]/I_LOCATION
, O O
two O B_MEASURE/B_PERSON
journal O B_MEASURE/I_PERSON
titles O B_MEASURE/I_PERSON
, O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
drug O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
names O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
and O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
topics O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
a O O
general O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
medical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
nature O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
retrieved O O
under O O
identical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
circumstances O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O O
conditions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
on O O
the O O
hosts O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DATA O I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
STAR O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
DIALOG O B_LOCATION/B_PERSON
, O O
DIMDI O B_LOCATION/B_ORGANIZATION
, O O
and O O
STN O B_ORGANIZATION/B_MEASURE
. O O

However O O
, O O
in O O
a O O
variation O O
of O O
this O O
assay O O
in O O
which O O
the O O
protease O O
is O O
omitted O O
, O O
the O O
mutant O O
enzymes O O
exhibited O O
substantial O O
levels O O
of O O
prolyl B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
isomerase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
( O O
5 O O
- O O
20 O O
% O O
of O O
wild O O
- O O
type O O
) O O
, O O
revealing O O
that O O
these O O
mutations O O
confer O O
sensitivity O O
to O O
protease O O
digestion O O
and O O
that O O
the O O
classic O O
in O O
vitro O O
assay O O
for O O
prolyl B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
isomerase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
may O O
be O O
misleading O O
. O O

As O O
a O O
test O O
of O O
this O O
hypothesis O O
, O O
we O O
predicted O O
that O O
mice O O
which O O
have O O
altered O O
expression O O
of O O
class O O
I O O
gene O O
products O O
, O O
the O O
beta2 B B_GENE
- I I_GENE
microglobulin I I_GENE
knockout O O
mice O O
, O O
[ B B_TIME[MEASURE]/B_LOCATION
beta2m I I_TIME[MEASURE]/I_LOCATION
( I I_TIME[MEASURE]/I_LOCATION
- I I_TIME[MEASURE]/I_LOCATION
/ I I_TIME[MEASURE]/I_LOCATION
- I I_TIME[MEASURE]/I_LOCATION
) I I_TIME[MEASURE]/I_LOCATION
] I I_TIME[MEASURE]/I_LOCATION
, O O
would O O
develop O O
Fe O O
overload O O
. O O

Nucleotide O O
sequence O O
of O O
the O O
gag B B_GENE
gene I I_GENE
and O O
gag B B_GENE/B_DISEASE
- O O
pol B B_GENE/B_DISEASE
junction O O
of O O
feline O O
leukemia O O
virus O O
. O O

Clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
endpoints O O
based O O
on O O
magnitude O B_MEASURE
of O O
reduction O B_DISEASE_ADJECTIVE[DISEASE]
in O O
HIV O B_DISEASE/B_GENE
- O O
1 O B_GENE/B_DISEASE
RNA O I_GENE/I_DISEASE
levels O I_GENE/I_DISEASE
provide O O
an O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complement O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
endpoints O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
based O O
on O O
percentage O B_MEASURE
of O O
patients O B_PERSON/B_DISEASE
achieving O O
complete O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
virologic O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
suppression O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

It O O
also O O
describes O O
the O O
preliminary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
Phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
II O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
trial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
going O O
on O O
at O O
the O O
Central O B_LOCATION/B_ORGANIZATION
Institute O I_LOCATION/I_ORGANIZATION
for O O
Tumors O B_DISEASE
in O O
Zagreb O B_LOCATION
, O O
using O O
a O O
combination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
cis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
DDP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
5 O B_MEASURE
- O O
fluorouracil O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
vincristine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

On O O
the O O
basis O O
of O O
the O O
physical O O
interactions O O
between O O
Sxl B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Snf B B_GENE/B_BACTERIUM[BIO]
, O O
we O O
present O O
a O O
model O O
for O O
Sxl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
splicing O O
regulation O O
. O O

Though O O
it O O
has O O
been O O
established O O
that O O
skinfold O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anthropometry O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
has O O
severe O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
limitations O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
as O O
a O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
deriving O O
total O B_MEASURE/B_PROTEIN[GENE]
body O B_MEASURE/I_PROTEIN[GENE]
fat O B_MEASURE/I_PROTEIN[GENE]
( O O
TBF O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
the O O
possibility O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O O
the O O
problem O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
might O O
be O O
related O O
more O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O O
the O O
assumptions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
implicit O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
densitometry O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
has O O
to O O
be O O
addressed O O
. O O

The O O
average O B_MEASURE
mean O I_MEASURE
difference O I_MEASURE
compared O O
with O O
the O O
low O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
intermediate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
calcium O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
11 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
for O O
the O O
femoral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
neck O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
, O O
8 O B_NUMBER[MEASURE]
- O O
11 O B_SEQUENCE[MEASURE]/B_PERSON
% O I_SEQUENCE[MEASURE]/I_PERSON
for O O
the O O
lumbar O B_BODY_PART_OR_ORGAN_COMPONENT
spine O I_BODY_PART_OR_ORGAN_COMPONENT
and O O
5 O B_NUMBER[MEASURE]
- O O
6 O B_SEQUENCE[MEASURE]/B_PERSON
% O I_SEQUENCE[MEASURE]/I_PERSON
for O O
total O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
body O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BMDs O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
cloned O O
the O O
BamHI B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
F I I_GENE/I_LOCATION
fragment I I_GENE/I_LOCATION
from O O
the O O
left O O
end O O
of O O
Ad4 O O
in O O
pUC13 O O
- O O
1 O O
between O O
the O O
SalI B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O O
BamHI B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
sites I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
order O O
to O O
carry O O
out O O
the O O
structural O O
analysis O O
of O O
the O O
E1A B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
region I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Ad4 I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

We O O
reviewed O O
81 O B_PERSON
patients O I_PERSON
with O O
dementia O B_DISEASE
and O O
autopsy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Alzheimer O B_DISEASE
' O I_DISEASE
s O I_DISEASE
disease O I_DISEASE
( O O
AD O B_DISEASE
) O O
to O O
identify O O
patients O B_PERSON
with O O
seizures O B_DISEASE
or O O
myoclonus O B_DISEASE
after O O
onset O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
dementia O B_DISEASE
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
In O O
lung O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protective O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strategy O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
expiratory O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
pressure O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
( O O
PEEP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
slightly O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
the O O
Pflex O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
the O O
airway O B_MEASURE/B_LOCATION
pressure O I_MEASURE/I_LOCATION
corresponding O I_MEASURE/I_LOCATION
to O O
the O O
lower O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inflection O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
point O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
LIP O B_LOCATION/B_PROTEIN[GENE]
) O O
on O O
the O O
inspiratory O B_MEASURE/B_LOCATION
pressure O I_MEASURE/I_LOCATION
- O O
volume O B_MEASURE
( O O
P O B_PROTEIN[GENE]/B_LOCATION
- O O
V O B_OTHER/B_PROTEIN[GENE]
) O O
curve O B_MEASURE
measured O O
with O O
ZEEP O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
is O O
generally O O
recommended O O
. O O

3 O B_NUMBER[MEASURE]
. O O

In O O
both O O
RAW O O
cells O O
and O O
the O O
microglia O O
cell O O
line O O
EOC20 O O
, O O
two O O
IFN B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gamma I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
activated O O
transcription O O
factors O O
, O O
STAT B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1alpha I I_GENE/I_DISEASE
and O O
IRF B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
1 I I_GENE/I_MEASURE
, O O
bind O O
the O O
GAS B B_GENE/B_BACTERIUM[BIO]
and O O
IRF B B_GENE
elements I I_GENE
, O O
respectively O O
. O O

Thermal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
changes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
the O O
bovine O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
uterus O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
following O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
estradiol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
17beta O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
. O O

The O O
starting O O
dose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O O
8 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
m2 O B_MEASURE
administered O O
intravenously O O
( O O
IV O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
as O O
a O O
short O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
infusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
daily O O
for O O
5 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
, O O
repeated O O
every O O
3 O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
with O O
dose O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
adjustments O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
depending O O
on O O
patient O B_DISEASE
tolerance O I_DISEASE
. O O

In O O
agreement O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
authors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
we O O
recommend O O
the O O
procedure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
as O O
a O O
safe O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
one O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
providing O O
satisfactory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

After O O
inhibition O O
of O O
monoamine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxidase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
pargyline O O
( O O
10 O O
mg O O
/ O O
kg O O
. O O
i O O
. O O
v O O
. O O
) O O
, O O
the O O
effects O O
of O O
tyramine O O
( O O
1000 O O
micrograms O O
) O O
injected O O
into O O
the O O
hepatic O O
artery O O
were O O
potentiated O O
. O O

Helenalin O O
triggers O O
a O O
CD95 B B_GENE
death I I_GENE
receptor I I_GENE
- O O
independent O O
apoptosis O O
that O O
is O O
not O O
affected O O
by O O
overexpression O O
of O O
Bcl B B_GENE
- I I_GENE
x I I_GENE
( I I_GENE
L I I_GENE
) I I_GENE
or O O
Bcl B B_GENE
- I I_GENE
2 I I_GENE
. O O

Of O O
the O O
47 O B_PERSON
women O I_PERSON
with O O
AGCUS O B_DISEASE
, O O
16 O B_MEASURE
had O O
intraepithelial O B_DISEASE_ADJECTIVE[DISEASE]
or O O
invasive O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
neoplasms O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
34 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
; O O
95 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
confidence O I_MEASURE/I_PERSON
interval O I_MEASURE/I_PERSON
, O O
21 O B_MEASURE
- O O
49 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
, O O
including O O
9 O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
low O I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
or O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
grade O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
squamous O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
intraepithelial O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
lesions O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
1 O B_DISEASE/B_MEASURE
adenocarcinoma O I_DISEASE/I_MEASURE
in O O
situ O B_DISEASE/B_PERSON
of O O
the O O
cervix O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
3 O B_DISEASE
adenocarcinomas O I_DISEASE
of O O
the O O
cervix O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
2 O B_NUMBER[MEASURE]/B_DISEASE
adenocarcinomas O I_NUMBER[MEASURE]/I_DISEASE
of O O
the O O
endometrium O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
1 O B_DISEASE/B_NUMBER[MEASURE]
adenoid O B_DISEASE/I_NUMBER[MEASURE]
basal O B_DISEASE/I_NUMBER[MEASURE]
cell O B_DISEASE/I_NUMBER[MEASURE]
carcinoma O B_DISEASE/I_NUMBER[MEASURE]
of O O
the O O
cervix O B_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
DF3 B B_GENE/B_LOCATION
/ O O
MUC1 B B_GENE/B_MEASURE
gene O O
encodes O O
a O O
high B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecular I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
weight I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mucin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
like I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glycoprotein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O O
is O O
overexpressed O O
at O O
the O O
transcriptional O O
level O O
in O O
the O O
majority O O
of O O
human O O
breast O O
cancers O O
. O O

The O O
organization O O
of O O
the O O
MBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
very O O
similar O O
to O O
the O O
arrangement O O
of O O
the O O
gene O O
encoding O O
the O O
highly O O
homologous B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pulmonary I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
surfactant I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
apoprotein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
although O O
one O O
of O O
the O O
intron O O
positions O O
is O O
shifted O O
by O O
a O O
single O O
amino O O
acid O O
. O O

Hip O B_TIME[MEASURE]/B_PERSON
fracture O I_TIME[MEASURE]/I_PERSON
mortality O I_TIME[MEASURE]/I_PERSON
and O O
prospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
payment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

These O O
results O O
indicate O O
that O O
patients O O
with O O
SS O O
and O O
evidence O O
of O O
exercise O O
- O O
induced O O
ST O O
- O O
segment O O
depression O O
may O O
have O O
decreased O O
myocardial O O
oxygen O O
supply O O
due O O
to O O
low O O
hemoglobin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
levels O O
and O O
increased O O
myocardial O O
oxygen O O
demand O O
( O O
elevated O O
double O O
products O O
) O O
when O O
compared O O
to O O
subjects O O
with O O
SS O O
who O O
do O O
not O O
have O O
exercise O O
- O O
induced O O
ST O O
- O O
segment O O
depression O O
. O O

Although O O
hSSTR5 B B_GENE/B_PERSON
displays O O
approximately O O
75 O O
% O O
sequence O O
identity O O
with O O
rat B B_GENE
SSTR5 I I_GENE
, O O
the O O
two O O
receptors O O
display O O
significantly O O
different O O
pharmacological O O
profiles O O
, O O
especially O O
with O O
respect O O
to O O
their O O
binding O O
affinities O O
for O O
the O O
SST B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analogue O O
SMS O O
201 O O
- O O
995 O O
. O O

A O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
specific O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reduction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
binaural O B_MEASURE
peak O I_MEASURE
amplitude O I_MEASURE
and O O
area O B_MEASURE/B_DISEASE
of O O
the O O
echo O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
evoked O O
middle O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
latency O B_MEASURE/B_LOCATION
component O B_MEASURE/I_LOCATION
Pa O B_MEASURE/I_LOCATION
was O O
observed O O
. O O

EMBO O B_NUMBER[MEASURE]/B_ORGANIZATION
( O O
Eur O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Using O O
this O O
oligonucleotide O O
as O O
a O O
probe O O
, O O
an O O
8 O O
- O O
kilobase O O
HindIII B B_MEASURE/B_LOCATION
fragment O O
of O O
genomic O O
DNA O O
was O O
isolated O O
and O O
subjected O O
to O O
Sanger O O
dideoxy O O
DNA O O
sequencing O O
. O O

Arg O O
- O O
130 O O
, O O
Gly O O
- O O
132 O O
and O O
Lys O O
- O O
167 O O
are O O
conserved O O
in O O
all O O
members O O
of O O
the O O
type B B_GENE/B_BIO
IB I I_GENE/I_BIO
topoisomerase I I_GENE/I_BIO
family I I_GENE/I_BIO
. O O

Four O O
cDNAs O O
( O O
Kox4 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Kox7 B B_MEASURE/B_GENE
, O O
Kox12 B B_MEASURE/B_GENE
, O O
and O O
Kox15 B B_MEASURE
) O O
were O O
identified O O
that O O
match O O
one O O
or O O
more O O
genomic O O
clones O O
; O O
these O O
matches O O
were O O
confirmed O O
by O O
nucleotide O O
sequence O O
analysis O O
. O O

2 O B_NUMBER[MEASURE]
. O O

Prevalence O O
of O O
use O O
, O O
claims O O
volume O O
, O O
and O O
expenditures O O
were O O
compared O O
for O O
cisapride O O
, O O
proton O O
pump O O
inhibitors O O
, O O
histamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antagonists O O
, O O
and O O
the O O
prokinetic O O
agent O O
metoclopramide O O
during O O
these O O
periods O O
. O O

Relaxant O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effect O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
prostaglandin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E1 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PGE1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
and O O
papaverine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PAP O B_PROTEIN[GENE]/B_DISEASE
) O O
were O O
measured O O
in O O
strips O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
corpus O B_BODY_PART_OR_ORGAN_COMPONENT
cavernosum O I_BODY_PART_OR_ORGAN_COMPONENT
smooth O I_BODY_PART_OR_ORGAN_COMPONENT
muscle O I_BODY_PART_OR_ORGAN_COMPONENT
taken O O
from O O
a O O
healthy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
men O B_PERSON/B_BIO
( O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
; O O
n O B_MEASURE/B_PROTEIN[GENE]
= O O
5 O B_MEASURE
) O O
, O O
from O O
arteriogenically O O
impotent O B_DISEASE_ADJECTIVE[DISEASE]
men O I_DISEASE_ADJECTIVE[DISEASE]
( O O
B O B_LOCATION/B_DISEASE
; O O
n O O
= O O
6 O B_MEASURE
) O O
and O O
from O O
additionally O O
diabetic O B_PERSON/B_BIO
impotent O I_PERSON/I_BIO
men O I_PERSON/I_BIO
( O O
C O B_PROTEIN[GENE]/B_LOCATION
; O O
n O B_MEASURE/B_PROTEIN[GENE]
= O O
5 O B_MEASURE
) O O
with O O
venous O B_DISEASE
leakage O I_DISEASE
. O O

Primer O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extension O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
dbcAMP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
differentiated O O
U937 O B_BIO/B_GENE
RNA O B_BIO/I_GENE
indicated O O
a O O
single O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcriptional O B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
initiation O B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site O B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
contrast O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
group O B_PERSON/B_ORGANIZATION
II O I_PERSON/I_ORGANIZATION
showed O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
improvement O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
peak O B_MEASURE/B_EDU[ORGANIZATION]
VO2 O B_MEASURE/I_EDU[ORGANIZATION]
with O O
rate O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
adaptive O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
AV O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
delay O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
compared O O
to O O
fixed O O
AV O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
delay O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
programming O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
P O B_MEASURE/B_PERSON
less O I_MEASURE/I_PERSON
than O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

Effect O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
family O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
visits O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
blood O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pressure O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
heart O B_MEASURE/B_DISEASE
rate O I_MEASURE/I_DISEASE
of O O
patients O B_PERSON
in O O
the O O
coronary O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
- O O
care O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
unit O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Sequence O O
analysis O O
and O O
electrophoretic O O
mobility O O
shift O O
experiments O O
suggest O O
that O O
GnSE B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
response I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
elements I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
interact O O
, O O
in O O
these O O
two O O
regions O O
, O O
with O O
GATA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
LIM I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
related I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
respectively O O
. O O

The O O
transfer O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
by O O
conjugation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
E O B_BACTERIUM[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
coli O B_BACTERIUM[BIO]/B_PERSON
K12 O I_BACTERIUM[BIO]/I_PERSON
of O O
ampicillin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
carbenicillin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
resistance O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
obtained O O
with O O
14 O B_BACTERIUM[BIO]/B_NUMBER[MEASURE]
strains O B_BACTERIUM[BIO]/I_NUMBER[MEASURE]
: O O
( O O
E O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
coli O B_BACTERIUM[BIO]
: O O
9 O B_NUMBER[MEASURE]
, O O
C O B_OTHER/B_GENE
. O O
freundii O B_BACTERIUM[BIO]/B_DISEASE
: O O
1 O B_NUMBER[MEASURE]
, O O
K O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
pneumoniae O B_BACTERIUM[BIO]/B_MEASURE
: O O
1 O B_NUMBER[MEASURE]
, O O
E O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
cloacae O B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
: O O
2 O B_NUMBER[MEASURE]
, O O
P O B_OTHER/B_LOCATION
. O O
stuartii O B_BACTERIUM[BIO]/B_MEASURE
: O O
1 O B_MEASURE
) O O
. O O

Wild O O
type O O
MEKK1 B B_GENE
enhances O O
promoter O O
activity O O
and O O
the O O
activity O O
can O O
be O O
inhibited O O
by O O
dominant O O
negative O O
MEKK1 B B_GENE
, O O
MEK1 B B_GENE
, O O
MEK7 B B_GENE
, O O
MEK3 B B_GENE
, O O
p38 B B_GENE/B_LOCATION
/ O O
RK B B_MEASURE/B_GENE
, O O
and O O
c B B_GENE
- I I_GENE
Jun I I_GENE
. O O

250 O B_MEASURE
, O O
302 O B_MEASURE
- O O
311 O B_MEASURE
] O I_MEASURE
. O O

The O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
permit O O
considering O O
the O O
detected O B_DISEASE_ADJECTIVE[DISEASE]
shifts O I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
immunity O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
system O O
an O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
component O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
pathogenesis O B_DISEASE
of O O
chronic O B_DISEASE
nontumorous O I_DISEASE
diseases O I_DISEASE
of O O
the O O
parotid O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
glands O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Coexistence O B_DISEASE_ADJECTIVE[DISEASE]
of O O
Turner O B_DISEASE
' O I_DISEASE
s O I_DISEASE
syndrome O I_DISEASE
and O O
schizophrenia O B_DISEASE

An O O
scrR B B_GENE
promoter I I_GENE
fragment I I_GENE
, O O
which O O
dose O O
not O O
contain O O
a O O
sequence O O
resembling O O
OB B B_GENE/B_DISEASE
, O O
was O O
not O O
shifted O O
by O O
the O O
fusion O O
protein O O
. O O

Using O O
the O O
conflict O O
drinking O O
test O O
as O O
a O O
model O O
, O O
we O O
studied O O
in O O
rats O O
the O O
effect O O
of O O
the O O
nonselective O O
beta B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
adrenoceptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blockers O O
pindolol O O
and O O
cyanopindolol O O
which O O
bind O O
to O O
5 B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HT1A I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HT1B I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
of O O
the O O
selective O O
beta B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adrenoceptor I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonists O O
betaxolol O O
and O O
ICI O O
118 O O
, O O
551 O O
, O O
respectively O O
, O O
which O O
have O O
a O O
negligible O O
affinity O O
for O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
HT I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Although O O
several O O
other O O
signal O O
transduction O O
molecules O O
also O O
contain O O
tandemly O O
occurring O O
SH3 B B_LOCATION/B_GENE
and O O
SH2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
domains I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
function O O
of O O
these O O
closely O O
spaced O O
domains O O
is O O
not O O
well O O
understood O O
. O O

Glycoprotein O O
biosynthesis O O
in O O
Saccharomyces O O
cerevisiae O O
: O O
ngd29 B B_LOCATION/B_GENE
, O O
an O O
N O O
- O O
glycosylation O O
mutant O O
allelic O O
to O O
och1 B B_SPECIES[BIO]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
having O O
a O O
defect O O
in O O
the O O
initiation O O
of O O
outer O O
chain O O
formation O O
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
In O O
the O O
majority O B_PERSON/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
of O O
patients O B_PERSON/B_BIO
with O O
severe O B_DISEASE/B_LOCATION
ulcerative O I_DISEASE/I_LOCATION
colitis O I_DISEASE/I_LOCATION
, O O
circulating O O
concentrations O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
NOX O B_GENE
are O O
increased O O
at O O
presentation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
fall O O
promptly O O
during O O
parenteral O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
steroid O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
irrespective O B_MEASURE/B_LOCATION
of O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcome O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
duration O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
naloxone O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
appears O O
to O O
be O O
dose O B_MEASURE
- O O
related O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
statistically O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
up O O
to O O
approximately O O
1 O B_MEASURE
. O O
5 O B_MEASURE
hr O I_MEASURE
. O O

But O O
if O O
one O O
equalizes O O
the O O
upper O O
limits O O
of O O
normal O O
for O O
both O O
markers O O
to O O
a O O
common O O
95 O O
% O O
specificity O O
, O O
the O O
tumour O O
- O O
indicating O O
sensitivity O O
of O O
CA B B_GENE/B_MEASURE
19 I I_GENE/I_MEASURE
- I I_GENE/I_MEASURE
9 I I_GENE/I_MEASURE
clearly O O
surpasses O O
that O O
of O O
CA B B_GENE/B_LOCATION
50 I I_GENE/I_LOCATION
. O O

These O O
motions O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
were O O
found O O
in O O
the O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
and O O
C O B_PROTEIN[GENE]/B_LOCATION
- O O
terminal O B_LOCATION/B_MEASURE
tails O I_LOCATION/I_MEASURE
, O O
in O O
segment O B_MEASURE/B_LOCATION
33 O I_MEASURE/I_LOCATION
- O O
35 O B_MEASURE
which O O
forms O O
the O O
turn O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
strands O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
S1 O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
S2 O B_MEASURE/B_PROTEIN[GENE]
, O O
and O O
residues O B_MEASURE
47 O I_MEASURE
- O O
52 O B_MEASURE
located O O
in O O
a O O
long O B_LOCATION/B_MEASURE
loop O I_LOCATION/I_MEASURE
preceding O O
strand O B_PROTEIN[GENE]/B_NUMBER[MEASURE]
S3 O I_PROTEIN[GENE]/I_NUMBER[MEASURE]
. O O

Genomic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Southern O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reveals O O
10 O B_NUMBER[MEASURE]
to O O
15 O B_MEASURE
hybridising O I_MEASURE
fragments O I_MEASURE
, O O
suggesting O O
that O O
maize O B_BIO/B_GENE
contains O O
a O O
small O B_GENE
gene O I_GENE
family O I_GENE
. O O

Custom O O
- O O
made O O
orthoses O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
play O O
an O O
invaluable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
role O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
achieving O O
a O O
wide O B_MEASURE/B_LOCATION
range O I_MEASURE/I_LOCATION
of O O
therapeutic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
goals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
improving O O
function O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
pinch O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
stabilizing O O
individual O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
joints O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
preventing O O
positional O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contractures O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
protecting O O
joints O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
from O O
trauma O B_DISEASE
, O O
stretching O O
the O O
intrinsic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
muscles O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
correcting O O
joint O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
and O O
soft O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
tissue O B_DISEASE_ADJECTIVE[DISEASE]
contractures O I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
controlling O O
inflammation O B_DISEASE/B_BACTERIUM[BIO]
. O O

Is O O
exposure O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
a O O
patient O B_PERSON/B_BIO
with O O
Crohn O B_DISEASE
' O I_DISEASE
s O I_DISEASE
disease O I_DISEASE
an O O
environmental O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
developing O O
the O O
disease O B_DISEASE
. O O

The O O
ZAG1 B B_GENE
protein I I_GENE
from O O
in O O
vitro O O
translations O O
binds O O
to O O
a O O
consensus O O
target O O
site O O
that O O
is O O
recognized O O
by O O
the O O
AG B B_GENE
protein I I_GENE
. O O

The O O
uap100 B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
cis O O
- O O
acting O O
, O O
up O O
- O O
promoter O O
, O O
constitutive O O
mutation O O
is O O
a O O
duplication O O
that O O
comprises O O
two O O
GATA O O
sites O O
and O O
suppresses O O
weakly O O
the O O
AREA B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
zinc I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
finger I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
but O O
does O O
not O O
alleviate O O
the O O
need O O
for O O
functional O O
UAY B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
AREA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Pituitary O B_DISEASE
thyrotropic O I_DISEASE
adenoma O I_DISEASE
associated O O
with O O
congenital O B_DISEASE/B_GENE
hypothyroidism O I_DISEASE/I_GENE
. O O

This O O
region O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O O
unfavourable O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
, O O
due O O
to O O
malaria O B_DISEASE
in O O
the O O
past O B_TIME[MEASURE]/B_LOCATION
. O O

Indeed O O
, O O
after O O
a O O
single O O
oral O O
dose O O
, O O
the O O
role O O
of O O
the O O
mu B B_GENE
- I I_GENE
receptor I I_GENE
agonist O O
component O O
of O O
the O O
antinociceptive O O
effect O O
of O O
tramadol O O
appears O O
to O O
be O O
minor O O
, O O
with O O
most O O
of O O
the O O
analgesic O O
effect O O
being O O
attributable O O
to O O
nonopioid O O
properties O O
of O O
the O O
parent O O
compound O O
. O O

CHIEF O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
OUTCOME O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MEASURES O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Endoluminal O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
release O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
prostacyclin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
6 O B_MEASURE
- O O
Keto O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
PGF1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
thromboxane O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
B2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
TxB2 O B_PROTEIN[GENE]
) O O
, O O
patency O B_DISEASE
, O O
EC O B_DISEASE_ADJECTIVE[DISEASE]
coverage O I_DISEASE_ADJECTIVE[DISEASE]
and O O
cell O B_DISEASE_ADJECTIVE[DISEASE]
identity O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Somatic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
visceral O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
inputs O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
to O O
the O O
thoracic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
spinal O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
cord O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
cat O B_BIO/B_DISEASE
: O O
effects O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
noxious O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
the O O
biliary O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

We O O
have O O
produced O O
the O O
Ure2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
high O O
yield O O
in O O
Escherichia O O
coli O O
from O O
a O O
synthetic O O
gene O O
. O O

Transfection O O
of O O
both O O
Calu O O
- O O
6 O O
and O O
JEG O O
- O O
3 O O
cells O O
with O O
a O O
PKA B B_GENE
expression O O
vector O O
resulted O O
in O O
a O O
10 O O
- O O
fold O O
induction O O
of O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
renin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcriptional O O
activity O O
in O O
constructs O O
containing O O
the O O
native O O
or O O
consensus O O
CRE O O
and O O
5 O O
- O O
fold O O
activation O O
in O O
a O O
construct O O
containing O O
a O O
nonfunctional O O
CRE O O
. O O

We O O
undertook O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
examine O O
the O O
relationship O B_PERSON/B_MEASURE
between O O
systemic O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
oxygen O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
delivery O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
DO2 O B_GENE/B_LOCATION
) O O
and O O
tissue O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
oxygen O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
tension O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
TPO2 O B_GENE/B_LOCATION
) O O
in O O
hypovolemic O B_DISEASE/B_SPECIES[BIO]
shock O B_DISEASE/I_SPECIES[BIO]
. O O

White O B_PERSON
female O I_PERSON
cases O I_PERSON
were O O
more O O
likely O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
have O O
worked O O
as O O
registered O O
nurses O B_PERSON/B_BIO
than O O
were O O
the O O
controls O B_PERSON/B_MEASURE
( O O
OR O O
= O O
1 O B_MEASURE
. O O
9 O B_MEASURE
, O O
95 O B_LOCATION/B_MEASURE
% O I_LOCATION/I_MEASURE
CI O I_LOCATION/I_MEASURE
= O O
1 O B_MEASURE
. O O
0 O B_MEASURE
- O O
3 O B_MEASURE
. O O
5 O B_MEASURE
) O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Children O B_PERSON
with O O
attention O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
deficit O B_DISEASE
/ O O
hyperactivity O B_DISEASE
disorder O I_DISEASE
( O O
ADHD O B_DISEASE
; O O
n O O
= O O
282 O B_MEASURE
) O O
, O O
all O O
subtypes O B_PERSON
, O O
ages O B_NUMBER[MEASURE]/B_LOCATION
6 O I_NUMBER[MEASURE]/I_LOCATION
to O O
12 O B_TIME[MEASURE]
years O I_TIME[MEASURE]
, O O
were O O
randomized O O
to O O
placebo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
n O B_MEASURE/B_LOCATION
= O O
90 O B_MEASURE
) O O
, O O
immediate O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
release O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
methylphenidate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
IR O B_DISEASE/B_PROTEIN[GENE]
MPH O B_DISEASE/I_PROTEIN[GENE]
) O O
3 O B_NUMBER[MEASURE]/B_LOCATION
times O I_NUMBER[MEASURE]/I_LOCATION
a O O
day O B_TIME[MEASURE]
( O O
tid O B_PROTEIN[GENE]/B_LOCATION
; O O
dosed O O
every O O
4 O B_TIME[MEASURE]/B_ENT
hours O I_TIME[MEASURE]/I_ENT
; O O
n O B_MEASURE/B_LOCATION
= O O
97 O B_MEASURE
) O O
, O O
or O O
OROS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MPH O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
once O O
a O O
day O B_TIME[MEASURE]
( O O
qd O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
; O O
n O B_OTHER/B_LOCATION
= O O
95 O B_MEASURE
) O O
in O O
a O O
double O B_MEASURE
- O O
blind O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
28 O B_NUMBER[MEASURE]
- O O
day O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
trial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

Immunologic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tolerance O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
rats O B_BIO/B_PERSON
during O O
13 O B_TIME[MEASURE]
weeks O I_TIME[MEASURE]
of O O
inhalation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
exposure O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
to O O
trimellitic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anhydride O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

They O O
cause O O
temporary O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disability O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
invalidity O B_DISEASE
and O O
mortality O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
a O O
great O B_MEASURE/B_PERSON
part O I_MEASURE/I_PERSON
of O O
the O O
productive O B_PERSON/B_LOCATION
population O I_PERSON/I_LOCATION
, O O
significantly O O
damaging O O
the O O
economic O B_MEASURE/B_ORGANIZATION
status O B_MEASURE/I_ORGANIZATION
of O O
the O O
country O B_LOCATION/B_PERSON
. O O

Cloning O O
and O O
sequence O O
analysis O O
of O O
a O O
chymotrypsinlike B B_DISEASE_ADJECTIVE[DISEASE]
protease I I_DISEASE_ADJECTIVE[DISEASE]
from I I_DISEASE_ADJECTIVE[DISEASE]
Treponema I I_DISEASE_ADJECTIVE[DISEASE]
denticola O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
AND O O
RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
: O O
The O O
QTd O B_LOCATION/B_DISEASE
and O O
JTd O B_MEASURE/B_DISEASE
intervals O B_MEASURE/I_DISEASE
in O O
39 O B_PERSON/B_ENT
children O I_PERSON/I_ENT
with O O
long O B_DISEASE/B_GENE
QT O I_DISEASE/I_GENE
syndrome O I_DISEASE/I_GENE
were O O
compared O O
to O O
those O O
of O O
50 O B_TIME[MEASURE]/B_PERSON
normal O I_TIME[MEASURE]/I_PERSON
age O I_TIME[MEASURE]/I_PERSON
- O O
matched O O
children O B_PERSON
. O O

V B B_DISEASE/B_LOCATION
- I I_DISEASE/I_LOCATION
ErbB I I_DISEASE/I_LOCATION
- I I_DISEASE/I_LOCATION
mediated I I_DISEASE/I_LOCATION
complex I I_DISEASE/I_LOCATION
formation O O
and O O
transformation O O
have O O
been O O
shown O O
to O O
occur O O
independently O O
of O O
Ras B B_GENE/B_DISEASE
activation O O
. O O

Both O O
parameters O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
determined O O
in O O
an O O
individual O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
eye O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
applying O O
the O O
dye O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
first O O
by O O
iontophoresis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
then O O
by O O
intravitreal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
injection O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
which O O
allows O O
the O O
influence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
fluorescein O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
glucuronide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
on O O
the O O
fluorophotometric O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
measurements O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
to O O
be O O
excluded O O
. O O

Organization O O
of O O
exons O O
suggests O O
that O O
, O O
similar O O
to O O
the O O
human B B_GENE/B_TIME[MEASURE]
VEGF I I_GENE/I_TIME[MEASURE]
gene I I_GENE/I_TIME[MEASURE]
, O O
alternative O O
splicing O O
generates O O
the O O
120 O O
- O O
, O O
164 O O
- O O
, O O
and O O
188 O O
- O O
amino O O
acid O O
isoforms O O
, O O
but O O
does O O
not O O
predict O O
a O O
fourth O O
VEGF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
isoform I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
corresponding O O
to O O
human B B_GENE/B_PERSON
VEGF206 I I_GENE/I_PERSON
. O O

Electron O O
microscopy O O
of O O
pH O O
7 O O
. O O
5 O O
- O O
treated O O
TMV O O
particles O O
incubated O O
in O O
SPN B B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
- O O
treated O O
wheatgerm O O
extract O O
or O O
rabbit O O
reticulocyte O O
lysate O O
, O O
showed O O
that O O
approximately O O
10 O O
% O O
of O O
virions O O
complexed O O
with O O
one O O
ribosome O O
and O O
approximately O O
10 O O
% O O
with O O
two O O
bound O O
ribosomes O O
, O O
confirming O O
that O O
omega O O
at O O
least O O
had O O
been O O
uncoated O O
. O O

The O O
sequence O B_LOCATION/B_PROTEIN[GENE]
contained O O
five O B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
repeats O I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
hypothetical O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
leucine O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
zipper O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
motif O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
: O O
one O B_NUMBER[MEASURE]
is O O
in O O
the O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
globular O B_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
domain O B_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
four O B_NUMBER[MEASURE]/B_PERSON
are O O
in O O
the O O
central O B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
alpha O I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
helical O B_LOCATION/B_GENE
stalk O I_LOCATION/I_GENE
. O O

Postheparin O O
lipoprotein B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lipase I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
measured O O
using O O
fat O O
emulsion O O
as O O
substrate O O
, O O
also O O
was O O
significantly O O
greater O O
in O O
female O O
rats O O
compared O O
with O O
males O O
. O O

The O O
authors O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
report O O
a O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
painful O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
wrist O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
related O O
to O O
a O O
" O O
Manieux O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
muscle O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
" O O
of O O
the O O
dorsal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
aspect O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
hand O B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Genomic O O
organization O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
multidrug I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
resistance I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MDR1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
origin O O
of O O
P B B_DISEASE_ADJECTIVE[DISEASE]
- I I_DISEASE_ADJECTIVE[DISEASE]
glycoproteins I I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
nitroglycerin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
however O O
, O O
remained O O
intact O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
regardless O O
of O O
initial O B_MEASURE/B_DISEASE
reperfusion O I_MEASURE/I_DISEASE
pressure O I_MEASURE/I_DISEASE
. O O

Deletion O O
analysis O O
revealed O O
that O O
only O O
the O O
TM O O
domain O O
of O O
E2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
required O O
for O O
Golgi O O
targeting O O
. O O

In O O
addition O O
, O O
putative O O
binding O O
sites O O
for O O
SH3 B B_LOCATION/B_GENE
and O O
SH2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
domains I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
present O O
in O O
the O O
amino O O
- O O
terminal O O
half O O
of O O
the O O
molecule O O
. O O

Since O O
nearly O O
all O O
transformants O O
involving O O
homeologous O O
DNAs O O
carried O O
a O O
single O O
recombinant O O
plasmid O O
in O O
both O O
Pms B B_LOCATION/B_DISEASE
+ I I_LOCATION/I_DISEASE
and O O
Pms B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
strains O O
, O O
stable O O
heteroduplex O O
DNA O O
appears O O
less O O
likely O O
than O O
for O O
homologous O O
DNAs O O
. O O

All O O
rights O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reserved O O
. O O

One O O
new O O
ORF O O
, O O
YBR0224 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
was O O
detected O O
, O O
coding O O
for O O
a O O
protein O O
with O O
918 O O
amino O O
acids O O
. O O

A O O
sequence O O
- O O
ready O O
3 O O
- O O
Mb O O
PAC O O
contig O O
covering O O
16 O O
breakpoints O O
of O O
the O O
Wilms B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
tumor I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
/ I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
anirida I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
region I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
human O O
chromosome O O
11p13 O O
. O O

The O O
MAP B B_ENZYME[GENE]/B_MEASURE
kinase I I_ENZYME[GENE]/I_MEASURE
kinase I I_ENZYME[GENE]/I_MEASURE
kinase I I_ENZYME[GENE]/I_MEASURE
MLK2 B I_ENZYME[GENE]/I_MEASURE
co O O
- O O
localizes O O
with O O
activated O O
JNK B B_GENE
along O O
microtubules O O
and O O
associates O O
with O O
kinesin B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
superfamily I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
motor O O
KIF3 B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Bone O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
scintigraphy O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
an O O
excellent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
screening O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
bone O B_DISEASE/B_LOCATION
lesions O I_DISEASE/I_LOCATION
and O O
Ga O B_LOCATION/B_ORGANIZATION
- O O
67 O B_TIME[MEASURE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scintigraphy O I_TIME[MEASURE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
useful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
tool O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O O
detecting O O
inflammatory O B_DISEASE
lesions O I_DISEASE
. O O

Spontaneous O B_DISEASE
fracture O I_DISEASE
of O O
the O O
tarsal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
bone O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O O
2 O B_PERSON/B_MEASURE
cases O I_PERSON/I_MEASURE
of O O
leprosy O B_DISEASE

They O O
are O O
transduced O O
through O O
TM O O
to O O
the O O
cytoplasmic O O
portion O O
( O O
cytoloops O O
and O O
the O O
C O O
- O O
terminal O O
tail O O
) O O
of O O
the O O
receptor O O
and O O
then O O
, O O
transferred O O
to O O
cytoplasmic O O
signaling O O
molecules O O
, O O
such O O
as O O
G B B_GENE
protein I I_GENE
. O O

Serum B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alkaline I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
creatine B B_ENZYME[GENE]
kinase I I_ENZYME[GENE]
activities O O
were O O
significantly O O
increased O O
in O O
the O O
A O O
praelongus O O
- O O
fed O O
pigs O O
and O O
significantly O O
decreased O O
in O O
Na2SeO4 O O
- O O
fed O O
pigs O O
. O O

This O O
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
the O O
presence O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
bacteria O B_BACTERIUM[BIO]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
infiltrated O O
at O O
the O O
dentinal O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
tubules O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
coronally O O
and O O
into O O
the O O
root O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
canals O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Seven O B_PERSON
Zebu O I_PERSON
cattle O I_PERSON
were O O
also O O
exposed O O
to O O
challenge O O
at O O
the O O
same O B_LOCATION
time O I_LOCATION
. O O

However O O
, O O
the O O
quasiparticle O B_PROTEIN[GENE]/B_MEASURE
scattering O I_PROTEIN[GENE]/I_MEASURE
rate O I_PROTEIN[GENE]/I_MEASURE
tau O I_PROTEIN[GENE]/I_MEASURE
( O O
- O O
1 O B_NUMBER[MEASURE]
) O O
is O O
such O B_MEASURE/B_LOCATION
that O O
Planck O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
' O O
s O O
over O O
2pi O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
tau O B_PROTEIN[GENE]/B_DISEASE
approximately O O
6t O B_MEASURE/B_LOCATION
( O O
perpendicular O B_TIME[MEASURE]
) O O
, O O
implying O O
that O O
kappa O B_PROTEIN[GENE]/B_LOCATION
- O O
( O O
BEDT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
TTF O B_PROTEIN[GENE]/B_LOCATION
) O O
2Cu O B_LOCATION
( O O
NCS O B_DISEASE/B_LOCATION
) O O
( O O
2 O B_TIME[MEASURE]/B_LOCATION
) O O
meets O O
the O O
criterion O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
used O O
to O O
identify O O
interlayer O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
incoherence O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
kidney O B_DISEASE
length O I_DISEASE
was O O
considerably O O
prolonged O O
compared O O
with O O
the O O
vascular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Although O O
polyubiquitin B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chains I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
linked O O
through O O
Lys O O
( O O
29 O O
) O O
of O O
ubiquitin B B_GENE
have O O
been O O
implicated O O
in O O
the O O
targeting O O
of O O
certain O O
substrates O O
to O O
proteasomes O O
, O O
the O O
signaling O O
properties O O
of O O
these O O
chains O O
are O O
poorly O O
understood O O
. O O

Diabetic O B_DISEASE/B_GENE
osteopenia O I_DISEASE/I_GENE
, O O
a O O
known O B_DISEASE_ADJECTIVE[DISEASE]
chronic O I_DISEASE_ADJECTIVE[DISEASE]
complication O I_DISEASE_ADJECTIVE[DISEASE]
of O O
diabetes O B_DISEASE
, O O
has O O
been O O
demonstrated O O
with O O
alterations O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
calcium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
vitamin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
D O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
endocrine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
system O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
. O O

An O O
in O O
vitro O O
Raf B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
assay O O
, O O
however O O
, O O
failed O O
to O O
detect O O
LPS O O
- O O
induced O O
Raf B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
in O O
RAW O O
264 O O
. O O
7 O O
cells O O
, O O
suggesting O O
that O O
in O O
RAW O O
264 O O
. O O
7 O O
cells O O
, O O
Raf B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
not O O
an O O
activating O O
component O O
of O O
the O O
LPS O O
signaling O O
pathway O O
regulating O O
MAPK B B_GENE
activity O O
or O O
sIL B B_GENE
- I I_GENE
1Ra I I_GENE
promoter I I_GENE
activity O O
. O O

Phosphorylation O O
of O O
the O O
ras B B_GENE/B_BIO
GTPase B I_GENE/I_BIO
- I I_GENE/I_BIO
activating I I_GENE/I_BIO
protein I I_GENE/I_BIO
( O O
GAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
by O O
the O O
p93c B B_ENZYME[GENE]
- I I_ENZYME[GENE]
fes I I_ENZYME[GENE]
protein B I_ENZYME[GENE]
- I I_ENZYME[GENE]
tyrosine I I_ENZYME[GENE]
kinase I I_ENZYME[GENE]
in O O
vitro O O
and O O
formation O O
of O O
GAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
fes B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
complexes O O
via O O
an O O
SH2 B B_GENE/B_DISEASE
domain O O
- O O
dependent O O
mechanism O O
. O O

Gingival O B_DISEASE_ADJECTIVE[DISEASE]
retraction O I_DISEASE_ADJECTIVE[DISEASE]
for O O
class O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
V O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
restorations O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

Two O O
methods O O
for O O
the O O
routine O O
determination O O
of O O
blood O O
hemoglobin B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
oxygen O O
affinity O O
are O O
described O O
. O O

Thirty O B_TIME[MEASURE]/B_ENT
minutes O I_TIME[MEASURE]/I_ENT
after O O
reperfusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
lung O B_MEASURE/B_PROTEIN[GENE]
lymph O B_MEASURE/I_PROTEIN[GENE]
flow O B_MEASURE/I_PROTEIN[GENE]
( O O
QL O B_PROTEIN[GENE]/B_LOCATION
) O O
increased O O
from O O
4 O B_MEASURE
. O O
3 O B_MEASURE
to O O
8 O B_MEASURE
. O O
3 O B_MEASURE
ml O I_MEASURE
/ O O
30 O B_TIME[MEASURE]/B_ENT
minutes O I_TIME[MEASURE]/I_ENT
( O O
p O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
0 O B_NUMBER[MEASURE]
. O O
05 O B_MEASURE
) O O
, O O
lymph O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
/ O O
plasma O B_MEASURE/B_BIO
protein O B_MEASURE/I_BIO
ratio O B_MEASURE/I_BIO
was O O
unchanged O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
from O O
0 O B_MEASURE
. O O
6 O B_MEASURE
, O O
and O O
the O O
lymph O B_MEASURE
protein O I_MEASURE
clearance O I_MEASURE
increased O O
from O O
2 O B_MEASURE
. O O
6 O B_MEASURE
to O O
4 O B_MEASURE
. O O
6 O B_MEASURE
ml O I_MEASURE
/ O O
30 O B_TIME[MEASURE]/B_ENT
minutes O I_TIME[MEASURE]/I_ENT
( O O
p O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
0 O B_NUMBER[MEASURE]
. O O
05 O B_MEASURE
) O O
, O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
consistent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
increased O O
microvascular O B_DISEASE
permeability O I_DISEASE
. O O

U O B_OTHER/B_MEASURE
. O O
S O B_OTHER/B_DISEASE
. O O
A O B_OTHER/B_ORGANIZATION
. O O

RET B B_GENE/B_LOCATION
/ O O
PTC B B_LOCATION/B_GENE
oncogenes O O
, O O
generated O O
by O O
chromosomal O O
rearrangements O O
in O O
papillary O O
thyroid O O
carcinomas O O
, O O
are O O
constitutively O O
activated O O
versions O O
of O O
proto B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
RET I I_GENE/I_LOCATION
, O O
a O O
gene O O
coding O O
for O O
a O O
receptor B B_GENE
- I I_GENE
type I I_GENE
tyrosine I I_GENE
kinase I I_GENE
( O O
TK B B_GENE/B_DISEASE
) O O
whose O O
ligand O O
is O O
still O O
unknown O O
. O O

PCC O O
6803 O O
mutant O O
impaired O O
in O O
cytochrome B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_ENZYME[GENE]
c I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_ENZYME[GENE]
maturation O O
. O O

STUDY O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
OBJECTIVE O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
to O O
characterize O O
gas O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
exchange O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
cardiopulmonary O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
performance O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
during O O
maximal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
progressive O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
arm O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
crank O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
exercise O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

In O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
we O O
show O O
that O O
the O O
activating O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
mutation O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
not O O
the O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
creating O O
an O O
exonic O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
splicing O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
enhancer O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ESE O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
or O O
disrupting O O
a O O
putative O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
secondary O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
structure O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
kinase O B_GENE
domains O I_GENE
encoded O O
in O O
the O O
COOH O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
moiety O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
are O O
94 O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
% O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
conserved O O
; O O
the O O
NH2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
moieties O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
are O O
approximately O O
65 O B_TIME[MEASURE]/B_PERSON
% O I_TIME[MEASURE]/I_PERSON
homologous O I_TIME[MEASURE]/I_PERSON
, O O
suggesting O O
this O O
region O B_LOCATION/B_BIO
may O O
encode O O
sequences O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
conferring O O
differential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
regulation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
two O B_ENZYME[GENE]
kinases O I_ENZYME[GENE]
. O O

In O O
rats O O
exposed O O
to O O
Cd O O
for O O
30 O O
d O O
, O O
the O O
levels O O
of O O
urinary O O
excretion O O
of O O
cAMP O O
after O O
treatment O O
with O O
parathyroid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormone I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
PTH B B_GENE/B_LOCATION
) O O
, O O
parathyroidectomy O O
( O O
PTX O O
) O O
, O O
or O O
1 O O
alpha O O
- O O
hydroxycholecalciferol O O
( O O
1 O O
alpha O O
- O O
OH O O
- O O
D3 O O
) O O
showed O O
almost O O
the O O
same O O
patterns O O
as O O
those O O
of O O
control O O
rats O O
: O O
the O O
response O O
of O O
urinary O O
cAMP O O
to O O
treatment O O
with O O
PTH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O O
not O O
influenced O O
by O O
continuous O O
oral O O
administration O O
of O O
Cd O O
. O O

The O O
goal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
of O O
this O O
investigation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
to O O
determine O O
whether O O
BMIPP O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
uptake O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
can O O
be O O
used O O
to O O
differentiate O O
viable O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
myocardium O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
from O O
scar O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tissue O I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
soon O O
after O O
coronary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
thrombolysis O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
for O O
acute O B_DISEASE/B_LOCATION
myocardial O I_DISEASE/I_LOCATION
infarction O I_DISEASE/I_LOCATION
. O O

There O O
are O O
three O B_MEASURE/B_LOCATION
types O I_MEASURE/I_LOCATION
of O O
problems O B_DISEASE
: O O
problems O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arising O O
before O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enters O O
the O O
body O B_BODY_PART_OR_ORGAN_COMPONENT
( O O
solubilization O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
stabilization O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
and O O
improved O B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
acceptability O B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
) O O
; O O
problems O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
associated O O
with O O
the O O
penetration O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
fate O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
body O B_BODY_PART_OR_ORGAN_COMPONENT
( O O
absorption O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
, O O
barrier O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
crossing O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
duration O B_MEASURE/B_LOCATION
of O O
action O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
; O O
problems O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
relating O O
to O O
the O O
therapeutic O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
selective O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
local O I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
delivery O I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
) O O
. O O

In O O
the O O
absence O O
of O O
shock O O
, O O
sepsis O O
, O O
or O O
other O O
identifiable O O
causes O O
of O O
lactic O O
acidosis O O
, O O
the O O
severe O O
anemia O O
( O O
hemoglobin B B_MEASURE/B_LOCATION
1 O O
. O O
2 O O
g O O
/ O O
dl O O
) O O
appeared O O
to O O
be O O
the O O
primary O O
etiologic O O
factor O O
. O O

The O O
cumulative O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
experience O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O O
liver O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
transplantation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
since O O
the O O
introduction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O O
cyclosporine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
confirmed O O
its O O
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
diverse O B_DISEASE
liver O I_DISEASE
diseases O I_DISEASE
in O O
children O B_PERSON/B_BIO
and O O
adults O B_PERSON/B_BIO
. O O

Northern O O
blot O O
analysis O O
of O O
liver O O
, O O
muscle O O
, O O
fat O O
, O O
and O O
pituitary O O
RNA O O
from O O
normal O O
( O O
DwDw O O
) O O
chickens O O
shows O O
a O O
major O O
transcript O O
of O O
4 O O
. O O
3 O O
kilobases O O
( O O
kb O O
) O O
and O O
three O O
minor O O
transcripts O O
( O O
0 O O
. O O
8 O O
, O O
1 O O
. O O
7 O O
, O O
and O O
3 O O
. O O
2 O O
kb O O
) O O
, O O
which O O
correspond O O
to O O
the O O
cGHR B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Copyright O B_LOCATION/B_PERSON
1999 O I_LOCATION/I_PERSON
Academic O I_LOCATION/I_PERSON
Press O I_LOCATION/I_PERSON
. O O

Despite O O
a O O
lowering O O
of O O
her O O
plasma O O
ACTH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentration O O
during O O
therapy O O
with O O
valproic O O
acid O O
, O O
the O O
patient O O
' O O
s O O
tumour O O
showed O O
no O O
evidence O O
of O O
regression O O
while O O
she O O
was O O
taking O O
the O O
drug O O
. O O

The O O
Htf9 B B_GENE
- I I_GENE
a I I_GENE
gene I I_GENE
encodes O O
the O O
RanBP1 B B_GENE
protein I I_GENE
, O O
a O O
major O O
partner O O
of O O
the O O
Ran B B_ENZYME[GENE]/B_LOCATION
GTPase I I_ENZYME[GENE]/I_LOCATION
. O O

STUDY O B_MEASURE/B_LOCATION
DESIGN O I_MEASURE/I_LOCATION
: O O
Retrospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
review O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Sequence O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
divergence O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
approximately O O
16 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
reduced O O
transformation O B_MEASURE/B_PERSON
frequencies O B_MEASURE/I_PERSON
by O O
at O O
least O O
10 O B_NUMBER[MEASURE]
- O O
fold O B_TIME[MEASURE]
. O O

Our O O
studies O O
suggest O O
that O O
the O O
helicase B B_GENE/B_DISEASE
assembly O O
protein O O
is O O
responsible O O
for O O
loading O O
T4 B B_GENE
gene I I_GENE
41 I I_GENE
helicase I I_GENE
specifically O O
at O O
replication O O
forks O O
, O O
and O O
that O O
its O O
binding O O
sites O O
for O O
each O O
arm O O
must O O
hold O O
more O O
than O O
six O O
, O O
but O O
not O O
more O O
than O O
12 O O
nucleotides O O
. O O

During O O
the O O
1st O B_TIME[MEASURE]/B_LOCATION
week O I_TIME[MEASURE]/I_LOCATION
of O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
all O O
subjects O B_PERSON
received O O
either O O
mianserin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
30 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
clomipramine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
75 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
once O O
daily O O
. O O

CBD O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
exploration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
was O O
avoided O O
in O O
7 O B_PERSON/B_TIME[MEASURE]
patients O I_PERSON/I_TIME[MEASURE]
with O O
normal O B_DISEASE
POC O I_DISEASE
. O O

The O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
SHBG I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proximal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
analyzed O O
by O O
DNase B B_GENE
I I I_GENE
footprinting O O
, O O
and O O
the O O
functional O O
significance O O
of O O
6 O O
footprinted O O
regions O O
( O O
FP1 O O
- O O
FP6 O O
) O O
within O O
the O O
proximal O O
promoter O O
was O O
studied O O
in O O
human O O
HepG2 O O
hepatoblastoma O O
cells O O
. O O

We O O
exposed O O
Dorper O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
cross O B_PERSON/B_SPECIES[BIO]
ewes O I_PERSON/I_SPECIES[BIO]
at O O
approximately O O
120 O B_MEASURE
- O O
135 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
of O O
gestation O B_ORGANISM_FUNCTION
to O O
a O O
hot O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
40 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
, O O
60 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
relative O I_MEASURE/I_LOCATION
humidity O I_MEASURE/I_LOCATION
) O O
and O O
a O O
cold O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
( O O
4 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
, O O
90 O B_MEASURE/B_LOCATION
% O B_MEASURE/I_LOCATION
relative O B_MEASURE/I_LOCATION
humidity O B_MEASURE/I_LOCATION
) O O
environment O B_LOCATION
and O O
to O O
treadmill O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
exercise O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
2 O B_MEASURE
. O O
1 O B_MEASURE/B_LOCATION
km O I_MEASURE/I_LOCATION
/ O O
h O O
, O O
5 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
gradient O I_MEASURE/I_LOCATION
) O O
and O O
measured O O
fetal O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
lamb O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
ewe O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
body O B_MEASURE/B_ORGANISM_FUNCTION
temperatures O I_MEASURE
using O O
previously O O
implanted O O
abdominal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEDICAL_DEVICE[OBJECT]
radiotelemeters O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
. O O

Previously O O
identified O O
mutations O O
in O O
this O O
variant O O
have O O
been O O
within O O
or O O
close O O
to O O
the O O
coding O O
region O O
of O O
exon O O
1 O O
of O O
the O O
HMBS B B_GENE/B_DISEASE
gene I I_GENE/I_DISEASE
, O O
the O O
only O O
exon O O
that O O
is O O
expressed O O
solely O O
in O O
the O O
ubiquitous O O
isoform O O
. O O

As O O
an O O
approach O O
to O O
the O O
determination O O
of O O
structure O O
- O O
function O O
relationships O O
in O O
the O O
PRP4 B B_GENE/B_BIO
protein I I_GENE/I_BIO
, O O
we O O
have O O
isolated O O
more O O
than O O
fifty O O
new O O
alleles O O
of O O
the O O
PRP4 B B_GENE
gene I I_GENE
through O O
random O O
and O O
site O O
- O O
directed O O
mutagenesis O O
, O O
and O O
have O O
analyzed O O
the O O
phenotypes O O
of O O
many O O
of O O
them O O
. O O

Over O O
a O O
period O B_MEASURE/B_LOCATION
of O O
five O B_TIME[MEASURE]
training O I_TIME[MEASURE]
sessions O I_TIME[MEASURE]
( O O
2 O B_MEASURE
. O O
5 O B_MEASURE/B_ENT
days O I_MEASURE/I_ENT
) O O
, O O
the O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
learned O O
not O O
to O O
breathe O O
, O O
and O O
the O O
number O B_MEASURE
of O O
stimuli O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
received O O
in O O
the O O
fifth O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
session O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
significantly O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
in O O
the O O
first O B_SEQUENCE[MEASURE]/B_PERSON
session O I_SEQUENCE[MEASURE]/I_PERSON
. O O

The O O
5 O B_LOCATION/B_GENE
' O I_LOCATION/I_GENE
- O O
flanking O O
region O B_LOCATION/B_MEASURE
of O O
the O O
gene O B_GENE
, O O
approximately O O
1 O B_MEASURE
. O O
1 O B_MEASURE
kbp O I_MEASURE
long O O
, O O
had O O
no O O
known O O
regulatory O B_GENE/B_LOCATION
elements O B_GENE/I_LOCATION
for O O
transcription O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
TATA O B_GENE/B_LOCATION
, O O
GC O B_LOCATION/B_DISEASE
, O O
and O O
CCAAT O B_LOCATION/B_GENE
boxes O I_LOCATION/I_GENE
. O O

We O O
find O O
that O O
Fus3p B B_GENE
and O O
Kss1p B B_GENE/B_DISEASE
both O O
control O O
G1 O O
arrest O O
through O O
multiple O O
functions O O
that O O
operate O O
in O O
parallel O O
with O O
Far1p B B_GENE
. O O

Tag B B_GENE
expression O O
induced O O
apoptosis O O
in O O
mammary O O
epithelial O O
cells O O
during O O
late O O
pregnancy O O
. O O

The O O
composition O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
renal O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stones O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysed O O
by O O
infrared O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spectroscopy O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

14 O O
. O O
9 O B_MEASURE
x O O
109 O B_MEASURE/B_LOCATION
L O I_MEASURE/I_LOCATION
- O O
1 O B_MEASURE/B_LOCATION
) O O
was O O
equal O B_MEASURE
for O O
both O O
groups O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
but O O
CCI O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
significantly O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
bedside O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
filtered O O
PC O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
14 O B_MEASURE
. O O
1 O B_MEASURE/B_LOCATION
+ O I_MEASURE/I_LOCATION
/ O O
- O O
9 O B_MEASURE
. O O
5 O B_MEASURE/B_SPORT[ENT]
vs O I_MEASURE/I_SPORT[ENT]
. O O

In O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
the O O
case O B_PERSON/B_DISEASE
of O O
a O O
patient O B_PERSON/B_BIO
presenting O O
a O O
second O B_DISEASE
hepatocellular O I_DISEASE
carcinoma O I_DISEASE
13 O I_DISEASE
years O I_DISEASE
after O O
resection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
a O O
first O B_DISEASE
tumor O I_DISEASE
of O O
the O O
same O B_BODY_PART_OR_ORGAN_COMPONENT
type O I_BODY_PART_OR_ORGAN_COMPONENT
is O O
reported O O
. O O

The O O
time O O
- O O
dependent O O
changes O O
in O O
measured O O
facility O O
of O O
outflow O O
or O O
" O O
washout O O
phenomenon O O
" O O
appeared O O
to O O
result O O
from O O
the O O
gradual O O
dissolution O O
of O O
the O O
hyaluronidase B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
sensitive O O
component O O
of O O
the O O
barriers O O
to O O
aqueous O O
outflow O O
in O O
the O O
canine O O
eye O O
. O O

The O O
factors O O
defective O O
in O O
groups O O
A O O
( O O
CIITA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
C O O
( O O
RFX5 B B_LOCATION/B_GENE
) O O
and O O
D O O
( O O
RFXAP B B_GENE/B_LOCATION
) O O
have O O
been O O
identified O O
. O O

It O O
differed O O
significantly O O
by O O
country O B_LOCATION/B_MEASURE
( O O
from O O
2 O B_MEASURE
. O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
in O O
the O O
United O B_LOCATION
Kingdom O I_LOCATION
to O O
24 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
in O O
Portugal O B_LOCATION
) O O
and O O
by O O
transmission O B_MEASURE/B_PERSON
category O I_MEASURE/I_PERSON
( O O
2 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
among O O
homo O B_PERSON
/ O O
bisexuals O B_PERSON/B_DISEASE
, O O
5 O B_MEASURE
. O O
8 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
among O O
injecting O O
drug O B_PERSON/B_ORGANIZATION
users O I_PERSON/I_ORGANIZATION
, O O
13 O B_MEASURE
. O O
6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
among O O
heterosexual O B_PERSON/B_DISEASE
subgroup O I_PERSON/I_DISEASE
1 O I_PERSON/I_DISEASE
) O O
. O O

On O O
a O O
national O B_MEASURE/B_LOCATION
level O I_MEASURE/I_LOCATION
, O O
undiscounted O B_MEASURE/B_PERSON
costs O B_MEASURE/I_PERSON
are O O
expected O O
to O O
increase O O
up O O
to O O
approximately O O
DF1 O O
42 O B_TIME[MEASURE]
million O I_TIME[MEASURE]
annually O O
during O O
the O O
first O B_TIME[MEASURE]/B_ENT
40 O I_TIME[MEASURE]/I_ENT
years O I_TIME[MEASURE]/I_ENT
after O O
introduction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
of O O
the O O
preventative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
strategy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

By O O
deletion O O
analysis O O
, O O
we O O
identified O O
the O O
regions O O
of O O
c B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
Jun I I_GENE/I_LOCATION
encoding O O
transformation O O
and O O
transactivation O O
functions O O
. O O

A O O
survey O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
274 O B_PERSON
late O I_PERSON
detected O I_PERSON
cases O I_PERSON
of O O
CDH O B_DISEASE/B_PERSON
born O O
in O O
the O O
years O B_TIME[MEASURE]/B_LOCATION
1970 O B_TIME[MEASURE]/I_LOCATION
- O O
- O O
74 O B_MEASURE
is O O
presented O O
. O O

To O O
test O O
for O O
progesterone B B_PROTEIN[GENE]
receptor I I_PROTEIN[GENE]
- O O
mediated O O
activation O O
of O O
transcription O O
in O O
yeast O O
, O O
reporter O O
plasmids O O
were O O
constructed O O
to O O
transform O O
yeast O O
cells O O
expressing O O
PRB B B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
C1C2 B B_GENE/B_LOCATION
receptors I I_GENE/I_LOCATION
. O O

Fli B B_GENE
- I I_GENE
1 I I_GENE
is O O
a O O
proto O O
- O O
oncogene O O
which O O
is O O
rearranged O O
in O O
tumors O O
induced O O
by O O
three O O
different O O
retroviruses O O
, O O
Cas O O
- O O
Br O O
- O O
E O O
, O O
F O O
- O O
MuLV O O
, O O
and O O
10A1 O O
. O O

Ionic O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
composition O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
Na O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
K O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
Ca O O
+ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O B_MEASURE/B_LOCATION
, O O
and O O
Mg2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
of O O
cerebrospinal O B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluid O I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
feeding O B_BODY_PART_OR_ORGAN_COMPONENT
behavior O I_BODY_PART_OR_ORGAN_COMPONENT
in O O
sheep O B_SPECIES[BIO]/B_PERSON
. O O

Materials O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
are O O
presented O O
of O O
a O O
comparative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
morphological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
cultural O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
virulence O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O O
liophylized O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
cultures O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
of O O
Leishmania O B_SPECIES[BIO]
tropica O I_SPECIES[BIO]
major O I_SPECIES[BIO]
after O O
their O O
rehydration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
or O O
after O O
a O O
long O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
passage O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O O
the O O
NNN O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
medium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
These O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imply O O
that O O
the O O
spinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cord O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O O
not O O
a O O
simple O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
command O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
carrying O O
medium O B_LOCATION
from O O
the O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
limbs O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
implies O O
that O O
some O O
computational O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
activities O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
take O O
place O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
at O O
the O O
spinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cord O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
level O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
101st O B_TIME[MEASURE]/B_LOCATION
annual O B_TIME[MEASURE]/I_LOCATION
meeting O B_TIME[MEASURE]/I_LOCATION
of O O
the O O
Japanese O B_ORGANIZATION/B_PERSON
Ophthalmological O I_ORGANIZATION/I_PERSON
Society O I_ORGANIZATION/I_PERSON
. O O

The O O
results O O
corroborate O O
the O O
proposed O O
physiological O O
function O O
of O O
CCoAOMT B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
elicited O O
plant O O
cells O O
and O O
may O O
shed O O
new O O
light O O
on O O
the O O
sequential O O
action O O
of O O
trans O O
- O O
active O O
factors O O
in O O
the O O
regulation O O
of O O
phenylpropanoid O O
genes O O
. O O

In O O
src B B_GENE/B_VIRUS[BIO]
- O O
transformed O O
cells O O
GAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
forms O O
heteromeric O O
complexes O O
, O O
notably O O
with O O
a O O
highly O O
tyrosine O O
phosphorylated O O
62 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kDa I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
p62 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
characteristics O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
adult O B_PERSON/B_BIO
asthmatics O I_PERSON/I_BIO
who O O
are O O
sensitized O O
by O O
cats O B_SPECIES[BIO]
and O O
dogs O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
allergens O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]

PrRP B B_GENE/B_PERSON
rapidly O O
and O O
transiently O O
activated O O
extracellular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ERK B B_GENE/B_LOCATION
) O O
in O O
both O O
types O O
of O O
cells O O
. O O

Cell O O
- O O
free O O
extracts O O
of O O
E O O
. O O
coli O O
( O O
fpg B B_PROTEIN[GENE]/B_LOCATION
mutY B I_PROTEIN[GENE]/I_LOCATION
) O O
harboring O O
pYSB10 O O
possess O O
an O O
enzymatic O O
activity O O
that O O
cleaves O O
a O O
34 O O
- O O
mer O O
oligonucleotide O O
containing O O
a O O
single O O
8 O O
- O O
oxoG O O
opposite O O
a O O
cytosine O O
( O O
8 O O
- O O
OxoG O O
/ O O
C O O
) O O
. O O

Estrogen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
pretreated O O
castrated O B_PERSON/B_BIO
males O I_PERSON/I_BIO
also O O
showed O O
no O O
change O B_DISEASE_ADJECTIVE[DISEASE]
in O O
myocardial O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
blood O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
flow O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
after O O
17 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
beta O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O O
estradiol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
coronary O B_MEASURE
flow O I_MEASURE
velocity O I_MEASURE
decreased O O
( O O
P O B_OTHER/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
compared O O
with O O
baseline O B_MEASURE/B_LOCATION
1 O I_MEASURE/I_LOCATION
h O O
after O O
the O O
200 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
kg O B_TIME[MEASURE]/B_LOCATION
dose O I_TIME[MEASURE]/I_LOCATION
( O O
from O O
1 O B_MEASURE
. O O
69 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_NUMBER[MEASURE]
. O O
61 O B_MEASURE
to O O
1 O B_MEASURE
. O O
41 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
42 O B_MEASURE
kHz O I_MEASURE
) O O
and O O
diastolic O B_MEASURE/B_LOCATION
coronary O I_MEASURE/I_LOCATION
resistance O I_MEASURE/I_LOCATION
increased O O
significantly O O
( O O
P O B_MEASURE/B_LOCATION
< O I_MEASURE/I_LOCATION
0 O I_MEASURE/I_LOCATION
. O O
01 O B_MEASURE
) O O
compared O O
with O O
control O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
at O O
this O O
time O B_MEASURE/B_LOCATION
( O O
51 O B_MEASURE/B_LOCATION
+ O I_MEASURE/I_LOCATION
/ O O
- O O
15 O B_MEASURE
compared O O
with O O
39 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
14 O B_MEASURE
mmHg O I_MEASURE
/ O O
mkHz O B_MEASURE
) O O
. O O

Acute O B_DISEASE/B_MEASURE
renal O I_DISEASE/I_MEASURE
vein O I_DISEASE/I_MEASURE
thrombosis O I_DISEASE/I_MEASURE
in O O
renal O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
allografts O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
: O O
detection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
duplex O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Doppler O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
US O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Several O B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
DNA O B_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
clones O B_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
were O O
obtained O O
by O O
this O O
procedure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
one O B_NUMBER[MEASURE]/B_PERSON
of O O
which O O
, O O
clone O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
18 O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O O
is O O
reported O O
and O O
characterized O O
here O O
. O O

Long O O
- O O
range O O
mapping O O
by O O
pulse O O
- O O
field O O
gel O O
electrophoresis O O
indicated O O
that O O
the O O
three O O
mdr B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
closely O O
linked O O
on O O
a O O
genomic O O
DNA O O
segment O O
of O O
approximately O O
625 O O
kilobases O O
. O O

These O O
sequences O O
were O O
further O O
tested O O
for O O
the O O
presence O O
of O O
an O O
enhancer O O
element O O
, O O
by O O
their O O
ability O O
to O O
activate O O
a O O
fusion O O
reporter O O
gene O O
consisting O O
of O O
the O O
CAT B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
linked O O
to O O
the O O
gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
globin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
in O O
erythroid O O
( O O
K562 O O
) O O
and O O
non O O
- O O
erythroid O O
( O O
HeLa O O
) O O
cells O O
. O O

Two O B_PERSON/B_ENT
sibs O I_PERSON/I_ENT
with O O
identical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
features O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
short O B_PERSON/B_MEASURE
- O O
limbed O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
dwarfism O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
normal O B_BODY_PART_OR_ORGAN_COMPONENT
skull O I_BODY_PART_OR_ORGAN_COMPONENT
and O O
face O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
normal O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
intelligence O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
are O O
described O O
. O O

This O O
article O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
describes O O
a O O
program O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O O
resulted O O
in O O
a O O
75 O B_NUMBER[MEASURE]
- O O
percent O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
reduction O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
inventory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
over O O
a O O
five O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]/B_LOCATION
interval O I_TIME[MEASURE]/I_LOCATION
. O O

Further O O
comparative O O
analysis O O
identified O O
an O O
ADNP B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
paralog O O
( O O
33 O O
% O O
identity O O
and O O
46 O O
% O O
similarity O O
) O O
, O O
indicating O O
that O O
these O O
genes O O
belong O O
to O O
a O O
novel O O
protein O O
family O O
with O O
a O O
nine O O
- O O
zinc O O
finger O O
motif O O
followed O O
by O O
a O O
homeobox O O
domain O O
. O O

All O O
patients O O
received O O
marrow O O
from O O
HLA B B_GENE
- O O
identical O O
sibling O O
donors O O
, O O
underwent O O
similar O O
myeloablative O O
regimens O O
, O O
and O O
had O O
similar O O
pretreatment O O
characteristics O O
. O O

In O O
female O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
toads O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
, O O
Bufo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
bufo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
feeding O O
at O O
different O B_TIME[MEASURE]/B_LOCATION
rates O I_TIME[MEASURE]/I_LOCATION
, O O
the O O
uncorrected O B_MEASURE
value O I_MEASURE
of O O
n O B_MEASURE/B_PROTEIN[GENE]
was O O
0 O B_MEASURE
. O O
44 O B_MEASURE
, O O
when O O
metabolism O B_ORGANISM_FUNCTION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
growth O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
were O O
expressed O O
as O O
kJ O B_MEASURE
kJ O I_MEASURE
- O O
1 O B_MEASURE/B_BIO
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Two O B_PERSON
patients O I_PERSON
developed O O
cervical O B_DISEASE
myelopathy O I_DISEASE
or O O
radiculopathy O B_DISEASE
after O O
spinal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
manipulation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
and O O
magnetic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
resonance O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
imaging O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
showed O O
herniated O O
cervical O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
discs O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
at O O
C4 O B_PROTEIN[GENE]
- O O
C5 O B_MEASURE/B_PROTEIN[GENE]
and O O
C6 O B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
C7 O B_MEASURE/B_PROTEIN[GENE]
, O O
respectively O O
. O O

Subclones O O
stably O O
expressing O O
alpha1A B B_PROTEIN[GENE]/B_LOCATION
- O O
, O O
alpha1B B B_PROTEIN[GENE]/B_LOCATION
- O O
, O O
and O O
alpha1D B B_GENE
- O O
ARs O O
under O O
control O O
of O O
an O O
inducible O O
promoter O O
, O O
or O O
at O O
high O O
and O O
low O O
receptor O O
density O O
, O O
were O O
isolated O O
and O O
characterized O O
. O O

Analysis O O
of O O
WT1 B B_GENE
target I I_GENE
gene I I_GENE
expression O O
in O O
stably O O
transfected O O
cell O O
lines O O
. O O

Soluble O O
recombinant O O
RI B B_GENE
and O O
soluble O O
recombinant O O
C B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
associate O O
in O O
vitro O O
and O O
be O O
activated O O
by O O
cyclic O O
AMP O O
. O O

IRIS B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
/ O O
GAS B B_VIRUS[BIO]/B_GENE
DNA O O
also O O
formed O O
a O O
number O O
of O O
specific O O
complexes O O
with O O
constitutively O O
expressed O O
factors O O
, O O
none O O
of O O
which O O
were O O
affected O O
by O O
the O O
above O O
Abs O O
. O O

Simulation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
based O O
on O O
the O O
presented O O
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
are O O
compared O O
with O O
the O O
experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
types O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cMUTs O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reported O O
in O O
the O O
recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
literature O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

Tre O B_GENE/B_LOCATION
during O O
exercise O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O O
35 O B_MEASURE/B_LOCATION
W O I_MEASURE/I_LOCATION
at O O
23 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
correlated O O
r O O
= O O
- O O
70 O B_MEASURE
with O O
Vo2max O B_MEASURE/B_LOCATION
and O O
r O B_PROTEIN[GENE]/B_MEASURE
= O O
0 O B_MEASURE
. O O
80 O B_MEASURE
with O O
Tre O B_PROTEIN[GENE]/B_LOCATION
during O O
exercise O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O O
heat O B_LOCATION
. O O

Electrophoretic O O
mobility O O
- O O
shift O O
assays O O
with O O
nuclear O O
extracts O O
from O O
COS O O
- O O
1 O O
cells O O
transfected O O
with O O
expression O O
vectors O O
for O O
SMADs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
5 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
indicate O O
that O O
SMAD3 B B_GENE/B_DISEASE
forms O O
a O O
complex O O
with O O
a O O
migration O O
similar O O
to O O
that O O
of O O
the O O
endogenous B B_GENE/B_MEASURE
TGF I I_GENE/I_MEASURE
- I I_GENE/I_MEASURE
beta I I_GENE/I_MEASURE
- I I_GENE/I_MEASURE
specific I I_GENE/I_MEASURE
complex I I_GENE/I_MEASURE
observed O O
in O O
fibroblast O O
extracts O O
. O O

The O O
newly O O
identified O O
NF B B_GENE/B_PERSON
kappa I I_GENE/I_PERSON
B I I_GENE/I_PERSON
enhancer I I_GENE/I_PERSON
( O O
TGGAAATTCC O O
) O O
is O O
bound O O
by O O
a O O
TNF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
induced O O
nuclear O O
protein O O
and O O
appears O O
to O O
be O O
the O O
key O O
element O O
in O O
rapid O O
transcription O O
induction O O
by O O
TNF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
and O O
TPA O O
) O O
, O O
while O O
transactivation O O
of O O
this O O
element O O
is O O
repressed O O
by O O
the O O
ligand O O
- O O
bound O O
glucocorticoid B B_GENE
receptor I I_GENE
. O O

Our O O
results O O
showed O O
that O O
the O O
5 O O
- O O
hydroxytryptamine O O
( O O
5 O O
- O O
HT O O
) O O
content O O
in O O
platelets O O
was O O
: O O
( O O
1 O O
) O O
increased O O
in O O
the O O
subgroup O O
of O O
anti O O
- O O
social O O
alcoholics O O
; O O
( O O
2 O O
) O O
transiently O O
and O O
differently O O
altered O O
in O O
alcoholics O O
compared O O
to O O
opiate O O
addicts O O
; O O
and O O
( O O
3 O O
) O O
lowered O O
in O O
drinking O O
alcoholics O O
and O O
normal O O
in O O
alcoholics O O
who O O
were O O
drinking O O
as O O
well O O
as O O
smoking O O
( O O
that O O
may O O
occur O O
via O O
MAO B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibition O O
by O O
smoke O O
) O O
. O O

In O O
the O O
second O O
group O O
, O O
which O O
consisted O O
of O O
babies O O
of O O
33 O O
to O O
36 O O
weeks O O
of O O
gestational O O
age O O
, O O
haptoglobin B B_DISEASE/B_GENE
was O O
detected O O
in O O
6 O O
infants O O
, O O
with O O
levels O O
less O O
than O O
25 O O
mg O O
/ O O
dl O O
in O O
3 O O
. O O

The O O
polypeptide O O
encoded O O
by O O
the O O
cDNA O O
contained O O
450 O O
amino O O
acids O O
with O O
a O O
calculated O O
M O O
( O O
r O O
) O O
of O O
52 O O
, O O
057 O O
, O O
and O O
showed O O
significant O O
homology O O
with O O
human O O
and O O
mouse B B_SPECIES[BIO]/B_GENE
CAD I I_SPECIES[BIO]/I_GENE
( O O
22 O O
% O O
identity O O
) O O
. O O

Correlation O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
alpha O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
frontal O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
occipital O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
cortex O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O O

In O O
situ O O
localization O O
of O O
PCP B B_GENE/B_BIO
- I I_GENE/I_BIO
A1 I I_GENE/I_BIO
transcripts I I_GENE/I_BIO
revealed O O
that O O
they O O
accumulate O O
specifically O O
in O O
pollen O O
at O O
the O O
late O O
binucleate O O
/ O O
trinucleate O O
stage O O
of O O
development O O
rather O O
than O O
in O O
the O O
tapetum O O
, O O
which O O
previously O O
was O O
taken O O
to O O
be O O
the O O
principal O O
source O O
of O O
the O O
pollen O O
coat O O
. O O

Successful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
resolution O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
progressive O B_DISEASE
multifocal O I_DISEASE
leukoencephalopathy O I_DISEASE
after O O
combination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O O
cidofovir O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cytosine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arabinoside O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
species O B_BACTERIUM[BIO]
composition O O
and O O
abundance O O
upon O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
manure O B_BIO/B_LOCATION
with O O
polyethylene O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
polystyrene O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O O
glass O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
particles O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
was O O
similar O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
that O O
of O O
the O O
treatment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
i O O
. O O
e O O
. O O
natural O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O O
inert O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
sand O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

However O O
, O O
H19 B B_GENE
and O O
IGF2 B B_GENE
lie O O
within O O
a O O
larger O O
imprinted O O
domain O O
, O O
and O O
the O O
gene O O
specificity O O
of O O
H19 B B_GENE/B_PERSON
epimutation O O
has O O
been O O
a O O
persistent O O
question O O
. O O

Here O O
we O O
report O O
the O O
cloning O O
, O O
by O O
either O O
peptide O O
sequencing O O
or O O
by O O
sequence O O
similarity O O
to O O
the O O
human O O
cDNAs O O
, O O
of O O
the O O
S O O
. O O
cerevisiae O O
genes O O
RFC1 B B_PROTEIN[GENE]/B_LOCATION
, O O
RFC2 B B_PROTEIN[GENE]/B_DISEASE
, O O
RFC3 B B_PROTEIN[GENE]/B_DISEASE
, O O
RFC4 B B_PROTEIN[GENE]/B_LOCATION
, O O
and O O
RFC5 B B_GENE/B_DISEASE
. O O

It O O
is O O
of O O
interest O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
, O O
aside O O
from O O
starvation O B_TIME[MEASURE]/B_DISEASE
, O O
the O O
nutrition O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
catastrophes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
past O B_TIME[MEASURE]/B_LOCATION
, O O
including O O
scurvy O B_DISEASE
( O O
vitamin O B_DISEASE
C O I_DISEASE
deficiency O I_DISEASE
) O O
resulting O O
from O O
lack O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
fresh O B_BIO/B_ORGANISM_FUNCTION
vegetables O I_BIO/I_ORGANISM_FUNCTION
and O O
fruit O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
beriberi O B_DISEASE/B_BIO
( O O
vitamin O B_DISEASE/B_BIO
B1 O I_DISEASE/I_BIO
deficiency O I_DISEASE/I_BIO
) O O
from O O
consumption O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
polished O B_BIO
rice O I_BIO
, O O
are O O
forgotten O O
and O O
only O O
of O O
interest O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
history O B_EDU[ORGANIZATION]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
sequence O O
can O O
interact O O
with O O
at O O
least O O
two O O
proteins O O
in O O
a O O
fibroblast O O
nuclear O O
extract O O
that O O
have O O
binding O O
characteristics O O
of O O
an O O
Ets B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
a O O
serum B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
like I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

As O O
much O O
thrombin B B_GENE
was O O
formed O O
during O O
cardiopulmonary O O
bypass O O
( O O
measured O O
by O O
the O O
prothrombin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fragment I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
F1 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
thrombin B B_GENE
- O O
antithrombin B B_GENE
complexes O O
) O O
as O O
in O O
normal O O
patients O O
, O O
showing O O
that O O
factor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
XII I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
not O O
necessary O O
for O O
thrombin B B_PROTEIN[GENE]
generation O O
. O O

The O O
molecular O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
event O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
s O O
) O O
underlying O O
the O O
functional O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specificities O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
receptors O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
in O O
regulating O O
the O O
expression O B_GENE
of O O
their O O
native O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
a O O
very O O
important O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
issue O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
remains O O
poorly O O
understood O O
. O O

MUS81 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
encodes O O
a O O
novel O O
helix B B_ENZYME[GENE]/B_MEASURE
- I I_ENZYME[GENE]/I_MEASURE
hairpin I I_ENZYME[GENE]/I_MEASURE
- I I_ENZYME[GENE]/I_MEASURE
helix I I_ENZYME[GENE]/I_MEASURE
protein I I_ENZYME[GENE]/I_MEASURE
involved O O
in O O
the O O
response O O
to O O
UV O O
- O O
and O O
methylation O O
- O O
induced O O
DNA O O
damage O O
in O O
Saccharomyces O O
cerevisiae O O
. O O

Treatment O O
of O O
chronic O O
hepatitis O O
B O O
with O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
: O O
experience O O
in O O
western O O
countries O O
. O O

Several O O
positive O O
clones O O
were O O
isolated O O
, O O
one O O
of O O
which O O
encoded O O
the O O
C O O
- O O
terminal O O
253 O O
amino O O
acids O O
of O O
a O O
putative O O
RNA B B_GENE/B_BIO
helicase I I_GENE/I_BIO
, O O
a O O
DEAD B B_GENE/B_PERSON
box I I_GENE/I_PERSON
protein I I_GENE/I_PERSON
designated O O
DDX3 B B_PROTEIN[GENE]
. O O

Kerstin O B_PERSON/B_LOCATION
takes O O
the O O
abbreviated O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
medical O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
education O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

In O O
vitro O O
binding O O
studies O O
previously O O
showed O O
that O O
NF B B_GENE/B_PERSON
- I I_GENE/I_PERSON
kappa I I_GENE/I_PERSON
B I I_GENE/I_PERSON
p50 B I_GENE/I_PERSON
homodimer O O
binds O O
the O O
switch B B_LOCATION
nuclear I I_LOCATION
B I I_LOCATION
- I I_LOCATION
site I I_LOCATION
protein I I_LOCATION
( O O
SNIP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
of O O
the O O
S B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
gamma I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
3 I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
tandem I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
repeat I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

In O O
this O O
case O O
myogenic O O
factors O O
are O O
not O O
initially O O
expressed O O
and O O
these O O
migratory O O
cells O O
are O O
characterized O O
by O O
the O O
expression O O
of O O
the O O
paired B B_MEASURE/B_PROTEIN[GENE]
- O O
box O O
gene O O
Pax3 B B_GENE/B_LOCATION
. O O

It O O
is O O
concluded O O
that O O
the O O
atherogenic O O
process O O
includes O O
stimulation O O
of O O
collagen B B_GENE/B_DISEASE
and O O
elastin B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
synthesis O O
. O O

These O O
results O O
indicate O O
that O O
( O O
1 O O
) O O
RXR B B_PROTEIN[GENE]/B_LOCATION
- O O
TR B B_PROTEIN[GENE]/B_DISEASE
heterodimers O O
play O O
a O O
role O O
in O O
basal O O
transactivation O O
and O O
T3 O O
suppression O O
of O O
negatively O O
regulated O O
genes O O
, O O
and O O
( O O
2 O O
) O O
RXRs B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
increase O O
the O O
dominant O O
negative O O
effect O O
of O O
some O O
mutant O O
TRs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
on O O
specific O O
negative O O
TREs O O
. O O

Phenotypic O O
responses O O
of O O
additional O O
mutants O O
, O O
including O O
exo1 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
srs2 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
rad5 B B_GENE/B_LOCATION
, O O
and O O
rdh54 B B_NUMBER[MEASURE]/B_GENE
strains O O
, O O
suggest O O
roles O O
in O O
recombinational O O
repair O O
, O O
but O O
not O O
in O O
NHEJ O O
. O O

Furthermore O O
, O O
the O O
induction O O
of O O
cytochrome B B_GENE/B_DISEASE
P I I_GENE/I_DISEASE
- I I_GENE/I_DISEASE
450 I I_GENE/I_DISEASE
1A1 I I_GENE/I_DISEASE
observed O O
in O O
the O O
cormorant O O
indicates O O
that O O
the O O
Ah B B_GENE
receptor I I_GENE
- O O
mediated O O
process O O
, O O
by O O
which O O
TCDD O O
and O O
related O O
chemicals O O
exert O O
many O O
of O O
their O O
toxicities O O
, O O
has O O
been O O
activated O O
. O O

RESULT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
S O B_OTHER/B_MEASURE
) O O
: O O
A O O
prospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
conducted O O
with O O
44 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cycles O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
34 O B_PERSON
couples O I_PERSON
with O O
nafarelin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
group O B_NUMBER[MEASURE]/B_LOCATION
1 O I_NUMBER[MEASURE]/I_LOCATION
) O O
and O O
47 O B_TIME[MEASURE]
cycles O I_TIME[MEASURE]
for O O
40 O B_TIME[MEASURE]/B_PERSON
couples O B_TIME[MEASURE]/I_PERSON
with O O
buserelin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
acetate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
group O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
with O O
a O O
long O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
IVF O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
protocol O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
; O O
68 O B_MEASURE/B_LOCATION
cycles O I_MEASURE/I_LOCATION
for O O
46 O B_PERSON
couples O I_PERSON
with O O
nafarelin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
group O B_NUMBER[MEASURE]/B_ORGANIZATION
3 O I_NUMBER[MEASURE]/I_ORGANIZATION
) O O
and O O
56 O B_MEASURE
cycles O I_MEASURE
for O O
39 O B_NUMBER[MEASURE]/B_PERSON
couples O B_NUMBER[MEASURE]/I_PERSON
with O O
buserelin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
group O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
with O O
a O O
short O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
IVF O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
protocol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
; O O
39 O B_TIME[MEASURE]
cycles O I_TIME[MEASURE]
for O O
32 O B_PERSON
couples O I_PERSON
with O O
nafarelin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
group O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
50 O B_MEASURE
cycles O I_MEASURE
for O O
30 O B_TIME[MEASURE]/B_PERSON
couples O B_TIME[MEASURE]/I_PERSON
with O O
buserelin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acetate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
group O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
with O O
a O O
long O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
ICSI O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
protocol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
; O O
and O O
87 O B_MEASURE
cycles O I_MEASURE
for O O
60 O B_TIME[MEASURE]/B_PERSON
couples O B_TIME[MEASURE]/I_PERSON
with O O
nafarelin O B_DISEASE/B_MEASURE
acetate O I_DISEASE/I_MEASURE
( O O
group O B_NUMBER[MEASURE]/B_ORGANIZATION
7 O I_NUMBER[MEASURE]/I_ORGANIZATION
) O O
and O O
81 O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cycles O I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
61 O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
couples O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
buserelin O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
acetate O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
( O O
group O B_NUMBER[MEASURE]/B_ORGANIZATION
8 O I_NUMBER[MEASURE]/I_ORGANIZATION
) O O
with O O
a O O
short O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ICSI O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protocol O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
demonstrates O O
the O O
feasibility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
potential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
usefulness O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
syngeneic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
BM O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Txp O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
myeloma O B_DISEASE/B_BIO
. O O

5 O O
. O O
3 O B_MEASURE
+ O O
/ O O
- O O
6 O B_MEASURE
. O O
6 O B_MEASURE
for O O
risperidone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O O
P O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
09 O B_MEASURE
) O O
. O O

In O O
this O O
work O O
, O O
we O O
determined O O
the O O
sequences O O
of O O
eight O O
VirF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
four O O
different O O
genes O O
, O O
by O O
DNase B B_GENE
I I I_GENE
or O O
hydroxyl O O
radical O O
footprinting O O
. O O

Although O O
they O O
are O O
similar O O
to O O
the O O
IL9R B B_GENE/B_TIME[MEASURE]
gene I I_GENE/I_TIME[MEASURE]
( O O
approximately O O
90 O O
% O O
identity O O
) O O
, O O
none O O
of O O
these O O
copies O O
encodes O O
a O O
functional O O
receptor O O
: O O
none O O
of O O
them O O
contains O O
sequences O O
homologous O O
to O O
the O O
5 O O
' O O
flanking O O
region O O
or O O
exon O O
1 O O
of O O
the O O
IL9R B B_GENE
gene I I_GENE
, O O
and O O
the O O
remaining O O
ORFs O O
have O O
been O O
inactivated O O
by O O
various O O
point O O
mutations O O
and O O
deletions O O
. O O

Type O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
II O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
neuroleptanalgesia O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
odonto O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
stomatology O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT

273 O B_MEASURE/B_LOCATION
, O O
27420 O B_TIME[MEASURE]/B_LOCATION
- O O
27429 O B_NUMBER[MEASURE]/B_LOCATION
) O O
a O O
putative O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
peroxisome O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
proliferator O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
activated O O
receptor O B_PROTEIN[GENE]/B_LOCATION
response O I_PROTEIN[GENE]/I_LOCATION
element O I_PROTEIN[GENE]/I_LOCATION
( O O
PPRE O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
from O O
- O O
458 O B_MEASURE
to O O
- O O
474 O B_MEASURE
. O O

While O O
reviewing O O
gastric O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specimens O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
215 O B_LOCATION
baboons O I_LOCATION
, O O
we O O
found O O
diffuse O B_DISEASE
giant O I_DISEASE
mucosal O I_DISEASE
folds O I_DISEASE
in O O
2 O B_NUMBER[MEASURE]
specimens O I_NUMBER[MEASURE]
and O O
multiple O B_DISEASE
giant O I_DISEASE
mucosal O I_DISEASE
nodules O I_DISEASE
in O O
another O O
3 O B_NUMBER[MEASURE]/B_BIO
. O O

To O O
investigate O O
whether O O
the O O
two O O
RPG B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
boxes I I_GENE/I_LOCATION
mediate O O
transcription O O
activation O O
of O O
both O O
the O O
L46 B B_PROTEIN[GENE]
and O O
S24 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
two O O
experimental O O
strategies O O
were O O
followed O O
: O O
cloning O O
of O O
the O O
respective O O
genes O O
on O O
multicopy O O
vectors O O
and O O
construction O O
of O O
fusion O O
genes O O
. O O

When O O
the O O
opioid O O
antagonist O O
was O O
administered O O
to O O
animals O O
24 O O
hr O O
after O O
termination O O
of O O
single O O
or O O
multiple O O
exposures O O
to O O
restraint O O
, O O
NALT O O
- O O
induced O O
increases O O
in O O
basal O O
plasma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
LH I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
significantly O O
attenuated O O
in O O
the O O
chronically O O
stressed O O
rats O O
compared O O
to O O
animals O O
subjected O O
to O O
stress O O
only O O
once O O
or O O
not O O
at O O
all O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O

The O O
psychosocial O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
features O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
people O B_PERSON
using O O
self O B_PERSON/B_DISEASE
- O O
ignition O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
as O O
a O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
suicide O B_PERSON/B_DISEASE
are O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
those O O
of O O
suicide O B_PERSON/B_ORGANIZATION
in O O
general O B_PERSON/B_ORGANIZATION
. O O

This O O
was O O
further O O
suggested O O
by O O
transactivation O O
assays O O
in O O
which O O
mouse O O
fibroblasts O O
were O O
transiently O O
transfected O O
with O O
a O O
human B B_GENE
beta I I_GENE
- I I_GENE
globin I I_GENE
reporter I I_GENE
gene I I_GENE
in O O
the O O
absence O O
and O O
presence O O
of O O
an O O
LKLF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cDNA I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
construct I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Plasma B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
colony I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
stimulating I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factor I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
analysis O O
and O O
the O O
clinical O O
significance O O

Thus O O
, O O
in O O
addition O O
to O O
the O O
previously O O
characterized O O
FAS B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
binding I I_GENE/I_LOCATION
factor I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
interacting O O
with O O
the O O
inositol O O
/ O O
choline O O
- O O
responsive O O
- O O
element O O
motif O O
, O O
a O O
second O O
motif O O
common O O
to O O
the O O
promoter O O
regions O O
of O O
both O O
FAS B B_GENE/B_BIO
genes I I_GENE/I_BIO
could O O
be O O
identified O O
. O O

Reconstruction O B_MEASURE/B_PERSON
time O I_MEASURE/I_PERSON
for O O
a O O
64 O B_MEASURE
x O O
64 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matrix O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
approximately O O
45 O B_MEASURE/B_ORGANIZATION
s O I_MEASURE/I_ORGANIZATION
/ O O
transaxial O B_MEASURE/B_LOCATION
slice O I_MEASURE/I_LOCATION
. O O

Sequence O O
analysis O O
identifies O O
a O O
ras B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
associating I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
RA B B_DISEASE/B_PROTEIN[GENE]
) O O
- O O
like O O
domain O O
in O O
the O O
N O O
- O O
termini O O
of O O
band B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
JEF I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domains I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
in O O
the O O
Grb7 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
/ I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
10 I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
/ I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
14 I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
adapter I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
family I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Patients O O
received O O
BPB O O
using O O
bupivacaine O O
2 O O
mg O O
kg O O
- O O
1 O O
with O O
adrenaline O O
1 O O
in O O
200 O O
, O O
000 O O
, O O
either O O
with O O
or O O
without O O
hyaluronidase B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
3000 O O
iu O O
, O O
in O O
a O O
volume O O
of O O
0 O O
. O O
5 O O
ml O O
per O O
2 O O
. O O
54 O O
cm O O
of O O
the O O
patient O O
' O O
s O O
height O O
. O O

Rhinovirus B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
2A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protease I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
foot B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mouth I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
disease I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
L I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
protease I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
used O O
to O O
analyze O O
the O O
association O O
of O O
eIF4G B B_GENE/B_DISEASE
with O O
eIF4A B B_GENE
, O O
eIF4E B B_GENE
, O O
and O O
eIF3 B B_GENE
. O O

One O O
hundred O O
cDNA O O
clones O O
were O O
sequenced O O
and O O
8 O O
RTKs B B_GENE/B_PERSON
were O O
identified O O
, O O
as O O
well O O
as O O
12 O O
non O O
- O O
RTKs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
2 O O
serine B B_GENE/B_BIO
/ I I_GENE/I_BIO
threonine I I_GENE/I_BIO
kinases I I_GENE/I_BIO
. O O

Roller O B_TIME[MEASURE]/B_LOCATION
pumps O I_TIME[MEASURE]/I_LOCATION
, O O
coronary O B_PRODUCT[OBJECT]/B_LOCATION
suction O I_PRODUCT[OBJECT]/I_LOCATION
and O O
an O O
open O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
cardiotomy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
reservoir O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
were O O
used O O
. O O

Furthermore O O
, O O
it O O
was O O
found O O
that O O
the O O
Shb B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
overexpressing O O
cells O O
extended O O
neurites O O
in O O
response O O
to O O
epidermal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
growth I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factor I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Levels O O
of O O
p53 B B_GENE
were O O
substantially O O
increased O O
by O O
E1A B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
during O O
adenovirus O O
infection O O
. O O

In O O
cases O O
of O O
intracapsular O O
prostatic O O
cancer O O
the O O
level O O
of O O
prostatic B B_GENE
acid I I_GENE
phosphatase I I_GENE
( O O
PAP B B_LOCATION/B_GENE
) O O
measured O O
by O O
radioimmunoassay O O
was O O
1 O O
. O O
4 O O
+ O O
/ O O
- O O
0 O O
. O O
8 O O
micrograms O O
/ O O
l O O
. O O

Healthy O B_PERSON
subjects O I_PERSON
received O O
the O O
following O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
regimens O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
dosed O O
to O O
steady O B_NUMBER[MEASURE]
state O I_NUMBER[MEASURE]
: O O
trovafloxacin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
300 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
24 O B_TIME[MEASURE]
h O I_TIME[MEASURE]
; O O
ciprofloxacin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
400 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
/ O O
12 O B_MEASURE
h O O
; O O
trovafloxacin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
300 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
24 O B_MEASURE
h O O
plus O O
cefepime O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
g O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
12 O B_MEASURE
h O O
, O O
and O O
ciprofloxacin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
400 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
12 O B_MEASURE
h O O
plus O O
cefepime O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
g O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
12 O B_MEASURE
h O O
. O O

In O O
EGF B B_GENE
receptor I I_GENE
- O O
mediated O O
signaling O O
, O O
the O O
protein B B_GENE
kinase I I_GENE
PKB I I_GENE
/ O O
Akt B B_GENE
and O O
the O O
mitogen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Jun I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
N I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
terminal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
not O O
extracellular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
function O O
downstream O O
of O O
phosphatidylinositol B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PI B B_GENE/B_LOCATION
3 I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
kinase I I_GENE/I_LOCATION
) O O
. O O

Immunoprecipitation O O
of O O
cell O O
lysates O O
with O O
anti B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
phosphotyrosine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
immunoblotting O O
showed O O
phosphorylated O O
forms O O
of O O
the O O
mitogenic O O
pathway O O
proteins O O
Shc B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
MAPK B B_GENE
in O O
addition O O
to O O
p185 B B_GENE
( O O
neu B B_GENE/B_DISEASE
) O O
, O O
suggesting O O
that O O
the O O
Ras B B_GENE/B_DISEASE
to O O
MAPK B B_GENE/B_PERSON
mitogenic O O
pathway O O
is O O
activated O O
. O O

Acad O B_LOCATION
. O O

We O O
suggest O O
that O O
this O O
effect O O
of O O
Myc B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
is O O
mediated O O
by O O
its O O
action O O
upstream O O
of O O
cyclin B B_GENE
E I I_GENE
- O O
CDK2 B B_GENE/B_DISEASE
, O O
and O O
occurs O O
via O O
the O O
neutralization O O
of O O
p27 B B_GENE
( O O
Kip1 B B_PROTEIN[GENE]/B_LOCATION
) O O
family O O
proteins O O
, O O
rather O O
than O O
induction O O
of O O
Cdc25A B B_GENE
. O O

Bile O B_DISEASE/B_LOCATION
reflux O I_DISEASE/I_LOCATION
demonstrated O O
by O O
99m O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Tc O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
disofenin O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

These O O
data O O
suggest O O
that O O
certain O O
of O O
the O O
nuclear O O
protein O O
import O O
functions O O
of O O
NTF2 B B_GENE/B_LOCATION
and O O
Ran B B_GENE/B_LOCATION
/ O O
TC4 B B_PROTEIN[GENE]/B_DISEASE
are O O
closely O O
linked O O
and O O
that O O
NTF2 B B_GENE/B_PERSON
may O O
serve O O
to O O
modulate O O
a O O
transport O O
step O O
involving O O
Ran B B_GENE/B_LOCATION
/ O O
TC4 B B_PROTEIN[GENE]/B_LOCATION
. O O

Almost O O
every O O
image O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O O
appears O O
during O O
a O O
therapy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
session O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
reveals O O
a O O
symbolic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nature O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
the O O
very O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
concept O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
symbol O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
not O O
free O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
from O O
ambiguity O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
some O O
positions O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
originated O O
in O O
different O B_LOCATION
areas O I_LOCATION
of O O
investigation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
are O O
mentioned O O
, O O
ending O O
with O O
a O O
description O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O O
the O O
traits O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
that O O
, O O
according O O
to O O
the O O
writer O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
bestow O O
a O O
symbolic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
character O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O O
images O B_ENT/B_PERSON
. O O

The O O
severity O B_MEASURE
of O O
the O O
psychomotor O B_DISEASE
retardation O I_DISEASE
varied O O
from O O
mild O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
severe O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

Both O O
oligonucleotide O O
cross O O
- O O
competition O O
and O O
antibody O O
supershift O O
experiments O O
established O O
that O O
the O O
double O O
- O O
strand O O
binding O O
protein O O
is O O
equivalent O O
to O O
Sp1 B B_GENE
. O O

The O O
wet O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
dry O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
methods O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
HA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
synthesis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
are O O
considered O O
. O O

All O O
these O O
abnormalities O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
returned O O
to O O
normal O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
removal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
tumor O B_DISEASE
. O O

Although O O
FKH2 B B_GENE
is O O
redundant O O
with O O
FKH1 B B_GENE
in O O
controlling O O
pseudohyphal O O
growth O O
, O O
the O O
two O O
genes O O
have O O
different O O
functions O O
in O O
silencing O O
HMRa B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

Molecular O O
analysis O O
indicated O O
that O O
inactivation O O
of O O
H B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2L I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
in O O
nearly O O
every O O
null O O
clone O O
resulted O O
from O O
an O O
apparent O O
deletion O O
or O O
rearrangement O O
of O O
5 B B_GENE
' I I_GENE
- I I_GENE
flanking I I_GENE
and I I_GENE
5 I I_GENE
' I I_GENE
- I I_GENE
coding I I_GENE
H I I_GENE
- I I_GENE
2L I I_GENE
sequences I I_GENE
, O O
with O O
breakpoints O O
consistently O O
mapping O O
to O O
within O O
a O O
550 O O
bp O O
GC O O
- O O
rich O O
region O O
between O O
exon O O
1 O O
and O O
the O O
middle O O
of O O
intron O O
2 O O
. O O

However O O
, O O
C B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
/ I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
EBP I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
beta I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
stimulated O O
transcription O O
primarily O O
through O O
the O O
cAMP O O
- O O
responsive O O
element O O
( O O
CRE O O
) O O
, O O
which O O
maps O O
between O O
positions O O
- O O
77 O O
to O O
- O O
94 O O
, O O
but O O
not O O
at O O
the O O
more O O
5 O O
' O O
- O O
binding O O
sites O O
. O O

Heliox O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
improves O O
pulsus O B_DISEASE/B_BIO
paradoxus O I_DISEASE/I_BIO
and O O
peak O B_DISEASE
expiratory O I_DISEASE
flow O I_DISEASE
in O O
nonintubated O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
with O O
severe O B_DISEASE/B_GENE
asthma O I_DISEASE/I_GENE
. O O

50 O B_NUMBER[MEASURE]
- O O
fold O B_MEASURE
increase O I_MEASURE
in O O
foreign O B_MEASURE/B_DISEASE
protein O I_MEASURE/I_DISEASE
production O I_MEASURE/I_DISEASE
. O O

Ion O B_PERSON/B_LANGUAGE
- O O
Bernstein O B_PERSON/B_MEASURE
- O O
wave O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
heating O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
improved O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
confinement O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
Alcator O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
C O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
tokamak O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

However O O
, O O
the O O
molecular O O
mechanisms O O
by O O
which O O
specific O O
cis O O
- O O
and O O
trans O O
- O O
acting O O
factors O O
control O O
activity O O
of O O
the O O
prodynorphin B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
are O O
not O O
as O O
clearly O O
defined O O
. O O

Finally O O
, O O
antisense O O
mediated O O
reduction O O
of O O
Elk B B_GENE
- I I_GENE
1 I I_GENE
in O O
GH4 O O
cells O O
decreased O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
increased O O
prolactin B B_GENE
gene I I_GENE
expression O O
and O O
confirmed O O
the O O
requirement O O
for O O
Elk B B_GENE
- I I_GENE
1 I I_GENE
for O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
increased O O
prolactin B B_GENE
gene I I_GENE
expression O O
. O O

Substitutions O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
Asp11 O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
led O O
to O O
dominant O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lethality O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Three O B_PERSON/B_ORGANIZATION
modern O B_PERSON/I_ORGANIZATION
hematology O B_PERSON/I_ORGANIZATION
analyzers O B_PERSON/I_ORGANIZATION
( O O
Abbott O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Cell O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O O
Dyn O B_MEASURE/B_LOCATION
3000 O I_MEASURE/I_LOCATION
, O O
Coulter O B_MEASURE/B_PERSON
STKS O I_MEASURE/I_PERSON
, O O
and O O
Sysmex O B_LOCATION/B_DISEASE
NE O I_LOCATION/I_DISEASE
- O O
8000 O B_MEASURE/B_LOCATION
) O O
with O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
throughput O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
5 O B_NUMBER[MEASURE]
- O O
part O B_MEASURE/B_LOCATION
differential O I_MEASURE/I_LOCATION
capability O I_MEASURE/I_LOCATION
were O O
evaluated O O
using O O
a O O
protocol O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
designed O O
by O O
a O O
quality O B_PERSON/B_ORGANIZATION
team O I_PERSON/I_ORGANIZATION
. O O

Each O O
subject O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
was O O
injected O O
in O O
the O O
antecubital O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
vein O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
with O O
7 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
of O O
sodium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorescein O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
25 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
% O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
solution O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
and O O
measurements O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
were O O
taken O O
1 O B_TIME[MEASURE]/B_LOCATION
hr O I_TIME[MEASURE]/I_LOCATION
postinjection O I_TIME[MEASURE]/I_LOCATION
at O O
4 O B_MEASURE
. O O
5 O B_MEASURE
mm O I_MEASURE
and O O
7 O B_MEASURE
. O O
5 O B_MEASURE
mm O I_MEASURE
from O O
the O O
retina O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
cleft O B_DISEASE/B_LOCATION
walls O B_DISEASE/I_LOCATION
are O O
lined O O
with O O
highly O O
conserved O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
residues O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
NADP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
is O O
bound O O
along O O
one O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
wall O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

cDNA O O
cloning O O
, O O
sequencing O O
and O O
chromosome O O
mapping O O
of O O
a O O
non B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
erythroid I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
spectrin I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fodrin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
aromatic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hydrocarbon I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
AHR B B_GENE/B_LOCATION
) O O
is O O
a O O
ligand O O
- O O
activated O O
transcription O O
factor O O
that O O
regulates O O
the O O
expression O O
of O O
several O O
drug O O
- O O
metabolizing O O
enzymes O O
and O O
has O O
been O O
implicated O O
in O O
immunosuppression O O
, O O
teratogenesis O O
, O O
cell O O
- O O
specific O O
hyperplasia O O
, O O
and O O
certain O O
types O O
of O O
malignancies O O
and O O
toxicities O O
. O O

( O O
1996 O B_MEASURE
) O O
J O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

To O O
define O O
the O O
molecular O O
mechanism O O
regulating O O
FGFR B B_GENE
- I I_GENE
1 I I_GENE
gene I I_GENE
expression O O
in O O
proliferating O O
myoblasts O O
and O O
post O O
- O O
mitotic O O
muscle O O
fibers O O
, O O
we O O
have O O
isolated O O
and O O
partially O O
characterized O O
the O O
avian O O
FGFR B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
- I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
1 I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
gene I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
promoter O O
. O O

Moreover O O
, O O
FACT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specifically O O
interacts O O
with O O
nucleosomes O O
and O O
histone O O
H2A B B_PROTEIN[GENE]
/ O O
H2B B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
dimers O O
, O O
indicating O O
that O O
it O O
may O O
work O O
by O O
promoting O O
nucleosome O O
disassembly O O
upon O O
transcription O O
. O O

Measures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
sedation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
BIS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
deltaBIS O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
absolute O B_MEASURE
change O I_MEASURE
of O O
BIS O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
after O O
a O O
painful O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
stimulus O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
) O O
, O O
memory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
drug O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
concentration O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O O
obtained O O
at O O
each O O
target O B_MEASURE/B_LOCATION
drug O B_MEASURE/I_LOCATION
concentration O B_MEASURE/I_LOCATION
. O O

ER O O
and O O
DR O O
were O O
significantly O O
correlated O O
with O O
MIB B B_GENE
- I I_GENE
1 I I_GENE
LI O O
( O O
P O O
< O O
0 O O
. O O
01 O O
and O O
P O O
< O O
0 O O
. O O
05 O O
, O O
respectively O O
) O O
, O O
but O O
RI O O
and O O
Td O O
/ O O
Te O O
were O O
not O O
. O O

Positive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
linear O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
correlations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
found O O
when O O
the O O
AUC O B_MEASURE
( O O
0 O B_MEASURE
- O O
12 O B_MEASURE
) O O
( O O
r O B_OTHER/B_GENE
= O O
0 O B_NUMBER[MEASURE]
. O O
68 O B_MEASURE
; O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_NUMBER[MEASURE]
. O O
01 O B_MEASURE
) O O
, O O
the O O
maximum O B_MEASURE
plasma O I_MEASURE
concentration O I_MEASURE
( O O
r O B_OTHER/B_GENE
= O O
0 O B_MEASURE
. O O
34 O B_MEASURE
; O O
P O B_MEASURE/B_PERSON
less O I_MEASURE/I_PERSON
than O O
0 O B_NUMBER[MEASURE]
. O O
01 O B_MEASURE
) O O
, O O
the O O
minimum O B_MEASURE/B_DISEASE
plasma O I_MEASURE/I_DISEASE
concentration O I_MEASURE/I_DISEASE
( O O
r O B_OTHER/B_GENE
= O O
0 O B_NUMBER[MEASURE]
. O O
55 O B_MEASURE
; O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_NUMBER[MEASURE]
. O O
01 O B_MEASURE
) O O
, O O
and O O
the O O
elimination O B_PROTEIN[GENE]/B_LOCATION
t1 O I_PROTEIN[GENE]/I_LOCATION
/ O O
2 O B_MEASURE
( O O
r O B_OTHER/B_GENE
= O O
0 O B_MEASURE
. O O
46 O B_MEASURE
; O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_NUMBER[MEASURE]
. O O
01 O B_MEASURE
) O O
were O O
regressed O O
with O O
age O B_MEASURE
. O O

Psychophysical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
given O O
for O O
the O O
existence O B_DISEASE/B_LOCATION
of O O
two O B_LOCATION/B_MEASURE
distinct O I_LOCATION/I_MEASURE
systems O I_LOCATION/I_MEASURE
in O O
human O B_EDU[ORGANIZATION]/B_DISEASE_ADJECTIVE[DISEASE]
vision O I_EDU[ORGANIZATION]/I_DISEASE_ADJECTIVE[DISEASE]
: O O
a O O
fast O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
sign O B_LOCATION/B_MEASURE
- O O
invariant O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concerned O O
with O O
extracting O O
contours O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
a O O
slower O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
sign O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
sensitive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
concerned O O
with O O
assigning O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_COLOR
surface O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_COLOR
color O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_COLOR
. O O

Peripheral O B_TIME[MEASURE]/B_PERSON
visual O I_TIME[MEASURE]/I_PERSON
acuity O I_TIME[MEASURE]/I_PERSON
with O O
monovision O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
contact O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
lens O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
corrections O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
for O O
presbyopia O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Fourteen O B_PERSON/B_ORGANIZATION
Centers O I_PERSON/I_ORGANIZATION
participated O O
in O O
this O O
trial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
program O O
for O O
myogenic O O
differentiation O O
is O O
subject O O
to O O
negative O O
control O O
by O O
several O O
peptide O O
growth O O
factors O O
and O O
by O O
the O O
products O O
of O O
mutationally O O
activated O O
ras B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oncogenes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
persistently O O
activate O O
intracellular O O
cascades O O
normally O O
triggered O O
by O O
specific O O
growth O O
factors O O
. O O

Tetrazepam O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
a O O
benzodiazepine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
which O O
dissociates O O
sedation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
from O O
other O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
benzodiazepine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
activities O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

The O O
difference O B_MEASURE/B_PERSON
between O O
the O O
effects O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
two O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
levels O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
Z O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Mutation O O
of O O
the O O
distal O O
E2F B B_GENE/B_LOCATION
binding I I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
in O O
the O O
cdc25A B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
abolished O O
E2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
repression O O
, O O
whereas O O
mutation O O
of O O
the O O
proximal O O
E2F B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
or O O
the O O
E2 B B_MEASURE/B_LOCATION
site I I_MEASURE/I_LOCATION
had O O
no O O
effect O O
. O O

Plasmid O O
pNK21 O O
, O O
in O O
which O O
2 O O
. O O
05 O O
- O O
kb O O
sequence O O
covering O O
the O O
region O O
encoding O O
the O O
nitrilase B B_ENZYME[GENE]/B_BACTERIUM[BIO]
was O O
was O O
placed O O
under O O
the O O
control O O
of O O
the O O
lac B B_GENE/B_BIO
promoter I I_GENE/I_BIO
, O O
directed O O
overproduction O O
of O O
enzymatically B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
active I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
nitrilase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
in O O
response O O
to O O
addition O O
of O O
isopropyl O O
beta O O
- O O
D O O
- O O
thiogalactopyranoside O O
in O O
Escherichia O O
coli O O
. O O

A O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
determining O O
the O O
toxicity O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
neutralizers O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
antimicrobial O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
agents O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
A O O
. O O
castellanii O B_BACTERIUM[BIO]/B_DISEASE
was O O
also O O
evaluated O O
. O O

Expression O B_GENE
in O O
all O O
lines O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
decreased O O
by O O
the O O
inclusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
regions O B_LOCATION/B_GENE
further O O
upstream O O
, O O
and O O
extinguished O O
by O O
the O O
inclusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
first O B_LOCATION/B_PERSON
intron O I_LOCATION/I_PERSON
. O O

Static O B_MEASURE/B_DISEASE
and O O
dynamic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
MRI O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
the O O
normal O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
pathological O B_DISEASE/B_MEASURE
female O I_DISEASE/I_MEASURE
pelvic O I_DISEASE/I_MEASURE
floor O I_DISEASE/I_MEASURE

IENF O B_GENE/B_DISEASE
density O B_GENE/I_DISEASE
at O O
the O O
calf O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
was O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
that O O
obtained O O
from O O
skin O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
at O O
more O O
proximal O B_MEASURE/B_LOCATION
sites O I_MEASURE/I_LOCATION
, O O
indicating O O
the O O
length O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dependency O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
small O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
fiber O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
loss O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
these O O
neuropathies O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

These O O
results O O
demonstrate O O
a O O
specific O O
association O O
of O O
SIV O O
and O O
HIV B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
2 I I_GENE/I_DISEASE
nef I I_GENE/I_DISEASE
, O O
but O O
not O O
HIV B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
nef I I_GENE/I_DISEASE
, O O
with O O
TCRzeta B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Insertion O O
of O O
alternatively O O
spliced O O
exon O O
W O O
into O O
CREB B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
mRNA I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
during O O
spermatogenesis O O
results O O
in O O
a O O
polycistronic O O
RNA O O
that O O
encodes O O
two O O
novel O O
internally O O
translated O O
CREB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
repressor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
isoforms I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
called O O
I B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CREBs I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
consisting O O
of O O
the O O
carboxy O O
- O O
terminal O O
DNA O O
- O O
binding O O
domain O O
devoid O O
of O O
the O O
transactivation O O
domains O O
. O O

A O O
continuous O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
flow O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
BIPAP O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
consists O O
of O O
a O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O O
flow O B_MEASURE/B_LOCATION
CPAP O I_MEASURE/I_LOCATION
system O I_MEASURE/I_LOCATION
, O O
a O O
reservoir O B_MEDICAL_DEVICE[OBJECT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
bag O I_MEDICAL_DEVICE[OBJECT]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
a O O
pneumatically O O
controlled O O
membrane O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
valve O I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
expiratory O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
limb O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Older O B_PERSON
females O I_PERSON
had O O
lumbar O O
( O O
0 O B_MEASURE
. O O
6 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
1 O B_NUMBER[MEASURE]
. O O
3 O B_MEASURE
) O O
and O O
TB O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
( O O
1 O B_MEASURE
. O O
1 O B_MEASURE/B_LOCATION
+ O I_MEASURE/I_LOCATION
/ O O
- O O
1 O B_NUMBER[MEASURE]
. O O
1 O B_MEASURE
) O O
BMD O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Z O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scores O O
greater O B_LOCATION/B_MEASURE
than O O
0 O B_MEASURE/B_PERSON
( O O
both O O
, O O
p O O
< O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
. O O

Smooth O B_DISEASE/B_MEASURE
pursuit O I_DISEASE/I_MEASURE
gain O I_DISEASE/I_MEASURE
and O O
the O O
percentage O B_MEASURE
of O O
total O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
eye O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
movement O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
due O O
to O O
various O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
saccadic O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
subtypes O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
computed O O
using O O
infrared O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
oculography O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
and O O
computerized O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pattern O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
recognition O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
software O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Upon O O
incubation O O
of O O
the O O
most O O
highly O O
purified O O
fractions O O
with O O
Mn O O
- O O
ATP O O
or O O
Mg O O
- O O
ATP O O
, O O
p40 B B_GENE
was O O
the O O
only O O
protein O O
phosphorylated O O
on O O
tyrosine O O
. O O

Consistent O O
with O O
this O O
hypothesis O O
, O O
alpha1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PDX I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prevents O O
cleavage O O
of O O
BMP B B_GENE
- I I_GENE
4 I I_GENE
in O O
an O O
oocyte O O
translation O O
assay O O
. O O

A O O
p53 B B_GENE
cDNA I I_GENE
deletion O O
mutant O O
( O O
delta O O
pro O O
AE O O
) O O
, O O
which O O
lacks O O
this O O
entire O O
proline O O
- O O
rich O O
domain O O
( O O
deleted O O
for O O
amino O O
acids O O
62 O O
- O O
91 O O
) O O
, O O
was O O
created O O
and O O
characterized O O
for O O
a O O
variety O O
of O O
p53 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
functions O O
. O O

Multiple O O
aortic O O
thrombi O O
associated O O
with O O
protein B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
S B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
deficiency O O
. O O

Our O O
results O O
suggest O O
that O O
Bry1 B B_GENE/B_LOCATION
/ O O
Skn7 B B_MEASURE/B_GENE
can O O
influence O O
the O O
expression O O
of O O
MCB O O
- O O
and O O
SCB O O
- O O
driven O O
gene O O
expression O O
in O O
budding O O
yeast O O
, O O
perhaps O O
including O O
genes O O
involved O O
in O O
cell O O
wall O O
metabolism O O
, O O
via O O
a O O
two O O
- O O
component O O
signal O O
transduction O O
pathway O O
which O O
activates O O
Bry1 B B_GENE
/ O O
Skn7 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
response O O
to O O
an O O
unidentified O O
signal O O
. O O

( O O
1992 O B_MEASURE
) O O
J O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

A O O
constructed O O
phylogenetic O O
tree O O
suggests O O
that O O
the O O
UbcP1 B B_BIO/B_GENE
protein I I_BIO/I_GENE
may O O
represent O O
a O O
member O O
of O O
a O O
distinct O O
subfamily O O
of O O
E2s B B_GENE/B_BIO
. O O

Platelet B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
4 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
in O O
patients O O
with O O
coronary O O
artery O O
disease O O
. O O

We O O
functionally O O
characterised O O
AtXPO1 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
its O O
interaction O O
with O O
NESs O O
of O O
animal O O
and O O
plant O O
proteins O O
, O O
which O O
is O O
inhibited O O
by O O
the O O
cytotoxin O O
leptomycin O O
B O O
( O O
LMB O O
) O O
, O O
and O O
also O O
by O O
its O O
interaction O O
with O O
the O O
small B B_GENE
GTPase I I_GENE
Ran1 B I_GENE
in O O
the O O
yeast O O
two O O
- O O
hybrid O O
system O O
. O O

A O O
backward O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
look O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
urinary O B_PERSON
tract O I_PERSON
infections O I_PERSON
. O O

The O O
expression O O
of O O
cor14b B B_GENE
was O O
strongly O O
impaired O O
in O O
the O O
barley O O
albino O O
mutant O O
an O O
, O O
suggesting O O
the O O
involvement O O
of O O
a O O
plastidial O O
factor O O
in O O
the O O
control O O
of O O
gene O O
expression O O
. O O

MRS O B_PERSON/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
allowed O O
the O O
differentiation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
the O O
following O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
metabolites O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
5 O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
patients O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
: O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
acetyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
aspartate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
NAA O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
creatine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
phosphocreatine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
phosphorylcholine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
glycerophosphorylcholine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
beta O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
gamma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
glutamate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
GLU O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Overall O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
, O O
free O B_DISEASE/B_MEASURE
- O O
chlorine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
treatments O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
0 O B_MEASURE/B_LOCATION
. O O
3 O B_MEASURE
or O O
1 O B_MEASURE
. O O
0 O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
L O B_OTHER/B_MEASURE
) O O
showed O O
significantly O O
lower O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
heterotrophic O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
plate O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
numbers O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
than O O
those O O
without O O
free O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chlorine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

S1 B B_GENE
nuclease I I_GENE
protection O O
mapping O O
and O O
primer O O
extension O O
analysis O O
allowed O O
us O O
to O O
propose O O
that O O
the O O
A O O
residue O O
located O O
19 O O
bp O O
upstream O O
from O O
the O O
translation O O
initiation O O
codon O O
is O O
the O O
site O O
of O O
transcription O O
initiation O O
. O O

Various O O
stimuli O O
inactivate O O
IkappaB B B_GENE
alpha I I_GENE
by O O
triggering O O
phosphorylation O O
of O O
the O O
N O O
- O O
terminal O O
residues O O
Ser32 O O
and O O
Ser36 O O
. O O

There O O
was O O
no O O
difference O B_MEASURE
in O O
the O O
day O B_MEASURE/B_LOCATION
- O O
42 O B_MEASURE
cure O I_MEASURE
rates O I_MEASURE
between O O
the O O
QC7 O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
n O B_OTHER/B_MEASURE
= O O
65 O B_MEASURE
) O O
and O O
A7 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
n O B_OTHER/B_LOCATION
= O O
64 O B_MEASURE
) O O
regimens O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O O
an O O
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
100 O B_MEASURE
% O I_MEASURE
in O O
both O O
, O O
confirmed O O
by O O
parasite O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
genotyping O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

In O O
addition O O
, O O
the O O
results O O
suggest O O
that O O
N O O
region O O
diversity O O
at O O
V B B_OTHER/B_NUMBER[MEASURE]
( O O
D B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
J B B_OTHER/B_PERSON
junctions O O
within O O
rearranged O O
immunoglobulin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
T B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
loci I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O O
only O O
be O O
introduced O O
after O O
the O O
generation O O
of O O
RAG B B_ENZYME[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
catalyzed O O
DNA O O
double O O
- O O
strand O O
breaks O O
, O O
i O O
. O O
e O O
. O O
during O O
the O O
DNA O O
end O O
joining O O
phase O O
of O O
the O O
V B B_OTHER/B_DISEASE_ADJECTIVE[DISEASE]
( O O
D B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
J B B_OTHER/B_GENE
recombination O O
reaction O O
. O O

We O O
conclude O O
that O O
99mTc O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
HL91 O B_MEASURE/B_GENE
is O O
a O O
potent O B_MEASURE/B_GENE
marker O I_MEASURE/I_GENE
of O O
myocardial O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
viability O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
when O O
used O O
during O O
the O O
early O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
acute O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
phase O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O O
reperfusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Three O B_PERSON/B_TIME[MEASURE]
patients O I_PERSON/I_TIME[MEASURE]
treated O O
with O O
amphotericin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
single O B_NUMBER[MEASURE]/B_LOCATION
course O I_NUMBER[MEASURE]/I_LOCATION
as O O
well O O
as O O
multiple O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
courses O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
and O O
other O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antifungal O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
agents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
hydroxystilbamidine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
miconazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
have O O
all O O
relapsed O O
. O O

An O O
infant O B_PERSON
of O O
8 O B_NUMBER[MEASURE]/B_PERSON
months O I_NUMBER[MEASURE]/I_PERSON
with O O
congenital O B_DISEASE/B_GENE
glaucoma O I_DISEASE/I_GENE
and O O
hemophilia O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
A O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
lost O O
one O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
eye O B_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
due O O
to O O
haemorrhages O B_DISEASE
after O O
trabeculotomy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
in O O
an O O
eye O B_LOCATION/B_PERSON
hospital O I_LOCATION/I_PERSON
. O O

Anderson O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
Hospital O B_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
Tumor O B_LOCATION/B_PERSON
Institute O I_LOCATION/I_PERSON
at O O
Houston O B_LOCATION
during O O
a O O
30 O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]/B_LOCATION
interval O I_TIME[MEASURE]/I_LOCATION
( O O
1944 O B_MEASURE
to O O
1974 O B_MEASURE
) O O
, O O
with O O
a O O
minimum O B_MEASURE/B_LOCATION
of O O
ten O B_TIME[MEASURE]/B_ENT
years O I_TIME[MEASURE]/I_ENT
of O O
follow O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
up O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
determined O O
that O O
the O O
major O B_MEASURE/B_PERSON
prognostic O I_MEASURE/I_PERSON
factor O I_MEASURE/I_PERSON
of O O
survival O B_DISEASE
was O O
the O O
number O B_MEASURE/B_LOCATION
of O O
positive O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
nodes O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

We O O
have O O
now O O
isolated O O
cDNA O O
for O O
an O O
invertebrate B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Pax I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sea I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
urchin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
embryos I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

To O O
study O O
structural O O
diversity O O
of O O
the O O
three O O
homologous O O
loci O O
encoding O O
a O O
KN1 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
like I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
homeobox I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
hexaploid O O
wheat O O
genome O O
, O O
we O O
isolated O O
clones O O
from O O
a O O
cDNA O O
library O O
of O O
young O O
spikes O O
of O O
Japanese O O
common O O
wheat O O
cultivar O O
' O O
Norin O O
26 O O
' O O
. O O

Whether O O
or O O
not O O
these O O
novel O O
repeated O O
sequences O O
throughout O O
the O O
SMA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
involved O O
in O O
the O O
disease O O
remains O O
to O O
be O O
determined O O
. O O

Thus O O
, O O
Shp2 B B_GENE
regulates O O
phosphotyrosine O O
- O O
signalling O O
events O O
during O O
the O O
complex O O
ectodermal O O
- O O
mesenchymal O O
interactions O O
that O O
regulate O O
mammalian O O
budding O O
morphogenesis O O
. O O

Moyamoya O B_DISEASE/B_LOCATION
is O O
an O O
intriguing O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
controversial O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
syndrome O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
elimination O O
of O O
the O O
kinase O O
activity O O
of O O
DCAMKL1 B B_GENE
has O O
no O O
detectable O O
effect O O
on O O
its O O
microtubule O O
polymerization O O
activity O O
. O O

We O O
have O O
thus O O
cloned O O
two O O
yeast O O
homologs O O
of O O
mammalian B B_GENE
p220 I I_GENE
. O O

The O O
glucose O O
effect O O
on O O
the O O
pyruvate B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
kinase I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
gene I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O O
reversibly O O
antagonized O O
by O O
agents O O
increasing O O
intracellular O O
cAMP O O
. O O

An O O
identical O B_GENE
polypeptide O I_GENE
was O O
detected O O
by O O
Western O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
K1F O B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
virions O I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Patients O B_PERSON/B_BIO
with O O
PLM O B_DISEASE/B_LOCATION
show O O
excessive O B_DISEASE
daytime O I_DISEASE
sleepiness O I_DISEASE
or O O
insomnia O B_DISEASE
. O O

Coexpression O O
of O O
CREB B B_GENE
- I I_GENE
binding I I_GENE
protein I I_GENE
( O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
/ O O
p300 B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
TReP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
132 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
an O O
additive O O
effect O O
on O O
promoter O O
activity O O
, O O
and O O
the O O
proteins O O
were O O
demonstrated O O
to O O
interact O O
physically O O
. O O

It O O
is O O
believed O O
that O O
the O O
operation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
effective O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
because O O
it O O
cuts O O
the O O
spinothalamic O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
tract O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
STT O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
a O O
primary O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
pathway O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
carrying O O
nociceptive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
information O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
from O O
the O O
spinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cord O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
in O O
humans O B_PERSON/B_SPECIES[BIO]
. O O

Catalase B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
plays O O
a O O
key O O
role O O
as O O
an O O
antioxidant O O
, O O
protecting O O
aerobic O O
organisms O O
from O O
the O O
toxic O O
effects O O
of O O
hydrogen O O
peroxide O O
, O O
and O O
in O O
some O O
cases O O
has O O
been O O
postulated O O
to O O
be O O
a O O
virulence O O
factor O O
. O O

Recovery O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rates O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
energy O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
level O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
and O O
intracellular O B_MEASURE/B_DISEASE
pH O I_MEASURE/I_DISEASE
during O O
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
at O O
100Hz O B_TIME[MEASURE]/B_LOCATION
were O O
greater O B_MEASURE
than O O
those O O
observed O O
during O O
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
at O O
30Hz O B_MEASURE/B_LOCATION
. O O

Exhaled O O
NO O O
was O O
assessed O O
by O O
controlled O O
- O O
flow O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chemoluminescence O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
after O O
adjusting O O
for O O
trapped O B_MEASURE/B_DISEASE
air O I_MEASURE/I_DISEASE
and O O
after O O
generating O O
pressure O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
oral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cavity O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
that O O
was O O
sufficient O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
close O O
the O O
soft O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
palate O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Eco O B_PROTEIN[GENE]/B_LOCATION
Physics O I_PROTEIN[GENE]/I_LOCATION
CLD O I_PROTEIN[GENE]/I_LOCATION
77 O I_PROTEIN[GENE]/I_LOCATION
AM O I_PROTEIN[GENE]/I_LOCATION
analyzer O I_PROTEIN[GENE]/I_LOCATION
) O O
. O O

Recent O O
developments O O
in O O
the O O
study O O
of O O
growth O O
factors O O
: O O
GRF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
somatomedins B B_GENE/B_BACTERIUM[BIO]
. O O

New O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
concepts O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
condyloma O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
acuminata O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
children O B_PERSON/B_LOCATION
. O O

This O O
is O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
clinical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
case O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
report O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O O
NIHF O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O O
to O O
fetal O B_PERSON
Kasabach O I_PERSON
- O O
Merritt O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
syndrome O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
that O O
was O O
prenatally O O
diagnosed O O
by O O
sonography O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
computerized O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tomography O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
percutaneous O O
umbilical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
blood O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sampling O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Acetoacetate B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
decarboxylase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ADC B B_DISEASE/B_GENE
) O O
( O O
EC4 B B_PROTEIN[GENE]/B_DISEASE
. I I_PROTEIN[GENE]/I_DISEASE
1 I I_PROTEIN[GENE]/I_DISEASE
. I I_PROTEIN[GENE]/I_DISEASE
1 I I_PROTEIN[GENE]/I_DISEASE
. I I_PROTEIN[GENE]/I_DISEASE
4 I I_PROTEIN[GENE]/I_DISEASE
) O O
of O O
Clostridium O O
acetobutylicum O O
DSM O O
792 O O
was O O
purified O O
to O O
homogeneity O O
, O O
and O O
its O O
first O O
25 O O
N O O
- O O
terminal O O
amino O O
acids O O
were O O
determined O O
. O O

Transfer O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
health O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
care O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
to O O
natives O B_PERSON/B_LOCATION
holds O O
much O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
promise O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
, O O
lecturers O B_PERSON
say O O
. O O

The O O
sequence O O
of O O
the O O
127 B B_PROTEIN[GENE]/B_BIO
residue I I_PROTEIN[GENE]/I_BIO
NrfF I I_PROTEIN[GENE]/I_BIO
polypeptide I I_PROTEIN[GENE]/I_BIO
, I I_PROTEIN[GENE]/I_BIO
M I I_PROTEIN[GENE]/I_BIO
( I I_PROTEIN[GENE]/I_BIO
r I I_PROTEIN[GENE]/I_BIO
) I I_PROTEIN[GENE]/I_BIO
14 I I_PROTEIN[GENE]/I_BIO
, I I_PROTEIN[GENE]/I_BIO
522 I I_PROTEIN[GENE]/I_BIO
, O O
is O O
strikingly O O
similar O O
to O O
the O O
CcI2 B B_GENE/B_BIO
protein I I_GENE/I_BIO
of O O
R O O
. O O
capsulatus O O
, O O
especially O O
in O O
the O O
putative O O
haem O O
- O O
binding O O
motif O O
, O O
RCPQCQNQN O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
400 O O
WORDS O O
) O O

CAT B B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assays O O
demonstrated O O
that O O
overexpression O O
of O O
RXRalpha B B_GENE/B_DISEASE
conferred O O
the O O
best O O
RA O O
response O O
, O O
consistent O O
with O O
our O O
previous O O
observation O O
that O O
9 O O
- O O
cis O O
- O O
RA O O
is O O
more O O
potent O O
than O O
all O O
- O O
trans O O
- O O
RA O O
for O O
inducing O O
the O O
expression O O
of O O
the O O
AFP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

For O O
rotating O O
stimuli O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
presented O O
to O O
the O O
dominant O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
eye O I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
this O O
class O B_PERSON/B_MEASURE
of O O
neurons O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
responded O O
best O O
to O O
rotation O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
visual O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
world O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
about O O
an O O
axis O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
oriented O O
near O O
the O O
horizontal O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
plane O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
approximately O O
45 O B_TIME[MEASURE]/B_LOCATION
degrees O B_TIME[MEASURE]/I_LOCATION
azimuth O B_TIME[MEASURE]/I_LOCATION
. O O

None O B_PERSON/B_NUMBER[MEASURE]
of O O
these O O
patients O B_PERSON/B_BIO
developed O O
clinical O B_DISEASE
events O I_DISEASE
before O O
disappearance O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
phospholipid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
dependent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
coagulation O B_GENE/B_DISEASE
. O O

In O O
spite O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
variability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
DD95 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
regard O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
body O B_MEASURE/B_DISEASE
weight O B_MEASURE/I_DISEASE
, O O
the O O
recovery O B_MEASURE
of O O
neuromuscular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transmission O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
patients O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
three O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
is O O
comparable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
have O O
studied O O
some O O
of O O
the O O
parameters O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
governing O O
the O O
expression O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
a O O
foreign O B_GENE
promoter O I_GENE
- O O
reporter O B_GENE/B_DISEASE
gene O I_GENE/I_DISEASE
construct O O
incorporated O O
into O O
herpes O B_DISEASE/B_VIRUS[BIO]
simplex O B_DISEASE/I_VIRUS[BIO]
virus O B_DISEASE/I_VIRUS[BIO]
( O O
HSV O B_VIRUS[BIO]/B_DISEASE
) O O
type O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
1 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Relation O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
clinical O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O O
roentgenological O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
scores O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
and O O
measures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
lung O B_DISEASE
function O I_DISEASE
in O O
cystic O B_DISEASE/B_PERSON
fibrosis O I_DISEASE/I_PERSON
, O O
with O O
special O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reference O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
pulmonary O B_DISEASE
Xenon133 O I_DISEASE
elimination O I_DISEASE
. O O

Each O O
fusion O O
leads O O
, O O
in O O
principle O O
, O O
to O O
the O O
same O O
effect O O
: O O
The O O
ret B B_GENE/B_LOCATION
tyrosine I I_GENE/I_LOCATION
kinase I I_GENE/I_LOCATION
is O O
uncoupled O O
from O O
its O O
stringent O O
physiological O O
regulation O O
by O O
replacement O O
of O O
its O O
5 O O
' O O
end O O
and O O
is O O
aberrantly O O
activated O O
by O O
the O O
5 O O
' O O
parts O O
of O O
fused O O
genes O O
in O O
thyrocytes O O
that O O
do O O
not O O
normally O O
express O O
ret B B_GENE
tyrosine I I_GENE
kinase I I_GENE
. O O

He O O
had O O
complained O O
of O O
fever O B_DISEASE
and O O
right O B_DISEASE
hypochondralgia O I_DISEASE
2 O I_DISEASE
months O I_DISEASE
after O O
being O O
operated O O
for O O
appendicitis O B_DISEASE/B_LOCATION
. O O

In O O
the O O
predicted O O
amino O O
acid O O
sequence O O
of O O
NPS1 B B_GENE
, O O
sequences O O
homologous O O
to O O
the O O
catalytic O O
domain O O
of O O
protein O O
kinases O O
were O O
found O O
. O O

Carcinoma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
related I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
production O O
may O O
have O O
played O O
a O O
role O O
in O O
the O O
development O O
of O O
the O O
observed O O
renal O O
lesions O O
. O O

These O O
results O O
provide O O
strong O O
evidence O O
that O O
conserved O O
interhelical O O
packing O O
interactions O O
in O O
the O O
gp41 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
core I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
important O O
determinants O O
of O O
HIV O O
- O O
1 O O
entry O O
and O O
its O O
inhibition O O
. O O

Lag O O
phases O O
were O O
14 O O
. O O
89 O O
hours O O
+ O O
/ O O
- O O
0 O O
. O O
77 O O
, O O
13 O O
. O O
33 O O
hours O O
+ O O
/ O O
- O O
0 O O
. O O
50 O O
, O O
20 O O
. O O
22 O O
hours O O
+ O O
/ O O
- O O
0 O O
. O O
76 O O
, O O
and O O
20 O O
. O O
00 O O
hours O O
+ O O
/ O O
- O O
0 O O
. O O
79 O O
, O O
respectively O O
, O O
for O O
endothelial O O
cell O O
- O O
induced O O
LDL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
oxidation O O
. O O

Forty O B_NUMBER[MEASURE]
- O O
eight O B_NUMBER[MEASURE]/B_PERSON
pregnant O I_NUMBER[MEASURE]/I_PERSON
adult O I_NUMBER[MEASURE]/I_PERSON
and O O
122 O B_PERSON/B_SPECIES[BIO]
fetal O I_PERSON/I_SPECIES[BIO]
guinea O I_PERSON/I_SPECIES[BIO]
pigs O I_PERSON/I_SPECIES[BIO]
were O O
sacrificed O O
at O O
intervals O B_TIME[MEASURE]/B_LOCATION
throughout O O
gestation O B_TIME[MEASURE]/B_LOCATION
and O O
the O O
carcasses O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
analyzed O O
for O O
a O O
variety O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
growth O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
parameters O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

Here O O
we O O
demonstrate O O
the O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
oligonucleotides O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O O
the O O
C4T O B_GENE/B_MEASURE
sequence O I_GENE/I_MEASURE
to O O
confer O O
heat O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
shock O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inducibility O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
reporter O B_GENE
gene O I_GENE
and O O
show O O
that O O
the O O
presence O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
two O B_GENE
such O I_GENE
elements O I_GENE
produces O O
more O B_MEASURE
than O O
additive O B_MEASURE
effects O I_MEASURE
on O O
induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE_EXPRESSION_ADJECTIVE[GENE]
. O O

The O O
HPV O O
E1 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
E2 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins O O
along O O
with O O
cellular O O
factors O O
, O O
are O O
required O O
for O O
replication O O
of O O
the O O
viral O O
genome O O
. O O

The O O
observed O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alterations O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
lung O B_DISEASE/B_GENE
functions O B_DISEASE/I_GENE
in O O
these O O
subjects O B_PERSON/B_BIO
indicate O O
that O O
individuals O B_PERSON/B_BIO
performing O O
heavy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
continuous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
exercise O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
are O O
more O O
likely O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
be O O
affected O O
by O O
lower O B_DISEASE/B_LOCATION
O3 O I_DISEASE/I_LOCATION
levels O I_DISEASE/I_LOCATION
. O O

In O O
ten O O
other O O
endotoxin O O
- O O
albumin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
treated O O
pigs O O
PGE1 O O
infusion O O
( O O
0 O O
. O O
25 O O
micrograms O O
X O O
kg O O
- O O
1 O O
X O O
min O O
- O O
1 O O
) O O
was O O
begun O O
after O O
established O O
pulmonary O O
and O O
cardiovascular O O
dysfunction O O
, O O
for O O
closer O O
mimicking O O
of O O
clinical O O
use O O
. O O

The O O
main O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
new O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
features O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
this O O
version O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O O
that O O
end O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
tidal O B_TIME[MEASURE]/B_LOCATION
PO2 O B_TIME[MEASURE]/I_LOCATION
instead O O
of O O
inspiratory O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PO2 O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
kept O O
constant O B_MEASURE
, O O
and O O
that O O
the O O
correcting O O
activity O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
both O O
controllers O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
capnostat O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
oxystat O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
proportional O B_MEASURE/B_PERSON
to O O
the O O
magnitude O B_MEASURE
of O O
the O O
difference O B_MEASURE
between O O
the O O
actual O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
adjusted O O
end O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
tidal O B_MEASURE/B_LOCATION
PCO2 O I_MEASURE/I_LOCATION
or O O
PO2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Like O O
the O O
human B B_GENE/B_PERSON
erythrocyte I I_GENE/I_PERSON
P4 I I_GENE/I_PERSON
. I I_GENE/I_PERSON
2 I I_GENE/I_PERSON
, O O
mouse B B_PROTEIN[GENE]/B_LOCATION
erythrocyte I I_PROTEIN[GENE]/I_LOCATION
P4 I I_PROTEIN[GENE]/I_LOCATION
. I I_PROTEIN[GENE]/I_LOCATION
2 I I_PROTEIN[GENE]/I_LOCATION
contains O O
regions O O
strikingly O O
homologous O O
with O O
the O O
transglutaminase O O
( O O
TGase O O
) O O
proteins O O
although O O
it O O
too O O
most O O
likely O O
lacks O O
TGase O O
crosslinking O O
activity O O
. O O

It O O
spans O O
20 O B_MEASURE/B_BIO
kilobases O I_MEASURE/I_BIO
, O O
consists O O
of O O
7 O B_NUMBER[MEASURE]
exons O I_NUMBER[MEASURE]
and O O
6 O B_GENE/B_LOCATION
introns O I_GENE/I_LOCATION
, O O
and O O
contains O O
a O O
TATA O B_GENE/B_LOCATION
motif O B_GENE/I_LOCATION
24 O B_GENE/I_LOCATION
nucleotides O B_GENE/I_LOCATION
upstream O O
of O O
the O O
transcriptional O B_GENE/B_BIO
start O I_GENE/I_BIO
site O I_GENE/I_BIO
. O O

Nine O O
months O O
after O O
the O O
end O O
of O O
the O O
vaccination O O
anti B B_DISEASE/B_GENE
- I B_DISEASE/I_GENE
HBsAg I B_DISEASE/I_GENE
levels O O
had O O
dropped O O
to O O
9 O O
+ O O
/ O O
- O O
4 O O
IU O O
/ O O
1 O O
( O O
M O O
+ O O
/ O O
- O O
SE O O
) O O
, O O
with O O
a O O
geometric O O
mean O O
of O O
5 O O
IU O O
/ O O
1 O O
, O O
in O O
the O O
nine O O
remaining O O
evaluable O O
patients O O
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Ultrasound O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
biomicroscopy O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O O
a O O
useful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tool O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
evaluation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
APVR O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
which O O
is O O
difficult O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
ordinary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
methods O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

It O O
is O O
postulated O O
that O O
the O O
synthesis O O
of O O
the O O
peptidoglycan O O
layer O O
was O O
affected O O
by O O
the O O
antimetabolites O O
since O O
the O O
morphological O O
effects O O
were O O
strikingly O O
similar O O
to O O
those O O
caused O O
by O O
treatment O O
of O O
E O O
. O O
cloacae O O
with O O
disodium O O
edetate O O
plus O O
lysozyme B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O O

DRAP27 B B_GENE/B_DISEASE
is O O
recognized O O
by O O
CD9 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Furthermore O O
we O O
elucidate O O
the O O
subtle O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
highly O O
anisotropic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interchain O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
reveal O O
the O O
detailed O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
atomic O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
temperature O B_MEASURE
( O O
8x2 O B_PROTEIN[GENE]/B_LOCATION
) O O
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Control O O
oligomers O O
of O O
scrambled O O
sequence O O
but O O
identical O O
base O O
composition O O
were O O
ineffective O O
, O O
and O O
no O O
TFO O O
- O O
induced O O
recombination O O
was O O
seen O O
in O O
a O O
control O O
LTK O O
( O O
- O O
) O O
cell O O
line O O
carrying O O
an O O
otherwise O O
identical O O
dual O O
TK B B_GENE
gene I I_GENE
construct I I_GENE
lacking O O
the O O
30 O O
- O O
bp O O
polypurine O O
target O O
site O O
. O O

To O O
quantify O O
the O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coupling O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patterns O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
fresh O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
cadaveric O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
human O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
lumbar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
spine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
specimens O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
L1 O B_PROTEIN[GENE]
- O O
S1 O B_MEASURE/B_PROTEIN[GENE]
) O O
were O O
used O O
. O O

One O O
cytoplasmic O O
target O O
which O O
reflects O O
the O O
functional O O
state O O
of O O
the O O
plastids O O
is O O
protein B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
three O O
chromosomes O O
share O O
the O O
transferrin B B_GENE
gene I I_GENE
( O O
TF B B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
the O O
myosin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
light I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
polypeptide I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MYL3 B B_GENE/B_LOCATION
) O O
, O O
and O O
the O O
acylpeptide B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hydrolase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
APEH B B_LOCATION/B_DISEASE
) O O
. O O

( O O
i O O
) O O
Several O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ribosomal O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
synthesized O O
in O O
substantial O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
excess O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
experience O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
would O O
recommend O O
consideration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O O
home O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
nutritional O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
support O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
patients O B_PERSON/B_LOCATION
with O O
systemic O B_DISEASE
scleroderma O I_DISEASE
when O O
the O O
disease O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
is O O
relatively O O
stable O B_DISEASE_ADJECTIVE[DISEASE]
and O O
no O O
major O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
organ O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
failure O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Based O O
on O O
our O O
sequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
ORF2 O B_GENE/B_BIO
from O O
most O B_BIO/B_PROTEIN[GENE]
isolates O B_BIO/I_PROTEIN[GENE]
excluding O O
G1 O B_GENE/B_LOCATION
encode O I_GENE/I_LOCATION
truncated O O
49 O B_GENE
aa O I_GENE
( O O
pORF2a O B_PROTEIN[GENE]/B_LOCATION
) O O
because O O
of O O
an O O
in O O
- O O
frame O B_GENE/B_LOCATION
stop O B_GENE/I_LOCATION
codon O B_GENE/I_LOCATION
, O O
although O O
ORF2s O B_GENE/B_BIO
from O O
most O B_PROTEIN[GENE]/B_MEASURE
G1 O I_PROTEIN[GENE]/I_MEASURE
isolates O I_PROTEIN[GENE]/I_MEASURE
encode O O
202 O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
aa O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
pORF2ab O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

In O O
the O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
we O O
prospectively O O
compared O O
side O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occurring O O
in O O
12 O B_TIME[MEASURE]/B_PERSON
patients O B_TIME[MEASURE]/I_PERSON
after O O
the O O
first O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
administration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
low O B_NUMBER[MEASURE]/B_COLOR
- O O
dose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
OKT3 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
0 O B_MEASURE
. O O
5 O B_MEASURE
mg O I_MEASURE
twice O O
daily O B_TIME[MEASURE]/B_LOCATION
) O O
induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
with O O
those O O
in O O
10 O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
who O O
were O O
treated O O
with O O
a O O
conventional O B_MEASURE
dose O I_MEASURE
of O O
OKT3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
5 O B_NUMBER[MEASURE]/B_LOCATION
mg O I_NUMBER[MEASURE]/I_LOCATION
daily O O
) O O
for O O
acute O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rejection O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

These O O
data O O
indicate O O
that O O
SB O O
203580 O O
sensitive O O
p38 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
MAP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
not O O
involved O O
in O O
okadaic O O
acid O O
mediated O O
increases O O
in O O
TRE O O
DNA O O
binding O O
and O O
transactivation O O
. O O

Together O O
, O O
these O O
results O O
indicate O O
that O O
YTS1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
bifunctional O O
protein O O
active O O
in O O
both O O
splicing O O
and O O
protein O O
synthesis O O
. O O

Oscillatory O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flow O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
reestablished O O
in O O
the O O
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
at O O
the O O
capillary O B_BODY_PART_OR_ORGAN_COMPONENT
- O O
cerebrospinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluid O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
capillary O B_BODY_PART_OR_ORGAN_COMPONENT
- O O
venous O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
interfaces O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Sgs B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
one O O
of O O
the O O
eight O O
known O O
genes O O
coding O O
for O O
larval O O
secretion O O
proteins O O
in O O
Drosophila O O
melanogaster O O
. O O

We O O
conclude O O
that O O
although O O
the O O
G3 O B_GENE/B_LOCATION
sequence O I_GENE/I_LOCATION
contains O O
two O B_GENE
protein O I_GENE
- O O
binding O O
motifs O B_PERSON/B_LOCATION
, O O
the O O
organization O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
G3 O B_PROTEIN[GENE]
enhancer O I_PROTEIN[GENE]
- O O
like O B_LOCATION/B_PERSON
element O I_LOCATION/I_PERSON
is O O
not O O
bipartite O B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
. O O

Human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
myotonic I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dystrophy I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
DMPK B B_GENE/B_LOCATION
) O O
is O O
a O O
member O O
of O O
a O O
novel O O
class O O
of O O
multidomain O O
protein O O
kinases O O
that O O
regulate O O
cell O O
size O O
and O O
shape O O
in O O
a O O
variety O O
of O O
organisms O O
. O O

The O O
human B B_GENE/B_LOCATION
BRCA1 I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
also O O
contains O O
a O O
conserved O O
E2F B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
is O O
similarly O O
regulated O O
by O O
E2F1 B B_GENE
and O O
Rb B B_GENE
. O O

The O O
translated O O
sequence O O
of O O
the O O
FLI B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LRR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
associated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
FLAP B B_DISEASE/B_GENE
) O O
encodes O O
a O O
novel O O
protein O O
not O O
represented O O
in O O
the O O
data O O
base O O
. O O

Corticosteroid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
before O O
, O O
during O O
, O O
or O O
after O O
fludarabine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O O
patients O B_PERSON/B_LOCATION
with O O
alkylator O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
resistant O B_DISEASE_ADJECTIVE[DISEASE]
, O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
grade O B_DISEASE/B_MEASURE
lymphoid O I_DISEASE/I_MEASURE
malignancies O I_DISEASE/I_MEASURE
who O O
have O O
not O O
received O O
PCP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
prophylaxis O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
associated O O
with O O
an O O
increased O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
opportunistic O B_DISEASE
pulmonary O I_DISEASE
infections O I_DISEASE
. O O

In O O
this O O
respect O O
, O O
the O O
promoter O O
structure O O
of O O
COX B B_BIO/B_GENE
genes I I_BIO/I_GENE
resemble O O
those O O
of O O
many O O
house O O
- O O
keeping O O
genes O O
. O O

In O O
vitro O O
, O O
cytokine O O
- O O
or O O
hypoxia O O
- O O
induced O O
up O O
- O O
regulation O O
of O O
Fas B B_GENE
expression O O
is O O
associated O O
with O O
RTC O O
apoptosis O O
. O O

The O O
site O O
of O O
acetylation O O
of O O
Tat B B_GENE
was O O
mapped O O
to O O
the O O
double O O
- O O
lysine O O
motif O O
in O O
a O O
highly O O
conserved O O
region O O
, O O
( O O
49 O O
) O O
RKKRRQ O O
( O O
54 O O
) O O
, O O
of O O
the O O
basic O O
RNA O O
- O O
binding O O
motif O O
of O O
Tat B B_GENE/B_DISEASE
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O O
that O O
the O O
PVB O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
not O O
sufficient O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
cure O O
the O O
cases O B_PERSON/B_DISEASE
with O O
choriocarcinoma O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
element O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
or O O
bulky O B_DISEASE
metastasis O I_DISEASE
. O O

The O O
KEMAR O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurements O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O O
that O O
the O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
give O O
an O O
improvement O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
signal O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
to O O
- O O
noise O B_MEASURE
ratio O I_MEASURE
of O O
approximately O O
7 O B_MEASURE
. O O
5 O B_MEASURE/B_ORGANIZATION
dB O I_MEASURE/I_ORGANIZATION
in O O
a O O
diffuse O B_TIME[MEASURE]/B_LOCATION
sound O B_TIME[MEASURE]/I_LOCATION
field O B_TIME[MEASURE]/I_LOCATION
. O O

Indirect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
determination O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
maximal O B_GENE/B_MEASURE
O2 O I_GENE/I_MEASURE
consumption O I_GENE/I_MEASURE
in O O
man O B_PERSON/B_BIO
. O O

Using O O
unidirectional O O
PCR O O
we O O
isolated O O
a O O
361 O O
- O O
bp O O
5 O O
' O O
promoter O O
region O O
and O O
delineated O O
the O O
intronic O O
/ O O
exonic O O
boundaries O O
which O O
include O O
a O O
non O O
- O O
coding O O
exon O O
1 O O
, O O
a O O
single O O
intron O O
, O O
and O O
a O O
coding O O
exon O O
2 O O
, O O
a O O
structure O O
that O O
is O O
typical O O
of O O
genes O O
of O O
the O O
RNase B B_SPECIES[BIO]/B_GENE
A I I_SPECIES[BIO]/I_GENE
superfamily I I_SPECIES[BIO]/I_GENE
. O O

When O O
severe O O
hypoxia O O
was O O
acutely O O
produced O O
by O O
ventilation O O
with O O
low O O
- O O
oxygen O O
mixtures O O
in O O
experimental O O
( O O
PaO2 O O
, O O
23 O O
. O O
7 O O
+ O O
/ O O
- O O
1 O O
. O O
7 O O
torr O O
) O O
and O O
control O O
animals O O
( O O
PaO2 O O
, O O
26 O O
. O O
3 O O
+ O O
/ O O
- O O
1 O O
. O O
0 O O
torr O O
) O O
, O O
plasma B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
insulin I B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
responses O O
were O O
markedly O O
inhibited O O
in O O
both O O
. O O

Uptake O O
of O O
colicins B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
required O O
different O O
domains O O
in O O
TonB B B_BACTERIUM[BIO]/B_PROTEIN[GENE]
, O O
for O O
colicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
B I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
M I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
around O O
residue O O
160 O O
and O O
for O O
colicin B B_PROTEIN[GENE]/B_BIO
Ia I I_PROTEIN[GENE]/I_BIO
, O O
a O O
domain O O
closer O O
to O O
the O O
C O O
- O O
terminal O O
end O O
. O O

D O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

When O O
lipid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
X O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
combined O O
with O O
ticarcillin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
survival O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
differences O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
both O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
prolonged O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

Central O B_LOCATION/B_PERSON
treatment O I_LOCATION/I_PERSON
unit O I_LOCATION/I_PERSON
saves O O
nurses O B_PERSON/B_MEASURE
, O O
adds O O
income O B_ORGANIZATION/B_PERSON
, O O
improves O O
care O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Gold O B_MEASURE/B_PERSON
flaxseed O O
( O O
whole O B_TIME[MEASURE]/B_BIO
or O O
ground O B_BIO
) O O
fed O O
at O O
levels O B_MEASURE/B_GENE
of O O
5 O B_NUMBER[MEASURE]
or O O
15 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
were O O
compared O O
to O O
a O O
1 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
menhaden O I_MEASURE
oil O I_MEASURE
or O O
a O O
typical O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
control O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
layer O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
ration O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

It O O
is O O
dangerous O O
to O O
label O O
such O O
conditions O O
as O O
' O O
inappropriate O O
' O O
secretion O O
of O O
ADH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
since O O
the O O
maintenance O O
of O O
circulating O O
volume O O
is O O
at O O
least O O
as O O
important O O
a O O
physiological O O
requirement O O
as O O
the O O
defence O O
of O O
tonicity O O
. O O

The O O
complete O B_GENE/B_MEASURE
nucleotide O I_GENE/I_MEASURE
sequence O I_GENE/I_MEASURE
of O O
odontoglossum O B_SPECIES[BIO]
ringspot O I_SPECIES[BIO]
virus O I_SPECIES[BIO]
( O O
Cy O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_VIRUS[BIO]/B_PROTEIN[GENE]
strain O B_VIRUS[BIO]/I_PROTEIN[GENE]
) O O
genomic O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

An O O
enhancement O B_DISEASE_ADJECTIVE[DISEASE]
of O O
benign O B_DISEASE/B_MEASURE
liver O I_DISEASE/I_MEASURE
tumors O I_DISEASE/I_MEASURE
( O O
tumorigenic O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
was O O
observed O O
only O O
in O O
CF1 O B_MEASURE/B_PERSON
male O I_MEASURE/I_PERSON
mice O I_MEASURE/I_PERSON
( O O
17 O B_MEASURE
/ O O
56 O B_MEASURE
at O O
the O O
only O B_MEASURE/B_ORGANIZATION
tested O O
dose O B_MEASURE/B_LOCATION
: O O
400 O B_MEASURE/B_LOCATION
ppm O I_MEASURE/I_LOCATION
vs O I_MEASURE/I_LOCATION
. O O

Cells O O
were O O
cotransfected O O
with O O
this O O
plasmid O O
, O O
and O O
the O O
appropriate O O
responder O O
plasmids O O
and O O
clonies O O
were O O
selected O O
on O O
the O O
basis O O
of O O
their O O
resistance O O
to O O
Geneticin O O
( O O
via O O
the O O
neomycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
aminoglycoside I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphotransferase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

This O O
C O O
- O O
terminal O O
domain O O
contains O O
several O O
YxxI O O
/ O O
L O O
motifs O O
reminiscent O O
of O O
LMP2A B B_GENE/B_DISEASE
and O O
a O O
putative O O
TRAF B B_GENE/B_LOCATION
binding I B_GENE/I_LOCATION
site I B_GENE/I_LOCATION
as O O
in O O
LMP1 B B_SPECIES[BIO]/B_GENE
. O O

Omitting O O
part O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
of O O
the O O
experimental O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NOE O B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
derived O O
distances O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
reduced O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
restraint O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
violations O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
lower O B_DISEASE_ADJECTIVE[DISEASE]
R O I_DISEASE_ADJECTIVE[DISEASE]
factors O I_DISEASE_ADJECTIVE[DISEASE]
but O O
impairs O O
structural O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
convergence O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
rMD O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
refinement O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Cardiac O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lesion O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
exotoxic O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
shock O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO

Risk O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
factors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
atherosclerosis O B_DISEASE
related O O
to O O
nutrition O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
hypercholesterolemia O B_DISEASE
, O O
hyperglycemia O B_DISEASE
- O O
diabetes O B_DISEASE
, O O
and O O
for O O
hypertension O B_DISEASE/B_PERSON
, O O
obesity O B_DISEASE
, O O
high O B_DISEASE
salt O I_DISEASE
intake O I_DISEASE
, O O
and O O
excessive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
use O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
alcohol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

This O O
mutation O O
was O O
associated O O
with O O
reduced O O
or O O
absent O O
expression O O
of O O
TGF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RI I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
p53 B B_GENE
protein I I_GENE
in O O
tumor O O
tissues O O
. O O

SCAN B B_DISEASE
boxes O O
are O O
found O O
in O O
eight O O
other O O
genes O O
in O O
the O O
GenBank O O
database O O
, O O
five O O
of O O
which O O
are O O
also O O
in O O
the O O
Kruppel B B_PERSON/B_LOCATION
family I B_PERSON/I_LOCATION
of O O
zinc B B_PROTEIN[GENE]/B_BIO
finger I I_PROTEIN[GENE]/I_BIO
proteins I I_PROTEIN[GENE]/I_BIO
lacking O O
KRAB B B_GENE/B_MEASURE
A I I_GENE/I_MEASURE
and I I_GENE/I_MEASURE
B I I_GENE/I_MEASURE
domains O O
and O O
thereby O O
define O O
a O O
new O O
subclass O O
of O O
zinc B B_GENE/B_BIO
finger I I_GENE/I_BIO
proteins I I_GENE/I_BIO
. O O

However O O
, O O
they O O
had O O
no O O
cross O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
resistance O B_DISEASE/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
quinolone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
josamycin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
and O O
tylosin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Seventy O B_NUMBER[MEASURE]
- O O
nine O B_NUMBER[MEASURE]
percent O I_NUMBER[MEASURE]
of O O
the O O
children O B_PERSON
screened O O
and O O
91 O B_MEASURE
. O O
0 O B_NUMBER[MEASURE]
% O I_NUMBER[MEASURE]
of O O
the O O
children O B_PERSON
with O O
PbB O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
at O O
least O O
10 O B_MEASURE
micrograms O I_MEASURE
/ O O
dL O B_MEASURE/B_PROTEIN[GENE]
were O O
Hispanic O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Normal O B_PERSON
dogs O I_PERSON
were O O
exposed O O
to O O
either O O
10 O B_NUMBER[MEASURE]
, O O
15 O B_MEASURE
, O O
or O O
30 O B_MEASURE/B_PERSON
Gy O I_MEASURE/I_PERSON
of O O
X O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rays O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
a O O
single O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
hemisphere O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
gross O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
histopathologic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
evaluated O O
qualitatively O O
. O O

YACs O O
selected O O
from O O
our O O
contig O O
will O O
be O O
the O O
starting O O
point O O
for O O
the O O
cloning O O
of O O
the O O
LGMD2B B B_GENE/B_BIO
gene I I_GENE/I_BIO
and O O
thereby O O
establish O O
the O O
biological O O
basis O O
for O O
this O O
form O O
of O O
muscular O O
dystrophy O O
and O O
its O O
relationship O O
with O O
the O O
other O O
limb O O
- O O
girdle O O
muscular O O
dystrophies O O
. O O

The O O
amount O O
of O O
ERCC1 B B_GENE
detectable O O
by O O
immunoblotting O O
is O O
reduced O O
in O O
group O O
1 O O
, O O
group O O
4 O O
and O O
XP O O
- O O
F O O
extracts O O
. O O

In O O
the O O
plant B B_BODY_PART_OR_ORGAN_COMPONENT
malate I I_BODY_PART_OR_ORGAN_COMPONENT
synthases I I_BODY_PART_OR_ORGAN_COMPONENT
, O O
the O O
extension O O
is O O
probably O O
involved O O
in O O
routing O O
to O O
the O O
microbodies O O
, O O
since O O
it O O
contains O O
the O O
potential O O
peroxisomal O O
targeting O O
signal O O
, O O
Ser O O
- O O
Arg O O
/ O O
Lys O O
- O O
Leu O O
, O O
at O O
the O O
carboxy O O
terminus O O
. O O

Optimized O O
USF B B_LOCATION/B_GENE
and O O
MYC B B_GENE/B_MEASURE
DNA O O
- O O
binding O O
sites O O
, O O
which O O
differ O O
in O O
the O O
nucleotides O O
bordering O O
the O O
hexanucleotide O O
box O O
displace O O
the O O
E B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
C4 I I_GENE/I_MEASURE
factor I I_GENE/I_MEASURE
in O O
competition O O
assays O O
but O O
with O O
lesser O O
efficiency O O
than O O
the O O
E B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
C4 I I_GENE/I_MEASURE
site I I_GENE/I_MEASURE
itself O O
. O O

Screening O O
of O O
human O O
cDNA O O
libraries O O
has O O
identified O O
two O O
different O O
5 O O
' O O
- O O
termini O O
and O O
alternatively O O
spliced O O
forms O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Fli I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Fli B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1b I I_GENE/I_LOCATION
) O O
, O O
suggesting O O
the O O
possible O O
existence O O
of O O
two O O
independent O O
promoters O O
. O O

A O O
surge O O
in O O
the O O
rate O O
of O O
ascorbyl O O
radical O O
production O O
, O O
directly O O
correlated O O
with O O
oxyradical O O
stress O O
and O O
an O O
abrupt O O
fall O O
in O O
superoxide B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
dismutase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
in O O
the O O
granuloma O O
, O O
indicates O O
' O O
switching O O
on O O
' O O
of O O
a O O
free O O
radical O O
- O O
dependent O O
machinery O O
for O O
the O O
formation O O
of O O
granuloma O O
after O O
vasectomy O O
. O O

After O O
5 O O
- O O
h O O
thermal O O
induction O O
of O O
cells O O
carrying O O
the O O
runaway O O
recombinant O O
pBS1 O O
, O O
protein B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B2 I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
constituted O O
40 O O
% O O
of O O
the O O
soluble O O
protein O O
fraction O O
of O O
the O O
cells O O
. O O

A O O
regulatory O O
element O O
of O O
the O O
empty B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spiracles I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
homeobox O O
gene O O
is O O
composed O O
of O O
three O O
distinct O O
conserved O O
regions O O
that O O
bind O O
regulatory O O
proteins O O
. O O

Peak O B_DISEASE/B_PROTEIN[GENE]
reactive O B_DISEASE/I_PROTEIN[GENE]
hyperemia O B_DISEASE/I_PROTEIN[GENE]
( O O
mL O B_MEASURE/B_LOCATION
. O O
min O B_MEASURE/B_PERSON
- O O
1 O B_MEASURE/B_LOCATION
. O O
100 O B_MEASURE
mL O I_MEASURE
- O O
1 O B_MEASURE
) O O
was O O
determined O O
in O O
the O O
calf O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
forearm O B_BODY_PART_OR_ORGAN_COMPONENT
immediately O O
before O O
and O O
after O O
12 O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
of O O
training O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

These O O
characteristics O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
add O O
to O O
the O O
suitability O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
NM441 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
an O O
effective O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prodrug O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
NM394 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Vorozole O O
( O O
Rivizor O O
) O O
is O O
a O O
potent O O
and O O
stereospecific O O
inhibitor O O
of O O
aromatase B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
having O O
shown O O
promising O O
endocrine O O
effects O O
in O O
phase O O
I O O
studies O O
. O O

In O O
5 O B_MEASURE
cases O I_MEASURE
, O O
combined O O
sensitization O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
mercury O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
other O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metal O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
salts O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
particularly O O
gold O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thiosulfate O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
GST O B_LOCATION/B_DISEASE
) O O
and O O
palladium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloride O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PDC O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
was O O
observed O O
. O O

Gene O B_GENE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
structure O B_GENE/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
and O O
precursor O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
processing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
content O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
monoamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
metabolites O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
5 O B_NUMBER[MEASURE]
- O O
hydroxyindoleacetic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
acid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
5 O B_NUMBER[MEASURE]
- O O
HIAA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
homovanillic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
HVA O B_DISEASE/B_PROTEIN[GENE]
) O O
, O O
and O O
- O O
- O O
for O O
17 O B_PERSON/B_MEASURE
patients O I_PERSON/I_MEASURE
- O O
- O O
tryptophan O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
in O O
the O O
cerebrospinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluid O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
determined O O
. O O

One O B_TIME[MEASURE]/B_LOCATION
month O I_TIME[MEASURE]/I_LOCATION
after O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
131I O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
the O O
29 O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cats O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluated O O
were O O
clinically O O
improved O O
, O O
and O O
24 O B_MEASURE
( O O
83 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
of O O
the O O
29 O B_BIO/B_MEASURE
cats O I_BIO/I_MEASURE
evaluated O O
had O O
normal O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serum O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T4 O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
3 O B_MEASURE/B_ENT
cats O I_MEASURE/I_ENT
( O O
10 O B_MEASURE
% O I_MEASURE
) O O
remained O O
hyperthyroxinemic O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
2 O B_NUMBER[MEASURE]/B_ENT
cats O I_NUMBER[MEASURE]/I_ENT
( O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
were O O
hypothyroxinemic O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
findings O O
suggest O O
that O O
T3R B B_GENE
can O O
repress O O
or O O
activate O O
transcription O O
while O O
tethered O O
to O O
the O O
LBD O O
of O O
GAL4 B B_PROTEIN[GENE]/B_SPECIES[BIO]
- O O
RXR B B_GENE
and O O
that O O
heterodimerization O O
can O O
occur O O
in O O
vivo O O
without O O
stabilization O O
by O O
hormone O O
response O O
elements O O
. O O

Most O O
interestingly O O
, O O
although O O
the O O
effector O O
plasmid O O
containing O O
the O O
ICP27 B B_GENE
gene I I_GENE
had O O
little O O
effect O O
on O O
its O O
own O O
, O O
two O O
different O O
and O O
marked O O
effects O O
depending O O
on O O
the O O
target O O
were O O
observed O O
when O O
ICP27 B B_GENE
was O O
combined O O
with O O
ICP4 B B_GENE
or O O
ICP0 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
both O O
. O O

In O O
renal O B_MEASURE
vein O I_MEASURE
thrombosis O I_MEASURE
, O O
similar O B_DISEASE_ADJECTIVE[DISEASE]
pattern O I_DISEASE_ADJECTIVE[DISEASE]
to O O
acute O B_DISEASE
tubular O I_DISEASE
necrosis O I_DISEASE
was O O
found O O
but O O
RI O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
venography O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
helpful O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

TOM1 B B_GENE/B_PERSON
encodes O O
a O O
member O O
of O O
the O O
hect B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
domain O O
- O O
containing O O
E3 B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
ubiquitin B I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
ligase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
family O O
that O O
is O O
required O O
for O O
growth O O
at O O
elevated O O
temperatures O O
. O O

Genomic O O
clones O O
containing O O
the O O
C O O
. O O
briggsae O O
gene O O
are O O
able O O
to O O
completely O O
rescue O O
the O O
unc B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
119 I I_DISEASE/I_GENE
phenotype I I_DISEASE/I_GENE
in O O
transgenic O O
C O O
. O O
elegans O O
mutants O O
. O O

The O O
rapid O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decrease O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
plasma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
potassium O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
during O O
the O O
first O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
two O B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hours O B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
standard O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
HD O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
causes O O
a O O
membrane O B_DISEASE
hyperpolarization O I_DISEASE
. O O

Region O O
- O O
specific O O
enhancers O O
near O O
two O O
mammalian B B_GENE/B_LOCATION
homeo I I_GENE/I_LOCATION
box I I_GENE/I_LOCATION
genes I I_GENE/I_LOCATION
define O O
adjacent O O
rostrocaudal O O
domains O O
in O O
the O O
central O O
nervous O O
system O O
. O O

In O O
this O O
study O O
, O O
we O O
report O O
the O O
cloning O O
and O O
sequencing O O
of O O
several O O
overlapping O O
cDNAs O O
encoding O O
approximately O O
4 O O
. O O
1 O O
kb O O
of O O
the O O
human B B_GENE
homologue I I_GENE
of I I_GENE
Wnt I I_GENE
- I I_GENE
5A I I_GENE
. O O

Subtype O O
- O O
and O O
response O O
element O O
- O O
dependent O O
differences O O
in O O
transactivation O O
by O O
peroxisome B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proliferator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

MRI O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
visualization O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
proteoglycan O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
depletion O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
articular O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
cartilage O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
via O O
intravenous O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
Gd O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
DTPA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

We O O
then O O
developed O O
a O O
yeast O B_GENE
artificial O I_GENE
chromosome O I_GENE
( O O
YAC O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
contig O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
this O O
region O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

We O O
suggest O O
that O O
the O O
induction O O
of O O
IFNA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
requires O O
cooperation O O
between O O
alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
F1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
IRF B B_GENE
- I I_GENE
1 I I_GENE
. O O

Heterologous O O
hybridization O O
with O O
a O O
rps12 B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
gene I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
specific O O
probe O O
from O O
Euglena O O
has O O
revealed O O
the O O
presence O O
of O O
rps12 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
homologous I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sequences I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
within O O
the O O
inverted O O
repeat O O
of O O
Spirodela O O
chloroplast O O
DNA O O
on O O
the O O
fragment B B_GENE
BamHI I I_GENE
- I I_GENE
V I I_GENE
. O O

To O O
investigate O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hyperthyroidism O B_DISEASE
on O O
the O O
pattern O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
time O B_MEASURE
course O I_MEASURE
of O O
O2 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
uptake O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
VO2 O B_PROTEIN[GENE]
) O O
following O O
the O O
transition O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
rest O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
exercise O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
six O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
and O O
six O B_PERSON
healthy O I_PERSON
subjects O I_PERSON
performed O O
cycle O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exercise O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
at O O
an O O
average O B_MEASURE/B_LOCATION
work O I_MEASURE/I_LOCATION
rate O I_MEASURE/I_LOCATION
( O O
WR O B_PROTEIN[GENE]/B_DISEASE
) O O
of O O
18 O B_MEASURE
and O O
20 O B_MEASURE/B_LOCATION
W O I_MEASURE/I_LOCATION
respectively O O
. O O

However O O
, O O
to O O
date O B_TIME[MEASURE]/B_PERSON
, O O
no O O
viable O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
generated O O
deletion O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mutant O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
PSTVd O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
been O O
reported O O
. O O

This O O
raises O O
the O O
possibility O O
that O O
recombination O O
occurred O O
between O O
corresponding O O
LTR O O
and O O
vif B B_PERSON/B_NUMBER[MEASURE]
loci I B_PERSON/I_NUMBER[MEASURE]
of O O
the O O
quasi O O
- O O
species O O
present O O
in O O
the O O
isolates O O
described O O
here O O
. O O

In O O
HMEC O O
stably O O
transfected O O
with O O
an O O
ER B B_GENE
mutant I I_GENE
containing O O
a O O
deletion O O
in O O
the O O
second O O
zinc O O
finger O O
of O O
the O O
DNA O O
- O O
binding O O
domain O O
, O O
E O O
and O O
HT O O
had O O
different O O
effects O O
on O O
EBBP B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
expression O O
; O O
EBBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulation O O
by O O
E O O
was O O
dramatically O O
reduced O O
while O O
the O O
effects O O
of O O
HT O O
were O O
augmented O O
. O O

The O O
gene B B_GENE
atp6 I I_GENE
, O O
encoding O O
subunit O O
6 O O
of O O
the O O
mitochondrial O O
F0 B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
ATPase B B_PROTEIN[GENE]/B_MEASURE
complex O O
, O O
has O O
been O O
characterized O O
from O O
both O O
the O O
normal O O
( O O
fertile O O
) O O
and O O
Ogura O O
( O O
male O O
- O O
sterile O O
) O O
radish O O
cytoplasms O O
in O O
order O O
to O O
determine O O
if O O
previously O O
identified O O
atp6 B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
transcriptional O O
differences O O
could O O
play O O
a O O
role O O
in O O
cytoplasmic O O
male O O
sterility O O
. O O

When O O
the O O
same O B_MEASURE
single O I_MEASURE
- O O
amino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
acid O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutations O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
directly O O
introduced O O
into O O
the O O
parental O B_PROTEIN[GENE]/B_DISEASE
PV O I_PROTEIN[GENE]/I_DISEASE
/ O O
CBV4 O B_PROTEIN[GENE]/B_LOCATION
- O O
2A O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genome O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
chimeric O B_BIO/B_DISEASE
viruses O I_BIO/I_DISEASE
with O O
a O O
large O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O O
plaque O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
phenotype O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
a O O
wild O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- O O
type O B_DISEASE_ADJECTIVE[DISEASE]/B_VIRUS[BIO]
PV O B_DISEASE_ADJECTIVE[DISEASE]/I_VIRUS[BIO]
- O O
like O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pattern O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
obtained O O
upon O O
transfection O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
an O O
observation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrating O O
that O O
these O O
point O B_DISEASE_ADJECTIVE[DISEASE]
mutations O I_DISEASE_ADJECTIVE[DISEASE]
alone O O
had O O
a O O
drastic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
growth O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
PV O B_DISEASE/B_PROTEIN[GENE]
/ O O
CBV4 O B_LOCATION/B_DISEASE
chimeric O I_LOCATION/I_DISEASE
virus O I_LOCATION/I_DISEASE
. O O

The O O
gag B B_GENE/B_LOCATION
- O O
myc B B_BACTERIUM[BIO]/B_GENE
proteins O O
encoded O O
by O O
these O O
variants O O
efficiently O O
localized O O
to O O
the O O
cell O O
nucleus O O
. O O

Hpr1 B B_PERSON/B_LOCATION
forms O O
, O O
together O O
with O O
Tho2 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Mft1 B B_GENE/B_LOCATION
, O O
and O O
Thp2 B B_GENE/B_PERSON
, O O
the O O
THO B B_LOCATION
complex I I_LOCATION
, O O
which O O
controls O O
transcription O O
elongation O O
and O O
genome O O
stability O O
in O O
Saccharomyces O O
cerevisiae O O
. O O

UPR O O
elements O O
present O O
in O O
other O O
ER O O
chaperone O O
genes O O
, O O
such O O
as O O
yeast B B_GENE
KAR2 I I_GENE
( O O
BiP B B_GENE/B_LOCATION
) O O
, O O
mammalian B B_GENE/B_DISEASE
GRP78 I I_GENE/I_DISEASE
( O O
BiP B B_GENE/B_DISEASE
) O O
, O O
and O O
GRP94 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
function O O
in O O
an O O
analogous O O
manner O O
to O O
that O O
in O O
FKB2 B B_GENE/B_BIO
. O O

The O O
objective O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
this O O
research O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
to O O
determine O O
if O O
ergotamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
an O O
ergopeptine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alkaloid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
isolated O O
from O O
Neotyphodium O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
infected O O
grasses O B_SPECIES[BIO]
and O O
associated O O
with O O
toxicoses O B_DISEASE/B_ORGANISM_FUNCTION
in O O
livestock O B_SPECIES[BIO]
, O O
altered O O
plasma O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
reproductive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormones O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
follicular O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
phase O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
heifers O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
in O O
cows O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
given O O
a O O
progestin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
implant O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Acute O B_DISEASE_ADJECTIVE[DISEASE]
spontaneous O I_DISEASE_ADJECTIVE[DISEASE]
subdural O I_DISEASE_ADJECTIVE[DISEASE]
haematoma O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Strains O O
carrying O O
a O O
snf1 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
are O O
unable O O
to O O
grow O O
on O O
sucrose O O
, O O
galactose O O
, O O
maltose O O
, O O
melibiose O O
, O O
or O O
nonfermentable O O
carbon O O
sources O O
; O O
utilization O O
of O O
these O O
carbon O O
sources O O
is O O
regulated O O
by O O
glucose O O
repression O O
. O O

2 O O
) O O
Depending O O
on O O
the O O
structure O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
certain O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
compounds O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
are O O
sequestered O O
in O O
the O O
cornea O B_BODY_PART_OR_ORGAN_COMPONENT
( O O
presumably O O
the O O
stroma O B_BODY_PART_OR_ORGAN_COMPONENT
) O O
and O O
form O O
a O O
release O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O O
the O O
anterior O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
aqueous O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
results O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
neural O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
network O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
compared O O
with O O
those O O
of O O
a O O
density O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
mask O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
thresholds O B_MEASURE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
- O O
750 O B_MEASURE
/ O O
- O O
300 O B_MEASURE
H O I_MEASURE
) O O
, O O
with O O
a O O
radiologist O B_PERSON/B_MEASURE
serving O B_PERSON/I_MEASURE
as O O
the O O
gold O B_PERSON
standard O I_PERSON
. O O

These O O
data O O
also O O
suggest O O
the O O
existence O O
of O O
a O O
mechanism O O
by O O
which O O
regulatory O O
subunits O O
modulate O O
the O O
PI B B_GENE
3 I I_GENE
- I I_GENE
kinase I I_GENE
- O O
mediated O O
signals O O
, O O
independent O O
of O O
the O O
kinase O O
activity O O
, O O
possibly O O
through O O
subcellular O O
localization O O
of O O
the O O
catalytic O O
subunit O O
or O O
interaction O O
with O O
additional O O
signaling O O
molecules O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O O
that O O
the O O
PVB O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
not O O
sufficient O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
cure O O
the O O
cases O B_PERSON/B_DISEASE
with O O
choriocarcinoma O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
element O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
or O O
bulky O B_DISEASE
metastasis O I_DISEASE
. O O

Right O O
- O O
sided O O
hemiplegia O B_DISEASE
of O O
5 O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
years O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
duration O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
occurred O O
in O O
the O O
remaining O O
case O B_PERSON
. O O

Plasmid O O
subclones O O
of O O
the O O
hr1a B B_GENE/B_SPECIES[BIO]
- O O
containing O O
AcMNPV O O
HindIII B B_MEASURE/B_PROTEIN[GENE]
- O O
N O O
fragment O O
were O O
examined O O
for O O
their O O
ability O O
to O O
replicate O O
in O O
virus O O
- O O
infected O O
( O O
Spodoptera O O
frugiperda O O
) O O
Sf9 O O
cells O O
, O O
and O O
to O O
stimulate O O
transcription O O
when O O
linked O O
in O O
cis O O
with O O
a O O
39K B B_GENE
gene I I_GENE
promoter I I_GENE
- I I_GENE
beta I I_GENE
- I I_GENE
glucuronidase I I_GENE
fusion I I_GENE
and O O
cotransfected O O
into O O
cells O O
along O O
with O O
a O O
plasmid O O
( O O
ple O O
- O O
1 O O
) O O
containing O O
the O O
gene O O
encoding O O
the O O
trans O O
- O O
acting O O
factor O O
IE B B_GENE
- I I_GENE
1 I I_GENE
. O O

Transfection O O
of O O
H B B_NUMBER[MEASURE]/B_PERSON
chain I I_NUMBER[MEASURE]/I_PERSON
loss I I_NUMBER[MEASURE]/I_PERSON
variant I I_NUMBER[MEASURE]/I_PERSON
myeloma O O
with O O
the O O
complete O O
12 O O
kb O O
construct O O
, O O
termed O O
238H B B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Cmicro I I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
resulted O O
in O O
secretion O O
of O O
intact O O
Ig O O
pairing O O
238H B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Cmicro I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
with O O
a O O
lambda B B_GENE
L I I_GENE
chain I I_GENE
; O O
however O O
, O O
transfectant B B_GENE/B_BIO
Ig I I_GENE/I_BIO
lacked O O
autoreactivity O O
and O O
pathogenicity O O
. O O

Divergent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
regions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
posterior O B_BODY_PART_OR_ORGAN_COMPONENT
left O O
hemisphere O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
used O O
for O O
decoding O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
storage O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O O
information O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
emerged O O
in O O
each O O
working O O
memory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
versus O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
task O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
comparison O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

In O O
normal O O
B O O
cells O O
stimulated O O
by O O
LPS O O
or O O
IL B B_LOCATION/B_GENE
- I I_LOCATION/I_GENE
4 I I_LOCATION/I_GENE
, O O
new O O
complexes O O
appear O O
that O O
bind O O
to O O
C B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EBP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
NF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
elements I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
respectively O O
, O O
located O O
within O O
the O O
- O O
125 O O
/ O O
- O O
101 O O
region O O
. O O

Here O O
, O O
we O O
describe O O
the O O
crystal O O
structure O O
at O O
2 O O
. O O
5 O O
A O O
resolution O O
of O O
a O O
fragment O O
of O O
the O O
integrase B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
of I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Rous I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sarcoma I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
residues I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
49 I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
286 I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
containing O O
both O O
the O O
conserved O O
catalytic O O
domain O O
and O O
a O O
modulatory O O
DNA O O
- O O
binding O O
domain O O
( O O
C O O
domain O O
) O O
. O O

Vectorcardiography O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
coronary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
patients O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O O
the O O
electrocardiographic O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RS O B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
segment O B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
V1 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
lead O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION

The O O
B B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
aphidicola I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
argS I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
rrn I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fragments I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
endosymbionts O O
from O O
seven O O
species O O
of O O
aphids O O
had O O
promoter O O
activities O O
in O O
E O O
. O O
coli O O
which O O
ranged O O
from O O
6 O O
to O O
135 O O
% O O
of O O
that O O
observed O O
with O O
a O O
comparable O O
DNA O O
fragment O O
of O O
E B B_BIO/B_GENE
. I I_BIO/I_GENE
coli I I_BIO/I_GENE
rrnB I I_BIO/I_GENE
. O O

The O O
adeno O O
- O O
associated O O
virus O O
type O O
2 O O
( O O
AAV O O
- O O
2 O O
) O O
Rep78 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
Rep68 B B_MEASURE/B_GENE
regulatory O O
proteins O O
are O O
pleiotropic O O
effectors O O
of O O
viral O O
and O O
cellular O O
DNA O O
replication O O
, O O
of O O
cellular O O
transformation O O
by O O
viral O O
and O O
cellular O O
oncogenes O O
, O O
and O O
of O O
homologous O O
and O O
heterologous O O
gene O O
expression O O
. O O

Role O O
of O O
the O O
CCAAT B B_GENE
/ I I_GENE
enhancer I I_GENE
binding I I_GENE
protein I I_GENE
- I I_GENE
alpha I I_GENE
transcription I I_GENE
factor I I_GENE
in O O
the O O
glucocorticoid O O
stimulation O O
of O O
p21waf1 B B_GENE
/ O O
cip1 B B_GENE/B_DISEASE
gene O O
promoter O O
activity O O
in O O
growth O O
- O O
arrested O O
rat O O
hepatoma O O
cells O O
. O O

Long O B_SEQUENCE[MEASURE]/B_PERSON
- O O
term O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ambulatory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measurement O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
transcutaneous O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
arterial O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
CO2 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
pressure O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
PCO2 O B_DISEASE/B_LOCATION
) O O
offers O O
an O O
opportunity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
test O O
directly O O
the O O
co O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
occurrence O B_DISEASE/B_PROTEIN[GENE]
of O O
panic O B_DISEASE
and O O
hyperventilation O B_DISEASE
under O O
natural O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
conditions O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
highly O O
conserved O O
region O O
of O O
U6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
snRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O O
a O O
structural O O
similarity O O
with O O
the O O
catalytic O O
domain O O
of O O
the O O
negative O O
strand O O
of O O
the O O
satellite O O
RNA O O
of O O
tobacco O O
ring O O
spot O O
virus O O
[ O O
( O O
- O O
) O O
sTRSV O O
] O O
, O O
suggesting O O
that O O
the O O
highly O O
conserved O O
region O O
of O O
U6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
snRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
forms O O
the O O
catalytic O O
center O O
. O O

Here O O
we O O
show O O
that O O
one O O
nudF B B_GENE
suppressor I I_GENE
also O O
suppresses O O
hs O O
- O O
mutations O O
in O O
nudA B B_GENE/B_DISEASE
, O O
nudC B B_DISEASE/B_PROTEIN[GENE]
, O O
and O O
nudG B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
deletions O O
in O O
nudA B B_LOCATION/B_ORGANIZATION
and O O
nudF B B_PROTEIN[GENE]/B_LOCATION
. O O

Treatment O O
of O O
cells O O
for O O
10 O O
min O O
with O O
TNF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
resulted O O
in O O
activation O O
of O O
p44 B B_GENE
/ I I_GENE
42 I I_GENE
MAPK O O
, O O
p38 B B_GENE/B_LOCATION
, O O
and O O
JNK B B_GENE
. O O

This O O
report O O
describes O O
the O O
isolation O O
and O O
recombinant O O
expression O O
of O O
a O O
cDNA O O
clone O O
encoding O O
HER4 B B_GENE
, O O
the O O
fourth O O
member O O
of O O
the O O
human B B_GENE
epidermal I I_GENE
growth I I_GENE
factor I I_GENE
receptor I I_GENE
( O O
EGFR B B_GENE/B_LOCATION
) O O
family O O
. O O

In O O
conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
when O O
pulmonary O B_DISEASE/B_LOCATION
abnormalities O I_DISEASE/I_LOCATION
are O O
found O O
in O O
HTLV O B_DISEASE/B_VIRUS[BIO]
- O O
1 O B_MEASURE/B_PERSON
carriers O I_MEASURE/I_PERSON
, O O
we O O
should O O
be O O
careful O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
determining O O
whether O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
pulmonary O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
involvements O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O O
etiologically O O
related O O
to O O
HTLV O B_DISEASE/B_VIRUS[BIO]
- O O
1 O B_DISEASE/B_PROTEIN[GENE]
infection O B_DISEASE/I_PROTEIN[GENE]
. O O

A O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
new O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mitomycin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
C O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
derivative O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
KW O B_MEASURE/B_PROTEIN[GENE]
- O O
2083 O B_MEASURE
( O O
7 O B_MEASURE
- O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
( O O
p O B_OTHER/B_MEASURE
- O O
hydroxyphenyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
- O O
mitomycin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O

Excess O O
recombinant B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PTB I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
squelches O O
the O O
splicing O O
switch O O
and O O
reestablishes O O
exon O O
skipping O O
as O O
the O O
predominant O O
splicing O O
pathway O O
. O O

A O O
child O O
presumed O O
to O O
have O O
the O O
21 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydroxylase I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deficiency O O
form O O
of O O
congenital O O
adrenal O O
hyperplasia O O
was O O
studied O O
extensively O O
as O O
an O O
infant O O
. O O

Sixtieth O O
anniversary O O
of O O
Angiotensin B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

Inability O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
niacin O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
protect O O
from O O
in O O
vivo O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hyperoxia O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
in O O
vitro O B_DISEASE
microsomal O I_DISEASE
lipid O I_DISEASE
peroxidation O I_DISEASE
. O O

MDA O O
- O O
MB O O
- O O
468 O O
cells O O
were O O
stably O O
transfected O O
with O O
either O O
a O O
plasmid O O
having O O
a O O
CMV B B_GENE
promoter I I_GENE
- O O
driven O O
rabbit B B_GENE
beta I I_GENE
- I I_GENE
globin I I_GENE
gene I I_GENE
or O O
plasmids O O
having O O
a O O
CMV B B_GENE
promoter I I_GENE
- O O
driven O O
chimeric O O
gadd45 B B_GENE/B_SPECIES[BIO]
5 O O
" O O
- O O
UTR O O
- O O
rabbit B B_GENE
beta I I_GENE
- I I_GENE
globin I I_GENE
gene O O
, O O
where O O
the O O
entire B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gadd45 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
5 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
" I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
UTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
+ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
+ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
298 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or O O
a O O
45 O O
bp O O
subfragment O O
of O O
the O O
gadd45 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
5 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
" I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
UTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
+ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
10 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
+ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
55 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
positioned O O
at O O
the O O
5 O O
" O O
- O O
end O O
of O O
the O O
rabbit B B_GENE
beta I I_GENE
- I I_GENE
globin I I_GENE
gene I I_GENE
. O O

The O O
University O B_LOCATION/B_ORGANIZATION
of O O
North O B_LOCATION
Carolina O I_LOCATION
caries O I_LOCATION
risk O I_LOCATION
assessment O I_LOCATION
was O O
conducted O O
between O O
1986 O B_MEASURE
and O O
1989 O B_MEASURE
with O O
5000 O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
children O B_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
initially O O
in O O
grades O B_LOCATION/B_PERSON
1 O I_LOCATION/I_PERSON
and O O
5 O B_NUMBER[MEASURE]
from O O
low O B_LOCATION/B_PERSON
fluoride O I_LOCATION/I_PERSON
sites O I_LOCATION/I_PERSON
in O O
South O B_LOCATION
Carolina O I_LOCATION
and O O
Maine O B_LOCATION
. O O

Following O O
EGF B B_GENE
or O O
NGF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulation O O
of O O
the O O
v O O
- O O
CrkPC12 O O
cells O O
, O O
the O O
v B B_GENE
- I I_GENE
Crk I I_GENE
protein O O
itself O O
became O O
tyrosine O O
phosphorylated O O
within O O
1 O O
min O O
. O O

BCR B B_GENE/B_LOCATION
- O O
ABL B B_PROTEIN[GENE]/B_LOCATION
expression O O
confers O O
cross O O
- O O
resistance O O
to O O
multiple O O
genotoxic O O
anticancer O O
drugs O O
by O O
inhibition O O
of O O
the O O
apoptotic O O
response O O
to O O
DNA O O
damage O O
in O O
association O O
with O O
cell O O
cycle O O
arrest O O
at O O
the O O
G2 O O
- O O
M O O
restriction O O
point O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
After O O
lavage O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
a O O
rapid O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decrease O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
arterial O B_DISEASE
pH O I_DISEASE
and O O
PaO2 O B_MEASURE/B_LOCATION
, O O
and O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
PaCO2 O B_DISEASE/B_PROTEIN[GENE]
and O O
PIP O B_DISEASE/B_PROTEIN[GENE]
were O O
observed O O
in O O
all O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CONCLUSIONS O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Elevation O B_DISEASE_ADJECTIVE[DISEASE]
of O O
TBARS O B_GENE
and O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
GSH O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
show O O
the O O
presence O B_DISEASE_ADJECTIVE[DISEASE]
of O O
oxidative O B_DISEASE/B_GENE
stress O I_DISEASE/I_GENE
during O O
the O O
PFD O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
hemodiafilter O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
SG3 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Ozone O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
uptake O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
assessed O O
in O O
awake O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
spontaneously O O
breathing O O
Fischer O B_PERSON/B_LOCATION
- O O
344 O B_PERSON/B_MEASURE
Sprague O I_PERSON/I_MEASURE
- O O
Dawley O B_PERSON
, O O
and O O
Long O B_PERSON
- O O
Evans O B_PERSON/B_LOCATION
rats O I_PERSON/I_LOCATION
and O O
Hartley O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
guinea O B_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pigs O B_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
provide O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O O
the O O
dosimetry O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
O3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
small O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
laboratory O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
animals O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

E O O
. O O
R O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
C O B_OTHER/B_PROTEIN[GENE]
. O O
P O B_OTHER/B_LOCATION
. O O

is O O
an O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
advance O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
diagnosis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Deletion O O
analysis O O
of O O
the O O
3 O O
. O O
5kb O O
DNA O O
fragment O O
revealed O O
that O O
the O O
region O O
between O O
- O O
125 O O
to O O
+ O O
1 O O
, O O
containing O O
a O O
single O O
Sp1 B B_GENE
binding I I_GENE
site I I_GENE
, O O
is O O
essential O O
for O O
transcription O O
of O O
the O O
embigin B B_GENE
gene I I_GENE
. O O

Resistance O B_PERSON/B_DISEASE
to O O
Mup O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
was O O
classified O O
as O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
minimal O B_LOCATION/B_MEASURE
inhibitory O I_LOCATION/I_MEASURE
concentration O I_LOCATION/I_MEASURE
[ O I_LOCATION/I_MEASURE
MIC O I_LOCATION/I_MEASURE
] O O
> O B_MEASURE/B_OTHER
or O O
= O O
8 O B_MEASURE
microg O I_MEASURE
/ O O
mL O B_MEASURE/B_LOCATION
) O O
or O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
( O O
MIC O B_MEASURE/B_LOCATION
> O I_MEASURE/I_LOCATION
or O O
= O O
512 O B_MEASURE
microg O I_MEASURE
/ O O
mL O B_MEASURE/B_LOCATION
) O O
degree O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Extragonadal O B_DISEASE/B_PERSON
endodermal O I_DISEASE/I_PERSON
sinus O I_DISEASE/I_PERSON
tumors O I_DISEASE/I_PERSON
in O O
the O O
head O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
neck O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
are O O
very O O
rare O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

Lesions O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
kind O B_LOCATION
resemble O O
those O O
in O O
vitamin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
A O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
deficient O B_DISEASE
chickens O I_DISEASE
and O O
are O O
the O O
first O B_SEQUENCE[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
be O O
induced O O
by O O
excess O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
vitamin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
E O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Essential O B_DISEASE
fatty O I_DISEASE
acid O I_DISEASE
deficiency O I_DISEASE
in O O
childhood O B_PERSON/B_DISEASE

The O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O O
GF O O
- O O
109203X O O
abolished O O
the O O
activation O O
by O O
phorbol O O
ester O O
and O O
inhibited O O
the O O
effect O O
of O O
CCK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
by O O
78 O O
% O O
but O O
had O O
no O O
effect O O
on O O
EGF B B_GENE
- O O
activated O O
MAPK B B_GENE
activity O O
. O O

Activated O O
FGFR3 B B_GENE/B_LOCATION
predominantly O O
interacts O O
with O O
GRB2 B B_GENE
. I I_GENE
Sos I I_GENE
in O O
complex O O
with O O
a O O
previously O O
identified O O
90 O O
- O O
kDa O O
protein O O
and O O
designated O O
protein B B_GENE
80K I I_GENE
- I I_GENE
H I I_GENE
. O O

The O O
rate O O
of O O
collagen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
synthesis O O
in O O
normal O O
scar O O
was O O
approximately O O
constant O O
between O O
6 O O
months O O
and O O
20 O O
years O O
after O O
the O O
initial O O
wounding O O
, O O
but O O
in O O
both O O
hypertrophic O O
scar O O
and O O
keloid O O
the O O
rate O O
was O O
initially O O
approximately O O
twice O O
that O O
in O O
normal O O
scar O O
, O O
and O O
2 O O
- O O
3 O O
years O O
after O O
wounding O O
it O O
fell O O
to O O
approximately O O
the O O
same O O
level O O
as O O
in O O
normal O O
scar O O
. O O

Evidence O O
for O O
a O O
role O O
of O O
Smad6 B B_GENE
in O O
chick O O
cardiac O O
development O O
. O O

Excellent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
recorded O O
in O O
390 O B_MEASURE
( O O
83 O B_MEASURE
. O O
69 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
of O O
the O O
patients O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
improvement O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
in O O
46 O B_MEASURE
( O O
9 O B_MEASURE
. O O
87 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
where O O
in O O
the O O
majority O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O O
varicose O B_PERSON/B_DISEASE
complex O I_PERSON/I_DISEASE
was O O
involved O O
. O O

Mutational O O
analysis O O
of O O
yeast B B_GENE/B_BIO
CEG1 I I_GENE/I_BIO
demonstrated O O
that O O
four O O
of O O
the O O
five O O
conserved O O
motifs O O
are O O
essential O O
for O O
capping B B_GENE/B_LOCATION
enzyme I I_GENE/I_LOCATION
function O O
in O O
vivo O O
. O O

We O O
report O O
on O O
a O O
case O B_PERSON/B_DISEASE
discovered O O
in O O
a O O
13 O B_TIME[MEASURE]/B_PERSON
year O I_TIME[MEASURE]/I_PERSON
- O O
old O B_PERSON
girl O I_PERSON
presenting O O
with O O
anaemia O B_DISEASE
. O O

The O O
LIF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appeared O O
to O O
be O O
released O O
by O O
the O O
patient O O
' O O
s O O
peripheral O O
blood O O
lymphocytes O O
when O O
cultured O O
with O O
optimal O O
doses O O
of O O
propranolol O O
. O O

STUDY O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
SELECTION O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O O
Not O O
applicable O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Co O O
- O O
expression O O
of O O
PLD1 B B_GENE
in O O
COS O O
- O O
7 O O
cells O O
with O O
the O O
two O O
recombinant B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
CK2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
subunits I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
alpha O O
or O O
beta O O
, O O
suggests O O
that O O
the O O
association O O
of O O
PLD1 B B_GENE
with O O
the O O
kinase O O
is O O
through O O
the O O
beta O O
subunit O O
. O O

For O O
capsules O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O O
only O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
the O O
value O B_MEASURE
of O O
T50 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
increased O O
as O O
the O O
particle O B_MEASURE/B_DISEASE
size O I_MEASURE/I_DISEASE
of O O
the O O
drug O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
decreased O O
. O O

The O O
LAB O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
the O O
cecum O B_LOCATION/B_BACTERIUM[BIO]
( O O
mean O B_MEASURE
9 O I_MEASURE
. O O
4 O B_MEASURE
log O I_MEASURE
CFU O I_MEASURE
/ O O
g O B_OTHER/B_MEASURE
) O O
increased O O
slightly O O
with O O
increasing O O
abattoir O B_MEASURE/B_LOCATION
holding O I_MEASURE/I_LOCATION
time O I_MEASURE/I_LOCATION
. O O

Our O O
objective O O
was O O
to O O
find O O
possible O O
predictors O O
for O O
the O O
expression O O
and O O
progression O O
of O O
LJM O O
and O O
to O O
evaluate O O
the O O
relationship O O
between O O
LJM O O
and O O
other O O
long O O
- O O
term O O
complications O O
of O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
dependent O O
diabetes O O
mellitus O O
. O O

Human B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
recombinant I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
erythropoietin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
r B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
HuEPO I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
EprexR B B_MEASURE/B_PROTEIN[GENE]
) O O
was O O
administered O O
to O O
8 O O
children O O
with O O
chronic O O
renal O O
failure O O
and O O
high O O
transfusion O O
requirement O O
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
LHB O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
simple O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
easy O B_DISEASE_ADJECTIVE[DISEASE]
and O O
safe O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
implement O O
, O O
and O O
is O O
the O O
only O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
technique O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
capable O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
maintaining O O
independent O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
upper O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
body O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
perfusion O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
pressure O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Northern O O
analyses O O
further O O
confirm O O
that O O
the O O
expression O O
of O O
endogenous O O
alpha B B_GENE
- I I_GENE
ENaC I I_GENE
gene I I_GENE
in O O
salivary O O
Pa O O
- O O
4 O O
cells O O
is O O
suppressed O O
by O O
an O O
ectopic O O
HMGI B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
overexpression O O
. O O

Removal O O
of O O
cyclin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dependant I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
cdks B B_LOCATION/B_GENE
) O O
or O O
cdk2 B B_GENE
from O O
these O O
extracts O O
using O O
affinity O O
matrices O O
severely O O
inhibits O O
initiation O O
of O O
S O O
phase O O
. O O

Gel O O
mobility O O
shift O O
analyses O O
reveal O O
that O O
FRTL O O
- O O
5 O O
thyroid O O
cell O O
nuclear O O
extracts O O
form O O
a O O
specific O O
protein O O
/ O O
DNA O O
complex O O
with O O
this O O
region O O
, O O
which O O
is O O
prevented O O
by O O
the O O
TTF B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
1 I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
binding I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
element I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O O
the O O
TG B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
; O O
FRT O O
and O O
BRL O O
cell O O
nuclear O O
extracts O O
do O O
not O O
have O O
TTF B B_GENE
- I I_GENE
1 I I_GENE
and O O
do O O
not O O
form O O
this O O
complex O O
. O O

The O O
Sty1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
stimulated O O
by O O
a O O
variety O O
of O O
different O O
stress O O
conditions O O
including O O
osmotic O O
and O O
oxidative O O
stress O O
and O O
heat O O
shock O O
. O O

No O O
viral O B_DISEASE_ADJECTIVE[DISEASE]
RNA O I_DISEASE_ADJECTIVE[DISEASE]
replication O I_DISEASE_ADJECTIVE[DISEASE]
could O O
be O O
detected O O
in O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
transfected O O
with O O
mutant O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNAs O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Acad O B_LOCATION
. O O

Comparison O O
of O O
the O O
genes O O
coding O O
for O O
mouse O O
and O O
human O O
p36 B B_GENE
( O O
annexin B B_GENE
II I I_GENE
) O O
and O O
mouse O O
, O O
rat O O
and O O
human O O
p35 B B_GENE
( O O
annexin B B_GENE
I I I_GENE
) O O
and O O
pigeon O O
cp35 B B_PROTEIN[GENE]
( O O
an O O
annexin B B_ENZYME[GENE]/B_NUMBER[MEASURE]
I I I_ENZYME[GENE]/I_NUMBER[MEASURE]
- I I_ENZYME[GENE]/I_NUMBER[MEASURE]
related I I_ENZYME[GENE]/I_NUMBER[MEASURE]
protein I I_ENZYME[GENE]/I_NUMBER[MEASURE]
) O O
shows O O
strong O O
genomic O O
structural O O
conservation O O
supporting O O
the O O
hypothesis O O
that O O
these O O
genes O O
had O O
a O O
common O O
ancestor O O
. O O

When O O
incubated O O
with O O
infective O B_BIO
larvae O I_BIO
which O O
had O O
penetrated O O
mouse O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
skin O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
both O O
normal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
immune O B_DISEASE
cells O I_DISEASE
attached O O
to O O
larvae O O
in O O
the O O
absence O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
serum O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
31 O B_MEASURE
- O O
year O B_TIME[MEASURE]
- O O
old O B_PERSON
man O I_PERSON
with O O
primary O B_DISEASE/B_GENE
myelofibrosis O I_DISEASE/I_GENE
initially O O
received O O
low O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
dose O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Ara O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
C O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Collectively O O
, O O
these O O
studies O O
suggest O O
that O O
the O O
major O O
EGF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
stimulated O O
mitotic O O
growth O O
pathways O O
may O O
not O O
be O O
absolutely O O
linked O O
to O O
the O O
stat91 B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O O
pathways O O
and O O
that O O
such O O
transcription O O
complexes O O
are O O
more O O
complex O O
than O O
previously O O
reported O O
. O O

FEurea O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
also O O
measured O O
during O O
stable O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
graft O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
function O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
7 O B_NUMBER[MEASURE]
- O O
14 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
prior O I_TIME[MEASURE]/I_ENT
to O O
allograft O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
dysfunction O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Nonsuicidal O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mortality O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
late O B_MEASURE/B_LOCATION
- O O
life O B_TIME[MEASURE]/B_PERSON
depression O I_TIME[MEASURE]/I_PERSON
. O O

Few O B_PERSON/B_LOCATION
triers O I_PERSON/I_LOCATION
or O O
users O B_PERSON
had O O
received O O
SLT O B_PERSON
counseling O I_PERSON
from O O
their O O
dentist O B_PERSON
despite O O
high O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dental O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
utilization O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
rates O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

However O O
, O O
UV O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
resistance O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
is O O
only O O
minimally O O
restored O O
, O O
and O O
mutant O B_DISEASE/B_BIO
cells O B_DISEASE/I_BIO
remain O O
sensitive O B_DISEASE_ADJECTIVE[DISEASE]
to O O
gamma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
radiation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

The O O
oxalate B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oxidase I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method O O
results O O
in O O
a O O
mean O O
and O O
reference O O
interval O O
for O O
oxalate O O
excretion O O
that O O
are O O
comparable O O
with O O
those O O
by O O
isotope O O
dilution O O
, O O
gas O O
- O O
chromatographic O O
, O O
colorimetric O O
, O O
and O O
other O O
enzymic O O
procedures O O
. O O

In O O
addition O O
, O O
we O O
show O O
that O O
expression O O
of O O
antisense O O
mRNA O O
for O O
p130CAS B B_GENE
resulted O O
in O O
reversion O O
of O O
the O O
transformed O O
phenotype O O
of O O
all O O
these O O
cell O O
lines O O
. O O

Starches O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
had O O
no O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Maximal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Expiratory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Flow O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Rates O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
such O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
as O O
Peak O B_MEASURE/B_LOCATION
Expiratory O I_MEASURE/I_LOCATION
Flow O I_MEASURE/I_LOCATION
Rate O I_MEASURE/I_LOCATION
( O O
PEFR O B_LOCATION/B_DISEASE
) O O
, O O
rates O B_DISEASE/B_MEASURE
at O O
25 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
, O O
50 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
and O O
75 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
of O O
forced O O
vital O B_TIME[MEASURE]/B_LOCATION
capacity O I_TIME[MEASURE]/I_LOCATION
( O O
V O B_MEASURE/B_LOCATION
max O B_MEASURE/I_LOCATION
25 O B_MEASURE/I_LOCATION
% O B_MEASURE/I_LOCATION
, O O
V O B_TIME[MEASURE]/B_LOCATION
max O I_TIME[MEASURE]/I_LOCATION
50 O I_TIME[MEASURE]/I_LOCATION
% O I_TIME[MEASURE]/I_LOCATION
and O O
V O B_MEASURE/B_LOCATION
max O I_MEASURE/I_LOCATION
75 O I_MEASURE/I_LOCATION
% O I_MEASURE/I_LOCATION
) O O
and O O
forced O O
expiratory O B_MEASURE
flow O I_MEASURE
during O O
the O O
middle O B_TIME[MEASURE]/B_LOCATION
half O I_TIME[MEASURE]/I_LOCATION
of O O
forced O O
vital O B_MEASURE/B_DISEASE
capacity O B_MEASURE/I_DISEASE
( O O
FEF O B_MEASURE/B_PROTEIN[GENE]
25 O I_MEASURE/I_PROTEIN[GENE]
- O O
75 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
were O O
measured O O
in O O
273 O B_MEASURE/B_PERSON
healthy O I_MEASURE/I_PERSON
non O O
- O O
smoking O O
adults O B_PERSON
( O O
144 O B_MEASURE/B_PERSON
males O I_MEASURE/I_PERSON
, O O
129 O B_PERSON/B_MEASURE
females O I_PERSON/I_MEASURE
) O O
aged O O
15 O B_MEASURE
- O O
63 O B_MEASURE/B_ENT
years O I_MEASURE/I_ENT
living O O
in O O
Madras O B_LOCATION
. O O

The O O
amino O O
acid O O
sequence O O
of O O
the O O
protein O O
encoded O O
by O O
MSK1 B B_GENE/B_LOCATION
is O O
homologous O O
to O O
yeast B B_GENE
cytoplasmic I I_GENE
lysyl I I_GENE
- I I_GENE
tRNA I I_GENE
synthetase I I_GENE
and O O
to O O
the O O
product O O
of O O
the O O
herC B B_GENE
gene I I_GENE
, O O
which O O
has O O
recently O O
been O O
suggested O O
to O O
code O O
for O O
the O O
Escherichia O O
coli O O
enzyme O O
. O O

Similar O O
to O O
the O O
D B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
B B B_PROTEIN[GENE]/B_DISEASE
/ O O
B B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
E B B_PROTEIN[GENE]/B_LOCATION
proteins I I_PROTEIN[GENE]/I_LOCATION
, O O
the O O
F B B_PROTEIN[GENE]/B_DISEASE
and O O
G B B_PROTEIN[GENE]/B_LOCATION
proteins I I_PROTEIN[GENE]/I_LOCATION
do O O
not O O
possess O O
any O O
of O O
the O O
known O O
RNA O O
binding O O
motifs O O
, O O
suggesting O O
that O O
other O O
types O O
of O O
RNA O O
- O O
protein O O
interactions O O
occur O O
in O O
the O O
snRNP O O
core O O
. O O

These O O
observations O O
suggest O O
that O O
clr4 B B_GENE
+ I I_GENE
and O O
rik1 B B_GENE
+ I I_GENE
must O O
play O O
a O O
role O O
in O O
the O O
assembly O O
of O O
Swi6p B B_GENE/B_BACTERIUM[BIO]
into O O
a O O
transcriptionally O O
silent O O
, O O
inaccessible O O
chromatin O O
structure O O
at O O
fission O O
yeast O O
centromeres O O
which O O
is O O
required O O
to O O
facilitate O O
interactions O O
with O O
spindle O O
microtubules O O
and O O
to O O
ensure O O
normal O O
chromosome O O
segregation O O
. O O

Characterization O O
of O O
a O O
DEAD B B_GENE
box I I_GENE
ATPase I I_GENE
/ O O
RNA B B_ENZYME[GENE]
helicase I I_ENZYME[GENE]
protein O O
of O O
Arabidopsis O O
thaliana O O
. O O

Amplitude O B_TIME[MEASURE]
of O O
late O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
surface O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
P2 O B_PROTEIN[GENE]
and O O
N2 O B_PROTEIN[GENE]
) O O
and O O
depth O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
B O B_PROTEIN[GENE]/B_DISEASE
and O O
C O B_PROTEIN[GENE]
) O O
components O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
significantly O O
decreased O O
when O O
patients O B_PERSON/B_MEASURE
shifted O O
from O O
SWS O B_LOCATION/B_PROTEIN[GENE]
IV O I_LOCATION/I_PROTEIN[GENE]
to O O
PS O B_PROTEIN[GENE]/B_LOCATION
and O O
increased O O
from O O
PS O B_PROTEIN[GENE]/B_LOCATION
to O O
W2 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Oligo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
alpha O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
deoxynucleotides O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
can O O
be O O
derived O O
by O O
stabilizing O O
( O O
intercalating O O
) O O
agents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
reactive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
groups O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
cleaving O O
reagents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
cross O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
linkers O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
. O O
. O O
) O O
. O O

This O O
vector O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O O
be O O
applicable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O O
throughput O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
characterization O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
new O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
open O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
reading O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
frames O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
found O O
in O O
genome O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequencing O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
subjects O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
17 O B_PERSON/B_DISEASE
patients O I_PERSON/I_DISEASE
with O O
android O B_DISEASE
obesity O I_DISEASE
( O O
four O B_NUMBER[MEASURE]/B_ENT
men O I_NUMBER[MEASURE]/I_ENT
and O O
13 O B_PERSON/B_NUMBER[MEASURE]
women O I_PERSON/I_NUMBER[MEASURE]
) O O
aged O O
21 O B_MEASURE
to O O
58 O B_MEASURE/B_ENT
years O I_MEASURE/I_ENT
with O O
a O O
body O B_MEASURE/B_BIO
mass O I_MEASURE/I_BIO
index O I_MEASURE/I_BIO
( O O
BMI O B_MEASURE/B_ORGANIZATION
) O O
ranging O O
from O O
32 O B_MEASURE
. O O
0 O B_MEASURE
to O O
52 O B_MEASURE
. O O
2 O B_MEASURE
kg O I_MEASURE
/ O O
m2 O B_MEASURE/B_PERSON
and O O
an O O
abdominal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
gluteal O B_MEASURE
ratio O I_MEASURE
greater O I_MEASURE
than O O
1 O B_MEASURE
. O O
0 O B_MEASURE
. O O

No O O
universally O O
accepted O O
standardized O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
classification O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
acne O B_DISEASE/B_LOCATION
vulgaris O I_DISEASE/I_LOCATION
exists O O
, O O
although O O
there O O
is O O
a O O
strong O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
need O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
it O O
. O O

Blood O O
samples O O
for O O
determination O O
of O O
fibrinolytic O O
activity O O
and O O
factor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
VIII I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
plasma O O
were O O
obtained O O
before O O
and O O
immediately O O
after O O
the O O
end O O
of O O
compression O O
and O O
application O O
of O O
a O O
stocking O O
, O O
respectively O O
. O O

Neither O O
symptoms O O
, O O
virions O O
, O O
nor O O
viral O O
RNA O O
was O O
detectable O O
in O O
plants O O
inoculated O O
with O O
this O O
mutant O O
or O O
a O O
mutant O O
with O O
a O O
frameshift O O
mutation O O
in O O
the O O
coat B B_GENE
gene I I_GENE
. O O

The O O
cumulative O B_MEASURE/B_LOCATION
length O I_MEASURE/I_LOCATION
of O O
the O O
RGSV O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genome O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
including O O
RNAs O B_MEASURE/B_PROTEIN[GENE]
5 O I_MEASURE/I_PROTEIN[GENE]
and O O
6 O B_MEASURE
, O O
was O O
25142 O B_MEASURE/B_GENE
nt O I_MEASURE/I_GENE
. O O

Risk O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ratios O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
decreased O O
with O O
increasing O O
age O B_MEASURE/B_DISEASE
and O O
increased O O
with O O
number O B_MEASURE
of O O
breast O B_PERSON/B_DISEASE
biopsies O I_PERSON/I_DISEASE
, O O
family O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
history O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
breast O B_DISEASE
cancer O I_DISEASE
, O O
estrogen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
use O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
time O B_MEASURE
between O O
screenings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
no O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
previous O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
mammograms O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
and O O
the O O
radiologist O B_PERSON/B_ORGANIZATION
' O O
s O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
tendency O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
to O O
call O O
mammograms O B_TIME[MEASURE]/B_PERSON
abnormal O I_TIME[MEASURE]/I_PERSON
. O O

The O O
AtNMT1 B B_GENE
expression O O
profile O O
indicated O O
ubiquity O O
in O O
roots O O
, O O
stem O O
, O O
leaves O O
, O O
flowers O O
, O O
and O O
siliques O O
( O O
approximately O O
1 O O
. O O
7 O O
kb O O
transcript O O
and O O
approximately O O
50 O O
kDa O O
immunoreactive O O
polypeptide O O
) O O
but O O
a O O
greater O O
level O O
in O O
the O O
younger O O
tissue O O
, O O
which O O
are O O
developmentally O O
very O O
active O O
. O O

The O O
ossification O B_LOCATION
was O O
located O O
on O O
the O O
left O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
side O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
of O O
C3 O B_PROTEIN[GENE]/B_LOCATION
- O O
4 O B_NUMBER[MEASURE]
. O O

At O O
a O O
cutoff O B_MEASURE/B_DISEASE
point O I_MEASURE/I_DISEASE
for O O
KISA O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
100 O B_NUMBER[MEASURE]/B_PERSON
, O O
280 O B_MEASURE
of O O
281 O B_PERSON/B_LOCATION
participants O I_PERSON/I_LOCATION
( O O
99 O B_MEASURE
. O O
6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
were O O
correctly O O
classified O O
. O O

Following O O
replicate O O
control O O
measurements O O
, O O
test O O
ramps O O
were O O
repeated O O
in O O
the O O
presence O O
of O O
sodium O O
nitroprusside O O
( O O
1 O O
microM O O
) O O
and O O
phentolamine O O
( O O
1 O O
microM O O
) O O
to O O
eliminate O O
potential O O
smooth O O
muscle O O
and O O
alpha B B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
1 I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
- I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
adrenoceptor I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
effects O O
, O O
respectively O O
. O O

Behavioral O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
benzodiazepine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ligands O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
non O O
- O O
dependent O B_PERSON/B_DISEASE
, O O
diazepam O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
diazepam O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
withdrawn O O
baboons O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
paper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
reports O O
estimates O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
prevalence O B_MEASURE/B_DISEASE
of O O
mental O B_DISEASE
retardation O I_DISEASE
and O O
associated O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
based O O
on O O
a O O
population O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
survey O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
2 O B_NUMBER[MEASURE]/B_LOCATION
- O O
to O O
9 O B_MEASURE
- O O
year O B_TIME[MEASURE]
- O O
old O B_PERSON/B_ENT
children O I_PERSON/I_ENT
in O O
Greater O B_LOCATION
Karachi O I_LOCATION
, O O
Pakistan O B_LOCATION
. O O

Thus O O
, O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
lactate O B_MEASURE
concentration O I_MEASURE
of O O
the O O
magnitude O B_BODY_PART_OR_ORGAN_COMPONENT
observed O O
during O O
alkali O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
need O O
not O O
indicate O O
a O O
worsening O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
metabolic O B_DISEASE_ADJECTIVE[DISEASE]
picture O I_DISEASE_ADJECTIVE[DISEASE]
in O O
lactic O B_DISEASE/B_BIO
acidosis O I_DISEASE/I_BIO
. O O

Adjusting O O
a O O
steady O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
state O B_MEASURE/B_LOCATION
warfarin O B_MEASURE/I_LOCATION
dose O B_MEASURE/I_LOCATION
depends O O
on O O
the O O
measured O B_MEASURE/B_EDU[ORGANIZATION]
INR O B_MEASURE/I_EDU[ORGANIZATION]
values O B_MEASURE/I_EDU[ORGANIZATION]
and O O
clinical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
factors O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O O
the O O
dose O B_MEASURE
does O O
not O O
need O O
to O O
be O O
adjusted O O
for O O
a O O
single O B_MEASURE
INR O I_MEASURE
that O O
is O O
slightly O O
out O O
of O O
range O B_MEASURE
, O O
and O O
most O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
changes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
should O O
alter O O
the O O
total O B_MEASURE
weekly O I_MEASURE
dose O I_MEASURE
by O O
5 O B_NUMBER[MEASURE]/B_LOCATION
% O I_NUMBER[MEASURE]/I_LOCATION
to O O
20 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
. O O

All O O
of O O
this O O
region O B_LOCATION/B_BIO
is O O
part O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
prominent O B_LOCATION/B_GENE
CpG O I_LOCATION/I_GENE
island O I_LOCATION/I_GENE
that O O
may O O
be O O
acting O O
as O O
an O O
extended O O
, O O
enhancer O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
independent O B_LOCATION/B_GENE
promoter O I_LOCATION/I_GENE
. O O

Comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
Healon O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Amvisc O B_PERSON/B_LOCATION
. O O

Large O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
volumes O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
bone O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
marrow O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
may O O
be O O
required O O
for O O
certain O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
types O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
autologous O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
bone O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
marrow O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
transplants O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Further O O
analysis O O
of O O
the O O
CAP59 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
locus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Cryptococcus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
neoformans I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O O
structure O O
defined O O
by O O
forced O O
expression O O
and O O
description O O
of O O
a O O
new O O
ribosomal B B_GENE
protein I I_GENE
- I I_GENE
encoding I I_GENE
gene I I_GENE
. O O

We O O
speculate O O
that O O
the O O
enhancing O O
effect O O
of O O
glucose O O
and O O
galactose O O
on O O
fructose O O
absorption O O
may O O
be O O
due O O
to O O
activation O O
of O O
the O O
fructose B B_ENZYME[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
carrier I I_ENZYME[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Virol O B_LOCATION/B_BACTERIUM[BIO]
. O O

The O O
DFGF B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
R I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
may O O
thus O O
participate O O
in O O
receiving O O
spatial O O
cues O O
that O O
guide O O
tracheal O O
cell O O
outgrowth O O
. O O

The O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
from O O
animal O B_MEASURE
experiments O I_MEASURE
indicate O O
that O O
the O O
incidence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
solid O B_DISEASE
tumors O I_DISEASE
in O O
marrow O B_PERSON/B_BIO
transplant O I_PERSON/I_BIO
patients O I_PERSON/I_BIO
may O O
still O O
rise O O
in O O
the O O
coming O B_TIME[MEASURE]/B_LOCATION
decades O I_TIME[MEASURE]/I_LOCATION
. O O

Patients O B_PERSON
adopt O O
new O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
sets O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
based O O
partly O O
on O O
the O O
original O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
topic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O O
partly O O
on O O
their O O
own O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
personal O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
idiosyncratic O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
concerns O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

The O O
NS B B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoforms I B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
resolved O O
at O O
a O O
pI O O
value O O
close O O
to O O
5 O O
. O O
5 O O
as O O
three O O
groups O O
of O O
unevenly O O
phosphorylated O O
polypeptides O O
, O O
each O O
composed O O
of O O
at O O
least O O
two O O
protein O O
species O O
. O O

Prevalence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
rheumatic O B_DISEASE
diseases O I_DISEASE
in O O
a O O
rural O B_LOCATION/B_PERSON
population O I_LOCATION/I_PERSON
in O O
western O B_LOCATION
India O I_LOCATION
: O O
a O O
WHO O O
- O O
ILAR O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
COPCORD O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

A O O
. O O
nidulans O O
transformants O O
secreted O O
high O O
amounts O O
of O O
PGI B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O O
PGII B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
comparison O O
to O O
the O O
previously O O
characterized O O
A O O
. O O
niger O O
transformants O O
and O O
a O O
novel O O
polygalacturonase B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
( O O
PGC B B_LOCATION/B_GENE
) O O
was O O
produced O O
at O O
high O O
levels O O
by O O
A O O
. O O
nidulans O O
transformed O O
with O O
the O O
subcloned O O
pgaC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
interaction O O
is O O
functional O O
as O O
it O O
leads O O
to O O
retargeting O O
of O O
NF B B_GENE
- I I_GENE
kappa I I_GENE
B I I_GENE
p50 B I_GENE
from O O
the O O
nucleus O O
to O O
the O O
cytoplasm O O
. O O

The O O
orf2 O O
gene O O
product O O
is O O
a O O
protein O O
of O O
79 O O
amino O O
acids O O
with O O
characteristics O O
similar O O
to O O
those O O
of O O
the O O
Tat B B_PROTEIN[GENE]/B_LOCATION
( O O
transactivator B B_PROTEIN[GENE]/B_LOCATION
) O O
proteins O O
of O O
the O O
ungulate O O
lentiviruses O O
. O O

The O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
medication O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
of O O
minor O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
importance O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
flight O B_DISEASE
phobia O I_DISEASE
. O O

Elevated O B_DISEASE_ADJECTIVE[DISEASE]
total O I_DISEASE_ADJECTIVE[DISEASE]
serum O I_DISEASE_ADJECTIVE[DISEASE]
calcium O I_DISEASE_ADJECTIVE[DISEASE]
to O O
a O O
level O B_MEASURE/B_LOCATION
of O O
11 O B_MEASURE
. O O
9 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
2 O B_MEASURE
mg O I_MEASURE
/ O O
dl O B_MEASURE/B_PROTEIN[GENE]
( O O
p O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
0 O B_MEASURE
. O O
001 O B_MEASURE
compared O O
to O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
) O O
developed O O
in O O
the O O
gentamicin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
1 O B_MEASURE
, O O
25 O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
OH O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
vitamin O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
D3 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
on O O
day O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
4 O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
2 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
days O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
prior O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
pronounced O O
structural O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
damage O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
continued O O
to O O
be O O
elevated O O
through O O
day O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
7 O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Rac2 B B_GENE
, O O
a O O
member O O
of O O
the O O
Rho B B_GENE/B_PERSON
family I I_GENE/I_PERSON
of O O
GTPases B B_GENE/B_BIO
, O O
is O O
highly O O
expressed O O
in O O
myeloid O O
cells O O
and O O
is O O
a O O
regulator O O
of O O
the O O
NADPH B B_GENE
- I I_GENE
oxidase I I_GENE
complex I I_GENE
. O O

In O O
vitro O O
kinase O O
assays O O
on O O
isolated O O
microvilli O O
and O O
microvillar O O
fractions O O
enriched O O
in O O
the O O
putative O O
signal O O
transduction O O
particle O O
showed O O
a O O
high O O
specific O O
activity O O
of O O
tyrosine B B_GENE/B_DISEASE
kinase I I_GENE/I_DISEASE
activity O O
compared O O
to O O
that O O
of O O
membranes O O
from O O
EGF B B_GENE
receptor I I_GENE
- O O
overexpressing O O
A431 O O
cells O O
maximally O O
activated O O
by O O
EGF B B_GENE
. O O

Effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
infantile O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
undernutrition O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
adult O B_DISEASE/B_ORGANISM_FUNCTION
sucrose O I_DISEASE/I_ORGANISM_FUNCTION
solution O I_DISEASE/I_ORGANISM_FUNCTION
consumption O I_DISEASE/I_ORGANISM_FUNCTION
in O O
the O O
rat O B_BIO/B_PERSON
. O O

In O O
the O O
studies O O
described O O
in O O
this O O
report O O
, O O
we O O
have O O
identified O O
two O O
potential O O
Ets B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
binding O O
sites O O
, O O
EBS1 B B_GENE/B_DISEASE
and O O
EBS2 B B_GENE
, O O
which O O
are O O
conserved O O
in O O
both O O
the O O
human O O
and O O
murine O O
interleukin B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
- I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
2 I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
enhancers O O
. O O

KatA B B_LOCATION/B_TIME[MEASURE]
, O O
AhpCF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
heme O O
biosynthesis O O
enzymes O O
, O O
and O O
MrgA B B_ENZYME[GENE]/B_BACTERIUM[BIO]
are O O
also O O
induced O O
upon O O
entry O O
into O O
stationary O O
phase O O
under O O
conditions O O
of O O
iron O O
and O O
manganese O O
limitation O O
. O O

Although O O
the O O
Gly252Arg O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
substitution O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
observed O O
in O O
UM O B_DISEASE/B_GENE
: O O
JG5 O B_MEASURE/B_GENE
is O O
non O O
- O O
conservative O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
it O O
was O O
not O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
distinguish O O
whether O O
it O O
is O O
a O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
or O O
a O O
polymorphism O B_GENE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
. O O

This O O
region O O
shows O O
46 O O
% O O
identity O O
with O O
the O O
calmodulin B B_LOCATION/B_GENE
- I I_LOCATION/I_GENE
binding I I_LOCATION/I_GENE
region I I_LOCATION/I_GENE
of O O
rat B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
brain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Ca2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
+ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
calmodulin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dependent I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
32 O O
% O O
identity O O
with O O
the O O
equivalent O O
region O O
of O O
chicken B B_GENE
smooth I I_GENE
muscle I I_GENE
myosin I I_GENE
light I I_GENE
chain I I_GENE
kinase I I_GENE
. O O

The O O
perforated O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splint O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gives O O
superior O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
by O O
virtue O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
fact O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
it O O
does O O
not O O
require O O
to O O
be O O
removed O O
for O O
purposes O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O O
hygiene O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
can O O
thus O O
produce O O
a O O
satisfactory O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
result O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
even O O
in O O
those O O
patients O B_PERSON
who O O
fail O O
to O O
grasp O O
the O O
technique O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
removal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
replacement O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
splint O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

It O O
contains O O
31 O O
exons O O
and O O
a O O
high O O
proportion O O
of O O
class O O
0 O O
introns O O
, O O
alternative O O
splicing O O
of O O
which O O
results O O
in O O
significant O O
levels O O
of O O
variant O O
transcripts O O
that O O
maintain O O
the O O
original O O
open O O
reading O O
frame O O
of O O
MRP B B_GENE
mRNA I I_GENE
. O O

Issues O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
discussed O O
include O O
the O O
validity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O O
the O O
MMPI O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Mf O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
scale O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
questions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
sample O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
representativeness O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
whether O O
" O O
straights O B_PERSON/B_ORGANIZATION
" O I_PERSON/I_ORGANIZATION
can O O
do O O
adequate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
on O O
homosexuality O B_PERSON/B_ORGANIZATION
, O O
differences O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
heterosexual O B_PERSON
and O O
homosexual O B_PERSON
sexuality O I_PERSON
, O O
the O O
role O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
subculture O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
acculturation O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O O
homosexual O B_PERSON
psychological O I_PERSON
adjustment O I_PERSON
, O O
and O O
the O O
use O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
cluster O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
generate O O
typologies O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
homosexualities O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O O

A O O
brief O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
discussion O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
the O O
relationship O B_PERSON/B_MEASURE
among O O
these O O
formulas O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
given O O
. O O

Lamivudine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
acute O B_DISEASE/B_PERSON
hepatitis O I_DISEASE/I_PERSON
B O I_DISEASE/I_PERSON
infection O I_DISEASE/I_PERSON
following O O
peripheral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
blood O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
stem O O
cell O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplantation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

These O O
findings O O
suggest O O
that O O
NMDA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
blockade O O
may O O
ameliorate O O
the O O
dyskinetic O O
complications O O
of O O
long O O
- O O
term O O
levodopa O O
therapy O O
, O O
without O O
diminishing O O
the O O
beneficial O O
effects O O
on O O
parkinsonian O O
signs O O
. O O

Furthermore O O
, O O
the O O
secondary O B_DISEASE_ADJECTIVE[DISEASE]
stress O I_DISEASE_ADJECTIVE[DISEASE]
responses O I_DISEASE_ADJECTIVE[DISEASE]
were O O
more O O
pronounced O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
recover O O
from O O
them O O
seemed O O
to O O
be O O
impaired O O
in O O
exposed O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
fish O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
as O O
compared O O
to O O
unexposed O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fish O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
distinct O O
spatial O O
pattern O O
of O O
expression O O
, O O
and O O
unusual O O
amino O O
acid O O
sequence O O
in O O
its O O
DNA O O
binding O O
domain O O
, O O
may O O
indicate O O
a O O
particular O O
role O O
for O O
DTEF B B_GENE
- I I_GENE
1 I I_GENE
in O O
cell O O
- O O
specific O O
gene O O
regulation O O
. O O

As O O
usual O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
tests O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
as O O
" O O
time O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
of O O
cephalin O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
are O O
slightly O O
sensible O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
LMW O B_DISEASE/B_PROTEIN[GENE]
- O O
Hep O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
only O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O O
Xa O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
used O O
. O O

Usher O B_DISEASE/B_GENE
syndrome O I_DISEASE/I_GENE
1C O I_DISEASE/I_GENE
( O O
USH1C O B_DISEASE/B_LOCATION
) O O
is O O
a O O
congenital O B_DISEASE
condition O I_DISEASE
manifesting O O
profound O B_DISEASE
hearing O I_DISEASE
loss O I_DISEASE
, O O
the O O
absence O B_DISEASE_ADJECTIVE[DISEASE]
of O O
vestibular O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
eventual O B_DISEASE
retinal O I_DISEASE
degeneration O I_DISEASE
. O O

Implantation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
is O O
contraindicated O O
for O O
severe O B_DISEASE_ADJECTIVE[DISEASE]
dysplasia O I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
cochlea O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
for O O
the O O
recently O O
described O O
variety O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
x O B_OTHER/B_MEASURE
- O O
linked O O
deafness O B_DISEASE
with O O
deficient O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
bone O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O O
the O O
fundus O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
of O O
the O O
internal O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
auditory O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
meatus O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Over O O
9 O B_MEASURE
kb O I_MEASURE
of O O
DNA O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
obtained O O
for O O
one O B_DISEASE/B_GENE
clone O B_DISEASE/I_GENE
( O O
A1 O B_PROTEIN[GENE]/B_MEASURE
) O O
with O O
a O O
total O B_MEASURE
IGS O I_MEASURE
length O I_MEASURE
of O O
approximately O O
12 O B_MEASURE
. O O
4 O B_MEASURE
kb O I_MEASURE
. O O

Scleraxis B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
overexpression O O
enhanced O O
expression O O
of O O
the O O
aggrecan B B_GENE
gene I I_GENE
, O O
which O O
is O O
not O O
normally O O
expressed O O
at O O
high O O
levels O O
in O O
these O O
osteoblastic O O
cells O O
. O O

This O O
study O O
demonstrates O O
that O O
the O O
exposure O O
to O O
sulphur O O
mustard O O
results O O
in O O
very O O
low O O
androgen O O
levels O O
and O O
hypo O O
- O O
responsiveness O O
to O O
GnRH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
the O O
first O O
five O O
weeks O O
and O O
normalization O O
by O O
the O O
twelfth O O
week O O
after O O
injury O O
. O O

New O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
importance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
optimization O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
postoperative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
course O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
] O O
Complications O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O O
major O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
surgery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
may O O
be O O
related O O
to O O
factors O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
surgical O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stress O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
endocrine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
metabolic O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
inflammatory O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
changes O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Four O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
multicannulated O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Holstein O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
steers O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
initial O B_MEASURE
BW O I_MEASURE
424 O I_MEASURE
+ O I_MEASURE
/ O O
- O O
16 O B_MEASURE
kg O I_MEASURE
) O O
were O O
used O O
in O O
a O O
4 O B_MEASURE
x O O
4 O B_NUMBER[MEASURE]/B_LOCATION
Latin O I_NUMBER[MEASURE]/I_LOCATION
square O I_NUMBER[MEASURE]/I_LOCATION
to O O
determine O O
the O O
influence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
protein O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
supplementation O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
on O O
forage O B_MEASURE/B_BIO
intake O I_MEASURE/I_BIO
, O O
site O B_LOCATION/B_MEASURE
and O O
extent O B_MEASURE
of O O
digestion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
, O O
and O O
nutrient O B_MEASURE/B_DISEASE
flow O I_MEASURE/I_DISEASE
in O O
steers O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consuming O O
dormant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
bluestem O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
range O B_BIO/B_LOCATION
forage O I_BIO/I_LOCATION
( O O
2 O B_MEASURE
. O O
3 O B_MEASURE
% O I_MEASURE
CP O I_MEASURE
) O O
. O O

Patients O B_PERSON/B_LOCATION
with O O
risk O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
compared O O
with O O
those O O
without O O
risk O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
dermatoglyphic O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pattern O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demostrates O O
a O O
distal O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
triradius O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
whorl O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
abnormalities O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
term O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Kartagener O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
syndrome O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
applies O O
to O O
this O O
syndrome O B_DISEASE/B_PERSON
when O O
accompanied O O
by O O
infertility O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
dextrocardia O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
or O O
situs O B_DISEASE
inversus O I_DISEASE
. O O

Finally O O
, O O
we O O
tested O O
whether O O
activation O O
by O O
either O O
of O O
these O O
factors O O
is O O
dependent O O
on O O
components O O
of O O
the O O
SAGA B B_GENE/B_LOCATION
complex I B_GENE/I_LOCATION
. O O

Eight O O
of O O
the O O
17 O O
seropositive O O
patients O O
failed O O
to O O
develop O O
detectable O O
hepatitis B B_DISEASE
B I I_DISEASE
surface I I_DISEASE
antibody I I_DISEASE
within O O
three O O
months O O
of O O
the O O
third O O
injection O O
compared O O
with O O
only O O
one O O
of O O
the O O
18 O O
seronegative O O
patients O O
( O O
p O O
less O O
than O O
0 O O
. O O
01 O O
) O O
. O O

The O O
antimicrobial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
choice O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O O
initial O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
prophylactic O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
among O O
asymptomatic O B_PERSON/B_BIO
pregnant O I_PERSON/I_BIO
women O I_PERSON/I_BIO
exposed O O
to O O
Bacillus O B_SPECIES[BIO]/B_DISEASE
anthracis O B_SPECIES[BIO]/I_DISEASE
is O O
ciprofloxacin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
500 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
twice O O
a O O
day O B_TIME[MEASURE]
for O O
60 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
days O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
. O O

Overexpression O O
of O O
eIF4E B B_GENE
transforms O O
cells O O
, O O
and O O
mutations O O
in O O
eIF4E B B_GENE
arrest O O
cells O O
in O O
G O O
, O O
in O O
cdc33 B B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
mutants I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
. O O

Benzyl O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alcohol O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
neonates O B_BIO/B_PERSON
. O O

Repression O O
of O O
the O O
herpes B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
simplex I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
its O O
gene O O
product O O
( O O
ICP4 B B_GENE/B_DISEASE
) O O
within O O
the O O
context O O
of O O
the O O
viral O O
genome O O
is O O
conditioned O O
by O O
the O O
distance O O
and O O
stereoaxial O O
alignment O O
of O O
the O O
ICP4 B B_GENE/B_LOCATION
DNA I I_GENE/I_LOCATION
binding I I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
relative O O
to O O
the O O
TATA O O
box O O
. O O

As O O
anticipated O O
, O O
both O O
intracellular O O
p54 B B_GENE
- O O
SAPKbeta B B_GENE
activation O O
and O O
Bcl B B_GENE
- I I_GENE
2 I I_GENE
phosphorylation O O
are O O
blocked O O
by O O
co O O
- O O
transfection O O
with O O
the O O
MAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specific O O
phosphatase O O
MKP3 B B_GENE
/ O O
PYST1 B B_GENE/B_MEASURE
. O O

Relation O O
between O O
circulating O O
immune O O
complexes O O
and O O
serum B B_DISEASE
ferritin I I_DISEASE
in O O
hemosiderosis O O
of O O
different O O
etiologies O O

PATIENT O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
S O B_OTHER/B_MEASURE
) O O
: O O
Two O B_NUMBER[MEASURE]/B_ENT
hundred O I_NUMBER[MEASURE]/I_ENT
thirty O I_NUMBER[MEASURE]/I_ENT
- O O
eight O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
with O O
RPLs O B_DISEASE/B_ORGANISM_FUNCTION
, O O
48 O B_TIME[MEASURE]
patients O I_TIME[MEASURE]
with O O
recurrent O B_DISEASE_ADJECTIVE[DISEASE]
IVF O I_DISEASE_ADJECTIVE[DISEASE]
- O O
ET O B_DISEASE/B_ORGANISM_FUNCTION
failure O B_DISEASE/I_ORGANISM_FUNCTION
and O O
179 O B_PERSON/B_DISEASE
nonpregnant O I_PERSON/I_DISEASE
and O O
120 O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
pregnant O B_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
control O B_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
group O B_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
women O B_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Many O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
metabolic O B_DISEASE_ADJECTIVE[DISEASE]
effects O I_DISEASE_ADJECTIVE[DISEASE]
induced O O
by O O
thiazide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
diuretics O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
however O O
, O O
can O O
be O O
limited O O
by O O
the O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
low O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
doses O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Teboroxime O B_PERSON/B_LOCATION
is O O
a O O
new O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
boronic O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
acid O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
adduct O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
technetium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dioxime O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
BATO O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
compound O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
demonstrates O O
favorable O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
characteristics O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
preliminary O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
studies O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

The O O
total O B_MEASURE
area O I_MEASURE
under O O
the O O
blood O B_MEASURE
glucose O I_MEASURE
curve O I_MEASURE
over O O
the O O
initial O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
value O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
was O O
not O O
altered O O
2 O B_MEASURE/B_LOCATION
h O O
after O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
with O O
SH O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
B O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
209 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
AB O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
or O O
Neogynon O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Treatment O O
of O O
excessive O O
bleeding O O
after O O
cardiopulmonary O O
bypass O O
was O O
based O O
on O O
an O O
algorithm O O
using O O
point O O
- O O
of O O
- O O
care O O
testing O O
with O O
whole O O
blood B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
prothrombin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
time O O
, O O
activated O O
partial O O
thromboplastin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
time O O
, O O
heparinase B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
activated O O
clotting O O
time O O
, O O
and O O
platelet O O
count O O
. O O

In O O
all O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
large O B_MEASURE
fraction O I_MEASURE
of O O
soluble O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Al O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
became O O
insoluble O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
stomach O B_BODY_PART_OR_ORGAN_COMPONENT
after O O
ingestion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O O

To O O
assess O O
the O O
safety O O
of O O
the O O
angiotensin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
converting I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enzyme I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O O
enalapril O O
a O O
multicenter O O
, O O
open O O
, O O
randomized O O
, O O
prazosin O O
- O O
controlled O O
trial O O
was O O
designed O O
comparing O O
the O O
incidence O O
and O O
severity O O
of O O
symptomatic O O
hypotension O O
on O O
the O O
first O O
day O O
of O O
treatment O O
. O O

Glucose O O
may O O
reduce O O
slightly O O
the O O
pool O O
of O O
amino O O
nitrogen O O
available O O
for O O
albumin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O O
urea O O
synthesis O O
by O O
diverting O O
some O O
of O O
the O O
infused O O
amino O O
acids O O
from O O
protein O O
synthesis O O
by O O
the O O
liver O O
to O O
muscle O O
. O O

BACKGROUND O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
have O O
previously O O
reported O O
the O O
first O O
isolation O O
of O O
a O O
c B B_DISEASE
- I I_DISEASE
myc I I_DISEASE
- I I_DISEASE
null I I_DISEASE
cell O O
line O O
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
demonstrated O O
that O O
for O O
both O O
S O B_LOCATION/B_DISEASE
. O O
europaea O B_SPECIES[BIO]/B_DISEASE
and O O
A O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
prostrata O B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
the O O
total O B_MEASURE
number O I_MEASURE
of O O
seeds O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
germinated O O
decreased O O
throughout O O
the O O
growing O O
season O B_TIME[MEASURE]
. O O

A O O
nationwide O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
record O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
linkage O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
Finnish O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Twin O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Cohort O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O O
FTCS O B_MEASURE/B_DISEASE
) O O
with O O
the O O
Hospital O B_ORGANIZATION/B_LOCATION
Discharge O I_ORGANIZATION/I_LOCATION
Registry O I_ORGANIZATION/I_LOCATION
and O O
the O O
Registry O B_TIME[MEASURE]/B_ORGANIZATION
of O O
Rights O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
Free O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
medication O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
is O O
presented O O
. O O

Considering O O
these O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
facts O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
together O O
, O O
we O O
propose O O
that O O
vasectomy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
may O O
lead O O
to O O
decrease O O
in O O
the O O
incidence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
prostatic O B_DISEASE
tumors O I_DISEASE
- O O
a O O
disease O B_DISEASE
that O O
claims O O
nearly O O
22 O B_MEASURE
, O O
000 O B_MEASURE/B_ENT
lives O I_MEASURE/I_ENT
each O O
year O B_TIME[MEASURE]
in O O
the O O
United O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
States O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
alone O O
. O O

Antibodies O O
specific O O
to O O
the O O
different O O
members O O
of O O
the O O
Jun B B_PERSON/B_GENE
and O O
Fos B B_GENE
family I I_GENE
of I I_GENE
transcription I I_GENE
factors I I_GENE
show O O
that O O
, O O
in O O
gel O O
retardation O O
assays O O
, O O
a O O
Jun B B_PROTEIN[GENE]/B_MEASURE
- I I_PROTEIN[GENE]/I_MEASURE
like I I_PROTEIN[GENE]/I_MEASURE
factor I I_PROTEIN[GENE]/I_MEASURE
is O O
a O O
component O O
of O O
the O O
H3 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specific I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

She O O
had O O
been O O
diagnosed O O
with O O
severe O B_DISEASE/B_GENE
aplastic O I_DISEASE/I_GENE
anemia O I_DISEASE/I_GENE
1 O I_DISEASE/I_GENE
year O I_DISEASE/I_GENE
previously O O
and O O
, O O
while O O
hospitalized O O
, O O
had O O
received O O
methyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
prednisolone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
pulse O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
which O O
was O O
not O O
successful O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
recombinant B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
L I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
F I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transferase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
as O O
active O O
as O O
the O O
previously O O
purified O O
wild O O
type O O
enzyme O O
and O O
contains O O
no O O
detectable O O
RNA O O
component O O
. O O

Cord O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
formation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
BACTEC O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
7H12 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
medium O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
rapid O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
presumptive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
identification O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Mycobacterium O B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
tuberculosis O I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
complex O I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Moreover O O
, O O
site O O
- O O
specific O O
integration O O
of O O
the O O
ITR O O
- O O
flanked O O
DNA O O
was O O
also O O
detected O O
by O O
PCR O O
amplification O O
of O O
the O O
ITR B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
aavs1 I I_GENE/I_LOCATION
junction I I_GENE/I_LOCATION
in O O
transduced O O
human O O
fibroblasts O O
. O O

Oct B B_GENE
- I I_GENE
1 I I_GENE
is O O
a O O
ubiquitously O O
expressed O O
regulatory O O
gene O O
of O O
the O O
POU B B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
domain I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
family I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
. O O

In O O
both O O
study O O
stages O O
. O O
post O O
- O O
exposure O O
treatment O O
consisted O O
of O O
five O O
injections O O
of O O
vaccine O O
[ O O
( O O
D O O
) O O
ays O O
0 O O
, O O
3 O O
, O O
7 O O
, O O
14 O O
, O O
28 O O
] O O
, O O
together O O
with O O
a O O
dose O O
of O O
rabies B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunoglobulin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
RIG B B_LOCATION/B_MEASURE
) O O
of O O
equine O O
or O O
human O O
origin O O
on O O
D0 O O
. O O

( O O
3 O O
) O O
With O O
the O O
exception O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
anteroposterior O B_LOCATION/B_MEASURE
direction O I_LOCATION/I_MEASURE
of O O
layers O B_LOCATION/B_MEASURE
II O I_LOCATION/I_MEASURE
- O O
- O O
III O B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
and O O
the O O
mediolateral O B_LOCATION/B_MEASURE
direction O I_LOCATION/I_MEASURE
of O O
layer O B_BODY_PART_OR_ORGAN_COMPONENT
IV O I_BODY_PART_OR_ORGAN_COMPONENT
, O O
the O O
vertical O B_MEASURE/B_LOCATION
conductivity O I_MEASURE/I_LOCATION
of O O
the O O
cortex O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
was O O
always O O
greater O B_MEASURE
than O O
either O O
of O O
the O O
horizontal O B_LOCATION
conductivities O I_LOCATION
. O O

Our O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
investigated O O
the O O
hypothesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
the O O
combination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
a O O
high O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
NaCl O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
diet O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
social O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
isolation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
stress O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
would O O
increase O O
systolic O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
blood O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
pressure O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
SBP O B_LOCATION/B_DISEASE
) O O
and O O
endogenous O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pump O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ligands O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SPL O B_LOCATION/B_ORGANIZATION
) O O
, O O
ouabainlike O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compound O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
OLC O B_LOCATION/B_DISEASE
) O O
, O O
and O O
marinobufagenin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MBG O B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

The O O
relationship O B_PERSON/B_MEASURE
between O O
polymorphonuclear O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
granulocytes O I_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
cartilage O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
destruction O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
in O O
rheumatoid O B_DISEASE/B_SPECIES[BIO]
arthritis O B_DISEASE/I_SPECIES[BIO]
. O O

It O O
is O O
suggested O O
that O O
the O O
loss O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
weight O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]
in O O
food O B_DISEASE/B_GENE
intake O I_DISEASE/I_GENE
and O O
the O O
increase O B_DISEASE_ADJECTIVE[DISEASE]
in O O
brain O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
MOPEG O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
SO4 O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
induced O O
by O O
cyanamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reflect O O
possible O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
anorectic O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
properties O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Twenty O B_NUMBER[MEASURE]
- O O
two O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
( O O
30 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
showed O O
ST O B_LOCATION/B_NUMBER[MEASURE]
- O O
segment O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
depression O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
during O O
AEM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
34 O B_NUMBER[MEASURE]
( O O
49 O B_MEASURE
% O I_MEASURE
) O O
on O O
ExT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

The O O
virus O O
must O O
progress O O
past O O
the O O
immediate O O
- O O
early O O
phase O O
and O O
express O O
an O O
early B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
product I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
s I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
activation O O
of O O
cyclin B B_GENE/B_DISEASE
E I I_GENE/I_DISEASE
expression O O
. O O

In O O
CYP7A1 B B_GENE/B_PERSON
transgenic O O
mice O O
, O O
livers O O
contained O O
approximately O O
3 O O
- O O
fold O O
more O O
sterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
response I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
element I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Adenocarcinoma O B_DISEASE/B_PERSON
and O O
large O B_DISEASE/B_LOCATION
cell O I_DISEASE/I_LOCATION
carcinoma O I_DISEASE/I_LOCATION
have O O
a O O
worse O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prognosis O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
squamous O B_DISEASE/B_PERSON
cell O I_DISEASE/I_PERSON
carcinoma O I_DISEASE/I_PERSON
in O O
the O O
T1N1 O B_PROTEIN[GENE]/B_DISEASE
and O O
T2N1 O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
subsets O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
. O O

In O O
group O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O O
during O O
the O O
pain O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
free O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
period O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
26 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
81 O B_PERSON
patients O I_PERSON
had O O
positive O B_MEASURE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thallium O I_MEASURE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
201 O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
scans O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
whereas O O
20 O B_TIME[MEASURE]
patients O I_TIME[MEASURE]
had O O
an O O
abnormal O B_DISEASE_ADJECTIVE[DISEASE]
ECG O I_DISEASE_ADJECTIVE[DISEASE]
at O O
that O O
time O B_MEASURE/B_LOCATION
; O O
during O O
angina O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
18 O I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
transient O B_DISEASE/B_LOCATION
ECG O I_DISEASE/I_LOCATION
changes O I_DISEASE/I_LOCATION
. O O

The O O
prototype O B_PERSON/B_ORGANIZATION
now O O
structures O O
oncology O B_DISEASE
- O O
related O O
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
available O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
on O O
the O O
Internet O B_ORGANIZATION/B_LOCATION
and O O
also O O
places O O
resources O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
maintained O O
locally O O
at O O
users O B_MEASURE/B_LOCATION
' O B_MEASURE/I_LOCATION
disposal O B_MEASURE/I_LOCATION
. O O

Binding O O
of O O
the O O
TorR B B_GENE/B_BIO
regulator I I_GENE/I_BIO
to O O
cis O O
- O O
acting O O
direct O O
repeats O O
activates O O
tor B B_GENE/B_BACTERIUM[BIO]
operon I I_GENE/I_BACTERIUM[BIO]
expression O O
. O O

For O O
the O O
most O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
part O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O O
only O O
aerobic O B_NUMBER[MEASURE]/B_ORGANIZATION
microbial O I_NUMBER[MEASURE]/I_ORGANIZATION
degradation O I_NUMBER[MEASURE]/I_ORGANIZATION
systems O I_NUMBER[MEASURE]/I_ORGANIZATION
have O O
been O O
reported O O
so O O
far O O
. O O

Asymptomatic O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ischaemia O B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
daily O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
life O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O O
stable O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
coronary O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
artery O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
disease O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
: O O
relevant O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
redundant O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
? O O

This O O
is O O
a O O
consensus O O
casein B B_ENZYME[GENE]
kinase I I_ENZYME[GENE]
II I I_ENZYME[GENE]
( O O
CKII B B_GENE/B_MEASURE
) O O
site O O
and O O
, O O
using O O
purified O O
wild O O
- O O
type O O
and O O
mutant O O
proteins O O
, O O
we O O
show O O
that O O
it O O
is O O
the O O
main O O
CKII B B_LOCATION/B_PERSON
site I I_LOCATION/I_PERSON
in O O
the O O
body O O
of O O
the O O
N O O
- O O
terminal O O
complex O O
- O O
forming O O
region O O
. O O

In O O
contrast O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
Phase O B_LOCATION/B_ORGANIZATION
III O I_LOCATION/I_ORGANIZATION
, O O
which O O
has O O
a O O
single O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
design O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
- O O
the O O
controlled O O
, O O
randomized O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
double O B_MEASURE/B_COLOR
- O O
blind O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
- O O
Phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
IV O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
requires O O
different O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
designs O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
each O O
of O O
the O O
many O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
different O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
questions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Treatment O O
with O O
polyinosinic O O
- O O
polycytidylic O O
acid O O
to O O
induce O O
expression O O
of O O
Cre B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulted O O
in O O
complete O O
disruption O O
of O O
the O O
Arnt B B_GENE
gene I I_GENE
and O O
loss O O
of O O
ARNT B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
messenger I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
mRNA O O
) O O
expression O O
in O O
liver O O
. O O

Physical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
map O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
the O O
genome O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
sonchus O B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
yellow O I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
net O I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
virus O I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
plant O B_SPECIES[BIO]/B_LOCATION
rhabdovirus O O
with O O
six O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
genes O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O O
conserved O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
gene O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
junction O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sequences O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

Tubular O O
dysfunction O O
in O O
renal O O
lithiasis O O
: O O
cause O O
or O O
consequence O O
? O O
] O O
To O O
investigate O O
whether O O
overall O O
tubular O O
dysfunction O O
is O O
encountered O O
in O O
a O O
particular O O
subgroup O O
of O O
patients O O
with O O
urolithiasis O O
, O O
the O O
following O O
parameters O O
of O O
renal O O
tubular O O
function O O
have O O
been O O
measured O O
in O O
fasting O O
morning O O
urine O O
in O O
124 O O
male O O
stone O O
formers O O
: O O
excretion O O
of O O
lysozyme B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O O
gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glutamyl I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transpeptidase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
gamma B B_LOCATION/B_PROTEIN[GENE]
- I I_LOCATION/I_PROTEIN[GENE]
GT I I_LOCATION/I_PROTEIN[GENE]
) O O
, O O
fractional O O
excretion O O
( O O
FE O O
) O O
or O O
glucose O O
, O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
bicarbonate O O
after O O
an O O
alkali O O
load O O
, O O
and O O
theoretical O O
phosphate O O
threshold O O
( O O
TmP O O
/ O O
GFR O O
) O O
. O O

Interaction O O
between O O
the O O
tobacco O O
DNA O O
- O O
binding O O
activity O O
CBF B B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
the O O
cyt B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
Agrobacterium O O
tumefaciens O O
T O O
- O O
DNA O O
gene O O
T B B_LOCATION/B_PERSON
- I I_LOCATION/I_PERSON
CYT I I_LOCATION/I_PERSON
correlates O O
with O O
cyt B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1 I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
directed O O
gene O O
expression O O
in O O
multiple O O
tobacco O O
tissue O O
types O O
. O O

As O O
expected O O
, O O
the O O
QOLS O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
N O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
a O O
lower O B_MEASURE
correlation O I_MEASURE
with O O
physical O B_DISEASE_ADJECTIVE[DISEASE]
health O I_DISEASE_ADJECTIVE[DISEASE]
( O O
r O B_OTHER/B_PROTEIN[GENE]
= O O
0 O B_NUMBER[MEASURE]
. O O
24 O B_MEASURE
, O O
p O O
< O O
0 O B_MEASURE
. O O
000 O B_MEASURE
) O O
and O O
self O B_PERSON/B_LOCATION
- O O
reported O O
symptoms O B_DISEASE
( O O
r O B_OTHER/B_GENE
= O O
- O O
0 O B_MEASURE
. O O
20 O B_MEASURE
, O O
p O O
< O B_MEASURE
0 O I_MEASURE
. O O
001 O B_MEASURE
) O O
, O O
and O O
a O O
higher O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
correlation O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
with O O
mental O B_DISEASE_ADJECTIVE[DISEASE]
health O I_DISEASE_ADJECTIVE[DISEASE]
( O O
r O B_OTHER/B_GENE
= O O
0 O B_MEASURE
. O O
52 O B_MEASURE
, O O
p O O
< O O
0 O B_MEASURE
. O O
000 O B_MEASURE
) O O
. O O

The O O
N1 O B_PROTEIN[GENE]/B_DISEASE
- O O
P2 O B_MEASURE
amplitudes O I_MEASURE
of O O
the O O
AEP O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
decreased O O
with O O
increasing O O
strength O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
muscular O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
innervation O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

SN O B_MEASURE/B_PROTEIN[GENE]
- O O
38 O B_MEASURE/B_BIO
rebound O B_MEASURE/I_BIO
concentrations O B_MEASURE/I_BIO
were O O
observed O O
in O O
many O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
courses O I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
at O O
about O O
0 O B_MEASURE/B_LOCATION
. O O
5 O B_MEASURE
to O O
1 O B_MEASURE/B_ENT
hour O I_MEASURE/I_ENT
following O O
the O O
end O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
i O O
. O O
v O B_PROTEIN[GENE]/B_MEASURE
. O O
infusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
which O O
is O O
suggestive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
enterohepatic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
recycling O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Sequence O O
analysis O O
of O O
AEBP2 B B_GENE
cDNA I I_GENE
revealed O O
that O O
it O O
encodes O O
a O O
protein O O
containing O O
three O O
Gli B B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
- O O
Kruppel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
Cys2 O O
- O O
His2 O O
) O O
- O O
type O O
zinc O O
fingers O O
. O O

In O O
the O O
case O O
of O O
the O O
pT181 O O
plasmid O O
, O O
inactivation O O
of O O
the O O
initiator B B_ENZYME[GENE]
RepC I I_ENZYME[GENE]
protein I I_ENZYME[GENE]
occurs O O
by O O
the O O
attachment O O
of O O
an O O
oligonucleotide O O
to O O
its O O
active O O
tyrosine O O
residue O O
. O O

Xanthoepocin O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
new O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
antibiotic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
from O O
Penicillium O B_LOCATION/B_BACTERIUM[BIO]
simplicissimum O I_LOCATION/I_BACTERIUM[BIO]
IFO5762 O I_LOCATION/I_BACTERIUM[BIO]
. O O

Extracellular B B_GENE
regulated I I_GENE
kinases I I_GENE
( I I_GENE
ERK I I_GENE
) I I_GENE
1 I I_GENE
and O O
ERK2 B B_GENE/B_MEASURE
are O O
authentic O O
substrates O O
for O O
the O O
dual B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
specificity I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
VHR I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Leukocytoclasic O B_DISEASE_ADJECTIVE[DISEASE]
vasculitis O I_DISEASE_ADJECTIVE[DISEASE]
during O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
dose O B_MEASURE
captopril O I_MEASURE

H O B_OTHER/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Truncations O O
from O O
Hip B B_GENE/B_DISEASE
' O O
s O O
N O O
terminus O O
resulted O O
in O O
an O O
apparent O O
loss O O
of O O
Hip B B_GENE/B_DISEASE
homo O O
- O O
oligomerization O O
, O O
but O O
these O O
mutants O O
retained O O
association O O
with O O
hsp70 B B_GENE
and O O
were O O
recovered O O
in O O
receptor O O
complexes O O
. O O

The O O
biological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
basis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
changes O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
CNAPs O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
produced O O
by O O
CS2 O B_DISEASE/B_GENE
is O O
under O O
investigation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
very O O
large O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
PC O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
LAN O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
as O O
the O O
basis O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
a O O
hospital O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
information O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

This O O
was O O
tragically O O
highlighted O O
by O O
the O O
death O B_PERSON/B_DISEASE
of O O
a O O
17 O B_PERSON
year O I_PERSON
old O I_PERSON
dental O I_PERSON
nurse O I_PERSON
after O O
taking O O
a O O
single O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
g O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tablet O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
sodium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nitrite O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
human O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
encoded O O
by O O
a O O
900 O B_NUMBER[MEASURE]
- O O
base O B_MEASURE/B_LOCATION
pair O I_MEASURE/I_LOCATION
- O O
long O B_GENE/B_LOCATION
mRNA O I_GENE/I_LOCATION
that O O
is O O
expressed O O
in O O
the O O
glandular O B_BODY_PART_OR_ORGAN_COMPONENT
epithelial O I_BODY_PART_OR_ORGAN_COMPONENT
cells O I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
endometrium O B_BODY_PART_OR_ORGAN_COMPONENT
in O O
a O O
cyclic O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
manner O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
; O O
in O O
addition O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
it O O
is O O
found O O
in O O
the O O
mucosal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
epithelial O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
fallopian O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tubes O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
this O O
report O O
, O O
we O O
describe O O
a O O
patient O O
with O O
renal O O
cell O O
carcinoma O O
who O O
experienced O O
ventricular O O
tachycardia O O
while O O
undergoing O O
treatment O O
with O O
high O O
- O O
dose O O
bolus O O
IL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Four O B_NUMBER[MEASURE]/B_PERSON
antifungal O I_NUMBER[MEASURE]/I_PERSON
agents O I_NUMBER[MEASURE]/I_PERSON
were O O
compared O O
: O O
amphotericin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
flucytosine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
miconazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
ketoconazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
regulatory O O
genes O O
cnrYXH B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
been O O
cloned O O
, O O
overexpressed O O
, O O
and O O
purified O O
in O O
Escherichia O O
coli O O
. O O

Examination O O
of O O
the O O
Coomassie O O
- O O
stained O O
gels O O
revealed O O
that O O
the O O
capsid O O
- O O
like O O
particles O O
composed O O
of O O
the O O
N11 B B_PERSON/B_VIRUS[BIO]
- I I_PERSON/I_VIRUS[BIO]
VP1 I I_PERSON/I_VIRUS[BIO]
protein O O
did O O
not O O
contain O O
any O O
host O O
- O O
derived O O
histones B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Conversion O O
of O O
an O O
NF B B_GENE
- I I_GENE
kappaB I I_GENE
into O O
a O O
GABP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding O O
site O O
is O O
likely O O
to O O
have O O
occurred O O
also O O
during O O
the O O
worldwide O O
spread O O
of O O
HIV O O
- O O
1 O O
, O O
as O O
we O O
noticed O O
the O O
same O O
LTR O O
modification O O
in O O
subtype O O
E O O
isolates O O
from O O
Thailand O O
. O O

Protein O O
binding O O
to O O
UAS1MLS1 B B_GENE
was O O
observed O O
with O O
extracts O O
from O O
derepressed O O
but O O
not O O
from O O
repressed O O
cells O O
, O O
and O O
could O O
be O O
competed O O
for O O
by O O
an O O
excess O O
of O O
the O O
unlabelled O O
CSRE O O
( O O
ICL1 B B_PROTEIN[GENE]/B_LOCATION
) O O
sequence O O
. O O

We O O
then O O
isolated O O
the O O
full O O
- O O
length O O
coding O O
region O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
BACH1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
using O O
expressed O O
sequence O O
tags O O
, O O
reverse O O
transcription O O
- O O
polymerase O O
chain O O
reaction O O
and O O
rapid O O
amplification O O
of O O
cDNA O O
ends O O
. O O

Authors O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
present O O
the O O
anatomical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
variations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
course O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
inferior O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
mesenteric O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
artery O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
and O O
its O O
branches O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
62 O B_PERSON/B_BIO
human O B_PERSON/I_BIO
fetus O B_PERSON/I_BIO
. O O

The O O
7 B B_GENE
. I I_GENE
2 I I_GENE
kb I I_GENE
EcoRI I I_GENE
fragment I I_GENE
of I I_GENE
AfMNPV I I_GENE
was O O
cloned O O
and O O
the O O
nucleotide O O
sequences O O
of O O
the O O
polyhedrin B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
coding O O
region O O
and O O
its O O
flanking O O
regions O O
were O O
determined O O
. O O

1 O B_NUMBER[MEASURE]
. O O

The O O
increments O O
in O O
median O O
plasma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
secretin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
concentration O O
were O O
1 O O
. O O
6 O O
, O O
3 O O
. O O
0 O O
, O O
and O O
6 O O
. O O
4 O O
pmol O O
x O O
1 O O
( O O
- O O
1 O O
) O O
after O O
secretin B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
125 O O
, O O
250 O O
and O O
500 O O
fmol O O
x O O
kg O O
- O O
1 O O
, O O
and O O
the O O
corresponding O O
15 O O
- O O
min O O
bicarbonate O O
output O O
283 O O
, O O
442 O O
, O O
and O O
1435 O O
micromol O O
, O O
respectively O O
. O O

The O O
resulting O O
threshold O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
elevation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
curves O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
fell O O
into O O
a O O
small O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
distinct O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
groups O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
suggesting O O
the O O
existence O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O O
discrete O B_DISEASE/B_MEASURE
spatial O I_DISEASE/I_MEASURE
frequency O I_DISEASE/I_MEASURE
mechanisms O I_DISEASE/I_MEASURE
in O O
human O B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
central O B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
vision O B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
. O O

Because O O
c B B_GENE
- I I_GENE
myb I I_GENE
encodes O O
a O O
transcriptional O O
activator O O
that O O
functions O O
via O O
DNA O O
binding O O
, O O
it O O
is O O
likely O O
that O O
c B B_GENE
- I I_GENE
myb I I_GENE
exerts O O
its O O
biological O O
activity O O
by O O
regulating O O
the O O
transcription O O
of O O
genes O O
required O O
for O O
DNA O O
synthesis O O
and O O
cell O O
cycle O O
progression O O
. O O

The O O
rest O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
3 O B_GENE/B_LOCATION
' O I_GENE/I_LOCATION
untranslated O I_GENE/I_LOCATION
sequences O I_GENE/I_LOCATION
were O O
common O B_DISEASE_ADJECTIVE[DISEASE]
to O O
both O O
cDNA O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
clones O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Coexpression O O
of O O
c B B_GENE
- I I_GENE
Rel I I_GENE
in O O
combination O O
with O O
ATF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
CREB2 B B_GENE
, O O
or O O
ATF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
CREB2 B B_GENE/B_MEASURE
leads O O
to O O
synergistic O O
transactivation O O
of O O
a O O
CD28RE B B_GENE
- I I_GENE
TRE I I_GENE
reporter I I_GENE
plasmid O O
in O O
quiescent O O
Jurkat O O
T O O
- O O
cells O O
. O O

Conventional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
toxicological O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
considerations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
suggest O O
that O O
the O O
adverse O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
health O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
effects O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
any O O
necessary O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increase O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
coal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
combustion O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effluents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
would O O
be O O
greatest O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
per O O
unit O B_ORGANIZATION/B_LOCATION
of O O
coal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
those O O
areas O B_LOCATION
which O O
are O O
most O O
heavily O O
populated O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
have O O
the O O
highest O B_MEASURE/B_LOCATION
preexisting O B_MEASURE/I_LOCATION
levels O B_MEASURE/I_LOCATION
of O O
the O O
gas O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
aerosol O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
complex O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

The O O
genes O O
on O O
each O O
chromosome O O
involved O O
in O O
this O O
translocation O O
have O O
been O O
identified O O
as O O
the O O
transcription O O
factor O O
- O O
encoding O O
genes O O
PAX3 B B_GENE/B_DISEASE
and O O
FKHR B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
search O O
was O O
conducted O O
for O O
suppressors O O
of O O
the O O
inositol O O
auxotrophic O O
phenotype O O
of O O
the O O
ino4 B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
8 I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
mutant I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
of O O
yeast O O
. O O

Anesthesia O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O O
induced O O
by O O
droperidol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
0 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O
2 O B_MEASURE
mg O I_MEASURE
. O O
kg O B_MEASURE
- O O
1 O B_NUMBER[MEASURE]
, O O
fentanyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
50 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
micrograms O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
thiamylal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
150 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
250 O B_MEASURE
mg O I_MEASURE
, O O
and O O
succinylcholine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O
kg O B_MEASURE
- O O
1 O B_NUMBER[MEASURE]
, O O
and O O
maintained O O
with O O
nitrous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
oxide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
O2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
67 O B_MEASURE
: O O
33 O B_MEASURE
) O O
supplemented O O
with O O
repeated O O
i O O
. O O
v O B_GENE/B_LOCATION
. O O
doses O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
fentanyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
within O O
15 O B_MEASURE/B_LOCATION
micrograms O I_MEASURE/I_LOCATION
. O O
kg O B_MEASURE
- O O
1 O B_NUMBER[MEASURE]
) O O
. O O

Complexities O B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
host O B_PERSON/B_BIO
- O O
pathogen O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
interactions O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
during O O
actual O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infection O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
Gram O B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
negative O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
bacteria O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
may O O
account O O
for O O
the O O
difficulties O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
demonstrating O O
this O O
phenomena O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
vivo O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
novel O O
TRPC7 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
could O O
be O O
a O O
candidate O O
gene O O
for O O
genetic O O
disorders O O
such O O
as O O
bipolar O O
affective O O
disorder O O
, O O
nonsyndromic O O
hereditary O O
deafness O O
, O O
Knobloch O O
syndrome O O
, O O
and O O
holoprosencephaly O O
, O O
which O O
were O O
mapped O O
to O O
this O O
region O O
. O O

Paradoxically O O
, O O
loop O O
3i O O
from O O
the O O
M1Ach B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
muscarinic I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
also O O
maximally O O
inhibited O O
GnRH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agonist O O
- O O
stimulated O O
cAMP O O
accumulation O O
and O O
PRL B B_GENE
release O O
by O O
40 O O
% O O
( O O
both O O
effects O O
mediated O O
through O O
activation O O
of O O
the O O
Gs B B_PROTEIN[GENE]/B_LOCATION
protein I I_PROTEIN[GENE]/I_LOCATION
) O O
. O O

We O O
present O O
the O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
patient O B_PERSON/B_BIO
who O O
presented O O
an O O
unusually O O
large O B_DISEASE/B_MEASURE
mucoid O I_DISEASE/I_MEASURE
cyst O I_DISEASE/I_MEASURE
measuring O O
38 O B_MEASURE
x O O
25 O B_MEASURE
mm O I_MEASURE
in O O
an O O
uncommon O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
localization O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
, O O
the O O
right O B_BODY_PART_OR_ORGAN_COMPONENT
maxillary O I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Acoustic O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
property O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurements O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
oxide O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
superconductor O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BaPb1 O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
xBixO3 O B_MEASURE
by O O
the O O
sphere O B_LOCATION/B_MEASURE
- O O
resonance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

In O O
7 O B_MEASURE/B_SPORT[ENT]
men O I_MEASURE/I_SPORT[ENT]
and O O
1 O B_PERSON
woman O I_PERSON
who O O
died O O
suddenly O O
the O O
functionally O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
areas O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
myocardium O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
in O O
the O O
sino O B_DISEASE/B_GENE
- O O
auricular O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
area O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
and O O
the O O
subendocardial O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
layers O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
left O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ventricle O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O O
obtained O O
by O O
necropsy O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
no O O
more O B_TIME[MEASURE]/B_LOCATION
than O O
3 O B_MEASURE
h O O
after O O
death O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
then O O
prepared O O
for O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
electron O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

IGF B B_PERSON/B_GENE
- I I_PERSON/I_GENE
I I I_PERSON/I_GENE
levels O O
were O O
measured O O
in O O
the O O
CSF O O
of O O
11 O O
children O O
with O O
autism O O
( O O
4 O O
females O O
, O O
7 O O
males O O
; O O
mean O O
age O O
3 O O
. O O
8 O O
years O O
, O O
SD O O
1 O O
. O O
1 O O
) O O
using O O
a O O
sensitive O O
radioimmunoassay O O
method O O
and O O
compared O O
with O O
levels O O
in O O
11 O O
control O O
participants O O
( O O
6 O O
females O O
, O O
5 O O
males O O
; O O
mean O O
age O O
3 O O
. O O
8 O O
years O O
) O O
. O O

In O O
a O O
subsequent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
phase O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
II O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clinical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
safety O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
transrectal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
HIFU O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
as O O
a O O
novel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
minimally O O
invasive O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
modality O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
patients O B_PERSON/B_BIO
with O O
symptomatic O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
benign O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
prostatic O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
hyperplasia O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
BPH O B_DISEASE
; O O
n O O
= O O
102 O B_MEASURE
) O O
was O O
determined O O
. O O

Three O O
high O O
- O O
amylose O O
rice O O
varieties O O
, O O
IR42 O O
, O O
IR36 O O
, O O
and O O
IR62 O O
, O O
with O O
similar O O
chemical O O
composition O O
including O O
amylose O O
content O O
( O O
26 O O
. O O
7 O O
- O O
27 O O
. O O
0 O O
% O O
) O O
, O O
were O O
cooked O O
under O O
the O O
same O O
conditions O O
and O O
tested O O
for O O
in O O
vitro O O
digestibility O O
as O O
well O O
as O O
blood O O
glucose O O
and O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
responses O O
in O O
healthy O O
human O O
volunteers O O
. O O

Slowly O O
adapting O O
type O B_MEASURE/B_DISEASE
I O O
mechanoreceptor O O
discharge O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
as O O
a O O
function O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
dynamic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
force O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
versus O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
dynamic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
displacement O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
glabrous O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
skin O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
raccoon O B_SPECIES[BIO]
and O O
squirrel O B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
monkey O I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
hand O I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Using O O
beta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AR I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
luciferase B B_GENE
reporter O O
recombinants O O
, O O
we O O
have O O
previously O O
determined O O
that O O
important O O
beta B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AR I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genetic O O
elements O O
controlling O O
expression O O
within O O
the O O
C6 O O
glioma O O
cell O O
line O O
are O O
contained O O
within O O
the O O
region O O
- O O
396 O O
to O O
- O O
299 O O
, O O
relative O O
to O O
the O O
translational O O
start O O
site O O
. O O

FACS O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
demonstrated O O
that O O
MCs O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
had O O
reached O O
middle O O
to O O
late O B_MEASURE/B_LOCATION
G1 O B_MEASURE/I_LOCATION
phase O B_MEASURE/I_LOCATION
of O O
cell O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cycle O B_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
progression O B_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
at O O
this O O
timepoint O B_TIME[MEASURE]/B_LOCATION
. O O

Our O O
case O O
, O O
however O O
, O O
had O O
no O O
histologic O O
evidence O O
of O O
malignancy O O
, O O
no O O
serum B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fetoprotein I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
7 O O
months O O
of O O
age O O
, O O
and O O
no O O
recurrence O O
at O O
1 O O
years O O
. O O

Analysis O O
of O O
tobacco O O
mRNA O O
using O O
the O O
ACBF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cDNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O O
probe O O
showed O O
that O O
while O O
ACBF B B_GENE
mRNA I I_GENE
was O O
present O O
in O O
all O O
tissues O O
examined O O
, O O
the O O
highest O O
transcript O O
accumulation O O
occurred O O
in O O
stem O O
tissues O O
. O O

Cotransfection O O
experiments O O
revealed O O
that O O
both O O
hGATA B B_GENE
- I I_GENE
4 I I_GENE
and O O
PMA O O
/ O O
A23187 O O
stimulation O O
are O O
necessary O O
for O O
the O O
IL B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
5 I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
activation O O
. O O

Here O O
we O O
show O O
that O O
expression O O
of O O
KRAB B B_GENE/B_DISEASE
domain I I_GENE/I_DISEASE
suppresses O O
in O O
vivo O O
the O O
activating O O
function O O
of O O
various O O
defined O O
activating B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
we O O
demonstrate O O
that O O
the O O
KRAB B B_GENE/B_LOCATION
domain I I_GENE/I_LOCATION
specifically O O
silences O O
the O O
activity O O
of O O
promoters O O
whose O O
initiation O O
is O O
dependent O O
on O O
the O O
presence O O
of O O
a O O
TATA O O
box O O
. O O

Adult O B_PERSON/B_TIME[MEASURE]
- O O
onset O B_DISEASE
parkinsonism O I_DISEASE
has O O
appeared O O
in O O
several O B_NUMBER[MEASURE]/B_PERSON
previously O O
unaffected O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
members O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
families O B_PERSON/B_SOCIAL_CIRCUMSTANCES
with O O
DRD O B_DISEASE/B_GENE
suggesting O O
that O O
this O O
may O O
be O O
an O O
additional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
phenotypical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
expression O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
disease O B_DISEASE/B_GENE
. O O

We O O
tested O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
antifungal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
adherence O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
Candida O B_SPECIES[BIO]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
albicans O B_SPECIES[BIO]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
vitro O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
signs O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
enterocolitis O B_DISEASE
, O O
pathological O B_DISEASE_ADJECTIVE[DISEASE]
microbial O I_DISEASE_ADJECTIVE[DISEASE]
flora O I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
stool O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
changes O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
colon O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
mucosa O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O O
absent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

These O O
results O O
support O O
an O O
in O O
vivo O O
interaction O O
between O O
Nck B B_GENE
and O O
CKI B B_GENE
- I I_GENE
gamma2 I I_GENE
and O O
suggest O O
that O O
CKI B B_GENE/B_PERSON
- I I_GENE/I_PERSON
gamma2 I I_GENE/I_PERSON
could O O
be O O
involved O O
in O O
signaling O O
pathways O O
downstream O O
of O O
RTKs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Correlation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
nitrogen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
carbohydrate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
lipid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
metabolic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
indices O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cooled O O
under O O
conditions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
an O O
altered O B_DISEASE/B_LOCATION
gaseous O I_DISEASE/I_LOCATION
environment O I_DISEASE/I_LOCATION

Reactivation O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hepatitis O B_DISEASE
B O I_DISEASE
virus O I_DISEASE
replication O I_DISEASE
is O O
a O O
rare O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
event O B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
the O O
natural O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
history O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
chronic O B_DISEASE
hepatitis O I_DISEASE
B O I_DISEASE
. O O

A O O
minimal O O
region O O
which O O
stimulates O O
origin O O
function O O
mapped O O
to O O
50 O O
amino O O
acids O O
within O O
the O O
C O O
- O O
terminus O O
of O O
Abf1p B B_GENE
. O O

Cutaneous O B_DISEASE/B_PERSON
melanoma O I_DISEASE/I_PERSON
and O O
bilateral O B_DISEASE
retinoblastoma O I_DISEASE
. O O

Treatment O O
of O O
JEA2 O O
cells O O
with O O
interleukin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
IL I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
7 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
induces O O
CBLB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
phosphorylation O O
as O O
well O O
. O O

Phosphorylation O O
by O O
Cdc28 B B_GENE
activates O O
the O O
Cdc20 B B_GENE
- O O
dependent O O
activity O O
of O O
the O O
anaphase O O
- O O
promoting O O
complex O O
. O O

METHOD O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
After O O
eligibility O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
patients O B_PERSON
were O O
randomly O O
allocated O O
in O O
one O B_NUMBER[MEASURE]/B_LOCATION
of O O
the O O
following O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
M O B_OTHER/B_LOCATION
= O O
methylprednisolone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
30 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O
kg O B_MEASURE/B_LOCATION
- O O
1 O B_NUMBER[MEASURE]/B_LOCATION
over O O
1 O B_NUMBER[MEASURE]/B_ENT
hour O I_NUMBER[MEASURE]/I_ENT
, O O
followed O O
by O O
5 O B_MEASURE
. O O
4 O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
kg O B_MEASURE/B_LOCATION
- O O
1 O B_NUMBER[MEASURE]
. O O
h O O
- O O
1 O B_NUMBER[MEASURE]
for O O
23 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
hours O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
, O O
N O B_OTHER/B_LOCATION
= O O
nimodipine O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
015 O B_MEASURE
mg O I_MEASURE
. O O
kg O B_MEASURE/B_LOCATION
- O O
1 O B_NUMBER[MEASURE]
. O O
h O O
- O O
1 O B_NUMBER[MEASURE]
over O O
2 O B_MEASURE/B_ENT
hours O I_MEASURE/I_ENT
followed O O
by O O
0 O B_MEASURE
. O O
03 O B_MEASURE/B_PERSON
mg O I_MEASURE/I_PERSON
. O O
kg O B_MEASURE/B_LOCATION
- O O
1 O B_NUMBER[MEASURE]
. O O
h O O
- O O
1 O B_NUMBER[MEASURE]
for O O
7 O B_ENT/B_LOCATION
days O I_ENT/I_LOCATION
, O O
MN O B_LOCATION/B_DISEASE
or O O
P O B_PROTEIN[GENE]/B_LOCATION
. O O

The O O
amount O B_MEASURE/B_LOCATION
of O O
overlap O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
VFI O B_LOCATION/B_DISEASE
, O O
EF O B_LOCATION/B_DISEASE
, O O
and O O
RVF O B_LOCATION/B_MEASURE
values O I_LOCATION/I_MEASURE
among O O
the O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
was O O
considerable O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

After O O
5 O B_MEASURE
, O O
850 O B_MEASURE
C14 O I_MEASURE
BP O I_MEASURE
, O O
the O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]
in O O
Acer O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
stands O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
could O O
be O O
attributed O O
to O O
fire O B_DISEASE
as O O
suggested O O
by O O
the O O
strong O B_DISEASE_ADJECTIVE[DISEASE]
increase O I_DISEASE_ADJECTIVE[DISEASE]
in O O
Betula O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
and O O
by O O
the O O
delayed O O
expansion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
Pinus O B_BIO/B_LOCATION
cembra O I_BIO/I_LOCATION
. O O

Assays O O
of O O
APRE O O
- O O
luciferase B B_GENE
reporter O O
plasmids O O
transfected O O
into O O
HepG2 O O
cells O O
show O O
that O O
a O O
mutated O O
APRE O O
that O O
binds O O
only O O
BPi B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functions O O
as O O
an O O
IL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
inducible O O
enhancer O O
, O O
whereas O O
a O O
mutated O O
APRE O O
that O O
binds O O
only O O
BPc B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
does O O
not O O
. O O

RNA O O
unwinding O O
in O O
U4 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
U6 B B_MEASURE
snRNPs O O
requires O O
ATP O O
hydrolysis O O
and O O
the O O
DEIH O O
- O O
box O O
splicing O O
factor O O
Brr2 B B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Several O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
sequences O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
resembling O O
binding O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
sites O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
for O O
liver O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
and O O
fat O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
body O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
transcription O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
factors O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
were O O
identified O O
within O O
1 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
kb O I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
upstream O O
and O O
downstream O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
gene O B_GENE/B_LOCATION
. O O

Northern O O
blot O O
analysis O O
linked O O
Plk B B_GENE
expression O O
to O O
the O O
proliferative O O
activity O O
of O O
cells O O
and O O
tissues O O
. O O

It O O
also O O
showed O O
which O O
amino O O
acid O O
residues O O
would O O
contact O O
an O O
extended O O
TATA O O
box O O
with O O
a O O
B B B_GENE
recognition I I_GENE
element I I_GENE
, O O
and O O
evolutionary O O
conservation O O
of O O
the O O
TBP B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
TFB B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
DNA O O
complex O O
orientation O O
between O O
two O O
archaeal O O
organisms O O
with O O
widely O O
different O O
optimal O O
temperature O O
for O O
growth O O
( O O
37 O O
and O O
100 O O
degrees O O
C O O
) O O
. O O

Studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
and O O
without O O
attenuating O O
media O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O O
performed O O
, O O
and O O
myocardium O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
to O O
- O O
defect O B_MEASURE/B_DISEASE
count O B_MEASURE/I_DISEASE
ratios O B_MEASURE/I_DISEASE
and O O
defect O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sizes O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
dual O B_NUMBER[MEASURE]/B_LOCATION
- O O
isotope O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
SPECT O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
images O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
compared O O
to O O
myocardium O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
to O O
- O O
defect O B_MEASURE/B_DISEASE
count O B_MEASURE/I_DISEASE
ratios O B_MEASURE/I_DISEASE
and O O
defect O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sizes O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
single O B_NUMBER[MEASURE]/B_PERSON
- O O
isotope O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
201Tl O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
99mTc O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
SPECT O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
images O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Comparison O O
of O O
this O O
gene O O
with O O
the O O
available O O
databases O O
reveals O O
very O O
significant O O
homology O O
to O O
the O O
ETS B B_MEASURE/B_GENE
factor I I_MEASURE/I_GENE
PE B I_MEASURE/I_GENE
- I I_MEASURE/I_GENE
1 I I_MEASURE/I_GENE
and O O
probable O O
near O O
- O O
identity O O
with O O
the O O
recently O O
cloned O O
factor O O
ERF B B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Patients O O
with O O
Eales O O
' O O
disease O O
, O O
chorioretinitis O O
, O O
central O O
serous O O
retinopathy O O
, O O
or O O
malignant O O
choroidal O O
melanoma O O
were O O
tested O O
for O O
HLA B B_GENE/B_VIRUS[BIO]
antigen O O
deviation O O
. O O

Copyright O B_LOCATION/B_PERSON
1999 O I_LOCATION/I_PERSON
Academic O I_LOCATION/I_PERSON
Press O I_LOCATION/I_PERSON
. O O

The O O
1 O B_MEASURE
. O O
5 O B_MEASURE
- O O
Mb O B_MEASURE/B_LOCATION
region O I_MEASURE/I_LOCATION
was O O
covered O O
by O O
137 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cosmids O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
with O O
a O O
minimum O B_MEASURE/B_LOCATION
overlap O I_MEASURE/I_LOCATION
set O I_MEASURE/I_LOCATION
of O O
52 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cosmids O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
assigned O O
to O O
17 O B_MEASURE
bins O I_MEASURE
and O O
9 O B_LOCATION/B_PERSON
contigs O I_LOCATION/I_PERSON
. O O

Similarly O O
, O O
beta B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
adrenoceptors I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
blockade O O
has O O
been O O
shown O O
to O O
be O O
of O O
value O O
in O O
achieving O O
continence O O
in O O
a O O
small O O
group O O
of O O
patients O O
. O O

Estrogen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
positive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
mood O B_DISEASE/B_ORGANISM_FUNCTION
, O O
sexual O B_DISEASE_ADJECTIVE[DISEASE]
function O I_DISEASE_ADJECTIVE[DISEASE]
, O O
target O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
end O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
organs O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
cognitive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
may O O
play O O
an O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
role O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
etiology O B_DISEASE
of O O
Alzheimer O B_DISEASE/B_LOCATION
' O I_DISEASE/I_LOCATION
s O I_DISEASE/I_LOCATION
Disease O I_DISEASE/I_LOCATION
by O O
acting O O
to O O
prevent O O
amyloid O B_DISEASE
plaque O I_DISEASE
formation O I_DISEASE
, O O
oxidative O B_DISEASE_ADJECTIVE[DISEASE]
stress O I_DISEASE_ADJECTIVE[DISEASE]
, O O
or O O
deterioration O B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
cholinergic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
neurotransmitter O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O O

These O O
data O O
also O O
demonstrate O O
that O O
insulin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
TPA O O
activate O O
MBP B B_GENE
/ O O
MAP2 B B_GENE
kinase O O
activity O O
by O O
de O O
novo O O
phosphorylation O O
of O O
threonine O O
and O O
tyrosine O O
residues O O
via O O
a O O
very O O
similar O O
pathway O O
. O O

Effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
capsaicin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
hexobarbital O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
anesthetized O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
rats O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE

Triethylene O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
glycol O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Such O O
tetranucleotides O O
are O O
common O O
in O O
promoter O O
regions O O
, O O
particularly O O
in O O
activating B B_GENE
transcription I I_GENE
factor I I_GENE
/ O O
cyclic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
AMP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
response I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ATF B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
CREB B B_GENE
) O O
and O O
E O O
- O O
box O O
motifs O O
, O O
suggesting O O
that O O
PIF B B_PERSON/B_GENE
may O O
modulate O O
the O O
transcription O O
of O O
many O O
genes O O
. O O

Red O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
99mTc O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
EC O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
131I O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
OIH O B_LOCATION/B_DISEASE
was O O
6 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
and O O
20 O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
% O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
respectively O O
. O O

The O O
dominant O O
inhibitory O O
biological O O
activity O O
of O O
the O O
N O O
terminus O O
correlated O O
with O O
its O O
ability O O
to O O
impair O O
EGF B B_GENE
- O O
dependent O O
activation O O
of O O
GTP B B_GENE
- I I_GENE
Ras I I_GENE
and O O
of O O
MAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
well O O
with O O
the O O
ability O O
of O O
endogenous O O
Sos B B_GENE/B_DISEASE
to O O
form O O
a O O
stable O O
complex O O
with O O
activated O O
EGF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Brainstem O B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
auditory O I_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evoked O O
potential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
responses O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
BAEPs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
were O O
recorded O O
from O O
CZ O B_LOCATION/B_PROTEIN[GENE]
- O O
A1 O B_PROTEIN[GENE]
and O O
CZ O B_LOCATION/B_PROTEIN[GENE]
- O O
A2 O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
scalp O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
regions O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
23 O B_NUMBER[MEASURE]
hypertensive O I_NUMBER[MEASURE]
and O O
14 O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
normotensive O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
subjects O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O O

SM B B_LOCATION/B_PERSON
binds O O
RNA O O
in O O
vitro O O
, O O
suggesting O O
that O O
sequence O O
- O O
or O O
structure O O
- O O
specific O O
mRNA O O
interactions O O
might O O
mediate O O
SM B B_PROTEIN[GENE]/B_DISEASE
specificity O O
. O O

The O O
characterization O O
of O O
fly O O
receptors O O
with O O
features O O
similar O O
to O O
mammalian B B_GENE/B_SPECIES[BIO]
glycoprotein I B_GENE/I_SPECIES[BIO]
hormone I B_GENE/I_SPECIES[BIO]
receptors I B_GENE/I_SPECIES[BIO]
allows O O
a O O
better O O
understanding O O
of O O
the O O
evolution O O
of O O
this O O
unique O O
group O O
of O O
GPCRs B B_GENE/B_BIO
and O O
future O O
elucidation O O
of O O
their O O
ligand O O
signaling O O
mechanisms O O
. O O

Here O O
we O O
show O O
that O O
these O O
sequences O O
are O O
essential O O
for O O
processing O O
of O O
U18 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
snR38 B B_GENE
snoRNAs I I_GENE
and O O
that O O
they O O
compensate O O
for O O
the O O
lack O O
of O O
a O O
canonical O O
terminal O O
stem O O
. O O

The O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
aluminum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
hydroxide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O O
associated O O
with O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
fecal O B_MEASURE/B_DISEASE
fluoride O I_MEASURE/I_DISEASE
excretion O I_MEASURE/I_DISEASE
and O O
a O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
net O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
absorption O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
fluoride O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
regardless O O
of O O
the O O
intake O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
fluoride O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
calcium O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
phosphorus O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
or O O
magnesium O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
humans O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
there O O
was O O
a O O
statistically O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
decrease O I_DISEASE_ADJECTIVE[DISEASE]
of O O
TEWL O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O O
both O O
forearm O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
thigh O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
in O O
CS O B_LOCATION
- O O
treated O O
patients O B_PERSON/B_BIO
compared O O
to O O
non O B_DISEASE
- O O
CS O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
patients O B_PERSON/B_BIO
and O O
controls O B_PERSON/B_BIO
( O O
p O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

Kramer O B_MEASURE/B_ENT
Hamburg O I_MEASURE/I_ENT
1988 O I_MEASURE/I_ENT
, O O
ISBN O B_ORGANIZATION/B_MEASURE
: O O
3 O B_MEASURE
926952 O I_MEASURE
07 O I_MEASURE
5 O I_MEASURE
) O O
, O O
the O O
syndromatic O B_TIME[MEASURE]/B_PERSON
day O I_TIME[MEASURE]/I_PERSON
- O O
to O O
- O O
day O B_TIME[MEASURE]
shifting O I_TIME[MEASURE]
of O O
the O O
psychopathological O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
features O I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
with O O
manic O B_DISEASE
, O O
depressive O B_DISEASE
and O O
several O B_DISEASE
mixed O I_DISEASE
states O I_DISEASE
has O O
a O O
well O O
- O O
defined O O
time O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
in O O
25 O B_PERSON/B_TIME[MEASURE]
patients O I_PERSON/I_TIME[MEASURE]
studied O O
and O O
reported O O
on O O
in O O
this O O
paper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
. O O

Ras B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
involvement O O
in O O
signal O O
transduction O O
by O O
the O O
serotonin B B_GENE
5 I I_GENE
- I I_GENE
HT2B I I_GENE
receptor I I_GENE
. O O

Analysis O O
of O O
exon O O
2 O O
of O O
the O O
factor B B_GENE/B_BIO
IX I I_GENE/I_BIO
gene I I_GENE/I_BIO
revealed O O
a O O
C O O
- O O
- O O
> O O
T O O
mutation O O
in O O
codon O O
10 O O
of O O
the O O
propeptide O O
region O O
, O O
resulting O O
in O O
the O O
substitution O O
of O O
alanine O O
by O O
valine O O
. O O

There O O
was O O
a O O
direct O B_MEASURE/B_LOCATION
proportional O I_MEASURE/I_LOCATION
relationship O I_MEASURE/I_LOCATION
between O O
the O O
spiral O B_MEASURE/B_DISEASE
artery O I_MEASURE/I_DISEASE
flow O I_MEASURE/I_DISEASE
and O O
the O O
pressure O B_MEASURE/B_DISEASE
difference O I_MEASURE/I_DISEASE
between O O
the O O
spiral O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
artery O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
and O O
the O O
amniotic O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluid O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
the O O
pressure O B_MEASURE
difference O I_MEASURE
per O O
flow O B_MEASURE/B_SPORT[ENT]
( O O
the O O
resistance O B_MEASURE/B_PERSON
of O O
the O O
cotyledonary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
unit O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
) O O
was O O
found O O
to O O
be O O
1 O B_MEASURE/B_LOCATION
- O O
- O O
3 O B_MEASURE
mm O I_MEASURE
Hg O I_MEASURE
. O O

ml O B_TIME[MEASURE]/B_PERSON
- O O
1 O B_MEASURE
. O O
min O B_PERSON/B_MEASURE
( O O
8 O B_MEASURE
- O O
- O O
24kPa O B_MEASURE
. O O
ml O B_MEASURE/B_PERSON
- O O
1 O B_MEASURE/B_LOCATION
. O O
s O O
) O O
. O O

Three O O
putative O O
ORFs O O
have O O
significant O O
homology O O
with O O
known O O
proteins O O
: O O
L0968 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
new O O
member O O
of O O
the O O
very O O
large O O
' B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seripauperins I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
family O O
, O O
comprising O O
at O O
least O O
20 O O
yeast O O
members O O
; O O
L1313 B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
new O O
ABC B B_GENE/B_LOCATION
transporter I I_GENE/I_LOCATION
highly O O
homologous O O
to O O
the O O
yeast O O
cadmium O O
resistance O O
protein O O
Ycf1p B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
to O O
the O O
human B B_GENE/B_BIO
multidrug I I_GENE/I_BIO
resistance I I_GENE/I_BIO
protein I I_GENE/I_BIO
hMRP1 B I_GENE/I_BIO
; O O
the O O
C O O
- O O
terminal O O
part O O
of O O
L1325 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
present O O
in O O
our O O
sequence O O
is O O
very O O
homologous O O
to O O
the O O
fruit O O
fly O O
abdominal O O
segment O O
formation O O
protein O O
Pumilio B B_PERSON/B_PROTEIN[GENE]
. O O

The O O
cells O B_BODY_PART_OR_ORGAN_COMPONENT
were O O
densely O O
ciliated O O
, O O
each O O
cilium O B_BIO/B_MEASURE
showing O O
a O O
typical O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
9 O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
+ O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
2 O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
fibrilar O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
pattern O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Immunofluorescence O O
obtained O O
using O O
antibodies O O
against O O
alphaI B B_GENE
SigmaI I I_GENE
/ I I_GENE
+ I I_GENE
+ I I_GENE
betaI I I_GENE
SigmaI I I_GENE
spectrin I I_GENE
and O O
Abl B B_GENE
tyrosine I I_GENE
kinase I I_GENE
but O O
not O O
against O O
alphaII B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
betaII I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
spectrin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
colocalized O O
with O O
the O O
overexpressed O O
green B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fluorescent I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
SH3 B B_GENE
- I I_GENE
binding I I_GENE
protein I I_GENE
. O O

Extracellular B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
cancer O O
biomarker O O
: O O
its O O
expression O O
by O O
tumor O O
cells O O
and O O
reversal O O
by O O
a O O
myristate O O
- O O
lacking O O
Calpha O O
and O O
RIIbeta O O
subunit O O
overexpression O O
. O O

Detection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
sinusoidal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
gratings O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
by O O
pattern O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
specific O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
detectors O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
correlation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
principle O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
human O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vision O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
B O O
- O O
box O O
is O O
not O O
present O O
in O O
ETS1 B B_GENE/B_DISEASE
, O O
ETS2 B B_GENE/B_DISEASE
, O O
PEA3 B B_GENE/B_DISEASE
or O O
PU B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
these O O
proteins O O
were O O
unable O O
to O O
form O O
ternary O O
complexes O O
with O O
SRF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
Egrl B B_PROTEIN[GENE]/B_BIO
- O O
SREs O O
or O O
c B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
fos I I_GENE/I_LOCATION
SRE O O
. O O

MADS B B_GENE
- I I_GENE
box I I_GENE
genes I I_GENE
in O O
plants O O
are O O
a O O
diverse O O
class O O
of O O
transcription O O
factors O O
that O O
are O O
involved O O
in O O
regulating O O
developmental O O
processes O O
, O O
particularly O O
meristem O O
and O O
organ O O
identity O O
during O O
floral O O
development O O
. O O

Elevated O O
systolic O O
blood O O
pressure O O
and O O
high O O
postglucose O O
serum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
insulin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
showed O O
an O O
independent O O
, O O
significant O O
association O O
with O O
left O O
ventricular O O
mass O O
in O O
female O O
diabetic O O
subjects O O
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
investigated O O
if O O
signal O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
- O O
averaged O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amplitude O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
atrial O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potentials O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
predict O O
atrial O B_DISEASE
fibrillation O I_DISEASE
or O O
flutter O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
AFF O B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

Thirty O B_NUMBER[MEASURE]
- O O
five O B_NUMBER[MEASURE]
pts O I_NUMBER[MEASURE]
were O O
transplanted O O
for O O
constitutional O B_DISEASE
disease O I_DISEASE
: O O
Fanconi O B_DISEASE
anemia O I_DISEASE
( O O
FA O B_LOCATION/B_PROTEIN[GENE]
) O O
( O O
26 O B_MEASURE/B_LOCATION
pts O I_MEASURE/I_LOCATION
) O O
, O O
Dyskeratosis O B_DISEASE/B_GENE
congenita O I_DISEASE/I_GENE
( O O
2 O B_LOCATION/B_PROTEIN[GENE]
pts O I_LOCATION/I_PROTEIN[GENE]
) O O
, O O
Blackfan O B_PERSON/B_DISEASE
- O O
Diamond O B_DISEASE/B_GENE
erythroblastopenia O I_DISEASE/I_GENE
( O O
2 O B_LOCATION/B_PERSON
pts O I_LOCATION/I_PERSON
) O O
, O O
Glanzmann O B_DISEASE
thrombasthenia O I_DISEASE
( O O
1 O B_LOCATION
pt O I_LOCATION
) O O
, O O
osteopetrosis O B_DISEASE
( O O
1 O B_MEASURE/B_LOCATION
pt O I_MEASURE/I_LOCATION
) O O
and O O
Gaucher O B_PERSON/B_LOCATION
' O O
s O B_DISEASE/B_GENE
disease O I_DISEASE
( O O
1 O B_LOCATION/B_PROTEIN[GENE]
pt O I_LOCATION/I_PROTEIN[GENE]
) O O
. O O

Viral B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
U I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Vpu B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
) O O
is O O
a O O
protein O O
encoded O O
by O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV O O
- O O
1 O O
) O O
that O O
promotes O O
the O O
degradation O O
of O O
the O O
virus O O
receptor O O
, O O
CD4 B B_GENE
, O O
and O O
enhances O O
the O O
release O O
of O O
virus O O
particles O O
from O O
cells O O
. O O

Because O O
the O O
variation O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
carbohydrate O B_MEASURE/B_ENT
content O I_MEASURE/I_ENT
of O O
human O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
milk O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
is O O
very O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
a O O
more O O
simple O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alternative O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
approach O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
would O O
be O O
to O O
include O O
only O O
an O O
average O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carbohydrate O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
value O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
an O O
estimate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
energy O B_MEASURE/B_BIO
content O I_MEASURE/I_BIO
. O O

Level O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mosaicism O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occurred O O
in O O
0 O B_MEASURE
. O O
9 O B_MEASURE
per O O
cent O B_SEQUENCE[MEASURE]
of O O
CVS O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
mesenchyme O I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
and O O
1 O B_MEASURE
. O O
5 O B_MEASURE
per O O
cent O B_SEQUENCE[MEASURE]
of O O
amniotic O B_DISEASE/B_PERSON
fluid O I_DISEASE/I_PERSON
cultures O I_DISEASE/I_PERSON
and O O
in O O
general O B_PERSON/B_MEASURE
was O O
not O O
perceived O O
to O O
be O O
of O O
sufficient O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concern O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
warrant O O
cytogenetic O B_DISEASE_ADJECTIVE[DISEASE]
follow O O
- O O
up O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Biol O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

IV O B_SEQUENCE[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Sleeping O O
position O B_LOCATION/B_DISEASE
and O O
sudden O B_DISEASE_ADJECTIVE[DISEASE]
infant O I_DISEASE_ADJECTIVE[DISEASE]
death O I_DISEASE_ADJECTIVE[DISEASE]
syndrome O I_DISEASE_ADJECTIVE[DISEASE]
( O O
SIDS O B_DISEASE/B_LOCATION
) O O
: O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
an O O
intervention O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
programme O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O O
avoid O O
prone O B_DISEASE
sleeping O I_DISEASE
. O O

CSEn B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulated O O
transcription O O
of O O
a O O
variety O O
of O O
promoters O O
, O O
including O O
the O O
hCS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
human B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
thymidine B B_GENE
kinase I I_GENE
, O O
and O O
Rous B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sarcoma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoters I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
in O O
human O O
choriocarcinoma O O
cell O O
lines O O
( O O
BeWo O O
and O O
JEG O O
- O O
3 O O
) O O
but O O
not O O
HeLa O O
cells O O
or O O
rat O O
somatolactotrophes O O
( O O
GC O O
) O O
. O O

Pretreatment O O
of O O
human O O
skin O O
with O O
tRA O O
inhibited O O
UV O O
induction O O
of O O
c B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Jun I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
, O O
consequently O O
, O O
AP B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
. O O

c B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Jun I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibition O O
occurred O O
via O O
a O O
posttranscriptional O O
mechanism O O
, O O
since O O
tRA O O
did O O
not O O
inhibit O O
UV O O
induction O O
of O O
c B B_GENE
- I I_GENE
Jun I I_GENE
mRNA I I_GENE
. O O

Thus O O
, O O
apoptosis O B_DISEASE
in O O
hematopoietic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
is O O
the O O
end O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
result O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
a O O
conflict O B_MEASURE/B_DISEASE
between O O
death O B_DISEASE
and O O
survival O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
signals O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
rather O O
than O O
a O O
simple O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
death O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
default O B_TIME[MEASURE]/B_DISEASE
. O O

Effect O O
of O O
age O O
on O O
glucose O O
, O O
reducing O O
sugars O O
and O O
plasma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
insulin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
blood O O
of O O
milk O O
- O O
fed O O
calves O O
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
both O O
male O B_PERSON
and O O
female O B_PERSON/B_ENT
soldiers O I_PERSON/I_ENT
who O O
are O O
diagnosed O O
with O O
chlamydia O B_DISEASE/B_LOCATION
infections O I_DISEASE/I_LOCATION
have O O
relatively O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
risks O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
reinfection O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
through O O
their O O
20s O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

During O O
seed O O
maturation O O
, O O
the O O
transcriptional O O
activity O O
of O O
napin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
regulated O O
by O O
developmental O O
signals O O
involving O O
the O O
transcriptional B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activator I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ABI3 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
abscisic O O
acid O O
( O O
ABA O O
) O O
. O O

DESIGN O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Intradermally O O
injected O O
human O B_DISEASE
squamous O I_DISEASE
cell O I_DISEASE
carcinoma O I_DISEASE
cells O I_DISEASE
were O O
grown O O
to O O
40 O B_MEASURE/B_LOCATION
to O O
80 O B_MEASURE
mm3 O I_MEASURE
in O O
athymic O B_MEASURE
nude O I_MEASURE
mice O I_MEASURE
and O O
irradiated O O
with O O
675 O B_MEASURE
- O O
nm O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
light O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
75 O B_MEASURE/B_LOCATION
J O I_MEASURE/I_LOCATION
/ O O
cm2 O B_MEASURE
, O O
75 O B_MEASURE/B_LOCATION
mW O B_MEASURE/I_LOCATION
/ O O
cm2 O B_MEASURE
) O O
24 O B_TIME[MEASURE]/B_SPORT[ENT]
hours O I_TIME[MEASURE]/I_SPORT[ENT]
after O O
the O O
intraperitoneal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
injection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
SiPc O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
IV O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
1 O B_MEASURE
. O O
0 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
) O O
. O O

This O O
results O O
in O O
a O O
decreased O O
secretion O O
of O O
immunoglobulin B B_GENE
A I I_GENE
, O O
and O O
, O O
consequently O O
, O O
a O O
decreased O O
resistance O O
against O O
infections O O
. O O

The O O
absolute O O
CD4 B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
count O O
of O O
patients O O
with O O
de O O
novo O O
IBD O O
was O O
210 O O
- O O
700 O O
cells O O
/ O O
ml O O
at O O
the O O
time O O
of O O
IBD O O
. O O

Categorisation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
different O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
substructures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
within O O
the O O
sections O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
allows O O
them O O
to O O
be O O
analysed O O
and O O
displayed O O
separately O O
. O O

To O O
study O O
the O O
mechanisms O O
and O O
the O O
signaling O O
pathways O O
involved O O
, O O
IGF B B_PERSON/B_GENE
- I I_PERSON/I_GENE
1R I I_PERSON/I_GENE
promoter I I_PERSON/I_GENE
reporter I I_PERSON/I_GENE
constructs I I_PERSON/I_GENE
were O O
transiently O O
transfected O O
in O O
CHO O O
- O O
AT1 O O
cells O O
that O O
overexpress O O
angiotensin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
AT1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

With O O
this O O
study O O
, O O
a O O
total O O
of O O
13 O O
operators O O
for O O
the O O
glp B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
regulon I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O O
been O O
characterized O O
. O O

Natl O B_PERSON/B_BACTERIUM[BIO]
. O O

Coexpression O O
of O O
a O O
dominant B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
negative I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
jun I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antagonized O O
the O O
ras B B_GENE/B_DISEASE
- O O
dependent O O
stimulation O O
of O O
the O O
92 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kDa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gelatinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter O O
- O O
driven O O
CAT B B_GENE
reporter I I_GENE
. O O

In O O
two O B_PERSON/B_MEASURE
patients O I_PERSON/I_MEASURE
, O O
a O O
male O B_PERSON/B_DISEASE
homosexual O I_PERSON/I_DISEASE
and O O
an O O
hemophiliac O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
, O O
thrombocytopenia O B_DISEASE
was O O
associated O O
with O O
AIDS O B_DISEASE
- O O
related O O
complex O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
LXRalpha B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibited O O
binding O O
of O O
PPARalpha B B_GENE
/ O O
RXRalpha B B_GENE
heterodimers O O
to O O
PPREs O O
, O O
and O O
coexpression O O
of O O
LXRalpha B B_GENE/B_PERSON
in O O
mammalian O O
cells O O
antagonized O O
peroxisome O O
proliferator O O
signaling O O
mediated O O
by O O
PPARalpha B B_GENE
/ O O
RXRalpha B B_GENE
in O O
vivo O O
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
can O O
be O O
summarized O O
as O O
follows O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

A O O
case O B_PERSON/B_LOCATION
of O O
heterotopic O B_DISEASE
gastric O I_DISEASE
mucosa O I_DISEASE
( O O
pyloric O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
gland O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
in O O
the O O
wall O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
of O O
the O O
gallbladder O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
was O O
reported O O
. O O

These O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
the O O
mechanism O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
ribosomal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
frameshifting O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
at O O
the O O
PVM O B_LOCATION/B_BIO
signal O I_LOCATION/I_BIO
is O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
from O O
the O O
one O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
described O O
by O O
the O O
' O B_PERSON
simultaneous O I_PERSON
slippage O I_PERSON
' O O
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
that O O
only O O
the O O
string O B_MEASURE
of O O
four O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
adenosine O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
nucleotides O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
represents O O
the O O
slippery O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involved O O
in O O
a O O
- O O
1 O B_NUMBER[MEASURE]/B_LOCATION
P O I_NUMBER[MEASURE]/I_LOCATION
- O O
site O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
slippage O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
. O O

CTDK1 B B_GENE/B_LOCATION
and O O
CTDK2 B B_GENE
also O O
differ O O
in O O
their O O
protein O O
substrate O O
specificity O O
. O O

This O O
communication O O
presents O O
two O O
patients O O
with O O
clinically O O
massive O O
PE O O
of O O
recent O O
onset O O
( O O
confirmed O O
by O O
lung O O
perfusion O O
scans O O
) O O
who O O
were O O
successfully O O
treated O O
with O O
a O O
single O O
i O O
. O O
v O O
. O O
dose O O
of O O
30 O O
mg O O
of O O
anisoylated B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
lys I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
plasminogen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
streptokinase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
activator I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
complex I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
APSAC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
comparable O O
to O O
1 O O
, O O
500 O O
, O O
000 O O
U O O
of O O
streptokinase B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
followed O O
by O O
systemic O O
heparinization O O
for O O
7 O O
days O O
. O O

A O O
Laboratory O B_SEQUENCE[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Manual O I_SEQUENCE[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
2nd O B_LOCATION/B_EDU[ORGANIZATION]
ed O I_LOCATION/I_EDU[ORGANIZATION]
. O O

Engineering O O
temperature O O
- O O
sensitive O O
SH3 B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
domains I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

A O O
mean O O
value O O
for O O
HbA1 B B_PROTEIN[GENE]/B_DISEASE
greater O O
than O O
10 O O
% O O
was O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
progression O O
of O O
retinopathy O O
and O O
a O O
mean O O
value O O
less O O
than O O
8 O O
. O O
7 O O
% O O
was O O
associated O O
with O O
a O O
diminished O O
risk O O
. O O

Allergic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
field O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
: O O
how O O
to O O
detect O O
it O O
? O O

At O O
1 O B_TIME[MEASURE]/B_PERSON
min O I_TIME[MEASURE]/I_PERSON
postalfentanil O I_TIME[MEASURE]/I_PERSON
, O O
N2O O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
caused O O
significantly O O
more O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
rigidity O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
100 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
O2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
p O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
. O O

The O O
preparative O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regimen O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consisted O O
of O O
fractionated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
total O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
body O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
irradiation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
TBI O B_DISEASE/B_LOCATION
) O O
and O O
cyclophosphamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CY O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

NGF B B_PERSON/B_GENE
also O O
induced O O
a O O
synthetic O O
promoter O O
with O O
repeated O O
Sp1 B B_GENE/B_LOCATION
sites I I_GENE/I_LOCATION
linked O O
to O O
a O O
core O O
promoter O O
, O O
and O O
a O O
plasmid O O
regulated O O
by O O
a O O
chimeric O O
transactivator O O
in O O
which O O
the O O
Gal4 B B_GENE/B_MEASURE
DNA I I_GENE/I_MEASURE
binding I I_GENE/I_MEASURE
domain I I_GENE/I_MEASURE
is O O
fused O O
to O O
the O O
Sp1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transactivation I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
indicating O O
that O O
this O O
transactivation O O
domain O O
is O O
regulated O O
by O O
NGF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
toxicity O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
copper O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
the O O
collembolan O B_BIO/B_LOCATION
Folsomia O I_BIO/I_LOCATION
fimetaria O I_BIO/I_LOCATION
L O I_BIO/I_LOCATION
. O O
was O O
studied O O
in O O
soil O B_BIO
incubated O O
with O O
copper O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sulfate O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
different O B_TIME[MEASURE]
periods O I_TIME[MEASURE]
before O O
the O O
introduction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
of O O
collembolans O B_BIO/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
to O O
assess O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
aging O O
of O O
contamination O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
on O O
the O O
toxicity O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
copper O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

The O O
frequency O B_MEASURE
of O O
severe O B_DISEASE
congestive O I_DISEASE
heart O I_DISEASE
failure O I_DISEASE
( O O
Killip O B_LOCATION/B_DISEASE
class O I_LOCATION/I_DISEASE
III O I_LOCATION/I_DISEASE
or O O
IV O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
) O O
at O O
admission O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O O
significantly O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
patients O B_PERSON
with O O
early O B_DISEASE_ADJECTIVE[DISEASE]
presentation O I_DISEASE_ADJECTIVE[DISEASE]
, O O
than O O
with O O
late O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
presentation O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O O
30 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
vs O O
7 O B_MEASURE
. O O
6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
p O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

Comparative O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ultrafiltration O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
UF O B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
BiGG O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
standard O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lactate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
La O B_LOCATION/B_MEASURE
) O O
solutions O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
rabbits O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
that O O
net O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
UF O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
La O B_LOCATION
solution O I_LOCATION
peaked O O
at O O
2 O B_MEASURE
h O O
and O O
decreased O O
significantly O O
at O O
4 O B_MEASURE
h O O
and O O
6 O B_MEASURE
h O O
. O O

The O O
Giessener O B_DISEASE/B_LOCATION
Tumordokumentationssystem O I_DISEASE/I_LOCATION
( O O
GTDS O B_DISEASE/B_LOCATION
) O O
is O O
such O O
a O O
disease O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
specific O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Measurement O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
protein O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
in O O
natural O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
rubber O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
latex O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
cotransfection O O
assays O O
, O O
a O O
small O O
fragment O O
of O O
Sin B B_GENE/B_DISEASE
retaining O O
the O O
Src B B_GENE
- O O
SH3 B B_GENE/B_LOCATION
- O O
binding O O
site O O
and O O
one O O
tyrosine O O
- O O
containing O O
motif O O
induced O O
c B B_GENE
- I I_GENE
Src I I_GENE
activation O O
as O O
measured O O
by O O
a O O
transcriptional O O
reporter O O
. O O

The O O
related O O
tumor O O
suppressor O O
, O O
p130 B B_GENE
, O O
also O O
effects O O
this O O
function O O
. O O

p107 B B_GENE/B_MEASURE
levels O O
increase O O
substantially O O
as O O
cells O O
progress O O
through O O
S O O
phase O O
. O O

p107 B B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
induction O O
of O O
E2F B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA O O
binding O O
was O O
observed O O
primarily O O
in O O
S O O
phase O O
cells O O
coincident O O
with O O
the O O
increase O O
in O O
p107 B B_GENE
protein I I_GENE
levels O O
. O O

Both O O
flavoproteins O O
are O O
active O O
as O O
AhpC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
reductases I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
and O O
mediate O O
electron O O
transfer O O
, O O
resulting O O
in O O
the O O
NADH O O
- O O
dependent O O
reduction O O
of O O
hydrogen O O
peroxide O O
and O O
cumene O O
hydroperoxide O O
. O O

Transcriptional O O
regulation O O
of O O
the O O
murine B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
k I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
- I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
fgf I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
gene I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Further O O
, O O
cells O O
cotransfected O O
with O O
a O O
UF B B_GENE
promoter I I_GENE
- O O
luciferase B B_GENE/B_DISEASE
( O O
- O O
1935UF B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Luc B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
reporter O O
gene O O
and O O
the O O
BTEB B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
expression O O
vector O O
had O O
2 O O
- O O
fold O O
higher O O
Luc B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O O
than O O
those O O
cotransfected O O
with O O
reporter O O
gene O O
and O O
pcDNA O O
- O O
3 O O
. O O

Evasion O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
host O B_DISEASE/B_BIO
immunity O I_DISEASE/I_BIO
by O O
Toxocara O B_SPECIES[BIO]/B_DISEASE
canis O I_SPECIES[BIO]/I_DISEASE
infective O I_SPECIES[BIO]/I_DISEASE
larvae O I_SPECIES[BIO]/I_DISEASE
is O O
mediated O O
by O O
the O O
nematode O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
surface O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
coat O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
is O O
shed O O
in O O
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
binding O O
by O O
host O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
antibody O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
molecules O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O O
effector O B_GENE
cells O I_GENE
. O O

A O O
Frank O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
vectorcardiogram O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
was O O
recorded O O
before O O
and O O
every O O
15 O B_MEASURE
- O O
30 O B_NUMBER[MEASURE]/B_ENT
minutes O I_NUMBER[MEASURE]/I_ENT
for O O
10 O B_TIME[MEASURE]/B_ENT
hours O I_TIME[MEASURE]/I_ENT
after O O
the O O
occlusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

In O O
agreement O O
with O O
this O O
, O O
archaea O O
appear O O
to O O
lack O O
eIF5 B B_GENE
, O O
eIF2B B B_GENE
and O O
the O O
lysine O O
- O O
rich O O
binding O O
domain O O
for O O
these O O
factors O O
in O O
their O O
eIF2beta B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
homolog I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Derepression O O
of O O
RAR B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O O
by O O
expressing O O
a O O
dominant O O
- O O
negative O O
corepressor O O
resulted O O
in O O
embryos O O
that O O
exhibited O O
phenotypes O O
similar O O
to O O
those O O
treated O O
by O O
RA O O
. O O

Chemiluminescence O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induced O O
by O O
opsonized O B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
zymosan O B_BACTERIUM[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increased O O
significantly O O
( O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
after O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
bacterial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
extracts O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
whereas O O
no O O
significant O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
observed O O
in O O
the O O
fMLP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
stimulated O O
PMNs O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Lastly O O
, O O
several O O
restriction O O
length O O
polymorphisms O O
were O O
identified O O
and O O
mapped O O
within O O
a O O
1 O O
kb O O
region O O
located O O
immediately O O
upstream O O
from O O
the O O
JH B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cluster I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Radiographic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
spatial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
frequencies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
essential O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
the O O
diagnosis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
incipient O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interproximal O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lesions O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Promoter O O
region O O
of O O
the O O
human B B_GENE/B_LOCATION
alpha I I_GENE/I_LOCATION
2A I I_GENE/I_LOCATION
adrenergic I I_GENE/I_LOCATION
receptor I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
. O O

( O O
1982 O B_MEASURE
) O O
. O O

( O O
99m O B_MEASURE
) O O
Tc O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ethyl O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Cysteinate O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Dimer O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stable O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
6h O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
has O O
contributed O O
to O O
develop O O
ictal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
evaluate O O
the O O
location O B_DISEASE_ADJECTIVE[DISEASE]
of O O
partial O B_DISEASE
seizure O I_DISEASE
. O O

LiF O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
thermoluminescence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
dosimeters O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
TLD O B_DISEASE/B_MEASURE
) O O
in O O
chip O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
form O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
placed O O
onto O O
1 O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
eyelid O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
, O O
the O O
skin O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
over O O
the O O
thyroid O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
the O O
patient O B_PERSON
' O O
s O B_BODY_PART_OR_ORGAN_COMPONENT
clothes O I_BODY_PART_OR_ORGAN_COMPONENT
covering O O
the O O
region O B_LOCATION/B_BIO
of O O
breasts O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
ovaries O B_BODY_PART_OR_ORGAN_COMPONENT
of O O
female O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
and O O
the O O
testicles O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O O
male O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
. O O

Thus O O
, O O
the O O
in O O
vivo O O
function O O
of O O
Gle2p B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
strictly O O
coupled O O
to O O
the O O
short O O
GLEBS B B_GENE/B_LOCATION
within O O
Nup116p B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
links O O
this O O
putative O O
mRNA O O
transport O O
factor O O
to O O
the O O
nuclear O O
pores O O
. O O

DNMT2 B B_GENE
binds O O
AdoHcy O O
in O O
the O O
same O O
conformation O O
as O O
confirmed O O
m B B_GENE
( I I_GENE
5 I I_GENE
) I I_GENE
C I I_GENE
MTases I I_GENE
and O O
, O O
while O O
DNMT2 B B_TIME[MEASURE]/B_LOCATION
shares O O
all O O
sequence O O
and O O
structural O O
features O O
with O O
m B B_GENE/B_DISEASE
( I I_GENE/I_DISEASE
5 I I_GENE/I_DISEASE
) I I_GENE/I_DISEASE
C I I_GENE/I_DISEASE
MTases I I_GENE/I_DISEASE
, O O
it O O
has O O
failed O O
to O O
demonstrate O O
detectable O O
transmethylase O O
activity O O
. O O

The O O
structure O O
of O O
the O O
murine B B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Dtk I B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
been O O
determined O O
. O O

In O O
previous O O
studies O O
, O O
we O O
showed O O
that O O
the O O
nuclear O O
import O O
of O O
SREBP B B_GENE
- I I_GENE
2 I I_GENE
occurs O O
via O O
the O O
direct O O
interaction O O
of O O
importin B B_GENE
beta I I_GENE
with O O
the O O
HLH O O
- O O
Zip O O
domain O O
. O O

In O O
the O O
normal O O
controls O O
the O O
plasma B B_GENE
FPA I I_GENE
level O O
( O O
mean O O
+ O O
/ O O
- O O
SD O O
) O O
was O O
1 O O
. O O
43 O O
+ O O
/ O O
- O O
0 O O
. O O
46 O O
ng O O
/ O O
ml O O
. O O

In O O
this O O
study O O
we O O
cloned O O
the O O
cDNA O O
of O O
AD1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Ag I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
a O O
rat O O
basophilic O O
leukemia O O
2H3 O O
cDNA O O
library O O
. O O

Ten O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
( O O
aged O B_MEASURE/B_PERSON
28 O I_MEASURE/I_PERSON
- O O
76 O B_MEASURE/B_ENT
years O I_MEASURE/I_ENT
) O O
with O O
a O O
terminal O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
jejunostomy O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
located O O
within O O
the O O
first O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
meter O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
jejunum O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
treated O O
by O O
infusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
an O O
elemental O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
diet O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
into O O
the O O
distal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
small O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
bowel O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
( O O
IEDDSB O B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

The O O
procedure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O O
technically O O
successful O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
12 O B_NUMBER[MEASURE]/B_PERSON
of O O
14 O B_NUMBER[MEASURE]
( O O
86 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
stenoses O B_DISEASE/B_PERSON
in O O
the O O
fibromuscular O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
dysplasia O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
subgroup O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
but O O
in O O
only O O
one O B_NUMBER[MEASURE]
of O O
five O B_NUMBER[MEASURE]
( O O
20 O B_NUMBER[MEASURE]/B_LOCATION
% O I_NUMBER[MEASURE]/I_LOCATION
) O O
lesions O B_DISEASE/B_PERSON
in O O
the O O
neurofibromatosis O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
subgroup O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Conventional O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
digital O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
radiography O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
the O O
heart O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
aorta O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
pulmonary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
vascularity O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Regulation O O
of O O
the O O
p21 B B_GENE
- I I_GENE
activated I I_GENE
kinase I I_GENE
( O O
PAK B B_GENE/B_PERSON
) O O
by O O
a O O
human B B_SPECIES[BIO]/B_GENE
Gbeta I I_SPECIES[BIO]/I_GENE
- I I_SPECIES[BIO]/I_GENE
like I I_SPECIES[BIO]/I_GENE
WD O O
- O O
repeat O O
protein O O
, O O
hPIP1 B B_GENE/B_LOCATION
. O O

Other O B_PERSON
clinicopathological O I_PERSON
features O I_PERSON
have O O
no O O
definite O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
influence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
survival O B_DISEASE
expectancy O I_DISEASE
. O O

These O O
studies O O
suggest O O
that O O
tandem O O
alpha O O
- O O
helices O O
located O O
near O O
the O O
C O O
- O O
terminus O O
of O O
PC B B_GENE
- I I_GENE
TP I I_GENE
facilitate O O
membrane O O
binding O O
and O O
extraction O O
of O O
phosphatidylcholines O O
. O O

The O O
striking O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
similarity O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
preference O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
mismatched O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
weakly O O
paired O O
nucleotides O B_LOCATION/B_BIO
for O O
binding O O
and O O
for O O
excision O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
suggests O O
a O O
functional O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
relationship O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
between O O
binding O B_TIME[MEASURE]/B_GENE
and O O
cleavage O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
reactions O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Interestingly O O
, O O
these O O
" O O
activation O O
- O O
defective O O
" O O
mutants O O
segregated O O
into O O
two O O
classes O O
: O O
1 O O
) O O
those O O
that O O
were O O
unable O O
to O O
form O O
dimers O O
but O O
that O O
could O O
still O O
form O O
higher O O
order O O
oligomers O O
and O O
transform O O
cells O O
, O O
and O O
2 O O
) O O
those O O
that O O
were O O
defective O O
for O O
PDGF B B_GENE
- I I_GENE
R I I_GENE
binding O O
and O O
were O O
transformation O O
- O O
incompetent O O
. O O

APL O O
patients O O
showed O O
a O O
low O O
, O O
yet O O
variable O O
, O O
level O O
of O O
JEM B B_GENE
- I I_GENE
1 I I_GENE
mRNA I I_GENE
in O O
bone O O
marrow O O
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
show O O
that O O
intranasal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
challenge O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O O
FLU O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induces O O
changes O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
leukocyte O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
histamine O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
release O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
, O O
but O O
not O O
other O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
systemic O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
immune O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
inflammatory O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
responses O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
have O O
shown O O
previously O O
that O O
EGF B B_GENE
receptor I I_GENE
activation O O
stimulates O O
gastrin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene O O
expression O O
through O O
a O O
GC O O
- O O
rich O O
element O O
called O O
gERE O O
. O O

We O O
have O O
earlier O O
proposed O O
that O O
CG O B_GENE/B_DISEASE
rich O I_GENE/I_DISEASE
sequences O I_GENE/I_DISEASE
resembling O O
CpG O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
islands O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
are O O
associated O O
with O O
many O B_DISEASE/B_GENE
imprinted O B_DISEASE/I_GENE
genes O B_DISEASE/I_GENE
and O O
often O O
subject O B_PERSON/B_TIME[MEASURE]
to O O
parental O B_PERSON/B_LOCATION
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methylation O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
could O O
act O O
as O O
a O O
common O B_GENE/B_PERSON
imprinting O I_GENE/I_PERSON
element O I_GENE/I_PERSON
. O O

The O O
secondary O O
end O O
points O O
included O O
creatine B B_ENZYME[GENE]/B_DISEASE
kinase I B_ENZYME[GENE]/I_DISEASE
peak O O
, O O
ventricular O O
fibrillation O O
/ O O
tachycardia O O
within O O
the O O
first O O
24 O O
hours O O
, O O
death O O
and O O
congestive O O
heart O O
failure O O
within O O
the O O
30 O O
- O O
day O O
follow O O
- O O
up O O
, O O
and O O
30 O O
- O O
day O O
left O O
ventricular O O
ejection O O
fraction O O
. O O

Prevention O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
gravid O B_DISEASE
Rhesus O I_DISEASE
isoimmunization O I_DISEASE

All O O
relapses O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occurred O O
within O O
the O O
first O B_TIME[MEASURE]/B_LOCATION
year O B_TIME[MEASURE]/I_LOCATION
and O O
were O O
confined O O
to O O
patients O B_PERSON/B_LOCATION
with O O
PS O B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
II O I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
disease O I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
four O B_NUMBER[MEASURE]
or O O
more O B_NUMBER[MEASURE]/B_ENT
sites O I_NUMBER[MEASURE]/I_ENT
of O O
involvement O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

This O O
demonstrates O O
the O O
presence O O
of O O
a O O
PKC B B_GENE
- O O
dependent O O
pathway O O
which O O
functions O O
independently O O
from O O
Lck B B_GENE/B_LOCATION
in O O
MAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation O O
. O O

This O O
interesting O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exon O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
junction O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulted O O
in O O
novel O B_TIME[MEASURE]/B_ENT
deduced O O
amino O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
terminal O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
open O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reading O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
frames O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
are O O
completely O O
in O O
- O O
frame O B_LOCATION/B_TIME[MEASURE]
with O O
sequences O B_LOCATION/B_DISEASE
located O O
further O O
downstream O B_LOCATION
. O O

Cell O O
lines O O
expressing O O
single O O
amino O O
acid O O
substitutions O O
of O O
the O O
carboxyl O O
- O O
terminal O O
asparagine O O
of O O
CD2 B B_GENE
are O O
incapable O O
of O O
avidity O O
regulation O O
by O O
TCR B B_GENE
signaling O O
, O O
PMA O O
treatment O O
, O O
or O O
elevation O O
of O O
intracellular O O
cAMP O O
levels O O
, O O
demonstrating O O
that O O
each O O
of O O
these O O
stimuli O O
utilizes O O
a O O
common O O
structural O O
element O O
for O O
regulating O O
CD2 B B_GENE
avidity O O
. O O

12 O B_NUMBER[MEASURE]
per O O
cent O B_MEASURE
was O O
observed O O
with O O
the O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
tetracycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
and O O
4 O B_MEASURE
- O O
epianhydrotetracycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
doses O B_MEASURE
of O O
1000 O B_MEASURE
and O O
100gamma O B_MEASURE/B_LOCATION
per O O
embryo O B_TIME[MEASURE]/B_PERSON
respectively O O
. O O

Present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
investigation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O O
undertaken O O
to O O
elucidate O O
what O O
pharmacokinetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parameters O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
animal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
experiment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
could O O
be O O
of O O
more O O
predictable O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
human O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
clinical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
trial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
beta O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
blocking O O
agents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
atpA B B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
reading O O
frame O O
ends O O
with O O
four O O
tandem O O
UGA O O
codons O O
which O O
overlap O O
four O O
tandem O O
AUG O O
codons O O
initiating O O
an O O
unidentified O O
reading O O
frame O O
, O O
orf214 O O
. O O

When O O
transfected O O
into O O
HepG2 O O
cells O O
, O O
which O O
lack O O
C B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EBP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
mouse B B_GENE
ob I I_GENE
promoter I I_GENE
was O O
only O O
weakly O O
active O O
. O O

Vasodilator O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
hypotensive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
optical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
isomers O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
nicardipine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
YC O B_LOCATION/B_PROTEIN[GENE]
- O O
93 O B_NUMBER[MEASURE]
) O O
, O O
a O O
new O B_PROTEIN[GENE]
Ca2 O I_PROTEIN[GENE]
+ O I_PROTEIN[GENE]
- O O
antagonist O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

Between O O
1988 O B_MEASURE
and O O
1995 O B_MEASURE
, O O
341 O B_PERSON/B_BIO
children O I_PERSON/I_BIO
with O O
acute O B_DISEASE
myeloid O I_DISEASE
leukaemia O I_DISEASE
( O O
AML O B_DISEASE/B_LOCATION
) O O
were O O
treated O O
on O O
the O O
Medical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Research O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Council O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Acute O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Myeloid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Leukaemia O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Trial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
MRC O B_MEASURE/B_GENE
AML10 O I_MEASURE/I_GENE
) O O
. O O

A O O
heterologous O O
promoter O O
construct O O
containing O O
three O O
repeats O O
of O O
a O O
consensus O O
Sp1 B B_GENE/B_LOCATION
site I I_GENE/I_LOCATION
, O O
cloned O O
upstream O O
of O O
a O O
single O O
copy O O
of O O
the O O
ZII B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CREB B B_GENE/B_LOCATION
/ O O
AP1 B B_GENE/B_LOCATION
) O O
element O O
from O O
the O O
BZLF1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
linked O O
to O O
the O O
beta B B_GENE/B_SPECIES[BIO]
- I B_GENE/I_SPECIES[BIO]
globin I B_GENE/I_SPECIES[BIO]
TATA O O
box O O
, O O
exhibited O O
phorbol O O
ester O O
inducibility O O
. O O

Nicotinic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
antagonists O O
mecamylamine O O
( O O
0 O O
. O O
5 O O
and O O
1 O O
mg O O
/ O O
kg O O
) O O
and O O
hexamethonium O O
( O O
5 O O
and O O
10 O O
mg O O
/ O O
kg O O
) O O
reduced O O
the O O
response O O
induced O O
by O O
nicotine O O
( O O
0 O O
. O O
25 O O
mg O O
/ O O
kg O O
) O O
. O O

Appl O B_PERSON/B_MEASURE
. O O

Thus O O
, O O
the O O
predicted O B_GENE
M3 O I_GENE
ORF O I_GENE
is O O
a O O
functional O B_GENE/B_MEASURE
gene O I_GENE/I_MEASURE
that O O
encodes O O
an O O
abundant O B_GENE
secreted O I_GENE
protein O I_GENE
which O O
is O O
a O O
candidate O B_PERSON/B_LOCATION
for O O
interacting O O
with O O
host O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cellular O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
receptors O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
or O O
cytokines O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Protein O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
metabolism O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disorders O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
burns O B_PERSON/B_DISEASE

The O O
cumulative O B_MEASURE/B_DISEASE
dose O I_MEASURE/I_DISEASE
to O O
nursing O B_DISEASE/B_MEASURE
staff O I_DISEASE/I_MEASURE
for O O
the O O
week O B_TIME[MEASURE]/B_DISEASE
after O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O O
dependent O B_PERSON/B_MEASURE
on O O
patient O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mobility O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
was O O
estimated O O
at O O
0 O B_MEASURE
. O O
08 O B_MEASURE
mSv O I_MEASURE
for O O
a O O
self O B_PERSON/B_LOCATION
- O O
caring O O
patient O B_PERSON
to O O
6 O B_MEASURE
. O O
3 O B_MEASURE
mSv O I_MEASURE
for O O
a O O
totally O O
helpless O B_PERSON
patient O I_PERSON
( O O
1840 O B_PERSON/B_LOCATION
MBq O I_PERSON/I_LOCATION
/ O O
group O B_MEASURE/B_LOCATION
A O I_MEASURE/I_LOCATION
) O O
. O O

JCAHO O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O O
use O O
ORYX O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
to O O
detect O O
sentinel O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
events O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
also O O
show O O
that O O
psbH B B_GENE/B_LOCATION
and O O
psbT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
transcribed O O
from O O
the O O
upstream O O
psbB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
that O O
the O O
psbH B B_GENE/B_MEASURE
mRNA I I_GENE/I_MEASURE
has O O
its O O
own O O
target O O
sequence O O
for O O
Mbb1 B B_GENE/B_PERSON
function O O
. O O

To O O
test O O
whether O O
Cd O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
exposure O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
would O O
increase O O
Ca O O
release O O
from O O
bone O B_BODY_PART_OR_ORGAN_COMPONENT
during O O
pregnancy O B_ORGANISM_FUNCTION/B_PERSON
and O O
lactation O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
in O O
relation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
the O O
etiological O B_DISEASE_ADJECTIVE[DISEASE]
mechanism O I_DISEASE_ADJECTIVE[DISEASE]
of O O
Itai O B_PERSON/B_LOCATION
- O O
Itai O B_DISEASE/B_LOCATION
disease O I_DISEASE/I_LOCATION
, O O
virgin O B_PERSON/B_BIO
female O I_PERSON/I_BIO
mice O I_PERSON/I_BIO
with O O
45Ca O B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
prelabeled O O
skeletons O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
( O O
15 O B_MEASURE/B_BIO
microCi O I_MEASURE/I_BIO
/ O O
mouse O B_BIO/B_MEASURE
) O O
were O O
subjected O O
to O O
one O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
round O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
pregnancy O B_ORGANISM_FUNCTION/B_DISEASE
/ O O
lactation O B_ORGANISM_FUNCTION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
were O O
exposed O O
to O O
a O O
Ca O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
deficient O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
diet O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
containing O O
0 O B_NUMBER[MEASURE]
, O O
5 O B_MEASURE
, O O
or O O
25 O B_TIME[MEASURE]
ppm O I_TIME[MEASURE]
Cd O I_TIME[MEASURE]
or O O
25 O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ppm O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Pb O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
32 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
from O O
conception O B_TIME[MEASURE]
until O O
Lactation O B_TIME[MEASURE]/B_ORGANISM_FUNCTION
Day O I_TIME[MEASURE]/I_ORGANISM_FUNCTION
14 O I_TIME[MEASURE]/I_ORGANISM_FUNCTION
. O O

O5257 B B_PERSON/B_GENE
shows O O
homology O O
with O O
the O O
SAS2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
another O O
hypothetical O O
protein O O
from O O
yeast O O
. O O

Principles O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
thyroid O B_EDU[ORGANIZATION]
hormone O I_EDU[ORGANIZATION]
treatment O I_EDU[ORGANIZATION]

Significance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
esophagocardiac O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reflexes O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
inducing O O
thoracic O B_DISEASE
pain O I_DISEASE

The O O
fate O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
ochratoxin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
A O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
during O O
malting O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
and O O
brewing O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
: O O
Precision O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
accuracy O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
measured O O
using O O
controls O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
comparison O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
. O O

Messenger O O
RNA O O
for O O
the O O
Ad2 B B_GENE/B_BIO
DNA I I_GENE/I_BIO
binding I I_GENE/I_BIO
protein I I_GENE/I_BIO
: O O
DNA O O
sequences O O
encoding O O
the O O
first O O
leader O O
and O O
heterogenity O O
at O O
the O O
mRNA O O
5 O O
' O O
end O O
. O O

Consistent O O
with O O
this O O
hypothesis O O
, O O
stimulation O O
of O O
A B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2A I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
R I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
PKA B B_GENE
enhanced O O
nuclear B B_GENE
aPKC I I_GENE
activity O O
. O O

Atrial O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dissociation O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
gene O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence O B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
predicts O O
a O O
150 O B_MEASURE
, O O
825 O B_MEASURE/B_LOCATION
mol O I_MEASURE/I_LOCATION
wt O I_MEASURE/I_LOCATION
apoprotein O I_MEASURE/I_LOCATION
of O O
1363 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amino O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acids O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
having O O
an O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_LOCATION/B_PROTEIN[GENE]
hydrophobic O I_LOCATION/I_PROTEIN[GENE]
signal O I_LOCATION/I_PROTEIN[GENE]
sequence O I_LOCATION/I_PROTEIN[GENE]
of O O
17 O B_MEASURE
amino O I_MEASURE
acids O I_MEASURE
, O O
19 O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potential O B_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N O B_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
linked O O
glycosylation O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
hydrophobic O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anchor O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
approximately O O
17 O B_MEASURE
amino O I_MEASURE
acids O I_MEASURE
near O O
the O O
C O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
terminus O B_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
a O O
hydrophilic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cysteine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
rich O B_LOCATION
C O I_LOCATION
terminus O I_LOCATION
of O O
35 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
amino O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
acids O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

However O O
, O O
depending O O
upon O O
the O O
promoter O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
context O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
we O O
observed O O
cooperative O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactions O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
two O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
domains O B_NUMBER[MEASURE]/I_PROTEIN[GENE]
to O O
confer O O
high O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
binding O O
affinity O B_GENE/B_MEASURE
and O O
specificity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

As O O
a O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
relative O B_MEASURE
biological O I_MEASURE
effects O I_MEASURE
( O O
RBE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
of O O
2 O B_NUMBER[MEASURE]
. O O
3 O B_MEASURE
- O O
2 O B_MEASURE
. O O
7 O B_MEASURE
was O O
obtained O O
from O O
the O O
straight O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
line O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
that O O
was O O
given O O
by O O
modifying O O
by O O
the O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
least O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
squares O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
curves O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
frequency O B_MEASURE/B_LOCATION
of O O
anomalous O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fetuses O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
total O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
implants O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
and O O
survived O O
embryos O B_LOCATION
irradiated O O
from O O
20 O B_MEASURE
to O O
120 O B_MEASURE/B_LOCATION
rad O I_MEASURE/I_LOCATION
by O O
Cf O B_LOCATION
- O O
252 O B_MEASURE
and O O
from O O
80 O B_MEASURE
to O O
220 O B_MEASURE/B_LOCATION
rad O I_MEASURE/I_LOCATION
by O O
Co O B_LOCATION
- O O
60 O B_MEASURE/B_LOCATION
on O O
day O B_TIME[MEASURE]
8 O I_TIME[MEASURE]
of O O
pregnancy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Samples O O
( O O
1 O O
g O O
) O O
were O O
extracted O O
with O O
0 O O
. O O
5 O O
% O O
potassium O O
chloride O O
( O O
KCl O O
) O O
in O O
70 O O
% O O
methanol O O
( O O
5 O O
ml O O
) O O
and O O
diluted O O
subsequently O O
to O O
give O O
two O O
- O O
fold O O
to O O
ten O O
- O O
fold O O
step O O
- O O
wise O O
dilutions O O
in O O
phosphate O O
- O O
buffered O O
saline O O
containing O O
0 O O
. O O
05 O O
% O O
Tween O O
20 O O
and O O
0 O O
. O O
2 O O
% O O
bovine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
serum I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
albumin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PBS O O
- O O
T O O
BSA B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

To O O
our O O
knowledge O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
108 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
cases O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
EAT O O
treated O O
by O O
catheter O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
ablation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
the O O
ectopic O B_DISEASE/B_PROTEIN[GENE]
focus O B_DISEASE/I_PROTEIN[GENE]
are O O
reported O O
in O O
the O O
literature O B_PERSON/B_LOCATION
with O O
a O O
success O B_MEASURE/B_LOCATION
rate O I_MEASURE/I_LOCATION
superior O I_MEASURE/I_LOCATION
to O O
90 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
% O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
. O O

Following O O
immunization O O
of O O
transgenic O O
mice O O
, O O
hybrid O O
molecules O O
were O O
isolated O O
from O O
B O O
cell O O
DNA O O
which O O
contained O O
the O O
transgene O O
recombined O O
with O O
the O O
endogenous B B_GENE
IgH I I_GENE
locus I I_GENE
. O O

It O O
produced O O
extrapyramidal O B_DISEASE
disturbances O I_DISEASE
in O O
nearly O O
every O O
subject O B_PERSON/B_LOCATION
, O O
the O O
most O O
common O B_DISEASE_ADJECTIVE[DISEASE]
being O I_DISEASE_ADJECTIVE[DISEASE]
akathisia O I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
most O O
severe O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
in O O
the O O
case O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
one O B_DISEASE
individual O I_DISEASE
, O O
being O O
acute O B_DISEASE
dystonia O I_DISEASE
. O O

Northern O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
indicated O O
that O O
both O O
human O B_SPECIES[BIO]
and O O
murine O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
encode O O
approximately O O
6 O B_MEASURE
- O O
kb O B_MEASURE/B_BIO
transcripts O I_MEASURE/I_BIO
. O O

Transforming B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activates O O
the O O
promoter O O
of O O
cyclin B B_GENE
- I I_GENE
dependent I I_GENE
kinase I I_GENE
inhibitor O O
p15INK4B B B_GENE
through O O
an O O
Sp1 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
consensus I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
site I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Cox O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
proportional O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
hazard O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
identified O O
dialysis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
modality O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
and O O
pre O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dialysis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
UV O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
less O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
1 O B_MEASURE
, O O
000 O B_MEASURE
ml O I_MEASURE
/ O O
m2 O B_MEASURE
per O O
24 O B_MEASURE
h O O
as O O
the O O
only O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
significant O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
risk O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
factors O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
for O O
UV O B_DISEASE
survival O I_DISEASE
. O O

The O O
hyperpigmentation O O
is O O
linked O O
to O O
the O O
presence O O
of O O
numerous O O
single O O
melanosomes O O
and O O
polymelanosomes O O
in O O
keratinocytes O O
at O O
all O O
levels O O
of O O
the O O
epidermis O O
, O O
and O O
in O O
dermal O O
Factor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
XIIIa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
positive O O
dendrocytes O O
. O O

Possible O O
or O O
definite O O
neglect O O
or O O
abuse O O
before O O
36 O O
months O O
of O O
age O O
was O O
correlated O O
with O O
low O O
DBH B B_PERSON/B_DISEASE
activity O O
. O O

Previously O O
, O O
we O O
identified O O
two O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
SMC I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
hCAP B B_LOCATION/B_DISEASE
- I I_LOCATION/I_DISEASE
C I I_LOCATION/I_DISEASE
and O O
hCAP B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
E I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
form O O
a O O
heterodimeric O O
complex O O
( O O
hCAP B B_DISEASE/B_LOCATION
- I B_DISEASE/I_LOCATION
C I B_DISEASE/I_LOCATION
- O O
hCAP B B_PROTEIN[GENE]/B_LOCATION
- I I_PROTEIN[GENE]/I_LOCATION
E I I_PROTEIN[GENE]/I_LOCATION
) O O
in O O
the O O
cell O O
. O O

The O O
mouse B B_GENE
alpha I I_GENE
A I I_GENE
- I I_GENE
CRYBP1 I I_GENE
gene I I_GENE
specifies O O
a O O
2 O O
, O O
688 O O
- O O
amino O O
acid O O
protein O O
with O O
72 O O
% O O
amino O O
acid O O
identity O O
to O O
its O O
human O O
homologue O O
, O O
PRDII B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BF1 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Methylation O O
interference O O
analysis O O
established O O
at O O
single O O
nucleotide O O
resolution O O
that O O
purified O O
recombinant O O
Fos B B_GENE/B_LOCATION
and O O
Jun B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bind O O
in O O
a O O
sequence O O
- O O
specific O O
manner O O
to O O
the O O
AP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
within O O
the O O
VDRE O O
and O O
OC B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
box I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
include O O
urinalysis O O
, O O
chest O O
X O O
- O O
P O O
, O O
ECG O O
, O O
hematological O O
examinations O O
( O O
RBC O O
, O O
WBC O O
, O O
Ht O O
, O O
Hb B B_LOCATION/B_PROTEIN[GENE]
, O O
PLT O O
and O O
ESR O O
) O O
and O O
biochemical O O
tests O O
( O O
AST B B_PROTEIN[GENE]/B_LOCATION
, O O
ALT B B_PROTEIN[GENE]/B_PERSON
, O O
ALP B B_PROTEIN[GENE]/B_LOCATION
, O O
gamma B B_LOCATION/B_GENE
GTP I I_LOCATION/I_GENE
, O O
LDH B B_PROTEIN[GENE]
, O O
CPK B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
Chol O O
, O O
T O O
- O O
Bil O O
, O O
TP O O
, O O
Alb B B_PROTEIN[GENE]/B_LOCATION
, O O
TG O O
, O O
BUN O O
, O O
Cr O O
, O O
Glu O O
, O O
Na O O
, O O
K O O
, O O
Ca O O
, O O
P O O
and O O
CRP B B_LOCATION/B_GENE
) O O
. O O

Both O O
the O O
inactive O O
domain B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
II I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
P68 I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
mutant I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
the O O
deletion O O
mutant O O
lacking O O
aa O O
91 O O
- O O
243 O O
were O O
less O O
inhibitory O O
to O O
growth O O
in O O
yeast O O
due O O
to O O
the O O
reduced O O
ability O O
to O O
phosphorylate O O
initiation B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
vivo O O
. O O

All O O
patients O B_PERSON/B_LOCATION
studied O O
were O O
pregnant O B_PERSON
women O I_PERSON
and O O
their O O
delivered O O
children O B_PERSON/B_BIO
. O O

Current O B_MEASURE/B_LOCATION
body O B_MEASURE/I_LOCATION
size O B_MEASURE/I_LOCATION
( O O
wt O B_MEASURE/B_LOCATION
/ O O
ht2 O B_MEASURE/B_LOCATION
) O O
was O O
significantly O O
associated O O
with O O
life O B_TIME[MEASURE]/B_LOCATION
- O O
time O B_TIME[MEASURE]/B_LOCATION
weight O I_TIME[MEASURE]/I_LOCATION
dissatisfaction O I_TIME[MEASURE]/I_LOCATION
in O O
both O O
sexes O B_BIO/B_PERSON
( O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE/B_LOCATION
. O O
0005 O B_MEASURE
) O O
. O O

Mad3 B B_GENE
and O O
Mad4 B B_GENE/B_LOCATION
: O O
novel O O
Max B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
interacting O O
transcriptional O O
repressors O O
that O O
suppress O O
c B B_GENE
- I I_GENE
myc I I_GENE
dependent O O
transformation O O
and O O
are O O
expressed O O
during O O
neural O O
and O O
epidermal O O
differentiation O O
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Patients O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
attainment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
TGB O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monotherapy O I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
associated O O
with O O
their O O
achievement O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
positive O B_DISEASE_ADJECTIVE[DISEASE]
changes O I_DISEASE_ADJECTIVE[DISEASE]
of O O
varying O O
degree O B_MEASURE
on O O
psychological O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
tests O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

The O O
pcaR B B_GENE/B_LOCATION
regulatory I I_GENE/I_LOCATION
locus I I_GENE/I_LOCATION
has O O
been O O
found O O
to O O
be O O
required O O
for O O
both O O
induction O O
of O O
all O O
of O O
the O O
genes O O
within O O
the O O
pca B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulon I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
pcaBDC B B_LOCATION/B_GENE
, O O
pcaIJ B B_LOCATION/B_GENE
, O O
and O O
pcaF B B_GENE/B_LOCATION
) O O
and O O
the O O
chemotactic O O
response O O
of O O
the O O
bacteria O O
to O O
aromatic O O
compounds O O
. O O

Furthermore O O
, O O
we O O
have O O
identified O O
the O O
major O O
open O O
reading O O
frame O O
( O O
RF4 O O
; O O
2 O O
. O O
3 O O
kb O O
) O O
as O O
being O O
essential O O
for O O
activation O O
, O O
and O O
we O O
have O O
shown O O
that O O
the O O
NF B B_GENE/B_LOCATION
kappa I I_GENE/I_LOCATION
B I I_GENE/I_LOCATION
, O O
SP1 B B_GENE/B_DISEASE
, O O
and O O
TATA O O
box O O
motifs O O
in O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
immunodeficiency I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
LTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
all O O
required O O
for O O
full O O
induction O O
of O O
the O O
promoter O O
by O O
the O O
HHV B B_GENE
- I I_GENE
6 I I_GENE
- I I_GENE
encoded I I_GENE
transactivator I I_GENE
. O O

However O O
, O O
mutations O O
of O O
the O O
C O O
- O O
rich O O
element O O
that O O
disrupted O O
a O O
GC O O
box O O
located O O
on O O
the O O
inverse O O
strand O O
eliminated O O
PMA O O
responsiveness O O
and O O
, O O
in O O
gel O O
mobility O O
shift O O
assays O O
, O O
eliminated O O
binding O O
of O O
Sp1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

TFIIB B B_GENE/B_LOCATION
and O O
VDR B B_GENE
can O O
also O O
interact O O
directly O O
, O O
and O O
these O O
factors O O
synergize O O
to O O
mediate O O
transactivation O O
. O O

Both O O
algorithms O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_EDU[ORGANIZATION]
have O O
been O O
implemented O O
and O O
applied O O
to O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
simulated O O
for O O
a O O
scanner O B_PRODUCT[OBJECT]/B_ENT
with O O
a O O
large O B_MEASURE/B_LOCATION
axial O I_MEASURE/I_LOCATION
aperture O I_MEASURE/I_LOCATION
( O O
30 O B_LOCATION/B_PROTEIN[GENE]
degrees O I_LOCATION/I_PROTEIN[GENE]
) O O
, O O
and O O
also O O
to O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acquired O O
with O O
the O O
ECAT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
HR O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
and O O
the O O
ECAT O B_ORGANIZATION
HR O I_ORGANIZATION
+ O I_ORGANIZATION
scanners O I_ORGANIZATION
. O O

The O O
well O O
- O O
trained O O
group O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
measured O O
once O O
in O O
the O O
respiration O B_LOCATION/B_TIME[MEASURE]
chamber O B_LOCATION/I_TIME[MEASURE]
for O O
36 O B_NUMBER[MEASURE]
h O O
according O O
to O O
the O O
same O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
protocol O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Samarium O B_MEASURE/B_PROTEIN[GENE]
- O O
153 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
intravascular O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
irradiation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
with O O
liquid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
filled O O
balloons O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEDICAL_DEVICE[OBJECT]
to O O
prevent O O
restenosis O B_DISEASE
: O O
acute O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
and O O
long O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
term O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
in O O
a O O
hypercholesterolemic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
rabbit O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
restenosis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Only O O
viable O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bacteria O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
a O O
high O B_MEASURE/B_LOCATION
concentration O B_MEASURE/I_LOCATION
induced O O
purulent O B_DISEASE
otitis O I_DISEASE
media O I_DISEASE
, O O
which O O
was O O
culture O B_DISEASE_ADJECTIVE[DISEASE]
positive O I_DISEASE_ADJECTIVE[DISEASE]
in O O
58 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
of O O
the O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
day O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Polyoma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
virus O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
urine O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
during O O
pregnancy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Transfer O O
of O O
F O O
- O O
like O O
plasmids O O
is O O
regulated O O
by O O
the O O
FinOP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
system O O
, O O
which O O
controls O O
the O O
expression O O
of O O
traJ B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
positive O O
regulator O O
of O O
the O O
transfer O O
operon O O
. O O

PKCI B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
is O O
a O O
member O O
of O O
the O O
HIT B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
family I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
of O O
proteins O O
, O O
shown O O
by O O
sequence O O
identity O O
to O O
be O O
conserved O O
in O O
a O O
broad O O
range O O
of O O
organisms O O
including O O
mycoplasma O O
, O O
plants O O
, O O
and O O
humans O O
. O O

Conversion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
glucose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
14C O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
glucose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
14C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
passage O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
through O O
human O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
brain O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O O
vivo O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
simple O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
technique O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
obtaining O O
ultra O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
thin O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sections O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
coccidian O B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
oocysts O I_BODY_PART_OR_ORGAN_COMPONENT/I_BACTERIUM[BIO]
is O O
reported O O
. O O

It O O
was O O
found O O
that O O
on O O
the O O
14th O O
and O O
21st O O
day O O
after O O
cimetidine O O
administration O O
serum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gastrin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
were O O
significantly O O
elevated O O
. O O

Dual O O
signal O O
peptides O O
mediate O O
the O O
signal B B_GENE/B_LOCATION
recognition I I_GENE/I_LOCATION
particle I I_GENE/I_LOCATION
/ O O
Sec B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
independent O O
insertion O O
of O O
a O O
thylakoid O O
membrane O O
polyprotein O O
, O O
PsbY B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
resulting O O
score O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
allowed O O
the O O
disease O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
be O O
expressed O O
as O O
a O O
continuous O B_MEASURE
variable O I_MEASURE
, O O
was O O
effectively O O
utilized O O
to O O
see O O
the O O
correlations O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
between O O
the O O
severity O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
coronary O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
arterial O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
disease O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
CAD O B_DISEASE/B_LOCATION
) O O
and O O
individual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
risk O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
risk O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
markers O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

On O O
guanidine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
botulism O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Electronic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
structure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
Si O B_LOCATION/B_NUMBER[MEASURE]
( O O
111 O B_MEASURE
) O O
- O O
NiSi2 O B_LOCATION/B_PERSON
( O O
111 O B_MEASURE
) O O
A O O
- O O
type O B_LOCATION/B_DISEASE
and O O
B O B_PROTEIN[GENE]/B_DISEASE
- O O
type O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
interfaces O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

In O O
our O O
case O O
the O O
development O O
of O O
the O O
tumor O O
at O O
the O O
posterior O O
side O O
of O O
the O O
prostate O O
, O O
the O O
lack O O
of O O
PSA B B_GENE
immunoreactivity O O
and O O
the O O
presence O O
of O O
mucinous O O
glands O O
, O O
sometimes O O
" O O
endocervical O O
- O O
like O O
" O O
, O O
could O O
suggest O O
an O O
origin O O
from O O
embryonic O O
mullerian O O
remnants O O
in O O
the O O
prostatic O O
utricle O O
rather O O
than O O
urogenital O O
sinus O O
. O O

Upon O O
increasing O O
the O O
Marangoni O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
beyond O O
this O O
threshold O B_LOCATION/B_MEASURE
, O O
the O O
initially O O
stationary O B_MEASURE
flow O I_MEASURE
becomes O O
quickly O O
time O B_DISEASE_ADJECTIVE[DISEASE]
dependent O I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
showed O O
differential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
each O O
parahippocampal O B_LOCATION/B_PERSON
region O I_LOCATION/I_PERSON
during O O
verbal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
memory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
tasks O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
which O O
the O O
side O B_LOCATION
activated O O
shifted O O
depending O O
on O O
the O O
nature O B_LOCATION/B_MEASURE
of O O
the O O
task O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
employed O O
; O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
rCBF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
the O O
left O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
parahippocampal O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
gyrus O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O O
associated O O
with O O
retrieval O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
strategy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
non O B_DISEASE/B_PERSON
- O O
matching O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
and O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
rCBF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
the O O
right O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
parahippocampal O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
gyrus O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O O
associated O O
with O O
retrieval O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
strategy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
matching O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Evolution O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
cytomegalovirus O B_DISEASE
antibodies O I_DISEASE
of O O
maternal O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
origin O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O O
acquired O O
, O O
throughout O O
the O O
first O B_TIME[MEASURE]/B_LOCATION
year O I_TIME[MEASURE]/I_LOCATION
of O O
life O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION

Demonstration O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
changes O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
fetal O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
liver O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
erythropoiesis O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
using O O
echo O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
- O O
planar O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
magnetic O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resonance O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaging O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
actual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
placement O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
lesions O B_DISEASE/B_PROTEIN[GENE]
was O O
determined O O
after O O
mapping O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
GPi O B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
by O O
microrecording O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
using O O
stimulation O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
identify O O
the O O
sensorimotor O B_LOCATION/B_DISEASE
region O B_LOCATION/I_DISEASE
and O O
its O O
somatotopic O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
organization O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

Effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
prostaglandin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
E2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
on O O
experimental O B_DISEASE/B_ORGANISM_FUNCTION
atherosclerosis O I_DISEASE/I_ORGANISM_FUNCTION
. O O

Both O O
the O O
arterial O B_BODY_PART_OR_ORGAN_COMPONENT/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
venous O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
thrombi O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O O
clearly O O
discernible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
2 O B_NUMBER[MEASURE]/B_LOCATION
to O O
8 O B_MEASURE
h O O
after O O
injection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
99Tcm O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
SZ O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
51 O B_NUMBER[MEASURE]
. O O

The O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
lung O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
edema O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
pulmonary O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vasoactivity O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
furosemide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
the O O
malaria O B_DISEASE/B_SPECIES[BIO]
vectors O O
Anopheles O B_SPECIES[BIO]/B_DISEASE
funestus O I_SPECIES[BIO]/I_DISEASE
and O O
An O O
. O O
gambiae O B_SPECIES[BIO]/B_LOCATION
have O O
both O O
become O O
more O O
abundant O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
during O O
the O O
1970s O B_TIME[MEASURE]
and O O
1980s O B_TIME[MEASURE]/B_BIO
and O O
sporozoite O B_SPECIES[BIO]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
positive O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
specimens O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
both O O
have O O
been O O
found O O
. O O

Soluble O O
extracts O O
from O O
FGF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
treated O O
as O O
compared O O
with O O
quiescent O O
fibroblasts O O
exhibited O O
up O O
to O O
3 O O
- O O
fold O O
higher O O
kinase O O
activity O O
towards O O
S6 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
exogenously O O
added O O
rat B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
liver I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
40S I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ribosomes I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
a O O
synthetic O O
peptide O O
, O O
RRLSSLRA O O
. O O

In O O
bell O O
pepper O O
, O O
a O O
gene O O
encoding O O
a O O
major O O
plastid O O
- O O
lipid O O
associated O O
protein O O
is O O
expressed O O
as O O
both O O
partially O O
and O O
totally O O
spliced O O
transcripts O O
( O O
respectively O O
PAP2 B B_GENE/B_DISEASE
and O O
PAP1 B B_GENE/B_DISEASE
) O O
. O O

Inhibitory O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
characterized O O
by O O
the O O
presence O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
a O O
characteristic O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
sequence O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
known O O
as O O
an O O
immunoreceptor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
tyrosine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
based O O
inhibitory O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
motif O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ITIM O B_ORGANIZATION/B_GENE
) O O
in O O
their O O
cytoplasmic O B_LOCATION/B_BIO
tail O B_LOCATION/I_BIO
. O O

We O O
conclude O O
that O O
LGCS O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
successful O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
treating O O
esophageal O B_DISEASE
varices O I_DISEASE
in O O
the O O
setting O B_LOCATION
of O O
hyperdynamic O B_DISEASE/B_PERSON
portal O I_DISEASE/I_PERSON
circulation O I_DISEASE/I_PERSON
with O O
acceptable O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
liver O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
function O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Candidate O O
factors O O
have O O
been O O
identified O O
by O O
the O O
observation O O
that O O
changes O O
in O O
glucocorticoid O O
induction O O
parameters O O
in O O
CV O O
- O O
1 O O
cells O O
could O O
be O O
reproduced O O
by O O
varying O O
the O O
cellular O O
levels O O
of O O
coactivators O O
[ O O
transcriptional B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
intermediary I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TIF2 B B_GENE
) O O
, O O
steroid B B_GENE/B_PERSON
receptor I I_GENE/I_PERSON
coactivator I I_GENE/I_PERSON
1 I I_GENE/I_PERSON
( O O
SRC B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
) O O
, O O
and O O
amplified B B_PROTEIN[GENE]/B_DISEASE
in I I_PROTEIN[GENE]/I_DISEASE
breast I I_PROTEIN[GENE]/I_DISEASE
cancer I I_PROTEIN[GENE]/I_DISEASE
1 I I_PROTEIN[GENE]/I_DISEASE
( O O
AIB1 B B_GENE/B_SPECIES[BIO]
) O O
] O O
, O O
comodulator O O
[ O O
CREB B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
] O O
, O O
or O O
corepressor O O
[ O O
silencing B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mediator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
for I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
retinoid I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
thyroid I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
hormone I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
SMRT B B_GENE/B_LOCATION
) O O
] O O
without O O
concomitant O O
increases O O
in O O
GR B B_GENE/B_DISEASE
. O O

Immunoblot O O
analyses O O
revealed O O
that O O
the O O
loss O O
of O O
activator O O
function O O
coincides O O
with O O
selective O O
removal O O
of O O
the O O
C B B_ENZYME[GENE]
- I I_ENZYME[GENE]
terminal I I_ENZYME[GENE]
domain I I_ENZYME[GENE]
( I I_ENZYME[GENE]
CTD I I_ENZYME[GENE]
) I I_ENZYME[GENE]
- I I_ENZYME[GENE]
hyperphosphorylated I I_ENZYME[GENE]
RNAP I I_ENZYME[GENE]
IIO I I_ENZYME[GENE]
along O O
with O O
NC2 B B_GENE
. O O

The O O
nucleotide O B_LOCATION
sequence O I_LOCATION
of O O
the O O
gene O B_GENE/B_LOCATION
encoding O O
this O O
product O B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
determined O O
and O O
the O O
amino O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deduced O O
. O O

At O O
9 O O
months O O
postpartum O O
, O O
serum O O
fT4 O O
and O O
fT3 O O
levels O O
were O O
low O O
normal O O
( O O
8 O O
. O O
0 O O
and O O
1 O O
. O O
7 O O
pmol O O
/ O O
L O O
, O O
respectively O O
) O O
, O O
but O O
TSH B B_GENE
was O O
not O O
raised O O
( O O
0 O O
. O O
4 O O
mU O O
/ O O
L O O
) O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Three O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
did O O
not O O
tolerate O O
PPI O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medication O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
were O O
managed O O
by O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
type O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
histamine O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
H2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
blockers O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
is O O
considered O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
therefore O O
, O O
when O O
treating O O
diabetic O B_PERSON
patients O I_PERSON
with O O
peripheral O B_DISEASE
neuropathy O I_DISEASE
not O O
to O O
assume O O
that O O
the O O
diabetes O B_DISEASE
itself O O
is O O
the O O
cause O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
all O O
cases O B_PERSON/B_DISEASE
. O O

TFIIIB B B_GENE/B_DISEASE
assembles O O
autonomously O O
on O O
the O O
upstream O O
promoter O O
of O O
the O O
yeast B B_GENE
U6 I I_GENE
snRNA I I_GENE
( O O
SNR6 B B_PROTEIN[GENE]/B_LOCATION
) O O
gene O O
in O O
vitro O O
, O O
through O O
the O O
interaction O O
of O O
its O O
TBP B B_GENE/B_LOCATION
subunit I I_GENE/I_LOCATION
with O O
a O O
consensus O O
TATA O O
box O O
located O O
at O O
base O O
pair O O
- O O
30 O O
. O O

Mutational O O
analysis O O
of O O
the O O
IME2 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
UAS I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reveals O O
two O O
critical O O
sequence O O
elements O O
: O O
a O O
G O O
+ O O
C O O
- O O
rich O O
sequence O O
( O O
called O O
URS1 O O
) O O
, O O
previously O O
identified O O
at O O
many O O
meiotic O O
genes O O
, O O
and O O
a O O
newly O O
described O O
element O O
, O O
the O O
T4C O O
site O O
, O O
that O O
we O O
found O O
at O O
a O O
subset O O
of O O
meiotic O O
genes O O
. O O

Molecular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
the O O
mannitol O B_GENE/B_BIO
operon O I_GENE/I_BIO
of O O
Clostridium O B_BIO/B_GENE
acetobutylicum O I_BIO/I_GENE
encoding O O
a O O
phosphotransferase O B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
system O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
a O O
putative O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
PTS O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
modulated O O
regulator O B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Our O O
results O O
show O O
that O O
a O O
combination O O
of O O
Pfu B B_GENE/B_BACTERIUM[BIO]
exo I I_GENE/I_BACTERIUM[BIO]
( I I_GENE/I_BACTERIUM[BIO]
- I I_GENE/I_BACTERIUM[BIO]
) I I_GENE/I_BACTERIUM[BIO]
at O O
the O O
primer O O
extension O O
step O O
and O O
Taq B B_LOCATION/B_GENE
at O O
the O O
PCR O O
amplification O O
step O O
is O O
ideal O O
for O O
in O O
vivo O O
DNA O O
analysis O O
and O O
DNA O O
damage O O
mapping O O
using O O
LMPCR O O
. O O

Effect O O
of O O
TNF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
IL B B_GENE
- I I_GENE
1 I I_GENE
, O O
and O O
IL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
proliferation O O
of O O
human O O
Tenon O O
' O O
s O O
capsule O O
fibroblasts O O
in O O
tissue O O
culture O O
. O O

Estimating O O
the O O
health O B_MEASURE/B_DISEASE
care O I_MEASURE/I_DISEASE
costs O I_MEASURE/I_DISEASE
of O O
smokers O B_DISEASE
. O O

Using O O
lacZ B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
inducible O O
T O O
cells O O
as O O
a O O
probe O O
, O O
we O O
screened O O
a O O
splenic O O
cDNA O O
library O O
in O O
transiently O O
transfected O O
antigen O O
- O O
presenting O O
cells O O
( O O
APCs O O
) O O
and O O
isolated O O
a O O
cDNA O O
clone O O
that O O
allowed O O
expression O O
of O O
the O O
appropriate O O
peptide B B_GENE
/ I I_GENE
Kb I I_GENE
MHC I I_GENE
complex I I_GENE
in O O
APC O O
. O O

Endotoxemia O B_DISEASE
and O O
bacteremia O B_DISEASE
in O O
patients O B_PERSON
with O O
sepsis O B_DISEASE
syndrome O I_DISEASE
in O O
the O O
intensive O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
care O B_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
unit O B_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Early O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
attempts O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
modifying O O
growth O B_MEASURE
functions O I_MEASURE
to O O
annual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
variations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
dating O O
back O O
up O O
to O O
2 O B_TIME[MEASURE]
decades O I_TIME[MEASURE]
are O O
recalled O O
together O O
with O O
examples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
their O O
application O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showing O O
rather O O
different O B_MEASURE
degrees O I_MEASURE
of O O
approximation O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

A O O
significant O O
reduction O O
in O O
total O O
cellular O O
p27 B B_GENE
protein I I_GENE
levels O O
and O O
a O O
moderate O O
reduction O O
in O O
p27 B B_GENE
mRNA I I_GENE
are O O
observed O O
, O O
but O O
no O O
changes O O
in O O
Cdk B B_GENE/B_PERSON
regulatory O O
kinases O O
and O O
phosphatases O O
occur O O
. O O

Genetic O O
linkage O O
mapping O O
of O O
the O O
CYP11A1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encoding O O
the O O
cholesterol O O
side O O
- O O
chain O O
cleavage O O
P450scc B B_GENE/B_LOCATION
close O O
to O O
the O O
CYP1A1 B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
gene I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
D15S204 B B_GENE/B_LOCATION
in O O
the O O
chromosome O O
15q22 O O
. O O
33 O O
- O O
q23 O O
region O O
. O O

Genetic O O
and O O
physiological O O
experiments O O
suggest O O
a O O
close O O
relationship O O
between O O
cdc27 B B_GENE
+ I I_GENE
and O O
the O O
cdc2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
+ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
key O O
regulator O O
of O O
mitosis O O
in O O
yeast O O
and O O
also O O
in O O
higher O O
eukaryotic O O
cells O O
. O O

The O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
performed O O
in O O
a O O
class O B_LOCATION
100 O I_LOCATION
laminar O I_LOCATION
flow O I_LOCATION
clean O I_LOCATION
bench O I_LOCATION
in O O
order O B_LOCATION/B_MEASURE
to O O
minimize O O
particulate O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contamination O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
extraneous O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sources O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
cloned O O
rRNA O O
operon O O
was O O
transcribed O O
in O O
vitro O O
by O O
using O O
purified B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
polymerase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Escherichia I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
coli I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Of O O
the O O
CSF O B_MEASURE
tested O O
, O O
24 O B_MEASURE
stimulated O O
oxygen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
consumption O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
above O O
our O O
cut O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
off O O
, O O
and O O
8 O B_NUMBER[MEASURE]
did O O
not O O
( O O
0 O B_MEASURE
. O O
84 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
34 O B_MEASURE
, O O
n O O
= O O
24 O B_MEASURE
compared O O
with O O
the O O
rate O B_MEASURE
of O O
0 O B_MEASURE
. O O
27 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
1 O B_MEASURE
mumol O I_MEASURE
/ O O
min O B_PERSON/B_MEASURE
/ O O
g O B_MEASURE
dry O I_MEASURE
wt O I_MEASURE
, O O
respectively O O
; O O
SD O B_MEASURE/B_PROTEIN[GENE]
n O B_MEASURE/I_PROTEIN[GENE]
= O O
8 O B_MEASURE
) O O
at O O
180 O B_MEASURE
minutes O I_MEASURE
. O O

The O O
sequence O O
of O O
the O O
gene O O
upstream O O
to O O
the O O
cap O O
site O O
contains O O
characteristic O O
RNA B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
polymerase I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
II I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
promoter I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
- I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
binding I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
sites I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
: O O
a O O
putative O O
TATA O O
box O O
at O O
position O O
- O O
29 O O
and O O
a O O
Sp B B_GENE
1 I I_GENE
binding I I_GENE
site I I_GENE
( O O
GGGGCGGAGA O O
) O O
at O O
position O O
- O O
48 O O
. O O

The O O
kinetics O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
[ O O
14C O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] O O
NG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
the O O
blood O B_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
dosed O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
followed O O
. O O

These O O
clones O O
contain O O
most O O
of O O
the O O
exon O O
of O O
cyclin B B_GENE/B_LOCATION
D2 I I_GENE/I_LOCATION
except O O
exon O O
5 O O
. O O

One O B_NUMBER[MEASURE]/B_PERSON
had O O
a O O
48 O B_MEASURE
- O O
hour O B_TIME[MEASURE]
cycle O I_TIME[MEASURE]
and O O
the O O
other O B_SEQUENCE[MEASURE]/B_LOCATION
a O O
24 O B_MEASURE
- O O
hour O B_TIME[MEASURE]/B_LOCATION
cycle O I_TIME[MEASURE]/I_LOCATION
. O O

This O O
action O O
could O O
be O O
antagonized O O
by O O
aminophylline O O
, O O
a O O
competitive O O
antagonist O O
on O O
P1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
purinoceptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Evidence O O
for O O
Gcr1p B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
Gcr2p B B_GENE
interaction O O
has O O
been O O
presented O O
earlier O O
and O O
is O O
now O O
supported O O
by O O
the O O
isolation O O
of O O
mutations O O
in O O
Gcr1p B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
suppressing O O
gcr2 B B_GENE
, O O
as O O
assessed O O
by O O
growth O O
and O O
enzyme O O
assay O O
. O O

Keys O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
used O O
for O O
identifying O O
species O B_BIO/B_PERSON
from O O
the O O
European O B_LOCATION
part O I_LOCATION
of O O
the O O
USSR O B_LOCATION/B_ORGANIZATION
and O O
north O O
- O O
eastern O B_LOCATION
Kazakhstan O I_LOCATION
. O O

Promoter O O
constructs O O
containing O O
mutations O O
in O O
the O O
PTRE B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
sequence I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O O
selectively O O
abolished O O
the O O
binding O O
of O O
either O O
one O O
or O O
both O O
complexes O O
exerted O O
opposite O O
effects O O
on O O
the O O
transcriptional O O
activity O O
of O O
trypsin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoters I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
A O O
. O O
gambiae O O
and O O
Aedes O O
aegypti O O
cell O O
lines O O
. O O

The O O
Rep78 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
adeno O O
- O O
associated O O
virus O O
( O O
AAV O O
) O O
contains O O
amino O O
acid O O
sequence O O
motifs O O
common O O
to O O
rolling B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
circle I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
replication I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
( I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
RCR I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
) I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
initiator I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Plasma O O
prolactin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
patients O O
with O O
colorectal O O
cancer O O
. O O

Reality O O
and O O
clinical O O
application O O
of O O
immunoglobulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
preparations O O

The O O
extent O B_DISEASE/B_MEASURE
of O O
myocardial O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ischemia O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
coronary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
sinus O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
was O O
significantly O O
correlated O O
to O O
the O O
coronary O B_MEASURE
diameters O I_MEASURE
of O O
the O O
proximal O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
middle O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
segments O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
Ramus O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interventricularis O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anterior O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
middle O B_MEASURE/B_LOCATION
segment O I_MEASURE/I_LOCATION
of O O
the O O
Ramus O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
circumflexus O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
r O B_OTHER/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
87 O B_MEASURE
, O O
p O O
< O O
0 O B_MEASURE
. O O
02 O B_MEASURE
) O O
. O O

The O O
in O O
- O O
plane O B_MEASURE/B_LOCATION
orientational O I_MEASURE/I_LOCATION
anisotropy O I_MEASURE/I_LOCATION
of O O
the O O
8CB O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
films O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
grown O O
on O O
unidirectionally O O
photopolymerized O B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PVCN O B_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
substrates O B_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
considerably O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
the O O
intrinsic O B_MEASURE
surface O I_MEASURE
orientational O I_MEASURE
anisotropy O I_MEASURE
of O O
these O O
substrates O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
which O O
can O O
explain O O
the O O
generally O O
found O O
weak O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
surface O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
anchoring O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
liquid O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
crystals O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O O
PVCN O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
alignment O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
layers O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Nuclear O O
transcription O O
assays O O
confirmed O O
that O O
cys B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
under O O
sulfur O O
- O O
regulated O O
transcriptional O O
control O O
and O O
that O O
cys B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
3 I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
+ I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
transcription O O
was O O
constitutive O O
in O O
sulfur B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
controller I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
scon B B_LOCATION/B_DISEASE
) O O
- O O
negative O O
regulator O O
mutants O O
. O O

The O O
rifampicin O O
resistance O O
of O O
uvsW B B_DISEASE/B_GENE
- O O
repressed O O
replication O O
suggests O O
that O O
it O O
involves O O
either O O
tertiary O O
initiation O O
or O O
some O O
novel O O
mode O O
of O O
initiation O O
. O O

Pharmacokinetics O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
skin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
penetration O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Furthermore O O
, O O
the O O
regulation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conferred O O
on O O
a O O
reporter O B_GENE/B_LOCATION
gene O I_GENE/I_LOCATION
in O O
Drosophila O B_SPECIES[BIO]
by O O
three O B_NUMBER[MEASURE]/B_PERSON
closely O O
related O B_LOCATION/B_PERSON
sequences O I_LOCATION/I_PERSON
demonstrates O O
that O O
even O O
subtle O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O O
an O O
E O B_GENE/B_MEASURE
box O I_GENE/I_MEASURE
or O O
flanking O B_GENE/B_LOCATION
bases O I_GENE/I_LOCATION
have O O
dramatic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
consequences O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
overall O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
repertoire O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
proteins O B_GENE/B_DISEASE
that O O
can O O
bind O O
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

Buspirone O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
Type O B_DISEASE
A O I_DISEASE
behavior O I_DISEASE
, O O
hostility O B_DISEASE
, O O
and O O
perceived O O
stress O B_DISEASE
in O O
cardiac O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
. O O

Recently O O
we O O
have O O
performed O O
a O O
detailed O O
analysis O O
of O O
specific O O
neuronal O O
populations O O
affected O O
by O O
the O O
mutation O O
which O O
shed O O
new O O
light O O
on O O
the O O
role O O
of O O
Krox B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
20 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
segmentation O O
and O O
on O O
the O O
physiological O O
consequences O O
of O O
its O O
inactivation O O
. O O

A O O
species O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comparison O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cDNA O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
sequences O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
isolation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
a O O
genomic O B_SPECIES[BIO]/B_GENE
clone O B_SPECIES[BIO]/I_GENE
. O O

The O O
inhibition O O
of O O
monoamine B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
oxidase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MAO B B_GENE/B_PERSON
) O O
by O O
tranylcypromine O O
was O O
studied O O
in O O
6 O O
healthy O O
volunteers O O
given O O
increasing O O
doses O O
of O O
10 O O
, O O
15 O O
, O O
20 O O
and O O
25 O O
mg O O
/ O O
day O O
over O O
a O O
4 O O
- O O
week O O
period O O
. O O

Deletion O O
mutagenesis O O
of O O
the O O
promoter O O
indicated O O
that O O
a O O
positive O O
regulatory O O
element O O
( O O
PRE O O
) O O
was O O
likely O O
to O O
exist O O
downstream O O
of O O
the O O
UL94 B B_GENE/B_PERSON
mRNA I I_GENE/I_PERSON
start I I_GENE/I_PERSON
site I I_GENE/I_PERSON
, O O
while O O
a O O
negative O O
regulatory O O
element O O
( O O
NRE O O
) O O
was O O
present O O
upstream O O
of O O
the O O
TATA O O
box O O
. O O

Expression O O
of O O
Helios B B_GENE/B_BIO
was O O
detected O O
in O O
the O O
earliest O O
hematopoietic O O
sites O O
of O O
the O O
embryo O O
, O O
in O O
hematopoietic O O
stem O O
cells O O
in O O
the O O
adult O O
and O O
was O O
subsequently O O
restricted O O
to O O
a O O
subset O O
of O O
cells O O
in O O
the O O
T O O
cell O O
lineage O O
. O O

Metapsychiatry O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
is O O
a O O
term O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
born O O
of O O
necessity O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
designate O O
the O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O O
hitherto O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
unclassified O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
interface O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
between O O
psychiatry O B_DISEASE/B_EDU[ORGANIZATION]
and O O
mysticism O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Effects O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
negative O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pi O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mesons O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
mouse O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bone O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
marrow O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Using O O
probes O O
containing O O
C B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EBP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
the O O
iNOS B B_GENE
gene I I_GENE
revealed O O
further O O
binding O O
of O O
different O O
complexes O O
, O O
all O O
of O O
which O O
were O O
strongly O O
inducible O O
by O O
cAMP O O
and O O
to O O
a O O
lower O O
extent O O
also O O
by O O
IL B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1beta I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
Pi O O
signals O O
are O O
conveyed O O
to O O
PHO8 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O O
binding O O
of O O
PHO4 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
positive O O
regulatory O O
factor O O
, O O
to O O
a O O
promoter O O
region O O
of O O
PHO8 B B_GENE/B_BIO
( O O
PHO8p B B_PROTEIN[GENE]/B_LOCATION
) O O
under O O
the O O
influence O O
of O O
the O O
PHO B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
regulatory O O
circuit O O
. O O

Thus O O
, O O
the O O
end O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O O
a O O
linearized O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fragment O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O O
initiate O O
new O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
DNA O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
synthesis O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O O
BIR O B_LOCATION/B_DISEASE
in O O
which O O
the O O
newly O O
synthesized O O
DNA O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O O
displaced O O
and O O
subsequently O O
forms O B_DISEASE_ADJECTIVE[DISEASE]
circles O I_DISEASE_ADJECTIVE[DISEASE]
by O O
NHEJ O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
would O O
seem O O
that O O
caution O O
should O O
be O O
exercised O O
in O O
using O O
HPL B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
values O O
as O O
an O O
index O O
of O O
placental O O
function O O
in O O
anaemic O O
women O O
. O O

A O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
acquired O O
immune O B_DISEASE
deficiency O I_DISEASE
syndrome O I_DISEASE
before O O
1980 O B_TIME[MEASURE]/B_PERSON
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
multiple O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genetic O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recombination O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O O
bacteriophages O B_BIO/B_GENE
with O O
different O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
immunities O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
took O O
place O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
to O O
generate O O
the O O
prophage O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
VT1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O O
Sakai O B_MEASURE/B_BIO
. O O

The O O
adenovirus B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E1B I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
19 I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
000 I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecular I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weight I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
19K I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
potent O O
inhibitor O O
of O O
apoptosis O O
and O O
cooperates O O
with O O
E1A B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
transform O O
primary O O
rodent O O
cells O O
. O O

Desensitization O O
of O O
the O O
growth B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormone I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
induced O O
Janus B B_GENE/B_LOCATION
kinase I I_GENE/I_LOCATION
2 I I_GENE/I_LOCATION
( O O
Jak B B_GENE
2 I I_GENE
) O O
/ O O
signal B B_GENE/B_MEASURE
transducer I I_GENE/I_MEASURE
and I I_GENE/I_MEASURE
activator I I_GENE/I_MEASURE
of I I_GENE/I_MEASURE
transcription I I_GENE/I_MEASURE
5 I I_GENE/I_MEASURE
( O O
Stat5 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
- O O
signaling O O
pathway O O
requires O O
protein O O
synthesis O O
and O O
phospholipase B B_GENE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
C I B_GENE/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
. O O

In O O
two O O
separate O O
studies O O
, O O
specimens O O
of O O
saliva O O
from O O
57 O O
individuals O O
over O O
the O O
age O O
of O O
65 O O
years O O
( O O
mean O O
age O O
, O O
76 O O
. O O
7 O O
years O O
) O O
and O O
37 O O
persons O O
under O O
the O O
age O O
of O O
40 O O
years O O
( O O
mean O O
age O O
, O O
28 O O
. O O
8 O O
years O O
) O O
were O O
examined O O
for O O
concentrations O O
of O O
IgA B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
functions O O
of O O
volume O O
, O O
total O O
protein O O
, O O
and O O
electrolyte O O
conductivity O O
; O O
some O O
were O O
also O O
tested O O
for O O
IgG B B_GENE
and O O
IgM B B_GENE
content O O
. O O

E2A B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
HLF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
mediated O O
cell O O
transformation O O
requires O O
both O O
the O O
trans O O
- O O
activation O O
domains O O
of O O
E2A B B_GENE/B_LOCATION
and O O
the O O
leucine O O
zipper O O
dimerization O O
domain O O
of O O
HLF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Two O O
adjacent O O
, O O
highly O O
homologous B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
endoglucanase I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
genes I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
celD B B_LOCATION/B_GENE
and O O
celE B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
Fibrobacter O O
succinogenes O O
S85 O O
, O O
which O O
were O O
separated O O
by O O
an O O
AT O O
- O O
rich O O
223 O O
- O O
nucleotide O O
intergenic O O
region O O
were O O
characterized O O
. O O

The O O
Seldinger O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
technique O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
difficult O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
transurethral O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
catheterization O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
: O O
a O O
gentle O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
alternative O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
to O O
suprapubic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
puncture O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Br O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Surg O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2000 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
87 O B_MEASURE
: O O
1729 O B_MEASURE
- O O
30 O B_MEASURE
) O O
. O O

We O O
screened O O
an O O
A O O
. O O
thaliana O O
cDNA O O
library O O
, O O
whose O O
inserts O O
are O O
under O O
the O O
control O O
of O O
the O O
galactose O O
- O O
inducible O O
GAL10 B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
, O O
for O O
cDNAs O O
which O O
enabled O O
YDH8 O O
cells O O
to O O
grow O O
at O O
the O O
restrictive O O
temperature O O
. O O

We O O
generated O O
" O O
signature O O
" O O
oligonucleotides O O
from O O
these O O
CDR3s B B_GENE
and O O
probed O O
PCR O O
amplified O O
V B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
products I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
the O O
synovium O O
and O O
PBLs O O
of O O
the O O
same O O
patient O O
, O O
and O O
from O O
PBLs O O
and O O
spleen O O
of O O
individuals O O
without O O
rheumatic O O
disease O O
. O O

One O O
of O O
the O O
major O O
transcripts O O
encodes O O
MEQ B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
339 O O
- O O
amino O O
- O O
acid O O
bZIP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O O
is O O
homologous O O
to O O
the O O
Jun B B_PERSON/B_GENE
/ O O
Fos B B_GENE/B_LOCATION
family O O
of O O
transcription O O
factors O O
. O O

It O O
is O O
concluded O O
that O O
the O O
new O O
class O O
of O O
competitive O O
NMDA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antagonists O O
, O O
exemplified O O
by O O
CGP O O
37849 O O
, O O
is O O
the O O
most O O
promising O O
candidate O O
for O O
clinical O O
trials O O
in O O
anxiety O O
disorders O O
. O O

An O O
emended O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
diagnosis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
Tylocephalum O B_DISEASE
is O O
proposed O O
excluding O O
this O O
feature O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
along O O
with O O
distribution O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
testes O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
preovarian O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
field O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
and O O
circummedullary O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distribution O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
vitelline O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
follicles O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Induction O O
of O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
IFNalpha B B_PROTEIN[GENE]/B_LOCATION
) O O
gene O O
expression O O
in O O
virus O O
- O O
infected O O
cells O O
requires O O
phosphorylation O O
- O O
induced O O
activation O O
of O O
the O O
transcription O O
factors O O
IRF3 B B_GENE
and O O
IRF7 B B_GENE
. O O

METHODS O O
: O O
The O O
prevalence O O
of O O
haemagglutination B B_DISEASE
inhibiting I I_DISEASE
( I I_DISEASE
HI I I_DISEASE
) I I_DISEASE
antibodies I I_DISEASE
to O O
JE O O
virus O O
( O O
JEV O O
) O O
, O O
West O O
Nile O O
virus O O
( O O
WNV O O
) O O
and O O
dengue O O
- O O
2 O O
virus O O
( O O
DEN O O
- O O
2 O O
) O O
was O O
detected O O
by O O
HI O O
test O O
and O O
IgM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
capture O O
ELISA O O
( O O
MAC O O
ELISA O O
) O O
was O O
performed O O
to O O
determine O O
recent O O
infections O O
with O O
JE O O
virus O O
. O O

Moreover O O
, O O
since O O
the O O
integrated O O
transforming O O
DNA O O
was O O
not O O
altered O O
or O O
lost O O
expression O O
of O O
the O O
RbcS2 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
: O O
aadA B B_GENE/B_BACTERIUM[BIO]
: O O
: O O
RbcS2 B B_GENE
gene I I_GENE
( I I_GENE
s I I_GENE
) I I_GENE
appears O O
to O O
be O O
repressed O O
. O O

Donehower O B_PERSON/B_LOCATION
and O O
H O B_OTHER/B_PERSON
. O O

A O O
characteristic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
feature O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
their O O
tendency O B_DISEASE
to O O
form O O
homo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
and O O
/ O O
or O O
heterodimeric O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
complexes O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Further O O
, O O
more O O
recent O O
communications O O
suggest O O
that O O
liver O O
disease O O
led O O
to O O
a O O
differential O O
alteration O O
of O O
the O O
cytochrome B B_BODY_PART_OR_ORGAN_COMPONENT/B_ENZYME[GENE]
P I I_BODY_PART_OR_ORGAN_COMPONENT/I_ENZYME[GENE]
- I I_BODY_PART_OR_ORGAN_COMPONENT/I_ENZYME[GENE]
450s I I_BODY_PART_OR_ORGAN_COMPONENT/I_ENZYME[GENE]
with O O
regard O O
to O O
protein O O
content O O
and O O
activity O O
. O O

Apparent O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Buschke O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Loewenstein O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
tumour O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
penis O B_BODY_PART_OR_ORGAN_COMPONENT
. O O

This O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
stronger O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
multiple O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
predoses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
sertraline O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O O
when O O
imipramine O B_MEASURE
Cmax O I_MEASURE
and O O
AUC O B_MEASURE/B_PROTEIN[GENE]
( O O
0 O B_MEASURE/B_LOCATION
- O O
infinity O B_MEASURE
) O O
were O O
increased O O
by O O
39 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
and O O
68 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
respectively O O
. O O

Mutations O O
in O O
nifR1 B B_GENE
( O O
ntrC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
and O O
nifR4 B B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
rpoN B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
encoding O O
sigma54 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
had O O
no O O
influence O O
on O O
xdh B B_GENE
gene I I_GENE
expression O O
. O O

We O O
therefore O O
propose O O
that O O
PRR2 B B_GENE/B_LOCATION
, O O
and O O
not O O
PVR B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
is O O
the O O
true O O
human O O
homolog O O
of O O
MPH B B_DISEASE/B_GENE
. O O

Swarming O O
of O O
Moraxella O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]

Biochem O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

In O O
contrast O O
, O O
vRel B B_GENE/B_PERSON
lacks O O
a O O
strong O O
C O O
- O O
terminal O O
gene O O
activation O O
function O O
, O O
since O O
a O O
LexA B B_GENE/B_LOCATION
fusion I I_GENE/I_LOCATION
protein I I_GENE/I_LOCATION
containing O O
C B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
terminal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
vRel I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequences I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alone O O
only O O
weakly O O
activated O O
transcription O O
. O O

The O O
crystal O O
structure O O
of O O
the O O
yeast O O
Phe B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tRNAPhe I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ternary I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
Thermus O O
aquaticus O O
EF B B_GENE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
- I B_GENE/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
Tu I B_GENE/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
- O O
GDPNP O O
( O O
Phe B B_GENE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
- I B_GENE/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
TC I B_GENE/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
) O O
has O O
previously O O
been O O
determined O O
as O O
one O O
representative O O
of O O
this O O
general O O
yet O O
highly O O
discriminating O O
complex O O
formation O O
. O O

Bovine O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
anaplasmosis O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
: O O
susceptibility O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
seronegative O B_SPECIES[BIO]/B_DISEASE
cows O I_SPECIES[BIO]/I_DISEASE
from O O
an O O
infected O B_DISEASE/B_LOCATION
herd O I_DISEASE/I_LOCATION
to O O
experimental O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infection O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
Anaplasma O B_SPECIES[BIO]/B_DISEASE
marginale O I_SPECIES[BIO]/I_DISEASE
. O O

Because O O
of O O
gut O B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE_ADJECTIVE[DISEASE]
fermentation O I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
substantial O B_MEASURE/B_PERSON
portion O I_MEASURE/I_PERSON
( O O
16 O B_MEASURE
- O O
80 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
of O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
absorbed O O
as O O
ammonia O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
N O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
NH3N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
. O O

Quantitative O O
measurement O O
of O O
antigamma B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
globulin I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
factors I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
rheumatoid B B_DISEASE/B_LOCATION
factors I I_DISEASE/I_LOCATION
) O O
using O O
laser O O
- O O
nephelometry O O
in O O
comparison O O
with O O
the O O
latex O O
agglutination O O
test O O
and O O
the O O
Waaler O O
- O O
Rose O O
test O O

The O O
densities O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
ranged O O
between O O
2 O B_MEASURE
and O O
3976 O B_MEASURE
neurites O I_MEASURE
/ O O
mm2 O B_MEASURE/B_BIO
skin O I_MEASURE/I_BIO
surface O I_MEASURE/I_BIO
, O O
but O O
the O O
overlap O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
between O O
subjects O B_PERSON/B_LOCATION
and O O
without O O
PHN O B_DISEASE/B_PERSON
was O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

Zoonotic O B_LOCATION/B_ORGANIZATION
areas O I_LOCATION/I_ORGANIZATION
in O O
which O O
HIV O B_DISEASE
co O I_DISEASE
- O O
infection O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
common O B_DISEASE_ADJECTIVE[DISEASE]
could O O
also O O
be O O
at O O
risk O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
as O O
sandflies O B_PERSON/B_DISEASE
can O O
become O O
infected O O
from O O
co O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
infected O O
individuals O B_PERSON/B_BIO
. O O

The O O
determination O O
of O O
antithrombin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
III I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
AT B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
III I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
its O O
clinical O O
significance O O

The O O
kinetics O B_DISEASE/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
erythromycin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
E O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
) O O
was O O
studied O O
in O O
16 O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
with O O
different O B_DISEASE_ADJECTIVE[DISEASE]
degrees O I_DISEASE_ADJECTIVE[DISEASE]
of O O
impairment O B_DISEASE_ADJECTIVE[DISEASE]
of O O
renal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
after O O
a O O
single O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
intravenous O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
dose O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Base O O
substitutions O O
within O O
this O O
NFIL B B_LOCATION/B_BIO
- I I_LOCATION/I_BIO
6 I I_LOCATION/I_BIO
site I I_LOCATION/I_BIO
resulted O O
in O O
virtual O O
elimination O O
of O O
LPS O O
- O O
induced O O
IL B B_GENE
- I I_GENE
1 I I_GENE
beta I I_GENE
gene I I_GENE
transcription O O
. O O

Mortality O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rates O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
not O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
chi2 O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
0 O B_MEASURE
. O O
0298 O B_MEASURE
, O O
p O O
> O O
0 O B_MEASURE
. O O
5 O B_MEASURE
) O O
. O O

The O O
MALDI O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
TOF O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
experiment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
however O O
, O O
proved O O
to O O
be O O
superior O B_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
GC O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
experiment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O O
particularly O O
with O O
regard O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
baseline O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resolution O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
unsaturated O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acids O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Modern O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
aspects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
shock O B_DISEASE/B_PERSON
- O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O O
extensive O B_PERSON/B_DISEASE
burns O I_PERSON/I_DISEASE
( O O
author O B_PERSON
' O O
s O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transl O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O

Of O O
the O O
private O B_ORGANIZATION/B_LOCATION
practices O B_ORGANIZATION/I_LOCATION
accredited O O
in O O
August O B_PERSON/B_LOCATION
1995 O I_PERSON/I_LOCATION
, O O
40 O B_MEASURE
. O O
6 O B_MEASURE
per O O
cent O B_MEASURE/B_PERSON
( O O
122 O B_MEASURE/B_PERSON
) O O
participated O O
. O O

A O O
Drosophila O O
subobscura O O
genomic O O
fragment O O
containing O O
all O O
the O O
exons O O
and O O
the O O
late O O
and O O
early O O
promotors O O
in O O
the O O
Sxl B B_GENE
gene I I_GENE
of I I_GENE
D I I_GENE
. I I_GENE
melanogaster I I_GENE
was O O
isolated O O
. O O

Collectively O O
, O O
a O O
unique O O
mechanism O O
involving O O
NF B B_GENE
- I I_GENE
ATp I I_GENE
appears O O
to O O
regulate O O
the O O
cell O O
type O O
- O O
specific O O
and O O
activation O O
- O O
dependent O O
expression O O
of O O
the O O
SCM B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
sensitivity O O
of O O
central B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dopamine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
assessed O O
with O O
the O O
growth B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
hormone I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
response O O
to O O
apomorphine O O
application O O
. O O

Oral O O
basal O O
body O O
temperature O O
( O O
BBT O O
) O O
recordings O O
of O O
46 O O
women O O
that O O
conceived O O
by O O
donor O O
insemination O O
and O O
who O O
had O O
midcycle O O
monitoring O O
of O O
luteinising B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hormone I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
LH B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
were O O
analysed O O
to O O
establish O O
features O O
associated O O
with O O
an O O
optimal O O
cycle O O
. O O

Our O O
results O O
admit O O
that O O
a O O
ribosome O O
scanning O O
mechanism O O
of O O
the O O
MP B B_GENE
gene I I_GENE
expression O O
from O O
I O O
( O O
2 O O
) O O
sgRNA O O
operates O O
concurrently O O
. O O

The O O
three O B_NUMBER[MEASURE]
- O O
dimensional O B_LOCATION/B_MEASURE
structure O I_LOCATION/I_MEASURE
of O O
the O O
E O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
coli O B_GENE
CR O I_GENE
domain O I_GENE
indicates O O
that O O
this O O
sequence O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conservation O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
likely O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
result O O
in O O
a O O
conserved O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structural O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
motif O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Otosclerosis O B_DISEASE
in O O
monozygotic O B_PERSON/B_LOCATION
twins O I_PERSON/I_LOCATION
: O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
genetical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

A O O
DNA O O
fragment O O
that O O
complements O O
the O O
uvs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
mutation O O
was O O
subcloned O O
by O O
monitoring O O
its O O
ability O O
to O O
transform O O
the O O
uvs B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
mutant I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
to O O
MMS O O
resistance O O
. O O

The O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
lbc I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
oncogene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
product I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
guanine B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
nucleotide I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
exchange I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
specifically O O
activates O O
the O O
Rho B B_GENE
small I I_GENE
GTP I I_GENE
binding I I_GENE
protein I I_GENE
, O O
thus O O
resulting O O
in O O
biologically O O
active O O
, O O
GTP O O
- O O
bound O O
Rho B B_GENE
, O O
which O O
in O O
turn O O
mediates O O
actin B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cytoskeletal O O
reorganization O O
, O O
gene O O
transcription O O
, O O
and O O
entry O O
into O O
the O O
mitotic O O
S O O
phase O O
. O O

Insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
stimulated O O
autophosphorylation O O
at O O
specific O O
sites O O
in O O
the O O
tyrosine B B_LOCATION/B_PERSON
kinase I I_LOCATION/I_PERSON
domain I I_LOCATION/I_PERSON
of O O
the O O
receptor O O
' O O
s O O
beta O O
- O O
subunit O O
is O O
correlated O O
kinetically O O
with O O
activation O O
of O O
kinase O O
- O O
catalyzed O O
phosphorylation O O
of O O
a O O
model O O
substrate O O
( O O
reduced O O
and O O
carboxyamidomethylated O O
lysozyme B B_GENE
; O O
RCAM B B_GENE
- I I_GENE
lysozyme I I_GENE
) O O
. O O

The O O
critical O B_DISEASE_ADJECTIVE[DISEASE]
obstacle O I_DISEASE_ADJECTIVE[DISEASE]
in O O
modeling O O
psychiatric O B_DISEASE/B_PERSON
disorders O I_DISEASE/I_PERSON
has O O
been O O
limited O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
information O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
about O O
their O O
origin O B_DISEASE
and O O
underlying O O
neural O B_DISEASE_ADJECTIVE[DISEASE]
mechanisms O I_DISEASE_ADJECTIVE[DISEASE]
. O O

BACKGROUND O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Allergic O B_DISEASE/B_LOCATION
rhinoconjunctivitis O I_DISEASE/I_LOCATION
is O O
a O O
common O B_DISEASE_ADJECTIVE[DISEASE]
disorder O I_DISEASE_ADJECTIVE[DISEASE]
, O O
affecting O O
> O B_MEASURE/B_DISEASE
20 O I_MEASURE/I_DISEASE
% O I_MEASURE/I_DISEASE
of O O
people O B_PERSON
of O O
all O O
socioeconomic O B_MEASURE/B_PERSON
strata O I_MEASURE/I_PERSON
. O O

The O O
results O O
of O O
these O O
studies O O
indicate O O
that O O
EHV B B_GENE
- I I_GENE
1 I I_GENE
gp13 I I_GENE
is O O
the O O
structural O O
homolog O O
of O O
herpes B B_GENE/B_VIRUS[BIO]
simplex I B_GENE/I_VIRUS[BIO]
virus I B_GENE/I_VIRUS[BIO]
glycoprotein I B_GENE/I_VIRUS[BIO]
C I B_GENE/I_VIRUS[BIO]
and O O
further O O
suggest O O
that O O
the O O
epitope O O
- O O
containing O O
N O O
- O O
terminal O O
amino O O
acid O O
sequences O O
of O O
the O O
herpesvirus B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
gC I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
like I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
glycoproteins I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
have O O
undergone O O
more O O
extensive O O
evolutionary O O
divergence O O
than O O
the O O
C O O
- O O
terminal O O
sequences O O
. O O

Within O O
the O O
final O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
11 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
amino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
acids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
there O O
are O O
5 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aromatic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
basic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
no O O
acidic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
residues O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
it O O
has O O
been O O
proposed O O
that O O
these O O
residues O B_MEASURE/B_LOCATION
stack O O
with O O
and O O
electrostatically O O
interact O B_MEASURE/B_LOCATION
with O O
the O O
kinked O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
DNA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
at O O
the O O
site O B_LOCATION/B_MEASURE
of O O
a O O
pyrimidine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
dimer O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

By O O
contrast O O
, O O
footprint O O
II O O
at O O
position O O
- O O
125 O O
is O O
common O O
to O O
both O O
HeLa O O
and O O
GH3 O O
cell O O
extracts O O
and O O
overlies O O
a O O
15 O O
- O O
base O O
- O O
pair O O
sequence O O
found O O
in O O
all O O
members O O
of O O
the O O
growth B B_BIO/B_GENE
hormone I I_BIO/I_GENE
gene I I_BIO/I_GENE
family I I_BIO/I_GENE
. O O

Significance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
determination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
vascular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
tonus O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
in O O
the O O
differential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
diagnosis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
of O O
rheumatic O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
arteriosclerotic O B_DISEASE_ADJECTIVE[DISEASE]
lesions O I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
heart O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
vessels O B_BODY_PART_OR_ORGAN_COMPONENT
in O O
middle O B_TIME[MEASURE]/B_LOCATION
- O O
aged O B_PERSON/B_MEASURE
and O O
elderly O B_PERSON
persons O I_PERSON
with O O
fibrillation O B_DISEASE
arrhythmia O I_DISEASE

The O O
gene O O
responsible O O
for O O
multiple O O
endocrine O O
neoplasia O O
type O O
1 O O
( O O
MEN1 B B_GENE/B_DISEASE
) O O
, O O
a O O
heritable O O
predisposition O O
to O O
endocrine O O
tumours O O
in O O
man O O
, O O
has O O
recently O O
been O O
identified O O
. O O

Toxicological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
dietary O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Maillard O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
products O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
rat O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

AST B B_GENE
activity O O
in O O
PMNs O O
was O O
significantly O O
low O O
, O O
approximately O O
2 O O
% O O
of O O
that O O
observed O O
in O O
HPLFs O O
. O O

Specifically O O
, O O
we O O
engineered O O
two O O
chimeras O O
in O O
which O O
the O O
N O O
- O O
terminal O O
lobe O O
of O O
the O O
SH1 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
domain I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
c B B_GENE
- I I_GENE
Abl I I_GENE
was O O
swapped O O
with O O
that O O
of O O
v B B_GENE
- I I_GENE
Src I I_GENE
. O O

Biochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analyses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
revealed O O
that O O
the O O
concentration O B_MEASURE
of O O
norepinephrine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
reduced O O
significantly O O
in O O
cortex O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
hippocampus O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
olfactory O B_BODY_PART_OR_ORGAN_COMPONENT
bulb O I_BODY_PART_OR_ORGAN_COMPONENT
but O O
not O O
in O O
other O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
regions O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
while O O
dopamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
serotonin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
not O O
altered O O
in O O
any O O
brain O B_LOCATION/B_BIO
region O I_LOCATION/I_BIO
examined O O
. O O

The O O
cDNA O O
contains O O
a O O
reading O O
frame O O
for O O
a O O
145 O O
- O O
amino O O
- O O
acid O O
protein O O
and O O
it O O
lacks O O
the O O
UGA O O
codons O O
, O O
which O O
have O O
been O O
found O O
in O O
the O O
reading O O
frame O O
of O O
the O O
mouse B B_GENE
MCS I I_GENE
cDNA I I_GENE
and O O
have O O
been O O
presumed O O
to O O
encode O O
the O O
selenocysteine O O
in O O
the O O
amino O O
terminal O O
of O O
the O O
deduced O O
mouse O O
amino O O
acid O O
sequence O O
. O O

These O O
results O O
suggest O O
that O O
repetitive O O
GAA O O
sequences O O
enhance O O
splicing O O
by O O
binding O O
a O O
protein O O
complex O O
containing O O
a O O
sequence O O
- O O
specific O O
RNA O O
binding O O
protein O O
and O O
a O O
general O O
splicing O O
activator O O
that O O
, O O
in O O
turn O O
, O O
recruit O O
additional O O
SR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Letter O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
: O O
Dehydrated O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strip O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
detection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
yeasts O B_DISEASE/B_BACTERIUM[BIO]
. O O

Cell O B_BODY_PART_OR_ORGAN_COMPONENT
sloughing O O
with O O
proparacaine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Cytomegalovirus O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infection O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
- O O
modern O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
diagnosis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE

Highly O O
conserved O O
regions O O
called O O
src B B_PROTEIN[GENE]
homology I I_PROTEIN[GENE]
2 I I_PROTEIN[GENE]
and O O
3 O O
( O O
SH2 B B_GENE
and O O
SH3 B B_PROTEIN[GENE]
) O O
, O O
comprising O O
amino O O
acid O O
residues O O
88 O O
to O O
250 O O
, O O
are O O
believed O O
to O O
modulate O O
the O O
protein B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
present O O
in O O
the O O
carboxy O O
- O O
terminal O O
halves O O
of O O
the O O
src B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Interestingly O O
, O O
the O O
NES B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
mutant I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
proteins I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
appeared O O
to O O
have O O
altered O O
interactions O O
with O O
the O O
splicing O O
complex O O
, O O
binding O O
more O O
tightly O O
to O O
SC35 B B_GENE/B_BIO
in O O
co O O
- O O
immunoprecipitation O O
assays O O
. O O

We O O
propose O O
2 O O
separate O O
PAI B B_GENE
- I I_GENE
1 I I_GENE
inductory O O
pathways O O
for O O
PMA O O
and O O
IL B B_GENE/B_NUMBER[MEASURE]
- I I_GENE/I_NUMBER[MEASURE]
1alpha I I_GENE/I_NUMBER[MEASURE]
in O O
HepG2 O O
, O O
both O O
involving O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activation O O
; O O
the O O
serum O O
- O O
induced O O
signaling O O
pathway O O
may O O
( O O
partially O O
) O O
overlap O O
with O O
the O O
PMA O O
- O O
activated O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
mitogen B B_GENE
- I I_GENE
activated I I_GENE
protein I I_GENE
kinase I I_GENE
kinase I I_GENE
pathway O O
, O O
leading O O
to O O
c B B_GENE
- I I_GENE
Jun I I_GENE
homodimer I I_GENE
binding O O
to O O
the O O
PAI B B_GENE
- I I_GENE
1 I I_GENE
TRE O O
. O O

We O O
show O O
that O O
sae1 B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
and O O
sae3 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mutations I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
each O O
confer O O
a O O
distinct O O
defect O O
in O O
meiotic O O
recombination O O
. O O

sae1 B B_PERSON/B_GENE
- I I_PERSON/I_GENE
1 I I_PERSON/I_GENE
produces O O
recombinants O O
but O O
very O O
slowly O O
and O O
ultimately O O
to O O
less O O
than O O
half O O
the O O
wild O O
- O O
type O O
level O O
; O O
sae3 B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
- I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
1 I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
makes O O
persistent O O
hyper O O
- O O
resected O O
meiotic O O
double O O
- O O
strand O O
breaks O O
and O O
has O O
a O O
severe O O
defect O O
in O O
formation O O
of O O
recombinants O O
. O O

G6620 B B_PROTEIN[GENE]
is O O
the O O
3 O O
' O O
end O O
of O O
the O O
MOL1 B B_GENE
gene I I_GENE
coding O O
for O O
a O O
polypeptide O O
similar O O
to O O
stress O O
- O O
inducible O O
proteins O O
from O O
Fusarium O O
; O O
G6630 B B_PROTEIN[GENE]
is O O
the O O
NAT2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O O
encodes O O
a O O
methionine B B_ENZYME[GENE]
N I I_ENZYME[GENE]
- I I_ENZYME[GENE]
acetyltransferase I I_ENZYME[GENE]
; O O
G6635 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
the O O
RPL30B B B_GENE
gene I I_GENE
coding O O
for O O
the O O
ribosomal B B_GENE
protein I I_GENE
L30 I I_GENE
; O O
G6658 B B_PROTEIN[GENE]/B_LOCATION
is O O
RSR1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
encoding O O
a O O
ras B B_ENZYME[GENE]
- I I_ENZYME[GENE]
related I I_ENZYME[GENE]
protein I I_ENZYME[GENE]
; O O
G6667 B B_PROTEIN[GENE]/B_LOCATION
is O O
CYS4 B B_GENE/B_LOCATION
, O O
the O O
gene O O
for O O
cystathionine B B_GENE
beta I I_GENE
- I I_GENE
synthase I I_GENE
; O O
G6670 B B_PROTEIN[GENE]/B_LOCATION
is O O
identical O O
to O O
ORF2 O O
located O O
close O O
to O O
CYS4 B B_GENE
; O O
G6673 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
PEM1 B B_PROTEIN[GENE]/B_LOCATION
/ O O
CHO2 B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
encoding O O
a O O
phosphatidylethanolamine B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
methyltransferase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
; O O
G7001 B B_PROTEIN[GENE]/B_PERSON
is O O
the O O
NSR1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
coding O O
for O O
a O O
nuclear O O
signal O O
recognition O O
protein O O
. O O

Transcriptional O O
analysis O O
of O O
this O O
gene O O
cluster O O
was O O
performed O O
by O O
detecting O O
the O O
presence O O
of O O
mRNAs O O
spanning O O
adjacent O O
genes O O
as O O
well O O
as O O
by O O
using O O
a O O
promoterless O O
lacZ B B_GENE
reporter I I_GENE
gene I I_GENE
fused O O
to O O
each O O
of O O
the O O
seven O O
genes O O
contained O O
in O O
the O O
tol B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
oprL B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
locus O O
. O O

Serum O O
IgG B B_GENE
and O O
IgA B B_GENE
level O O
were O O
decreased O O
. O O

Histopathologically O O
, O O
( O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
killed O O
with O O
high O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
doses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
GMC O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
II O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
given O O
orally O O
) O O
there O O
were O O
diffuse O B_DISEASE
hyperemia O I_DISEASE
of O O
the O O
liver O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
parenchymal O B_DISEASE
degeneration O I_DISEASE
of O O
the O O
kidney O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tubuli O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
epithelium O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
edema O B_DISEASE
and O O
emphysema O B_DISEASE
of O O
the O O
lungs O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

The O O
contribution O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
reviewers O B_PERSON
and O O
editors O B_PERSON
to O O
the O O
scientific O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
work O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
the O O
authors O B_PERSON/B_ORGANIZATION

The O O
effects O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
space O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
radiation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
are O O
partially O O
known O O
on O O
astronauts O B_BIO/B_PERSON
, O O
but O O
much O O
remains O O
to O O
be O O
discovered O O
. O O

Therefore O O
the O O
effect O O
of O O
GAL11 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
on O O
PGK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription O O
must O O
be O O
mediated O O
at O O
the O O
PGK B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
UAS I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
presumably O O
as O O
part O O
of O O
the O O
activation O O
complex O O
. O O

Wingless B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
Wnt B B_GENE/B_DISEASE
signaling O O
directs O O
cell O O
- O O
fate O O
choices O O
during O O
embryonic O O
development O O
. O O

RNase B B_GENE
protection O O
analysis O O
reveals O O
a O O
10 O O
- O O
fold O O
increase O O
in O O
the O O
expression O O
of O O
SCD2 B B_GENE
mRNA I I_GENE
during O O
3T3 O O
- O O
L1 O O
preadipocyte O O
differentiation O O
. O O

To O O
determine O O
whether O O
transcription O O
of O O
orfX O O
and O O
vfr B B_LOCATION/B_PROTEIN[GENE]
are O O
controlled O O
by O O
the O O
same O O
mechanisms O O
that O O
control O O
transcription O O
of O O
the O O
region O O
of O O
the O O
divergent O O
ORF O O
( O O
dorf O O
) O O
and O O
of O O
crp B B_GENE
, O O
we O O
compared O O
the O O
vfr B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
orfX O O
and O O
crp B B_GENE/B_DISEASE
- O O
dorf O O
intergenic O O
regions O O
. O O

As O O
a O O
member O O
of O O
the O O
uncoupling B B_GENE/B_PERSON
protein I I_GENE/I_PERSON
family I I_GENE/I_PERSON
, O O
UCP2 B B_GENE
is O O
ubiquitously O O
expressed O O
in O O
rodents O O
and O O
humans O O
, O O
implicating O O
a O O
major O O
role O O
in O O
thermogenesis O O
. O O

Copyright O B_LOCATION/B_PERSON
1998 O I_LOCATION/I_PERSON
Academic O I_LOCATION/I_PERSON
Press O I_LOCATION/I_PERSON
. O O

Parental O O
and O O
vector O O
- O O
transfected O O
MCF7 O O
cells O O
, O O
which O O
were O O
sensitive O O
to O O
the O O
growth O O
- O O
inhibitory O O
effects O O
of O O
atRA O O
, O O
exhibited O O
atRA O O
- O O
dependent O O
retinoic B B_GENE
acid I I_GENE
receptor I I_GENE
( O O
RAR B B_PROTEIN[GENE]/B_LOCATION
) O O
transactivation O O
and O O
transrepression O O
of O O
12 O O
- O O
O O O
- O O
tetradecanoylphorbol O O
- O O
13 O O
- O O
acetate O O
- O O
induced O O
AP B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
activity O O
. O O

The O O
majority O B_PERSON/B_MEASURE
of O O
the O O
respondents O B_PERSON/B_LOCATION
( O O
83 O B_MEASURE
. O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
considered O O
that O O
coitus O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
should O O
not O O
be O O
stopped O O
during O O
pregnancy O B_DISEASE/B_PERSON
. O O

Based O O
on O O
the O O
ratios O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
areas O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
under O O
the O O
concentration O B_TIME[MEASURE]/B_LOCATION
- O O
time O B_MEASURE/B_LOCATION
curves O B_MEASURE/I_LOCATION
in O O
CSF O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
serum O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
overall O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
penetration O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
rifampicin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O O
CSF O B_BODY_PART_OR_ORGAN_COMPONENT
was O O
0 O B_MEASURE
. O O
13 O B_MEASURE
- O O
0 O B_MEASURE
. O O
42 O B_MEASURE
( O O
median O B_MEASURE/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
22 O B_MEASURE
) O O
. O O

The O O
differential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
mineral O B_DISEASE
oil O I_DISEASE
lipidosis O I_DISEASE
in O O
lymph O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
nodes O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
with O O
reaction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
radiopaque O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oils O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
Whipple O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
' O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
s O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
disease O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
discussed O O
. O O

With O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fed O O
on O O
the O O
Zn O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
sufficient O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
diet O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
NaFe3 O B_LOCATION/B_PERSON
+ O O
EDTA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
Na2EDTA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
similarly O O
increased O O
the O O
absorption O B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
urinary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
excretion O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
retention O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
Zn O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
but O O
to O O
a O O
lesser O B_DISEASE/B_MEASURE
extent O B_DISEASE/I_MEASURE
. O O

99Tcm O O
- O O
labelled O O
albumin B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
colloid O O
, O O
albures O O
( O O
radius O O
250 O O
nm O O
) O O
or O O
nanocoll O O
( O O
radius O O
25 O O
nm O O
) O O
, O O
or O O
both O O
were O O
used O O
as O O
test O O
substances O O
to O O
study O O
the O O
kinetics O O
of O O
vascular O O
clearance O O
after O O
RES O O
stimulation O O
. O O

Meq B B_GENE/B_PERSON
/ O O
c B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
Jun I I_GENE/I_LOCATION
heterodimers O O
bind O O
to O O
an O O
AP1 B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
like I I_GENE/I_LOCATION
sequence I I_GENE/I_LOCATION
in O O
the O O
meq B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
region I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
an O O
affinity O O
much O O
greater O O
than O O
that O O
of O O
Meq B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
Meq B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
c B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
Jun I I_GENE/I_LOCATION
/ O O
c B B_GENE/B_PERSON
- I I_GENE/I_PERSON
Jun I I_GENE/I_PERSON
homodimers O O
. O O

Moreover O O
, O O
the O O
noncoordinate O O
effects O O
of O O
FSK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O O
PMA O O
- O O
stimulated O O
MKK B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
MAPK B B_GENE
activities O O
indicates O O
the O O
presence O O
of O O
a O O
additional O O
distal O O
cAMP O O
- O O
dependent O O
inhibitory O O
mechanisms O O
. O O

These O O
findings O O
indicated O O
that O O
p35 B B_GENE
is O O
a O O
trans O O
- O O
dominant O O
factor O O
that O O
facilitates O O
AcMNPV O O
growth O O
in O O
a O O
cell O O
line O O
- O O
specific O O
manner O O
. O O

Pseudotumor O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
form O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
pulmonary O B_DISEASE
nocardia O I_DISEASE
infection O I_DISEASE
( O O
Nocardia O B_LOCATION/B_DISEASE
nova O I_LOCATION/I_DISEASE
) O O
in O O
a O O
renal O B_PERSON/B_BIO
transplant O I_PERSON/I_BIO
patient O I_PERSON/I_BIO

Hematological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
parameters O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
leukocyte O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O O
neutrophil O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
and O O
platelet O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
counts O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
) O O
and O O
liver O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
function O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
tests O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O O
determined O O
by O O
standard O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
procedures O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Karyo O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
cytometric O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cortical O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
layer O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
V O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
pyramidal O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
neurons O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
albino O B_PERSON/B_BIO
rat O O
after O O
three O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
various O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
fixations O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE

Clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
experience O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
gained O O
from O O
a O O
combined O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
252Cf O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
brachytherapy O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
by O O
the O O
staff O B_PERSON/B_ORGANIZATION
- O O
members O B_PERSON
of O O
the O O
Research O B_LOCATION/B_ORGANIZATION
Institute O B_LOCATION/I_ORGANIZATION
of O O
Medical O B_LOCATION/B_ORGANIZATION
Radiology O I_LOCATION/I_ORGANIZATION
, O O
USSR O B_LOCATION/B_PERSON
AMS O I_LOCATION/I_PERSON
, O O
was O O
generalized O O
. O O

The O O
team O B_PERSON
physician O I_PERSON
and O O
conditioning O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
athletes O B_PERSON/B_ORGANIZATION
for O O
sports O B_SPORT[ENT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
: O O
a O O
consensus O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
statement O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

To O O
probe O O
the O O
inter O O
- O O
relationship O O
between O O
the O O
virion O O
- O O
anchoring O O
function O O
and O O
the O O
oligomerization O O
function O O
, O O
we O O
constructed O O
two O O
serotype O O
3 O O
( O O
T3 O O
) O O
sigma B B_LOCATION/B_GENE
1 I B_LOCATION/I_GENE
deletion O O
mutants O O
in O O
SV40 O O
expression O O
vectors O O
, O O
one O O
lacking O O
the O O
hydrophobic O O
tail O O
and O O
the O O
hinge O O
, O O
and O O
the O O
other O O
lacking O O
an O O
adjacent O O
region O O
which O O
constituted O O
part O O
of O O
the O O
coiled O O
- O O
coil O O
. O O

AIMS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
The O O
aim O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
to O O
assess O O
static O B_MEASURE/B_DISEASE
and O O
dynamic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bone O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
patients O B_PERSON/B_BIO
suffering O O
from O O
rickets O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
law O B_PERSON/B_ORGANIZATION
and O O
the O O
chiropractor O B_ORGANIZATION/B_BIO
. O O

In O O
contrast O O
, O O
overexpression O O
of O O
the O O
DREB2A B B_GENE
cDNA I I_GENE
induced O O
weak O O
expression O O
of O O
the O O
target O O
genes O O
under O O
unstressed O O
conditions O O
and O O
caused O O
growth O O
retardation O O
of O O
the O O
transgenic O O
plants O O
. O O

Our O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O O
that O O
AIF O B_DISEASE/B_GENE
may O O
be O O
a O O
morphologic O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
correlate O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
tumor O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regression O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
following O O
preoperative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
cytotoxic O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
chemotherapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
. O O

Mean O B_MEASURE/B_PERSON
total O I_MEASURE/I_PERSON
homocysteine O I_MEASURE/I_PERSON
( O O
tHcy O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
was O O
21 O B_MEASURE
. O O
1 O B_MEASURE/B_LOCATION
+ O I_MEASURE/I_LOCATION
/ O O
- O O
9 O B_MEASURE
. O O
5 O B_MEASURE
micromol O I_MEASURE
/ O O
L O B_OTHER/B_MEASURE
and O O
median O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentration O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
19 O B_MEASURE/B_PERSON
micromol O I_MEASURE/I_PERSON
/ O O
L O B_OTHER/B_MEASURE
. O O

Efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
probiotic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
feed O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
additives O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
guidelines O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
evaluation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
efficiency O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
microorganisms O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
dogs O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
cats O B_SPECIES[BIO]
, O O
and O O
horses O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
] O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
Probiotic O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
microorganisms O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
frequently O O
in O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
as O O
feed O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
additives O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
for O O
farm O B_LOCATION/B_BIO
and O O
pet O B_LOCATION/B_PERSON
animals O I_LOCATION/I_PERSON
. O O

Lung O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplantation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
warranted O O
for O O
stable O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
, O O
ventilator O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recipients O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Site O O
- O O
directed O O
mutagenesis O O
shows O O
that O O
sites O O
throughout O O
the O O
IRE B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alter O O
negative O O
control O O
and O O
IRE B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
BP I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
binding O O
reflecting O O
the O O
fact O O
that O O
the O O
footprint O O
of O O
the O O
IRE B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BP I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
over O O
the O O
entire O O
IRE B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

An O O
alternative O O
approach O O
to O O
random O O
integration O O
of O O
large O O
DNA O O
fragments O O
into O O
plants O O
is O O
to O O
utilize O O
one O O
of O O
several O O
site O O
- O O
specific O O
recombination O O
( O O
SSR O O
) O O
systems O O
, O O
such O O
as O O
Cre B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
lox B B_GENE/B_BIO
. O O

Neonatal O B_PERSON/B_LOCATION
masculinization O I_PERSON/I_LOCATION
affects O O
maternal O B_DISEASE/B_ORGANISM_FUNCTION
behavior O B_DISEASE/I_ORGANISM_FUNCTION
sensitivity O B_DISEASE/I_ORGANISM_FUNCTION
in O O
female O B_PERSON/B_BIO
rats O I_PERSON/I_BIO
. O O

Recombinant B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mouse I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
GSTT1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
catalytically O O
active O O
towards O O
1 O O
, O O
2 O O
- O O
epoxy O O
- O O
3 O O
- O O
( O O
p O O
- O O
nitrophenoxy O O
) O O
propane O O
, O O
4 O O
- O O
nitrobenzyl O O
chloride O O
and O O
dichloromethane O O
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
six O B_PERSON/B_LOCATION
other O I_PERSON/I_LOCATION
landmarks O I_PERSON/I_LOCATION
favored O O
the O O
xeroradiograph O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
but O O
not O O
to O O
the O O
degree O B_MEASURE/B_LOCATION
of O O
statistical O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significance O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Nonlethal O O
sec71 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1 I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O O
sec72 B B_DISEASE/B_LOCATION
- I B_DISEASE/I_LOCATION
1 I B_DISEASE/I_LOCATION
mutations I B_DISEASE/I_LOCATION
eliminate O O
proteins O O
associated O O
with O O
the O O
Sec63p B B_GENE/B_LOCATION
- O O
BiP B B_GENE/B_MEASURE
complex O O
from O O
S O O
. O O
cerevisiae O O
. O O

Sequence O O
and O O
deletion O O
analysis O O
of O O
the O O
recombination B B_GENE/B_BIO
enhancement I I_GENE/I_BIO
gene I I_GENE/I_BIO
( O O
ref B B_PROTEIN[GENE]/B_DISEASE
) O O
of O O
bacteriophage O O
P1 O O
: O O
evidence O O
for O O
promoter O O
- O O
operator O O
and O O
attenuator O O
- O O
antiterminator O O
control O O
. O O

A O O
high O O
titer O O
of O O
anti B B_DISEASE/B_GENE
- I B_DISEASE/I_GENE
HBc I B_DISEASE/I_GENE
, O O
thus O O
suggested O O
to O O
be O O
an O O
indicator O O
of O O
persistent O O
hepatitis O O
B O O
virus O O
infection O O
, O O
was O O
found O O
rarely O O
in O O
seronegative O O
patients O O
with O O
chronic O O
hepatitis O O
, O O
non O O
- O O
alcoholic O O
cirrhosis O O
, O O
or O O
alcoholic O O
liver O O
diseases O O
. O O

Adaptability O B_DISEASE_ADJECTIVE[DISEASE]
of O O
Nippostrongylus O B_BIO/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
brasiliensis O I_BIO/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Travassos O B_PERSON/B_LOCATION
, O O
1914 O B_MEASURE
) O O
to O O
lead O O
contamination O B_DISEASE/B_BIO

Eph B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
their O O
membrane O O
- O O
associated O O
ephrin B B_PERSON/B_GENE
ligands I I_PERSON/I_GENE
regulate O O
cell O O
- O O
cell O O
interactions O O
during O O
development O O
. O O

We O O
discuss O O
the O O
possibility O O
that O O
DNA O O
- O O
protein O O
interactions O O
at O O
homologous O O
nucleotide O O
sequences O O
like O O
those O O
identified O O
in O O
PII O O
are O O
part O O
of O O
a O O
regulatory O O
gene O O
cascade O O
that O O
participates O O
in O O
timing O O
fla B B_GENE
gene I I_GENE
expression O O
in O O
the O O
C O O
. O O
crescentus O O
cell O O
cycle O O
. O O

Postcontrast O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
images O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
also O O
acquired O O
in O O
the O O
sagittal O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
( O O
six O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
) O O
and O O
coronal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
( O O
three O B_NUMBER[MEASURE]/B_LOCATION
patients O I_NUMBER[MEASURE]/I_LOCATION
) O O
planes O B_LOCATION/B_DISEASE
. O O

Nature O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
thermopower O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
bipolar O B_LOCATION/B_ORGANIZATION
semiconductors O I_LOCATION/I_ORGANIZATION
. O O

To O O
increase O O
the O O
number O O
of O O
circulating O O
polymorphonuclear O O
neutrophils O O
, O O
the O O
patient O O
was O O
treated O O
with O O
recombinant O O
granulocyte B B_GENE
- I I_GENE
macrophage I I_GENE
colony I I_GENE
- I I_GENE
stimulating I I_GENE
factor I I_GENE
( O O
GM B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- I I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
CSF I I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
at O O
a O O
dose O O
of O O
2 O O
micrograms O O
protein O O
/ O O
kg O O
bodyweight O O
s O O
. O O
c O O
. O O
/ O O
12 O O
h O O
. O O

By O O
using O O
methanol O O
- O O
0 O O
. O O
15 O O
M O O
borate O O
buffer O O
of O O
pH O O
8 O O
. O O
0 O O
, O O
cate B B_ENZYME[GENE]
- I I_ENZYME[GENE]
chol I I_ENZYME[GENE]
- I I_ENZYME[GENE]
O I I_ENZYME[GENE]
- I I_ENZYME[GENE]
methyltransferase I I_ENZYME[GENE]
activity O O
might O O
be O O
assayed O O
. O O

All O O
patients O B_PERSON
were O O
peritonitis O B_DISEASE
- O O
free O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
at O O
least O O
6 O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
before O O
each O O
PET O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
amino O O
acid O O
residues O O
and O O
subdomains O O
important O O
for O O
DNA O O
binding O O
, O O
hormone O O
binding O O
, O O
dimerization O O
, O O
and O O
transactivation O O
are O O
mostly O O
conserved O O
among O O
all O O
VDR B B_GENE/B_SPECIES[BIO]
species O O
. O O

Transcripts O O
appear O O
to O O
be O O
initiated O O
from O O
an O O
upstream O O
promoter O O
, O O
P1 O O
, O O
located O O
in O O
front O O
of O O
the O O
tRNA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
met1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
from O O
three O O
internal O O
promoters O O
: O O
P2 O O
is O O
located O O
immediately O O
in O O
front O O
of O O
the O O
tRNA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
met2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
; O O
PL10 O O
is O O
near O O
the O O
beginning O O
of O O
the O O
L1 B B_PROTEIN[GENE]
- O O
L10 B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intergenic O O
space O O
, O O
and O O
PL12 O O
is O O
at O O
the O O
end O O
of O O
the O O
L10 B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Based O O
on O O
the O O
deduced O O
amino O O
acid O O
sequence O O
identity O O
we O O
designated O O
GAPC1 B B_GENE
and O O
GAPC2 B B_PROTEIN[GENE]
as O O
group O O
I O O
( O O
97 O O
% O O
identical O O
) O O
and O O
GAPC3 B B_GENE
and O O
GAPC4 B B_PROTEIN[GENE]
as O O
group O O
II O O
( O O
99 O O
. O O
4 O O
% O O
identical O O
) O O
. O O

A O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
functioning O O
parathyroid O B_DISEASE/B_PERSON
carcinoma O B_DISEASE/I_PERSON
with O O
hypereninemic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hypertension O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Finally O O
, O O
gel O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
shift O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
assays O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O O
that O O
ORF2 O B_GENE/B_BIO
was O O
able O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
bind O O
to O O
promoter O B_LOCATION/B_GENE
fragment O I_LOCATION/I_GENE
566 O I_LOCATION/I_GENE
- O O
888 O B_MEASURE
. O O

Critical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
review O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
general O B_TIME[MEASURE]/B_ENT
results O B_TIME[MEASURE]/I_ENT

Saturated O O
fatty O O
acids O O
induce O O
a O O
1 O O
. O O
6 O O
- O O
fold O O
increase O O
in O O
transcription O O
activity O O
, O O
whereas O O
a O O
large O O
family O O
of O O
unsaturated O O
fatty O O
acids O O
repress O O
OLE1 B B_GENE/B_BIO
transcription O O
as O O
much O O
as O O
60 O O
- O O
fold O O
. O O

This O O
polypeptide O O
includes O O
the O O
first O O
three O O
zinc O O
fingers O O
of O O
the O O
TFIIIA B B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
DNA I I_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
binding I I_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
domain I I_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

An O O
exception O O
is O O
the O O
Bcl B B_GENE
- I I_GENE
6 I I_GENE
gene I I_GENE
, O O
encoding O O
a O O
transcription O O
factor O O
, O O
which O O
was O O
found O O
to O O
be O O
mutated O O
in O O
normal O O
human O O
memory O O
B O O
cells O O
. O O

3 O B_NUMBER[MEASURE]
. O O

A O O
chest O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
X O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ray O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
film O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O O
infiltrative O B_DISEASE
shadows O I_DISEASE
in O O
the O O
right O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
middle O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
and O O
lower O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
lung O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
fields O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
but O O
a O O
chest O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
CT O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
scan O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
showed O O
an O O
abnormal O B_DISEASE/B_LOCATION
lung O I_DISEASE/I_LOCATION
density O I_DISEASE/I_LOCATION
in O O
the O O
right O O
lower O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lobe O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
both O O
liver O O
and O O
pancreatic O O
islet O O
, O O
glucokinase B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
is O O
subject O O
to O O
inhibition O O
by O O
a O O
regulatory O O
protein O O
( O O
GCKR B B_GENE
) O O
. O O

MRI O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
measurements O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
the O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Similarly O O
, O O
TAM B B_PERSON/B_ORGANIZATION
- I I_PERSON/I_ORGANIZATION
67 I I_PERSON/I_ORGANIZATION
reverted O O
the O O
morphology O O
of O O
the O O
AdoMetDC B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antisense I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expressors I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Of O O
concern O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O O
the O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, O O
unexplained O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
prevalence O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
BV O B_DISEASE
among O O
African O B_PERSON/B_LOCATION
- O O
American O B_PERSON/B_LOCATION
women O I_PERSON/I_LOCATION
, O O
who O O
are O O
also O O
at O O
extremely O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
risk O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
for O O
preterm O B_DISEASE
birth O I_DISEASE
. O O

The O O
use O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
bentonite O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
in O O
the O O
compounding O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
of O O
hydrogels O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO

Cotransfection O O
of O O
expression O O
plasmids O O
encoding O O
the O O
protein B B_GENE
kinase I I_GENE
A I I_GENE
inhibitor O O
, O O
or O O
an O O
inactive O O
protein B B_ENZYME[GENE]
kinase I I_ENZYME[GENE]
A I I_ENZYME[GENE]
( O O
PKA B B_GENE/B_LOCATION
) O O
catalytic O O
beta O O
subunit O O
, O O
inhibited O O
both O O
forskolin O O
and O O
PACAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activation O O
of O O
chromogranin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription O O
, O O
revealing O O
that O O
PACAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
trans O O
- O O
activation O O
is O O
highly O O
dependent O O
on O O
PKA B B_GENE
. O O

GH B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
rapid O O
tyrosine O O
phosphorylation O O
of O O
a O O
protein O O
at O O
approximately O O
93 O O
kDa O O
in O O
normal O O
fibroblasts O O
, O O
and O O
Western O O
blotting O O
with O O
STAT B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
specific I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
revealed O O
STAT5 B B_GENE
activation O O
( O O
phosphorylation O O
) O O
by O O
GH O O
. O O

The O O
most O O
valid O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
the O O
AXB O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
bearing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O O
the O O
cephalometric O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clinical O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O O
90 O B_MEASURE
. O O
91 O B_MEASURE
% O I_MEASURE
concordance O I_MEASURE
. O O

The O O
cdc42W97R B B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
temperature I I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
- I I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
sensitive I I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
allele I I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
in O O
S O O
. O O
cerevisiae O O
displayed O O
the O O
same O O
cell O O
- O O
division O O
- O O
cycle O O
arrest O O
phenotype O O
( O O
large O O
, O O
round O O
unbudded O O
cells O O
) O O
as O O
the O O
cdc42 B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
- I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
1ts I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
mutant I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

The O O
cyanobacterial B B_BIO/B_PROTEIN[GENE]
phycobilisome I B_BIO/I_PROTEIN[GENE]
is O O
a O O
large O O
protein O O
complex O O
located O O
on O O
the O O
photosynthetic O O
membrane O O
. O O

One O B_TIME[MEASURE]/B_LOCATION
day O I_TIME[MEASURE]/I_LOCATION
after O O
injection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
48 O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
% O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
the O O
injected O O
activity O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O O
in O O
the O O
skeleton O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
9 O B_MEASURE
. O O
3 O B_MEASURE
% O I_MEASURE
in O O
the O O
liver O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
3 O B_MEASURE
% O I_MEASURE
in O O
the O O
kidneys O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
4 O B_MEASURE
. O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
in O O
the O O
rest O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
organs O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O O

OBJECTIVE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
To O O
assess O O
laboratory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
practice O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
the O O
examination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
blood O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
films O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
for O O
malarial O B_DISEASE
parasites O I_DISEASE
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
A O O
thorough O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
understanding O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
malignant O B_DISEASE
fibrous O I_DISEASE
histiocytoma O I_DISEASE
( O O
MFH O B_LOCATION/B_PROTEIN[GENE]
) O O
, O O
the O O
most O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
subtype O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
of O O
soft O B_DISEASE/B_LOCATION
tissue O I_DISEASE/I_LOCATION
sarcoma O I_DISEASE/I_LOCATION
, O O
will O O
lead O O
to O O
improved O O
histologic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
specific O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
protocols O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Sequence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analyses O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
revealed O O
a O O
partial O B_GENE/B_LOCATION
941 O I_GENE/I_LOCATION
bp O I_GENE/I_LOCATION
cDNA O I_GENE/I_LOCATION
that O O
encoded O O
a O O
313 O B_MEASURE
- O O
amino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
acid O B_PROTEIN[GENE]
polypeptide O I_PROTEIN[GENE]
. O O

Furthermore O O
, O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
p300 B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulated O O
both O O
TGF B B_GENE
- I I_GENE
beta I I_GENE
- O O
and O O
Smad B B_GENE
- O O
induced O O
transcription O O
in O O
a O O
Smad4 B B_GENE
/ O O
DPC4 B B_MEASURE/B_PROTEIN[GENE]
- O O
dependent O O
fashion O O
. O O

Sequences O O
within O O
and O O
flanking O O
hypersensitive O O
sites O O
3 O O
and O O
2 O O
of O O
the O O
beta B B_PROTEIN[GENE]/B_DISEASE
- I I_PROTEIN[GENE]/I_DISEASE
globin I I_PROTEIN[GENE]/I_DISEASE
locus O O
control O O
region O O
required O O
for O O
synergistic O O
versus O O
additive O O
interaction O O
with O O
the O O
epsilon B B_GENE/B_BIO
- I I_GENE/I_BIO
globin I I_GENE/I_BIO
gene I I_GENE/I_BIO
promoter I I_GENE/I_BIO
. O O

Sequence O O
analysis O O
revealed O O
100 O O
% O O
homology O O
of O O
all O O
RA O O
- O O
derived O O
PTEN B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fragments I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
those O O
from O O
normal O O
SF O O
as O O
well O O
as O O
to O O
the O O
published O O
GenBank O O
sequence O O
( O O
accession O O
number O O
U93051 B B_MEASURE/B_PERSON
) O O
. O O

174 O B_MEASURE
, O O
233 O B_MEASURE
- O O
247 O B_MEASURE
) O O
and O O
Serrate O B_NUMBER[MEASURE]/B_LOCATION
( O O
Serrate1 O B_TIME[MEASURE]/B_PROTEIN[GENE]
and O O
2 O B_NUMBER[MEASURE]
; O O
Myat O B_PERSON/B_LOCATION
, O O
A O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O
, O O
Henrique O B_PERSON
, O O
D O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
Ish O B_PERSON/B_LOCATION
- O O
Horowicz O B_PERSON/B_LOCATION
, O O
D O B_OTHER/B_LOCATION
. O O
and O O
Lewis O B_PERSON
, O O
J O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
1996 O B_MEASURE/B_PERSON
. O O

Many O B_SPECIES[BIO]/B_MEASURE
retroviruses O I_SPECIES[BIO]/I_MEASURE
, O O
including O O
the O O
human O B_SPECIES[BIO]
and O O
simian O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
immunodeficiency O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
viruses O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
contain O O
a O O
leucine O B_GENE
zipper O I_GENE
- O O
like O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
repeat O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
highly O O
conserved O B_LOCATION/B_TIME[MEASURE]
region O B_LOCATION/I_TIME[MEASURE]
of O O
the O O
external O B_LOCATION/B_ORGANIZATION
domain O I_LOCATION/I_ORGANIZATION
of O O
the O O
transmembrane O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
( O O
TM O B_LOCATION/B_DISEASE
) O O
glycoprotein O B_PROTEIN[GENE]/B_LOCATION
. O O

Functional O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
importance O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
properly O O
folded O O
surface O B_LOCATION
loop O I_LOCATION
covering O O
the O O
catalytic O B_LOCATION
center O I_LOCATION
. O O

The O O
most O O
frequent O O
abnormality O O
was O O
GH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
deficiency O O
( O O
six O O
cases O O
) O O
, O O
followed O O
by O O
gonadotropin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
four O O
cases O O
) O O
, O O
cortisol O O
( O O
four O O
cases O O
) O O
, O O
and O O
TSH B B_GENE
( O O
one O O
case O O
) O O
, O O
whereas O O
four O O
patients O O
showed O O
high O O
serum B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PRL I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
values O O
. O O

Recombinant O O
vaccinia O O
viruses O O
that O O
express O O
the O O
bacteriophage B B_GENE
T3 I I_GENE
RNA I I_GENE
polymerase I I_GENE
( O O
VV B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T3pol I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
or O O
the O O
Escherichia B B_ENZYME[GENE]
coli I I_ENZYME[GENE]
lac I I_ENZYME[GENE]
repressor I I_ENZYME[GENE]
( O O
VV B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lacI I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
under O O
control O O
of O O
the O O
early B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
late I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
vaccinia I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
P7 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
5 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
constructed O O
. O O

Internal O O
controls O O
over O O
the O O
volume O O
of O O
milk O O
suckled O O
do O O
not O O
appear O O
until O O
infant O O
rats O O
are O O
about O O
2 O O
weeks O O
of O O
age O O
at O O
which O O
time O O
gastric O O
distension O O
, O O
milk O O
, O O
systemic O O
dehydration O O
, O O
and O O
intestinal B B_DISEASE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone I I_DISEASE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cholecystokinin I I_DISEASE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suppress O O
milk O O
intake O O
derived O O
through O O
suckling O O
. O O

Shields O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
needed O O
for O O
pacemakers O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
. O O

Concerning O O
the O O
practical O O
approach O O
in O O
a O O
clinical O O
setting O O
, O O
it O O
has O O
to O O
be O O
pointed O O
out O O
that O O
with O O
these O O
diseases O O
a O O
hepatitis O O
C O O
infection O O
has O O
to O O
be O O
considered O O
and O O
testing O O
for O O
hepatitis B B_DISEASE
C I I_DISEASE
antibodies I I_DISEASE
and O O
, O O
if O O
positive O O
, O O
hepatitis B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RNA I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
indicated O O
. O O

Confocal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
fluorescent O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
microscopy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
demonstrated O O
that O O
WT O B_GENE/B_LOCATION
, O O
VaI O B_LOCATION/B_PROTEIN[GENE]
, O O
and O O
VaII O B_LOCATION/B_PROTEIN[GENE]
all O O
distribute O O
equally O O
to O O
the O O
cell O B_BODY_PART_OR_ORGAN_COMPONENT
surface O I_BODY_PART_OR_ORGAN_COMPONENT
while O O
, O O
as O O
expected O O
, O O
a O O
WT O B_GENE
mutant O I_GENE
lacking O O
the O O
two O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
valine O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
residues O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
does O O
not O O
. O O

However O O
, O O
it O O
is O O
not O O
easy O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
establish O O
the O O
diagnosis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
thoracic O B_DISEASE
MFH O I_DISEASE
. O O

In O O
both O O
cell O O
types O O
, O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
led O O
to O O
a O O
dose O O
- O O
dependent O O
increase O O
in O O
the O O
association O O
of O O
tyrosine B B_GENE
phosphorylated I I_GENE
IRS I I_GENE
- I I_GENE
1 I I_GENE
with O O
the O O
SH2 B B_PROTEIN[GENE]
domain I I_PROTEIN[GENE]
of O O
the O O
p85 B B_ENZYME[GENE]/B_PERSON
regulatory I I_ENZYME[GENE]/I_PERSON
subunit I I_ENZYME[GENE]/I_PERSON
of O O
PI B B_GENE
- I I_GENE
3 I I_GENE
kinase I I_GENE
, O O
and O O
also O O
increased O O
the O O
amount O O
of O O
PI B B_ENZYME[GENE]
kinase I I_ENZYME[GENE]
activity O O
detected O O
in O O
anti B B_GENE/B_PERSON
- I I_GENE/I_PERSON
IRS I I_GENE/I_PERSON
- I I_GENE/I_PERSON
1 I I_GENE/I_PERSON
immunoprecipitates O O
. O O

The O O
" O O
Ulm O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEDICAL_DEVICE[OBJECT]
Zucker O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
Uhr O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
System O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
" O O
comprises O O
a O O
microdialysis O B_PERSON/B_MEDICAL_DEVICE[OBJECT]
probe O I_PERSON/I_MEDICAL_DEVICE[OBJECT]
, O O
a O O
biosensor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
( O O
Glucosensor O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Unitec O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Ulm O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
s O O
. O O
c O B_OTHER/B_DISEASE
. O O
) O O
, O O
a O O
sender O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEDICAL_DEVICE[OBJECT]
transferring O O
telemetrically O O
the O O
glucose O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEDICAL_DEVICE[OBJECT]
concentrations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
, O O
and O O
a O O
receiving O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
indicator O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

The O O
Xenopus B B_GENE
annexin I I_GENE
II I I_GENE
heavy I I_GENE
chain I I_GENE
lacks O O
the O O
highly O O
conserved O O
tyrosine O O
at O O
position O O
23 O O
which O O
is O O
the O O
site O O
of O O
src B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
oncogene I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
tyrosine B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
kinase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
phosphorylation O O
in O O
the O O
murine O O
protein O O
. O O

No O O
bafilomycin O O
- O O
sensitive O O
ATPase B B_ENZYME[GENE]
is O O
detected O O
in O O
a O O
vacuolar O O
fraction O O
. O O

Plasmids O O
bearing O O
the O O
P B B_PROTEIN[GENE]/B_DISEASE
. I I_PROTEIN[GENE]/I_DISEASE
stipitis I I_PROTEIN[GENE]/I_DISEASE
URA3 I I_PROTEIN[GENE]/I_DISEASE
gene I I_PROTEIN[GENE]/I_DISEASE
and O O
ARS2 O O
element O O
produced O O
more O O
than O O
30 O O
, O O
000 O O
transformants O O
per O O
micrograms O O
of O O
plasmid O O
DNA O O
. O O

Unfractionated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
heparin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
UFH O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
given O O
at O O
a O O
dose O B_MEASURE/B_LOCATION
of O O
0 O B_MEASURE
. O O
3 O B_MEASURE
mg O I_MEASURE
x O O
kg O B_MEASURE/B_LOCATION
- O O
1 O B_MEASURE
bolus O I_MEASURE
+ O I_MEASURE
0 O I_MEASURE
. O O
3 O B_MEASURE
mg O I_MEASURE
x O O
kg O B_MEASURE/B_LOCATION
- O O
1 O B_NUMBER[MEASURE]
x O O
h O B_TIME[MEASURE]/B_OTHER
- O O
1 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O O
not O O
improve O O
the O O
incidence O B_MEASURE
of O O
reperfusion O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
lower O O
the O O
incidence O B_MEASURE
of O O
reocclusion O B_DISEASE
. O O

The O O
scores O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
these O O
three O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
factors O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
which O O
corresponded O O
to O O
recognizable O B_MEASURE/B_LOCATION
dimensions O I_MEASURE/I_LOCATION
of O O
depressive O B_DISEASE/B_GENE
illness O I_DISEASE/I_GENE
, O O
were O O
then O O
correlated O O
with O O
rCBF O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Cloning O O
, O O
sequence O O
analysis O O
, O O
and O O
expression O O
of O O
the O O
gene B B_GENE
encoding I I_GENE
formaldehyde I I_GENE
dismutase I I_GENE
from I I_GENE
Pseudomonas I I_GENE
putida I I_GENE
F61 I I_GENE
. O O

However O O
, O O
at O O
the O O
time O O
of O O
salvage O O
treatment O O
, O O
the O O
mean O O
serum B B_GENE
PSA I I_GENE
levels O O
were O O
9 O O
. O O
1 O O
and O O
1 O O
. O O
1 O O
ng O O
/ O O
mL O O
for O O
the O O
salvage O O
RP O O
and O O
salvage O O
RT O O
groups O O
, O O
respectively O O
( O O
P O O
= O O
0 O O
. O O
0001 O O
) O O
. O O

Protease O O
digestion O O
and O O
alkaline O O
extraction O O
of O O
microsomes O O
containing O O
labeled O O
mutant O O
proteins O O
further O O
showed O O
that O O
segment O O
3 O O
was O O
sufficient O O
for O O
stable O O
membrane O O
anchoring O O
of O O
the O O
glycoproteins O O
, O O
indicating O O
that O O
this O O
segment O O
may O O
specify O O
the O O
transmembrane O O
domain O O
of O O
the O O
gB B B_GENE
glycoprotein I I_GENE
. O O

The O O
mean O B_TIME[MEASURE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
times O B_TIME[MEASURE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
LNR O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
in O O
these O O
groups O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
42 O B_MEASURE
. O O
0 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
( O O
range O B_LOCATION/B_MEASURE
, O O
3 O B_MEASURE
. O O
0 O B_MEASURE
- O O
194 O B_MEASURE
. O O
5 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
) O O
and O O
49 O B_MEASURE
. O O
0 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
( O O
range O B_LOCATION/B_MEASURE
, O O
3 O B_MEASURE
. O O
6 O B_MEASURE
- O O
209 O B_MEASURE
. O O
0 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
) O O
respectively O O
. O O

A O O
gene O O
( O O
FMR B B_GENE
- I I_GENE
1 I I_GENE
) O O
was O O
identified O O
within O O
a O O
four O O
cosmid O O
contig O O
of O O
YAC O O
DNA O O
that O O
expresses O O
a O O
4 O O
. O O
8 O O
kb O O
message O O
in O O
human O O
brain O O
. O O

Detailed O O
comparison O O
of O O
the O O
sequences O O
of O O
cp35 B B_SPECIES[BIO]
and O O
human B B_MEASURE/B_GENE
calpactin I I_MEASURE/I_GENE
II I I_MEASURE/I_GENE
shows O O
that O O
the O O
only O O
substantial O O
sequence O O
dissimilarity O O
is O O
a O O
domain O O
encoding O O
amino O O
acids O O
between O O
residues O O
20 O O
and O O
40 O O
which O O
includes O O
a O O
tyrosine O O
phosphorylation O O
site O O
in O O
the O O
human O O
molecule O O
, O O
along O O
with O O
other O O
residues O O
of O O
possible O O
physiological O O
significance O O
. O O

Exogenous O B_PERSON
heart O I_PERSON
stress O I_PERSON
raised O O
log O B_MEASURE/B_LOCATION
circulating O O
NE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentration O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
proportion O B_MEASURE
to O O
the O O
rise O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in O O
heart O B_MEASURE/B_DISEASE
rate O I_MEASURE/I_DISEASE
at O O
a O O
given O O
work O B_TIME[MEASURE]/B_LOCATION
load O I_TIME[MEASURE]/I_LOCATION
so O O
that O O
the O O
usual O B_PERSON/B_MEASURE
relationship O I_PERSON/I_MEASURE
between O O
these O O
variables O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
previously O O
observed O O
during O O
other O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stresses O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
was O O
preserved O O
. O O

The O O
implication O O
of O O
Rac B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Cdc42 B B_GENE
was O O
analyzed O O
in O O
transient O O
transfection O O
experiments O O
using O O
either O O
constitutively O O
active O O
( O O
V12 O O
) O O
or O O
dominant O O
- O O
interfering O O
( O O
N17 O O
) O O
mutants O O
. O O

Alternative O O
immune B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
globulin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preparation O O
when O O
standard O O
immune B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serum I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
globulin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
not O O
available O O
. O O

Plasma B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
insulin I B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
responses O O
to O O
glucose O O
in O O
femoral O O
, O O
hepatic O O
, O O
and O O
pancreatic O O
veins O O
in O O
dogs O O
. O O

The O O
bioconversion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
penicillin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
G O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
an O O
inexpensive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
substrate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
to O O
the O O
valuable O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intermediate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
semisynthetic O B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
cephalosporin O B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
production O B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
, O O
deacetoxycephalosporin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
G O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
( O O
DAOG O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
, O O
had O O
been O O
recently O O
shown O O
to O O
be O O
increased O O
by O O
eliminating O O
agitation O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
adding O O
decane O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

Elevated O O
potassium O O
stimulation O O
of O O
GAL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
completely O O
blocked O O
, O O
but O O
pituitary O O
adenylyl B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cyclase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activating I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
polypeptide I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
histamine O O
stimulations O O
were O O
only O O
partially O O
blocked O O
, O O
by O O
cycloheximide O O
. O O

In O O
lyzozyme B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
activity O O
there O O
was O O
periodicity O O
in O O
three O O
groups O O
but O O
not O O
in O O
the O O
youngest O O
foals O O
. O O

GBF1 B B_GENE/B_DISEASE
and O O
GBF2 B B_PROTEIN[GENE]
mRNA I I_PROTEIN[GENE]
is O O
present O O
in O O
light O O
and O O
dark O O
grown O O
leaves O O
as O O
well O O
as O O
in O O
roots O O
. O O

We O O
now O O
report O O
identification O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
transcriptional O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activities O I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediated O O
by O O
three O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cis O I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
acting O O
sites O B_LOCATION/B_ENT
within O O
a O O
90 O B_MEASURE/B_LOCATION
- O O
bp O B_MEASURE/B_LOCATION
portion O I_MEASURE/I_LOCATION
of O O
the O O
rDNA O B_GENE/B_LOCATION
enhancer O I_GENE/I_LOCATION
designated O O
the O O
modulator O B_LOCATION/B_PERSON
region O I_LOCATION/I_PERSON
. O O

A O O
porcine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
diffuse O B_DISEASE
axonal O I_DISEASE
injury O I_DISEASE
, O O
developed O O
with O O
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
from O O
these O O
physical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
earlier O O
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
tissue O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
modeling O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O O
is O O
used O O
to O O
correlate O O
histologic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
radiologic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
evidence O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
axonal O B_DISEASE
injury O I_DISEASE
to O O
predicted O B_LOCATION
regions O I_LOCATION
of O O
injury O B_DISEASE
from O O
the O O
experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
theoretical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Sample O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
size O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
requirement O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
repeated O O
measurements O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
continuous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

A O O
transient O O
induction O O
of O O
both O O
c B B_GENE
- I I_GENE
fos I I_GENE
and O O
c B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
jun I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNAs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
TPA O O
was O O
observed O O
in O O
both O O
cell O O
populations O O
, O O
together O O
with O O
an O O
associated O O
suppression O O
of O O
BSP B B_GENE
mRNA I I_GENE
in O O
the O O
fetal O O
rat O O
calvarial O O
cells O O
. O O

Videoanalysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
confirms O O
the O O
ballistic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
character O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
initial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
phase O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
reaching O O
movement O B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
isomerization O O
of O O
the O O
pre O O
- O O
existing O O
closed O O
complex O O
to O O
an O O
open O O
promoter O O
form O O
, O O
as O O
judged O O
by O O
the O O
local O O
denaturation O O
of O O
promoter O O
DNA O O
which O O
rendered O O
sequences O O
from O O
+ O O
5 O O
to O O
- O O
10 O O
reactive O O
towards O O
KMnO4 O O
, O O
was O O
shown O O
to O O
be O O
fully O O
dependent O O
on O O
NifA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
. O O

HPV O B_VIRUS[BIO]/B_GENE
- O O
16 O B_MEASURE/B_GENE
MARs O B_MEASURE/I_GENE
are O O
context O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
dependent O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
transcriptional O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
enhancers O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O O
and O O
activated O O
expression O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
HPV O B_VIRUS[BIO]/B_GENE
- O O
16 O B_MEASURE
oncogenes O I_MEASURE
dependent O I_MEASURE
on O O
chromosomal O B_GENE/B_LOCATION
integration O I_GENE/I_LOCATION
may O O
positively O O
select O O
tumorigenic O B_DISEASE/B_BIO
cells O I_DISEASE/I_BIO
during O O
the O O
multistep O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
etiology O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O O
cervical O B_DISEASE/B_LOCATION
cancer O I_DISEASE/I_LOCATION
. O O

Sociological O B_PERSON/B_EDU[ORGANIZATION]
analysis O I_PERSON/I_EDU[ORGANIZATION]
of O O
the O O
family O B_PERSON/B_LOCATION
. O O

This O O
enhancer O O
element O O
functioned O O
in O O
a O O
position O O
- O O
and O O
orientation O O
- O O
independent O O
manner O O
both O O
on O O
the O O
Pax B B_SPECIES[BIO]/B_GENE
- I I_SPECIES[BIO]/I_GENE
QNR I I_SPECIES[BIO]/I_GENE
P0 I I_SPECIES[BIO]/I_GENE
promoter I I_SPECIES[BIO]/I_GENE
and O O
the O O
heterologous B B_GENE/B_BIO
thymidine I I_GENE/I_BIO
kinase I I_GENE/I_BIO
promoter I I_GENE/I_BIO
. O O

These O O
data O O
suggest O O
that O O
overexpression O O
of O O
MT B B_GENE/B_DISEASE
potentiates O O
the O O
growth O O
of O O
MCF7 O O
cells O O
, O O
whereas O O
downregulation O O
of O O
MT B B_GENE/B_DISEASE
elicits O O
antiproliferative O O
effects O O
. O O

A O O
multivariant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
pituitary O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adenoma O B_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
obtainment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
two O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
logistic O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regression O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
equations O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
an O O
auxiliary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
support O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
the O O
diagnosis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
tumors O B_DISEASE/B_PERSON
. O O

Bile O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
salts O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
hormonal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
control O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
and O O
the O O
male O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
disadvantage O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Number O B_MEASURE/B_LOCATION
of O O
warm O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
units O B_LOCATION
with O O
higher O B_MEASURE
rates O I_MEASURE
of O O
firing O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
and O O
greater O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
thermal O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
coefficients O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
comparable O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
to O O
those O O
of O O
warm O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
units O B_LOCATION
in O O
the O O
adult O B_PERSON/B_LOCATION
, O O
gradually O O
increased O O
with O O
growth O B_MEASURE/B_LOCATION
. O O

Such O O
unique O O
recognition O O
capabilities O O
are O O
generated O O
with O O
minimal O O
alterations O O
in O O
the O O
CDR3 B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
loops O O
of O O
the O O
TCR B B_GENE
. O O

To O O
this O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
the O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
survey O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
puts O O
in O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
the O O
maximum O B_MEASURE/B_LOCATION
delay O I_MEASURE/I_LOCATION
of O O
stream O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
that O O
guarantees O O
the O O
good O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dimensional O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stability O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
class O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
A O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
alginates O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O O
of O O
45 O B_MEASURE/B_ENT
minutes O I_MEASURE/I_ENT
in O O
the O O
hot O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
humid O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
climatic O B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
tropical O B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
country O B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
conditions O B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
. O O

Gene B B_GENE/B_LOCATION
1 I B_GENE/I_LOCATION
of I B_GENE/I_LOCATION
the I B_GENE/I_LOCATION
murine I B_GENE/I_LOCATION
coronavirus I B_GENE/I_LOCATION
, I B_GENE/I_LOCATION
MHV I B_GENE/I_LOCATION
- I B_GENE/I_LOCATION
A59 I B_GENE/I_LOCATION
, O O
encodes O O
approximately O O
800 O O
kDa O O
of O O
protein O O
products O O
within O O
two O O
overlapping O O
open O O
reading O O
frames O O
( O O
ORFs O O
1a O O
and O O
1b O O
) O O
. O O

For O O
this O O
interaction O O
, O O
the O O
C O O
- O O
terminal O O
part O O
of O O
Sp1 B B_GENE
and O O
the O O
N O O
terminus O O
of O O
E2F1 B B_GENE
, O O
a O O
domain O O
also O O
present O O
in O O
E2F2 B B_GENE
and O O
E2F3 B B_GENE
but O O
absent O O
in O O
E2F4 B B_GENE
and O O
E2F5 B B_GENE
, O O
were O O
essential O O
. O O

Our O O
results O O
suggest O O
a O O
biological O O
role O O
for O O
Elf B B_GENE
- I I_GENE
1 I I_GENE
in O O
the O O
regulation O O
of O O
IgH B B_GENE
gene I I_GENE
expression O O
, O O
attribute O O
a O O
functional O O
role O O
for O O
receptor O O
- O O
induced O O
AP B B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
B O O
lymphocytes O O
and O O
provide O O
evidence O O
for O O
a O O
direct O O
link O O
between O O
IgM B B_GENE
receptor I I_GENE
- O O
mediated O O
signalling O O
and O O
3 O O
' O O
enhancer O O
activation O O
. O O

Oncogenic O O
activation O O
of O O
RET B B_GENE
is O O
detected O O
in O O
human O O
papillary O O
thyroid O O
tumours O O
and O O
in O O
multiple O O
endocrine O O
neoplasia O O
type O O
2 O O
syndromes O O
. O O

CD4 B B_GENE
degradation O O
mediated O O
by O O
Vpu B B_GENE/B_BACTERIUM[BIO]
does O O
not O O
require O O
the O O
ER O O
chaperone O O
calnexin B B_GENE/B_LOCATION
and O O
is O O
dependent O O
on O O
an O O
intact O O
ubiquitin B B_GENE
- O O
conjugating O O
system O O
. O O

The O O
maternal B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
par I I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
segregation O O
of O O
cell O O
fate O O
specification O O
activities O O
in O O
early O O
Caenorhabditis O O
elegans O O
embryos O O
. O O

These O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
antagonized O O
by O O
prior O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
1 O B_MEASURE
- O O
( O O
2 O B_MEASURE
- O O
methoxyphenyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
- O O
4 O B_MEASURE
- O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
( O O
2 O B_MEASURE
- O O
phthalimido O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
) O O
butyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
piperazine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
( O O
0 O B_MEASURE
. O O
5 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_TIME[MEASURE]
, O O
i O O
. O O
p O B_MEASURE/B_LOCATION
. O O
) O O
. O O

PURPOSE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
To O O
evaluate O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
adding O O
a O O
pulsating O O
bristle O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
action O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
established O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
oscillating O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
/ O O
rotating O O
action O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O O
the O O
Braun O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
Oral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O O
B O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Ultra O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Plaque O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Remover O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
D9 O B_LOCATION/B_PROTEIN[GENE]
) O O
on O O
plaque O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
removal O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Detailed O O
analysis O O
of O O
the O O
predicted O O
amino O O
acid O O
sequence O O
revealed O O
sequence O O
elements O O
which O O
are O O
conserved O O
in O O
many O O
DNA B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
and I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
RNA I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
polymerases I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Sub O B_DISEASE
- O O
inhibitory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
post O B_DISEASE/B_MEASURE
- O O
antibiotic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
effects O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
spiramycin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
erythromycin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
Staphylococcus O B_BACTERIUM[BIO]/B_DISEASE
aureus O I_BACTERIUM[BIO]/I_DISEASE
. O O

The O O
CydDC B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
system I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
appears O O
to O O
be O O
the O O
first O O
prokaryotic O O
example O O
of O O
a O O
heterodimeric B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
ABC I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transport I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
system I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
which O O
each O O
polypeptide O O
contains O O
both O O
hydrophobic O O
and O O
ATP O O
- O O
binding O O
domains O O
. O O

The O O
single O O
- O O
copy O O
U20 B B_GENE
sequence I I_GENE
is O O
located O O
on O O
the O O
same O O
DNA O O
strand O O
as O O
the O O
nucleolin B B_GENE/B_BIO
mRNA I I_GENE/I_BIO
. O O

Gel O O
shift O O
and O O
southwestern O O
experiments O O
revealed O O
nuclear O O
proteins O O
of O O
43 O O
kDa O O
and O O
30 O O
kDa O O
in O O
GC O O
and O O
fish O O
cells O O
, O O
respectively O O
, O O
that O O
bind O O
specifically O O
to O O
the O O
tGH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
CRE O O
, O O
suggesting O O
the O O
involvement O O
of O O
CRE B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
activating B B_GENE
- I I_GENE
transcription I I_GENE
- I I_GENE
factor I I_GENE
- I I_GENE
l I I_GENE
- O O
related O O
peptides O O
in O O
cAMP O O
response O O
. O O

The O O
coding O O
sequence O O
of O O
rat B B_GENE
MEK I I_GENE
kinase I I_GENE
1 I I_GENE
( O O
MEKK1 B B_GENE/B_DISEASE
) O O
has O O
been O O
determined O O
from O O
multiple O O
, O O
independent O O
cDNA O O
clones O O
. O O

In O O
response O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
need O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
better O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
quantitative O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
estimates O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
regional O B_MEASURE/B_LOCATION
distribution O I_MEASURE/I_LOCATION
of O O
the O O
active O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
bone O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
marrow O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
organ O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
infants O B_PERSON/B_BIO
and O O
children O B_PERSON/B_BIO
, O O
a O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
using O O
various O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anatomical O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
data O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
has O O
been O O
developed O O
. O O

We O O
compared O O
these O O
responses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
six O B_NUMBER[MEASURE]/B_PERSON
hatchling O I_NUMBER[MEASURE]/I_PERSON
and O O
eight O B_NUMBER[MEASURE]/B_PERSON
adult O I_NUMBER[MEASURE]/I_PERSON
Chrysemys O I_NUMBER[MEASURE]/I_PERSON
picta O I_NUMBER[MEASURE]/I_PERSON
from O O
an O O
Ohio O B_MEASURE/B_LOCATION
population O I_MEASURE/I_LOCATION
. O O

On O O
the O O
basis O O
of O O
experiments O O
with O O
mutant O O
virus O O
and O O
transfection O O
with O O
isolated O O
genes O O
, O O
the O O
herpes B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
simplex I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
virus I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
immediate I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
early I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
gene I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
product O O
ICP4 B B_GENE/B_MEASURE
is O O
known O O
to O O
positively O O
regulate O O
the O O
transcription O O
of O O
viral B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
early I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
late I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
negatively O O
regulate O O
expression O O
from O O
its O O
own O O
promoter O O
. O O

A O O
female O B_PERSON
infant O I_PERSON
with O O
isolated O B_DISEASE
noncompaction O I_DISEASE
of O O
ventricular O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
myocardium O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
who O O
developed O O
ventricular O B_DISEASE
tachyarrhythmia O I_DISEASE
is O O
described O O
. O O

Recent O B_TIME[MEASURE]/B_EDU[ORGANIZATION]
, O O
highly O O
visible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reviews O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
subject O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
clearly O O
pointed O O
out O O
that O O
little O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
is O O
known O O
about O O
the O O
cellular O B_LOCATION
mechanisms O I_LOCATION
through O O
which O O
inhaled O O
asbestos O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fibers O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cause O O
the O O
well O O
known O O
, O O
debilitating O O
lung O B_DISEASE/B_GENE
disease O I_DISEASE/I_GENE
- O O
asbestosis O B_DISEASE
( O O
i O O
. O O
e O O
. O O
interstitial O B_DISEASE
pulmonary O I_DISEASE
fibrosis O I_DISEASE
) O O
. O O

The O O
POU B B_GENE/B_DISEASE
- O O
specific O O
domain O O
of O O
Pit B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
is O O
essential O O
for O O
sequence O O
- O O
specific O O
, O O
high O O
affinity O O
DNA O O
binding O O
and O O
DNA O O
- O O
dependent O O
Pit B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
- O O
Pit B B_GENE
- I I_GENE
1 I I_GENE
interactions O O
. O O

Also O O
, O O
the O O
placebo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
nondepressed O O
patients O B_PERSON
had O O
significantly O O
better O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcome O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O O
with O O
the O O
placebo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
depressed O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
patients O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Obtaining O O
kidney O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
a O O
beagle O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
puppy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
RPB O B_LOCATION/B_DISEASE
- O O
1 O B_NUMBER[MEASURE]
) O O
and O O
the O O
establishment O B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
a O O
cryopreservation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
bank O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE

These O O
results O O
suggest O O
an O O
essential O O
role O O
of O O
the O O
binding O O
of O O
HNF B B_GENE
- I I_GENE
4 I I_GENE
and O O
/ O O
or O O
HNF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
related I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
6 O O
beta O O
A O O
- O O
A O O
site O O
on O O
the O O
basal O O
transcriptional O O
activation O O
of O O
the O O
CYP3A2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
liver O O
cells O O
. O O

It O O
is O O
envisaged O O
that O O
the O O
WHOQOL O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
BREF O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
will O O
be O O
most O O
useful O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O O
require O O
a O O
brief O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
assessment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
quality O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
life O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
for O O
example O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
in O O
large O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
epidemiological O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
trials O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
where O O
quality O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
life O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
of O O
interest O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Restriction O O
mapping O O
showed O O
that O O
the O O
two O O
recombinant O O
plasmids O O
shared O O
an O O
EcoRI B B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
fragment I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
8 O O
. O O
9 O O
kb O O
. O O

Usefulness O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
congestive O B_DISEASE/B_LOCATION
heart O I_DISEASE/I_LOCATION
failure O I_DISEASE/I_LOCATION

The O O
chromosomal O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
location O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
YACs O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
was O O
verified O O
using O O
FISH O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
which O O
also O O
demonstrated O O
their O O
nonchimeric O B_DISEASE_ADJECTIVE[DISEASE]
nature O I_DISEASE_ADJECTIVE[DISEASE]
. O O

After O O
first O O
strand O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cDNA O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
synthesis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O O
fetal O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
brain O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
mRNAs O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O O
short O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fragment O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cDNAs O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
sf O B_PROTEIN[GENE]/B_LOCATION
- O O
cDNAs O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
were O O
synthesized O O
with O O
a O O
two O B_NUMBER[MEASURE]
- O O
step O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
amplification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
by O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O O
our O O
modified O O
Degenerate O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Oligonucleotide O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Primed O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Shuttle O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Polymerase O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Chain O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Reaction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
DOP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
Shuttle O B_PERSON/B_PROTEIN[GENE]
- O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

For O O
evaluation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
the O O
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
simulations O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
physiological O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
excitation O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
of O O
pathologies O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
Wolff O B_PERSON/B_LOCATION
- O O
Parkinson O B_PERSON
- O O
White O B_DISEASE/B_LOCATION
syndrome O I_DISEASE/I_LOCATION
, O O
complete O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
AV O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
- O O
block O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
inferior O B_DISEASE
wall O I_DISEASE
ischaemia O I_DISEASE
) O O
were O O
examined O O
. O O

Profilins B B_NUMBER[MEASURE]/B_PERSON
IIa I I_NUMBER[MEASURE]/I_PERSON
and I I_NUMBER[MEASURE]/I_PERSON
IIb I I_NUMBER[MEASURE]/I_PERSON
are O O
also O O
present O O
in O O
humans O O
, O O
suggesting O O
that O O
all O O
mammals O O
have O O
three O O
profilin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
isoforms I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Using O O
the O O
yeast O O
two O O
- O O
hybrid O O
system O O
, O O
we O O
have O O
isolated O O
an O O
835 O O
amino O O
acid O O
RING O O
finger O O
( O O
C3HC4 O O
zinc O O
finger O O
) O O
protein O O
, O O
TIF1 B B_GENE
beta I I_GENE
( O O
also O O
named O O
KAP B B_GENE
- I I_GENE
1 I I_GENE
) O O
, O O
that O O
specifically O O
interacts O O
with O O
the O O
KRAB B B_GENE/B_LOCATION
domain I I_GENE/I_LOCATION
of O O
the O O
human O O
zinc O O
finger O O
factor O O
KOX1 B B_PROTEIN[GENE]/B_MEASURE
/ O O
ZNF10 B B_MEASURE
. O O

The O O
authors O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
report O O
about O O
the O O
exeresis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
a O O
pyelonephrictic O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
left O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
kidney O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
with O O
laparoscopic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
surgery O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

New O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
protein O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O O
free O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
products O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
diet O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
in O O
chronic O B_LOCATION
renal O I_LOCATION
insufficiency O I_LOCATION

Unestablished O O
quail O O
myoblasts O O
were O O
infected O O
with O O
a O O
retroviral O O
vector O O
encoding O O
the O O
oncogenic O O
form O O
of O O
H B B_GENE
- I I_GENE
Ras I I_GENE
in O O
order O O
to O O
investigate O O
the O O
mechanism O O
by O O
which O O
this O O
oncoprotein O O
interferes O O
with O O
terminal O O
differentiation O O
. O O

Early O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detection O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
signs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hepatoangiosarcoma O B_DISEASE
among O O
vinyl O B_PERSON/B_BIO
chloride O I_PERSON/I_BIO
workers O I_PERSON/I_BIO
. O O

The O O
reduced O O
expression O O
caused O O
by O O
multimerization O O
of O O
UAS2 O O
in O O
the O O
native O O
promoter O O
was O O
observed O O
only O O
in O O
the O O
presence O O
of O O
ADR1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

VP4 B B_GENE/B_SPECIES[BIO]
differentially O O
regulates O O
TRAF2 B B_GENE
signaling O O
, O O
disengaging O O
JNK B B_GENE
activation O O
while O O
directing O O
NF B B_GENE
- I I_GENE
kappa I I_GENE
B I I_GENE
to O O
effect O O
rotavirus O O
- O O
specific O O
cellular O O
responses O O
. O O

On O O
the O O
3rd O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
day O I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
after O O
ischemia O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
remained O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
kidney O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
for O O
30 O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
min O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
structural O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
components O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
walls O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
glomerular O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
arterioles O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
those O O
of O O
the O O
filtration O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
reabsorption O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
barrier O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
undergo O O
certain O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
ultrastructural O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
changes O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O O
that O O
with O O
time O B_TIME[MEASURE]
elapsed O O
( O O
7 O B_MEASURE
, O O
14 O B_MEASURE/B_ENT
days O I_MEASURE/I_ENT
) O O
gradually O O
pass O O
away O O
, O O
and O O
amount O B_MEASURE/B_DISEASE
of O O
cells O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
with O O
hypertrophic O B_DISEASE/B_MEASURE
processes O I_DISEASE/I_MEASURE
increases O I_DISEASE/I_MEASURE
. O O

The O O
purified O O
RAG1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
overexpressed O O
in O O
E O O
. O O
coli O O
exhibited O O
the O O
expected O O
cleavage O O
activity O O
when O O
combined O O
with O O
RAG2 B B_GENE
purified O O
from O O
transfected O O
293T O O
cells O O
. O O

19 O B_MEASURE
, O O
4967 O B_MEASURE
- O O
4973 O B_MEASURE
) O O
. O O

Preventing O O
the O O
heterosexual O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
spread O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
HIV O B_DISEASE
into O O
this O O
vulnerable O B_LOCATION/B_PERSON
population O I_LOCATION/I_PERSON
is O O
a O O
formidable O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
public O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
health O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
challenge O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Moreover O O
, O O
we O O
show O O
that O O
GATA B B_GENE
- I I_GENE
1 I I_GENE
and O O
Sp1 B B_GENE
synergize O O
from O O
a O O
distance O O
in O O
constructs O O
designed O O
to O O
mimic O O
the O O
architecture O O
of O O
globin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
locus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
control I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regions I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
downstream O O
globin B B_GENE/B_LOCATION
promoters I B_GENE/I_LOCATION
. O O

Superovulation O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
intrauterine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
insemination O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SO O B_DISEASE/B_PROTEIN[GENE]
- O O
IUI O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
has O O
been O O
suggested O O
as O O
an O O
alternative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
gamete O O
intrafallopian O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
transfer O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
GIFT O B_TIME[MEASURE]/B_PERSON
) O O
, O O
despite O O
the O O
absence O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
controlled O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
comparative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
trials O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Mammalian O O
chromosome O O
ends O O
contain O O
long O O
arrays O O
of O O
TTAGGG O O
repeats O O
that O O
are O O
complexed O O
to O O
a O O
telomere O O
specific O O
protein O O
, O O
the O O
TTAGGG B B_GENE
repeat I I_GENE
binding I I_GENE
factor I I_GENE
, O O
TRF1 B B_GENE/B_DISEASE
. O O

Genotype O B_MEASURE/B_PERSON
- O O
phenotype O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
correlations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
male O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
with O O
a O O
partial O B_DISEASE/B_LOCATION
nullisomy O I_DISEASE/I_LOCATION
of O O
the O O
X O B_GENE
chromosome O I_GENE
have O O
suggested O O
that O O
at O O
least O O
one O B_GENE/B_PERSON
locus O I_GENE/I_PERSON
involved O O
in O O
MRX O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
on O O
Xp22 O B_MEASURE/B_LOCATION
. O O
3 O B_MEASURE
. O O

Mean O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
disposition O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
constants O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
+ O B_MEASURE/B_DISEASE
/ O O
- O O
SD O B_DISEASE/B_PROTEIN[GENE]
) O O
were O O
obtained O O
from O O
individualized O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fits O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
V1 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
: O O
0 O B_MEASURE
. O O
398 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
336 O B_MEASURE
LITER O I_MEASURE
/ O O
KG O B_MEASURE
, O O
Vdarea O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
: O O
2 O B_MEASURE
. O O
53 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
72 O B_TIME[MEASURE]
liter O I_TIME[MEASURE]
/ O O
kg O B_MEASURE
, O O
alpha O B_PROTEIN[GENE]/B_MEASURE
: O O
0 O B_NUMBER[MEASURE]
. O O
316 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_NUMBER[MEASURE]
. O O
294 O B_MEASURE/B_PERSON
min O I_MEASURE/I_PERSON
- O O
1 O B_NUMBER[MEASURE]
, O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
0 O B_NUMBER[MEASURE]
. O O
00204 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_NUMBER[MEASURE]
. O O
00262 O B_MEASURE/B_PERSON
min O I_MEASURE/I_PERSON
- O O
1 O B_NUMBER[MEASURE]
, O O
k2 O O
: O O
0 O B_NUMBER[MEASURE]
. O O
0305 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_NUMBER[MEASURE]
. O O
0101 O B_MEASURE/B_PERSON
min O I_MEASURE/I_PERSON
- O O
1 O B_NUMBER[MEASURE]
) O O
. O O

The O O
gene O B_GENE/B_LOCATION
, O O
from O O
the O O
initiator O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
methionine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
to O O
the O O
polyadenylation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
is O O
contained O O
within O O
13 O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
244 O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
basepairs O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
contains O O
19 O B_GENE
exons O I_GENE
. O O

In O O
the O O
unit O B_LOCATION
housing O I_LOCATION
of O O
a O O
compact O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cyclotron O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
positron O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
emission O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
CT O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
PET O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
, O O
positron O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
emitting O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
gas O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
such O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
as O O
15O O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
11C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
C15O2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
C15O O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
etc O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

is O O
supplied O O
from O O
a O O
cyclotron O B_LOCATION
to O O
a O O
PET O B_LOCATION/B_PRODUCT[OBJECT]
room O B_LOCATION/I_PRODUCT[OBJECT]
through O O
a O O
transportation O B_LOCATION/B_PRODUCT[OBJECT]
pipe O B_LOCATION/I_PRODUCT[OBJECT]
with O O
an O O
appropriate O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
shield O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
reduce O O
positron O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
annihilation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
radiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Adhesion O O
was O O
inhibited O O
by O O
mAbs O O
against O O
the O O
COOH O O
- O O
terminus O O
and O O
central O O
cell O O
binding O O
domains O O
of O O
fibronectin B B_GENE
, O O
as O O
well O O
as O O
by O O
the O O
corresponding O O
CS1 B B_GENE/B_LOCATION
and O O
RGD B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptides I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
were O O
not O O
obtained O O
using O O
either O O
preimmune O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sera O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
or O O
antiserum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
specific O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O O
the O O
luminal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
portion O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
the O O
glycoprotein O B_BODY_PART_OR_ORGAN_COMPONENT/B_PROTEIN[GENE]
precursor O I_BODY_PART_OR_ORGAN_COMPONENT/I_PROTEIN[GENE]
. O O

Cerebral O B_DISEASE/B_PROTEIN[GENE]
blood O B_DISEASE/I_PROTEIN[GENE]
flow O B_DISEASE/I_PROTEIN[GENE]
was O O
measured O O
using O O
the O O
iv O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
133 O B_MEASURE/B_PROTEIN[GENE]
- O O
Xe O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CBF O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
determination O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
AVDO2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
measured O O
using O O
systemic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
arterial O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
- O O
jugular O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
venous O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oxygen O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
content O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Activation O O
of O O
the O O
mitogen B B_GENE
- I I_GENE
activated I I_GENE
protein I I_GENE
kinase I I_GENE
( O O
MAPK B B_GENE/B_LOCATION
) O O
pathway O O
enhances O O
long O O
- O O
range O O
transactivation O O
by O O
the O O
beta B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
globin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
locus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
control I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
LCR O O
) O O
( O O
W O O
. O O

In O O
situ O O
hybridization O O
of O O
whole O O
- O O
mount O O
mouse O O
embryos O O
with O O
Mex5 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antisense I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
provide O O
no O O
evidence O O
for O O
the O O
exclusion O O
of O O
Mex5 B B_GENE
during O O
embryonic O O
development O O
. O O

In O O
three O B_PERSON/B_TIME[MEASURE]
other O B_PERSON/I_TIME[MEASURE]
patients O B_PERSON/I_TIME[MEASURE]
the O O
electrophysiologic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
characteristics O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
atrioventricular O B_DISEASE/B_BIO
conduction O I_DISEASE/I_BIO
prevented O O
a O O
demonstration O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
these O O
differences O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Human O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
psychophysical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
receptive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
field O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
like O B_LOCATION/B_PROTEIN[GENE]
properties O B_LOCATION/I_PROTEIN[GENE]
- O O
- O O
II O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O O

3 O B_NUMBER[MEASURE]
. O O

New O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
strategies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O O
needed O O
to O O
prevent O O
coronary O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rethrombosis O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
patients O B_PERSON/B_LOCATION
with O O
minimal O B_DISEASE
atherosclerosis O I_DISEASE
after O O
thrombolytic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
for O O
acute O B_DISEASE/B_LOCATION
myocardial O I_DISEASE/I_LOCATION
infarction O I_DISEASE/I_LOCATION
. O O

The O O
Ick B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
not O O
involved O O
in O O
antibody O O
- O O
mediated O O
CD4 B B_GENE
( O O
CDR3 B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
loop I I_GENE/I_DISEASE
) O O
signal O O
transduction O O
that O O
inhibits O O
HIV O O
- O O
1 O O
transcription O O
. O O

Programmed O O
peritoneal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lavage O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
suppurative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
complications O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
perforated O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ulcer O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
stomach O B_BODY_PART_OR_ORGAN_COMPONENT

Deletion O O
analysis O O
of O O
the O O
7 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kb I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
GATA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
revealed O O
that O O
a O O
1 O O
. O O
1 O O
- O O
kb O O
DNA O O
sequence O O
is O O
critical O O
for O O
expression O O
of O O
GATA B B_GENE
- I I_GENE
2 I I_GENE
in O O
neurons O O
. O O

The O O
model O O
therefore O O
predicts O O
that O O
1 O O
) O O
on O O
- O O
line O O
calculation O O
of O O
airway O O
dead O O
space O O
and O O
end O O
- O O
expired O O
lung O O
volume O O
can O O
be O O
made O O
by O O
the O O
addition O O
of O O
an O O
oxygen O O
sine O O
- O O
wave O O
perturbation O O
component O O
to O O
the O O
mean O O
FIO2 O O
; O O
and O O
( O O
2 O O
) O O
QS O O
/ O O
QT O O
can O O
be O O
measured O O
from O O
the O O
resultant O O
oxygen O O
perturbation O O
sine O O
- O O
wave O O
amplitudes O O
in O O
the O O
expired O O
gas O O
and O O
in O O
arterial O O
and O O
mixed O O
- O O
venous O O
blood O O
and O O
is O O
independent O O
of O O
the O O
mean O O
blood O O
oxygen O O
partial O O
pressure O O
and O O
oxyhemoglobin B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
saturation O O
values O O
. O O

Consistent O O
with O O
this O O
, O O
rh5 B B_GENE/B_SPECIES[BIO]
expression O O
in O O
R8 B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disappears O O
when O O
R7 O O
cells O O
are O O
absent O O
( O O
in O O
sevenless B B_PERSON/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutant I I_PERSON/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

The O O
fusion O O
gene O O
cassette O O
was O O
placed O O
under O O
the O O
control O O
of O O
a O O
vaccinia B B_GENE/B_PERSON
virus I I_GENE/I_PERSON
early I I_GENE/I_PERSON
promoter I I_GENE/I_PERSON
and O O
cloned O O
in O O
a O O
host O O
- O O
restricted O O
fowlpox O O
viral O O
vector O O
. O O

Psoriasis O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O O
tumor O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Fulminant O O
hepatic O O
failure O O
in O O
these O O
cases O O
could O O
be O O
characterized O O
by O O
: O O
( O O
1 O O
) O O
rapid O O
decrease O O
in O O
serum B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
alanine I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transaminase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ALT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
level O O
after O O
discontinuation O O
of O O
ecarazine O O
, O O
( O O
2 O O
) O O
prolonged O O
jaundice O O
despite O O
discontinuation O O
of O O
ecarazine O O
, O O
( O O
3 O O
) O O
high O O
incidence O O
of O O
anti B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
nuclear I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
antibody I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
ANA B B_DISEASE/B_GENE
) O O
( O O
57 O O
% O O
) O O
, O O
and O O
( O O
4 O O
) O O
histological O O
findings O O
of O O
extensive O O
hepatocellular O O
necrosis O O
ranging O O
from O O
bridging O O
necrosis O O
to O O
massive O O
necrosis O O
. O O

These O O
data O O
suggest O O
that O O
the O O
secreted O O
, O O
truncated O O
receptor O O
encoded O O
by O O
the O O
2 B B_GENE
. I I_GENE
6 I I_GENE
- I I_GENE
kb I I_GENE
c I I_GENE
- I I_GENE
erbB I I_GENE
transcript I I_GENE
can O O
bind O O
to O O
TGF B B_GENE
alpha I I_GENE
and O O
may O O
play O O
an O O
important O O
growth O O
- O O
regulatory O O
function O O
in O O
vitro O O
. O O

Localization O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
porcine O B_PROTEIN[GENE]
enzyme O I_PROTEIN[GENE]
in O O
the O O
endoplasmic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
reticulum O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
immuno O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
- O O
electron O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
microscopic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
pig O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
hepatocytes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

A O O
close O O
homologue O O
of O O
the O O
APK2a B B_GENE/B_BIO
gene I I_GENE/I_BIO
, O O
named O O
APK2b B B_PROTEIN[GENE]/B_BIO
, O O
was O O
also O O
isolated O O
from O O
the O O
Arabidopsis O O
cDNA O O
library O O
. O O

Thus O O
, O O
the O O
rates O O
of O O
a B B_GENE
- I I_GENE
factor I I_GENE
receptor I I_GENE
endocytosis O O
and O O
consequent O O
vacuolar O O
turnover O O
depend O O
on O O
the O O
available O O
level O O
of O O
ubiquitin B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
in O O
the O O
cell O O
. O O

Using O O
the O O
same O O
approach O O
we O O
have O O
shown O O
that O O
hFIRE B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binds O O
the O O
stimulatory O O
proteins O O
Sp1 B B_GENE/B_LOCATION
and O O
Sp3 B B_GENE
in O O
addition O O
to O O
CBF B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Non O B_DISEASE
- O O
specific O B_DISEASE/B_PERSON
immunological O I_DISEASE/I_PERSON
abnormalities O I_DISEASE/I_PERSON
were O O
detected O O
in O O
8 O B_NUMBER[MEASURE]
of O O
the O O
13 O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
in O O
whom O O
they O O
were O O
looked O O
for O O
. O O

Using O O
a O O
combined O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pharmacokinetic O I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
pharmacodynamic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
impact O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
various O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
effective O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
bioavailability O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
on O O
its O O
estimation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
using O O
the O O
intravenous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
to O O
- O O
oral O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
dose O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
ratio O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
required O O
to O O
produce O O
the O O
same O B_LOCATION/B_MEASURE
area O B_LOCATION/I_MEASURE
under O O
the O O
response O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
time O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
curve O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
acute O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
administration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
, O O
are O O
explored O O
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
: O O
The O O
RRM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
one O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
most O O
common O B_DISEASE_ADJECTIVE[DISEASE]
and O O
best O B_DISEASE_ADJECTIVE[DISEASE]
characterized O O
RNA O B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
binding O O
motifs O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
cyclin B B_GENE/B_BIO
- I I_GENE/I_BIO
dependent I I_GENE/I_BIO
kinase I I_GENE/I_BIO
Cdk2 B I_GENE/I_BIO
associates O O
with O O
cyclins B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
D I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
has O O
been O O
implicated O O
in O O
the O O
control O O
of O O
the O O
G1 O O
to O O
S O O
phase O O
transition O O
in O O
mammals O O
. O O

Mol O B_PERSON/B_BIO
. O O

The O O
amino B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
terminal I I_GENE/I_LOCATION
gag I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
encoded I I_GENE/I_LOCATION
region I I_GENE/I_LOCATION
of O O
P140gag B B_GENE/B_MEASURE
- O O
fps B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
contains O O
a O O
phosphotyrosine O O
residue O O
in O O
addition O O
to O O
normal O O
gag B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphorylation O O
sites O O
. O O

Rad18 B B_GENE/B_SPECIES[BIO]
is O O
required O O
for O O
DNA O O
repair O O
and O O
checkpoint O O
responses O O
in O O
fission O O
yeast O O
. O O

A O O
less O O
common O B_DISEASE_ADJECTIVE[DISEASE]
and O O
much O O
more O O
perplexing O B_DISEASE_ADJECTIVE[DISEASE]
circumstance O I_DISEASE_ADJECTIVE[DISEASE]
occurs O O
when O O
evaluating O O
patients O B_PERSON/B_BIO
with O O
sarcoidosis O B_DISEASE
established O O
for O O
several O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
years O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
present O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
progressive O B_DISEASE_ADJECTIVE[DISEASE]
or O O
chronic O B_DISEASE_ADJECTIVE[DISEASE]
pulmonary O I_DISEASE_ADJECTIVE[DISEASE]
involvement O I_DISEASE_ADJECTIVE[DISEASE]
and O O
dyspnea O B_DISEASE
. O O

2 O O
, O O
4 O B_NUMBER[MEASURE]
- O O
and O O
2 O B_NUMBER[MEASURE]
, O O
6 O B_NUMBER[MEASURE]
- O O
toluenediamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
hydrolysed O B_BODY_PART_OR_ORGAN_COMPONENT
plasma O I_BODY_PART_OR_ORGAN_COMPONENT
and O O
urine O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
test O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
chamber O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
exposure O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
humans O B_PERSON/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
2 O B_NUMBER[MEASURE]
, O O
4 O B_NUMBER[MEASURE]
- O O
and O O
2 O B_NUMBER[MEASURE]
, O O
6 O B_NUMBER[MEASURE]
- O O
toluene O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
diisocyanate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O O
warranted O O
to O O
determine O O
whether O O
these O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
idiosyncratic O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
coincidental O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
or O O
a O O
more O O
general O B_DISEASE_ADJECTIVE[DISEASE]
phenomenon O I_DISEASE_ADJECTIVE[DISEASE]
. O O

After O O
1 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
day O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
none O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
labeled O O
erythrocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
detected O O
. O O

This O O
substrate O O
was O O
cleaved O O
efficiently O O
in O O
trans O O
by O O
protease B B_ENZYME[GENE]
3C I I_ENZYME[GENE]
derived O O
from O O
another O O
recombinant O O
vaccinia O O
virus O O
expressing O O
a O O
3C B B_ENZYME[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
precursor I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
activity O O
of O O
gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glutamyl I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transpeptidase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
serum O O
of O O
problem O O
drinkers O O
. O O

Patients O B_PERSON/B_BIO
with O O
endocarditis O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
or O O
vascular O B_DISEASE
infection O I_DISEASE
were O O
more O O
frequently O O
immunocompromised O O
and O O
older O B_TIME[MEASURE]/B_DISEASE
than O O
those O O
with O O
acute O B_DISEASE
Q O I_DISEASE
fever O I_DISEASE
. O O

The O O
effects O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
oxalate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
containing O O
products O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O O
the O O
exposed O O
dentine O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
surface O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
: O O
an O O
SEM O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
technique O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
used O O
by O O
this O O
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
involves O O
a O O
transient O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
externally O O
applied O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
resistance O B_DISEASE/B_MEASURE
to O O
breathing O B_DISEASE/B_MEASURE
. O O

We O O
evaluated O O
99mTc O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
ECD O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
SPECT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
comparing O O
with O O
rCBF O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
images O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
obtained O O
by O O
PET O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
12 O B_PERSON/B_TIME[MEASURE]
patients O I_PERSON/I_TIME[MEASURE]
with O O
spinocerebellar O B_DISEASE
degeneration O I_DISEASE
( O O
SCD O B_MEASURE/B_DISEASE
) O O
. O O

Monoclonal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
the O O
hapten O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phenyloxazolone O I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
raised O O
7 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
after O O
immunization O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O O
mice O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
six O B_NUMBER[MEASURE]/B_BIO
strains O I_NUMBER[MEASURE]/I_BIO
( O O
BALB O B_SPECIES[BIO]/B_PROTEIN[GENE]
/ O O
c O B_DISEASE/B_LOCATION
, O O
C57BL O B_BIO/B_PROTEIN[GENE]
- O O
Igha O B_MEASURE/B_DISEASE
, O O
DBA2 O B_LOCATION/B_PROTEIN[GENE]
, O O
RF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
/ O O
J O B_OTHER/B_PROTEIN[GENE]
, O O
and O O
CE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
. O O

In O O
particular O O
, O O
lacZ B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
synthesised O O
this O O
way O O
are O O
highly O O
unstable O O
and O O
yield O O
little O O
beta B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
galactosidase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Six O O
cDNAs O O
represent O O
human O O
homologs O O
of O O
genes O O
known O O
in O O
other O O
species O O
, O O
namely O O
, O O
mouse B B_GENE/B_SPECIES[BIO]
HSPE71 I B_GENE/I_SPECIES[BIO]
, O O
Rat B B_GENE
RhoGAP I I_GENE
protein I I_GENE
, O O
S B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
cerevisiae I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
leucyl I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
tRNA I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
synthetase I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
S B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cerevisiae I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chromosome I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ORF I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
YBLO44W I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
thalamic O B_DISEASE/B_PROTEIN[GENE]
SD O B_DISEASE/I_PROTEIN[GENE]
was O O
regularly O O
triggered O O
by O O
short O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
0 O B_MEASURE/B_LOCATION
. O O
02 O B_MEASURE
- O O
0 O B_MEASURE
. O O
05 O B_MEASURE
s O I_MEASURE
) O O
high O B_GENE/B_MEASURE
- O O
frequency O B_MEASURE
( O O
200 O B_MEASURE
- O O
500 O B_MEASURE
Hz O I_MEASURE
) O O
ES O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
parietal O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cortical O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
surface O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

All O O
three O O
SSV O O
- O O
transformed O O
cells O O
secreted O O
v B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sis I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
product I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
p44 B B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

p44 B B_GENE
was O O
secreted O O
but O O
remained O O
tightly O O
associated O O
with O O
the O O
cell O O
surface O O
. O O

It O O
is O O
suggested O O
that O O
the O O
mechanism O B_LOCATION/B_MEASURE
of O O
intestinal O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
absorption O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
vitamin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
D O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
25 O B_MEASURE
- O O
hydroxy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
vitamin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
differ O O
in O O
man O B_PERSON/B_MEASURE
, O O
the O O
absorption O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
25 O B_MEASURE
- O O
hydroxy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
vitamin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
possibly O O
being O O
less O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]
on O O
bile O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
acids O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

To O O
determine O O
the O O
role O O
of O O
elevated O O
FAK B B_GENE
expression O O
in O O
facilitating O O
epidermal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
growth I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
EGF B B_GENE
) O O
- O O
stimulated O O
human O O
adenocarcinoma O O
( O O
A549 O O
) O O
cell O O
motility O O
, O O
antisense O O
oligonucleotides O O
were O O
used O O
to O O
reduce O O
FAK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
> O O
75 O O
% O O
. O O

It O O
tends O O
to O O
be O O
higher O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
between O O
frazioni O B_PERSON/B_LOCATION
of O O
the O O
same O B_LOCATION/B_PERSON
community O I_LOCATION/I_PERSON
than O O
between O O
communities O B_LOCATION/B_PERSON
. O O

The O O
BRSV B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
L I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
6573 O O
nt O O
in O O
length O O
and O O
the O O
derived O O
polypeptide O O
has O O
2162 O O
aa O O
. O O

To O O
further O O
study O O
the O O
role O O
of O O
tTG B B_GENE
in O O
liver O O
disease O O
, O O
we O O
initiated O O
investigations O O
into O O
the O O
effect O O
of O O
a O O
proinflammatory O O
mediator O O
, O O
tumor B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
necrosis I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TNF I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
on O O
tTG B B_GENE
activity O O
in O O
cultured O O
liver O O
cells O O
. O O

Availability O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
a O O
less O O
palatable O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
diet O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
chow O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
following O O
presentation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
palatable O B_DISEASE
diets O I_DISEASE
will O O
not O O
result O O
in O O
diminished O B_DISEASE/B_MEASURE
caloric O I_DISEASE/I_MEASURE
intake O I_DISEASE/I_MEASURE
, O O
body O B_DISEASE/B_GENE
weight O I_DISEASE/I_GENE
, O O
obesity O B_DISEASE
and O O
hyperinsulinemia O B_DISEASE/B_MEASURE
. O O

By O O
contrast O O
, O O
CIS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
failed O O
to O O
affect O O
the O O
IL B B_DISEASE_ADJECTIVE[DISEASE]
- I I_DISEASE_ADJECTIVE[DISEASE]
9 I I_DISEASE_ADJECTIVE[DISEASE]
response O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
AND O O
RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
: O O
With O O
an O O
array O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
112 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
unipole O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
epicardial O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
maps O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
electrically O O
induced O O
AF O B_DISEASE/B_PROTEIN[GENE]
in O O
6 O B_MEASURE
dogs O I_MEASURE
( O O
acute O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
group O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
) O O
, O O
self O B_DISEASE_ADJECTIVE[DISEASE]
- O O
sustained O O
AF O B_DISEASE
in O O
6 O B_NUMBER[MEASURE]/B_BIO
dogs O B_NUMBER[MEASURE]/I_BIO
( O O
chronic O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
and O O
sinus O B_DISEASE
rhythm O I_DISEASE
and O O
atrial O B_DISEASE
pacing O I_DISEASE
in O O
3 O B_MEASURE
dogs O I_MEASURE
( O O
control O B_DISEASE_ADJECTIVE[DISEASE]
group O I_DISEASE_ADJECTIVE[DISEASE]
) O O
were O O
analyzed O O
before O O
and O O
after O O
creating O O
linear O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
radiofrequency O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ablation O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lesions O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
both O O
atria O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
that O O
eliminated O O
the O O
AF O B_DISEASE/B_PROTEIN[GENE]
. O O

In O O
response O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
phosphorus O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
limitation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
fungus O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
Neurospora O I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
crassa O I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
synthesizes O O
a O O
number O B_MEASURE/B_LOCATION
of O O
enzymes O B_ENZYME[GENE]
that O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
bring O O
more O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphate O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O O
the O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
. O O

The O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
of O O
inoculum O B_MEASURE
size O I_MEASURE
, O O
medium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
temperature O B_MEASURE
, O O
and O O
duration O B_MEASURE
of O O
growth O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
on O O
the O O
in O O
vitro O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
susceptibility O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
testing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
of O O
Aspergillus O B_BACTERIUM[BIO]
fumigatus O I_BACTERIUM[BIO]
were O O
investigated O O
using O O
broth O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
micro O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
and O O
macro O B_DISEASE
- O O
dilution O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
techniques O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

We O O
have O O
analyzed O O
the O O
function O O
of O O
these O O
putative O O
SL O O
structures O O
in O O
RNA O O
translation O O
by O O
constructing O O
chimeric B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
chloramphenicol I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
acetyltransferase I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( B B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
CAT I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
) I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
RNAs I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
flanked O O
either O O
by O O
both O O
5 O O
' O O
- O O
and O O
3 O O
' O O
- O O
terminal O O
sequence O O
domains O O
from O O
the O O
RV O O
genome O O
or O O
several O O
deletion O O
derivatives O O
of O O
the O O
same O O
sequences O O
. O O

Periarteritis O B_DISEASE
nodosa O O
with O O
ruptures O B_DISEASE
of O O
the O O
renal O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
vessels O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
the O O
persistence O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
hepatitis O B_DISEASE/B_PROTEIN[GENE]
B O B_DISEASE/I_PROTEIN[GENE]
and O O
C O B_DISEASE/B_PROTEIN[GENE]
viruses O B_DISEASE/I_PROTEIN[GENE]
in O O
the O O
blood O B_BODY_PART_OR_ORGAN_COMPONENT

Despite O O
the O O
fact O O
that O O
biochemical O O
estimates O O
of O O
bone O O
turnover O O
indicate O O
that O O
( O O
short O O
- O O
term O O
) O O
administration O O
of O O
rhGH B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
IGF B B_GENE
- I I_GENE
I I I_GENE
stimulates O O
bone O O
metabolism O O
in O O
non O O
- O O
osteoporotic O O
older O O
people O O
, O O
no O O
significant O O
changes O O
have O O
been O O
observed O O
in O O
bone O O
mineral O O
density O O
at O O
the O O
proximal O O
femur O O
. O O

Compression O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
pulmonary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
right O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
ventricular O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
outflow O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
tract O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
by O O
aneurysm O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
ascending O O
aorta O B_BODY_PART_OR_ORGAN_COMPONENT
. O O

However O O
, O O
patients O B_PERSON/B_DISEASE
with O O
DPX O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O O
be O O
observed O O
for O O
the O O
potential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
occurrence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
an O O
associated O B_DISEASE
condition O I_DISEASE
. O O

Blood O O
pressure O O
was O O
controlled O O
long O O
term O O
( O O
with O O
/ O O
without O O
diuretics O O
/ O O
beta B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
- I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
adrenoreceptor I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
blocking O O
drugs O O
) O O
in O O
sixteen O O
out O O
of O O
nineteen O O
patients O O
with O O
mild O O
- O O
moderate O O
hypertension O O
. O O

However O O
, O O
FosB B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
L I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
FosB B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
S I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
do O O
not O O
differ O O
in O O
all O O
trans O O
- O O
regulatory O O
properties O O
: O O
Trans O O
- O O
activation O O
of O O
a O O
5x O O
TRE B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CAT I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reporter O O
construct O O
in O O
HeLa O O
and O O
NIH O O
- O O
3T3 O O
cells O O
was O O
found O O
with O O
both O O
FosB B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
forms O O
. O O

Mutations O O
in O O
glnB B B_GENE/B_BACTERIUM[BIO]
, O O
nifR1 B B_GENE
( O O
ntrC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
, O O
and O O
NifR4 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ntrA B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
encoding O O
sigma B B_GENE/B_LOCATION
54 I I_GENE/I_LOCATION
) O O
had O O
no O O
influence O O
on O O
put B B_GENE
gene I I_GENE
expression O O
. O O

Disruption O O
of O O
INP53 B B_GENE/B_BIO
, O O
but O O
not O O
the O O
related O O
INP51 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
INP52 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
resulted O O
in O O
alpha B B_DISEASE_ADJECTIVE[DISEASE]
- I I_DISEASE_ADJECTIVE[DISEASE]
factor I I_DISEASE_ADJECTIVE[DISEASE]
maturation O O
defects O O
and O O
exacerbated O O
alpha B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
factor I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
maturation O O
defects O O
when O O
combined O O
with O O
chc1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
521 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Impact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cytokine O B_DISEASE
gene O I_DISEASE
polymorphisms O I_DISEASE
on O O
outcomes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
coronary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
artery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
bypass O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
graft O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
surgery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Regardless O O
of O O
muscle O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
tensioning O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
or O O
marination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatments O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
aging O O
of O O
the O O
carcass O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
for O O
24 O B_MEASURE
h O O
( O O
T1 O B_PROTEIN[GENE]
, O O
T2 O B_PROTEIN[GENE]
, O O
and O O
T3 O B_PROTEIN[GENE]
) O O
produced O O
meats O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
with O O
lower O B_MEASURE
shear O I_MEASURE
values O I_MEASURE
than O O
those O O
from O O
hot O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
- O O
boned O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
carcasses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
T4 O B_PROTEIN[GENE]
and O O
T5 O B_PROTEIN[GENE]
) O O
. O O

Blood O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
whole O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mercury O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
determined O O
in O O
pups O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
PN O B_MEASURE/B_PROTEIN[GENE]
0 O I_MEASURE/I_PROTEIN[GENE]
( O O
birth O B_TIME[MEASURE]/B_PERSON
) O O
and O O
PN O B_MEASURE
21 O I_MEASURE
( O O
weaning O O
) O O
. O O

By O O
subtractive O O
and O O
differential O O
screening O O
, O O
we O O
have O O
cloned O O
12 O O
of O O
these O O
sequences O O
, O O
2 O O
of O O
which O O
were O O
c B B_GENE
- I I_GENE
fos I I_GENE
and O O
krox B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
24 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

When O O
stratifying O O
FLM O B_MEASURE/B_LOCATION
values O B_MEASURE/I_LOCATION
< O O
34 O B_MEASURE
and O O
> O B_MEASURE/B_LOCATION
34 O I_MEASURE/I_LOCATION
wks O I_MEASURE/I_LOCATION
' O I_MEASURE/I_LOCATION
gestation O I_MEASURE/I_LOCATION
, O O
again O O
no O O
difference O B_MEASURE
was O O
found O O
in O O
mean O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
difference O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
L O B_OTHER/B_PROTEIN[GENE]
/ O O
S O B_OTHER/B_PROTEIN[GENE]
and O O
LB O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
before O O
and O O
after O O
34 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
wks O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
. O O

Cotransfection O O
of O O
a O O
junB B B_GENE/B_BACTERIUM[BIO]
stimulated O O
the O O
basal O O
activity O O
of O O
the O O
alpha B B_GENE
2 I I_GENE
( I I_GENE
I I I_GENE
) I I_GENE
collagen I I_GENE
promoter I I_GENE
93 O O
- O O
fold O O
, O O
respectively O O
. O O

Glutathione B B_GENE/B_PERSON
reductase I I_GENE/I_PERSON
( O O
GR B B_LOCATION/B_PROTEIN[GENE]
) O O
was O O
purified O O
from O O
the O O
cyanobacterium O O
Anabaena O O
PCC O O
7120 O O
. O O

Additional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
simulations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
account O O
for O O
interactions O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
spatial O B_MEASURE
frequency O I_MEASURE
with O O
stimulus O B_MEASURE/B_LOCATION
duration O B_MEASURE/I_LOCATION
, O O
effects O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
adaptation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O O
and O O
properties O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
residual O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
traces O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
as O O
opposed O O
to O O
visual O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
persistence O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Fractional O B_MEASURE
Ca O I_MEASURE
retention O B_MEASURE/B_DISEASE
was O O
measured O O
from O O
the O O
72 O B_MEASURE
- O O
h O B_MEASURE/B_PERSON
postdose O I_MEASURE/I_PERSON
WBR O I_MEASURE/I_PERSON
divided O O
by O O
WBR O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
time O B_MEASURE/B_LOCATION
0 O I_MEASURE/I_LOCATION
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
The O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
population O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
included O O
70 O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
with O O
acute O B_DISEASE
coronary O I_DISEASE
syndromes O I_DISEASE
( O O
14 O B_MEASURE
with O O
recent O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
acute O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
myocardial O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
56 O B_NUMBER[MEASURE]
with O O
unstable O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
angina O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pectoris O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
, O O
105 O B_MEASURE
patients O I_MEASURE
with O O
stable O B_DISEASE/B_GENE
angina O I_DISEASE/I_GENE
pectoris O I_DISEASE/I_GENE
, O O
and O O
75 O B_PERSON
control O I_PERSON
subjects O I_PERSON
. O O

Furthermore O O
, O O
rubella B B_DISEASE
IgM I I_DISEASE
antibody I I_DISEASE
was O O
never O O
detected O O
after O O
immunization O O
in O O
women O O
who O O
were O O
HAI O O
- O O
negative O O
and O O
LA O O
- O O
positive O O
during O O
pregnancy O O
. O O

Disease O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
free O B_MEASURE/B_LOCATION
interval O I_MEASURE/I_LOCATION
was O O
greater O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
node O B_DISEASE/B_GENE
- O O
negative O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
Lx O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
patients O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
for O O
both O O
T1 O B_PROTEIN[GENE]
( O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE
. O O
007 O B_MEASURE
) O O
and O O
T2 O B_PROTEIN[GENE]
( O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
presentations O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

5 O O
' O O
- O O
Deletion O O
of O O
the O O
Stat B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
abolished O O
all O O
promoter O O
- O O
reporter O O
activity O O
in O O
response O O
to O O
PRL B B_GENE
. O O

A O O
review O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
156 O B_PERSON/B_TIME[MEASURE]
patients O I_PERSON/I_TIME[MEASURE]
younger O I_PERSON/I_TIME[MEASURE]
than O O
40 O B_NUMBER[MEASURE]
treated O O
at O O
our O O
Department O B_LOCATION/B_ORGANIZATION
between O O
1960 O B_MEASURE
and O O
1991 O B_MEASURE
with O O
transitional O B_DISEASE
cell O I_DISEASE
carcinoma O I_DISEASE
of O O
the O O
bladder O B_BODY_PART_OR_ORGAN_COMPONENT
revealed O O
that O O
89 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
had O O
superficial O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
Ta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
T1 O B_PROTEIN[GENE]/B_LOCATION
) O O
disease O B_DISEASE
and O O
the O O
remaining O O
10 O B_MEASURE
. O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
presented O O
with O O
invasive O B_DISEASE
disease O I_DISEASE
. O O

Plasma B B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
beta I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
thromboglobulin I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
( O O
beta B B_PROTEIN[GENE]/B_LOCATION
- I I_PROTEIN[GENE]/I_LOCATION
TG I I_PROTEIN[GENE]/I_LOCATION
) O O
, O O
a O O
platelet O O
- O O
specific O O
protein O O
, O O
is O O
a O O
marker O O
of O O
intravascular O O
platelet O O
degranulation O O
. O O

John O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
s O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
wort O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

DESIGN O B_PERSON/B_MEASURE
, O O
SETTING O O
AND O O
SUBJECTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
The O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
based O O
on O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
collected O O
in O O
the O O
first O B_MEASURE/B_LOCATION
two O B_MEASURE/I_LOCATION
rounds O B_MEASURE/I_LOCATION
of O O
the O O
nationally O O
representative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ghana O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Living O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Standards O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Survey O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
held O O
in O O
1987 O B_MEASURE
/ O O
88 O B_MEASURE
( O O
GLSS O B_DISEASE/B_LOCATION
- O O
I O B_OTHER/B_PROTEIN[GENE]
) O O
and O O
1988 O B_MEASURE
/ O O
89 O B_MEASURE
( O O
GLSS O B_DISEASE/B_LOCATION
- O O
II O B_TIME[MEASURE]/B_PROTEIN[GENE]
) O O
, O O
with O O
both O O
surveys O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
covering O O
approximately O O
3000 O B_MEASURE/B_LOCATION
households O B_MEASURE/I_LOCATION
. O O

The O O
DNA O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
binding O O
proteins O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O O
without O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
transcription O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
plasmids O B_GENE/B_BACTERIUM[BIO]
lacking O O
binding O O
sites O B_LOCATION/B_ENT
or O O
when O O
the O O
binding O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
located O O
further O O
upstream O O
. O O

The O O
Gastrointestinal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Tumor O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
GITSG O B_DISEASE/B_ORGANIZATION
) O O
protocol O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GI O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
7175 O B_NUMBER[MEASURE]/B_LOCATION
randomized O O
227 O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
1975 O B_MEASURE
and O O
1980 O B_MEASURE
following O O
complete O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
surgical O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
resection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
stages O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
B2 O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
C O B_PROTEIN[GENE]
rectal O O
adenocarcinoma O B_DISEASE
to O O
four O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arms O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
( O O
1 O B_SEQUENCE[MEASURE]/B_LOCATION
) O O
no O O
adjuvant O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
( O O
2 O B_NUMBER[MEASURE]/B_PERSON
) O O
chemotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
only O O
, O O
( O O
3 O B_NUMBER[MEASURE]/B_LOCATION
) O O
radiotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
only O O
, O O
and O O
( O O
4 O B_NUMBER[MEASURE]
) O O
radiotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
chemotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
combined O O
modality O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
) O O
. O O

The O O
RTI40 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
spans O O
35 O O
kilobase O O
pairs O O
; O O
it O O
contains O O
6 O O
exons O O
and O O
at O O
least O O
6 O O
rat O O
Identifier O O
repetitive O O
elements O O
. O O

The O O
DNA O O
element O O
through O O
which O O
EBNA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
3C I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
activates O O
the O O
LMP B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
includes O O
a O O
Spi B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
/ O O
Spi B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O O
site O O
, O O
previously O O
characterized O O
as O O
an O O
important O O
EBNA B B_MEASURE/B_LOCATION
- I B_MEASURE/I_LOCATION
2 I B_MEASURE/I_LOCATION
response I B_MEASURE/I_LOCATION
element I B_MEASURE/I_LOCATION
. O O

DP B B_PROTEIN[GENE]
- I I_PROTEIN[GENE]
1 I I_PROTEIN[GENE]
and O O
DP B B_GENE
- I I_GENE
2 I I_GENE
encode O O
maternally O O
stored O O
transcripts O O
that O O
are O O
expressed O O
during O O
early O O
development O O
. O O

Furthermore O O
, O O
deletion O O
of O O
two O O
potential O O
Ste11 B B_GENE/B_LOCATION
recognition I I_GENE/I_LOCATION
sites I I_GENE/I_LOCATION
in O O
the O O
fus1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region O O
abolished O O
transcription O O
, O O
and O O
expression O O
could O O
be O O
restored O O
when O O
we O O
inserted O O
a O O
different O O
Ste11 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O O
the O O
mat1 B B_TIME[MEASURE]/B_PERSON
- I I_TIME[MEASURE]/I_PERSON
P I I_TIME[MEASURE]/I_PERSON
promoter I I_TIME[MEASURE]/I_PERSON
. O O

However O O
, O O
an O O
analogous O O
myristoylated O O
peptide O O
derived O O
from O O
c B B_GENE
- I I_GENE
Yes I I_GENE
also O O
has O O
no O O
inhibitory O O
activity O O
. O O

The O O
oral O B_DISEASE_ADJECTIVE[DISEASE]
movements O I_DISEASE_ADJECTIVE[DISEASE]
which O O
did O O
occur O O
in O O
the O O
HAL O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
treated O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
slower O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O O
normal O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Finally O O
, O O
we O O
demonstrate O O
that O O
animals O O
carrying O O
a O O
snf B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mutation O O
that O O
converts O O
SNF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
a O O
bifunctional O O
protein O O
to O O
a O O
U1 B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
snRNP I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
specific I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
viable O O
. O O

These O O
sequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
differences O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
reflected O O
in O O
differences O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
gene O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
three O B_DISEASE/B_BIO
cell O B_DISEASE/I_BIO
lines O B_DISEASE/I_BIO
. O O

This O O
pathway O O
has O O
been O O
reported O O
to O O
mediate O O
heterodimer O O
interactions O O
with O O
the O O
proapoptotic O O
regulator O O
, O O
Bad B B_GENE
. O O

Mutating O O
bases O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
- O O
142 O B_MEASURE
to O O
- O O
151 O B_MEASURE
abolishes O I_MEASURE
formation O I_MEASURE
of O O
complex O B_LOCATION/B_BIO
VII O I_LOCATION/I_BIO
and O O
partially O O
inhibits O O
complex O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
IV O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
, O O
suggesting O O
that O O
the O O
proteins O B_LOCATION/B_GENE
forming O O
these O O
complexes O B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bind O O
neighboring O B_LOCATION/B_BIO
segments O I_LOCATION/I_BIO
of O O
DNA O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
DFA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
slide O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
prepared O O
from O O
the O O
ThinPrep O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
Test O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
the O O
conventional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DFA O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sample O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prepared O O
from O O
the O O
endocervical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
swab O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
evaluated O O
independently O O
. O O

Moclobemide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
a O O
well O O
- O O
tolerated O O
alternative O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antidepressant O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
there O O
is O O
a O O
need O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
prospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
controlled O O
trials O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
evaluate O O
its O O
long O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
term O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
efficacy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

METHODS O B_MEASURE
: O O
Autocapture O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
devices O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
( O O
Pacesetter O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Microny O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SR O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
- O O
and O O
Regency O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SR O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
- O O
; O O
Pacesetter O B_PERSON/B_TIME[MEASURE]
, O O
Solna O B_PERSON/B_LOCATION
, O O
Sweden O B_LOCATION
) O O
and O O
steroid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
eluting O O
epicardial O B_MEDICAL_DEVICE[OBJECT]/B_DISEASE_ADJECTIVE[DISEASE]
pacing O I_MEDICAL_DEVICE[OBJECT]/I_DISEASE_ADJECTIVE[DISEASE]
leads O I_MEDICAL_DEVICE[OBJECT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Medtronic O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CapSure O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Epi O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10366 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
Medtronic O B_PERSON/B_LOCATION
, O O
Inc O B_ORGANIZATION/B_MEASURE
, O O
Minneapolis O B_LOCATION/B_PERSON
, O O
MN O B_LOCATION
) O O
were O O
implanted O O
in O O
14 O B_PERSON/B_ENT
children O I_PERSON/I_ENT
. O O

Hormonal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
replacement O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
for O O
women O B_PERSON
with O O
a O O
personal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
history O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
breast O B_DISEASE
cancer O I_DISEASE
? O O

Recently O O
, O O
we O O
reported O O
that O O
SMRT B B_GENE
also O O
directly O O
associates O O
with O O
LAZ3 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
BCL B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
6 I I_GENE/I_DISEASE
) O O
, O O
a O O
POZ O O
/ O O
Zn O O
finger O O
transcriptional O O
repressor O O
involvedin O O
the O O
pathogenesis O O
of O O
non O O
- O O
Hodgkin O O
lymphomas O O
. O O

Using O O
reporter O O
gene O O
constructs O O
driven O O
by O O
the O O
CD4 B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
, O O
we O O
report O O
that O O
HHV O O
- O O
6 O O
can O O
efficiently O O
transactivate O O
such O O
genetic O O
elements O O
. O O

Characterization O O
of O O
a O O
cDNA B B_GENE/B_LOCATION
encoding I I_GENE/I_LOCATION
CNN I I_GENE/I_LOCATION
predicts O O
a O O
novel O O
structural O O
protein O O
with O O
three O O
leucine O O
zipper O O
motifs O O
and O O
several O O
coiled O O
- O O
coil O O
domains O O
exhibiting O O
limited O O
homology O O
to O O
the O O
rod O O
portion O O
of O O
myosin B B_GENE
. O O

A O O
preformed O O
SREBP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1a I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
32P I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bound O O
specifically O O
to O O
membrane O O
- O O
immobilized O O
GST B B_GENE/B_BIO
- O O
CBP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
fusion O O
proteins O O
that O O
contained O O
amino O O
- O O
terminal O O
portions O O
of O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Pyridostigmine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
pretreatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
supplemented O O
by O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
two O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
doses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
an O O
antidotal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
combination O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
A O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
TM O B_PROTEIN[GENE]/B_DISEASE
, O O
B O B_OTHER/B_LOCATION
) O O
consisting O O
of O O
0 O B_MEASURE
. O O
05 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
atropine O I_MEASURE
, O O
2 O B_MEASURE
. O O
24 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE/B_LOCATION
TMB O I_MEASURE/I_LOCATION
- O O
4 O B_NUMBER[MEASURE]
, O O
and O O
0 O B_MEASURE
. O O
4 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
benactyzine O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
assured O O
survival O B_DISEASE_ADJECTIVE[DISEASE]
in O O
five O B_NUMBER[MEASURE]/B_BIO
of O O
six O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
animals O I_ENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
following O O
three O B_NUMBER[MEASURE]/B_LOCATION
separate O I_NUMBER[MEASURE]/I_LOCATION
exposures O I_NUMBER[MEASURE]/I_LOCATION
to O O
10 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
LD50 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
soman O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Previous O O
work O O
established O O
that O O
the O O
TAL1 B B_GENE
proteins I I_GENE
are O O
phosphorylated O O
exclusively O O
on O O
serine O O
and O O
identified O O
Ser122 O O
as O O
a O O
substrate O O
for O O
the O O
mitogen B B_ENZYME[GENE]
- I I_ENZYME[GENE]
activated I I_ENZYME[GENE]
protein I I_ENZYME[GENE]
kinase I I_ENZYME[GENE]
ERK B I_ENZYME[GENE]
- I I_ENZYME[GENE]
1 I I_ENZYME[GENE]
. O O

Rapid O B_SEQUENCE[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
sensitive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gas O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chromatographic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
8 O B_MEASURE
- O O
methoxypsoralen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
in O O
human O B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
plasma O I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O O

If O O
the O O
size O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
cystic O B_DISEASE/B_MEASURE
liver O I_DISEASE/I_MEASURE
- O O
lesions O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
excludes O O
a O O
curative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
operative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
or O O
if O O
the O O
patient O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
refuses O O
surgery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
the O O
indication O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O O
chemotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
mebendazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
given O O
. O O

When O O
cotransfected O O
with O O
the O O
HIV B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
LTR I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CAT B I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O O
CV O O
- O O
1 O O
cells O O
, O O
both O O
the O O
pCD41 B B_GENE/B_MEASURE
and O O
pGD41 B B_GENE
clones O O
trans O O
- O O
activated O O
the O O
HIV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
induction O O
of O O
the O O
composite O O
H B B_PROTEIN[GENE]/B_LOCATION
- I I_PROTEIN[GENE]/I_LOCATION
PK I I_PROTEIN[GENE]/I_LOCATION
/ O O
Tag B B_GENE/B_MEASURE
and O O
SV B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
PK I I_GENE/I_LOCATION
/ O O
Tag B B_GENE/B_LOCATION
transgenes O O
by O O
a O O
carbohydrate O O
- O O
rich O O
diet O O
in O O
the O O
liver O O
was O O
similar O O
to O O
that O O
of O O
the O O
endogenous B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
L I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
- I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
PK I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Patients O B_PERSON/B_BIO
with O O
advanced O B_DISEASE/B_LOCATION
ovarian O I_DISEASE/I_LOCATION
carcinoma O I_DISEASE/I_LOCATION
, O O
Stage O B_PROTEIN[GENE]/B_TIME[MEASURE]
III O I_PROTEIN[GENE]/I_TIME[MEASURE]
or O O
IV O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
International O B_ORGANIZATION/B_LOCATION
Federation O I_ORGANIZATION/I_LOCATION
of O O
Gynaecology O B_PERSON/B_DISEASE
and O O
Obstetrics O B_DISEASE/B_LOCATION
) O O
, O O
were O O
randomized O O
to O O
primary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
chemotherapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
doxorubicin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Adriamycin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
and O O
cisplatin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O O
or O O
minus O B_MEASURE
hexamethylmelamine O I_MEASURE
, O O
and O O
cyclophosphamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CHAP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Exit O O
from O O
mitosis O O
in O O
Drosophila O O
syncytial O O
embryos O O
requires O O
proteolysis O O
and O O
cyclin B B_GENE
degradation O O
, O O
and O O
is O O
associated O O
with O O
localized O O
dephosphorylation O O
. O O

Cough O B_DISEASE/B_PROTEIN[GENE]
- O O
CPR O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
, O O
a O O
deep O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
rhythmic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
forceful O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cough O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
repeated O O
30 O B_MEASURE
- O O
60 O B_TIME[MEASURE]/B_ENT
times O I_TIME[MEASURE]/I_ENT
per O O
minute O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
can O O
be O O
an O O
effective O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
resuscitative O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
technique O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
during O O
emergencies O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
occurring O O
in O O
the O O
cardiac O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
catheterization O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
laboratory O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

To O O
understand O O
this O O
dramatic O O
effect O O
, O O
we O O
examined O O
the O O
localization O O
of O O
SR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
found O O
that O O
SC35 B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
shifted O O
to O O
the O O
cytoplasm O O
in O O
sky1Delta B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
yeast O O
, O O
although O O
this O O
phenomenon O O
was O O
not O O
obvious O O
with O O
ASF B B_LOCATION/B_GENE
/ O O
SF2 B B_GENE/B_LOCATION
, O O
indicating O O
that O O
nuclear O O
import O O
of O O
SR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
may O O
be O O
differentially O O
regulated O O
by O O
phosphorylation O O
. O O

Probiotics O B_TIME[MEASURE]/B_LOCATION
, O O
prebiotics O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
vaccination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
acidification O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
drinking O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
water O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O O
assessed O O
as O O
means O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
reducing O O
Salmonella O B_DISEASE/B_BACTERIUM[BIO]
. O O

On O O
the O O
contrary O O
i O O
. O O
v O O
. O O
administration O O
of O O
calcitonin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increased O O
intrapyloric O O
pressure O O
via O O
vagal O O
nerves O O
in O O
atropinized O O
or O O
gallaminized O O
animals O O
. O O

We O O
conclude O O
that O O
in O O
the O O
presence O O
of O O
fatty O O
acids O O
in O O
the O O
medium O O
transcription O O
of O O
SPS19 B B_GENE
is O O
directly O O
regulated O O
by O O
both O O
Pip2p B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
Oaf1p B B_MEASURE
and O O
Adr1p B B_GENE
. O O

Gas O B_PERSON/B_DISEASE
exchange O I_PERSON/I_DISEASE
was O O
measured O O
breath O B_BODY_PART_OR_ORGAN_COMPONENT
by O O
breath O B_BODY_PART_OR_ORGAN_COMPONENT/B_TIME[MEASURE]
. O O

We O O
found O O
that O O
in O O
premature O O
infants O O
plasminogen B B_GENE
levels O O
are O O
low O O
; O O
thus O O
, O O
defense O O
against O O
intra O O
- O O
alveolar O O
fibrin B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deposition O O
during O O
birth O O
trauma O O
is O O
reduced O O
. O O

Analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
nt O B_GENE
sequence O I_GENE
was O O
carried O O
out O O
on O O
three O B_NUMBER[MEASURE]
out O O
of O O
the O O
more O B_MEASURE
than O O
15 O B_NUMBER[MEASURE]
of O O
these O O
regions O B_PERSON/B_GENE
present O B_PERSON/I_GENE
in O O
the O O
mouse O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genome O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Studies O O
on O O
the O O
reaction O O
of O O
cytochrome B B_BIO/B_DISEASE
c I I_BIO/I_DISEASE
with O O
corticosteroids O O
. O O

However O O
, O O
both O O
RAR B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
RXR B B_PROTEIN[GENE]/B_LOCATION
- O O
specific O O
ligands O O
increase O O
CaSki O O
number O O
by O O
> O O
or O O
= O O
20 O O
% O O
. O O

Also O O
, O O
in O O
patients O B_PERSON/B_MEASURE
with O O
MYD O B_DISEASE
, O O
there O O
was O O
a O O
significant O B_MEASURE
decrease O I_MEASURE
in O O
arterial O B_DISEASE/B_GENE
PO2 O I_DISEASE/I_GENE
from O O
the O O
seated O B_LOCATION/B_TIME[MEASURE]
posture O B_LOCATION/I_TIME[MEASURE]
to O O
the O O
supine O B_DISEASE/B_LOCATION
posture O I_DISEASE/I_LOCATION
, O O
without O O
a O O
significant O B_MEASURE/B_DISEASE
change O B_MEASURE/I_DISEASE
in O O
the O O
arterial O B_MEASURE/B_DISEASE
PCO2 O B_MEASURE/I_DISEASE
. O O

The O O
primary O O
structures O O
of O O
the O O
human B B_SPECIES[BIO]/B_PROTEIN[GENE]
KB I I_SPECIES[BIO]/I_PROTEIN[GENE]
cell I I_SPECIES[BIO]/I_PROTEIN[GENE]
( I I_SPECIES[BIO]/I_PROTEIN[GENE]
FR I I_SPECIES[BIO]/I_PROTEIN[GENE]
- I I_SPECIES[BIO]/I_PROTEIN[GENE]
KB1 I I_SPECIES[BIO]/I_PROTEIN[GENE]
) I I_SPECIES[BIO]/I_PROTEIN[GENE]
folate I I_SPECIES[BIO]/I_PROTEIN[GENE]
receptor I I_SPECIES[BIO]/I_PROTEIN[GENE]
( O O
FR B B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
and O O
of O O
a O O
human B B_GENE/B_BIO
placental I I_GENE/I_BIO
( I I_GENE/I_BIO
FR I I_GENE/I_BIO
- I I_GENE/I_BIO
P2 I I_GENE/I_BIO
) I I_GENE/I_BIO
FR I I_GENE/I_BIO
, O O
proteins O O
important O O
in O O
cellular O O
accumulation O O
of O O
folates O O
, O O
have O O
been O O
deduced O O
from O O
cDNA O O
sequences O O
. O O

The O O
general O O
concept O O
of O O
RARE B B_DISEASE/B_GENE
- O O
cleavage O O
mapping O O
as O O
well O O
as O O
its O O
applications O O
and O O
limitations O O
are O O
discussed O O
. O O

To O O
further O O
investigate O O
the O O
role O O
of O O
PKR B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
transcriptional O O
signaling O O
, O O
we O O
expressed O O
the O O
wild B B_GENE
type I I_GENE
human I I_GENE
PKR I I_GENE
and O O
a O O
catalytically O O
inactive O O
dominant O O
negative O O
PKR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutant I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
murine O O
pre O O
- O O
B O O
lymphoma O O
70Z O O
/ O O
3 O O
cells O O
. O O

Selective O O
upper O O
abdominal O O
sympathectomy O O
increased O O
basal O O
acid O O
output O O
in O O
rats O O
but O O
was O O
without O O
effect O O
on O O
stimulated O O
acid O O
output O O
, O O
serum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gastrin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
concentration O O
, O O
and O O
gastric B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
mucosal I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
histidine I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
decarboxylase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
. O O

Reasons O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O O
presented O O
to O O
support O O
the O O
contention O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
this O O
increase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
in O O
part O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
real O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Patients O B_PERSON
received O O
either O O
sodium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cephalothin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
placebo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intravenously O O
before O O
the O O
procedure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
and O O
for O O
up O O
to O O
8 O B_TIME[MEASURE]
additional O I_TIME[MEASURE]
doses O I_TIME[MEASURE]
. O O

In O O
- O O
111 O O
- O O
BLMC O O
uptake O O
was O O
directly O O
proportional O O
to O O
Ki B B_GENE
- I I_GENE
67 I I_GENE
/ O O
MIB B B_MEASURE/B_GENE
- I I_MEASURE/I_GENE
1 I I_MEASURE/I_GENE
activity O O
and O O
number O O
of O O
mitoses O O
in O O
tumor O O
tissue O O
. O O

Heating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
had O O
no O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
upon O O
either O O
force O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decline O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
slowing O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
relaxation O B_DISEASE/B_ORGANISM_FUNCTION
during O O
fatiguing O O
contractions O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Binding O O
of O O
transformed O O
Ah B B_GENE
receptor I I_GENE
complex I I_GENE
to O O
a O O
dioxin O O
responsive O O
transcriptional O O
enhancer O O
: O O
evidence O O
for O O
two O O
distinct O O
heteromeric O O
DNA O O
- O O
binding O O
forms O O
. O O

Interestingly O O
, O O
VDR B B_GENE
was O O
able O O
to O O
bind O O
to O O
VDREs O O
with O O
high O O
affinity O O
and O O
to O O
fully O O
activate O O
transcription O O
in O O
intact O O
yeast O O
cells O O
in O O
the O O
presence O O
of O O
the O O
retinoid B B_GENE
X I I_GENE
receptor I I_GENE
( O O
RXR B B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

Thus O O
, O O
it O O
appears O O
that O O
moxalactam O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
reliable O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
useful O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antibiotic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
complicated O B_DISEASE/B_LOCATION
urinary O I_DISEASE/I_LOCATION
tract O I_DISEASE/I_LOCATION
infections O I_DISEASE/I_LOCATION
. O O

A O O
fine O O
- O O
structure O O
radiation O O
hybrid O O
map O O
for O O
the O O
region O O
that O O
extends O O
from O O
D8S520 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
distal O O
) O O
to O O
D8S1759 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
proximal O O
) O O
was O O
prepared O O
, O O
followed O O
by O O
construction O O
of O O
a O O
single O O
, O O
integrated O O
YAC O O
/ O O
BAC O O
contig O O
for O O
the O O
interval O O
. O O

The O O
protein O O
contains O O
a O O
SHAQKYF O O
amino O O
acid O O
signature O O
motif O O
in O O
the O O
second O O
myb B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
like I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
repeat I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
is O O
highly O O
conserved O O
in O O
a O O
number O O
of O O
recently O O
identified O O
plant B B_GENE/B_BIO
myb I I_GENE/I_BIO
- I I_GENE/I_BIO
related I I_GENE/I_BIO
genes I I_GENE/I_BIO
, O O
thus O O
defining O O
a O O
new O O
class O O
of O O
plant O O
DNA O O
- O O
binding O O
proteins O O
. O O

IV O B_SEQUENCE[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
has O O
been O O
shown O O
that O O
renin B B_GENE
secretion O O
is O O
stimulated O O
by O O
endothelin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
a O O
recently O O
discovered O O
peptide O O
with O O
strong O O
vasoconstrictive O O
properties O O
and O O
stimulating O O
effects O O
on O O
renin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
secretion O O
. O O

Here O O
we O O
describe O O
the O O
cloning O O
and O O
initial O O
characterization O O
of O O
IPP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
novel O O
human O O
gene O O
that O O
predicts O O
a O O
kelch B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
homologous O O
to O O
the O O
mouse B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Ipp I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
previously O O
described O O
kelch B B_PERSON/B_BIO
family I B_PERSON/I_BIO
member I B_PERSON/I_BIO
. O O

The O O
encoded O O
260 B B_MEASURE/B_PROTEIN[GENE]
- I I_MEASURE/I_PROTEIN[GENE]
amino I I_MEASURE/I_PROTEIN[GENE]
- I I_MEASURE/I_PROTEIN[GENE]
acid I I_MEASURE/I_PROTEIN[GENE]
( I I_MEASURE/I_PROTEIN[GENE]
aa I I_MEASURE/I_PROTEIN[GENE]
) I I_MEASURE/I_PROTEIN[GENE]
( I I_MEASURE/I_PROTEIN[GENE]
H1 I I_MEASURE/I_PROTEIN[GENE]
- I I_MEASURE/I_PROTEIN[GENE]
I I I_MEASURE/I_PROTEIN[GENE]
) I I_MEASURE/I_PROTEIN[GENE]
and O O
240 B B_PROTEIN[GENE]/B_LOCATION
- I I_PROTEIN[GENE]/I_LOCATION
aa I I_PROTEIN[GENE]/I_LOCATION
( I I_PROTEIN[GENE]/I_LOCATION
H1 I I_PROTEIN[GENE]/I_LOCATION
- I I_PROTEIN[GENE]/I_LOCATION
II I I_PROTEIN[GENE]/I_LOCATION
) I I_PROTEIN[GENE]/I_LOCATION
polypeptides I I_PROTEIN[GENE]/I_LOCATION
possess O O
the O O
typical O O
tripartite O O
organization O O
of O O
animal B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
H1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
histones I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
with O O
variable O O
N O O
- O O
and O O
C O O
- O O
terminal O O
domains O O
flanking O O
a O O
conserved O O
' O O
globular O O
' O O
DNA O O
- O O
binding O O
domain O O
. O O

Instead O O
, O O
the O O
large O O
difference O O
in O O
ssDNA O O
- O O
binding O O
affinities O O
reflects O O
the O O
loss O O
of O O
hexamerization O O
ability O O
by O O
uvsY B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
suggesting O O
that O O
a O O
form O O
of O O
intrahexamer O O
synergism O O
or O O
cooperativity O O
between O O
binding O O
sites O O
within O O
the O O
uvsY B B_ENZYME[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hexamer I I_ENZYME[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leads O O
to O O
its O O
high O O
observed O O
affinity O O
for O O
ssDNA O O
. O O

No O O
significant O O
difference O O
was O O
seen O O
found O O
between O O
the O O
two O O
groups O O
in O O
the O O
degree O O
of O O
postoperative O O
deterioration O O
in O O
cardiopulmonary O O
function O O
or O O
in O O
interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
. O O

The O O
PK O O
domain O O
showed O O
pairwise O O
in O O
vitro O O
binding O O
interactions O O
with O O
the O O
pseudokinase O O
, O O
HisRS B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
C O O
- O O
term O O
domains O O
; O O
additionally O O
, O O
the O O
HisRS B B_ENZYME[GENE]/B_LOCATION
domain I I_ENZYME[GENE]/I_LOCATION
interacted O O
with O O
the O O
C O O
- O O
term O O
region O O
. O O

The O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
erythrosine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Red O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
rose O O
bengal O B_LOCATION/B_COLOR
B O I_LOCATION/I_COLOR
( O O
Red O B_MEASURE/B_PROTEIN[GENE]
105 O I_MEASURE/I_PROTEIN[GENE]
) O O
and O O
thyroidectomy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
thyroid O B_DISEASE
tumor O I_DISEASE
were O O
examined O O
in O O
male O B_SPECIES[BIO]/B_GENE
Wistar O I_SPECIES[BIO]/I_GENE
rats O I_SPECIES[BIO]/I_GENE
treated O O
with O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_OTHER
- O O
bis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
2 O B_MEASURE
- O O
hydroxypropyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
nitrosamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DHPN O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

The O O
AmyI B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
specific O O
3 O O
' O O
- O O
UTR O O
is O O
characterized O O
by O O
the O O
absence O O
of O O
IR O O
sequences O O
and O O
the O O
presence O O
of O O
a O O
putative O O
' O O
AATAAA O O
' O O
polyadenylation O O
signal O O
. O O

To O O
initiate O O
our O O
analysis O O
of O O
factors O O
required O O
for O O
eIF B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
2 I I_GENE/I_DISEASE
alpha I I_GENE/I_DISEASE
expression O O
, O O
selected O O
a O O
CAP O O
- O O
proximal O O
element O O
shown O O
by O O
in O O
vivo O O
methylation O O
protection O O
analysis O O
to O O
bind O O
a O O
potential O O
regulatory O O
factor O O
. O O

Furthermore O O
, O O
addition O O
of O O
the O O
recombinant B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
NF I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
YA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
subunit I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
restores O O
NF B B_GENE
- I I_GENE
Y I I_GENE
binding O O
. O O

Reversible O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
pressure O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
induced O O
amorphization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
solid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
C70 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O O
Raman O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
photoluminescence O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Alternative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
roles O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
these O O
DNA O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
motifs O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O O
activators O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
early O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
as O O
an O O
initiator O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
element O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O O
late O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
mRNA O I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transcription O I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
help O O
explain O O
how O O
polyomavirus O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
regulated O O
during O O
lytic O B_DISEASE/B_ORGANISM_FUNCTION
growth O B_DISEASE/I_ORGANISM_FUNCTION
and O O
provides O O
a O O
model O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
cellular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transcription O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
during O O
development O B_DISEASE/B_ORGANISM_FUNCTION
. O O

Our O O
results O O
suggest O O
that O O
Sp1 B B_GENE/B_LOCATION
binding I I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
can O O
function O O
as O O
a O O
distinct O O
TGF B B_GENE/B_PERSON
- I I_GENE/I_PERSON
beta I I_GENE/I_PERSON
responsive I I_GENE/I_PERSON
element I I_GENE/I_PERSON
for O O
TGF B B_GENE
- I I_GENE
beta I I_GENE
mediated O O
promoter O O
expression O O
and O O
Sp1 B B_GENE/B_LOCATION
per O O
se O O
can O O
mediate O O
this O O
response O O
. O O

Effect O O
of O O
bromocriptine O O
and O O
metoclopramide O O
on O O
serum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
prolactin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
in O O
patients O O
with O O
amyotrophic O O
lateral O O
sclerosis O O
. O O

Phase O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O O
study O O
of O O
5 O B_MEASURE
- O O
fluorouracil O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
leucovorin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
a O O
14 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]/B_LOCATION
circadian O B_TIME[MEASURE]/I_LOCATION
infusion O B_TIME[MEASURE]/I_LOCATION
in O O
metastatic O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
adenocarcinoma O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
patients O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrate O O
that O O
release O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
a O O
single O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
pulley O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
after O O
repair O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
tendons O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
in O O
this O O
area O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
improved O O
gliding O O
excursions O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
tendons O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
reduced O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
resistance O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O O
motion O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
repaired O O
tendons O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
and O O
provide O O
support O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O O
partial O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
A2 O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pulley O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
incision O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O O
repair O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
tendons O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
in O O
the O O
area O B_LOCATION/B_MEASURE
of O O
the O O
pulley O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Heart O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rate O B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
oxygen O B_DISEASE/B_PROTEIN[GENE]
consumption O B_DISEASE/I_PROTEIN[GENE]
increased O O
75 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
4 O B_TIME[MEASURE]
bpm O I_TIME[MEASURE]
and O O
26 O B_MEASURE
. O O
3 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
1 O B_MEASURE
. O O
4 O B_MEASURE
ml O I_MEASURE
O2 O I_MEASURE
/ O O
kg O B_MEASURE
x O O
min O B_MEASURE/B_PERSON
( O O
- O O
1 O B_MEASURE
) O O
from O O
supine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
resting O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
values O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
respectively O O
. O O

To O O
evaluate O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
selective O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
thromboxane O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
A2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blockade O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
platelet O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reactivity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
refractory O B_DISEASE
unstable O I_DISEASE
angina O I_DISEASE
, O O
OKY O B_PROTEIN[GENE]/B_LOCATION
- O O
046 O B_NUMBER[MEASURE]
( O O
600 O B_TIME[MEASURE]
mg O I_TIME[MEASURE]
/ O O
day O B_TIME[MEASURE]
, O O
p O B_TIME[MEASURE]/B_DISEASE
. O O
o O O
. O O
) O O
was O O
administered O O
to O O
another O O
14 O B_PERSON/B_LOCATION
patients O I_PERSON/I_LOCATION
with O O
refractory O B_DISEASE
unstable O I_DISEASE
angina O I_DISEASE
in O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
conventional O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Prolongation O O
of O O
prothrombin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
time O O
was O O
not O O
due O O
to O O
depletion O O
of O O
vitamin O O
K O O
- O O
dependent O O
coagulation O O
factors O O
or O O
manifest O O
fibrinolysis O O
, O O
but O O
due O O
to O O
the O O
presence O O
of O O
circulating O O
fibrinogen B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fibrinmonomer I I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
FDP O O
complexes O O
. O O

Effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
tetracycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
the O O
glycogen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
producing O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
liver O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
intestinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
microflora O I_BODY_PART_OR_ORGAN_COMPONENT/I_BACTERIUM[BIO]
in O O
white O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mice O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

A O O
case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
report O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Mutation O O
of O O
K14 O O
in O O
H3 B B_GENE
, O O
which O O
serves O O
as O O
the O O
major O O
target O O
of O O
recombinant B B_GENE
Gcn5p I I_GENE
acetylation O O
in O O
vitro O O
, O O
confers O O
a O O
strong O O
, O O
synthetic O O
growth O O
defect O O
in O O
gcn5 B B_GENE/B_DISEASE
cells O O
. O O

On O O
the O O
other O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
hand O I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
V3 O B_MEASURE/B_PERSON
" O B_MEASURE/I_PERSON
values O B_MEASURE/I_PERSON
were O O
not O O
significantly O O
correlated O O
with O O
the O O
degree O B_MEASURE/B_DISEASE
of O O
tremor O B_DISEASE
, O O
seborrhea O B_BIO/B_MEASURE
, O O
and O O
duration O B_MEASURE/B_DISEASE
of O O
the O O
illness O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

All O O
patients O O
whose O O
PSA B B_GENE
levels O O
reached O O
0 O O
. O O
1 O O
ng O O
. O O
/ O O
ml O O
. O O

In O O
addition O O
, O O
we O O
found O O
that O O
the O O
transactivation O O
mediated O O
by O O
the O O
p68c B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
ets I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
pr I I_GENE/I_LOCATION
p55erg B I_GENE/I_LOCATION
through O O
the O O
Polyomavirus B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enhancer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
specifically O O
inhibited O O
by O O
the O O
p46kDaPax B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
QNR I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
transient O O
transfection O O
assay O O
. O O

Treatment O O
with O O
ACE B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inhibitors O O
after O O
acute O O
myocardial O O
infarction O O

Conversely O O
, O O
as O O
a O O
GAL B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
4 I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
chimera I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
the O O
isolated O O
LAZ3 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
BCL6 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
BTB B I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
POZ O O
domain O O
appears O O
nearly O O
as O O
efficient O O
as O O
the O O
entire O O
protein O O
at O O
inducing O O
transcriptional O O
repression O O
. O O

A O O
new O O
myocyte B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specific I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhancer I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
recognizes O O
a O O
conserved O O
element O O
associated O O
with O O
multiple O O
muscle O O
- O O
specific O O
genes O O
. O O

Diclofenac O O
sodium O O
: O O
blood O O
concentration O O
of O O
the O O
slow O O
- O O
release O O
form O O
and O O
influence O O
on O O
the O O
metabolism O O
of O O
kallikrein B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O O

The O O
LS B B_GENE/B_BIO
gene I I_GENE/I_BIO
promoter I I_GENE/I_BIO
sequence I I_GENE/I_BIO
has O O
homology O O
with O O
Escherichia O O
coli O O
promoter O O
sequences O O
; O O
its O O
terminator O O
sequence O O
is O O
capable O O
of O O
forming O O
a O O
stem O O
- O O
and O O
- O O
loop O O
structure O O
. O O

We O O
demonstrate O O
that O O
the O O
recently O O
proposed O O
synthetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
imaging O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
technique O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
[ O O
J O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Overexpression O O
of O O
either O O
Sp1 B B_GENE
or O O
phosphorylated B B_GENE
CREB I I_GENE
transactivated O O
the O O
mCgA B B_GENE
promoter I I_GENE
dose O O
dependently O O
, O O
while O O
coexpression O O
of O O
both O O
transcription O O
factors O O
resulted O O
in O O
an O O
additive O O
mCgA B B_GENE
promoter I I_GENE
response O O
. O O

mCgA B B_MEASURE/B_GENE
- O O
92 O O
to O O
- O O
64 O O
bp O O
, O O
comprising O O
the O O
Sp1 B B_GENE/B_LOCATION
/ O O
Egr B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
1 I I_GENE/I_MEASURE
site O O
and O O
the O O
CRE O O
motif O O
, O O
conferred O O
gastrin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
responsiveness O O
to O O
a O O
heterologous B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thymidine I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promoter I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O O
, O O
and O O
therefore O O
functions O O
as O O
a O O
" O O
true O O
" O O
enhancer O O
element O O
. O O

Together O O
with O O
the O O
up O O
- O O
regulation O O
of O O
the O O
cAMP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
response I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
modulator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CREM B B_GENE/B_LOCATION
) O O
mRNA O O
and O O
protein O O
levels O O
demonstrated O O
previously O O
in O O
CREB B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mutant I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
mice O O
, O O
we O O
suggest O O
that O O
the O O
up O O
- O O
regulation O O
of O O
CREB B B_GENE
beta I I_GENE
may O O
also O O
contribute O O
to O O
compensation O O
within O O
the O O
CREB B B_GENE/B_LOCATION
/ O O
ATF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
family O O
of O O
transcription O O
factors O O
, O O
when O O
CREB B B_GENE
delta I I_GENE
and O O
CREB B B_GENE
alpha I I_GENE
are O O
absent O O
. O O

The O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
obtained O O
with O O
cellular O B_GENE/B_BIO
RNA O I_GENE/I_BIO
from O O
HepG2 O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
demonstrated O O
that O O
transcription O B_GENE
is O O
initiated O O
891 O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
bases O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
upstream O O
of O O
the O O
translation O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
start O B_LOCATION/B_MEASURE
site O I_LOCATION/I_MEASURE
and O O
that O O
the O O
polyadenylation O B_GENE/B_TIME[MEASURE]
site O I_GENE/I_TIME[MEASURE]
is O O
located O O
550 O B_MEASURE/B_LOCATION
bases O B_MEASURE/I_LOCATION
downstream O O
of O O
the O O
stop O B_GENE
codon O I_GENE
. O O

Finally O O
, O O
there O O
is O O
now O O
appropriate O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
recognition O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
the O O
pivotal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
BP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
reduction O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
forestalling O O
pressure O B_DISEASE
- O O
related O O
cardiovascular O B_DISEASE_ADJECTIVE[DISEASE]
complications O I_DISEASE_ADJECTIVE[DISEASE]
, O O
even O O
among O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O O
risk O B_PERSON/B_ORGANIZATION
persons O I_PERSON/I_ORGANIZATION
with O O
diabetes O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
mellitus O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
renal O B_DISEASE
insufficiency O I_DISEASE
. O O

Individual O O
and O O
combined O O
effects O O
of O O
fumonisin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
B1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
present O O
in O O
Fusarium O O
moniliforme O O
culture O O
material O O
and O O
diacetoxyscirpenol O O
or O O
ochratoxin O O
A O O
in O O
turkey O O
poults O O
. O O

It O O
is O O
hypothesized O O
this O O
occurs O O
through O O
antagonism O O
of O O
PML B B_GENE/B_DISEASE
/ O O
RAR B B_GENE/B_LOCATION
alpha I I_GENE/I_LOCATION
actions O O
in O O
these O O
leukemic O O
cells O O
. O O

13 O O
: O O
961 O O
- O O
969 O O
, O O
1993 O O
) O O
suggested O O
that O O
T B B_GENE
antigen I I_GENE
could O O
mediate O O
transcriptional O O
activation O O
through O O
interaction O O
with O O
the O O
TATA B B_GENE/B_BIO
- I I_GENE/I_BIO
binding I I_GENE/I_BIO
protein I I_GENE/I_BIO
, O O
as O O
well O O
as O O
upstream O O
bound O O
transcription O O
factors O O
. O O

The O O
Grb2 B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
SH3 B B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
C I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
) I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
binding I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
region I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
Gab1 B B_GENE
has O O
significant O O
homology O O
to O O
a O O
region O O
of O O
the O O
adapter B B_BIO/B_GENE
protein I I_BIO/I_GENE
SLP I I_BIO/I_GENE
- I I_BIO/I_GENE
76 I I_BIO/I_GENE
. O O

A O O
phase O O
II O O
study O O
of O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
interleukin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
5 O O
- O O
fluorouracil O O
in O O
advanced O O
renal O O
carcinoma O O
: O O
clinical O O
data O O
and O O
laboratory O O
evidence O O
of O O
protease O O
activation O O
. O O

Activation O O
of O O
the O O
cytotactin B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
promoter I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
by O O
the O O
homeobox B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Evx I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
/ O O
INTERPRETATION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
We O O
found O O
an O O
increased O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
hip O B_DISEASE/B_LOCATION
fracture O I_DISEASE/I_LOCATION
in O O
women O B_PERSON
younger O I_PERSON
than O O
75 O B_NUMBER[MEASURE]/B_ENT
years O I_NUMBER[MEASURE]/I_ENT
with O O
Type O B_MEASURE/B_ORGANIZATION
I O O
diabetes O B_DISEASE/B_PERSON
or O O
with O O
Type O B_DISEASE
II O I_DISEASE
diabetes O I_DISEASE
of O O
long O B_PERSON
duration O I_PERSON
. O O

Maternal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
behavior O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
assessed O O
using O O
observational O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
techniques O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Rat B B_GENE/B_DISEASE
p8 I I_GENE/I_DISEASE
mRNA I I_GENE/I_DISEASE
was O O
discovered O O
because O O
of O O
its O O
strong O O
activation O O
in O O
pancreas O O
during O O
the O O
acute O O
phase O O
of O O
pancreatitis O O
. O O

LV O B_DISEASE/B_PROTEIN[GENE]
compliance O B_DISEASE/I_PROTEIN[GENE]
was O O
determined O O
from O O
the O O
slope O B_MEASURE
of O O
the O O
LV O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
diastolic O B_MEASURE/B_LOCATION
pressure O B_MEASURE/I_LOCATION
( O O
LVEDP O B_LOCATION/B_DISEASE
) O O
vs O B_DISEASE/B_MEASURE
. O O

The O O
practice O O
of O O
measuring O O
of O O
AChE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
in O O
acute O O
poisoning O O
is O O
limited O O
. O O

Vasodilation O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
congestive O B_DISEASE/B_PERSON
heart O I_DISEASE/I_PERSON
failure O I_DISEASE/I_PERSON
is O O
an O O
established O O
therapeutic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
principal O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
collicular O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
labels O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
found O O
after O O
injections O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
within O O
the O O
MST O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
area O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exhibited O O
their O O
distribution O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
over O O
the O O
deep O B_DISEASE/B_PROTEIN[GENE]
SC O B_DISEASE/I_PROTEIN[GENE]
subdivision O B_DISEASE/I_PROTEIN[GENE]
, O O
whereas O O
they O O
spared O O
all O O
the O O
superficial O B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
layers O B_LOCATION/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
but O O
the O O
deep O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
part O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
SO O B_LOCATION/B_PROTEIN[GENE]
. O O

When O O
furA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
alone O O
was O O
introduced O O
into O O
the O O
Delta O O
( O O
furA B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
- O O
katG B B_GENE
) O O
mutant O O
, O O
survival O O
in O O
mouse O O
lungs O O
was O O
moderately O O
increased O O
, O O
suggesting O O
that O O
FurA B B_BACTERIUM[BIO]/B_GENE
could O O
regulate O O
genes O O
, O O
other O O
than O O
katG B B_GENE
, O O
that O O
are O O
involved O O
in O O
pathogenesis O O
. O O

The O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cefazolin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
given O O
into O O
the O O
III O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cerebral O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
ventricle O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
at O O
different O B_TIME[MEASURE]/B_PERSON
doses O I_TIME[MEASURE]/I_PERSON
were O O
studied O O
on O O
GABA O B_GENE
content O I_GENE
, O O
GAD O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
GABA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
T O B_GENE
in O O
the O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
- O O
stem O B_BODY_PART_OR_ORGAN_COMPONENT
of O O
young O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
chickens O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Gallus O B_BIO/B_PROTEIN[GENE]
domesticus O B_BIO/I_PROTEIN[GENE]
) O O
. O O

Subclones O O
of O O
R15 O O
which O O
reverted O O
to O O
kappa B B_GENE/B_DISEASE
light I I_GENE/I_DISEASE
chain I I_GENE/I_DISEASE
production O O
contained O O
genomic O O
deletions O O
of O O
R15ns O O
and O O
/ O O
or O O
the O O
surrounding O O
intron O O
. O O

The O O
disorders O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
are O O
accompanied O O
by O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, O O
but O O
similarly O O
reversible O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
electroencephalographic O B_DISEASE_ADJECTIVE[DISEASE]
changes O I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
delayed O O
activation O O
of O O
the O O
prostaglandin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
G I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
H I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promoter O O
in O O
bovine O O
granulosa O O
cells O O
is O O
associated O O
with O O
down O O
- O O
regulation O O
of O O
truncated O O
upstream B B_GENE
stimulatory I I_GENE
factor I I_GENE
- I I_GENE
2 I I_GENE
. O O

The O O
authors O O
recommend O O
in O O
cases O O
with O O
an O O
elevated O O
transaminase O O
serum O O
activity O O
more O O
frequent O O
check O O
- O O
up O O
examinations O O
to O O
avoid O O
missing O O
of O O
a O O
relapse O O
, O O
and O O
to O O
examine O O
repeatedly O O
IgM B B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
anti B I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
- I I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
HAV I I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
as O O
in O O
protracted O O
forms O O
of O O
hepatitis O O
IgM B B_DISEASE/B_PERSON
anti B I_DISEASE/I_PERSON
- I I_DISEASE/I_PERSON
HAV I I_DISEASE/I_PERSON
may O O
persist O O
even O O
when O O
the O O
transaminase O O
activity O O
is O O
normal O O
. O O

Mean O B_PERSON
latency O I_PERSON
periods O I_PERSON
were O O
29 O B_MEASURE
. O O
6 O B_MEASURE
among O O
insulators O B_PERSON
, O O
35 O B_MEASURE
. O O
4 O B_MEASURE
among O O
dock O B_PERSON/B_ORGANIZATION
workers O I_PERSON/I_ORGANIZATION
, O O
43 O B_MEASURE
. O O
7 O B_SEQUENCE[MEASURE]
in O O
a O O
heterogeneous O B_MEASURE/B_LOCATION
group O B_MEASURE/I_LOCATION
defined O O
as O O
various O B_NUMBER[MEASURE]/B_PERSON
, O O
46 O B_MEASURE
. O O
4 O B_MEASURE
in O O
non O B_DISEASE/B_LOCATION
- O O
shipbuilding O B_PERSON/B_ORGANIZATION
industry O I_PERSON/I_ORGANIZATION
workers O I_PERSON/I_ORGANIZATION
, O O
49 O B_MEASURE
. O O
4 O B_MEASURE
in O O
shipyard O B_PERSON/B_ORGANIZATION
workers O I_PERSON/I_ORGANIZATION
, O O
51 O B_MEASURE
. O O
7 O B_MEASURE
among O O
women O B_PERSON
with O O
a O O
history O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
domestic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
asbestos O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
and O O
56 O B_MEASURE
. O O
2 O B_MEASURE
in O O
people O B_PERSON
employed O O
in O O
maritime O B_LOCATION/B_ORGANIZATION
trades O I_LOCATION/I_ORGANIZATION
. O O

The O O
strategy O O
uses O O
RNA B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ligase I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
add O O
DNA O O
oligonucleotide O O
priming O O
sites O O
to O O
the O O
RNA O O
for O O
subsequent O O
reverse O O
transcription O O
and O O
PCR O O
( O O
RNA B B_PROTEIN[GENE]/B_LOCATION
ligase I I_PROTEIN[GENE]/I_LOCATION
, O O
reverse O O
transcription O O
- O O
PCR O O
, O O
or O O
RL O O
/ O O
RT O O
/ O O
PCR O O
) O O
. O O

We O O
analyzed O O
the O O
effects O O
of O O
light O O
on O O
tubulin B B_GENE
mRNA I I_GENE
abundance O O
in O O
Arabidopsis O O
seedlings O O
using O O
RNA O O
gel O O
blot O O
hybridizations O O
and O O
gene O O
- O O
specific O O
probes O O
. O O

More O O
important O O
, O O
ligand O O
- O O
activated O O
insulin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
IGF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphorylate O O
SHC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
vitro O O
, O O
indicating O O
that O O
SHC B B_GENE/B_PERSON
proteins I I_GENE/I_PERSON
could O O
be O O
direct O O
substrates O O
for O O
insulin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
IGF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
chimera O O
transduced O O
IL B B_GENE
- I I_GENE
4 I I_GENE
- O O
specific O O
signals O O
in O O
response O O
to O O
IL B B_GENE
- I I_GENE
2 I I_GENE
binding O O
and O O
dramatically O O
enhanced O O
type O O
2 O O
responses O O
( O O
IL B B_GENE
- I I_GENE
4 I I_GENE
, O O
IL B B_GENE
- I I_GENE
5 I I_GENE
, O O
and O O
immunoglobulin B B_GENE
E I I_GENE
production O O
) O O
upon O O
in O O
vitro O O
TCR B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulation O O
or O O
in O O
vivo O O
antigen O O
challenge O O
. O O

A O O
distinct O B_DISEASE/B_MEASURE
5 O I_DISEASE/I_MEASURE
' O I_DISEASE/I_MEASURE
- O O
sequence O B_LOCATION/B_GENE
in O O
clone O B_GENE/B_BIO
hMIWC2 O I_GENE/I_BIO
suggested O O
an O O
alternative O B_GENE
upstream O I_GENE
transcription O I_GENE
initiation O I_GENE
site O I_GENE
. O O

Two O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
beta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
N I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acetylglucosaminyltransferases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
forming O O
the O O
core O O
2 O O
O O O
- O O
glycan O O
branch O O
, O O
C2GnT O O
and O O
the O O
I B B_MEASURE/B_GENE
antigen I I_MEASURE/I_GENE
, O O
IGnT B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
are O O
homologous O O
to O O
each O O
other O O
in O O
three O O
regions O O
of O O
the O O
catalytic O O
domain O O
( O O
A O O
, O O
B O O
, O O
C O O
) O O
and O O
their O O
genes O O
reside O O
at O O
the O O
same O O
locus O O
, O O
chromosome O O
9 O O
, O O
band O O
q21 O O
( O O
Bierhuizen O O
, O O
M O O
. O O
F O O
. O O
A O O
. O O
, O O
Mattei O O
, O O
M O O
. O O
- O O
G O O
. O O
and O O
Fukuda O O
, O O
M O O
. O O
, O O
Genes O O
Dev O O
. O O
, O O
7 O O
, O O
468 O O
- O O
478 O O
, O O
1993 O O
) O O
. O O

Significantly O O
higher O O
levels O O
of O O
vitamin O O
C O O
and O O
catalase B B_ENZYME[GENE]
activity O O
were O O
found O O
in O O
vegetarians O O
( O O
C O O
- O O
63 O O
. O O
6 O O
and O O
86 O O
. O O
5 O O
mumol O O
/ O O
l O O
; O O
CAT O O
- O O
1497 O O
and O O
1313 O O
U O O
/ O O
ml O O
for O O
males O O
and O O
females O O
, O O
respectively O O
) O O
when O O
compared O O
to O O
nonvegetarians O O
( O O
C O O
- O O
41 O O
. O O
3 O O
and O O
54 O O
. O O
4 O O
mumol O O
/ O O
l O O
; O O
CAT O O
- O O
1192 O O
and O O
1086 O O
U O O
/ O O
ml O O
) O O
. O O

Cutting O O
the O O
intraorbital O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
nerves O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
produced O O
a O O
temporary O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
retrieval O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
impairment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
that O O
was O O
indistinguishable O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
from O O
that O O
produced O O
by O O
intramystacial O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
lidocaine O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
injection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Developmental O O
regulation O O
of O O
expression O O
of O O
the O O
malate B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
synthase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
transgenic O O
plants O O
. O O

In O O
contrast O O
, O O
no O O
change O O
in O O
the O O
level O O
of O O
either O O
p53 B B_GENE
or O O
activation O O
of O O
mdm2 B B_GENE
protein I I_GENE
by O O
p53 B B_GENE
was O O
observed O O
in O O
hamster O O
UV61 O O
cells O O
after O O
UV O O
exposure O O
. O O

On O O
day O B_TIME[MEASURE]/B_LOCATION
1 O I_TIME[MEASURE]/I_LOCATION
at O O
3500 O B_MEASURE/B_ORGANISM_FUNCTION
m O B_MEASURE/I_ORGANISM_FUNCTION
, O O
RI O B_PROTEIN[GENE]/B_LOCATION
showed O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
fall O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
body O B_MEASURE/B_LOCATION
weight O I_MEASURE/I_LOCATION
( O O
BW O B_LOCATION/B_MEASURE
) O O
with O O
respect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
SL O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
but O O
AI O B_LOCATION/B_PROTEIN[GENE]
maintained O O
it O O
. O O

Transcriptional O O
activation O O
of O O
the O O
proopiomelanocortin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
cyclic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
AMP I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
responsive I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
element I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
NF1 B B_PERSON/B_LOCATION
family I B_PERSON/I_LOCATION
members O O
and O O
HNF4 B B_GENE/B_PERSON
interacted O O
with O O
overlapping O O
sequences O O
of O O
the O O
L O O
- O O
II O O
element O O
, O O
wherein O O
the O O
5 O O
' O O
half O O
- O O
site O O
was O O
more O O
critical O O
for O O
NF1 B B_GENE/B_DISEASE
binding O O
, O O
and O O
the O O
3 O O
' O O
site O O
was O O
more O O
important O O
for O O
HNF4 B B_GENE/B_LOCATION
binding O O
. O O

RAP B B_GENE/B_DISEASE
has O O
been O O
shown O O
to O O
be O O
a O O
useful O O
vaccine O O
target O O
site O O
, O O
and O O
RIP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
inhibitory O O
AIPs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O O
therapeutic O O
molecules O O
to O O
prevent O O
and O O
suppress O O
S O O
. O O
aureus O O
infections O O
. O O

After O O
institution O O
of O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
, O O
diabetic O O
control O O
was O O
improved O O
as O O
demonstrated O O
by O O
decreasing O O
levels O O
of O O
HbA1 B B_DISEASE/B_GENE
. O O

The O O
mouse O O
lactoferrin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene O O
promoter O O
was O O
active O O
in O O
human O O
endometrium O O
carcinoma O O
RL O O
95 O O
- O O
2 O O
cells O O
and O O
in O O
rat O O
glioma O O
C6 O O
cells O O
. O O

The O O
1 O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]
and O O
2 O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]
survival O I_TIME[MEASURE]
rates O I_TIME[MEASURE]
for O O
the O O
patients O B_PERSON/B_BIO
with O O
N0 O B_LOCATION/B_PROTEIN[GENE]
- O O
3 O B_NUMBER[MEASURE]/B_DISEASE
significantly O O
exceeded O O
those O O
of O O
N4 O B_PERSON/B_DISEASE
patients O I_PERSON/I_DISEASE
. O O

Measurement O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
spectral O B_PROTEIN[GENE]/B_LOCATION
sensitivity O I_PROTEIN[GENE]/I_LOCATION
and O O
the O O
ERG O B_MEASURE
can O O
thus O O
help O O
in O O
the O O
diagnosis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
three O B_DISEASE_ADJECTIVE[DISEASE]
hereditary O I_DISEASE_ADJECTIVE[DISEASE]
diseases O I_DISEASE_ADJECTIVE[DISEASE]
. O O

As O O
a O O
quantitative O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
index O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cochlear O B_MEASURE/B_DISEASE
function O I_MEASURE/I_DISEASE
, O O
2f1 O B_PROTEIN[GENE]/B_MEASURE
- O O
f2 O B_MEASURE
distortion O I_MEASURE
- O O
product O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
otoacoustic O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
emissions O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
DPOAEs O B_DISEASE/B_LOCATION
) O O
were O O
monitored O O
systematically O O
over O O
time O B_TIME[MEASURE]/B_LOCATION
in O O
three O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
rabbits O B_BIO/B_PERSON
, O O
with O O
each O O
group O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiencing O O
a O O
unique O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
paradigm O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
incorporated O O
repeated O O
exposure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O O
the O O
low O B_MEASURE/B_COLOR
- O O
frequency O B_MEASURE/B_LOCATION
tone O I_MEASURE/I_LOCATION
. O O

The O O
subjects O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lungs O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
ventilated O O
with O O
N2O O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
O2 O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
FIO2 O B_MEASURE/B_LOCATION
0 O I_MEASURE/I_LOCATION
. O O
3 O B_MEASURE
) O O
to O O
the O O
end O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
tidal O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CO2 O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
present O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O O
anesthesia O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
and O O
then O O
CBF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
measured O O
using O O
intravenous O B_NUMBER[MEASURE]
133Xe O I_NUMBER[MEASURE]
and O O
ten O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scintillation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
counters O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
five O B_NUMBER[MEASURE]/B_LOCATION
over O O
each O O
cerebral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
hemisphere O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
indicates O O
changes O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
postvaccination O B_DISEASE_ADJECTIVE[DISEASE]
allergy O I_DISEASE_ADJECTIVE[DISEASE]
to O O
BCG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Analysis O O
of O O
1 O O
Mb O O
of O O
published O O
sequence O O
from O O
the O O
region O O
of O O
conserved O O
synteny O O
on O O
human O O
chromosome O O
5q31 O O
- O O
q33 O O
identified O O
45 O O
gene O O
candidates O O
, O O
including O O
35 O O
expressed O O
genes O O
in O O
the O O
human B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
IL I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
4 I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
cytokine I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
gene I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
cluster O O
. O O

There O O
is O O
no O O
indication O O
from O O
these O O
experiments O O
that O O
linker B B_PERSON/B_GENE
histones I I_PERSON/I_GENE
bind O O
fundamentally O O
differently O O
to O O
5 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
S I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
bulk O O
nucleosomes O O
. O O

Km O O
values O O
of O O
the O O
uncoupled O O
enzymes O O
IIGlc B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
glucose O O
ranged O O
from O O
0 O O
. O O
5 O O
to O O
2 O O
. O O
5 O O
mM O O
, O O
2 O O
orders O O
of O O
magnitude O O
higher O O
than O O
the O O
value O O
of O O
normal O O
IIGlc B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Cytochrome B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
bd I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
biosynthesis O O
in O O
Escherichia O O
coli O O
: O O
the O O
sequences O O
of O O
the O O
cydC B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cydD B B_LOCATION/B_GENE
genes I I_LOCATION/I_GENE
suggest O O
that O O
they O O
encode O O
the O O
components O O
of O O
an O O
ABC B B_ENZYME[GENE]/B_BIO
membrane I I_ENZYME[GENE]/I_BIO
transporter I I_ENZYME[GENE]/I_BIO
. O O

In O O
contrast O O
, O O
inhibition O O
of O O
MAPK B B_GENE
activity O O
by O O
MAPK B B_GENE
kinase I I_GENE
inhibitor O O
( O O
PD O O
98059 O O
) O O
or O O
by O O
overexpression O O
of O O
kinase O O
- O O
deficient O O
MAPKs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activated O O
basal O O
and O O
GnRH B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
stimulated O O
GnRHR B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Luc B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O O
. O O

The O O
influence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
gas O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
composition O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
the O O
air O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cell O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
on O O
pipping O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
liver O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
metabolism O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O O
embryonic O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
chicks O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Historically O O
, O O
Cyps B B_BIO/B_PERSON
were O O
first O O
identified O O
by O O
their O O
ability O O
to O O
bind O O
the O O
immunosuppressive O O
agent O O
cyclosporin O O
A O O
( O O
CsA O O
) O O
with O O
high O O
affinity O O
; O O
they O O
later O O
were O O
found O O
to O O
have O O
peptidyl B B_ENZYME[GENE]
- I I_ENZYME[GENE]
prolyl I I_ENZYME[GENE]
cis I I_ENZYME[GENE]
- I I_ENZYME[GENE]
trans I I_ENZYME[GENE]
isomerase I I_ENZYME[GENE]
( O O
PPIase B B_GENE/B_LOCATION
) O O
activity O O
, O O
which O O
catalyzes O O
the O O
folding O O
of O O
oligopeptides O O
at O O
proline O O
- O O
peptide O O
bonds O O
in O O
vitro O O
and O O
may O O
be O O
important O O
for O O
protein O O
folding O O
in O O
vivo O O
. O O

Thus O O
, O O
oxyR B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mutants I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O O
locked O O
on O O
for O O
Ag43 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
, O O
whereas O O
dam B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mutants I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O O
locked O O
off O O
for O O
Ag43 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
. O O

A O O
rare O O
tRNA B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
Arg I I_GENE/I_MEASURE
( I I_GENE/I_MEASURE
CCU I I_GENE/I_MEASURE
) I I_GENE/I_MEASURE
that O O
regulates O O
Ty1 B B_DISEASE_ADJECTIVE[DISEASE]
element I I_DISEASE_ADJECTIVE[DISEASE]
ribosomal O O
frameshifting O O
is O O
essential O O
for O O
Ty1 B B_GENE
retrotransposition O O
in O O
Saccharomyces O O
cerevisiae O O
. O O

Several O O
35 O O
- O O
mm O O
slides O O
of O O
dystrophin B B_GENE
- O O
, O O
laminin B B_GENE
- O O
, O O
and O O
concanavalin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ConA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
- O O
stained O O
muscle O O
sections O O
were O O
used O O
to O O
calculate O O
myofiber O O
cross O O
- O O
sectional O O
areas O O
and O O
to O O
compare O O
different O O
techniques O O
and O O
settings O O
of O O
an O O
image O O
capture O O
system O O
. O O

In O O
addition O O
, O O
both O O
inhibitors O O
blocked O O
phosphatidylcholine O O
hydrolysis O O
and O O
protein B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
C I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
translocation O O
. O O

New O O
, O O
selective O O
catechol B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
O I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
methyltransferase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors O O
as O O
therapeutic O O
agents O O
in O O
Parkinson O O
' O O
s O O
disease O O
. O O

Furthermore O O
, O O
the O O
social O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
learning O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
theory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
depression O B_TIME[MEASURE]/B_DISEASE
, O O
developed O O
by O O
Lewinsohn O B_PERSON
, O O
is O O
described O O
. O O

Laser O O
soldering O O
with O O
exogenous O O
fibrinogen B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
feasible O O
without O O
topical O O
administration O O
of O O
additional O O
clotting O O
agents O O
, O O
significantly O O
improves O O
the O O
bursting O O
strength O O
of O O
primary O O
laser O O
welded O O
anastomoses O O
, O O
and O O
appears O O
to O O
result O O
from O O
urokinase B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
- O O
resistant O O
fibrinogen B B_GENE
cross O O
- O O
linking O O
. O O

Intensity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
variations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
from O O
the O O
variable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TR O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
removed O O
, O O
and O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
evaluated O O
for O O
correlation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O O
the O O
lateralized O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
stimulus O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Routine O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
imaging O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
modalities O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
revealed O O
a O O
total O B_MEASURE/B_LOCATION
of O O
79 O B_NUMBER[MEASURE]/B_ORGANIZATION
metastases O I_NUMBER[MEASURE]/I_ORGANIZATION
. O O

We O O
have O O
previously O O
reported O O
that O O
analgesic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
morphine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
accelerate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mortality O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposed O O
to O O
hemorrhage O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Feuerstein O B_PERSON/B_LOCATION
and O O
Siren O B_PERSON
: O O
Circ O B_MEASURE/B_ENT
Shock O I_MEASURE/I_ENT
19 O I_MEASURE/I_ENT
: O O
293 O B_MEASURE
- O O
300 O B_MEASURE
, O O
1986 O B_MEASURE
) O O
. O O

We O O
describe O O
a O O
novel O O
stat B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
related I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
p93 B B_GENE
, O O
that O O
is O O
found O O
in O O
EGF B B_GENE
- O O
treated O O
A431 O O
cell O O
extracts O O
but O O
appears O O
to O O
be O O
absent O O
in O O
bovine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fibroblast I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
bFGF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
IFN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
gamma I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
tumor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
necrosis I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factor I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
TNF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
and O O
untreated O O
cells O O
. O O

p93 B B_GENE/B_PERSON
appears O O
to O O
be O O
antigenically O O
related O O
to O O
stat91 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_VIRUS[BIO]
. O O

p185c B B_GENE
- O O
neu B B_GENE
+ O O
, O O
EGFr B B_GENE
+ I I_GENE
( O O
M1 B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
and O O
p185c B B_GENE
- O O
neu B B_GENE
- O O
kinase O O
inactive O O
, O O
EGFr B B_GENE
+ I I_GENE
( O O
NEN757 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
expressing O O
cells O O
undergo O O
different O O
mitotic O O
responses O O
to O O
EGF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

In O O
addition O O
, O O
Fc B B_GENE
epsilon I I_GENE
R1 I I_GENE
cross O O
- O O
linking O O
activates O O
PI B B_GENE
3 I I_GENE
- I I_GENE
kinase I I_GENE
. O O

When O O
single O O
- O O
point O O
mutation O O
was O O
introduced O O
to O O
each O O
GC O O
box O O
, O O
EBS B B_DISEASE/B_GENE
, O O
and O O
GT O O
box O O
in O O
PFP9a20 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
at O O
least O O
3 O O
- O O
fold O O
less O O
CAT B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activity O O
was O O
observed O O
in O O
CTLL O O
- O O
R8 O O
cells O O
. O O

Ribosome O O
association O O
of O O
GCN2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
translational O O
activator O O
of O O
the O O
GCN4 B B_GENE
gene I I_GENE
of O O
Saccharomyces O O
cerevisiae O O
. O O

Treatment O O
with O O
H7 O O
did O O
not O O
affect O O
IL B B_GENE
- I I_GENE
4R I I_GENE
- O O
mediated O O
immediate O O
signaling O O
events O O
such O O
as O O
tyrosine O O
phosphorylation O O
of O O
Jak1 B B_GENE
, O O
Jak3 B B_GENE
, O O
insulin B B_GENE
receptor I I_GENE
substrate I I_GENE
( I I_GENE
IRS I I_GENE
) I I_GENE
- I I_GENE
1 I I_GENE
and O O
IRS B B_GENE
- I I_GENE
2 I I_GENE
, O O
or O O
tyrosine O O
phosphorylation O O
and O O
DNA O O
binding O O
of O O
Stat6 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Thus O O
, O O
STK1 B B_NUMBER[MEASURE]/B_PERSON
is O O
most O O
likely O O
the O O
human B B_PERSON/B_GENE
homologue I I_PERSON/I_GENE
of I I_PERSON/I_GENE
MO15 I I_PERSON/I_GENE
. O O

BACKGROUND O O
: O O
Recent O O
iterative O O
methods O O
for O O
sequence O O
alignment O O
have O O
indicated O O
that O O
the O O
380 O O
kDa O O
motor O O
unit O O
of O O
dynein B B_BACTERIUM[BIO]/B_GENE
belongs O O
to O O
the O O
AAA B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
class I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
chaperone B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
like I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
ATPases I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

When O O
the O O
VBP B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
1 I I_GENE/I_MEASURE
protein I I_GENE/I_MEASURE
was O O
solely O O
expressed O O
, O O
it O O
located O O
to O O
the O O
cytoplasm O O
and O O
did O O
not O O
localize O O
to O O
the O O
nucleus O O
. O O

Consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
experiments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O O
these O O
compounds O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
cocaine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O O
the O O
most O O
potent O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
group O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
significance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
these O O
changes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
relation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
the O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
phosphorus O B_ORGANISM_FUNCTION/B_DISEASE
balance O I_ORGANISM_FUNCTION/I_DISEASE
in O O
ruminants O B_SPECIES[BIO]/B_PERSON
is O O
discussed O O
. O O

Transfection O O
assays O O
using O O
the O O
first O O
600 O O
bp O O
of O O
the O O
upstream O O
nucleotide O O
sequences O O
indicated O O
that O O
a O O
region O O
from O O
- O O
75 O O
to O O
- O O
120 O O
was O O
necessary O O
for O O
the O O
ALDH2 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
gene I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
expression O O
, O O
and O O
especially O O
NF B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
Y I I_GENE/I_LOCATION
/ O O
CP1 B B_GENE
binding O O
site O O
from O O
- O O
92 O O
to O O
- O O
96 O O
( O O
CCAAT O O
box O O
) O O
is O O
important O O
in O O
the O O
expression O O
of O O
the O O
gene O O
. O O

This O O
distinct O O
biochemical O O
difference O O
between O O
STAT5A B B_GENE
and O O
STAT5B B B_GENE
was O O
confirmed O O
with O O
purified O O
activated O O
STAT5 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
recombinant I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
show O O
that O O
in O O
uninfected O B_PERSON/B_PROTEIN[GENE]
NIH O B_PERSON/I_PROTEIN[GENE]
- O O
3T3 O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
Avarol O I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
i O B_OTHER/B_DISEASE
) O O
causes O O
a O O
50 O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
% O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reduction O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
growth O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
rate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
only O O
at O O
the O O
high O B_MEASURE/B_LOCATION
concentration O I_MEASURE/I_LOCATION
of O O
29 O B_MEASURE
. O O
6 O B_MEASURE
microM O I_MEASURE
and O O
( O O
ii O B_MEASURE/B_PROTEIN[GENE]
) O O
is O O
accumulated O O
in O O
the O O
cytoplasm O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
close O O
to O O
the O O
nucleus O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
. O O

Blood B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
coagulation I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
X I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
its O O
activated O O
form O O
Factor B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
Xa I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
play O O
an O O
essential O O
role O O
in O O
the O O
midphase O O
of O O
the O O
clotting O O
cascade O O
. O O

The O O
exon O O
sequences O O
determined O O
from O O
genomic O O
DNA O O
sequencing O O
showed O O
some O O
differences O O
when O O
compared O O
to O O
the O O
published O O
rat B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
GLUT2 I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
cDNA I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Intramolecular O O
interaction O O
is O O
believed O O
to O O
result O O
in O O
the O O
formation O O
of O O
MxA B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
monomers I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
, O O
whereas O O
intermolecular O O
interaction O O
may O O
induce O O
the O O
formation O O
of O O
large B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
MxA I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
oligomers I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
psbA B B_GENE
gene I I_GENE
encodes O O
the O O
D1 B B_PROTEIN[GENE]/B_PERSON
protein I I_PROTEIN[GENE]/I_PERSON
of O O
photosystem B B_BIO/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I I_BIO/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
is O O
synthesized O O
at O O
very O O
high O O
rates O O
in O O
the O O
light O O
in O O
order O O
to O O
replace O O
photodamaged O O
protein O O
. O O

The O O
three O O
more O O
slower O O
migrating O O
Stat5B B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bands O O
observed O O
in O O
response O O
to O O
GH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
contain O O
phosphorylated O O
tyrosyl O O
residues O O
. O O

The O O
maximum O B_MEASURE
levels O I_MEASURE
of O O
reporter O B_GENE
proteins O I_GENE
attained O O
in O O
transformed O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
after O O
prolonged O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induction O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
represented O O
from O O
1 O B_NUMBER[MEASURE]/B_LOCATION
% O I_NUMBER[MEASURE]/I_LOCATION
to O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
total O B_MEASURE/B_PERSON
cellular O B_MEASURE/I_PERSON
protein O B_MEASURE/I_PERSON
. O O

Specifically O O
, O O
we O O
demonstrate O O
that O O
this O O
25 O O
- O O
base O O
pair O O
region O O
mediates O O
the O O
up O O
- O O
regulatory O O
effect O O
of O O
TGF B B_GENE
- I I_GENE
beta I I_GENE
on O O
COL1A2 B B_GENE
promoter I I_GENE
activity O O
and O O
allows O O
antagonistic O O
activity O O
of O O
TNF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
TGF B B_GENE
- I I_GENE
beta I I_GENE
effect O O
. O O

Sin4 B B_GENE
and O O
Srb10 B B_GENE/B_DISEASE
, O O
components O O
of O O
specific O O
RNA B B_GENE/B_BIO
polymerase I I_GENE/I_BIO
II I I_GENE/I_BIO
sub I I_GENE/I_BIO
- I I_GENE/I_BIO
complexes I I_GENE/I_BIO
that O O
are O O
required O O
for O O
Ssn6 B B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Tup1 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
repression O O
activity O O
, O O
are O O
found O O
to O O
be O O
required O O
for O O
Sfl1 B B_GENE/B_BIO
repression O O
function O O
. O O

Translation O O
of O O
mok B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
tightly O O
regulated O O
by O O
Sok B B_GENE/B_BIO
RNA I I_GENE/I_BIO
, O O
and O O
Sok B B_GENE/B_BIO
RNA I I_GENE/I_BIO
thus O O
regulates O O
hok B B_SPECIES[BIO]/B_GENE
translation O O
indirectly O O
through O O
mok B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Depending O O
on O O
the O O
patient O B_PERSON/B_BIO
' O O
s O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
body O I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
position O I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
telemetrically O O
measured O O
CSF O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
pressures O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
varied O O
between O O
- O O
20 O B_MEASURE
cmH2O O I_MEASURE
in O O
erect O B_DISEASE/B_LOCATION
and O O
15 O B_MEASURE
cmH2O O I_MEASURE
in O O
supine O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
position O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

One O B_NUMBER[MEASURE]
- O O
hour O B_MEASURE
O3 O I_MEASURE
, O O
NO2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
and O O
SO2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
personal O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
exposures O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
measured O O
using O O
samplers O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
developed O O
in O O
our O O
laboratory O B_LOCATION/B_ORGANIZATION
, O O
while O O
short O B_PERSON/B_MEASURE
- O O
term O B_MEASURE/B_LOCATION
PM2 O I_MEASURE/I_LOCATION
. O O
5 O B_MEASURE
, O O
CO O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
and O O
VOCs O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposures O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
measured O O
using O O
currently O O
available O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monitors O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
Tlr B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
family I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
members I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
unlike O O
others O O
reported O O
to O O
date O O
, O O
were O O
identified O O
within O O
a O O
genomic O O
database O O
. O O

We O O
hypothesized O O
that O O
subjects O B_PERSON/B_BIO
would O O
demonstrate O O
PKAR O B_DISEASE/B_GENE
during O O
both O O
hopping O O
and O O
stepping O O
, O O
adding O O
support O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
the O O
hypothesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
PKAR O B_GENE/B_LOCATION
is O O
a O O
centrally O O
mediated O O
adaptation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
general O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
locomotor O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
trajectory O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
that O O
is O O
not O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
the O O
form O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
locomotion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
used O O
while O O
on O O
the O O
rotating O O
disk O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O O

In O O
this O O
study O O
, O O
transcriptional O O
fusions O O
were O O
constructed O O
between O O
the O O
xcpP B B_GENE/B_BACTERIUM[BIO]
and O O
xcpR B B_GENE
genes I I_GENE
and O O
the O O
lacZ B B_GENE/B_PERSON
reporter I I_GENE/I_PERSON
. O O

To O O
explore O O
the O O
mechanism O O
of O O
insulin B B_GENE
receptor I I_GENE
phosphorylation O O
we O O
have O O
used O O
NIH3T3 O O
cells O O
transfected O O
with O O
two O O
receptor O O
constructs O O
: O O
one O O
encoding O O
a O O
chimeric O O
receptor O O
composed O O
of O O
the O O
extracellular O O
domain O O
of O O
the O O
human B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
EGF I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
receptor I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O O
the O O
cytosolic O O
domain O O
of O O
the O O
human B B_GENE
insulin I I_GENE
receptor I I_GENE
beta I I_GENE
- I I_GENE
subunit I I_GENE
, O O
and O O
a O O
second O O
construct O O
encoding O O
a O O
kinase O O
- O O
defiecient O O
human B B_PROTEIN[GENE]
insulin I I_PROTEIN[GENE]
receptor I I_PROTEIN[GENE]
. O O

It O O
is O O
pathogenetically O O
proved O O
to O O
use O O
antithrombin B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
III I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PROTEIN[GENE]
concentrate O O
preparations O O
with O O
anti O O
- O O
and O O
dysaggregatory O O
properties O O
, O O
fibronectin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
preparations O O
, O O
trasylol O O
or O O
its O O
analogs O O
during O O
complex O O
preoperative O O
preparation O O
of O O
patients O O
. O O

Stimulation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
endosteal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bone O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
formation O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rate O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
mainly O O
impaired O O
in O O
D O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
depleted O O
rats O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
resulting O O
in O O
trabecular O B_DISEASE/B_GENE
bone O I_DISEASE/I_GENE
loss O I_DISEASE/I_GENE
, O O
which O O
, O O
in O O
- O O
D O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mother O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
was O O
associated O O
with O O
decreased O O
bone O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ash O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
total O B_MEASURE/B_DISEASE
bone O B_MEASURE/I_DISEASE
calcium O B_MEASURE/I_DISEASE
. O O

Hematopoietic B B_GENE
progenitor I I_GENE
kinase I I_GENE
1 I I_GENE
( O O
HPK1 B B_GENE/B_LOCATION
) O O
is O O
a O O
member O O
of O O
the O O
mitogen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MAP4K B B_GENE/B_LOCATION
) O O
family O O
and O O
an O O
upstream O O
activator O O
of O O
the O O
c B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
Jun I I_GENE/I_DISEASE
N I I_GENE/I_DISEASE
- I I_GENE/I_DISEASE
terminal I I_GENE/I_DISEASE
kinase I I_GENE/I_DISEASE
( O O
JNK B B_GENE/B_ORGANIZATION
) O O
signaling O O
cascade O O
. O O

We O O
have O O
used O O
the O O
chloramphenicol B B_GENE
acetyltransferase I I_GENE
( O O
CAT B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
reporter O O
gene O O
system O O
to O O
study O O
the O O
effect O O
of O O
T B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
the O O
long O O
terminal O O
repeats O O
( O O
LTRs O O
) O O
of O O
a O O
large O O
family O O
of O O
human O O
endogenous O O
retrovirus O O
- O O
like O O
sequences O O
, O O
RTVL O O
- O O
H O O
. O O

To O O
investigate O O
this O O
possibility O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
conducted O O
split O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
visual O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
field O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
which O O
we O O
manipulated O O
stimulus O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sets O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
recognition O B_MEASURE/B_LOCATION
task O I_MEASURE/I_LOCATION
, O O
and O O
exposure O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
duration O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
ANH O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
had O O
no O O
negative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
endocrine O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
stress O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
response O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
during O O
orthopedic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
surgery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
under O O
epidural O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anesthesia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Finally O O
, O O
the O O
conservation O O
of O O
the O O
two O O
residues O O
most O O
sensitive O O
to O O
mutations O O
( O O
Y949 O O
and O O
Y953 O O
) O O
in O O
TM11 O O
, O O
and O O
in O O
the O O
homologous O O
TM5 O O
, O O
of O O
all O O
mammalian B B_BIO/B_GENE
P I I_BIO/I_GENE
- I I_BIO/I_GENE
gps I I_BIO/I_GENE
and O O
also O O
in O O
other O O
ABC B B_BIO/B_GENE
transporters I I_BIO/I_GENE
, O O
suggests O O
that O O
these O O
residues O O
and O O
domains O O
may O O
play O O
an O O
important O O
role O O
in O O
structural O O
as O O
well O O
as O O
mechanistic O O
aspects O O
common O O
to O O
this O O
family O O
of O O
proteins O O
. O O

Based O O
on O O
the O O
requirement O O
for O O
CREM B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
ICER B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
Rad6B B B_GENE
proteins I I_GENE
in O O
spermatogenesis O O
, O O
we O O
determined O O
expression O O
of O O
Cdc34 B B_GENE
, O O
Rad6B B B_GENE/B_BACTERIUM[BIO]
, O O
CREM B B_LOCATION/B_DISEASE
/ O O
ICER B B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoforms O O
, O O
and O O
the O O
Skp1 B B_GENE
- O O
Cullin B B_PROTEIN[GENE]/B_DISEASE
- O O
F O O
- O O
box O O
ubiquitin B B_GENE/B_BIO
protein O O
ligase O O
subunits O O
Cul B B_GENE
- I I_GENE
1 I I_GENE
and O O
Cul B B_PROTEIN[GENE]/B_MEASURE
- I I_PROTEIN[GENE]/I_MEASURE
2 I I_PROTEIN[GENE]/I_MEASURE
, O O
which O O
are O O
associated O O
with O O
Cdc34 B B_GENE
activity O O
during O O
murine O O
testicular O O
development O O
. O O

The O O
enigma O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
aging O O
bone O B_DISEASE/B_LOCATION
loss O I_DISEASE/I_LOCATION
. O O

Transcription B B_GENE
factor I I_GENE
IIIC I I_GENE
( O O
TFIIIC B B_PROTEIN[GENE]/B_DISEASE
) O O
is O O
required O O
for O O
the O O
assembly O O
of O O
a O O
preinitiation O O
complex O O
on O O
5S B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
tRNA O O
, O O
and O O
adenovirus B B_VIRUS[BIO]/B_PERSON
VA I I_VIRUS[BIO]/I_PERSON
RNA O O
genes O O
and O O
contains O O
two O O
separable O O
components O O
, O O
TFIIIC1 B B_PROTEIN[GENE]/B_DISEASE
and O O
TFIIIC2 B B_PROTEIN[GENE]
. O O

Furthermore O O
, O O
we O O
show O O
that O O
Nck B B_GENE
- I I_GENE
2 I I_GENE
is O O
capable O O
of O O
recognizing O O
several O O
key O O
components O O
of O O
growth B B_GENE
factor I I_GENE
receptor I I_GENE
kinase I I_GENE
- O O
signaling O O
pathways O O
including O O
EGF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
PDGF B B_GENE
receptor I I_GENE
- I I_GENE
beta I I_GENE
, O O
and O O
IRS B B_GENE
- I I_GENE
1 I I_GENE
. O O

These O O
two O O
enhancer O O
elements O O
also O O
enhanced O O
transcription O O
when O O
fused O O
separately O O
to O O
the O O
basal O O
promoter O O
region O O
of O O
the O O
chicken B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
vimentin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

When O O
they O O
were O O
exposed O O
to O O
intermittent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
schedules O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O O
punishment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
fixed O O
- O O
interval O B_MEASURE/B_LOCATION
[ O O
FI O B_LOCATION/B_MEASURE
] O I_MEASURE
120 O B_MEASURE
s O I_MEASURE
or O O
FI O B_MEASURE
300 O I_MEASURE
s O I_MEASURE
) O O
, O O
SIB O B_DISEASE/B_ORGANIZATION
for O O
all O O
but O O
1 O B_NUMBER[MEASURE]
of O O
the O O
participants O B_PERSON
increased O O
to O O
levels O B_MEASURE/B_LOCATION
similar O I_MEASURE/I_LOCATION
to O O
those O O
observed O O
during O O
baseline O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Deep O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
bite O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
CL O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
II O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
Div O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

Patients O B_PERSON
with O O
binocular O B_DISEASE
pregeniculate O I_DISEASE
visual O I_DISEASE
loss O I_DISEASE
, O O
patients O B_PERSON
with O O
balanced O B_DISEASE/B_GENE
binocular O I_DISEASE/I_GENE
pregeniculate O I_DISEASE/I_GENE
loss O I_DISEASE/I_GENE
without O O
RAPD O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
patients O B_PERSON/B_BIO
with O O
monocular O B_DISEASE
pregeniculate O I_DISEASE
visual O I_DISEASE
loss O I_DISEASE
had O O
significantly O O
larger O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
pupils O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
age O B_TIME[MEASURE]/B_PERSON
- O O
matched O O
controls O B_PERSON/B_BIO
. O O

Protein O O
sequencing O O
, O O
electrophoretic O O
mobility O O
shift O O
assay O O
, O O
and O O
immunoblot O O
analyses O O
identify O O
p54 B B_GENE
and O O
p47 B B_GENE
/ I I_GENE
48 I I_GENE
as O O
members O O
of O O
the O O
hepatocyte B B_GENE/B_DISEASE
nuclear I I_GENE/I_DISEASE
factor I I_GENE/I_DISEASE
3 I I_GENE/I_DISEASE
( O O
HNF3 B B_GENE/B_LOCATION
[ O O
forkhead B B_PROTEIN[GENE]/B_BIO
] O O
) O O
family O O
of O O
transcription O O
factors O O
. O O

p54 B B_GENE/B_DISEASE
belongs O O
to O O
the O O
subfamily O O
of O O
HNF3 B B_GENE/B_BIO
beta I I_GENE/I_BIO
proteins I I_GENE/I_BIO
, O O
while O O
p47 B B_GENE/B_TIME[MEASURE]
/ I I_GENE/I_TIME[MEASURE]
48 I I_GENE/I_TIME[MEASURE]
binding O O
activity O O
includes O O
HNF3 B B_GENE/B_PERSON
gamma I I_GENE/I_PERSON
. O O

In O O
this O O
cross O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
over O O
controlled O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
five O B_PERSON
male O I_PERSON
volunteers O I_PERSON
donated O O
one O B_MEASURE/B_LOCATION
unit O I_MEASURE/I_LOCATION
of O O
red O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
by O O
MCS O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
one O B_NUMBER[MEASURE]/B_ORGANIZATION
unit O I_NUMBER[MEASURE]/I_ORGANIZATION
of O O
whole O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
the O O
conventional O B_DISEASE/B_LOCATION
manual O B_DISEASE/I_LOCATION
method O B_DISEASE/I_LOCATION
, O O
3 O B_TIME[MEASURE]/B_LOCATION
months O I_TIME[MEASURE]/I_LOCATION
apart O O
. O O

Promoter O O
activity O O
was O O
assayed O O
by O O
transient O O
transfection O O
of O O
luciferase B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
reporter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
constructs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
containing O O
nested O O
deletions O O
of O O
the O O
upstream O O
sequence O O
in O O
the O O
human O O
RPE O O
cell O O
lines O O
ARPE19 O O
and O O
D407 O O
, O O
as O O
well O O
as O O
in O O
the O O
SK O O
- O O
Mel O O
- O O
28 O O
and O O
HeLa O O
cell O O
lines O O
. O O

This O O
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
exploits O O
the O O
polyomavirus O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
late O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
termination O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
polyadenylation O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
signals O I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
are O O
sufficiently O O
weak O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
allow O O
the O O
production O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
many O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
multigenome O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
- O O
length O B_MEASURE/B_GENE
primary O B_MEASURE/I_GENE
transcripts O B_MEASURE/I_GENE
with O O
repeating O O
introns O B_GENE/B_LOCATION
, O O
exons O B_GENE/B_LOCATION
, O O
and O O
poly O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
sites O B_LOCATION/B_ENT
. O O

Magnification O B_TIME[MEASURE]/B_PERSON
- O O
corrected O O
planimetry O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
parapapillary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
region O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O O
performed O O
according O O
to O O
Littmann O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
' O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
s O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
method O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
312 O B_PERSON/B_ENT
unselected O I_PERSON/I_ENT
eyes O I_PERSON/I_ENT
with O O
chronic O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
primary O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
open O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
- O O
angle O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
glaucoma O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
in O O
125 O B_PERSON/B_LOCATION
normal O I_PERSON/I_LOCATION
eyes O I_PERSON/I_LOCATION
of O O
an O O
age O B_MEASURE/B_LOCATION
- O O
and O O
refraction O B_DISEASE/B_MEASURE
- O O
matched O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
using O O
optic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
disk O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
photographs O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Although O O
the O O
elevated O O
signalling O O
is O O
eliminated O O
by O O
deletion O O
of O O
Ste20p B B_GENE/B_BIO
( O O
or O O
components O O
downstream O O
of O O
Ste20p B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
the O O
growth O O
and O O
morphological O O
abnormalities O O
of O O
cells O O
lacking O O
Akr1p B B_GENE/B_SPECIES[BIO]
are O O
not O O
rescued O O
by O O
deletion O O
of O O
any O O
of O O
the O O
known O O
pheromone O O
response O O
pathway O O
components O O
. O O

Southern O O
hybridization O O
of O O
genomic O O
DNA O O
from O O
WT O O
and O O
Lp B B_PROTEIN[GENE]/B_LOCATION
/ O O
Lp B B_PROTEIN[GENE]/B_LOCATION
embryos O O
failed O O
to O O
identify O O
specific O O
rearrangements O O
at O O
or O O
near O O
the O O
Nhlh1 B B_GENE/B_LOCATION
locus I I_GENE/I_LOCATION
, O O
and O O
Northern O O
RNA O O
blotting O O
and O O
RT O O
- O O
PCR O O
evaluation O O
of O O
Nhlh1 B B_GENE
mRNA I I_GENE
expression O O
indicated O O
that O O
both O O
the O O
levels O O
and O O
types O O
of O O
Nhlh1 B B_GENE
mRNAs I I_GENE
produced O O
in O O
WT O O
and O O
Lp B B_LOCATION/B_PROTEIN[GENE]
/ O O
Lp B B_PROTEIN[GENE]/B_LOCATION
embryos O O
were O O
indistinguishable O O
. O O

In O O
addition O O
, O O
mrp17 B B_GENE/B_PERSON
- I I_GENE/I_PERSON
1 I I_GENE/I_PERSON
, O O
in O O
combination O O
with O O
some O O
mutations O O
affecting O O
another O O
mitochondrial O O
ribosomal O O
protein O O
, O O
caused O O
a O O
synthetic O O
defective O O
phenotype O O
. O O

Expression O O
, O O
characterization O O
, O O
and O O
genomic O O
structure O O
of O O
carp B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
JAK1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Significantly O O
, O O
the O O
murine B B_GENE/B_BIO
P I I_GENE/I_BIO
- I I_GENE/I_BIO
selectin I I_GENE/I_BIO
gene I I_GENE/I_BIO
had O O
several O O
features O O
not O O
found O O
in O O
the O O
human O O
gene O O
. O O

Fluorescent O O
in O O
situ O O
hybridization O O
( O O
FISH O O
) O O
analysis O O
showed O O
that O O
the O O
novel O O
regions O O
involved O O
in O O
the O O
NFKB2 B B_GENE
rearrangement O O
originated O O
from O O
chromosome O O
7q34 O O
, O O
thus O O
implying O O
the O O
occurrence O O
of O O
a O O
t O O
( O O
7 O O
; O O
10 O O
) O O
( O O
q34 O O
; O O
q24 O O
) O O
reciprocal O O
chromosomal O O
translocation O O
. O O

Transient O O
- O O
expression O O
assay O O
analysis O O
of O O
subclones O O
of O O
pPstI O O
- O O
G O O
localized O O
the O O
trans O O
- O O
active O O
factor O O
to O O
a O O
3 B B_GENE
. I I_GENE
0 I I_GENE
- I I_GENE
kilobase I I_GENE
XbaI I I_GENE
fragment I I_GENE
. O O

MGF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
novel O O
member O O
of O O
the O O
cytokine B B_ORGANIZATION/B_LOCATION
- I I_ORGANIZATION/I_LOCATION
regulated I I_ORGANIZATION/I_LOCATION
transcription I I_ORGANIZATION/I_LOCATION
factor I I_ORGANIZATION/I_LOCATION
gene I I_ORGANIZATION/I_LOCATION
family I I_ORGANIZATION/I_LOCATION
. O O

This O O
is O O
the O O
first O O
report O O
that O O
the O O
PH B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domain I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
an O O
IRS B B_GENE/B_DISEASE
protein I I_GENE/I_DISEASE
can O O
function O O
in O O
a O O
dominant O O
negative O O
manner O O
to O O
inhibit O O
insulin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O O
. O O

A O O
29 O B_MEASURE
. O O
425 O B_MEASURE
kb O I_MEASURE
segment O I_MEASURE
on O O
the O O
left O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
arm O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
of O O
yeast O B_GENE/B_SPECIES[BIO]
chromosome O B_GENE/I_SPECIES[BIO]
XV O B_GENE/I_SPECIES[BIO]
contains O O
more O B_MEASURE
than O O
twice O O
as O O
many O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
unknown O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
as O O
known O O
open O B_GENE/B_BIO
reading O I_GENE/I_BIO
frames O I_GENE/I_BIO
. O O

This O O
result O O
, O O
together O O
with O O
the O O
fact O O
that O O
unrearranged B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
V I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
kappa I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
genes I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O O
transcriptionally O O
silent O O
, O O
suggests O O
that O O
structural O O
features O O
of O O
both O O
the O O
V B B_PROTEIN[GENE]
kappa I I_PROTEIN[GENE]
and O O
C B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
loci I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contribute O O
to O O
the O O
overall O O
transcriptional O O
efficiency O O
of O O
a O O
rearranged O O
V B B_MEASURE/B_DISEASE
kappa I B_MEASURE/I_DISEASE
- O O
C B B_GENE
kappa I I_GENE
gene O O
. O O

The O O
first O B_GENE/B_LOCATION
270 O I_GENE/I_LOCATION
bp O I_GENE/I_LOCATION
of O O
the O O
promoter O B_GENE/B_LOCATION
region O I_GENE/I_LOCATION
were O O
sequenced O O
and O O
found O O
to O O
contain O O
a O O
CATAA O B_GENE/B_DISEASE
box O B_GENE/I_DISEASE
rather O O
than O O
a O O
TATAA O B_GENE/B_LOCATION
box O I_GENE/I_LOCATION
and O O
several O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
DNA O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
motifs O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
found O O
in O O
activation O B_GENE/B_SPECIES[BIO]
genes O B_GENE/I_SPECIES[BIO]
. O O

C O O
. O O
glabrata O O
cells O O
containing O O
the O O
CBF1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
under O O
the O O
influence O O
of O O
a O O
shutdown O O
promoter O O
( O O
tetO O O
- O O
ScHOP O O
) O O
arrested O O
their O O
growth O O
after O O
5 O O
h O O
of O O
cultivation O O
in O O
the O O
presence O O
of O O
the O O
reactive O O
drug O O
doxycycline O O
. O O

SF1 B B_GENE/B_LOCATION
/ O O
mBBP B B_MEASURE/B_PROTEIN[GENE]
utilizes O O
a O O
" B B_GENE/B_MEASURE
maxi I I_GENE/I_MEASURE
- I I_GENE/I_MEASURE
K I I_GENE/I_MEASURE
homology I I_GENE/I_MEASURE
" I I_GENE/I_MEASURE
( O O
maxi B B_PROTEIN[GENE]/B_LOCATION
- I I_PROTEIN[GENE]/I_LOCATION
KH I I_PROTEIN[GENE]/I_LOCATION
) O O
domain O O
for O O
recognition O O
of O O
the O O
single O O
- O O
stranded O O
BPS O O
and O O
requires O O
a O O
cooperative O O
interaction O O
with O O
splicing O O
factor O O
U2AF65 B B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bound O O
to O O
an O O
adjacent O O
polypyrimidine O O
tract O O
( O O
PPT O O
) O O
for O O
high O O
- O O
affinity O O
binding O O
. O O

An O O
X O O
- O O
linked O O
zinc B B_GENE/B_DISEASE
finger I B_GENE/I_DISEASE
gene I B_GENE/I_DISEASE
mapping O O
to O O
Xq21 O O
. O O
1 O O
- O O
q21 O O
. O O
3 O O
closely O O
related O O
to O O
ZFX B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
ZFY B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
: O O
possible O O
origins O O
from O O
a O O
common O O
ancestral O O
gene O O
. O O

Validity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
short O B_NUMBER[MEASURE]
- O O
form O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
QIF O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
assessed O O
by O O
correlation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O O
motor O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scores O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
using O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
variance O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
motor O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
motor O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
score O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
groupings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Juvenile O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
angiofibromas O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

Comment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O O
" O O
Critical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
binary O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mixture O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
protein O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
and O O
salt O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
water O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
" O O

The O O
pineal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
melatonin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
MLT O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
able O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
exert O O
an O O
oncostatic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
action O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

In O O
addition O O
, O O
there O O
was O O
an O O
increase O O
in O O
the O O
amount O O
of O O
p120 B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
Ras I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
specific O O
GTPase B B_GENE
- I I_GENE
activating I I_GENE
protein I I_GENE
( O O
GAP B B_LOCATION/B_GENE
) O O
and O O
GAP B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
- O O
associated O O
p190 O O
. O O

Additional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transection O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
both O O
ADN O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
eliminated O O
the O O
remaining O O
sigmoidal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
correlation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
between O O
MAP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
RSNA O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
further O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increases O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
resting O O
MAP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
RSNA O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Pregnancy O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
ensued O O
in O O
4 O B_TIME[MEASURE]
cases O I_TIME[MEASURE]
in O O
group O B_ORGANIZATION/B_MEASURE
I O O
. O O

The O O
1 O O
. O O
3 O O
- O O
kb O O
DNA O O
, O O
when O O
placed O O
upstream O O
of O O
the O O
chloramphenicol B B_GENE/B_BIO
acetyltransferase I I_GENE/I_BIO
gene I I_GENE/I_BIO
, O O
was O O
shown O O
to O O
be O O
functionally O O
active O O
. O O

Controversy O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
exists O O
regarding O O
both O O
the O O
natural O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
life O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cycle O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
this O O
parasite O B_SPECIES[BIO]
as O O
well O O
as O O
the O O
species O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
identity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
opossum O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
Sarcocystis O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
mean O B_MEASURE
was O O
66 O B_MEASURE
cells O I_MEASURE
/ O O
mm2 O B_MEASURE
in O O
the O O
laser O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O O
63 O B_MEASURE
. O O
7 O B_MEASURE
cells O I_MEASURE
/ O O
mm2 O B_MEASURE
in O O
the O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

Prazosin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
high O B_DISEASE/B_GENE
blood O I_DISEASE/I_GENE
pressure O I_DISEASE/I_GENE

The O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
HT3 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
antagonist O O
ondansetron O O
reduced O O
alcohol O O
intake O O
in O O
both O O
the O O
medium O O
and O O
high O O
alcohol O O
preferring O O
rats O O
at O O
doses O O
between O O
0 O O
. O O
01 O O
and O O
0 O O
. O O
16 O O
mg O O
/ O O
kg O O
. O O

Oral O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
hypoglycemic O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
agents O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]

1 O B_NUMBER[MEASURE]
. O O

In O O
this O O
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
enhancers O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
act O O
primarily O O
to O O
increase O O
the O O
probability O B_MEASURE
of O O
rapid O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
efficient O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transcription O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
complex O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
formation O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
initiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
. O O

The O O
relationship O O
between O O
donor O O
status O O
for O O
antibody O O
to O O
hepatitis B B_DISEASE
B I I_DISEASE
core I I_DISEASE
antigen I I_DISEASE
and O O
the O O
occurrence O O
of O O
non O O
- O O
A O O
, O O
non O O
- O O
B O O
posttransfusion O O
hepatitis O O
in O O
the O O
recipient O O
was O O
prospectively O O
studied O O
in O O
112 O O
patients O O
undergoing O O
open O O
- O O
heart O O
surgery O O
who O O
were O O
followed O O
for O O
6 O O
. O O
5 O O
months O O
after O O
surgery O O
. O O

By O O
sequencing O O
of O O
exonuclease B B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
III I I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
deletion O O
clones O O
an O O
open O O
reading O O
frame O O
of O O
405 O O
nucleotides O O
was O O
found O O
coding O O
for O O
a O O
protein O O
of O O
135 O O
amino O O
acids O O
with O O
a O O
molecular O O
mass O O
of O O
15 O O
kDa O O
. O O

The O O
pepI B B_GENE
gene I I_GENE
was O O
overexpressed O O
in O O
Escherichia O O
coli O O
. O O

Treatment O O
of O O
steroid O O
resistant O O
rejection O O
following O O
renal O O
transplantation O O
: O O
benefits O O
and O O
risks O O
of O O
OKT3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
therapy O O
. O O

The O O
level O B_MEASURE/B_LOCATION
of O O
transcription O B_TIME[MEASURE]/B_GENE
generated O O
by O O
all O O
of O O
these O O
activators O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
greater O B_MEASURE
than O O
the O O
sum O B_MEASURE/B_LOCATION
of O O
the O O
levels O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
generated O O
by O O
individual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
factors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
a O O
phenomenon O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
designated O O
transcriptional O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synergy O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Conservation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
zinc O B_LOCATION/B_GENE
finger O B_LOCATION/I_GENE
motif O B_LOCATION/I_GENE
from O O
yeast O B_SPECIES[BIO]
to O O
mouse O B_SPECIES[BIO]/B_DISEASE
and O O
human O B_SPECIES[BIO]/B_PERSON
implies O O
functional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
importance O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
nuclear O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
/ O O
organellar O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
gene O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
transfer O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
event O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
is O O
strikingly O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
experimentally O O
accessible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
process O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
nuclear O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
integration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
introduced O O
heterologous O B_GENE/B_BIO
DNA O I_GENE/I_BIO
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
In O O
the O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
set O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O O
the O O
single O B_NUMBER[MEASURE]
- O O
sample O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
model O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
was O O
confirmed O O
to O O
give O O
excellent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
estimation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
AUC O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
AUC O B_MEASURE/B_LOCATION
( O O
mg O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
ml O B_MEASURE/B_PERSON
x O O
min O B_TIME[MEASURE]/B_PERSON
) O O
= O O
0 O B_MEASURE
. O O
93 O B_MEASURE
x O O
C3h O B_MEASURE
+ O O
0 O B_MEASURE
. O O
47 O B_MEASURE
( O O
MPE O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
= O O
4 O B_MEASURE
. O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
RMSE O B_MEASURE/B_LOCATION
% O B_MEASURE/I_LOCATION
= O O
8 O B_MEASURE
. O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
. O O

SH3A B B_GENE
competes O O
with O O
the O O
SH3 B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domains I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Grb2 B B_GENE
in O O
binding O O
to O O
mSos1 B B_GENE
, O O
and O O
the O O
intersectin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mSos1 B B_GENE
complex O O
can O O
be O O
separated O O
from O O
Grb2 B B_GENE
by O O
sucrose O O
gradient O O
centrifugation O O
. O O

Comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
between O O
the O O
Ricketts O B_PERSON/B_SPECIES[BIO]
and O O
Bimler O B_PERSON/B_ORGANIZATION
therapeutic O I_PERSON/I_ORGANIZATION
technics O I_PERSON/I_ORGANIZATION
in O O
the O O
treatment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
cases O B_PERSON/B_DISEASE
of O O
class O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
division O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
I O O
mmalocclusion O O

This O O
resulted O O
in O O
a O O
shift O O
of O O
C1 O O
/ O O
C2 O O
, O O
so O O
that O O
the O O
effect O O
of O O
collagen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
more O O
pronounced O O
( O O
maximal O O
increase O O
of O O
C1 O O
/ O O
C2 O O
= O O
134 O O
% O O
) O O
than O O
ADP O O
( O O
maximal O O
increase O O
of O O
C1 O O
/ O O
C2 O O
= O O
79 O O
% O O
) O O
. O O

We O O
conclude O O
that O O
exercise O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
ST O B_MEASURE/B_LOCATION
- O O
segment O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
elevation O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O O
patients O B_PERSON/B_BIO
without O O
a O O
history O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
myocardial O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
left O O
ventricular O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
aneurysm O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
is O O
caused O O
by O O
coronary O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
spasm O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
a O O
major O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
coronary O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
vessel O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Xnr3 B B_GENE
is O O
transcriptionally O O
activated O O
by O O
wnt B B_GENE
signaling O O
during O O
gastrulation O O
in O O
the O O
Xenopus O O
embryo O O
. O O

For O O
economical O B_PERSON/B_TIME[MEASURE]
reasons O I_PERSON/I_TIME[MEASURE]
, O O
we O O
could O O
not O O
send O O
a O O
questionnaire O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
all O O
the O O
35 O B_MEASURE
, O O
779 O B_MEASURE/B_PERSON
individuals O I_MEASURE/I_PERSON
, O O
but O O
based O O
the O O
investigation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
on O O
a O O
SRS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
4 O B_MEASURE
, O O
000 O B_MEASURE/B_SPORT[ENT]
men O I_MEASURE/I_SPORT[ENT]
, O O
post O B_LOCATION/B_DISEASE
- O O
stratified O O
in O O
a O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
a O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
risk O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Several O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
waveforms O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
both O O
the O O
somatosensory O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
N20 O B_LOCATION/B_PROTEIN[GENE]
, O O
P O B_OTHER/B_PROTEIN[GENE]
/ O O
N O B_MEASURE/B_PROTEIN[GENE]
30 O I_MEASURE/I_PROTEIN[GENE]
, O O
and O O
P200 O B_PROTEIN[GENE]/B_MEASURE
) O O
and O O
the O O
brainstem O B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
auditory O I_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
evoked O O
response O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
I O B_OTHER/B_PROTEIN[GENE]
, O O
III O B_TIME[MEASURE]/B_PROTEIN[GENE]
, O O
IV O B_TIME[MEASURE]/B_PROTEIN[GENE]
, O O
and O O
V O B_OTHER/B_PROTEIN[GENE]
) O O
demonstrated O O
shorter O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
p O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
latencies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
growth O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
retarded O O
fetuses O B_PERSON
relative O I_PERSON
to O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
sized O B_BIO/B_TIME[MEASURE]
fetuses O B_BIO/I_TIME[MEASURE]
. O O

Effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
choline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
magnesium O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trisalicylate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
prostacyclin O B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
production O B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
by O O
isolated O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
vascular O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
tissue O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
rat O B_SPECIES[BIO]/B_GENE
. O O

The O O
sequences O O
of O O
two O O
previously O O
known O O
tail B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
R B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
S B B_PROTEIN[GENE]/B_DISEASE
, O O
of O O
the O O
temperate O O
bacteriophage O O
P2 O O
and O O
the O O
sequence O O
of O O
an O O
additional O O
open O O
reading O O
frame O O
( O O
orf O O
- O O
30 O O
) O O
located O O
between O O
S B B_OTHER/B_PROTEIN[GENE]
and O O
V B B_PROTEIN[GENE]/B_LOCATION
, O O
were O O
determined O O
. O O

The O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prevalence O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
atrial O B_DISEASE/B_LOCATION
septal O I_DISEASE/I_LOCATION
defect O I_DISEASE/I_LOCATION
in O O
tetralogy O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
of O O
Fallot O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
is O O
cited O O
as O O
a O O
possible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analogy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O O
right O B_DISEASE/B_MEASURE
ventricular O I_DISEASE/I_MEASURE
pressure O I_DISEASE/I_MEASURE
is O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O O
right O B_MEASURE/B_DISEASE
ventricular O B_MEASURE/I_DISEASE
compliance O B_MEASURE/I_DISEASE
is O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
from O O
birth O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
stress O B_DISEASE
/ O O
BHV O B_DISEASE/B_PROTEIN[GENE]
- O O
1 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
model O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
resulted O O
in O O
a O O
mild O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
respiratory O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infection O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
all O O
calves O B_PERSON/B_LOCATION
with O O
no O O
difference O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observed O O
between O O
treatment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Solution O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
Boltzmann O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
equation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
a O O
random O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
magnetic O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
field O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

GH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
signals O O
by O O
interacting O O
with O O
GH B B_GENE
receptor I I_GENE
( O O
GHR B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Ultraviolet O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
crosslinking O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
element O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
B O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
revealed O O
the O O
specific O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
binding O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
two O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
approximately O O
43 O B_MEASURE
and O O
80 O B_MEASURE
kDa O I_MEASURE
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
At O O
short O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dwell O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
times O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
uncorrected O B_MEASURE
( O O
whole O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
plasma O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
) O O
D O B_OTHER/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
P O B_OTHER/B_PROTEIN[GENE]
and O O
Cp O B_LOCATION/B_PROTEIN[GENE]
of O O
urea O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
the O O
corrected O O
( O O
plasma O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
water O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
) O O
values O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
by O O
5 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
- O O
5 O B_MEASURE
. O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
. O O

The O O
recovery O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
xanthomegnin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
added O O
to O O
corn O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
levels O B_MEASURE/B_GENE
of O O
0 O B_MEASURE
. O O
75 O B_MEASURE
- O O
- O O
9 O B_MEASURE
. O O
6 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
averaged O O
41 O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
with O O
a O O
coefficient O B_MEASURE/B_LOCATION
of O O
variation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
25 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
. O O

The O O
extraordinary O O
high O O
substrate O O
specificity O O
of O O
rPulA B B_PROTEIN[GENE]/B_SPECIES[BIO]
together O O
with O O
its O O
thermal O O
stability O O
makes O O
this O O
enzyme O O
a O O
good O O
candidate O O
for O O
biotechnological O O
applications O O
in O O
the O O
starch O O
- O O
processing O O
industry O O
. O O

A O O
relationship O B_PERSON/B_MEASURE
between O O
the O O
immunological O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
changes O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
disease O B_DISEASE
stage O I_DISEASE
was O O
discovered O O
: O O
the O O
index O B_MEASURE
of O O
the O O
3H O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
thymidine O B_MEASURE/B_LOCATION
incorporation O I_MEASURE/I_LOCATION
was O O
found O O
to O O
be O O
67 O B_MEASURE
. O O
9 O B_MEASURE
at O O
the O O
stage O B_ENT/B_MEASURE
of O O
disease O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
exacerbation O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
208 O B_MEASURE
. O O
8 O B_MEASURE
at O O
the O O
stage O B_ENT/B_MEASURE
of O O
remission O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
; O O
the O O
complement O B_MEASURE
titre O I_MEASURE
reached O O
, O O
respectively O O
, O O
46 O B_MEASURE
. O O
64 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
5 O B_MEASURE
. O O
28 O B_MEASURE
and O O
112 O B_MEASURE
. O O
0 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
6 O B_MEASURE
. O O
0 O B_MEASURE
units O I_MEASURE
per O O
ml O B_TIME[MEASURE]/B_PERSON
. O O

Sodium O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dodecylsulfate O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
polyacrylamide O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
gel O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
electrophoresis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
SDS O B_PERSON/B_PROTEIN[GENE]
- O O
PAGE O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
showed O O
two O B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bands O B_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
about O O
the O O
same O B_MEASURE/B_LOCATION
intensity O I_MEASURE/I_LOCATION
with O O
apparent O B_MEASURE/B_LOCATION
molecular O I_MEASURE/I_LOCATION
masses O I_MEASURE/I_LOCATION
of O O
24 O B_MEASURE
. O O
5 O B_MEASURE
and O O
22 O B_MEASURE
. O O
5 O B_MEASURE
kDa O I_MEASURE
. O O

Consistent O O
with O O
an O O
effect O O
on O O
transcription O O
, O O
p21 B B_GENE
was O O
localized O O
in O O
nuclei O O
of O O
transfected O O
cells O O
. O O

Analysis O O
of O O
pseudo B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
VH I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
gene I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
segment I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
recombination I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
products I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
reveals O O
no O O
bias O O
in O O
D B B_MEASURE/B_GENE
gene I I_MEASURE/I_GENE
segment I I_MEASURE/I_GENE
reading O O
frame O O
utilization O O
. O O

Plasma B B_GENE/B_MEASURE
prolactin I B_GENE/I_MEASURE
concentrations O O
during O O
incubation O O
, O O
25 O O
. O O
8 O O
+ O O
/ O O
- O O
2 O O
. O O
3 O O
ng O O
/ O O
ml O O
, O O
decreased O O
to O O
baseline O O
levels O O
, O O
10 O O
. O O
8 O O
+ O O
/ O O
- O O
1 O O
. O O
9 O O
ng O O
/ O O
ml O O
, O O
within O O
24 O O
hr O O
after O O
nestbox O O
removal O O
. O O

After O O
30 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
weeks O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
amifostine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
the O O
morphology O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
MDS O B_DISEASE
switched O O
to O O
a O O
chronic O B_DISEASE_ADJECTIVE[DISEASE]
myelomonocytic O I_DISEASE_ADJECTIVE[DISEASE]
leukemia O I_DISEASE_ADJECTIVE[DISEASE]
( O O
CMML O B_DISEASE/B_LOCATION
) O O
- O O
like O B_DISEASE/B_MEASURE
appearance O I_DISEASE/I_MEASURE
, O O
with O O
continuously O O
increasing O O
leukocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
, O O
so O O
that O O
we O O
discontinued O O
amifostine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
1 O B_TIME[MEASURE]
month O I_TIME[MEASURE]
to O O
exclude O O
a O O
possible O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
amifostine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Heart O B_DISEASE_ADJECTIVE[DISEASE]
disease O I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
new O O
B O O
- O O
cell O O
- O O
specific O O
enhancer O O
element O O
has O O
been O O
identified O O
3 O O
' O O
of O O
E4 B B_GENE/B_MEASURE
and O O
the O O
octamerlike O O
motifs O O
in O O
the O O
human B B_GENE/B_BIO
immunoglobulin I I_GENE/I_BIO
heavy I I_GENE/I_BIO
- I I_GENE/I_BIO
chain I I_GENE/I_BIO
gene I I_GENE/I_BIO
enhancer I I_GENE/I_BIO
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
This O O
initial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
experience O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
indicates O O
that O O
there O O
is O O
short O B_PERSON/B_MEASURE
- O O
to O O
middle O B_MEASURE/B_PERSON
- O O
term O B_MEASURE/B_DISEASE
efficiency O I_MEASURE/I_DISEASE
and O O
safety O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
when O O
using O O
GKS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
treat O O
MTLE O B_DISEASE/B_GENE
. O O

Two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cases O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
Paraquat O B_DISEASE
poisoning O I_DISEASE
of O O
anticonservative O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
origin O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
described O O
. O O

Genetic O O
mutation O O
or O O
loss O O
of O O
activin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
transforming B B_GENE/B_LOCATION
growth I I_GENE/I_LOCATION
factor I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
beta I I_GENE/I_LOCATION
( I I_GENE/I_LOCATION
TGFbeta I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
receptor I I_GENE/I_LOCATION
function O O
has O O
been O O
shown O O
in O O
human O O
lymphoid O O
, O O
breast O O
, O O
and O O
colorectal O O
tumors O O
as O O
well O O
as O O
Hep2B O O
and O O
Mv1Lu O O
cell O O
lines O O
. O O

A O O
poly O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ortho O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ester O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
designed O O
for O O
combined O O
ocular O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
delivery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
5 O B_MEASURE
- O O
fluorouracil O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
: O O
subconjunctival O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tolerance O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
release O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
. O O

We O O
now O O
describe O O
a O O
HepG2 B B_GENE/B_LOCATION
cell I I_GENE/I_LOCATION
casein I I_GENE/I_LOCATION
kinase I I_GENE/I_LOCATION
II I I_GENE/I_LOCATION
beta I I_GENE/I_LOCATION
subunit I I_GENE/I_LOCATION
cDNA I I_GENE/I_LOCATION
of O O
2 O O
. O O
57 O O
kb O O
containing O O
96 O O
bases O O
of O O
5 O O
' O O
untranslated O O
sequence O O
, O O
645 O O
bases O O
of O O
open O O
reading O O
frame O O
, O O
and O O
1832 O O
bases O O
of O O
3 O O
' O O
untranslated O O
sequence O O
with O O
two O O
polyadenylation O O
consensus O O
signal O O
sequences O O
and O O
two O O
poly O O
( O O
A O O
) O O
stretches O O
. O O

Brome B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mosaic I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
polymerase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
like O O
protein B B_GENE
2a I I_GENE
is O O
directed O O
to O O
the O O
endoplasmic O O
reticulum O O
by O O
helicase B B_GENE
- O O
like O O
viral B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
protein I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
1a I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
. O O

Diagnostic O O
importance O O
of O O
determining O O
leucine B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
aminotransferase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
in O O
acute O O
pancreatitis O O

Therapeutic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
iodine O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
125 O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
hyperthyroidism O B_DISEASE
: O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
a O O
special O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
radiobiological O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
effect O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
on O O
the O O
follicular O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
cell O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O O

Maintenance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
metabolizable O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
- O O
energy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
ME O B_DISEASE/B_PROTEIN[GENE]
) O O
requirement O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
averaged O O
31 O B_MEASURE
. O O
0 O B_MEASURE/B_LOCATION
kcal O I_MEASURE/I_LOCATION
/ O O
kg O B_MEASURE
body O I_MEASURE
wt O I_MEASURE
. O O

This O O
finding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
of O O
importance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
because O O
it O O
completes O O
an O O
explanation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
central O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
near O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
location O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
errors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
partial O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
- O O
report O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
bar O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O O
probe O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
task O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

A O O
DNA O B_GENE/B_LOCATION
binding O I_GENE/I_LOCATION
protein O I_GENE/I_LOCATION
was O O
identified O O
which O O
binds O O
to O O
two O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
novel O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
like O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequences O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O O
( O O
i O O
) O O
at O O
the O O
5 O B_NUMBER[MEASURE]
' O O
flanking O O
site O B_LOCATION/B_MEASURE
of O O
the O O
breakpoint O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
junction O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
chromosome O B_GENE/B_DISEASE
8 O I_GENE/I_DISEASE
in O O
a O O
patient O B_PERSON/B_LOCATION
with O O
T O B_PROTEIN[GENE]/B_DISEASE
- O O
acute O B_DISEASE
lymphoblastic O I_DISEASE
leukemia O I_DISEASE
( O O
ALL O B_DISEASE/B_NUMBER[MEASURE]
) O O
carrying O O
the O O
t O B_DISEASE/B_GENE
( O O
8 O B_NUMBER[MEASURE]
; O O
14 O B_MEASURE
) O O
( O O
q24 O O
; O O
q11 O O
) O O
rearrangement O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
and O O
( O O
ii O B_TIME[MEASURE]/B_PROTEIN[GENE]
) O O
on O O
chromosome O B_GENE/B_MEASURE
1 O I_GENE/I_MEASURE
in O O
three O B_NUMBER[MEASURE]/B_PERSON
of O O
five O B_DISEASE/B_PROTEIN[GENE]
T O B_DISEASE/I_PROTEIN[GENE]
- O O
ALL O B_LOCATION/B_DISEASE
patients O I_LOCATION/I_DISEASE
with O O
the O O
t O B_DISEASE/B_GENE
( O O
1 O B_NUMBER[MEASURE]
; O O
14 O B_MEASURE
) O O
( O O
p32 O B_MEASURE/B_GENE
; O O
q11 O B_MEASURE
) O O
rearrangement O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. O O

Nedocromil O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
sodium O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
shifted O O
the O O
severity O B_MEASURE
of O O
the O O
early O B_DISEASE
allergic O I_DISEASE
reaction O I_DISEASE
( O O
EAR O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
) O O
from O O
mean O B_MEASURE/B_LOCATION
- O O
34 O B_MEASURE
. O O
8 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
to O O
- O O
6 O B_MEASURE
. O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
and O O
inhibited O O
the O O
later O B_DISEASE_ADJECTIVE[DISEASE]
allergic O I_DISEASE_ADJECTIVE[DISEASE]
reaction O I_DISEASE_ADJECTIVE[DISEASE]
( O O
LAR O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
) O O
from O O
- O O
30 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
to O O
+ O O
0 O B_MEASURE
. O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
( O O
p O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE
. O O
005 O B_MEASURE
) O O
. O O

The O O
Mer1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contains O O
the O O
KH O O
motif O O
found O O
in O O
some O O
RNA O O
- O O
binding O O
proteins O O
, O O
and O O
RNA O O
gel O O
mobility O O
shift O O
assays O O
demonstrate O O
that O O
Mer1 B B_GENE/B_BIO
binds O O
specifically O O
to O O
MER2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
obtained O O
from O O
the O O
tritium O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
test O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
direct O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
chemical O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
analysis O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
compared O O
. O O

We O O
found O O
that O O
in O O
anesthetized O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
, O O
paralyzed O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
cats O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
visual O B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evoked O O
potential O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
VEP O B_DISEASE/B_PROTEIN[GENE]
) O O
was O O
dependent O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
only O O
on O O
magnitude O B_MEASURE
of O O
delta O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
at O O
each O O
pattern O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transition O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
was O O
independent O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
starting O B_TIME[MEASURE]/B_LOCATION
or O O
ending O O
contrast O B_MEASURE/B_LOCATION
level O B_MEASURE/I_LOCATION
. O O

Experiment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
B O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
: O O
Clinical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
biochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
histological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
variables O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O O
measured O O
over O O
a O O
12 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]/B_LOCATION
period O I_TIME[MEASURE]/I_LOCATION
after O O
the O O
zymosan O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
had O O
been O O
given O O
. O O

Direct O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
saturation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]

From O O
this O O
asymmetry O O
, O O
we O O
suggested O O
previously O O
that O O
GCN4 B B_GENE
interacts O O
with O O
nonequivalent O O
and O O
possibly O O
overlapping O O
half O O
- O O
sites O O
( O O
ATGAC O O
and O O
ATGAG O O
) O O
that O O
have O O
different O O
affinities O O
. O O

Furthermore O O
the O O
aldosterone O O
stimulating O O
effect O O
of O O
low O O
sodium O O
diet O O
( O O
17 O O
children O O
) O O
, O O
severe O O
and O O
prolonged O O
vomiting O O
( O O
19 O O
children O O
) O O
and O O
synthetic O O
ACTH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
10 O O
children O O
) O O
has O O
been O O
studied O O
by O O
our O O
modified O O
method O O
. O O

A O O
case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
1 O B_MEASURE
: O O
2 O B_MEASURE
) O O
of O O
182 O B_MEASURE/B_PERSON
pairs O I_MEASURE/I_PERSON
of O O
Hepatitis O B_PERSON/B_DISEASE
A O I_PERSON/I_DISEASE
was O O
carried O O
out O O
in O O
Weng O B_PERSON/B_LOCATION
- O O
ling O B_PERSON/B_LOCATION
Zhe O I_PERSON/I_LOCATION
- O O
jiang O B_PERSON/B_LOCATION
during O O
April O B_TIME[MEASURE]/B_PERSON
1988 O I_TIME[MEASURE]/I_PERSON
. O O

The O O
mutant O O
strain O O
carries O O
three O O
tandem O O
copies O O
of O O
the O O
18 O O
bp O O
sequence O O
that O O
is O O
duplicated O O
in O O
the O O
amdI66 B B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutation O O
. O O

Although O O
cDNA O O
encoding O O
a O O
human B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
phagocyte I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
formyl I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
peptide I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
has O O
been O O
reported O O
recently O O
( O O
Boulay O O
, O O
F O O
. O O
, O O
Tardif O O
, O O
M O O
. O O
, O O
Brouchon O O
, O O
L O O
. O O
, O O
and O O
Vignais O O
, O O
P O O
. O O

In O O
NIH O O
3T3 O O
fibroblasts O O
the O O
high O O
affinity O O
IL B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2R I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bearing O O
a O O
deletion O O
of O O
a O O
region O O
rich O O
in O O
acidic O O
amino O O
acids O O
( O O
the O O
" O O
acidic O O
" O O
region O O
) O O
in O O
the O O
IL B B_GENE
- I I_GENE
2R I I_GENE
beta I I_GENE
- I I_GENE
chain I I_GENE
failed O O
to O O
induce O O
the O O
tyrosine O O
phosphorylation O O
of O O
MAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
well O O
as O O
the O O
expression O O
of O O
the O O
all O O
three O O
nuclear O O
proto O O
- O O
oncogenes O O
. O O

A O O
small O O
molecule O O
ILK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
inhibitor O O
suppresses O O
the O O
phosphorylation O O
of O O
PKB B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
the O O
Ser O O
- O O
473 O O
but O O
not O O
the O O
Thr O O
- O O
308 O O
site O O
in O O
the O O
PTEN B B_GENE/B_DISEASE
mutant O O
cells O O
. O O

The O O
avian O O
carcinoma O O
virus O O
MH2 O O
contains O O
a O O
hybrid O O
gene O O
delta B B_PROTEIN[GENE]/B_VIRUS[BIO]
gag I I_PROTEIN[GENE]/I_VIRUS[BIO]
- O O
mht B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
a O O
contiguous O O
open O O
reading O O
frame O O
of O O
2682 O O
base O O
pairs O O
as O O
well O O
as O O
v B B_SPECIES[BIO]/B_GENE
- I I_SPECIES[BIO]/I_GENE
myc I I_SPECIES[BIO]/I_GENE
and O O
avian O O
helper O O
virus O O
- O O
related O O
sequences O O
. O O
delta B B_GENE/B_VIRUS[BIO]
gag I I_GENE/I_VIRUS[BIO]
is O O
a O O
partial O O
retroviral B B_GENE
core I I_GENE
protein I I_GENE
gene I I_GENE
while O O
v B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mht I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
v B B_GENE
- I I_GENE
myc I I_GENE
are O O
cell O O
- O O
drived O O
sequences O O
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
untreated O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
patients O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
demonstrate O O
the O O
primary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
importance O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
bulk O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
initial O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
laparotomy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Of O O
3841 O O
serum O O
samples O O
from O O
sows O O
received O O
from O O
the O O
Tennessee O O
State O O
Diagnostic O O
Laboratory O O
in O O
1991 O O
- O O
1992 O O
, O O
1130 O O
were O O
positive O O
for O O
Toxoplasma B B_DISEASE
gondii I I_DISEASE
antibody I I_DISEASE
. O O

These O O
findings O O
also O O
demonstrate O O
that O O
unless O O
excluded O O
by O O
other O O
factors O O
, O O
the O O
C B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
likely O O
to O O
be O O
located O O
along O O
the O O
length O O
of O O
nascent O O
transcripts O O
. O O

In O O
this O O
group O O
of O O
patients O O
, O O
the O O
mean O O
LH B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
9 O O
. O O
3 O O
+ O O
/ O O
- O O
5 O O
. O O
9 O O
IU O O
/ O O
l O O
) O O
and O O
sex B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
hormone I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
globulin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
SHBG B B_GENE/B_LOCATION
) O O
( O O
54 O O
. O O
5 O O
+ O O
/ O O
- O O
22 O O
. O O
9 O O
nmol O O
/ O O
l O O
) O O
concentrations O O
were O O
significantly O O
greater O O
than O O
those O O
of O O
five O O
normal O O
control O O
subjects O O
( O O
4 O O
. O O
7 O O
+ O O
/ O O
- O O
1 O O
. O O
11 O O
IU O O
/ O O
l O O
and O O
26 O O
. O O
0 O O
+ O O
/ O O
- O O
7 O O
. O O
0 O O
nmol O O
/ O O
l O O
respectively O O
) O O
. O O

We O O
have O O
now O O
completed O O
the O O
primary O O
structure O O
of O O
fibrillin B B_GENE
, O O
elucidated O O
the O O
exon O O
/ O O
intron O O
organization O O
of O O
the O O
gene O O
and O O
derived O O
a O O
physical O O
map O O
of O O
the O O
genetic O O
locus O O
. O O

The O O
BCL B B_GENE/B_SPECIES[BIO]
- I B_GENE/I_SPECIES[BIO]
6 I B_GENE/I_SPECIES[BIO]
POZ O O
domain O O
and O O
other O O
POZ O O
domains O O
interact O O
with O O
the O O
co O O
- O O
repressors O O
N B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CoR I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
SMRT B B_GENE/B_LOCATION
. O O

Cytokine O O
inducibility O O
of O O
VCAM1 B B_GENE/B_DISEASE
in O O
endothelial O O
cells O O
utilizes O O
the O O
interaction O O
of O O
heterodimeric O O
p50 B B_GENE
/ O O
p65 B B_GENE/B_MEASURE
proteins O O
with O O
IRF B B_GENE
- I I_GENE
1 I I_GENE
. O O

In O O
particular O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
MF O B_PERSON/B_BIO
males O I_PERSON/I_BIO
receiving O O
either O O
a O O
5 O B_MEASURE
. O O
0 O B_MEASURE
- O O
mg O B_MEASURE/B_LOCATION
/ O O
kg O B_MEASURE
CDP O I_MEASURE
dose O I_MEASURE
or O O
a O O
3 O B_MEASURE
. O O
0 O B_MEASURE
- O O
mg O B_MEASURE/B_LOCATION
/ O O
kg O B_MEASURE
RO O I_MEASURE
dose O I_MEASURE
explored O O
the O O
object O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
more O O
often O O
than O O
MM O B_PERSON
males O I_PERSON
. O O
( O O
ABSTRACT O B_TIME[MEASURE]/B_ORGANIZATION
TRUNCATED O I_TIME[MEASURE]/I_ORGANIZATION
AT O O
250 O B_LOCATION/B_MEASURE
WORDS O I_LOCATION/I_MEASURE
) O O

To O O
gain O O
additional O O
insights O O
into O O
this O O
novel O O
apoptotic O O
checkpoint O O
, O O
we O O
have O O
now O O
characterized O O
the O O
mouse B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
survivin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
locus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Both O O
proteins O O
share O O
sequence O O
similarity O O
with O O
the O O
myelin B B_GENE
- I I_GENE
associated I I_GENE
glycoprotein I I_GENE
, O O
an O O
adhesion O O
molecule O O
of O O
oligodendrocytes O O
and O O
Schwann O O
cells O O
that O O
has O O
been O O
implicated O O
in O O
the O O
process O O
of O O
myelination O O
, O O
raising O O
the O O
important O O
question O O
of O O
whether O O
myelin B B_GENE/B_BIO
- I I_GENE/I_BIO
associated I I_GENE/I_BIO
glycoprotein I I_GENE/I_BIO
is O O
also O O
a O O
sialic B B_PROTEIN[GENE]/B_PERSON
acid I I_PROTEIN[GENE]/I_PERSON
- I I_PROTEIN[GENE]/I_PERSON
binding I I_PROTEIN[GENE]/I_PERSON
protein I I_PROTEIN[GENE]/I_PERSON
. O O

Localized O O
Bicaudal B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encodes O O
a O O
protein O O
containing O O
a O O
KH O O
domain O O
, O O
the O O
RNA O O
binding O O
motif O O
of O O
FMR1 B B_GENE
. O O

To O O
facilitate O O
the O O
characterization O O
of O O
NF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
functions O O
in O O
human O O
cells O O
, O O
we O O
isolated O O
cDNAs O O
encoding O O
two O O
members O O
of O O
the O O
small B B_PERSON/B_BIO
Maf I B_PERSON/I_BIO
family I B_PERSON/I_BIO
, O O
MafK B B_LOCATION/B_GENE
and O O
MafG B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
. O O

Indigenous O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
microbial O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
flora O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
large O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
intestine O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
in O O
tadpoles O B_SPECIES[BIO]/B_LOCATION
. O O

Copyright O B_MEASURE/B_LOCATION
1998 O I_MEASURE/I_LOCATION
The O O
Association O B_ORGANIZATION/B_LOCATION
for O O
the O O
Study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Animal O B_EDU[ORGANIZATION]/B_PERSON
Behaviour O I_EDU[ORGANIZATION]/I_PERSON
. O O

In O O
contrast O O
to O O
the O O
restricted O O
tissue O O
expression O O
of O O
gonadotropin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
TSH B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
gonads O O
and O O
thyroid O O
, O O
respectively O O
, O O
LGR4 B B_GENE
is O O
expressed O O
in O O
diverse O O
tissues O O
including O O
ovary O O
, O O
testis O O
, O O
adrenal O O
, O O
placenta O O
, O O
thymus O O
, O O
spinal O O
cord O O
, O O
and O O
thyroid O O
, O O
whereas O O
LGR5 B B_GENE/B_MEASURE
is O O
found O O
in O O
muscle O O
, O O
placenta O O
, O O
spinal O O
cord O O
, O O
and O O
brain O O
. O O

Not O O
only O O
will O O
it O O
substantially O O
reduce O O
incident O B_DISEASE
cases O I_DISEASE
of O O
hepatitis O B_DISEASE
B O I_DISEASE
for O O
the O O
next O B_PERSON/B_LOCATION
decade O I_PERSON/I_LOCATION
, O O
it O O
will O O
also O O
provide O O
a O O
framework O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
successful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
introduction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
future O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
adolescent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
vaccine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
initiatives O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
Australia O B_LOCATION
. O O

A O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
technique O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
the O O
identification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
phases O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contained O O
within O O
a O O
polymer O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blend O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
described O O
in O O
this O O
paper O B_PRODUCT[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Radioactively O O
labeled O O
microspheres O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
used O O
to O O
determine O O
and O O
compare O O
the O O
hemodynamic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
sodium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitroprusside O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SNP O B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
nitroglycerin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
NTG O B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
and O O
deep O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
enflurane O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
anesthesia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
oral O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
tissues O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
during O O
controlled O O
hypotension O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
when O O
compared O O
with O O
controls O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Their O O
central O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
projections O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
indistinguishable O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
from O O
those O O
of O O
control O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
axons O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
all O O
four O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
trigeminal O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
subnuclei O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

The O O
JNK B B_GENE/B_DISEASE
/ O O
SAPK B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activator O O
mixed B B_GENE/B_LOCATION
lineage I I_GENE/I_LOCATION
kinase I I_GENE/I_LOCATION
3 I I_GENE/I_LOCATION
( O O
MLK3 B B_GENE
) O O
transforms O O
NIH O O
3T3 O O
cells O O
in O O
a O O
MEK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
dependent O O
fashion O O
. O O

The O O
decision O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
support O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
uses O O
the O O
network O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
at O O
its O O
core O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
helps O O
not O O
only O O
in O O
reaching O O
a O O
diagnosis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
but O O
also O O
in O O
finding O O
the O O
optimal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
way O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
reach O O
that O O
diagnosis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
contrast O O
to O O
the O O
effect O O
on O O
DNA O O
replication O O
, O O
the O O
L13V O O
substitution O O
in O O
large B B_GENE/B_BIO
T I I_GENE/I_BIO
antigen I I_GENE/I_BIO
did O O
not O O
prevent O O
complex O O
formation O O
with O O
Hsc70 B B_GENE
and O O
the O O
Rb B B_GENE/B_BIO
protein I I_GENE/I_BIO
. O O

To O O
explore O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
persistent O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
cardiomegaly O O
on O O
cardiovascular O B_DISEASE/B_ORGANISM_FUNCTION
function O I_DISEASE/I_ORGANISM_FUNCTION
, O O
groups O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
newborn O B_PERSON/B_BIO
rats O I_PERSON/I_BIO
inhaled O O
up O O
to O O
500 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ppm O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
CO O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
33 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
after O O
which O O
development O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
continued O O
in O O
ambient O B_MEASURE/B_PERSON
air O I_MEASURE/I_PERSON
. O O

Bandwidth O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
auditory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
units O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
chick O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
forebrain O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
( O O
field O B_LOCATION
L O I_LOCATION
/ O O
Hv O B_MEASURE/B_PROTEIN[GENE]
complex O I_MEASURE/I_PROTEIN[GENE]
) O O
was O O
measured O O
with O O
isointensity O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tone O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
stimuli O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Members O O
of O O
the O O
steroid B B_GENE/B_BIO
/ I I_GENE/I_BIO
hormone I I_GENE/I_BIO
nuclear I I_GENE/I_BIO
receptor I I_GENE/I_BIO
superfamily I I_GENE/I_BIO
regulate O O
target O O
gene O O
transcription O O
via O O
recognition O O
and O O
association O O
with O O
specific O O
cis O O
- O O
acting O O
sequences O O
of O O
DNA O O
, O O
called O O
hormone O O
response O O
elements O O
( O O
HREs O O
) O O
. O O

Indeed O O
, O O
DEX O O
also O O
enhanced O O
the O O
RA O O
- O O
dependent O O
increase O O
in O O
RARbeta B B_GENE
mRNA I I_GENE
in O O
a O O
cycloheximide O O
- O O
sensitive O O
manner O O
. O O

The O O
highest O B_MEASURE
concentration O I_MEASURE
of O O
respirable O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mineral O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fibres O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
found O O
during O O
the O O
overhaul O B_SEQUENCE[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
a O O
truck O B_PRODUCT[OBJECT]/B_LOCATION
with O O
asbestos O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
insulation O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
; O O
respirable O B_MEASURE/B_LOCATION
fibre O B_MEASURE/I_LOCATION
concentration O B_MEASURE/I_LOCATION
reached O O
the O O
value O B_MEASURE/B_LOCATION
of O O
5 O B_MEASURE
f O O
/ O O
cm3 O B_MEASURE
, O O
and O O
total O B_MEASURE/B_LOCATION
dust O B_MEASURE/I_LOCATION
concentration O B_MEASURE/I_LOCATION
- O O
the O O
value O B_MEASURE/B_LOCATION
of O O
about O O
80 O B_MEASURE
mg O I_MEASURE
/ O O
m3 O B_MEASURE
. O O

Avian B B_GENE/B_BIO
EMILIN I I_GENE/I_BIO
was O O
extracted O O
from O O
19 O O
- O O
day O O
- O O
old O O
embryonic O O
chick O O
aortas O O
and O O
associated O O
blood O O
vessels O O
and O O
purified O O
by O O
ion O O
- O O
exchange O O
chromatography O O
and O O
gel O O
filtration O O
. O O

CYP51P1 B B_GENE
is O O
96 O O
. O O
5 O O
% O O
identical O O
to O O
the O O
human B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
CYP51 I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
coding O O
sequence O O
and O O
is O O
not O O
interrupted O O
with O O
introns O O
but O O
has O O
six O O
in O O
- O O
frame O O
stop O O
codons O O
resulting O O
from O O
point O O
mutations O O
. O O

We O O
report O O
here O O
that O O
AChE B B_GENE/B_BIO
activity O O
tends O O
to O O
decrease O O
in O O
individuals O O
sampled O O
in O O
tanks O O
at O O
a O O
salinity O O
of O O
30 O O
per O O
thousand O O
as O O
temperature O O
increases O O
. O O

Three O O
RasV12 B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mutants I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O O
S35 B B_PROTEIN[GENE]
, O O
G37 B B_PROTEIN[GENE]
, O O
and O O
C40 B B_PROTEIN[GENE]/B_MEASURE
) O O
which O O
differ O O
by O O
their O O
ability O O
to O O
bind O O
to O O
Ras B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
effectors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Raf B B_GENE/B_DISEASE
, O O
Ral B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GEFs I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
the O O
p110 B B_GENE/B_PERSON
subunit I I_GENE/I_PERSON
of I I_GENE/I_PERSON
PI I I_GENE/I_PERSON
3 I I_GENE/I_PERSON
- I I_GENE/I_PERSON
kinase I I_GENE/I_PERSON
, O O
respectively O O
) O O
were O O
able O O
to O O
induce O O
sustained O O
NR O O
cell O O
proliferation O O
, O O
although O O
none O O
of O O
these O O
mutants O O
was O O
reported O O
to O O
transform O O
NIH O O
3T3 O O
cells O O
. O O

Mating O B_TIME[MEASURE]/B_PERSON
response O I_TIME[MEASURE]/I_PERSON
, O O
ovulation O B_MEASURE/B_BIO
rate O I_MEASURE/I_BIO
, O O
follicle O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
corpus O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
luteum O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
size O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
gestation O B_MEASURE/B_LOCATION
length O I_MEASURE/I_LOCATION
, O O
pregnancy O B_MEASURE/B_LOCATION
rate O I_MEASURE/I_LOCATION
, O O
lambing O B_MEASURE/B_PERSON
rate O I_MEASURE/I_PERSON
, O O
and O O
lamb O B_MEASURE/B_ORGANISM_FUNCTION
birth O I_MEASURE/I_ORGANISM_FUNCTION
weight O I_MEASURE/I_ORGANISM_FUNCTION
were O O
recorded O O
. O O

Membrane O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extraction O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
been O O
interfaced O O
with O O
gas O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chromatography O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
mass O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
spectroscopy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
volatile O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
organics O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
water O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

A O O
significant O O
difference O O
in O O
the O O
distribution O O
of O O
antibodies O O
to O O
thyroglobulin B B_GENE
and O O
thyroid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
peroxidase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
found O O
in O O
subgroup O O
2 O O
. O O

Here O O
, O O
we O O
characterize O O
TCR B B_GENE
/ O O
CD48 B B_GENE
and O O
TCR B B_GENE
/ O O
CD28 B B_GENE/B_LOCATION
costimulation O O
in O O
T O O
cells O O
expressing O O
Lck B B_GENE
Src B I_GENE
homology I I_GENE
3 I I_GENE
( O O
SH3 B B_GENE
) O O
mutants O O
. O O

High O O
expression O O
of O O
p51A B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
TAp63gamma B B_GENE/B_LOCATION
) O O
in O O
the O O
skeletal O O
muscle O O
tissue O O
drove O O
us O O
to O O
investigate O O
a O O
differentiation O O
- O O
inducible O O
myoblastic O O
cell O O
line O O
which O O
showed O O
increased O O
p51A B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O O
after O O
differentiation O O
induction O O
. O O

The O O
rate O B_DISEASE
for O O
Arm O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
III O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O O
CAF O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
) O O
was O O
61 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
( O O
32 O B_MEASURE
/ O O
52 O B_MEASURE
) O O
, O O
a O O
little O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
higher O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
that O O
for O O
the O O
other O B_PERSON/B_LOCATION
two O B_PERSON/I_LOCATION
. O O

These O O
results O O
induce O O
that O O
the O O
putative O O
TATA O O
box O O
and O O
initiator O O
are O O
not O O
involved O O
in O O
the O O
promoter O O
activity O O
, O O
and O O
that O O
the O O
vitronectin B B_GENE
promoter I I_GENE
lacks O O
the O O
TATA O O
box O O
, O O
initiator O O
and O O
GC O O
box O O
. O O

Using O O
the O O
interaction O O
- O O
trap O O
assay O O
to O O
identify O O
candidate O O
proteins O O
that O O
bind O O
the O O
cytoplasmic O O
region O O
of O O
the O O
LAR B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
transmembrane I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PT B B_LOCATION/B_GENE
- I I_LOCATION/I_GENE
Pase I I_LOCATION/I_GENE
) O O
, O O
we O O
isolated O O
a O O
cDNA O O
encoding O O
a O O
2861 O O
- O O
amino O O
acid O O
protein O O
termed O O
Trio B B_GENE/B_ENT
that O O
contains O O
three O O
enzyme O O
domains O O
: O O
two O O
functional O O
GEF B B_LOCATION/B_PERSON
domains I I_LOCATION/I_PERSON
and O O
a O O
protein B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
serine I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
threonine I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PSK B B_GENE/B_LOCATION
) O O
domain O O
. O O

We O O
have O O
isolated O O
two O O
H19 B B_GENE
cDNAs I I_GENE
( O O
AP B B_LOCATION
and O O
ES B B_LOCATION/B_PROTEIN[GENE]
) O O
that O O
contain O O
this O O
ORF4 O O
and O O
correspond O O
to O O
incomplete O O
copies O O
of O O
the O O
unique O O
2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kb I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
H19 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
combined O O
in O O
vitro O O
effects O O
of O O
ethanol O O
wih O O
methaqualone O O
, O O
phenobarbital O O
, O O
pyrazole O O
or O O
disulfiram O O
were O O
studied O O
using O O
rat B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
brain I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microsomal I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NA I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
K I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ATPase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
related O O
adhesion B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
focal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
tyrosine O O
- O O
phosphorylated O O
after O O
beta1 B B_GENE
- I I_GENE
integrin I I_GENE
stimulation O O
in O O
B O O
cells O O
and O O
binds O O
to O O
p130cas B B_GENE
. O O

Earlier O O
reports O O
have O O
localized O O
mutations O O
which O O
affect O O
the O O
processing O O
and O O
transport O O
of O O
herpes O O
simplex O O
virus O O
1 O O
glycoproteins O O
to O O
a O O
region O O
located O O
between O O
the O O
genes O O
specifying O O
glycoprotein B B_GENE/B_ORGANISM_FUNCTION
B I I_GENE/I_ORGANISM_FUNCTION
and O O
the O O
major O O
viral O O
DNA O O
- O O
binding O O
protein O O
( O O
beta B B_GENE/B_DISEASE
8 I I_GENE/I_DISEASE
) O O
. O O

These O O
results O O
indicate O O
that O O
the O O
2127 O O
- O O
bp O O
cDNA O O
encodes O O
a O O
functional O O
feline O O
L B B_ENZYME[GENE]/B_MEASURE
/ I I_ENZYME[GENE]/I_MEASURE
B I I_ENZYME[GENE]/I_MEASURE
/ I I_ENZYME[GENE]/I_MEASURE
K I I_ENZYME[GENE]/I_MEASURE
- I I_ENZYME[GENE]/I_MEASURE
type I I_ENZYME[GENE]/I_MEASURE
ALP I I_ENZYME[GENE]/I_MEASURE
expressed O O
on O O
cell O O
surfaces O O
via O O
phosphatidylinositol O O
- O O
glycan O O
linkage O O
. O O

Our O O
experience O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggests O O
that O O
T2 O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
weighting O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O O
adequate O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
is O O
the O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
choice O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O O
the O O
early O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
recognition O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
necrosis O B_DISEASE
of O O
the O O
lunate O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Analysis O O
of O O
a O O
Het B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
mutation O O
in O O
Anabaena O O
sp O O
. O O
strain O O
PCC O O
7120 O O
implicates O O
a O O
secondary O O
metabolite O O
in O O
the O O
regulation O O
of O O
heterocyst O O
spacing O O
. O O

Here O O
we O O
report O O
that O O
components O O
of O O
the O O
Ras B B_GENE/B_DISEASE
/ O O
Raf B B_GENE/B_DISEASE
/ O O
MAPK B B_GENE/B_LOCATION
pathway O O
are O O
constitutively O O
activated O O
in O O
these O O
lck B B_VIRUS[BIO]/B_DISEASE
- O O
transformed O O
immature O O
thymoblasts O O
. O O

p56 B B_GENE/B_DISEASE
( O O
lck B B_GENE/B_BACTERIUM[BIO]
) O O
utilizes O O
Shc B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Grb2 B B_GENE/B_LOCATION
adaptors I I_GENE/I_LOCATION
to O O
mediate O O
activation O O
of O O
p21 B B_GENE/B_DISEASE
( O O
ras B B_GENE/B_DISEASE
) O O
in O O
the O O
thymoblast O O
lines O O
by O O
promoting O O
tyrosine O O
phosphorylation O O
of O O
the O O
Shc B B_GENE/B_BIO
protein I I_GENE/I_BIO
and O O
constitutive O O
interaction O O
between O O
Shc B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Grb2 B B_GENE
. O O

The O O
rec8 B B_GENE/B_DISEASE
( I I_GENE/I_DISEASE
+ I I_GENE/I_DISEASE
) I I_GENE/I_DISEASE
, O O
rec10 B B_MEASURE/B_GENE
( I I_MEASURE/I_GENE
+ I I_MEASURE/I_GENE
) I I_MEASURE/I_GENE
, O O
and O O
rec11 B B_GENE/B_BIO
( I I_GENE/I_BIO
+ I I_GENE/I_BIO
) I I_GENE/I_BIO
genes I I_GENE/I_BIO
of I I_GENE/I_BIO
the I I_GENE/I_BIO
fission I I_GENE/I_BIO
yeast I I_GENE/I_BIO
Schizosaccharomyces I I_GENE/I_BIO
pombe I I_GENE/I_BIO
exhibit O O
similar O O
specificities O O
for O O
meiotic O O
recombination O O
and O O
rec8 B B_GENE/B_LOCATION
( I I_GENE/I_LOCATION
+ I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
is O O
required O O
for O O
sister O O
chromatid O O
cohesion O O
and O O
homolog O O
pairing O O
. O O

Based O O
on O O
the O O
results O O
of O O
this O O
analysis O O
, O O
we O O
also O O
predict O O
that O O
the O O
budding B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
yeast I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
arsenate I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
resistance I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Acr2 B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
ORF B B_GENE/B_PERSON
Ygr203w I I_GENE/I_PERSON
encode O O
protein O O
phosphatases O O
with O O
catalytic O O
properties O O
similar O O
to O O
that O O
of O O
the O O
Cdc25 B B_SPECIES[BIO]/B_GENE
family I I_SPECIES[BIO]/I_GENE
. O O

At O O
onset O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
first O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
post O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
weaning O O
estrus O B_LOCATION/B_PERSON
, O O
sows O B_PERSON/B_SPECIES[BIO]
received O O
either O O
an O O
intravulval O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
injection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
3 O B_MEASURE
. O O
75 O B_MEASURE
mg O I_MEASURE
of O O
prostaglandin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analogue O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
PGF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
or O O
, O O
served O O
as O O
a O O
non O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
injected O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
CON O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
. O O

We O O
concluded O O
that O O
HFV O B_PERSON/B_DISEASE
can O O
achieve O O
values O B_MEASURE
of O O
CO2 O B_DISEASE/B_PROTEIN[GENE]
elimination O B_DISEASE/I_PROTEIN[GENE]
close O O
to O O
the O O
estimated O O
metabolic O B_MEASURE/B_LOCATION
CO2 O I_MEASURE/I_LOCATION
production O I_MEASURE/I_LOCATION
in O O
normal O B_BIO/B_PERSON
unintubated O I_BIO/I_PERSON
subjects O I_BIO/I_PERSON
over O O
short O B_TIME[MEASURE]/B_LOCATION
periods O I_TIME[MEASURE]/I_LOCATION
of O O
time O B_TIME[MEASURE]
. O O

The O O
PHO5 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
is O O
activated O O
by O O
the O O
Pho4p B B_GENE
transcription I I_GENE
factor I I_GENE
, O O
which O O
itself O O
is O O
negatively O O
regulated O O
through O O
phosphorylation O O
by O O
the O O
products O O
of O O
PHO80 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
PHO85 B B_GENE
. O O

Although O O
the O O
only O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
authoritative O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
way O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
determine O O
the O O
effect O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
diet O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
on O O
urinary O B_DISEASE/B_ORGANISM_FUNCTION
pH O I_DISEASE/I_ORGANISM_FUNCTION
is O O
a O O
feeding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
there O O
is O O
no O O
universally O O
accepted O O
protocol O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
measuring O O
urinary O B_DISEASE/B_MEASURE
pH O I_DISEASE/I_MEASURE
. O O

Analysis O O
of O O
the O O
DNA O O
sequence O O
upstream O O
of O O
the O O
narQ B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
encodes O O
the O O
second O O
nitrate O O
- O O
responsive O O
sensor O O
- O O
transmitter O O
protein O O
in O O
Escherichia O O
coli O O
, O O
revealed O O
an O O
open O O
reading O O
frame O O
( O O
ORF O O
) O O
whose O O
product O O
shows O O
a O O
high O O
degree O O
of O O
similarity O O
to O O
a O O
number O O
of O O
iron B B_GENE/B_BIO
- I I_GENE/I_BIO
sulfur I I_GENE/I_BIO
proteins I I_GENE/I_BIO
as O O
well O O
as O O
to O O
the O O
beta O O
subunit O O
of O O
glutamate B B_ENZYME[GENE]
synthase I I_ENZYME[GENE]
( O O
gltD B B_DISEASE/B_LOCATION
) O O
of O O
E O O
. O O
coli O O
. O O

Endothelial O B_DISEASE_ADJECTIVE[DISEASE]
purine O I_DISEASE_ADJECTIVE[DISEASE]
content O I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
suggest O O
that O O
the O O
responses O O
to O O
types B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
I I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
II I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
collagen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
caused O O
by O O
a O O
cross O O
- O O
reaction O O
with O O
type B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
III I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
collagen I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
peptides O O
. O O

Possibilities O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
limints O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
immunofluorescence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
the O O
laboratory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
rabies O B_DISEASE/B_LOCATION

The O O
5 O O
' O O
half O O
of O O
the O O
EWS B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O O
recently O O
been O O
described O O
to O O
be O O
fused O O
to O O
the O O
3 O O
' O O
regions O O
of O O
genes O O
encoding O O
the O O
DNA O O
- O O
binding O O
domain O O
of O O
several O O
transcriptional O O
regulators O O
, O O
including O O
ATF1 B B_GENE/B_LOCATION
, O O
FLI B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
, O O
and O O
ERG B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
in O O
several O O
human O O
tumors O O
. O O

PDGF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulated O O
CDK2 B B_GENE
activity O O
in O O
mesangial O O
cells O O
and O O
decreased O O
the O O
level O O
of O O
p27 B B_GENE
( O O
kip1 B B_PROTEIN[GENE]/B_LOCATION
) O O
cyclin O O
kinase O O
inhibitor O O
protein O O
. O O

Recombinant B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
apoA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
recovered O O
from O O
the O O
soluble O O
fraction O O
of O O
the O O
bacterial O O
cell O O
pellet O O
was O O
purified O O
to O O
greater O O
than O O
95 O O
% O O
homogeneity O O
by O O
reversed O O
- O O
phase O O
high O O
- O O
performance O O
liquid O O
chromatography O O
. O O

The O O
influence O O
of O O
different O O
temperatures O O
between O O
13 O O
degrees O O
C O O
and O O
45 O O
degrees O O
C O O
on O O
coagulation O O
factors O O
in O O
vitro O O
was O O
studied O O
by O O
measuring O O
clotting O O
time O O
with O O
the O O
recalcification O O
time O O
, O O
partial O O
thromboplastin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
time O O
( O O
PTT O O
) O O
, O O
and O O
thromboplastin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
time O O
test O O
. O O

On O O
average O B_MEASURE/B_SOCIAL_CIRCUMSTANCES
, O O
rCMRglc O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
23 O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
below O O
control O B_MEASURE/B_LOCATION
values O I_MEASURE/I_LOCATION
for O O
all O O
regions O B_LOCATION/B_BIO
studied O O
, O O
with O O
the O O
greatest O B_MEASURE
differences O I_MEASURE
in O O
posterior O B_BODY_PART_OR_ORGAN_COMPONENT
brain O I_BODY_PART_OR_ORGAN_COMPONENT
regions O I_BODY_PART_OR_ORGAN_COMPONENT
( O O
visual O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
association O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
cortex O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
primary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
visual O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
cortex O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
parietal O B_BODY_PART_OR_ORGAN_COMPONENT
cortex O I_BODY_PART_OR_ORGAN_COMPONENT
) O O
and O O
thalamus O B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Thus O O
, O O
transgene O O
expression O O
directed O O
by O O
both O O
the O O
human O O
and O O
mouse B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
Rb I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
promoters I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
restricted O O
to O O
a O O
subset O O
of O O
tissues O O
in O O
which O O
Rb B B_GENE/B_DISEASE
is O O
normally O O
expressed O O
during O O
embryogenesis O O
. O O

Thus O O
, O O
Tax1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activates O O
CArG O O
- O O
mediated O O
transcription O O
without O O
mitogenic O O
signals O O
through O O
interaction O O
with O O
a O O
CArG B B_GENE/B_PERSON
- I I_GENE/I_PERSON
binding I I_GENE/I_PERSON
factor I I_GENE/I_PERSON
, O O
p67SRF B B_GENE
. O O

In O O
experiment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
subjects O B_PERSON
were O O
required O O
to O O
discriminate O O
male O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
from O O
female O B_PERSON/B_ENT
faces O I_PERSON/I_ENT
and O O
no O O
hemispheric O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
asymmetries O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
found O O
. O O

Membrane O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
depolarization O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
critical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
element O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
neuronal O B_DISEASE_ADJECTIVE[DISEASE]
signaling O I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
transcription O O
start O O
site O O
was O O
localized O O
224 O O
bp O O
upstream O O
the O O
ATG O O
codon O O
by O O
RNase B B_ENZYME[GENE]
protection O O
and O O
primer O O
extension O O
mapping O O
. O O

All O O
the O O
cognate O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
gene O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
clones O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
constructed O O
, O O
using O O
either O O
PCR O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
amplified O O
from O O
genomic O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
or O O
gap O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
repair O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Rising O O
antibody O O
titres O O
to O O
the O O
astrovirus O O
particles O O
were O O
demonstrated O O
in O O
one O O
child O O
, O O
and O O
IgM B B_GENE/B_DISEASE
was O O
also O O
demonstrated O O
in O O
this O O
patient O O
' O O
s O O
serum O O
. O O

Effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
isobarin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O O
electrocardiographic O B_DISEASE
indices O I_DISEASE
in O O
hypertensive O B_DISEASE/B_SPECIES[BIO]
disease O B_DISEASE/I_SPECIES[BIO]

Although O O
RAD17 B B_GENE/B_DISEASE
, O O
RAD24 B B_GENE/B_DISEASE
and O O
MEC3 B B_GENE/B_MEASURE
are O O
not O O
required O O
for O O
cell O O
cycle O O
arrest O O
when O O
S O O
phase O O
is O O
inhibited O O
by O O
hydroxyurea O O
( O O
HU O O
) O O
, O O
they O O
do O O
contribute O O
to O O
the O O
viability O O
of O O
yeast O O
cells O O
grown O O
in O O
the O O
presence O O
of O O
HU O O
, O O
possibly O O
because O O
they O O
are O O
required O O
for O O
the O O
repair O O
of O O
HU O O
- O O
induced O O
DNA O O
damage O O
. O O

Long O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chain O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acyl O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
CoA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
esters O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
important O B_LOCATION/B_MEASURE
intermediates O I_LOCATION/I_MEASURE
in O O
degradation O B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
synthesis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
fatty O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acids O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
well O O
as O O
having O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functions O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
regulation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
intermediary O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
metabolism O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O O
gene O B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
expression O B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
. O O

PTP1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
lacZ B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O O
indicate O O
that O O
PTP1 B B_GENE
is O O
spatially O O
localized O O
to O O
prestalk O O
and O O
anterior O O
- O O
like O O
cell O O
types O O
. O O

When O O
translated O O
in O O
- O O
frame O O
with O O
PKC B B_GENE
zeta I I_GENE
, O O
a O O
stop O O
codon O O
is O O
located O O
28 O O
amino O O
acids O O
towards O O
the O O
N O O
- O O
terminus O O
of O O
the O O
divergence O O
point O O
and O O
the O O
intervening O O
sequence O O
lacks O O
an O O
expected O O
initiating O O
methionine O O
. O O
psi B B_GENE
PKC I I_GENE
zeta I I_GENE
is O O
non O O
- O O
functional O O
in O O
terms O O
of O O
protein O O
synthesis O O
since O O
Western O O
blotting O O
with O O
an O O
antibody O O
directed O O
against O O
the O O
C O O
- O O
terminus O O
of O O
PKC B B_GENE
zeta I I_GENE
failed O O
to O O
reveal O O
a O O
protein O O
smaller O O
than O O
PKC B B_GENE/B_MEASURE
zeta I B_GENE/I_MEASURE
, O O
and O O
synthetic O O
psi B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
PKC I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
zeta I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
RNA I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
failed O O
to O O
support O O
protein O O
synthesis O O
in O O
a O O
translation O O
system O O
in O O
vitro O O
. O O

W O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
and O O
Touster O B_PERSON
, O O
O O B_OTHER/B_PERSON
. O O

Electrically O O
induced O O
undulations O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
their O O
competition O B_SPORT[ENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
electrically O O
induced O O
convection O B_DISEASE_ADJECTIVE[DISEASE]
in O O
cholesteric O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
liquid O B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
crystals O B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
sequence O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immediately O O
upstream O O
of O O
the O O
translation O B_GENE
start O I_GENE
site O I_GENE
was O O
G O B_PROTEIN[GENE]/B_LOCATION
+ O O
C O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
rich O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
greater O B_MEASURE
than O O
75 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
and O O
contained O O
a O O
consensus O B_GENE
CCAAT O I_GENE
sequence O I_GENE
despite O O
the O O
absence O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
a O O
TATA O B_GENE
box O I_GENE
. O O

These O O
conditions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
may O O
determine O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
level O B_MEASURE/B_LOCATION
of O O
indoor O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pollutants O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
tobacco O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
smoke O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
gases O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O O
by O O
cooling O O
processes O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
etc O I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
) O O
and O O
of O O
allergens O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
derived O O
from O O
mites O B_BIO/B_DISEASE
, O O
domestic O B_BIO
animals O I_BIO
and O O
cockroaches O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Nevertheless O O
, O O
lower O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
alone O O
were O O
lacking O O
in O O
activity O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
100 O B_MEASURE
- O O
250 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
B1 O I_MEASURE
and O O
B6 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
, O O
1 O B_MEASURE
- O O
2 O B_MEASURE
. O O
5 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE/B_LOCATION
B12 O I_MEASURE/I_LOCATION
p O I_MEASURE/I_LOCATION
. O O
o O B_MEASURE
. O O
) O O
dose O B_MEASURE
- O O
dependently O O
potentiated O O
the O O
antinociceptive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
diclofenac O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

For O O
O3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
the O O
correlation O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
personal O B_LOCATION/B_ORGANIZATION
exposures O I_LOCATION/I_ORGANIZATION
and O O
ambient O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
levels O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
weakest O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
in O O
the O O
winter O B_TIME[MEASURE]/B_LOCATION
for O O
residential O B_PERSON/B_LOCATION
microenvironments O I_PERSON/I_LOCATION
( O O
rs O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O O
0 O B_MEASURE
. O O
05 O B_MEASURE
, O O
p O B_MEASURE
> O B_MEASURE/B_LOCATION
0 O I_MEASURE
. O O
05 O B_MEASURE
) O O
, O O
and O O
was O O
strongest O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
summer O B_TIME[MEASURE]
for O O
outdoor O B_LOCATION/B_ORGANIZATION
near O O
- O O
roadway O B_LOCATION/B_ORGANIZATION
microenvironments O I_LOCATION/I_ORGANIZATION
( O O
rs O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O O
0 O B_MEASURE
. O O
91 O B_MEASURE
, O O
p O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_NUMBER[MEASURE]
. O O
05 O B_MEASURE
) O O
. O O

Changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
water O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
electrolyte O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
content O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
edema O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
formation O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
after O O
acute O B_DISEASE_ADJECTIVE[DISEASE]
, O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
hypertension O B_DISEASE
were O O
studied O O
in O O
albino O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rabbits O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Like O O
Rev B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Erb B B_PROTEIN[GENE]/B_MEASURE
, O O
BD73 B B_GENE/B_LOCATION
binds O O
as O O
a O O
monomer O O
to O O
a O O
DNA O O
sequence O O
which O O
consists O O
of O O
a O O
specific O O
A O O
/ O O
T O O
- O O
rich O O
sequence O O
upstream O O
of O O
the O O
consensus O O
hexameric O O
half O O
- O O
site O O
specified O O
by O O
the O O
P O O
box O O
of O O
the O O
DNA O O
- O O
binding O O
domain O O
. O O

In O O
contrast O O
, O O
the O O
holo B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
dTFIIA I I_GENE/I_MEASURE
( O O
L O O
/ O O
S O O
) O O
binds O O
TBP B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
high O O
affinity O O
. O O

Overexpression O O
of O O
wild O O
type O O
and O O
SeCys O O
/ O O
Cys O O
mutant O O
of O O
human B B_GENE/B_LOCATION
thioredoxin I I_GENE/I_LOCATION
reductase I I_GENE/I_LOCATION
in O O
E O O
. O O
coli O O
: O O
the O O
role O O
of O O
selenocysteine O O
in O O
the O O
catalytic O O
activity O O
. O O

Biopsy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
lesion O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
revealed O O
granulomatous O B_DISEASE_ADJECTIVE[DISEASE]
inflammation O I_DISEASE_ADJECTIVE[DISEASE]
and O O
numerous O B_DISEASE
septate O I_DISEASE
hyphae O I_DISEASE
. O O

Western O O
and O O
immunocytochemical O O
analysis O O
implied O O
that O O
PREB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
accumulates O O
specifically O O
in O O
GH3 O O
cell O O
nuclei O O
. O O

Two O O
genes O O
from O O
the O O
family O O
encoding O O
mouse B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ribosomal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
S16 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
cloned O O
, O O
sequenced O O
, O O
and O O
analyzed O O
. O O

A O O
novel O O
serine B B_ENZYME[GENE]/B_LOCATION
kinase I I_ENZYME[GENE]/I_LOCATION
activated O O
by O O
rac1 B B_GENE/B_DISEASE
/ O O
CDC42Hs B B_GENE/B_BIO
- O O
dependent O O
autophosphorylation O O
is O O
related O O
to O O
PAK65 B B_GENE
and O O
STE20 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
deduced O O
gene O O
product O O
was O O
found O O
to O O
have O O
significant O O
sequence O O
similarity O O
to O O
the O O
yeast B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
prokaryotic I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
polymerase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
subunits I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
involved O O
with O O
subunit O O
assembly O O
. O O

Maximum O O
overexpression O O
of O O
holoenzyme O O
activity O O
was O O
achieved O O
by O O
the O O
inclusion O O
in O O
such O O
plasmids O O
of O O
Salmonella O O
typhimurium O O
cysG O O
, O O
which O O
encodes O O
a O O
uroporphyrinogen B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
III I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
methyltransferase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
required O O
for O O
the O O
synthesis O O
of O O
siroheme O O
, O O
a O O
cofactor O O
for O O
the O O
hemoprotein O O
. O O

Overexpression O O
of O O
SNURF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
cultured O O
mammalian O O
cells O O
enhanced O O
not O O
only O O
androgen O O
, O O
glucocorticoid O O
, O O
and O O
progesterone B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dependent O O
transactivation O O
but O O
also O O
basal O O
transcription O O
from O O
steroid O O
- O O
regulated O O
promoters O O
. O O

The O O
human O O
protein O O
binds O O
most O O
strongly O O
to O O
the O O
SH3 B B_GENE/B_LOCATION
domain I I_GENE/I_LOCATION
from O O
the O O
abl B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
proto I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
- I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
oncogene I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Suprapubic O B_BODY_PART_OR_ORGAN_COMPONENT/B_EDU[ORGANIZATION]
and O O
intravesical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ENT
methods O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ENT

These O O
data O O
show O O
that O O
tyrosine O O
phosphorylation O O
by O O
FES B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
affects O O
the O O
interaction O O
of O O
BCR B B_GENE
with O O
multiple O O
signaling O O
partners O O
and O O
suggest O O
a O O
general O O
role O O
for O O
BCR B B_GENE/B_DISEASE
in O O
non O O
- O O
receptor O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulation O O
and O O
signal O O
transduction O O
. O O

We O O
have O O
shown O O
that O O
the O O
human O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
MRC O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
closely O O
resembles O O
the O O
murine O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
MRC O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
in O O
both O O
its O O
protein O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
composition O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
its O O
fractionation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
chromatographic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profile O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

From O O
1977 O B_MEASURE
to O O
1985 O B_MEASURE
, O O
42 O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
with O O
squamous O B_DISEASE
cell O I_DISEASE
carcinoma O I_DISEASE
of O O
the O O
anal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
canal O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O O
treated O O
with O O
mitomycin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
15 O B_MEASURE
mg O I_MEASURE
/ O O
m2 O B_MEASURE
) O O
and O O
5 O B_MEASURE
- O O
fluorouracil O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
750 O B_MEASURE
mg O I_MEASURE
/ O O
m2 O B_MEASURE
) O O
on O O
day O B_TIME[MEASURE]
1 O I_TIME[MEASURE]
, O O
5 O B_TIME[MEASURE]/B_PERSON
- O O
FU O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
( O O
750 O B_MEASURE
mg O I_MEASURE
/ O O
m2 O B_MEASURE
/ O O
d O B_OTHER/B_TIME[MEASURE]
) O O
alone O O
on O O
days O B_NUMBER[MEASURE]/B_ENT
2 O I_NUMBER[MEASURE]/I_ENT
to O O
5 O B_MEASURE
, O O
and O O
radiation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
3000 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cGy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
on O O
days O B_TIME[MEASURE]
7 O I_TIME[MEASURE]
to O O
28 O B_SEQUENCE[MEASURE]
. O O

For O O
any O O
given O O
age O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
high O O
- O O
stressed O O
plantaris O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tendons O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O O
of O O
a O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
fatigue O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
quality O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
low O O
- O O
stressed O O
extensor O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
tendons O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
. O O

In O O
addition O O
to O O
TAK1 B B_GENE
, O O
TGF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
beta I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
also O O
stimulated O O
JNK B B_GENE
activity O O
. O O

Foamy O O
viruses O O
( O O
FVs O O
) O O
express O O
the O O
Gag B B_GENE
protein I I_GENE
as O O
a O O
precursor O O
with O O
a O O
molecular O O
mass O O
of O O
74 O O
kDa O O
( O O
pr74 B B_PROTEIN[GENE]/B_MEASURE
) O O
from O O
which O O
a O O
70 O O
- O O
kDa O O
protein O O
( O O
p70 B B_PROTEIN[GENE]/B_DISEASE
) O O
is O O
cleaved O O
by O O
the O O
viral O O
protease O O
. O O

Our O O
results O O
suggest O O
that O O
at O O
least O O
some O O
chloroplast B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
like I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
wheat O O
mtDNA O O
are O O
transcribed O O
, O O
with O O
transcripts O O
undergoing O O
processing O O
, O O
post O O
- O O
transcriptional O O
modification O O
and O O
3 O O
' O O
- O O
CCA O O
addition O O
, O O
to O O
produce O O
mature O O
tRNAs O O
that O O
may O O
participate O O
in O O
mitochondrial O O
protein O O
synthesis O O
. O O

If O O
, O O
however O O
, O O
myocardial O B_DISEASE
stunning O I_DISEASE
is O O
severe O B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
it O O
involves O O
large O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
parts O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
LV O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
and O O
thus O O
impairs O O
global O B_DISEASE_ADJECTIVE[DISEASE]
LV O I_DISEASE_ADJECTIVE[DISEASE]
function O I_DISEASE_ADJECTIVE[DISEASE]
, O O
it O O
can O O
be O O
reversed O O
with O O
inotropic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
agents O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
procedures O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

268 O B_MEASURE
, O O
6858 O B_MEASURE
- O O
6861 O B_MEASURE
) O O
. O O

The O O
occurrence O O
of O O
the O O
different O O
types O O
of O O
TCRB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
rearrangement O O
patterns O O
has O O
implications O O
for O O
PCR O O
- O O
based O O
clonality O O
assessment O O
and O O
for O O
PCR O O
- O O
based O O
detection O O
of O O
minimal O O
residual O O
disease O O
via O O
TCRB B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
gene I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
analysis O O
. O O

Under O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
conditions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
pretreatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
lithium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
7 O B_ENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days O I_ENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
did O O
not O O
modify O O
the O O
hyperlocomotion O B_DISEASE_ADJECTIVE[DISEASE]
produced O O
by O O
d O B_PROTEIN[GENE]/B_DISEASE
- O O
amphetamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Six O B_PERSON
patients O I_PERSON
underwent O O
an O O
electrophysiologic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
study O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Rats O B_BIO/B_PERSON
on O O
the O O
multiple O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oral O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
dosage O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
regimen O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
given O O
unlabelled O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
HMCF O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
their O O
drinking O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
water O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
13 O B_TIME[MEASURE]
days O I_TIME[MEASURE]
before O O
the O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
a O O
bolus O B_MEASURE
dose O I_MEASURE
of O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
14C O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
HMCF O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O O
day O B_TIME[MEASURE]/B_PERSON
14 O B_TIME[MEASURE]/I_PERSON
. O O

After O O
multivariate O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
analysis O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
TWA O B_DISEASE/B_LOCATION
correlated O O
with O O
age O B_TIME[MEASURE]/B_LOCATION
( O O
P O B_OTHER/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
02 O B_MEASURE
) O O
and O O
LV O B_DISEASE/B_MEASURE
function O I_DISEASE/I_MEASURE
( O O
P O B_OTHER/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
002 O B_MEASURE
) O O
and O O
occurred O O
more O O
often O O
in O O
patients O B_PERSON/B_BIO
after O O
nonanterior O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
MI O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
P O B_OTHER/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
03 O B_MEASURE
) O O
. O O

No O O
patient O O
demonstrated O O
a O O
decrease O O
in O O
bone O O
marrow O O
fibrosis O O
as O O
determined O O
by O O
serial O O
procollagen B B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
PC B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
III I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
serum O O
level O O
analysis O O
. O O

Asthma O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
diagnoses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
made O O
according O O
to O O
recommended O O
National O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Asthma O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Expert O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Panel O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Guidelines O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Charcot O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
joints O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

Idealized O B_PERSON
versus O I_PERSON
realized O O
overall O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
times O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Non O B_DISEASE
- O O
suppressed O O
thyroidal O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
radioactive O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
iodine O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
uptake O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
RAIU O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
in O O
thyrotoxic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
phase O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
a O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
subacute O B_DISEASE/B_PERSON
thyroiditis O I_DISEASE/I_PERSON
with O O
thyroid O O
- O O
stimulating O O
antibodies O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
TSAb O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Ultra O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
energy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
UHE O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
imaging O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
usually O O
performed O O
in O O
simultaneous O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
F O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
18 O B_MEASURE
FDG O I_MEASURE
/ O O
Tc O B_PROTEIN[GENE]/B_LOCATION
- O O
99m O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
MIBI O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
studies O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Bilateral O B_DISEASE/B_MEASURE
renal O I_DISEASE/I_MEASURE
oncocytoma O I_DISEASE/I_MEASURE
in O O
a O O
Greyhound O B_SPECIES[BIO]/B_PERSON
dog O I_SPECIES[BIO]/I_PERSON
. O O

Uncoupling O O
gene O O
activity O O
from O O
chromatin O O
structure O O
: O O
promoter O O
mutations O O
can O O
inactivate O O
transcription O O
of O O
the O O
yeast B B_GENE/B_BIO
HSP82 I I_GENE/I_BIO
gene I I_GENE/I_BIO
without O O
eliminating O O
nucleosome O O
- O O
free O O
regions O O
. O O

Ectopic O O
expression O O
of O O
cyclin B B_GENE
D1 I I_GENE
in O O
progestin O O
- O O
inhibited O O
cells O O
led O O
to O O
the O O
reappearance O O
of O O
the O O
120 O O
- O O
kDa O O
active O O
form O O
of O O
cyclin B B_GENE
E I I_GENE
- O O
Cdk2 B B_PROTEIN[GENE]/B_MEASURE
preceding O O
the O O
resumption O O
of O O
cell O O
cycle O O
progression O O
. O O

Unlike O O
these O O
contaminant O O
- O O
responsive O O
T O O
cells O O
, O O
those O O
that O O
are O O
truly O O
specific O O
for O O
natural O O
AChR B B_DISEASE
epitopes I I_DISEASE
appear O O
less O O
heterogeneous O O
and O O
therefore O O
more O O
suitable O O
targets O O
for O O
selective O O
immunotherapy O O
. O O

Because O O
the O O
wa B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
2 I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
was O O
mapped O O
previously O O
to O O
the O O
vicinity O O
of O O
the O O
EGF B B_GENE/B_DISEASE
/ I I_GENE/I_DISEASE
TGF I I_GENE/I_DISEASE
- I I_GENE/I_DISEASE
alpha I I_GENE/I_DISEASE
receptor I I_GENE/I_DISEASE
( O O
EGFR B B_GENE/B_LOCATION
) O O
gene O O
on O O
mouse O O
chromosome O O
11 O O
, O O
we O O
hypothesized O O
that O O
the O O
wa B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
2 I I_DISEASE/I_GENE
phenotype I I_DISEASE/I_GENE
might O O
result O O
from O O
a O O
defect O O
in O O
either O O
the O O
expression O O
or O O
activity O O
of O O
EGFR B B_GENE/B_BIO
, O O
or O O
both O O
. O O

Region O B_LOCATION/B_PERSON
I O O
includes O O
the O O
two O B_MEASURE/B_PERSON
cysteine O I_MEASURE/I_PERSON
- O O
cysteine O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
zinc O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fingers O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
comprise O O
a O O
DNA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
binding O O
domain O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
which O O
typifies O O
all O O
members O B_PERSON/B_LOCATION
of O O
the O O
superfamily O O
. O O

Southern O O
zoo O O
blot O O
analysis O O
indicated O O
that O O
ZNF236 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
conserved O O
in O O
the O O
genomes O O
of O O
all O O
mammalian O O
species O O
tested O O
, O O
but O O
not O O
in O O
yeast O O
. O O

RNA O O
determinants O O
required O O
for O O
L4 B B_GENE/B_DISEASE
- O O
mediated O O
attenuation O O
control O O
of O O
the O O
S10 B B_GENE/B_BIO
r I I_GENE/I_BIO
- I I_GENE/I_BIO
protein I I_GENE/I_BIO
operon I I_GENE/I_BIO
of I I_GENE/I_BIO
Escherichia I I_GENE/I_BIO
coli I I_GENE/I_BIO
. O O

Spodoptera O O
frugiperda O O
( O O
Sf9 O O
) O O
cells O O
have O O
proved O O
a O O
suitable O O
cell O O
system O O
in O O
which O O
to O O
study O O
this O O
association O O
and O O
to O O
produce O O
recombinant B B_GENE
CR3 I I_GENE
, O O
and O O
we O O
show O O
here O O
that O O
another O O
lepidopteran O O
cell O O
line O O
, O O
Trichoplusia O O
niTN O O
- O O
5B1 O O
- O O
4 O O
( O O
High O O
- O O
Five O O
) O O
cells O O
, O O
allows O O
the O O
recovery O O
of O O
large O O
amounts O O
of O O
functional B B_GENE
recombinant I I_GENE
CR3 I I_GENE
. O O

INTERVENTIONS O O
: O O
Postoperative O O
follow O O
- O O
up O O
consisted O O
of O O
serial O O
determination O O
of O O
different O O
biochemical O O
markers O O
( O O
CK B B_GENE/B_LOCATION
, O O
CK B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
MB I I_GENE/I_LOCATION
, O O
cTnI B B_LOCATION/B_GENE
) O O
, O O
ECGs O O
, O O
and O O
echocardiography O O
. O O

At O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
phase O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
1 O B_MEASURE
- O O
43 O B_MEASURE
ms O I_MEASURE
for O O
the O O
VMN O B_LOCATION/B_PROTEIN[GENE]
and O O
1 O B_MEASURE
- O O
10 O B_MEASURE
ms O I_MEASURE
for O O
the O O
LN O B_LOCATION/B_DISEASE
) O O
the O O
hypothalamic O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
cortical O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
responses O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
completely O O
inhibited O O
the O O
formation O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
the O O
VC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
response O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O O
the O O
light O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulus O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

6 O B_MEASURE
, O O
320 O B_MEASURE
cells O I_MEASURE
/ O O
mm3 O B_MEASURE
, O O
respectively O O
; O O
P O B_MEASURE/B_PERSON
less O I_MEASURE/I_PERSON
than O O
. O O
005 O B_MEASURE
) O O
; O O
twelve O B_NUMBER[MEASURE]
( O O
86 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
) O O
of O O
the O O
14 O B_PERSON
inmates O I_PERSON
who O O
developed O O
AIDS O B_DISEASE/B_GENE
had O O
counts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
of O O
less O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
5 O B_MEASURE
, O O
000 O B_MEASURE
cells O I_MEASURE
/ O O
mm3 O B_MEASURE
, O O
compared O O
with O O
only O O
six O B_NUMBER[MEASURE]
( O O
14 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
) O O
of O O
the O O
42 O B_PERSON
controls O I_PERSON
( O O
P O B_MEASURE
less O I_MEASURE
than O O
. O O
00001 O B_MEASURE
) O O
. O O

There O O
is O O
, O O
however O O
, O O
uncertainty O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
to O O
how O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
obtained O O
in O O
recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
experiments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
scale O O
up O O
to O O
landscape O B_LOCATION/B_PERSON
and O O
regional O B_LOCATION/B_BIO
levels O I_LOCATION/I_BIO
and O O
generalize O O
across O O
ecosystem O B_LOCATION/B_ORGANIZATION
types O I_LOCATION/I_ORGANIZATION
and O O
processes O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

The O O
facilitation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
started O O
preceding O O
the O O
onset O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
electromyographic O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
masseter O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
muscle O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
recruitment O O
of O O
constitutively O O
phosphorylated O O
p185 B B_GENE/B_DISEASE
( O O
neu B B_GENE/B_DISEASE
) O O
and O O
the O O
activated O O
mitogenic O O
pathway O O
proteins O O
to O O
this O O
membrane O O
- O O
microfilament O O
interaction O O
site O O
provides O O
a O O
physical O O
model O O
for O O
integrating O O
the O O
assembly O O
of O O
the O O
mitogenic O O
pathway O O
with O O
the O O
transmission O O
of O O
growth O O
factor O O
signal O O
to O O
the O O
cytoskeleton O O
. O O

Deletion O O
of O O
the O O
region O O
from O O
amino O O
acid O O
residues O O
2 O O
- O O
67 O O
in O O
E1A B B_GENE/B_MEASURE
, O O
which O O
has O O
been O O
postulated O O
to O O
interact O O
with O O
p300 B B_GENE/B_LOCATION
/ O O
CBP B B_MEASURE/B_GENE
, O O
also O O
abolished O O
the O O
inhibitory O O
effect O O
of O O
E1A B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
whereas O O
deletion O O
of O O
the O O
region O O
from O O
residues O O
120 O O
to O O
140 O O
had O O
no O O
effect O O
. O O

Quantitative O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Tl O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
201 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
stress O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
has O O
also O O
shown O O
viable O B_DISEASE_ADJECTIVE[DISEASE]
myocardium O I_DISEASE_ADJECTIVE[DISEASE]
in O O
most O O
mild O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
moderate O O
( O O
51 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
to O O
85 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
normal O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
uptake O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
irreversible O B_LOCATION/B_DISEASE
Tl O I_LOCATION/I_DISEASE
- O O
201 O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
defects O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
point O O
mutation O O
Asp O O
- O O
316 O O
- O O
- O O
> O O
Asn O O
in O O
the O O
C O O
- O O
terminus O O
of O O
p38 B B_GENE
, O O
analogous O O
to O O
the O O
ERK2 B B_GENE
( O O
extracellular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
signal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
sevenmaker B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutation O O
, O O
dramatically O O
decreases O O
its O O
binding O O
to O O
MKP B B_GENE
- I I_GENE
1 I I_GENE
and O O
substantially O O
compromises O O
its O O
stimulatory O O
effect O O
on O O
the O O
catalytic O O
activity O O
of O O
this O O
phosphatase O O
. O O

J O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Causal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
modeling O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
combines O O
theory O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
research O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
because O O
the O O
interpretation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
is O O
possible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
only O O
within O O
the O O
context O B_LOCATION
of O O
the O O
proposed O O
theory O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
it O O
offers O O
an O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
advancing O O
the O O
science O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
while O O
maintaining O O
the O O
specificity O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
practice O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
one O O
trial O O
, O O
116 O O
subjects O O
with O O
transfusion O O
- O O
related O O
chronic O O
hepatitis O O
C O O
were O O
treated O O
with O O
lymphoblastoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
interferon I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
5 O O
MU O O
/ O O
m2 O O
three O O
times O O
a O O
week O O
for O O
2 O O
mo O O
, O O
then O O
3 O O
MU O O
/ O O
m2 O O
three O O
times O O
a O O
week O O
for O O
4 O O
or O O
10 O O
mo O O
) O O
. O O

A O O
derived O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
RA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
resistant O B_LOCATION/B_GENE
line O I_LOCATION/I_GENE
, O O
NT2 O B_PROTEIN[GENE]/B_LOCATION
/ O O
D1 O B_LOCATION/B_PROTEIN[GENE]
- O O
R1 O B_MEASURE/B_PERSON
, O O
is O O
deficient O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
this O O
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
is O O
co O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
resistant O B_DISEASE_ADJECTIVE[DISEASE]
to O O
cisplatin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

BCR B B_PROTEIN[GENE]/B_LOCATION
- O O
ABL B B_MEASURE/B_GENE
elicits O O
transformation O O
of O O
both O O
fibroblast O O
and O O
hematopoietic O O
cells O O
and O O
blocks O O
apoptosis O O
following O O
cytokine O O
deprivation O O
in O O
various O O
factor O O
- O O
dependent O O
cells O O
. O O

Aggregation O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
washed O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
platelets O B_BIO/B_LOCATION
from O O
rats O B_BIO/B_PERSON
with O O
diabetes O B_DISEASE/B_LOCATION
was O O
enhanced O O
. O O

Sequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
region O B_GENE/B_LOCATION
showed O O
it O O
contained O O
five O B_MEASURE/B_LOCATION
potential O B_MEASURE/I_LOCATION
copies O B_MEASURE/I_LOCATION
of O O
the O O
sterol O B_GENE
regulatory O I_GENE
element O I_GENE
( O O
SRE O B_PROTEIN[GENE]/B_DISEASE
- O O
1 O B_NUMBER[MEASURE]
) O O
( O O
Smith O B_PERSON
, O O
J O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
R O B_OTHER/B_LOCATION
. O O
, O O
Osborne O B_PERSON/B_ORGANIZATION
, O O
T O B_PROTEIN[GENE]/B_LOCATION
. O O
F O B_OTHER/B_LOCATION
. O O
, O O
Brown O B_PERSON
, O O
M O B_LOCATION
. O O
S O B_OTHER/B_LOCATION
. O O
, O O
Goldstein O B_PERSON
, O O
J O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
L O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
and O O
Gil O B_PERSON
, O O
G O B_OTHER/B_PERSON
. O O

Mutations O O
in O O
Saccharomyces O O
cerevisiae O O
that O O
block O O
meiotic O O
prophase O O
chromosome O O
metabolism O O
and O O
confer O O
cell O O
cycle O O
arrest O O
at O O
pachytene O O
identify O O
two O O
new O O
meiosis B B_GENE/B_BIO
- I I_GENE/I_BIO
specific I I_GENE/I_BIO
genes I I_GENE/I_BIO
SAE1 I I_GENE/I_BIO
and O O
SAE3 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Isolation O O
and O O
characterization O O
of O O
human O O
orthologs O O
of O O
yeast O O
CCR4 B B_GENE
- O O
NOT B B_GENE/B_LOCATION
complex O O
subunits O O
. O O

Thus O O
, O O
the O O
i B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
leader I I_GENE/I_MEASURE
protein I I_GENE/I_MEASURE
is O O
a O O
viral O O
gene O O
product O O
of O O
unknown O O
function O O
and O O
high O O
stability O O
that O O
is O O
made O O
in O O
large O O
quantities O O
at O O
intermediate O O
times O O
of O O
productive O O
infection O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
400 O O
WORDS O O
) O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Latanoprost O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
administered O O
once O O
daily O O
was O O
significantly O O
more O O
effective O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
reducing O O
IOP O B_DISEASE/B_PROTEIN[GENE]
compared O O
with O O
unoprostone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
administered O O
twice O O
daily O O
in O O
patients O B_PERSON
with O O
POAG O B_LOCATION/B_DISEASE
and O O
OH O B_DISEASE
. O O

The O O
molecular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dynamics O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
simulations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
provide O O
insight O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O O
the O O
conformational O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
flexibility O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
these O O
analogs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
alfalfa O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
the O O
insecticides O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
caused O O
significant O B_DISEASE
mortality O I_DISEASE
to O O
most O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
insects O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluated O O
. O O

Therefore O O
, O O
we O O
have O O
reevaluated O O
the O O
age O O
- O O
related O O
changes O O
in O O
serum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
leptin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
and O O
their O O
relationship O O
with O O
adiposity O O
and O O
androgen O O
levels O O
in O O
a O O
large O O
group O O
of O O
community O O
dwelling O O
men O O
. O O

Injections O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
PD O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
solutions O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
with O O
13 O B_MEASURE
. O O
6 O B_MEASURE
, O O
22 O B_MEASURE
. O O
7 O B_MEASURE
, O O
and O O
38 O B_MEASURE
. O O
6 O B_MEASURE
g O I_MEASURE
/ O O
liter O B_MEASURE
of O O
glucose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
reduced O O
the O O
ingestion O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
sucrose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
by O O
12 O B_MEASURE
. O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
23 O B_MEASURE
. O O
6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
and O O
36 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
, O O
respectively O O
, O O
but O O
did O O
not O O
affect O O
the O O
ingestion O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
protein O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
. O O

It O O
is O O
recommended O O
that O O
area O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
correction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
be O O
attempted O O
in O O
bioequivalence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
drugs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
where O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
intrasubject O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
variability O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
clearance O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
known O O
or O O
suspected O O
. O O

Expression O O
of O O
the O O
E2 B B_GENE
protein I I_GENE
resulted O O
in O O
rapid O O
repression O O
of O O
HPV B B_GENE/B_VIRUS[BIO]
E6 I I_GENE/I_VIRUS[BIO]
and O O
E7 B B_PROTEIN[GENE]
expression O O
, O O
followed O O
approximately O O
12 O O
h O O
later O O
by O O
profound O O
inhibition O O
of O O
cellular O O
DNA O O
synthesis O O
. O O

Plasma B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
renin I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
activity O O
in O O
end O O
- O O
stage O O
kidney O O
disease O O
. O O

Immunoblotting O O
with O O
antiphosphotyrosine O O
antibody O O
showed O O
that O O
many O O
yeast O O
proteins O O
, O O
including O O
the O O
p34CDC28 B B_ENZYME[GENE]
kinase I I_ENZYME[GENE]
, O O
became O O
phosphorylated O O
at O O
tyrosine O O
in O O
cells O O
expressing O O
v B B_GENE
- I I_GENE
src I I_GENE
. O O

Renal O B_DISEASE/B_PERSON
cell O I_DISEASE/I_PERSON
carcinoma O I_DISEASE/I_PERSON
induced O O
Coombs O B_DISEASE
negative O I_DISEASE
autoimmune O I_DISEASE
hemolytic O I_DISEASE
anemia O I_DISEASE
and O O
severe O B_DISEASE_ADJECTIVE[DISEASE]
thrombocytopenia O I_DISEASE_ADJECTIVE[DISEASE]
responsive O I_DISEASE_ADJECTIVE[DISEASE]
to O O
nephrectomy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Pretreatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
different O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
dose O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
levels O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
CCl4 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulted O O
in O O
a O O
prolongation O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
TMO O B_MEASURE/B_LOCATION
half O B_MEASURE/I_LOCATION
- O O
life O B_TIME[MEASURE]/B_LOCATION
, O O
and O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
area O B_LOCATION/B_MEASURE
under O O
the O O
curve O B_MEASURE
( O O
AUC O B_LOCATION/B_MEASURE
) O O
, O O
and O O
a O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
clearance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
but O O
the O O
apparent O B_MEASURE/B_LOCATION
volume O I_MEASURE/I_LOCATION
of O O
distribution O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Vd O B_LOCATION/B_DISEASE
) O O
was O O
not O O
significantly O O
decreased O O
. O O

In O O
cells O O
co O O
- O O
expressing O O
high O O
levels O O
of O O
the O O
p38 B B_GENE
( O O
MAPK B B_GENE
) O O
kinase O O
( O O
MKK3 B B_GENE
) O O
together O O
with O O
the O O
p38 B B_GENE
( O O
MAPK B B_GENE/B_DISEASE
) O O
, O O
a O O
significant O O
inhibition O O
of O O
mitogen O O
- O O
induced O O
cyclin B B_GENE
D1 I I_GENE
expression O O
was O O
observed O O
. O O

In O O
patients O B_PERSON/B_BIO
autografted O O
in O O
CR1 O B_MEASURE
, O O
the O O
transplant O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
- O O
related O O
mortality O B_DISEASE
( O O
TRM O B_LOCATION/B_DISEASE
) O O
was O O
15 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
the O O
relapse O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
incidence O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
RI O B_LOCATION/B_PROTEIN[GENE]
) O O
was O O
58 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
5 O B_MEASURE
% O I_MEASURE
, O O
the O O
leukaemia O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
free O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
survival O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
LFS O B_DISEASE
) O O
was O O
36 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
5 O B_MEASURE
% O I_MEASURE
and O O
the O O
overall O B_DISEASE
survival O I_DISEASE
was O O
47 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
5 O B_MEASURE
% O I_MEASURE
at O O
3 O B_MEASURE/B_ENT
years O I_MEASURE/I_ENT
. O O

Administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
FR O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
34235 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
reduced O O
aortic O B_DISEASE
blood O I_DISEASE
pressure O I_DISEASE
and O O
increased O O
cardiac O B_DISEASE/B_GENE
output O I_DISEASE/I_GENE
in O O
anesthetized O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dogs O I_SPECIES[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
an O O
ameroid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
induced O O
coronary O B_DISEASE
artery O I_DISEASE
occlusion O I_DISEASE
. O O

The O O
primary O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
conditions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
acceptable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hospital O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
that O O
exhaled O O
- O O
volume O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
monitoring O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
be O O
performed O O
for O O
all O O
patients O B_PERSON/B_LOCATION
and O O
that O O
O2 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
monitoring O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
be O O
performed O O
both O O
when O O
setting O O
FIO2 O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
continuously O O
when O O
FIO2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
are O O
critical O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

The O O
RHO1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encodes O O
a O O
homolog O O
of O O
the O O
mammalian O O
RhoA B B_GENE/B_BIO
small I I_GENE/I_BIO
GTP I I_GENE/I_BIO
- I I_GENE/I_BIO
binding I I_GENE/I_BIO
protein I I_GENE/I_BIO
in O O
the O O
yeast O O
Saccharomyces O O
cerevisiae O O
. O O

As O O
regards O O
the O O
short O O
stature O O
, O O
they O O
have O O
proved O O
that O O
the O O
syndrome O O
is O O
related O O
to O O
low O O
levels O O
of O O
somatomedin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
C I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
SmC B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
. O O

2 O B_NUMBER[MEASURE]
. O O

Menstrual O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
and O O
lunar O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cycles O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

HBO O O
had O O
marked O O
effects O O
on O O
these O O
enzymes O O
: O O
lung B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
SOD I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
increased O O
( O O
guinea O O
pigs O O
47 O O
% O O
, O O
rats O O
88 O O
% O O
) O O
and O O
CAT B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
GSHPx B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activities O O
decreased O O
( O O
33 O O
% O O
) O O
in O O
brain O O
and O O
lung O O
. O O

Smectic O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
A O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ordering O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
at O O
a O O
liquid O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
vapor O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
interface O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Phylogenetic O O
analysis O O
of O O
yeast O O
, O O
invertebrate O O
, O O
and O O
multiple O O
mammalian O O
isoforms O O
of O O
SNF4 B B_GENE
shows O O
that O O
the O O
gene O O
duplication O O
likely O O
occurred O O
early O O
in O O
the O O
metazoan O O
lineage O O
, O O
as O O
the O O
protein O O
products O O
of O O
the O O
different O O
loci O O
are O O
relatively O O
divergent O O
. O O

Hard O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
methacrylic O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
polymers O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

Thus O O
the O O
Hi O O
- O O
RARE O O
represents O O
a O O
new O O
type O O
of O O
RA O O
response O O
element O O
with O O
a O O
role O O
in O O
the O O
modulation O O
of O O
the O O
expression O O
of O O
MHC B B_GENE
class I I_GENE
1 I I_GENE
family O O
genes O O
. O O

We O O
found O O
multiple O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
start O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
located O O
within O O
a O O
15 O B_NUMBER[MEASURE]
- O O
base O B_MEASURE/B_LOCATION
pair O I_MEASURE/I_LOCATION
region O I_MEASURE/I_LOCATION
, O O
205 O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
base O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
pairs O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
upstream O O
of O O
the O O
translation O B_GENE/B_PERSON
start O I_GENE/I_PERSON
codon O I_GENE/I_PERSON
. O O

During O O
the O O
last O B_TIME[MEASURE]/B_ENT
three O I_TIME[MEASURE]/I_ENT
days O I_TIME[MEASURE]/I_ENT
of O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
mean O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
urine O B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
osmolality O B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Uosm O B_LOCATION/B_PROTEIN[GENE]
) O O
and O O
free O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
water O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reabsorption O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TCH2O O B_PROTEIN[GENE]/B_LOCATION
) O O
increased O O
significantly O O
: O O
[ O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
formula O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O O
see O O
text O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

The O O
structural O O
intestinal O O
defects O O
are O O
presumed O O
to O O
be O O
the O O
result O O
of O O
defective O O
collagen B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthesis O O
in O O
these O O
hereditary O O
connective O O
tissue O O
disorders O O
. O O

Rev O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Although O O
indomethacin O O
is O O
useful O O
for O O
examining O O
the O O
role O O
of O O
cyclooxygenase B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
products I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
asthmatic O O
responses O O
, O O
it O O
should O O
not O O
be O O
considered O O
in O O
the O O
treatment O O
of O O
asthma O O
. O O

Incidence O O
of O O
beta O O
- O O
thalassemia O O
carriers O O
and O O
those O O
deficient O O
in O O
erythrocyte B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucose I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphate I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dehydrogenase I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
greater O O
Buenos O O
Aires O O
area O O

Both O O
v B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Myb I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
c B B_GENE
- I I_GENE
Myb I I_GENE
bind O O
specifically O O
to O O
delta B B_GENE
E3 I I_GENE
. O O

Anatomical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
considerations O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O O
transsphenoidal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_EDU[ORGANIZATION]
hypophysectomy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_EDU[ORGANIZATION]
. O O

The O O
salt O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sensitivity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
interaction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O O
that O O
two O B_NUMBER[MEASURE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ion O I_NUMBER[MEASURE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pairs O I_NUMBER[MEASURE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
involved O O
in O O
the O O
association O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Zn2 O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
NC O B_DISEASE/B_PROTEIN[GENE]
- O O
F1 O B_PROTEIN[GENE]/B_MEASURE
) O O
with O O
polynucleotide O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
whereas O O
one O B_NUMBER[MEASURE]/B_PERSON
ion O I_NUMBER[MEASURE]/I_PERSON
pair O I_NUMBER[MEASURE]/I_PERSON
is O O
found O O
in O O
the O O
metal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
free O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
peptide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
nucleic O B_PROTEIN[GENE]
acid O I_PROTEIN[GENE]
complex O I_PROTEIN[GENE]
. O O

Investigation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O O
the O O
asymmetrical O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induced O O
yields O B_DISEASE
in O O
90Sr O B_LOCATION/B_PROTEIN[GENE]
- O O
90Y O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
beta O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
irradiated O O
D O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
and O O
L O B_PROTEIN[GENE]/B_LOCATION
- O O
alanines O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

An O O
hcr1 B B_GENE
null O O
mutant O O
was O O
viable O O
, O O
but O O
showed O O
slight O O
reduction O O
of O O
growth O O
when O O
compared O O
with O O
the O O
wild O O
- O O
type O O
strain O O
. O O

Serum O O
levels O O
of O O
total O O
and O O
specific B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunoglobulin I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
IgE B B_PROTEIN[GENE]/B_LOCATION
) O O
have O O
been O O
determined O O
by O O
radioimmunoassays O O
in O O
sixty O O
- O O
nine O O
allergic O O
subjects O O
. O O

IgE B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
Psocoptera O O
were O O
determined O O
by O O
immunoblotting O O
experiments O O
. O O

We O O
also O O
show O O
that O O
the O O
products O O
of O O
both O O
the O O
GIY B B_TIME[MEASURE]/B_GENE
- I I_TIME[MEASURE]/I_GENE
YIG I I_TIME[MEASURE]/I_GENE
ORF O O
and O O
the O O
non O O
- O O
canonical O O
LAGLI B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_VIRUS[BIO]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_VIRUS[BIO]
DADG I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_VIRUS[BIO]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_VIRUS[BIO]
GIY I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_VIRUS[BIO]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_VIRUS[BIO]
YIG I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_VIRUS[BIO]
ORF O O
, O O
which O O
is O O
generated O O
by O O
its O O
integration O O
, O O
have O O
endonuclease O O
activities O O
which O O
recognize O O
and O O
cut O O
the O O
insertion O O
site O O
of O O
the O O
optional O O
sequence O O
. O O

Further O O
, O O
we O O
find O O
that O O
the O O
BMI1 B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
can O O
also O O
interact O O
with O O
itself O O
. O O

Indeed O O
, O O
ectopic O O
expression O O
of O O
MOX4 B B_GENE
in O O
aerobic O O
cells O O
resulted O O
in O O
partially O O
constitutive O O
expression O O
of O O
DAN1 B B_GENE
. O O

We O O
measured O O
electromyograms O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
EMG O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
of O O
the O O
alae O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
nasi O I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
to O O
determine O O
the O O
relationship O B_PERSON/B_MEASURE
between O O
their O O
activity O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
timing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
contraction O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
rib O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cage O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
muscles O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
diaphragm O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
during O O
obstructive O B_DISEASE/B_ORGANISM_FUNCTION
apnea O I_DISEASE/I_ORGANISM_FUNCTION
in O O
nine O B_PERSON/B_TIME[MEASURE]
patients O I_PERSON/I_TIME[MEASURE]
. O O

Hybridization O O
was O O
detected O O
between O O
polyadenylated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
H I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
isolated O O
from O O
the O O
majority O O
of O O
the O O
hybridomas O O
, O O
and O O
the O O
VH B B_DISEASE/B_GENE
probe O O
. O O

Identification O O
of O O
a O O
putative O O
infC B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
rpmI B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
rplT B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
operon O O
flanked O O
by O O
long O O
inverted O O
repeats O O
in O O
Mycoplasma O O
fermentans O O
( O O
incognitus O O
strain O O
) O O
. O O

The O O
standardized O B_MEASURE
incidence O I_MEASURE
in O O
Europeans O B_LOCATION/B_BIO
has O O
risen O O
significantly O O
to O O
4 O B_MEASURE
. O O
7 O B_MEASURE
/ O O
10 O B_MEASURE
( O O
5 O B_MEASURE
) O O
/ O O
year O B_TIME[MEASURE]/B_PERSON
from O O
3 O B_MEASURE
. O O
4 O B_MEASURE
/ O O
10 O B_MEASURE
( O O
5 O B_MEASURE
) O O
/ O O
year O B_TIME[MEASURE]/B_PERSON
in O O
the O O
1970s O B_TIME[MEASURE]/B_LOCATION
( O O
chi O B_PERSON/B_PROTEIN[GENE]
2 O I_PERSON/I_PROTEIN[GENE]
= O O
8 O B_MEASURE
. O O
1 O B_MEASURE
, O O
p O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE
. O O
005 O B_MEASURE
) O O
. O O

Neurological O B_DISEASE
toxicity O I_DISEASE
occurred O O
in O O
8 O B_MEASURE
/ O O
219 O B_MEASURE
patients O I_MEASURE
treated O O
with O O
fludarabine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
FAMP O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
30 O B_MEASURE
mg O I_MEASURE
/ O O
m2 O B_MEASURE
per O O
day O B_TIME[MEASURE]
and O O
cytosine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arabinoside O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Ara O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
- O O
C O B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
0 O B_MEASURE
. O O
5 O B_MEASURE
g O I_MEASURE
/ O O
m2 O O
per O O
hour O B_TIME[MEASURE]/B_ENT
for O O
2 O B_NUMBER[MEASURE]
- O O
6 O B_TIME[MEASURE]/B_SPORT[ENT]
hours O I_TIME[MEASURE]/I_SPORT[ENT]
for O O
5 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days O B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
for O O
new O B_DISEASE_ADJECTIVE[DISEASE]
or O O
relapsed O B_DISEASE_ADJECTIVE[DISEASE]
acute O I_DISEASE_ADJECTIVE[DISEASE]
leukemia O I_DISEASE_ADJECTIVE[DISEASE]
or O O
myelodysplasia O B_DISEASE
. O O

Evaluation O O
of O O
gamma B B_DISEASE_ADJECTIVE[DISEASE]
- I I_DISEASE_ADJECTIVE[DISEASE]
glutamyl I I_DISEASE_ADJECTIVE[DISEASE]
transpeptidase I I_DISEASE_ADJECTIVE[DISEASE]
in O O
myocardial O O
infarction O O
. O O

Loss O O
of O O
pRb B B_GENE
or O O
p107 B B_GENE
binding O O
results O O
in O O
the O O
loss O O
of O O
transforming O O
activity O O
. O O

The O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
suggests O O
that O O
seroprevalence O B_DISEASE/B_MEASURE
of O O
Lyme O B_DISEASE/B_SPECIES[BIO]
borreliosis O I_DISEASE/I_SPECIES[BIO]
in O O
dogs O B_BIO/B_PERSON
of O O
the O O
Kosice O B_LOCATION/B_BIO
region O I_LOCATION/I_BIO
is O O
not O O
negligible O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

Peak O O
insulin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O O
to O O
glucose O O
infusion O O
declined O O
from O O
Groups O O
1 O O
to O O
3 O O
( O O
51 O O
+ O O
/ O O
- O O
14 O O
, O O
42 O O
. O O
4 O O
+ O O
/ O O
- O O
31 O O
, O O
20 O O
. O O
4 O O
+ O O
/ O O
- O O
6 O O
. O O
8 O O
microU O O
/ O O
ml O O
, O O
respectively O O
) O O
with O O
Group O O
3 O O
exhibiting O O
a O O
significantly O O
decreased O O
mean O O
peak O O
level O O
compared O O
to O O
the O O
other O O
groups O O
. O O

Iris O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
binding O I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
bioavailability O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

The O O
influence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
high O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
n O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
PUFA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
intake O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
measures O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
lipid O B_DISEASE/B_GENE
peroxidation O I_DISEASE/I_GENE
has O O
been O O
equivocal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
proliferative O O
potential O O
of O O
the O O
pilocytic O O
astrocytoma O O
: O O
the O O
relation O O
between O O
MIB B B_GENE
- I I_GENE
1 I I_GENE
labeling O O
and O O
clinical O O
and O O
neuro O O
- O O
radiological O O
follow O O
- O O
up O O
. O O

RESULTS O O
: O O
Here O O
, O O
we O O
report O O
the O O
identification O O
of O O
two O O
major O O
and O O
novel O O
Shc B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tyrosine O O
phosphorylation O O
sites O O
, O O
Y239 O O
and O O
Y240 O O
. O O

Dominant O O
- O O
negative O O
upf1 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutations O O
were O O
isolated O O
following O O
in O O
vitro O O
mutagenesis O O
of O O
a O O
plasmid O O
containing O O
the O O
UPF1 B B_GENE
gene I I_GENE
. O O

The O O
tensile O B_MEASURE
strengths O I_MEASURE
of O O
an O O
adhesive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
luting O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
resin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
' O O
Panavia O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
EX O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
' O O
to O O
the O O
bovine O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dentin O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
decreased O O
significantly O O
by O O
the O O
zinc O B_TIME[MEASURE]
iontophoresis O I_TIME[MEASURE]
. O O

We O O
previously O O
identified O O
a O O
highly O O
conserved O O
L O O
- O O
X O O
- O O
X O O
- O O
L O O
- O O
F O O
sequence O O
near O O
the O O
C O O
terminus O O
of O O
the O O
p6 B B_GENE/B_LOCATION
domain I I_GENE/I_LOCATION
of O O
the O O
Gag B B_GENE
precursor I I_GENE
as O O
the O O
major O O
virion O O
association O O
motif O O
for O O
HIV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Vpr I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Papillomavirus O O
type O O
16 O O
oncogenes O O
downregulate O O
expression O O
of O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
responsive O O
genes O O
and O O
upregulate O O
proliferation O O
- O O
associated O O
and O O
NF B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
kappaB I I_GENE/I_DISEASE
- O O
responsive O O
genes O O
in O O
cervical O O
keratinocytes O O
. O O

The O O
A3B3 O B_GENE
domain O I_GENE
had O O
a O O
mass O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
34 O B_MEASURE
, O O
462 O B_MEASURE
, O O
with O O
a O O
glycosylation O B_MEASURE/B_LOCATION
mass O I_MEASURE/I_LOCATION
of O O
14 O B_MEASURE
, O O
900 O B_MEASURE
, O O
in O O
good O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
agreement O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O O
seven O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
N O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
linked O O
glycosylation O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
sites O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
of O O
average O B_GENE
mass O I_GENE
2100 O I_GENE
. O O

We O O
found O O
that O O
the O O
frequency O B_MEASURE/B_ENT
spectrum O I_MEASURE/I_ENT
of O O
physiologic O B_DISEASE/B_ENT
chest O I_DISEASE/I_ENT
sounds O I_DISEASE/I_ENT
is O O
contained O O
entirely O O
within O O
that O O
of O O
jet O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
rotocraft O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
noise O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
CA11 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
appears O O
to O O
be O O
located O O
between O O
the O O
secretor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
type I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fucosyltransferase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cluster I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
FUT1 B B_PROTEIN[GENE]
- O O
FUT2 B B_PROTEIN[GENE]/B_MEASURE
- O O
FUT2P B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
the O O
D B B_GENE
- I I_GENE
site I I_GENE
binding I I_GENE
protein I I_GENE
gene I I_GENE
( O O
DBP B B_GENE/B_DISEASE
) O O
on O O
chromosome O O
19q13 O O
. O O
3 O O
. O O

An O O
anoerxiant O O
, O O
mazindol O O
suppresses O O
food O O
intake O O
by O O
1 O O
) O O
stimulating O O
beta B B_DISEASE/B_ORGANISM_FUNCTION
- I I_DISEASE/I_ORGANISM_FUNCTION
adrenergic I I_DISEASE/I_ORGANISM_FUNCTION
receptors I I_DISEASE/I_ORGANISM_FUNCTION
, O O
2 O O
) O O
inhibiting O O
the O O
feeding O O
center O O
and O O
, O O
3 O O
) O O
stimulating O O
the O O
satiety O O
center O O
in O O
the O O
hypothalamus O O
. O O

These O O
segments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
may O O
represent O O
pseudogenes O B_DISEASE/B_BACTERIUM[BIO]
. O O

The O O
fusion O O
of O O
AML1 B B_GENE/B_DISEASE
to O O
MDS1 B B_GENE/B_DISEASE
is O O
in O O
frame O O
, O O
and O O
adds O O
127 O O
codons O O
to O O
the O O
interrupted O O
AML1 B B_GENE/B_LOCATION
. O O

In O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
antibiotic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lasalocid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
rumen O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
anaerobic O B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
fungus O B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
Neocallimastix O B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
frontalis O B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
RK O B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
21 O B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
was O O
examined O O
. O O

WBC O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differential O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SEG O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
BAND O B_ENT/B_GENE
, O O
LYMPH O B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
MONO O B_LOCATION/B_DISEASE
, O O
EOSINO O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
BASO O B_LOCATION/B_MEASURE
) O O
usually O O
showed O O
log O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
normal O B_MEASURE/B_LOCATION
distribution O I_MEASURE/I_LOCATION
. O O

A O O
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
oligomerization O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subunit O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
folding O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Chromosome O B_BIO/B_GENE
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
STSs O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
for O O
27 O B_DISEASE
telomeres O I_DISEASE
were O O
identified O O
from O O
the O O
196 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
TYACs O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

Second O O
, O O
overexpression O O
of O O
RIM11 B B_GENE
can O O
suppress O O
an O O
ime1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
missense O O
mutation O O
( O O
ime1 B B_PROTEIN[GENE]/B_DISEASE
- I I_PROTEIN[GENE]/I_DISEASE
L321F I I_PROTEIN[GENE]/I_DISEASE
) O O
but O O
not O O
an O O
ime1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deletion O O
. O O

Calculation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
energy O B_MEASURE/B_LOCATION
levels O I_MEASURE/I_LOCATION
, O O
E1 O O
transition O B_MEASURE/B_ORGANIZATION
amplitudes O I_MEASURE/I_ORGANIZATION
, O O
and O O
parity O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
violation O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
francium O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

All O O
except O O
the O O
last O B_SEQUENCE[MEASURE]
two O I_SEQUENCE[MEASURE]
interventions O I_SEQUENCE[MEASURE]
are O O
physical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
create O O
a O O
wound O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
tissue O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
environment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
conducive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
healing O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

This O O
50 O O
- O O
kDa O O
protein O O
contains O O
two O O
SH2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
domains I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
an O O
inter B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
SH2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
p85alpha B B_GENE
, O O
but O O
the O O
SH3 B B_GENE
and O O
bcr B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
homology I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
domains I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
p85alpha B B_GENE/B_PERSON
were O O
replaced O O
by O O
a O O
unique O O
6 O O
- O O
amino O O
acid O O
sequence O O
. O O

Hydropathy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
deduced O B_GENE
A4 O I_GENE
amino O I_GENE
acid O I_GENE
sequence O I_GENE
revealed O O
four O B_MEASURE/B_LOCATION
putative O B_MEASURE/I_LOCATION
membrane O B_MEASURE/I_LOCATION
- O O
spanning O O
alpha O B_PROTEIN[GENE]/B_NUMBER[MEASURE]
- O O
helices O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

A O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
double O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
blind O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
topical O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
miconazole O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
clotrimazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O O
superficial O B_DISEASE
fungal O I_DISEASE
infections O I_DISEASE
and O O
erythrasma O B_DISEASE
. O O

Studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O O
low O B_MEASURE/B_COLOR
- O O
dose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
oral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contraceptives O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O O
cervical O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
mucus O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
plasma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
changes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
relation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
circulating O O
D O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
norgestrel O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
17alpha O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
ethynyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O O
estradiol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentrations O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Herewith O B_LOCATION
C O I_LOCATION
. O O
psittaci O B_BACTERIUM[BIO]/B_PERSON
could O O
be O O
diagnosed O O
in O O
all O O
positive O B_LOCATION/B_PERSON
samples O I_LOCATION/I_PERSON
. O O

The O O
more O O
sustained O O
effect O O
of O O
cyclofenil O O
on O O
prolactin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
secretion O O
with O O
a O O
reduced O O
frequency O O
of O O
relapse O O
, O O
and O O
the O O
lower O O
oestradiol O O
level O O
, O O
which O O
might O O
indicate O O
a O O
reduced O O
risk O O
of O O
thromboembolism O O
, O O
suggest O O
that O O
this O O
drug O O
has O O
some O O
advantage O O
over O O
bromocriptine O O
in O O
the O O
inhibition O O
of O O
postpartum O O
lactation O O
. O O

Response O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
surface O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
methodology O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
employed O O
to O O
describe O O
the O O
relationship O B_PERSON/B_MEASURE
between O O
soman O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
induced O O
incapacitation O B_DISEASE
and O O
the O O
ATR O B_LOCATION/B_PROTEIN[GENE]
/ O O
DZ O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
ATR O B_LOCATION/B_PROTEIN[GENE]
/ O O
SCP O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
dosages O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
brains O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
bisected O O
and O O
T1 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
T2 O B_PROTEIN[GENE]/B_LOCATION
relaxation O I_PROTEIN[GENE]/I_LOCATION
times O I_PROTEIN[GENE]/I_LOCATION
were O O
determined O O
for O O
the O O
right O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
and O O
left O O
hemispheres O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
MR O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
spectroscopy O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
immediately O O
after O O
dissection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Simulations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
velocities O B_MEASURE/B_DISEASE
, O O
vorticity O B_MEASURE/B_LOCATION
, O O
pressure O B_DISEASE/B_MEASURE
and O O
certain O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
stress O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
values O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
were O O
developed O O
by O O
a O O
computer O B_PRODUCT[OBJECT]/B_PERSON
and O O
displayed O O
for O O
man O B_PERSON
- O O
machine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
interaction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

In O O
the O O
present O O
study O O
, O O
we O O
report O O
the O O
entire O O
genomic O O
structure O O
of O O
KCNQ1 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
consists O O
of O O
19 O O
exons O O
spanning O O
400 O O
kb O O
on O O
chromosome O O
11p15 O O
. O O
5 O O
. O O

Northern O O
( O O
RNA O O
) O O
blot O O
hybridization O O
analysis O O
with O O
the O O
p68c B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
- I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
ets I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
- I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
1 I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
specific O O
sequence O O
and O O
RNase B B_ENZYME[GENE]
protection O O
experiments O O
showed O O
that O O
the O O
corresponding O O
mRNA O O
was O O
expressed O O
in O O
normal O O
chicken O O
spleen O O
and O O
not O O
in O O
normal O O
chicken O O
thymus O O
or O O
in O O
various O O
T O O
lymphoid O O
cell O O
lines O O
. O O

To O O
investigate O O
this O O
issue O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
we O O
used O O
a O O
recognition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
task O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
which O O
two O B_ENT/B_MEASURE
strings O I_ENT/I_MEASURE
of O O
letters O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O O
presented O O
sequentially O O
. O O

Kettin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
large O O
modular O O
protein O O
associated O O
with O O
thin O O
filaments O O
in O O
the O O
Z O O
- O O
disc O O
region O O
of O O
insect O O
muscles O O
. O O

Enzymatic O B_GENE
and O O
chemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
structure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
probing O O
revealed O O
mainly O O
the O O
conserved O B_LOCATION/B_MEASURE
terminal O I_LOCATION/I_MEASURE
part O I_LOCATION/I_MEASURE
( O O
termed O O
3 O B_NUMBER[MEASURE]
' O O
C O B_PROTEIN[GENE]/B_LOCATION
) O O
of O O
the O O
DI9c O B_MEASURE
3 O I_MEASURE
' O O
UTR O B_GENE/B_LOCATION
containing O O
distinctive O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
RNA O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
motifs O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O O
i O O
. O O
e O O
. O O
, O O
a O O
stable O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
stem O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
- O O
loop O B_LOCATION/B_ORGANIZATION
, O O
SL O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
I O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
near O O
the O O
RNA O B_NUMBER[MEASURE]
3 O I_NUMBER[MEASURE]
' O O
terminus O B_LOCATION/B_MEASURE
and O O
a O O
considerably O O
less O O
stable O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
stem O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
- O O
loop O B_LOCATION
, O O
SL O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
II O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
that O O
forms O O
the O O
5 O B_NUMBER[MEASURE]
' O O
portion O B_MEASURE/B_LOCATION
of O O
3 O B_NUMBER[MEASURE]
' O O
C O B_GENE/B_LOCATION
. O O

This O O
review O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
chronicles O O
the O O
characteristics O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
deliberate O B_DISEASE_ADJECTIVE[DISEASE]
and O O
accidental O B_DISEASE
mass O I_DISEASE
poisonings O I_DISEASE
that O O
occurred O O
in O O
World O B_TIME[MEASURE]/B_PROTEIN[GENE]
Wars O I_TIME[MEASURE]/I_PROTEIN[GENE]
I O I_TIME[MEASURE]/I_PROTEIN[GENE]
and O O
II O B_TIME[MEASURE]/B_PROTEIN[GENE]
, O O
in O O
Bhopal O B_LOCATION/B_PERSON
, O O
and O O
in O O
other O B_LOCATION
historical O I_LOCATION
cases O I_LOCATION
up O O
to O O
and O O
including O O
modern O B_LOCATION/B_ENT
wars O I_LOCATION/I_ENT
. O O

The O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
4 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
weeks O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
cyclosporin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
7 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
per O O
day O B_TIME[MEASURE]/B_PERSON
) O O
( O O
CyA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
on O O
the O O
survival O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
vascularized O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
osteochondral O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
grafts O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
between O O
rat O B_PERSON/B_LOCATION
strains O I_PERSON/I_LOCATION
[ O I_PERSON
DA O I_PERSON
( O O
donor O B_PERSON
) O O
and O O
Lewis O B_PROTEIN[GENE]/B_BIO
( O O
recipient O B_PERSON/B_BIO
) O O
] O B_OTHER/B_DISEASE
and O O
the O O
presence O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
and O O
significance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
host O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immune O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tolerance O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
graft O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
antigen O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
modulation O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O O
cessation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
immunosuppression O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
been O O
examined O O
. O O

By O O
incorporating O O
a O O
stent O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEDICAL_DEVICE[OBJECT]
with O O
posts O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
that O O
pivot O O
about O O
their O O
base O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
, O O
such O B_TIME[MEASURE]/B_LOCATION
that O O
a O O
10 O B_TIME[MEASURE]/B_LOCATION
% O I_TIME[MEASURE]/I_LOCATION
expansion O I_TIME[MEASURE]/I_LOCATION
at O O
the O O
commissures O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
is O O
realized O O
, O O
we O O
were O O
able O B_TIME[MEASURE]/B_PERSON
to O O
reduce O O
the O O
compressive O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
commissural O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
stressing O O
from O O
250 O B_MEASURE
to O O
150 O B_MEASURE
kPa O I_MEASURE
. O O

In O O
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
mean O O
z O B_MEASURE
- O O
score O B_MEASURE/B_ENT
for O O
GFR O B_NUMBER[MEASURE]/B_PERSON
was O O
- O O
0 O B_MEASURE
. O O
27 O B_MEASURE
( O O
94 O B_MEASURE
. O O
6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
normal O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
in O O
group O B_MEASURE/B_PERSON
2 O I_MEASURE/I_PERSON
mean O I_MEASURE/I_PERSON
z O O
- O O
score O B_MEASURE/B_ENT
was O O
- O O
1 O B_MEASURE
. O O
51 O B_MEASURE
( O O
72 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
normal O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
two O B_DISEASE_ADJECTIVE[DISEASE]/B_ENT
kidneys O I_DISEASE_ADJECTIVE[DISEASE]/I_ENT
) O O
( O O
P O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
022 O B_MEASURE
, O O
Mann O B_PERSON
- O O
Whitney O B_PERSON
U O I_PERSON
- O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
. O O

The O O
cooperation O B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
health O B_PERSON/B_LOCATION
and O O
hospital O B_ORGANIZATION/B_PERSON
services O I_ORGANIZATION/I_PERSON

The O O
free O B_MEASURE/B_DISEASE
fraction O I_MEASURE/I_DISEASE
of O O
amitriptyline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
AT O O
) O O
, O O
measured O O
by O O
equilibrium O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
dialysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
plasma O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
from O O
29 O B_MEASURE
AT O O
- O O
treated O O
depressed O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
was O O
5 O B_NUMBER[MEASURE]
. O O
4 O B_MEASURE
- O O
9 O B_NUMBER[MEASURE]
. O O
8 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
( O O
mean O B_MEASURE
7 O I_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
, O O
which O O
was O O
the O O
same O B_MEASURE/B_LOCATION
as O O
the O O
values O B_MEASURE
in O O
26 O B_PERSON/B_MEASURE
healthy O I_PERSON/I_MEASURE
controls O I_PERSON/I_MEASURE
( O O
4 O B_NUMBER[MEASURE]
. O O
9 O B_MEASURE
- O O
9 O B_MEASURE
. O O
6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
mean O O
7 O B_MEASURE
. O O
6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
. O O

Different O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
reoxygenation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
electrical O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
ventricular O B_BODY_PART_OR_ORGAN_COMPONENT
muscle O I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Metastatic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tumours O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
bone O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
in O O
Nigerians O B_BIO/B_PERSON
. O O

However O O
, O O
microinjection O O
of O O
reconstituted O O
mRNPs O O
into O O
Xenopus O O
oocytes O O
demonstrates O O
that O O
although O O
translational O O
repression O O
occurs O O
in O O
the O O
absence O O
of O O
consensus O O
RNA O O
binding O O
sequences O O
for O O
FRGY2 B B_GENE
, O O
the O O
presence O O
of O O
FRGY2 B B_GENE
recognition I I_GENE
elements I I_GENE
within O O
mRNA O O
potentiates O O
translational O O
repression O O
. O O

Any O O
respectative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
material O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
class O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
0 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
was O O
not O O
obtained O O
from O O
334 O B_MEASURE
patients O I_MEASURE
( O O
4 O B_MEASURE
. O O
2 O B_MEASURE
% O I_MEASURE
) O O
, O O
class O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O O
- O O
II O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
findings O I_NUMBER[MEASURE]/I_PROTEIN[GENE]
belonged O O
to O O
6m141 O B_MEASURE
patients O I_MEASURE
( O O
76 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
, O O
950 O B_MEASURE
patients O I_MEASURE
( O O
11 O B_MEASURE
. O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
were O O
classified O O
as O O
class O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
HII O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
IV O B_MEASURE
, O O
578 O B_MEASURE
patients O I_MEASURE
( O O
7 O B_MEASURE
. O O
2 O B_MEASURE
% O I_MEASURE
) O O
as O O
class O B_LOCATION/B_PERSON
V O B_LOCATION/I_PERSON
. O O

However O O
, O O
whether O O
this O O
was O O
associated O O
with O O
spleen O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
removal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
after O O
adjustment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
not O O
determined O O
. O O

Virgin O B_PERSON/B_COLOR
, O O
P O B_OTHER/B_MEASURE
. O O

IL B B_GENE/B_BACTERIUM[BIO]
- I B_GENE/I_BACTERIUM[BIO]
6 I B_GENE/I_BACTERIUM[BIO]
was O O
detected O O
in O O
the O O
urine O O
of O O
52 O O
% O O
of O O
children O O
with O O
pyelonephritis O O
compared O O
with O O
15 O O
% O O
of O O
other O O
children O O
( O O
P O O
< O O
0 O O
. O O
001 O O
) O O
. O O

We O O
have O O
determined O O
the O O
complete O O
cDNA O O
sequence O O
of O O
rat B B_GENE
plectin I I_GENE
from O O
a O O
number O O
of O O
well O O
- O O
characterized O O
overlapping O O
lambda O O
gt11 O O
clones O O
. O O

SETTING O O
- O O
- O O
Hospital O B_LOCATION/B_PERSON
laboratories O B_LOCATION/I_PERSON
in O O
the O O
United O B_LOCATION
States O I_LOCATION
submitting O O
pneumococcal O B_VIRUS[BIO]/B_DISEASE
isolates O O
to O O
the O O
CDC O B_ORGANIZATION/B_LOCATION
between O O
October O B_TIME[MEASURE]
1 O I_TIME[MEASURE]
, O O
1991 O B_MEASURE
, O O
and O O
September O B_TIME[MEASURE]
30 O I_TIME[MEASURE]
, O O
1992 O B_MEASURE
. O O

The O O
terminal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O O
sequence O B_LOCATION/B_GENE
of O O
the O O
herpes O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
simplex O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genome O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contains O O
the O O
promoter O B_GENE
of O O
a O O
gene O B_GENE/B_LOCATION
located O O
in O O
the O O
repeat O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
sequences O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
L O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
component O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
contrast O O
to O O
p62 B B_GENE
( O O
dok B B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O O
, O O
DOKL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
lacks O O
YxxP O O
motifs O O
in O O
the O O
C O O
terminus O O
and O O
does O O
not O O
bind O O
to O O
Ras B B_GENE
GTPase I I_GENE
- I I_GENE
activating I I_GENE
protein I I_GENE
( O O
RasGAP B B_GENE/B_DISEASE
) O O
upon O O
phosphorylation O O
. O O

These O O
observations O O
demonstrate O O
that O O
KSR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
capable O O
of O O
uncoupling O O
the O O
MAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation O O
from O O
its O O
target O O
phosphorylation O O
, O O
and O O
thus O O
provide O O
a O O
novel O O
mechanism O O
for O O
modulating O O
the O O
Ras B B_GENE/B_DISEASE
- O O
MAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O O
pathway O O
. O O

G B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
CSF I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
10 O O
microg O O
/ O O
kg O O
) O O
was O O
started O O
on O O
day O O
+ O O
1 O O
and O O
all O O
patients O O
engrafted O O
within O O
a O O
median O O
day O O
number O O
of O O
12 O O
( O O
range O O
, O O
10 O O
- O O
22 O O
) O O
until O O
leukocytes O O
> O O
1 O O
. O O
0 O O
x O O
10 O O
( O O
9 O O
) O O
/ O O
l O O
and O O
a O O
median O O
day O O
number O O
of O O
56 O O
( O O
range O O
, O O
10 O O
- O O
180 O O
) O O
until O O
platelets O O
> O O
20 O O
. O O
0 O O
x O O
10 O O
( O O
9 O O
) O O
/ O O
l O O
( O O
ie O O
platelet O O
transfusion O O
independence O O
) O O
. O O

A O O
higher O O
percentage O O
of O O
children O O
with O O
cerebral O O
malaria O O
( O O
40 O O
per O O
cent O O
) O O
than O O
with O O
non O O
- O O
cerebral O O
malaria O O
( O O
29 O O
per O O
cent O O
) O O
or O O
controls O O
( O O
20 O O
per O O
cent O O
) O O
also O O
had O O
either O O
serum B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ferritin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
< O O
100 O O
micrograms O O
/ O O
l O O
and O O
inflammation O O
or O O
sTfR B B_GENE
> O O
7 O O
. O O
3 O O
mg O O
/ O O
l O O
or O O
both O O
. O O

During O O
the O O
burst O O
period O O
( O O
approximately O O
5 O O
- O O
10 O O
min O O
) O O
, O O
local O O
blood O O
H2O2 O O
concentrations O O
and O O
xanthine B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
oxidase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activities O O
were O O
highly O O
correlated O O
( O O
r O O
= O O
0 O O
. O O
999 O O
) O O
. O O

Previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O O
demonstrated O O
that O O
the O O
21 O B_MEASURE
- O O
or O O
the O O
72 O B_MEASURE
- O O
bp O B_LOCATION/B_MEASURE
repeat O I_LOCATION
transcriptional O B_LOCATION/B_PERSON
control O I_LOCATION
elements O I_LOCATION
enhance O O
the O O
efficiency O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
SV40 O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
DNA O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
replication O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
provided O O
either O O
of O O
these O O
repeats O B_GENE/B_DISEASE
is O O
located O O
near O O
the O O
end O B_LOCATION
of O O
the O O
core O B_GENE/B_LOCATION
replication O I_GENE/I_LOCATION
origin O I_GENE/I_LOCATION
containing O O
the O O
17 O B_MEASURE
- O O
bp O B_LOCATION/B_GENE
A O I_LOCATION/I_GENE
+ O I_LOCATION/I_GENE
T O I_LOCATION/I_GENE
- O O
containing O O
sequence O B_GENE/B_LOCATION
. O O

UV O O
cross O O
- O O
linking O O
and O O
Southwestern O O
analysis O O
suggested O O
that O O
KTP1 B B_GENE
is O O
a O O
DNA O O
- O O
binding O O
protein O O
clearly O O
distinct O O
from O O
AP2 B B_GENE
, O O
and O O
this O O
protein O O
may O O
be O O
responsible O O
for O O
the O O
basal O O
keratinocyte O O
- O O
specific O O
expression O O
of O O
the O O
BPAG1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
model O O
of O O
the O O
complex O O
provides O O
a O O
rationale O O
for O O
conserved O O
ITAM B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
residues O O
, O O
substrate O O
specificity O O
, O O
and O O
suggests O O
that O O
substrate O O
binds O O
only O O
the O O
active O O
conformation O O
of O O
the O O
Src B B_ENZYME[GENE]
family I I_ENZYME[GENE]
tyrosine I I_ENZYME[GENE]
kinase I I_ENZYME[GENE]
, O O
unlike O O
the O O
ATP O O
cofactor O O
, O O
which O O
can O O
bind O O
the O O
inactive O O
form O O
. O O

Here O O
we O O
demonstrate O O
that O O
a O O
region O O
of O O
high O O
homology O O
between O O
the O O
members O O
of O O
this O O
class O O
of O O
proteins O O
contains O O
a O O
type O O
A O O
nucleotide O O
binding O O
site O O
consensus O O
sequence O O
which O O
has O O
ATPase B B_ENZYME[GENE]
activity O O
and O O
is O O
sufficient O O
to O O
bind O O
DNA O O
containing O O
specific O O
mismatched O O
residues O O
. O O

Copyright O B_LOCATION/B_PERSON
1999 O I_LOCATION/I_PERSON
Academic O I_LOCATION/I_PERSON
Press O I_LOCATION/I_PERSON
. O O

Nickel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
release O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
tools O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
on O O
the O O
Swedish O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
market O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

S O O
- O O
phase O O
- O O
promoting O O
cyclin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dependent I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Cdks B B_GENE/B_LOCATION
) O O
and O O
the O O
kinase O O
Dbf4 B B_GENE
- O O
Cdc7 B B_MEASURE
then O O
act O O
to O O
initiate O O
replication O O
. O O

NF B B_GENE
- I I_GENE
kappaB I I_GENE
only O O
partially O O
mediates O O
Epstein B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
Barr I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
virus I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
latent I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
membrane I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
protein I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1 I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activation O O
of O O
B O O
cells O O
. O O

Purified O O
fER B B_GENE
exhibited O O
a O O
distribution O O
constant O O
( O O
KD O O
) O O
for O O
17 O O
beta O O
- O O
estradiol O O
of O O
0 O O
. O O
45 O O
nM O O
. O O

The O O
long O B_GENE/B_LOCATION
terminal O I_GENE/I_LOCATION
repeat O I_GENE/I_LOCATION
is O O
590 O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
bp O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
length O B_MEASURE/B_BIO
, O O
with O O
the O O
U3 O B_LOCATION/B_BIO
region O I_LOCATION/I_BIO
containing O O
consensus O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
sequences O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
likely O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
to O O
be O O
involved O O
in O O
viral O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
gene O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
expression O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
. O O

An O O
incorrect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
trial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
enhanced O O
the O O
accuracy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
current O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O O
in O O
the O O
left O B_TIME[MEASURE]/B_LOCATION
visual O I_TIME[MEASURE]/I_LOCATION
field O I_TIME[MEASURE]/I_LOCATION
( O O
LVF O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

The O O
peptides O O
are O O
generated O O
in O O
the O O
cytosol O O
, O O
then O O
translocated O O
across O O
the O O
membrane O O
of O O
the O O
endoplasmic O O
reticulum O O
by O O
the O O
transporter B B_ENZYME[GENE]
associated I I_ENZYME[GENE]
with I I_ENZYME[GENE]
antigen I I_ENZYME[GENE]
processing I I_ENZYME[GENE]
( O O
TAP B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

It O O
competes O O
with O O
the O O
calcium O O
ion O O
which O O
brings O O
about O O
inhibition O O
of O O
myosine B B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
therefore O O
a O O
drop O O
in O O
phosphorylated O O
myosine O O
. O O

Comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
development O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
hemodynamic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION

Sera O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
collected O O
in O O
1973 O B_TIME[MEASURE]/B_LOCATION
- O O
1975 O B_MEASURE
from O O
3053 O B_NUMBER[MEASURE]/B_LOCATION
residents O I_NUMBER[MEASURE]/I_LOCATION
of O O
12 O B_NUMBER[MEASURE]
selected O O
Alaskan O B_LOCATION
Eskimo O I_LOCATION
villages O I_LOCATION
were O O
tested O O
for O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hepatitis O B_DISEASE
B O I_DISEASE
virus O I_DISEASE
infection O I_DISEASE
. O O

Injection O O
of O O
horseradish B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
peroxidase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
HRP B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
into O O
the O O
cerebellar O O
flocculus O O
of O O
the O O
rat O O
was O O
employed O O
to O O
identify O O
neurons O O
in O O
the O O
abducens O O
nucleus O O
that O O
project O O
to O O
the O O
flocculus O O
. O O

To O O
assay O O
for O O
sequences O O
that O O
could O O
potentially O O
regulate O O
Xenopus B B_GENE
proenkephalin I I_GENE
expression O O
, O O
we O O
transfected O O
constructs O O
that O O
contained O O
upstream O O
genomic O O
sequences O O
linked O O
to O O
the O O
CAT B B_GENE
reporter I I_GENE
gene I I_GENE
into O O
various O O
eukaryotic O O
cell O O
lines O O
. O O

This O O
suggests O O
that O O
the O O
ratio O O
of O O
IL B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
6 I I_GENE/I_LOCATION
to O O
IL B B_GENE
- I I_GENE
10 I I_GENE
may O O
be O O
used O O
to O O
predict O O
the O O
injury O O
severity O O
after O O
trauma O O
. O O

UVB O O
- O O
induced O O
association O O
of O O
tumor B B_GENE
necrosis I I_GENE
factor I I_GENE
( I I_GENE
TNF I I_GENE
) I I_GENE
receptor I I_GENE
1 I I_GENE
/ O O
TNF B B_GENE/B_MEASURE
receptor I I_GENE/I_MEASURE
- I I_GENE/I_MEASURE
associated I I_GENE/I_MEASURE
factor I I_GENE/I_MEASURE
- I I_GENE/I_MEASURE
2 I I_GENE/I_MEASURE
mediates O O
activation O O
of O O
Rel B B_GENE
proteins I I_GENE
. O O

A O O
major O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
feature O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
genomic O B_GENE
sequence O I_GENE
is O O
the O O
presence O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
first O B_GENE
intron O I_GENE
( O O
Il O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
215 O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
bp O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
long O O
, O O
located O O
48 O B_LOCATION
bp O I_LOCATION
downstream O I_LOCATION
of O O
the O O
translation O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
start O O
ATG O B_LOCATION/B_GENE
codon O I_LOCATION/I_GENE
. O O

Experimental O O
studies O O
and O O
clinical O O
application O O
of O O
plasma B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
ACTH I B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
radioimmunoassay O O
kit O O
without O O
extraction O O
process O O

In O O
the O O
cervical O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
enlargement O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
they O O
were O O
located O O
in O O
the O O
middle O B_LOCATION/B_BIO
part O I_LOCATION/I_BIO
of O O
lamina O B_BODY_PART_OR_ORGAN_COMPONENT/B_PROTEIN[GENE]
VII O B_BODY_PART_OR_ORGAN_COMPONENT/I_PROTEIN[GENE]
and O O
in O O
lamina O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
VIII O I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
accounting O O
for O O
about O O
25 O B_SEQUENCE[MEASURE]/B_LOCATION
% O I_SEQUENCE[MEASURE]/I_LOCATION
of O O
the O O
total O B_MEASURE
labeled O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
. O O

Nature O B_MEASURE/B_DISEASE
and O O
incidence O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
conditioned O B_DISEASE
responses O I_DISEASE
in O O
a O O
methadone O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
population O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
: O O
a O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
laboratory O B_LOCATION/B_PERSON
, O O
clinic O B_LOCATION/B_EDU[ORGANIZATION]
, O O
and O O
naturalistic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
settings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

While O O
some O O
still O O
automatically O O
refuse O O
all O O
patients O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
positive O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediastinoscopy O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
most O B_PERSON
authors O I_PERSON
still O O
remain O O
very O O
interventionistic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
for O O
N2 O B_PERSON/B_DISEASE
patients O I_PERSON/I_DISEASE
selected O O
on O O
very O O
accurate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
criteria O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
that O O
are O O
analyzed O O
above O O
. O O

Our O O
previous O O
studies O O
demonstrated O O
that O O
the O O
promyelocytic O O
leukemia O O
gene O O
, O O
PML B B_GENE/B_DISEASE
which O O
involved O O
in O O
the O O
15 O O
; O O
17 O O
translocation O O
in O O
acute O O
promyelocytic O O
leukemia O O
( O O
APL O O
) O O
is O O
a O O
growth O O
and O O
transformation O O
suppressor O O
. O O

A O O
sharp O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
transition O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
from O O
a O O
random O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
chaotic O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
state O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
to O O
a O O
correlated O O
turbulent O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
state O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
finite O B_MEASURE
coherence O I_MEASURE
time O I_MEASURE
is O O
found O O
when O O
the O O
Rayleigh O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
becomes O O
larger O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
a O O
critical O B_MEASURE
value O I_MEASURE
Ra O O
( O O
c O B_OTHER/B_PROTEIN[GENE]
) O O
approximately O O
equal O B_MEASURE
to O O
5 O B_NUMBER[MEASURE]
x O O
10 O B_MEASURE
( O O
7 O B_MEASURE/B_LOCATION
) O O
. O O

Our O O
data O O
define O O
Ile O O
( O O
16 O O
) O O
, O O
Val O O
( O O
18 O O
) O O
, O O
Val O O
( O O
31 O O
) O O
, O O
and O O
Ile O O
( O O
33 O O
) O O
as O O
crucial O O
for O O
protein B B_GENE/B_BIO
S I I_GENE/I_BIO
binding O O
, O O
with O O
secondary O O
effects O O
from O O
Leu O O
( O O
38 O O
) O O
and O O
Val O O
( O O
39 O O
) O O
. O O

In O O
the O O
yeast O O
two O O
- O O
hybrid O O
assays O O
, O O
PNRC B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interacted O O
with O O
the O O
orphan O O
receptors O O
SF1 B B_GENE/B_LOCATION
and O O
ERRalpha1 B B_GENE
in O O
a O O
ligand O O
- O O
independent O O
manner O O
. O O

Nuclear O O
export O O
of O O
proteins O O
in O O
plants O O
: O O
AtXPO1 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
the O O
export O O
receptor O O
for O O
leucine O O
- O O
rich O O
nuclear O O
export O O
signals O O
in O O
Arabidopsis O O
thaliana O O
. O O

Thus O O
, O O
CR2 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
possesses O O
an O O
essential O O
function O O
besides O O
pRb B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
binding O O
. O O

From O O
the O O
autopsy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
findings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O O
in O O
5 O B_NUMBER[MEASURE]
out O O
of O O
the O O
remaining O O
23 O B_MEASURE
expired O O
patients O B_PERSON
, O O
Legionella O B_DISEASE
pneumonia O I_DISEASE
seemed O O
to O O
be O O
successfully O O
treated O O
, O O
but O O
other O B_DISEASE/B_BACTERIUM[BIO]
disease O B_DISEASE/I_BACTERIUM[BIO]
or O O
other O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
bacterial O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pneumonia O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
put O O
an O O
end O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
patients O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Nitroglycerin O O
( O O
glyceryl O O
trinitrate O O
) O O
as O O
a O O
monoamine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxidase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O O
. O O

This O O
high O B_MEASURE/B_PROTEIN[GENE]
dose O B_MEASURE/I_PROTEIN[GENE]
5 O B_MEASURE/I_PROTEIN[GENE]
- O O
FU O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
+ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
Act O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O O
D O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protocol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
effective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
drug O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
resistant O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
cases O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
with O O
MEA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
protocol O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

With O O
stimulation O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
beyond O O
the O O
theta O B_PROTEIN[GENE]/B_MEASURE
- O O
range O B_MEASURE/B_LOCATION
three O B_MEASURE/I_LOCATION
phenomena O B_MEASURE/I_LOCATION
occurred O O
: O O
shift O O
of O O
the O O
burst O B_MEASURE
frequencies O I_MEASURE
to O O
higher O B_MEASURE/B_LOCATION
or O O
lower O B_MEASURE
harmonics O I_MEASURE
of O O
stimulation O B_MEASURE/B_ENT
frequencies O I_MEASURE/I_ENT
; O O
complex O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
interactions O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
basic O B_MEASURE
background O I_MEASURE
frequency O I_MEASURE
with O O
rhythm O B_TIME[MEASURE]/B_ENT
of O O
stimulation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
" O O
beating O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
" O O
) O O
; O O
return O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
background O O
theta O O
- O O
burst O B_MEASURE/B_LOCATION
frequency O I_MEASURE/I_LOCATION
in O O
spite O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
continuing O O
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O O
" O O
escape O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
) O O
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Transpulmonary O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stable O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
air O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
microbubbles O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
bound O O
to O O
a O O
galactose O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carrier O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
represent O O
a O O
useful O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
safe O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
contrast O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
agent O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
in O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
an O O
insufficient O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
native O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signal O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
transcranial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
Doppler O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
investigation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

K562 O O
erythroleukemia O O
cells O O
stably O O
transfected O O
with O O
constructs O O
containing O O
the O O
human B B_GENE/B_LOCATION
Agamma I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
globin I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
linked O O
to O O
an O O
enhanced B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
green I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fluorescent I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
EGFP B B_GENE/B_DISEASE
) O O
reporter O O
, O O
with O O
or O O
without O O
HS2 O O
, O O
were O O
analyzed O O
for O O
EGFP B B_GENE
expression O O
by O O
flow O O
cytometry O O
. O O

Gastrin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulates O O
transcription O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
histidine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
decarboxylase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
HDC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
gene O O
through O O
binding O O
to O O
the O O
G B B_GENE
- I I_GENE
protein I I_GENE
- O O
coupled O O
cholecystokinin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
gastrin B B_PROTEIN[GENE]
receptor I I_PROTEIN[GENE]
. O O

Here O O
, O O
we O O
report O O
the O O
isolation O O
of O O
a O O
new O O
spindle O O
checkpoint O O
gene O O
, O O
mph1 B B_GENE/B_DISEASE
( O O
Mps1p B B_LOCATION/B_SPECIES[BIO]
- I B_LOCATION/I_SPECIES[BIO]
like I B_LOCATION/I_SPECIES[BIO]
pombe I B_LOCATION/I_SPECIES[BIO]
homolog I B_LOCATION/I_SPECIES[BIO]
) O O
, O O
in O O
the O O
fission O O
yeast O O
Schizosaccharomyces O O
pombe O O
, O O
that O O
is O O
required O O
for O O
checkpoint O O
activation O O
in O O
response O O
to O O
spindle O O
defects O O
. O O

mph1 B B_GENE/B_DISEASE
functions O O
upstream O O
of O O
mad2 B B_GENE/B_BIO
, O O
a O O
previously O O
characterized O O
component O O
of O O
the O O
spindle O O
checkpoint O O
. O O

Hepatocyte B B_GENE/B_MEASURE
growth I I_GENE/I_MEASURE
factor I I_GENE/I_MEASURE
( O O
HGF B B_GENE
) O O
is O O
an O O
inducible O O
cytokine O O
that O O
is O O
essential O O
for O O
the O O
normal O O
growth O O
and O O
development O O
of O O
various O O
tissues O O
, O O
such O O
as O O
the O O
liver O O
. O O

However O O
, O O
all O O
pathophysiologic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
assessments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
reported O O
to O O
date O B_TIME[MEASURE]/B_PERSON
have O O
been O O
carried O O
out O O
during O O
or O O
immediately O O
after O O
IVOX O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
utilization O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Reduced O O
concentrations O O
of O O
antithrombin B B_GENE
III I I_GENE
, O O
plasminogen B B_GENE
, O O
( O O
free O O
) O O
protein B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
S I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
and O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
found O O
in O O
some O O
patients O O
but O O
were O O
not O O
associated O O
with O O
either O O
thrombosis O O
or O O
lupus O O
anticoagulant O O
. O O

The O O
first O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
decision O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
management O B_PERSON/B_MEASURE
is O O
to O O
consider O O
cardioversion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
which O O
can O O
be O O
achieved O O
in O O
suitable O B_PERSON/B_LOCATION
cases O I_PERSON/I_LOCATION
electrically O O
, O O
or O O
pharmacologically O O
with O O
a O O
class O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antiarrhythmic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
like O O
flecainide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
propafenone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Structure O O
and O O
chromosomal O O
localization O O
of O O
the O O
human O O
gene O O
of O O
the O O
phosphotyrosyl B B_GENE/B_MEASURE
phosphatase I I_GENE/I_MEASURE
activator I I_GENE/I_MEASURE
( O O
PTPA B B_GENE/B_DISEASE
) O O
of O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

R O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
chest O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
wall O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
maximum O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
35 O B_MEASURE
. O O
6 O B_MEASURE
cmH2O O I_MEASURE
. O O
L O B_OTHER/B_MEASURE
- O O
1 O B_MEASURE/B_LOCATION
. O O
sec O B_ORGANIZATION/B_MEASURE
- O O
1 O B_MEASURE/B_LOCATION
+ O I_MEASURE/I_LOCATION
/ O O
- O O
2 O B_MEASURE
. O O
2 O B_MEASURE/B_LOCATION
SE O I_MEASURE/I_LOCATION
) O O
at O O
0 O B_MEASURE
. O O
2 O B_MEASURE
Hz O I_MEASURE
- O O
10 O B_MEASURE/B_LOCATION
ml O I_MEASURE/I_LOCATION
and O O
decreased O O
with O O
increasing O O
f O O
and O O
VT O B_PROTEIN[GENE]/B_MEASURE
, O O
although O O
the O O
VT O B_MEASURE/B_DISEASE
effect O I_MEASURE/I_DISEASE
diminished O O
at O O
the O O
higher O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
f O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Since O O
1988 O B_MEASURE/B_ENT
Modulit O I_MEASURE/I_ENT
- O O
SZ O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
20 O B_NUMBER[MEASURE]
has O O
been O O
tested O O
for O O
localization O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
nephroliths O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
ureteroliths O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

JCAHO O B_PERSON/B_ORGANIZATION
moves O O
to O O
rewrite O O
many O B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
rules O I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
to O O
lessen O O
hospitals O B_DISEASE/B_MEASURE
' O I_DISEASE/I_MEASURE
regulatory O I_DISEASE/I_MEASURE
burden O I_DISEASE/I_MEASURE
. O O

These O O
transcripts O O
directed O O
the O O
synthesis O O
of O O
three O O
proteins O O
: O O
the O O
virus B B_GENE
trans I I_GENE
- I I_GENE
activator I I_GENE
protein I I_GENE
( O O
EIAV B B_GENE/B_DISEASE
Tat I I_GENE/I_DISEASE
) O O
encoded O O
by O O
ORF O O
S1 O O
, O O
a O O
protein O O
of O O
unknown O O
function O O
encoded O O
by O O
ORF O O
S2 O O
, O O
and O O
the O O
virus O O
envelope B B_GENE
glycoprotein I I_GENE
. O O

However O O
, O O
no O O
significant O B_MEASURE
difference O I_MEASURE
in O O
either O O
the O O
Valsalva O B_MEASURE/B_PROTEIN[GENE]
ratio O B_MEASURE/I_PROTEIN[GENE]
or O O
delta O B_MEASURE
SBP O I_MEASURE
was O O
found O O
between O O
diabetic O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
and O O
controls O B_PERSON/B_BIO
. O O

Transmural O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
metabolic O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
heterogeneity O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
at O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiac O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
work O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
states O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
therefore O O
investigated O O
whether O O
the O O
promoter O O
activity O O
of O O
the O O
mouse B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
TRH I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
directly O O
regulated O O
by O O
RA O O
using O O
a O O
transient O O
transfection O O
assay O O
into O O
CV O O
- O O
1 O O
cells O O
. O O

Spinal O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injuries O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
a O O
multiple O B_DISEASE/B_PERSON
trauma O I_DISEASE/I_PERSON
patient O I_DISEASE/I_PERSON
. O O

The O O
unusual O O
properties O O
of O O
TRAC B B_ENZYME[GENE]/B_MEASURE
activity O O
and O O
its O O
relationship O O
, O O
if O O
any O O
, O O
with O O
the O O
enigmatic O O
Ku B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
protein I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
are O O
discussed O O
. O O

Statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aspects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
relation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
radioprotective O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
action O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
mercaptoethylamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derivatives O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
analogs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
their O O
electron O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
parameters O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE

Cerebellar O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
functional O B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
compensation O B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
after O O
its O O
complete O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
destruction O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O O
a O O
neoplasm O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE

The O O
RNA O B_GENE/B_BIO
, O O
whether O O
antisense O B_GENE
, O O
ribozyme O B_GENE/B_BIO
, O O
or O O
RNA O B_GENE/B_BIO
aptamer O I_GENE/I_BIO
, O O
must O O
be O O
efficiently O O
transcribed O O
, O O
stabilized O O
against O O
rapid O B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
degradation O B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
, O O
folded O O
correctly O O
, O O
and O O
directed O O
to O O
the O O
part O B_MEASURE/B_LOCATION
of O O
the O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
where O O
it O O
can O O
be O O
most O O
effective O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
have O O
isolated O O
and O O
determined O O
the O O
complete O O
nucleotide O O
sequence O O
of O O
another O O
operon O O
, O O
cpeCD B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
, O O
that O O
encodes O O
the O O
linker O O
proteins O O
associated O O
with O O
phycoerythrin B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
hexamers I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
phycobilisome B B_BIO
. O O

A B B_PERSON/B_LOCATION
. I I_PERSON/I_LOCATION
thaliana I I_PERSON/I_LOCATION
cystathionine I I_PERSON/I_LOCATION
beta I I_PERSON/I_LOCATION
- I I_PERSON/I_LOCATION
lyase I I_PERSON/I_LOCATION
exhibits O O
22 O O
% O O
sequence O O
identity O O
with O O
the O O
E O O
. O O
coli O O
corresponding O O
enzyme O O
and O O
contains O O
a O O
70 O O
amino O O
acid O O
N O O
- O O
terminal O O
additional O O
sequence O O
compared O O
with O O
the O O
bacterial O O
protein O O
. O O

The O O
enzyme B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
ACC I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
oxidase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
catalyses O O
the O O
last O O
step O O
of O O
ethylene O O
biosynthesis O O
in O O
plants O O
, O O
converting O O
1 O O
- O O
aminocyclopropane O O
- O O
1 O O
- O O
carboxylic O O
acid O O
( O O
ACC O O
) O O
to O O
ethylene O O
. O O

A O O
99m O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Tc O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
bone O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
scan O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O O
a O O
focal O B_DISEASE/B_MEASURE
area O I_DISEASE/I_MEASURE
of O O
an O O
increased O O
uptake O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
at O O
the O O
site O B_LOCATION/B_MEASURE
of O O
the O O
mass O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
below O O
the O O
calcaneus O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O O

Renal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
function O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
evaluated O O
in O O
a O O
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
24 O B_NUMBER[MEASURE]/B_PERSON
patients O B_NUMBER[MEASURE]/I_PERSON
( O O
21 O B_TIME[MEASURE]/B_PERSON
men O I_TIME[MEASURE]/I_PERSON
and O O
3 O B_PERSON/B_NUMBER[MEASURE]
women O I_PERSON/I_NUMBER[MEASURE]
, O O
mean O O
age O B_NUMBER[MEASURE]/B_PERSON
47 O I_NUMBER[MEASURE]/I_PERSON
years O I_NUMBER[MEASURE]/I_PERSON
) O O
who O O
had O O
survived O O
the O O
malignant O B_DISEASE_ADJECTIVE[DISEASE]
phase O I_DISEASE_ADJECTIVE[DISEASE]
of O O
hypertension O B_DISEASE/B_LOCATION
during O O
the O O
period O B_TIME[MEASURE]/B_DISEASE
of O O
1969 O B_MEASURE
- O O
1979 O B_MEASURE
. O O

The O O
need O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
for O O
such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
guidelines O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
clear O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
on O O
both O O
clinical O B_PERSON/B_EDU[ORGANIZATION]
and O O
scientific O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
grounds O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

When O O
expressed O O
in O O
thymidine B B_GENE
kinase I I_GENE
- O O
deficient O O
L O O
cells O O
or O O
3T3 O O
cells O O
, O O
C B B_GENE
/ I I_GENE
EBPalpha I I_GENE
is O O
detected O O
in O O
a O O
protein O O
complex O O
which O O
binds O O
to O O
the O O
E2F B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
found O O
in O O
the O O
promoters O O
of O O
the O O
genes O O
for O O
E2F B B_GENE
- I I_GENE
1 I I_GENE
and O O
dihydrofolate B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
reductase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
DHFR B B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

Members O O
of O O
the O O
CRE B B_GENE
- I I_GENE
binding I I_GENE
protein I I_GENE
( O O
CREB B B_GENE/B_DISEASE
) O O
/ O O
activating B B_GENE
transcription I I_GENE
factor I I_GENE
transcription O O
family O O
as O O
well O O
as O O
members O O
of O O
the O O
Jun B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
Fos B B_GENE/B_LOCATION
family O O
have O O
been O O
shown O O
to O O
bind O O
to O O
this O O
sequence O O
. O O

Csk B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
C B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
terminal I I_GENE/I_LOCATION
Src I I_GENE/I_LOCATION
kinase I I_GENE/I_LOCATION
) O O
is O O
a O O
protein B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
phosphorylates O O
Src B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
member I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
terminal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tails I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
resulting O O
in O O
downregulation O O
of O O
Src B B_GENE/B_NUMBER[MEASURE]
family O O
members O O
. O O

Role O O
of O O
double B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
stranded I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dependent I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
mediating O O
hypersensitivity O O
of O O
Fanconi O O
anemia O O
complementation O O
group O O
C O O
cells O O
to O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gamma I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
tumor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
double O O
- O O
stranded O O
RNA O O
. O O

In O O
clinical O B_PERSON
stroke O I_PERSON
cardiovascular O I_PERSON
abnormalities O I_PERSON
are O O
frequently O O
neglected O O
although O O
they O O
occur O O
more O O
often O O
than O O
it O O
is O O
generally O O
assumed O O
. O O

In O O
the O O
presence O B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
high O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
concentrations O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
propofol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
100 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
microg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
mL O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O O
1 O B_NUMBER[MEASURE]
, O O
thiopental O B_MEASURE/B_LOCATION
50 O B_MEASURE/I_LOCATION
microg O B_MEASURE/I_LOCATION
mL O B_MEASURE/I_LOCATION
- O O
1 O B_NUMBER[MEASURE]
) O O
marked O O
relaxation O B_DISEASE
was O O
observed O O
( O O
propofol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
32 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
up O O
to O O
- O O
49 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
P O B_OTHER/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
, O O
05 O B_MEASURE
; O O
thiopental O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
23 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
up O O
to O O
- O O
67 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
P O B_OTHER/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

Our O O
results O O
suggest O O
a O O
dose O O
- O O
dependent O O
activity O O
of O O
lysine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
vasopressin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
on O O
the O O
EEG O O
, O O
which O O
might O O
be O O
similar O O
to O O
that O O
observed O O
in O O
animal O O
and O O
man O O
after O O
administration O O
of O O
nicotine O O
. O O

Mutations O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PTEN I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Guanylyl B B_GENE/B_LOCATION
cyclase I I_GENE/I_LOCATION
C I I_GENE/I_LOCATION
, O O
the O O
apparent O O
guanylin B B_GENE/B_PERSON
receptor I I_GENE/I_PERSON
, O O
was O O
found O O
in O O
abundant O O
amounts O O
in O O
the O O
intestine O O
by O O
Northern O O
analysis O O
, O O
and O O
by O O
the O O
polymerase O O
chain O O
reaction O O
or O O
cDNA O O
cloning O O
it O O
was O O
also O O
found O O
in O O
adrenal O O
gland O O
, O O
airway O O
epithelial O O
cells O O
, O O
brain O O
, O O
and O O
olfactory O O
and O O
tracheal O O
mucosa O O
. O O

In O O
the O O
present O O
study O O
we O O
have O O
used O O
Southern O O
blot O O
analysis O O
to O O
demonstrate O O
that O O
TSG6 B B_GENE
is O O
a O O
single O O
- O O
copy O O
gene O O
in O O
the O O
human O O
and O O
murine O O
species O O
. O O

Reaction O O
of O O
aromatic O O
/ O O
heterocyclic O O
sulfonamides O O
possessing O O
free O O
amino O O
, O O
imino O O
or O O
hydrazino O O
moieties O O
with O O
7 O O
- O O
chloro O O
- O O
4 O O
- O O
chloromethylcoumarin O O
afforded O O
a O O
series O O
of O O
N O O
- O O
[ O O
( O O
7 O O
- O O
chloro O O
- O O
4 O O
- O O
coumarinyl O O
) O O
- O O
methyl O O
] O O
- O O
derivatives O O
which O O
showed O O
effective O O
inhibition O O
of O O
three O O
carbonic B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
anhydrase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CA B B_LOCATION/B_ORGANIZATION
) O O
isozymes O O
. O O

As O O
well O O
, O O
variation O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
capillary O B_MEASURE
size O I_MEASURE
and O O
density O B_MEASURE/B_LOCATION
was O O
apparent O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
ventricles O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
in O O
the O O
fetal O B_PERSON
and O O
neonatal O B_PERSON
periods O I_PERSON
. O O

The O O
Polycomb B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
group I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
involved O O
in O O
maintenance O O
of O O
the O O
silenced O O
state O O
of O O
several O O
developmentally O O
regulated O O
genes O O
. O O

Uncertainty O O
exists O O
about O O
the O O
function O O
of O O
these O O
potential O O
isoforms O O
of O O
the O O
Cbfa1 B B_GENE
gene I I_GENE
. O O

When O O
using O O
the O O
high O B_DISEASE/B_MEASURE
- O O
impedance O B_MEASURE/B_LOCATION
testing O I_MEASURE/I_LOCATION
device O I_MEASURE/I_LOCATION
, O O
the O O
post O B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shock O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rhythm O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
initially O O
displayed O O
as O O
' O O
no O O
signal O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
' O O
( O O
Hewlett O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Packard O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
XL O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
or O O
' O O
asystole O B_DISEASE_ADJECTIVE[DISEASE]
' O O
( O O
Physio O B_TIME[MEASURE]/B_PERSON
- O O
Control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
LIFEPAK O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
9 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
. O O

Human B B_GENE
CD38 I I_GENE
, O O
a O O
leukocyte O O
receptor O O
and O O
ectoenzyme O O
, O O
is O O
a O O
member O O
of O O
a O O
novel O O
eukaryotic O O
gene O O
family O O
of O O
nicotinamide B B_GENE/B_NUMBER[MEASURE]
adenine I I_GENE/I_NUMBER[MEASURE]
dinucleotide I I_GENE/I_NUMBER[MEASURE]
+ I I_GENE/I_NUMBER[MEASURE]
- I I_GENE/I_NUMBER[MEASURE]
converting I I_GENE/I_NUMBER[MEASURE]
enzymes I I_GENE/I_NUMBER[MEASURE]
: O O
extensive O O
structural O O
homology O O
with O O
the O O
genes O O
for O O
murine B B_SPECIES[BIO]/B_GENE
bone I I_SPECIES[BIO]/I_GENE
marrow I I_SPECIES[BIO]/I_GENE
stromal I I_SPECIES[BIO]/I_GENE
cell I I_SPECIES[BIO]/I_GENE
antigen I I_SPECIES[BIO]/I_GENE
1 I I_SPECIES[BIO]/I_GENE
and O O
aplysian B B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ADP I I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ribosyl I I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cyclase I I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
is O O
noteworthy O O
that O O
under O O
more O O
physiological O O
conditions O O
mimicking O O
the O O
cellular O O
GDP O O
/ O O
GTP O O
ratio O O
, O O
Raf B B_GENE/B_DISEASE
enhances O O
the O O
GEF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
stimulated O O
GDP O O
/ O O
GTP O O
exchange O O
on O O
Ha B B_GENE
- I I_GENE
Ras I I_GENE
, O O
in O O
agreement O O
with O O
the O O
sequestration O O
of O O
Ras B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
GTP I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
by O O
Raf B B_GENE/B_DISEASE
. O O

When O O
O O O
- O O
2A O O
/ O O
c B B_PROTEIN[GENE]/B_MEASURE
- I I_PROTEIN[GENE]/I_MEASURE
myc I I_PROTEIN[GENE]/I_MEASURE
cells O O
underwent O O
terminal O O
differentiation O O
APprog B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes I I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
lost O O
and O O
conventional O O
AP B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
DNA O O
- O O
binding O O
activity O O
became O O
evident O O
, O O
particularly O O
in O O
astrocytes O O
. O O

From O O
the O O
deduced O O
amino O O
acid O O
sequence O O
, O O
a O O
molecular O O
weight O O
of O O
38 O O
, O O
549 O O
was O O
calculated O O
for O O
the O O
ADH B B_GENE
subunit I I_GENE
. O O

The O O
higher O B_MEASURE
level O I_MEASURE
of O O
calories O B_DISEASE
was O O
attained O O
by O O
an O O
increased O O
intake O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
carbohydrates O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

A O O
simple O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
algorithm O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
fitting O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
the O O
moving O O
192Ir O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
source O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O O
proposed O O
. O O

TAF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activates O O
transcription O O
constitutively O O
and O O
was O O
mapped O O
to O O
the O O
first O O
32 O O
amino O O
acids O O
of O O
the O O
A O O
- O O
region O O
. O O

For O O
the O O
first O B_SEQUENCE[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
short O B_MEASURE
- O O
term O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
concurrent O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
) O O
TAL O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
two O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
different O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
- O O
flavored O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
stimuli O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
presented O O
at O O
the O O
same O B_TIME[MEASURE]/B_LOCATION
time O B_TIME[MEASURE]/I_LOCATION
, O O
one O B_NUMBER[MEASURE]/B_PERSON
associated O O
with O O
simultaneous O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
intragastric O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
administration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
of O O
an O O
aversive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
product O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
hypertonic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NaCl O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
the O O
other O B_SEQUENCE[MEASURE]/B_LOCATION
with O O
saline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

The O O
great O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
cardiac O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
vein O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
flow O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
became O O
zero O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
due O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
cardiac O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
arrest O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
remained O O
at O O
zero O B_MEASURE/B_LOCATION
for O O
a O O
moment O B_TIME[MEASURE]
( O O
dead O B_TIME[MEASURE]/B_ENT
time O I_TIME[MEASURE]/I_ENT
) O O
after O O
the O O
initiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
reperfusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

INTERNET O B_ORGANIZATION/B_PERSON
is O O
literally O O
a O O
world O B_LOCATION/B_ORGANIZATION
of O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
dialogue O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
discourse O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
on O O
any O O
topic O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaginable O I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
right O O
at O O
your O O
fingertips O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O O

Attention O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
devoted O O
in O O
particular O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
action O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
thermoregulating O O
nervous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
hormonal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
mechanisms O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
mammalian O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
UPR O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
is O O
mediated O O
by O O
the O O
cis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
acting O O
ER O B_GENE/B_LOCATION
stress O I_GENE/I_LOCATION
response O I_GENE/I_LOCATION
element O I_GENE/I_LOCATION
consisting O O
of O O
19 O B_MEASURE/B_GENE
nt O B_MEASURE/I_GENE
( O O
CCAATN O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
9 O B_NUMBER[MEASURE]/B_LOCATION
) O O
CCACG O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
) O O
, O O
the O O
CCACG O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
part O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
which O O
is O O
considered O O
to O O
provide O O
specificity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
formation O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
a O O
D O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
loop O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
an O O
essential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
step O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
DNA O B_NUMBER[MEASURE]/B_LOCATION
double O I_NUMBER[MEASURE]/I_LOCATION
- O O
strand O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
break O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
repair O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
through O O
recombination O B_GENE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
. O O

The O O
cDNA O O
is O O
predicted O O
to O O
encode O O
a O O
polypeptide O O
of O O
298 O O
amino O O
acids O O
that O O
is O O
homologous O O
to O O
the O O
Y B B_GENE
- I I_GENE
box I I_GENE
( I I_GENE
inverted I I_GENE
CCAAT I I_GENE
) I I_GENE
family I I_GENE
of I I_GENE
DNA I I_GENE
- I I_GENE
binding I I_GENE
transcription I I_GENE
factors I I_GENE
. O O

Toward O O
this O O
end O O
, O O
we O O
used O O
two O O
cultured O O
colon O O
cancer O O
cell O O
lines O O
; O O
one O O
( O O
RKO O O
) O O
has O O
a O O
transcriptionally O O
activated O O
u B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
PAR I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
, O O
and O O
the O O
other O O
( O O
GEO O O
) O O
overexpresses O O
the O O
receptor O O
only O O
after O O
phorbol O O
ester O O
treatment O O
. O O

Site O O
- O O
directed O O
mutagenesis O O
of O O
the O O
conserved O O
cysteine O O
residue O O
( O O
tom1C3235A B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
in O O
the O O
hect B B_GENE
- I I_GENE
domain I I_GENE
, O O
supposed O O
to O O
be O O
necessary O O
for O O
thioester O O
- O O
bond O O
formation O O
with O O
ubiquitin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
, O O
abolished O O
the O O
gene O O
function O O
. O O

The O O
two O O
yeast B B_PROTEIN[GENE]/B_BIO
pheromone I I_PROTEIN[GENE]/I_BIO
receptors I I_PROTEIN[GENE]/I_BIO
, O O
the O O
a B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
alpha I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
factor I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
receptors I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
share O O
many O O
functional O O
similarities O O
: O O
both O O
G B B_GENE/B_LOCATION
protein I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
coupled I I_GENE/I_LOCATION
receptors I I_GENE/I_LOCATION
couple O O
to O O
the O O
same O O
downstream O O
signal O O
transduction O O
pathway O O
, O O
and O O
both O O
receptors O O
undergo O O
feedback O O
regulation O O
involving O O
increased O O
phosphorylation O O
on O O
their O O
C O O
- O O
terminal O O
domains O O
in O O
response O O
to O O
ligand O O
challenge O O
. O O

Moreover O O
, O O
the O O
formation O O
of O O
the O O
complex O O
between O O
IclR B B_GENE
and O O
the O O
operator O O
/ O O
promoter O O
region O O
has O O
been O O
found O O
to O O
be O O
impaired O O
by O O
phosphoenol O O
pyruvate O O
but O O
insensitive O O
to O O
acetate O O
, O O
acetyl O O
- O O
CoA O O
, O O
pyruvate O O
, O O
and O O
oxaloacetate O O
. O O

After O O
enzymatic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hydrolysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
water O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
soluble O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
fraction O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
it O O
is O O
shown O O
that O O
28 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O O
again O O
extractable O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
DCM O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
which O O
57 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
consists O O
of O O
unchanged O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
SC4453 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
which O O
is O O
therefore O O
the O O
main O B_PERSON/B_MEASURE
partner O B_PERSON/I_MEASURE
of O O
conjugated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
products O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

The O O
expression O O
pattern O O
of O O
the O O
reporter O O
gene O O
was O O
compared O O
to O O
that O O
of O O
the O O
endogenous B B_GENE/B_PERSON
PDGFbeta I I_GENE/I_PERSON
r I I_GENE/I_PERSON
gene I I_GENE/I_PERSON
. O O

The O O
two O O
SH3 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
domains I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
separated O O
by O O
a O O
54 O O
amino O O
acid O O
linker O O
region O O
, O O
whose O O
length O O
is O O
highly O O
conserved O O
in O O
xenopus O O
, O O
chicken O O
, O O
and O O
mamalian B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
Crk I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
II I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
complex O O
was O O
eliminated O O
by O O
mutation O O
of O O
either O O
half O O
- O O
site O O
, O O
and O O
it O O
was O O
supershifted O O
by O O
antibodies O O
against O O
chicken B B_GENE
ovalbumin I I_GENE
upstream I I_GENE
promoter I I_GENE
- I I_GENE
transcription I I_GENE
factor I I_GENE
( O O
COUP B B_PROTEIN[GENE]/B_LOCATION
- I I_PROTEIN[GENE]/I_LOCATION
TF I I_PROTEIN[GENE]/I_LOCATION
) O O
. O O

The O O
fz B B_GENE
- I I_GENE
1 I I_GENE
and O O
fz B B_GENE
- I I_GENE
2 I I_GENE
genes I I_GENE
are O O
widely O O
expressed O O
in O O
rat O O
tissues O O
with O O
the O O
highest O O
steady O O
- O O
state O O
levels O O
of O O
mRNA O O
in O O
kidney O O
, O O
liver O O
, O O
heart O O
, O O
uterus O O
, O O
and O O
ovary O O
. O O

fz B B_GENE/B_PERSON
- I I_GENE/I_PERSON
1 I I_GENE/I_PERSON
and I I_GENE/I_PERSON
- I I_GENE/I_PERSON
2 I I_GENE/I_PERSON
mRNA I I_GENE/I_PERSON
levels O O
were O O
greater O O
in O O
neonatal O O
than O O
in O O
corresponding O O
adult O O
tissues O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
the O O
changes O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
patient O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
' O O
s O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
thyroid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
scan O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
RAIU O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O O
attributable O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
the O O
presence O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
TSAb O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O O
were O O
the O O
AOAC O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
method O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
dilution O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
heating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
; O O
the O O
addition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
mercuric O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloride O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
charcoal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
Carrez O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reagents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
2 O B_TIME[MEASURE]/B_LOCATION
different O I_TIME[MEASURE]/I_LOCATION
pH O I_TIME[MEASURE]/I_LOCATION
values O I_TIME[MEASURE]/I_LOCATION
; O O
and O O
direct O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
sample O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
supernatants O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
no O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Cytochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
and O O
ultrastructural O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
observations O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
tegument O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
trematode O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
Megalodiscus O I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
temperatus O I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

In O O
this O O
report O O
, O O
we O O
establish O O
that O O
the O O
heteromeric O O
CCAAT B B_PROTEIN[GENE]/B_LOCATION
- I I_PROTEIN[GENE]/I_LOCATION
binding I I_PROTEIN[GENE]/I_LOCATION
factor I I_PROTEIN[GENE]/I_LOCATION
CBF B I_PROTEIN[GENE]/I_LOCATION
is O O
the O O
major O O
component O O
of O O
the O O
C1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
C1F B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
in O O
human O O
cells O O
. O O

A O O
40 O O
- O O
fold O O
stimulation O O
of O O
chloramphenicol B B_GENE
acetyltransferase I I_GENE
activity O O
mediated O O
by O O
four O O
tandem O O
repeats O O
of O O
the O O
SNE B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
be O O
induced O O
within O O
2 O O
h O O
( O O
and O O
up O O
to O O
250 O O
- O O
fold O O
within O O
6 O O
h O O
) O O
after O O
addition O O
of O O
TPA O O
in O O
DNA O O
- O O
transfected O O
U O O
- O O
937 O O
cells O O
, O O
indicating O O
that O O
the O O
stimulation O O
appeared O O
likely O O
to O O
be O O
a O O
true O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
mediated O O
signal O O
transduction O O
event O O
rather O O
than O O
a O O
differentiation O O
response O O
. O O

This O O
increased O O
frequency O B_MEASURE
of O O
infection O B_DISEASE
has O O
been O O
accompanied O O
by O O
significant O B_DISEASE
excess O I_DISEASE
mortality O I_DISEASE
. O O

Deletion O O
mutants O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
CHOP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
identify O O
a O O
region O O
comprising O O
nucleotides O O
- O O
75 O O
to O O
- O O
104 O O
required O O
for O O
both O O
constitutive O O
and O O
ER O O
- O O
stress O O
- O O
inducible O O
expression O O
. O O

The O O
duration O B_MEASURE/B_LOCATION
of O O
PGE2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
PGF2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alpha O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
elevations O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
as O O
well O O
as O O
the O O
peak O B_MEASURE/B_PERSON
values O I_MEASURE/I_PERSON
were O O
influenced O O
by O O
day O B_TIME[MEASURE]/B_LOCATION
of O O
the O O
cycle O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

We O O
propose O O
that O O
the O O
cDNA O B_GENE
encodes O O
an O O
apical O B_GENE
plasma O I_GENE
membrane O I_GENE
protein O I_GENE
that O O
plays O O
a O O
role O B_MEASURE/B_PERSON
in O O
the O O
functional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
expression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
the O O
amiloride O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
sensitive O B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
epithelial O I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium O I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
channel O I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Electrophysiology O B_EDU[ORGANIZATION]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
pharmacology O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
epicardial O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
, O O
endocardial O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
, O O
and O O
M O B_BODY_PART_OR_ORGAN_COMPONENT
cells O I_BODY_PART_OR_ORGAN_COMPONENT
. O O

In O O
contrast O O
, O O
an O O
N B B_GENE/B_BIO
- I I_GENE/I_BIO
terminal I I_GENE/I_BIO
RNAP I I_GENE/I_BIO
mutant I I_GENE/I_BIO
that O O
has O O
a O O
decreased O O
capacity O O
to O O
bind O O
single O O
- O O
stranded O O
RNA O O
forms O O
halted O O
complexes O O
with O O
much O O
lower O O
levels O O
of O O
stability O O
than O O
the O O
WT O O
enzyme O O
, O O
and O O
these O O
complexes O O
are O O
not O O
stabilized O O
by O O
the O O
presence O O
of O O
the O O
NT O O
strand O O
. O O

A O O
cephalothoracophagus O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
disymmetros O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
buffalo O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
calf O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

A O O
mouse O O
brain O O
cDNA O O
library O O
in O O
lambdagt11 O O
was O O
screened O O
for O O
this O O
association O O
, O O
and O O
two O O
positive O O
clones O O
encoding O O
tyrosine B B_GENE
phosphatase I I_GENE
SH B I_GENE
- I I_GENE
PTP2 I I_GENE
were O O
isolated O O
. O O

Disorganization O O
scores O O
of O O
the O O
hypertrophy O O
zone O O
and O O
trabecular O O
bone O O
were O O
low O O
, O O
approaching O O
normal O O
( O O
P O O
< O O
0 O O
. O O
05 O O
) O O
, O O
for O O
turkey O O
poults O O
fed O O
on O O
diets O O
with O O
phytase B B_LOCATION/B_PROTEIN[GENE]
supplementation O O
, O O
and O O
tibial O O
abnormality O O
scores O O
were O O
linearly O O
decreased O O
( O O
P O O
< O O
0 O O
. O O
001 O O
) O O
as O O
nP O O
levels O O
increased O O
( O O
zero O O
score O O
is O O
considered O O
normal O O
) O O
. O O

Repression O O
was O O
strictly O O
dependent O O
on O O
the O O
presence O O
of O O
upstream O O
Oshox1 B B_GENE/B_LOCATION
binding O O
sites O O
in O O
the O O
reporter O O
gene O O
constructs O O
and O O
a O O
function O O
of O O
the O O
N O O
- O O
terminal O O
region O O
of O O
Oshox1 B B_GENE
, O O
preceding O O
the O O
homeodomain B B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Ondansetron O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
thus O O
an O O
effective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
first O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O O
line O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
antiemetic O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
in O O
children O B_PERSON/B_BIO
undergoing O O
chemotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
radiotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
surgery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

To O O
elucidate O O
the O O
molecular O O
mechanism O O
by O O
which O O
the O O
Ras B B_GENE/B_DISEASE
signaling O O
pathway O O
activates O O
a O O
cell O O
- O O
type O O
- O O
specific O O
gene O O
, O O
we O O
have O O
used O O
the O O
pituitary B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specific I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rat I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prolactin I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
rPRL B B_PROTEIN[GENE]/B_DISEASE
) O O
promoter O O
as O O
a O O
target O O
of O O
oncogenic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Ras I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
Raf B B_GENE/B_DISEASE
in O O
GH4 O O
rat O O
pituitary O O
cells O O
. O O

The O O
human O O
RFC B B_GENE/B_BIO
- I I_GENE/I_BIO
1 I I_GENE/I_BIO
gene I I_GENE/I_BIO
differs O O
from O O
the O O
mouse O O
and O O
hamster O O
genes O O
both O O
in O O
terms O O
of O O
the O O
total O O
number O O
of O O
exons O O
and O O
in O O
regard O O
to O O
alternatives O O
of O O
exon O O
1 O O
which O O
encode O O
5 O O
' O O
end O O
heterogeneity O O
. O O

Type O B_PERSON/B_BIO
C O I_PERSON/I_BIO
units O I_PERSON/I_BIO
summate O O
the O O
responses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
the O O
two O B_NUMBER[MEASURE]/B_COLOR
- O O
tone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
stimulus O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
and O O
show O O
little O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O O
no O O
inhibitory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
influences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

HGF B B_MEASURE/B_GENE
treatment O O
increased O O
cyclin B B_GENE
A I I_GENE
, O O
cyclin B B_GENE
G1 I I_GENE
and O O
nuclear O O
transcriptional O O
factor O O
( O O
NFkappaB B B_GENE/B_DISEASE
) O O
protein O O
expression O O
. O O

Since O O
blood O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
serotonin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
primarily O O
produced O O
peripherally O O
, O O
these O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O O
that O O
some O O
aspect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
peripheral O B_DISEASE_ADJECTIVE[DISEASE]
serotonin O I_DISEASE_ADJECTIVE[DISEASE]
metabolism O I_DISEASE_ADJECTIVE[DISEASE]
is O O
abnormal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
major O B_DISEASE/B_LOCATION
depression O I_DISEASE/I_LOCATION
. O O

Although O O
several O B_NUMBER[MEASURE]/B_PERSON
large O B_NUMBER[MEASURE]/I_PERSON
waterborne O B_NUMBER[MEASURE]/I_PERSON
outbreaks O B_NUMBER[MEASURE]/I_PERSON
occurred O O
during O O
the O O
past O B_TIME[MEASURE]/B_ORGANIZATION
decade O I_TIME[MEASURE]/I_ORGANIZATION
, O O
most O B_NUMBER[MEASURE]/B_PERSON
were O O
in O O
small O B_LOCATION/B_SPORT[ENT]
communities O I_LOCATION/I_SPORT[ENT]
. O O

Cytogenetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
structures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O O
a O O
mixte O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
karyotype O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
: O O
mosaicim O B_MEASURE/B_PERSON
46 O I_MEASURE/I_PERSON
XX O I_MEASURE/I_PERSON
/ O O
46 O B_MEASURE
XY O I_MEASURE
with O O
a O O
ratio O B_MEASURE/B_LOCATION
of O O
a O O
80 O B_NUMBER[MEASURE]
/ O O
20 O B_MEASURE
. O O

The O O
1 O O
. O O
6 O O
- O O
kb O O
cDNA O O
( O O
CBF B B_PROTEIN[GENE]/B_MEASURE
- I I_PROTEIN[GENE]/I_MEASURE
A I I_PROTEIN[GENE]/I_MEASURE
) O O
encoding O O
285 O O
amino O O
acids O O
( O O
aa O O
) O O
was O O
obtained O O
, O O
and O O
a O O
beta B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
galactosidase I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
fusion I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
bacterially O O
produced O O
from O O
the O O
cDNA O O
, O O
bound O O
to O O
DNA O O
fragments O O
containing O O
several O O
CArG O O
boxes O O
. O O

Mutant B B_PERSON/B_GENE
M I I_PERSON/I_GENE
proteins I I_PERSON/I_GENE
were O O
tested O O
for O O
their O O
ability O O
to O O
complement O O
growth O O
of O O
the O O
temperature O O
- O O
sensitive O O
M B B_DISEASE/B_SPECIES[BIO]
protein I B_DISEASE/I_SPECIES[BIO]
mutant I B_DISEASE/I_SPECIES[BIO]
virus O O
tsO23 O O
at O O
the O O
nonpermissive O O
temperature O O
. O O

In O O
this O O
paper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
we O O
review O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
on O O
smoking O B_DISEASE
and O O
lung O B_DISEASE
cancer O I_DISEASE
among O O
Latinos O B_PERSON/B_ORGANIZATION
, O O
including O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
from O O
several O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
unpublished O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O O
technical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
reports O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

The O O
yjr041c B B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
delta I I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
haploid O O
cells O O
gave O O
rise O O
to O O
microcolonies O O
comprising O O
about O O
20 O O
to O O
50 O O
cells O O
. O O

Despite O O
these O O
high O O
initial O O
rates O O
of O O
transcription O O
, O O
of O O
all O O
the O O
promoter O O
constructs O O
only O O
LAT B B_DISEASE/B_PROTEIN[GENE]
- O O
LTR O O
was O O
able O O
to O O
remain O O
transcriptionally O O
active O O
after O O
the O O
establishment O O
of O O
a O O
latent O O
state O O
. O O

Two O O
mutants O O
, O O
mapping O O
at O O
the O O
HindIII B B_LOCATION/B_MEASURE
site I I_LOCATION/I_MEASURE
( O O
between O O
the O O
consensus O O
sequences O O
) O O
of O O
the O O
pSC101 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tetA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
were O O
studied O O
: O O
MA2 O O
corresponds O O
to O O
a O O
4 O O
bp O O
deletion O O
between O O
positions O O
- O O
12 O O
and O O
- O O
15 O O
; O O
B30 O O
bears O O
a O O
44 O O
bp O O
insertion O O
C O O
( O O
TA O O
) O O
21 O O
G O O
at O O
the O O
HindIII B B_LOCATION
site I I_LOCATION
. O O

We O O
concluded O O
that O O
these O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
support O O
the O O
feasibility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
usefulness O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
N O B_OTHER/B_MEASURE
- O O
of O O
- O O
1 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
RCT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
rheumatology O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
practice O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Sci O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Effects O O
of O O
timepidium O O
bromide O O
( O O
TB O O
; O O
anticholinergic O O
agent O O
) O O
, O O
acetylcholine O O
( O O
ACh O O
) O O
and O O
neostigmine O O
( O O
Neost O O
) O O
on O O
gastric O O
and O O
duodenal O O
blood O O
flow O O
distribution O O
were O O
studied O O
by O O
the O O
use O O
of O O
131I O O
- O O
labeled O O
macroaggregated O O
human O O
serum O O
albumin O O
( O O
MAA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
in O O
rabbits O O
. O O

These O O
extrachromosomal O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
copies O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
can O O
be O O
isolated O O
as O O
covalently O O
closed O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
molecules O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
with O O
lengths O B_MEASURE/B_LOCATION
around O O
3mu O B_NUMBER[MEASURE]
. O O

Comparison O O
of O O
the O O
footprint O O
patterns O O
of O O
the O O
mouse B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
human I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
HPRT I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
demonstrated O O
that O O
the O O
in O O
vivo O O
binding O O
of O O
regulatory O O
proteins O O
between O O
these O O
species O O
is O O
generally O O
conserved O O
but O O
not O O
identical O O
. O O

Here O O
, O O
we O O
describe O O
the O O
three O B_NUMBER[MEASURE]
- O O
dimensional O B_MEASURE/B_LOCATION
structure O B_MEASURE/I_LOCATION
of O O
the O O
enzyme O B_ENZYME[GENE]/B_LOCATION
from O O
Escherichia O B_BACTERIUM[BIO]
colidetermined O O
and O O
refined O O
to O O
2 O B_MEASURE
. O O
0 O B_MEASURE
A O O
resolution O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O O

Our O O
Northern O O
and O O
Southern O O
blot O O
analyses O O
of O O
meningiomas O O
clearly O O
suggest O O
the O O
CLH B B_GENE
- I I_GENE
22 I I_GENE
gene I I_GENE
may O O
be O O
involved O O
in O O
the O O
tumor O O
development O O
and O O
can O O
be O O
considered O O
as O O
a O O
candidate O O
for O O
a O O
tumor O O
suppressor O O
. O O

Plasmodium O B_DISEASE_ADJECTIVE[DISEASE]
vivax O I_DISEASE_ADJECTIVE[DISEASE]
malaria O I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
set O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
genetic O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
physical O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactions O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggests O O
a O O
role O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
yeast O B_GENE/B_BIO
RNA O I_GENE/I_BIO
- O O
binding O O
proteins O B_LOCATION/B_GENE
in O O
transcriptional O B_GENE/B_BIO
regulation O B_GENE/I_BIO
. O O

POPULATION O B_PERSON/B_TIME[MEASURE]
AND O O
METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
105 O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
followed O O
prospectively O O
( O O
male O B_PERSON/B_MEASURE
: O O
87 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
; O O
age O B_TIME[MEASURE]/B_PERSON
: O O
56 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
10 O B_TIME[MEASURE]/B_PERSON
) O O
; O O
clinical O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
evaluation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
performed O O
in O O
the O O
1st O B_SEQUENCE[MEASURE]
, O O
3rd O B_SEQUENCE[MEASURE]
and O O
6th O B_SEQUENCE[MEASURE]
month O I_SEQUENCE[MEASURE]
, O O
SEKG O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
the O O
4th O B_SEQUENCE[MEASURE]
month O I_SEQUENCE[MEASURE]
and O O
recatheterization O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
angiographic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
control O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O O
the O O
6th O B_TIME[MEASURE]
month O I_TIME[MEASURE]
. O O

All O O
other O B_DISEASE/B_PERSON
cysts O I_DISEASE/I_PERSON
showed O O
a O O
unilocular O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
purely O O
cystic O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
pattern O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
with O O
homogeneous O B_DISEASE/B_MEASURE
fluids O I_DISEASE/I_MEASURE
, O O
although O O
the O O
T2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
relaxation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
times O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
four O B_DISEASE/B_PERSON
lesions O I_DISEASE/I_PERSON
overlapped O O
those O O
of O O
odontogenic O B_NUMBER[MEASURE]/B_PERSON
keratocysts O I_NUMBER[MEASURE]/I_PERSON
. O O

Genetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
respiratory O B_DISEASE/B_LOCATION
diseases O I_DISEASE/I_LOCATION

The O O
c B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Jun I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
delta I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
domain I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
inhibits O O
neuroendocrine O O
promoter O O
activity O O
in O O
a O O
DNA O O
sequence O O
- O O
and O O
pituitary O O
- O O
specific O O
manner O O
. O O

Cross O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
sectional O B_LOCATION/B_ORGANIZATION
studies O I_LOCATION/I_ORGANIZATION
continue O O
to O O
dominate O O
. O O

The O O
role O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
medical O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
facilities O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
prognosis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
patient O B_PERSON
with O O
tetanus O B_DISEASE
specially O O
the O O
importance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
considering O O
at O O
the O O
same O B_TIME[MEASURE]/B_LOCATION
time O B_TIME[MEASURE]/I_LOCATION
the O O
severity O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
the O O
disease O B_DISEASE
and O O
the O O
characteristics O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
deserve O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
order O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
contribute O O
to O O
the O O
development O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
medical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
assistance O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
patients O B_PERSON
with O O
tetanus O B_DISEASE
. O O

Differences O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O O
not O O
found O O
in O O
colons O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
SEM O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Increasing O O
the O O
height O B_MEASURE/B_DISEASE
of O O
the O O
agar O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
column O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
overlying O O
the O O
SN O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
fabric O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
diminished O O
the O O
inhibitory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
SN O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
on O O
microbial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
growth O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
. O O

Neither O O
raw O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
nor O O
retrograded O O
resistant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
starch O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
lowers O O
fasting O O
serum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cholesterol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
healthy O B_PERSON/B_BIO
normolipidemic O B_PERSON/I_BIO
subjects O B_PERSON/I_BIO
. O O

( O O
5 O B_MEASURE
) O O
. O O

Hepatitis O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
B O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
markers O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O O
Lancashire O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
police O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
officers O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
the O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
two O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
NAAR O B_LOCATION/B_DISEASE
and O O
PLA O B_LOCATION/B_PROTEIN[GENE]
) O O
, O O
no O O
variation O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
this O O
serum O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
protease O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
was O O
observed O O
. O O

Maximum O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
likelihood O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
estimation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
covariance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
structure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O O
truncated O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

A O O
single O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
dose O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
Cef O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
administered O O
intravenously O O
to O O
11 O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
with O O
autoimmune O B_DISEASE/B_GENE
diseases O I_DISEASE/I_GENE
and O O
varying O O
degrees O B_MEASURE
of O O
renal O B_DISEASE
impairment O I_DISEASE
( O O
Group O B_ORGANIZATION/B_MEASURE
I O O
CLCR O O
less O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
50 O B_MEASURE
ml O I_MEASURE
/ O O
min O B_TIME[MEASURE]/B_PERSON
, O O
Group O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
II O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
CLCR O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
greater O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
50 O B_MEASURE
ml O I_MEASURE
/ O O
min O B_TIME[MEASURE]/B_PERSON
) O O
. O O

The O O
liver O O
- O O
specific O O
sequence O O
contains O O
unique O O
consensus O O
sites O O
for O O
phosphorylation O O
by O O
cyclic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
AMP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dependent I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
by O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
gentamycin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
the O O
kidney O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
functional O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
state O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
experimental O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
pyelonephritis O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]

They O O
represent O O
a O O
physiologically O O
more O O
meaningful O B_MEASURE
pattern O I_MEASURE
than O O
the O O
arithmetic O B_MEASURE/B_PERSON
mean O B_MEASURE/I_PERSON
with O O
standard O B_MEASURE/B_PERSON
deviation O I_MEASURE/I_PERSON
. O O

The O O
Valpha B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Vbeta B B_GENE
domains I I_GENE
have O O
the O O
canonical O O
features O O
of O O
known O O
teleost B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
mammalian I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
TCR I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
V I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
domains I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
including O O
conserved O O
residues O O
in O O
the O O
beginning O O
of O O
FR2 B B_PROTEIN[GENE]/B_LOCATION
and O O
at O O
the O O
end O O
of O O
FR3 B B_GENE
. O O

Whether O O
this O O
lack O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
preferential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
repair O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
to O O
be O O
explained O O
by O O
a O O
defect O B_DISEASE_ADJECTIVE[DISEASE]
in O O
repair O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
or O O
in O O
general O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
unclear O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
at O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
examines O O
LEIBNIZ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
idea O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
Veterinary O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medicine O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
biographical O B_LOCATION/B_PERSON
context O I_LOCATION/I_PERSON
. O O

Dipetalonema O B_BACTERIUM[BIO]/B_MEASURE
( O O
Acanthocheilonema O B_DISEASE/B_PROTEIN[GENE]
) O O
didelphis O B_BACTERIUM[BIO]/B_PERSON
sp O I_PERSON
. O O

n O B_OTHER/B_MEASURE
. O O

However O O
, O O
the O O
MCMI O B_LOCATION/B_DISEASE
- O O
III O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profile O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
significantly O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
magnitude O B_MEASURE
compared O O
with O O
the O O
MCMI O B_LOCATION/B_DISEASE
- O O
II O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
. O O

While O O
there O O
is O O
growing O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
perception O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
imagery O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
share O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neural O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
substrates O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
fact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
D O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
F O B_OTHER/B_LOCATION
. O O
shows O O
intact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
visual O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imagery O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
face O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
of O O
a O O
massive O B_DISEASE
perceptual O I_DISEASE
deficit O I_DISEASE
in O O
form O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
vision O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
challenges O O
recent O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggestions O I_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
these O O
two O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
psychological O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
processes O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
share O O
common O B_LOCATION
input O I_LOCATION
pathways O I_LOCATION
in O O
early O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vision O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

An O O
ethnic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
made O O
of O O
8947 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cases O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
primary O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
central O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
nervous O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
system O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
CNS O B_DISEASE/B_LOCATION
) O O
tumors O B_DISEASE
seen O O
at O O
the O O
Armed O B_LOCATION/B_ORGANIZATION
Forces O B_LOCATION/I_ORGANIZATION
Institute O B_LOCATION/I_ORGANIZATION
of O O
Pathology O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
( O O
AFIP O B_DISEASE/B_ORGANIZATION
) O O
, O O
Washington O B_LOCATION/B_PERSON
, O O
DC O B_LOCATION
, O O
from O O
1971 O B_MEASURE
to O O
1985 O B_MEASURE
. O O

The O O
exact O O
function O O
of O O
IP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
30 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
not O O
yet O O
known O O
, O O
but O O
it O O
may O O
play O O
a O O
role O O
in O O
gamma B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interferon I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediated O O
immune O O
reactions O O
. O O

The O O
levels O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
products O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expressed O O
from O O
these O O
chimeric O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cDNAs O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
COS O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
were O O
assessed O O
by O O
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
by O O
metabolic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
labeling O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
proteins O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
followed O O
by O O
immunoprecipitation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
SDS O B_PROTEIN[GENE]/B_DISEASE
- O O
PAGE O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

In O O
this O O
report O O
, O O
we O O
demonstrate O O
that O O
FRS2 B B_GENE
forms O O
a O O
complex O O
with O O
the O O
N B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
terminal I I_GENE/I_MEASURE
SH2 I I_GENE/I_MEASURE
domain I I_GENE/I_MEASURE
of O O
the O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Shp2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
response O O
to O O
FGF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation O O
. O O

It O O
is O O
concluded O O
that O O
the O O
drinking O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
ampules O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
VP O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
16 O B_MEASURE
- O O
213 O B_MEASURE
can O O
be O O
replaced O O
with O O
the O O
new O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
oral O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
capsules O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O O
a O O
recommended O O
initial O B_MEASURE
dose O I_MEASURE
of O O
100 O B_MEASURE
- O O
130 O B_MEASURE/B_LOCATION
mg O I_MEASURE/I_LOCATION
/ O O
m2 O B_MEASURE
given O O
in O O
5 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]/B_LOCATION
courses O I_TIME[MEASURE]/I_LOCATION
every O O
21 O B_MEASURE
- O O
28 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
. O O

The O O
H5 B B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutants I B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
: O O
DH5 B B_PROTEIN[GENE]
( O O
all O O
amino O O
acids O O
in O O
D O O
configuration O O
) O O
and O O
H5F B B_PROTEIN[GENE]/B_BIO
( O O
where O O
all O O
His O O
are O O
replaced O O
by O O
Phe O O
at O O
positions O O
3 O O
, O O
7 O O
, O O
8 O O
, O O
15 O O
, O O
18 O O
, O O
19 O O
, O O
21 O O
) O O
. O O

Although O O
the O O
number O B_MEASURE/B_ORGANIZATION
of O O
kits O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
has O O
increased O O
, O O
the O O
precision O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
has O O
improved O O
, O O
showing O O
that O O
more O B_NUMBER[MEASURE]/B_PERSON
robust O I_NUMBER[MEASURE]/I_PERSON
methods O I_NUMBER[MEASURE]/I_PERSON
are O O
now O O
employed O O
. O O

These O O
results O O
establish O O
that O O
the O O
DNA O O
fragment O O
we O O
have O O
isolated O O
contains O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gp130 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
that O O
interleukin B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
6 I I_GENE/I_DISEASE
type I I_GENE/I_DISEASE
cytokines I I_GENE/I_DISEASE
may O O
influence O O
the O O
activity O O
of O O
this O O
promoter O O
via O O
activated O O
STATs B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

When O O
targeted O O
to O O
the O O
GAL1 B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
promoter I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
by O O
fusing O O
with O O
the O O
Gal4p B B_GENE
DNA I I_GENE
- I I_GENE
binding I I_GENE
domain I I_GENE
, O O
Sko1p B B_GENE
acts O O
as O O
an O O
Ssn6 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
Tup1p B B_MEASURE/B_BIO
- O O
dependent O O
repressor O O
regulated O O
by O O
osmotic O O
stress O O
. O O

The O O
unexpected O O
prevalence O O
of O O
c B B_GENE
- I I_GENE
myc I I_GENE
and O O
alpha B B_GENE
- I I_GENE
tubulin I I_GENE
in O O
the O O
S O O
- O O
phase O O
library O O
is O O
supported O O
by O O
Northern O O
analysis O O
of O O
RNA O O
from O O
phase O O
- O O
synchronous O O
cells O O
. O O

Growth O O
factors O O
promote O O
cell O O
survival O O
through O O
phosphorylation O O
of O O
Bad B B_GENE
, O O
resulting O O
in O O
its O O
dissociation O O
from O O
Bcl B B_GENE
- I I_GENE
2 I I_GENE
and O O
Bcl B B_GENE
- I I_GENE
x I I_GENE
( I I_GENE
L I I_GENE
) I I_GENE
and O O
its O O
association O O
with O O
14 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3tau I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
representative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
patients O B_PERSON/B_BIO
undergoing O O
open O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
radical O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
nephrectomy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
for O O
clinical O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
T1 O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
T2 O B_DISEASE/B_LOCATION
lesions O I_DISEASE/I_LOCATION
was O O
also O O
identified O O
. O O

By O O
applying O O
a O O
sufficiently O O
strong O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
crusher O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
gradient O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
the O O
EPI O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
pulse O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
sequence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
the O O
temporal O B_MEASURE
variation O I_MEASURE
induced O O
by O O
SSFP O B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disturbance O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
suppressed O O
due O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
diffusion O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

However O O
, O O
in O O
each O O
case O O
in O O
which O O
either O O
the O O
DQ B B_GENE/B_MEASURE
alpha I I_GENE/I_MEASURE
- I I_GENE/I_MEASURE
or I I_GENE/I_MEASURE
DQ I I_GENE/I_MEASURE
beta I I_GENE/I_MEASURE
- I I_GENE/I_MEASURE
chain I I_GENE/I_MEASURE
was O O
exchanged O O
, O O
major O O
alterations O O
or O O
reversals O O
of O O
this O O
pattern O O
of O O
interaction O O
were O O
observed O O
. O O

Only O O
the O O
native O O
structure O O
of O O
phosphorylated O O
ERK B B_GENE
was O O
recognized O O
by O O
VHR B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
was O O
inactivated O O
with O O
a O O
second O O
- O O
order O O
rate O O
constant O O
of O O
40 O O
, O O
000 O O
M O O
- O O
1 O O
s O O
- O O
1 O O
. O O

From O O
1998 O B_MEASURE
to O O
1999 O B_MEASURE
, O O
a O O
large O B_MEASURE/B_LOCATION
number O B_MEASURE/I_LOCATION
of O O
community O B_ORGANIZATION/B_LOCATION
- O O
acquired O O
respiratory O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
tract O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
isolates O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
of O O
Streptococcus O B_BACTERIUM[BIO]/B_DISEASE
pneumoniae O I_BACTERIUM[BIO]/I_DISEASE
( O O
n O B_MEASURE
= O O
566 O B_MEASURE
) O O
, O O
Haemophilus O B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
influenzae O I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
n O B_MEASURE
= O O
513 O B_MEASURE
) O O
and O O
Moraxella O B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
catarrhalis O I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
n O B_MEASURE
= O O
228 O B_MEASURE
) O O
were O O
collected O O
from O O
15 O B_LOCATION/B_MEASURE
centres O I_LOCATION/I_MEASURE
in O O
Australia O B_LOCATION
, O O
Hong O B_LOCATION
Kong O I_LOCATION
, O O
Japan O B_LOCATION
, O O
China O B_LOCATION
, O O
the O O
Philippines O B_LOCATION
, O O
Singapore O B_LOCATION
, O O
South O B_LOCATION
Africa O I_LOCATION
and O O
Taiwan O B_LOCATION
through O O
the O O
SENTRY O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
Antimicrobial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
Surveillance O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
Program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

Diethyldithiocarbamate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
amphetamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stereotype O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
used O O
an O O
immobilized O O
template O O
- O O
based O O
assay O O
to O O
examine O O
transcription O O
termination O O
by O O
VA1 B B_PROTEIN[GENE]/B_DISEASE
, O O
7SL B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
Alu B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
class I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
III I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
templates O O
and O O
the O O
role O O
of O O
transcript O O
release O O
in O O
the O O
pol B B_LOCATION/B_GENE
III I B_LOCATION/I_GENE
terminator O O
- O O
dependent O O
inhibition O O
of O O
processing O O
of O O
B1 B B_PROTEIN[GENE]/B_DISEASE
- O O
Alu B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
transcripts O O
. O O

A O O
novel O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
zinc O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
finger O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
containing O O
RNA O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
binding O O
protein O B_GENE/B_BACTERIUM[BIO]
conserved O O
from O O
fruitflies O B_SPECIES[BIO]
to O O
humans O B_SPECIES[BIO]
. O O

Although O O
IL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O O
activate O O
ERK B B_GENE
- I I_GENE
1 I I_GENE
in O O
HepG2 O O
cells O O
, O O
STAT3 B B_GENE
transactivation O O
and O O
Ser O O
( O O
727 O O
) O O
phosphorylation O O
were O O
not O O
reduced O O
by O O
using O O
the O O
MAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
ERK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MEK B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
inhibitor O O
PD98059 O O
or O O
by O O
overexpression O O
of O O
dominant O O
- O O
negative O O
Raf B B_GENE/B_DISEASE
. O O

6 O B_MEASURE/B_LOCATION
h O O
after O O
ingestion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
aspirin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O O
day O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
1 O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
day O B_TIME[MEASURE]
14 O I_TIME[MEASURE]
, O O
both O O
TX O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
PGI2 O B_LOCATION/B_PROTEIN[GENE]
levels O I_LOCATION/I_PROTEIN[GENE]
also O O
significantly O O
decreased O O
( O O
p O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
0001 O B_MEASURE
) O O
. O O

Tritiated O B_MEASURE
1 O I_MEASURE
, O O
24 O B_MEASURE
, O O
25 O B_MEASURE
- O O
trihydroxyvitamin O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D3 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
synthesized O O
biologically O O
and O O
used O O
as O O
tracer O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
monitor O O
the O O
recovery O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
endogenous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolite O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
isolation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
serum O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Joint O O
ultrasonography O O
demonstrating O O
thickening O O
of O O
synoviae O O
and O O
tendons O O
has O O
become O O
a O O
useful O O
non O O
- O O
invasive O O
diagnostic O O
tool O O
, O O
although O O
it O O
is O O
not O O
specific O O
for O O
beta B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
M I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amyloidosis O O
, O O
and O O
results O O
depend O O
on O O
observer O O
experience O O
. O O

Immunofluorescence O O
tests O O
for O O
Borrelia B B_DISEASE/B_VIRUS[BIO]
burgdorferi I B_DISEASE/I_VIRUS[BIO]
serum I B_DISEASE/I_VIRUS[BIO]
antibodies I B_DISEASE/I_VIRUS[BIO]
had O O
positive O O
results O O
, O O
but O O
G O O
- O O
penicillin O O
treatment O O
was O O
ineffective O O
. O O

The O O
size O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
the O O
predicted O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_GENE/B_LOCATION
sequence O B_GENE/I_LOCATION
of O O
the O O
mouse O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
confirmed O O
experimentally O O
. O O

Nuclear O O
runoff O O
assays O O
show O O
that O O
complementation O O
by O O
HPV16 B B_DISEASE/B_GENE
E7 I B_DISEASE/I_GENE
restores O O
the O O
ability O O
of O O
the O O
E1A B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutants I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
to O O
stimulate O O
early B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
at O O
the O O
level O O
of O O
transcription O O
. O O

Yet O O
IL B B_GENE
- I I_GENE
2 I I_GENE
and O O
IFN B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gamma I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production O O
are O O
independently O O
regulated O O
, O O
as O O
demonstrated O O
by O O
their O O
differential O O
expression O O
in O O
certain O O
T O O
cell O O
subsets O O
, O O
suggesting O O
that O O
the O O
regulatory O O
elements O O
in O O
these O O
two O O
genes O O
must O O
differ O O
. O O

We O O
conclude O O
that O O
a O O
0 O O
. O O
25 O O
mg O O
dose O O
of O O
triazolam O O
does O O
not O O
effectively O O
counteract O O
a O O
posture O O
- O O
induced O O
sleep O O
disturbance O O
, O O
but O O
induces O O
changes O O
in O O
the O O
EEG O O
spectra O O
which O O
are O O
typical O O
for O O
benzodiazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
agonists O O
. O O

Anisotropy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Hc2 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
the O O
breadth O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
resistive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transition O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
polycrystalline O B_LOCATION/B_PROTEIN[GENE]
YBa2Cu O B_LOCATION/I_PROTEIN[GENE]

Microscopic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examination O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
colonies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
a O O
high O B_MEASURE/B_LOCATION
percentage O I_MEASURE/I_LOCATION
of O O
histiocytes O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
identical O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
those O O
seen O O
in O O
the O O
patient O B_PERSON/B_BIO
' O O
s O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bone O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
marrow O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Functional O O
uncoupling O O
of O O
the O O
Janus B B_GENE
kinase I I_GENE
3 I I_GENE
- O O
Stat5 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathway O O
in O O
malignant O O
growth O O
of O O
human O O
T O O
cell O O
leukemia O O
virus O O
type O O
1 O O
- O O
transformed O O
human O O
T O O
cells O O
. O O

The O O
herpesvirus B B_GENE
entry I I_GENE
mediator I I_GENE
C I I_GENE
( O O
HveC B B_LOCATION/B_DISEASE
) O O
, O O
previously O O
known O O
as O O
poliovirus B B_GENE
receptor I I_GENE
- I I_GENE
related I I_GENE
protein I I_GENE
1 I I_GENE
( O O
PRR1 B B_GENE/B_LOCATION
) O O
, O O
and O O
the O O
herpesvirus B B_GENE
Ig I I_GENE
- I I_GENE
like I I_GENE
receptor I I_GENE
( O O
HIgR B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
are O O
the O O
bona O O
fide O O
receptors O O
employed O O
by O O
herpes O O
simplex O O
virus O O
- O O
1 O O
and O O
- O O
2 O O
( O O
HSV O O
- O O
1 O O
and O O
- O O
2 O O
) O O
for O O
entry O O
into O O
the O O
human O O
cell O O
lines O O
most O O
frequently O O
used O O
in O O
HSV O O
studies O O
. O O

4 O O
- O O
Hydroxyproline O O
assays O O
were O O
performed O O
to O O
determine O O
collagen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
content O O
. O O

The O O
combination O O
of O O
ICP47 B B_GENE
and O O
US11 B B_MEASURE/B_GENE
rendered O O
fibroblasts O O
negative O O
for O O
surface B B_GENE
class I I_GENE
I I I_GENE
MHC I I_GENE
and O O
allowed O O
a O O
class B B_GENE/B_DISEASE
I I I_GENE/I_DISEASE
MHC I I_GENE/I_DISEASE
- O O
low O O
population O O
of O O
T O O
cells O O
to O O
be O O
sorted O O
by O O
flow O O
cytometry O O
. O O

Although O O
IRS B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
1 I I_GENE/I_MEASURE
, I I_GENE/I_MEASURE
- I I_GENE/I_MEASURE
2 I I_GENE/I_MEASURE
, I I_GENE/I_MEASURE
and I I_GENE/I_MEASURE
- I I_GENE/I_MEASURE
4 I I_GENE/I_MEASURE
are O O
similar O O
in O O
overall O O
structure O O
, O O
IRS B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
3 I I_GENE/I_MEASURE
is O O
approximately O O
50 O O
% O O
shorter O O
and O O
differs O O
with O O
respect O O
to O O
sites O O
of O O
tyrosine O O
phosphorylation O O
. O O

The O O
interaction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O O
different O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
protein O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
systems O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
microtubules O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
is O O
a O O
critical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
step O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
the O O
cellular O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
function O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
of O O
these O O
organelles O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
addition O O
, O O
we O O
mapped O O
a O O
putative O O
hnRNP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
A1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
U5 B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
RNA I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
demonstrated O O
that O O
p40CRS B B_GENE
( O O
hnRNP B B_PROTEIN[GENE]/B_MEASURE
A1 I I_PROTEIN[GENE]/I_MEASURE
) O O
binding O O
to O O
that O O
site O O
correlates O O
with O O
CRS B B_DISEASE/B_GENE
function O O
. O O

Sailer O B_PERSON
, O O
K O B_OTHER/B_PERSON
. O O

Copyright O B_LOCATION/B_PERSON
2000 O I_LOCATION/I_PERSON
Academic O I_LOCATION/I_PERSON
Press O I_LOCATION/I_PERSON
. O O

This O O
element O O
was O O
required O O
for O O
both O O
basal O O
and O O
activated O O
expression O O
and O O
almost O O
certainly O O
functions O O
as O O
a O O
TATA B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
binding I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
protein I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
interaction O O
site O O
. O O

In O O
HepG2 O O
cells O O
, O O
SREBP B B_GENE
- I I_GENE
1c I I_GENE
mRNA I I_GENE
and O O
precursor O O
protein O O
levels O O
were O O
induced O O
by O O
treatment O O
with O O
22 O O
( O O
R O O
) O O
- O O
hydroxycholesterol O O
and O O
9 O O
- O O
cis O O
- O O
retinoic O O
acid O O
, O O
confirming O O
that O O
endogenous O O
LXR B B_PROTEIN[GENE]/B_MEASURE
- O O
RXR B B_PROTEIN[GENE]/B_DISEASE
activation O O
can O O
induce O O
endogenous B B_GENE
SREBP I I_GENE
- I I_GENE
1c I I_GENE
expression O O
. O O

Univariate O B_TIME[MEASURE]/B_PERSON
and O O
multivariate O B_MEASURE
analysis O I_MEASURE
was O O
used O O
to O O
calculate O O
the O O
5 O B_NUMBER[MEASURE]
- O O
year O B_MEASURE/B_LOCATION
survival O I_MEASURE/I_LOCATION
probabilities O I_MEASURE/I_LOCATION
with O O
respect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
the O O
following O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
variables O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O O
age O B_MEASURE/B_LOCATION
( O O
< O B_OTHER/B_LOCATION
or O O
= O O
65 O B_MEASURE
, O O
> O O
65 O B_MEASURE
) O O
, O O
sex O B_PERSON/B_DISEASE
, O O
depth O B_MEASURE/B_LOCATION
of O O
invasion O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
mucosal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
submucosal O B_BODY_PART_OR_ORGAN_COMPONENT
) O O
tumor O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
location O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
upper O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
, O O
middle O B_SEQUENCE[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
lower O B_LOCATION/B_MEASURE
third O I_LOCATION/I_MEASURE
) O O
, O O
gross O B_MEASURE/B_LOCATION
appearance O I_MEASURE/I_LOCATION
( O O
type O B_MEASURE/B_LOCATION
I O O
, O O
type O B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
II O I_SEQUENCE[MEASURE]/I_PROTEIN[GENE]
and O O
type O B_SEQUENCE[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
III O I_SEQUENCE[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
size O B_MEASURE/B_LOCATION
( O O
< O B_MEASURE/B_OTHER
or O O
= O O
1 O B_MEASURE
. O O
5 O B_MEASURE
cm O I_MEASURE
, O O
> O O
1 O B_MEASURE
. O O
5 O B_MEASURE
cm O I_MEASURE
) O O
, O O
presence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O O
absence O B_MEASURE/B_DISEASE
of O O
lymph O B_DISEASE
node O I_DISEASE
metastasis O I_DISEASE
, O O
histological O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
type O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
intestinal O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
diffuse O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
) O O
, O O
extent O B_DISEASE/B_MEASURE
of O O
lymphadenectomy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O O
limited O O
or O O
extended O O
) O O
, O O
and O O
type O B_MEASURE/B_LOCATION
of O O
gastrectomy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O O
total O B_MEASURE/B_LOCATION
or O O
distal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
subtotal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
) O O
. O O

This O O
integration O O
results O O
in O O
the O O
production O O
of O O
MMTV B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
/ I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mdr3 I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
fusion I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
transcripts I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
that O O
originate O O
from O O
the O O
antisense O O
5 B B_GENE/B_LOCATION
' I B_GENE/I_LOCATION
LTR I B_GENE/I_LOCATION
of O O
the O O
provirus O O
. O O

In O O
32 O B_NUMBER[MEASURE]/B_PERSON
of O O
them O O
the O O
results O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
an O O
exercise O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
performance O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
based O O
on O O
heart O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
rate O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
response O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
submaximal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exercise O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
VO2 O B_MEASURE
, O O
170 O B_TIME[MEASURE]
[ O I_TIME[MEASURE]
bpm O I_TIME[MEASURE]
] O I_TIME[MEASURE]
) O O
was O O
compared O O
with O O
another O O
index O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
physical O B_DISEASE_ADJECTIVE[DISEASE]
performance O I_DISEASE_ADJECTIVE[DISEASE]
capacity O I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
is O O
independent O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
from O O
heart O B_MEASURE
rate O I_MEASURE
: O O
the O O
ventilatory O B_MEASURE/B_ORGANIZATION
threshold O B_MEASURE/I_ORGANIZATION
. O O

Sequence O O
comparisons O O
reveal O O
that O O
the O O
P B B_GENE/B_BIO
. I I_GENE/I_BIO
woesei I I_GENE/I_BIO
GTP I I_GENE/I_BIO
- I I_GENE/I_BIO
binding I I_GENE/I_BIO
protein I I_GENE/I_BIO
is O O
strikingly O O
related O O
in O O
sequence O O
to O O
eubacterial B B_SPECIES[BIO]/B_GENE
FtsZ I I_SPECIES[BIO]/I_GENE
and O O
is O O
marginally O O
more O O
similar O O
to O O
eukaryotic B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
tubulins I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
than O O
are O O
bacterial B B_SPECIES[BIO]/B_GENE
FtsZ I I_SPECIES[BIO]/I_GENE
proteins I I_SPECIES[BIO]/I_GENE
. O O

Four O O
of O O
15 O O
patients O O
with O O
R2 B B_DISEASE/B_GENE
had O O
rheumatoid O O
arthritis O O
and O O
in O O
two O O
of O O
these O O
four O O
cases O O
the O O
antibody O O
was O O
of O O
the O O
IgA B B_PROTEIN[GENE]/B_DISEASE
class O O
. O O

Phosphate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
compounds O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
isolated O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, O O
perfused O O
hearts O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
pH O O
variation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
due O O
to O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
extracellular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
PCO2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
bicarbonate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE

Vav B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
Dbl B B_GENE
are O O
members O O
of O O
a O O
novel O O
class O O
of O O
oncogene O O
proteins O O
that O O
share O O
significant O O
sequence O O
identity O O
in O O
a O O
approximately O O
250 O O
- O O
amino O O
- O O
acid O O
domain O O
, O O
designated O O
the O O
Dbl B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
homology I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
domain I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Serum O O
AFP B B_GENE
is O O
a O O
useful O O
tumor O O
marker O O
for O O
monitoring O O
the O O
results O O
of O O
therapy O O
. O O

The O O
possible O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
equivalency O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
a O O
short O B_MEASURE/B_PERSON
form O B_MEASURE/I_PERSON
and O O
the O O
long O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
form O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
Multiple O B_TIME[MEASURE]/B_DISEASE
Affect O O
Adjective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Check O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
List O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
Revised O O
( O O
MAACL O B_LOCATION/B_DISEASE
- O O
R O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
Zuckerman O B_PERSON
& O O
Lubin O B_PERSON
, O O
1985 O B_MEASURE
) O O
was O O
studied O O
by O O
correlating O O
both O O
forms O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
MAACL O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
R O B_OTHER/B_PROTEIN[GENE]
with O O
the O O
State O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Trait O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Personality O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Inventory O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
Spielberger O B_PERSON
, O O
1995 O B_MEASURE
) O O
; O O
the O O
Affect O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Balance O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Scale O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Bradburn O B_PERSON
, O O
1969 O B_MEASURE
) O O
; O O
and O O
the O O
Sensation O B_DISEASE/B_GENE
Seeking O O
Scale O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Zuckerman O B_PERSON
, O O
1978 O B_MEASURE
) O O
. O O

The O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O O
that O O
processing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
time O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
as O O
a O O
function O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
intensity O B_MEASURE/B_LOCATION
is O O
modified O O
not O O
only O O
at O O
the O O
retina O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
but O O
also O O
at O O
later O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
processing O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
sites O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Identification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
masked O O
toxins O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
in O O
the O O
exotoxin O B_BIO
complex O I_BIO
of O O
Staphylococcus O B_LOCATION/B_BACTERIUM[BIO]
pyogenes O I_LOCATION/I_BACTERIUM[BIO]
und O I_LOCATION/I_BACTERIUM[BIO]
Cl O I_LOCATION/I_BACTERIUM[BIO]
. O O
perfringens O B_BACTERIUM[BIO]/B_PERSON
; O O
significance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
their O O
existence O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
clarifying O O
of O O
the O O
masking O B_DISEASE/B_BIO
mechanism O I_DISEASE/I_BIO

Unlike O O
LANA1 B B_GENE
, O O
LANA2 B B_GENE/B_LOCATION
does O O
not O O
elicit O O
a O O
serologic O O
response O O
from O O
patients O O
with O O
KS O O
, O O
PEL O O
, O O
or O O
CD O O
as O O
measured O O
by O O
Western O O
blot O O
hybridization O O
. O O

However O O
, O O
this O O
posttranslational O O
modification O O
of O O
the O O
gar2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
does O O
not O O
appear O O
to O O
be O O
essential O O
for O O
normal O O
production O O
of O O
18S B B_GENE
rRNA I I_GENE
. O O

Here O O
, O O
we O O
analyzed O O
the O O
interaction O O
of O O
CYT B B_GENE
- I I_GENE
18 I I_GENE
with O O
a O O
small O O
RNA O O
( O O
P4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
P6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
corresponding O O
to O O
the O O
isolated O O
P4 B B_GENE/B_LOCATION
- I B_GENE/I_LOCATION
P6 I B_GENE/I_LOCATION
domain I B_GENE/I_LOCATION
of O O
the O O
N B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
crassa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mitochondrial I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
large I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
subunit I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ribosomal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
intron I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
deduced O O
amino O O
acid O O
sequence O O
of O O
PutR B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
154 O O
amino O O
acid O O
residues O O
) O O
showed O O
homology O O
to O O
the O O
small O O
regulatory O O
proteins O O
Lrp B B_GENE
, O O
BkdR B B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O O
and O O
AsnC B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

When O O
yeast O O
cells O O
reach O O
a O O
critical O O
size O O
in O O
late O O
G1 O O
they O O
simultaneously O O
start O O
budding O O
, O O
initiate O O
DNA O O
synthesis O O
, O O
and O O
activate O O
transcription O O
of O O
a O O
set O O
of O O
genes O O
that O O
includes O O
G1 B B_GENE/B_DISEASE
cyclins I I_GENE/I_DISEASE
CLN1 B I_GENE/I_DISEASE
, O O
CLN2 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
many O O
DNA O O
synthesis O O
genes O O
. O O

Functional O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PET O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scanning O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
preoperative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assessment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cerebral O B_DISEASE
arteriovenous O I_DISEASE
malformations O I_DISEASE
. O O

In O O
addition O B_MEASURE/B_LOCATION
, O O
269 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mice O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O O
a O O
( O O
Mus O B_DISEASE/B_PROTEIN[GENE]
spretus O B_DISEASE/I_PROTEIN[GENE]
x O O
C57BL O B_BIO/B_PROTEIN[GENE]
/ O O
6J O B_MEASURE
) O O
F1 O B_PROTEIN[GENE]/B_SPECIES[BIO]
x O O
C57BL O B_BIO/B_PROTEIN[GENE]
/ O O
6J O B_MEASURE/B_PERSON
interspecific O I_MEASURE/I_PERSON
backcross O I_MEASURE/I_PERSON
were O O
also O O
used O O
to O O
order O O
marker O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loci O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
calculate O O
intergene O B_MEASURE/B_GENE
distances O I_MEASURE/I_GENE
for O O
this O O
region O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Accordingly O O
, O O
superpeptide O O
antigenic O O
material O O
was O O
readily O O
detected O O
by O O
immunoblotting O O
cell O O
extracts O O
and O O
enriched O O
in O O
vacuolar O O
preparations O O
of O O
PrA B B_GENE
deficient O O
mutant O O
cells O O
. O O

Blockade O O
of O O
T O O
cell O O
activation O O
using O O
a O O
surface O O
- O O
linked O O
single O O
- O O
chain O O
antibody O O
to O O
CTLA B B_GENE
- I I_GENE
4 I I_GENE
( O O
CD152 B B_GENE
) O O
. O O

Water O B_NUMBER[MEASURE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pair O I_NUMBER[MEASURE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
three O B_NUMBER[MEASURE]/B_LOCATION
- O O
body O B_MEASURE/B_LOCATION
potential O I_MEASURE/I_LOCATION
of O O
spectroscopic O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
quality O B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
Ab O B_LOCATION/B_MEASURE
initio O I_LOCATION/I_MEASURE
calculations O I_LOCATION/I_MEASURE

4 O O
) O O
Mutation O O
of O O
the O O
three O O
extracellular O O
cysteine O O
residues O O
of O O
GFKAR B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O O
that O O
the O O
two O O
conserved O O
cysteine O O
residues O O
( O O
C305 O O
and O O
C385 O O
) O O
, O O
located O O
between O O
two O O
transmembrane O O
segments O O
, O O
form O O
a O O
solvent O O
- O O
accessible O O
disulfide O O
bond O O
. O O

In O O
this O O
work O O
, O O
we O O
have O O
used O O
Xenopus O O
oocyte O O
maturation O O
as O O
a O O
read O O
- O O
out O O
for O O
examining O O
the O O
ability O O
of O O
the O O
neu B B_GENE/B_BIO
tyrosine B I_GENE/I_BIO
kinase I I_GENE/I_BIO
( O O
p185neu B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
to O O
participate O O
with O O
the O O
epidermal B B_GENE/B_BIO
growth I I_GENE/I_BIO
factor I I_GENE/I_BIO
( I I_GENE/I_BIO
EGF I I_GENE/I_BIO
) I I_GENE/I_BIO
receptor I I_GENE/I_BIO
in O O
a O O
common O O
signal O O
transduction O O
pathway O O
. O O

The O O
best O O
- O O
studied O O
neurotrophin O O
, O O
nerve B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NGF B B_GENE/B_LOCATION
) O O
, O O
is O O
a O O
major O O
survival O O
factor O O
in O O
sympathetic O O
and O O
sensory O O
neurons O O
and O O
promotes O O
differentiation O O
in O O
a O O
well O O
- O O
studied O O
model O O
system O O
, O O
PC12 O O
cells O O
. O O

In O O
contrast O O
, O O
MAPK B B_GENE/B_LOCATION
activation O O
stimulated O O
by O O
the O O
Gq B B_GENE
- O O
coupled O O
alpha O O
1B O O
AR O O
or O O
M1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
muscarinic B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cholinergic I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
unaffected O O
by O O
expression O O
of O O
beta B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ARKct I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
RasN17 B B_GENE
expression O O
or O O
by O O
PTK B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inhibitors O O
, O O
but O O
is O O
blocked O O
by O O
expression O O
of O O
N B B_GENE
delta I I_GENE
Raf I I_GENE
or O O
by O O
PKC B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
depletion O O
. O O

Transcriptional O O
analysis O O
indicates O O
that O O
human B B_GENE/B_SPECIES[BIO]
TBP I I_GENE/I_SPECIES[BIO]
functions O O
poorly O O
at O O
promoters O O
recognized O O
by O O
RNA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
polymerases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
III I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
at O O
RNA B B_GENE/B_LOCATION
Pol I I_GENE/I_LOCATION
II I I_GENE/I_LOCATION
promoters I I_GENE/I_LOCATION
lacking O O
a O O
conventional O O
TATA O O
element O O
. O O

The O O
steady O O
- O O
state O O
levels O O
of O O
Cdk2 B B_GENE
, O O
Cdk4 B B_GENE
and O O
Cyclin B B_GENE
A I I_GENE
proteins I I_GENE
were O O
unaffected O O
by O O
HPR O O
, O O
while O O
those O O
of O O
Cyclin B B_GENE
D1 I I_GENE
were O O
significantly O O
reduced O O
in O O
all O O
three O O
cell O O
lines O O
. O O

Mapping O O
the O O
5 O O
' O O
and O O
3 O O
' O O
termini O O
of O O
TED B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNAs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
indicated O O
that O O
the O O
LTRs O O
have O O
a O O
retroviral O O
U3 O O
- O O
R O O
- O O
U5 O O
structural O O
organization O O
that O O
is O O
capable O O
of O O
directing O O
the O O
synthesis O O
of O O
transcripts O O
that O O
represent O O
potential O O
substrates O O
for O O
reverse O O
transcription O O
and O O
intermediates O O
in O O
transposition O O
. O O

Human O B_PERSON/B_PROTEIN[GENE]
forearm O I_PERSON/I_PROTEIN[GENE]
was O O
used O O
as O O
a O O
dummy O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
ear O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O O
the O O
electrode O B_LOCATION
HN O I_LOCATION
- O O
5 O B_MEASURE
was O O
fixed O O
thereon O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
, O O
and O O
a O O
sound O B_MEASURE
stimulus O I_MEASURE
of O O
90dBnHL O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
delivered O O
by O O
the O O
earphone O B_PRODUCT[OBJECT]/B_PERSON
( O O
NC O B_LOCATION/B_PROTEIN[GENE]
- O O
3 O B_MEASURE
) O O
. O O

These O O
proteins O O
were O O
detected O O
by O O
an O O
antibody O O
which O O
recognizes O O
the O O
N O O
- O O
terminus O O
of O O
SRK3 B B_GENE
and O O
, O O
in O O
an O O
F2 O O
progeny O O
segregating O O
for O O
the O O
S3 B B_GENE/B_MEASURE
haplotype I I_GENE/I_MEASURE
, O O
were O O
only O O
expressed O O
in O O
plants O O
possessing O O
the O O
S3 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
haplotype I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
blood O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pressures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
43 O B_PERSON/B_BIO
subjects O B_PERSON/I_BIO
were O O
compared O O
during O O
rapid O B_DISEASE_ADJECTIVE[DISEASE]
weight O I_DISEASE_ADJECTIVE[DISEASE]
loss O I_DISEASE_ADJECTIVE[DISEASE]
and O O
at O O
identical O B_MEASURE/B_PERSON
weights O I_MEASURE/I_PERSON
during O O
post O B_DISEASE/B_MEASURE
- O O
fast O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
weight O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
gain O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
A O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
. O O

The O O
animals O O
were O O
followed O O
over O O
a O O
1 O O
- O O
to O O
6 O O
- O O
h O O
posttraumatic O O
course O O
, O O
and O O
processed O O
for O O
the O O
LM O O
and O O
TEM O O
visualization O O
of O O
HRP B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Total O B_MEASURE/B_LOCATION
body O I_MEASURE/I_LOCATION
water O I_MEASURE/I_LOCATION
and O O
distribution O B_MEASURE/B_LOCATION
space O I_MEASURE/I_LOCATION
of O O
Na24 O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
women O B_PERSON/B_MEASURE
with O O
various O B_DISEASE/B_LOCATION
body O I_DISEASE/I_LOCATION
weight O I_DISEASE/I_LOCATION

Three O O
experiments O O
using O O
20 O O
microM O O
2 O O
- O O
( O O
hydroxyamino O O
) O O
- O O
1 O O
- O O
methyl O O
- O O
6 O O
- O O
phenylimidazo O O
[ O O
4 O O
, O O
5 O O
- O O
b O O
] O O
pyridine O O
( O O
N O O
- O O
OH O O
- O O
PhIP O O
) O O
were O O
performed O O
to O O
induce O O
mutations O O
in O O
the O O
dihydrofolate B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
reductase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
DHFR B B_PROTEIN[GENE]/B_LOCATION
) O O
gene O O
of O O
a O O
hemizygous O O
Chinese O O
hamster O O
ovary O O
( O O
CHO O O
) O O
cell O O
line O O
( O O
UA21 O O
) O O
. O O

This O O
is O O
mediated O O
by O O
vascular O B_DISEASE/B_GENE
remodeling O I_DISEASE/I_GENE
, O O
an O O
active O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
process O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
results O O
in O O
a O O
change O B_TIME[MEASURE]
in O O
the O O
geometry O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
blood O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
vessel O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Our O O
results O O
separate O O
these O O
factors O O
into O O
four O O
regulatory O O
classes O O
: O O
( O O
i O O
) O O
constitutive O O
factors O O
, O O
such O O
as O O
Oct B B_GENE
- I I_GENE
1 I I_GENE
and O O
probably O O
Sp1 B B_GENE
, O O
that O O
are O O
expressed O O
in O O
thymocytes O O
at O O
all O O
stages O O
; O O
( O O
ii O O
) O O
inducible O O
factors O O
, O O
such O O
as O O
NF B B_GENE
- I I_GENE
kappa I I_GENE
B I I_GENE
and O O
complexes O O
binding O O
to O O
the O O
region O O
of O O
a O O
CD28 B B_GENE
response I I_GENE
element I I_GENE
, O O
that O O
can O O
be O O
activated O O
in O O
all O O
thymocytes O O
, O O
including O O
those O O
cells O O
( O O
CD4 B B_GENE
+ I I_GENE
CD8 B I_GENE
+ I I_GENE
TcRlow B I_GENE
) O O
that O O
can O O
undergo O O
selection O O
; O O
( O O
iii O O
) O O
inducible O O
factors O O
, O O
such O O
as O O
NF B B_GENE
- I I_GENE
AT I I_GENE
and O O
AP B B_GENE
- I I_GENE
1 I I_GENE
, O O
that O O
can O O
be O O
activated O O
in O O
mature O O
( O O
CD4 B B_GENE/B_PERSON
+ I I_GENE/I_PERSON
CD8 B I_GENE/I_PERSON
- I I_GENE/I_PERSON
TcRhigh B I_GENE/I_PERSON
) O O
and O O
immature O O
( O O
CD4 B B_GENE/B_PERSON
- I I_GENE/I_PERSON
CD8 B I_GENE/I_PERSON
- I I_GENE/I_PERSON
TcR B I_GENE/I_PERSON
- I I_GENE/I_PERSON
) O O
thymocytes O O
alike O O
but O O
not O O
in O O
the O O
transitional O O
stages O O
when O O
the O O
cells O O
( O O
CD4 B B_GENE/B_MEASURE
+ I I_GENE/I_MEASURE
CD8 B I_GENE/I_MEASURE
+ I I_GENE/I_MEASURE
TcRlow B I_GENE/I_MEASURE
) O O
are O O
subject O O
to O O
selection O O
; O O
and O O
( O O
iv O O
) O O
a O O
factor O O
containing O O
CREB B B_GENE/B_MEASURE
, O O
which O O
can O O
be O O
activated O O
in O O
thymocytes O O
of O O
all O O
developmental O O
stages O O
by O O
culture O O
but O O
does O O
not O O
require O O
specific O O
induction O O
. O O

Thus O O
, O O
22 O B_PERSON
% O I_PERSON
of O O
MDS O B_PERSON
responded O O
to O O
oral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
PLAC O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Posterior O B_DISEASE
osteophytes O I_DISEASE
around O O
the O O
posterior O B_LOCATION/B_MEASURE
edges O I_LOCATION/I_MEASURE
of O O
vertebral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
body O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
resulted O O
in O O
intervertebral O B_DISEASE
insufficiency O I_DISEASE
, O O
and O O
corresponded O O
to O O
hypertrophic O B_DISEASE
spur O I_DISEASE
in O O
osteochondrosis O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O O

They O O
showed O O
moderate O B_DISEASE_ADJECTIVE[DISEASE]
in O O
vitro O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
antifungal O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
activity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
against O O
a O O
wide O B_MEASURE
variety O I_MEASURE
of O O
fungi O B_SPECIES[BIO]
and O O
yeasts O B_SPECIES[BIO]
including O O
clinically O O
important O B_SPECIES[BIO]
pathogens O I_SPECIES[BIO]
, O O
and O O
were O O
highly O O
effective O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
systemic O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infection O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
Candida O B_SPECIES[BIO]/B_DISEASE
albicans O I_SPECIES[BIO]/I_DISEASE
in O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
iv O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
im O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
administrations O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Of O O
these O O
four O O
PP2C B B_GENE/B_LOCATION
genes I I_GENE/I_LOCATION
, O O
the O O
expression O O
of O O
the O O
PP2Cbeta B B_SEQUENCE[MEASURE]/B_PERSON
gene I I_SEQUENCE[MEASURE]/I_PERSON
has O O
been O O
reported O O
to O O
be O O
tissue O O
- O O
specific O O
and O O
development O O
- O O
dependent O O
. O O

We O O
also O O
show O O
that O O
in O O
fusions O O
with O O
the O O
DNA O O
binding O O
domain O O
of O O
GAL4 B B_GENE/B_SPECIES[BIO]
, O O
full O O
activity O O
requires O O
the O O
entire O O
BHV B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
alpha I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
TIF I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
although O O
both O O
amino O O
and O O
carboxyl O O
termini O O
display O O
some O O
activity O O
on O O
their O O
own O O
. O O

The O O
induction O O
by O O
dexamethasone O O
of O O
rat B B_GENE
liver I I_GENE
CYP3A1 I I_GENE
differs O O
from O O
classical O O
glucocorticoid O O
gene O O
regulation O O
in O O
part O O
because O O
both O O
glucocorticoids O O
and O O
antiglucocorticoids O O
such O O
as O O
pregnenolone O O
16 O O
alpha O O
- O O
carbonitrile O O
( O O
PCN O O
) O O
induce O O
CYP3A1 B B_GENE
through O O
transcriptional O O
gene O O
activation O O
. O O

Moreover O O
, O O
antibody O O
binding O O
to O O
the O O
same O O
two O O
determinants O O
was O O
also O O
inhibited O O
when O O
ZAP B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
70 I I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
the O O
SH2 B B_PROTEIN[GENE]/B_BIO
domains I I_PROTEIN[GENE]/I_BIO
bound O O
to O O
the O O
zeta O O
chain O O
or O O
to O O
a O O
2pY B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ITAM I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

This O O
surface O B_LOCATION/B_BIO
in O O
specimens O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
from O O
unfertilized O B_LOCATION
eggs O I_LOCATION
is O O
almost O O
flat O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

Fetal O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transplants O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rescue O O
axial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
muscle O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
representations O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
M1 O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
cortex O I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
of O O
neonatally O O
transected O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
develop O O
weight O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
support O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
examined O O
the O O
contribution O O
of O O
the O O
M B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MuLV I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancers I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
transcriptional O O
activity O O
and O O
pathogenesis O O
of O O
M O O
- O O
MuLV O O
by O O
constructing O O
LTRs O O
containing O O
heterologous O O
enhancer O O
elements O O
. O O

There O O
were O O
no O O
major O B_DISEASE_ADJECTIVE[DISEASE]
postoperative O I_DISEASE_ADJECTIVE[DISEASE]
complications O I_DISEASE_ADJECTIVE[DISEASE]
and O O
at O O
follow O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
up O B_LOCATION/B_NUMBER[MEASURE]
of O O
the O O
13 O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
10 O B_MEASURE/B_LOCATION
to O O
26 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
after O O
operation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
satisfactory O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
immunoreactive O O
antithrombin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
III I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
increased O O
significantly O O
while O O
the O O
increase O O
in O O
antithrombin B B_GENE
III I I_GENE
activity O O
was O O
insignificant O O
in O O
20 O O
male O O
Caucasian O O
Danes O O
upon O O
3 O O
weeks O O
supplementation O O
of O O
the O O
diet O O
with O O
10 O O
ml O O
daily O O
of O O
a O O
cod O O
liver O O
oil O O
concentrate O O
. O O

Northern O O
blot O O
analysis O O
confirmed O O
that O O
ADAMTS B B_GENE
- I I_GENE
1 I I_GENE
was O O
up O O
- O O
regulated O O
in O O
both O O
metaphyseal O O
( O O
14 O O
- O O
to O O
35 O O
- O O
fold O O
) O O
and O O
diaphyseal O O
( O O
4 O O
. O O
2 O O
- O O
fold O O
) O O
bone O O
1 O O
h O O
after O O
PTH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
38 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
injection O O
and O O
returned O O
to O O
control O O
levels O O
by O O
24 O O
h O O
. O O

The O O
transcriptional B B_GENE/B_DISEASE
transactivator I I_GENE/I_DISEASE
( O O
Tas B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
of O O
simian O O
foamy O O
virus O O
type O O
1 O O
strongly O O
augments O O
gene O O
expression O O
directed O O
by O O
both O O
the O O
promoter O O
in O O
the O O
viral O O
long O O
terminal O O
repeat O O
and O O
the O O
newly O O
discovered O O
internal O O
promoter O O
located O O
within O O
the O O
env B B_GENE
gene I I_GENE
. O O

In O O
the O O
other O B_TIME[MEASURE]/B_LOCATION
two O B_TIME[MEASURE]/I_LOCATION
cases O B_TIME[MEASURE]/I_LOCATION
, O O
fluoxetine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adjunct O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O O
benefits O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
no O O
additional O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Deletion O O
of O O
this O O
consensus O O
element O O
from O O
the O O
spo6 B B_GENE/B_BIO
promoter I I_GENE/I_BIO
abolished O O
the O O
transcription O O
of O O
spo6 B B_GENE
+ I I_GENE
and O O
resulted O O
in O O
a O O
sporulation O O
deficiency O O
. O O

Chem O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

Mutations O O
in O O
the O O
beta B B_GENE
- I I_GENE
galactosidase I I_GENE
gene I I_GENE
result O O
in O O
the O O
lysosomal O O
storage O O
disorders O O
GM1 O O
- O O
gangliosidosis O O
and O O
Morquio O O
B O O
syndrome O O
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
indicated O O
that O O
hobbies O B_PERSON/B_LOCATION
/ O O
leisure O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
activities O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
mobility O B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
transport O B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
social O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relationships O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
working O O
capacity O B_TIME[MEASURE]/B_LOCATION
, O O
energy O B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
doing O O
things O B_PERSON/B_LOCATION
slower O O
were O O
aspects O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
relevant O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O O
IPF O B_DISEASE/B_ORGANIZATION
patients O I_DISEASE/I_ORGANIZATION
' O I_DISEASE/I_ORGANIZATION
QOL O I_DISEASE/I_ORGANIZATION
. O O

We O O
have O O
generated O O
transgenic O O
fly O O
strains O O
with O O
mutations O O
affecting O O
specific O O
TRA B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
2 I I_GENE/I_LOCATION
isoforms I I_GENE/I_LOCATION
to O O
investigate O O
their O O
individual O O
roles O O
in O O
regulating O O
the O O
alternative O O
processing O O
of O O
doublesex B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
exuperantia B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O O
tra B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pre I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRNA I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
IR4 O O
ORF O O
exhibits O O
significant O O
homology O O
to O O
the O O
immediate B B_GENE/B_BIO
- I I_GENE/I_BIO
early I I_GENE/I_BIO
gene I I_GENE/I_BIO
US1 B I_GENE/I_BIO
( O O
ICP22 B B_PROTEIN[GENE]/B_LOCATION
) O O
of O O
herpes O O
simplex O O
virus O O
type O O
1 O O
and O O
to O O
the O O
ICP22 B B_SPECIES[BIO]/B_MEASURE
homologs O O
of O O
varicella O O
- O O
zoster O O
virus O O
( O O
ORF63 B B_PROTEIN[GENE]/B_VIRUS[BIO]
) O O
, O O
pseudorabies O O
virus O O
( O O
RSp40 B B_PROTEIN[GENE]/B_DISEASE
) O O
, O O
and O O
equine O O
herpesvirus O O
4 O O
( O O
ORF4 O O
) O O
. O O

These O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
define O O
a O O
class O B_PERSON/B_LOCATION
of O O
DNA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
elements O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
a O O
mode O B_LOCATION/B_MEASURE
of O O
action O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
that O O
has O O
not O O
been O O
heretofore O O
described O O
. O O

We O O
were O O
able O O
to O O
demonstrate O O
a O O
significant O O
statistical O O
interaction O O
effect O O
between O O
gender O O
and O O
globulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
protein I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
concentration O O
on O O
Vu O O
( O O
p O O
= O O
0 O O
. O O
022 O O
) O O
. O O

Chest O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
X O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
P O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
revealed O O
an O O
abnormal O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shadow O I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
left O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
upper O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
lobe O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

From O O
the O O
frozen O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
specimen O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
a O O
large O B_MEASURE
number O I_MEASURE
of O O
sections O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
good O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
morphologic O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
characteristics O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
may O O
be O O
produced O O
. O O

These O O
include O O
not O O
only O O
antioxidants O O
, O O
N B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
methyl I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
D I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
aspartate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antagonists O O
, O O
inhibitors O O
of O O
glutamate O O
release O O
, O O
calcium O O
channel O O
blockers O O
, O O
polyamine O O
antagonists O O
, O O
and O O
nitric B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxide I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
synthase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors O O
, O O
but O O
cannabinoids O O
, O O
aspirin O O
, O O
melatonin O O
, O O
and O O
vitamin O O
B O O
- O O
12 O O
. O O

A O O
series O O
of O O
mutations O O
were O O
constructed O O
within O O
the O O
E2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
open O O
reading O O
frame O O
which O O
delete O O
various O O
regions O O
of O O
the O O
conserved O O
DNA O O
binding O O
and O O
transactivation O O
domains O O
as O O
well O O
as O O
the O O
internal O O
hinge O O
region O O
. O O

CrkII B B_GENE
and O O
CrkL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
constitutively O O
formed O O
complex O O
with O O
the O O
guanine B B_GENE
nucleotide I I_GENE
exchange I I_GENE
factor I I_GENE
C3G B I_GENE
, O O
in O O
unstimulated O O
as O O
well O O
as O O
PDGF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
stimulated O O
cells O O
. O O

In O O
further O O
support O O
of O O
the O O
biological O O
significance O O
of O O
these O O
DNA O O
- O O
protein O O
interactions O O
, O O
the O O
IL2RA B B_GENE/B_MEASURE
oligonucleotide O O
from O O
- O O
291 O O
to O O
- O O
245 O O
proved O O
to O O
be O O
sufficient O O
in O O
either O O
orientation O O
to O O
confer O O
PMA O O
inducibility O O
to O O
the O O
mitogen O O
- O O
insensitive O O
thymidine B B_GENE/B_LOCATION
kinase I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
in O O
Jurkat O O
cells O O
. O O

The O O
plasma O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
steroid O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
levels O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
the O O
CAPD O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
patients O I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
after O O
each O O
infusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rate O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
equal O B_MEASURE
to O O
or O O
greater O B_MEASURE
than O O
the O O
levels O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
normal O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subjects O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

With O O
BCPP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protocol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
12 O B_NUMBER[MEASURE]
achieved O O
a O O
complete O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
response O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
11 O B_MEASURE
evidenced O O
a O O
75 O B_MEASURE
% O I_MEASURE
response O I_MEASURE
, O O
and O O
7 O B_NUMBER[MEASURE]
displayed O O
a O O
50 O B_DISEASE
% O I_DISEASE
response O I_DISEASE
. O O

The O O
RPC31 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encoding O O
the O O
C31 B B_ENZYME[GENE]
subunit I I_ENZYME[GENE]
of I I_ENZYME[GENE]
Saccharomyces I I_ENZYME[GENE]
cerevisiae I I_ENZYME[GENE]
RNA I I_ENZYME[GENE]
polymerase I I_ENZYME[GENE]
C I I_ENZYME[GENE]
( I I_ENZYME[GENE]
III I I_ENZYME[GENE]
) I I_ENZYME[GENE]
has O O
been O O
isolated O O
, O O
starting O O
from O O
a O O
C O O
- O O
terminal O O
fragment O O
cloned O O
on O O
a O O
lambda O O
gt11 O O
library O O
. O O

Electrophoretic O O
mobility O O
shift O O
assays O O
demonstrated O O
that O O
sequences O O
within O O
this O O
region O O
bind O O
members O O
of O O
the O O
Sp1 B B_GENE/B_BIO
family I I_GENE/I_BIO
of I I_GENE/I_BIO
transcription I I_GENE/I_BIO
factors I I_GENE/I_BIO
. O O

The O O
phosphatase O B_LOCATION
active O I_LOCATION
site O I_LOCATION
is O O
located O O
within O O
residues O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
367 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
- O O
374 O B_MEASURE
. O O

After O O
at O O
least O O
one O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
year O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
follow O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
up O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
argon O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
laser O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O O
a O O
statistically O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
effect O I_DISEASE_ADJECTIVE[DISEASE]
( O O
p O B_MEASURE
less O I_MEASURE
of O O
0 O B_MEASURE
, O O
01 O B_MEASURE
; O O
Kolmogorow O B_PERSON
- O O
Smirnov O B_MEASURE/B_SPORT[ENT]
test O I_MEASURE/I_SPORT[ENT]
) O O
on O O
the O O
stabilization O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
or O O
the O O
amelioration O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
visual O B_DISEASE
acuity O I_DISEASE
compared O O
with O O
the O O
non O B_TIME[MEASURE]/B_DISEASE
treated O O
group O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Further O O
studies O O
aim O O
at O O
characterizing O O
the O O
trans O O
- O O
acting O O
factors O O
that O O
mediate O O
the O O
spatial O O
and O O
temporal O O
expression O O
of O O
Hox B B_GENE
genes I I_GENE
in O O
the O O
developing O O
embryo O O
. O O

Contraindications O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
to O O
adenosine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
interactions O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
noted O O
in O O
this O O
article O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

As O O
to O O
the O O
side O O
effects O O
of O O
SISO O O
, O O
cylindruria O O
with O O
aggravation O O
of O O
microscopic O O
hematuria O O
and O O
elevations O O
of O O
GOT B B_GENE/B_DISEASE
, O O
GPT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A1 B B_LOCATION/B_GENE
- I I_LOCATION/I_GENE
P I I_LOCATION/I_GENE
were O O
observed O O
each O O
one O O
of O O
them O O
, O O
respectively O O
. O O

Serum B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
C3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
measured O O
in O O
1 O O
, O O
282 O O
school O O
children O O
with O O
abnormal O O
urinary O O
findings O O
between O O
1980 O O
and O O
1997 O O
. O O

Two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
measures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
sensory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inhibition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O O
employed O O
, O O
S2 O B_PROTEIN[GENE]/B_MEASURE
/ O O
S1 O B_MEASURE
x O O
100 O B_MEASURE
amplitude O I_MEASURE
ratio O I_MEASURE
and O O
S1 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
S2 O B_MEASURE
amplitude O I_MEASURE
difference O I_MEASURE
. O O

Computer O O
analysis O O
revealed O O
that O O
the O O
human B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
P1 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequence I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
corresponding O O
to O O
amino O O
acid O O
residues O O
within O O
the O O
N O O
- O O
terminal O O
RNA O O
binding O O
domain O O
displays O O
high O O
homology O O
( O O
greater O O
than O O
54 O O
% O O
identity O O
; O O
61 O O
to O O
94 O O
% O O
similarity O O
) O O
with O O
two O O
animal O O
virus O O
proteins O O
which O O
possess O O
RNA O O
binding O O
activity O O
( O O
vaccinia B B_PROTEIN[GENE]/B_SPECIES[BIO]
virus I I_PROTEIN[GENE]/I_SPECIES[BIO]
E3L I I_PROTEIN[GENE]/I_SPECIES[BIO]
; O O
rotavirus B B_VIRUS[BIO]/B_PROTEIN[GENE]
VP2 I B_VIRUS[BIO]/I_PROTEIN[GENE]
) O O
and O O
two O O
proteins O O
of O O
unknown O O
function O O
( O O
murine B B_GENE
TIK I I_GENE
; O O
rotavirus B B_VIRUS[BIO]/B_GENE
NS34 I I_VIRUS[BIO]/I_GENE
) O O
, O O
but O O
which O O
are O O
likely O O
RNA O O
binding O O
proteins O O
. O O

Determinants O O
of O O
recurrent O O
ischaemia O O
and O O
revascularisation O O
procedures O O
after O O
thrombolysis O O
with O O
recombinant O O
tissue B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
plasminogen I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
primary O O
coronary O O
occlusion O O
. O O

For O O
large O B_DISEASE/B_MEASURE
breasts O I_DISEASE/I_MEASURE
( O O
> O O
70 O B_MEASURE
mm O I_MEASURE
) O O
the O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O O
X O B_PROTEIN[GENE]/B_NUMBER[MEASURE]
- O O
ray O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
sets O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
such O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
as O O
the O O
IGE O B_PRODUCT[OBJECT]/B_ENT
DMR O I_PRODUCT[OBJECT]/I_ENT
, O O
which O O
automatically O O
select O O
the O O
beam O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
quality O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
for O O
each O O
breast O B_BIO/B_DISEASE
, O O
resulted O O
in O O
lower O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O O
with O O
sets O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
using O O
manual O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tube O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
potential O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
selection O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
poults O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
with O O
each O O
of O O
two O B_NUMBER[MEASURE]/B_PERSON
strains O B_NUMBER[MEASURE]/I_PERSON
representing O O
the O O
rarely O O
reported O O
capsular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
B O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
indicated O O
that O O
both O O
were O O
virulent O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Computer O B_ORGANIZATION/B_PERSON
system O B_ORGANIZATION/I_PERSON
trains O O
employees O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
meet O O
JCAHO O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
safety O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
ED O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
requirements O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Finally O O
, O O
transfection O O
of O O
Grb10 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
specific O O
mutations O O
in O O
their O O
SH2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
domains I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
induces O O
apoptosis O O
in O O
HTC O O
- O O
IR O O
and O O
COS O O
- O O
7 O O
cells O O
. O O

Comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
dose O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
volume O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
histograms O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
revealed O O
that O O
the O O
6 O B_MEASURE
- O O
field O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
plan O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
spared O O
relatively O O
more O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
heart O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
whereas O O
the O O
8 O B_MEASURE
- O O
field O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
plan O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
spared O O
relatively O O
more O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
lung O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

We O O
have O O
demonstrated O O
that O O
a O O
putative O O
HOX B B_GENE/B_MEASURE
cofactor I I_GENE/I_MEASURE
, O O
PBX1A B B_GENE
, O O
participates O O
in O O
cooperative O O
DNA O O
binding O O
with O O
HOXA B B_GENE
- I I_GENE
1 I I_GENE
and O O
the O O
Deformed B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
group O O
protein O O
HOXD B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
4 I I_GENE/I_LOCATION
. O O

The O O
CHL B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CTF B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
gene O O
product O O
of O O
Saccharomyces O O
cerevisiae O O
is O O
important O O
for O O
chromosome O O
transmission O O
and O O
normal O O
cell O O
cycle O O
progression O O
in O O
G2 O O
/ O O
M O O
. O O

Heterotrimeric O O
guanine B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
nucleotide I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
G B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
function O O
as O O
signal O O
transducers O O
for O O
a O O
variety O O
of O O
hormone O O
- O O
coupled O O
enzyme O O
and O O
ion O O
transport O O
systems O O
in O O
eukaryotic O O
cells O O
. O O

In O O
contrast O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
polypropylene O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
glycol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
PG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
C O B_MEASURE/B_OTHER
, O O
and O O
corn O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oil O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
all O O
removed O O
68 O B_MEASURE
- O O
86 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
the O O
MDI O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
the O O
first O B_SEQUENCE[MEASURE]
h O O
, O O
74 O B_MEASURE
- O O
79 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
at O O
4 O B_NUMBER[MEASURE]
h O O
, O O
and O O
72 O B_MEASURE
- O O
86 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
at O O
8 O B_MEASURE
h O O
. O O

DDD O B_DISEASE_ADJECTIVE[DISEASE]
( O O
R O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
pacing O O
with O O
automatic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
mode O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
switch O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
patients O B_PERSON
with O O
paroxysmal O B_DISEASE
atrial O I_DISEASE
fibrillation O I_DISEASE
following O O
AV O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
nodal O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
ablation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

There O O
was O O
a O O
highly O O
significant O O
decrease O O
in O O
serum B B_DISEASE/B_GENE
eosinophil I I_DISEASE/I_GENE
cationic I I_DISEASE/I_GENE
protein I I_DISEASE/I_GENE
in O O
patients O O
with O O
elevated O O
AGA B B_GENE/B_DISEASE
. O O

Sequence O O
analysis O O
revealed O O
that O O
Hv B B_GENE/B_BIO
- I I_GENE/I_BIO
p68 I I_GENE/I_BIO
belongs O O
to O O
the O O
large O O
family O O
of O O
FAD B B_ENZYME[GENE]/B_BIO
- I I_ENZYME[GENE]/I_BIO
dependent I I_ENZYME[GENE]/I_BIO
glucose I I_ENZYME[GENE]/I_BIO
methanol I I_ENZYME[GENE]/I_BIO
choline I I_ENZYME[GENE]/I_BIO
oxidoreductases I I_ENZYME[GENE]/I_BIO
and O O
that O O
it O O
shares O O
significant O O
sequence O O
identity O O
( O O
> O O
67 O O
% O O
) O O
with O O
the O O
alcohol B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
oxidases I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
methylotrophic O O
yeasts O O
. O O

It O O
is O O
required O O
for O O
correct O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
expression O I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
both O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
the O O
HIV B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
LTR I B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
this O O
region O O
has O O
been O O
demonstrated O O
to O O
have O O
both O O
positive O O
and O O
negative O O
regulatory O O
effects O O
on O O
HIV O O
gene O O
expression O O
. O O

A O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
between O O
attenuation O B_MEASURE/B_DISEASE
- O O
corrected O O
and O O
- O O
uncorrected O O
transmission O B_DISEASE/B_MEASURE
- O O
emission O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
SPECT O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
images O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
obtained O O
with O O
Tl O B_LOCATION/B_PROTEIN[GENE]
- O O
201 O B_NUMBER[MEASURE]/B_BIO
in O O
CAD O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
patients O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION

Accumulation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
amines O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
isolated O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
perfused O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
rabbit O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
lung O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Since O O
it O O
is O O
often O O
necessary O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
resort O O
to O O
thoracotomy O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
final O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
step O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
making O O
such O O
a O O
diagnosis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
we O O
have O O
sought O O
a O O
procedure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
that O O
is O O
simpler O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
while O O
capable O B_PERSON/B_LOCATION
of O O
providing O O
the O O
same O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
information O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Both O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Mn O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
exposed O O
quail O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
accumulated O O
5 O B_NUMBER[MEASURE]/B_LOCATION
to O O
10 O B_TIME[MEASURE]
times O I_TIME[MEASURE]
more O I_TIME[MEASURE]
Mn O I_TIME[MEASURE]
in O O
their O O
livers O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
than O O
similarly O O
treated O O
rodents O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Small B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
t I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
also O O
inhibited O O
the O O
dephosphorylation O O
of O O
cAMP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dependent I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PKA B B_GENE/B_LOCATION
) O O
- O O
phosphorylated O O
CREB B B_GENE
in O O
rat O O
liver O O
nuclear O O
extracts O O
. O O

A O O
retrospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
accumulated O O
over O O
a O O
21 O B_NUMBER[MEASURE]
- O O
month O B_TIME[MEASURE]
period O I_TIME[MEASURE]
, O O
from O O
December O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1989 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
September O B_TIME[MEASURE]
1991 O I_TIME[MEASURE]
, O O
regarding O O
investigational O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
use O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
of O O
a O O
308 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
nanometer O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
Xenon O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
Chloride O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
Excimer O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
Laser O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
Coronary O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
Angioplasty O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
ELCA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
system O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEDICAL_DEVICE[OBJECT]
( O O
Advanced O B_ORGANIZATION/B_PERSON
Interventional O B_ORGANIZATION/I_PERSON
Systems O B_ORGANIZATION/I_PERSON
, O O
Inc O B_ORGANIZATION/B_LOCATION
. O O
, O O
Irvine O B_LOCATION/B_PERSON
, O O
CA O B_LOCATION
) O O
was O O
performed O O
. O O

Presently O O
, O O
we O O
made O O
chain O O
pair O O
switch O O
, O O
chimeric O O
, O O
and O O
site O O
mutant B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gamma I B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
delta I B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
TCRs I B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
transfected O O
them O O
into O O
TCR O O
- O O
mutant O O
Jurkat O O
T O O
cells O O
to O O
examine O O
the O O
effects O O
of O O
changing O O
the O O
TCR B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
gamma I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
junctional I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
region I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sequences I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
on O O
reactivity O O
to O O
prenyl B B_GENE
pyrophosphate I I_GENE
Ags I I_GENE
. O O

Fos B B_GENE/B_LOCATION
/ O O
Jun B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bound O O
to O O
an O O
unacetylated O O
nucleosome O O
with O O
only O O
a O O
4 O O
- O O
to O O
5 O O
- O O
fold O O
reduction O O
in O O
DNA O O
binding O O
affinity O O
compared O O
with O O
naked O O
DNA O O
. O O

Activated B B_GENE
Ki I I_GENE
- I I_GENE
Ras I I_GENE
suppresses O O
12 O O
- O O
O O O
- O O
tetradecanoylphorbol O O
- O O
13 O O
- O O
acetate O O
- O O
induced O O
activation O O
of O O
the O O
c B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Jun I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NH2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
terminal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
human O O
colon O O
cancer O O
cells O O
. O O

Electromobility O O
shift O O
analysis O O
using O O
oligonucleotides O O
encompassing O O
the O O
proximal O O
, O O
distal O O
, O O
and O O
BED O O
/ O O
AP B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
- O O
binding O O
regions O O
failed O O
to O O
demonstrate O O
selective O O
transactivation O O
after O O
CD2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O O
of O O
LPMC O O
. O O

The O O
present O O
report O O
shows O O
that O O
a O O
cis O O
- O O
acting O O
element O O
between O O
- O O
189 O O
and O O
- O O
175 O O
bp O O
, O O
which O O
binds O O
thyroid B B_GENE
transcription I I_GENE
factor I I_GENE
- I I_GENE
1 I I_GENE
( O O
TTF B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
) O O
, O O
is O O
involved O O
in O O
both O O
activities O O
. O O

Increased O O
platelet B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
derived I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
growth I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
production O O
and O O
intimal O O
thickening O O
during O O
healing O O
of O O
Dacron O O
grafts O O
in O O
a O O
canine O O
model O O
. O O

Despite O O
their O O
high O O
degree O O
of O O
sequence O O
similarity O O
, O O
all O O
five O O
RFC B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
essential O O
for O O
cell O O
proliferation O O
in O O
S O O
. O O
cerevisiae O O
. O O

Moreover O O
, O O
we O O
show O O
that O O
ectopic O O
expression O O
of O O
the O O
E2A B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E12 B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
this O O
macrophage O O
line O O
results O O
in O O
the O O
induction O O
of O O
many O O
B O O
lineage O O
genes O O
, O O
including O O
EBF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
IL7Ralpha B B_GENE
, O O
lambda5 B B_GENE
, O O
and O O
Rag B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
the O O
ability O O
to O O
induce O O
kappa B B_GENE/B_DISEASE
light I I_GENE/I_DISEASE
chain I I_GENE/I_DISEASE
in O O
response O O
to O O
mitogen O O
. O O

Also O O
, O O
anti B B_GENE
- I I_GENE
HIV I I_GENE
gp120 I I_GENE
and O O
anti B B_GENE
- I I_GENE
CD4 I I_GENE
crosslinking O O
induced O O
a O O
10 O O
- O O
15 O O
- O O
fold O O
increase O O
in O O
levels O O
of O O
both O O
PI B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
3 I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
PI I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
4 I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
in O O
anti B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
CD4 I I_DISEASE/I_GENE
precipitates O O
. O O

The O O
differences O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
percentages O B_DISEASE_ADJECTIVE[DISEASE]
for O O
HIV O B_DISEASE
- O O
1 O B_DISEASE/B_GENE
infection O I_DISEASE/I_GENE
in O O
intravenous O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
drug O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
users O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IVDU O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
were O O
67 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
and O O
in O O
non O B_MEASURE/B_PERSON
IVDU O B_MEASURE/I_PERSON
were O O
3 O B_MEASURE
. O O
8 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
with O O
a O O
significant O B_MEASURE/B_DISEASE
statistical O B_MEASURE/I_DISEASE
difference O B_MEASURE/I_DISEASE
( O O
chi O B_PROTEIN[GENE]/B_PERSON
2 O I_PROTEIN[GENE]/I_PERSON
= O O
557 O B_MEASURE
. O O
5 O B_MEASURE
; O O
p O O
< O O
0 O B_MEASURE
. O O
0001 O B_MEASURE
) O O
. O O

One O O
of O O
the O O
ORFs O O
in O O
the O O
Methanococcus O O
jannaschii O O
genome O O
possesses O O
high O O
similarity O O
to O O
the O O
M B B_SPECIES[BIO]/B_SEQUENCE[MEASURE]
. I I_SPECIES[BIO]/I_SEQUENCE[MEASURE]
aeolicus I I_SPECIES[BIO]/I_SEQUENCE[MEASURE]
ilvB I I_SPECIES[BIO]/I_SEQUENCE[MEASURE]
, O O
indicating O O
that O O
it O O
is O O
an O O
authentic O O
AHAS B B_GENE/B_MEASURE
. O O

More O B_MEASURE
than O O
80 O B_MEASURE
% O I_MEASURE
appropriate O I_MEASURE
lever O I_MEASURE
responding O O
was O O
established O O
after O O
27 O B_MEASURE
, O O
38 O B_MEASURE
and O O
44 O B_TIME[MEASURE]
daily O I_TIME[MEASURE]
training O I_TIME[MEASURE]
sessions O I_TIME[MEASURE]
with O O
DN O B_LOCATION/B_DISEASE
- O O
2327 O B_MEASURE
, O O
diazepam O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
PTZ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
respectively O O
, O O
as O O
the O O
training O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
have O O
used O O
nuclear O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
magnetic O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
resonance O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
NMR O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
to O O
obtain O O
the O O
structure O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
an O O
RNA O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
" O O
kissing O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
" O O
hairpin O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
complex O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
formed O O
between O O
the O O
HIV O B_DISEASE/B_GENE
- O O
2 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
TAR O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
hairpin O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
loop O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
a O O
hairpin O B_GENE
with O O
a O O
complementary O B_GENE/B_LOCATION
loop O I_GENE/I_LOCATION
sequence O I_GENE/I_LOCATION
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
In O O
men O B_PERSON/B_MEASURE
, O O
weight O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
/ O O
height2 O B_MEASURE/B_LOCATION
met O O
the O O
criteria O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
a O O
satisfactory O B_MEASURE/B_PERSON
index O B_MEASURE/I_PERSON
in O O
that O O
there O O
was O O
a O O
very O O
strong O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
correlation O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
with O O
triceps O B_MEASURE/B_BIO
skinfold O I_MEASURE/I_BIO
, O O
and O O
a O O
negligible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlation O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
height O B_MEASURE/B_GENE
. O O

PRP20 B B_GENE/B_PERSON
is O O
related O O
, O O
both O O
in O O
structure O O
and O O
function O O
, O O
to O O
the O O
RCC1 B B_GENE/B_BIO
gene I I_GENE/I_BIO
of O O
mammals O O
and O O
the O O
PIM1 B B_GENE/B_BIO
gene I I_GENE/I_BIO
of O O
Schizosaccharomyces O O
pombe O O
, O O
both O O
of O O
which O O
appear O O
to O O
regulate O O
entry O O
into O O
mitosis O O
and O O
chromosome O O
condensation O O
. O O

No O O
consensus O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sequence O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
could O O
be O O
discerned O O
in O O
these O O
fragments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
bound O O
factor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
in O O
rapid O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
equilibrium O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
unbound O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

A O O
selective O O
transcriptional O O
induction O O
system O O
for O O
mammalian O O
cells O O
based O O
on O O
Gal4 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
estrogen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fusion O O
proteins O O
. O O

Kinase O O
renaturation O O
tests O O
designed O O
to O O
detect O O
reactivated O O
protein O O
kinases O O
after O O
electrophoresis O O
in O O
sodium O O
dodecyl O O
sulfate O O
- O O
polyacrylamide O O
gels O O
revealed O O
the O O
presence O O
of O O
a O O
60 O O
- O O
kDa O O
kinase O O
in O O
the O O
washed O O
immunoprecipitate O O
obtained O O
from O O
liver O O
cytosol O O
using O O
anti B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
AHR I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
IgG B B_GENE/B_LOCATION
) O O
and O O
protein O O
A O O
/ O O
G O O
/ O O
agarose O O
beads O O
but O O
not O O
when O O
a O O
nonspecific O O
IgG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
used O O
instead O O
of O O
anti B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
AHR I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Immunoblotting O O
using O O
a O O
phosphospecific B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anti I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Src I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
416Y I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
a O O
ceramide O O
- O O
induced O O
increase O O
in O O
pp60 B B_GENE/B_DISEASE
( O O
src B B_GENE/B_MEASURE
) O O
tyrosine O O
phosphorylation O O
. O O

In O O
contrast O O
, O O
dominant B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
negative I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Rac I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
N17Rac1 B B_PROTEIN[GENE]/B_LOCATION
) O O
inhibited O O
JNK B B_GENE
activation O O
by O O
Galpha12 B B_GENE
in O O
HEK293 O O
cells O O
as O O
well O O
as O O
three O O
other O O
cell O O
lines O O
. O O

Metabolic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
tetrabenazine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
psychotropic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
man O B_PERSON/B_BIO
. O O

Reading O O
disability O B_DISEASE
in O O
twins O B_PERSON/B_LOCATION
. O O

These O O
results O O
suggest O O
that O O
1a B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
also O O
interacts O O
independently O O
with O O
the O O
ER O O
and O O
viral O O
RNA O O
, O O
is O O
a O O
key O O
organizer O O
of O O
RNA O O
replication O O
complex O O
assembly O O
. O O

HrpE B B_BACTERIUM[BIO]/B_LOCATION
is O O
similar O O
to O O
YscL B B_BIO/B_GENE
of O O
Yersinia O O
spp O O
. O O

Effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
high O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sugar O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intake O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
some O O
metabolic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
regulatory O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
indicators O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
young O B_PERSON/B_BIO
men O I_PERSON/I_BIO
. O O

Production O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
chicken O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
meat O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
infusion O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
broth O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
suitable O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
for O O
the O O
mass O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
production O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
a O O
Haemophilus O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gallinarum O B_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bacterin O B_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
results O O
indicate O O
that O O
expression O O
of O O
proU B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
E O O
. O O
coli O O
is O O
directed O O
from O O
two O O
promoters O O
, O O
one O O
( O O
P2 O O
) O O
characterized O O
earlier O O
by O O
other O O
workers O O
with O O
the O O
start O O
site O O
of O O
transcription O O
60 O O
nucleotides O O
upstream O O
of O O
the O O
initiation O O
codon O O
of O O
the O O
first O O
structural O O
gene O O
( O O
proV B B_LOCATION/B_PROTEIN[GENE]
) O O
, O O
and O O
the O O
other O O
( O O
P1 O O
) O O
situated O O
250 O O
nucleotides O O
upstream O O
of O O
proV B B_GENE
. O O

The O O
maximal O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
rise O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
plasma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
adrenaline O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
of O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
magnitude O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
all O O
three O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
but O O
a O O
lower O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
plasma O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
glucose O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
required O O
to O O
stimulate O O
this O O
hormonal O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
response O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
the O O
' O B_PERSON/B_ORGANIZATION
unaware O I_PERSON/I_ORGANIZATION
' O O
patients O B_PERSON/B_ORGANIZATION
, O O
in O O
whom O O
the O O
plasma O B_MEASURE
adrenaline O I_MEASURE
concentration O I_MEASURE
was O O
lower O B_MEASURE
at O O
the O O
time O B_TIME[MEASURE]/B_LOCATION
of O O
the O O
reaction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Through O O
interactions O O
with O O
the O O
pre O O
- O O
mRNA O O
and O O
the O O
CTD O O
domain O O
of O O
the O O
Polymerase B B_GENE/B_LOCATION
II I I_GENE/I_LOCATION
, O O
SR B B_GENE/B_BIO
proteins I I_GENE/I_BIO
have O O
been O O
shown O O
to O O
regulate O O
alternative O O
splicing O O
. O O

One O B_PERSON
child O I_PERSON
, O O
recently O O
fed O O
, O O
vomited O O
a O O
small O B_MEASURE
amount O I_MEASURE
of O O
breast O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
milk O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
after O O
a O O
short O B_TIME[MEASURE]
period O I_TIME[MEASURE]
of O O
crying O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
apparently O O
had O O
a O O
laryngospasm O B_DISEASE
, O O
shown O O
by O O
a O O
sudden O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
drop O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
the O O
PtcO2 O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
level O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
without O O
any O O
other O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signs O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
discomfort O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
size O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
organisation O B_ORGANIZATION/B_LOCATION
of O O
the O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
in O O
man O B_PERSON
and O O
his O O
ancestors O B_PERSON/B_ORGANIZATION
. O O

Only O O
Staphylococcus O B_BACTERIUM[BIO]/B_NUMBER[MEASURE]
xylosus O B_BACTERIUM[BIO]/I_NUMBER[MEASURE]
SX63 O B_BACTERIUM[BIO]/I_NUMBER[MEASURE]
was O O
detected O O
as O O
a O O
strain O B_BIO
with O O
high O B_DISEASE
adherence O I_DISEASE
activity O I_DISEASE
. O O

It O O
also O O
produces O O
an O O
NH2 O O
terminus O O
that O O
corresponds O O
to O O
an O O
equivalent O O
NH2 O O
terminus O O
on O O
the O O
processed O O
matrix O O
form O O
of O O
the O O
similar O O
alpha1 B B_PROTEIN[GENE]
( I I_PROTEIN[GENE]
XI I I_PROTEIN[GENE]
) I I_PROTEIN[GENE]
chain I I_PROTEIN[GENE]
, O O
thus O O
suggesting O O
physiological O O
significance O O
. O O

Transmission O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
mutans O B_BACTERIUM[BIO]/B_PERSON
streptococci O O
to O O
infants O B_PERSON/B_BIO
following O O
short O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
term O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
application O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
of O O
an O O
iodine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
NaF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
solution O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
mothers O B_PERSON/B_BIO
' O I_PERSON/I_BIO
dentition O I_PERSON/I_BIO
. O O

Expression O O
of O O
Msx B B_GENE
- I I_GENE
1 I I_GENE
and O O
Msx B B_GENE
- I I_GENE
2 I I_GENE
has O O
been O O
studied O O
during O O
development O O
of O O
the O O
osteoblast O O
phenotype O O
, O O
but O O
the O O
role O O
of O O
Dlx B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
this O O
context O O
and O O
in O O
the O O
regulation O O
of O O
bone O O
- O O
expressed O O
genes O O
is O O
unknown O O
. O O

Scalp O B_MEASURE/B_PROTEIN[GENE]
blood O B_MEASURE/I_PROTEIN[GENE]
flow O B_MEASURE/I_PROTEIN[GENE]
was O O
recorded O O
by O O
a O O
laser O B_PRODUCT[OBJECT]
Doppler O I_PRODUCT[OBJECT]
flow O I_PRODUCT[OBJECT]
sensor O I_PRODUCT[OBJECT]
that O O
was O O
incorporated O O
in O O
the O O
transcutaneous O B_PRODUCT[OBJECT]/B_ENT
PO2 O I_PRODUCT[OBJECT]/I_ENT
electrode O I_PRODUCT[OBJECT]/I_ENT
. O O

DESIGN O O
: O O
Activating B B_GENE
protein I I_GENE
- I I_GENE
1 I I_GENE
( O O
AP B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
) O O
and O O
Tat B B_GENE
- O O
induced O O
transcription O O
were O O
assessed O O
using O O
Jun B B_PERSON/B_MEASURE
and O O
hybrid O O
Tat B B_GENE
/ O O
Jun B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
expression O O
plasmids O O
and O O
reporter O O
gene O O
constructs O O
which O O
contained O O
AP B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
binding I I_GENE/I_LOCATION
sites I I_GENE/I_LOCATION
upstream O O
of O O
the O O
rat B B_GENE
prolactin I I_GENE
TATAA I I_GENE
element I I_GENE
or O O
an O O
HIV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
LTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
construct I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
which O O
AP B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
1 I I_GENE/I_MEASURE
binding I I_GENE/I_MEASURE
sites I I_GENE/I_MEASURE
replaced O O
the O O
TAR O O
element O O
. O O

Mycobacterium O O
tuberculosis O O
inhibits O O
IFN B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gamma I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcriptional O O
responses O O
without O O
inhibiting O O
activation O O
of O O
STAT1 B B_GENE
. O O

Rabbit B B_SPECIES[BIO]/B_GENE
KCC1 I I_SPECIES[BIO]/I_GENE
( O O
rbKCC1 B B_GENE
) O O
and O O
rat B B_GENE
KCC1 I I_GENE
( O O
rtKCC1 B B_GENE/B_SPECIES[BIO]
) O O
were O O
cloned O O
by O O
screening O O
rabbit O O
kidney O O
and O O
rat O O
brain O O
cDNA O O
libraries O O
using O O
homologous O O
cDNA O O
probes O O
. O O

However O O
, O O
using O O
wet O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weight O B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
dry O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
weight O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
methodology O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
we O O
found O O
that O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
U74006F O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
significantly O O
reduced O O
water O B_DISEASE/B_MEASURE
content O I_DISEASE/I_MEASURE
in O O
the O O
right O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
hippocampus O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
contralateral O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
to O O
the O O
site O B_LOCATION/B_MEASURE
of O O
injury O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
compared O O
to O O
saline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
treated O O
animals O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
p O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

GH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulated O O
the O O
activity O O
of O O
promoter O O
fragments O O
with O O
5 O O
' O O
- O O
ends O O
between O O
nucleotide O O
( O O
nt O O
) O O
- O O
2001 O O
and O O
nt O O
- O O
653 O O
by O O
1 O O
. O O
9 O O
- O O
to O O
2 O O
. O O
7 O O
- O O
fold O O
. O O

We O O
have O O
recently O O
shown O O
that O O
induced O O
expression O O
of O O
a O O
CDK B B_GENE/B_DISEASE
target O O
site O O
- O O
deficient O O
mutant O O
, O O
Op18 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
S25A O O
, O O
S38A O O
, O O
blocks O O
human O O
cell O O
lines O O
during O O
G2 O O
/ O O
M O O
transition O O
. O O

A O O
protein O O
which O O
promotes O O
DNA O O
strand O O
transfer O O
between O O
linear O O
double O O
- O O
stranded O O
M13mp19 O O
DNA O O
and O O
single O O
- O O
stranded O O
viral O O
M13mp19 O O
DNA O O
has O O
been O O
isolated O O
from O O
recA B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E O O
. O O
coli O O
. O O

The O O
brains O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
were O O
processed O O
according O O
to O O
the O O
tetramethylbenzidine O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
TMB O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
protocol O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
Mesulam O B_LOCATION/B_DISEASE
( O O
' O O
78 O B_MEASURE
) O O
and O O
studied O O
with O O
darkfield O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Seizure O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recurrence O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
HR O B_MEASURE/B_PROTEIN[GENE]
1 O I_MEASURE/I_PROTEIN[GENE]
. O O
30 O B_MEASURE
; O O
95 O B_LOCATION/B_MEASURE
% O I_LOCATION/I_MEASURE
CI O I_LOCATION/I_MEASURE
= O O
0 O B_MEASURE
. O O
84 O B_MEASURE
, O O
2 O B_NUMBER[MEASURE]
. O O
01 O B_MEASURE
) O O
and O O
antiepileptic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
drug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O O
HR O B_MEASURE/B_DISEASE
0 O I_MEASURE/I_DISEASE
. O O
97 O B_MEASURE
; O O
95 O B_LOCATION/B_MEASURE
% O I_LOCATION/I_MEASURE
CI O I_LOCATION/I_MEASURE
= O O
0 O B_MEASURE
. O O
67 O B_MEASURE
, O O
1 O B_MEASURE
. O O
38 O B_MEASURE
) O O
did O O
not O O
influence O O
mortality O B_DISEASE
rate O I_DISEASE
. O O

One O O
day O O
postoperatively O O
, O O
the O O
mononuclear O O
leukocyte O O
beta B B_GENE/B_MEASURE
2 I B_GENE/I_MEASURE
- I B_GENE/I_MEASURE
receptor I B_GENE/I_MEASURE
density O O
decreased O O
maximally O O
by O O
45 O O
+ O O
/ O O
- O O
11 O O
% O O
in O O
the O O
enflurane O O
patients O O
, O O
and O O
by O O
53 O O
+ O O
/ O O
- O O
6 O O
% O O
in O O
the O O
neurolept O O
patients O O
. O O

The O O
serum O O
levels O O
of O O
cortisol O O
and O O
prolactin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
after O O
nasal O O
instillation O O
of O O
a O O
suspension O O
of O O
vaginal O O
exudate O O
showed O O
lower O O
values O O
than O O
in O O
control O O
conditions O O
( O O
nasal O O
instillation O O
of O O
saline O O
) O O
. O O

IgE B B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
antibody I I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
twelve O O
common O O
food O O
and O O
inhalant O O
allergens O O
was O O
measured O O
by O O
enzyme O O
- O O
linked O O
immunosorbent O O
assay O O
( O O
ELISA O O
) O O
in O O
the O O
sera O O
of O O
thirteen O O
atopic O O
patients O O
with O O
one O O
or O O
more O O
allergic O O
disorders O O
( O O
asthma O O
occurring O O
in O O
eleven O O
; O O
rhinitis O O
in O O
ten O O
; O O
eczema O O
in O O
six O O
; O O
urticaria O O
in O O
four O O
; O O
mouth O O
and O O
gastro O O
- O O
intestinal O O
symptoms O O
in O O
six O O
) O O
, O O
of O O
twelve O O
non O O
- O O
atopic O O
patients O O
with O O
various O O
clinical O O
symptoms O O
( O O
asthma O O
in O O
four O O
; O O
rhinitis O O
in O O
four O O
; O O
eczema O O
in O O
one O O
; O O
urticaria O O
in O O
two O O
; O O
mouth O O
and O O
gastro O O
- O O
intestinal O O
symptoms O O
in O O
four O O
) O O
and O O
sixteen O O
cord O O
blood O O
sera O O
. O O

Innervation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
reticular O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
papillae O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O O
sheep O B_SPECIES[BIO]
and O O
goats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Biochemical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
status O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
examined O O
using O O
erythrocyte O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
enzyme O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
function O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
blood O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vitamin O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Sexual O B_DISEASE
adventurism O I_DISEASE
, O O
high O B_MEASURE/B_DISEASE
- O O
risk O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
behavior O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
and O O
human O B_DISEASE
immunodeficiency O I_DISEASE
virus O I_DISEASE
- O O
1 O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seroconversion O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O O
the O O
Chicago O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MACS O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
CCS O B_MEASURE/B_PERSON
cohort O I_MEASURE/I_PERSON
, O O
1984 O B_MEASURE
to O O
1992 O B_MEASURE
. O O

Pendulin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
Drosophila O O
protein O O
with O O
cell O O
cycle O O
- O O
dependent O O
nuclear O O
localization O O
, O O
is O O
required O O
for O O
normal O O
cell O O
proliferation O O
. O O

Paradoxically O O
there O O
is O O
a O O
decrease O O
in O O
the O O
level O O
of O O
soluble B B_GENE
A I I_GENE
beta I I_GENE
secreted O O
from O O
the O O
cells O O
. O O

Signaling O O
through O O
mitogen B B_GENE
- I I_GENE
activated I I_GENE
protein I I_GENE
kinase I I_GENE
and O O
Rac B B_GENE/B_PERSON
/ O O
Rho B B_GENE
does O O
not O O
duplicate O O
the O O
effects O O
of O O
activated O O
Ras B B_GENE/B_DISEASE
on O O
skeletal O O
myogenesis O O
. O O

Internalization O O
of O O
prolactin B B_GENE
receptor I I_GENE
and O O
prolactin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
transfected O O
cells O O
does O O
not O O
involve O O
nuclear O O
translocation O O
. O O

Using O O
mammalian O O
expression O O
vectors O O
( O O
pRSV O O
- O O
neo O O
and O O
pSV2 O O
- O O
neo O O
) O O
, O O
antisense O O
constructs O O
for O O
perforin B B_GENE/B_BACTERIUM[BIO]
and O O
granzyme B B_GENE
B I I_GENE
were O O
independently O O
electroporated O O
into O O
YT O O
- O O
INDY O O
, O O
a O O
human O O
non O O
- O O
MHC B B_GENE/B_DISEASE
- O O
restricted O O
, O O
IL B B_GENE
- I I_GENE
2 I I_GENE
- O O
independent O O
, O O
cytotoxic O O
lymphocyte O O
. O O

When O O
expressed O O
in O O
Escherichia O O
coli O O
, O O
SH B B_GENE
- I I_GENE
PTP2 I I_GENE
displays O O
tyrosine B B_ENZYME[GENE]
- I I_ENZYME[GENE]
specific I I_ENZYME[GENE]
phosphatase I I_ENZYME[GENE]
activity O O
. O O

The O O
structure O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
elucidation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
iridoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
compounds O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
and O O
3 O B_NUMBER[MEASURE]
are O O
discussed O O
in O O
detail O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
a O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
investigate O O
the O O
effectiveness O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
propolis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
containing O O
mouthrinse O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
de O B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
novo O B_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
plaque O B_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
formation O B_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
are O O
presented O O
. O O

Effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
shosaikoto O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
, O O
an O O
oriental O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
herbal O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
medicinal O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mixture O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
on O O
restraint O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
stressed O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
region O O
surrounding O O
the O O
ZNF35 B B_DISEASE/B_GENE
zinc I I_DISEASE/I_GENE
finger I I_DISEASE/I_GENE
protein I I_DISEASE/I_GENE
gene I I_DISEASE/I_GENE
on O O
3p21 O O
is O O
of O O
particular O O
interest O O
, O O
as O O
this O O
region O O
of O O
chromosome O O
3 O O
is O O
frequently O O
involved O O
in O O
rearrangements O O
and O O
/ O O
or O O
deletions O O
associated O O
with O O
various O O
human O O
tumors O O
including O O
lung O O
and O O
renal O O
carcinoma O O
. O O

In O O
the O O
promoters O O
of O O
many O O
immediate B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
early I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
including O O
c B B_GENE
- I I_GENE
fos I I_GENE
, O O
CArG O O
DNA O O
regulatory O O
elements O O
mediate O O
basal O O
constituitive O O
expression O O
and O O
rapid O O
and O O
transient O O
serum O O
induction O O
. O O

The O O
biological O O
activity O O
of O O
these O O
mutants O O
was O O
tested O O
by O O
determining O O
their O O
capacity O O
to O O
( O O
i O O
) O O
reconstitute O O
RNA B B_ENZYME[GENE]/B_BIO
polymerase I I_ENZYME[GENE]/I_BIO
activity O O
in O O
vivo O O
by O O
cotransfection O O
with O O
proteins O O
NP B B_PROTEIN[GENE]/B_DISEASE
, O O
PB1 B B_PROTEIN[GENE]/B_LOCATION
, O O
and O O
PA B B_PROTEIN[GENE]/B_DISEASE
and O O
a O O
virion O O
- O O
like O O
RNA O O
encoding O O
the O O
cat B B_PROTEIN[GENE]/B_DISEASE
gene O O
into O O
vaccinia O O
virus O O
T7 O O
- O O
infected O O
COS O O
- O O
1 O O
cells O O
and O O
( O O
ii O O
) O O
complete O O
with O O
the O O
wild B B_GENE
- I I_GENE
type I I_GENE
PB2 I I_GENE
activity O O
. O O

Transient O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thyrotoxicosis O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
primary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
phospholipid O B_DISEASE/B_GENE
syndrome O I_DISEASE/I_GENE
. O O

We O O
were O O
unable O O
to O O
construct O O
chvI B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O O
chvG B B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
insertion I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
mutants I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
of O O
R O O
. O O
meliloti O O
, O O
whereas O O
mutants O O
carrying O O
insertions O O
outside O O
of O O
these O O
genes O O
were O O
readily O O
obtained O O
. O O

Western O O
blot O O
analyses O O
reveals O O
that O O
cJun B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
C B B_GENE/B_PERSON
/ I I_GENE/I_PERSON
EBP I I_GENE/I_PERSON
family I I_GENE/I_PERSON
member I I_GENE/I_PERSON
C B I_GENE/I_PERSON
/ I I_GENE/I_PERSON
EBP I I_GENE/I_PERSON
- I I_GENE/I_PERSON
beta I I_GENE/I_PERSON
are O O
physiologically O O
relevant O O
transcription O O
factors O O
whose O O
expression O O
corresponds O O
with O O
mda B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
7 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
. O O

In O O
isolated O O
olfactory O O
cilia O O
certain O O
odorants O O
elicit O O
a O O
rapid O O
and O O
transient O O
cAMP O O
response O O
, O O
terminated O O
by O O
a O O
concerted O O
process O O
which O O
requires O O
the O O
action O O
of O O
two O O
protein O O
kinases O O
, O O
protein B B_ENZYME[GENE]
kinase I I_ENZYME[GENE]
A I I_ENZYME[GENE]
( O O
PKA B B_GENE/B_LOCATION
) O O
and O O
a O O
receptor B B_GENE/B_PERSON
- I I_GENE/I_PERSON
specific I I_GENE/I_PERSON
kinase I I_GENE/I_PERSON
( O O
GRK3 B B_GENE/B_LOCATION
) O O
( O O
Schleicher O O
, O O
S O O
. O O
, O O
Boekhoff O O
, O O
I O O
. O O

Acetyl B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CoA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
carboxylase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
yeast O O
is O O
an O O
essential O O
enzyme O O
and O O
is O O
regulated O O
by O O
factors O O
that O O
control O O
phospholipid O O
metabolism O O
. O O

To O O
investigate O O
the O O
role O O
of O O
this O O
domain O O
in O O
the O O
incorporation O O
of O O
the O O
SIV B B_GENE
Env I I_GENE
into O O
virions O O
, O O
we O O
generated O O
a O O
series O O
of O O
SIV B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
Env I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutants I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
carrying O O
small O O
in O O
- O O
frame O O
deletions O O
within O O
the O O
cytoplasmic O O
domain O O
. O O

Computer O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
simple O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
correlation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
hypothesis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
and O O
distribution O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O O
1 O B_MEASURE/B_LOCATION
degree O I_MEASURE/I_LOCATION
of O O
freedom O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
revealed O O
significant O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlation O I_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
vertical O B_DISEASE
root O I_DISEASE
fracture O I_DISEASE
and O O
the O O
technique O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
instrumentation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
obturation O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
the O O
canal O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
p O B_MEASURE/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
025 O B_MEASURE
) O O
, O O
the O O
length O B_MEASURE/B_LOCATION
of O O
the O O
post O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
p O B_MEASURE/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
, O O
and O O
the O O
existence O B_DISEASE/B_MEASURE
of O O
the O O
post O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
p O B_MEASURE/B_PROTEIN[GENE]
= O O
0 O B_NUMBER[MEASURE]
. O O
05 O B_MEASURE
) O O
. O O

Minute B B_GENE/B_DISEASE
virus I I_GENE/I_DISEASE
of I I_GENE/I_DISEASE
mice I I_GENE/I_DISEASE
NS1 I I_GENE/I_DISEASE
, O O
an O O
83 O O
- O O
kDa O O
mainly O O
nuclear O O
phosphoprotein O O
, O O
is O O
the O O
only O O
viral O O
nonstructural O O
protein O O
required O O
in O O
all O O
cell O O
types O O
and O O
it O O
is O O
involved O O
in O O
multiple O O
processes O O
necessary O O
for O O
virus O O
propagation O O
. O O

The O O
TDx O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
cyclosporine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
its O O
metabolites O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
blood O B_MEASURE/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
samples O I_MEASURE/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
compared O O
with O O
HPLC O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
RIA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
methods O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

However O O
, O O
the O O
sequence O O
of O O
mRAR B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
region I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differs O O
from O O
that O O
of O O
mRAR B B_PROTEIN[GENE]/B_MEASURE
- I I_PROTEIN[GENE]/I_MEASURE
beta I I_PROTEIN[GENE]/I_MEASURE
1 I I_PROTEIN[GENE]/I_MEASURE
by O O
an O O
additional O O
27 O O
C O O
- O O
terminal O O
amino O O
acids O O
encoded O O
in O O
an O O
81 O O
nucleotide O O
- O O
long O O
putative O O
exon O O
which O O
is O O
spliced O O
in O O
between O O
the O O
exons O O
encoding O O
the O O
A B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regions I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRAR I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
propose O O
that O O
GCD7 B B_GENE
and O O
GCD2 B B_GENE
play O O
important O O
roles O O
in O O
the O O
regulatory O O
interaction O O
between O O
eIF B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
2 I I_GENE/I_LOCATION
and O O
eIF B B_GENE
- I I_GENE
2B I I_GENE
and O O
that O O
the O O
suppressor O O
mutations O O
we O O
isolated O O
in O O
these O O
genes O O
decrease O O
the O O
susceptibility O O
of O O
eIF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
2B I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O O
the O O
inhibitory O O
effects O O
of O O
phosphorylated O O
eIF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
without O O
impairing O O
the O O
essential O O
catalytic O O
function O O
of O O
eIF B B_GENE
- I I_GENE
2B I I_GENE
in O O
translation O O
initiation O O
. O O

The O O
3 O O
' O O
region O O
of O O
the O O
transcript O O
contained O O
a O O
fully O O
conserved O O
, O O
correctly O O
spliced O O
TCR B B_GENE/B_LOCATION
alpha I I_GENE/I_LOCATION
C I I_GENE/I_LOCATION
region I I_GENE/I_LOCATION
which O O
was O O
polyadenylated O O
at O O
the O O
3 O O
' O O
end O O
. O O

These O O
data O O
demonstrate O O
that O O
CCTalpha B B_GENE
can O O
be O O
regulated O O
by O O
lipids O O
by O O
two O O
independent O O
domains O O
: O O
( O O
i O O
) O O
the O O
three O O
amphipathic O O
alpha O O
- O O
helical O O
repeats O O
that O O
interact O O
with O O
both O O
neutral O O
and O O
anionic O O
lipid O O
mixtures O O
and O O
( O O
ii O O
) O O
the O O
last O O
57 O O
residues O O
that O O
interact O O
with O O
anionic O O
lipids O O
. O O

Sorting O O
information O O
to O O
the O O
chloroplastic O O
inner O O
envelope O O
is O O
contained O O
in O O
an O O
NH2 O O
- O O
proximal O O
part O O
of O O
mature B B_GENE
IEP110 I I_GENE
( O O
110N B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
. O O

Most O B_NUMBER[MEASURE]/B_PERSON
of O O
these O O
elements O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O O
adjacent O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O O
type O B_GENE/B_BIO
X O I_GENE/I_BIO
telomeric O I_GENE/I_BIO
repeats O I_GENE/I_BIO
, O O
and O O
regions O B_LOCATION/B_DISEASE
flanking O O
four O B_NUMBER[MEASURE]/B_PERSON
of O O
five O B_NUMBER[MEASURE]/B_PERSON
characterized O O
S O B_DISEASE/B_PROTEIN[GENE]
. O O
paradoxus O B_SPECIES[BIO]/B_GENE
insertions O I_SPECIES[BIO]/I_GENE
carry O O
autonomously O O
replicating O O
sequences O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. O O

From O O
1981 O B_MEASURE
to O O
1989 O B_MEASURE
, O O
a O O
total O B_MEASURE
of O O
26 O B_PERSON
women O I_PERSON
with O O
locally O O
or O O
regionally O O
advanced O B_DISEASE
carcinoma O I_DISEASE
of O O
the O O
uterine O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
cervix O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
were O O
treated O O
with O O
radiotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
RT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
) O O
and O O
pelvic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
regional O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hyperthermia O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
HT O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
in O O
the O O
Divisions O B_LOCATION/B_ORGANIZATION
of O O
Radiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
Oncology O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
at O O
the O O
University O B_LOCATION/B_ORGANIZATION
of O O
Utah O B_LOCATION
Medical O I_LOCATION
Center O I_LOCATION
( O O
UU O B_LOCATION/B_DISEASE
) O O
and O O
the O O
Kenneth O B_LOCATION/B_ORGANIZATION
Norris O I_LOCATION/I_ORGANIZATION
Jr O I_LOCATION/I_ORGANIZATION
Cancer O I_LOCATION/I_ORGANIZATION
Hospital O I_LOCATION/I_ORGANIZATION
of O O
the O O
University O B_LOCATION/B_ORGANIZATION
of O O
Southern O B_LOCATION
California O I_LOCATION
( O O
USC O B_LOCATION/B_ORGANIZATION
) O O
. O O

The O O
ARE O O
is O O
loosely O O
defined O O
as O O
the O O
five O B_NUMBER[MEASURE]
- O O
nucleotide O B_GENE/B_LOCATION
sequence O B_GENE/I_LOCATION
AUUUA O B_GENE/I_LOCATION
embedded O O
in O O
a O O
uracil O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
rich O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
region O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

Lack O O
of O O
changes O O
in O O
milk O O
production O O
and O O
milk O O
composition O O
suggest O O
that O O
acute O O
increases O O
in O O
somatotropin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
with O O
concomitant O O
increases O O
in O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O O
not O O
sufficient O O
to O O
stimulate O O
synthesis O O
of O O
milk O O
and O O
milk O O
components O O
by O O
cows O O
during O O
established O O
lactation O O
. O O

The O O
material O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
then O O
was O O
cut O O
with O O
a O O
diamond O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEDICAL_DEVICE[OBJECT]
saw O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEDICAL_DEVICE[OBJECT]
into O O
sheets O B_PRODUCT[OBJECT]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
8 O B_MEASURE
x O O
10 O B_MEASURE
x O O
3 O B_MEASURE
mm O I_MEASURE
, O O
and O O
the O O
upper O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
surface O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
polished O O
by O O
colloidal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
SiO2 O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
and O O
/ O O
or O O
covered O O
with O O
a O O
carbon O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
titanium O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
C O B_LOCATION/B_GENE
: O O
Ti O B_PERSON/B_LOCATION
) O O
layer O B_LOCATION
( O O
3 O B_MEASURE
. O O
3 O B_MEASURE/B_PERSON
microm O I_MEASURE/I_PERSON
) O O
using O O
the O O
plasma O B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
enhanced O O
physical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
vapor O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
deposition O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
method O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Iomazenil O O
- O O
SPECT O O
revealed O O
a O O
highly O O
significant O O
increase O O
in O O
the O O
benzodiazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
uptake O O
in O O
all O O
studied O O
cortical O O
regions O O
except O O
temporal O O
cortices O O
. O O

Both O O
in O O
the O O
Federal O B_LOCATION/B_MEASURE
Republic O I_LOCATION/I_MEASURE
of O O
Germany O B_LOCATION
and O O
in O O
some O O
neighbouring O B_LOCATION
countries O I_LOCATION
the O O
epizootic O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
situation O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Aujeszky O B_DISEASE
' O I_DISEASE
s O I_DISEASE
disease O I_DISEASE
has O O
been O O
unsatisfactory O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
a O O
long O B_TIME[MEASURE]/B_LOCATION
time O I_TIME[MEASURE]/I_LOCATION
, O O
especially O O
in O O
areas O B_LOCATION/B_PERSON
with O O
a O O
high O B_LOCATION/B_DISEASE
pig O I_LOCATION/I_DISEASE
density O I_LOCATION/I_DISEASE
. O O

Since O O
RIP140 B B_PROTEIN[GENE]/B_LOCATION
generally O O
down O O
- O O
regulates O O
receptor O O
activity O O
in O O
mammalian O O
cells O O
and O O
specifically O O
down O O
- O O
regulates O O
coactivation O O
mediated O O
by O O
SRC B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
, O O
we O O
propose O O
a O O
model O O
in O O
which O O
RIP140 B B_GENE
indirectly O O
regulates O O
nuclear B B_GENE/B_LOCATION
receptor I I_GENE/I_LOCATION
AF I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
2 I I_GENE/I_LOCATION
activity O O
by O O
competition O O
for O O
coactivators O O
such O O
as O O
SRC B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
. O O

DIC O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
low O B_DISEASE
grade O I_DISEASE
fibrinolysis O I_DISEASE
may O O
account O O
for O O
the O O
coagulation O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
abnormalities O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O O
the O O
syndrome O B_DISEASE/B_PERSON
. O O

As O O
in O O
the O O
case O O
of O O
the O O
chicken O O
homologue O O
, O O
there O O
are O O
two O O
hPR B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
forms O O
, O O
A O O
and O O
B O O
, O O
which O O
originate O O
from O O
translational O O
initiation O O
at O O
AUG2 O O
( O O
codon O O
165 O O
) O O
and O O
AUG1 O O
, O O
respectively O O
. O O

Fluctuations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
measured O O
ECF O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
energy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
- O O
related O O
substances O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
corresponded O O
to O O
various O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clinical O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
events O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presumably O O
involving O O
hypoxia O B_DISEASE
/ O O
ischemia O B_DISEASE
. O O

Using O O
lasers O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
diabetic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
wound O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
healing O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Furthermore O O
, O O
the O O
zincon O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
loaded O O
resin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
applied O O
to O O
the O O
selective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
trace O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
amounts O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
chalcophile O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
elements O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
natural O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
water O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
samples O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
prior O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O O
neutron O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
cells O O
stably O O
transfected O O
with O O
G B B_GENE
alpha I I_GENE
i I I_GENE
- I I_GENE
2 I I_GENE
or O O
G B B_GENE/B_LOCATION
alpha I I_GENE/I_LOCATION
i I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
3 I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
5 O O
' O O
- O O
flanking O O
sequences O O
fused O O
to O O
firefly O O
luciferase B B_GENE/B_BIO
cDNA O O
reporter O O
, O O
temporal O O
10 O O
- O O
15 O O
- O O
fold O O
transcriptional O O
activation O O
of O O
both O O
genes O O
occurred O O
before O O
cellular O O
polarization O O
. O O

CONCLUSIONS O O
: O O
These O O
results O O
suggest O O
that O O
histamine B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
2 I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptor I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O O
mechanisms O O
may O O
not O O
be O O
involved O O
in O O
postoperative O O
IL B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthesis O O
. O O

In O O
resume O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
response O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
usual O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regimens O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
doxycycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
plus O O
streptomycin O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O O
doxycycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
rifampicin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
good O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
being O O
however O O
time O B_TIME[MEASURE]
elapsed O O
until O O
pain O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ceases O O
of O O
mean O B_MEASURE
length O I_MEASURE
in O O
hospital O B_PERSON/B_ORGANIZATION
stay O I_PERSON/I_ORGANIZATION
shorter O I_PERSON/I_ORGANIZATION
in O O
the O O
group O B_ORGANIZATION/B_PERSON
receiving O O
doxycycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O O
streptomycin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Fibrosis O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
adjacent O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
myocardium O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
was O O
seen O O
in O O
five O B_TIME[MEASURE]/B_PERSON
cases O B_TIME[MEASURE]/I_PERSON
. O O

Purified O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preparations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
all O O
four O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AGT O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutants O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
an O O
approximately O O
similar O B_MEASURE
degree O I_MEASURE
( O O
74 O B_MEASURE
- O O
120 O B_MEASURE
- O O
fold O B_MEASURE
) O O
of O O
reduction O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
the O O
rate O B_MEASURE/B_LOCATION
of O O
reaction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
O6 O B_GENE/B_NUMBER[MEASURE]
- O O
benzylguanine O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Significant O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reductions O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
noted O O
in O O
vertical O B_MEASURE/B_LOCATION
GRFs O I_MEASURE/I_LOCATION
per O O
newton O B_PERSON/B_MEASURE
of O O
body O B_MEASURE/B_DISEASE
weight O I_MEASURE/I_DISEASE
exerted O O
at O O
10 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
( O O
P O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
0009 O B_MEASURE
) O O
and O O
20 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
( O O
P O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
0383 O B_MEASURE
) O O
of O O
stance O B_MEASURE/B_LOCATION
phase O I_MEASURE/I_LOCATION
and O O
in O O
anteroposterior O B_MEASURE/B_PERSON
GRFs O I_MEASURE/I_PERSON
exerted O O
at O O
10 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
( O O
P O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
0009 O B_MEASURE
) O O
and O O
50 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
( O O
P O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
0033 O B_MEASURE
) O O
of O O
stance O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
phase O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
when O O
ambulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
was O O
compared O O
with O O
and O O
without O O
the O O
orthotic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PRODUCT[OBJECT]
device O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PRODUCT[OBJECT]
. O O

Identification O O
of O O
a O O
68 B B_GENE
- I I_GENE
kilodalton I I_GENE
nuclear I I_GENE
ATP I I_GENE
- I I_GENE
binding I I_GENE
phosphoprotein I I_GENE
encoded O O
by O O
bovine O O
papillomavirus O O
type O O
1 O O
. O O

It O O
is O O
suggested O O
that O O
biliary O B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
secretion O B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
both O O
TBZ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O O
FBZ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
their O O
metabolites O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
contribute O O
to O O
this O O
recycling O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

During O O
chordotonal O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
organ O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
development O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O O
the O O
3 O B_GENE
' O I_GENE
enhancer O I_GENE
directs O O
expression O B_GENE
in O O
proneural O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
clusters O I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
; O O
whereas O O
successive O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
modular O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
enhancers O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
located O O
in O O
the O O
5 O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
' O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
region O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
drive O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
tissue O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
specific O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
chordotonal O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
organ O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
precursors O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O O
the O O
embryo O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
and O O
larval O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
leg O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
, O O
wing O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
antennal O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaginal O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
discs O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
use O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
self O B_PERSON/B_LOCATION
- O O
measured O O
blood O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pressure O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
determinations O O
in O O
assessing O O
dynamics O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
of O O
drug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
compliance O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O O
a O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
amlodipine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
once O O
a O O
day O B_TIME[MEASURE]
, O O
morning O B_MEASURE/B_LOCATION
versus O I_MEASURE/I_LOCATION
evening O I_MEASURE/I_LOCATION
. O O

Nucleocapsid O B_MEASURE/B_ORGANIZATION
structure O I_MEASURE/I_ORGANIZATION
and O O
thermostability O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
virion O B_GENE
, O O
nucleocapsid O B_BIO/B_GENE
and O O
polymerase O B_GENE
complex O I_GENE
. O O

A O O
vascular O B_DISEASE_ADJECTIVE[DISEASE]
component O I_DISEASE_ADJECTIVE[DISEASE]
to O O
impotence O B_DISEASE
was O O
shown O O
to O O
be O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
those O O
with O O
neurological O B_DISEASE
impairment O I_DISEASE
, O O
and O O
may O O
alter O O
management O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
- O O
The O O
maximal O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
early O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
asthmatic O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
response O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
after O O
allergen O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
placebo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
18 O B_MEASURE
. O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
( O O
SE O B_MEASURE
4 O I_MEASURE
. O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
and O O
with O O
WEB O B_MEASURE/B_ORGANIZATION
2086 O I_MEASURE/I_ORGANIZATION
18 O I_MEASURE/I_ORGANIZATION
. O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
( O O
4 O B_MEASURE
. O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
. O O

Column O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
chromatographic O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
determination O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
polymyxin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
B O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sulfate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Usefulness O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
computerized O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
tomography O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
hemodialysis O B_PERSON/B_LOCATION
patients O I_PERSON/I_LOCATION
. O O

The O O
aim O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
our O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
to O O
determine O O
whether O O
exercise O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
training O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
augment O O
left O O
ventricular O B_BODY_PART_OR_ORGAN_COMPONENT
diastolic O I_BODY_PART_OR_ORGAN_COMPONENT
filling O O
at O O
rest O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
during O O
exercise O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O O
patients O B_PERSON/B_BIO
with O O
ischemic O B_DISEASE
cardiomyopathy O I_DISEASE
and O O
whether O O
any O O
correlation O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exists O O
between O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
diastolic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
filling O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
changes O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
exercise O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tolerance O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

On O O
the O O
pharmacology O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
9 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
10 O B_MEASURE
- O O
dihydro O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
10 O B_MEASURE
- O O
( O O
1 O B_MEASURE
- O O
methyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
4 O B_MEASURE
- O O
piperidylidene O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
) O O
- O O
9 O B_MEASURE
- O O
anthrol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
WA O B_MEASURE/B_LOCATION
335 O B_MEASURE/I_LOCATION
) O O
, O O
a O O
histamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
serotonin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antagonist O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE

METHODOLOGY O B_MEASURE/B_EDU[ORGANIZATION]
: O O
A O O
case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
survivors O B_PERSON/B_BIO
with O O
gestational O B_MEASURE/B_PERSON
age O I_MEASURE/I_PERSON
( O O
GA O B_LOCATION/B_DISEASE
) O O
< O O
28 O B_MEASURE/B_ENT
weeks O I_MEASURE/I_ENT
or O O
birthweight O B_MEASURE/B_PERSON
( O O
BW O B_LOCATION/B_PROTEIN[GENE]
) O O
< O O
1000 O B_MEASURE
g O I_MEASURE
using O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
collected O O
prospectively O O
in O O
our O O
Neonatal O B_LOCATION
Intensive O I_LOCATION
Care O I_LOCATION
Unit O I_LOCATION
database O I_LOCATION
. O O

There O O
are O O
two O O
regulatory O O
regions O O
between O O
the O O
US3 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
US6 B B_GENE
transcription I I_GENE
units I I_GENE
. O O

Database O O
searches O O
revealed O O
a O O
50 O O
- O O
63 O O
% O O
similarity O O
and O O
34 O O
- O O
42 O O
% O O
identity O O
with O O
several O O
families O O
of O O
serine B B_BIO/B_GENE
proteases I I_BIO/I_GENE
, O O
in O O
particular O O
the O O
trypsin B B_BIO/B_ENZYME[GENE]
- I I_BIO/I_ENZYME[GENE]
like I I_BIO/I_ENZYME[GENE]
proteases I I_BIO/I_ENZYME[GENE]
, O O
members O O
of O O
the O O
glandular B B_PERSON/B_BIO
kallikrein I I_PERSON/I_BIO
family I I_PERSON/I_BIO
( O O
including O O
prostate B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
specific I I_GENE/I_DISEASE
antigen I I_GENE/I_DISEASE
, O O
nerve B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
epidermal B B_GENE
growth I I_GENE
factor I I_GENE
- I I_GENE
binding I I_GENE
protein I I_GENE
) O O
and O O
the O O
activators O O
for O O
the O O
kringle B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
family I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
including O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tissue I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
plasminogen I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hepatocyte I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

Manifestation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
superfluidity O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
an O O
evolving O O
bose O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
- O O
einstein O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
condensed O I_PERSON
Gas O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
We O O
study O O
the O O
generation O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
excitations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
due O O
to O O
an O O
" O O
impurity O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
( O O
static O B_PROTEIN[GENE]/B_LOCATION
perturbation O I_PROTEIN[GENE]/I_LOCATION
) O O
placed O O
into O O
an O O
oscillating O O
Bose O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Einstein O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
condensed O B_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gas O B_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
time O B_MEASURE/B_LOCATION
- O O
dependent O B_LOCATION/B_MEASURE
trapping O I_LOCATION/I_MEASURE
field O I_LOCATION/I_MEASURE
. O O

4 O O
. O O
7 O B_MEASURE
+ O O
/ O O
- O O
0 O B_MEASURE
. O O
6 O B_MEASURE
micromol O I_MEASURE
. O O

kg O B_MEASURE
- O O
1 O B_MEASURE/B_LOCATION
. O O

min O O
- O O
1 O B_TIME[MEASURE]
) O O
but O O
was O O
not O O
changed O O
by O O
training O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

We O O
established O O
that O O
, O O
in O O
unstimulated O O
lymphocytes O O
, O O
the O O
Src B B_GENE
homology I I_GENE
2 I I_GENE
( O O
SH2 B B_GENE/B_DISEASE
) O O
and O O
SH3 B B_GENE/B_PERSON
domain I I_GENE/I_PERSON
- I I_GENE/I_PERSON
containing I I_GENE/I_PERSON
protein I I_GENE/I_PERSON
Grb2 B I_GENE/I_PERSON
and O O
the O O
p85 B B_GENE
subunit O O
of O O
phosphatidylinositol B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
associate O O
constitutively O O
with O O
Cbl B B_GENE
via O O
their O O
SH3 B B_GENE/B_BIO
domains I I_GENE/I_BIO
. O O

Zta B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulated O O
the O O
HAT B B_ENZYME[GENE]/B_DISEASE
activity O O
of O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
had O O
been O O
partially O O
purified O O
or O O
immunoprecipitated O O
from O O
mammalian O O
cells O O
as O O
well O O
as O O
from O O
affinity O O
- O O
purified O O
, O O
baculovirus O O
expressed O O
CBP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Increased O O
gliadin B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O O
were O O
found O O
more O O
frequently O O
in O O
patients O O
with O O
subtotal O O
villous O O
atrophy O O
( O O
9 O O
out O O
of O O
17 O O
patients O O
, O O
or O O
53 O O
% O O
; O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
than O O
in O O
patients O O
with O O
partial O O
villous O O
atrophy O O
( O O
2 O O
out O O
of O O
13 O O
patients O O
, O O
or O O
15 O O
% O O
) O O
or O O
normal O O
villous O O
appearance O O
( O O
2 O O
out O O
of O O
10 O O
patients O O
, O O
or O O
20 O O
% O O
) O O
. O O

However O O
, O O
the O O
optimum O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compressive O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strength O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reached O O
values O B_MEASURE
up O O
to O O
40 O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
% O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
higher O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
CC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
free O B_MEASURE
samples O I_MEASURE
. O O

Expression O O
of O O
the O O
Hox B B_GENE/B_DISEASE
genes I I_GENE/I_DISEASE
egl B I_GENE/I_DISEASE
- I I_GENE/I_DISEASE
5 I I_GENE/I_DISEASE
and O O
mab B B_MEASURE/B_GENE
- I I_MEASURE/I_GENE
5 I I_MEASURE/I_GENE
is O O
reduced O O
in O O
lin B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
49 I I_GENE/I_LOCATION
and O O
lin B B_MEASURE/B_PERSON
- I I_MEASURE/I_PERSON
59 I I_MEASURE/I_PERSON
mutants I I_MEASURE/I_PERSON
, O O
suggesting O O
lin B B_GENE/B_PERSON
- I I_GENE/I_PERSON
49 I I_GENE/I_PERSON
and O O
lin B B_MEASURE/B_GENE
- I I_MEASURE/I_GENE
59 I I_MEASURE/I_GENE
regulate O O
HOM B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
in O O
C O O
. O O
elegans O O
as O O
the O O
trx B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
G I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
genes I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
do O O
in O O
Drosophila O O
. O O

lin B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
49 I I_GENE/I_DISEASE
and O O
lin B B_MEASURE/B_GENE
- I I_MEASURE/I_GENE
59 I I_MEASURE/I_GENE
transgenes I I_MEASURE/I_GENE
are O O
expressed O O
widely O O
throughout O O
C O O
. O O
elegans O O
animals O O
. O O

Interleukin B B_PERSON/B_LOCATION
- I I_PERSON/I_LOCATION
1 I I_PERSON/I_LOCATION
increased O O
the O O
noradrenaline O O
release O O
. O O

Magnetic O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
field O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
influence O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
central O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
nervous O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
system O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
function O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

3 O O
patients O O
with O O
acute O O
leukaemia O O
, O O
HLA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antibodies O O
and O O
thrombocytopenia O O
refractory O O
to O O
random O O
donor O O
platelet O O
transfusions O O
were O O
treated O O
with O O
high O O
- O O
dose O O
i O O
. O O
v O O
. O O
immunoglobulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Two O O
genes O O
( O O
ptsI B B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
and O O
ptsA B B_PROTEIN[GENE]/B_LOCATION
) O O
that O O
encode O O
homologues O O
of O O
the O O
energy O O
coupling O O
Enzyme B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
phosphoenolpyruvate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dependent I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sugar I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transporting I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphotransferase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O O
( O O
PTS O O
) O O
have O O
previously O O
been O O
identified O O
on O O
the O O
Escherichia O O
coli O O
chromosome O O
. O O

Eight O O
of O O
these O O
suppressors O O
for O O
into O O
two O O
complementation O O
groups O O
, O O
designated O O
KCS1 B B_GENE/B_DISEASE
and O O
KCS2 B B_PROTEIN[GENE]/B_DISEASE
. O O

These O O
results O O
point O O
towards O O
post O O
- O O
translational O O
steric O O
and O O
/ O O
or O O
allosteric O O
control O O
of O O
EKLF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O O
that O O
may O O
be O O
important O O
not O O
just O O
for O O
its O O
DNA O O
binding O O
ability O O
, O O
but O O
also O O
for O O
its O O
potential O O
to O O
interact O O
with O O
other O O
proteins O O
that O O
fully O O
establish O O
the O O
correct O O
stereospecific O O
array O O
leading O O
to O O
efficient O O
switching O O
of O O
beta B B_GENE
- I I_GENE
globin I I_GENE
transcription O O
during O O
development O O
. O O

Oxalates O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
digestive O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
tract O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO

However O O
, O O
the O O
addition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
intravenous O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
injection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
FPFD O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
101 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulted O O
in O O
a O O
marked O O
improvement O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
their O O
symptoms O B_DISEASE
. O O

Western O O
blot O O
experiments O O
detected O O
SMBP B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
as O O
a O O
70 O O
kDa O O
protein O O
that O O
may O O
be O O
further O O
cleaved O O
into O O
an O O
active O O
34 O O
kDa O O
N O O
- O O
terminal O O
polypeptide O O
. O O

The O O
aetiology O B_DISEASE
and O O
management O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
diabetic O B_DISEASE
impotence O I_DISEASE
is O O
well O O
- O O
documented O O
; O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
diabetes O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
female O B_DISEASE_ADJECTIVE[DISEASE]
sexuality O I_DISEASE_ADJECTIVE[DISEASE]
are O O
not O O
so O O
clear O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
diabetes O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
retinal O B_DISEASE
complications O I_DISEASE

The O O
activated O O
glucocorticoid B B_GENE/B_LOCATION
receptor I I_GENE/I_LOCATION
forms O O
a O O
complex O O
with O O
Stat5 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
enhances O O
Stat5 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mediated O O
transcriptional O O
induction O O
. O O

Taken O O
together O O
, O O
these O O
findings O O
demonstrate O O
that O O
ZNF76 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
ZNF143 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
two O O
members O O
of O O
a O O
same O O
family O O
of O O
transactivator O O
proteins O O
. O O

For O O
example O O
, O O
the O O
presence O O
of O O
two O O
related O O
genes O O
, O O
b B B_PROTEIN[GENE]/B_DISEASE
and O O
b B B_PROTEIN[GENE]/B_DISEASE
' I I_PROTEIN[GENE]/I_DISEASE
, O O
in O O
the O O
cyanobacterium O O
suggests O O
that O O
its O O
ATP B B_GENE
synthase I I_GENE
is O O
a O O
complex O O
of O O
nine O O
polypeptides O O
, O O
and O O
that O O
it O O
may O O
have O O
single O O
copies O O
of O O
related O O
b B B_PROTEIN[GENE]/B_DISEASE
and O O
b B B_PROTEIN[GENE]
' I I_PROTEIN[GENE]
proteins I I_PROTEIN[GENE]
rather O O
than O O
two O O
copies O O
of O O
identical O O
b B B_GENE/B_LOCATION
subunits I I_GENE/I_LOCATION
as O O
found O O
in O O
the O O
E O O
. O O
coli O O
enzyme O O
. O O
4 O O
+ O O
off O O

Antiserum O O
raised O O
against O O
rat B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
liver I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
S6 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specifically O O
immunoprecipitates O O
the O O
purified O O
32P O O
- O O
labeled O O
H4 O O
hepatoma O O
insulin O O
- O O
stimulated O O
S6 B B_ENZYME[GENE]/B_MEASURE
kinase I I_ENZYME[GENE]/I_MEASURE
. O O

CRKL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
an O O
SH2 B B_GENE/B_DISEASE
- O O
SH3 B B_LOCATION/B_GENE
- O O
SH3 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
adapter O O
protein O O
, O O
is O O
one O O
of O O
the O O
major O O
tyrosine B B_GENE/B_BIO
phosphoproteins I I_GENE/I_BIO
detected O O
in O O
primary O O
leukemic O O
neutrophils O O
from O O
patients O O
with O O
CML O O
. O O

KU O B_PERSON/B_PROTEIN[GENE]
- O O
1257 O B_NUMBER[MEASURE]
also O O
significantly O O
accelerated O O
the O O
healing O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
acetic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
induced O O
duodenal O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
ulcers O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
as O O
well O O
as O O
famotidine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
roxatidine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
acetate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

To O O
further O O
identify O O
the O O
residues O O
responsible O O
for O O
the O O
activity O O
, O O
we O O
isolated O O
the O O
mutant O O
viruses O O
that O O
were O O
not O O
neutralized O O
with O O
the O O
soluble O O
form O O
of O O
MHV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
since O O
such O O
mutants O O
were O O
expected O O
to O O
have O O
mutations O O
in O O
amino O O
acids O O
responsible O O
for O O
receptor O O
- O O
binding O O
activity O O
. O O

It O O
is O O
suggested O O
that O O
death O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
S O B_DISEASE/B_LOCATION
. O O
mansoni O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
cercariae O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
during O O
penetration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
mammalian O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
host O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
skin O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
probably O O
due O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O O
exhaustion O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
their O O
energy O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
reserves O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Especially O O
if O O
the O O
number O B_MEASURE/B_LOCATION
of O O
dimensions O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
large O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
it O O
can O O
be O O
said O O
that O O
BPN O B_DISEASE/B_MEASURE
is O O
better O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O O
k O B_MEASURE/B_PROTEIN[GENE]
- O O
NN O B_MEASURE/B_BIO
in O O
classification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ability O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

In O O
contrast O O
, O O
inactivation O O
of O O
the O O
Sir4p B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
interacting I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Rap1p I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
reduces O O
partitioning O O
by O O
a O O
LexA B B_GENE/B_BACTERIUM[BIO]
- O O
Sir4p B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
fusion O O
. O O

Nine O B_PERSON/B_ENT
individuals O I_PERSON/I_ENT
who O O
were O O
stable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
1 O B_TIME[MEASURE]/B_LOCATION
month O I_TIME[MEASURE]/I_LOCATION
of O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O O
low O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dosage O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
randomized O O
to O O
a O O
further O B_TIME[MEASURE]/B_ORGANIZATION
month O I_TIME[MEASURE]/I_ORGANIZATION
of O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
dosage O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
during O O
which O O
one O B_NUMBER[MEASURE]/B_PERSON
of O O
four O B_NUMBER[MEASURE]/B_PERSON
at O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
dosage O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
had O O
a O O
partial O B_DISEASE_ADJECTIVE[DISEASE]
response O I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
none O B_PERSON/B_NUMBER[MEASURE]
of O O
five O B_NUMBER[MEASURE]/B_PERSON
at O O
low O B_MEASURE
dosage O I_MEASURE
manifested O I_MEASURE
response O I_MEASURE
. O O

BACKGROUND O O
: O O
Murine B B_GENE/B_PERSON
Nramp I I_GENE/I_PERSON
is O O
a O O
candidate O O
for O O
the O O
macrophage O O
resistance O O
gene O O
Ity B B_LOCATION/B_PERSON
/ O O
Lsh B B_LOCATION/B_PERSON
/ O O
Bcg B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

In O O
cases O O
in O O
which O O
it O O
was O O
identified O O
, O O
insulitis O O
affected O O
23 O O
% O O
of O O
islets O O
containing O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
affected O O
only O O
1 O O
% O O
of O O
islets O O
which O O
were O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
deficient O O
, O O
thus O O
supporting O O
the O O
concept O O
that O O
insulitis O O
represents O O
an O O
immunologically O O
mediated O O
destruction O O
of O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
secreting O O
B O O
cells O O
. O O

( O O
4 O B_TIME[MEASURE]/B_LOCATION
) O O
Expression O B_GENE
in O O
different O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
sites O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
central O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nervous O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
system O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
driven O O
by O O
separable O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
elements O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
widely O O
dispersed O O
throughout O O
8 O B_MEASURE
kb O I_MEASURE
3 O I_MEASURE
' O O
of O O
the O O
gene O B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

To O O
investigate O O
possible O O
roles O O
for O O
HCP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
during O O
late O O
erythroid O O
differentiation O O
, O O
effects O O
of O O
manipulating O O
HCP B B_PROTEIN[GENE]/B_BIO
expression O O
or O O
recruitment O O
on O O
EPO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
hemoglobinization O O
in O O
erythroleukemic O O
SKT6 O O
cells O O
have O O
been O O
investigated O O
. O O

The O O
other O O
end O O
of O O
this O O
cluster O O
contained O O
the O O
human B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
type I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
I I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
cytokeratin I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
K20 B I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
K12 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
loci O O
. O O

An O O
11 O B_MEASURE
. O O
5 O B_MEASURE
- O O
kb O B_GENE/B_LOCATION
intron O I_GENE/I_LOCATION
is O O
found O O
at O O
the O O
end O B_LOCATION
of O O
transmembrane O B_GENE
6 O I_GENE
, O O
and O O
the O O
rest O B_LOCATION/B_MEASURE
of O O
the O O
ORF O B_GENE/B_LOCATION
is O O
in O O
exon O B_GENE/B_LOCATION
3 O I_GENE/I_LOCATION
. O O

Are O O
there O O
any O O
lessons O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
be O O
learnt O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
? O O

Eighteen O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
with O O
advanced O B_DISEASE
epidermoid O I_DISEASE
carcinoma O I_DISEASE
of O O
the O O
head O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
neck O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
were O O
entered O O
into O O
a O O
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
II O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
trial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
N O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Methylformamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
NMF O B_DISEASE/B_MEASURE
) O O
, O O
800 O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
M2 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IV O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
daily O O
for O O
5 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
every O O
4 O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
. O O

We O O
provided O O
evidence O O
that O O
CaM B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
played O O
a O O
role O O
in O O
regulating O O
neurite O O
outgrowth O O
and O O
growth O O
cone O O
motility O O
in O O
these O O
cells O O
, O O
and O O
that O O
the O O
autophosphorylation O O
is O O
essential O O
for O O
the O O
kinase O O
to O O
sufficiently O O
exert O O
its O O
cellular O O
function O O
in O O
vivo O O
[ O O
Y O O
. O O

However O O
, O O
in O O
transient O O
transfection O O
assays O O
, O O
a O O
truncation O O
of O O
as O O
little O O
as O O
15 O O
Nurr1 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
COOH O O
- O O
terminal O O
amino O O
acids O O
diminished O O
transcriptional O O
activation O O
of O O
B1A B B_GENE/B_BIO
- O O
thymidine B B_GENE
kinase I I_GENE
- O O
chloramphenicol B B_GENE
acetyltransferase I I_GENE
reporter O O
. O O

All O O
sows O B_NUMBER[MEASURE]/B_PERSON
nursed O O
nine O B_TIME[MEASURE]/B_PERSON
pigs O B_TIME[MEASURE]/I_PERSON
. O O

In O O
the O O
second O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
the O O
untreated O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
fellow O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
eye O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
microscopically O O
intact O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
but O O
was O O
shown O O
( O O
as O O
the O O
treated O O
eye O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
) O O
to O O
alter O O
the O O
concentration O B_MEASURE
of O O
uronic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
different O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
parts O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
of O O
the O O
sclera O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O O
studied O O
of O O
extremely O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
frequency O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
electromagnetic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
radiation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
EHF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
EMR O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
on O O
indices O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
immune O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
endocrine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
systems O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
a O O
series O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
48 O B_PERSON/B_TIME[MEASURE]
patients O I_PERSON/I_TIME[MEASURE]
presenting O O
with O O
hyperplastic O B_DISEASE
processes O I_DISEASE
in O O
endometrium O B_LOCATION/B_PERSON
. O O

Characterization O O
of O O
human B B_GENE
activating I I_GENE
transcription I I_GENE
factor I I_GENE
4 I I_GENE
, O O
a O O
transcriptional O O
activator O O
that O O
interacts O O
with O O
multiple O O
domains O O
of O O
cAMP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
responsive I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CREB B B_GENE/B_DISEASE
) O O
- O O
binding O O
protein O O
. O O

Effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
constant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
magnetic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
field O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
different O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
carcinogenesis O B_DISEASE

In O O
contrast O O
to O O
the O O
reciprocal O O
effects O O
of O O
Gab1 B B_GENE
and O O
Gab2 B B_GENE
in O O
mediating O O
Elk B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
induction O O
, O O
these O O
two O O
molecules O O
have O O
a O O
similar O O
function O O
in O O
extracellular B B_GENE
signal I I_GENE
- I I_GENE
regulated I I_GENE
kinase I I_GENE
activation O O
induced O O
by O O
either O O
oncogenic O O
Ras B B_GENE/B_DISEASE
or O O
growth O O
factor O O
stimulation O O
. O O

This O O
result O O
is O O
consistent O O
with O O
the O O
previous O O
observation O O
that O O
expression O O
of O O
the O O
hsp70 B B_GENE/B_BACTERIUM[BIO]
genes I I_GENE/I_BACTERIUM[BIO]
in I I_GENE/I_BACTERIUM[BIO]
T I I_GENE/I_BACTERIUM[BIO]
. I I_GENE/I_BACTERIUM[BIO]
brucei I I_GENE/I_BACTERIUM[BIO]
is O O
mainly O O
controlled O O
at O O
the O O
posttranscriptional O O
level O O
. O O

A O O
definition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
bias O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
founded O O
on O O
the O O
concept O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
base O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Chromaffin O O
cells O O
transfected O O
with O O
a O O
plasmid O O
with O O
the O O
entire O O
coding O O
sequence O O
of O O
c B B_GENE
- I I_GENE
Rabphilin3a I I_GENE
inserted O O
in O O
the O O
antisense O O
orientation O O
inhibited O O
secretion O O
of O O
co O O
- O O
expressed O O
GH B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
approximately O O
30 O O
% O O
. O O

Using O O
a O O
set O O
of O O
sera O O
for O O
which O O
full O O
chlamydial O O
micro O O
- O O
immunofluorescence O O
results O O
suggested O O
a O O
clear O O
diagnosis O O
, O O
we O O
have O O
evaluated O O
the O O
Chlamydia O O
Spot O O
- O O
IF O O
test O O
( O O
bioMerieux O O
) O O
, O O
which O O
allows O O
a O O
comparison O O
of O O
titres O O
to O O
Chlamydia B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trachomatis I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
psittaci I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antigens I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

An O O
environmental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
found O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
suboptimal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
food O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
storage O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
cooking O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
temperatures O B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O O
Restaurant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
A O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
; O O
cross O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
contamination O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
foods O B_BIO
may O O
have O O
contributed O O
to O O
the O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
attributable O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
risk O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
identified O O
for O O
chile O B_DISEASE/B_LOCATION
rellenos O I_DISEASE/I_LOCATION
. O O

Evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
from O O
four O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
areas O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
- O O
- O O
sensory O B_DISEASE/B_LOCATION
deprivation O I_DISEASE/I_LOCATION
, O O
enriched O O
environments O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
, O O
nervous O B_DISEASE/B_PERSON
system O I_DISEASE/I_PERSON
plasticity O I_DISEASE/I_PERSON
, O O
and O O
sensitive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
periods O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
neurodevelopment O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
- O O
suggests O O
that O O
sensory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
stimulation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
programs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O O
potentially O O
beneficial O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
STR O B_PERSON/B_DISEASE
patients O I_PERSON/I_DISEASE
. O O

In O O
each O O
study O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
elevated O O
levels O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
serum O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O O
were O O
observed O O
. O O

With O O
repetitive O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
intermittent O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
exercise O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
gradual O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
increases O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
blood O B_MEASURE/B_DISEASE
lactate O I_MEASURE/I_DISEASE
concentration O I_MEASURE/I_DISEASE
[ O I_MEASURE/I_DISEASE
( O O
LA O B_LOCATION/B_PROTEIN[GENE]
] O I_LOCATION/I_PROTEIN[GENE]
b O I_LOCATION/I_PROTEIN[GENE]
) O O
occurred O O
, O O
whereas O O
its O O
rate O B_MEASURE
of O O
accumulation O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
delta O B_LOCATION/B_MEASURE
[ O I_LOCATION/I_MEASURE
LA O I_LOCATION/I_MEASURE
] O I_LOCATION/I_MEASURE
b O I_LOCATION/I_MEASURE
) O O
decreased O O
. O O

A O O
physical O O
and O O
genetic O O
map O O
covering O O
the O O
entire O O
RP12 B B_LOCATION/B_GENE
candidate I I_LOCATION/I_GENE
gene I I_LOCATION/I_GENE
region I I_LOCATION/I_GENE
was O O
constructed O O
. O O

The O O
single O O
copy O O
flotillin B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
is O O
located O O
at O O
6p21 O O
. O O
3 O O
in O O
the O O
MHC B B_SPECIES[BIO]/B_MEASURE
class I I_SPECIES[BIO]/I_MEASURE
I I I_SPECIES[BIO]/I_MEASURE
region I I_SPECIES[BIO]/I_MEASURE
and O O
consists O O
of O O
13 O O
exons O O
over O O
15 O O
kb O O
. O O

An O O
atypical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
form O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
juvenile O B_DISEASE
myasthenia O I_DISEASE
gravis O I_DISEASE
associated O O
with O O
severe O B_DISEASE
emaciation O I_DISEASE
, O O
muscle O B_DISEASE
atrophy O I_DISEASE
, O O
ophthalmoplegia O B_DISEASE
, O O
bulbar O B_DISEASE
signs O I_DISEASE
and O O
joint O B_DISEASE
contracture O I_DISEASE

The O O
in O O
vivo O O
response O O
of O O
the O O
PacC B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
like I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
decamers I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
to O O
external O O
pH O O
was O O
dependent O O
on O O
the O O
status O O
of O O
the O O
pH O O
- O O
regulated O O
activator O O
YlRim101p B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
is O O
homologous O O
to O O
the O O
A O O
. O O
nidulans O O
PacC B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
regulator O O
. O O

Electron O O
microscopic O O
visualization O O
of O O
the O O
general O O
population O O
of O O
active O O
genes O O
in O O
flies O O
overexpressing O O
hnRNP B B_GENE
proteins I I_GENE
also O O
indicated O O
that O O
the O O
great O O
majority O O
of O O
genes O O
seemed O O
normal O O
in O O
terms O O
of O O
cotranscriptional O O
RNA O O
processing O O
events O O
, O O
although O O
there O O
were O O
a O O
few O O
abnormalities O O
consistent O O
with O O
rare O O
exon O O
- O O
skipping O O
events O O
. O O

Having O O
demonstrated O O
proper O O
localization O O
of O O
GFP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
calmodulin B B_GENE
in O O
budding O O
yeast O O
, O O
we O O
examined O O
the O O
localization O O
of O O
a O O
fusion O O
between O O
GFP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
calmodulin B B_GENE
( O O
GFP B B_PROTEIN[GENE]/B_LOCATION
- I I_PROTEIN[GENE]/I_LOCATION
Camlp I I_PROTEIN[GENE]/I_LOCATION
) O O
in O O
fission O O
yeast O O
, O O
where O O
calmodulin B B_GENE/B_BIO
had O O
not O O
been O O
localized O O
by O O
any O O
method O O
. O O

Sera O O
from O O
33 O O
newborn O O
infants O O
with O O
gestational O O
ages O O
ranging O O
from O O
27 O O
to O O
41 O O
weeks O O
were O O
tested O O
by O O
radioimmunoassay O O
for O O
IgG B B_GENE/B_MEASURE
antibodies O O
to O O
surface O O
antigens O O
of O O
group O O
B O O
streptococci O O
( O O
GBS O O
) O O
types O O
Ia O O
, O O
Ib O O
, O O
II O O
and O O
III O O
. O O

In O O
frozen O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sections O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
the O O
spots O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
appear O O
as O O
blue O B_COLOR/B_DISEASE_ADJECTIVE[DISEASE]
labelled O O
neurones O B_LOCATION/B_BIO
with O O
a O O
light O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscope O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
or O O
as O O
a O O
brilliant O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
red O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
neurones O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
surrounded O O
by O O
reddish O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_COLOR
tissue O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_COLOR
with O O
a O O
fluorescence O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
microscope O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
percentage O B_MEASURE
distribution O I_MEASURE
of O O
types O B_DISEASE/B_MEASURE
of O O
fixation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
disparity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
curves O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
found O O
to O O
be O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
some O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
with O O
a O O
higher O B_MEASURE/B_LOCATION
prevalence O I_MEASURE/I_LOCATION
of O O
Type O B_MEASURE/B_ORGANIZATION
I O O
curve O B_MEASURE
( O O
64 O B_MEASURE
. O O
3 O B_MEASURE
% O I_MEASURE
) O O
, O O
followed O O
by O O
Type O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
II O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
( O O
28 O B_MEASURE
. O O
6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
and O O
Type O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
III O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
7 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
) O O
curves O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
BUR O B_MEASURE/B_PROTEIN[GENE]
was O O
set O O
at O O
20 O B_MEASURE
/ O O
min O B_MEASURE/B_PERSON
and O O
the O O
IT O O
at O O
. O O
5 O B_MEASURE/B_ENT
seconds O I_MEASURE/I_ENT
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
discussed O O
in O O
the O O
context O B_LOCATION
of O O
the O O
pathogenesis O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
differential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
EEC O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Seminal O O
prolactin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
were O O
significantly O O
elevated O O
in O O
all O O
infertile O O
males O O
. O O

Northern O O
blot O O
analysis O O
identified O O
retina O O
- O O
specific O O
transcripts O O
of O O
3 O O
. O O
0 O O
kb O O
for O O
rod B B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
G I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
alpha I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
t I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
and O O
2 O O
. O O
6 O O
kb O O
for O O
cone B B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
G I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
alpha I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
t I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
. O O

In O O
the O O
univariate O O
models O O
of O O
either O O
fixed O O
or O O
time O O
dependent O O
covariates O O
, O O
many O O
variables O O
were O O
significantly O O
associated O O
with O O
risk O O
of O O
progression O O
to O O
AIDS O O
( O O
T4 O O
cell O O
count O O
, O O
T4 O O
/ O O
T8 O O
ratio O O
, O O
blastogenic O O
responses O O
to O O
phytohemagglutinin B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
concanavalin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
A I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
pokeweed B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mitogen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
serum B B_DISEASE
IgA I I_DISEASE
, O O
appearance O O
of O O
p24 B B_DISEASE/B_GENE
antigen I I_DISEASE/I_GENE
, O O
and O O
the O O
development O O
of O O
oral O O
hairy O O
leukoplakia O O
, O O
thrush O O
, O O
or O O
herpes O O
zoster O O
) O O
. O O

Adenovirus O O
- O O
mediated O O
gene O O
transfer O O
of O O
MMAC1 B B_GENE
/ O O
PTEN B B_PROTEIN[GENE]/B_MEASURE
to O O
glioblastoma O O
cells O O
inhibits O O
S O O
phase O O
entry O O
by O O
the O O
recruitment O O
of O O
p27Kip1 B B_GENE
into O O
cyclin B B_GENE
E I I_GENE
/ O O
CDK2 B B_GENE
complexes O O
. O O

Cost O B_LOCATION/B_ORGANIZATION
analysis O I_LOCATION/I_ORGANIZATION
and O O
the O O
HSA O B_LOCATION/B_ORGANIZATION
: O O
a O O
framework O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

These O O
cells O O
also O O
showed O O
an O O
increase O O
in O O
cyclin B B_GENE
A I I_GENE
and O O
cyclin B B_GENE
A I I_GENE
- I I_GENE
and I I_GENE
E I I_GENE
- I I_GENE
associated I I_GENE
kinase I I_GENE
activities O O
characteristic O O
of O O
S O O
phase O O
induction O O
. O O

Characterization O O
of O O
a O O
tonB B B_GENE/B_BACTERIUM[BIO]
- O O
phoA B B_BACTERIUM[BIO]/B_GENE
gene O O
fusion O O
suggests O O
that O O
the O O
amino O O
- O O
terminal O O
41 O O
amino O O
acids O O
of O O
TonB B B_GENE/B_BACTERIUM[BIO]
are O O
sufficient O O
to O O
promote O O
export O O
of O O
the O O
fusion O O
protein O O
and O O
presumably O O
TonB B B_BACTERIUM[BIO]/B_GENE
as O O
well O O
. O O

Calcium O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
bilirubinate O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
crystals O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O O
seen O O
in O O
gallbladder O B_BODY_PART_OR_ORGAN_COMPONENT
bile O I_BODY_PART_OR_ORGAN_COMPONENT
or O O
wall O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scrapings O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
7 O B_NUMBER[MEASURE]
of O O
8 O B_NUMBER[MEASURE]/B_PERSON
TPN O I_NUMBER[MEASURE]/I_PERSON
animals O I_NUMBER[MEASURE]/I_PERSON
but O O
in O O
none O B_PERSON/B_NUMBER[MEASURE]
of O O
the O O
controls O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE/B_LOCATION
. O O
001 O B_MEASURE
) O O
. O O

This O O
domain O O
encompasses O O
the O O
region O O
of O O
ARP B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
/ O O
COUP B B_PROTEIN[GENE]/B_MEASURE
- I I_PROTEIN[GENE]/I_MEASURE
TFII I I_PROTEIN[GENE]/I_MEASURE
corresponding O O
to O O
helices O O
3 O O
to O O
12 O O
in O O
the O O
recently O O
published O O
crystal O O
structure O O
of O O
other O O
members O O
of O O
the O O
nuclear B B_GENE/B_BIO
receptor I I_GENE/I_BIO
superfamily I I_GENE/I_BIO
. O O

Different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clinical O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variants O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
empty O B_DISEASE_ADJECTIVE[DISEASE]
sella O I_DISEASE_ADJECTIVE[DISEASE]
turcica O I_DISEASE_ADJECTIVE[DISEASE]
syndrome O I_DISEASE_ADJECTIVE[DISEASE]
are O O
demonstrated O O
, O O
including O O
variants O B_LOCATION/B_DISEASE
resultant O O
from O O
substitution O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
thyroid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hypofunction O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
from O O
dopamine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
agonist O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
hyperprolactinemic O B_DISEASE
hypogonadism O I_DISEASE
, O O
from O O
radiotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
hypophyseal O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
adenoma O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Both O O
genes B B_GENE
ARO3 I I_GENE
and O O
ARO4 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
strongly O O
regulated O O
under O O
the O O
general O O
control O O
regulatory O O
system O O
. O O

Polar O O
effects O O
of O O
transposon O O
insertions O O
demonstrated O O
that O O
all O O
of O O
these O O
mRNAs O O
arose O O
from O O
a O O
single O O
promoter O O
region O O
, O O
where O O
transcription O O
initiated O O
80 O O
bp O O
5 O O
' O O
to O O
nifH B B_TIME[MEASURE]/B_LOCATION
. O O

J O B_OTHER/B_LOCATION
. O O
, O O
& O O
Olefsky O B_PERSON/B_LOCATION
, O O
J O B_OTHER/B_PERSON
. O O

Importantly O O
, O O
a O O
single O O
base O O
change O O
in O O
the O O
fifth O O
position O O
of O O
the O O
c B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
fos I I_GENE/I_LOCATION
sequence I I_GENE/I_LOCATION
( O O
GGTCTnnnAGACC O O
to O O
GGTCA O O
/ O O
GnnnAGACC O O
) O O
produced O O
an O O
element O O
that O O
bound O O
the O O
estrogen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
conferred O O
estrogen O O
- O O
dependent O O
transcriptional O O
activation O O
of O O
a O O
reporter O O
gene O O
. O O

Measuring O O
the O O
dim O B_MEASURE/B_LOCATION
light O I_MEASURE/I_LOCATION
melatonin O I_MEASURE/I_LOCATION
onset O I_MEASURE/I_LOCATION
( O O
DLMO O B_LOCATION/B_DISEASE
) O O
is O O
a O O
useful O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
practical O B_DISEASE_ADJECTIVE[DISEASE]
way O I_DISEASE_ADJECTIVE[DISEASE]
to O O
assess O O
circadian O B_DISEASE
phase O I_DISEASE
position O I_DISEASE
in O O
humans O B_PERSON/B_BIO
. O O

Co O O
- O O
expression O O
of O O
a O O
gag B B_GENE
- O O
TRalpha B B_GENE
fusion O O
protein O O
in O O
AEV O O
- O O
transformed O O
cells O O
and O O
addition O O
of O O
ligand O O
derepresses O O
CAII B B_GENE/B_VIRUS[BIO]
transcription O O
. O O

The O O
IB2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
HGMW O O
- O O
approved O O
symbol O O
MAPK8IP2 B B_GENE/B_TIME[MEASURE]
) O O
maps O O
to O O
human O O
chromosome O O
22q13 O O
and O O
contains O O
10 O O
coding O O
exons O O
. O O

Transcription O O
start O O
sites O O
of O O
sal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
salR B B_GENE
genes I I_GENE
were O O
determined O O
to O O
lie O O
30 O O
- O O
and O O
24 O O
- O O
bp O O
upstream O O
of O O
the O O
respective O O
initiation O O
codons O O
and O O
separated O O
from O O
each O O
other O O
by O O
78 O O
nucleotides O O
. O O

1 O O
. O O
23 O O
) O O
as O O
a O O
PPARalpha B B_MEASURE/B_GENE
- I I_MEASURE/I_GENE
interacting I I_MEASURE/I_GENE
protein I I_MEASURE/I_GENE
. O O

Here O O
we O O
demonstrate O O
that O O
the O O
T B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigen I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
zeta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
associated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ZAP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
70 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
T B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigen I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
zeta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
immunoreceptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
based I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activation I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
motifs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
essential O O
for O O
the O O
membrane O O
recruitment O O
of O O
SOS B B_GENE/B_DISEASE
and O O
Vav B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
carried O O
out O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
experiments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
investigate O O
this O O
problem O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

When O O
linked O O
to O O
the O O
herpes O O
simplex O O
thymidine B B_ENZYME[GENE]/B_VIRUS[BIO]
kinase I B_ENZYME[GENE]/I_VIRUS[BIO]
minimal O O
promoter O O
, O O
this O O
fragment O O
acts O O
as O O
an O O
enhancing O O
element O O
in O O
Rcho O O
but O O
not O O
GC O O
cells O O
. O O

A O O
mammalian O O
protein O O
called O O
RFX B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
NF B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
X I I_GENE/I_DISEASE
binds O O
to O O
the O O
X O O
box O O
( O O
or O O
X1 O O
box O O
) O O
in O O
the O O
promoters O O
of O O
a O O
number O O
of O O
major B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
histocompatibility I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MHC I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
class I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Site O B_LOCATION/B_BIO
- O O
directed O O
mutagenesis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
was O O
conducted O O
to O O
investigate O O
the O O
functional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
significance O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
this O O
element O B_LOCATION
and O O
the O O
3 O B_NUMBER[MEASURE]
' O I_NUMBER[MEASURE]
minus O I_NUMBER[MEASURE]
- O O
strand O B_GENE/B_LOCATION
terminal O I_GENE/I_LOCATION
sequence O I_GENE/I_LOCATION
" O O
3 O B_NUMBER[MEASURE]
' O O
- O O
OH O B_LOCATION/B_PROTEIN[GENE]
- O O
CCCUAU O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
" O O
which O O
contains O O
the O O
minus O B_NUMBER[MEASURE]
- O O
strand O B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
3 O I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
' O I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
end O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
sequence O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
" O O
3 O B_MEASURE/B_LOCATION
' O I_MEASURE/I_LOCATION
- O O
OH O B_LOCATION/B_PROTEIN[GENE]
- O O
CC O B_LOCATION/B_DISEASE
( O O
1 O B_MEASURE/B_LOCATION
- O O
2 O B_NUMBER[MEASURE]/B_LOCATION
) O O
( O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
/ O O
U O B_OTHER/B_LOCATION
) O O
( O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
/ O O
U O B_OTHER/B_LOCATION
) O O
( O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
/ O O
U O B_OTHER/B_LOCATION
) O O
" O O
found O O
in O O
all O O
carmovirus O B_BIO/B_GENE
RNAs O I_BIO/I_GENE
. O O

The O O
incidence O O
of O O
the O O
variability O O
of O O
the O O
free O O
PSA B B_PROTEIN[GENE]
/ O O
total O O
PSA B B_GENE
ratio O O
on O O
the O O
early O O
diagnosis O O
of O O
prostate O O
cancer O O

VBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
a1 B B_GENE
/ I I_GENE
EBP I I_GENE
could O O
mediate O O
the O O
high O O
rates O O
of O O
ALV O O
and O O
RSV B B_DISEASE/B_VIRUS[BIO]
LTR I B_DISEASE/I_VIRUS[BIO]
- O O
enhanced O O
transcription O O
in O O
bursal O O
lymphoma O O
cells O O
and O O
many O O
other O O
cell O O
types O O
. O O

In O O
the O O
second O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
37 O B_PERSON/B_BIO
students O I_PERSON/I_BIO
were O O
given O O
trimethoprim O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
sulphamethoxazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
160 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
mg O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
TMP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O O
SMX O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
800 O I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
38 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TMP O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
200 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
mg O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
, O O
and O O
in O O
35 O B_NUMBER[MEASURE]
a O O
placebo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O O
given O O
b O B_DISEASE/B_MEASURE
. O O
i O O
. O O
d O O
. O O
for O O
five O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Developmental O O
slot O O
blots O O
demonstrate O O
that O O
mRNAs O O
corresponding O O
to O O
the O O
three O O
LHM B B_GENE/B_LOCATION
cDNAs I I_GENE/I_LOCATION
are O O
transcribed O O
from O O
prophase O O
of O O
meiosis O O
I O O
to O O
the O O
uninucleate O O
microspore O O
stage O O
, O O
while O O
Northern O O
analysis O O
reveals O O
these O O
tapetally O O
expressed O O
cDNAs O O
to O O
correspond O O
with O O
transcripts O O
of O O
some O O
500 O O
bp O O
. O O

One O B_PERSON/B_ENT
hundred O I_PERSON/I_ENT
men O I_PERSON/I_ENT
who O O
received O O
alpha O B_PROTEIN[GENE]
- O O
tocopherol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
matched O O
on O O
age O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
study O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
center O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
length O B_MEASURE/B_LOCATION
of O O
time O B_TIME[MEASURE]/B_DISEASE
between O O
blood O B_BODY_PART_OR_ORGAN_COMPONENT/B_NUMBER[MEASURE]
draws O O
to O O
100 O B_PERSON/B_SPORT[ENT]
men O I_PERSON/I_SPORT[ENT]
who O O
received O O
a O O
placebo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

The O O
contribution O O
of O O
residues O O
outside O O
the O O
Ras B B_LOCATION/B_PERSON
binding I I_LOCATION/I_PERSON
domain I I_LOCATION/I_PERSON
of O O
Raf B B_GENE/B_DISEASE
( O O
RafRBD B B_PROTEIN[GENE]/B_LOCATION
) O O
to O O
Ras B B_GENE/B_DISEASE
- O O
Raf B B_GENE/B_DISEASE
interaction O O
and O O
Ras B B_GENE/B_DISEASE
- O O
dependent O O
Raf B B_GENE/B_DISEASE
activation O O
has O O
remained O O
unresolved O O
. O O

Other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
recommendations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
enhancing O O
the O O
safety O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
potent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antiplatelet O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
variety O B_ENT/B_MEASURE
of O O
clinical O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
situations O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
are O O
provided O O
. O O

RESULTS O B_MEASURE/B_LOCATION
- O O
- O O
261 O B_MEASURE/B_PERSON
patients O I_MEASURE/I_PERSON
were O O
enrolled O O
into O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
of O O
these O O
, O O
138 O B_MEASURE
( O O
53 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
patients O B_PERSON/B_LOCATION
attended O O
for O O
repeat O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colposcopy O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cytology O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
at O O
one O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
year O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Changes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
greater O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
omentum O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
different O B_BIO/B_MEASURE
strains O I_BIO/I_MEASURE
after O O
intraperitoneal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
immunization O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
sheep O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
erythrocytes O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
this O O
study O O
, O O
we O O
sought O O
to O O
determine O O
the O O
specific O O
effect O O
of O O
HIV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protease I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors O O
on O O
patient O O
weight O O
. O O

However O O
massive O B_DISEASE/B_NUMBER[MEASURE]
necrosis O I_DISEASE/I_NUMBER[MEASURE]
of O O
the O O
renal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tubules O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
had O O
been O O
found O O
with O O
more O B_MEASURE
than O O
15mg O B_TIME[MEASURE]
of O O
DSM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
characteristics O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
a O O
simple O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
apparatus O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
use O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O O
measure O O
DEOAEs O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
described O O
together O O
with O O
typical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
examples O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
emissions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

To O O
obtain O O
information O O
on O O
the O O
functional O O
role O O
of O O
the O O
Rac1 B B_GENE
/ O O
p38 B B_GENE
/ O O
MAPKAPK B B_GENE
- I I_GENE
2 I I_GENE
pathway O O
in O O
RA O O
signaling O O
, O O
the O O
effects O O
of O O
pharmacological O O
inhibition O O
of O O
p38 B B_GENE
on O O
RA O O
- O O
induced O O
gene O O
transcription O O
and O O
cell O O
differentiation O O
were O O
determined O O
. O O

The O O
cost O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
effectiveness O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
nurse O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
education O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
- O O
1 O B_NUMBER[MEASURE]
. O O

The O O
ATF B B_LOCATION/B_GENE
/ O O
CRE O O
site O O
is O O
also O O
essential O O
for O O
CD4 B B_GENE/B_MEASURE
promoter I I_GENE/I_MEASURE
activation O O
by O O
forskolin O O
, O O
an O O
activator O O
of O O
adenylate B B_GENE
cyclase I I_GENE
. O O

YLL031c B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
an O O
essential O O
gene O O
. O O

Restricted O O
expression O O
of O O
a O O
novel O O
murine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
atonal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
related I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bHLH I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
undifferentiated O O
neural O O
precursors O O
. O O

Since O O
the O O
early O B_TIME[MEASURE]
1900s O I_TIME[MEASURE]
, O O
a O O
genetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
hypothesis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
has O O
been O O
suggested O O
. O O

We O O
report O O
the O O
genomic O O
organization O O
of O O
the O O
mouse O O
orphan B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
related I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Ryk B B_GENE
) O O
, O O
a O O
structurally O O
unclassified O O
member O O
of O O
the O O
growth B B_GENE
factor I I_GENE
receptor I I_GENE
family O O
. O O

In O O
contrast O O
, O O
T229E B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
p70s6k I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
migrated O O
more O O
slowly O O
in O O
SDS O O
- O O
polyacrylamide O O
gels O O
, O O
but O O
demonstrated O O
partial O O
kinase O O
activity O O
( O O
approximately O O
20 O O
% O O
compared O O
with O O
the O O
wild O O
type O O
) O O
. O O

The O O
structure O O
and O O
expression O O
of O O
the O O
murine B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
encoding I I_GENE/I_LOCATION
granulocyte I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
macrophage I I_GENE/I_LOCATION
colony I I_GENE/I_LOCATION
stimulating I I_GENE/I_LOCATION
factor I I_GENE/I_LOCATION
: O O
evidence O O
for O O
utilisation O O
of O O
alternative O O
promoters O O
. O O

Thus O O
, O O
the O O
search O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
genetic O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
acquired O O
susceptibility O B_DISEASE/B_LOCATION
to O O
nontuberculous O B_DISEASE
mycobacteria O I_DISEASE
is O O
also O O
a O O
search O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
susceptibility O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
factors O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
for O O
MTB O B_DISEASE/B_PERSON
as O O
well O O
as O O
an O O
opportunity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
recognize O O
endogenous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pathways O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
can O O
be O O
exploited O O
therapeutically O O
. O O

Liver O O
disease O O
and O O
HCV O O
infection O O
after O O
transplantation O O
of O O
organs O O
from O O
hepatitis B B_DISEASE/B_GENE
C I I_DISEASE/I_GENE
antibody I I_DISEASE/I_GENE
positive O O
donors O O
. O O

After O O
dialysis O O
online O O
, O O
lactate O O
was O O
converted O O
by O O
means O O
of O O
lactate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxidase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
immobilized O O
to O O
porous O O
glass O O
, O O
and O O
the O O
depletion O O
of O O
oxygen O O
was O O
registered O O
by O O
means O O
of O O
a O O
Clark O O
electrode O O
. O O

The O O
deduced O O
amino O O
- O O
acid O O
sequence O O
of O O
the O O
mature O O
enzyme O O
showed O O
very O O
low O O
homology O O
( O O
< O O
20 O O
. O O
4 O O
% O O
identity O O
) O O
to O O
those O O
of O O
known O O
pectinolytic O O
enzymes O O
in O O
the O O
large O O
pectate B B_LOCATION/B_PERSON
lyase I I_LOCATION/I_PERSON
superfamily I I_LOCATION/I_PERSON
( O O
the O O
polysaccharide B B_PERSON/B_LOCATION
lyase I I_PERSON/I_LOCATION
family I I_PERSON/I_LOCATION
1 I I_PERSON/I_LOCATION
) O O
. O O

Incubation O O
of O O
HeLa O O
cell O O
cytoplasmic O O
extracts O O
with O O
a O O
purified O O
recombinant O O
glutathione B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
S I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transferase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
raf B B_GENE/B_DISEASE
fusion O O
protein O O
in O O
the O O
presence O O
of O O
ATP O O
released O O
active O O
NF B B_GENE
- I I_GENE
kappa I I_GENE
B I I_GENE
that O O
could O O
be O O
detected O O
by O O
electrophoretic O O
gel O O
mobility O O
shift O O
assay O O
. O O

Despite O O
this O O
loss O O
, O O
YEpFAS1 B B_PERSON
is O O
still O O
able O O
to O O
complement O O
a O O
fas1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutation O O
at O O
the O O
enoyl B B_PROTEIN[GENE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
reductase I B_PROTEIN[GENE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
domain O O
. O O

Cross O O
- O O
species O O
characterization O O
of O O
the O O
promoter B B_GENE/B_LOCATION
region I I_GENE/I_LOCATION
of I I_GENE/I_LOCATION
the I I_GENE/I_LOCATION
cystic I I_GENE/I_LOCATION
fibrosis I I_GENE/I_LOCATION
transmembrane I I_GENE/I_LOCATION
conductance I I_GENE/I_LOCATION
regulator I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
reveals O O
multiple O O
levels O O
of O O
regulation O O
. O O

Pretreatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
lipid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
X O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
not O O
necessary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
improve O O
survival O B_DISEASE_ADJECTIVE[DISEASE]
: O O
16 O B_MEASURE
of O O
17 O B_MEASURE
( O O
94 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
infected O O
and O O
visibly O O
ill O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
animals O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
received O O
lipid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
X O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
ticarcillin O B_MEASURE
6 O I_MEASURE
h O O
after O O
thigh O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
inoculation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
survived O O
versus O B_MEASURE
30 O I_MEASURE
of O O
44 O B_MEASURE
( O O
68 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
control O B_SPECIES[BIO]/B_ORGANIZATION
animals O I_SPECIES[BIO]/I_ORGANIZATION
treated O O
with O O
ticarcillin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alone O O
( O O
P O B_MEASURE/B_PERSON
less O I_MEASURE/I_PERSON
than O O
0 O B_MEASURE
. O O
0001 O B_MEASURE
) O O
. O O

The O O
predicted O O
vav B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oncogene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
exhibits O O
several O O
motifs O O
reminiscent O O
of O O
transcriptional O O
factors O O
. O O

The O O
pharmacokinetics O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
best O O
described O O
by O O
a O O
two O B_NUMBER[MEASURE]
- O O
compartment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
open O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
giving O O
distribution O B_MEASURE/B_LOCATION
half O I_MEASURE/I_LOCATION
- O O
lives O B_PERSON/B_TIME[MEASURE]
of O O
0 O B_MEASURE
. O O
31 O B_MEASURE
h O O
and O O
1 O B_MEASURE
. O O
53 O B_MEASURE
h O O
, O O
and O O
elimination O B_MEASURE/B_PERSON
half O I_MEASURE/I_PERSON
- O O
lives O B_PERSON/B_TIME[MEASURE]
of O O
69 O B_MEASURE
. O O
7 O B_MEASURE
h O O
and O O
60 O B_MEASURE
. O O
3 O B_MEASURE
h O O
for O O
oxolinic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
oxytetracycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
respectively O O
. O O

The O O
predictive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
value O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
remotely O O
sensed O O
map O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
based O O
on O O
NDVI O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
appears O O
to O O
be O O
better O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O O
that O O
from O O
forecast O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
indices O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
based O O
only O O
on O O
climatic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

It O O
has O O
been O O
confirmed O O
in O O
animal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
experiments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
that O O
the O O
number O B_MEASURE/B_LOCATION
of O O
microspheres O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
myocardial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
sample O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
approximately O O
follows O O
a O O
Poisson O B_MEASURE
distribution O I_MEASURE
, O O
under O O
adequate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
experimental O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
conditions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Hepatitis B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immune I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
globulins I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
HIV B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
gene O O
is O O
divided O O
into O O
six O O
exons O O
spanning O O
about O O
3kb O O
, O O
and O O
encodes O O
a O O
175 O O
amino O O
acid O O
protein O O
with O O
40 O O
- O O
52 O O
% O O
identity O O
with O O
the O O
other O O
five O O
mouse B B_GENE/B_PERSON
Reg I I_GENE/I_PERSON
( O O
regenerating B B_PROTEIN[GENE]/B_LOCATION
gene I I_PROTEIN[GENE]/I_LOCATION
product I I_PROTEIN[GENE]/I_LOCATION
) O O
proteins O O
. O O

The O O
p63 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequence I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
also O O
features O O
an O O
acidic O O
domain O O
characteristic O O
of O O
transcriptional O O
activation O O
factors O O
, O O
as O O
well O O
as O O
sequence O O
blocks O O
displaying O O
limited O O
similarity O O
to O O
positionally O O
equivalent O O
regions O O
in O O
sigma B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
eubacteria O O
related O O
to O O
mitochondria O O
. O O

In O O
contrast O O
, O O
a O O
similar O O
fusion O O
protein O O
( O O
hGH B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
LDLR B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
DAF17 B B_GENE
, O O
abbreviated O O
HLD B B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
) O O
containing O O
a O O
fragment O O
of O O
the O O
serine O O
/ O O
threonine O O
- O O
rich O O
domain O O
of O O
the O O
LDL B B_GENE
receptor I I_GENE
( O O
LDLR B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
in O O
place O O
of O O
the O O
DAF B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
derived I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
serine I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
threonine I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
rich I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequences I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
does O O
not O O
become O O
GPI O O
anchored O O
. O O

Thus O O
, O O
the O O
pathway O O
to O O
Fc B B_GENE
epsilonRI I I_GENE
- O O
mediated O O
MEK B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
ERK B B_GENE
and O O
ERK B B_GENE
activation O O
can O O
apparently O O
bypass O O
Ras B B_GENE/B_DISEASE
and O O
Raf B B_GENE
- I I_GENE
1 I I_GENE
. O O

To O O
assess O O
whether O O
thallium O B_LOCATION
- O O
201 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
thallous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
chloride O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
Tl O B_PROTEIN[GENE]/B_LOCATION
) O O
can O O
detect O O
childhood O B_DISEASE
tumors O I_DISEASE
and O O
whether O O
diagnostic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effectiveness O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
improves O O
with O O
combined O O
blood O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flow O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaging O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
28 O B_PERSON/B_ENT
children O I_PERSON/I_ENT
( O O
1 O B_MEASURE
. O O
0 O B_MEASURE
- O O
18 O B_NUMBER[MEASURE]
. O O
6 O B_TIME[MEASURE]
years O I_TIME[MEASURE]
) O O
were O O
studied O O
using O O
single O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
photon O B_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
emission O B_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
computed O O
tomography O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SPECT O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
: O O
Tl O B_NUMBER[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O B_MEASURE
. O O
3 O B_MEASURE
- O O
1 O B_MEASURE
. O O
8 O B_MEASURE
mCi O I_MEASURE
intravenously O O
) O O
, O O
followed O O
in O O
13 O B_NUMBER[MEASURE]
of O O
the O O
patients O B_PERSON/B_MEASURE
by O O
technetium O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
99m O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
hexamethylpropyleneamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
oxime O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
( O O
99mTc O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
HMPAO O B_MEASURE/B_DISEASE
; O O
8 O B_NUMBER[MEASURE]
- O O
18 O B_TIME[MEASURE]/B_LOCATION
mCi O I_TIME[MEASURE]/I_LOCATION
intravenously O O
) O O
. O O

Ftz B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
on O O
the O O
other O O
hand O O
, O O
influences O O
Ftz B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
F1 B B_GENE
activity O O
by O O
interacting O O
with O O
its O O
AF O O
- O O
2 O O
domain O O
in O O
a O O
manner O O
that O O
mimics O O
a O O
nuclear O O
receptor O O
coactivator O O
. O O

Successive O O
5 O O
' O O
deletions O O
of O O
the O O
[ O O
- O O
326 O O
; O O
+ O O
20 O O
] O O
type B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sPLA2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
indicated O O
that O O
the O O
region O O
upstream O O
of O O
position O O
- O O
195 O O
inhibits O O
the O O
transcription O O
activity O O
sixfold O O
in O O
HepG2 O O
cells O O
but O O
not O O
in O O
HeLa O O
cells O O
. O O

Forty O B_NUMBER[MEASURE]
- O O
five O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
with O O
recent O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
onset O B_DISEASE/B_ORGANISM_FUNCTION
hyperthyroidism O I_DISEASE/I_ORGANISM_FUNCTION
( O O
< O B_PROTEIN[GENE]/B_LOCATION
12 O I_PROTEIN[GENE]/I_LOCATION
weeks O I_PROTEIN[GENE]/I_LOCATION
) O O
were O O
sex O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
menopause O B_PERSON/B_MEASURE
stratified O O
and O O
randomly O O
allocated O O
to O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
carbimazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Neotomizol O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
carbimazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O O
low O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
dose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
CT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
( O O
Calsynar O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
; O O
100 O B_MEASURE/B_LOCATION
IU O I_MEASURE/I_LOCATION
/ O O
day O B_TIME[MEASURE]
, O O
2 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
/ O O
week O B_TIME[MEASURE]
) O O
, O O
or O O
carbimazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O O
high O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CT O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Calsynar O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
; O O
100 O B_MEASURE
IU O I_MEASURE
/ O O
day O B_TIME[MEASURE]
, O O
14 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
/ O O
month O B_TIME[MEASURE]
) O O
. O O

The O O
cloning O O
of O O
CWH43 B B_BIO/B_GENE
showed O O
that O O
it O O
corresponds O O
to O O
YCR017c B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
encodes O O
a O O
protein O O
with O O
14 O O
- O O
16 O O
transmembrane O O
segments O O
containing O O
several O O
putative O O
phosphorylation O O
and O O
glycosylation O O
sites O O
. O O

However O O
, O O
strains O O
in O O
which O O
both O O
of O O
the O O
two O O
most O O
highly O O
related O O
genes O O
, O O
DdPIK1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
DdPIK2 B B_GENE/B_DISEASE
, O O
were O O
disrupted O O
showed O O
both O O
growth O O
and O O
developmental O O
defects O O
, O O
while O O
double O O
knockouts O O
of O O
DdPIK1 B B_GENE/B_BIO
and O O
DdPIK3 B B_GENE
and O O
DdPIK2 B B_GENE
and O O
DdPIK3 B B_GENE/B_LOCATION
appear O O
to O O
be O O
lethal O O
. O O

This O O
mechanism O O
seems O O
to O O
be O O
involved O O
in O O
VIP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
PRL B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
gene I B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
regulation O O
. O O

Competition O O
and O O
methylation O O
interference O O
assays O O
showed O O
that O O
the O O
binding O O
site O O
for O O
the O O
novel O O
factor O O
was O O
limited O O
to O O
nucleotides O O
in O O
the O O
3 O O
' O O
half O O
of O O
the O O
kappa B B_GENE/B_LOCATION
B I I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
. O O

These O O
properties O O
prompted O O
us O O
to O O
investigate O O
Ets B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
in O O
32 O O
human O O
astroglial O O
tumors O O
of O O
WHO O O
grades O O
I O O
- O O
IV O O
and O O
to O O
correlate O O
the O O
data O O
with O O
the O O
expression O O
pattern O O
of O O
VEGF B B_GENE
, O O
Flt B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
, O O
and O O
KDR B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Mean O O
concentration O O
of O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
maternal O O
plasma O O
across O O
all O O
sampling O O
times O O
was O O
higher O O
in O O
ethanol O O
treated O O
animals O O
. O O

The O O
strongly O O
DNA O O
binding O O
p50 B B_PROTEIN[GENE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subunit I B_PROTEIN[GENE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
only O O
very O O
weak O O
, O O
if O O
any O O
, O O
induction O O
of O O
gene O O
expression O O
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
obtained O O
demonstrate O O
the O O
applicability O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
countercurrent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
chromatography O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
the O O
determination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
ultratrace O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
elements O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

E1A B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O O
cHa B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ras I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transformed O O
rat O O
embryo O O
fibroblast O O
cells O O
are O O
characterized O O
by O O
high O O
and O O
constitutive O O
DNA O O
binding O O
activities O O
of O O
AP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dimers I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
significantly O O
altered O O
composition O O
. O O

Minor O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
changes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
within O O
the O O
transmembrane O B_PROTEIN[GENE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domains O B_PROTEIN[GENE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
TMs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
sometimes O O
produced O O
major O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
effects O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
more O O
drastic O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
TMs O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
ablated O O
surface O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
expression O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
entirely O O
. O O

Nuclear O O
localization O O
of O O
this O O
SNF2 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
like I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
putative O O
helicase B B_ENZYME[GENE]/B_LOCATION
is O O
dependent O O
on O O
a O O
nuclear O O
localization O O
sequence O O
located O O
in O O
the O O
NH2 O O
- O O
terminal O O
region O O
. O O

The O O
feasibility O O
of O O
creating O O
CR1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
Ig B B_GENE/B_LOCATION
chimeras O O
makes O O
possible O O
a O O
new O O
strategy O O
of O O
targeting O O
complement O O
inhibition O O
by O O
the O O
use O O
of O O
Ig B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fusion I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
partners I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
having O O
particular O O
antigenic O O
specificities O O
. O O

Morphological O B_LOCATION/B_DISEASE
- O O
functional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
status O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
of O O
the O O
edentulous O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
mandible O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
and O O
selection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
most O O
effective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
functional O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
impression O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
taking O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION

They O O
are O O
both O O
insensitive O O
to O O
inhibitors O O
of O O
serine B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
aspartyl I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
proteinases I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
but O O
are O O
sensitive O O
to O O
sulfhydryl O O
reagents O O
and O O
0 O O
. O O
5 O O
mM O O
ZnCl2 O O
. O O

The O O
tau O B_PROTEIN[GENE]/B_MEASURE
v O B_PROTEIN[GENE]/I_MEASURE
at O O
rest O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O O
4 O B_MEASURE
. O O
06 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
2 O B_NUMBER[MEASURE]
. O O
16 O B_MEASURE
s O I_MEASURE
and O O
decreased O O
to O O
2 O B_MEASURE
. O O
44 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
1 O B_MEASURE
. O O
07 O B_TIME[MEASURE]
s O I_TIME[MEASURE]
( O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
at O O
1 O B_TIME[MEASURE]/B_LOCATION
Hz O I_TIME[MEASURE]/I_LOCATION
and O O
to O O
1 O B_MEASURE
. O O
81 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
4 O B_MEASURE/B_LOCATION
s O I_MEASURE/I_LOCATION
at O O
5 O B_MEASURE/B_LOCATION
Hz O I_MEASURE/I_LOCATION
. O O

The O O
authors O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigate O O
in O O
a O O
group O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
211 O B_PERSON
children O I_PERSON
aged O O
2 O B_NUMBER[MEASURE]/B_LOCATION
- O O
6 O B_TIME[MEASURE]
years O I_TIME[MEASURE]
, O O
incl O O
. O O
in O O
particular O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O O
group O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
33 O B_NUMBER[MEASURE]
2 O I_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]
- O O
old O B_PERSON
ones O I_PERSON
, O O
in O O
1990 O B_MEASURE
and O O
checked O O
in O O
1991 O B_MEASURE
at O O
two O B_LOCATION/B_ENT
sites O I_LOCATION/I_ENT
in O O
Bratislava O B_LOCATION
- O O
- O O
a O O
town O B_LOCATION
with O O
a O O
varying O O
concentration O B_MEASURE/B_LOCATION
of O O
NOX O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
SO2 O B_HAZARDOUS_OR_POISONOUS_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
dustiness O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
dust O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fallout O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
- O O
their O O
influence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
incidence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
type O B_DISEASE
and O O
course O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
relapsing O O
respiratory O B_DISEASE
disease O I_DISEASE
. O O

However O O
, O O
no O O
statistical O B_MEASURE
difference O I_MEASURE
in O O
the O O
Ca O B_LOCATION
/ O O
P O B_MEASURE/B_LOCATION
ratio O I_MEASURE/I_LOCATION
, O O
carbon O B_MEASURE/B_LOCATION
concentration O I_MEASURE/I_LOCATION
and O O
surface O B_MEASURE
energy O I_MEASURE
were O O
observed O O
with O O
different O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
heat O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatments O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Using O O
in O O
vivo O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
genomic O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
dimethyl O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sulfate O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
KMnO4 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
footprinting O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
we O O
showed O O
that O O
the O O
promoter O B_ENZYME[GENE]/B_LOCATION
region O I_ENZYME[GENE]/I_LOCATION
is O O
differentially O O
protected O O
, O O
depending O O
upon O O
which O O
holoenzyme O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
is O O
bound O O
. O O

Here O O
we O O
show O O
that O O
inhibition O O
occurs O O
with O O
a O O
NS1 B B_GENE/B_BIO
- O O
Rev B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chimera O O
in O O
which O O
the O O
78 O O
amino O O
- O O
terminal O O
amino O O
acids O O
of O O
the O O
NS1A B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
comprising O O
its O O
entire O O
RNA O O
- O O
binding O O
domain O O
is O O
deleted O O
, O O
thereby O O
establishing O O
that O O
this O O
carboxyl O O
portion O O
of O O
the O O
NS1A B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
can O O
function O O
as O O
an O O
independent O O
effector O O
domain O O
. O O

Overall O O
, O O
it O O
appears O O
that O O
prenatal O B_PERSON/B_MEASURE
exposure O I_PERSON/I_MEASURE
to O O
androgen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
based O O
synthetic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
progestin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exerted O O
a O O
masculinizing O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
/ O O
or O O
defeminizing O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
influence O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
human O B_PERSON
behavioral O I_PERSON
development O I_PERSON
, O O
whereas O O
prenatal O B_PERSON/B_MEASURE
exposure O I_PERSON/I_MEASURE
to O O
natural O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
progesterone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
progesterone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
based O O
synthetic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
progestin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
a O O
feminizing O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
/ O O
or O O
demasculinizing O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
influence O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
particularly O O
among O O
female O B_PERSON
subjects O I_PERSON
. O O

The O O
testes O O
of O O
8 O O
specimens O O
of O O
Triturus O O
marmoratus O O
were O O
collected O O
during O O
each O O
month O O
of O O
1987 O O
and O O
processed O O
for O O
electron O O
microscopy O O
and O O
light O O
microscopy O O
demonstration O O
of O O
testosterone O O
( O O
T O O
) O O
following O O
the O O
ABC B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
avidin B B_LOCATION
- I I_LOCATION
biotin I I_LOCATION
peroxidase I I_LOCATION
complex I I_LOCATION
) O O
method O O
. O O

MTX O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
decreased O O
Ga O B_LOCATION/B_ORGANIZATION
- O O
67 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
uptake O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
liver O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
tumor O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
muscle O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

In O O
stage O B_ENT/B_MEASURE
I O O
, O O
histochemistry O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
copper O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
11 O B_NUMBER[MEASURE]
out O O
of O O
21 O B_MEASURE
cases O I_MEASURE
: O O
6 O B_MEASURE
cases O I_MEASURE
were O O
T O B_PROTEIN[GENE]/B_DISEASE
+ O I_PROTEIN[GENE]/I_DISEASE
; O O
1 O B_PERSON/B_PROTEIN[GENE]
case O B_PERSON/I_PROTEIN[GENE]
R O B_PERSON/I_PROTEIN[GENE]
+ O B_PERSON/I_PROTEIN[GENE]
and O O
2 O B_DISEASE
cases O I_DISEASE
O O I_DISEASE
+ O I_DISEASE
; O O
2 O B_NUMBER[MEASURE]/B_PERSON
cases O I_NUMBER[MEASURE]/I_PERSON
were O O
T O B_GENE
+ O I_GENE
, O O
R O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
O O B_LOCATION/B_MEASURE
+ O I_LOCATION/I_MEASURE
. O O

Encapsulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
sodium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorescein O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
dye O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
release O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Primer O O
extension O O
analysis O O
and O O
subcloning O O
of O O
the O O
virJ B B_SPECIES[BIO]/B_GENE
- O O
phoA B B_GENE/B_BACTERIUM[BIO]
fusion O O
indicate O O
that O O
the O O
acetosyringone O O
- O O
inducible O O
promoter O O
lies O O
directly O O
upstream O O
of O O
the O O
virJ B B_GENE/B_BIO
structural I I_GENE/I_BIO
gene I I_GENE/I_BIO
. O O

To O O
isolate O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
contain O O
zinc O B_GENE/B_MEASURE
finger O I_GENE/I_MEASURE
motifs O I_GENE/I_MEASURE
, O O
a O O
human O B_GENE
brain O I_GENE
cDNA O I_GENE
library O I_GENE
was O O
screened O O
with O O
an O O
oligonucleotide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
complementary O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
the O O
conserved O O
" O B_LOCATION/B_PERSON
linker O I_LOCATION/I_PERSON
" O I_LOCATION/I_PERSON
sequence O I_LOCATION/I_PERSON
between O O
adjacent O B_LOCATION/B_GENE
zinc O I_LOCATION/I_GENE
fingers O I_LOCATION/I_GENE
. O O

Percentage O B_MEASURE/B_LOCATION
incremental O B_MEASURE/I_LOCATION
18 O B_MEASURE/I_LOCATION
- O O
OHB O B_TIME[MEASURE]/B_LOCATION
responses O I_TIME[MEASURE]/I_LOCATION
to O O
metoclopramide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O O
greater O B_MEASURE
( O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
in O O
the O O
subjects O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
after O O
5 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
on O O
a O O
200 O B_MEASURE
- O O
meq O B_MEASURE
sodium O I_MEASURE
intake O I_MEASURE
than O O
after O O
5 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
on O O
a O O
10 O B_MEASURE
- O O
meq O B_MEASURE
sodium O I_MEASURE
intake O I_MEASURE
. O O

Using O O
in O O
vivo O O
screening O O
, O O
we O O
first O O
identified O O
a O O
gene O O
that O O
appeared O O
to O O
interfere O O
with O O
the O O
His O O
- O O
Asp O O
phosphorelay O O
between O O
the O O
HPt O O
domain O O
and O O
the O O
receiver O O
domain O O
of O O
OmpR B B_GENE/B_BACTERIUM[BIO]
, O O
provided O O
that O O
the O O
gene O O
product O O
was O O
expressed O O
through O O
a O O
multicopy O O
plasmid O O
. O O

The O O
non B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
major I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
histocompatibility I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
complex I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
MHC B B_GENE/B_LOCATION
) O O
- O O
encoded O O
CD1 B B_GENE/B_LOCATION
family I I_GENE/I_LOCATION
has O O
recently O O
emerged O O
as O O
a O O
new O O
antigen O O
- O O
presenting O O
system O O
that O O
is O O
distinct O O
from O O
either O O
MHC B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
class I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
I I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
or I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
class I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
II I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
molecules I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

The O O
predicted O O
amino O O
acid O O
sequence O O
of O O
Pst1p B B_GENE/B_MEASURE
possessed O O
high O O
sequence O O
homology O O
with O O
the O O
Sin3 B B_LOCATION/B_GENE
family I I_LOCATION/I_GENE
of O O
proteins O O
, O O
known O O
for O O
their O O
interaction O O
with O O
histone B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
deacetylases I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Quinethazone O B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O O
nitrogen O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
containing O O
heterocyclic O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
compounds O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Removal O O
of O O
ink4a B B_GENE
dramatically O O
reduces O O
the O O
lymphoid O O
and O O
neurological O O
defects O O
seen O O
in O O
bmi B B_GENE
- I I_GENE
1 I I_GENE
- O O
deficient O O
mice O O
, O O
indicating O O
that O O
ink4a B B_GENE
is O O
a O O
critical O O
in O O
vivo O O
target O O
for O O
Bmi B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
found O O
that O O
RXR B B_GENE/B_LOCATION
and O O
VDR B B_GENE/B_LOCATION
transactivated O O
selectively O O
from O O
VDRE O O
- O O
linked O O
templates O O
exclusively O O
as O O
a O O
heterodimeric O O
complex O O
, O O
since O O
neither O O
receptor O O
alone O O
enhanced O O
transcription O O
in O O
vitro O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
We O O
performed O O
nasal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
mupirocin O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
on O O
10 O B_PERSON/B_BIO
infants O I_PERSON/I_BIO
who O O
were O O
MRSA O B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
either O O
in O O
the O O
nose O B_BODY_PART_OR_ORGAN_COMPONENT
or O O
the O O
pharynx O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
evaluated O O
the O O
effect O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
mupirocin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
on O O
the O O
eradication O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
MRSA O B_BACTERIUM[BIO]/B_DISEASE
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Of O O
10 O B_MEASURE
, O O
709 O B_MEASURE
, O O
701 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemistry O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specimens O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
submitted O O
to O O
the O O
participating O O
laboratories O B_LOCATION/B_ORGANIZATION
during O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
collection O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
period O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
37 O B_MEASURE
, O O
208 O B_MEASURE
( O O
0 O B_MEASURE
. O O
35 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
were O O
rejected O O
prior O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
testing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O O

Early O O
complement O O
components O O
, O O
C1q B B_PROTEIN[GENE]
and O O
C4 B B_PROTEIN[GENE]
, O O
and O O
IgA B B_NUMBER[MEASURE]/B_PERSON
secretory O O
piece O O
were O O
absent O O
. O O

Administration O O
of O O
SnCl2 O O
and O O
ZnSO4 O O
( O O
group O O
V O O
) O O
resulted O O
in O O
a O O
decrease O O
of O O
ALA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
D I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
and O O
in O O
an O O
increase O O
in O O
CP O O
- O O
U O O
. O O

Using O O
a O O
dominant O O
negative O O
form O O
of O O
Sp3 B B_GENE
and O O
transcriptional O O
activation O O
assays O O
in O O
Schneider O O
SL O O
- O O
2 O O
insect O O
cells O O
, O O
it O O
was O O
confirmed O O
that O O
ERalpha B B_GENE/B_LOCATION
- O O
Sp3 B B_GENE/B_LOCATION
interactions O O
define O O
a O O
pathway O O
for O O
E2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mediated O O
inhibition O O
of O O
gene O O
expression O O
, O O
and O O
this O O
represents O O
a O O
new O O
mechanism O O
for O O
decreased O O
gene O O
expression O O
by O O
E2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

From O O
the O O
supposition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
that O O
there O O
exists O O
a O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
connection O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
certain O B_DISEASE
psychopathological O I_DISEASE
symptoms O I_DISEASE
, O O
and O O
/ O O
or O O
syndromes O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
e O B_PROTEIN[GENE]/B_DISEASE
. O O
g O B_DISEASE/B_MEASURE
. O O
, O O
hallucinations O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
regional O B_DISEASE
cerebral O I_DISEASE
dysfunction O I_DISEASE
, O O
patients O B_PERSON/B_BIO
suffering O O
from O O
auditory O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
tactile O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
hallucinations O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
were O O
investigated O O
, O O
in O O
a O O
symptom O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
oriented O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
using O O
the O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
technetium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
99m O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Hexamethyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
propylenamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Oxime O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
99m O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Tc O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
HMPAO O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
- O O
Single O B_LOCATION/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Photon O B_LOCATION/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Emission O B_LOCATION/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Computed O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Tomography O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SPECT O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
) O O
and O O
compared O O
with O O
normal O B_PERSON/B_BIO
controls O I_PERSON/I_BIO
. O O

The O O
lack O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
chronically O O
depressed O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
LCBF O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
after O O
1 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
day O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
) O O
may O O
be O O
related O O
to O O
the O O
quick O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
structural O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
repair O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
endothelium O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

In O O
this O O
study O O
, O O
to O O
elucidate O O
the O O
possible O O
mechanism O O
of O O
action O O
of O O
EM O O
, O O
we O O
examined O O
the O O
effect O O
of O O
the O O
drug O O
on O O
the O O
expression O O
of O O
neutrophil O O
adhesion O O
molecules O O
such O O
as O O
L B B_GENE
- I I_GENE
selectin I I_GENE
and O O
Mac B B_GENE
- I I_GENE
1 I I_GENE
. O O

Tissue O B_DISEASE/B_PROTEIN[GENE]
expansion O B_DISEASE/I_PROTEIN[GENE]
was O O
used O O
successfully O O
to O O
prepare O O
adequate O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
soft O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
tissue O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
for O O
closure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
following O O
a O O
difficult O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
clubfoot O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
correction O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
transcription O B_GENE
start O I_GENE
site O I_GENE
was O O
identified O O
by O O
primer O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extension O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
over O O
800 O B_MEASURE/B_LOCATION
bp O I_MEASURE/I_LOCATION
of O O
5 O B_MEASURE/B_GENE
' O I_MEASURE/I_GENE
flanking O O
DNA O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O O
sequenced O O
. O O

The O O
reporter O B_GENE
gene O I_GENE
with O O
two O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
copies O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
wild O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
type O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Repeat O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
+ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
3 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
transcribed O O
actively O O
in O O
sterol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
deprived O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
and O O
was O O
repressed O O
by O O
more O B_MEASURE
than O O
80 O B_NUMBER[MEASURE]/B_LOCATION
% O I_NUMBER[MEASURE]/I_LOCATION
when O O
sterols O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Changes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
tension O B_DISEASE/B_MEASURE
were O O
monitored O O
isometrically O O
on O O
spiral O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
strips O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
freshly O O
obtained O O
bovine O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
basilar O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
arteries O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
. O O

A O O
1 O B_MEASURE
. O O
5 O B_MEASURE
- O O
month O B_TIME[MEASURE]
- O O
old O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
boy O B_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
Sandifer O B_DISEASE
' O I_DISEASE
s O I_DISEASE
syndrome O I_DISEASE
is O O
described O O
. O O

However O O
, O O
PC12 O O
cell O O
clones O O
which O O
expressed O O
p33rsu B B_GENE
- I I_GENE
1 I I_GENE
at O O
an O O
increased O O
level O O
in O O
a O O
regulatable O O
fashion O O
in O O
response O O
to O O
dexamethasone O O
were O O
isolated O O
. O O

In O O
this O O
study O O
, O O
we O O
verified O O
that O O
PI B B_GENE
3 I I_GENE
- I I_GENE
kinase I I_GENE
associates O O
with O O
the O O
CD4 B B_GENE/B_DISEASE
: O O
p56lck B B_GENE/B_LOCATION
complex I I_GENE/I_LOCATION
as O O
judged O O
by O O
the O O
presence O O
of O O
PI O O
3 O O
- O O
phosphate O O
generated O O
from O O
anti B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
CD4 I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
immunoprecipitates O O
and O O
detected O O
by O O
high O O
- O O
pressure O O
liquid O O
chromatographic O O
analysis O O
. O O

The O O
clinical O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
picture O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
light O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
electron O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microscopic O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appearance O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
the O O
histochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
findings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
described O O
in O O
six O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cases O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
fibroma O B_DISEASE
of O O
tendon O B_BODY_PART_OR_ORGAN_COMPONENT
sheath O I_BODY_PART_OR_ORGAN_COMPONENT
. O O

However O O
, O O
their O O
stability O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
was O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O O
already O O
reported O O
for O O
the O O
ARS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
S O B_OTHER/B_LOCATION
. O O
occidentalis O B_LOCATION/B_BACTERIUM[BIO]
. O O

In O O
this O O
study O O
, O O
a O O
site O O
of O O
PDGF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
tyrosine O O
phosphorylation O O
was O O
mapped O O
to O O
Tyr O O
138 O O
in O O
the O O
SH3 B B_GENE
domain I I_GENE
; O O
Tyr O O
138 O O
is O O
exposed O O
on O O
the O O
SH3 B B_PROTEIN[GENE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
peptide I B_PROTEIN[GENE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
binding I B_PROTEIN[GENE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
surface I B_PROTEIN[GENE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
in O O
patients O B_PERSON/B_BIO
with O O
syndrome O B_DISEASE/B_GENE
X O I_DISEASE/I_GENE
, O O
myocardial O B_DISEASE
ischemia O I_DISEASE
frequently O O
develops O O
during O O
daily O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
life O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
; O O
silent O B_DISEASE
ischemia O I_DISEASE
is O O
an O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
component O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
this O O
syndrome O B_DISEASE
; O O
and O O
increased O O
oxygen O B_DISEASE
demand O I_DISEASE
in O O
the O O
presence O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
impaired O B_DISEASE
coronary O I_DISEASE
vasodilatory O I_DISEASE
capacity O I_DISEASE
is O O
not O O
the O O
only O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
cause O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
myocardial O B_DISEASE
ischemia O I_DISEASE
. O O

We O O
also O O
identified O O
a O O
DNA O O
fragment O O
, O O
10 O O
. O O
7 O O
kbp O O
upstream O O
from O O
the O O
first O O
coding O O
exon O O
of O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
aFGF I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
whose O O
sequence O O
is O O
conserved O O
in O O
both O O
the O O
primate O O
and O O
rodent O O
genomes O O
. O O

The O O
false O B_MEASURE/B_DISEASE
positive O I_MEASURE/I_DISEASE
fraction O I_MEASURE/I_DISEASE
( O O
FPF O B_PROTEIN[GENE]/B_LOCATION
) O O
decreased O O
significantly O O
if O O
the O O
count O B_MEASURE/B_DISEASE
density O I_MEASURE/I_DISEASE
increased O O
; O O
no O O
difference O B_MEASURE
in O O
FPF O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
found O O
for O O
a O O
change O B_MEASURE
in O O
lesion O B_MEASURE/B_PERSON
tracer O I_MEASURE/I_PERSON
concentration O I_MEASURE/I_PERSON
. O O

These O O
events O O
were O O
only O O
weakly O O
stimulated O O
by O O
the O O
activated B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
PDGF I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Human B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
plastin I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
genes I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

Buserelin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
offers O O
an O O
effective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alternative O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
carcinoma O B_DISEASE
of O O
the O O
prostate O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
, O O
apart O O
from O O
impotence O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
does O O
not O O
have O O
the O O
side O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
oestrogens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

C B B_GENE
/ I I_GENE
EBP I I_GENE
delta I I_GENE
( O O
NFIL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
was O O
not O O
detected O O
in O O
complexes O O
utilizing O O
extracts O O
from O O
the O O
IL B B_TIME[MEASURE]/B_SPECIES[BIO]
- I I_TIME[MEASURE]/I_SPECIES[BIO]
1 I I_TIME[MEASURE]/I_SPECIES[BIO]
nonproducing O O
T O O
cell O O
line O O
. O O

Reduced O O
risk O O
of O O
upper O O
gastrointestinal O O
ulcer O O
complications O O
with O O
celecoxib O O
, O O
a O O
novel O O
COX B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O O
. O O

Moreover O O
, O O
our O O
recent O O
findings O O
on O O
the O O
Tc52 B B_GENE
encoding I I_GENE
gene I I_GENE
underline O O
the O O
interest O O
of O O
genetic O O
manipulation O O
of O O
T O O
. O O
cruzi O O
, O O
not O O
only O O
making O O
it O O
possible O O
to O O
use O O
more O O
closely O O
an O O
in O O
vitro O O
approach O O
to O O
find O O
out O O
how O O
genes O O
function O O
, O O
but O O
also O O
to O O
obtain O O
' O O
attenuated O O
' O O
strains O O
that O O
could O O
be O O
used O O
in O O
the O O
development O O
of O O
vaccinal O O
strategies O O
. O O

Infra O B_COLOR/B_DISEASE
- O O
red O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
spectroscopy O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
tissues O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
the O O
700 O B_MEASURE
- O O
400 O B_MEASURE
cm O I_MEASURE
- O O
1 O B_LOCATION/B_MEASURE
region O B_LOCATION/I_MEASURE
. O O

YDL003w B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
also O O
termed O O
MCD1 B B_GENE/B_DISEASE
) O O
is O O
a O O
homologue O O
of O O
Schizosaccharomyces B B_GENE/B_BACTERIUM[BIO]
pombe I I_GENE/I_BACTERIUM[BIO]
rad21 I I_GENE/I_BACTERIUM[BIO]
, O O
an O O
essential O O
gene O O
implicated O O
in O O
DNA O O
double O O
- O O
strand O O
break O O
repair O O
and O O
nuclear O O
organization O O
in O O
fission O O
yeast O O
. O O

The O O
recent O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
concept O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
of O O
a O O
bioartificial O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
organ O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
an O O
attempt O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
avoid O O
such O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disadvantages O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
objectives O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
1 O B_NUMBER[MEASURE]
) O O
to O O
quantify O O
the O O
comparative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
structural O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
static O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
fatigue O B_DISEASE_ADJECTIVE[DISEASE]
properties O I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
pointe O B_PRODUCT[OBJECT]/B_DISEASE_ADJECTIVE[DISEASE]
shoe O I_PRODUCT[OBJECT]/I_DISEASE_ADJECTIVE[DISEASE]
toe O I_PRODUCT[OBJECT]/I_DISEASE_ADJECTIVE[DISEASE]
box O I_PRODUCT[OBJECT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
2 O B_SEQUENCE[MEASURE]
) O O
to O O
evaluate O O
the O O
preferred O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
shoe O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
characteristics O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
as O O
determined O O
by O O
a O O
survey O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
local O B_PERSON/B_SPORT[ENT]
dancers O I_PERSON/I_SPORT[ENT]
. O O

In O O
the O O
postoperative O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patient O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
tetralogy O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
Fallot O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
with O O
symptomatic O B_DISEASE
ventricular O I_DISEASE
arrhythmias O I_DISEASE
, O O
it O O
is O O
concluded O O
that O O
electrophysiologic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
study O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O O
useful O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
reproducing O O
clinical O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
episodes O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
VT O B_DISEASE
and O O
in O O
selecting O O
effective O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
antiarrhythmic O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
medication O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
; O O
a O O
small O B_MEASURE
number O I_MEASURE
of O O
patients O B_PERSON
with O O
ventricular O B_DISEASE
premature O I_DISEASE
complexes O I_DISEASE
alone O O
will O O
have O O
inducible O B_DISEASE_ADJECTIVE[DISEASE]
sustained O O
VT O B_DISEASE
during O O
electrophysiologic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
prognosis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
these O O
patients O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
improved O O
by O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
that O O
results O O
in O O
prevention O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
VT O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induction O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
; O O
and O O
in O O
patients O B_PERSON/B_LOCATION
with O O
right O B_DISEASE
ventricular O I_DISEASE
hypertension O I_DISEASE
, O O
VT O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
likely O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
be O O
refractory O B_DISEASE_ADJECTIVE[DISEASE]
to O O
drug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Indications O O
for O O
therapy O O
using O O
MAO B B_GENE
inhibitors O O

The O O
absorbance O B_MEASURE/B_LOCATION
of O O
the O O
eluent O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
monitored O O
at O O
254 O B_MEASURE/B_LOCATION
nm O I_MEASURE/I_LOCATION
. O O

Here O O
, O O
we O O
describe O O
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
detailed O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aimed O O
at O O
identifying O O
the O O
gene O B_GENE
or O O
genes O B_PROTEIN[GENE]/B_LOCATION
responsible O I_PROTEIN[GENE]/I_LOCATION
for O O
the O O
rapid O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
growth O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
- O O
arrest O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
obtained O O
with O O
human O B_GENE/B_LOCATION
chromosome O I_GENE/I_LOCATION
- O O
9 O B_NUMBER[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Footprints O O
on O O
the O O
HPV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
18 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
show O O
five O O
protected O O
regions O O
with O O
homologies O O
to O O
NF1 B B_GENE/B_DISEASE
, O O
AP1 B B_GENE/B_DISEASE
and O O
EFII B B_GENE/B_LOCATION
transcription I I_GENE/I_LOCATION
factor I I_GENE/I_LOCATION
binding I I_GENE/I_LOCATION
motifs I I_GENE/I_LOCATION
. O O

Insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding O O
to O O
the O O
alpha O O
- O O
subunit O O
of O O
its O O
receptor O O
stimulates O O
the O O
receptor B B_GENE
tyrosine I I_GENE
kinase I I_GENE
to O O
phosphorylate O O
the O O
beta O O
- O O
subunit O O
and O O
several O O
endogenous O O
protein O O
substrates O O
, O O
including O O
pp120 B B_GENE/B_LOCATION
/ O O
HA4 B B_MEASURE/B_GENE
, O O
a O O
liver O O
- O O
specific O O
plasma O O
membrane O O
glycoprotein O O
of O O
M O O
( O O
r O O
) O O
20 O O
, O O
000 O O
. O O

Motilin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
serum O O
levels O O
were O O
measured O O
for O O
one O O
hour O O
. O O

The O O
role O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
phosphorylation O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
receptor O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
desensitization O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
assessed O O
using O O
receptor O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutants O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expressed O O
in O O
COS O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_SPECIES[BIO]
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_SPECIES[BIO]
or O O
Chinese O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
hamster O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
lung O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
fibroblasts O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

First O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aid O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Improvement O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
some O O
pharmaceutical O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
properties O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
clofibrate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
cyclodextrin O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexation O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
detection O B_MEASURE
limits O I_MEASURE
obtained O O
by O O
using O O
the O O
mixed O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
eluent O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O O
0 O B_MEASURE/B_LOCATION
. O O
05 O B_MEASURE
- O O
0 O B_MEASURE
. O O
13 O B_MEASURE
mg O I_MEASURE
/ O O
L O B_OTHER/B_MEASURE
, O O
several O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
times O B_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
lower O B_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
than O O
those O O
obtained O O
by O O
using O O
single O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
KHPh O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
eluent O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Early O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
diagnosis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
early O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
surgical O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
division O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
biliary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tract O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
pancreatic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
duct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O O
recommended O O
for O O
children O B_PERSON
with O O
AAPBD O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
have O O
analyzed O O
herein O O
the O O
roles O O
that O O
four O O
different O O
PIAS B B_GENE/B_BIO
proteins I I_GENE/I_BIO
( O O
ARIP3 B B_GENE/B_DISEASE
/ O O
PIASx B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Miz1 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
PIASx B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
GBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
PIAS1 B B_GENE/B_DISEASE
, O O
and O O
PIAS3 B B_GENE
) O O
play O O
in O O
the O O
regulation O O
of O O
steroid B B_GENE
receptor I I_GENE
- O O
or O O
STAT B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
mediated O O
transcriptional O O
activation O O
. O O

Comparison O O
of O O
the O O
predicted O O
amino O O
acid O O
sequence O O
with O O
that O O
of O O
the O O
Drosophila B B_GENE/B_BIO
virilis I I_GENE/I_BIO
gene I I_GENE/I_BIO
shows O O
that O O
several O O
blocks O O
of O O
amino O O
acid O O
sequence O O
have O O
been O O
very O O
highly O O
conserved O O
. O O

Analyses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
focused O O
on O O
two O B_NUMBER[MEASURE]/B_PERSON
platyrrhine O I_NUMBER[MEASURE]/I_PERSON
( O O
New O B_PROTEIN[GENE]/B_SPECIES[BIO]
World O I_PROTEIN[GENE]/I_SPECIES[BIO]
monkey O I_PROTEIN[GENE]/I_SPECIES[BIO]
) O O
species O B_BIO/B_LOCATION
: O O
the O O
common O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
marmoset O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Callithrix O B_SPECIES[BIO]/B_LOCATION
jacchus O I_SPECIES[BIO]/I_LOCATION
) O O
and O O
the O O
brown O B_SPECIES[BIO]
capuchin O I_SPECIES[BIO]
monkey O I_SPECIES[BIO]
( O O
Cebus O B_SPECIES[BIO]
apella O I_SPECIES[BIO]
) O O
, O O
each O O
of O O
which O O
has O O
paired O O
, O O
non O B_DISEASE/B_NUMBER[MEASURE]
- O O
allelic O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
gamma O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
loci O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
( O O
5 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
gamma O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
gamma O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
3 O B_MEASURE
' O O
) O O
. O O

A O O
phase O O
II O O
clinical O O
trial O O
on O O
MDS O O
was O O
conducted O O
in O O
a O O
cooperative O O
study O O
with O O
orally O O
administrable O O
ara O O
- O O
C O O
analogue O O
, O O
PLAC O O
, O O
which O O
is O O
resistant O O
to O O
cytidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
deaminase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
had O O
shown O O
an O O
anti O O
- O O
tumor O O
activity O O
on O O
various O O
experimental O O
tumors O O
by O O
oral O O
route O O
. O O

A O O
decrease O O
was O O
also O O
found O O
of O O
the O O
levels O O
of O O
total O O
cholesterol O O
and O O
LDL B B_GENE
- I I_GENE
cholesterol I I_GENE
. O O

Previously O O
, O O
we O O
had O O
shown O O
that O O
interleukin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
8 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
IL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
8 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
is O O
constitutively O O
expressed O O
in O O
HTLV O O
- O O
I O O
- O O
infected O O
cells O O
and O O
in O O
cells O O
transiently O O
expressing O O
Tax B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Unlike O O
JNK B B_GENE/B_DISEASE
activation O O
, O O
ERK B B_GENE/B_LOCATION
activation O O
could O O
not O O
be O O
mapped O O
to O O
specific O O
reovirus O O
gene O O
segments O O
, O O
suggesting O O
that O O
ERK B B_GENE/B_LOCATION
activation O O
and O O
JNK B B_GENE/B_DISEASE
activation O O
are O O
triggered O O
by O O
different O O
events O O
during O O
virus O O
- O O
host O O
cell O O
interaction O O
. O O

Despite O O
the O O
same O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decreases O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
increases O B_DISEASE_ADJECTIVE[DISEASE]
in O O
MAP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
RSNA O B_DISEASE/B_PROTEIN[GENE]
was O O
attenuated O O
after O O
15 O B_MEASURE
and O O
30 O B_TIME[MEASURE]
min O I_TIME[MEASURE]
of O O
propofol O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
infusion O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O O
both O O
groups O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
compared O O
with O O
control O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
P O B_MEASURE/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

To O O
address O O
this O O
question O O
with O O
respect O O
to O O
skeletal O O
muscle O O
, O O
we O O
have O O
examined O O
the O O
effects O O
of O O
the O O
Providence O O
mutation O O
in O O
cultured O O
muscle O O
cells O O
, O O
after O O
adoptive O O
gene O O
transfer O O
to O O
adult O O
mice O O
, O O
and O O
in O O
two O O
infants O O
homozygous O O
for O O
spectrin B B_DISEASE/B_PERSON
Providence I I_DISEASE/I_PERSON
. O O

It O O
appears O O
to O O
be O O
useful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
untreated O B_PERSON
patients O I_PERSON
with O O
stage O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
I O O
or O O
II O B_TIME[MEASURE]/B_DISEASE
NHL O I_TIME[MEASURE]/I_DISEASE
but O O
no O O
definite O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
radiographic O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abnormalities O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
or O O
with O O
abnormal O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
radiographs O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
but O O
no O O
extrathoracic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
spread O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
in O O
treated O O
patients O B_PERSON/B_LOCATION
with O O
questionable O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
radiographs O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

B B B_PROTEIN[GENE]/B_DISEASE
and O O
C1 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
fusions I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
yeast B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
GAL4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcriptional I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activation I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domains I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
also O O
found O O
to O O
interact O O
when O O
synthesized O O
and O O
assayed O O
in O O
yeast O O
. O O

Because O O
of O O
the O O
data O O
, O O
we O O
suggest O O
that O O
LAC9 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
contacts O O
positions O O
6 O O
, O O
7 O O
, O O
and O O
8 O O
, O O
both O O
plus O O
and O O
minus O O
, O O
of O O
the O O
UAS O O
, O O
which O O
are O O
separated O O
by O O
more O O
than O O
one O O
turn O O
of O O
the O O
DNA O O
helix O O
, O O
and O O
twists O O
part O O
way O O
around O O
the O O
DNA O O
, O O
thus O O
protecting O O
the O O
broad O O
region O O
of O O
the O O
minor O O
groove O O
between O O
the O O
major O O
- O O
groove O O
contacts O O
. O O

On O O
the O O
optic O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
tentacle O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
- O O
gonadal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
axis O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
male O B_PERSON/B_NUMBER[MEASURE]
- O O
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
ovotestis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
the O O
slug O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
Ariolimax O B_SPECIES[BIO]/B_LOCATION
californicus O I_SPECIES[BIO]/I_LOCATION
) O O
. O O

Substitution O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cholinergic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O O
Alzheimer O B_DISEASE/B_GENE
type O I_DISEASE/I_GENE
dementia O I_DISEASE/I_GENE
( O O
AD O B_LOCATION/B_DISEASE
/ O O
SDAT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
has O O
hitherto O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
not O O
been O O
very O O
successful O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Here O O
we O O
show O O
that O O
the O O
nucleotide O O
in O O
the O O
middle O O
of O O
the O O
anticodon O O
( O O
i O O
. O O
e O O
. O O
, O O
psi O O
35 O O
) O O
also O O
contributes O O
to O O
the O O
suppressor O O
efficiency O O
displayed O O
by O O
cytoplasmic B B_GENE/B_DISEASE
tRNA I I_GENE/I_DISEASE
( I I_GENE/I_DISEASE
Tyr I I_GENE/I_DISEASE
) I I_GENE/I_DISEASE
. O O

The O O
root O B_MEASURE
- O O
mean O B_MEASURE/B_LOCATION
- O O
square O B_MEASURE/B_LOCATION
deviation O I_MEASURE/I_LOCATION
of O O
bond O B_MEASURE
lengths O I_MEASURE
from O O
the O O
ideal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
values O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O O
0 O B_MEASURE
. O O
02 O B_MEASURE
A O I_MEASURE
. O O

Jet O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
lag O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
melatonin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

In O O
addition O O
, O O
these O O
results O O
suggest O O
that O O
the O O
interactions O O
, O O
and O O
consequently O O
the O O
mechanisms O O
, O O
governing O O
transcriptional O O
activation O O
by O O
CTF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
are O O
distinct O O
from O O
those O O
mediating O O
DNA O O
replication O O
. O O

A O O
TAAATA O B_GENE/B_LOCATION
sequence O I_GENE/I_LOCATION
is O O
present O B_DISEASE_ADJECTIVE[DISEASE]
26 O I_DISEASE_ADJECTIVE[DISEASE]
nt O I_DISEASE_ADJECTIVE[DISEASE]
upstream O O
from O O
the O O
major O B_GENE/B_LOCATION
CAP O I_GENE/I_LOCATION
site O I_GENE/I_LOCATION
, O O
and O O
within O O
the O O
5 O B_LOCATION/B_GENE
' O I_LOCATION/I_GENE
- O O
flanking O O
region O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
there O O
are O O
several O B_DISEASE_ADJECTIVE[DISEASE]
putative O I_DISEASE_ADJECTIVE[DISEASE]
transcription O I_DISEASE_ADJECTIVE[DISEASE]
factor O I_DISEASE_ADJECTIVE[DISEASE]
binding O O
sites O B_LOCATION/B_ENT
. O O

It O O
was O O
found O O
that O O
both O O
versions O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
brief O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SL O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
& O O
amp O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
; O O
shy O B_PERSON/B_LOCATION
; O O
ASIA O B_LOCATION/B_PERSON
had O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
target O B_MEASURE
variables O I_MEASURE
as O O
the O O
full O B_LOCATION/B_PROTEIN[GENE]
scale O I_LOCATION/I_PROTEIN[GENE]
SL O I_LOCATION/I_PROTEIN[GENE]
& O O
amp O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
shy O B_PERSON/B_LOCATION
; O O
ASIA O B_LOCATION/B_MEASURE
. O O

The O O
reconstituted O O
enzyme O O
binds O O
DNA O O
with O O
an O O
affinity O O
that O O
is O O
approximately O O
20 O O
- O O
fold O O
lower O O
than O O
that O O
of O O
the O O
intact O O
topo70 B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
KP O B_MEASURE/B_PROTEIN[GENE]
- O O
45 O B_MEASURE
preparation O I_MEASURE
usually O O
resulted O O
in O O
partial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
tumor O B_DISEASE
growth O I_DISEASE
, O O
accompanied O O
by O O
improvement O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
state O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
these O O
patients O B_PERSON/B_DISEASE
, O O
as O O
well O O
as O O
reappearance O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
normal O B_DISEASE_ADJECTIVE[DISEASE]
values O I_DISEASE_ADJECTIVE[DISEASE]
of O O
blood O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
picture O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
biochemical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
parameters O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Istanbul O B_LOCATION
, O O
Turkey O B_LOCATION/B_PERSON
. O O

We O O
propose O O
that O O
optimal O O
transcription O O
of O O
the O O
gD B B_GENE
gene I I_GENE
depends O O
on O O
the O O
interaction O O
of O O
ICP4 B B_GENE
with O O
multiple O O
binding O O
sites O O
across O O
the O O
gene O O
and O O
cellular O O
factors O O
that O O
recognize O O
specific O O
sequence O O
elements O O
in O O
the O O
promoter O O
. O O

Recently O O
, O O
we O O
and O O
other O O
laboratories O O
have O O
identified O O
a O O
family O O
of O O
caveolin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
related I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
; O O
caveolin B B_LOCATION/B_PERSON
has O O
been O O
re O O
- O O
termed O O
caveolin B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
. O O

Role O O
of O O
zinc B B_GENE
- I I_GENE
finger I I_GENE
proteins I I_GENE
Sp1 I I_GENE
and O O
zif268 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
egr B B_MEASURE
- I I_MEASURE
1 I I_MEASURE
in O O
transcriptional O O
regulation O O
of O O
the O O
human B B_GENE
synaptobrevin I I_GENE
II I I_GENE
gene I I_GENE
. O O

The O O
human B B_GENE
Fc I I_GENE
gamma I I_GENE
receptor I I_GENE
gene I I_GENE
Fc B I_GENE
gamma I I_GENE
RIIA I I_GENE
is O O
expressed O O
in O O
platelets O O
, O O
neutrophils O O
, O O
monocytes O O
and O O
macrophages O O
. O O

This O O
dip O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
also O O
occurred O O
during O O
prednisone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
vitamin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
D O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
but O O
did O O
not O O
occur O O
when O O
calcium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
added O O
to O O
prednisone O O
, O O
although O O
the O O
baseline O B_MEASURE
value O I_MEASURE
was O O
lower O B_MEASURE
at O O
the O O
start O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O O
combined O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
prednisone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
calcium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

E O O
. O O
granulosus O O
infection O O
has O O
been O O
confirmed O O
in O O
25 O O
patients O O
( O O
20 O O
. O O
6 O O
% O O
) O O
, O O
in O O
16 O O
cases O O
by O O
finding O O
parasite O O
protoscoleces O O
or O O
hooks O O
and O O
in O O
nine O O
cases O O
by O O
detection O O
of O O
an O O
antigen O O
specific O O
for O O
E B B_SPECIES[BIO]/B_GENE
. I I_SPECIES[BIO]/I_GENE
granulosus I I_SPECIES[BIO]/I_GENE
, I I_SPECIES[BIO]/I_GENE
antigen I I_SPECIES[BIO]/I_GENE
5 I I_SPECIES[BIO]/I_GENE
( O O
Ag5 B B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

The O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
entopeduncular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
nucleus O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
EP O B_ENT/B_PROTEIN[GENE]
) O O
on O O
the O O
jaw O B_BODY_PART_OR_ORGAN_COMPONENT
- O O
opening O O
reflex O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
JOR O B_LOCATION/B_GENE
) O O
was O O
studied O O
in O O
the O O
cat O B_SPECIES[BIO]/B_DISEASE
anesthetized O O
with O O
sodium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pentobarbital O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
Premenstrual O B_DISEASE_ADJECTIVE[DISEASE]
Syndrome O I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
late O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
luteal O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
phase O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
disorder O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
of O O
DSM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
IIIR O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
criteria O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
was O O
identified O O
in O O
6 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
of O O
the O O
women O B_PERSON
. O O

First O O
, O O
mutations O O
in O O
the O O
IFNgamma B B_GENE/B_BIO
- I I_GENE/I_BIO
activated I I_GENE/I_BIO
sequence I I_GENE/I_BIO
( O O
GAS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
, O O
either O O
multimerized O O
or O O
in O O
the O O
context O O
of O O
the O O
1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
7 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kb I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IRF I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
failed O O
to O O
mediate O O
a O O
PRL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
response O O
, O O
showing O O
that O O
the O O
IRF B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
GAS B I_GENE/I_DISEASE
is O O
a O O
target O O
of O O
PRL B B_GENE
signaling O O
. O O

025 O B_MEASURE
) O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
PET O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
revealed O O
wide O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
variations O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
CBF O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
regions O B_LOCATION/B_DISEASE
during O O
isoflurane O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anaesthesia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
particularly O O
in O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O O
propofol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
anaesthesia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
while O O
rCMRO2 O B_MEASURE/B_PERSON
decreased O O
globally O O
in O O
a O O
dose O B_MEASURE/B_LOCATION
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
manner O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
during O O
both O O
isoflurane O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
propofol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anaesthesia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

This O O
selective O O
squelching O O
activity O O
suggests O O
that O O
GRIM B B_GENE/B_DISEASE
can O O
interact O O
with O O
an O O
essential O O
component O O
of O O
the O O
RNA B B_SPECIES[BIO]/B_GENE
polymerase I I_SPECIES[BIO]/I_GENE
II I I_SPECIES[BIO]/I_GENE
transcription O O
machinery O O
. O O

This O O
is O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
description O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
an O O
integron O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
located O O
on O O
a O O
composite O B_BACTERIUM[BIO]/B_GENE
transposon O B_BACTERIUM[BIO]/I_GENE
. O O

The O O
nine O B_PERSON/B_BIO
subjects O I_PERSON/I_BIO
were O O
treated O O
in O O
random O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
sequence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
with O O
cimetidine O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
8 O B_MEASURE
- O O
1 O B_MEASURE
- O O
0 O B_MEASURE
g O I_MEASURE
on O O
one O B_NUMBER[MEASURE]/B_LOCATION
day O I_NUMBER[MEASURE]/I_LOCATION
and O O
placebo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
capsules O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
other O B_SEQUENCE[MEASURE]/B_LOCATION
. O O

The O O
protein O B_ENZYME[GENE]/B_BACTERIUM[BIO]
was O O
overexpressed O O
in O O
Escherichia O B_BIO
coli O I_BIO
and O O
purified O O
to O O
homogeneity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Identification O O
and O O
characterization O O
of O O
a O O
yeast O O
gene O O
encoding O O
the O O
U2 B B_ENZYME[GENE]
small I I_ENZYME[GENE]
nuclear I I_ENZYME[GENE]
ribonucleoprotein I I_ENZYME[GENE]
particle I I_ENZYME[GENE]
B I I_ENZYME[GENE]
" I I_ENZYME[GENE]
protein I I_ENZYME[GENE]
. O O

A O O
360 O O
- O O
bp O O
DNA O O
fragment O O
located O O
over O O
500 O O
bp O O
upstream O O
from O O
the O O
cfl B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcriptional O O
start O O
site O O
was O O
used O O
in O O
DNase B B_GENE
I I I_GENE
protection O O
assays O O
to O O
define O O
the O O
specific O O
bases O O
bound O O
by O O
CorR B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Taking O O
into O O
account O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
certain O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
well O O
defined O O
conditions O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
frequent O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
feedings O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
no O O
supplementary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
feeding O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
before O O
4 O B_NUMBER[MEASURE]
- O O
6 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
, O O
method O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
only O O
to O O
be O O
used O O
in O O
the O O
absence O B_DISEASE/B_TIME[MEASURE]
of O O
menstruation O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
, O O
LAM O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
relied O O
on O O
for O O
contraceptive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
protection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O O
up O O
to O O
1 O B_TIME[MEASURE]
year O I_TIME[MEASURE]
post O I_TIME[MEASURE]
partum O I_TIME[MEASURE]
. O O

Nramp2 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contains O O
a O O
classical O O
iron O O
responsive O O
element O O
in O O
the O O
3 O O
' O O
untranslated O O
region O O
that O O
confers O O
iron O O
dependent O O
mRNA O O
stabilization O O
. O O

Likewise O O
, O O
epidural O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
morphine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
does O O
not O O
modify O O
the O O
intraoperative O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
metabolic O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
hormonal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
responses O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

CONCLUSIONS O O
- O O
- O O
Postlumbar O O
puncture O O
headache O O
may O O
be O O
mediated O O
by O O
the O O
release O O
of O O
substance B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
P I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
triggered O O
by O O
lumbar O O
puncture O O
, O O
in O O
patients O O
predisposed O O
to O O
headache O O
by O O
a O O
hypersensitivity O O
to O O
substance B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
P I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Continuous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
arterial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
blood O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
sampling O I_TIME[MEASURE]
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
based O O
on O O
the O O
microsphere O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
model O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
used O O
as O O
a O O
quantitative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
rCBF O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measurement O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

A O O
mutated B B_DISEASE/B_PROTEIN[GENE]
ABF1 I B_DISEASE/I_PROTEIN[GENE]
site I B_DISEASE/I_PROTEIN[GENE]
that O O
displays O O
a O O
very O O
low O O
affinity O O
for O O
ABF1 B B_GENE
does O O
not O O
functionally O O
replace O O
the O O
ILV1 B B_GENE/B_LOCATION
REB1 B I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
. O O

Given O O
a O O
rapid O O
induction O O
of O O
Egr B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
on O O
stimulation O O
with O O
growth O O
factors O O
or O O
injury O O
, O O
these O O
findings O O
may O O
represent O O
at O O
least O O
one O O
of O O
the O O
molecular O O
mechanisms O O
underlying O O
phenotypic O O
modulation O O
of O O
smooth O O
muscles O O
after O O
vascular O O
injury O O
. O O

A O O
nationwide O O
survey O O
uncovered O O
a O O
tenfold O O
variation O O
between O O
counties O O
in O O
the O O
prescribing O O
of O O
IFNB B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
this O O
first O B_SEQUENCE[MEASURE]
- O O
person O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
account O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
the O O
author O B_PERSON/B_ENT
chronicles O O
her O O
experience O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
being O O
mentally O O
ill O B_DISEASE_ADJECTIVE[DISEASE]
and O O
homeless O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
in O O
New O B_LOCATION
York O I_LOCATION
and O O
New O B_LOCATION
Jersey O I_LOCATION
in O O
the O O
early O B_TIME[MEASURE]/B_LOCATION
1980s O I_TIME[MEASURE]/I_LOCATION
. O O

Rectal O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
temperatures O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
the O O
walk O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
were O O
greater O B_MEASURE
( O O
P O B_MEASURE
< O I_MEASURE
. O O
001 O B_MEASURE
) O O
in O O
native O B_SPECIES[BIO]/B_LOCATION
Simmental O I_SPECIES[BIO]/I_LOCATION
( O O
39 O B_MEASURE
. O O
87 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
. O O
05 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
) O O
than O O
in O O
Bos O B_LOCATION
indicus O I_LOCATION
( O O
39 O B_MEASURE
. O O
46 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
. O O
05 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
) O O
. O O

Dominant O O
- O O
negative O O
mutations O O
in O O
the O O
G B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
protein I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
coupled I I_GENE/I_LOCATION
alpha I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
factor I I_GENE/I_LOCATION
receptor I I_GENE/I_LOCATION
map O O
to O O
the O O
extracellular O O
ends O O
of O O
the O O
transmembrane O O
segments O O
. O O

Such O B_PERSON
simple O I_PERSON
injuries O I_PERSON
may O O
however O O
be O O
accompanied O O
by O O
far O O
reaching O O
consequences O B_DISEASE
. O O

This O O
is O O
the O O
first O O
report O O
which O O
clearly O O
proved O O
CEA B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthesis O O
in O O
the O O
cells O O
of O O
HCC O O
. O O

By O O
screening O O
a O O
human O O
testis O O
cDNA O O
library O O
with O O
a O O
probe O O
containing O O
the O O
mouse B B_GENE
PEA3 I I_GENE
ETS B I_GENE
domain O O
, O O
we O O
isolated O O
a O O
2 O O
. O O
2 O O
kb O O
clone O O
containing O O
a O O
510 O O
AA O O
open O O
reading O O
frame O O
. O O

AU O O
- O O
rich O O
elements O O
in O O
the O O
3 O O
' O O
- O O
untranslated O O
region O O
of O O
a O O
new O O
mucin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
family O O
of O O
Trypanosoma O O
cruzi O O
confers O O
mRNA O O
instability O O
and O O
modulates O O
translation O O
efficiency O O
. O O

These O O
findings O O
suggest O O
that O O
IL B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
stimulated O O
, O O
Rho B B_GENE
- O O
dependent O O
cytoskeletal O O
reorganization O O
may O O
cluster O O
signaling O O
molecules O O
in O O
specific O O
architectures O O
that O O
are O O
necessary O O
for O O
persistent O O
cell O O
activation O O
in O O
chronic O O
inflammatory O O
disease O O
. O O

Changes O O
in O O
testicular O O
testosterone O O
and O O
acid O O
and O O
alkaline B B_ENZYME[GENE]
phosphatase I I_ENZYME[GENE]
activity O O
in O O
testis O O
and O O
accessory O O
sex O O
organs O O
after O O
induction O O
of O O
varicocele O O
in O O
Noble O O
rats O O
. O O

M O B_PROTEIN[GENE]/B_LOCATION
. O O
, O O
Apps O B_PERSON/B_ORGANIZATION
, O O
D O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
data O O
suggest O O
that O O
weight O O
gain O O
or O O
increased O O
caloric O O
intake O O
, O O
in O O
contrast O O
to O O
its O O
large O O
effect O O
on O O
peripheral O O
thyroid O O
function O O
, O O
has O O
relatively O O
little O O
effect O O
on O O
CNS B B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TRH I I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O O
. O O

Alfalfa O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
phosphorus O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
release O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
kinetics O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
bacterial O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
phosphorus O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
contamination O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

The O O
quantitative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
1 O B_MEASURE
- O O
alpha O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
acetylmethadol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
its O O
principal O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolites O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
biological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
specimens O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
by O O
gas O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chromatography O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
chemical O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ionization O B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
multiple O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ion O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
monitoring O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mass O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
spectrometry O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
provides O O
tentative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggestions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O O
( O O
a O O
) O O
possible O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
additional O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
risk O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
cigarette O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
smoking O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
b O B_PROTEIN[GENE]/B_DISEASE
) O O
avoidance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
venography O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
c O B_OTHER/B_PROTEIN[GENE]
) O O
avoidance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
varicose O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
vein O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
surgery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
prolonged O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
labour O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pains O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
Th O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
1165a O B_BIO/B_PERSON
and O O
Isoptin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O O
the O O
heart O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
circulation O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
, O O
organ O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
metabolic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
parameters O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
mother O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT

Skytthe O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
K O B_OTHER/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
the O O
Saccharomyces B B_BIO/B_GENE
cerevisiae I I_BIO/I_GENE
actin I I_BIO/I_GENE
intron I I_BIO/I_GENE
a O O
silent O O
branch O O
point O O
- O O
like O O
sequence O O
( O O
UACUAAG O O
) O O
is O O
located O O
7 O O
nt O O
upstream O O
of O O
the O O
canonical O O
sequence O O
. O O

The O O
requirement O O
for O O
an O O
essential O O
interaction O O
between O O
NPH B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
H4L B B_PROTEIN[GENE]/B_LOCATION
provides O O
an O O
explanation O O
for O O
the O O
observed O O
restriction O O
of O O
transcription O O
termination O O
to O O
early O O
viral O O
genes O O
. O O

After O O
birth O O
, O O
there O O
was O O
a O O
significantly O O
higher O O
increase O O
of O O
IgA B B_GENE
and O O
IgM B B_GENE/B_LOCATION
anti I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
M I I_GENE/I_LOCATION
. I I_GENE/I_LOCATION
leprae I I_GENE/I_LOCATION
antibody I I_GENE/I_LOCATION
activity O O
in O O
sera O O
taken O O
3 O O
- O O
6 O O
months O O
after O O
birth O O
from O O
babies O O
of O O
Group O O
1 O O
compared O O
to O O
Group O O
2 O O
, O O
but O O
the O O
IgA B B_GENE
and O O
IgM B B_GENE
activity O O
in O O
sera O O
taken O O
after O O
6 O O
months O O
of O O
age O O
showed O O
the O O
same O O
increase O O
in O O
the O O
two O O
groups O O
. O O

The O O
relation O O
between O O
the O O
changes O O
of O O
bone O O
density O O
and O O
the O O
level O O
of O O
blood O O
calcium O O
, O O
blood O O
phosphorus O O
and O O
alkaline B B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphatase I B_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
AKP B B_DISEASE/B_GENE
) O O
as O O
well O O
as O O
the O O
metabolism O O
of O O
vitamin O O
D O O
was O O
studied O O
. O O

These O O
results O O
demonstrate O O
the O O
extensive O O
homology O O
in O O
sequence O O
among O O
light O O
chains O O
of O O
IgM B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
autoantibodies I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
indicate O O
that O O
a O O
particular O O
V B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
kappa I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
germ I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
line I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
kappa B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
IIIb I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
is O O
expressed O O
as O O
a O O
phylogenetic O O
response O O
to O O
certain O O
self O O
antigens O O
or O O
as O O
part O O
of O O
a O O
selection O O
process O O
by O O
which O O
these O O
autoimmune O O
responses O O
are O O
regulated O O
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
the O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
confirmed O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
showed O O
that O O
monkeys O B_BIO/B_PERSON
with O O
total O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
bilateral O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
striatectomies O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
could O O
require O O
the O O
ability O B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
execute O O
accurate O B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
visually O O
guided O O
reaches O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
. O O

Comparison O O
of O O
the O O
sequences O O
of O O
the O O
alpha B B_GENE/B_BIO
- I I_GENE/I_BIO
like I I_GENE/I_BIO
DNA I I_GENE/I_BIO
polymerases I I_GENE/I_BIO
including O O
E B B_GENE/B_PERSON
. I I_GENE/I_PERSON
coli I I_GENE/I_PERSON
DNA I I_GENE/I_PERSON
polymerase I I_GENE/I_PERSON
II I I_GENE/I_PERSON
showed O O
that O O
there O O
were O O
nine O O
highly O O
conserved O O
regions O O
, O O
and O O
we O O
constructed O O
an O O
unrooted O O
phylogenetic O O
tree O O
of O O
the O O
DNA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
polymerases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
based O O
on O O
the O O
differences O O
in O O
these O O
conserved O O
regions O O
. O O

Before O O
and O O
6 O O
and O O
12 O O
months O O
after O O
H O O
. O O
pylori O O
eradication O O
the O O
patients O O
were O O
evaluated O O
for O O
fasting O O
gastrinemia O O
and O O
pepsinogen B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
basal O O
and O O
peak O O
acid O O
output O O
, O O
and O O
detailed O O
histological O O
assessment O O
including O O
the O O
ECL O O
cell O O
proliferative O O
patterns O O
. O O

Four O B_PERSON
experiments O I_PERSON
examined O O
the O O
role O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
cholinergic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
projections O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
the O O
septum O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
and O O
vertical O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
limb O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
nucleus O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
diagonal O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
band O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
Broca O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
VDB O B_MEASURE/B_PROTEIN[GENE]
) O O
in O O
acquisition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
performance O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
a O O
conditional O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
visual O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
discrimination O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

trans O O
- O O
activation O O
of O O
the O O
HIV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
LTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
the O O
HIV B B_GENE
- I I_GENE
1 I I_GENE
Tat I I_GENE
and O O
HTLV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Tax I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
mediated O O
by O O
different O O
cis O O
- O O
acting O O
sequences O O
. O O

Defective O O
concanavalin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
A I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
suppression O O
in O O
bancroftian O O
filariasis O O
. O O

For O O
more O O
detailed O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mapping O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
constructed O O
mouse O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
A9 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
cells O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
containing O O
STFs O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
derived O O
from O O
human O B_GENE/B_BIO
chromosome O I_GENE/I_BIO
2 O I_GENE/I_BIO
tagged O O
with O O
pSTneo O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
different O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
regions O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
in O O
2q31 O B_MEASURE/B_BIO
- O O
qter O B_MEASURE/B_PERSON
. O O

Left O O
ventricular O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
insufficiency O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
requires O O
two O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
SP O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
/ O O
patient O B_PERSON/B_TIME[MEASURE]
, O O
with O O
good O B_DISEASE_ADJECTIVE[DISEASE]
results O I_DISEASE_ADJECTIVE[DISEASE]
in O O
approximately O O
81 O B_MEASURE
p O I_MEASURE
. O O
cent O B_MEASURE/B_LOCATION
. O O

However O O
, O O
there O O
are O O
some O O
cows O B_BIO/B_PERSON
that O O
fail O O
to O O
produce O O
adequate O B_MEASURE/B_LOCATION
1 O I_MEASURE/I_LOCATION
, O O
25 O B_NUMBER[MEASURE]
- O O
dihydroxyvitamin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
D O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
at O O
the O O
onset O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
of O O
lactation O B_ORGANISM_FUNCTION/B_DISEASE
. O O

Acidic O O
carboxyl O O
- O O
terminal O O
domain O O
of O O
gene B B_GENE
2 I I_GENE
. I I_GENE
5 I I_GENE
protein I I_GENE
of I I_GENE
bacteriophage I I_GENE
T7 I I_GENE
is O O
essential O O
for O O
protein O O
- O O
protein O O
interactions O O
. O O

This O O
result O O
, O O
together O O
with O O
the O O
fact O O
that O O
unrearranged B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
V I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
kappa I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
genes I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O O
transcriptionally O O
silent O O
, O O
suggests O O
that O O
structural O O
features O O
of O O
both O O
the O O
V B B_PROTEIN[GENE]
kappa I I_PROTEIN[GENE]
and O O
C B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
loci I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contribute O O
to O O
the O O
overall O O
transcriptional O O
efficiency O O
of O O
a O O
rearranged B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
V I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
total O B_MEASURE
of O O
10 O B_MEASURE
, O O
763 O B_MEASURE/B_PERSON
men O I_MEASURE/I_PERSON
and O O
3 O B_NUMBER[MEASURE]
, O O
118 O B_MEASURE/B_PERSON
women O I_MEASURE/I_PERSON
has O O
been O O
studied O O
, O O
of O O
whom O O
97 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
and O O
89 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
respectively O O
, O O
have O O
been O O
traced O O
and O O
36 O B_TIME[MEASURE]/B_PERSON
% O I_TIME[MEASURE]/I_PERSON
and O O
16 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
have O O
died O O
. O O

NSD1 B B_GENE/B_SPECIES[BIO]
contains O O
a O O
SET B B_MEASURE/B_LOCATION
domain I B_MEASURE/I_LOCATION
and O O
multiple O O
PHD O O
fingers O O
. O O

EMG O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
based O O
measures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
fatigue O B_DISEASE
during O O
a O O
repetitive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
squat O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
exercise O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

We O O
have O O
introduced O O
the O O
same O O
change O O
in O O
a O O
yeast B B_GENE
tRNA I I_GENE
( I I_GENE
Trp I I_GENE
) I I_GENE
gene I I_GENE
and O O
demonstrated O O
that O O
the O O
tRNA O O
acts O O
as O O
an O O
efficient O O
amber O O
suppressor O O
in O O
vivo O O
. O O

This O O
evaluation O O
examines O O
several O O
analytical O O
and O O
cost O O
parameters O O
for O O
five O O
representative O O
assays O O
: O O
IgG B B_GENE/B_DISEASE
, O O
IgA B B_GENE
, O O
IgM B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
phenytoin O O
, O O
and O O
phenobarbital O O
. O O

These O O
results O O
suggest O O
that O O
UvrA B B_GENE/B_BACTERIUM[BIO]
is O O
involved O O
in O O
triplet O O
repeat O O
instability O O
in O O
cells O O
. O O

Among O O
women O O
, O O
plasma B B_LOCATION/B_DISEASE
factor I I_LOCATION/I_DISEASE
VII I I_LOCATION/I_DISEASE
: O O
Ag O O
was O O
inversely O O
associated O O
with O O
income O O
. O O

A O O
novel O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PKC B B_GENE
) O O
- O O
interacting O O
protein O O
was O O
identified O O
by O O
the O O
yeast O O
two O O
- O O
hybrid O O
screening O O
using O O
the O O
regulatory O O
domain O O
of O O
PKC B B_GENE
beta I I_GENE
I I I_GENE
as O O
a O O
bait O O
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
The O O
number O B_MEASURE/B_PERSON
of O O
Spanish O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
articles O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
published O O
in O O
Anesthesiology O B_ORGANIZATION/B_PERSON
, O O
BJA O B_DISEASE/B_EDU[ORGANIZATION]
, O O
and O O
Anesth O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
Analg O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
is O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
although O O
the O O
comparison O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
our O O
productivity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O O
that O O
of O O
other O B_PERSON/B_LOCATION
EU O I_PERSON/I_LOCATION
countries O I_PERSON/I_LOCATION
in O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
GNPpc O B_LOCATION/B_MEASURE
places O O
us O O
in O O
an O O
intermediate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
position O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

One O O
of O O
the O O
repeating O O
domains O O
( O O
Yheb1 B B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
consisting O O
of O O
67 O O
amino O O
acids O O
, O O
was O O
cloned O O
from O O
the O O
E O O
. O O
coli O O
chromosome O O
and O O
purified O O
by O O
metal O O
chelating O O
chromatography O O
. O O

Phosphorylation O O
at O O
Ser O O
( O O
670 O O
) O O
impairs O O
the O O
ability O O
of O O
GRK2 B B_GENE
to O O
phosphorylate O O
both O O
soluble O O
and O O
membrane O O
- O O
incorporated O O
receptor O O
substrates O O
and O O
dramatically O O
attenuates O O
Gbetagamma B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mediated O O
activation O O
of O O
this O O
enzyme O O
. O O

METHODS O O
: O O
CD4 B B_GENE/B_MEASURE
cell O O
counts O O
and O O
interview O O
data O O
were O O
recorded O O
in O O
a O O
survey O O
of O O
136 O O
adult O O
patients O O
attending O O
a O O
community O O
hospital O O
- O O
based O O
HIV O O
outpatient O O
clinic O O
. O O

Biol O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Inhibition O O
of O O
endogenous B B_GENE
Cdk2 I I_GENE
by O O
dominant B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
negative I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Cdk2 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
attenuated O O
phosphorylation O O
of O O
Thr447 O O
, O O
Thr490 O O
and O O
Thr497 O O
, O O
but O O
had O O
no O O
effect O O
upon O O
Ser581 O O
modification O O
. O O

A O O
rabbit O O
antiserum O O
raised O O
against O O
a O O
unique O O
( O O
V3 O O
domain O O
) O O
bacterially O O
expressed O O
PKC B B_GENE
theta I I_GENE
fragment I I_GENE
immunoprecipitated O O
specifically O O
an O O
82 O O
- O O
kDa O O
protein O O
from O O
Jurkat O O
cell O O
lysates O O
. O O

Histological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examination O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O O
variable O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
loss O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
motor O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
neurons O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
limited O O
to O O
the O O
injection O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
is O O
the O O
most O O
northern O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
, O O
at O O
the O O
same O B_MEASURE/B_LOCATION
time O I_MEASURE/I_LOCATION
largest O I_MEASURE/I_LOCATION
, O O
Q O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
fever O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
epidemic O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
recorded O O
in O O
Germany O B_LOCATION
over O O
the O O
last O B_TIME[MEASURE]/B_ENT
28 O I_TIME[MEASURE]/I_ENT
years O I_TIME[MEASURE]/I_ENT
. O O

Symptoms O O
, O O
skin O O
- O O
prick O O
tests O O
( O O
SPT O O
) O O
with O O
environmental O O
allergens O O
and O O
Pt O O
salt O O
, O O
total O O
serum B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IgE I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
lung O O
function O O
, O O
and O O
bronchial O O
hyperresponsiveness O O
were O O
assessed O O
by O O
standard O O
procedures O O
. O O

Binding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sites O B_LOCATION/B_ENT
were O O
mapped O O
for O O
each O O
factor O B_PROTEIN[GENE]
. O O

Complementary O O
DNA O O
libraries O O
from O O
liver O O
and O O
ovary O O
of O O
an O O
immature O O
female O O
channel O O
catfish O O
were O O
screened O O
with O O
a O O
homologous B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ERalpha I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cDNA I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
probe O O
. O O

The O O
binding O O
of O O
PTB B B_GENE/B_DISEASE
was O O
antagonistic O O
to O O
the O O
binding O O
of O O
U2AF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
enhancer O O
- O O
located O O
pyrimidine O O
tract O O
. O O

VLA B B_GENE
- I I_GENE
4 I I_GENE
integrin I I_GENE
cross O O
- O O
linking O O
on O O
human O O
monocytic O O
THP O O
- O O
1 O O
cells O O
induces O O
tissue O O
factor O O
expression O O
by O O
a O O
mechanism O O
involving O O
mitogen B B_GENE
- I I_GENE
activated I I_GENE
protein I I_GENE
kinase I I_GENE
. O O

However O O
, O O
studies O O
using O O
the O O
A20 B B_GENE
promoter I I_GENE
demonstrated O O
that O O
LMP1 B B_GENE
transcriptionally O O
activates O O
the O O
A20 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
through O O
cis O O
- O O
acting O O
kappa B B_GENE/B_LOCATION
B I I_GENE/I_LOCATION
sites I I_GENE/I_LOCATION
. O O

Southern O O
blot O O
analysis O O
revealed O O
that O O
CCaMK B B_GENE/B_PERSON
is O O
encoded O O
by O O
a O O
single O O
gene O O
. O O

Surgical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methods O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
rhinophyma O B_DISEASE
. O O

Phenazopyridine O O
- O O
induced O O
hemolytic O O
anemia O O
in O O
a O O
patient O O
with O O
G6PD B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deficiency O O
. O O

Finally O O
, O O
we O O
demonstrated O O
that O O
although O O
the O O
DNA O O
- O O
binding O O
domain O O
of O O
c B B_GENE
- I I_GENE
myb I I_GENE
is O O
required O O
for O O
both O O
the O O
differentiation O O
block O O
and O O
the O O
shift O O
in O O
cell O O
cycle O O
after O O
PMA O O
treatment O O
, O O
phosphorylation O O
by O O
casein B B_GENE
kinase I I_GENE
II I I_GENE
and O O
mitogen B B_GENE
- I I_GENE
activated I I_GENE
protein I I_GENE
kinase I I_GENE
at O O
positions O O
11 O O
and O O
12 O O
or O O
532 O O
of O O
c B B_GENE
- I I_GENE
myb I I_GENE
, O O
respectively O O
, O O
are O O
not O O
. O O

The O O
activation O O
of O O
NF B B_GENE
- I I_GENE
kappaB I I_GENE
- O O
dependent O O
reporter O O
gene O O
transcription O O
by O O
E1A B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
potently O O
suppressed O O
upon O O
coexpression O O
of O O
the O O
E1B B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
19 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kDa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
19K I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Our O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
that O O
direct O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
enantiomeric O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
separation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
mephenytoin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
obtained O O
by O O
using O O
a O O
chiral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
capillary O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
column O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
the O O
retention O B_MEASURE/B_LOCATION
times O I_MEASURE/I_LOCATION
for O O
S O B_PROTEIN[GENE]/B_DISEASE
- O O
and O O
R O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
mephenytoin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O O
25 O B_MEASURE
. O O
5 O B_MEASURE
and O O
26 O B_MEASURE
. O O
2 O B_MEASURE/B_PERSON
min O I_MEASURE/I_PERSON
respectively O O
, O O
with O O
a O O
detection O B_MEASURE
limit O I_MEASURE
less O I_MEASURE
than O O
50 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
ml O B_MEASURE/B_PERSON
of O O
mephenytoin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
myeloid B B_GENE
zinc I I_GENE
finger I I_GENE
gene I I_GENE
1 I I_GENE
( O O
MZF1 B B_GENE/B_DISEASE
) O O
encodes O O
a O O
C B B_GENE/B_MEASURE
( I I_GENE/I_MEASURE
2 I I_GENE/I_MEASURE
) I I_GENE/I_MEASURE
H I I_GENE/I_MEASURE
( I I_GENE/I_MEASURE
2 I I_GENE/I_MEASURE
) I I_GENE/I_MEASURE
zinc I I_GENE/I_MEASURE
finger I I_GENE/I_MEASURE
transcription I I_GENE/I_MEASURE
factor I I_GENE/I_MEASURE
that O O
regulates O O
granulopoiesis O O
and O O
may O O
have O O
a O O
regulatory O O
role O O
in O O
cellular O O
proliferation O O
and O O
oncogenesis O O
. O O

Snails O B_BIO/B_PERSON
infected O O
with O O
three O B_NUMBER[MEASURE]
or O O
five O B_NUMBER[MEASURE]
miracidia O I_NUMBER[MEASURE]
produced O O
more O O
metacercariae O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
those O O
infected O O
with O O
a O O
single O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
miracidium O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
. O O

We O O
conclude O O
that O O
GRF1 B B_GENE/B_DISEASE
and O O
GRF2 B B_GENE/B_DISEASE
can O O
form O O
homo O O
- O O
and O O
hetero O O
- O O
oligomers O O
via O O
their O O
DH B B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
domains I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
that O O
mutational O O
inactivation O O
of O O
oligomer O O
formation O O
by O O
GRF1 B B_GENE
is O O
associated O O
with O O
impaired O O
biological O O
and O O
signaling O O
activities O O
, O O
and O O
that O O
in O O
293T O O
cells O O
GRF1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mediates O O
at O O
least O O
two O O
pathways O O
for O O
Raf B B_GENE/B_DISEASE
activation O O
: O O
one O O
a O O
constitutive O O
signal O O
that O O
is O O
mainly O O
Ras B B_GENE/B_DISEASE
- O O
dependent O O
, O O
and O O
one O O
an O O
ionomycin O O
- O O
induced O O
signal O O
that O O
cooperates O O
with O O
the O O
constitutive O O
signal O O
without O O
further O O
augmenting O O
the O O
level O O
of O O
GTP B B_GENE
- I I_GENE
Ras I I_GENE
. O O

For O O
the O O
target O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimuli O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
P3 O B_MEASURE/B_DISEASE
amplitude O I_MEASURE/I_DISEASE
and O O
latency O B_MEASURE
were O O
negatively O O
correlated O O
and O O
most O O
tightly O O
coupled O O
over O O
the O O
frontal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
central O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
right O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
medial O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
/ O O
lateral O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
recording O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
sites O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Mitoxantrone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plus O O
ara O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
C O B_OTHER/B_PROTEIN[GENE]
is O O
an O O
active O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
combination O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
great O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
promise O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
for O O
the O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
previously O O
untreated O B_DISEASE/B_PERSON
patients O I_DISEASE/I_PERSON
with O O
AML O B_DISEASE
. O O

In O O
the O O
renal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cortex O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
spleen O O
, O O
distal O B_BODY_PART_OR_ORGAN_COMPONENT
colon O I_BODY_PART_OR_ORGAN_COMPONENT
, O O
ileum O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
gallbladder O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
and O O
stomach O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
body O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
, O O
regional O B_DISEASE
O2 O I_DISEASE
delivery O I_DISEASE
was O O
significantly O O
decreased O O
with O O
hemodilution O B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
20 O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
both O O
groups O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

( O O
A O O
short O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
account O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
Karl O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Touton O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
s O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
life O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
is O O
also O O
included O O
. O O
) O O
After O O
reviewing O O
the O O
historical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
development O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
concept O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
giant O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
current O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
interpretations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
their O O
nature O B_EDU[ORGANIZATION]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
unitarian O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
view O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
polykaryons O B_LOCATION/B_BIO
now O O
favored O O
by O O
workers O B_PERSON
in O O
the O O
field O B_LOCATION
is O O
extended O O
to O O
include O O
also O O
the O O
" O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
xanthelasmatic O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
giant O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
cell O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
" O O
of O O
Touton O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
whose O O
characteristic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appearance O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
determined O O
merely O O
by O O
the O O
presence O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
demonstrable O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
lipid O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_PROTEIN[GENE]
in O O
the O O
cytoplasm O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Chronic O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
active O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hepatitis O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
pregnancy O B_DISEASE
. O O

Influenza O O
virus O O
- O O
induced O O
NF B B_GENE
- I I_GENE
kappaB I I_GENE
- I I_GENE
dependent I I_GENE
gene I I_GENE
expression O O
is O O
mediated O O
by O O
overexpression O O
of O O
viral O O
proteins O O
and O O
involves O O
oxidative O O
radicals O O
and O O
activation O O
of O O
IkappaB B B_GENE
kinase I I_GENE
. O O

These O O
observed O O
changes O O
were O O
not O O
found O O
when O O
assessing O O
NPY B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level O O
in O O
plasma O O
fluid O O
. O O

Reversible O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
topology O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
a O O
bifunctional O B_GENE
transmembrane O I_GENE
protein O I_GENE
depends O O
upon O O
the O O
charge O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
balance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
around O O
its O O
transmembrane O B_LOCATION/B_BIO
domain O I_LOCATION/I_BIO
. O O

Protein B B_LOCATION/B_GENE
kinase I I_LOCATION/I_GENE
C I I_LOCATION/I_GENE
( O O
PKC B B_GENE
) O O
activation O O
after O O
treatment O O
of O O
human O O
neuroblastoma O O
SK O O
- O O
N O O
- O O
BE O O
( O O
2 O O
) O O
C O O
cells O O
with O O
phorbol O O
12 O O
- O O
myristate O O
13 O O
- O O
acetate O O
( O O
PMA O O
) O O
was O O
found O O
to O O
enhance O O
transcription O O
of O O
the O O
human O O
dopamine B B_ENZYME[GENE]
beta I I_ENZYME[GENE]
- I I_ENZYME[GENE]
hydroxylase I I_ENZYME[GENE]
( O O
DBH B B_GENE/B_LOCATION
) O O
in O O
those O O
cells O O
. O O

The O O
second O B_SEQUENCE[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O O
represented O O
by O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosed O O
as O O
HSIL O B_DISEASE
by O O
cytology O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

The O O
illuminator O B_LOCATION/B_PERSON
uses O O
a O O
grain O B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
of O O
- O O
wheat O B_BIO/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
light O B_BIO/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bulb O B_BIO/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
an O O
adjustable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
bulb O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
holder O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
fashioned O O
from O O
bent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
paper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
clips O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Bedbug O O
( O O
Cimex O O
lectularius O O
) O O
samples O O
adult O O
and O O
nymphs O O
either O O
engorged O O
or O O
starved O O
from O O
Central O O
Security O O
Forces O O
sleeping O O
wards O O
, O O
laboratory O O
animal O O
house O O
and O O
control O O
samples O O
from O O
laboratory O O
reared O O
colonies O O
were O O
ground O O
and O O
subjected O O
to O O
ELISA O O
test O O
of O O
hepatitis B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
surface I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antigen I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
together O O
with O O
276 O O
serum O O
samples O O
from O O
the O O
recruits O O
slept O O
in O O
those O O
wards O O
. O O

The O O
genomic O O
organization O O
in O O
this O O
region O O
is O O
similar O O
to O O
the O O
neural O O
- O O
restricted O O
family O O
members O O
, O O
Hel B B_PROTEIN[GENE]/B_DISEASE
- I I_PROTEIN[GENE]/I_DISEASE
N1 I I_PROTEIN[GENE]/I_DISEASE
( O O
ELAVL2 B B_GENE
) O O
and O O
mHuD B B_PROTEIN[GENE]/B_DISEASE
( O O
Elavl4 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Synergistic O O
induction O O
of O O
apoptosis O O
in O O
human O O
leukemia O O
cells O O
( O O
U937 O O
) O O
exposed O O
to O O
bryostatin O O
1 O O
and O O
the O O
proteasome O O
inhibitor O O
lactacystin O O
involves O O
dysregulation O O
of O O
the O O
PKC B B_GENE
/ O O
MAPK B B_GENE
cascade O O
. O O

With O O
the O O
help O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
partially O O
overlapping O O
parenchymatous O B_DISEASE_ADJECTIVE[DISEASE]/B_MEDICAL_DEVICE[OBJECT]
sutures O B_DISEASE_ADJECTIVE[DISEASE]/I_MEDICAL_DEVICE[OBJECT]
, O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
renal O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
segments O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
were O O
devitalized O O
. O O

Promoter O O
elements O O
and O O
transcriptional O O
control O O
of O O
the O O
mouse B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
acetylcholinesterase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
average O B_MEASURE/B_LOCATION
cumulative O I_MEASURE/I_LOCATION
UVA O I_MEASURE/I_LOCATION
dose O I_MEASURE/I_LOCATION
was O O
65 O B_MEASURE
J O I_MEASURE
/ O O
cm2 O B_MEASURE
; O O
40 O B_PERSON
patients O I_PERSON
had O O
received O O
more O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
200 O B_MEASURE/B_PERSON
J O I_MEASURE/I_PERSON
/ O O
cm2 O B_MEASURE/B_LOCATION
. O O

Malformations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
regenerating O O
optic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tectum O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
larvae O B_SPECIES[BIO]/B_DISEASE
of O O
the O O
Egyptian O B_SPECIES[BIO]
toad O I_SPECIES[BIO]
, O O
Bufo O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regularis O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Reuss O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
morphological O O
changes O O
are O O
associated O O
with O O
a O O
marked O O
induction O O
of O O
P450arom B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
. O O

The O O
immunoprofile O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
60 O B_PERSON/B_TIME[MEASURE]
adult O I_PERSON/I_TIME[MEASURE]
patients O I_PERSON/I_TIME[MEASURE]
of O O
pulmonary O B_DISEASE/B_LOCATION
tuberculosis O I_DISEASE/I_LOCATION
was O O
studied O O
and O O
compared O O
with O O
22 O B_PERSON/B_DISEASE
normal O I_PERSON/I_DISEASE
controls O I_PERSON/I_DISEASE
. O O

Central O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
venous O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
catheter O B_MEDICAL_DEVICE[OBJECT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
related O O
infection O B_DISEASE
is O O
readily O O
diagnosed O O
by O O
comparing O O
simultaneous O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
quantitative O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
cultures O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
blood O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
obtained O O
via O O
the O O
catheter O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
and O O
a O O
peripheral O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
vein O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

The O O
role O O
of O O
haptoglobin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
asphyxia O O
mechanism O O
( O O
II O O
) O O
- O O
- O O
Acute O O
drowning O O
and O O
hanging O O

Processing O O
MES O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
requires O O
large O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
bit O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
manipulations O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
heavy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
memory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
storage O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
requirements O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Thus O O
, O O
BCR B B_GENE
ligation O O
initiates O O
a O O
PI B B_GENE
3 I I_GENE
- I I_GENE
kinase I I_GENE
/ O O
Akt B B_GENE
/ O O
GSK B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
3 I I_GENE/I_LOCATION
signaling O O
pathway O O
. O O

cDNA O O
cloning O O
and O O
transcriptional O O
properties O O
of O O
a O O
novel O O
GC B B_GENE/B_PERSON
box I I_GENE/I_PERSON
- I I_GENE/I_PERSON
binding I I_GENE/I_PERSON
protein I I_GENE/I_PERSON
, O O
BTEB2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
activity O O
creates O O
a O O
4 O O
- O O
bp O O
staggered O O
cut O O
with O O
3 O O
' O O
OH O O
overhangs O O
within O O
a O O
specific O O
sequence O O
of O O
the O O
21S B B_GENE/B_LOCATION
rRNA I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
of O O
omega O O
- O O
strains O O
. O O

The O O
two O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ORFs O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
had O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
similarity O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
with O O
the O O
putative O B_GENE/B_BIO
replication O I_GENE/I_BIO
protein O I_GENE/I_BIO
from O O
plasmid O B_BIO/B_GENE
pTiK12 O I_BIO/I_GENE
of O O
Thiobacillus O B_BACTERIUM[BIO]
intermedius O I_BACTERIUM[BIO]
and O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
CoIE2 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
- O O
related O O
plasmids O B_BIO/B_GENE
. O O

In O O
contrast O O
SF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
not O O
GM B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- I I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
CSF I I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O O
IL B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
3 I I_GENE/I_LOCATION
, O O
induced O O
tyrosine O O
phosphorylation O O
of O O
phospholipase B B_GENE
C I I_GENE
- I I_GENE
gamma I I_GENE
( O O
PLC B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
gamma I I_GENE/I_LOCATION
) O O
. O O

Phase O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O O
a O O
combination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
methotrexate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
mitomycin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Replacement O O
of O O
Val20 O O
- O O
Leu21 O O
with O O
Ala O O
- O O
Ala O O
produced O O
a O O
dimeric B B_PROTEIN[GENE]
RII I I_PROTEIN[GENE]
beta I I_PROTEIN[GENE]
protein I I_PROTEIN[GENE]
that O O
binds O O
AKAP75 B B_LOCATION/B_GENE
approximately O O
4 O O
% O O
as O O
avidly O O
as O O
wild B B_GENE
- I I_GENE
type I I_GENE
RII I I_GENE
beta I I_GENE
. O O

The O O
temporal O O
expression O O
of O O
CRAlBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
similar O O
to O O
IRBP B B_LOCATION/B_GENE
while O O
bFGF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
not O O
expressed O O
until O O
after O O
photoreceptor O O
differentiation O O
is O O
complete O O
. O O

I O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
T O O
cells O O
these O O
two O O
signal O O
pathways O O
are O O
critical O O
for O O
interleukin B B_GENE
- I I_GENE
2 I I_GENE
production O O
. O O

Replacement O O
of O O
a O O
valine O O
( O O
V68 O O
) O O
in O O
the O O
ETS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
domain O O
of O O
SAP1a B B_GENE
by O O
aspartic O O
acid O O
( O O
as O O
found O O
in O O
c B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
Ets I I_GENE/I_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
, O O
Elk B B_PROTEIN[GENE]/B_MEASURE
- I I_PROTEIN[GENE]/I_MEASURE
1 I I_PROTEIN[GENE]/I_MEASURE
, O O
and O O
Net B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
enhanced O O
ternary O O
complex O O
formation O O
by O O
more O O
than O O
60 O O
- O O
fold O O
. O O

In O O
order O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O O
investigate O O
the O O
effect O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
local O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
direct O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
action O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
danazol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
upon O O
endometriosis O B_DISEASE/B_ORGANISM_FUNCTION
, O O
intravaginal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
intrauterine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
application O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
were O O
tried O O
. O O

The O O
NF B B_GENE
- I I_GENE
kappaB I I_GENE
/ O O
Rel B B_GENE/B_LOCATION
transcription O O
factors O O
participate O O
in O O
the O O
activation O O
of O O
immune O O
system O O
regulatory O O
genes O O
and O O
viral B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
early I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
including O O
the O O
human B B_DISEASE/B_GENE
immunodeficiency I B_DISEASE/I_GENE
virus I B_DISEASE/I_GENE
type I B_DISEASE/I_GENE
1 I B_DISEASE/I_GENE
long I B_DISEASE/I_GENE
terminal I B_DISEASE/I_GENE
repeat I B_DISEASE/I_GENE
. O O

A O O
total O B_MEASURE
of O O
4 O B_MEASURE
, O O
916 O B_MEASURE/B_LOCATION
children O I_MEASURE/I_LOCATION
were O O
examined O O
and O O
the O O
questionnaire O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
satisfactorily O O
completed O O
by O O
a O O
relative O B_PERSON
or O O
guardian O B_PERSON
( O O
usually O O
the O O
mother O B_PERSON
) O O
of O O
4 O B_MEASURE
, O O
651 O B_MEASURE
. O O

cDNA O O
cloning O O
reveals O O
two O O
mouse B B_GENE
beta5 I I_GENE
integrin I I_GENE
transcripts I I_GENE
distinct O O
in O O
cytoplasmic O O
domains O O
as O O
a O O
result O O
of O O
alternative O O
splicing O O
. O O

Earlier O B_PERSON/B_LOCATION
nonoptical O I_PERSON/I_LOCATION
methods O I_PERSON/I_LOCATION
probably O O
did O O
not O O
include O O
the O O
portion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
film O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
contained O O
mucus O B_BODY_PART_OR_ORGAN_COMPONENT/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

OBJECTIVE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
To O O
summarise O O
quantitatively O O
the O O
association O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
moderate O B_DISEASE
alcohol O I_DISEASE
intake O I_DISEASE
and O O
biological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
markers O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
risk O B_DISEASE_ADJECTIVE[DISEASE]
of O O
coronary O B_DISEASE
heart O I_DISEASE
disease O I_DISEASE
and O O
to O O
predict O O
how O O
these O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
would O O
lower O O
the O O
risk O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Like O O
other O O
known O O
GCD B B_GENE/B_BIO
genes I I_GENE/I_BIO
, O O
GCD14 B B_MEASURE/B_GENE
and O O
GCD15 B B_MEASURE/B_GENE
are O O
therefore O O
probably O O
required O O
for O O
general O O
translation O O
initiation O O
in O O
addition O O
to O O
their O O
roles O O
in O O
GCN4 B B_GENE
- O O
specific O O
translational O O
control O O
. O O

The O O
presence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
highly O O
correlated O B_MEASURE
frequencies O I_MEASURE
provided O O
strong O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
a O O
medium O B_MEASURE/B_LOCATION
- O O
frequency O B_MEASURE/B_LOCATION
pattern O I_MEASURE/I_LOCATION
generator O I_MEASURE/I_LOCATION
which O O
may O O
remain O O
operative O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
beyond O O
the O O
neonatal O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
period O I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

This O O
gene O O
is O O
named O O
PKNOX1 B B_GENE/B_LOCATION
by O O
the O O
Human O O
Nomenclature O O
Committee O O
. O O

Differentiation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
porcine O B_DISEASE/B_BIO
mycoplasma O I_DISEASE/I_BIO
strains O I_DISEASE/I_BIO
by O O
means O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
a O O
simple O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
paper O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chromatography O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

HIV O B_DISEASE/B_GENE
- O O
2 O B_TIME[MEASURE]/B_DISEASE
in O O
Spain O B_LOCATION
. O O

No O O
effect O O
of O O
4 O O
beta O O
- O O
phorbol O O
12 O O
- O O
myristate O O
13 O O
- O O
acetate O O
was O O
observed O O
on O O
the O O
expression O O
of O O
hnRNP B B_GENE
H I I_GENE
. O O

Patients O B_PERSON/B_LOCATION
commonly O O
considered O O
the O O
external O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
frame O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cumbersome O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

D O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
atf1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
+ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Schizosaccharomyces I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pombe I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encodes O O
a O O
bZIP B B_ENZYME[GENE]/B_MEASURE
transcription I I_ENZYME[GENE]/I_MEASURE
factor I I_ENZYME[GENE]/I_MEASURE
with O O
strong O O
homology O O
to O O
the O O
mammalian B B_GENE/B_BIO
factor I I_GENE/I_BIO
ATF I I_GENE/I_BIO
- I I_GENE/I_BIO
2 I I_GENE/I_BIO
. O O

The O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sources O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
commercial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
rations O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
on O O
the O O
humoral O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
immune O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
response O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
broilers O B_PERSON/B_SPECIES[BIO]
to O O
Newcastle O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
disease O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
vaccination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
. O O

Multiple O O
attempts O O
aimed O O
at O O
disruption O O
of O O
the O O
chromosomal B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
fabG I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O O
unsuccessful O O
. O O

Primary O B_PERSON
TJRs O I_PERSON
were O O
clinically O O
evaluated O O
for O O
degree O B_DISEASE_ADJECTIVE[DISEASE]
of O O
osteoarthrosis O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Radiation O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
sensitivity O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
rats O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
irradiated O O
in O O
a O O
condition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
hypoxia O B_DISEASE

The O O
activity O O
of O O
plasminogen B B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activator I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
been O O
measured O O
in O O
tissue O O
sections O O
with O O
the O O
aid O O
of O O
a O O
modified O O
Todd O O
technique O O
. O O

The O O
complexity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
some O O
of O O
the O O
reports O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
VACURG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
studies O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
has O O
led O O
some O O
to O O
believe O O
that O O
this O O
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O O
opposed O O
to O O
estrogens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
but O O
that O O
is O O
not O O
true O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

Thus O O
, O O
the O O
mutants O O
are O O
deficient O O
in O O
production O O
of O O
the O O
O B B_ENZYME[GENE]/B_SPECIES[BIO]
- I I_ENZYME[GENE]/I_SPECIES[BIO]
antigen I I_ENZYME[GENE]/I_SPECIES[BIO]
polymerase I I_ENZYME[GENE]/I_SPECIES[BIO]
and O O
were O O
termed O O
rfc B B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
mutants I I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
. O O

Up O O
to O O
1988 O B_MEASURE
, O O
145 O B_NUMBER[MEASURE]/B_PERSON
cases O I_NUMBER[MEASURE]/I_PERSON
had O O
been O O
reported O O
in O O
literature O B_LOCATION/B_PERSON
and O O
32 O B_MEASURE/B_ENT
cases O B_MEASURE/I_ENT
in O O
our O O
country O B_LOCATION
. O O

Focal O B_DISEASE
glomerulosclerosis O I_DISEASE
- O O
like O B_DISEASE/B_MEASURE
disease O I_DISEASE/I_MEASURE
with O O
nephrotic O B_DISEASE
syndrome O I_DISEASE
in O O
a O O
horse O B_BIO/B_PERSON
. O O

The O O
antihypertensive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
action O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
corresponds O O
to O O
those O O
of O O
established O O
diuretics O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Interconversions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
between O O
haloperidol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
reduced O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
haloperidol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
schizophrenic O B_SPECIES[BIO]/B_LOCATION
patients O I_SPECIES[BIO]/I_LOCATION
and O O
guinea O B_PERSON/B_BIO
pigs O I_PERSON/I_BIO
: O O
a O O
steady O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
state O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

The O O
frequency O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
eating O O
dark O B_COLOR/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
meat O B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fish O I_BIO/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
positively O O
associated O O
with O O
serum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
eicosapentaenoic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
docosahexaenoic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
acid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
omega3 O B_DISEASE_ADJECTIVE[DISEASE]
fatty O I_DISEASE_ADJECTIVE[DISEASE]
acids O I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
inversely O O
associated O O
with O O
serum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
stearic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
linoleic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Effect O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
food O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O O
hemodynamics O B_DISEASE/B_ORGANISM_FUNCTION
. O O

The O O
D443N B B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
substitution I I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
is O O
an O O
activating O O
mutation O O
that O O
increases O O
the O O
activity O O
of O O
SCAP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
renders O O
it O O
resistant O O
to O O
inhibition O O
by O O
25 O O
- O O
hydroxycholesterol O O
. O O

Central O O
( O O
heart O O
rate O O
, O O
VE O O
, O O
VO2 O O
) O O
or O O
local O O
( O O
muscle O O
and O O
blood O O
lactate O O
, O O
adenosine O O
triphosphate O O
, O O
creatine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
phosphokinase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
glycogen O O
) O O
cues O O
highlighted O O
in O O
these O O
studies O O
demonstrate O O
both O O
the O O
complexity O O
of O O
effort O O
perception O O
, O O
and O O
the O O
need O O
for O O
better O O
understanding O O
of O O
the O O
physiological O O
components O O
upon O O
which O O
it O O
is O O
based O O
. O O

The O O
gene O B_GENE/B_MEASURE
is O O
predicted O O
to O O
encode O O
an O O
880 O B_NUMBER[MEASURE]
- O O
amino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
acid O B_PROTEIN[GENE]
protein O I_PROTEIN[GENE]
which O O
contains O O
two O B_GENE
C2H2 O I_GENE
zinc O I_GENE
fingers O I_GENE
, O O
a O O
nuclear O B_GENE
localization O I_GENE
sequence O I_GENE
and O O
two O B_GENE
transcriptional O I_GENE
activation O I_GENE
domains O I_GENE
. O O

This O O
approach O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
allowed O O
examination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
baseline O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
factors O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
as O O
well O O
as O O
the O O
effect O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
change O B_MEASURE
in O O
mileage O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
occurrence O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
musculoskeletal O B_DISEASE
problem O I_DISEASE
, O O
or O O
the O O
occurrence O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
another O O
health O B_DISEASE_ADJECTIVE[DISEASE]
problem O I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
rate O B_MEASURE
of O O
dropout O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O O

Microalbuminuria O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
a O O
marker O B_MEASURE/B_DISEASE
of O O
systemic O B_DISEASE/B_GENE
disease O I_DISEASE/I_GENE
. O O

Regulation O O
of O O
activating B B_GENE
transcription I I_GENE
factor I I_GENE
- I I_GENE
1 I I_GENE
and O O
the O O
cAMP B B_GENE/B_TIME[MEASURE]
response I I_GENE/I_TIME[MEASURE]
element I I_GENE/I_TIME[MEASURE]
- I I_GENE/I_TIME[MEASURE]
binding I I_GENE/I_TIME[MEASURE]
protein I I_GENE/I_TIME[MEASURE]
by O O
Ca2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
+ I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
/ I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
calmodulin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
dependent I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
type I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
I I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
II I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
IV I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Coronary O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
arteries O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
found O O
in O O
the O O
biopsy O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tissue O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
30 O B_MEASURE
( O O
76 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
of O O
the O O
39 O B_PERSON
patients O I_PERSON
who O O
formed O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Serum B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
amyloid I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
A I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
SAA B B_LOCATION/B_PROTEIN[GENE]
) O O
is O O
a O O
plasma O O
protein O O
which O O
has O O
been O O
associated O O
with O O
several O O
diseases O O
, O O
including O O
amyloidosis O O
, O O
arthritis O O
, O O
and O O
atherosclerosis O O
, O O
and O O
its O O
abnormal O O
expression O O
, O O
particularly O O
in O O
nonhepatic O O
cells O O
, O O
is O O
implicated O O
in O O
the O O
pathogenesis O O
of O O
these O O
diseases O O
. O O

Phenacetin O B_DISEASE_ADJECTIVE[DISEASE]
nephritis O I_DISEASE_ADJECTIVE[DISEASE]

We O O
have O O
been O O
developing O O
a O O
digital O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluoroscopic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaging O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
replace O O
the O O
portal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
films O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
are O O
currently O O
used O O
to O O
verify O O
patient O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
positioning O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
radiotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatments O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p18 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
spans O O
at O O
least O O
7 O O
. O O
5 O O
kb O O
and O O
is O O
composed O O
of O O
three O O
exons O O
, O O
two O O
of O O
which O O
encode O O
the O O
p18 B B_GENE
protein I I_GENE
. O O

Serum O O
creatinine B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
was O O
7 O O
, O O
800 O O
- O O
17 O O
, O O
500 O O
U O O
/ O O
l O O
, O O
making O O
acute O O
muscle O O
damage O O
likely O O
, O O
probably O O
rhabdomyolysis O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
termination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
is O O
a O O
highly O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
event O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
and O O
not O O
merely O O
a O O
consequence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
decreased O O
stability O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
EC O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Like O O
Mdm2 B B_GENE/B_DISEASE
, O O
MdmX B B_GENE/B_BACTERIUM[BIO]
is O O
able O O
to O O
bind O O
p53 B B_GENE/B_DISEASE
and O O
inhibit O O
p53 B B_GENE/B_LOCATION
transactivation O O
; O O
however O O
, O O
the O O
ability O O
of O O
MdmX B B_GENE/B_BIO
to O O
degrade O O
p53 B B_GENE
has O O
yet O O
to O O
be O O
examined O O
. O O

PURPOSE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Second O B_DISEASE
malignant O I_DISEASE
neoplasms O I_DISEASE
( O O
SMNs O B_DISEASE/B_PROTEIN[GENE]
) O O
are O O
a O O
rare O B_DISEASE
occurrence O I_DISEASE
after O O
the O O
successful O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
childhood O B_DISEASE
cancer O I_DISEASE
. O O

Recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
geological O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
focusing O O
on O O
the O O
Davie O B_LOCATION/B_ORGANIZATION
Fracture O I_LOCATION/I_ORGANIZATION
Zone O I_LOCATION/I_ORGANIZATION
of O O
the O O
Mozambique O B_LOCATION
Channel O I_LOCATION
offer O O
a O O
resolution O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
this O O
situation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
by O O
suggesting O O
the O O
presence O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
of O O
a O O
land O B_LOCATION
- O O
bridge O B_LOCATION
from O O
the O O
mid O B_TIME[MEASURE]/B_DISEASE
- O O
Eocene O B_TIME[MEASURE]/B_LOCATION
to O O
the O O
early O B_TIME[MEASURE]/B_LOCATION
Miocene O I_TIME[MEASURE]/I_LOCATION
, O O
an O O
interval O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
matches O O
the O O
ages O B_TIME[MEASURE]/B_BIO
of O O
Madagascar O B_BIO/B_LOCATION
' O I_BIO/I_LOCATION
s O I_BIO/I_LOCATION
mammalian O I_BIO/I_LOCATION
groups O I_BIO/I_LOCATION
. O O

The O O
nucleotide O O
sequence O O
of O O
a O O
PCR O O
- O O
amplified O O
SMT3A B B_SPECIES[BIO]/B_GENE
genomic O O
DNA O O
fragment O O
was O O
found O O
to O O
be O O
identical O O
to O O
that O O
of O O
SMT3A B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
cDNA I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
indicating O O
the O O
absence O O
of O O
intron O O
( O O
s O O
) O O
in O O
its O O
protein O O
coding O O
region O O
. O O

Mutant O O
p53 B B_GENE/B_DISEASE
DNA I B_GENE/I_DISEASE
clones O O
from O O
human O O
colon O O
carcinomas O O
cooperate O O
with O O
ras B B_GENE/B_DISEASE
in O O
transforming O O
primary O O
rat O O
cells O O
: O O
a O O
comparison O O
of O O
the O O
" O O
hot O O
spot O O
" O O
mutant O O
phenotypes O O
. O O

Gas O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chromatographic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
headspace O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
alkalinized O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
vaginal O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
discharges O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
indicated O O
the O O
presence O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
trimethylamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
in O O
all O O
11 O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
samples O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
with O O
the O O
fishy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
odor O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
but O O
not O O
in O O
the O O
other O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Standing O B_TIME[MEASURE]/B_ENT
values O I_TIME[MEASURE]/I_ENT
: O O
placebo O B_MEASURE/B_PERSON
114 O I_MEASURE/I_PERSON
/ O O
79 O B_MEASURE
; O O
BHT O B_MEASURE/B_PROTEIN[GENE]
- O O
933 O B_MEASURE/B_PERSON
92 O I_MEASURE/I_PERSON
/ O O
67 O B_MEASURE
. O O

The O O
Ixodes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
fauna O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
in O O
the O O
Michourin O B_LOCATION
region O I_LOCATION
, O O
where O O
the O O
pastures O B_LOCATION/B_SPECIES[BIO]
in O O
1971 O B_TIME[MEASURE]/B_LOCATION
were O O
grazed O O
only O O
by O O
sheep O B_SPECIES[BIO]
, O O
shows O O
the O O
following O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trends O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O O
H O B_PROTEIN[GENE]/B_LOCATION
. O O
punctata O B_SPECIES[BIO]/B_DISEASE
and O O
R O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
turanicus O B_SPECIES[BIO]/B_DISEASE
ticks O I_SPECIES[BIO]/I_DISEASE
, O O
which O O
are O O
preferably O O
parasitising O O
in O O
sheep O B_SPECIES[BIO]/B_LOCATION
, O O
increase O O
their O O
relative O B_MEASURE/B_LOCATION
share O I_MEASURE/I_LOCATION
. O O

The O O
SEC27 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
cloned O O
, O O
and O O
the O O
sequence O O
predicts O O
a O O
99 O O
. O O
4 O O
- O O
kDa O O
protein O O
with O O
45 O O
% O O
sequence O O
identity O O
to O O
mammalian O O
beta B B_GENE/B_PERSON
' I I_GENE/I_PERSON
- I I_GENE/I_PERSON
COP I I_GENE/I_PERSON
. O O

Studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
fetal O B_MEASURE/B_EDU[ORGANIZATION]
maturity O B_MEASURE/I_EDU[ORGANIZATION]

Fetal O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
arterial O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
and O O
sagittal O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
sinus O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
pH O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
base O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
excess O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
po2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
and O O
oxygen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
saturation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
decreased O O
, O O
and O O
hydrogen O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ion O B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations O B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
pco2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
increased O O
during O O
asphyxia O B_DISEASE
alone O O
and O O
asphyxia O B_DISEASE
plus O O
isoflurane O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
oxygen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Therefore O O
, O O
it O O
appears O O
that O O
GCN2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
function O O
is O O
stimulated O O
posttranslationally O O
in O O
amino O O
acid O O
- O O
starved O O
cells O O
. O O

Although O O
paclitaxel O O
alone O O
failed O O
to O O
induce O O
p38 B B_GENE
MAPK O O
activation O O
, O O
subsequent O O
( O O
but O O
not O O
prior O O
) O O
exposure O O
to O O
PD98059 O O
induced O O
a O O
dramatic O O
increase O O
in O O
p38 B B_GENE
MAPK O O
phosphorylation O O
. O O

In O O
3 O B_NUMBER[MEASURE]
of O O
the O O
5 O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
AVNRT O B_DISEASE/B_LOCATION
and O O
AJR O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
junctional O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beats O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
served O O
as O O
a O O
trigger O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
reentry O B_DISEASE
. O O

The O O
three O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
respective O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
time O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
C5 O B_PROTEIN[GENE]
, O O
C10 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
C15 O B_PROTEIN[GENE]/B_MEASURE
) O O
were O O
injected O O
with O O
saline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
solution O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Sequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
cDNA O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
clones O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encoding O O
human O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gamma O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
revealed O O
an O O
open O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reading O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
frame O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
predicting O O
a O O
protein O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
of O O
299 O B_MEASURE
amino O I_MEASURE
acids O I_MEASURE
( O O
approximately O O
32 O B_MEASURE
kDa O I_MEASURE
) O O
, O O
half O O
the O O
size O B_MEASURE/B_LOCATION
of O O
the O O
bovine O B_GENE
gamma O I_GENE
subunit O I_GENE
. O O

A O O
positive O O
FTA B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ABS I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
19S I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IgM I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test O O
indicates O O
the O O
necessity O O
of O O
treatment O O
. O O

Our O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
some O O
defects O B_DISEASE
observed O O
in O O
BS O B_LOCATION/B_DISEASE
, O O
WS O B_DISEASE/B_PROTEIN[GENE]
or O O
RTS O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
the O O
consequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
unrestrained O B_DISEASE
recombination O I_DISEASE
. O O

The O O
promoter O O
for O O
HMG B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CoA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
synthase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contains O O
two O O
binding O O
sites O O
for O O
the O O
sterol B B_GENE/B_BIO
regulatory I I_GENE/I_BIO
element I I_GENE/I_BIO
- I I_GENE/I_BIO
binding I I_GENE/I_BIO
proteins I I_GENE/I_BIO
( O O
SREBPs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
chromatic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
processing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
areas O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
V1 O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
V2 O B_PROTEIN[GENE]/B_LOCATION
is O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
V4 O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lesions O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
, O O
together O O
with O O
the O O
behavioural O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
that O O
these O O
areas O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O O
sufficient O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
some O O
basic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
aspects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
colour O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
perception O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
curse O B_PERSON/B_TIME[MEASURE]
of O O
the O O
Pharaohs O B_PERSON/B_LOCATION
. O O

Covariates O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
extremity O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
range O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
motion O B_ENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
sensory O B_MEASURE/B_DISEASE
status O I_MEASURE/I_DISEASE
. O O

Characterization O O
and O O
targeted O O
disruption O O
of O O
murine B B_GENE
Nup50 I I_GENE
, O O
a O O
p27 B B_GENE
( O O
Kip1 B B_PROTEIN[GENE]/B_LOCATION
) O O
- O O
interacting O O
component O O
of O O
the O O
nuclear O O
pore O O
complex O O
. O O

p27 B B_GENE
( O O
Kip1 B B_GENE/B_LOCATION
) O O
is O O
a O O
member O O
of O O
the O O
Cip B B_DISEASE/B_GENE
- O O
Kip B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
family O O
of O O
cyclin B B_GENE
- I I_GENE
dependent I I_GENE
kinase I I_GENE
( O O
Cdk B B_GENE/B_LOCATION
) O O
inhibitors O O
that O O
binds O O
to O O
cyclin B B_GENE
- O O
Cdk B B_GENE
complexes O O
and O O
inhibits O O
their O O
catalytic O O
activity O O
in O O
response O O
to O O
antiproliferative O O
stimuli O O
. O O

p27 B B_GENE
( O O
Kip1 B B_GENE/B_DISEASE
) O O
is O O
regulated O O
by O O
several O O
posttranscriptional O O
mechanisms O O
, O O
including O O
subcellular O O
localization O O
. O O

Therefore O O
, O O
the O O
Ogg1 B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
eukaryotic O O
DNA B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
glycosylase I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
AP B B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lyase I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

One O B_PERSON/B_NUMBER[MEASURE]
patient O I_PERSON/I_NUMBER[MEASURE]
had O O
chronic O B_DISEASE
dysphoria O I_DISEASE
and O O
one O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
encephalopatia O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toxica O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Alveoli O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
capillary O B_LOCATION
diffusion O I_LOCATION
. O O

Mutations O O
of O O
SIN4 B B_GENE
, O O
ROX3 B B_GENE
, O O
SRB8 B B_GENE
, O O
SRB9 B B_GENE
, O O
SRB10 B B_GENE
, O O
SRB11 B B_GENE
, O O
and O O
two O O
novel O O
genes O O
, O O
NUT1 B B_GENE/B_DISEASE
and O O
NUT2 B B_GENE/B_DISEASE
, O O
relieve O O
the O O
requirement O O
of O O
Swi4p B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
for O O
expression O O
of O O
this O O
reporter O O
. O O

The O O
software O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
in O O
BASIC O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
adapted O O
for O O
the O O
Hewlett O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
Packard O B_PERSON/B_PROTEIN[GENE]
calculators O I_PERSON/I_PROTEIN[GENE]
HP O I_PERSON/I_PROTEIN[GENE]
- O O
9845B O B_MEASURE
and O O
HP O B_ORGANIZATION/B_PROTEIN[GENE]
- O O
85A O B_MEASURE/B_PERSON
. O O

For O O
Thermus O O
strain O O
ZO5 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dihydroorotase I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DHOase B B_PROTEIN[GENE]
; O O
encoded O O
by O O
pyrC B B_GENE/B_BACTERIUM[BIO]
) O O
, O O
the O O
highest O O
similarity O O
scores O O
( O O
about O O
40 O O
% O O
identity O O
) O O
were O O
obtained O O
with O O
DHOases B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
B O O
. O O
caldolyticus O O
and O O
Bacillus O O
subtilis O O
. O O

Precision O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
from O O
models O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
sodium O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinetics O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
hemodialysis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE

These O O
data O O
suggest O O
that O O
the O O
fibrinogen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Gly190 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Val202 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
functions O O
as O O
a O O
minimal O O
recognition O O
sequence O O
for O O
the O O
leukocyte O O
integrin O O
CD11b B B_GENE
/ O O
CD18 B B_GENE/B_MEASURE
. O O

Attenuated O O
serum O O
cortisol O O
responses O O
were O O
found O O
in O O
six O O
of O O
the O O
patients O O
despite O O
a O O
normal O O
ACTH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
test O O
. O O

We O O
recently O O
described O O
the O O
isolation O O
and O O
characterization O O
of O O
nontoxic O O
PAP B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutants I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
NT123 O O
- O O
2 O O
, O O
which O O
has O O
a O O
point O O
mutation O O
( O O
E176V O O
) O O
in O O
the O O
active O O
site O O
that O O
abolishes O O
enzymatic O O
activity O O
, O O
and O O
NT124 O O
- O O
3 O O
, O O
which O O
has O O
a O O
nonsense O O
mutation O O
that O O
results O O
in O O
deletion O O
of O O
the O O
C O O
- O O
terminal O O
25 O O
aa O O
( O O
W237Stop O O
) O O
. O O

Toxicity O O
of O O
benzoyl O O
chloride O O
( O O
2 O O
, O O
4 O O
, O O
6 O O
- O O
trichlorophenyl O O
) O O
hydrazone O O
( O O
Banamite O O
) O O
and O O
potential O O
metabolites O O
to O O
twospotted O O
spider O O
mites O O
and O O
potency O O
as O O
inhibitors O O
of O O
rat B B_GENE
liver I I_GENE
monoamine I I_GENE
oxidase I I_GENE
. O O

The O O
screen O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
identifies O O
mutants O B_DISEASE/B_BIO
whose O O
growth O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
depends O O
on O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
expression O B_GENE
of O O
that O O
gene O B_ENZYME[GENE]/B_MEASURE
. O O

The O O
genes O O
expressed O O
during O O
the O O
embryonic O O
( O O
zeta B B_PROTEIN[GENE]
) O O
or O O
fetal O O
and O O
adult O O
stage O O
( O O
alpha B B_PROTEIN[GENE]
2 I I_PROTEIN[GENE]
and O O
alpha B B_PROTEIN[GENE]
1 I I_PROTEIN[GENE]
) O O
can O O
be O O
modified O O
by O O
point O O
mutations O O
which O O
affect O O
either O O
the O O
processing O O
- O O
translation O O
of O O
mRNA O O
or O O
make O O
the O O
polypeptide O O
chains O O
extremely O O
unstable O O
. O O

In O O
a O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
Singapore O B_LOCATION/B_MEASURE
, O O
Chinese O B_LOCATION/B_PERSON
, O O
Malay O B_PERSON/B_LOCATION
and O O
Indian O B_PERSON/B_LOCATION
patients O I_PERSON/I_LOCATION
with O O
pulmonary O B_DISEASE
tuberculosis O I_DISEASE
received O O
2 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
of O O
daily O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
streptomycin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
isoniazid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
rifampicin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
pyrazinamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
followed O O
by O O
daily O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoniazid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
rifampicin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
either O O
with O O
pyrazinamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
SHRZ O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
HRZ O B_LOCATION/B_PROTEIN[GENE]
) O O
or O O
without O O
it O O
( O O
SHRZ O B_LOCATION/B_PROTEIN[GENE]
/ O O
HR O B_LOCATION/B_PROTEIN[GENE]
) O O
, O O
allocated O O
at O O
random O B_PERSON/B_MEASURE
. O O

Kaposi O O
' O O
s O O
sarcoma O O
- O O
associated O O
herpesvirus O O
/ O O
human O O
herpesvirus O O
- O O
8 O O
ORF50 B B_GENE
gene O O
product O O
contains O O
a O O
potent O O
C O O
- O O
terminal O O
activation O O
domain O O
which O O
activates O O
gene O O
expression O O
via O O
a O O
specific O O
target O O
sequence O O
. O O

NSAIDS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
the O O
microcirculation O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
stomach O B_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
efficiency O O
of O O
transfections O O
was O O
normalized O O
relative O O
to O O
the O O
net O O
amount O O
of O O
CAT B B_BIO/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
plasmid O O
actually O O
transfected O O
into O O
recipient O O
cells O O
, O O
determined O O
by O O
a O O
modified O O
Southern O O
hybridization O O
procedure O O
. O O

Genomic O O
Southern O O
blot O O
analysis O O
suggests O O
that O O
the O O
human O O
haploid O O
genome O O
contains O O
a O O
single O O
Gs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Evaluation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
chelation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
with O O
time O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
following O O
strontium O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
exposure O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
mice O B_BIO/B_DISEASE
. O O

In O O
the O O
present O O
study O O
we O O
found O O
that O O
CD34 B B_GENE
downregulation O O
during O O
hematopoiesis O O
occured O O
at O O
the O O
level O O
of O O
transcriptional O O
initiation O O
. O O

Allergen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
stimulated O O
levels O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
PGD2 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
1274 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
565 O B_MEASURE
versus O I_MEASURE
1468 O I_MEASURE
+ O I_MEASURE
/ O O
- O O
679 O B_MEASURE
after O O
prednisone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
; O O
likewise O O
, O O
allergen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
stimulated O O
5 O B_MEASURE
- O O
HETE O B_PROTEIN[GENE]
levels O I_PROTEIN[GENE]
were O O
95 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
21 O B_MEASURE
versus O I_MEASURE
82 O I_MEASURE
+ O I_MEASURE
/ O O
- O O
21 O B_MEASURE
; O O
those O O
of O O
LTE4 O B_GENE/B_MEASURE
were O O
54 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
20 O B_MEASURE
versus O I_MEASURE
91 O I_MEASURE
+ O I_MEASURE
/ O O
- O O
51 O B_MEASURE
; O O
and O O
those O O
of O O
15 O B_NUMBER[MEASURE]
- O O
HETE O B_MEASURE/B_PROTEIN[GENE]
were O O
63 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
19 O B_MEASURE
versus O I_MEASURE
60 O I_MEASURE
+ O I_MEASURE
/ O O
- O O
25 O B_MEASURE
. O O

Foreign O B_GENE/B_BIO
DNA O I_GENE/I_BIO
inserts O I_GENE/I_BIO
contained O O
within O O
the O O
fowlpox O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
virus O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
transferred O O
to O O
the O O
viral O B_BIO/B_GENE
genome O I_BIO/I_GENE
by O O
homologous O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
recombination O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
occurring O O
in O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
infected O O
with O O
a O O
fowlpox O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
virus O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
temperature O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
sensitive O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mutant O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
transfected O O
with O O
both O O
wild O B_PERSON/B_BIO
- O O
type O B_MEASURE/B_PERSON
viral O B_MEASURE/I_PERSON
DNA O B_MEASURE/I_PERSON
and O O
plasmid O B_GENE/B_BIO
DNA O I_GENE/I_BIO
. O O

Although O O
there O O
is O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
cone O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ratios O I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
do O O
determine O O
colour O B_MEASURE/B_PERSON
appearance O I_MEASURE/I_PERSON
under O O
many O B_LOCATION
conditions O I_LOCATION
, O O
the O O
site O B_LOCATION/B_TIME[MEASURE]
or O O
sites O B_LOCATION/B_MEASURE
of O O
their O O
computation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
unknown O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
. O O

Furthermore O O
, O O
we O O
demonstrate O O
that O O
in O O
myeloid O O
and O O
B O O
cell O O
extracts O O
, O O
PU B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
forms O O
a O O
novel O O
, O O
specific O O
, O O
more O O
slowly O O
migrating O O
complex O O
( O O
PU B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
SF I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
when O O
binding O O
the O O
GM B B_GENE/B_DISEASE
- I B_GENE/I_DISEASE
CSF I B_GENE/I_DISEASE
receptor I B_GENE/I_DISEASE
alpha I B_GENE/I_DISEASE
promoter O O
PU B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. I I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site O O
. O O

Several O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
components O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
cytokine O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
signaling O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
remain O O
unidentified O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
. O O

This O O
is O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
report O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrating O O
specificity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
at O O
the O O
level O B_MEASURE/B_LOCATION
of O O
the O O
energy O B_LOCATION/B_PERSON
coupling O I_LOCATION/I_PERSON
proteins O I_LOCATION/I_PERSON
of O O
the O O
PTS O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O O

In O O
contrast O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
stem O B_BODY_PART_OR_ORGAN_COMPONENT/B_PROTEIN[GENE]
- O O
loop O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
structures O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
2 O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
3 O B_NUMBER[MEASURE]
, O O
and O O
4 O B_NUMBER[MEASURE]
of O O
the O O
3 O B_NUMBER[MEASURE]/B_PERSON
' O O
domain O B_LOCATION/B_GENE
showed O O
great O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variations O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
size O B_MEASURE/B_LOCATION
, O O
sequence O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
and O O
structure O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

A O O
spectrophotometric O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
the O O
microdetermination O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
periodate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O O
as O O
followed O O
: O O
1 O B_NUMBER[MEASURE]
) O O
Early O O
cancer O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
like O B_DISEASE/B_ENT
advanced O I_DISEASE/I_ENT
cancers O I_DISEASE/I_ENT
were O O
consisted O O
of O O
133 O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
lesions O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
of O O
which O O
128 O B_MEASURE
lesions O I_MEASURE
( O O
96 O B_MEASURE
. O O
2 O B_MEASURE
% O I_MEASURE
) O O
had O O
peptic O B_DISEASE
ulcer O I_DISEASE
in O O
cancerous O B_DISEASE/B_MEASURE
lesion O B_DISEASE/I_MEASURE
( O O
73 O B_MEASURE
lesions O I_MEASURE
were O O
active O B_DISEASE_ADJECTIVE[DISEASE]
stage O I_DISEASE_ADJECTIVE[DISEASE]
and O O
55 O B_MEASURE
lesions O I_MEASURE
were O O
scarring O O
stage O B_DISEASE/B_MEASURE
) O O
. O O

Effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hyperaemia O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O O
thallium O B_LOCATION/B_DISEASE
- O O
201 O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
redistribution O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
normal O B_DISEASE/B_BIO
canine O I_DISEASE/I_BIO
myocardium O I_DISEASE/I_BIO
. O O

Immunoblotting O O
showed O O
that O O
both O O
the O O
( O O
1 O O
- O O
404 O O
) O O
- O O
peptide O O
and O O
( O O
1 O O
- O O
506 O O
) O O
- O O
peptide O O
are O O
recognized O O
by O O
95J10 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
a O O
monoclonal O O
antibody O O
that O O
was O O
previously O O
raised O O
against O O
perlecan B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
24 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
404 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptide I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expressed O O
in O O
Escherichia O O
coli O O
. O O

The O O
anesthesiologist O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
the O O
cardiac O B_PERSON
surgeon O I_PERSON
. O O

To O O
gain O O
further O O
insights O O
into O O
these O O
events O O
, O O
the O O
porcine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
G I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
i I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
minimal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
characterized O O
and O O
found O O
67 O O
base O O
pairs O O
upstream O O
from O O
the O O
major O O
transcription O O
start O O
site O O
. O O

FDP O B_LOCATION/B_GENE
- O O
1 O B_NUMBER[MEASURE]
( O O
200 O B_MEASURE
micrograms O I_MEASURE
. O O
kg O B_MEASURE/B_LOCATION
- O O
1 O B_MEASURE/B_LOCATION
) O O
of O O
intracoronary O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
injection O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
increased O O
collateral O B_DISEASE
flow O I_DISEASE
, O O
reduced O O
systemic O B_DISEASE/B_GENE
artery O I_DISEASE/I_GENE
resistance O I_DISEASE/I_GENE
, O O
and O O
coronary O B_DISEASE/B_MEASURE
systolic O I_DISEASE/I_MEASURE
pressure O I_DISEASE/I_MEASURE
in O O
infarcted O B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
region O B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
and O O
the O O
area O B_LOCATION/B_MEASURE
of O O
infarction O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decreased O O
from O O
28 O B_MEASURE
. O O
9 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
1 O B_MEASURE
. O O
3 O B_MEASURE
% O I_MEASURE
to O O
15 O B_MEASURE
. O O
3 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
1 O B_MEASURE
. O O
2 O B_MEASURE
% O I_MEASURE
( O O
P O B_MEASURE/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
01 O B_MEASURE
, O O
n O B_OTHER/B_PROTEIN[GENE]
= O O
6 O B_MEASURE
) O O
. O O

Pathophysiologic O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mechanisms O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
underlying O O
spatial O B_DISEASE
disorientation O I_DISEASE
in O O
patients O B_PERSON/B_BIO
with O O
Alzheimer O B_DISEASE
' O I_DISEASE
s O I_DISEASE
disease O I_DISEASE
. O O

Many O O
human O O
malignant O O
cells O O
lack O O
methylthioadenosine B B_GENE/B_DISEASE
phosphorylase I I_GENE/I_DISEASE
( O O
MTAP B B_LOCATION/B_GENE
) O O
enzyme O O
activity O O
. O O

Following O O
40 O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
min O I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
" O O
ischemia O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
" O O
, O O
preparations O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
treated O O
with O O
PC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
recovered O O
from O O
transmural O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
conduction O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
block O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
more O O
rapidly O O
( O O
PC1 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
4 O B_MEASURE/B_PERSON
min O I_MEASURE/I_PERSON
, O O
P O B_MEASURE/B_PERSON
less O I_MEASURE/I_PERSON
than O O
0 O B_MEASURE
. O O
05 O B_MEASURE
; O O
PC2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
23 O B_MEASURE/B_PERSON
min O I_MEASURE/I_PERSON
, O O
ns O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
, O O
compared O O
to O O
control O O
. O O
( O O
ABSTRACT O B_MEASURE/B_LOCATION
TRUNCATED O I_MEASURE/I_LOCATION
AT O O
250 O B_MEASURE/B_LOCATION
WORDS O I_MEASURE/I_LOCATION
) O O

The O O
novel O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spans O O
16 O B_MEASURE
. O O
7 O B_MEASURE
kb O I_MEASURE
of O O
genomic O B_GENE/B_MEASURE
sequence O I_GENE/I_MEASURE
and O O
it O O
is O O
formed O O
of O O
11 O B_NUMBER[MEASURE]
exons O I_NUMBER[MEASURE]
and O O
10 O B_NUMBER[MEASURE]
intervening O O
introns O B_GENE/B_LOCATION
. O O

G B B_GENE/B_PERSON
- I I_GENE/I_PERSON
box I I_GENE/I_PERSON
binding I I_GENE/I_PERSON
factors I I_GENE/I_PERSON
( O O
GBFs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
constitute O O
a O O
family O O
of O O
plant O O
DNA O O
- O O
binding O O
proteins O O
that O O
bind O O
to O O
the O O
G O O
- O O
box O O
motif O O
, O O
a O O
regulatory O O
cis O O
element O O
present O O
in O O
many O O
plant O O
genes O O
with O O
a O O
palindromic O O
DNA O O
motif O O
of O O
CACGTG O O
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
In O O
an O O
acute O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
canine O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
progressive O B_DISEASE
LCX O I_DISEASE
coronary O I_DISEASE
stenosis O I_DISEASE
, O O
CFR O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O O
impaired O O
in O O
both O O
ischemic O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
and O O
remote O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nonischemic O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regions O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
association O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
mild O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
moderate O B_DISEASE_ADJECTIVE[DISEASE]
ischemic O I_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
regional O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
myocardial O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dysfunction O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

A O O
third O B_SEQUENCE[MEASURE]
- O O
order O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
polynominal O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
fit O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
showed O O
a O O
good O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
correlation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
the O O
parameter O B_MEASURE/B_PROTEIN[GENE]
Q O B_MEASURE/I_PROTEIN[GENE]
* O O
and O O
MTT O B_PROTEIN[GENE]/B_MEASURE
, O O
whereas O O
T O B_GENE/B_MEASURE
and O O
SImax O B_LOCATION/B_MEASURE
were O O
found O O
to O O
have O O
a O O
poor O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
correlation O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

Late O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
urotuberculosis O B_DISEASE/B_BACTERIUM[BIO]

Changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
frequency O B_MEASURE/B_LOCATION
of O O
X O B_DISEASE
- O O
chromatin O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
in O O
women O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
under O O
Prednisone O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Other O B_DISEASE_ADJECTIVE[DISEASE]
toxicities O I_DISEASE_ADJECTIVE[DISEASE]
attributed O O
to O O
CPT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
11 O B_NUMBER[MEASURE]
included O O
dehydration O B_DISEASE
, O O
nausea O B_DISEASE
, O O
vomiting O B_DISEASE
, O O
and O O
asthenia O B_DISEASE
. O O

Proceedings O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Influence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
halothane O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O O
mortality O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O O
murine O B_DISEASE
hepatitis O I_DISEASE
virus O I_DISEASE
( O O
MHV3 O B_MEASURE/B_GENE
) O O
. O O

These O O
results O O
extend O O
our O O
knowledge O O
of O O
this O O
SNF2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
like I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
member I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
suggest O O
a O O
role O O
for O O
PASG B B_GENE/B_PERSON
in O O
leukemogenesis O O
. O O

The O O
difference O O
between O O
the O O
results O O
in O O
the O O
high O O
dose O O
AHLG B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
and O O
in O O
the O O
control O O
group O O
was O O
significant O O
( O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
when O O
amniotic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fluid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O O
stored O O
frozen O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_TIME[MEASURE]
and O O
strict O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
quality O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
control O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O O
maintained O O
in O O
analytic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
procedures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
only O O
minimal O B_DISEASE_ADJECTIVE[DISEASE]
changes O I_DISEASE_ADJECTIVE[DISEASE]
occur O O
in O O
phospholipid O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concentrations O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
over O O
12 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
. O O

Retinoic O O
acid O O
, O O
which O O
inhibits O O
the O O
progression O O
of O O
certain O O
cancers O O
, O O
repressed O O
v B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
src I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
MMP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription O O
. O O

The O O
pattern O O
of O O
net B B_GENE/B_BACTERIUM[BIO]
RNA I I_GENE/I_BACTERIUM[BIO]
expression O O
in O O
adult O O
mouse O O
tissues O O
is O O
different O O
. O O

Immunoprecipitation O O
of O O
spinophilin B B_GENE/B_BACTERIUM[BIO]
or O O
neurabin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
crude O O
brain O O
extracts O O
selectively O O
coprecipitated O O
PP1gamma B B_GENE
( I I_GENE
1 I I_GENE
) I I_GENE
over O O
PP1beta B B_GENE/B_BIO
. O O

The O O
authors O B_PERSON/B_ORGANIZATION
discussed O O
their O O
experience O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
investigating O O
20 O B_TIME[MEASURE]/B_PERSON
patients O B_TIME[MEASURE]/I_PERSON
with O O
maxillary O B_DISEASE/B_LOCATION
malignant O I_DISEASE/I_LOCATION
tumors O I_DISEASE/I_LOCATION
using O O
routine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
x O O
- O O
ray O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
MR O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
tomography O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
13 O B_TIME[MEASURE]/B_LOCATION
patients O I_TIME[MEASURE]/I_LOCATION
, O O
investigated O O
in O O
the O O
same O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
way O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
plus O O
CT O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Reduction O O
of O O
p53 B B_GENE/B_DISEASE
protein I I_GENE/I_DISEASE
was O O
detected O O
after O O
1 O O
day O O
of O O
OM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O O
and O O
reached O O
maximal O O
suppression O O
of O O
10 O O
- O O
20 O O
% O O
of O O
control O O
after O O
3 O O
days O O
in O O
H3922 O O
and O O
40 O O
% O O
of O O
control O O
after O O
4 O O
days O O
in O O
MCF O O
- O O
7 O O
cells O O
. O O

Association O O
of O O
Syk B B_GENE
protein B I_GENE
tyrosine I I_GENE
kinase I I_GENE
( O O
PTK B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
with O O
LMP2A B B_GENE/B_DISEASE
occurs O O
at O O
the O O
two O O
tyrosines O O
of O O
the O O
LMP2A B B_GENE
immunoreceptor I I_GENE
tyrosine O O
- O O
based O O
activation O O
motif O O
, O O
and O O
it O O
is O O
hypothesized O O
that O O
Lyn B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PTK B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
associates O O
with O O
the O O
YEEA O O
amino O O
acid O O
motif O O
at O O
LMP2A B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
tyrosine O O
112 O O
( O O
Y112 O O
) O O
. O O

The O O
treatment O O
with O O
glucocorticoids O O
and O O
immunosuppressants O O
resulted O O
in O O
a O O
more O O
noticeable O O
decrease O O
in O O
the O O
levels O O
of O O
T3 O O
and O O
E B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RCF I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Four O O
of O O
these O O
fibroblast O O
clones O O
were O O
infected O O
with O O
a O O
retrovirus O O
containing O O
the O O
cDNA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
encoding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
myoD I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
a O O
puromycin O O
selection O O
marker O O
. O O

Serum O O
estriol O O
levels O O
during O O
beta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agonist O O
infusion O O
in O O
the O O
third O O
trimester O O
of O O
pregnancy O O
. O O

In O O
this O O
study O O
, O O
we O O
investigated O O
the O O
mechanism O O
by O O
which O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activates O O
gene O O
expression O O
in O O
conjunction O O
with O O
members O O
of O O
the O O
ATF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
CREB B B_GENE/B_LOCATION
family O O
. O O

Four O B_NUMBER[MEASURE]/B_LOCATION
of O O
12 O B_NUMBER[MEASURE]/B_PERSON
patients O B_NUMBER[MEASURE]/I_PERSON
( O O
33 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
) O O
were O O
initially O O
diagnosed O O
as O O
having O O
a O O
benign O B_DISEASE
disease O I_DISEASE
( O O
false O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
negatives O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

However O O
, O O
it O O
was O O
observed O O
that O O
storage O B_MEASURE/B_DISEASE
time O B_MEASURE/I_DISEASE
affected O O
significantly O O
the O O
biochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
changes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
occurring O O
in O O
the O O
constituents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
carrots O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
exposed O O
to O O
gamma O B_PROTEIN[GENE]
- O O
irradiation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Suppression O O
of O O
the O O
cka1 B B_DISEASE_ADJECTIVE[DISEASE]
delta I I_DISEASE_ADJECTIVE[DISEASE]
cka2 I I_DISEASE_ADJECTIVE[DISEASE]
- I I_DISEASE_ADJECTIVE[DISEASE]
8 I I_DISEASE_ADJECTIVE[DISEASE]
mutant I I_DISEASE_ADJECTIVE[DISEASE]
phenotype O O
occurs O O
by O O
interaction O O
of O O
CKB1 B B_GENE
with O O
the O O
defective O O
, O O
cka2 B B_GENE
- I I_GENE
8 I I_GENE
- O O
encoded O O
, O O
catalytic O O
subunit O O
. O O

The O O
median O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cumulative O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
incidence O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rates O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
found O O
to O O
be O O
341 O B_MEASURE
per O O
million O B_MEASURE
for O O
males O B_PERSON
and O O
296 O B_MEASURE
per O O
million O B_MEASURE
for O O
females O B_PERSON/B_BIO
. O O

Thomas O B_PERSON
, O O
S O B_PROTEIN[GENE]/B_DISEASE
. O O
S O B_OTHER/B_DISEASE
. O O

Similarly O O
, O O
antisense B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
TGF I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
beta I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
type I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
II I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
oligodeoxynucleotides I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
40 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
microM I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
resulted O O
in O O
a O O
58 O O
% O O
increase O O
in O O
branching O O
, O O
compared O O
to O O
scrambled O O
and O O
mismatched O O
sequence O O
controls O O
, O O
while O O
TGF B B_GENE
- I I_GENE
beta I I_GENE
, I I_GENE
type I I_GENE
II I I_GENE
receptor I I_GENE
mRNA I I_GENE
and O O
its O O
protein O O
expression O O
levels O O
were O O
suppressed O O
by O O
95 O O
and O O
84 O O
% O O
, O O
respectively O O
. O O

Secretion O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
cuticle O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
over O O
and O O
between O O
the O O
domed O O
apical O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
surfaces O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
these O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
leads O O
to O O
a O O
honeycomb O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
like O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
structure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
gives O O
the O O
superficial O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
wart O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
- O O
like O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
phenotype O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
mitotic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
clones O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
on O O
the O O
adult O B_PERSON/B_BIO
. O O

Taken O O
together O O
, O O
these O O
results O O
indicate O O
that O O
ICSBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
PU B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
critical O O
elements O O
for O O
IL B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
18 I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
expression O O
. O O

Based O O
on O O
these O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
it O O
has O O
been O O
concluded O O
that O O
an O O
IPFSA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O O
promote O O
the O O
healing O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
process O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
in O O
the O O
avascular O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
zone O I_LOCATION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
a O O
torn O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
meniscus O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
in O O
rabbits O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
that O O
systemic O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
vascularity O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
the O O
synovium O B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
or O O
the O O
meniscus O B_BODY_PART_OR_ORGAN_COMPONENT
is O O
not O O
essential O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
healing O O
to O O
occur O O
. O O

NASA O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CR O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1223 O B_NUMBER[MEASURE]
. O O

The O O
magnitude O B_MEASURE
of O O
all O O
four O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
parameters O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
increased O O
in O O
an O O
exponential O B_TIME[MEASURE]/B_ORGANIZATION
fashion O I_TIME[MEASURE]/I_ORGANIZATION
with O O
increasing O O
sperm O B_MEASURE
number O I_MEASURE
up O O
to O O
400 O B_MEASURE
x O O
10 O B_NUMBER[MEASURE]
( O O
6 O B_MEASURE
) O O
per O O
ejaculate O B_TIME[MEASURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

We O O
studied O O
about O O
the O O
histological O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
findings O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
kidneys O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
including O O
of O O
the O O
infiltrated O O
macrophages O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
in O O
one O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hour O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
post O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
transplantation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
kidney O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
biopsies O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O O
one O B_MEASURE/B_ENT
hour O I_MEASURE/I_ENT
biopsies O I_MEASURE/I_ENT
) O O
and O O
re O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
biopsies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
11 O B_PERSON/B_TIME[MEASURE]
patients O I_PERSON/I_TIME[MEASURE]
. O O

An O O
additional O O
stimulation O O
of O O
D1 B B_PROTEIN[GENE]/B_BIO
receptors I B_PROTEIN[GENE]/I_BIO
by O O
giving O O
SKF38393 O O
30 O O
min O O
later O O
produced O O
an O O
almost O O
continuous O O
pattern O O
of O O
jaw O O
openings O O
but O O
less O O
closure O O
movements O O
from O O
the O O
rest O O
position O O
, O O
and O O
the O O
openings O O
were O O
accompanied O O
by O O
frequent O O
tongue O O
protrusions O O
. O O

( O O
control O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hearts O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

The O O
( O O
0 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
diffraction O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
synthesized O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
HAp O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
crystals O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
a O O
Col O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fiber O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O O
an O O
around O O
60 O B_MEASURE
arching O I_MEASURE
angle O I_MEASURE
, O O
while O O
that O O
on O O
a O O
ChS O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
fiber O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
showed O O
just O O
around O O
10 O B_MEASURE
degrees O I_MEASURE
. O O

During O O
4 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
% O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
O2 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
ventilation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
baseline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
pulmonary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
vascular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
resistance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
PVR O B_LOCATION/B_DISEASE
) O O
and O O
the O O
dilator O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
response O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
both O O
ACh O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
SNP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
greater O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
2D O B_PERSON/B_MEASURE
lungs O I_PERSON/I_MEASURE
. O O

To O O
determine O O
the O O
role O O
of O O
the O O
transmembrane O O
region O O
of O O
HN B B_PROTEIN[GENE]/B_DISEASE
on O O
fusion O O
- O O
promoting O O
activity O O
, O O
mutant B B_GENE/B_BIO
HN I I_GENE/I_BIO
proteins I I_GENE/I_BIO
were O O
expressed O O
and O O
their O O
biological O O
activities O O
examined O O
. O O

To O O
be O O
a O O
nurse O B_PERSON
. O O

Transient O O
transfection O O
assays O O
indicated O O
that O O
the O O
( O O
- O O
4551 O O
) O O
UCP1 B B_GENE/B_LOCATION
- O O
CAT B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
construct O O
, O O
containing O O
the O O
5 O O
' O O
- O O
regulatory O O
region O O
of O O
the O O
rat B B_GENE
ucp I I_GENE
- I I_GENE
1 I I_GENE
gene I I_GENE
, O O
was O O
activated O O
by O O
PPARalpha B B_GENE
co O O
- O O
transfection O O
in O O
a O O
dose O O
- O O
dependent O O
manner O O
and O O
this O O
activation O O
was O O
potentiated O O
by O O
Wy O O
14 O O
, O O
643 O O
and O O
retinoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
X I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Synthesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
2 O B_MEASURE
- O O
( O O
2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
thiazolyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
alkanebenzimidazoles O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
- O O
potential O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
anthelmintics O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]

Human B B_GENE
CR2 I I_GENE
has O O
a O O
restricted O O
cellular O O
distribution O O
, O O
being O O
expressed O O
on O O
B O O
lymphocytes O O
, O O
dendritic O O
cells O O
of O O
the O O
spleen O O
, O O
pharyngeal O O
epithelial O O
cells O O
, O O
and O O
at O O
low O O
levels O O
on O O
some O O
T O O
lymphocytes O O
. O O

ADR1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
extracts O O
made O O
from O O
glucose O O
- O O
repressed O O
and O O
- O O
derepressed O O
cells O O
bound O O
UAS1 O O
DNA O O
with O O
similar O O
affinities O O
despite O O
having O O
greatly O O
different O O
abilities O O
to O O
activate O O
ADH2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
in O O
vivo O O
. O O

Furthermore O O
, O O
agonist O O
action O O
at O O
a O O
5 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
HT1 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
antagonist O O
action O O
at O O
5 B B_GENE/B_PERSON
- I I_GENE/I_PERSON
HT2 I I_GENE/I_PERSON
receptors I I_GENE/I_PERSON
both O O
appear O O
to O O
contribute O O
to O O
antidepressant O O
- O O
like O O
activity O O
on O O
the O O
DRL O O
72 O O
- O O
s O O
schedule O O
. O O

MsEPV O O
genes O O
with O O
putative O O
functions O O
in O O
prevention O O
and O O
repair O O
of O O
DNA O O
damage O O
include O O
a O O
complete O O
base O O
excision O O
repair O O
pathway O O
( O O
uracil B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glycosylase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
AP B B_ENZYME[GENE]
endonuclease I I_ENZYME[GENE]
, O O
DNA B B_GENE
polymerase I I_GENE
beta I I_GENE
, O O
and O O
an O O
NAD B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
+ I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
dependent I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
DNA I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
ligase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
a O O
photoreactivation O O
repair O O
pathway O O
( O O
cyclobutane B B_GENE/B_DISEASE
pyrimidine I I_GENE/I_DISEASE
dimer I I_GENE/I_DISEASE
photolyase I I_GENE/I_DISEASE
) O O
, O O
a O O
LINE B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
type I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
reverse I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transcriptase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
a O O
mutT B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
homologue I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
three O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O O
further O O
examined O O
with O O
regard O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
modulation O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
discharge O B_MEASURE/B_BIO
rate O I_MEASURE/I_BIO
i O O
) O O
during O O
motor O B_DISEASE/B_PROTEIN[GENE]
activity O B_DISEASE/I_PROTEIN[GENE]
in O O
W O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
ii O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O O
at O O
the O O
transitional O B_TIME[MEASURE]/B_LOCATION
phase O I_TIME[MEASURE]/I_LOCATION
from O O
SS O B_DISEASE/B_PROTEIN[GENE]
to O O
paradoxical O B_DISEASE
sleep O I_DISEASE
( O O
PS O B_LOCATION/B_PROTEIN[GENE]
) O O
, O O
iii O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O O
during O O
rapid O B_DISEASE_ADJECTIVE[DISEASE]
eye O I_DISEASE_ADJECTIVE[DISEASE]
movements O I_DISEASE_ADJECTIVE[DISEASE]
( O O
REMs O B_DISEASE/B_LOCATION
) O O
in O O
PS O B_LOCATION/B_PROTEIN[GENE]
, O O
and O O
iv O B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
) O O
following O O
electrical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
the O O
midbrain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
reticular O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
formation O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MRF O B_LOCATION/B_PROTEIN[GENE]
) O O
. O O

Likewise O O
, O O
the O O
consensus O O
signal O O
believed O O
to O O
be O O
involved O O
in O O
terminating O O
VV B B_GENE
early I I_GENE
gene I I_GENE
transcription O O
, O O
TTTTTNT O O
, O O
was O O
evident O O
at O O
the O O
3 O O
' O O
- O O
boundary O O
of O O
both O O
the O O
N2 O O
and O O
M1 O O
ORFs O O
suggesting O O
that O O
these O O
genes O O
may O O
be O O
VV B B_DISEASE_ADJECTIVE[DISEASE]
early I I_DISEASE_ADJECTIVE[DISEASE]
genes I I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
radiolabeled O O
, O O
900 O B_MEASURE
- O O
bp O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
amplicon O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
used O O
as O O
a O O
hybridization O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
probe O B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
screen O O
a O O
cDNA O B_GENE
library O I_GENE
constructed O O
from O O
poly O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
( O O
+ O B_PROTEIN[GENE]/B_DISEASE
) O O
RNA O B_GENE/B_BIO
isolated O O
from O O
induced O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
Taxus O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
from O O
which O O
a O O
full O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
length O B_GENE/B_MEASURE
transacetylase O I_GENE/I_MEASURE
sequence O I_GENE/I_MEASURE
was O O
obtained O O
. O O

Low O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
temperature O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
8 O B_PROTEIN[GENE]/B_LOCATION
degrees O I_PROTEIN[GENE]/I_LOCATION
C O I_PROTEIN[GENE]/I_LOCATION
) O O
impairs O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
secretory O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
again O O
independently O O
of O O
the O O
photoperiod O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
selected O O
. O O

Left O O
ventricle O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
to O O
coronary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
sinus O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
fistula O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
this O O
report O O
we O O
describe O O
the O O
structure O O
and O O
DNA O O
sequence O O
of O O
transcriptional O O
control O O
regions O O
from O O
both O O
human B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Wistar I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rat I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
single I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
copy I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
EGF I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
their O O
functional O O
analysis O O
in O O
epithelial O O
cell O O
cultures O O
. O O

The O O
magnesium O B_MEASURE
content O I_MEASURE
in O O
leukocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
could O O
not O O
be O O
estimated O O
because O O
of O O
interaction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
ion O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
Percoll O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
R O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
media O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

The O O
sequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
three O B_NUMBER[MEASURE]/B_ENT
of O O
them O O
revealed O O
pure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
CAG O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
stretches O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Furthermore O O
, O O
mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
in O O
element O B_GENE
II O I_GENE
result O O
in O O
changes O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
RNA O B_LOCATION/B_BIO
structure O I_LOCATION/I_BIO
near O O
element O B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
III O I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
a O O
long O B_MEASURE/B_LOCATION
- O O
range O B_PERSON/B_GENE
interaction O B_PERSON/I_GENE
that O O
may O O
promote O O
translation O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Although O O
the O O
QT O B_MEASURE
duration O I_MEASURE
was O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
p O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
0001 O B_MEASURE
) O O
at O O
night O B_MEASURE/B_LOCATION
, O O
the O O
beat O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
to O O
- O O
beat O B_MEASURE/B_LOCATION
variability O I_MEASURE/I_LOCATION
of O O
this O O
interval O B_MEASURE
was O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
: O O
in O O
the O O
time O B_MEASURE/B_LOCATION
domain O I_MEASURE/I_LOCATION
( O O
decreased O O
standard O B_MEASURE
deviation O I_MEASURE
, O O
p O O
= O O
0 O B_NUMBER[MEASURE]
. O O
0005 O B_MEASURE
) O O
, O O
in O O
the O O
frequency O B_MEASURE/B_LOCATION
domain O I_MEASURE/I_LOCATION
( O O
decreased O O
low O B_MEASURE/B_DISEASE
- O O
frequency O B_MEASURE
power O I_MEASURE
of O O
the O O
spectra O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
p O O
= O O
0 O B_MEASURE
. O O
004 O B_MEASURE
) O O
, O O
and O O
the O O
chaotic O B_MEASURE/B_LOCATION
domain O I_MEASURE/I_LOCATION
( O O
tighter O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clustering O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
points O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
the O O
Poincare O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
plots O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

The O O
biological O O
functions O O
of O O
rat O O
surfactant B B_GENE
protein I I_GENE
A I I_GENE
( O O
SP B B_DISEASE/B_LOCATION
- I I_DISEASE/I_LOCATION
A I I_DISEASE/I_LOCATION
) O O
, O O
an O O
oligomer O O
composed O O
of O O
18 O O
polypeptide O O
subunits O O
derived O O
from O O
a O O
single O O
gene O O
, O O
are O O
dependent O O
on O O
intact O O
disulfide O O
bonds O O
. O O

A O O
V1 B B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
mutant I B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
generated O O
in O O
vivo O O
with O O
11 O O
of O O
the O O
14 O O
N O O
- O O
terminal O O
amino O O
acids O O
altered O O
, O O
was O O
viable O O
and O O
produced O O
symptoms O O
typical O O
of O O
a O O
wild O O
- O O
type O O
infection O O
. O O

This O O
seems O O
to O O
take O O
place O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
the O O
same O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
nuclear O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
compartment O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
as O O
normal O B_GENE/B_BIO
cis O I_GENE/I_BIO
splicing O I_GENE/I_BIO
and O O
proceeds O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
through O O
Y O O
- O O
branched O O
intermediates O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
analogous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
the O O
lariats O B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
formed O O
in O O
cis O B_GENE/B_SPECIES[BIO]
splicing O B_GENE/I_SPECIES[BIO]
. O O

We O O
have O O
demonstrated O O
that O O
the O O
specific O O
determination O O
and O O
identification O O
of O O
plasma O O
FbDP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alone O O
is O O
not O O
sufficient O O
to O O
follow O O
the O O
effectiveness O O
of O O
thrombolytic O O
therapy O O
. O O

Chronic O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
recurrent O B_DISEASE_ADJECTIVE[DISEASE]
multifocal O I_DISEASE_ADJECTIVE[DISEASE]
osteomyelitis O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Maximum O B_MEASURE/B_PERSON
baroreceptor O I_MEASURE/I_PERSON
activity O I_MEASURE/I_PERSON
measured O O
at O O
140 O B_MEASURE/B_LOCATION
mm O I_MEASURE/I_LOCATION
Hg O I_MEASURE/I_LOCATION
and O O
the O O
slope O B_MEASURE/B_LOCATION
of O O
the O O
pressure O B_MEASURE/B_DISEASE
- O O
activity O B_MEASURE/B_LOCATION
curve O I_MEASURE/I_LOCATION
were O O
reduced O O
in O O
atherosclerotic O B_DISEASE/B_GENE
( O O
n O B_MEASURE/B_LOCATION
= O I_MEASURE/I_LOCATION
15 O I_MEASURE/I_LOCATION
) O O
compared O O
with O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
n O B_OTHER/B_MEASURE
= O O
13 O B_MEASURE
) O O
rabbits O B_BIO/B_PERSON
( O O
425 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
34 O B_MEASURE
versus O I_MEASURE
721 O I_MEASURE
+ O I_MEASURE
/ O O
- O O
30 O B_MEASURE/B_LOCATION
spikes O I_MEASURE/I_LOCATION
per O O
second O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
6 O B_MEASURE
. O O
2 O B_MEASURE/B_LOCATION
+ O I_MEASURE/I_LOCATION
/ O O
- O O
0 O B_MEASURE
. O O
6 O B_MEASURE
versus O I_MEASURE
10 O I_MEASURE
. O O
8 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
8 O B_MEASURE
spikes O I_MEASURE
per O O
second O B_SEQUENCE[MEASURE]
per O O
mm O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
Hg O I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
respectively O O
, O O
P O B_MEASURE/B_LOCATION
< O I_MEASURE/I_LOCATION
. O O
05 O B_MEASURE
) O O
. O O

A O O
pathogenetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
relation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O O
the O O
Eisenmenger O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
' O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
s O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
syndrome O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
is O O
discussed O O
. O O

Coronary O O
vasoconstriction O O
caused O O
by O O
endothelin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O O
enhanced O O
by O O
ischemia O O
- O O
reperfusion O O
and O O
by O O
norepinephrine O O
present O O
in O O
concentrations O O
typically O O
observed O O
after O O
neonatal O O
cardiopulmonary O O
bypass O O
. O O

Located O O
between O O
the O O
3 O O
' O O
trans O O
- O O
spliced O O
leader O O
acceptor O O
site O O
and O O
the O O
translational O O
initiation O O
codon O O
of O O
the O O
GP63 B B_GENE
gene I I_GENE
is O O
an O O
area O O
of O O
conserved O O
hexanucleotide O O
direct O O
repeats O O
( O O
CTCGCC O O
) O O
which O O
vary O O
in O O
number O O
according O O
to O O
species O O
. O O

An O O
association O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
found O O
between O O
zafirlukast O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
plasma O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
concentrations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
increases O B_DISEASE_ADJECTIVE[DISEASE]
in O O
PC8SRaw O B_MEASURE
10 O I_MEASURE
h O O
after O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
p O B_OTHER/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
. O O

Insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
secreting O O
islet O O
- O O
cell O O
tumours O O
of O O
the O O
pancreas O O
. O O

Disruption O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
and O O
reconstruction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
: O O
narrative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
insights O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
into O O
the O O
experience O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
family O B_PERSON/B_LOCATION
members O I_PERSON/I_LOCATION
caring O O
for O O
a O O
relative O B_PERSON
diagnosed O O
with O O
serious O B_DISEASE/B_LOCATION
mental O I_DISEASE/I_LOCATION
illness O I_DISEASE/I_LOCATION
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
the O O
posterior O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
wall O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
is O O
more O O
compliant O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
than O O
the O O
anterior O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
wall O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
that O O
is O O
, O O
for O O
a O O
given O O
difference O B_MEASURE
in O O
transmural O B_MEASURE/B_LOCATION
pressure O I_MEASURE/I_LOCATION
, O O
the O O
local O B_MEASURE
segment O I_MEASURE
length O I_MEASURE
change O I_MEASURE
of O O
the O O
posterior O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
wall O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
was O O
greater O B_MEASURE
) O O
. O O

We O O
have O O
previously O O
demonstrated O O
that O O
pyrene O O
in O O
diesel O O
- O O
exhaust O O
particles O O
( O O
DEP O O
) O O
has O O
an O O
adjuvant O O
activity O O
on O O
immunoglobulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
E I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
IgE B B_PROTEIN[GENE]/B_LOCATION
) O O
antibody O O
production O O
in O O
mice O O
immunized O O
with O O
Japanese O O
cedar O O
pollen O O
allergen O O
( O O
JCPA O O
) O O
or O O
ovalbumin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O O
OA B B_LOCATION/B_DISEASE
) O O
intraperitoneally O O
. O O

Partial O O
characterization O O
of O O
the O O
CCAAT O O
box O O
in O O
the O O
promoter O O
of O O
the O O
hLGFBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O O
interaction O O
with O O
negatively O O
acting O O
transcription O O
factors O O
in O O
decidualized O O
human O O
endometrial O O
stromal O O
cells O O
. O O

We O O
conclude O O
that O O
transcription O O
of O O
both O O
SCD1 B B_GENE/B_LOCATION
and O O
SCD2 B B_GENE/B_DISEASE
genes I I_GENE/I_DISEASE
is O O
responsive O O
to O O
cellular O O
sterol O O
levels O O
and O O
to O O
the O O
levels O O
of O O
nuclear O O
SREBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
ADD1 B B_PROTEIN[GENE]/B_LOCATION
and O O
that O O
transcriptional O O
induction O O
requires O O
three O O
spatially O O
conserved O O
cis O O
elements O O
, O O
that O O
bind O O
SREBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
NF B B_GENE
- I I_GENE
Y I I_GENE
. O O

Three O O
transcriptional O O
control O O
elements O O
within O O
300 O O
base O O
pairs O O
of O O
the O O
5 O O
' O O
- O O
flanking O O
region O O
of O O
the O O
rat B B_GENE/B_LOCATION
glucagon I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
interact O O
with O O
regulatory O O
cellular O O
proteins O O
and O O
direct O O
transcription O O
only O O
in O O
glucagon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
producing O O
islet O O
cells O O
. O O

A O O
role O O
for O O
phosphatidylinositol B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
regulation O O
of O O
beta B B_GENE
1 I I_GENE
integrin I I_GENE
activity O O
by O O
the O O
CD2 B B_GENE/B_PERSON
antigen O O
. O O

Relationship O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
age O B_DISEASE
- O O
associated O O
endocrine O B_DISEASE
deficiencies O I_DISEASE
and O O
muscle O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
elderly O B_PERSON/B_DISEASE
women O I_PERSON/I_DISEASE
: O O
a O O
cross O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
sectional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

In O O
contrast O O
, O O
the O O
sequences O O
essential O O
for O O
the O O
transcription O O
of O O
EFT1 B B_GENE
were O O
localized O O
to O O
the O O
region O O
between O O
the O O
start O O
ATG O O
and O O
the O O
stop O O
codon O O
of O O
the O O
VPS17 B B_GENE
gene I I_GENE
that O O
terminates O O
267 O O
nt O O
upstream O O
on O O
the O O
same O O
strand O O
. O O

Exposure O O
of O O
raft O O
cultures O O
to O O
activators O O
of O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
such O O
as O O
phorbol O O
esters O O
, O O
results O O
in O O
the O O
further O O
induction O O
of O O
late B B_GENE
gene I I_GENE
expression O O
as O O
well O O
as O O
virion O O
assembly O O
. O O

A O O
case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
2 O B_DISEASE
cancers O I_DISEASE
of O O
the O O
colon O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE

The O O
" O O
Gregg O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phenomenon O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
implies O O
that O O
myocardial O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
oxygen O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
consumption O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
MVO2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
increase O B_DISEASE_ADJECTIVE[DISEASE]
when O O
coronary O B_DISEASE
perfusion O I_DISEASE
is O O
enhanced O O
within O O
or O O
above O O
the O O
autoregulatory O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
range O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

We O O
have O O
mapped O O
the O O
specific O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
domains O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
within O O
each O O
of O O
the O O
proteins O B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responsible O I_LOCATION/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
this O O
interaction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
each O O
of O O
the O O
studied O O
HPV O O
types O O
, O O
the O O
two O O
CDP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
Cut B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding O O
sites O O
of O O
PSM B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
overlap O O
with O O
the O O
known O O
or O O
presumed O O
binding O O
sites O O
of O O
the O O
replication B B_PROTEIN[GENE]/B_BIO
initiator I I_PROTEIN[GENE]/I_BIO
protein I I_PROTEIN[GENE]/I_BIO
E1 I I_PROTEIN[GENE]/I_BIO
. O O

Reduced O O
cell O B_MEASURE/B_LOCATION
numbers O I_MEASURE/I_LOCATION
72 O I_MEASURE/I_LOCATION
h O O
after O O
insonation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
were O O
recorded O O
when O O
the O O
cells O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
were O O
insonated O O
at O O
an O O
antinode O B_LOCATION
but O O
not O O
when O O
they O O
were O O
at O O
a O O
node O B_LOCATION/B_DISEASE
. O O

Hydroxyl O O
radical O O
footprinting O O
of O O
DNA O O
complexes O O
of O O
the O O
ets B B_GENE/B_LOCATION
domain I B_GENE/I_LOCATION
of O O
PU B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
its O O
comparison O O
to O O
the O O
crystal O O
structure O O
. O O

ATF O O
is O O
formulated O O
from O O
the O O
prothrombin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
time O O
( O O
PT O O
) O O
, O O
fibrinogen B B_MEASURE/B_PROTEIN[GENE]
transformation O O
rate O O
( O O
FTR O O
) O O
( O O
a O O
representation O O
of O O
thrombin B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O O
) O O
, O O
and O O
a O O
consideration O O
of O O
the O O
fibrinogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
FBG B B_PROTEIN[GENE]/B_LOCATION
) O O
content O O
of O O
blood O O
plasma O O
. O O

( O O
LH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
P O O
< O O
0 O O
. O O
05 O O
, O O
LH B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
FSH B B_GENE
P O O
< O O
0 O O
. O O
01 O O
) O O
. O O

Inhibition O O
of O O
Raf B B_GENE
- I I_GENE
1 I I_GENE
signaling O O
by O O
a O O
monoclonal O O
antibody O O
, O O
which O O
interferes O O
with O O
Raf B B_GENE
- I I_GENE
1 I I_GENE
activation O O
and O O
with O O
Mek B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
substrate O O
binding O O
. O O

Phenotypic O O
and O O
molecular O O
analyses O O
of O O
patients O O
with O O
partial O O
chromosome O O
21 O O
monosomy O O
enabled O O
us O O
to O O
define O O
a O O
region O O
, O O
spanning O O
2 O O
. O O
4 O O
Mb O O
between O O
D21S190 B B_GENE
and O O
D21S226 B B_GENE/B_TIME[MEASURE]
, O O
associated O O
with O O
arthrogryposis O O
, O O
mental O O
retardation O O
, O O
hypertonia O O
, O O
and O O
several O O
facial O O
anomalies O O
. O O

The O O
classic O O
sterol O O
regulatory O O
cis O O
element O O
( O O
sre O O
- O O
1 O O
) O O
in O O
the O O
LDL B B_GENE
receptor I I_GENE
promoter O O
mediates O O
sterol B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulatory I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
element I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SREBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
- O O
binding O O
and O O
the O O
effects O O
of O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
platelet B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
derived I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
growth I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PDGF B B_GENE
) O O
. O O

The O O
Ca2 O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O O
concentration O B_MEASURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
in O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serum O O
after O O
intragastrically O O
fenarimol O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
administration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
doses O O
1 O B_MEASURE
/ O O
40 O B_MEASURE
, O O
1 O B_NUMBER[MEASURE]
/ O O
20 O B_MEASURE
and O O
1 O B_NUMBER[MEASURE]
/ O O
10 O B_MEASURE
LD50 O I_MEASURE
) O O
during O O
5 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
days O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
was O O
investigated O O
. O O

In O O
Cos O O
7 O O
cells O O
transfected O O
with O O
oCRF1var B B_GENE
, O O
cAMP O O
accumulation O O
was O O
only O O
observed O O
at O O
the O O
highest O O
concentration O O
of O O
oCRF B B_PROTEIN[GENE]/B_DISEASE
utilized O O
( O O
100 O O
nM O O
) O O
. O O

Pyknotic O B_DISEASE/B_GENE
osteocytes O B_DISEASE/I_GENE
increased O O
at O O
12 O B_MEASURE
h O O
( O O
p O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
and O O
2 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
( O O
p O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
of O O
ischemia O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
right O B_BODY_PART_OR_ORGAN_COMPONENT
cornea O I_BODY_PART_OR_ORGAN_COMPONENT
of O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
cauterized O O
by O O
drops O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
1 O B_MEASURE
. O O
5 O B_MEASURE/B_PERSON
N O I_MEASURE/I_PERSON
HC1 O I_MEASURE/I_PERSON
over O O
30 O B_TIME[MEASURE]/B_BIO
s O B_TIME[MEASURE]/I_BIO
; O O
the O O
left O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
one O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
served O O
as O O
a O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

The O O
isoproterenol O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
infusion O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
was O O
adjusted O O
so O O
that O O
heart O B_MEASURE/B_LOCATION
rate O B_MEASURE/I_LOCATION
( O O
HR O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
) O O
was O O
at O O
least O O
30 O B_MEASURE
beats O I_MEASURE
/ O O
min O B_TIME[MEASURE]/B_LOCATION
greater O I_TIME[MEASURE]/I_LOCATION
than O O
baseline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

This O O
is O O
probably O O
because O O
, O O
in O O
vivo O O
, O O
some O O
bacteria O O
( O O
perhaps O O
dormant O O
forms O O
) O O
are O O
not O O
entirely O O
dependent O O
upon O O
urease B B_BACTERIUM[BIO]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
survival O O
. O O

The O O
system O O
consists O O
of O O
a O O
microcomputer O O
and O O
six O O
laboratory O O
analyzers O O
: O O
a O O
blood O O
gas O O
analyzer O O
, O O
a O O
flame O O
photometer O O
, O O
a O O
plasma O O
osmotic O O
pressure O O
meter O O
, O O
a O O
chloride O O
ion O O
titrator O O
, O O
a O O
blood O O
sugar O O
analyzer O O
, O O
and O O
a O O
hemoglobin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
concentration O O
and O O
saturation O O
meter O O
. O O

Comparing O O
the O O
outcome O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
group O B_ORGANIZATION/B_PERSON
having O O
histologically O O
normal O B_DISEASE_ADJECTIVE[DISEASE]
biopsies O I_DISEASE_ADJECTIVE[DISEASE]
with O O
the O O
group O B_ORGANIZATION/B_PERSON
having O O
nonspecifically O O
abnormal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ones O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
it O O
is O O
concluded O O
that O O
frontal O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
biopsy O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
not O O
of O O
such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
high O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
prognostic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
value O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
as O O
has O O
been O O
claimed O O
in O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
reports O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

He O O
presented O O
with O O
left O O
lower O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
abdominal O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
pain O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
hematoma O B_DISEASE
after O O
a O O
fall O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Fusion O O
of O O
mouse B B_GENE
CD8 I I_GENE
+ I I_GENE
class B I_GENE
I I I_GENE
MHC I I_GENE
- O O
restricted O O
T O O
cells O O
with O O
the O O
BW5147 O O
thymoma O O
invariably O O
yields O O
CD8 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
hybridomas O O
in O O
which O O
RNA O O
transcribed O O
from O O
the O O
CD8 B B_GENE
alpha I I_GENE
( O O
Lyt B B_PROTEIN[GENE]/B_MEASURE
- I I_PROTEIN[GENE]/I_MEASURE
2 I I_PROTEIN[GENE]/I_MEASURE
) O O
gene O O
is O O
undetectable O O
. O O

Peak O O
plasma O O
ACTH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
responses O O
were O O
not O O
significantly O O
different O O
between O O
control O O
and O O
patient O O
groups O O
. O O

For O O
the O O
P B B_GENE/B_LOCATION
transcript I I_GENE/I_LOCATION
from O O
phage O O
with O O
the O O
G O O
( O O
- O O
) O O
orientation O O
, O O
full O O
termination O O
activity O O
required O O
both O O
the O O
region O O
containing O O
the O O
stem O O
- O O
loop O O
structure O O
and O O
upstream O O
sequences O O
. O O

Development O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
neural O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
control O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
alimentary O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
motor O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
function O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O O
the O O
vertebrates O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Nb2 O O
- O O
11C O O
cells O O
expressed O O
three O O
PNR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
related I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
2 O O
. O O
5 O O
, O O
3 O O
. O O
0 O O
and O O
> O O
10 O O
kb O O
. O O

These O O
results O O
suggest O O
that O O
the O O
Reg1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
Glc7 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
phosphatase O O
is O O
a O O
cytoplasmic O O
component O O
of O O
the O O
machinery O O
responsible O O
for O O
returning O O
Snf1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
to O O
its O O
basal O O
level O O
and O O
reestablishing O O
glucose O O
repression O O
. O O

However O O
, O O
the O O
blend O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
Metanil O B_COLOR/B_BIO
yellow O I_COLOR/I_BIO
and O O
Orange O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
II O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
( O O
1 O B_MEASURE
: O O
1 O B_MEASURE
) O O
resulted O O
in O O
the O O
D1 O B_MEASURE/B_PERSON
50 O I_MEASURE/I_PERSON
. O O
value O B_MEASURE
of O O
288 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
min O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
majority O O
of O O
these O O
cells O O
were O O
also O O
OKT4 B B_GENE
positive O O
( O O
helper O O
/ O O
inducer O O
T O O
lymphocytes O O
) O O
, O O
while O O
the O O
minority O O
were O O
OKT8 B B_GENE
positive O O
( O O
suppressor O O
/ O O
cytotoxic O O
T O O
lymphocytes O O
) O O
. O O

AIMS O O
: O O
We O O
postulated O O
that O O
perhexiline O O
, O O
a O O
novel O O
anti O O
- O O
ischaemic O O
agent O O
with O O
an O O
oxygen O O
- O O
sparing O O
metabolic O O
effect O O
in O O
the O O
myocardium O O
( O O
via O O
inhibition O O
of O O
carnitine B B_GENE
palmitoyltransferase I I_GENE
- I I_GENE
1 I I_GENE
) O O
and O O
no O O
adverse O O
haemodynamic O O
effects O O
, O O
may O O
improve O O
symptomatic O O
status O O
in O O
elderly O O
patients O O
with O O
severe O O
aortic O O
stenosis O O
. O O

The O O
IFNAR B B_GENE
chain I I_GENE
interacts O O
with O O
both O O
IFN B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
IFN B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
demonstrated O O
by O O
cross O O
- O O
linking O O
. O O

To O O
clone O O
cDNAs O O
for O O
the O O
beta O O
subunit O O
of O O
rabbit B B_GENE
eIF I I_GENE
- I I_GENE
2B I I_GENE
, O O
amino O O
acid O O
sequence O O
data O O
was O O
first O O
obtained O O
and O O
used O O
to O O
design O O
redundant O O
oligonucleotide O O
primers O O
for O O
use O O
in O O
PCR O O
. O O

We O O
report O O
the O O
cloning O O
of O O
the O O
ade1 B B_GENE
gene I I_GENE
on O O
a O O
4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kb I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Sau3A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
insert I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
yeast O O
shuttle O O
vector O O
pWH5 O O
. O O

Nimodipine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
5 O B_MEASURE
micrograms O I_MEASURE
/ O O
kg O B_MEASURE
) O O
followed O O
by O O
infusion O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
0 O B_MEASURE
. O O
75 O B_MEASURE
microgram O I_MEASURE
/ O O
kg O B_MEASURE/B_PERSON
/ O O
min O B_PERSON/B_TIME[MEASURE]
lowered O O
the O O
blood O B_DISEASE/B_GENE
pressure O B_DISEASE/I_GENE
by O O
10 O B_NUMBER[MEASURE]
% O I_NUMBER[MEASURE]
in O O
both O O
normotensive O B_DISEASE_ADJECTIVE[DISEASE]
and O O
hypertensive O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
the O O
same O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
dose O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
schedule O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
nifedipine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O O
not O O
lower O B_DISEASE_ADJECTIVE[DISEASE]
MAP O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
may O O
be O O
relevant O B_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
pathogenesis O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
alveolitis O B_DISEASE_ADJECTIVE[DISEASE]
in O O
organic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dust O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
lung O B_DISEASE/B_LOCATION
diseases O I_DISEASE/I_LOCATION
. O O

The O O
odds O B_MEASURE
of O O
atopy O B_DISEASE
( O O
defined O O
as O O
a O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
at O O
least O O
one O B_NUMBER[MEASURE]
of O O
the O O
antigens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
were O O
5 O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
times O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
higher O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
odds O B_MEASURE/B_LOCATION
ratio O I_MEASURE/I_LOCATION
= O O
7 O B_MEASURE
. O O
0 O B_MEASURE
; O O
95 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
confidence O I_MEASURE/I_LOCATION
interval O I_MEASURE/I_LOCATION
= O O
1 O B_MEASURE
. O O
6 O B_MEASURE
- O O
31 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
; O O
p O O
= O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
in O O
the O O
uninfected O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
after O O
taking O O
into O O
account O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
potential O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
influence O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
gender O B_PERSON/B_MEASURE
and O O
age O B_MEASURE/B_DISEASE
. O O

A O O
selectable O O
marker O O
for O O
transformation O O
was O O
constructed O O
by O O
transcriptional O O
fusion O O
of O O
a O O
Ustilago B B_GENE
maydis I I_GENE
heat I I_GENE
shock I I_GENE
gene I I_GENE
promoter I I_GENE
with O O
the O O
hygromycin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphotransferase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Escherichia I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
coli I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
structure O O
of O O
the O O
mAR B B_DISEASE_ADJECTIVE[DISEASE]/B_SEQUENCE[MEASURE]
ORF O O
was O O
confirmed O O
by O O
sequence O O
analysis O O
of O O
mAR B B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
cDNA O O
fragments O O
, O O
which O O
were O O
obtained O O
by O O
PCR O O
amplification O O
of O O
mouse O O
testis O O
cDNA O O
, O O
using O O
mAR B B_NUMBER[MEASURE]/B_BIO
specific O O
primers O O
. O O

The O O
aim O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
to O O
determine O O
the O O
response O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
human O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
visual O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
cortex O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
to O O
chromatic O O
stimuli O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
using O O
magnetoencephalography O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
MEG O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
. O O

The O O
role O O
of O O
NUT1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
regulation O O
of O O
nitrogen O O
metabolism O O
in O O
the O O
disease O O
process O O
was O O
evaluated O O
by O O
pathogenicity O O
assays O O
. O O

These O O
three O O
phases O O
of O O
cyclin B B_GENE
E I I_GENE
association O O
with O O
chromatin O O
may O O
facilitate O O
the O O
diverse O O
activities O O
of O O
cyclin B B_GENE/B_DISEASE
E I I_GENE/I_DISEASE
- O O
- O O
Cdk2 B B_GENE/B_MEASURE
in O O
initiating O O
replication O O
, O O
blocking O O
rereplication O O
, O O
and O O
allowing O O
resetting O O
of O O
origins O O
after O O
mitosis O O
. O O

No O O
IORT O B_DISEASE
related O I_DISEASE
mortality O I_DISEASE
has O O
been O O
observed O O
. O O

Dermatophagoides O O
farinae O O
- O O
sensitized O O
lymphocytes O O
in O O
asthmatic O O
children O O
as O O
evaluated O O
by O O
interleukin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
IL B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
2 I I_GENE/I_MEASURE
) O O
production O O
and O O
acquisition O O
of O O
IL B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
2 I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
responsiveness O O

Enterotoxin O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
production O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O O
staphylococci O B_BACTERIUM[BIO]/B_DISEASE
isolated O O
from O O
foods O B_LOCATION/B_PERSON
in O O
France O B_LOCATION/B_BIO
. O O

Measurements O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
given O O
a O O
dose O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
propranolol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O O
partially O O
inhibited O O
the O O
NA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
Q O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
IBAT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
indicated O O
that O O
the O O
decline O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
ENAIBAT O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O O
attributable O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
primarily O O
to O O
the O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
Q O B_MEASURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
rather O O
than O O
to O O
increasing O O
saturation O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
uptake O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mechanisms O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Plasma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LH I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
progesterone O O
levels O O
after O O
single O O
or O O
multiple O O
injections O O
of O O
synthetic O O
LH B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
RH B B_PROTEIN[GENE]/B_DISEASE
in O O
anoestrous O O
ewes O O
and O O
comparison O O
with O O
levels O O
during O O
the O O
oestrous O O
cycle O O
. O O

MATERIAL O B_LOCATION/B_TIME[MEASURE]
AND O O
METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O

But O O
, O O
when O O
mated O O
males O B_PERSON/B_BIO
built O O
nests O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
absence O B_DISEASE/B_LOCATION
of O O
young O B_PERSON/B_BIO
, O O
T O B_MEASURE/B_LOCATION
levels O I_MEASURE/I_LOCATION
were O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
in O O
all O O
other O B_PERSON/B_LOCATION
conditions O I_PERSON/I_LOCATION
, O O
though O O
only O O
for O O
early O B_PERSON/B_BIO
broods O I_PERSON/I_BIO
. O O

Primers O O
were O O
developed O O
for O O
specific O O
amplification O O
of O O
9804 B B_GENE/B_DISEASE
gene I I_GENE/I_DISEASE
fragments I I_GENE/I_DISEASE
. O O

The O O
promyelocytic B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
leukemia I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
protein I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
interacts O O
with O O
Sp1 B B_GENE
and O O
inhibits O O
its O O
transactivation O O
of O O
the O O
epidermal B B_GENE
growth I I_GENE
factor I I_GENE
receptor I I_GENE
promoter O O
. O O

The O O
mutants O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
retained O O
the O O
parental O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ability O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
participate O O
in O O
intergeneric O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coaggregation O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
human O B_BIO/B_GENE
oral O B_BIO/I_GENE
actinomyces O B_BIO/I_GENE
, O O
indicating O O
the O O
specificity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
in O O
altering O O
intrageneric O B_DISEASE_ADJECTIVE[DISEASE]
coaggregations O I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
Saccharomyces O O
cerevisiae O O
targets O O
of O O
rapamycin O O
, O O
TOR1 B B_GENE
and O O
TOR2 B B_GENE
, O O
signal O O
activation O O
of O O
cell O O
growth O O
in O O
response O O
to O O
nutrient O O
availability O O
. O O

Biology O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Anopheles O B_SPECIES[BIO]/B_DISEASE
quadrimaculatus O B_SPECIES[BIO]/I_DISEASE
under O O
field O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
central O B_LOCATION
Florida O I_LOCATION
. O O

Immunogenicity O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
tested O O
in O O
experiments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
on O O
guinea O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
pigs O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
rabbits O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
not O O
reduced O O
and O O
corresponded O O
to O O
that O O
of O O
the O O
reference O B_DISEASE/B_PROTEIN[GENE]
STI O B_DISEASE/I_PROTEIN[GENE]
- O O
1 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vaccine O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
Thrombolysis O O
in O O
Myocardial O O
Infarction O O
( O O
TIMI O O
) O O
Phase O O
II O O
Trial O O
randomized O O
3 O O
, O O
339 O O
patients O O
to O O
either O O
an O O
invasive O O
( O O
INV O O
, O O
n O O
= O O
1 O O
, O O
681 O O
) O O
or O O
a O O
conservative O O
( O O
CON O O
, O O
n O O
= O O
1 O O
, O O
658 O O
) O O
strategy O O
after O O
intravenous O O
recombinant B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tissue I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
type I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
plasminogen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
activator I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
rt B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PA I I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
for O O
acute O O
myocardial O O
infarction O O
. O O

In O O
addition O O
, O O
mutations O O
within O O
the O O
Ubx B B_GENE/B_BIO
unit I I_GENE/I_BIO
exons I I_GENE/I_BIO
are O O
known O O
and O O
most O O
of O O
these O O
behave O O
as O O
null O O
alleles O O
. O O

Taken O O
together O O
, O O
these O O
data O O
suggest O O
that O O
the O O
Smad3 B B_GENE
/ O O
Smad4 B B_GENE/B_MEASURE
complex O O
has O O
at O O
least O O
two O O
separable O O
nuclear O O
functions O O
: O O
it O O
forms O O
a O O
rapid O O
, O O
yet O O
transient O O
sequence O O
- O O
specific O O
DNA O O
binding O O
complex O O
, O O
and O O
it O O
potentiates O O
AP1 B B_GENE
- O O
dependent O O
transcriptional O O
activation O O
. O O

When O O
phentermine O O
was O O
mixed O O
with O O
other O O
unlabeled O O
reversible O O
MAO B B_ENZYME[GENE]
inhibitors O O
( O O
e O O
. O O
g O O
. O O
pseudoephedrine O O
, O O
ephedrine O O
, O O
norephedrine O O
; O O
estradiol O O
benzoate O O
) O O
, O O
the O O
degree O O
of O O
MAO B B_GENE
inhibition O O
was O O
additive O O
. O O

Here O O
we O O
report O O
that O O
point O O
mutations O O
of O O
the O O
Abd B B_GENE
- I I_GENE
B I I_GENE
gene I I_GENE
in O O
trans O O
suppress O O
the O O
Fab B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
7 I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
phenotype I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
a O O
pairing O O
- O O
dependent O O
manner O O
and O O
thus O O
represent O O
a O O
type O O
of O O
transvection O O
. O O

4 O O
382 O O
new O O
mothers O O
were O O
examined O O
retrospectively O O
with O O
the O O
enzyme O O
- O O
linked O O
immunosorbent O O
assay O O
( O O
ELISA O O
) O O
for O O
IgG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activity O O
to O O
cytomegalovirus O O
( O O
CMV O O
) O O
during O O
pregnancy O O
. O O

Also O O
, O O
residues O O
273 O O
to O O
287 O O
, O O
which O O
are O O
identical O O
in O O
sequence O O
to O O
a O O
15 O O
- O O
amino O O
- O O
acid O O
segment O O
near O O
the O O
carboxy O O
terminus O O
of O O
the O O
simian B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
foamy I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcriptional I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Taf I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
can O O
independently O O
enhance O O
the O O
activity O O
of O O
the O O
minimal O O
activator O O
region O O
. O O

An O O
analogue O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
calcium O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
strontium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
chloride O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Sr O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
89 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
rapidly O O
cleared O O
from O O
the O O
blood O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
after O O
i O O
. O O
v O B_PROTEIN[GENE]/B_LOCATION
. O O
injection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
pneumoperitoneum O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
dissemination O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
scar O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
implantation O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
intra O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
abdominal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tumor O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
two O B_NUMBER[MEASURE]
of O O
these O O
nine O B_PERSON/B_TIME[MEASURE]
patients O I_PERSON/I_TIME[MEASURE]
, O O
a O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
dyskinesia O B_DISEASE
score O I_DISEASE
was O O
observed O O
without O O
a O O
concomitant O B_DISEASE_ADJECTIVE[DISEASE]
worsening O I_DISEASE_ADJECTIVE[DISEASE]
of O O
parkinsonian O B_DISEASE
symptoms O I_DISEASE
, O O
whereas O O
in O O
the O O
remaining O O
seven O B_NUMBER[MEASURE]/B_PERSON
, O O
full O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
parkinsonian O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
akinesia O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
followed O O
THDL O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Alterations O O
in O O
TCR B B_GENE
- O O
MHC B B_GENE/B_DISEASE
contacts O O
subsequent O O
to O O
cross O O
- O O
recognition O O
of O O
class B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MHC I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
singly O O
substituted O O
peptide O O
variants O O
. O O

Two O B_PERSON
patients O I_PERSON
with O O
Ewing O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
' O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
s O O
sarcoma O B_DISEASE
relapsed O O
( O O
1 O B_PERSON/B_TIME[MEASURE]
patient O B_PERSON/I_TIME[MEASURE]
with O O
both O O
local O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
distant O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
failure O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
) O O
at O O
26 O B_MEASURE
and O O
58 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
and O O
were O O
again O O
rendered O O
disease O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
free O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
with O O
surgery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
total O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
body O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
irradiation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
further O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
chemotherapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

The O O
cloning O O
of O O
human B B_GENE/B_SPECIES[BIO]
apo I B_GENE/I_SPECIES[BIO]
B I B_GENE/I_SPECIES[BIO]
- I B_GENE/I_SPECIES[BIO]
100 I B_GENE/I_SPECIES[BIO]
has O O
provided O O
new O O
insights O O
into O O
the O O
structure O O
and O O
physicochemical O O
properties O O
of O O
apo B B_GENE
B I I_GENE
- I I_GENE
100 I I_GENE
and O O
will O O
facilitate O O
studies O O
on O O
the O O
factors O O
modulating O O
apo B B_GENE
B I I_GENE
- I I_GENE
100 I I_GENE
biosynthesis O O
and O O
the O O
expression O O
of O O
the O O
apo B B_GENE/B_DISEASE
B I I_GENE/I_DISEASE
- I I_GENE/I_DISEASE
100 I I_GENE/I_DISEASE
gene I I_GENE/I_DISEASE
in O O
patients O O
with O O
dyslipoproteinemias O O
. O O

Angiographic O B_PERSON
follow O I_PERSON
- O O
up O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O O
obtained O O
in O O
92 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
patients O B_PERSON
with O O
a O O
primary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
success O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
angioplasty O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
. O O

Acceptability O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
home O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
monitoring O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
as O O
an O O
aid O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
conception O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Repeated O O
interferon B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
IFN B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
silencer O O
B O O
motifs O O
and O O
a O O
lysozyme B B_GENE/B_MEASURE
silencer I I_GENE/I_MEASURE
1 I I_GENE/I_MEASURE
motif I I_GENE/I_MEASURE
have O O
been O O
found O O
in O O
the O O
CD95 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
at O O
approximately O O
- O O
1 O O
, O O
600 O O
and O O
- O O
1 O O
, O O
100 O O
, O O
respectively O O
. O O

Action O O
against O O
Vibrio O O
cholerae O O
O1 O O
Tox B B_GENE/B_DISEASE
+ I B_GENE/I_DISEASE
of O O
chemical O O
products O O
used O O
in O O
the O O
lemon O O
production O O
. O O

Patients O O
with O O
the O O
chronic O O
photosensitivity O O
dermatitis O O
with O O
actinic O O
reticuloid O O
syndrome O O
have O O
high O O
total O O
serum O O
IgE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
concentrations O O
. O O

The O O
sequence O B_LOCATION/B_MEASURE
of O O
the O O
25 O B_MEASURE
- O O
kDa O B_PROTEIN[GENE]/B_MEASURE
chain O I_PROTEIN[GENE]/I_MEASURE
of O O
the O O
alpha O B_GENE
subunit O I_GENE
was O O
found O O
in O O
a O O
cDNA O B_GENE
clone O I_GENE
, O O
and O O
the O O
amino O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
acid O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
deduced O O
from O O
the O O
cDNA O B_GENE
establishes O O
the O O
complete O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amino O I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid O I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence O I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
25 O B_MEASURE
- O O
kDa O B_PROTEIN[GENE]/B_MEASURE
chain O I_PROTEIN[GENE]/I_MEASURE
. O O

Characterization O O
of O O
the O O
chromosome O O
19 O O
breakpoint O O
region O O
revealed O O
that O O
the O O
transcription B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
- I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
encoding I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
USF2 I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
is O O
affected O O
. O O

Tax B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
active O O
Tax B B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutants I B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
able O O
to O O
abrogate O O
the O O
G1 O O
arrest O O
and O O
apoptosis O O
induced O O
by O O
p53 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
this O O
effect O O
does O O
not O O
correlate O O
with O O
an O O
altered O O
localization O O
of O O
nuclear B B_GENE
p53 I I_GENE
or O O
with O O
the O O
disruption O O
of O O
p53 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complexes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

When O O
patients O B_PERSON/B_BIO
were O O
admitted O O
within O O
one O B_TIME[MEASURE]
week O I_TIME[MEASURE]
of O O
the O O
onset O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
dark O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
urine O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
45 O B_PERSON/B_NUMBER[MEASURE]
% O I_PERSON/I_NUMBER[MEASURE]
were O O
found O O
to O O
be O O
shedding O O
HAV O B_VIRUS[BIO]/B_DISEASE
, O O
whereas O O
only O O
11 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
of O O
specimens O B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
obtained O O
from O O
patients O B_PERSON/B_LOCATION
admitted O O
during O O
the O O
second O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
week O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contained O O
virus O B_DISEASE/B_BIO
. O O

Biochemical O O
studies O O
have O O
identified O O
a O O
cellular O O
non B B_PROTEIN[GENE]/B_MEASURE
- I I_PROTEIN[GENE]/I_MEASURE
P I I_PROTEIN[GENE]/I_MEASURE
element I I_PROTEIN[GENE]/I_MEASURE
- I I_PROTEIN[GENE]/I_MEASURE
encoded I I_PROTEIN[GENE]/I_MEASURE
DNA I I_PROTEIN[GENE]/I_MEASURE
binding I I_PROTEIN[GENE]/I_MEASURE
protein I I_PROTEIN[GENE]/I_MEASURE
, O O
termed O O
the O O
inverted B B_GENE/B_MEASURE
repeat I I_GENE/I_MEASURE
binding I I_GENE/I_MEASURE
protein I I_GENE/I_MEASURE
( O O
IRBP B B_DISEASE/B_GENE
) O O
, O O
that O O
specifically O O
interacts O O
with O O
the O O
outer O O
half O O
of O O
the O O
31 O O
- O O
bp O O
terminal O O
inverted O O
repeats O O
. O O

Threefold O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
risks O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
observed O O
for O O
men O B_PERSON/B_LOCATION
with O O
the O O
highest O B_MEASURE/B_LOCATION
level O I_MEASURE/I_LOCATION
of O O
intensity O B_MEASURE/B_DISEASE
and O O
for O O
those O O
with O O
the O O
highest O B_MEASURE
probability O I_MEASURE
of O O
EMF O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
although O O
women O B_PERSON
with O O
heavy O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
EMF O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
exposure O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
did O O
not O O
experience O O
increased O O
risk O B_DISEASE
. O O

In O O
the O O
spontaneous O O
abortion O O
group O O
, O O
the O O
levels O O
of O O
PAPP B B_GENE
- I I_GENE
A I I_GENE
were O O
significantly O O
lower O O
than O O
in O O
normal O O
pregnancy O O
but O O
higher O O
than O O
in O O
non O O
- O O
pregnant O O
controls O O
. O O

We O O
report O O
the O O
sequence O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
7941 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
bp O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fragment O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
the O O
left O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
arm O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
chromosome O B_GENE
VII O I_GENE
of O O
Saccharomyces O B_SPECIES[BIO]
cerevisiae O I_SPECIES[BIO]
which O O
contains O O
four O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
open O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reading O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
frames O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ORFs O B_GENE/B_BIO
) O O
of O O
greater O B_LOCATION/B_MEASURE
than O O
100 O B_NUMBER[MEASURE]
amino O I_NUMBER[MEASURE]
acid O I_NUMBER[MEASURE]
residues O I_NUMBER[MEASURE]
. O O

A O O
4 O O
. O O
0 O O
- O O
kb O O
Nlk B B_GENE/B_LOCATION
message I I_GENE/I_LOCATION
is O O
also O O
present O O
during O O
embryogenesis O O
, O O
detectable O O
at O O
day O O
E10 O O
. O O

Promoting O O
fat O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
utilisation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
reducing O O
the O O
carbohydrate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
fat O B_MEASURE/B_LOCATION
ratio O I_MEASURE/I_LOCATION
of O O
the O O
TPN O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
reduces O O
free O B_DISEASE/B_MEASURE
radical O I_DISEASE/I_MEASURE
activity O I_DISEASE/I_MEASURE
to O O
a O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
extent O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
as O O
fat O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exclusion O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

In O O
cells O O
infected O O
with O O
a O O
recombinant O O
vaccinia O O
virus O O
expressing O O
HCV O O
structural O O
proteins O O
( O O
core B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
E1 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
E2 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
DDX3 B B_PROTEIN[GENE]/B_LOCATION
and O O
core B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colocalized O O
in O O
distinct O O
spots O O
in O O
the O O
perinuclear O O
region O O
of O O
the O O
cytoplasm O O
. O O

Mutating O O
this O O
sequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
eliminated O O
complex O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
formation O I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
markedly O O
reduced O O
basal O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cAMP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
dependent O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
promoter O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
activity O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
transfected O B_GENE
reporter O I_GENE
genes O I_GENE
. O O

The O O
lowest O B_MEASURE
PaCO2 O I_MEASURE
values O I_MEASURE
were O O
significantly O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
MCE O B_PROTEIN[GENE]/B_MEASURE
than O O
in O O
the O O
F O B_PROTEIN[GENE]/B_DISEASE
, O O
W O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
D O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
F O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
W O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
group O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
controls O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

The O O
translational O O
product O O
of O O
UL26 B B_GENE/B_TIME[MEASURE]
. I I_GENE/I_TIME[MEASURE]
5 I I_GENE/I_TIME[MEASURE]
is O O
infected B B_GENE
- I I_GENE
cell I I_GENE
protein I I_GENE
35c I I_GENE
, I I_GENE
d I I_GENE
( O O
ICP35c B B_NUMBER[MEASURE]/B_LOCATION
, I I_NUMBER[MEASURE]/I_LOCATION
d I I_NUMBER[MEASURE]/I_LOCATION
) O O
( O O
F O O
. O O

The O O
mouse B B_GENE/B_LOCATION
tapasin I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
was O O
mapped O O
about O O
70 O O
kilobases O O
from O O
H2 B B_LOCATION/B_PERSON
- I I_LOCATION/I_PERSON
K I I_LOCATION/I_PERSON
at O O
the O O
centromeric O O
end O O
of O O
the O O
mouse B B_GENE/B_LOCATION
MHC I I_GENE/I_LOCATION
. O O

Due O O
to O O
significant O O
homology O O
to O O
the O O
C O O
- O O
terminus O O
of O O
the O O
Mutator B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transposase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
this O O
alternative O O
gene O O
product O O
was O O
named O O
Trap B B_GENE/B_DISEASE
( O O
transposon B B_PROTEIN[GENE]/B_LOCATION
- I I_PROTEIN[GENE]/I_LOCATION
associated I I_PROTEIN[GENE]/I_LOCATION
protein I I_PROTEIN[GENE]/I_LOCATION
) O O
. O O

Nonetheless O O
, O O
the O O
majority O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
were O O
located O O
within O O
three O B_LOCATION/B_BIO
short O I_LOCATION/I_BIO
sequences O I_LOCATION/I_BIO
at O O
the O O
N O B_LOCATION
terminus O I_LOCATION
, O O
middle O B_DISEASE/B_LOCATION
, O O
and O O
C O B_LOCATION
terminus O I_LOCATION
that O O
are O O
phylogenetically O O
conserved O O
among O O
all O O
known O O
eubacterial O B_SPECIES[BIO]
and O O
chloroplast O B_GENE/B_BIO
versions O I_GENE/I_BIO
of O O
this O O
protein O B_GENE/B_BACTERIUM[BIO]
. O O

The O O
c B B_GENE/B_BIO
- I I_GENE/I_BIO
raf I I_GENE/I_BIO
- I I_GENE/I_BIO
1 I I_GENE/I_BIO
proto I I_GENE/I_BIO
- I I_GENE/I_BIO
oncogene I I_GENE/I_BIO
is O O
the O O
cellular B B_GENE/B_PERSON
homologue I I_GENE/I_PERSON
of I I_GENE/I_PERSON
v I I_GENE/I_PERSON
- I I_GENE/I_PERSON
raf I I_GENE/I_PERSON
, O O
the O O
oncogene O O
of O O
the O O
acutely O O
transforming O O
retrovirus O O
3611 O O
- O O
MSV O O
. O O

Using O O
gel O O
retardation O O
analysis O O
, O O
four O O
binding O O
sites O O
for O O
Rap1p B B_GENE
have O O
been O O
identified O O
within O O
the O O
promoter O O
of O O
the O O
RAP1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
general O B_PERSON/B_BIO
, O O
the O O
scallop O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
extract O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
potentiated O O
phototactic O B_DISEASE
suppression O I_DISEASE
. O O

Alcohol O B_DISEASE_ADJECTIVE[DISEASE]
abuse O I_DISEASE_ADJECTIVE[DISEASE]
and O O
treatment O B_DISEASE
resistance O I_DISEASE
in O O
skin O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
disease O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

The O O
mean O B_MEASURE
serum O I_MEASURE
CDT O I_MEASURE
increased O O
from O O
8 O B_MEASURE
. O O
5 O B_MEASURE
( O O
SD O B_MEASURE
2 O I_MEASURE
. O O
2 O B_MEASURE
) O O
U O B_MEASURE/B_OTHER
/ O O
l O B_MEASURE/B_DISEASE
to O O
16 O B_MEASURE
. O O
6 O B_MEASURE
( O O
SD O B_MEASURE/B_LOCATION
7 O I_MEASURE/I_LOCATION
. O O
2 O B_MEASURE
) O O
U O B_MEASURE/B_OTHER
/ O O
l O B_MEASURE/B_DISEASE
( O O
P O B_OTHER/B_MEASURE
< O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
. O O

Subsequent O O
analysis O O
revealed O O
that O O
MyD88 B B_GENE
possesses O O
a O O
unique O O
modular O O
structure O O
, O O
which O O
consists O O
of O O
an O O
N O O
- O O
terminal O O
" O O
death O O
domain O O
, O O
" O O
similar O O
to O O
the O O
intracellular O O
segments O O
of O O
TNF B B_GENE
receptor I I_GENE
1 I I_GENE
and O O
Fas B B_GENE/B_MEASURE
, O O
and O O
a O O
C O O
- O O
terminal O O
region O O
related O O
to O O
the O O
cytoplasmic O O
domains O O
of O O
the O O
Drosophila B B_SPECIES[BIO]
morphogen I I_SPECIES[BIO]
Toll I I_SPECIES[BIO]
and O O
vertebrate O O
interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

RT O O
- O O
PCR O O
analysis O O
of O O
FGFR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
showed O O
the O O
presence O O
of O O
a O O
splice O O
variant O O
in O O
which O O
exons O O
7 O O
and O O
8 O O
are O O
deleted O O
. O O

In O O
human O O
myxoid O O
liposarcoma O O
, O O
a O O
chromosomal O O
rearrangement O O
leads O O
to O O
fusion O O
of O O
the O O
growth O O
- O O
arresting O O
and O O
DNA O O
- O O
damage O O
- O O
inducible O O
transcription O O
factor O O
CHOP B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
( O O
GADD153 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
to O O
a O O
peptide O O
fragment O O
encoded O O
by O O
the O O
TLS B B_GENE/B_DISEASE
gene I I_GENE/I_DISEASE
. O O

They O O
also O O
show O O
that O O
M O B_OTHER/B_LOCATION
. O O
malmoense O B_DISEASE/B_BACTERIUM[BIO]
can O O
be O O
isolated O O
from O O
the O O
environment O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
which O O
may O O
be O O
the O O
source O B_LOCATION
of O O
the O O
infection O B_BIO/B_DISEASE
. O O

The O O
monkeys O B_BIO/B_PERSON
had O O
been O O
administered O O
a O O
common O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
lead O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
isotope O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
" O O
mix O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
" O O
at O O
the O O
rate O B_MEASURE/B_LOCATION
of O O
about O O
1300 O B_MEASURE
micrograms O I_MEASURE
Pb O I_MEASURE
/ O O
kg O B_MEASURE
body O I_MEASURE
wt O I_MEASURE
/ O O
day O B_MEASURE
from O O
age O B_TIME[MEASURE]/B_ORGANISM_FUNCTION
10 O I_TIME[MEASURE]/I_ORGANISM_FUNCTION
months O I_TIME[MEASURE]/I_ORGANISM_FUNCTION
until O O
the O O
start O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
previously O O
described O O
the O O
upregulation O O
of O O
the O O
MT2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antigen I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
during O O
urodele O O
limb O O
regeneration O O
and O O
characterized O O
the O O
MT2 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
antigen I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
as O O
a O O
310 O O
- O O
to O O
325 O O
- O O
kDa O O
chondroitin O O
- O O
sulfated O O
glycoprotein O O
with O O
a O O
core O O
protein O O
of O O
285 O O
- O O
300 O O
kDa O O
. O O

Analysis O O
of O O
the O O
MCV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RPO1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
revealed O O
high O O
amino O O
acid O O
homologies O O
to O O
the O O
corresponding O O
polypeptides O O
of O O
vaccinia O O
and O O
variola O O
virus O O
. O O

The O O
effects O O
of O O
dopamine O O
and O O
of O O
dopamine B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D2 I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocker O O
haloperidol O O
on O O
the O O
activity O O
of O O
carotid O O
chemoreceptors O O
were O O
studied O O
in O O
24 O O
anesthetized O O
, O O
paralyzed O O
and O O
artificially O O
ventilated O O
newborn O O
kittens O O
aged O O
0 O O
- O O
17 O O
days O O
. O O

Fifty O B_NUMBER[MEASURE]
- O O
seven O B_NUMBER[MEASURE]
per O O
cent O B_SEQUENCE[MEASURE]
of O O
the O O
primary O B_PERSON
patients O I_PERSON
reporting O O
mild O B_DISEASE
symptoms O I_DISEASE
had O O
abnormal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
levels O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
leucocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
their O O
CSF O B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O O

When O O
proper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
controls O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
used O O
, O O
the O O
psychophysical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
computer O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
simulation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gave O O
remarkably O O
comparable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Patients O B_PERSON/B_BIO
were O O
treated O O
with O O
either O O
4 O B_MEASURE
. O O
8 O B_MEASURE
million O I_MEASURE
units O I_MEASURE
of O O
procaine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
penicillin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
g O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
probenecid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
3 O B_NUMBER[MEASURE]
. O O
5 O B_MEASURE
or O O
4 O B_MEASURE
. O O
5 O B_MEASURE
g O I_MEASURE
of O O
ampicillin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
g O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
probenecid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
or O O
9 O B_MEASURE
. O O
5 O B_MEASURE
g O I_MEASURE
of O O
tetracycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
given O O
over O O
4 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
the O O
Improved O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
Crest O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
Complete O I_BODY_PART_OR_ORGAN_COMPONENT
with O O
longer O O
rippled O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
outer O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
bristles O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
provided O O
significantly O O
superior O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
p O B_MEASURE/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
interproximal O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
penetration O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
overall O O
and O O
at O O
the O O
gumline O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
the O O
Colgate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Total O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
Oral O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
B O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Advantage O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
brushes O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Cardiac O B_DISEASE/B_PROTEIN[GENE]
NE O B_DISEASE/I_PROTEIN[GENE]
spillover O B_DISEASE/I_PROTEIN[GENE]
was O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
P O B_MEASURE/B_LOCATION
< O I_MEASURE/I_LOCATION
. O O
05 O B_MEASURE
) O O
at O O
baseline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
in O O
the O O
patient O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O B_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
in O O
healthy O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subjects O I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
whereas O O
renal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
whole O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
- O O
body O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NE O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spillovers O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
study O B_PERSON/B_ORGANIZATION
groups O I_PERSON/I_ORGANIZATION
. O O

The O O
activity O O
of O O
platelet B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
plasma O O
of O O
healthy O O
and O O
high O O
risk O O
newborns O O
. O O

Plasma B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
renin I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activity O O
in O O
essential O O
arterial O O
hypertension O O
. O O

A O O
trend O B_MEASURE
was O O
observed O O
toward O O
increased O O
graft O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
half O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O O
life O B_TIME[MEASURE]
in O O
era O B_PERSON/B_BIO
2 O I_PERSON/I_BIO
( O O
p O B_OTHER/B_MEASURE
= O O
NS O B_MEASURE
) O O
. O O

The O O
proteins O O
encoded O O
by O O
these O O
genes O O
, O O
called O O
GF14 B B_GENE/B_BIO
proteins I I_GENE/I_BIO
, O O
participate O O
in O O
protein O O
/ O O
DNA O O
complexes O O
and O O
show O O
more O O
than O O
60 O O
% O O
identity O O
with O O
a O O
highly O O
conserved O O
, O O
widely O O
distributed O O
protein O O
family O O
, O O
collectively O O
referred O O
to O O
as O O
14 B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
3 I I_GENE/I_MEASURE
- I I_GENE/I_MEASURE
3 I I_GENE/I_MEASURE
proteins O O
. O O

The O O
p58 B B_GENE
( O O
PITSLRE B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
protein O O
kinase O O
( O O
PK O O
) O O
is O O
a O O
member O O
of O O
a O O
large O O
supergene O O
family O O
related O O
to O O
the O O
master B B_GENE
mitotic I I_GENE
protein I I_GENE
kinase I I_GENE
, O O
p34cdc2 B B_GENE
. O O

Maximal O B_TIME[MEASURE]/B_LOCATION
exercise O I_TIME[MEASURE]/I_LOCATION
duration O I_TIME[MEASURE]/I_LOCATION
and O O
peak O B_MEASURE/B_LOCATION
oxygen O I_MEASURE/I_LOCATION
consumption O I_MEASURE/I_LOCATION
were O O
not O O
changed O O
. O O

In O O
contrast O O
, O O
NF B B_GENE
- I I_GENE
kappa I I_GENE
B I I_GENE
activation O O
was O O
observed O O
in O O
these O O
cells O O
after O O
PMA O O
stimulation O O
. O O

PtdIns B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
4 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
5 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
P2 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
synthesis O O
, O O
on O O
the O O
other O O
hand O O
, O O
is O O
only O O
moderately O O
affected O O
even O O
in O O
fab1Delta B B_PERSON/B_DISEASE
mutants I I_PERSON/I_DISEASE
. O O

A O O
simple O O
procedure O O
for O O
accurate O O
quantitation O O
of O O
factor B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
VIII I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors O O
. O O

We O O
found O O
that O O
48 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
of O O
the O O
patients O B_PERSON/B_BIO
had O O
their O O
thoracolumbar O B_DISEASE_ADJECTIVE[DISEASE]
blood O I_DISEASE_ADJECTIVE[DISEASE]
supply O I_DISEASE_ADJECTIVE[DISEASE]
based O O
on O O
two O B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anterior O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
radiculospinal O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arteries O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
lowest O B_SEQUENCE[MEASURE]/B_LOCATION
of O O
which O O
was O O
located O O
at O O
, O O
or O O
lower O B_TIME[MEASURE]
than O O
, O O
T12 O B_PROTEIN[GENE]
, O O
and O O
the O O
second O B_SEQUENCE[MEASURE]/B_LOCATION
and O O
higher O B_SEQUENCE[MEASURE]
one O I_SEQUENCE[MEASURE]
between O O
T6 O B_PROTEIN[GENE]
and O O
T10 O B_MEASURE/B_PROTEIN[GENE]
. O O

Low O O
serum B B_DISEASE/B_GENE
C3 I B_DISEASE/I_GENE
values O O
were O O
observed O O
in O O
all O O
11 O O
children O O
at O O
some O O
stage O O
of O O
their O O
illness O O
. O O

The O O
plants O O
were O O
then O O
brought O O
to O O
our O O
Houston O O
laboratory O O
where O O
they O O
were O O
measured O O
and O O
analyzed O O
for O O
lignin O O
and O O
protein O O
content O O
and O O
for O O
phenylalanine B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
ammonia I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
lyase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PAL B B_DISEASE/B_LOCATION
) O O
and O O
peroxidase B B_ENZYME[GENE]/B_DISEASE
activities O O
. O O

Pax B B_GENE/B_TIME[MEASURE]
- I I_GENE/I_TIME[MEASURE]
6 I I_GENE/I_TIME[MEASURE]
constructs O O
lacking O O
the O O
C O O
- O O
terminal O O
activation O O
domain O O
repressed O O
betaB1 B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
crystallin I I_GENE/I_DISEASE
promoter I I_GENE/I_DISEASE
activity O O
as O O
effectively O O
as O O
the O O
full O O
- O O
length O O
protein O O
, O O
but O O
the O O
PD B B_DISEASE/B_GENE
alone O O
or O O
Pax B B_GENE/B_MEASURE
- I B_GENE/I_MEASURE
6 I B_GENE/I_MEASURE
( I B_GENE/I_MEASURE
5a I B_GENE/I_MEASURE
) I B_GENE/I_MEASURE
, O O
a O O
splice O O
variant O O
with O O
an O O
altered O O
PD B B_DISEASE/B_LOCATION
affecting O O
its O O
DNA O O
binding O O
specificity O O
, O O
did O O
not O O
. O O

A O O
regression O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
showed O O
that O O
86 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
of O O
the O O
variance O B_MEASURE
in O O
weight O B_DISEASE_ADJECTIVE[DISEASE]
gain O I_DISEASE_ADJECTIVE[DISEASE]
was O O
predicted O O
by O O
two O B_NUMBER[MEASURE]
leading O O
indicators O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O O
the O O
middle O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O O

OBJECTIVE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Respiratory O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
related O B_MEASURE
electromyographic O I_MEASURE
( O O
EMG O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
activity O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
superior O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pharyngeal O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
constrictor O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
SPC O B_DISEASE/B_PROTEIN[GENE]
) O O
muscle O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
was O O
analyzed O O
during O O
the O O
early O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stage O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
forced O B_DISEASE/B_ORGANISM_FUNCTION
breathing O B_DISEASE/I_ORGANISM_FUNCTION
. O O

The O O
predicted O O
amino O O
acid O O
sequence O O
contained O O
all O O
consensus O O
regions O O
for O O
S B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
adenosyl I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
methionine I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
methyltransferases I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
presented O O
26 O O
% O O
identity O O
with O O
Saccharomyces B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
cerevisiae I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
DHHB I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
methyltransferase I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
38 O O
% O O
identity O O
with O O
the O O
rat O O
protein O O
, O O
as O O
well O O
as O O
with O O
a O O
bacterial O O
( O O
Escherichia O O
coli O O
and O O
Salmonella O O
typhimurium O O
) O O
methyltransferase B B_ENZYME[GENE]/B_BIO
encoded O O
by O O
the O O
UBIG B B_GENE
gene I I_GENE
. O O

Letter O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
: O O
Ballistocardiography O B_MEASURE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
introduction O O
of O O
FWD1 B B_GENE
into O O
cells O O
significantly O O
promotes O O
ubiquitination O O
and O O
degradation O O
of O O
IkappaBalpha B B_GENE
in O O
concert O O
with O O
IkappaB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
resulting O O
in O O
nuclear O O
translocation O O
of O O
NF B B_GENE
- I I_GENE
kappaB I I_GENE
. O O

Fosinopril O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
decreased O O
blood O B_DISEASE/B_GENE
pressure O I_DISEASE/I_GENE
from O O
174 O B_MEASURE
/ O O
101 O B_MEASURE
mm O I_MEASURE
Hg O I_MEASURE
to O O
149 O B_MEASURE
/ O O
88 O B_MEASURE
mm O I_MEASURE
Hg O I_MEASURE
in O O
patients O B_PERSON
with O O
diastolic O B_DISEASE
hypertension O I_DISEASE
and O O
from O O
182 O B_MEASURE
/ O O
86 O B_MEASURE
mm O I_MEASURE
Hg O I_MEASURE
to O O
151 O B_MEASURE
/ O O
80 O B_MEASURE
mm O I_MEASURE
Hg O I_MEASURE
in O O
patients O B_PERSON
with O O
ISH O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Although O O
CB O B_LOCATION
- O O
4 O B_MEASURE/B_BIO
isolates O I_MEASURE/I_BIO
were O O
less O O
resistant O B_DISEASE_ADJECTIVE[DISEASE]
to O O
chlorine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
CB O B_LOCATION
- O O
5 O B_MEASURE
isolates O I_MEASURE
, O O
after O O
1 O B_MEASURE
, O O
000 O B_TIME[MEASURE]/B_PERSON
min O I_TIME[MEASURE]/I_PERSON
of O O
contact O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
0 O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
. O O
01 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
the O O
input O B_BIO
virus O I_BIO
was O O
still O O
infectious O B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
Sudeck O B_PERSON/B_LOCATION
' O O
s O O
atrophy O B_DISEASE
in O O
the O O
upper O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
limb O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
by O O
sympathetic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
blockade O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

To O O
assess O O
the O O
effect O O
on O O
thrombus O O
growth O O
, O O
we O O
determined O O
the O O
accretion O O
of O O
125I O O
- O O
labeled O O
fibrinogen B B_GENE
onto O O
autologous O O
non O O
- O O
radioactive O O
thrombi O O
preformed O O
in O O
the O O
jugular O O
veins O O
of O O
rabbits O O
. O O

Thallium O B_LOCATION/B_DISEASE
- O O
201 O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
scintigraphy O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
after O O
dipyridamole O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infusion O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
low O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exercise O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
kinetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
99mTc O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
DMSA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
the O O
rat O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
. O O

Crude O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
from O O
aquatic O B_LOCATION/B_PERSON
plants O I_LOCATION/I_PERSON
. O O

Yet O O
testosterone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
predominant O B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
plasma O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
Type O B_BIO/B_PERSON
II O I_BIO/I_PERSON
male O I_BIO/I_PERSON
morph O I_BIO/I_PERSON
which O O
neither O O
courts O B_PERSON/B_BIO
females O I_PERSON/I_BIO
nor O O
nests O B_LOCATION/B_PERSON
, O O
but O O
instead O O
parasitizes O O
Type O B_MEASURE/B_ORGANIZATION
I O O
males O O
with O O
sneak O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
or O O
satellite O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
spawning O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
tactics O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

Comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
therapeutic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effectiveness O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
membrane O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
centrifugation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
plasmapheresis O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT

Amino O O
- O O
terminal O O
polymorphisms O O
of O O
the O O
human B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
beta I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
adrenergic I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
impart O O
distinct O O
agonist O O
- O O
promoted O O
regulatory O O
properties O O
. O O

Hence O O
, O O
it O O
is O O
perhaps O O
not O O
necessary O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
perform O O
spinal O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
puncture O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
if O O
the O O
only O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
purpose O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
is O O
to O O
determine O O
the O O
CSF O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
/ O O
serum O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
ratio O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Two O O
plasmids O O
, O O
one O O
containing O O
the O O
amino O O
terminus O O
of O O
P O O
fused O O
to O O
the O O
DNA O O
- O O
binding O O
domain O O
of O O
the O O
yeast O O
transactivator O O
, O O
GAL4 B B_GENE/B_SPECIES[BIO]
, O O
and O O
the O O
other O O
containing O O
the O O
amino O O
terminus O O
of O O
NP B B_PROTEIN[GENE]/B_DISEASE
fused O O
to O O
the O O
herpesvirus O O
transactivator O O
, O O
VP16 B B_GENE/B_LOCATION
, O O
were O O
transfected O O
in O O
COS O O
- O O
1 O O
cells O O
along O O
with O O
a O O
chloramphenicol B B_ENZYME[GENE]
acetyltransferase I I_ENZYME[GENE]
( O O
CAT B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
reporter O O
plasmid O O
containing O O
GAL4 B B_NUMBER[MEASURE]/B_PERSON
DNA O O
- O O
binding O O
sites O O
. O O

Biochemical O O
experiments O O
and O O
genome O O
sequencing O O
have O O
shown O O
that O O
, O O
despite O O
the O O
prokaryotic O O
cell O O
and O O
genome O O
organization O O
, O O
basal O O
transcriptional O O
elements O O
of O O
members O O
of O O
the O O
domain O O
Archaea O O
( O O
i O O
. O O
e O O
. O O
, O O
TATA O O
box O O
- O O
like O O
sequences O O
, O O
RNA B B_GENE
polymerase I I_GENE
, O O
and O O
transcription O O
factors O O
TBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
TFIIB B B_GENE/B_DISEASE
, O O
and O O
TFIIS B B_GENE/B_DISEASE
) O O
are O O
of O O
the O O
eukaryotic O O
type O O
. O O

Humoral O O
immunity O O
is O O
altered O O
with O O
the O O
drop O O
in O O
IgG B B_GENE
levels O O
. O O

For O O
the O O
second O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
phase O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
it O O
was O O
12 O B_MEASURE
. O O
5 O B_MEASURE
wk O I_MEASURE
for O O
RIR O B_PROTEIN[GENE]/B_PERSON
and O O
10 O B_NUMBER[MEASURE]
for O O
WL O B_PERSON/B_PROTEIN[GENE]
males O I_PERSON/I_PROTEIN[GENE]
, O O
whereas O O
it O O
was O O
5 O B_MEASURE
wk O I_MEASURE
for O O
RIR O B_LOCATION/B_PROTEIN[GENE]
and O O
6 O B_MEASURE
for O O
WL O B_PERSON
females O I_PERSON
. O O

Modified O O
Grocott O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
s O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
methenamine O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
silver O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
nitrate O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O O
quick O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
staining O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Pneumocystis O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
carinii O B_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Additionally O O
, O O
VAHS O B_DISEASE
is O O
often O O
associated O O
with O O
fatal O B_DISEASE
infectious O I_DISEASE
mononucleosis O I_DISEASE
( O O
IM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
In O O
patients O B_PERSON/B_SPECIES[BIO]
with O O
necrotising O O
fasciitis O B_DISEASE
the O O
arterial O B_MEASURE/B_PROTEIN[GENE]
PO2 O B_MEASURE/I_PROTEIN[GENE]
rose O O
about O O
7 O B_NUMBER[MEASURE]
- O O
fold O B_SEQUENCE[MEASURE]
whereas O O
the O O
arterial O B_MEASURE/B_LOCATION
PCO2 O I_MEASURE/I_LOCATION
increased O O
only O O
slightly O O
during O O
exposure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O O
2 O B_MEASURE
. O O
5 O B_MEASURE
absolute O I_MEASURE
atmospheres O I_MEASURE
( O O
ATA O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
of O O
oxygen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

We O O
report O O
on O O
a O O
case O O
of O O
a O O
43 O O
- O O
old O O
- O O
male O O
with O O
a O O
bronchogenic O O
cyst O O
in O O
the O O
distal O O
esophagus O O
, O O
which O O
was O O
misdiagnosed O O
as O O
a O O
malignant O O
esophageal O O
tumor O O
based O O
on O O
preoperative O O
imaging O O
and O O
high O O
levels O O
of O O
the O O
tumor O O
markers O O
CA B B_GENE/B_DISEASE
19 I I_GENE/I_DISEASE
- I I_GENE/I_DISEASE
9 I I_GENE/I_DISEASE
and O O
CA B B_MEASURE/B_GENE
125 I I_MEASURE/I_GENE
. O O

100 O B_MEASURE
and O O
51 O B_MEASURE/B_LOCATION
p O I_MEASURE/I_LOCATION
. O O

A O O
plasma O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
rich O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
infiltrate O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
was O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
connective O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissue O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
cores O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
papillae O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

During O O
normoxic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
exercise O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
at O O
a O O
mean O B_MEASURE
O2 O I_MEASURE
uptake O I_MEASURE
( O O
VO2 O B_PROTEIN[GENE]/B_LOCATION
) O O
of O O
4 O B_MEASURE
. O O
0 O B_MEASURE/B_LOCATION
l O I_MEASURE/I_LOCATION
/ O O
min O B_TIME[MEASURE]/B_PERSON
, O O
almitrine O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increased O O
arterial O B_PROTEIN[GENE]/B_LOCATION
PO2 O I_PROTEIN[GENE]/I_LOCATION
( O O
PaO2 O B_MEASURE/B_PROTEIN[GENE]
) O O
( O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
, O O
SaO2 O B_MEASURE/B_PROTEIN[GENE]
( O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
, O O
and O O
VE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
and O O
decreased O O
arterial O B_PROTEIN[GENE]/B_DISEASE
PCO2 O I_PROTEIN[GENE]/I_DISEASE
( O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
, O O
without O O
affecting O O
pulmonary O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
hemodynamics O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
or O O
ventilation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
perfusion O B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distributions O B_DISEASE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Gene B B_GENE/B_DISEASE
GPR I B_GENE/I_DISEASE
51 I B_GENE/I_DISEASE
was O O
localized O O
by O O
radiation O O
hybrid O O
mapping O O
to O O
chromosome O O
9 O O
, O O
4 O O
. O O
81 O O
cR O O
from O O
the O O
WI O O
- O O
8684 O O
marker O O
, O O
and O O
proximal O O
to O O
the O O
hereditary B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
sensory I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
neuropathy I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
type I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1 I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
locus I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

We O O
conclude O O
that O O
the O O
outcome O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
patients O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
uterine O B_DISEASE/B_GENE
MMMT O I_DISEASE/I_GENE
is O O
mainly O O
influenced O O
by O O
the O O
initial O B_MEASURE/B_LOCATION
stage O I_MEASURE/I_LOCATION
and O O
the O O
type O B_MEASURE/B_LOCATION
of O O
epithelial O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
component O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
expression O O
of O O
the O O
leukocyte B B_GENE
EL I I_GENE
- I I_GENE
246 I I_GENE
antigen I I_GENE
was O O
regulated O O
in O O
the O O
same O O
manner O O
as O O
L B B_GENE
- I I_GENE
selectin I I_GENE
and O O
EL B B_TIME[MEASURE]/B_PERSON
- I I_TIME[MEASURE]/I_PERSON
246 I I_TIME[MEASURE]/I_PERSON
recognized O O
anti B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
- I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
L I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
- I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
selectin I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
mAb I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
affinity O O
- O O
purified O O
antigen O O
in O O
SDS O O
/ O O
PAGE O O
Western O O
blot O O
analysis O O
. O O

Other O B_MEASURE/B_PERSON
Fischer O I_MEASURE/I_PERSON
- O O
344 O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
also O O
exposed O O
for O O
1 O B_TIME[MEASURE]
hr O I_TIME[MEASURE]
to O O
0 O B_MEASURE
. O O
0 O B_MEASURE
or O O
to O O
0 O B_MEASURE
. O O
6 O B_TIME[MEASURE]
ppm O I_TIME[MEASURE]
O3 O I_TIME[MEASURE]
. O O

A O O
computerized O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
database O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
veterans O B_PERSON
discharged O O
from O O
the O O
military O B_ORGANIZATION/B_LOCATION
after O O
1967 O B_MEASURE/B_ORGANIZATION
was O O
selected O O
as O O
the O O
source O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
because O O
it O O
contains O O
about O O
50 O B_SEQUENCE[MEASURE]/B_PERSON
% O I_SEQUENCE[MEASURE]/I_PERSON
of O O
the O O
total O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Vietnam O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
era O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
veteran O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
population O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
is O O
reasonably O O
unbiased O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
, O O
and O O
provides O O
a O O
feasible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
identifying O O
twins O B_PERSON
. O O

To O O
examine O O
the O O
functional O O
relationship O O
between O O
distinct O O
cis O O
- O O
active O O
elements O O
within O O
the O O
distal O O
enhancer O O
region O O
of O O
the O O
rat B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PRL I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
we O O
have O O
used O O
deletional O O
and O O
mutational O O
analysis O O
of O O
that O O
region O O
in O O
transient O O
transfection O O
studies O O
in O O
GH3 O O
pituitary O O
tumor O O
cells O O
. O O

The O O
entire O O
coding O O
region O O
of O O
an O O
ovine B B_GENE
endometrial I I_GENE
oxytocin I I_GENE
receptor I I_GENE
( O O
OTR B B_LOCATION/B_GENE
) O O
cDNA O O
was O O
generated O O
by O O
PCR O O
, O O
subcloned O O
into O O
the O O
SV40 B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
major I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
late I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
vector O O
pSVLJ O O
and O O
transiently O O
expressed O O
in O O
Cos O O
- O O
7 O O
cells O O
. O O

Alcohol O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
stomach O B_DISEASE
diseases O I_DISEASE

These O O
operons O O
encode O O
subunits O O
of O O
photosystems B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
I I I_PROTEIN[GENE]/I_BACTERIUM[BIO]
( O O
psa B B_DISEASE/B_LOCATION
) O O
and O O
II O O
( O O
psb B B_DISEASE/B_LOCATION
) O O
, O O
the O O
cytochrome B B_ENZYME[GENE]
bGf I I_ENZYME[GENE]
complex I I_ENZYME[GENE]
( O O
pet B B_LOCATION/B_PROTEIN[GENE]
) O O
, O O
the O O
plastid O O
NAD B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
P I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
H I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ndh B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
, O O
and O O
the O O
unidentified O O
open O O
reading O O
frame O O
ycf9 B B_GENE/B_MEASURE
. O O

The O O
phosphatidylglycerol B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
/ I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphatidylinositol I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transfer I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PG B B_GENE/B_LOCATION
/ I I_GENE/I_LOCATION
PI I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
TP I I_GENE/I_LOCATION
) O O
is O O
a O O
new O O
and O O
original O O
phospholipid B B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transfer I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PLTP B B_GENE/B_DISEASE
) O O
isolated O O
from O O
the O O
Deuteromycete O O
, O O
Aspergillus O O
oryzae O O
. O O

Transcriptional O O
modulation O O
of O O
the O O
anti B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
apoptotic I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
BCL I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
XL I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
the O O
paired B B_GENE
box I I_GENE
transcription I I_GENE
factors I I_GENE
PAX3 B I_GENE
and O O
PAX3 B B_GENE/B_LOCATION
/ O O
FKHR B B_MEASURE
. O O

The O O
level O O
of O O
expression O O
of O O
the O O
PDE B B_GENE
protein I I_GENE
was O O
monitored O O
by O O
immunoblot O O
analysis O O
using O O
two O O
specific O O
cAMP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PDE I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polyclonal I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
by O O
measuring O O
the O O
PDE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
activity O O
. O O

Blotting O O
analysis O O
of O O
intestinal O O
RNA O O
and O O
hybridization O O
of O O
the O O
blots O O
with O O
carboxy O O
apoB B B_GENE/B_MEASURE
cDNA O O
probes O O
produced O O
a O O
single O O
15 O O
- O O
kb O O
hybridization O O
band O O
whereas O O
hybridization O O
with O O
amino O O
terminal O O
probes O O
produced O O
two O O
hybridization O O
bands O O
of O O
15 O O
and O O
8 O O
kb O O
. O O

Since O O
UmuD B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
proteolytically O O
processed O O
to O O
an O O
active O O
form O O
( O O
UmuD B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
* I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
in O O
a O O
RecA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
* O O
- O O
dependent O O
fashion O O
, O O
and O O
MucA B B_TIME[MEASURE]/B_BACTERIUM[BIO]
shares O O
extensive O O
amino O O
acid O O
homology O O
with O O
UmuD B B_GENE/B_BIO
, O O
we O O
examined O O
whether O O
MucA B B_BACTERIUM[BIO]/B_PERSON
is O O
similarly O O
processed O O
in O O
the O O
cell O O
, O O
using O O
antiserum O O
against O O
a O O
LacZ B B_MEASURE/B_GENE
' I I_MEASURE/I_GENE
- O O
' B B_GENE/B_BACTERIUM[BIO]
MucA I I_GENE/I_BACTERIUM[BIO]
fusion O O
protein O O
. O O

Influence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
long O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
term O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
zimelidine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
treatment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
on O O
LSD O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
behavioural O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
have O O
determined O O
the O O
molecular O O
organization O O
and O O
transcription O O
start O O
points O O
( O O
tsp O O
) O O
for O O
the O O
murine O O
gene O O
( O O
TK B B_GENE/B_DISEASE
) O O
encoding O O
thymidine B B_GENE
kinase I I_GENE
. O O

Together O O
with O O
a O O
number O B_MEASURE/B_PERSON
of O O
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
II O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
trials O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
I O O
trials O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
utilizing O O
escalating O O
doses O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
carboplatin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
paclitaxel O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
growth O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
factor O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
or O O
growth O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
factor O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
and O O
blood O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
stem O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
- O O
cell O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
support O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
have O O
shown O O
that O O
substantial O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increases O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
dose O B_MEASURE/B_DISEASE
intensity O B_MEASURE/I_DISEASE
can O O
be O O
achieved O O
. O O

It O O
is O O
an O O
untested O O
argument O O
that O O
conventional O O
beta B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
adrenoceptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antagonists O O
possess O O
unwanted O O
metabolic O O
effects O O
that O O
may O O
counter O O
some O O
of O O
their O O
potential O O
cardiac O O
benefits O O
. O O

Genetic O O
polymorphisms O O
in O O
the O O
5 O O
' O O
- O O
flanking O O
region O O
change O O
transcriptional O O
regulation O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytochrome I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
P450IIE1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Although O O
the O O
occurrence O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
any O O
ventricular O B_DISEASE
ectopic O I_DISEASE
activity O I_DISEASE
, O O
as O O
detected O O
by O O
either O O
or O O
both O O
methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
was O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
the O O
incidence O B_MEASURE/B_DISEASE
was O O
significantly O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
in O O
patients O B_PERSON
with O O
coronary O B_DISEASE/B_LOCATION
heart O I_DISEASE/I_LOCATION
disease O I_DISEASE/I_LOCATION
( O O
86 O B_MEASURE/B_PERSON
percent O I_MEASURE/I_PERSON
; O O
77 O B_MEASURE
/ O O
90 O B_MEASURE
) O O
, O O
as O O
compared O O
to O O
that O O
in O O
normal O B_PERSON/B_DISEASE
subjects O I_PERSON/I_DISEASE
( O O
40 O B_MEASURE
percent O I_MEASURE
; O O
12 O B_MEASURE
/ O O
30 O B_MEASURE
) O O
. O O

Increased O O
trabecular O B_MEASURE/B_DISEASE
spacing O I_MEASURE/I_DISEASE
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
it O O
occurs O O
in O O
osteoporosis O B_DISEASE
, O O
reduces O O
the O O
spatial O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
field O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
inhomogeneity O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
thus O O
prolongs O O
T2 O B_MEASURE/B_PROTEIN[GENE]
* O O
, O O
which O O
has O O
been O O
shown O O
both O O
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
in O O
vivo O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Healthy O B_PERSON
preterm O I_PERSON
infants O I_PERSON
of O O
gestational O B_MEASURE/B_PERSON
age O I_MEASURE/I_PERSON
26 O I_MEASURE/I_PERSON
- O O
29 O B_MEASURE/B_ENT
weeks O I_MEASURE/I_ENT
showed O O
a O O
' O O
mature O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
' O O
pattern O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
permeability O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
at O O
birth O B_PERSON/B_TIME[MEASURE]
, O O
followed O O
by O O
a O O
temporary O B_MEASURE/B_LOCATION
period O I_MEASURE/I_LOCATION
of O O
enhanced O O
permeability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
after O O
3 O B_SEQUENCE[MEASURE]/B_LOCATION
- O O
4 O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
of O O
life O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O O

These O O
studies O O
reveal O O
that O O
CREM B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
tissue O O
- O O
specific O O
factor O O
, O O
is O O
expressed O O
and O O
regulated O O
by O O
gonadotropins B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
ovary O O
, O O
that O O
the O O
predominant O O
CREM B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
transcripts O O
encode O O
the O O
repressor B B_GENE/B_MEASURE
protein I I_GENE/I_MEASURE
ICER I I_GENE/I_MEASURE
, O O
and O O
that O O
ICER B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
capable O O
of O O
inhibiting O O
cAMP O O
- O O
induced O O
expression O O
of O O
the O O
inhibin B B_GENE/B_MEASURE
alpha I I_GENE/I_MEASURE
- I I_GENE/I_MEASURE
subunit I I_GENE/I_MEASURE
gene I I_GENE/I_MEASURE
. O O

The O O
Brassica B B_GENE/B_BIO
BTH1 I I_GENE/I_BIO
gene I I_GENE/I_BIO
may O O
correspond O O
to O O
the O O
Arabidopsis B B_BIO/B_GENE
TH I I_BIO/I_GENE
- I I_BIO/I_GENE
1 I I_BIO/I_GENE
gene I I_BIO/I_GENE
. O O

The O O
same O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pattern O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
firing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
seen O O
with O O
saccades O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
light O B_COLOR/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
in O O
complete O B_DISEASE_ADJECTIVE[DISEASE]/B_ENT
darkness O I_DISEASE_ADJECTIVE[DISEASE]/I_ENT
. O O

While O O
these O O
could O O
be O O
unusual O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cases O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
chronic O B_DISEASE/B_GENE
non O I_DISEASE/I_GENE
- O O
A O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
non O B_DISEASE/B_LOCATION
- O O
B O B_DISEASE
hepatitis O I_DISEASE
, O O
this O O
can O O
be O O
only O O
speculation O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
until O O
a O O
serologic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
non O B_DISEASE/B_GENE
- O O
A O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
non O B_DISEASE/B_LOCATION
- O O
B O B_DISEASE/B_PROTEIN[GENE]
hepatitis O B_DISEASE/I_PROTEIN[GENE]
becomes O O
available O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Acanthamoeba B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
myosin I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heavy I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chain I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MIHCK B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
phosphorylates O O
the O O
heavy O O
chains O O
of O O
amoeba B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
myosins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
increasing O O
their O O
actin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O O
activated O O
ATPase B B_ENZYME[GENE]
activities O O
. O O

Mutation O O
of O O
the O O
HNF3 B B_GENE/B_MEASURE
element I I_GENE/I_MEASURE
significantly O O
reduced O O
promoter O O
activity O O
in O O
HepG2 O O
cells O O
, O O
whereas O O
this O O
element O O
in O O
isolation O O
conferred O O
HNF3beta B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
responsiveness O O
to O O
a O O
heterologous O O
promoter O O
. O O

The O O
mitochondrial B B_ENZYME[GENE]
tyrosyl I I_ENZYME[GENE]
- I I_ENZYME[GENE]
tRNA I I_ENZYME[GENE]
synthetase I I_ENZYME[GENE]
of O O
Podospora O O
anserina O O
is O O
a O O
bifunctional O O
enzyme O O
active O O
in O O
protein O O
synthesis O O
and O O
RNA O O
splicing O O
. O O

The O O
findings O O
in O O
the O O
human O O
multiple O O
myeloma O O
cell O O
lines O O
represent O O
the O O
first O O
examples O O
of O O
B O O
cells O O
with O O
downregulated O O
PU B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
and O O
apparently O O
contradict O O
observations O O
in O O
the O O
murine O O
system O O
in O O
which O O
PU B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
expressed O O
and O O
active O O
in O O
plasmacytoma O O
cell O O
lines O O
. O O

The O O
traW B B_GENE
gene I I_GENE
of I I_GENE
the I I_GENE
Escherichia I I_GENE
coli I I_GENE
K I I_GENE
- I I_GENE
12 I I_GENE
sex I I_GENE
factor I I_GENE
, O O
F O O
, O O
encodes O O
one O O
of O O
the O O
numerous O O
proteins O O
required O O
for O O
conjugative O O
transfer O O
of O O
this O O
plasmid O O
. O O

Mibefradil O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Ro O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
40 O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
5967 O B_MEASURE
) O O
is O O
a O O
novel O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
nondihydropyridine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
calcium O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
antagonist O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

However O O
, O O
technical O O
advances O O
have O O
shown O O
the O O
limitations O O
of O O
these O O
tests O O
as O O
tests O O
for O O
IgM B B_GENE/B_DISEASE
can O O
be O O
positive O O
because O O
of O O
residual O O
specific O O
IgM B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
even O O
in O O
subjects O O
free O O
of O O
acute O O
infection O O
due O O
to O O
the O O
existence O O
of O O
natural O O
interfering O O
IgM B B_GENE/B_BIO
. O O

Carcinogenic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
action O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
of O O
groundnut O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
meal O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
containing O O
aflatoxin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
rats O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

( O O
1991 O B_MEASURE
) O O
EMBO O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
have O O
utilized O O
transient O O
transfections O O
, O O
mutation O O
analysis O O
, O O
electromobility O O
gel O O
- O O
shifts O O
, O O
and O O
immunoblot O O
analysis O O
to O O
test O O
the O O
hypothesis O O
that O O
expression O O
of O O
the O O
CTalpha B B_GENE
gene I I_GENE
is O O
controlled O O
in O O
part O O
by O O
the O O
binding O O
of O O
three O O
trans O O
- O O
acting O O
nuclear O O
factors O O
, O O
Sp1 B B_GENE/B_LOCATION
, O O
Sp2 B B_GENE
, O O
and O O
Sp3 B B_GENE/B_DISEASE
. O O

AMPK B B_GENE
is O O
a O O
heterotrimer O O
composed O O
of O O
a O O
catalytic O O
subunit O O
( O O
alpha O O
) O O
and O O
two O O
regulatory O O
subunits O O
( O O
beta O O
and O O
gamma O O
) O O
. O O

The O O
evolutionary O O
significance O O
of O O
the O O
similarities O O
of O O
intron O O
secondary O O
structures O O
and O O
open O O
reading O O
frames O O
of O O
the O O
ND3 B B_GENE/B_BIO
, I I_GENE/I_BIO
4 I I_GENE/I_BIO
and I I_GENE/I_BIO
ATPase I I_GENE/I_BIO
6 I I_GENE/I_BIO
genes I I_GENE/I_BIO
is O O
discussed O O
, O O
including O O
the O O
possible O O
separate O O
evolution O O
of O O
structural O O
and O O
coding O O
sequences O O
. O O

Antinuclear O O
antibodies O O
, O O
rheumatoid B B_GENE/B_DISEASE
factor I I_GENE/I_DISEASE
and O O
C B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reactive I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
serum O O
of O O
normal O O
women O O
using O O
oral O O
contraceptives O O
. O O

The O O
destruction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
mesometrium O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O O
not O O
lengthen O O
the O O
oestrous O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cycle O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Concentrations O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
platelet O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nitrite O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
total O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nitrate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
nitrite O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
determined O O
using O O
simple O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
sensitive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitrate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
nitrite O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorometric O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
techniques O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Power O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
deposition O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
by O O
inverse O B_MEASURE
- O O
bremsstrahlung O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
modeled O O
with O O
a O O
scheme O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
based O O
on O O
Gaussian O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
quadrature O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
accommodate O O
a O O
deposition O B_MEASURE/B_LOCATION
rate O B_MEASURE/I_LOCATION
whose O O
spatial O B_MEASURE/B_LOCATION
variation O I_MEASURE/I_LOCATION
is O O
highly O O
nonuniform O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

The O O
sulfur O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
species O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
be O O
separated O O
within O O
less O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
4 O B_MEASURE/B_PERSON
min O I_MEASURE/I_PERSON
by O O
CZE O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O O
a O O
pyromellitic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acid O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
electrolyte O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
at O O
pH O B_MEASURE/B_LOCATION
3 O I_MEASURE/I_LOCATION
. O O
5 O B_MEASURE
to O O
5 O B_MEASURE
. O O
0 O B_MEASURE
. O O

We O O
propose O O
that O O
unc B B_PERSON/B_LOCATION
- I I_PERSON/I_LOCATION
37 I I_PERSON/I_LOCATION
may O O
be O O
regulated O O
by O O
unc B B_GENE
- I I_GENE
4 I I_GENE
. O O

Adenovirus O O
infection O O
of O O
hepatoma O O
cells O O
inhibited O O
transcription O O
of O O
the O O
phosphoenolpyruvate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
carboxykinase I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
GTP O O
) O O
( O O
EC B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
4 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
32 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
( O O
PEPCK B B_GENE/B_SPECIES[BIO]
) O O
gene O O
and O O
virtually O O
eliminated O O
transcription O O
of O O
a O O
chimeric O O
gene O O
which O O
contained O O
the O O
PEPCK B B_GENE
promoter I I_GENE
linked O O
to O O
the O O
structural O O
gene O O
for O O
chloramphenicol B B_GENE
acetyltransferase I I_GENE
( O O
CAT B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

After O O
discharge O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
he O O
was O O
finally O O
given O O
a O O
diagnosis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
PCH O B_DISEASE
because O O
a O O
Donath O B_PERSON/B_DISEASE
- O O
Landsteiner O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O O
positive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
second O B_GENE/B_SEQUENCE[MEASURE]
intron O B_GENE/I_SEQUENCE[MEASURE]
is O O
the O O
smallest O B_SEQUENCE[MEASURE]/B_LOCATION
of O O
all O O
the O O
introns O B_GENE/B_LOCATION
( O O
116 O B_TIME[MEASURE]/B_GENE
bp O I_TIME[MEASURE]/I_GENE
) O O
. O O

Expression O O
of O O
the O O
gene O O
encoding O O
transcription B B_GENE
factor I I_GENE
cyclic I I_GENE
adenosine I I_GENE
3 I I_GENE
' I I_GENE
, I I_GENE
5 I I_GENE
' I I_GENE
- I I_GENE
monophosphate I I_GENE
( I I_GENE
cAMP I I_GENE
) I I_GENE
response I I_GENE
element I I_GENE
- I I_GENE
binding I I_GENE
protein I I_GENE
( O O
CREB B B_GENE/B_DISEASE
) O O
: O O
regulation O O
by O O
follicle B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
stimulating I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
hormone I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
induced O O
cAMP O O
signaling O O
in O O
primary O O
rat O O
Sertoli O O
cells O O
. O O

Efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
evaluated O O
in O O
24 O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
, O O
of O O
whom O O
eight O B_NUMBER[MEASURE]
received O O
RD O B_DISEASE/B_PROTEIN[GENE]
and O O
16 O B_MEASURE/B_LOCATION
SD O B_MEASURE/I_LOCATION
. O O

A O O
silica O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
based O O
, O O
fluoride O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
free O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
placebo O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
containing O O
NaTPP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
a O O
NaF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
containing O O
silica O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
based O O
USP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reference O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
standard O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toothpaste O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
used O O
as O O
negative O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
positive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
toothpastes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
respectively O O
. O O

The O O
overall O B_MEASURE/B_PERSON
response O I_MEASURE/I_PERSON
rate O I_MEASURE/I_PERSON
including O O
CR O B_LOCATION/B_DISEASE
and O O
PR O B_LOCATION/B_DISEASE
was O O
23 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
( O O
4 O B_MEASURE
/ O O
17 O B_MEASURE
) O O
. O O

High O O
and O O
pathological O O
PAI B B_GENE
- I I_GENE
1 I I_GENE
levels O O
before O O
and O O
after O O
the O O
VO O O
test O O
were O O
consistent O O
with O O
a O O
defective O O
fibrinolytic O O
potential O O
due O O
to O O
the O O
inhibitory O O
effect O O
of O O
PAI B B_PROTEIN[GENE]/B_DISEASE
- I I_PROTEIN[GENE]/I_DISEASE
1 I I_PROTEIN[GENE]/I_DISEASE
on O O
plasminogen B B_GENE
activation O O
. O O

During O O
hexamethylene O O
bisactamide O O
( O O
HMBA O O
) O O
- O O
induced O O
differentiation O O
of O O
murine O O
erythroleukemia O O
( O O
MEL O O
) O O
cells O O
erythroid O O
genes O O
are O O
transcriptionally O O
activated O O
while O O
c B B_GENE
- I I_GENE
myb I I_GENE
and O O
several O O
other O O
nuclear O O
proto O O
- O O
oncogenes O O
are O O
down O O
- O O
regulated O O
. O O

The O O
recovery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
adults O B_SPECIES[BIO]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
schistosomes O B_SPECIES[BIO]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O O
extracorporeal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
filtration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Torsion O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
contralateral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
testis O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
5 O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
years O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
after O O
orchiopexy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Frequency O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
recurrence O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
fibroids O B_DISEASE
after O O
myomectomy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
has O O
been O O
evaluated O O
in O O
145 O B_PERSON
women O I_PERSON
( O O
median O B_MEASURE/B_PERSON
age O I_MEASURE/I_PERSON
38 O I_MEASURE/I_PERSON
years O I_MEASURE/I_PERSON
, O O
range O B_MEASURE/B_LOCATION
21 O I_MEASURE/I_LOCATION
- O O
52 O B_MEASURE
) O O
who O O
underwent O O
myomectomy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Choline B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
acetyltransferase I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
immunohistochemistry O O
combined O O
with O O
the O O
retrograde O O
transport O O
of O O
horseradish B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
peroxidase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
showed O O
that O O
the O O
reticular O O
and O O
mediodorsal O O
thalamic O O
nuclei O O
of O O
the O O
cat O O
receive O O
an O O
important O O
input O O
from O O
cholinergic O O
and O O
non O O
- O O
cholinergic O O
neurons O O
of O O
substantia O O
innominata O O
and O O
adjacent O O
structures O O
in O O
the O O
basal O O
forebrain O O
. O O

( O O
i O O
) O O
The O O
chimeric O O
gene O O
consisting O O
of O O
the O O
coding O O
and O O
5 O O
' O O
nontranslated O O
leader O O
regions O O
of O O
the O O
TK B B_GENE
gene I I_GENE
fused O O
to O O
portions O O
of O O
the O O
domain O O
of O O
alpha B B_GENE
gene I I_GENE
0 I I_GENE
extending O O
largely O O
upstream O O
from O O
the O O
site O O
of O O
initiation O O
of O O
transcription O O
of O O
alpha B B_GENE
gene I I_GENE
0 I I_GENE
was O O
regulated O O
in O O
the O O
same O O
fashion O O
as O O
the O O
alpha B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
4 I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
- I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
and I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
27 I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
- I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
TK I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
chimeras O O
. O O

Ethanol O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preference O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
strains O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
selectively O O
bred O O
for O O
behavioral O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
characteristics O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

For O O
the O O
albino O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
both O O
the O O
ST1 O B_PROTEIN[GENE]/B_LOCATION
and O O
ST2 O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
spatial O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
responses O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
peak O O
at O O
around O O
0 O B_MEASURE
. O O
3 O B_MEASURE/B_LOCATION
cycles O I_MEASURE/I_LOCATION
deg O I_MEASURE/I_LOCATION
- O O
1 O B_MEASURE
, O O
and O O
both O O
curves O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O O
displaced O O
considerably O O
to O O
the O O
low O B_LOCATION/B_MEASURE
spatial O I_LOCATION/I_MEASURE
frequency O I_LOCATION/I_MEASURE
side O I_LOCATION/I_MEASURE
of O O
the O O
normal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
ST2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
spatial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Nuclear O O
proteins O O
bound O O
the O O
cad B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
+ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
55 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
+ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
75 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
cell O O
cycle O O
- O O
dependent O O
manner O O
in O O
electromobility O O
shift O O
assays O O
; O O
antibodies O O
specific O O
to O O
USF B B_PERSON/B_GENE
and O O
Max B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
blocked O O
the O O
DNA O O
- O O
binding O O
activity O O
of O O
different O O
growth O O
- O O
regulated O O
protein O O
- O O
DNA O O
complexes O O
. O O

Thus O O
, O O
an O O
unmodified O O
threonine O O
at O O
position O O
169 O O
in O O
Cdc28 B B_GENE
is O O
important O O
for O O
interaction O O
with O O
G1 B B_GENE
cyclins I I_GENE
. O O

Additional O O
genetic O O
analyses O O
described O O
herein O O
suggest O O
that O O
Skb1 B B_GENE
is O O
a O O
component O O
of O O
the O O
morphology O O
control O O
branch O O
of O O
the O O
Ras B B_GENE/B_DISEASE
signaling O O
cascade O O
in O O
S O O
. O O
pombe O O
and O O
that O O
it O O
positively O O
modulates O O
Shk1 B B_GENE
function O O
. O O

Recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O O
concentrated O O
on O O
the O O
methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
preparation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O O
coffee O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
which O O
vary O O
from O O
country O B_LOCATION
to O O
country O B_LOCATION/B_ORGANIZATION
. O O

From O O
a O O
chromosomal O O
cosmid O O
library O O
of O O
Streptomyces O O
argillaceus O O
, O O
a O O
Mtm B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
producer O O
, O O
a O O
clone O O
( O O
cosAR7 O O
) O O
was O O
isolated O O
by O O
homology O O
to O O
the O O
actI B B_GENE
/ I I_GENE
III I I_GENE
region I I_GENE
of O O
S O O
. O O
coelicolor O O
and O O
the O O
strDEM B B_GENE/B_BIO
genes I I_GENE/I_BIO
of O O
S O O
. O O
griseus O O
. O O

In O O
this O O
report O O
, O O
we O O
investigated O O
whether O O
the O O
cleavage O O
of O O
the O O
RRKR O O
motif O O
of O O
MT B B_GENE
- I I_GENE
MMP1 I I_GENE
by O O
Golgi B B_GENE
- I I_GENE
associated I I_GENE
furin I I_GENE
is O O
analogous O O
to O O
a O O
similar O O
enzyme O O
activation O O
mechanism O O
observed O O
with O O
stromelysin B B_GENE
- I I_GENE
3 I I_GENE
. O O

Coexpression O O
of O O
C B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EBP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
altered O O
the O O
cell O O
specificity O O
. O O

A O O
preterm O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
formula O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
with O O
a O O
traditional O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
corn O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
oil O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
MCT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
blend O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
containing O O
38 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
MCTs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MCT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
was O O
compared O O
to O O
a O O
new O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
fat O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
blend O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O O
designed O O
to O O
resemble O O
human O B_BIO/B_DISEASE
milk O I_BIO/I_DISEASE
more O I_BIO/I_DISEASE
, O O
containing O O
6 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
MCTs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
LCT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Thirty O B_NUMBER[MEASURE]
- O O
three O B_NUMBER[MEASURE]
small O I_NUMBER[MEASURE]
glottic O I_NUMBER[MEASURE]
carcinomas O I_NUMBER[MEASURE]
( O O
T1 O B_PROTEIN[GENE]
and O O
small O B_PROTEIN[GENE]/B_DISEASE
T2 O I_PROTEIN[GENE]/I_DISEASE
; O O
UICC O B_PERSON
, O O
1978 O B_MEASURE
) O O
were O O
examined O O
by O O
malignancy O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
grading O O
using O O
the O O
8 O B_NUMBER[MEASURE]
- O O
factor O B_MEASURE/B_LOCATION
system O I_MEASURE/I_LOCATION
proposed O O
by O O
Jakobsson O B_PERSON/B_ORGANIZATION
et O I_PERSON/I_ORGANIZATION
al O I_PERSON/I_ORGANIZATION
. O O

Phenylalanine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
and O O
tyrosine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
those O O
who O O
received O O
Vamin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucose O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O O
55 O B_PERSON/B_MEASURE
% O B_PERSON/I_MEASURE
of O O
infants O B_PERSON/B_LOCATION
given O O
Vamin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Infant O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
had O O
tyrosine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
below O O
the O O
lower O B_MEASURE/B_LOCATION
limit O B_MEASURE/I_LOCATION
of O O
the O O
target O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
range O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
sought O O
to O O
test O O
whether O O
a O O
prolonged O O
infusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
magnesium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MgSO O B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
4 O B_MEASURE/B_LOCATION
) O O
; O O
40 O B_MEASURE/B_LOCATION
mmol O I_MEASURE/I_LOCATION
/ O O
24 O B_MEASURE/B_SPORT[ENT]
hours O I_MEASURE/I_SPORT[ENT]
) O O
would O O
normalize O O
QT O B_DISEASE/B_GENE
interval O I_DISEASE/I_GENE
variability O I_DISEASE/I_GENE
in O O
patients O B_PERSON
with O O
compensated O B_DISEASE/B_GENE
heart O I_DISEASE/I_GENE
failure O I_DISEASE/I_GENE
. O O

Escherichia O O
coli O O
strains O O
carrying O O
recA730 B B_GENE/B_LOCATION
( O O
or O O
other O O
recA B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
* I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
alleles I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
) O O
exhibit O O
dramatic O O
increases O O
in O O
SOS O O
- O O
dependent O O
spontaneous O O
mutator O O
activity O O
. O O

Outlook O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
oral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
cutaneous O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
Kaposi O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
' O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
s O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
sarcoma O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

We O O
report O O
the O O
complete O O
nucleotide O O
sequence O O
of O O
the O O
camC B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
along O O
with O O
155 O O
base O O
pairs O O
of O O
5 O O
' O O
and O O
175 O O
base O O
pairs O O
of O O
3 O O
' O O
flanking O O
sequence O O
. O O

However O O
, O O
it O O
is O O
only O O
loosely O O
associated O O
, O O
or O O
not O O
associated O O
, O O
with O O
viral O B_DISEASE
particles O I_DISEASE
. O O

gp170 B B_PROTEIN[GENE]/B_DISEASE
is O O
generated O O
by O O
an O O
alternatively O O
spliced O O
Env B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
using O O
a O O
splice O O
donor O O
and O O
splice O O
acceptor O O
pair O O
localized O O
within O O
the O O
env B B_GENE
open I I_GENE
reading I I_GENE
frame I I_GENE
( I I_GENE
ORF I I_GENE
) I I_GENE
, O O
which O O
is O O
normally O O
used O O
to O O
generate O O
Bell B B_GENE/B_LOCATION
and O O
Bet B B_GENE/B_BIO
transcripts I I_GENE/I_BIO
derived O O
from O O
the O O
internal O O
promoter O O
within O O
the O O
env B B_GENE/B_VIRUS[BIO]
ORF I I_GENE/I_VIRUS[BIO]
. O O

gp170 B B_GENE/B_DISEASE
is O O
expressed O O
at O O
a O O
level O O
30 O O
to O O
50 O O
% O O
of O O
the O O
Env B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
precursor I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
gp130 B B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

In O O
marked O O
contrast O O
to O O
the O O
previously O O
published O O
human B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
CD6 I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sequence I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
mouse O O
sequence O O
predicts O O
a O O
long O O
cytoplasmic O O
tail O O
that O O
is O O
not O O
closely O O
related O O
to O O
other O O
proteins O O
and O O
possesses O O
two O O
proline O O
- O O
rich O O
motifs O O
containing O O
the O O
SH3 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domain I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consensus I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
three O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphorylation I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
motifs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
nine O O
casein B B_GENE/B_LOCATION
kinase I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
2 I I_GENE/I_LOCATION
phosphorylation I I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
motifs I I_GENE/I_LOCATION
, O O
and O O
a O O
serine O O
- O O
threonine O O
- O O
rich O O
motif O O
repeated O O
three O O
times O O
. O O

ET B B_PERSON/B_DISEASE
- I I_PERSON/I_DISEASE
1 I I_PERSON/I_DISEASE
limited O O
the O O
electrocardiographic O O
evidence O O
of O O
subendocardial O O
ischemia O O
and O O
attenuated O O
contractile O O
dysfunction O O
compared O O
with O O
mechanical O O
stenosis O O
at O O
the O O
same O O
coronary O O
flows O O
, O O
even O O
though O O
lactate O O
flux O O
was O O
similar O O
. O O

Our O O
results O O
are O O
consistent O O
with O O
TCOF1 B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutations I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leading O O
to O O
the O O
Treacher O O
Collins O O
syndrome O O
phenotype O O
. O O

Experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
syndrome O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analogous O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
hydramnios O B_DISEASE/B_BACTERIUM[BIO]
in O O
the O O
rat O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
fetus O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]

Total O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cross O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
sections O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
electron O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scattering O O
by O O
CO2 O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
molecules O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
energy O B_TIME[MEASURE]/B_LOCATION
range O I_TIME[MEASURE]/I_LOCATION
400 O I_TIME[MEASURE]/I_LOCATION
- O O
5000 O B_MEASURE
eV O I_MEASURE
. O O

Thus O O
, O O
the O O
cognitive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
performance O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
elderly O B_PERSON/B_BIO
subjects O I_PERSON/I_BIO
could O O
be O O
trained O O
to O O
a O O
large O B_MEASURE
extent O I_MEASURE
. O O

Partial O B_DISEASE
albinism O I_DISEASE
and O O
immunodeficiency O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
ultrastructural O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
haemophagocytosis O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
bone O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
marrow O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
erythroblasts O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
one O B_PERSON/B_BIO
case O I_PERSON/I_BIO
. O O

Residues O O
that O O
affect O O
PLCbeta B B_GENE
and O O
adenylyl B B_GENE
cyclase I I_GENE
II I I_GENE
activity O O
are O O
found O O
on O O
opposite O O
sides O O
of O O
the O O
central O O
tunnel O O
, O O
suggesting O O
that O O
PLC B B_GENE/B_DISEASE
and O O
adenylyl B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cyclase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
like O O
the O O
alpha O O
subunit O O
, O O
make O O
many O O
contacts O O
on O O
the O O
top O O
surface O O
. O O

The O O
dynamics O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
protozoa O B_BIO/B_ORGANISM_FUNCTION
were O O
studied O O
in O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
groups O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
rumen O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
- O O
fistulated O O
cattle O B_SPECIES[BIO]
fed O O
on O O
a O O
basal O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
diet O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
molasses O B_BIO/B_PROTEIN[GENE]
ad O B_BIO/I_PROTEIN[GENE]
lib O B_BIO/I_PROTEIN[GENE]
. O O
, O O
with O O
oaten O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
chaff O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
given O O
at O O
6 O B_MEASURE
or O O
18 O B_MEASURE
g O I_MEASURE
/ O O
kg O B_MEASURE
live O I_MEASURE
weight O I_MEASURE
. O O

The O O
CBS B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
mapped O O
to O O
human O O
chromosome O O
10p12 O O
between O O
markers O O
WI B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
8535 I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
WI B B_MEASURE/B_GENE
- I I_MEASURE/I_GENE
4724 I I_MEASURE/I_GENE
, O O
and O O
is O O
tightly O O
linked O O
to O O
the O O
two O O
STRP O O
markers O O
of O O
D10S1789 B B_GENE/B_LOCATION
and O O
D10S550 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Blood O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ammonia O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
significantly O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
males O B_PERSON/B_BIO
at O O
70 O B_MEASURE
, O O
80 O B_MEASURE
and O O
90 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
of O O
VO2 O B_PERSON/B_MEASURE
peak O I_PERSON/I_MEASURE
. O O

Value O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
bone O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
scintigraphy O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
with O O
Tc99MDP O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
early O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
mobilization O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
total O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
hip O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
prosthesis O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]

Youssoufian O B_PERSON/B_COLOR
, O O
A O O
. O O

The O O
dipper O B_MEASURE/B_PERSON
( O O
RONF O B_MEASURE/B_LOCATION
of O O
BP O B_LOCATION/B_PROTEIN[GENE]
( O O
or O O
HR O B_LOCATION/B_PROTEIN[GENE]
) O O
> O B_MEASURE/B_OTHER
or O O
= O O
10 O B_MEASURE/B_LOCATION
% O B_MEASURE/I_LOCATION
2 O B_MEASURE/I_LOCATION
. O O

In O O
the O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O O
we O O
have O O
investigated O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
SDZ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ENA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
713 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
spatial O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
learning O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
deficits O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
aged O B_SPECIES[BIO]/B_DISEASE
rats O I_SPECIES[BIO]/I_DISEASE
. O O

MATERIALS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
AND O O
METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
A O O
seven O B_NUMBER[MEASURE]
- O O
wavelength O B_MEASURE/B_LOCATION
frequency O I_MEASURE/I_LOCATION
- O O
domain O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
photon O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
migration O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
probe O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
used O O
to O O
perform O O
noninvasive O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
NIR O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
measurements O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
the O O
breasts O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
28 O B_PERSON
healthy O I_PERSON
women O I_PERSON
, O O
both O O
pre O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
postmenopausal O B_PERSON
, O O
aged O O
18 O B_MEASURE
- O O
64 O B_MEASURE/B_ENT
years O I_MEASURE/I_ENT
. O O

YACs O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
BACs O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
cosmids O B_DISEASE/B_BACTERIUM[BIO]
, O O
and O O
STSs O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
are O O
defined O O
to O O
aid O O
in O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
gene O B_PERSON/B_BIO
. O O

HCVR O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
L O B_PROTEIN[GENE]/B_LOCATION
significantly O O
increased O O
dVAS O B_DISEASE/B_PROTEIN[GENE]
/ O O
dPCO2 O B_MEASURE/B_PROTEIN[GENE]
to O O
4 O B_MEASURE
. O O
9 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
7 O B_MEASURE
mm O I_MEASURE
/ O O
Torr O B_MEASURE/B_PERSON
compared O O
to O O
HCVR O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
S O B_PROTEIN[GENE]/B_DISEASE
( O O
p O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

The O O
MEF B B_GENE/B_BIO
- I I_GENE/I_BIO
2 I I_GENE/I_BIO
proteins I I_GENE/I_BIO
are O O
a O O
family O O
of O O
transcriptional O O
activators O O
that O O
have O O
been O O
detected O O
in O O
a O O
wide O O
variety O O
of O O
cell O O
types O O
. O O

The O O
ferric B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
uptake I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
regulation I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
fur B B_BIO/B_PROTEIN[GENE]
) O O
gene O O
product O O
participates O O
in O O
regulating O O
expression O O
of O O
the O O
manganese O O
- O O
and O O
iron O O
- O O
containing O O
superoxide B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
dismutase I I_PROTEIN[GENE]/I_BACTERIUM[BIO]
genes I I_PROTEIN[GENE]/I_BACTERIUM[BIO]
of I I_PROTEIN[GENE]/I_BACTERIUM[BIO]
Escherichia I I_PROTEIN[GENE]/I_BACTERIUM[BIO]
coli I I_PROTEIN[GENE]/I_BACTERIUM[BIO]
. O O

To O O
date O O
, O O
6 O O
mammalian O O
GRKs B B_GENE/B_BIO
have O O
been O O
identified O O
by O O
molecular O O
cloning O O
. O O

[ O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
OP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
2Cu O B_LOCATION
] O O
+ O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
detected O O
protections O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
the O O
C O B_PROTEIN[GENE]/B_NUMBER[MEASURE]
alpha O B_PROTEIN[GENE]/I_NUMBER[MEASURE]
- O O
helix O B_LOCATION
, O O
the O O
interdomain O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
hinge O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
strands O B_PROTEIN[GENE]/B_LOCATION
2 O I_PROTEIN[GENE]/I_LOCATION
- O O
7 O B_MEASURE
. O O

The O O
aim O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O O
to O O
investigate O O
the O O
influence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
long O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
term O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
intravenous O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
administration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
of O O
naftidrofuryl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Dusodril O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
Lipha O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Arzn O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
twice O O
daily O O
in O O
a O O
dose O B_MEASURE/B_LOCATION
of O O
200 O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
continuous O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
4 O B_NUMBER[MEASURE]
- O O
hour O B_TIME[MEASURE]
infusion O I_TIME[MEASURE]
in O O
500 O B_MEASURE
ml O I_MEASURE
0 O I_MEASURE
. O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
NaCl O I_MEASURE/I_PERSON
to O O
the O O
patients O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
suffering O O
from O O
a O O
peripheral O B_DISEASE
arterial O I_DISEASE
occlusive O I_DISEASE
disease O I_DISEASE
( O O
PAOD O B_DISEASE/B_LOCATION
) O O
in O O
a O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
condition O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
with O O
special O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
attention O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
paid O O
to O O
transcutaneous O O
partial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
oxygen O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
pressure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measurements O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
tcPO2 O B_DISEASE/B_LOCATION
) O O
and O O
rheographic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
parameters O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Vertebrate O O
U6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
small I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
snRNA O O
) O O
loci O O
exemplify O O
a O O
novel O O
class O O
of O O
polymerase B B_DISEASE/B_LOCATION
III I I_DISEASE/I_LOCATION
- O O
transcribed O O
genes O O
that O O
lack O O
an O O
intragenic O O
control O O
region O O
( O O
ICR O O
) O O
. O O

Elements O O
of O O
the O O
hAT B B_GENE/B_LOCATION
transposon I I_GENE/I_LOCATION
family I I_GENE/I_LOCATION
, O O
such O O
as O O
the O O
maize B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activator I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Ac B B_DISEASE/B_LOCATION
) O O
, O O
have O O
been O O
discovered O O
in O O
a O O
large O O
number O O
of O O
eukaryotic O O
species O O
. O O

Judge O B_PERSON/B_LOCATION
Christian O I_PERSON/I_LOCATION
Byk O I_PERSON/I_LOCATION
renders O O
service O B_ORGANIZATION/B_PERSON
to O O
the O O
Steering O B_ORGANIZATION/B_PERSON
Committee O I_ORGANIZATION/I_PERSON
on O O
Bioethics O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
Council O B_ORGANIZATION/B_LOCATION
of O O
Europe O B_LOCATION/B_PERSON
( O O
CDBI O B_DISEASE/B_ORGANIZATION
) O O
by O O
proposing O O
a O O
draft O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
the O O
protocol O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
destined O O
to O O
fill O O
in O O
a O O
gap O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
international O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
law O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O O
the O O
status O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
the O O
human O B_ORGANIZATION/B_PERSON
embryo O I_ORGANIZATION/I_PERSON
. O O

Correlation O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coefficients O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
SF O B_MEASURE/B_LOCATION
thickness O B_MEASURE/I_LOCATION
and O O
NIR O B_MEASURE
optical O I_MEASURE
density O I_MEASURE
readings O I_MEASURE
at O O
940 O B_MEASURE
nm O I_MEASURE
( O O
OD1 O B_PROTEIN[GENE]/B_MEASURE
) O O
and O O
950 O B_MEASURE
nm O I_MEASURE
( O O
OD2 O B_PROTEIN[GENE]/B_MEASURE
) O O
wavelengths O B_LOCATION/B_DISEASE
ranged O O
from O O
r O B_PROTEIN[GENE]/B_MEASURE
= O O
- O O
0 O B_NUMBER[MEASURE]
. O O
30 O B_MEASURE
( O O
subscapula O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
) O O
to O O
r O B_PROTEIN[GENE]/B_MEASURE
= O O
- O O
0 O B_NUMBER[MEASURE]
. O O
67 O B_MEASURE
( O O
biceps O B_BODY_PART_OR_ORGAN_COMPONENT
) O O
for O O
OD1 O B_PROTEIN[GENE]/B_DISEASE
and O O
r O B_MEASURE/B_LOCATION
= O I_MEASURE/I_LOCATION
- O O
0 O B_NUMBER[MEASURE]
. O O
39 O B_MEASURE
( O O
axilla O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
) O O
to O O
r O B_PROTEIN[GENE]/B_MEASURE
= O O
- O O
0 O B_NUMBER[MEASURE]
. O O
68 O B_MEASURE
( O O
biceps O B_BODY_PART_OR_ORGAN_COMPONENT
) O O
for O O
OD2 O B_PROTEIN[GENE]/B_DISEASE
. O O

We O O
found O O
both O O
the O O
v B B_PROTEIN[GENE]/B_LOCATION
- I B_PROTEIN[GENE]/I_LOCATION
Ras I B_PROTEIN[GENE]/I_LOCATION
- O O
and O O
PC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
PLC I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
transformed O O
cells O O
to O O
be O O
insensitive O O
to O O
stimulation O O
with O O
platelet B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
derived I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PDGF B B_GENE
) O O
. O O

Analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
domain O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
deletion O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
mutants O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
demonstrated O O
strong O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synergy O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
RRM O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
and O O
a O O
central O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
degenerate O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RRM O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
repeat O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
binding O O
to O O
RNA O B_GENE/B_BIO
. O O

Sequence O O
analysis O O
of O O
the O O
catfish O O
JH B B_PROTEIN[GENE]/B_LOCATION
- O O
CH B B_LOCATION/B_DISEASE
intron O O
suggests O O
that O O
several O O
sequences O O
are O O
present O O
which O O
appear O O
similar O O
to O O
important O O
transcriptional O O
regulatory O O
elements O O
found O O
within O O
JH B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
CH B B_LOCATION/B_DISEASE
introns O O
of O O
higher O O
vertebrates O O
. O O

The O O
patient O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
consisted O O
of O O
31 O B_MEASURE
with O O
dilated O B_DISEASE
cardiomyopathy O I_DISEASE
, O O
22 O B_MEASURE
with O O
hypertrophic O B_DISEASE
cardiomyopathy O I_DISEASE
, O O
38 O B_MEASURE
with O O
myocardial O B_DISEASE
infarction O I_DISEASE
, O O
15 O B_MEASURE
with O O
angina O B_DISEASE
pectoris O I_DISEASE
and O O
26 O B_NUMBER[MEASURE]
with O O
rheumatic O B_DISEASE/B_PERSON
valvular O I_DISEASE/I_PERSON
disease O I_DISEASE/I_PERSON
. O O

100 O B_NUMBER[MEASURE]
. O O

However O O
, O O
the O O
pre3 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
2 I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
strengthened O O
phenotypes O O
induced O O
by O O
other O O
20 B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
S I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteasomal I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutations I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
indicating O O
that O O
the O O
peptidylglutamyl O O
peptide O O
- O O
hydrolyzing O O
activity O O
has O O
to O O
fulfill O O
some O O
rescue O O
functions O O
. O O

Whereas O O
Sprague O B_PERSON
- O O
Dawleys O B_MEASURE/B_PERSON
displayed O O
lights O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
off O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
lights O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
on O O
peaks O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
ingestive O B_DISEASE/B_ORGANISM_FUNCTION
activity O B_DISEASE/I_ORGANISM_FUNCTION
, O O
only O O
a O O
minority O B_PERSON/B_MEASURE
of O O
Fisher O B_PERSON/B_LOCATION
- O O
344s O B_PERSON
displayed O O
a O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
lights O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
- O O
on O O
peak O B_MEASURE
of O O
ingestive O B_DISEASE/B_ORGANISM_FUNCTION
activity O B_DISEASE/I_ORGANISM_FUNCTION
. O O

RESULTS O B_MEASURE
: O O
In O O
76 O B_MEASURE/B_SPORT[ENT]
trials O I_MEASURE/I_SPORT[ENT]
, O O
5 O B_MEASURE
, O O
351 O B_MEASURE
patients O I_MEASURE
received O O
24 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
different O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
regimens O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
droperidol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

The O O
tro B B_GENE/B_LOCATION
operon I I_GENE/I_LOCATION
is O O
flanked O O
by O O
a O O
Holliday B B_GENE
structure I I_GENE
DNA I I_GENE
helicase I I_GENE
homolog O O
( O O
upstream O O
) O O
and O O
two O O
ORFs O O
representing O O
a O O
purine B B_ENZYME[GENE]/B_SPECIES[BIO]
nucleoside I B_ENZYME[GENE]/I_SPECIES[BIO]
phosphorylase I B_ENZYME[GENE]/I_SPECIES[BIO]
homolog O O
and O O
tpp15 B B_GENE/B_LOCATION
, O O
a O O
previously O O
characterized O O
gene O O
encoding O O
a O O
membrane O O
lipoprotein O O
( O O
downstream O O
) O O
. O O

We O O
report O O
nine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
consecutive O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
cases O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
ACB O B_DISEASE/B_GENE
, O O
which O O
occurred O O
in O O
five O B_PERSON
males O I_PERSON
and O O
four O B_PERSON
females O I_PERSON
and O O
were O O
detected O O
in O O
11 O B_MEASURE
, O O
159 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
routine O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spiral O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CT O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examinations O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
chest O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
performed O O
between O O
1994 O B_MEASURE
and O O
1998 O B_MEASURE
. O O

In O O
order O O
to O O
search O O
for O O
mutations O O
in O O
the O O
multicopy B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RBM I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
might O O
be O O
associated O O
with O O
male O O
infertility O O
, O O
we O O
have O O
used O O
sequence O O
data O O
from O O
the O O
reported O O
cDNA O O
clone O O
to O O
determine O O
the O O
intron O O
exon O O
boundaries O O
of O O
the O O
YRRM B B_GENE
1 I I_GENE
gene I I_GENE
. O O

98 O B_MEASURE
, O O
93 O B_MEASURE
- O O
98 O B_MEASURE
) O O
. O O

Studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
excretion O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
selenium O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
urine O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
feces O B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
and O O
distribution O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
the O O
organs O B_BODY_PART_OR_ORGAN_COMPONENT
of O O
rats O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
a O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
radioactivity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurement O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
use O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pharmacokinetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
parameters O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
t1 O B_LOCATION/B_PROTEIN[GENE]
/ O O
2 O B_NUMBER[MEASURE]
and O O
Cltp O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
, O O
as O O
indices O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
drug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
elimination O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
ability O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
are O O
discussed O O
. O O

Gastric O B_DISEASE
secretory O I_DISEASE
inhibition O I_DISEASE
induced O O
by O O
three O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
methyl O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
analogs O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
prostaglandin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
E2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
administered O O
intragastrically O O
to O O
man O B_PERSON/B_SPECIES[BIO]
. O O

By O O
RT O O
- O O
PCR O O
, O O
different O O
levels O O
of O O
E75 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O O
can O O
be O O
detected O O
in O O
the O O
epidermis O O
, O O
nerve O O
cord O O
and O O
the O O
eyestalk O O
of O O
early O O
pre O O
- O O
molt O O
shrimp O O
. O O

The O O
vicinity O B_LOCATION
of O O
large O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
industrial O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
emissions O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O O
lead O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
where O O
mean O B_MEASURE/B_PROTEIN[GENE]
Pb O B_MEASURE/I_PROTEIN[GENE]
- O O
B O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concentrations O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
usually O O
twice O O
as O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
as O O
in O O
rural O B_LOCATION/B_MEASURE
areas O I_LOCATION/I_MEASURE
of O O
the O O
Katowice O B_LOCATION
voivodship O I_LOCATION
. O O

Forty O B_NUMBER[MEASURE]
- O O
five O B_NUMBER[MEASURE]
per O O
cent O B_MEASURE
of O O
the O O
dose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O O
excreted O O
as O O
methyldopa O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
as O O
opposed O O
to O O
18 O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
% O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
normally O O
seen O O
after O O
oral O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
methyldopa O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
dosages O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

No O O
cleavage O O
of O O
gp B B_GENE
130 I I_GENE
was O O
observed O O
in O O
analogous O O
pulse O O
- O O
chase O O
radiolabelling O O
of O O
Ad O O
- O O
gB B B_LOCATION/B_DISEASE
- O O
infected O O
human O O
fibroblasts O O
, O O
even O O
though O O
these O O
cells O O
are O O
permissive O O
for O O
HCMV O O
replication O O
and O O
can O O
process O O
the O O
native B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gB I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
molecule I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
phylogenetic O O
comparison O O
of O O
32 O O
species O O
showed O O
minor O O
differences O O
in O O
the O O
apoB B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRNA I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
the O O
apoB B B_GENE
mRNA I I_GENE
from O O
31 O O
species O O
was O O
robustly O O
edited O O
in O O
vitro O O
. O O

The O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
five O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O O
within O O
the O O
SRO O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
may O O
provide O O
an O O
entrance O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
point O I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
cloning O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
candidate O B_GENE
genes O I_GENE
for O O
neuroblastoma O B_DISEASE
. O O

Sugar O O
analysis O O
was O O
performed O O
on O O
alpha B B_BIO/B_GENE
- I I_BIO/I_GENE
TM I I_BIO/I_GENE
to O O
investigate O O
a O O
possible O O
biosynthetic O O
mechanism O O
for O O
part O O
- O O
time O O
PGs O O
. O O

Pediatric O B_PERSON/B_LOCATION
patients O I_PERSON/I_LOCATION
- O O
- O O
handle O B_PERSON
with O O
care O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
include O O
the O O
genes O O
, O O
undefined B B_PROTEIN[GENE]
1 I I_PROTEIN[GENE]
( O O
UD1 B B_GENE/B_DISEASE
) O O
, O O
UD2 B B_GENE/B_DISEASE
, O O
and O O
UD3 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
each O O
coding O O
for O O
proteins O O
of O O
unknown O O
function O O
, O O
the O O
ken B B_PERSON/B_GENE
gene I I_PERSON/I_GENE
encoding O O
a O O
new O O
Kruppel B B_ENZYME[GENE]
- I I_ENZYME[GENE]
like I I_ENZYME[GENE]
putative I I_ENZYME[GENE]
transcription I I_ENZYME[GENE]
factor I I_ENZYME[GENE]
, O O
the O O
fly O O
homologues O O
of O O
the O O
mammalian B B_ENZYME[GENE]/B_BIO
mitochondrial I I_ENZYME[GENE]/I_BIO
trifunctional I I_ENZYME[GENE]/I_BIO
enzyme I I_ENZYME[GENE]/I_BIO
( O O
thiolase B B_LOCATION/B_GENE
) O O
, O O
and O O
the O O
TAR B B_BIO/B_GENE
DNA I I_BIO/I_GENE
- I I_BIO/I_GENE
binding I I_BIO/I_GENE
protein I I_BIO/I_GENE
- I I_BIO/I_GENE
43 I I_BIO/I_GENE
( O O
TBPH B B_DISEASE/B_GENE
) O O
, O O
the O O
first O O
nonvertebrate O O
member O O
of O O
the O O
transmembrane B B_GENE
4 I I_GENE
superfamily I I_GENE
( O O
TM4SF B B_GENE/B_MEASURE
) O O
gene O O
, O O
a O O
new O O
homeodomain B B_GENE/B_BIO
gene I I_GENE/I_BIO
, O O
and O O
a O O
gene O O
coding O O
for O O
a O O
putative O O
nuclear O O
binding O O
protein O O
( O O
PNBP O O
) O O
that O O
is O O
homologous O O
to O O
maleless B B_PERSON/B_BIO
, O O
and O O
a O O
Copia B B_GENE/B_BIO
- I I_GENE/I_BIO
like I I_GENE/I_BIO
element I I_GENE/I_BIO
. O O

TRAF2 B B_GENE/B_DISEASE
has O O
previously O O
been O O
demonstrated O O
to O O
activate O O
both O O
transcription O O
factor O O
nuclear B B_PROTEIN[GENE]/B_MEASURE
factor I I_PROTEIN[GENE]/I_MEASURE
kappaB I I_PROTEIN[GENE]/I_MEASURE
( O O
NFkappaB B B_GENE/B_LOCATION
) O O
and O O
the O O
c B B_GENE
- I I_GENE
Jun I I_GENE
N I I_GENE
- I I_GENE
terminal I I_GENE
kinase I I_GENE
/ O O
stress B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
JNK B B_GENE/B_LOCATION
/ O O
SAPK B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
pathway O O
, O O
which O O
in O O
turn O O
stimulates O O
transcription B B_GENE
factor I I_GENE
activating I I_GENE
protein I I_GENE
1 I I_GENE
( O O
AP1 B B_GENE/B_DISEASE
) O O
mainly O O
via O O
phosphorylation O O
of O O
the O O
c B B_GENE
- I I_GENE
Jun I I_GENE
component O O
. O O

A O O
procaryotic O O
regulatory O O
factor O O
with O O
a O O
histone B B_GENE
H1 I I_GENE
- I I_GENE
like I I_GENE
carboxy I I_GENE
- I I_GENE
terminal I I_GENE
domain I I_GENE
: O O
clonal O O
variation O O
of O O
repeats O O
within O O
algP B B_GENE
, O O
a O O
gene O O
involved O O
in O O
regulation O O
of O O
mucoidy O O
in O O
Pseudomonas O O
aeruginosa O O
. O O

The O O
host O O
range O O
( O O
HR O O
) O O
of O O
poliovirus O O
is O O
thought O O
to O O
be O O
primarily O O
determined O O
by O O
a O O
cell O O
surface O O
molecule O O
that O O
functions O O
as O O
poliovirus B B_GENE/B_BIO
receptor I I_GENE/I_BIO
( O O
PVR B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
since O O
it O O
has O O
been O O
shown O O
that O O
transgenic O O
mice O O
are O O
made O O
poliovirus O O
sensitive O O
by O O
introducing O O
the O O
human B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
PVR I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
into O O
the O O
genome O O
. O O

Human B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
alcohol I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ADH B B_DISEASE/B_GENE
) O O
exists O O
as O O
a O O
heterogeneous O O
group O O
of O O
isozymes O O
capable O O
of O O
oxidizing O O
a O O
wide O O
variety O O
of O O
aliphatic O O
and O O
aromatic O O
alcohols O O
. O O

The O O
control O O
of O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
aromatase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
is O O
complex O O
in O O
that O O
several O O
promoters O O
drive O O
aromatase B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
in O O
a O O
tissue O O
- O O
specific O O
manner O O
. O O

In O O
addition O B_MEASURE/B_LOCATION
, O O
renal O B_DISEASE/B_GENE
sympathetic O B_DISEASE/I_GENE
activity O B_DISEASE/I_GENE
was O O
measured O O
in O O
a O O
separate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
rats O B_BIO/B_PERSON
. O O

This O O
incompatibility O O
phenotype O O
requires O O
the O O
global O O
transcriptional O O
repressor O O
, O O
KorB B B_GENE/B_BACTERIUM[BIO]
, O O
and O O
the O O
target O O
for O O
incC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
- O O
mediated O O
incompatibility O O
is O O
a O O
KorB B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
site I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
O I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
B I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Bodily O O
referents O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
the O O
experience O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
affect O B_DISEASE/B_PERSON
. O O

The O O
effect O O
of O O
the O O
negative O O
regulatory O O
element O O
is O O
negated O O
by O O
the O O
viral B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IE2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
L O O
. O O

RXRalpha B B_GENE/B_LOCATION
/ O O
RARalpha B B_GENE
heterodimers O O
and O O
HNF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
homodimers I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bind O O
to O O
DR O O
- O O
1 O O
motifs O O
on O O
elements O O
B O O
and O O
I4 O O
, O O
respectively O O
. O O

Evidence O O
for O O
involvement O O
of O O
proteins O O
HU B B_GENE/B_DISEASE
and O O
RpoS B B_PROTEIN[GENE]/B_LOCATION
in O O
transcription O O
of O O
the O O
osmoresponsive O O
proU B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
operon I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
Escherichia O O
coli O O
. O O

However O O
, O O
a O O
lesser O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
extent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
noticed O O
in O O
nonpregnant O B_PERSON/B_BIO
than O O
seen O O
in O O
pregnant O B_PERSON/B_DISEASE
rats O I_PERSON/I_DISEASE
. O O

Morphine O B_PERSON/B_LOCATION
administration O I_PERSON/I_LOCATION
acutely O O
reduced O O
plasma O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
clearance O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
sulfobromophthalein O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
BSP O B_LOCATION/B_DISEASE
) O O
in O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
increased O O
hepatic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
retention O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
dye O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Buchstein O B_PERSON
, O O
L O B_OTHER/B_PROTEIN[GENE]
. O O
- O O
L O B_OTHER/B_PERSON
. O O

Intraspinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
mediastinal O B_DISEASE/B_LOCATION
foregut O I_DISEASE/I_LOCATION
cyst O I_DISEASE/I_LOCATION
compressing O O
the O O
spinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cord O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
nutraceuticals O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
of O O
specific O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
vitamins O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
minerals O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
phytoestrogens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
essential O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
fatty O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
supplementations O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
are O O
a O O
vital O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
component O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
risk O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
reduction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
health O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Characterization O O
of O O
a O O
unique O O
protein O O
component O O
of O O
yeast B B_SPECIES[BIO]/B_ENZYME[GENE]
RNase I I_SPECIES[BIO]/I_ENZYME[GENE]
MRP I I_SPECIES[BIO]/I_ENZYME[GENE]
: O O
an O O
RNA O O
- O O
binding O O
protein O O
with O O
a O O
zinc O O
- O O
cluster O O
domain O O
. O O

The O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicates O O
that O O
the O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
dose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
5 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
fluorouracil O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regimen O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shows O O
weak O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
activity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
advanced O B_DISEASE/B_GENE
pancreatic O I_DISEASE/I_GENE
cancer O I_DISEASE/I_GENE
which O O
seems O O
comparable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
gemcitabine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Like O O
the O O
nuclear O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
envelope O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
intranuclear O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
double O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
membrane O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lamellae O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
enclosed O O
a O O
defined O O
cisterna O B_LOCATION/B_MEASURE
that O O
was O O
interrupted O O
by O O
pores O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
but O O
, O O
unlike O O
the O O
nuclear O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
envelope O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
pores O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
, O O
they O O
lacked O O
NPCs O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
. O O

The O O
22 O B_NUMBER[MEASURE]
- O O
d O B_TIME[MEASURE]/B_LOCATION
orbital O I_TIME[MEASURE]/I_LOCATION
flight O I_TIME[MEASURE]/I_LOCATION
of O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
onboard O O
the O O
Cosmos O B_LOCATION/B_PROTEIN[GENE]
- O O
605 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biosatellite O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
followed O O
by O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
erythroblastosis O B_DISEASE_ADJECTIVE[DISEASE]
, O O
alteration O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
morphology O B_MEASURE/B_ORGANIZATION
of O O
megakaryocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
myelopoiesis O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

An O O
OD O B_MEASURE/B_LOCATION
650 O I_MEASURE/I_LOCATION
greater O I_MEASURE/I_LOCATION
than O O
0 O B_MEASURE
. O O
15 O B_MEASURE
appears O O
to O O
be O O
a O O
rapid O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
reliable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
indicator O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
fetal O B_DISEASE
lung O I_DISEASE
maturity O I_DISEASE
. O O

The O O
role O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
PORT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
in O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
N2 O B_DISEASE/B_LOCATION
tumours O I_DISEASE/I_LOCATION
is O O
not O O
clear O B_DISEASE_ADJECTIVE[DISEASE]
and O O
may O O
justify O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
concluded O O
that O O
RXR B B_GENE
- I I_GENE
gamma I I_GENE
induced O O
terminal O O
differentiation O O
in O O
SCC O O
lines O O
, O O
suggesting O O
a O O
potential O O
tumor O O
suppressor O O
function O O
for O O
this O O
transcription O O
factor O O
. O O

Phosphorylated O B_PERSON
tyrosine O I_PERSON
residues O I_PERSON
were O O
subsequently O O
identified O O
by O O
sequencing O O
the O O
separated O O
phosphopeptides O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
matrix O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
assisted O O
laser O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
desorption O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
ionization O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
mass O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
spectrometry O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
MALDI O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
MS O B_LOCATION/B_DISEASE
) O O
and O O
Edman O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
degradation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
. O O

The O O
infection O O
of O O
cells O O
with O O
Moloney O O
murine O O
leukemia O O
virus O O
( O O
M O O
- O O
MuLV O O
) O O
causes O O
an O O
increase O O
in O O
specific O O
cellular O O
gene O O
products O O
, O O
including O O
the O O
major B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
histocompatibility I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complex I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MHC I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
class I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigens I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
data O O
demonstrate O O
that O O
oleosin B B_GENE
gene I I_GENE
transcription O O
is O O
regulated O O
in O O
a O O
tissue O O
- O O
specific O O
and O O
temporally O O
regulated O O
manner O O
and O O
clearly O O
indicate O O
that O O
oleosin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
is O O
co O O
- O O
ordinated O O
primarily O O
at O O
the O O
transcriptional O O
level O O
. O O

Myocardial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
technetium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O O
99m O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
teboroxime O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
uptake O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
during O O
adenosine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
hyperemia O B_DISEASE
in O O
dogs O B_BIO/B_PERSON
with O O
either O O
a O O
critical O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O O
mild O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
coronary O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
stenosis O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
: O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
thallium O B_LOCATION/B_DISEASE
- O O
201 O B_MEASURE/B_PERSON
and O O
regional O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
blood O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
flow O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

UICC O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
criteria O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
for O O
VM O B_DISEASE/B_LOCATION
and O O
35 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
for O O
VE O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
not O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

Although O O
immunoglobulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
CRP B B_GENE
concentration O O
increased O O
, O O
anemia O O
obviously O O
improved O O
with O O
hemoglobin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
levels O O
increasing O O
from O O
4 O O
. O O
8 O O
g O O
/ O O
dl O O
to O O
8 O O
. O O
5 O O
g O O
/ O O
dl O O
without O O
any O O
side O O
effects O O
. O O

Diff O B_DISEASE/B_MEASURE
- O O
Quik O B_LOCATION/B_PERSON
stain O I_LOCATION/I_PERSON
for O O
Tzanck O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
smears O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Experience O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
using O O
the O O
Romashka O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEDICAL_DEVICE[OBJECT]
laser O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEDICAL_DEVICE[OBJECT]
surgical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEDICAL_DEVICE[OBJECT]
unit O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEDICAL_DEVICE[OBJECT]
in O O
treating O O
suppurative O B_DISEASE/B_GENE
wounds O I_DISEASE/I_GENE

At O O
D28 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
149 O B_MEASURE
of O O
386 O B_PERSON
patients O I_PERSON
( O O
49 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
had O O
had O O
episodes O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
automatic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mode O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
switch O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prompted O O
by O O
atrial O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
arrhythmias O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Together O O
, O O
these O O
results O O
implicate O O
Fal1p B B_GENE
in O O
the O O
18S B B_GENE
rRNA I I_GENE
maturation O O
pathway O O
rather O O
than O O
in O O
translation O O
initiation O O
. O O

Most O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
other O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
these O O
two O B_BIO/B_GENE
Leporipoxviruses O B_BIO/I_GENE
are O O
located O O
in O O
the O O
telomeres O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O O

We O O
challenge O O
each O O
of O O
55 O B_NUMBER[MEASURE]/B_PERSON
consecutive O B_NUMBER[MEASURE]/I_PERSON
ragweed O O
( O O
RW O B_LOCATION/B_PROTEIN[GENE]
) O O
- O O
allergic O B_PERSON/B_DISEASE
patients O I_PERSON/I_DISEASE
with O O
hay O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fever O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
with O O
graded O B_TIME[MEASURE]
increasing O O
doses O B_MEASURE
of O O
ragweed O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
extract O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
investigate O O
the O O
frequency O B_MEASURE/B_PERSON
and O O
relationship O B_PERSON/B_MEASURE
between O O
the O O
early O B_DISEASE_ADJECTIVE[DISEASE]
( O O
ER O B_LOCATION/B_PROTEIN[GENE]
) O O
, O O
late O O
( O O
LPR O B_LOCATION
) O O
, O O
and O O
rechallenge O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
reactions O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
RCRs O B_LOCATION/B_DISEASE
) O O
to O O
nasal O O
challenge O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

The O O
expression O O
of O O
CAPL B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
second O O
protein O O
involved O O
in O O
calcium O O
metabolism O O
, O O
was O O
only O O
moderately O O
elevated O O
in O O
the O O
doxorubicin O O
- O O
resistant O O
cells O O
. O O

The O O
central O B_LOCATION/B_MEASURE
region O I_LOCATION/I_MEASURE
of O O
the O O
sarcomere O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
coincident O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
with O O
the O O
M O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
line O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
was O O
selectively O O
labeled O O
with O O
antibodies O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
the O O
short O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
C O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
terminal O B_LOCATION/B_MEASURE
form O I_LOCATION/I_MEASURE
. O O

Despite O O
this O O
dependency O O
, O O
however O O
, O O
a O O
B B B_DISEASE_ADJECTIVE[DISEASE]
. I I_DISEASE_ADJECTIVE[DISEASE]
japonicum I I_DISEASE_ADJECTIVE[DISEASE]
fixK I I_DISEASE_ADJECTIVE[DISEASE]
mutant I I_DISEASE_ADJECTIVE[DISEASE]
did O O
not O O
have O O
the O O
phenotypic O O
characteristics O O
of O O
B B B_LOCATION/B_BIO
. I I_LOCATION/I_BIO
japonicum I I_LOCATION/I_BIO
fixL I I_LOCATION/I_BIO
and O O
fixJ B B_DISEASE/B_LOCATION
mutants I I_DISEASE/I_LOCATION
: O O
the O O
fixK B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
mutant I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
was O O
neither O O
Fix O O
- O O
in O O
symbiosis O O
with O O
soybean O O
plants O O
nor O O
defective O O
in O O
anaerobic O O
respiration O O
with O O
nitrate O O
as O O
the O O
terminal O O
electron O O
acceptor O O
. O O

ANL O B_MEASURE/B_PROTEIN[GENE]
- O O
7535 O B_MEASURE/B_LOCATION
. O O

The O O
QCS O B_DISEASE
appears O O
comparable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
MMSE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
is O O
quicker O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
administer O O
. O O

We O O
used O O
high O B_MEASURE/B_LOCATION
- O O
resolution O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ultrasound O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
characterize O O
postprandial O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antral O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
excursion O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characteristics O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
15 O B_PERSON/B_BIO
healthy O B_PERSON/I_BIO
volunteers O B_PERSON/I_BIO
. O O

Copyright O B_LOCATION/B_PERSON
1998 O I_LOCATION/I_PERSON
Academic O I_LOCATION/I_PERSON
Press O I_LOCATION/I_PERSON
. O O

Human B B_GENE
PDNP3 I I_GENE
is O O
expressed O O
in O O
glioma O O
cells O O
, O O
prostate O O
, O O
and O O
uterus O O
, O O
but O O
not O O
in O O
the O O
alimentary O O
tract O O
. O O

Epithelial O B_PERSON
cells O I_PERSON
had O O
abnormal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
accelerated O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exfoliation O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
resulted O O
in O O
multifocal O B_DISEASE
epithelial O I_DISEASE
defects O I_DISEASE
. O O

Tight O O
- O O
binding O O
band O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
structure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
calculations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
beta O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
MNX O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
M O B_LOCATION
= O O
Zr O B_LOCATION/B_PERSON
, O O
X O B_OTHER/B_LOCATION
= O O
Cl O B_LOCATION
, O O
Br O B_LOCATION/B_PERSON
; O O
M O B_LOCATION
= O O
Hf O B_LOCATION
, O O
X O B_LOCATION
= O I_LOCATION
Cl O I_LOCATION
) O O
, O O
ZrCl O B_LOCATION
, O O
and O O
Y O B_OTHER/B_LOCATION
( O O
2 O B_NUMBER[MEASURE]
) O O
C O B_LOCATION/B_GENE
( O O
2 O B_NUMBER[MEASURE]
) O O
Br O B_LOCATION/B_ORGANIZATION
( O O
2 O B_NUMBER[MEASURE]/B_LOCATION
) O O
are O O
reported O O
. O O

Screening O O
of O O
a O O
human O O
foetal O O
brain O O
genomic O O
DNA O O
library O O
allowed O O
us O O
to O O
isolate O O
an O O
EcoRI B B_GENE/B_DISEASE
- O O
EcoRI B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fragment O O
containing O O
6 O O
kb O O
of O O
the O O
5 O O
' O O
- O O
flanking O O
region O O
, O O
the O O
open O O
reading O O
frame O O
and O O
4 O O
kb O O
of O O
the O O
3 O O
' O O
- O O
flanking O O
region O O
of O O
the O O
alpha2C4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
psychosomatic O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
approach O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O O
temporomandibular O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
arthrosis O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE

The O O
rate O O
of O O
decrease O O
of O O
PRA O O
after O O
REM O O
onset O O
closely O O
approximates O O
the O O
most O O
recent O O
estimations O O
of O O
PRA O O
half O O
- O O
life O O
, O O
which O O
suggests O O
that O O
REM O O
onset O O
is O O
associated O O
with O O
a O O
virtual O O
cessation O O
in O O
renin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production O O
. O O

Similarly O O
, O O
interfering O O
with O O
MEKK B B_GENE
, O O
which O O
lies O O
upstream O O
of O O
JNK1 B B_GENE
, O O
using O O
a O O
dominant O O
negative O O
expression O O
vector O O
reduced O O
MMP B B_GENE
- I I_GENE
9 I I_GENE
promoter I I_GENE
activity O O
over O O
the O O
same O O
concentration O O
range O O
which O O
repressed O O
the O O
AP B B_GENE
- I I_GENE
1 I I_GENE
- O O
thymidine B B_GENE
kinase I I_GENE
CAT B I_GENE
reporter O O
construct O O
. O O

There O O
was O O
no O O
difference O O
in O O
serum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
albumin I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
transferrin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
levels O O
, O O
but O O
serum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
prealbumin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
levels O O
in O O
the O O
group O O
fed O O
early O O
were O O
more O O
desirable O O
than O O
those O O
of O O
the O O
control O O
group O O
( O O
from O O
15 O O
. O O
8 O O
+ O O
/ O O
- O O
2 O O
. O O
5 O O
mg O O
/ O O
dl O O
to O O
28 O O
. O O
9 O O
+ O O
/ O O
- O O
3 O O
. O O
8 O O
mg O O
/ O O
dl O O
vs O O
from O O
18 O O
. O O
0 O O
+ O O
/ O O
- O O
2 O O
. O O
0 O O
mg O O
/ O O
dl O O
to O O
25 O O
. O O
9 O O
+ O O
/ O O
- O O
3 O O
. O O
9 O O
mg O O
/ O O
dl O O
) O O
. O O

The O O
repeats O B_GENE/B_DISEASE
are O O
highly O O
conserved O O
both O O
within O O
a O O
given O O
element O B_MEASURE/B_GENE
as O O
well O O
as O O
between O O
different O B_PERSON/B_LOCATION
members O I_PERSON/I_LOCATION
of O O
the O O
family O B_PERSON/B_BIO
( O O
less O B_MEASURE
than O O
10 O B_MEASURE
% O I_MEASURE
divergence O I_MEASURE
) O O
. O O

Utility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
thallium O B_LOCATION/B_DISEASE
- O O
201 O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
scintigraphy O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
detecting O O
right O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ventricular O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dysfunction O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
pulmonary O B_DISEASE/B_PERSON
embolism O I_DISEASE/I_PERSON
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
The O O
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
developed O O
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
can O O
be O O
used O O
as O O
a O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
detect O O
air O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
trapping O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
during O O
TGI O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
carboxyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
terminal O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
75 O B_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
amino O B_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
acids O B_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
two O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
contain O O
the O O
bHLH O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
motif O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
differ O O
from O O
each O O
other O B_NUMBER[MEASURE]/B_PERSON
by O O
only O O
three O B_NUMBER[MEASURE]/B_LOCATION
conservative O I_NUMBER[MEASURE]/I_LOCATION
amino O I_NUMBER[MEASURE]/I_LOCATION
acid O I_NUMBER[MEASURE]/I_LOCATION
changes O I_NUMBER[MEASURE]/I_LOCATION
, O O
while O O
the O O
amino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
portions O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
are O O
markedly O O
divergent O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
from O O
each O O
other O B_NUMBER[MEASURE]/B_PERSON
. O O

In O O
a O O
rat O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
SAH O B_DISEASE
, O O
we O O
assessed O O
BBB O B_DISEASE_ADJECTIVE[DISEASE]
changes O I_DISEASE_ADJECTIVE[DISEASE]
by O O
means O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
quantitative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
[ O O
14C O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
alpha O B_PROTEIN[GENE]
- O O
aminoisobutyric O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
technique O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Pollinosis O B_BIO/B_TIME[MEASURE]
in O O
the O O
U O B_OTHER/B_LOCATION
. O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O O
R O B_OTHER/B_LOCATION
. O O

Northern O O
blot O O
analysis O O
of O O
enoyl B B_GENE/B_BIO
- I I_GENE/I_BIO
ACP I I_GENE/I_BIO
reductase I I_GENE/I_BIO
mRNA I I_GENE/I_BIO
steady O O
- O O
state O O
levels O O
during O O
seed O O
development O O
suggests O O
that O O
the O O
increase O O
in O O
enzyme O O
activity O O
during O O
the O O
phase O O
of O O
storage O O
lipid O O
accumulation O O
is O O
regulated O O
at O O
the O O
level O O
of O O
gene O O
expression O O
. O O

Time O B_TIME[MEASURE]/B_PERSON
between O O
tests O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
usually O O
less O B_MEASURE
than O O
one O B_TIME[MEASURE]
year O I_TIME[MEASURE]
) O O
did O O
not O O
affect O O
the O O
correlations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
but O O
MMPI O B_MEASURE/B_LOCATION
response O I_MEASURE/I_LOCATION
- O O
set O B_MEASURE/B_LOCATION
variables O I_MEASURE/I_LOCATION
( O O
L O B_OTHER/B_PROTEIN[GENE]
, O O
F O B_LOCATION/B_DISEASE
, O O
K O B_OTHER/B_LOCATION
, O O
F O B_PROTEIN[GENE]/B_DISEASE
- O O
K O B_OTHER/B_PROTEIN[GENE]
) O O
did O O
. O O

The O O
differences O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
binding O O
( O O
Kdapp O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
incorporation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
extension O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
kinetics O B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
8 O B_NUMBER[MEASURE]
- O O
oxo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
- O O
dGTP O B_PROTEIN[GENE]/B_LOCATION
compared O O
to O O
normal O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
dNTP O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
incorporation O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
at O O
template O B_MEASURE
8 O I_MEASURE
- O O
oxo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
- O O
G O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
adducts O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
indicate O O
that O O
polymerase O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fidelity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
does O O
not O O
depend O O
solely O O
upon O O
the O O
overall O B_LOCATION/B_MEASURE
geometry O I_LOCATION/I_MEASURE
of O O
Watson O B_PERSON/B_LOCATION
- O O
Crick O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
base O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
pairs O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
and O O
reflects O O
the O O
asymmetry O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O O
the O O
enzyme O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
active O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
constant O O
expression O O
profile O O
, O O
coupled O O
with O O
the O O
observation O O
that O O
over O O
- O O
expression O O
of O O
mSin3A B B_GENE
does O O
not O O
augment O O
the O O
anti B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Myc I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O O
of O O
Mxi1 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
SR O O
in O O
the O O
rat O O
embryo O O
fibroblast O O
( O O
REF O O
) O O
transformation O O
assay O O
, O O
suggests O O
that O O
mSin3A B B_GENE
is O O
not O O
a O O
limiting O O
factor O O
in O O
the O O
regulation O O
of O O
Myc B B_GENE/B_BIO
superfamily I I_GENE/I_BIO
function O O
. O O

The O O
sequences O O
at O O
- O O
10 O O
and O O
- O O
35 O O
relative O O
to O O
the O O
transcriptional O O
starting O O
site O O
showed O O
55 O O
% O O
homology O O
with O O
the O O
consensus O O
sequences O O
of O O
the O O
Escherichia B B_GENE/B_BIO
coli I I_GENE/I_BIO
sigma I I_GENE/I_BIO
70 I I_GENE/I_BIO
- I I_GENE/I_BIO
type I I_GENE/I_BIO
promoter I I_GENE/I_BIO
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O O
subjected O O
to O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
23 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
autopsies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
carried O O
out O O
in O O
children O B_PERSON/B_BIO
dying O O
of O O
intoxication O B_DISEASE/B_PERSON
with O O
Amanita O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
phalloides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

METHODS O O
: O O
The O O
Die O O
Deutsche O O
Diabetes O O
Dialyse O O
Studie O O
is O O
a O O
prospective O O
randomized O O
placebo O O
- O O
controlled O O
trial O O
that O O
tests O O
the O O
hypothesis O O
that O O
atorvastatin O O
, O O
a O O
hydroxymethyl B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glutaryl I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
coenzyme I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reductase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O O
, O O
decreases O O
the O O
rate O O
of O O
cardiovascular O O
mortality O O
and O O
of O O
nonfatal O O
myocardial O O
infarction O O
in O O
patients O O
with O O
type O O
2 O O
diabetes O O
who O O
have O O
been O O
on O O
hemodialysis O O
treatment O O
for O O
no O O
more O O
than O O
two O O
years O O
. O O

There O O
was O O
no O O
significant O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
correlation O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
between O O
serum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
amiodarone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
or O O
desethylamiodarone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
levels O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
dosage O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
amiodarone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
monaural O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
middle O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ear O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
destruction O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
postnatal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
development O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
mouse O B_DISEASE/B_PERSON
inferior O I_DISEASE/I_PERSON
colliculus O I_DISEASE/I_PERSON
. O O

This O O
unusual O O
behaviour O O
may O O
be O O
explained O O
by O O
the O O
18 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amino I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
long I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CDR I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
H3 I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
could O O
be O O
of O O
value O O
in O O
the O O
design O O
of O O
' O O
single O O
domain O O
' O O
antibodies O O
. O O

A O O
definitive O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
answer O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
to O O
the O O
question O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
must O O
come O O
from O O
large O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scale O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mortality O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
patients O B_PERSON/B_LOCATION
in O O
whom O O
the O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
/ O O
benefit O B_DISEASE_ADJECTIVE[DISEASE]
ratio O I_DISEASE_ADJECTIVE[DISEASE]
of O O
thrombolysis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
not O O
unacceptably O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, O O
in O O
whom O O
electrocardiographic O B_DISEASE/B_LOCATION
criteria O B_DISEASE/I_LOCATION
of O O
infarction O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
are O O
unequivocal O B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
in O O
whom O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
can O O
be O O
initiated O O
early O O
after O O
the O O
onset O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
symptoms O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
regimens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
will O O
induce O O
not O O
only O O
early O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
recanalization O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
but O O
also O O
sustained O O
patency O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
infarct O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
related O O
arteries O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Parameters O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
sperm O B_MEASURE/B_LOCATION
quality O I_MEASURE/I_LOCATION
were O O
evaluated O O
before O O
and O O
after O O
freezing O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
/ O O
thawing O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

It O O
has O O
also O O
been O O
previously O O
demonstrated O O
that O O
LPS O O
treatment O O
of O O
splenic O O
B O O
cells O O
from O O
athymic O O
mice O O
results O O
in O O
a O O
decrease O O
in O O
steady O O
state O O
mRNA O O
encoding O O
the O O
A B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
class I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Amongst O B_MEASURE/B_LOCATION
53 O I_MEASURE/I_LOCATION
" O O
inoperable O B_DISEASE_ADJECTIVE[DISEASE]
" O O
( O O
T4 O B_PROTEIN[GENE]/B_DISEASE
, O O
N0 O B_PROTEIN[GENE]
, O O
N1 O B_PROTEIN[GENE]
, O O
T O B_PROTEIN[GENE]/B_LOCATION
. O O
, O O
N2 O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
N3 O B_PROTEIN[GENE]/B_DISEASE
) O O
cases O B_PERSON/B_DISEASE
, O O
5 O B_MEASURE
( O O
10 O B_MEASURE
% O I_MEASURE
) O O
had O O
a O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scan O I_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
5 O B_NUMBER[MEASURE]
a O O
doubtful O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
scan O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Chemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
structure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
antibiotic O B_MEASURE/B_PROTEIN[GENE]
SF O I_MEASURE/I_PROTEIN[GENE]
- O O
837 O B_NUMBER[MEASURE]
. O O

Aspirin O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
therapy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
rheumatic O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
diseases O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

Is O O
conventional O B_TIME[MEASURE]/B_LOCATION
sperm O I_TIME[MEASURE]/I_LOCATION
analysis O I_TIME[MEASURE]/I_LOCATION
of O O
any O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
? O O

The O O
computerised O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
records O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
867 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
couples O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
used O O
to O O
investigate O O
the O O
prognostic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
significance O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
semen O B_MEASURE/B_PERSON
volume O I_MEASURE/I_PERSON
, O O
motility O B_MEASURE/B_COLOR
, O O
density O B_MEASURE/B_PERSON
and O O
morphology O B_MEASURE/B_DISEASE
. O O

It O O
was O O
observed O O
that O O
muscle O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
infarction O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
IPC O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O O
24 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
2 O B_MEASURE
% O I_MEASURE
) O O
and O O
preischemic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
LMK O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
21 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
2 O B_MEASURE
% O I_MEASURE
) O O
groups O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
were O O
smaller O B_MEASURE
( O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
than O O
that O O
in O O
the O O
control O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O O
42 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
2 O B_MEASURE
% O I_MEASURE
) O O
. O O

High O O
- O O
affinity O O
binding O O
was O O
also O O
observed O O
with O O
recombinant B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SH2 I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domains I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
v B B_GENE
- I I_GENE
src I I_GENE
and O O
v B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fps I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
raising O O
the O O
possibility O O
of O O
protein O O
- O O
protein O O
interactions O O
between O O
various O O
members O O
of O O
the O O
cytoplasmic B B_GENE/B_BIO
PTK I I_GENE/I_BIO
family I I_GENE/I_BIO
. O O

Mutational O O
analysis O O
of O O
the O O
putative O O
effector O O
domain O O
of O O
the O O
GTP B B_GENE/B_BIO
- I I_GENE/I_BIO
binding I I_GENE/I_BIO
Ypt1 I I_GENE/I_BIO
protein I I_GENE/I_BIO
in O O
yeast O O
suggests O O
specific O O
regulation O O
by O O
a O O
novel O O
GAP B B_LOCATION/B_GENE
activity O O
. O O

The O O
interaction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
obtained O O
with O O
DBM O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scores O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
further O O
qualified O O
by O O
a O O
three O B_NUMBER[MEASURE]
- O O
way O B_MEASURE
interaction O I_MEASURE
that O O
limited O O
this O O
pattern O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
participants O B_PERSON
scoring O O
higher O O
on O O
self O B_PERSON/B_DISEASE
- O O
deception O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
broad O O
range O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O O
genistein O O
and O O
the O O
phosphatidylinositol B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors O O
wortmannin O O
and O O
LY O O
294002 O O
( O O
2 O O
- O O
( O O
4 O O
- O O
morpholinyl O O
) O O
- O O
8 O O
- O O
phenyl O O
- O O
4H O O
- O O
1 O O
- O O
benzopyran O O
- O O
4 O O
- O O
one O O
) O O
also O O
blocked O O
adenosine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
A3 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
stimulation O O
of O O
p42 B B_GENE
/ O O
p44 B B_MEASURE/B_GENE
MAPK O O
. O O

Surprisingly O O
, O O
although O O
Mist1 B B_GENE/B_LOCATION
binds O O
to O O
E O O
- O O
boxes O O
in O O
vivo O O
, O O
the O O
Mist1 B B_GENE/B_BIO
protein I I_GENE/I_BIO
lacks O O
a O O
functional O O
transcription O O
activation O O
domain O O
. O O

As O O
exogenously O O
expressed O O
PKR B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
form O O
heterodimers O O
with O O
endogenous B B_GENE
PKR I I_GENE
, O O
the O O
results O O
obtained O O
on O O
the O O
functional O O
characterization O O
of O O
mutant O O
forms O O
of O O
PKR B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
been O O
taken O O
with O O
caution O O
. O O

Orlistat O O
is O O
a O O
specific O O
lipase B B_GENE
inhibitor O O
that O O
impairs O O
fat O O
absorption O O
, O O
thereby O O
reducing O O
fat O O
uptake O O
. O O

The O O
metalloproteinase B B_ENZYME[GENE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediating O O
Met B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cleavage O O
was O O
specifically O O
inhibited O O
by O O
the O O
tissue B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitor I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
metalloproteinases I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
TIMP I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
not O O
by O O
TIMP B B_GENE
- I I_GENE
1 I I_GENE
or O O
TIMP B B_GENE
- I I_GENE
2 I I_GENE
. O O

This O O
demonstrates O O
a O O
relative O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
independence O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
given O O
synchronizer O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
rhythmicity O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
at O O
a O O
tissue O B_MEASURE/B_LOCATION
level O I_MEASURE/I_LOCATION
from O O
any O O
influence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
higher O B_LOCATION/B_PERSON
regulatory O B_LOCATION/I_PERSON
center O B_LOCATION/I_PERSON
. O O

It O O
is O O
also O O
conceivable O O
that O O
elevated O O
insulin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O O
may O O
cause O O
hypertriglyceridaemia O O
and O O
possibly O O
other O O
abnormalities O O
of O O
lipid O O
metabolism O O
. O O

Flicker O B_ENT/B_LOCATION
thresholds O B_ENT/I_LOCATION
were O O
measured O O
from O O
1 O B_NUMBER[MEASURE]
to O O
40 O B_MEASURE
Hz O I_MEASURE
with O O
a O O
vertical O B_LOCATION/B_NUMBER[MEASURE]
- O O
line O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O O
for O O
the O O
asynchrony O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
thresholds O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
clr1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
locus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulates O O
the O O
expression O O
of O O
the O O
cryptic B B_GENE
mating I I_GENE
- I I_GENE
type I I_GENE
loci I I_GENE
of I I_GENE
fission I I_GENE
yeast I I_GENE
. O O

Use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
ELISAs O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O O
the O O
diagnosis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
canine O B_DISEASE
atopy O I_DISEASE
. O O

A O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Instead O O
, O O
HBx B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
shown O O
to O O
activate O O
the O O
cyclin B B_GENE/B_LOCATION
A I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
, O O
induce O O
cyclin B B_GENE
A I I_GENE
- O O
cyclin B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
dependent I I_GENE/I_DISEASE
kinase I I_GENE/I_DISEASE
2 I I_GENE/I_DISEASE
complexes O O
, O O
and O O
promote O O
cycling O O
of O O
growth O O
- O O
arrested O O
cells O O
into O O
G1 O O
through O O
a O O
pathway O O
involving O O
activation O O
of O O
Src B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Growth B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exerts O O
its O O
effects O O
on O O
the O O
ovarian O O
follicular O O
cycle O O
directly O O
or O O
by O O
local O O
production O O
of O O
insulin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
like I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IGF B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
) O O
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
evaluate O O
the O O
impact O O
of O O
the O O
ESRD O O
treatment O O
modality O O
on O O
the O O
quality O O
of O O
life O O
in O O
patients O O
with O O
Type O O
I O O
( O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
dependent O O
) O O
diabetes O O
mellitus O O
. O O

The O O
subjects O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
started O O
on O O
indomethacin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
25 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
thrice O O
daily O O
. O O

A O O
Buddhist O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
view O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
of O O
abortion O B_PERSON/B_LOCATION
. O O

The O O
arterial O B_DISEASE/B_PROTEIN[GENE]
blood O B_DISEASE/I_PROTEIN[GENE]
pressure O B_DISEASE/I_PROTEIN[GENE]
was O O
measured O O
by O O
using O O
bloody O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
anesthizied O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
animals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

After O O
15 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
min O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
hemorrhage O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
the O O
cardiovascular O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parameters O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
the O O
same O B_MEASURE/B_LOCATION
in O O
fed O B_PERSON/B_DISEASE
and O O
starved O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
at O O
45 O B_MEASURE
min O I_MEASURE
striking O I_MEASURE
differences O I_MEASURE
were O O
observed O O
. O O

Decidual B B_TIME[MEASURE]/B_GENE
/ I I_TIME[MEASURE]/I_GENE
trophoblast I I_TIME[MEASURE]/I_GENE
prolactin I I_TIME[MEASURE]/I_GENE
- I I_TIME[MEASURE]/I_GENE
related I I_TIME[MEASURE]/I_GENE
protein I I_TIME[MEASURE]/I_GENE
: O O
characterization O O
of O O
gene O O
structure O O
and O O
cell O O
- O O
specific O O
expression O O
. O O

Fluorescence O O
in O O
situ O O
hybridization O O
was O O
used O O
to O O
investigate O O
the O O
physical O O
distribution O O
and O O
revealed O O
that O O
both O O
retrotransposon O O
families O O
are O O
present O O
on O O
all O O
sugar O O
beet O O
chromosomes O O
and O O
largely O O
excluded O O
from O O
chromosomal O O
regions O O
harbouring O O
the O O
18S B B_GENE/B_DISEASE
- O O
5 B B_MEASURE/B_LOCATION
. I I_MEASURE/I_LOCATION
8S I I_MEASURE/I_LOCATION
- O O
25S B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
rRNA O O
genes O O
. O O

Plasma O B_LOCATION/B_PROTEIN[GENE]
NE O I_LOCATION/I_PROTEIN[GENE]
and O O
E O B_OTHER/B_PROTEIN[GENE]
increased O O
to O O
significantly O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
values O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
after O O
15 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
min O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O O
the O O
young O B_PERSON/B_TIME[MEASURE]
subjects O I_PERSON/I_TIME[MEASURE]
: O O
1 O B_MEASURE
. O O
68 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
18 O B_MEASURE/B_SPORT[ENT]
vs O I_MEASURE/I_SPORT[ENT]
. O O

An O O
insertion O O
sequence O O
element O O
( O O
IS1170 O O
) O O
was O O
identified O O
upstream O O
of O O
the O O
nimC B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
gene I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
organelles O O
synthesize O O
their O O
own O O
set O O
of O O
Fe B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
S I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
they O O
initiate O O
the O O
generation O O
of O O
extramitochondrial B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Fe I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
/ I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
S I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Most O O
significantly O O
, O O
the O O
cyclin B B_GENE
E I I_GENE
- O O
Cdk2 B B_GENE
complex O O
is O O
maximally O O
active O O
at O O
the O O
G1 O O
/ O O
S O O
transition O O
, O O
and O O
overexpression O O
of O O
cyclin B B_GENE
E I I_GENE
decreases O O
the O O
time O O
it O O
takes O O
the O O
cell O O
to O O
complete O O
G1 O O
and O O
enter O O
S O O
phase O O
. O O

A O O
genomic O O
clone O O
of O O
the O O
chicken B B_GENE
osteopontin I I_GENE
- I I_GENE
encoding I I_GENE
gene I I_GENE
( O O
opn B B_GENE
) O O
was O O
isolated O O
and O O
found O O
to O O
be O O
organized O O
as O O
follows O O
: O O
an O O
untranslated O O
5 O O
' O O
exon O O
; O O
a O O
signal O O
peptide O O
; O O
a O O
recognition O O
sequence O O
for O O
phosphorylation O O
by O O
casein B B_GENE
kinase I I_GENE
II I I_GENE
; O O
a O O
domain O O
containing O O
a O O
possible O O
O O O
- O O
linkage O O
site O O
for O O
glycosylation O O
; O O
a O O
second O O
casein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphorylation I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
; O O
an O O
exon O O
containing O O
three O O
functional O O
regions O O
, O O
the O O
poly O O
- O O
Asp O O
sequence O O
of O O
seven O O
consecutive O O
Asp O O
residues O O
, O O
the O O
RGD B B_LOCATION/B_TIME[MEASURE]
integrin I B_LOCATION/I_TIME[MEASURE]
recognition I B_LOCATION/I_TIME[MEASURE]
site I B_LOCATION/I_TIME[MEASURE]
and O O
a O O
potential O O
N O O
- O O
linkage O O
site O O
for O O
glycosylation O O
; O O
and O O
a O O
large O O
C O O
- O O
terminal O O
exon O O
which O O
also O O
contains O O
a O O
potential O O
N O O
- O O
linkage O O
site O O
for O O
glycosylation O O
. O O

However O O
, O O
neither O O
SF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nor O O
NGF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IB I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
, O O
binding O O
as O O
monomers O O
, O O
increases O O
transcription O O
. O O

Satisfactory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
correlation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
also O O
obtained O O
between O O
the O O
in O O
vivo O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
in O O
vitro O B_TIME[MEASURE]/B_ORGANIZATION
results O I_TIME[MEASURE]/I_ORGANIZATION
. O O

Structural O O
organization O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Elk1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
its O O
processed O O
pseudogene B B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Elk2 I B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

After O O
cumulative O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
occlusions O B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
of O O
15 O B_MEASURE
, O O
30 O B_MEASURE
, O O
45 O B_MEASURE
, O O
and O O
90 O B_TIME[MEASURE]
min O I_TIME[MEASURE]
, O O
transmural O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
needle O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
biopsies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O O
taken O O
from O O
the O O
ischemic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
area O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
to O O
be O O
analyzed O O
for O O
adenine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
nucleotides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
nucleosides O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
creatine O B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphate O I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
ultrastructural O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
prevalence O B_MEASURE
of O O
ocular O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
/ O O
adnexal O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
SCC O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
was O O
significantly O O
greater O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
for O O
all O O
hair O B_MEASURE/B_PERSON
colors O I_MEASURE/I_PERSON
when O O
compared O O
with O O
bay O B_LOCATION/B_COLOR
, O O
brown O B_PERSON/B_COLOR
, O O
or O O
black O B_COLOR/B_BIO
( O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
. O O

Seven O B_PERSON
patients O I_PERSON
were O O
without O O
a O O
syndromic O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis O I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
treatments O B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
R1 O I_PROTEIN[GENE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
R2 O B_PROTEIN[GENE]
, O O
feed O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
quality O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
was O O
restricted O O
by O O
withholding O O
concentrates O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
3 O B_NUMBER[MEASURE]
and O O
4 O B_MEASURE
. O O
5 O B_MEASURE/B_PERSON
mo O I_MEASURE/I_PERSON
, O O
respectively O O
. O O

In O O
addition O O
, O O
while O O
GCN1 B B_GENE
is O O
required O O
in O O
vivo O O
for O O
phosphorylation O O
of O O
eIF B B_GENE
- I I_GENE
2 I I_GENE
alpha I I_GENE
by O O
GCN2 B B_GENE
, O O
cell O O
extracts O O
from O O
gcn1 B B_GENE/B_NUMBER[MEASURE]
delta I I_GENE/I_NUMBER[MEASURE]
strains O O
contained O O
wild O O
- O O
type O O
levels O O
of O O
GCN2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
eIF B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
kinase O O
activity O O
. O O

SCOF B B_GENE/B_PERSON
- I I_GENE/I_PERSON
1 I I_GENE/I_PERSON
localized O O
to O O
the O O
nucleus O O
but O O
did O O
not O O
bind O O
directly O O
to O O
either O O
C O O
- O O
repeat O O
/ O O
dehydration O O
( O O
CRT O O
/ O O
DRE O O
) O O
or O O
ABA O O
responsive O O
element O O
( O O
ABRE O O
) O O
, O O
cis O O
- O O
acting O O
DNA O O
regulatory O O
elements O O
present O O
in O O
COR B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promoters I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

On O O
the O O
basis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
these O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
we O O
suggest O O
that O O
the O O
acceptor O B_PROTEIN[GENE]
peptide O I_PROTEIN[GENE]
binds O O
the O O
transferase O B_ENZYME[GENE]
in O O
a O O
beta O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
like O B_LOCATION
conformation O I_LOCATION
and O O
that O O
penultimate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
residue O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
side O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
chain O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
steric O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
interactions O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
may O O
play O O
a O O
role O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
determining O O
extent O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
that O O
a O O
given O O
Ser O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
Thr O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
is O O
glycosylated O O
. O O

The O O
concentration O B_MEASURE
of O O
vitamin O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B1 O I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
B2 O B_PROTEIN[GENE]
and O O
B6 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
found O O
to O O
be O O
9 O B_MEASURE
. O O
96 O B_MEASURE
, O O
9 O B_MEASURE
. O O
92 O B_MEASURE
and O O
3 O B_MEASURE
. O O
01 O B_MEASURE
mg O I_MEASURE
, O O
respectively O O
in O O
240 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
capsule O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
powder O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
of O O
a O O
standard O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
company O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O O
name O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
has O O
not O O
been O O
disclosed O O
due O O
to O O
secrecy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
purpose O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
) O O
. O O

Polymorphisms O O
in O O
the O O
CCR5 B B_GENE/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
genes I B_GENE/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
of O O
African O O
green O O
monkeys O O
and O O
mice O O
implicate O O
specific O O
amino O O
acids O O
in O O
infections O O
by O O
simian O O
and O O
human O O
immunodeficiency O O
viruses O O
. O O

Furthermore O O
, O O
we O O
detect O O
hCoch B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
5B2 I I_GENE/I_DISEASE
on O O
three O O
overlapping O O
YACs O O
, O O
two O O
of O O
which O O
also O O
contain O O
one O O
of O O
the O O
markers O O
linked O O
to O O
DFNA9 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

mCoch B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
5B2 I I_GENE/I_DISEASE
was O O
genetically O O
mapped O O
in O O
the O O
mouse O O
to O O
chromosome O O
12 O O
, O O
in O O
a O O
region O O
of O O
homologous O O
synteny O O
with O O
human O O
14q11 O O
. O O
2 O O
- O O
q13 O O
, O O
which O O
contains O O
the O O
asp1 B B_PROTEIN[GENE]/B_DISEASE
( O O
audiogenic B B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
seizure I B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
prone I B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
) O O
locus O O
in O O
the O O
mouse O O
. O O

Absence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
nitroso O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
formation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
( O O
14C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
methomyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
sodium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nitrite O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
under O O
simulated O O
stomach O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
conditions O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Although O O
no O O
detectable O O
phenotypes O O
are O O
associated O O
with O O
a O O
disruption O O
allele O O
of O O
ABP1 B B_GENE
, O O
mutations O O
that O O
create O O
a O O
requirement O O
for O O
this O O
protein O O
have O O
now O O
been O O
isolated O O
in O O
the O O
previously O O
identified O O
gene B B_GENE/B_BIO
SAC6 I I_GENE/I_BIO
and O O
in O O
two O O
new O O
genes O O
, O O
SLA1 B B_PROTEIN[GENE]/B_LOCATION
and O O
SLA2 B B_GENE/B_DISEASE
. O O

The O O
local O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
median O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scores O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ranges O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
of O O
the O O
above O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
tests O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
as O O
follows O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
AMT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
: O O
9 O B_MEASURE
( O O
6 O B_SEQUENCE[MEASURE]
- O O
10 O B_MEASURE
) O O
; O O
CMMS O B_LOCATION/B_DISEASE
: O O
25 O B_MEASURE
( O O
16 O B_MEASURE
- O O
28 O B_MEASURE
) O O
; O O
SBT O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
2 O B_MEASURE
( O O
0 O B_MEASURE
- O O
10 O B_MEASURE
) O O
; O O
WL O B_DISEASE/B_PROTEIN[GENE]
- O O
i O B_DISEASE/B_PROTEIN[GENE]
: O O
17 O B_MEASURE
( O O
8 O B_MEASURE
- O O
27 O B_MEASURE
) O O
; O O
WL O B_DISEASE/B_PROTEIN[GENE]
- O O
d O B_PROTEIN[GENE]/B_DISEASE
: O O
5 O B_MEASURE
( O I_MEASURE
0 O I_MEASURE
- O O
10 O B_MEASURE
) O O
; O O
WL O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
r O B_PROTEIN[GENE]/B_LOCATION
: O O
9 O B_MEASURE
( O O
1 O B_MEASURE
- O O
10 O B_MEASURE
) O O
; O O
ST O B_LOCATION/B_DISEASE
: O O
13 O B_MEASURE
( O O
6 O B_MEASURE
- O O
25 O B_MEASURE
) O O
; O O
BNT O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
: O O
14 O B_MEASURE
( O O
10 O B_MEASURE
- O O
15 O B_MEASURE
) O O
; O O
CPT O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
1 O B_MEASURE
( O O
0 O B_MEASURE
- O O
3 O B_MEASURE
) O O
; O O
BDT O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
19 O B_MEASURE
( O O
0 O B_MEASURE
- O O
42 O B_MEASURE
) O O
; O O
OAT O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
20 O B_MEASURE
( O O
3 O B_MEASURE
- O O
33 O B_MEASURE
) O O
. O O

Antigen O B_TIME[MEASURE]/B_LOCATION
dose O I_TIME[MEASURE]/I_LOCATION
- O O
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
curves O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
drawn O O
, O O
and O O
the O O
cumulative O B_MEASURE/B_LOCATION
dose O I_MEASURE/I_LOCATION
required O O
for O O
a O O
35 O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
% O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
reduction O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
specific O B_DISEASE
airway O I_DISEASE
conductance O I_DISEASE
was O O
calculated O O
and O O
designated O O
Provocation O B_MEASURE/B_LOCATION
Dose O B_MEASURE/I_LOCATION
( O O
PD35 O B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

Cross O O
- O O
talk O O
between O O
transcription O O
factors O O
NF B B_GENE
- I I_GENE
kappa I I_GENE
B I I_GENE
and O O
C B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EBP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
transcriptional O O
regulation O O
of O O
genes O O
. O O

Elective O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
replacement O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
aortic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
root O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O O
Marfan O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
' O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
s O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
syndrome O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

The O O
detergent O O
- O O
solubilized O O
complex O O
oxidizes O O
caldariella O O
quinol O O
at O O
high O O
rates O O
and O O
is O O
completely O O
inhibited O O
by O O
cyanide O O
and O O
by O O
quinolone O O
analogs O O
, O O
potent O O
inhibitors O O
of O O
quinol B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
oxidases I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
have O O
characterized O O
a O O
new O O
cDNA O O
, O O
33k O O
- O O
6 O O
, O O
potentially O O
encoding O O
a O O
tobacco B B_ENZYME[GENE]
33 I I_ENZYME[GENE]
kDa I I_ENZYME[GENE]
chloroplast I I_ENZYME[GENE]
RNP I I_ENZYME[GENE]
( I I_ENZYME[GENE]
cp33 I I_ENZYME[GENE]
) I I_ENZYME[GENE]
homologue I I_ENZYME[GENE]
. O O

The O O
regions O B_GENE/B_DISEASE
encoding O O
the O O
mature O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteinases O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
cloned O O
into O O
an O O
expression O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
vector O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
recombinant O B_DISEASE_ADJECTIVE[DISEASE]
protein O I_DISEASE_ADJECTIVE[DISEASE]
produced O O
in O O
Escherichia O B_SPECIES[BIO]
coli O I_SPECIES[BIO]
. O O

Furthermore O O
, O O
CL100 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
suppresses O O
the O O
[ O O
val12 O O
] O O
ras B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
activation O O
of O O
MAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
cell O O
- O O
free O O
system O O
from O O
Xenopus O O
oocytes O O
. O O

The O O
Xenopus B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
homeobox I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
twin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mediates O O
Wnt B B_GENE
induction O O
of O O
goosecoid B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
establishment O O
of O O
Spemann O O
' O O
s O O
organizer O O
. O O

Between O O
1988 O B_MEASURE
and O O
1994 O B_MEASURE
, O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
3 O B_LOCATION
large O I_LOCATION
sites O I_LOCATION
revealed O O
a O O
3 O B_NUMBER[MEASURE]
- O O
5 O B_MEASURE/B_LOCATION
fold O I_MEASURE/I_LOCATION
increase O I_MEASURE/I_LOCATION
in O O
the O O
prevalence O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
antidepressant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
ATD O B_DISEASE/B_PROTEIN[GENE]
) O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
for O O
U O B_OTHER/B_LOCATION
. O O
S O B_LOCATION/B_DISEASE
. O O
youths O B_PERSON
aged O O
2 O B_NUMBER[MEASURE]
- O O
19 O B_MEASURE/B_ENT
years O I_MEASURE/I_ENT
. O O

The O O
vaccinia O O
virus O O
D6R B B_GENE
open O O
reading O O
frame O O
encodes O O
the O O
small O O
subunit O O
of O O
the O O
heterodimeric O O
vaccinia B B_ENZYME[GENE]/B_LOCATION
virus I I_ENZYME[GENE]/I_LOCATION
early I I_ENZYME[GENE]/I_LOCATION
transcription I I_ENZYME[GENE]/I_LOCATION
factor I I_ENZYME[GENE]/I_LOCATION
( O O
VETF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
that O O
activates O O
transcription O O
of O O
early B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
vitro O O
. O O

The O O
Sensititre O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
MIC O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
panels O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
containing O O
meropenem O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
offer O O
a O O
convenient O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
valid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alternative O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
NCCLS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reference O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
the O O
susceptibility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
testing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
potential O B_BACTERIUM[BIO]
pathogens O I_BACTERIUM[BIO]
likely O I_BACTERIUM[BIO]
to O O
be O O
recovered O O
from O O
mixed O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
infections O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O O

Recognition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
DNA O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O O
single O B_PERSON/B_NUMBER[MEASURE]
- O O
chain O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
derivatives O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
the O O
phage O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
434 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
repressor O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O O
high O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
affinity O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
depends O O
on O O
both O O
the O O
contacted O O
and O O
non O O
- O O
contacted O O
base O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
pairs O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

The O O
paper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
calls O O
for O O
standardized O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
question O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
formats O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O O
a O O
centralized O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
body O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
monitor O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
these O O
parameters O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
sexual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
behaviour O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
show O O
that O O
GCNF B B_GENE
binds O O
to O O
one O O
of O O
the O O
two O O
DRO O O
sequences O O
in O O
the O O
Prm1 B B_GENE/B_BIO
promoter I I_GENE/I_BIO
, O O
and O O
to O O
the O O
DRO O O
sequence O O
in O O
the O O
Prm2 B B_GENE/B_MEASURE
promoter I I_GENE/I_MEASURE
in O O
a O O
specific O O
manner O O
. O O

139La O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
NQR O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
relaxation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
microSR O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Zn O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
doping O O
effects O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
La2CuO4 O B_LOCATION/B_BIO
. O O

The O O
data O O
also O O
suggest O O
that O O
gamma B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
CACCC I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
box I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
mediate O O
LCR B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
- I B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
gamma I B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
interactions O O
which O O
normally O O
enhance O O
gamma B B_GENE
- I I_GENE
globin I I_GENE
and O O
suppress O O
beta B B_GENE
- I I_GENE
globin I I_GENE
gene I I_GENE
expression O O
in O O
fetal O O
erythroid O O
cells O O
. O O

However O O
, O O
the O O
in O O
vivo O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
attachment O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
strength O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
CSTi O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
2 O B_MEASURE
coating O I_MEASURE
was O O
comparable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
both O O
to O O
CSTi O B_LOCATION/B_GENE
- O O
1 O B_NUMBER[MEASURE]
and O O
to O O
an O O
HA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
coated O O
control O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
after O O
8 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Octamer O O
recognition O O
is O O
mediated O O
by O O
the O O
POU B B_GENE/B_DISEASE
domain O O
, O O
a O O
conserved O O
structural O O
motif O O
which O O
- O O
- O O
like O O
the O O
zinc O O
finger O O
and O O
leucine O O
zipper O O
- O O
- O O
defines O O
a O O
family O O
of O O
related O O
transcription O O
factors O O
. O O

All O O
testosterone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
treatments O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
raised O O
plasma O B_MEASURE/B_GENE
testosterone O I_MEASURE/I_GENE
concentrations O I_MEASURE/I_GENE
above O O
control O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
and O O
pretreatment O B_MEASURE
levels O I_MEASURE
( O O
testosterone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
synovex O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
testosterone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
> O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synovex O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
> O O
control O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
; O O
all O O
P O B_MEASURE
< O I_MEASURE
0 O I_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

Lifestyle O B_PERSON
characteristics O I_PERSON
were O O
ascertained O O
by O O
a O O
self O B_PERSON/B_LOCATION
- O O
administered O O
questionnaire O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

The O O
major O O
promoter O O
element O O
of O O
the O O
Xenopus B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
laevis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
5S I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
located O O
within O O
the O O
transcribed O O
region O O
of O O
the O O
gene O O
and O O
forms O O
the O O
binding O O
site O O
for O O
the O O
transcription O O
initiation O O
factor O O
TFIIIA B B_GENE/B_LOCATION
. O O

During O O
each O O
step O O
of O O
the O O
pulse O O
infusion O O
the O O
osteocalcin B B_GENE
responses O O
to O O
changes O O
in O O
CaI O O
in O O
general O O
were O O
parallel O O
to O O
the O O
changes O O
in O O
PTH B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
r O O
= O O
0 O O
. O O
462 O O
; O O
P O O
= O O
0 O O
. O O
02 O O
) O O
and O O
were O O
inversely O O
correlated O O
to O O
CaI O O
( O O
r O O
= O O
- O O
0 O O
. O O
562 O O
; O O
P O O
= O O
0 O O
. O O
003 O O
) O O
. O O

The O O
gamma B B_GENE
- I I_GENE
GCS I I_GENE
gene I I_GENE
is O O
expressed O O
ubiquitously O O
and O O
induced O O
coordinately O O
with O O
NAD B B_GENE
( I I_GENE
P I I_GENE
) I I_GENE
H I I_GENE
: I I_GENE
quinone I I_GENE
oxidoreductase I I_GENE
( I I_GENE
1 I I_GENE
) I I_GENE
( O O
NQO1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
glutathione B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
S I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transferase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Ya I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
GST B B_GENE
Ya I I_GENE
) O O
in O O
response O O
to O O
xenobiotics O O
and O O
antioxidants O O
. O O

Interestingly O O
, O O
the O O
expression O O
of O O
Id4 B B_GENE
in O O
Sertoli O O
cells O O
is O O
only O O
detectable O O
after O O
stimulation O O
with O O
FSH B B_GENE
or O O
cAMP O O
. O O

We O O
determined O O
their O O
N O O
- O O
terminal O O
amino O O
acid O O
sequence O O
and O O
found O O
that O O
these O O
polypeptides O O
were O O
CotT B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
YeeK B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
YxeE B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
CotF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
YrbA B B_LOCATION/B_GENE
( O O
31 O O
and O O
45 O O
kDa O O
) O O
, O O
and O O
SpoIVA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
respectively O O
. O O

The O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
betamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
duodenal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
calcium O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
absorption O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
1 O B_MEASURE
, O O
25 O B_MEASURE
- O O
dihydroxy O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
vitamin O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
D3 O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
production O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
chick O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Furthermore O O
, O O
it O O
is O O
also O O
established O O
that O O
serine O O
phosphorylation O O
of O O
STAT5a B B_GENE/B_PERSON
transactivation O O
domain O O
, O O
via O O
the O O
MAPK B B_GENE
pathway O O
, O O
is O O
a O O
means O O
of O O
modifying O O
GH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
transcriptional O O
activation O O
. O O

ES O O
cells O O
in O O
which O O
the O O
gene O O
for O O
the O O
erythroid O O
transcription O O
factor O O
GATA B B_GENE
- I I_GENE
1 I I_GENE
has O O
been O O
disrupted O O
fail O O
to O O
produce O O
mature O O
erythroid O O
cells O O
either O O
in O O
vivo O O
or O O
in O O
vitro O O
. O O

Two O B_MEASURE/B_LOCATION
conserved O I_MEASURE/I_LOCATION
motifs O I_MEASURE/I_LOCATION
, O O
W89RKRRY94 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
P156KKIKP161 O B_GENE/B_DISEASE
, O O
seemed O O
to O O
act O O
as O O
nuclear O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
addressing O O
signals O B_PRODUCT[OBJECT]/B_LOCATION
. O O

It O O
is O O
concluded O O
that O O
the O O
predominant O O
action O O
of O O
LSD O O
on O O
the O O
female O O
copulatory O O
response O O
is O O
not O O
mediated O O
by O O
increased O O
dopamine B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O O
but O O
that O O
the O O
LSD O O
effect O O
might O O
be O O
modulated O O
by O O
decreased O O
dopaminergic O O
activity O O
. O O

Therefore O O
, O O
in O O
VDR B B_GENE
- O O
mediated O O
transcriptional O O
activation O O
, O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
binding O O
to O O
VDR B B_GENE/B_LOCATION
alters O O
the O O
conformation O O
of O O
the O O
ligand O O
binding O O
domain O O
such O O
that O O
it O O
: O O
( O O
i O O
) O O
engages O O
in O O
strong O O
heterodimerization O O
with O O
RXR B B_GENE/B_LOCATION
to O O
facilitate O O
VDRE O O
binding O O
, O O
( O O
ii O O
) O O
influences O O
the O O
RXR B B_GENE/B_LOCATION
ligand I I_GENE/I_LOCATION
binding I I_GENE/I_LOCATION
domain I I_GENE/I_LOCATION
such O O
that O O
it O O
is O O
resistant O O
to O O
the O O
binding O O
of O O
9 O O
- O O
cis O O
RA O O
but O O
active O O
in O O
recruiting O O
coactivator O O
to O O
its O O
AF O O
- O O
2 O O
and O O
( O O
iii O O
) O O
presents O O
the O O
AF O O
- O O
2 O O
region O O
in O O
VDR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
for O O
coactivator O O
association O O
. O O

In O O
patients O O
, O O
750 O O
mL O O
of O O
saline O O
lowered O O
DL O O
( O O
CO O O
) O O
( O O
- O O
8 O O
% O O
, O O
P O O
< O O
0 O O
. O O
01 O O
versus O O
baseline O O
) O O
, O O
D O O
( O O
M O O
) O O
( O O
- O O
10 O O
% O O
, O O
P O O
< O O
0 O O
. O O
01 O O
versus O O
baseline O O
) O O
, O O
aldosterone O O
( O O
- O O
29 O O
% O O
, O O
P O O
< O O
0 O O
. O O
01 O O
versus O O
baseline O O
) O O
, O O
renin B B_GENE
( O O
- O O
52 O O
% O O
, O O
P O O
< O O
0 O O
. O O
01 O O
versus O O
baseline O O
) O O
, O O
and O O
hematocrit O O
( O O
- O O
6 O O
% O O
, O O
P O O
< O O
0 O O
. O O
05 O O
versus O O
baseline O O
) O O
and O O
increased O O
V O O
( O O
C O O
) O O
( O O
20 O O
% O O
, O O
P O O
< O O
0 O O
. O O
01 O O
versus O O
baseline O O
) O O
, O O
without O O
changing O O
rap O O
and O O
wpp O O
. O O

We O O
have O O
previously O O
identified O O
LIT1 B B_GENE/B_LOCATION
, O O
a O O
paternally O O
expressed O O
antisense O O
RNA O O
within O O
the O O
KvLQT1 B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
locus I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
through O O
a O O
positional O O
screening O O
approach O O
using O O
human O O
monochromosomal O O
hybrids O O
. O O

A O O
series O B_SPORT[ENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
deletion O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutants O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
expressed O O
transiently O O
in O O
two O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
human O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
hepatocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
HepG2 O B_PERSON/B_PROTEIN[GENE]
and O O
PLC O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O O

The O O
predicted O O
amino O O
acid O O
sequence O O
of O O
the O O
FlaB2 B B_GENE
polypeptide I I_GENE
was O O
92 O O
% O O
identical O O
to O O
that O O
of O O
T B B_SPECIES[BIO]/B_GENE
. I B_SPECIES[BIO]/I_GENE
pallidum I B_SPECIES[BIO]/I_GENE
FlaB2 I B_SPECIES[BIO]/I_GENE
, O O
with O O
a O O
76 O O
% O O
identity O O
at O O
the O O
nucleotide O O
level O O
. O O

Comparative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analyses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
indicate O O
that O O
the O O
5 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
peripheral O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
domain O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
exhibits O O
a O O
75 O B_MEASURE/B_LOCATION
- O O
bp O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
length O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymorphism O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
near O O
sequences O B_LOCATION
associated O O
with O O
the O O
termination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O O
the O O
H O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
- O O
strand O B_GENE/B_LOCATION
replication O I_GENE/I_LOCATION
. O O

The O O
survival O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
patients O B_PERSON/B_BIO
with O O
a O O
short O B_DISEASE
bowel O I_DISEASE
, O O
even O O
if O O
they O O
need O O
long O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
term O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
parenteral O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
nutrition O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
is O O
good O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Thus O O
, O O
cross O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
resistance O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
between O O
fluoroquinolones O B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
shown O O
for O O
both O O
enterococci O B_BACTERIUM[BIO]/B_LOCATION
and O O
MRSA O B_BACTERIUM[BIO]
. O O

The O O
5 O O
' O O
ends O O
of O O
the O O
P B B_OTHER/B_PROTEIN[GENE]
and O O
O B B_PROTEIN[GENE]/B_LOCATION
gene I I_PROTEIN[GENE]/I_LOCATION
mRNAs I I_PROTEIN[GENE]/I_LOCATION
are O O
separated O O
by O O
109 O O
nucleotide O O
pairs O O
in O O
the O O
DNA O O
template O O
. O O

Using O O
community O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
development O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
approaches O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Biol O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
have O O
cloned O O
the O O
cDNA O O
for O O
the O O
SLBP B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
from O O
humans O O
, O O
mice O O
, O O
and O O
frogs O O
, O O
using O O
the O O
recently O O
developed O O
yeast O O
three O O
- O O
hybrid O O
system O O
. O O

Along O O
with O O
these O O
species O B_BIO
, O O
F O B_LOCATION/B_DISEASE
. O O
graminearum O B_BACTERIUM[BIO]/B_DISEASE
group O I_BACTERIUM[BIO]/I_DISEASE
2 O I_BACTERIUM[BIO]/I_DISEASE
( O O
ZON O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
DON O B_PERSON/B_MEASURE
and O O
/ O O
or O O
3AcDON O B_MEASURE
or O O
15AcDON O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
; O O
F O B_LOCATION/B_DISEASE
. O O
chlamydosporum O B_BACTERIUM[BIO]/B_DISEASE
; O O
F O B_LOCATION/B_DISEASE
. O O
acuminatum O B_DISEASE/B_BACTERIUM[BIO]
( O O
type O B_DISEASE/B_MEASURE
- O O
A O B_BIO/B_PROTEIN[GENE]
trichothecene O B_BIO/I_PROTEIN[GENE]
derivatives O B_BIO/I_PROTEIN[GENE]
) O O
; O O
and O O
F O B_LOCATION/B_DISEASE
. O O
semitectum O B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
were O O
often O O
found O O
to O O
be O O
associated O O
. O O

TGF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta1 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
phosphorylation O O
of O O
Smad2 B B_GENE
and O O
Smad3 B B_GENE
in O O
Mv1Lu O O
mink O O
lung O O
epithelial O O
cells O O
. O O

There O O
is O O
little O O
supportive O O
evidence O O
that O O
ACE B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inhibitors O O
( O O
captopril O O
or O O
enalapril O O
) O O
are O O
teratogenic O O
. O O

Thus O O
, O O
the O O
potential O O
induction O O
of O O
this O O
gene O O
rearrangement O O
by O O
E1A B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
is O O
unlikely O O
to O O
be O O
clinically O O
significant O O
in O O
the O O
treatment O O
of O O
advanced O O
malignant O O
disease O O
. O O

Although O O
the O O
cDNAs O O
of O O
HMG B B_GENE
- I I_GENE
14 I I_GENE
and O O
HMG B B_MEASURE/B_GENE
- I I_MEASURE/I_GENE
17 I I_MEASURE/I_GENE
do O O
not O O
cross O O
- O O
hybridize O O
, O O
they O O
have O O
several O O
similar O O
structural O O
features O O
: O O
the O O
open O O
reading O O
frame O O
comprises O O
only O O
23 O O
% O O
of O O
the O O
transcripts O O
, O O
the O O
5 O O
' O O
- O O
untranslated O O
region O O
is O O
extremely O O
GC O O
rich O O
whereas O O
the O O
3 O O
' O O
- O O
untranslated O O
region O O
is O O
unusually O O
long O O
and O O
AT O O
rich O O
. O O

Previously O O
, O O
we O O
reported O O
the O O
identification O O
of O O
a O O
23 O O
- O O
kD O O
protein O O
that O O
interacts O O
with O O
zyxin B B_GENE/B_BACTERIUM[BIO]
in O O
vitro O O
( O O
Sadler O O
et O O
al O O
. O O
, O O
1992 O O
) O O
. O O

If O O
vascular O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
induction O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
between O O
a O O
vascular O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
carrier O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
and O O
the O O
selected O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
jejunal O I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
segment O I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
is O O
done O O
as O O
a O O
kind O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
flap O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
prefabrication O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
the O O
jejunal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
interposition O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
flap O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
can O O
be O O
used O O
without O O
the O O
need O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
for O O
complex O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
microsurgery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

In O O
gel O O
mobility O O
shift O O
assays O O
, O O
high O O
binding O O
activities O O
of O O
ATPC B B_GENE
- I I_GENE
2 I I_GENE
and O O
low O O
binding O O
activities O O
of O O
CBF B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
observed O O
with O O
nuclear O O
extracts O O
from O O
tissue O O
with O O
low O O
AtpC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O O
levels O O
, O O
and O O
the O O
opposite O O
was O O
observed O O
with O O
extracts O O
from O O
tissues O O
with O O
high O O
AtpC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O O
levels O O
. O O

Activation O O
of O O
tyrosine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
containing I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
heterotrimeric B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
G I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhanced O O
the O O
activities O O
of O O
both O O
MEK B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
isoforms I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
293 O O
and O O
PC12 O O
cells O O
. O O

The O O
Fugu O O
rubripes O O
( O O
Fugu O O
) O O
gene O O
fragment O O
was O O
used O O
to O O
isolate O O
the O O
GH B B_GENE/B_BIO
gene I B_GENE/I_BIO
from O O
a O O
Fugu O O
genomic O O
library O O
. O O

An O O
in O O
vitro O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
' O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
glass O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
stomach O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
' O O
( O O
containing O O
various O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
volumes O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
hydrochloric O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
HCl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O O
and O O
ammonium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
chloride O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
[ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
NH4Cl O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) O O
was O O
used O O
to O O
evaluate O O
the O O
means O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
increasing O O
' O O
gastric O B_DISEASE/B_MEASURE
' O O
pH O B_MEASURE
to O O
that O O
of O O
the O O
NH4 O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
- O O
> O B_MEASURE
NH3 O I_MEASURE
transition O I_MEASURE
that O O
occurs O O
significantly O O
at O O
pH O B_MEASURE
9 O I_MEASURE
. O O
24 O B_MEASURE
. O O

Acyclovir O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
3 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ointment O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
used O O
topically O O
one O B_NUMBER[MEASURE]/B_LOCATION
to O O
five O B_NUMBER[MEASURE]/B_ENT
times O I_NUMBER[MEASURE]/I_ENT
a O O
day O B_TIME[MEASURE]
on O O
acute O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ocular O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HSV O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infection O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gave O O
beneficial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
measured O O
by O O
a O O
reduction O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
corneal O B_DISEASE
involvement O I_DISEASE
, O O
conjunctivitis O B_DISEASE
, O O
iritis O B_DISEASE
, O O
and O O
corneal O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clouding O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
have O O
documented O O
previously O O
that O O
glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormones O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
modulate O O
the O O
posttranslational O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
localization O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
cell O B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
surface O I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
mouse O I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
mammary O I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
tumor O I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
virus O I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MMTV O B_VIRUS[BIO]/B_DISEASE
) O O
glycoproteins O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
viral O B_DISEASE/B_VIRUS[BIO]
- O O
infected O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
M1 O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
. O O
54 O B_TIME[MEASURE]/B_DISEASE
rat O I_TIME[MEASURE]/I_DISEASE
HTC O I_TIME[MEASURE]/I_DISEASE
hepatoma O I_TIME[MEASURE]/I_DISEASE
cell O I_TIME[MEASURE]/I_DISEASE
line O I_TIME[MEASURE]/I_DISEASE
. O O

Partial O O
proteolysis O O
of O O
cell O O
surface O O
- O O
iodinated O O
B B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
G I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
molecules I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
generates O O
extremely O O
similar O O
patterns O O
of O O
spots O O
, O O
both O O
within O O
and O O
between O O
haplotypes O O
. O O

SETTING O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
University O B_LOCATION
research O I_LOCATION
laboratory O I_LOCATION
. O O

There O O
was O O
a O O
57 O O
% O O
reduction O O
in O O
IGF B B_GENE
IR I I_GENE
mRNA I I_GENE
levels O O
in O O
clone O O
CA9 O O
after O O
confluence O O
compared O O
with O O
clone O O
ME10 O O
. O O

Oligomers O O
corresponding O O
to O O
the O O
region O O
of O O
the O O
mlc B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
/ I I_GENE/I_LOCATION
3 I I_GENE/I_LOCATION
enhancer I I_GENE/I_LOCATION
, O O
which O O
encompasses O O
this O O
conserved O O
sequence O O
, O O
bound O O
MEF B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
competed O O
for O O
its O O
binding O O
to O O
the O O
mck B B_SPECIES[BIO]/B_GENE
enhancer O O
. O O

Similar O O
tissue O O
- O O
specific O O
patterns O O
are O O
observed O O
with O O
a O O
fusion O O
between O O
the O O
caufliflower B B_GENE/B_BIO
mosaic I I_GENE/I_BIO
virus I I_GENE/I_BIO
35S I I_GENE/I_BIO
RNA I I_GENE/I_BIO
promotor I I_GENE/I_BIO
and O O
the O O
GUS B B_GENE
gene I I_GENE
. O O

This O O
difference O O
between O O
SP B B_GENE
- I I_GENE
1 I I_GENE
and O O
SP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
peptides I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
not O O
due O O
to O O
their O O
differential O O
uptake O O
by O O
cell O O
, O O
since O O
approximately O O
100 O O
times O O
more O O
SP B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
2 I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
peptide I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
could O O
be O O
found O O
in O O
cytoplasmic O O
extracts O O
than O O
SP B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptide I I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
experiments O O
using O O
radiolabeled O O
peptides O O
. O O

One O O
function O O
of O O
p53 B B_GENE
is O O
in O O
regulating O O
cell O O
cycle O O
check O O
- O O
point O O
control O O
after O O
DNA O O
damage O O
. O O

We O O
used O O
event O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
related O O
functional O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
magnetic O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resonance O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaging O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
fMRI O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
during O O
a O O
cued O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
spatial O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
- O O
attention O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
task O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
dissociate O O
brain O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
activity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
related O O
to O O
attentional O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
control O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
from O O
that O O
related O O
to O O
selective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
processing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
target O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
stimuli O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
: O O
The O O
extract O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
medicinal O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
plants O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
containing O O
curcumin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
is O O
traditionally O O
believed O O
to O O
have O O
a O O
positive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contraction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
human O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
gall O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
- O O
bladder O B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Apoptosis O O
triggered O O
through O O
Fas B B_GENE
and O O
F B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
F I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
inhibited O O
by O O
coexpression O O
of O O
CrmA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
p35 B B_GENE
, O O
but O O
not O O
Bcl B B_GENE
- I I_GENE
xL I I_GENE
. O O

The O O
product O O
of O O
one O O
gene O O
, O O
Bv80 B B_GENE/B_LOCATION
, O O
has O O
a O O
single O O
divergent O O
copy O O
of O O
a O O
sequence O O
of O O
149 O O
amino O O
acids O O
( O O
approx O O
. O O

The O O
1031 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bp I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
wild I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
HIT1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O O
contained O O
an O O
open O O
reading O O
frame O O
encoding O O
a O O
protein O O
of O O
164 O O
amino O O
acids O O
and O O
the O O
AGG B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
arginine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complemented O O
all O O
hit1 B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
1 I I_DISEASE/I_GENE
mutant I I_DISEASE/I_GENE
phenotypes I I_DISEASE/I_GENE
, O O
indicating O O
that O O
the O O
mutant O O
phenotypes O O
were O O
caused O O
by O O
the O O
deletion O O
of O O
these O O
genes O O
. O O

We O O
found O O
a O O
prevalence O O
of O O
eating O O
disorders O O
of O O
5 O O
. O O
9 O O
% O O
( O O
lifetime O O
prevalence O O
of O O
10 O O
% O O
) O O
, O O
irrespective O O
of O O
gender O O
and O O
type O O
of O O
diabetes O O
; O O
4 O O
. O O
1 O O
% O O
of O O
the O O
whole O O
sample O O
reported O O
intentional O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
undertreatment O O
or O O
omission O O
. O O

Tilisolol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
carboxymethylcellulose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
salt O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CMC O B_DISEASE
) O O
were O O
used O O
as O O
the O O
model O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ophthalmic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
viscous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
polymer O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
respectively O O
. O O

These O O
results O O
are O O
discussed O O
in O O
the O O
context O O
of O O
a O O
model O O
of O O
the O O
myogenic O O
lineage O O
that O O
is O O
based O O
on O O
the O O
expression O O
of O O
desmin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
identified O O
two O O
potential O O
phosphorylation O O
sites O O
at O O
serine49 O O
and O O
serine133 O O
, O O
both O O
of O O
which O O
seem O O
to O O
be O O
necessary O O
for O O
Myf B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
5 I I_GENE/I_MEASURE
activity O O
. O O

We O O
constructed O O
a O O
series O O
of O O
chimeric O O
genes O O
containing O O
part O O
of O O
the O O
first O O
exon O O
and O O
increasingly O O
longer O O
5 O O
' O O
flanking O O
sequences O O
of O O
the O O
ODC B B_GENE
gene I I_GENE
fused O O
to O O
either O O
bacterial B B_ENZYME[GENE]
chloramphenicol I I_ENZYME[GENE]
acetyltransferase I I_ENZYME[GENE]
( O O
CAT B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
or O O
luciferase B B_GENE
reporter I I_GENE
genes I I_GENE
. O O

CVO2 O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
saturation O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O O
a O O
reliable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
sensitive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
detecting O O
blood O B_DISEASE/B_GENE
loss O I_DISEASE/I_GENE
. O O

The O O
gene O O
encoding O O
the O O
Neisseria B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
lactamica I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
III I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
DNA I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
methyltransferase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
M B B_SPECIES[BIO]/B_GENE
. I B_SPECIES[BIO]/I_GENE
NlaIII I B_SPECIES[BIO]/I_GENE
) O O
which O O
recognizes O O
the O O
sequence O O
CATG O O
has O O
been O O
cloned O O
and O O
expressed O O
in O O
Escherichia O O
coli O O
. O O

This O O
latter O O
complex O O
reacts O O
with O O
an O O
antibody O O
to O O
serum B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SRF B B_GENE/B_LOCATION
) O O
and O O
exhibits O O
the O O
same O O
binding O O
characteristics O O
as O O
purified O O
SRF B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
second O B_PERSON/B_DISEASE
patient O B_PERSON/I_DISEASE
was O O
successfully O O
treated O O
with O O
intravenous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prostaglandin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
F2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PGF2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
alpha O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
. O O

Alignment O O
of O O
the O O
rat B B_GENE
and I I_GENE
human I I_GENE
WIN I I_GENE
cDNAs I I_GENE
and O O
their O O
comparison O O
with O O
mouse O O
genomic O O
sequence O O
revealed O O
that O O
the O O
WIN B B_GENE/B_MEASURE
DNA I I_GENE/I_MEASURE
binding I I_GENE/I_MEASURE
domain I I_GENE/I_MEASURE
is O O
encoded O O
by O O
four O O
exons O O
, O O
two O O
of O O
which O O
( O O
exons O O
4 O O
and O O
6 O O
) O O
are O O
alternatively O O
spliced O O
to O O
generate O O
at O O
least O O
three O O
classes O O
of O O
mRNA O O
transcripts O O
. O O

In O O
a O O
pilot O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
which O O
two O B_PERSON/B_BIO
dogs O I_PERSON/I_BIO
were O O
given O O
parenteral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rifampin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O O
and O O
after O O
operation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
grafts O B_PERSON
were O O
preclotted O O
with O O
blood O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
that O O
contained O O
rifampin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
it O O
was O O
suggested O O
that O O
there O O
was O O
a O O
slight O B_DISEASE/B_MEASURE
increase O B_DISEASE/I_MEASURE
in O O
inhibition O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O O
24 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hours O B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
93 O B_TIME[MEASURE]/B_PERSON
% O I_TIME[MEASURE]/I_PERSON
) O O
. O O

A O O
flow O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
probe O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
direct O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurement O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
blood O B_MEASURE/B_LOCATION
flow O I_MEASURE/I_LOCATION
of O O
the O O
mitral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
valve O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O O
devised O O
. O O

Here O O
, O O
we O O
analyzed O O
the O O
interaction O O
of O O
the O O
Lactococcus B B_PROTEIN[GENE]
lactis I I_PROTEIN[GENE]
Ll I I_PROTEIN[GENE]
. I I_PROTEIN[GENE]
LtrB I I_PROTEIN[GENE]
group I I_PROTEIN[GENE]
II I I_PROTEIN[GENE]
intron I I_PROTEIN[GENE]
endonuclease I I_PROTEIN[GENE]
with O O
its O O
DNA O O
target O O
site O O
by O O
DNA O O
footprinting O O
and O O
modification O O
- O O
interference O O
approaches O O
. O O

Clinical O B_PERSON/B_ORGANIZATION
trials O I_PERSON/I_ORGANIZATION
bring O O
informations O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O O
pharmacology O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
epidemiology O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
. O O

In O O
several O O
steps O O
we O O
converted O O
the O O
retinoid O O
specific O O
response O O
element O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
retinoic I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acid I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
into O O
the O O
vitamin O O
D O O
/ O O
retinoic O O
acid O O
response O O
element O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
osteocalcin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
immediate O O
5 O O
' O O
- O O
flanking O O
region O O
was O O
GC O O
- O O
rich O O
with O O
3 O O
SP B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
like I I_GENE/I_LOCATION
and O O
2 O O
AP B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
2 I I_GENE/I_LOCATION
sites I I_GENE/I_LOCATION
identified O O
in O O
close O O
proximity O O
to O O
the O O
transcription O O
start O O
site O O
. O O

Akt B B_GENE
- O O
dependent O O
antiapoptotic O O
action O O
of O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
sensitive O O
to O O
farnesyltransferase O O
inhibitor O O
. O O

For O O
all O O
samples O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
sensitivity O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
blast O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
flag O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
CD3500 O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
85 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
with O O
a O O
specificity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
91 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
( O O
STKS O B_LOCATION/B_DISEASE
: O O
sensitivity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
75 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
; O O
specificity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
85 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
; O O
the O O
sensitivity O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
CD3500 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IG O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flag O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
72 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
with O O
a O O
specificity O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
76 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
( O O
STKS O B_LOCATION/B_DISEASE
: O O
sensitivity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
75 O B_LOCATION/B_PERSON
% O I_LOCATION/I_PERSON
: O O
specificity O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
73 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
; O O
and O O
the O O
sensitivity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
NRBC O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
flag O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
43 O B_MEASURE
% O I_MEASURE
with O O
a O O
specificity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
94 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
( O O
STKS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sensitivity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
37 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
; O O
specificity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
88 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
. O O

Control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
ovulation O B_ORGANISM_FUNCTION/B_BODY_PART_OR_ORGAN_COMPONENT
in O O
mares O B_SPECIES[BIO]/B_LOCATION
in O O
the O O
early O B_TIME[MEASURE]/B_LOCATION
breeding O B_TIME[MEASURE]/I_LOCATION
season O B_TIME[MEASURE]/I_LOCATION
with O O
ovarian O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
steroids O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
prostaglandin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Reasons O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O O
given O O
for O O
suggesting O O
that O O
tiapamil O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
warrants O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
further O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clinical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
after O O
which O O
it O O
may O O
join O O
the O O
more O O
established O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
calcium O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antagonists O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
as O O
a O O
valuable O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapeutic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
agent O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

The O O
central O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
venous O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
O2 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
saturation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
acute O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
pulmonary O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
fat O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
embolism O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

Two O O
of O O
the O O
proteins O O
UPRF B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
and O O
UPRF B B_GENE
- I I_GENE
2 I I_GENE
( O O
which O O
is O O
apparently O O
a O O
proteolytic O O
degradation O O
product O O
of O O
UPRF B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
) O O
bind O O
inefficiently O O
to O O
mutant O O
versions O O
of O O
the O O
UPR O O
that O O
are O O
unable O O
to O O
confer O O
responsiveness O O
to O O
unfolded O O
proteins O O
to O O
the O O
( O O
CYC1 B B_GENE/B_SPECIES[BIO]
) O O
promoter O O
. O O

Identification O O
of O O
domains O O
mediating O O
transcription O O
activation O O
, O O
repression O O
, O O
and O O
inhibition O O
in O O
the O O
paired B B_GENE/B_BIO
- I I_GENE/I_BIO
related I I_GENE/I_BIO
homeobox I I_GENE/I_BIO
protein I I_GENE/I_BIO
, O O
Prx2 B B_GENE
( O O
S8 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
A O O
spatial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
counting O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
approach O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
which O O
the O O
location O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
each O O
and O O
every O O
PN O B_LOCATION/B_PROTEIN[GENE]
and O O
NP O B_LOCATION/B_PROTEIN[GENE]
in O O
the O O
stratum O B_LOCATION/B_MEASURE
pyramidale O I_LOCATION/I_MEASURE
of O O
sectors O B_PROTEIN[GENE]/B_LOCATION
CA1 O I_PROTEIN[GENE]/I_LOCATION
- O O
4 O B_MEASURE
was O O
applied O O
to O O
11 O B_MEASURE
normal O I_MEASURE
control O I_MEASURE
( O O
CONs O B_LOCATION/B_PROTEIN[GENE]
) O O
and O O
10 O B_MEASURE/B_PERSON
SZs O I_MEASURE/I_PERSON
matched O O
for O O
age O B_TIME[MEASURE]/B_DISEASE
and O O
postmortem O B_MEASURE/B_DISEASE
interval O I_MEASURE/I_DISEASE
, O O
as O O
well O O
as O O
4 O B_DISEASE
manic O I_DISEASE
depressive O I_DISEASE
( O O
MD O B_DISEASE/B_PROTEIN[GENE]
) O O
subjects O B_PERSON/B_LOCATION
matched O O
for O O
age O B_TIME[MEASURE]/B_PERSON
. O O

Analytical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scanning O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoelectrofocusing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Upstream B B_GENE
stimulatory I I_GENE
factor I I_GENE
USF B I_GENE
is O O
a O O
human O O
transcriptional O O
activation O O
factor O O
, O O
which O O
uses O O
a O O
basic O O
/ O O
helix O O
- O O
loop O O
- O O
helix O O
/ O O
leucin O O
zipper O O
( O O
b O O
/ O O
HLH O O
/ O O
Z O O
) O O
motif O O
to O O
homodimerize O O
and O O
recognize O O
specific O O
sequences O O
in O O
the O O
promoter O O
region O O
of O O
both O O
nuclear O O
and O O
viral O O
genes O O
transcribed O O
by O O
RNA B B_GENE/B_VIRUS[BIO]
polymerase I B_GENE/I_VIRUS[BIO]
II I B_GENE/I_VIRUS[BIO]
. O O

43 O O
% O O
, O O
6 O O
/ O O
14 O O
; O O
P O O
= O O
0 O O
. O O
013 O O
) O O
, O O
whereas O O
, O O
in O O
RCC O O
samples O O
with O O
VHL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
methylation O O
or O O
mutation O O
, O O
the O O
frequency O O
of O O
3p14 O O
- O O
p21 O O
LOH O O
did O O
not O O
differ O O
from O O
that O O
of O O
sp25 O O
- O O
p26 O O
( O O
72 O O
% O O
, O O
18 O O
/ O O
25 O O
vs O O
. O O

Sequences O O
homologous O O
to O O
the O O
consensus O O
TUF B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
binding I I_GENE/I_LOCATION
UAS I I_GENE/I_LOCATION
boxes I I_GENE/I_LOCATION
are O O
present O O
in O O
the O O
5 O O
' O O
flanking O O
regions O O
of O O
both O O
genes O O
. O O

The O O
analysis O O
predicted O O
that O O
progressive O O
increases O O
in O O
serum O O
creatinine O O
or O O
aspartate B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
transaminase I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
activity O O
will O O
result O O
in O O
only O O
a O O
50 O O
% O O
reduction O O
of O O
clearance O O
. O O

RESULTS O O
: O O
Although O O
low O O
levels O O
of O O
vIRF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNAs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O O
be O O
detected O O
in O O
the O O
HHV O O
- O O
8 O O
- O O
positive O O
BCBL O O
- O O
1 O O
tumor O O
cell O O
line O O
, O O
12 O O
- O O
0 O O
- O O
tetradecanoylphorbol O O
- O O
13 O O
- O O
acetate O O
( O O
TPA O O
) O O
treatment O O
does O O
not O O
stimulate O O
expression O O
of O O
vIRF B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
2 I I_GENE/I_DISEASE
gene I I_GENE/I_DISEASE
together O O
with O O
primary O O
lytic O O
cycle O O
genes O O
. O O

Central O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
projections O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
gastric O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
afferent O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
vagal O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
inputs O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O O

DNA O O
sequence O O
of O O
the O O
UL6 B B_PROTEIN[GENE]/B_DISEASE
to O O
UL20 B B_MEASURE/B_GENE
genes I I_MEASURE/I_GENE
of O O
infectious O O
laryngotracheitis O O
virus O O
and O O
characterization O O
of O O
the O O
UL10 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
product I I_GENE/I_LOCATION
as O O
a O O
nonglycosylated O O
and O O
nonessential O O
virion O O
protein O O
. O O

Coimmunoprecipitation O O
analysis O O
suggests O O
that O O
these O O
residues O O
likely O O
contribute O O
to O O
the O O
multimerization O O
function O O
required O O
for O O
homomeric O O
complex O O
formation O O
or O O
heteromeric O O
complex O O
formation O O
with O O
p50 B B_GENE
in O O
that O O
no O O
association O O
of O O
p65 B B_GENE
delta I I_GENE
with O O
itself O O
or O O
with O O
p50 B B_GENE
was O O
evident O O
. O O

Cytostatic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
some O O
essential O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oils O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
against O O
HEp O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
2 O B_PROTEIN[GENE]/B_MEASURE
cells O I_PROTEIN[GENE]/I_MEASURE
. O O

A O O
yeast O O
mitochondrial O O
translation O O
initiation O O
codon O O
mutation O O
affecting O O
the O O
gene O O
for O O
cytochrome B B_GENE
oxidase I I_GENE
subunit I I_GENE
III I I_GENE
( O O
COX3 B B_PROTEIN[GENE]/B_LOCATION
) O O
was O O
partially O O
suppressed O O
by O O
a O O
spontaneous O O
nuclear O O
mutation O O
. O O

Only O O
the O O
27 O O
- O O
kDa O O
protein O O
was O O
detected O O
after O O
N B B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glycosidase I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
, O O
indicating O O
that O O
PLP B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
H I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
glycoprotein O O
. O O

Moreover O O
, O O
we O O
studied O O
the O O
relationship O B_PERSON/B_MEASURE
between O O
initial O B_MEASURE/B_DISEASE
percentage O B_MEASURE/I_DISEASE
of O O
bone O B_DISEASE
marrow O I_DISEASE
plasma O I_DISEASE
cells O I_DISEASE
and O O
prognosis O B_DISEASE
. O O

These O O
results O O
demonstrate O O
that O O
GGTase B B_GENE
- I I_GENE
I I I_GENE
inhibitors O O
arrest O O
cells O O
in O O
G0 O O
/ O O
G1 O O
and O O
induce O O
accumulation O O
of O O
p21WAF B B_GENE
in O O
a O O
p53 B B_GENE/B_MEASURE
- O O
independent O O
manner O O
and O O
that O O
FTase B B_GENE/B_PERSON
inhibitors O O
can O O
interfere O O
with O O
cell O O
cycle O O
events O O
by O O
a O O
mechanism O O
that O O
involves O O
neither O O
p21WAF B B_GENE
nor O O
p27KIP B B_GENE
. O O

We O O
report O O
here O O
on O O
an O O
eight O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]
- O O
old O B_PERSON
boy O I_PERSON
who O O
first O O
developed O O
acute O B_DISEASE
intravascular O I_DISEASE
hemolysis O I_DISEASE
following O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
amphotericin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
AmB O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
and O O
subsequently O O
a O O
delayed O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hemolytic O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transfusion O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reaction O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
due O O
to O O
alloantibodies O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O O

The O O
temporal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
sequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
organ O B_DISEASE_ADJECTIVE[DISEASE]
failure O I_DISEASE_ADJECTIVE[DISEASE]
was O O
lung O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
clotting O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
kidney O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
liver O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

The O O
potential O O
biological O O
significance O O
of O O
the O O
identified O O
structural O O
motif O O
shared O O
by O O
the O O
human B B_GENE
CCR5 I I_GENE
, O O
CCR3 B B_GENE
, O O
CCR2B B B_GENE
and O O
other O O
GPCRs B B_GENE/B_BIO
is O O
discussed O O
. O O

Analysis O O
of O O
rat O O
brain O O
, O O
heart O O
, O O
lung O O
, O O
liver O O
, O O
kidney O O
and O O
skeletal O O
muscle O O
revealed O O
psi B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PKC I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
zeta I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRNA I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O O
in O O
brain O O
. O O

The O O
papers O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provide O O
a O O
broad O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
perspective O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
MPAs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
include O O
social O B_EDU[ORGANIZATION]/B_LOCATION
, O O
economic O B_EDU[ORGANIZATION]/B_LOCATION
, O O
cultural O B_EDU[ORGANIZATION]/B_PERSON
, O O
biological O B_EDU[ORGANIZATION]/B_PERSON
and O O
statistical O B_EDU[ORGANIZATION]/B_LOCATION
components O I_EDU[ORGANIZATION]/I_LOCATION
. O O

Management O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
patients O B_PERSON/B_DISEASE
with O O
Ewing O B_DISEASE
' O I_DISEASE
s O I_DISEASE
sarcoma O I_DISEASE
has O O
been O O
discussed O O
with O O
reference O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
the O O
need O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
achieve O O
an O O
excellent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
local O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
result O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
from O O
radiation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
therapy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
now O O
that O O
patients O B_PERSON
are O O
experiencing O O
long O B_TIME[MEASURE]/B_LOCATION
- O O
term O B_MEASURE
survival O I_MEASURE
. O O

Furthermore O O
, O O
the O O
rapid O O
light O O
- O O
mediated O O
increase O O
of O O
CPRF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
insensitive O O
to O O
transcriptional O O
inhibitors O O
, O O
suggesting O O
that O O
a O O
post O O
- O O
transcriptional O O
mechanism O O
controls O O
CPRF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
accumulation O O
. O O

In O O
those O O
patients O O
who O O
before O O
transplantation O O
were O O
serological O O
negative O O
for O O
CMV O O
but O O
had O O
received O O
organs O O
from O O
CMV B B_DISEASE
- I I_DISEASE
IgG I I_DISEASE
positive O O
donors O O
, O O
the O O
incidence O O
of O O
the O O
disease O O
was O O
highest O O
. O O

Since O O
1985 O O
the O O
combination O O
of O O
chlorambucil O O
( O O
10 O O
mg O O
daily O O
, O O
initially O O
for O O
six O O
weeks O O
, O O
then O O
alternating O O
fortnights O O
for O O
12 O O
weeks O O
) O O
and O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2b I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Schering O O
- O O
Plough O O
; O O
2 O O
x O O
10 O O
( O O
6 O O
) O O
U O O
/ O O
m2 O O
three O O
times O O
weekly O O
by O O
subcutaneous O O
injection O O
for O O
18 O O
weeks O O
) O O
has O O
been O O
compared O O
in O O
a O O
randomised O O
trial O O
with O O
chlorambucil O O
alone O O
in O O
previously O O
untreated O O
patients O O
with O O
stage O O
III O O
or O O
IV O O
follicular O O
lymphoma O O
. O O

The O O
BDU O B_LOCATION/B_PROTEIN[GENE]
neurons O I_LOCATION/I_PROTEIN[GENE]
and O O
the O O
ALM O B_LOCATION/B_DISEASE
touch O I_LOCATION/I_DISEASE
neurons O I_LOCATION/I_DISEASE
are O O
lineal O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
sister O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
cells O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O O
the O O
AB O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
a O O
lineage O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O O
the O O
VA O B_LOCATION/B_PROTEIN[GENE]
and O O
VB O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
motor O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
neurons O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
are O O
lineal O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sister O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
AB O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
p O B_GENE/B_LOCATION
lineage O I_GENE/I_LOCATION
. O O

We O O
compared O O
retrospectively O O
the O O
efficacy O O
of O O
granulocyte B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colony I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulating I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
G B B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- I I_LOCATION/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
CSF I I_LOCATION/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
alone O O
with O O
chemotherapy O O
plus O O
G B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CSF I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
mobilizing O O
CD34 B B_GENE
- O O
positive O O
cells O O
in O O
patients O O
with O O
malignant O O
lymphoma O O
. O O

Serum O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hormones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
patients O B_PERSON/B_BIO
classified O O
as O O
C O B_OTHER/B_DISEASE
were O O
characteristically O O
and O O
inclined O B_DISEASE_ADJECTIVE[DISEASE]
to O O
be O O
hypergonadotropic O B_DISEASE_ADJECTIVE[DISEASE]
and O O
hypoestrogenic O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Cervical O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
CT O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
revealed O O
an O O
irregular O B_DISEASE/B_LOCATION
low O I_DISEASE/I_LOCATION
density O I_DISEASE/I_LOCATION
at O O
the O O
periphery O B_LOCATION/B_MEASURE
of O O
the O O
cervical O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
vertebra O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
from O O
the O O
C2 O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
to O O
C4 O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
level O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Incorporation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
brought O O
about O O
a O O
revised O O
five O B_NUMBER[MEASURE]
- O O
year O B_SEQUENCE[MEASURE]/B_LOCATION
survival O I_SEQUENCE[MEASURE]/I_LOCATION
estimate O I_SEQUENCE[MEASURE]/I_LOCATION
of O O
55 O B_DISEASE/B_GENE
percent O I_DISEASE/I_GENE
. O O

These O O
motifs O B_LOCATION/B_GENE
, O O
and O O
their O O
cognate O B_PERSON/B_GENE
transcription O I_PERSON/I_GENE
factors O I_PERSON/I_GENE
, O O
appear O O
to O O
act O O
in O O
concert O B_ENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
with O O
partial O B_MEASURE/B_GENE
redundancy O I_MEASURE/I_GENE
, O O
so O O
that O O
discrete O B_PERSON/B_BIO
mutations O I_PERSON/I_BIO
were O O
only O O
partially O O
effective O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
reducing O O
transcriptional O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
now O O
show O O
that O O
purified O O
recombinant O O
c B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
PDGF B B_GENE
can O O
induce O O
this O O
binding O O
activity O O
which O O
we O O
have O O
termed O O
SIF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
for O O
sis B B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
inducible I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Statistical O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
conservation O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
laws O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
turbulent O B_LOCATION/B_ORGANIZATION
transport O I_LOCATION/I_ORGANIZATION
. O O

Expression O O
of O O
the O O
bacteriophage B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T4 I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
terminase I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
16 I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
17 I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
yields O O
multiple O O
proteins O O
. O O

Erdheim O B_LOCATION/B_DISEASE
- O O
Chester O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
disease O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
: O O
a O O
distinct O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
lipoidosis O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
or O O
part O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
spectrum O B_DISEASE/B_MEASURE
of O O
histiocytosis O B_DISEASE
? O O

Erdheim O B_LOCATION/B_PERSON
- O O
Chester O B_DISEASE/B_PERSON
disease O I_DISEASE/I_PERSON
has O O
always O O
been O O
considered O O
a O O
distinct O B_DISEASE
lipoidosis O I_DISEASE
based O O
on O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
radiographic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
criteria O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Self O B_PERSON/B_LOCATION
- O O
consistent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
calculation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
the O O
surface O B_MEASURE/B_LOCATION
electronic O I_MEASURE/I_LOCATION
structure O I_MEASURE/I_LOCATION
of O O
the O O
( O O
1 O B_MEASURE
x O O
2 O B_MEASURE
) O O
reconstructed O O
Au O B_LOCATION
( O O
110 O B_TIME[MEASURE]/B_LOCATION
) O O
surface O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

The O O
plasmid O B_GENE
was O O
found O O
to O O
confer O O
drug O B_DISEASE_ADJECTIVE[DISEASE]
resistance O I_DISEASE_ADJECTIVE[DISEASE]
specifically O O
to O O
LMB O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Two O B_PERSON/B_ORGANIZATION
pharmacokinetic O I_PERSON/I_ORGANIZATION
models O I_PERSON/I_ORGANIZATION
were O O
compared O O
. O O

A O O
higher O B_MEASURE/B_LOCATION
median O I_MEASURE/I_LOCATION
proportion O I_MEASURE/I_LOCATION
of O O
spirochaetes O B_DISEASE
was O O
observed O O
in O O
sites O B_LOCATION/B_PERSON
after O O
diagnosis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
loss O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O O
attachment O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Ocular O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injuries O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
general O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
anesthesia O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Of O O
81 O B_NUMBER[MEASURE]/B_LOCATION
girls O I_NUMBER[MEASURE]/I_LOCATION
cured O O
from O O
the O O
bacteriuria O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BACTERIUM[BIO]
24 O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BACTERIUM[BIO]
recurred O O
, O O
5 O B_NUMBER[MEASURE]
with O O
a O O
symptomatic O B_DISEASE
pyelonephritis O I_DISEASE
and O O
3 O B_NUMBER[MEASURE]
with O O
cystitis O B_DISEASE
. O O

The O O
performances O O
of O O
two O O
tests O O
, O O
the O O
ProstAsure O O
index O O
and O O
the O O
percent O O
free O O
PSA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
test O O
, O O
were O O
evaluated O O
in O O
detecting O O
cancer O O
. O O

The O O
protein O O
encoded O O
by O O
the O O
NF2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O O
a O O
similarity O O
to O O
ezrin B B_GENE/B_BACTERIUM[BIO]
, O O
radixin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
moesin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ERM B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
proteins O O
that O O
link O O
membrane O O
proteins O O
to O O
the O O
cytoskeleton O O
. O O

PATIENTS O B_PERSON/B_MEASURE
- O O
- O O
125 O B_TIME[MEASURE]/B_LOCATION
women O B_TIME[MEASURE]/I_LOCATION
consulting O O
the O O
general O B_PERSON/B_LOCATION
practitioner O B_PERSON/I_LOCATION
for O O
symptomatic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
bacterial O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
vaginosis O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

In O O
the O O
healing O O
tendons O O
, O O
the O O
rate O O
of O O
collagen B B_GENE/B_DISEASE
synthesis O O
decreased O O
and O O
the O O
rate O O
of O O
noncollagen O O
protein O O
synthesis O O
remained O O
unchanged O O
. O O

From O O
our O O
own O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
phantoms O B_ENT
, O O
the O O
smallest O B_MEASURE/B_ENT
signal O B_MEASURE/I_ENT
- O O
to O O
- O O
noise O B_MEASURE/B_ENT
ratio O B_MEASURE/I_ENT
( O O
delta O B_MEASURE/B_PROTEIN[GENE]
S O B_MEASURE/I_PROTEIN[GENE]
min O B_MEASURE/I_PROTEIN[GENE]
/ O O
delta O B_MEASURE
R O I_MEASURE
) O O
was O O
obtained O O
which O O
determines O O
the O O
minimal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
contrast O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
given O O
the O O
film O B_MEASURE/B_ORGANIZATION
properties O I_MEASURE/I_ORGANIZATION
( O O
film O B_MEASURE
response O I_MEASURE
S O I_MEASURE
, O O
film O B_MEASURE
gradient O I_MEASURE
gamma O I_MEASURE
) O O
and O O
the O O
amount O B_MEASURE/B_LOCATION
of O O
scatter O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

However O O
, O O
one O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
activity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
binds O O
preferentially O O
to O O
G O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
rich O B_LOCATION/B_GENE
promoters O B_LOCATION/I_GENE
, O O
and O O
another O O
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
appears O O
to O O
bind O O
preferentially O O
to O O
only O O
two O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
promoters O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
tested O O
. O O

Cardiovascular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
man O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
intravenous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prizidilol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrochloride O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SK O B_LOCATION/B_PROTEIN[GENE]
& O O
F O B_LOCATION/B_PERSON
92657 O I_LOCATION/I_PERSON
) O O
; O O
a O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antihypertensive O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
agent O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

From O O
the O O
Centers O B_LOCATION/B_ORGANIZATION
for O O
Disease O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
Prevention O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Expression O O
of O O
a O O
cDNA O O
clone O O
in O O
yeast O O
containing O O
a O O
large O O
portion O O
of O O
the O O
open O O
reading O O
frame O O
produced O O
cAMP B B_GENE
PDEase I I_GENE
activity O O
identical O O
in O O
properties O O
to O O
the O O
Drosophila O O
enzyme O O
affected O O
by O O
the O O
dnc B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

FdsR B B_GENE
purified O O
to O O
homogeneity O O
after O O
overexpression O O
of O O
fdsR B B_GENE
in O O
E O O
. O O
coli O O
is O O
a O O
130 O O
kDa O O
homotetramer O O
binding O O
to O O
the O O
fds B B_GENE/B_BIO
control O O
region O O
located O O
between O O
the O O
fdsR B B_GENE
and O O
fdsG B B_GENE/B_LOCATION
genes I I_GENE/I_LOCATION
. O O

ZNS O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
in O O
the O O
mmolar O B_BODY_PART_OR_ORGAN_COMPONENT
range O I_BODY_PART_OR_ORGAN_COMPONENT
, O O
scavenged O O
hydroxyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
nitric O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
radicals O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
dose O B_MEASURE
- O O
dependent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
manner O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
orthologs O O
of O O
the O O
Y B B_GENE/B_MEASURE
( I I_GENE/I_MEASURE
1 I I_GENE/I_MEASURE
) I I_GENE/I_MEASURE
and O O
Y B B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
subtypes I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
display O O
high O O
amino O O
acid O O
sequence O O
identities O O
between O O
pig O O
, O O
human O O
, O O
and O O
mouse O O
( O O
92 O O
% O O
- O O
94 O O
% O O
) O O
, O O
whereas O O
the O O
Y B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
4 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
Y B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
5 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
y B B_MEASURE/B_BIO
( I I_MEASURE/I_BIO
6 I I_MEASURE/I_BIO
) I I_MEASURE/I_BIO
subtypes I I_MEASURE/I_BIO
display O O
lower O O
identities O O
( O O
76 O O
% O O
- O O
87 O O
% O O
) O O
. O O

Binding O O
of O O
ZAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
70 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
phospho O O
- O O
TAMs O O
is O O
notable O O
for O O
the O O
high O O
level O O
of O O
cooperativity O O
between O O
the O O
two O O
SH2 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
domains I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
individually O O
demonstrate O O
low O O
affinity O O
interaction O O
with O O
the O O
ligand O O
. O O

The O O
benzo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
pyrone O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Venalot O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
a O O
considerable O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effect O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
reducing O O
the O O
protein O B_MEASURE/B_DISEASE
concentration O B_MEASURE/I_DISEASE
in O O
the O O
air O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
spaces O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
interstitial O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
tissue O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
, O O
and O O
of O O
the O O
oedema O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
latter O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Radiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O O
delivered O O
in O O
a O O
single O B_MEASURE
4 O I_MEASURE
- O O
mJ O B_TIME[MEASURE]/B_LOCATION
pulse O I_TIME[MEASURE]/I_LOCATION
of O O
200 O B_MEASURE/B_LOCATION
microseconds O I_MEASURE/I_LOCATION
duration O I_MEASURE/I_LOCATION
by O O
means O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
an O O
articulated O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
zirconium O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
fluoride O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
optical O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
fibre O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
a O O
320 O B_NUMBER[MEASURE]
- O O
microns O B_MEASURE/B_LOCATION
quartz O I_MEASURE/I_LOCATION
- O O
fibre O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tip O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Perception O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
sweetness O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
cannot O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
be O O
used O O
to O O
accurately O O
meter O O
the O O
metabolizable O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
energy O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
nutritive O B_MEASURE/B_BIO
value O I_MEASURE/I_BIO
of O O
a O O
food O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O O

The O O
leader O O
peptide O O
was O O
hypothesized O O
to O O
inhibit O O
ribosome O O
release O O
at O O
the O O
tnaC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
stop I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
codon I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
thereby O O
blocking O O
Rho B B_GENE
' O O
s O O
access O O
to O O
the O O
transcript O O
. O O

Response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
properties O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
single O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
units O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
accessory O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
optic O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
of O O
the O O
dark O O
- O O
reared O O
cat O B_SPECIES[BIO]/B_DISEASE
. O O

Excretion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
radiopharmaceuticals O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
into O O
breast O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
milk O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Influence O O
of O O
huanglian O O
used O O
in O O
combination O O
with O O
huangqin O O
and O O
gancao O O
on O O
the O O
erythrocytic O O
osmotic O O
fragilitas O O
of O O
experimental O O
glucose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
6 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
deficiency O O
in O O
rats O O
] O O
OBJECTIVE O O
: O O
To O O
study O O
the O O
influence O O
of O O
common O O
combination O O
of O O
Huanglian O O
( O O
Coptis O O
chinensis O O
) O O
on O O
the O O
erythrocytic O O
osmotic O O
fragilitas O O
of O O
glucose B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
6 I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphate I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
G6PD B B_GENE/B_LOCATION
) O O
deficiency O O
in O O
rats O O
. O O

The O O
leukotriene B B_GENE
receptor I I_GENE
antagonist O O
zafirlukast O O
inhibits O O
sulfur O O
dioxide O O
- O O
induced O O
bronchoconstriction O O
in O O
patients O O
with O O
asthma O O
. O O

This O O
sequence O O
was O O
sufficient O O
to O O
confer O O
p53 B B_GENE
- O O
dependent O O
activation O O
to O O
a O O
heterologous O O
promoter O O
and O O
p53 B B_GENE/B_LOCATION
was O O
capable O O
of O O
binding O O
to O O
this O O
sequence O O
as O O
assessed O O
by O O
gel O O
shift O O
analysis O O
. O O

The O O
embryology O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O O
the O O
vertebral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
column O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
is O O
reviewed O O
briefly O O
, O O
and O O
the O O
origin O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
each O O
anomaly O O
of O O
the O O
C2 O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
vertebra O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
is O O
traced O O
to O O
one O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
two O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
early O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stages O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
development O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
as O O
follows O O
: O O
1 O B_SEQUENCE[MEASURE]
) O O
the O O
formation O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
mesenchymal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
vertebra O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
or O O
2 O B_NUMBER[MEASURE]
) O O
its O O
induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
to O O
cartilage O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

Two O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
three O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
groups O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
were O O
submitted O O
to O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
different O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hypoxia O B_DISEASE
( O O
FiO2 O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
05 O B_MEASURE
, O O
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
F5 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
FiO2 O B_MEASURE/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
1 O B_MEASURE
, O O
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
F10 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
and O O
the O O
third O B_SEQUENCE[MEASURE]/B_PERSON
to O O
normoxia O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
FiO2 O B_MEASURE/B_PROTEIN[GENE]
= O O
0 O B_MEASURE/B_LOCATION
. O O
21 O B_MEASURE
, O O
group O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
F21 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
in O O
a O O
thermoneutral O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
controlled O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
environment O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

Parathyroid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hormone I B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
responses O O
of O O
cyclic O O
AMP O O
- O O
, O O
serum O O
- O O
and O O
phorbol O O
ester O O
- O O
responsive O O
reporter O O
genes O O
in O O
osteoblast O O
- O O
like O O
UMR O O
- O O
106 O O
cells O O
. O O

Our O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strongly O O
suggest O O
that O O
activation O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
beta O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
origin O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
a O O
distant O B_GENE
replication O I_GENE
enhancer O I_GENE
element O I_GENE
requires O O
a O O
small O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
target O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sequence O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
essential O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
initiator O B_GENE
protein O I_GENE
- O O
mediated O O
DNA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
looping O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
. O O

HNF4alpha7 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
also O O
found O O
in O O
totipotent O O
embryonic O O
stem O O
cells O O
. O O

Penicillamine O O
- O O
induced O O
myasthenia O O
gravis O O
associated O O
with O O
antibodies O O
to O O
acetylcholine B B_GENE
receptor I I_GENE
. O O

Magnetic O B_DISEASE/B_MEASURE
force O I_DISEASE/I_MEASURE
and O O
torque O B_MEASURE/B_DISEASE
at O O
1 O B_MEASURE
. O O
5 O B_MEASURE/B_LOCATION
T O I_MEASURE/I_LOCATION
did O O
not O O
dislodge O O
the O O
GF O B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
result O O
in O O
perforation O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
canine O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
IVC O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
by O O
the O O
GF O B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

A O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

LCCH1 B B_GENE/B_PERSON
was O O
identical O O
to O O
the O O
Rdl B B_GENE
gene I I_GENE
, O O
a O O
known O O
GABA B B_GENE/B_PERSON
receptor I I_GENE/I_PERSON
subunit I I_GENE/I_PERSON
gene I I_GENE/I_PERSON
from O O
D O O
. O O
melanogaster O O
, O O
whereas O O
LCCH2 B B_GENE/B_PERSON
and O O
LCCH3 B B_PROTEIN[GENE]/B_MEASURE
were O O
novel O O
D O O
. O O
melanogaster O O
sequences O O
that O O
exhibited O O
structural O O
similarity O O
to O O
other O O
members O O
of O O
the O O
ligand B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
gated I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
chloride I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
channel I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
family I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
gastric O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mucosal O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
permeability O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
observed O O
in O O
six O B_PERSON/B_SPECIES[BIO]
normal O I_PERSON/I_SPECIES[BIO]
human O I_PERSON/I_SPECIES[BIO]
subjects O I_PERSON/I_SPECIES[BIO]
after O O
instillation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
ethanol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
20 O B_MEASURE
percent O I_MEASURE
v O O
/ O O
v O B_OTHER/B_MEASURE
) O O
. O O

Using O O
a O O
simulated O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cough O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
machine O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
analyzed O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
adding O O
tensio O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
active O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
liquids O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
as O O
sol O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phase O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
simulant O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
clearance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
gel O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mucus O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
simulant O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
cough O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

First O O
, O O
the O O
amino O O
- O O
terminal O O
regulatory O O
arm O O
of O O
the O O
GDI B B_ENZYME[GENE]/B_BIO
binds O O
to O O
the O O
switch O O
I O O
and O O
II O O
domains O O
of O O
Cdc42 B B_GENE
leading O O
to O O
the O O
inhibition O O
of O O
both O O
GDP O O
dissociation O O
and O O
GTP O O
hydrolysis O O
. O O

By O O
a O O
combination O O
of O O
alternative O O
promoter O O
usage O O
and O O
exon O O
splicing O O
, O O
each O O
ROR B B_GENE
gene I I_GENE
generates O O
several O O
isoforms O O
that O O
differ O O
only O O
in O O
their O O
amino O O
terminus O O
. O O

Electrophoretic O O
mobility O O
- O O
shift O O
assays O O
showed O O
a O O
rapid O O
induction O O
of O O
nuclear O O
proteins O O
that O O
bound O O
to O O
the O O
consensus B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
motif I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Analysis O O
of O O
larger O O
cDNA O O
clones O O
demonstrates O O
that O O
there O O
are O O
at O O
least O O
two O O
isoforms O O
of O O
RIP14 B B_GENE
that O O
differ O O
in O O
the O O
N O O
- O O
terminal O O
( O O
A O O
and O O
B O O
) O O
and O O
hinge O O
( O O
D O O
) O O
domains O O
. O O

Multiple O B_MEASURE/B_LOCATION
copies O I_MEASURE/I_LOCATION
of O O
this O O
binding O B_GENE/B_LOCATION
site O I_GENE/I_LOCATION
are O O
found O O
in O O
the O O
viral O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genomes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

During O O
subsequent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
CS O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
alone O O
trials O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
the O O
responses O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
( O O
+ O B_MEASURE/B_DISEASE
) O O
MK O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
801 O B_NUMBER[MEASURE]
- O O
injected O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
extinguished O O
as O O
easily O O
as O O
those O O
of O O
saline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
injected O O
mice O B_BIO/B_PERSON
. O O

In O O
contrast O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
tail O B_BODY_PART_OR_ORGAN_COMPONENT
deviated O O
ipsilaterally O O
in O O
cats O B_BIO/B_PERSON
with O O
a O O
hemisection O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
the O O
tail O B_BODY_PART_OR_ORGAN_COMPONENT
was O O
ventroflexed O O
in O O
cats O B_BIO/B_PERSON
with O O
a O O
transection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

The O O
major O O
open O O
reading O O
frame O O
of O O
the O O
cDNA O O
predicts O O
a O O
protein O O
of O O
59 O O
kD O O
, O O
with O O
a O O
leucine O O
zipper O O
situated O O
adjacent O O
to O O
an O O
myc B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
related I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
motif I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
has O O
been O O
proposed O O
to O O
assume O O
a O O
helix O O
- O O
loop O O
- O O
helix O O
structure O O
. O O

This O O
residue O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
although O O
located O O
55 O B_MEASURE
rather O O
than O O
35 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
residues O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
NH2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
terminal O B_LOCATION/B_MEASURE
of O O
the O O
essential O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
glutamate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
is O O
undoubtedly O O
the O O
analog O B_MEASURE/B_LOCATION
of O O
the O O
second O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
aspartate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
Asp O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Asp O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
35 O B_MEASURE/B_LOCATION
- O O
Glu O B_LOCATION/B_MEASURE
motif O I_LOCATION/I_MEASURE
found O O
in O O
other O B_SPECIES[BIO]
family O I_SPECIES[BIO]
members O I_SPECIES[BIO]
. O O

In O O
addition O O
to O O
loss O O
of O O
digit O O
identity O O
and O O
varying O O
degrees O O
of O O
polydactyly O O
, O O
proximal O O
skeletal O O
elements O O
are O O
severely O O
shortened O O
in O O
Xt B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
ld B B_DISEASE/B_MEASURE
double O O
homozygous O O
limbs O O
. O O

The O O
PEP4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
isolated O O
from O O
a O O
genomic O O
DNA O O
library O O
by O O
complementation O O
of O O
the O O
pep4 B B_GENE/B_TIME[MEASURE]
- I I_GENE/I_TIME[MEASURE]
3 I I_GENE/I_TIME[MEASURE]
mutation O O
. O O

A O O
gene O O
with O O
a O O
high O O
degree O O
of O O
sequence O O
identity O O
with O O
mammalian B B_GENE/B_BIO
ADP I I_GENE/I_BIO
- I I_GENE/I_BIO
ribosylation I I_GENE/I_BIO
factors I I_GENE/I_BIO
( O O
ARFs B B_DISEASE/B_GENE
) O O
, O O
believed O O
to O O
be O O
important O O
in O O
vesicular O O
transport O O
, O O
was O O
identified O O
. O O

Off O O
- O O
shell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
Rydberg O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
atom O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
alkali O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
atom O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
scattering O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Short O B_PERSON/B_MEASURE
- O O
term O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
rhythms O B_DISEASE
, O O
chaos O B_PERSON/B_DISEASE
, O O
or O O
noise O B_ENT/B_DISEASE
? O O

Association O B_ORGANIZATION/B_TIME[MEASURE]
between O O
diaphragm O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
asymptomatic O B_DISEASE
bacteriuria O I_DISEASE
. O O

The O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
iron O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
toxigenicity O B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
of O O
Vibrio O B_BACTERIUM[BIO]/B_DISEASE
cholerae O I_BACTERIUM[BIO]/I_DISEASE
. O O

The O O
Tat B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
coded O O
by O O
human O O
immunodeficiency O O
virus O O
( O O
HIV O O
) O O
is O O
a O O
strong O O
activator O O
of O O
viral O O
gene O O
expression O O
from O O
the O O
long O O
terminal O O
repeat O O
( O O
LTR O O
) O O
. O O

Is O O
it O O
time O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
a O O
wine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
trial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
? O O

The O O
average O B_MEASURE
coefficient O I_MEASURE
of O O
variation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
between O O
assays O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
gas O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chromatography O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mass O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
spectrometry O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
5 O B_MEASURE
. O O
8 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
and O O
for O O
radioimmunoassay O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
12 O B_MEASURE
. O O
3 O B_MEASURE
% O I_MEASURE
, O O
while O O
the O O
average O B_MEASURE
coefficient O I_MEASURE
of O O
variation O B_MEASURE
within O O
assays O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O O
gas O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chromatography O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mass O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
spectrometry O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
4 O B_MEASURE
. O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
and O O
for O O
radioimmunoassay O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
. O O

Macrophages O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
: O O
modulators O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
immunity O B_DISEASE
. O O

The O O
NH2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_PROTEIN[GENE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fragments O B_PROTEIN[GENE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
tested O O
for O O
susceptibility O B_DISEASE
to O O
modification O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
Nalpha O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
( O O
3 O B_MEASURE
- O O
maleimidylpropionyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
biocytin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
which O O
attaches O O
a O O
biotin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
group O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
cysteine O O
sulfhydryls O B_MEASURE/B_BIO
. O O

Production O O
of O O
VT O O
was O O
also O O
examined O O
retrospectively O O
in O O
32 O O
E O O
. O O
coli O O
strains O O
of O O
serotype O O
O26 O O
: O O
H11 O O
isolated O O
from O O
children O O
with O O
diarrhoea O O
; O O
eight O O
( O O
25 O O
% O O
) O O
of O O
them O O
produced O O
moderate O O
to O O
high O O
levels O O
of O O
verotoxin B B_DISEASE/B_PROTEIN[GENE]
1 I B_DISEASE/I_PROTEIN[GENE]
despite O O
several O O
years O O
storage O O
in O O
vitro O O
. O O

Serum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pituitary O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
steroid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
levels O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
the O O
adult O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
male O B_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
: O O
one O B_NUMBER[MEASURE]
value O I_NUMBER[MEASURE]
is O O
as O O
good O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O O
the O O
mean O B_MEASURE
of O O
three O B_NUMBER[MEASURE]/B_PERSON
. O O

The O O
sections O O
were O O
stained O O
with O O
anti O O
- O O
polymorphonuclear O O
leukocyte O O
antibody O O
, O O
the O O
endothelial O O
marker O O
factor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
VIII I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
related I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antigen I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
and O O
with O O
hematoxylin O O
and O O
eosin O O
. O O

Mapping O O
of O O
the O O
region O O
in O O
KAP B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
required O O
for O O
HP1 B B_GENE/B_MEASURE
interaction O O
showed O O
that O O
amino O O
acid O O
substitutions O O
which O O
abolish O O
HP1 B B_GENE/B_BIO
binding O O
in O O
vitro O O
reduce O O
KAP B B_GENE/B_PERSON
- I I_GENE/I_PERSON
1 I I_GENE/I_PERSON
mediated O O
repression O O
in O O
vivo O O
. O O

The O O
flanking O B_GENE/B_LOCATION
open O I_GENE/I_LOCATION
reading O I_GENE/I_LOCATION
frames O I_GENE/I_LOCATION
in O O
pARGC2 O B_BIO/B_MEASURE
showed O O
no O O
homologies O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
arginine O O
biosynthetic O B_ENZYME[GENE]
genes O I_ENZYME[GENE]
. O O

Promoter O O
activity O O
of O O
the O O
proliferating B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
cell I I_GENE/I_LOCATION
nuclear I I_GENE/I_LOCATION
antigen I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
is O O
associated O O
with O O
inducible O O
CRE B B_GENE
- I I_GENE
binding I I_GENE
proteins I I_GENE
in O O
interleukin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
stimulated O O
T O O
lymphocytes O O
. O O

METHODS O O
: O O
Levels O O
of O O
sIL B B_GENE
- I I_GENE
2R I I_GENE
were O O
measured O O
simultaneously O O
in O O
plasma O O
and O O
pleural O O
fluid O O
in O O
111 O O
patients O O
with O O
pleural O O
effusions O O
of O O
unknown O O
causes O O
. O O

The O O
GIS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
software O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
ArcView O B_LOCATION/B_ORGANIZATION
, O O
was O O
used O O
for O O
spatial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
distance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
calculations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

chi2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Tests O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
used O O
to O O
compare O O
the O O
distribution O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
characteristics O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
between O O
intersection O B_LOCATION/B_MEASURE
and O O
midblock O B_LOCATION/B_MEASURE
collisions O I_LOCATION/I_MEASURE
. O O

A O O
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
initiated O O
to O O
evaluate O O
the O O
effect O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
a O O
combination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
pure O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
L O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
isomer O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
LV O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
5 O B_TIME[MEASURE]/B_LOCATION
- O O
FU O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
along O O
with O O
epirubicin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
patients O B_PERSON/B_BIO
with O O
advanced O B_DISEASE/B_LOCATION
pancreatic O I_DISEASE/I_LOCATION
cancer O I_DISEASE/I_LOCATION
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
After O O
3 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ENT
weeks O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ENT
of O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
the O O
patient O B_PERSON/B_BIO
had O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
platelet O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
count O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
from O O
a O O
baseline O B_MEASURE/B_LOCATION
of O O
5 O B_MEASURE
, O O
000 O B_MEASURE
to O O
8 O B_MEASURE
, O O
000 O B_MEASURE
/ O O
microliter O B_MEASURE
to O O
a O O
maximal O B_MEASURE/B_LOCATION
level O I_MEASURE/I_LOCATION
of O O
33 O B_MEASURE
, O O
000 O B_MEASURE
/ O O
microliter O B_MEASURE
. O O

The O O
specificity O O
of O O
the O O
transcriptional O O
activation O O
by O O
ISGF3 B B_GENE
is O O
mediated O O
by O O
specific O O
elements O O
termed O O
IFN B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
stimulatory I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
response I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ISRE B B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
located O O
in O O
the O O
promoter O O
region O O
of O O
IFN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
inducible O O
genes O O
. O O

It O O
appears O O
that O O
the O O
K O B_OTHER/B_PROTEIN[GENE]
- O O
ABC O B_PROTEIN[GENE]/B_DISEASE
is O O
a O O
relatively O O
nonbiased O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suitable O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
evaluation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
both O O
gifted O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O O
nongifted O B_PERSON/B_ORGANIZATION
children O I_PERSON/I_ORGANIZATION
regardless O O
of O O
race O B_SPORT[ENT]/B_PERSON
or O O
gender O B_PERSON/B_LOCATION
. O O

In O O
another O O
patient O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
IRPF O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recurred O O
in O O
the O O
ureter O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
of O O
a O O
living O O
related O B_PERSON/B_BIO
renal O B_PERSON/I_BIO
graft O B_PERSON/I_BIO
6 O B_PERSON/I_BIO
months O B_PERSON/I_BIO
after O O
transplantation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

These O O
mutants O B_DISEASE/B_GENE
, O O
assayed O O
by O O
injection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
into O O
Xenopus O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
oocyte O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
nuclei O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
delimit O O
the O O
promoter O B_GENE/B_LOCATION
to O O
36 O B_LOCATION/B_MEASURE
bp O I_LOCATION/I_MEASURE
of O O
DNA O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
upstream O I_LOCATION
of O O
the O O
cap O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
site O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
73 O B_LOCATION
bp O I_LOCATION
of O O
the O O
untranslated O B_GENE/B_BIO
mRNA O I_GENE/I_BIO
leader O I_GENE/I_BIO
. O O

Upstream O O
tissue B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
inhibitor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
metalloproteinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
TIMP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
novel O O
and O O
essential O O
regulatory O O
DNA O O
motif O O
in O O
the O O
human B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
TIMP I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
- I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
1 I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
gene I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
promoter I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
directly O O
interacts O O
with O O
a O O
30 O O
- O O
kDa O O
nuclear O O
protein O O
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
these O O
experiments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O O
that O O
charcoal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
imbiber O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
beads O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
and O O
the O O
anion O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exchanges O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resins O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Dowex O B_LOCATION/B_PROTEIN[GENE]
XFS O I_LOCATION/I_PROTEIN[GENE]
- O O
4022 O B_NUMBER[MEASURE]
and O O
Dowex O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
SBR O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O O
C1 O B_MEASURE
, O O
would O O
not O O
be O O
useful O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agents O I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
increasing O O
the O O
amount O B_MEASURE/B_LOCATION
of O O
dieldrin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
eliminated O O
via O O
feces O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BACTERIUM[BIO]
( O O
droppings O B_LOCATION/B_PROTEIN[GENE]
) O O
of O O
chickens O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
receptor O O
for O O
CSF B B_GENE
- I I_GENE
1 I I_GENE
, O O
c B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Fms I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
is O O
expressed O O
in O O
osteoclasts O O
, O O
possesses O O
intrinsic O O
tyrosine B B_ENZYME[GENE]
- I I_ENZYME[GENE]
kinase I I_ENZYME[GENE]
activity O O
, O O
and O O
signals O O
via O O
rapid O O
phosphorylation O O
of O O
selected O O
proteins O O
. O O

Adaptive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
repeated O O
immersion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
exposure O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
on O O
the O O
human O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
body O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION

To O O
this O O
end O O
we O O
generated O O
a O O
detailed O O
physical O O
map O O
of O O
the O O
genomic O O
region O O
spanning O O
between O O
sequence O O
- O O
tagged O O
site O O
markers O O
D16S518 B B_GENE
and O O
D16S516 B B_GENE
. O O

Spinophilin B B_MEASURE/B_LOCATION
, O O
a O O
novel O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
localized O O
to O O
dendritic O O
spines O O
. O O

We O O
have O O
found O O
that O O
pro B B_GENE
- I I_GENE
IGF I I_GENE
- I I_GENE
2 I I_GENE
can O O
initially O O
form O O
two O O
disulfide O O
isomers O O
that O O
undergo O O
rearrangement O O
to O O
a O O
single O O
conformation O O
in O O
vivo O O
. O O

While O O
working O O
on O O
the O O
toxicity O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
war O B_LOCATION/B_MEASURE
gases O I_LOCATION/I_MEASURE
. O O

he O O
formulated O O
' O O
Haber O B_PERSON/B_COLOR
' O O
s O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
rule O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
' O O
, O O
also O O
known O O
as O O
C O B_PROTEIN[GENE]/B_MEASURE
x O O
T O B_PROTEIN[GENE]/B_OTHER
= O O
constant O B_MEASURE/B_DISEASE
in O O
order O B_EDU[ORGANIZATION]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
characterize O O
the O O
toxicity O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
an O O
inhalant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
existence O O
of O O
a O O
TFIIIB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
assembly O O
pathway O O
leading O O
to O O
the O O
faithful O O
transcription O O
of O O
natural O O
eukaryotic O O
tRNA O O
genes O O
in O O
the O O
absence O O
of O O
TFIIIC B B_GENE
provides O O
novel O O
insights O O
into O O
the O O
functional O O
flexibility O O
of O O
the O O
eukaryotic O O
tRNA O O
gene O O
transcription O O
machinery O O
and O O
on O O
its O O
evolution O O
from O O
an O O
ancestral O O
RNA B B_GENE
polymerase I I_GENE
III I I_GENE
system O O
relying O O
on O O
upstream O O
, O O
TATA O O
- O O
centered O O
control O O
elements O O
. O O

Ectopic O O
Xbra B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
can O O
induce O O
Xegr B B_GENE
- I I_GENE
1 I I_GENE
transcription O O
by O O
an O O
indirect O O
mechanism O O
that O O
appears O O
to O O
operate O O
via O O
primary O O
activation O O
of O O
fibroblast B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
growth I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
secretion O O
. O O

A O O
rapid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mixing O O
device O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
quasielastic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
light O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
scattering O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
studies O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
reacting O O
systems O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

The O O
major O B_GENE/B_LOCATION
transcription O I_GENE/I_LOCATION
start O I_GENE/I_LOCATION
site O I_GENE/I_LOCATION
, O O
designated O O
as O O
+ O B_PROTEIN[GENE]
1 O I_PROTEIN[GENE]
, O O
was O O
determined O O
by O O
RACE O B_DISEASE/B_GENE
( O O
rapid O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
amplification O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
cDNA O B_GENE
ends O I_GENE
) O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
human O B_GENE
liver O I_GENE
cDNA O I_GENE
and O O
was O O
found O O
to O O
be O O
located O O
50 O B_MEASURE/B_LOCATION
bp O B_MEASURE/I_LOCATION
upstream O O
from O O
the O O
translation O B_LOCATION/B_ORGANIZATION
start O I_LOCATION/I_ORGANIZATION
site O I_LOCATION/I_ORGANIZATION
. O O

These O O
aa O O
residues O O
correspond O O
to O O
codons O O
59 O O
and O O
108 O O
in O O
the O O
P B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
falciparum I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
DHFR I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
active I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
site I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
which O O
similar O O
aa O O
substitutions O O
( O O
Cys O O
Arg O O
- O O
59 O O
and O O
Ser O O
Asn O O
- O O
108 O O
) O O
are O O
associated O O
with O O
pyrimethamine O O
resistance O O
. O O

Of O O
all O O
YASR O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
syndromes O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O O
the O O
highest O B_MEASURE
stability O I_MEASURE
was O O
for O O
the O O
Anxious O B_DISEASE
/ O O
Depressed O B_DISEASE_ADJECTIVE[DISEASE]
scale O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Here O O
we O O
investigate O O
the O O
mechanism O O
of O O
TPA O O
induction O O
of O O
FGF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BP I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene O O
expression O O
in O O
the O O
human O O
ME O O
- O O
180 O O
SCC O O
cell O O
line O O
. O O

Between O O
the O O
RNA O O
initiation O O
site O O
and O O
the O O
coding O O
region O O
is O O
a O O
GC O O
- O O
rich O O
hairpin O O
structure O O
followed O O
by O O
8 O O
T O O
residues O O
that O O
looks O O
like O O
a O O
rho B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
independent I I_GENE/I_LOCATION
transcription I I_GENE/I_LOCATION
terminator I I_GENE/I_LOCATION
. O O

Conversely O O
the O O
rate O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
bioavailability O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
was O O
significantly O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
because O O
from O O
the O O
Reference O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
patch O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
the O O
release O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rate O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
fast O O
in O O
the O O
first O B_MEASURE/B_LOCATION
24 O B_MEASURE/I_LOCATION
h O B_MEASURE/I_LOCATION
, O O
leading O O
to O O
an O O
E2 O B_MEASURE/B_DISEASE
peak O I_MEASURE/I_DISEASE
at O O
8 O B_MEASURE
h O O
and O O
to O O
a O O
Cmax O B_MEASURE/B_LOCATION
in O O
average O B_MEASURE/B_SOCIAL_CIRCUMSTANCES
at O O
23 O B_MEASURE
h O O
. O O

3 O O
) O O
The O O
progress O O
of O O
fibrinolysis O O
was O O
observed O O
by O O
serial O O
collection O O
of O O
middle O O
ear O O
fluid O O
in O O
the O O
same O O
side O O
ear O O
of O O
5 O O
cases O O
out O O
of O O
17 O O
cases O O
having O O
much O O
activity O O
for O O
fibrin B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
degradation O O
, O O
and O O
lowering O O
of O O
fibrinolytic O O
activity O O
was O O
revealed O O
in O O
4 O O
out O O
of O O
these O O
5 O O
cases O O
as O O
the O O
result O O
. O O

Thus O O
G17 B B_GENE
targets O O
the O O
c B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
fos I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
promoter I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
CArG I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
sequence I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
via O O
Rho B B_GENE
A I I_GENE
- O O
dependent O O
pathways O O
, O O
and O O
Rho B B_GENE/B_TIME[MEASURE]
A I I_GENE/I_TIME[MEASURE]
appears O O
to O O
play O O
an O O
important O O
role O O
in O O
the O O
regulation O O
of O O
the O O
trophic O O
action O O
of O O
G17 B B_GENE
. O O

The O O
MIC90 O O
of O O
ABK O O
against O O
coagulase B B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
type I B_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
IV I B_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
strains O O
was O O
rather O O
high O O
, O O
12 O O
. O O
5 O O
micrograms O O
/ O O
ml O O
. O O

In O O
each O O
patient O B_PERSON/B_LOCATION
, O O
MBF O B_DISEASE
was O O
quantified O O
in O O
the O O
three O B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
major O I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
vascular O I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
territories O I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O O
the O O
left O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
anterior O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
descending O O
and O O
left O O
circumflex O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
coronary O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
artery O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
territories O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
the O O
right O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
coronary O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
artery O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
control O B_DISEASE/B_LOCATION
region O I_DISEASE/I_LOCATION
) O O
territory O B_LOCATION
. O O

These O O
results O O
demonstrate O O
that O O
m2 B B_GENE
receptors I I_GENE
couple O O
to O O
both O O
G B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
i2 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
G B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
i3 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
vivo O O
and O O
that O O
this O O
interaction O O
is O O
integral O O
to O O
both O O
positive O O
and O O
negative O O
regulatory O O
pathways O O
leading O O
to O O
activation O O
of O O
PLC B B_GENE/B_DISEASE
and O O
desensitization O O
of O O
receptor O O
signaling O O
. O O

Platelet O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
count O B_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
and O O
plasma O B_MEASURE/B_ORGANISM_FUNCTION
volume O I_MEASURE/I_ORGANISM_FUNCTION
were O O
significantly O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
group O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
in O O
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
B O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
throughout O O
pregnancy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

The O O
fru B B_GENE/B_MEASURE
gene I I_GENE/I_MEASURE
has O O
seven O O
exons O O
spanning O O
15 O O
- O O
kb O O
encoding O O
two O O
transcripts O O
with O O
ORFs O O
of O O
841 O O
and O O
695 O O
amino O O
acids O O
. O O

HC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
toxin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
exerts O O
a O O
potent O O
cytostatic O O
effect O O
on O O
plant O O
and O O
animal O O
cells O O
by O O
inhibiting O O
histone B B_GENE
deacetylase I I_GENE
. O O

The O O
human O O
RIL B B_GENE
gene I I_GENE
: O O
mapping O O
to O O
human O O
chromosome O O
5q31 O O
. O O
1 O O
, O O
genomic O O
organization O O
and O O
alternative O O
transcripts O O
. O O

The O O
delta O B_PROTEIN[GENE]/B_MEASURE
mean O O
VAF O B_DISEASE/B_PROTEIN[GENE]
and O O
delta O B_PROTEIN[GENE]/B_MEASURE
mean O O
SABP O B_DISEASE
indicated O O
varied O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mean O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
VAF O B_DISEASE/B_PROTEIN[GENE]
and O O
SABP O B_DISEASE/B_PROTEIN[GENE]
, O O
respectively O O
. O O

Azoospermia O B_DISEASE/B_SPECIES[BIO]
was O O
graded O O
in O O
the O O
following O O
way O B_LOCATION
: O O
adequate O B_DISEASE_ADJECTIVE[DISEASE]
spermatozoa O I_DISEASE_ADJECTIVE[DISEASE]
( O O
A1 O B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
scanty O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O O
rare O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spermatozoa O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
A2 O B_PROTEIN[GENE]
) O O
, O O
spermatid O B_DISEASE/B_ORGANISM_FUNCTION
arrest O I_DISEASE/I_ORGANISM_FUNCTION
( O O
B1 O B_PROTEIN[GENE]
) O O
, O O
spermatocyte O B_DISEASE/B_ORGANISM_FUNCTION
arrest O I_DISEASE/I_ORGANISM_FUNCTION
( O O
B2 O B_PROTEIN[GENE]
) O O
, O O
Sertoli O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
cell O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
- O O
only O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pattern O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
C O B_PROTEIN[GENE]
) O O
and O O
sclerosis O B_DISEASE
( O O
D O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

